<SEC-DOCUMENT>0001193125-21-221832.txt : 20210722
<SEC-HEADER>0001193125-21-221832.hdr.sgml : 20210722
<ACCEPTANCE-DATETIME>20210722160440
ACCESSION NUMBER:		0001193125-21-221832
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		44
FILED AS OF DATE:		20210722
DATE AS OF CHANGE:		20210722

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Rallybio Corp
		CENTRAL INDEX KEY:			0001739410
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				851083789
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-257655
		FILM NUMBER:		211107634

	BUSINESS ADDRESS:	
		STREET 1:		234 CHURCH STREET
		STREET 2:		SUITE 1020
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510
		BUSINESS PHONE:		203- 859-3820

	MAIL ADDRESS:	
		STREET 1:		234 CHURCH STREET
		STREET 2:		SUITE 1020
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rallybio Holdings, LLC
		DATE OF NAME CHANGE:	20180502
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d99471ds1a.htm
<DESCRIPTION>S-1/A #1
<TEXT>
<HTML><HEAD>
<TITLE>S-1/A #1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>As filed with the Securities and Exchange Commission on July 22, 2021. </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-257655</FONT> </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:13pt; font-family:ARIAL" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:13pt; font-family:ARIAL" ALIGN="center"><B>Amendment No. 1
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:ARIAL" ALIGN="center"><B>To </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:ARIAL" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>UNDER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>THE SECURITIES ACT OF&nbsp;1933 </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:13pt; font-family:ARIAL" ALIGN="center"><B>Rallybio Corporation </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">(Exact name of registrant
as specified in its charter) </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>85-1083789</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL" ALIGN="center">(State or other jurisdiction of</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL" ALIGN="center">incorporation or organization)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL" ALIGN="center">(Primary Standard Industrial&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL" ALIGN="center">Classification Code Number)&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL" ALIGN="center">(I.R.S. Employer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL" ALIGN="center">Identification No.)</P></TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>234 Church Street, Suite 1020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>New Haven, CT 06510 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>(203) <FONT
STYLE="white-space:nowrap">859-3820</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal
executive offices) </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Martin W. Mackay, Ph.D. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Chief Executive
Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>234 Church Street, Suite 1020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>New Haven, CT 06510 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>(203) <FONT
STYLE="white-space:nowrap">859-3820</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">(Name, address, including zip code, and telephone number, including area code, of agent for service)
</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Copies to:</B></P> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Marc Rubenstein<BR>Zachary Blume<BR>Ropes&nbsp;&amp; Gray&nbsp;LLP<BR>Prudential Tower<BR>800 Boylston Street<BR>Boston, MA
<FONT STYLE="white-space:nowrap">02199-3600</FONT><BR><FONT STYLE="white-space:nowrap">(617)&nbsp;951-7000</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Michael Greco<BR>General Counsel<BR>234 Church Street, Suite 1020<BR>New Haven, CT 06510<BR>(203) <FONT STYLE="white-space:nowrap">859-3820</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Lisa Firenze<BR>Molly W. Fox<BR>Wilmer Cutler Pickering Hale&nbsp;&amp; Dorr LLP<BR>7 World Trade Center<BR>250 Greenwich Street<BR>New York, NY 10007<BR>(212)
<FONT STYLE="white-space:nowrap">230-8880</FONT><BR></B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Approximate date of commencement of proposed sale to the public: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>As soon as practicable after the effective date of this Registration Statement. </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of 1933,
check the following box.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">If this Form is filed to register additional securities for an
offering pursuant to Rule&nbsp;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT
STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">If this Form is a <FONT STYLE="white-space:nowrap">post-effective</FONT> amendment filed pursuant to
Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">If this Form is a <FONT STYLE="white-space:nowrap">post-effective</FONT> amendment
filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT
STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT
STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and
&#147;emerging growth company&#148; in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top">Large&nbsp;accelerated&nbsp;filer&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Accelerated filer&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Non-accelerated&nbsp;filer&nbsp;&nbsp;</FONT><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL" ALIGN="right">Smaller&nbsp;reporting&nbsp;company&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9746;</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:ARIAL" ALIGN="right">Emerging growth company&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9746;</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Title of each Class of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Securities to be Registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Amount</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>to
be </B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Registered<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Offering</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Price </B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>per&nbsp;Share<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Aggregate<BR>Offering&nbsp;Price<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Amount of<BR>Registration Fee<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.65em; text-indent:-1.65em; font-size:8.5pt; font-family:ARIAL">Common Stock, par value $0.0001 per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">6,612,500</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$15.00</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$99,187,500</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$10,822</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes 862,500 shares that the underwriters have an option to purchase. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(a) under the Securities Act of 1933, as amended. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Previously paid by the Registrant in connection with the initial filing of this Registration Statement on Form&nbsp;S-1 on July 2, 2021. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a
further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective
on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>EXPLANATORY NOTE </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We previously operated as Rallybio Holdings, LLC, a Delaware limited liability company, or the LLC Entity. On June&nbsp;30, 2021, we completed a series of transactions
pursuant to which (i)&nbsp;Rallybio IPD, LLC, a direct subsidiary of the LLC Entity, was converted from a Delaware limited liability company to a Delaware corporation and changed its name to Rallybio Corporation, or the Corporation, and
(ii)&nbsp;four recently-formed direct subsidiaries of the Corporation, each a Delaware limited liability company, or collectively the Merger Subs, each consummated a separate merger with one of the LLC Entity&#146;s direct subsidiaries, other than
Rallybio IPD, LLC, or collectively the Asset Subsidiaries, with the Asset Subsidiaries surviving the mergers and the LLC Entity receiving common stock of the Corporation in exchange for its interest in each Asset Subsidiary, which resulted in the
Asset Subsidiaries becoming subsidiaries of the Corporation and the Corporation becoming the only direct subsidiary of the LLC Entity. Prior to the completion of this offering, the LLC Entity will liquidate and distribute 100% of the capital stock
of the Corporation, consisting solely of common stock, to the unitholders of the LLC Entity. We refer to the liquidation of the LLC Entity and distribution of the capital stock of the Corporation to the unitholders of the LLC Entity as the
&#147;Liquidation&#148; and to the Liquidation and these other transactions throughout the prospectus included in this registration statement collectively as the &#147;Reorganization.&#148; As a result of the Reorganization, the unitholders of the
LLC Entity will become the holders of common stock of the Corporation, and the Corporation will become the registrant for purposes of this offering, and our consolidated financial statements will be reported from the Corporation. See &#147;The
Reorganization&#148; for further detail regarding these transactions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Shares of the common stock of the Corporation are being offered by the prospectus included in
this registration statement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>FINANCIAL STATEMENT PRESENTATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except as disclosed in this prospectus, the audited consolidated financial statements for the years ended December&nbsp;31, 2020 and 2019 and the notes thereto, the
unaudited condensed consolidated financial statements for the three months ended March 31, 2021 and 2020 and the notes thereto, and selected historical consolidated financial data and other financial information included in this registration
statement are those of the LLC Entity and do not give effect to the Reorganization. </P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#c21128"><B>The information in this preliminary prospectus is not complete and may be changed. We may not sell
these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting offers to buy these securities in any
jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><FONT
 COLOR="#c21128">SUBJECT TO COMPLETION, DATED JULY 22, 2021 </FONT></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PRELIMINARY PROSPECTUS </B></P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>5,750,000 Shares </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g01k65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>Rallybio Corporation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are offering 5,750,000 shares of our
common stock. This is an initial public offering, and no public market currently exists for our common stock. We expect the initial public offering price to be between $13.00 and $15.00 per share. We have applied for listing of our common stock on
the Nasdaq Global Market under the symbol &#147;RLYB.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; under
federal securities laws and are subject to reduced public company reporting requirements. See &#147;Prospectus Summary&#151;Implications of Being an Emerging Growth Company and a Smaller Reporting Company.&#148; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER&nbsp;SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Underwriting discounts and commissions<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Underwriting&#148; for additional disclosure regarding underwriting compensation. </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investing in our
common stock involves a high degree of risk. See &#147;<A HREF="#toc99471_2">Risk Factors</A>&#148; beginning on page&nbsp;13 of this prospectus. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the adequacy or
accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Delivery of the shares of common stock is expected to be made on or
about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. We have granted the underwriters an option for a period of 30 days to purchase an additional 862,500 shares of our common stock. If the
underwriters exercise the option in full, the total underwriting discounts and commissions payable by us will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and the total proceeds to us, before
expenses, will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Evercore&nbsp;ISI</B></TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Prospectus dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021.
</P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_">PROSPECTUS SUMMARY </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_3">SPECIAL NOTE REGARDING <FONT STYLE="white-space:nowrap">FORWARD-LOOKING</FONT> STATEMENTS
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_4">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_5">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_6">THE REORGANIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_7">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_8">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_9">SELECTED FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_10">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_11">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_12">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_13">EXECUTIVE AND DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_14">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_15">PRINCIPAL STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_16">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_17">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_18">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT STYLE="white-space:nowrap">NON-U.S.
</FONT> HOLDERS OF OUR COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_19">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_20">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_21">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_22">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc99471_23">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither we nor the underwriters have authorized anyone to provide any information other than that contained in this
prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We
and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front
cover of this prospectus, regardless of the time of delivery of this prospectus or any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For investors outside of the United States: Neither we nor the underwriters have done anything that would permit this offering or possession or distribution of this
prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions
relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Through and
including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2021 (the 25th&nbsp;day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not
participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or
subscriptions. </P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>TRADEMARKS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
use Rallybio as a trademark in the United States and/or in other countries. This prospectus contains references to our trademark and to those belonging to other entities, including
Affibody<B><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></B>. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear without the&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;or TM symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable
licensor to these trademarks and trade names. We do not intend our use or display of other entities&#146; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>MARKET AND INDUSTRY DATA </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise indicated,
information contained in this prospectus concerning our industry and the markets in which we operate, including our general expectations, market position and market opportunity, is based on our management&#146;s estimates and research, as well as
industry and general publications and research and studies conducted by third parties. We believe that the information from these <FONT STYLE="white-space:nowrap">third-party</FONT> publications, research and studies included in this prospectus is
reliable. Management&#146;s estimates are derived from publicly available information, their knowledge of our industry and their assumptions based on such information and knowledge, which we believe to be reasonable. This data involves a number of
assumptions and limitations which are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &#147;Risk Factors.&#148; These and other factors could cause our future performance to
differ materially from our assumptions and estimates. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>REORGANIZATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We previously operated as Rallybio Holdings, LLC, a Delaware limited liability company, or the LLC Entity. On June&nbsp;30, 2021, we completed a series of transactions
pursuant to which (i)&nbsp;Rallybio IPD, LLC, a direct subsidiary of the LLC Entity, was converted from a Delaware limited liability company to a Delaware corporation and changed its name to Rallybio Corporation, or the Corporation, and
(ii)&nbsp;four recently-formed direct subsidiaries of the Corporation, each a Delaware limited liability company, or collectively the Merger Subs, consummated a separate merger with one of the LLC Entity&#146;s direct subsidiaries, other than
Rallybio IPD, LLC, or collectively the Asset Subsidiaries, with the Asset Subsidiaries surviving the mergers and the LLC Entity receiving common stock of the Corporation in exchange for its interest in each Asset Subsidiary, which resulted in the
Asset Subsidiaries becoming subsidiaries of the Corporation and the Corporation becoming the only direct subsidiary of the LLC Entity. Prior to the completion of this offering, the LLC Entity will liquidate and distribute 100% of the capital stock
of the Corporation, consisting solely of common stock, to the unitholders of the LLC Entity. We refer to the liquidation of the LLC Entity and distribution of the capital stock of the Corporation to the unitholders of the LLC Entity as the
&#147;Liquidation&#148; and to the Liquidation and these other transactions collectively as the &#147;Reorganization.&#148; As a result of the Reorganization, the unitholders of the LLC Entity will become the holders of common stock of the
Corporation, and the Corporation will become the registrant for purposes of this offering, and our consolidated financial statements will be reported from the Corporation. See &#147;The Reorganization&#148; for further detail regarding these
transactions. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Shares of the common stock of the Corporation are being offered by the prospectus included in this registration statement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>FINANCIAL STATEMENT PRESENTATION </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except as disclosed in
this prospectus, the audited consolidated financial statements for the years ended December&nbsp;31, 2020 and 2019 and the notes thereto, the unaudited condensed consolidated financial statements for the three months ended March 31, 2021 and 2020
and the notes thereto, and selected historical consolidated financial data and other financial information included in this prospectus are those of the LLC Entity and do not give effect to the Reorganization. </P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>This summary highlights information included elsewhere in this prospectus. This summary does not contain all the information you should consider before investing in
our common stock. You should read and consider this entire prospectus carefully, including the sections titled &#147;Risk Factors,&#148; &#147;Special Note Regarding Forward-Looking Statements&#148; and &#147;Management&#146;s Discussion and
Analysis of Financial Condition and Results of Operations&#148; and our financial statements and the related notes included elsewhere in the prospectus, before making any investment decision. Except where the context otherwise requires or where
otherwise indicated, the terms &#147;Rallybio,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;our company,&#148; &#147;the company,&#148; and &#147;our business&#148; refer, prior to the Reorganization discussed below, to Rallybio
Holdings, LLC and its consolidated subsidiaries and, after the Reorganization, to Rallybio Corporation and its consolidated subsidiaries. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical-stage biotechnology company built around a team of seasoned industry experts with a shared purpose and a track record of success in discovering,
developing, manufacturing and delivering therapies that meaningfully improve the lives of patients suffering from severe and rare diseases. Our mission at Rallybio is aligned with our expertise, and we believe we have assembled the best people,
partners and science to forge new paths to life-changing therapies. Since our launch in January&nbsp;2018, we have acquired a portfolio of promising product candidates that consists of five programs, and we are focused on further expanding our
portfolio with the goal of making a profound impact on the lives of even more patients. We are drawing on our decades of knowledge and experience with a determination to tackle the undone, the too difficult, the inaccessible &#150; and change the
odds for rare disease patients. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our most advanced program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, or FNAIT, a potentially
life-threatening rare hematological disease that impacts fetuses and newborns. We are evaluating RLYB211, a polyclonal anti-HPA-1a antibody, in a Phase&nbsp;1/2 clinical trial, which we believe has established proof of concept for RLYB211 and
provides support for our proposed mechanism of action. We plan to move our FNAIT program forward with our lead product candidate, RLYB212, a monoclonal anti-HPA-1a antibody. We submitted a clinical trial application, or CTA, for RLYB212 in
July&nbsp;2021, and subject to the acceptance of our CTA submission, we expect to initiate a Phase&nbsp;1 first-in-human trial in Germany in the first quarter of 2022. We are also focused on developing therapies that address diseases of complement
dysregulation, including paroxysmal nocturnal hemoglobinuria, or PNH, generalized myasthenia gravis, or gMG, and ophthalmic disorders. RLYB116 is a novel, potentially long-acting, subcutaneously administered inhibitor of complement factor&nbsp;5, or
C5, in development for the treatment of patients with PNH and gMG. We expect to submit a CTA for RLYB116 in the fourth quarter of 2021 to support the initiation of a Phase&nbsp;1 trial in healthy participants. RLYB114 is a pegylated C5 inhibitor in
preclinical development for the treatment of complement-mediated ophthalmic diseases, and we expect to submit a CTA for this product candidate in the first half of 2023. Additionally, in collaboration with Exscientia Limited, or Exscientia, we have
two discovery-stage programs focused on the identification of small molecule therapeutics for patients with rare metabolic diseases. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Approach </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At Rallybio, we do not accept that millions of patients suffering from devastating rare diseases should have to live without transformative treatments. There are an
estimated 25 to 30&nbsp;million people affected by as many as 7,000 rare diseases in the United States alone, with a significantly greater number of affected people globally. We are building a diversified pipeline of product candidates that we
believe have the potential to transform the lives of patients in need. Our goal is to deliver therapeutics that provide meaningful clinical benefits to patients so they can become unbound and undefined by the diseases from which they suffer. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe the success of our company is built on three key strengths: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Our extensive knowledge of rare diseases and our scientific expertise positions us to identify therapies with the
potential for transformative impact. We seek to acquire and develop product candidates that possess a clear mechanism of action and that aim to address diseases with a well-understood pathophysiology for which there is a significant unmet medical
need. We believe that a product candidate&#146;s mechanism of action should target the causal biology of the disease to provide the highest </B></P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">1 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
probability of dramatically improving the lives of patients. We believe that our team&#146;s extensive experience in rare diseases and our scientific expertise position us to identify
opportunities where these links can be made, which may go unnoticed by others. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Our ability to source, to identify and to evaluate potential high-quality product candidates</B>. We apply decades of
experience across drug discovery, research, development, regulatory strategy and manufacturing to source, to identify and to evaluate therapeutic targets and product candidates that we believe have a high probability of success. Our ability to
source these product candidates is facilitated by our extensive network of relationships with leaders in industry and in academic clinical centers worldwide. We view ourselves as partners of choice given our team&#146;s track record of success in
developing and delivering new therapies to patients. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Our team&#146;s proven execution capability to drive product candidates through clinical development to regulatory
approvals. </B>We have assembled a team with a proven history of successfully advancing product candidates from discovery to clinical development and through regulatory approval. Members of our team have played critical roles in the approval of more
than 30 drugs, including seven approvals for rare disease therapeutics since 2013, and secured approvals from regulatory authorities in the Americas, Europe, Australia, and Asia. In doing so, our employees previously developed and implemented novel
clinical trial designs and successfully conducted clinical trials in never-before treated patient populations. We believe this collective prior experience positions us to efficiently and expertly execute at each step in the research and development
process and enhances the value we can bring to product candidates and to patients. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Company </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We were founded in January 2018 by Martin W. Mackay, Ph.D., Stephen Uden, M.D., and Jeffrey M. Fryer, CPA to identify and accelerate the development of
life-transforming therapies for patients with severe and rare disorders. Our founders were previously executives at Alexion Pharmaceuticals, Inc., where Dr.&nbsp;Mackay was Global Head of Research&nbsp;&amp; Development, Dr.&nbsp;Uden served as Head
of Research, and Mr.&nbsp;Fryer was Chief Tax Officer. We believe our team&#146;s prior industry contributions have made a significant positive impact on the lives of thousands of patients around the world. As a strong and experienced team, we
believe we can transform the lives of thousands more. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Pipeline </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
pipeline is illustrated in the chart below. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g02j59.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:8pt; font-family:ARIAL"><B>FNAIT: Fetal and neonatal alloimmune thrombocytopenia; <FONT STYLE="white-space:nowrap">HPA-1a:</FONT> Human
platelet antigen 1a; PNH: Paroxysmal nocturnal hemoglobinuria; gMG: Generalized myasthenia gravis; ABD: Albumin binding domain; HPP: Hypophosphatasia; ENPP1: Ectonucleotide pyrophosphatase/phosphodiesterase 1; PoC: Proof of concept; CTA: Clinical
trial application </B></P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">2 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>RLYB211 and RLYB212 for the Prevention of FNAIT </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">FNAIT is a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns. FNAIT can arise during pregnancy due to an immune
incompatibility between an expectant mother and her fetus in a specific platelet antigen called human platelet antigen 1, or <FONT STYLE="white-space:nowrap">HPA-1.</FONT> We estimate that there are over 22,000&nbsp;pregnancies at high risk of
developing FNAIT each year in the United States, Canada, United Kingdom, other major European countries and Australia. There is currently no approved therapy for the prevention or treatment of FNAIT. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The lead product candidate in our FNAIT prevention program is RLYB212, a preclinical-stage monoclonal
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibody. We are evaluating RLYB211, a polyclonal <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibody, in a
Phase&nbsp;1/2 clinical trial, which we believe has established proof of concept for RLYB211 and provides support for our proposed mechanism of action. Data generated from the first cohort of healthy participants in this trial, which was presented
in July&nbsp;2021 at the International Society on Thrombosis and Haemostasis, or ISTH Congress, demonstrated the ability of an <FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT> antibody to rapidly eliminate transfused <FONT
STYLE="white-space:nowrap">HPA-1a</FONT> positive platelets from the circulation of healthy HPA-1a negative participants. Based on these results, we believe that targeting <FONT STYLE="white-space:nowrap">HPA-1a</FONT> with an anti-HPA-1a antibody
has the potential to prevent maternal alloimmunization and therefore the occurrence of FNAIT. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For RLYB212, our lead product candidate, we submitted a CTA in
July&nbsp;2021, and subject to the acceptance of our CTA submission, we expect to initiate a Phase 1 first-in-human trial in Germany in the first quarter of 2022, with proof of concept data from a Phase 1b trial planned for mid-2022. We also
anticipate reporting additional data from our Phase&nbsp;1/2 clinical trial for RLYB211 in the fourth quarter of 2021. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>RLYB116 and RLYB114 for the
Treatment of Diseases Related to Complement Pathway Dysregulation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our next two programs target diseases related to complement pathway dysregulation. The
complement system plays a central role in innate immunity, as well as shaping adaptive immune response. Dysregulation of the complement pathway has been implicated in the pathogenesis of a growing number of diseases, making it an attractive target
for therapeutic intervention. Antibody inhibitors of C5 have been successfully developed to treat diseases caused by complement pathway dysregulation, including PNH, refractory gMG, atypical hemolytic uremic syndrome, and relapsing neuromyelitis
optica spectrum disorder. Despite the approval of antibody-based C5 inhibitors for patients with these diseases, we believe there remains significant need in the market for safe, effective, patient-friendly and accessible therapies. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our team has a track record of success and significant expertise in designing, developing and securing approval for complement inhibitors, including Soliris and
Ultomiris, for patients with severe and rare diseases around the world. We believe our internal knowledge and expertise positions us to successfully advance our programs and deliver transformative benefits to patients in need. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our most advanced product candidate in this therapeutic area is RLYB116, an inhibitor of complement factor C5, which is a central component of the complement pathway.
RLYB116 is an Affibody<B><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></B> molecule attached to an albumin binding domain that has the potential to drive the rapid, complete and sustained inhibition of C5 with a subcutaneous injection.
We plan to pursue PNH and gMG as our lead indications for RLYB116. We also plan to evaluate the development of RLYB116 for the treatment of additional rare complement-mediated diseases. We expect to submit a CTA for RLYB116 in the fourth quarter of
2021, and to initiate a Phase 1 clinical trial in healthy participants in the first quarter of 2022. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our second C5 inhibitor, RLYB114, is a pegylated <FONT
STYLE="white-space:nowrap">C5-targeted</FONT> Affibody<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> molecule with pharmacokinetic properties designed for the treatment of complement-mediated ophthalmic diseases. Preclinical data
generated with RLYB114 demonstrate that it is well-tolerated in animal models with no serious adverse effects. RLYB114 is in preclinical development, and we expect to submit a CTA for RLYB114 in the first half of 2023. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Artificial Intelligence Drug Discovery Collaboration with Exscientia </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We established a partnership with Exscientia, an Oxford, <FONT STYLE="white-space:nowrap">UK-based</FONT> artificial intelligence-driven pharmatech company that is a
leader in the use of computational tools and machine learning capabilities to rapidly and </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">3 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
efficiently discover novel small molecule drug candidates. Our partnership consists of two joint ventures that each focus on the discovery and development of small molecule therapeutics for the
treatment of patients with rare metabolic diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Strategy </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
mission at Rallybio is aligned with our expertise: to identify and accelerate the development of life-transforming therapies for patients with severe and rare disorders. To achieve this mission, our strategy includes the following key components:
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Establish a leading rare disease company through a team that delivers transformative medicines to patients;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Advance RLYB212 into and through clinical development for the prevention of FNAIT; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Advance RLYB116 and RLYB114 into and through clinical development for the treatment of diseases of complement
dysregulation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Identify and advance pipeline product candidates for rare metabolic diseases through our joint ventures with Exscientia;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Expand our pipeline through partnering, acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> additional
product candidates that target validated biology; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Maximize the value of pipeline product candidates through commercial independence in key markets and select partnerships.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Summary of Risks Associated with Our Business </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more fully in the &#147;Risk Factors&#148; section of this prospectus immediately following this prospectus
summary. These risks include the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We have incurred significant losses since our inception and anticipate that we will continue to incur losses in the
foreseeable future.&nbsp;We have not commercialized any products and have never generated revenue from the commercialization of any product.&nbsp;We are not currently profitable, and we may never achieve or sustain profitability;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Even if this offering is successful, we will require significant additional capital to fund our operations, and if we fail
to obtain necessary financing, we may not be able to complete the development and commercialization of RLYB212, RLYB116 or any additional product candidates we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in this offering,
restrict our operations or require us to relinquish rights to our technologies or product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic in the United States and other countries has
resulted in and may further result in disruptions to our preclinical studies, clinical trials, manufacturing and other business operations, which could adversely affect our business and the market price of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We are heavily dependent on the success of RLYB212 and RLYB116, which are in preclinical
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> activities.&nbsp;If we are not able to develop, obtain regulatory approval for, or successfully commercialize our product candidates, or if we experience significant delays in doing so, our
business will be materially harmed; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We may not be successful in our efforts to identify additional product candidates.&nbsp;Due to our limited resources and
access to capital, we must prioritize development of certain product candidates, the choice of which may prove to be wrong and adversely affect our business; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Preclinical studies and clinical trials are expensive, time consuming, and difficult to design and implement, and involve
uncertain outcomes.&nbsp;Any product candidates that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval.&nbsp;We
</P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">4 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more
difficult or rendered impossible by multiple factors outside our control, including our focus on rare diseases; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Results of preclinical studies, clinical trials, or analyses that we may announce or publish from time to time, may not be
indicative of results obtained in later trials, and any interim results we may publish could be different than final results; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Any product candidates that we develop or the administration thereof, may cause serious adverse events or undesirable side
effects, which may halt their clinical development, delay or prevent marketing approval, or, if approved, require them to be taken off the market, include safety warnings, or otherwise limit their sales; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The regulatory approval processes of the U.S. Food and Drug Administration, or FDA, the European Medicines Agency, or EMA,
and comparable foreign regulatory authorities are lengthy, time- consuming, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for RLYB212, RLYB116 or any of our other product candidates, our business will be
substantially harmed; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our product candidates target rare diseases and conditions, and the market opportunities for RLYB212 and RLYB116, if
approved, may be smaller than we anticipate. As a result, our commercial opportunity may be limited and because the target populations of our product candidates are for rare diseases, we must be able to successfully identify patients and capture a
significant market share to achieve profitability and growth; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The FDA, EMA or other comparable foreign regulatory authorities could require the clearance or approval of an in vitro
diagnostic or companion diagnostic device as a condition of approval for any product candidate that requires or would commercially benefit from such tests.&nbsp;Failure to successfully validate, develop and obtain regulatory clearance or approval
for companion diagnostics on a timely basis or at all could harm our drug development strategy and we may not realize the commercial potential of any such product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We face significant competition from biotechnology and pharmaceutical companies, and our operating results will suffer if
we fail to compete effectively; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We intend to continue to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> rights to additional product
candidates or collaborate with third parties for the development and commercialization of our product candidates.&nbsp;We may not succeed in identifying and acquiring businesses or assets, <FONT STYLE="white-space:nowrap">in-licensing</FONT>
intellectual property rights or establishing and maintaining collaborations, which may significantly limit our ability to successfully develop and commercialize our other product candidates, if at all, and these transactions could disrupt our
business, cause dilution to our stockholders or reduce our financial resources; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If we are unable to obtain, maintain and enforce patent protection for our technology and product candidates, or if the
scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and
product candidates may be adversely affected. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The foregoing is only a summary of some of our risks. For a more detailed discussion of these and
other risks you should consider before making an investment in our common stock, see &#147;Risk Factors.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Implications of Being an Emerging Growth Company
and a Smaller Reporting Company </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS
Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies, including reduced disclosure about our executive compensation arrangements,
exemption from the requirements to hold <FONT STYLE="white-space:nowrap">non-binding</FONT> </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">5 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
advisory votes on executive compensation and golden parachute payments and exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may take advantage of these exemptions until the last day of the fiscal year following the fifth anniversary of this offering or such earlier time that we are
no longer an emerging growth company. We would cease to be an emerging growth company earlier if we have more than $1.07&nbsp;billion in annual revenue, we have more than $700.0&nbsp;million in market value of our stock held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> (and we have been a public company for at least 12&nbsp;months and have filed one Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K)</FONT> or we issue more than $1.0&nbsp;billion of <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt securities over a <FONT STYLE="white-space:nowrap">three-year</FONT> period. For so long as we remain an emerging growth company, we are permitted, and intend, to rely on exemptions from certain
disclosure requirements that are applicable to other public companies that are not emerging growth companies. We may choose to take advantage of some, but not all, of the available exemptions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which this prospectus is a part and may elect to
take advantage of other reduced reporting requirements in future filings. In particular, in this prospectus, we have provided only two years of audited financial statements and have not included all of the executive compensation related information
that would be required if we were not an emerging growth company. As a result, the information that we provide to our stockholders may be different than you might receive from other public reporting companies in which you hold equity interests. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting
standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to &#147;opt out&#148; of such extended transition period,
which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so
until such time that we either (i)&nbsp;irrevocably elect to &#147;opt out&#148; of such extended transition period or (ii)&nbsp;no longer qualify as an emerging growth company. We may choose to early adopt any new or revised accounting standards
whenever such early adoption is permitted for private companies. Therefore, the reported results of operations contained in our financial statements may not be directly comparable to those of other public companies. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are also a &#147;smaller reporting company,&#148; meaning that the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the
proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700.0&nbsp;million and our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year. We may continue to be a smaller
reporting company after this offering if either (i)&nbsp;the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million or (ii)&nbsp;our annual revenue is less than $100.0&nbsp;million
during the most recently completed fiscal year and the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million. If we are a smaller reporting company at the time we cease to be an
emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent
fiscal years of audited financial statements in our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding
executive compensation. We may continue to be a smaller reporting company until the fiscal year following the determination that we no longer meet the requirements necessary to be considered a smaller reporting company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Corporate Information </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio Holdings, LLC, or the LLC Entity, was
formed in Delaware in March 2018 and Rallybio IPD, LLC, its wholly-owned subsidiary, was formed in Delaware in May 2020. On June 30, 2021, Rallybio IPD, LLC was converted into a Delaware corporation and changed its name to Rallybio Corporation, or
the Corporation. The Corporation will be the issuer of the shares of common stock being offered by this prospectus. See &#147;The </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">6 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Reorganization.&#148; Our principal executive offices are located at 234 Church Street, Suite 1020, New Haven, CT&nbsp;06510 and our telephone number is (203)
<FONT STYLE="white-space:nowrap">859-3820.</FONT> Our corporate website address is https://www.rallybio.com. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in
this prospectus is an inactive textual reference only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Reorganization </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On June 30, 2021, we completed a series of transactions pursuant to which (i)&nbsp;Rallybio IPD, LLC, a direct subsidiary of the LLC Entity, was converted from a
Delaware limited liability company to a Delaware corporation and changed its name to Rallybio Corporation, and (ii)&nbsp;four recently-formed direct subsidiaries of the Corporation, each a Delaware limited liability company, or collectively the
Merger Subs, consummated a separate merger with one of the LLC Entity&#146;s direct subsidiaries, other than Rallybio IPD, LLC, or collectively the Asset Subsidiaries, with the Asset Subsidiaries surviving the mergers and the LLC Entity receiving
common stock of the Corporation in exchange for its interest in each Asset Subsidiary, which resulted in the Asset Subsidiaries becoming subsidiaries of the Corporation and the Corporation becoming the only direct subsidiary of the LLC Entity. Prior
to the completion of this offering, the LLC Entity will liquidate and distribute 100% of the capital stock of the Corporation, consisting solely of common stock, to the unitholders of the LLC Entity. See &#147;The Reorganization&#148; and
&#147;Description of Capital Stock&#148; for additional information, including a description of the terms of our capital stock following the Reorganization and the terms of our amended and restated certificate of incorporation and amended and
restated bylaws that will be in effect prior to the consummation of this offering. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Currently, the capital structure of the LLC Entity consists of four classes
of membership units: common units; Series A-1 preferred units; Series A-2 preferred units; and Series B preferred units. Certain of the common units were issued as incentive units. The number of shares of common stock that the holders of each class
of units will receive in the Liquidation will be based on the value of the LLC Entity immediately prior to the Liquidation, determined by reference to the initial public offering price per share in this offering. In this prospectus, we have assumed
a valuation based on an initial public offering price of $14.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus. Assuming an initial public offering price of $14.00 per share, the holders of Series
A-1 preferred units and Series A-2 preferred units will receive an aggregate of 5,245,488 shares of our common stock, the holders of Series B preferred units will receive an aggregate of 16,364,481 shares of our common stock, the holders of common
and restricted common units will receive an aggregate of 893,094 shares of our common stock and the holders of incentive units will receive an aggregate of 2,496,909 shares of our common stock. Assuming an initial public offering price of $15.00 per
share, which is the high end of the price range set forth on the cover page of this prospectus, the holders of Series A-1 preferred units and Series A-2 preferred units will receive an aggregate of 5,235,000 shares of our common stock, the holders
of Series B preferred units will receive an aggregate of 16,331,760 shares of our common stock, the holders of common and restricted common units will receive an aggregate of 891,309 shares of our common stock and the holders of incentive units will
receive an aggregate of 2,541,907 shares of our common stock. Assuming an initial public offering price of $13.00 per share, which is the low end of the price range set forth on the cover page of this prospectus, the holders of Series A-1 preferred
units and Series A-2 preferred units will receive an aggregate of 5,257,590 shares of our common stock, the holders of Series B preferred units will receive an aggregate of 16,402,235 shares of our common stock, the holders of common and restricted
common units will receive an aggregate of 895,155 shares of our common stock and the holders of incentive units will receive an aggregate of 2,444,990 shares of our common stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result of the Reorganization, assuming an initial public offering price of $14.00 per share, which is the midpoint of the price range set forth on the cover page
of this prospectus, the holders of existing units in the LLC Entity will collectively own an aggregate of 24,999,972 shares of our common stock immediately prior to the consummation of this offering. Assuming an initial public offering price of
$15.00 per share, which is the high end of the price range set forth on the cover page of this prospectus, the holders of existing units of the </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">7 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
LLC Entity will collectively own an aggregate of 24,999,976 shares of our common stock as of immediately prior to the consummation of this offering. Assuming an initial public offering price of
$13.00 per share, which is the low end of the price range per share set forth on the cover page of this prospectus, the holders of existing units of the LLC Entity will collectively own an aggregate of 24,999,970 shares of our common stock
immediately prior to the consummation of this offering. See &#147;The Reorganization.&#148; </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">8 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE OFFERING </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Common stock offered by us </P></TD>
<TD>5,750,000 shares. </TD></TR></TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Common stock to be outstanding after this offering </P></TD>
<TD><BR>30,749,972 shares (31,612,472 shares if the underwriters exercise their option to purchase additional shares in full). </TD></TR></TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Underwriters&#146; option to purchase additional shares of common stock from us </P></TD>
<TD><BR>We have granted the underwriters an option to purchase up to an aggregate of 862,500 additional shares of common stock from us at the initial public offering price, less the estimated underwriting discounts and commissions, for a period of
30&nbsp;days after the date of this prospectus. </TD></TR></TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Use of proceeds </P></TD>
<TD>We estimate that our net proceeds from the sale of our common stock in this offering will be approximately $71.8&nbsp;million, assuming an initial public offering price of $14.00 per share, which is the midpoint of the price range set forth on
the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD>We intend to use the net proceeds from this offering, together with cash on hand, as follows: (i)&nbsp;approximately $75.0 million to $83.0 million to advance our FNAIT prevention program, including completion of our Phase 1/2 clinical trial for
RLYB211 and completion of our Phase&nbsp;1 and Phase&nbsp;1b clinical trials for RLYB212, (ii)&nbsp;approximately $35.0 million to $41.0 million to advance our complement program, including completion of our Phase&nbsp;1 clinical trial for RLYB116,
and initiation of our Phase 1 clinical trial for RLYB114, (iii)&nbsp;approximately $10.0 million to $14.0 million to advance our joint ventures with Exscientia, including the initiation of our Phase&nbsp;1 clinical trial for our ENPP1 inhibitor, and
(iv)&nbsp;any remaining proceeds for business development activities, working capital needs and other general corporate purposes. See &#147;Use of Proceeds.&#148; </TD></TR></TABLE>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Dividend policy </P></TD>
<TD>We do not anticipate declaring or paying any cash dividends on our capital stock in the foreseeable future. See &#147;Dividend Policy.&#148; </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Risk factors </P></TD>
<TD>You should carefully read the &#147;Risk Factors&#148; section of this prospectus and the other information included in this prospectus for a discussion of factors that you should consider before deciding to invest in our common stock.
</TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Proposed Nasdaq Global Market symbol </P></TD>
<TD><BR>&#147;RLYB&#148; </TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">9 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The number of shares of our common stock to be outstanding immediately following the completion of this offering
is based on 24,999,972 shares outstanding as of June 30, 2021, after giving effect to the Reorganization, including the issuance by the Corporation of an aggregate of 24,999,972 shares of its common stock and the subsequent distribution of those
shares to members of the LLC Entity, assuming an initial public offering price of $14.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus. These amounts exclude: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">5,440,344 shares of our common stock reserved for issuance under the Rallybio Corporation 2021 Equity Incentive Plan, or
the 2021 Plan, which will become effective in connection with this offering, including 2,455,722 shares of our common stock that will be issued in respect of outstanding unvested restricted common units and outstanding unvested incentive units,
137,189 shares of our common stock were available for issuance under the Rallybio Holdings, LLC 2018 Share Plan, or the 2018 Plan, and 734,080 shares of our common stock issuable upon the exercise of options to be granted in connection with this
offering under the 2021 Plan with an exercise price per share equal to the initial public offering price in this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">291,324 shares of common stock reserved for issuance under the Rallybio Corporation 2021 Employee Stock Purchase Plan, or
the ESPP, which will become effective in connection with this offering. </P></TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except as otherwise noted, all information in this prospectus
assumes or gives effect to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the completion of the Reorganization, including the issuance by the Corporation of an aggregate of 24,999,972 shares of
its common stock and the subsequent distribution to the members of the LLC Entity of those shares to members of the LLC Entity, prior to the completion of this offering, assuming an initial public offering price of $14.00 per share, which is the
midpoint of the price range set forth on the cover page of this prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">no exercise by the underwriters of their option to purchase up to an additional 862,500 shares of our common stock from
us; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">no purchase of shares of our common stock in this offering by current members of the LLC Entity; </P></TD></TR></TABLE>
 <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the filing and effectiveness of our amended and restated certificate of incorporation and the adoption of our amended and
restated bylaws prior to the consummation of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">no issuance of stock options on or after June 30, 2021, under the 2018 Plan or the 2021 Plan. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">10 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SUMMARY FINANCIAL DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You should read the following summary financial data together with the sections titled &#147;Selected Financial Data&#148; and &#147;Management&#146;s Discussion and
Analysis of Financial Condition and Results of Operations&#148; of this prospectus and our financial statements and the related notes included elsewhere in this prospectus. The statements of operations and comprehensive loss data for the years ended
December&nbsp;31, 2020 and 2019 and the balance sheet data as of December&nbsp;31, 2020 and 2019 have been derived from our audited financial statements included elsewhere in this prospectus. The statements of operations and comprehensive loss data
for the three months ended March&nbsp;31, 2021 and 2020 and our balance sheet as of March&nbsp;31, 2021 have been derived from our unaudited financial statements included elsewhere in this prospectus. In the opinion of management, the unaudited
financial data reflect all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of such financial information in those statements. Our historical results are not necessarily indicative of the results that may
be expected in the future. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED</B><br><B>DECEMBER 31, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE MONTHS ENDED<BR>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share amounts) </B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Statement of Operations and Comprehensive Loss Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,642</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,824</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,844</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value of Series A-2 financing right obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,749</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss on investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per common unit, basic and
diluted&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9.95</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average common units outstanding&#151;basic and diluted <SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,659,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,715,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,228,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,968,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net loss per share, basic and diluted
<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma weighted average common stock outstanding, basic and diluted <SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,348,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,195,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>    <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">11 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MARCH 31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTUAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO<BR>FORMA <SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA&nbsp;AS<BR>ADJUSTED <SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Consolidated Balance Sheet Data: </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">127,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">127,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional paid-in-capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total members&#146;/stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(58,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">123,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">195,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>    <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See Note 11 to our audited consolidated financial statements and Note 8 to our unaudited condensed consolidated financial statements included elsewhere in this prospectus for details on the calculation of basic and
diluted net loss per common unit attributable to common unitholders. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2</SUP><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The calculations for the unaudited pro forma net loss per share attributable to common stockholders, basic and diluted, and the unaudited pro forma weighted-average common shares outstanding, basic and diluted, for the
year ended December 31, 2020 and the quarter ended March 31, 2021 give effect to the Reorganization, including the issuance by the Corporation of approximately 24,999,972 shares of its common stock and the subsequent distribution of those shares to
members of the LLC entity, including all preferred units, common units, and incentive units outstanding as of January 1, 2020 or the issuance date of those units, if later, assuming an initial public offering price of $14.00 per share, which is the
midpoint of the price range set forth on the cover page of this prospectus, as if the Reorganization had occurred as of January 1, 2020. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We define working capital as current assets, less current liabilities. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The pro forma balance sheet data gives effect to (i)&nbsp;the Reorganization, including the issuance by the Corporation of an aggregate of 24,999,972 shares of its common stock and the subsequent distribution of those
shares to members of the LLC Entity, prior to the completion of this offering, as if the Reorganization had occurred as of March&nbsp;31, 2021, assuming an initial public offering price of $14.00 per share, which is the midpoint of the price range
set forth on the cover page of this prospectus, and (ii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation and amended and restated bylaws. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The pro forma as adjusted balance sheet data give further effect to our issuance and sale of 5,750,000 shares of our common stock in this offering at an assumed initial public offering price of $14.00 per share, which
is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:8pt; font-family:ARIAL">The pro forma as adjusted information discussed above is illustrative only and will change based on the actual initial public offering price and other
terms of this offering determined at pricing. A $1.00 increase (decrease) in the assumed initial public offering price of $14.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase
(decrease) the pro forma as adjusted amount of each of cash, working capital, total assets and total stockholders&#146; equity (deficit) by approximately $5.3 million, assuming that the number of shares offered by us, as set forth on the cover page
of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase (decrease) of 1,000,000 shares in the number of shares offered by us, as set forth
on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash, working capital, total assets and total stockholders&#146; equity by approximately $13.0 million, assuming no change in the assumed
initial public offering price per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">12 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below together with all of the
other information contained in this prospectus, including our financial statements and related notes appearing at the end of this prospectus and the section of this prospectus titled &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations,&#148; before deciding to invest in our common stock. Some of the following risks and uncertainties are, and will be, exacerbated by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic (including any
resurgences thereof) and any worsening of the global business and economic environment as a result. Negative consequences from these risks could harm our business, prospects, operating results and financial condition or cause the trading price of
our common stock to decline, which could result in the loss of all or part of your investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we
currently believe to be immaterial may also adversely affect our business. See &#147;Special Note Regarding Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related
to Our Financial Position and Need for Additional Capital </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have incurred significant losses since our inception and anticipate that we will continue to
incur losses in the foreseeable future. We have not commercialized any products and have never generated revenue from the commercialization of any product. We are not currently profitable, and we may never achieve or sustain profitability.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical-stage biotechnology company with a limited operating history. As a result, we are not profitable and have incurred significant losses
since our formation. We had net losses of $26.4&nbsp;million and $17.6&nbsp;million for the years ended December&nbsp;31, 2020 and 2019, respectively, and net losses of $13.3 million and $3.9 million for the three months ended March&nbsp;31, 2021
and 2020, respectively. As of March&nbsp;31, 2021, we had an accumulated deficit of $60.3 million. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant
risk that any potential product candidate will fail to gain regulatory approval and become commercially viable. Since inception, we have devoted substantially all of our resources to raising capital, organizing and staffing our company, business
planning, conducting discovery and research activities, acquiring or discovering product candidates, establishing and protecting our intellectual property portfolio, developing and progressing our product candidates and preparing for clinical trials
and establishing arrangements with third parties for the manufacture of our product candidates and component materials, including activities relating to our preclinical development and manufacturing activities for each of our five programs and our
Phase 1/2 clinical trial for RLYB211. We do not have any product candidates approved for sale and have not generated any revenue from product sales. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to
incur significant additional operating losses in the foreseeable future as we advance our programs through preclinical and clinical development, expand our research and development activities, acquire and develop new product candidates, complete
preclinical studies and clinical trials, finance our business development strategy, seek regulatory approval for the commercialization of our product candidates and commercialize our products, if approved. The costs of advancing product candidates
through each clinical phase tend to increase substantially over the duration of the clinical development process. Therefore, the total costs to advance any product candidate to marketing approval in even a single jurisdiction are substantial.
Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to begin generating revenue from the
commercialization of any product candidates or achieve or maintain profitability. Our expenses will increase substantially if and as we: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">file a clinical trial application, or CTA, and initiate a Phase 1 clinical trial for RLYB212, our lead product candidate
for our fetal and neonatal alloimmune thrombocytopenia, or FNAIT, program; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">file a CTA and initiate our clinical trial for RLYB116, and file an investigational new drug application, or IND, or a CTA
for other product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">initiate a natural history alloimmunization study of FNAIT, or our FNAIT Natural History Alloimmunization Study, and other
studies to support our development program and related regulatory submissions for RLYB212; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">continue to develop and conduct clinical trials with respect to RLYB211; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">13 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">seek regulatory approvals for RLYB212, RLYB116 and any other product candidates, as well as for any related companion
diagnostic, if required; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">continue and expand upon our discovery and development joint ventures with Exscientia Limited, or Exscientia;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">continue to discover and develop additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">hire additional clinical, scientific, and commercial personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">add operational, financial, and management personnel, including personnel to support our product development and planned
future commercialization efforts and to support our transition to a public company; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates or technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">maintain, expand, and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">secure a commercial manufacturing source and supply chain capacity sufficient to produce commercial quantities of any
product candidate for which we obtain regulatory approval; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establish a sales, marketing, and distribution infrastructure to commercialize our programs, if approved, and for any
other product candidates for which we may obtain marketing approval. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not know when or whether we will become profitable. Our ability to
generate revenue and become profitable depends upon our ability to successfully complete the development of our product candidates and to obtain the necessary regulatory approvals for their commercialization, which is subject to substantial
additional risks and uncertainties, as described under &#147;&#151; Risks Related to Discovery, Development, Clinical Testing, Manufacturing, and Regulatory Approval.&#148; Each of our product candidates will require additional preclinical and/or
clinical development, regulatory approval in multiple jurisdictions, the securing of manufacturing supply, capacity, distribution channels and expertise, the use of external vendors, the building of a commercial organization, substantial investment
and significant marketing efforts before we generate any revenue from product sales. As a result, we expect to continue to incur net losses and negative cash flows in the foreseeable future. These net losses and negative cash flows have had, and
will continue to have, an adverse effect on our stockholders&#146; equity and working capital. The amount of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. If we are
unable to develop and commercialize one or more product candidates, either alone or through current or future collaborations, or if revenues from any product that receives marketing approval are insufficient, we will not achieve profitability. Even
if we successfully commercialize RLYB212, RLYB116 or any of our other product candidates, we may continue to incur substantial research and development and other expenses to identify and develop other product candidates. Even if we do achieve
profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis or meet outside expectations for our profitability. Our failure to become and remain profitable would decrease the value of our company and could
impair our ability to raise capital, maintain our research and development efforts, expand our business, execute our business plan or continue our operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if this offering is successful, we will require significant additional capital to fund our operations, and if we fail to obtain necessary financing, we may
not be able to complete the development and commercialization of RLYB212, RLYB116 or any additional product candidates we may develop. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to spend
significant amounts of capital to complete the development of, seek regulatory approvals for and, if approved, commercialize RLYB212 and RLYB116. These expenditures will include costs related to our ongoing Phase 1/2 clinical trial for RLYB211. We
expect similar expenditures as we initiate our planned clinical trials for RLYB212 and for RLYB116, and our FNAIT Natural History Alloimmunization Study. In addition, we are obligated to make certain milestone and royalty payments in connection with
achievement of certain development and commercial milestones as well as the sale of resulting products under our agreements with Prophylix AS, or Prophylix, Swedish Orphan Biovitrum AB (Publ), or Sobi, and Affibody AB, or Affibody. We may also spend
significant capital to develop laboratory tests, and if required by the U.S. Food and Drug Administration, or the FDA, or other healthcare agencies, one or more companion diagnostics, to identify patients for inclusion in our clinical trials or who
are likely to respond to our product candidates. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based upon our current operating plan, we believe that the anticipated net proceeds from this offering,
together with our existing cash and cash equivalents as of June 30, 2021, will be sufficient to fund our operating expenses and capital expenditure requirements for the next 24 months. This estimate and our expectation regarding the sufficiency
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">14 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
of the net proceeds from this offering to advance the preclinical and clinical development of RLYB212, RLYB116 and any other product candidates are based on assumptions that may prove to be
wrong, and we could exhaust our available capital resources sooner than we expect, or our clinical trials may be more expensive, time consuming or difficult to design or implement than we currently anticipate. Changing circumstances, including any
unanticipated expenses, could cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control. Because of the numerous risks and
uncertainties, the length of time and scope of activities associated with development of RLYB212, RLYB116 or any product candidate we may develop is highly uncertain, we are unable to estimate the actual amount of funds we will require for
development, approval and any approved marketing and commercialization activities. Our future capital requirements, both near and long-term, will depend on many factors, including, but not limited to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the initiation, progress, timing, costs and results of our clinical trials through all phases of development, including
our ongoing Phase 1/2 clinical trial for RLYB211, the planned clinical trials for RLYB212 and RLYB116 and the development of any other product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the identification, assessment, acquisition and/or development of additional research programs and additional product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the outcome, timing and cost of meeting regulatory requirements established by the FDA, the European Medicines Agency, or
the EMA, and other comparable foreign regulatory authorities, including any additional clinical trials required by the FDA, EMA or other comparable foreign regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the willingness of the FDA, EMA and other comparable foreign regulatory authorities to accept our clinical trial designs,
as well as data from our completed and planned preclinical studies and clinical trials, as the basis for review and approval of RLYB212, RLYB116 and any other product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the progress, timing and costs of the development by us or third parties of companion diagnostics, if required, for
RLYB212 or any other product candidates, including design, manufacturing and regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of filing, prosecuting, and enforcing our patent claims and other intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of defending potential intellectual property disputes, including patent infringement actions brought by third
parties against us; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs associated with potential clinical trial liability or product liability claims, including the costs associated
with obtaining insurance against such claims and with defending against such claims; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the effect of competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to develop and commercialize products that are considered medically and/or financially differentiated to
competitive products by physicians, patients and payers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost and timing of completion of commercial-scale manufacturing activities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of making royalty, milestone or other payments under any future
<FONT STYLE="white-space:nowrap">in-license</FONT> agreements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to maintain our collaboration with Exscientia on favorable terms and establish new collaborations;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the extent to which we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire additional product candidates or
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the severity, duration and impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which may adversely
impact our business; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of establishing sales, marketing and distribution capabilities for our product candidates, if approved;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the initiation, progress and timing of our commercialization of RLYB212 and RLYB116, if approved, or any other product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the availability of third-party coverage and reimbursement for and pricing of any approved products; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs of operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even with the net proceeds from this offering, we will require significant additional capital to advance the development and potential commercialization of our product
candidates, which we may raise through equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. Depending on our business performance, the
economic climate and market conditions, we may be unable to raise additional funds when needed on acceptable terms, or at all. Moreover, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic is impacting the global economy, and the U.S.
economy in particular, with the potential for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">15 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
economic downturn to be severe and prolonged. A severe or prolonged economic downturn as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic could result in a variety of
challenges for our business, including disruptions in the financial markets, which could adversely impact our ability to raise additional capital when needed or on acceptable terms, if at all. If we do not succeed in raising additional funds on
acceptable terms, we may need to significantly delay, scale back or discontinue the development of one or more of our product candidates or the commercialization of any product that may be approved for marketing, and we could be forced to
discontinue operations. In addition, attempting to secure additional financing may divert the time and attention of our management from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and harm
our product candidate development efforts. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in this
offering, restrict our operations or require us to relinquish rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Until such time, if ever, as we generate
significant revenue from product sales, we expect to finance our operations through the sale of equity, debt financings, marketing and distribution arrangements and collaborations, strategic alliances and licensing arrangements or other sources. We
do not currently have any committed external source of funds. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future
operating plans. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent that we raise additional capital through the future sale of equity or convertible debt securities, your ownership interest will be
diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. In addition, debt financing and preferred equity financing, if available, may involve agreements that
include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through debt financing, we may be subject to
covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, and we may need to dedicate a substantial additional portion of any operating cash flows
to the payment of principal and interest on such indebtedness. Any future indebtedness, combined with our other financial obligations, could increase our vulnerability to adverse changes in general economic, industry and market conditions, limit our
flexibility in planning for, or reacting to, changes in our business and the industry and impose a competitive disadvantage compared to our competitors that have less debt or better debt servicing options. If we raise additional funds through
collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, intellectual property, future revenue streams or product candidates or
grant licenses on terms that may not be favorable to us. Furthermore, any capital raising efforts may divert our management from their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may
adversely affect our ability to advance research programs, product development activities or product candidates. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate product candidate
development or future commercialization efforts. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have a limited operating history and no history of commercializing pharmaceutical products, which may
make it difficult to evaluate the prospects for our future viability. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We were formed in January 2018, and our operations to date have been limited to
financing and staffing our company, identifying, evaluating and acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> product candidates and technologies, conducting preclinical studies and our clinical trial for RLYB211 and preclinical
studies for RLYB212 and RLYB116, and developing a pipeline of other preclinical and research programs. We have not yet demonstrated the ability to complete successfully a large-scale, pivotal clinical trial, obtain marketing approval, manufacture a
commercial-scale product, or arrange for a third-party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about our future success or viability may not be
as accurate as they could be if we had a longer operating history or a history of successfully developing, obtaining marketing approval for and commercializing pharmaceutical products. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown
challenges. We will eventually need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition and, as a result, our business may be
adversely affected. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our quarterly and annual financial results may fluctuate, which makes our results difficult to predict and may cause our results to fall short
of expectations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">16 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our financial condition and operating results have varied in the past and will continue to fluctuate from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year</FONT></FONT> in the future due to a variety of factors, many of which
are beyond our control. Factors relating to our business that may contribute to these fluctuations include the following, as well as other factors described elsewhere in this prospectus: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">variations in the level of expense related to the ongoing development of our product candidates or research pipeline;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays or failures in advancement of existing or future product candidates into the clinic or in clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the feasibility of developing, manufacturing and commercializing our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our relationships, and any associated exclusivity terms, with strategic collaborators; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our execution of any additional collaboration, licensing or similar arrangements, and the timing of payments we may make
or receive under existing or future arrangements, or the termination or modification of any such existing or future arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our operation in a net loss position in the foreseeable future; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability, ourselves or with collaborators, to develop a companion diagnostic, if required, and obtain marketing
approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to consistently manufacture our product candidates, including in sufficient quantities for clinical or
commercial purposes; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our dependence on, and the need to attract and retain, key management and other personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developments or disputes concerning patents or other proprietary rights, litigation matters and our ability to obtain and
maintain patent protection for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic
investments or changes in business strategy; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">if any of our product candidates receives regulatory approval, the terms of such approval and market acceptance and demand
for such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">business interruptions such as power outages, strikes, civil unrest, wars, acts of terrorism or natural disasters;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">potential advantages that our competitors and potential competitors may have in developing and commercializing competing
technologies or products, securing funding for or obtaining the rights to critical intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory developments affecting our product candidates or those of our competitors; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to use our net operating loss, or NOL, and income tax credit carryforwards to offset income tax.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Due to these and other factors, the results of any of our prior quarterly or annual periods should not be relied upon as indications of our
future operating performance, and a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparison of our results of operations may not be a meaningful indication of our future performance. In any
particular quarter or quarters, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our ability to use our net operating loss and income tax credit carryforwards to offset future income tax liabilities may be subject to certain limitations.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have incurred substantial NOLs during our history. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset
future taxable income, if any, until such unused losses expire. NOLs generated in taxable years beginning after December&nbsp;31, 2017 are not subject to expiration. Federal NOLs generated in taxable years beginning after December 31, 2017 generally
may not be carried back to prior taxable years except that, under the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, federal NOLs generated in taxable years beginning after December 31, 2017 and before January 1, 2021 may be
carried back to each of the five taxable years preceding the taxable year in which the loss arises. Additionally, the deduction for NOLs arising in taxable years beginning after December 31, 2017 is generally limited to 80% of current year taxable
income, however, as a result of the CARES Act, for taxable years beginning before January 1, 2021, the deductibility of federal NOLs generated in taxable years beginning after December&nbsp;31, 2017 is not so limited. We also have substantial
federal and state research and development and other tax credit carryforwards that expire at various dates. These tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">17 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
In addition, in general, under Sections 382 and 383 of the U.S. Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an &#147;ownership change&#148; is subject to
limitations on its ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and tax credit carryforwards to offset future taxable income. For these purposes, an ownership change generally occurs where the aggregate stock ownership
of one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#146;s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing period. We may
experience such ownership changes in the future as a result of this offering and/or future transactions in our stock, some of which may be outside our control. If we undergo an ownership change in connection with or after this offering, our ability
to use our NOLs and income tax credit carryforwards could be further limited. For these reasons, we may not be able to use a material portion of our NOLs or tax credit carryforwards, even if we attain profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Discovery, Development, Clinical Testing, Manufacturing, and Regulatory Approval </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic in the United States and other countries has resulted in and may further result in
disruptions to our preclinical studies, clinical trials, manufacturing and other business operations, which could adversely affect our business and the market price of our common stock. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ongoing global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic is impacting worldwide economic activity, particularly economic activity in the United
States, and poses the risk that we or our employees, contractors, suppliers, or other partners may be prevented from or delayed in conducting business activities for an indefinite period of time, including due to shutdowns, quarantines and other
public health measures that may be requested or mandated by governmental authorities. The continued prevalence of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and the measures taken by the governments of countries affected could disrupt the
supply chain and the manufacture or shipment of both drug substance and finished drug product for our product candidates for preclinical testing or clinical trials, cause diversion of healthcare resources away from the conduct of preclinical and
clinical trial matters to focus on pandemic concerns, limit travel in a manner that interrupts key trial activities, such as trial site initiations and monitoring, delay regulatory filings with regulatory agencies in affected areas or adversely
affect our ability to obtain or timing to obtain regulatory approvals. These actions have in the past, continue to and could in the future negatively affect our preclinical studies, clinical trials, manufacturing and other business operations,
including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Preclinical studies and clinical trials:</B> The impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> may cause
delays and disruptions to some of our preclinical studies and clinical trials. The response to <FONT STYLE="white-space:nowrap">COVID-19</FONT> by healthcare providers may delay site initiation, may slow down enrollment and make the ongoing
collection of data for patients enrolled in trials more difficult or intermittent. In addition, some participants and clinical investigators may be unable or unwilling to comply with clinical trial protocols. For example, quarantines or other travel
limitations have been implemented in many countries and across the United States that may impede participant movement, affect sponsor access to study sites, and/or interrupt healthcare services, which may negatively impact the execution of clinical
trials. We are initiating a global natural history study for FNAIT in 2021 that requires screening a large number of potential participants, and we could experience delays in screening due to <FONT STYLE="white-space:nowrap">COVID-19.</FONT>
Significant delays or disruptions to our preclinical studies or clinical trials could adversely affect our ability to timely initiate studies, conduct successful studies, generate scientifically robust clinical data, obtain regulatory approvals or
commercialize our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Manufacturing and supply:</B> We have encountered only limited disruptions to our manufacturing and supply chain as a
result of <FONT STYLE="white-space:nowrap">COVID-19</FONT> to date, which have not had a material adverse impact on our business, but significant or prolonged disruptions could materially impact our business, operations or financial results. Even if
our manufacturing operations are not materially disrupted, pandemic-related disruptions in other businesses, such as shipping and logistics companies, could affect the availability of our product candidates for our preclinical studies and clinical
trials. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Operations:</B> In accordance with direction from state and local government authorities to protect the health of our
employees, their families, and our communities, we made several changes to our operations in response to <FONT STYLE="white-space:nowrap">COVID-19.</FONT> This response included performing all office-based work outside of the office. Our increased
reliance on personnel working from home may negatively impact productivity or disrupt, delay or otherwise adversely impact our business. In addition, remote working could increase our cyber security risk. Government authorities could impose further
restrictions, including mandated shutdown of businesses, which may negatively affect our operations. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">18 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Stock Price:</B> The extent and duration of the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic
on our stock price following this offering is uncertain. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may cause our stock price to be more volatile, and our ability to raise capital could be impaired. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Regulatory agencies may redirect resources in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic in a way that would adversely impact our ability
to progress and achieve regulatory approvals. In addition, measures intended to limit <FONT STYLE="white-space:nowrap">in-person</FONT> interactions with regulatory agencies may interfere with our ability to hold required regulatory meetings and
restrict the feedback necessary to advance filings. If global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly
impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are
monitoring the potential impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business and financial statements. To date, we have not incurred impairment losses in the carrying values of our assets as a result of the
pandemic and we are not aware of any specific related event or circumstance that would require us to revise our estimates reflected in our financial statements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
cannot be certain what the overall impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic will be on our business and prospects. The extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic will directly or
indirectly impact our business, results of operations, financial condition and liquidity, including planned and future clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a
result of new information that may emerge concerning <FONT STYLE="white-space:nowrap">COVID-19,</FONT> the actions taken to contain or treat it, including the availability and administration of vaccines, and the duration and intensity of the related
effects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are heavily dependent on the success of RLYB212 and RLYB116, which are in preclinical <FONT STYLE="white-space:nowrap">IND-enabling</FONT>
activities. If we are not able to develop, obtain regulatory approval for, or successfully commercialize our product candidates, or if we experience significant delays in doing so, our business will be materially harmed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our lead programs are in early-stage clinical development or preclinical <FONT STYLE="white-space:nowrap">IND-enabling</FONT> activities, and we do not currently have
any commercial products that generate revenues or any other sources of revenue. To date, we have invested a significant portion of our efforts and financial resources in the development of RLYB211 and RLYB212 for the prevention of FNAIT and the
development of RLYB116. Our future success is substantially dependent on our ability to successfully complete preclinical and clinical development for, obtain regulatory approval for, and successfully commercialize, our product candidates, which may
never occur. We currently have no products that are approved for commercial sale and may never be able to develop a marketable product. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we
submitted a CTA in Germany for RLYB212 in July 2021 and subject to the acceptance of our CTA submission, we expect to initiate a Phase 1 first-in-human trial in Germany in the first quarter of 2022, with proof of concept data from a Phase 1b trial
planned for mid-2022. There is no guarantee that the regulatory authority will accept our CTA submission, and the regulatory authority may require additional information. We could also be required to perform additional studies prior to the
acceptance of our CTA submission. Any delays in the commencement of our Phase 1 trial for RLYB212 could impact our product development timelines, result in increased costs, affect our ability to obtain marketing approval for RLYB212 according to our
plans, and delay commercialization. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate the safety
and efficacy of our investigational product candidates for use in each target indication through lengthy, complex and expensive preclinical studies and clinical trials. Failure can occur at any time during the preclinical study and clinical trial
processes, and, because our product candidates are in an early-stage of development, there is a high risk of failure, and we may never succeed in developing marketable products. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ability to generate product revenue will depend heavily on the successful development and eventual commercialization of our product candidates, which may never
occur. Ongoing and future preclinical studies and clinical trials of our product candidates may not show sufficient safety or efficacy or be of sufficient quality to obtain or maintain regulatory approvals. There can be no assurance that any of our
product candidates, even if approved, will prove to be commercially viable therapeutics. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RLYB212 and RLYB116 are designed for subcutaneous self-administration. The
formulation or physical properties of RLYB212 and RLYB116 may ultimately be determined to be inadequate to support this route of administration. If </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">19 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
subcutaneous administration is not feasible, then we may need to identify additional formulations or routes of administration, which could delay initiation of our clinical trials or
commercialization and result in significant additional costs. Further, alternative formulations and routes of administration may be required to differentiate our product candidates from competitors and/or secure access to support successful
commercialization. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Commercialization of product candidates we may develop will require additional preclinical and clinical development; regulatory and marketing
approval in multiple jurisdictions, including by the FDA and the EMA; obtaining manufacturing supply, capacity and expertise; building of a commercial organization; and significant marketing efforts. The success of our most advanced product
candidates and other product candidates will depend on several factors, including the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">successful and timely initiation of preclinical studies, and successful and timely initiation of, enrollment in, and
completion of our clinical trials with results that support a finding of safety and effectiveness and an acceptable risk-benefit profile of our product candidates in the intended populations within the timeframes we have projected;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory grants of authorization to proceed under INDs or CTAs such that we can commence planned or future clinical
trials of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">receipt of regulatory approvals from applicable regulatory authorities for our product candidates, and if required, in
vitro diagnostic devices including companion diagnostics; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to successfully utilize certain delivery systems, such as <FONT STYLE="white-space:nowrap">pre-filled</FONT>
syringes, or PFSs, <FONT STYLE="white-space:nowrap">pen-injectors</FONT> and/or autoinjectors, for certain of our product candidates and to obtain regulatory approval of any such drug/device combination product; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the outcome, timing, and cost of meeting regulatory requirements, including any post-marketing commitments, established by
the FDA, EMA and other comparable foreign regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing commercially viable arrangements with third-party manufacturers for clinical supply and commercial
manufacturing; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing sales, marketing and distribution capabilities, whether alone or through a collaboration, to support
commercialization of our product candidates, if and when approved; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">acceptance of the product candidates, if and when approved, by patients, the medical community and third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">effectively differentiating and competing with other therapies approved and/or used for the same indications as our
product candidates, particularly RLYB116; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing appropriate prices for any product candidates that receive regulatory approval that reflect the value that
the product candidates offer in the indications for which they are approved; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtaining and maintaining third-party coverage and reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">enforcing and defending intellectual property rights and claims; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">maintaining an acceptable safety profile of the product candidates following approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to commercialize our product
candidates successfully, which would materially harm our business. Due to the uncertain and time-consuming clinical development and regulatory approval process, we may not successfully develop any of our product candidates and may choose to
discontinue the development of any of our product candidates. If we discontinue development of a product candidate, we will not receive anticipated revenues from that product candidate and we may not receive any return on our investment in that
product candidate. We may discontinue a product candidate for clinical reasons if it does not prove to be safe and effective for its targeted indications. During clinical development, companies in our field often need to discontinue the development
of product candidates if such product candidates do not achieve the necessary efficacy at tolerated doses required for patient benefit. In addition, there may be important facts about the safety, efficacy and risk versus benefit of our product
candidates that are not known to us at this time. Any unexpected safety events or our failure to generate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">20 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
sufficient data in our clinical trials to demonstrate efficacy may cause a product candidate to fail clinical development. Furthermore, even if that product candidate meets its safety and
efficacy endpoints, we may discontinue its development for various reasons, such as changes in the competitive environment or the standard of care and the prioritization of our resources. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not be successful in our efforts to identify additional product candidates. Due to our limited resources and access to capital, we must prioritize
development of certain product candidates, the choice of which may prove to be wrong and adversely affect our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An important component of our
strategy is expanding our pipeline through partnering, acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> additional product candidates that target validated biology. We also seek to identify and develop product candidates under our
joint ventures with Exscientia Limited, or Exscientia. If we fail to identify additional potential product candidates, or fail to partner, acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> additional product candidates, our business
could be materially harmed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research programs to develop additional product candidates require substantial technical, financial, and human resources whether or not
they are ultimately successful. Our efforts may initially show promise in identifying potential indications or product candidates, yet fail to yield results for clinical development for several reasons, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the research methodology used may not be successful in identifying potential indications or product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">potential product candidates may, after further study, be shown to have harmful or unexpected adverse effects or other
characteristics that indicate they are unlikely to be effective drugs; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">it may take greater human and financial resources than we possess to identify additional therapeutic opportunities for our
product candidates or to develop suitable potential product candidates through research programs, thereby limiting our ability to develop, diversify, and expand our product portfolio. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because we have limited financial and human resources, we intend to focus initially on research programs and product candidates for a limited set of indications. As a
result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that could have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to
capitalize on viable commercial products or profitable market opportunities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accordingly, there can be no assurance that we will ever be able to identify
additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, which could materially adversely affect our future growth and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Preclinical studies and clinical trials are expensive, time consuming and difficult to design and implement, and involve uncertain outcomes. Any product
candidates that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval. We may incur additional costs or experience delays in completing, or ultimately be unable to complete,
the development and commercialization of our product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before obtaining marketing approval from the FDA, EMA or other comparable regulatory
authorities for the sale of our product candidates, we must complete preclinical studies and extensive clinical trials to demonstrate the safety and efficacy of our product candidates. To initiate clinical trials for any future product candidates,
we must submit the results of preclinical studies to the FDA, EMA or other comparable foreign regulatory authorities, along with other information, including information about chemistry, manufacturing and controls, or CMC, and our proposed clinical
trial protocol, as part of an IND or similar regulatory filing that must be accepted by the FDA, EMA or other applicable regulatory authorities before we may proceed with clinical development. In the event that regulators require us to complete
additional preclinical studies or we are required to satisfy other regulator requests, such as obtaining alignment on the device regulatory pathway for our FNAIT prevention program, the start of our clinical trials may be delayed or prevented. Even
after we receive and incorporate guidance from these regulatory authorities, the FDA, EMA or other regulatory authorities could (i)&nbsp;disagree that we have satisfied their requirements to commence our clinical trial, (ii)&nbsp;change their
position on the acceptability of our data, trial design or the clinical endpoints selected, which may require us to complete additional preclinical studies or clinical trials or (iii)&nbsp;impose stricter requirements for approval than we currently
expect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">21 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may experience delays in initiating and completing any clinical trials that we intend to conduct, and we do not know
whether planned preclinical studies or clinical trials, will begin on time, need to be redesigned, enroll an adequate number of patients on time, or be completed on schedule, or at all. We may experience numerous unforeseen events that could delay
or prevent our ability to complete current clinical trials or initiate and complete new trials, any of which may delay or prevent us from receiving marketing approval or commercializing our product candidates. These events include, but are not
limited to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA, EMA or other comparable foreign regulatory authorities requiring us to submit additional data or imposing other
requirements before permitting us to commence a trial; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays in receiving or denial by regulatory agencies of permission to proceed with our planned clinical trials or any
other clinical trials we may initiate, or placement of a clinical trial on hold; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">negative results from our <FONT STYLE="white-space:nowrap">non-clinical</FONT> trials or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">challenges, delays and cost involved in identifying, recruiting and retaining suitable patients and clinical trial sites
in sufficient numbers to participate in clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays in reaching an agreement on acceptable terms with prospective contract research organizations, or CROs, and
clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays in obtaining Institutional Review Board, or IRB, approval at each site within the United States, or Independent
Ethics Committee, or IEC, approval at sites outside the United States; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays or problems in analyzing data, or the need for additional analysis or data or the need to enroll additional
patients; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure by us, our CROs, trial sites or investigators to adhere to clinical trial, regulatory, legal or contractual
requirements and perform trials in accordance with the FDA&#146;s good clinical practices, or GCP, requirements and trial protocol; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">inadequate quantity or quality of product candidate or other materials necessary to conduct clinical trials, for example
as a result of delays in defining and implementing the manufacturing process for materials used in clinical trials or for the manufacture of larger quantities or other delays or issues arising in the manufacturing of sufficient supply of finished
drug product; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">with respect to RLYB211, our inability to source a sustained, dependable long-term supply, including due to the scarcity
of potential donors who maintain an adequate level of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibodies and because supply will decrease if RLYB211 becomes clinically successful in preventing
FNAIT; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">problems with designing and readiness of in vitro diagnostic devices, including companion diagnostic testing, if required,
and our inability, or that of our collaborators, to develop any required laboratory diagnostic tests or companion diagnostics for RLYB212 or any other product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">lack of adequate funding to continue a clinical trial, including as a result of unanticipated costs or increases in costs
of clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">occurrence of serious adverse events including unexpected serious adverse events, associated with the product candidate or
reports from <FONT STYLE="white-space:nowrap">non-clinical</FONT> or clinical testing of our own or competing therapies that raise safety or efficacy concerns, or delays or failures in addressing patient safety concerns that arise during the course
of a trial; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in regulatory requirements and guidance that require changes to planned or ongoing preclinical and clinical
studies, or the conduct of additional studies; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">difficulties recruiting and retaining employees, consultants or contractors with the required level of expertise.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, disruptions caused by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may increase the likelihood that we encounter
such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs or IECs of the institutions in
which such trials are being conducted, the FDA, EMA or other regulatory authorities, or recommended for termination by a Data and Safety Monitoring Board, or DSMB, for such trial. Such authorities may impose a suspension or termination or recommend
an alteration to clinical trials due to several factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, the identification of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">22 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions. Furthermore, we rely and will rely on
CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and, while we have agreements governing their committed activities, we have limited influence over their actual performance, as described in the section
titled &#147;&#151; Risks Related to Our Dependence on Third Parties.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our lead product candidates, RLYB212 and RLYB116, are still in development and will
require the successful completion of one or more registrational clinical trials before we are prepared to submit a Biologics License Application, or BLA, for regulatory approval by the FDA. We cannot predict with any certainty if or when we might
complete the development of RLYB212 or RLYB116, submit a BLA for regulatory approval or whether any such BLA will be approved by the FDA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Principal investigators
for our clinical trials could serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the
FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of a clinical trial. The FDA may therefore question the integrity of the data
generated at the applicable clinical trial site, and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial
of marketing approval of our product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we experience delays in the completion, or termination, of any clinical trial of our product candidates, the
commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed or prevented. Moreover, any delays in completing our clinical trials will increase our
costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in
the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Any delays to our clinical trials that occur as a result could shorten any period during which we may have
the exclusive right to commercialize our product candidates and our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may
harm our business, financial condition and prospects significantly. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Enrollment and retention of patients in clinical trials is an expensive and
time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, including our focus on rare diseases. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timely completion of clinical trials in
accordance with their protocols depends, among other things, on the speed at which we can recruit eligible patients to participate in testing our product candidates and our ability to enroll a sufficient number of patients who remain in the study
until its conclusion. Clinical trial recruitment delays often result in increased costs, delays in advancing product development, delays in testing the effectiveness of technologies, delays in obtaining regulatory approval or termination of clinical
trials. We may be unable to enroll a sufficient number of patients to complete any of our clinical trials, and even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patient enrollment and retention in clinical trials depends on many factors, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the design of the clinical trial, including the patient eligibility criteria defined in the protocol;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the size and nature of the patient population required for analysis of the trial&#146;s primary endpoints;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the existing body of safety and efficacy data with respect to the product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the proximity of patients to clinical sites; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">clinicians&#146; and patients&#146; perceptions as to the potential advantages of the product candidate being studied in
relation to other available therapies, including any new drugs or medical devices that may be approved for the indications we are investigating; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">competing clinical trials being conducted by other companies or institutions, particularly for RLYB116;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">23 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to obtain and maintain patient consents; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the risk that patients enrolled in clinical trials will drop out of the trials before completion; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">other factors we may not be able to control, such as the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic
that may limit patients, principal investigators or staff, or clinical site availability. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, we may have difficulty identifying and
enrolling patients for our planned clinical trials because the conditions for which we plan to evaluate our current product candidates are rare diseases and we anticipate that there will be limited patient pools from which to draw for clinical
trials. Further, because screening for many of these diseases is not widely adopted, and because it can be difficult to diagnose these diseases in the absence of screening, we may have difficulty finding patients who are eligible to participate in
our studies or trials. For example, participants in clinical trials for RLYB211 and RLYB212 have the rare HPA-1b/b genotype and we may have difficulty identifying participants for these clinical trials. In addition, our clinical trials for RLYB116
will compete with other clinical trials for product candidates that are currently being tested in clinical trials for paroxysmal nocturnal hemoglobinuria, or PNH, and generalized myasthenia gravis, or gMG, and this competition will reduce the number
and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Furthermore, any negative results we may report in clinical
trials of any of our product candidates may make it difficult or impossible to recruit and retain patients in other clinical trials of that same or a similar product candidate. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Outside of the United States, our ability to initiate, enroll and complete a clinical trial successfully is subject to numerous additional risks, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">difficulty in establishing or managing relationships with CROs and physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">different standards for the conduct of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our inability to locate qualified local consultants, physicians and partners; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including
the regulation of pharmaceutical and biotechnology products and treatment. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may not be able to initiate or continue clinical trials required by
the FDA, the EMA or other regulatory authorities if we cannot enroll a sufficient number of eligible patients to participate in the clinical trials. If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as
planned, we may need to delay, limit or terminate ongoing or planned clinical trials. Delays or failures in planned patient enrollment or retention may result in increased costs or program delays, which could have a harmful effect on our ability to
develop our product candidates or could render further development impossible. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Results of preclinical studies, clinical trials or analyses that we may
announce or publish from time to time, may not be indicative of results obtained in later trials, and any interim results we may publish could be different than final results. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The results of preclinical studies, clinical trials or analyses of the results from such trials, may not be predictive of the results of later clinical trials. Product
candidates in later clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and prior clinical trials or having shown promising results based on analyses of data from earlier
trials. Late-stage clinical trials may include a larger number of patients and could differ in other significant ways from early-stage clinical trials, including changes to inclusion and exclusion criteria, patient population, efficacy endpoints,
dosing regimen and statistical design. Our Phase 1/2 clinical trial for RLYB211 is single blinded, making it difficult to predict how rapid platelet clearance will lead to prevention of alloimmunization in pregnant women at higher risk for FNAIT and
whether any favorable results that we may observe in such trial will be repeated in larger and more advanced clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in later-stage clinical trials
due to lack of efficacy or adverse safety profiles, notwithstanding earlier promising results. In addition, conclusions based on promising data from analyses of clinical results, such as the prospective and post hoc analysis of results may be shown
to be incorrect in subsequent clinical trials that have <FONT STYLE="white-space:nowrap">pre-specified</FONT> end points or may not be considered adequate by regulatory authorities. We believe data from our Phase 1/2 clinical trial of RLYB211 has
demonstrated proof of concept of our proposed mechanism of action and supports advancing RLYB212 into clinical trials, however, we cannot guarantee that clinical trial results will be similar for RLYB212. Even if we complete later clinical trials as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">24 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
planned, we cannot be certain that their results will support the safety and efficacy requirements sufficient to obtain regulatory approval, and, as a result, our clinical development plans may
be materially harmed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, interim, <FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> and preliminary data from our clinical trials that we
announce or publish may change as more patient data become available or as additional analyses are conducted. The data obtained in such clinical trial are subject to additional audit and verification procedures and following such procedures, such
interim data could be materially different from the final data. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Any product candidates that we develop or the administration thereof, may cause serious
adverse events or undesirable side effects, which may halt their clinical development, delay or prevent marketing approval, or, if approved, require them to be taken off the market, include safety warnings, or otherwise limit their sales.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Adverse events or undesirable side effects caused by any product candidates we develop could cause us or regulatory authorities or IRBs, IECs or DSMBs,
where applicable, to interrupt, delay, or halt clinical trials and, if we seek approval of any such product candidate, could result in a more restrictive label, imposition of a Risk Evaluation and Mitigation Strategy, or REMS, program by the FDA or
the delay or denial of regulatory approval by the FDA, EMA or other comparable foreign regulatory authorities. Additionally, the administration process or related procedures associated with our product candidates also may cause adverse side effects.
Even if we determine that serious adverse events are unrelated to study treatment, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Results of any clinical trial we conduct could reveal a
high and unacceptable severity and prevalence of side effects. For example, complement inhibitors have, by design, immunosuppressive effects and, in some cases, may be administered to patients with significantly compromised health. As a result,
administration of RLYB116 could make patients more susceptible to infection. The chronic dosing of patients with RLYB116 could lead to an immune response that causes adverse reactions or impairs the activity and/or efficacy. Patients may develop an
allergic reaction to the drug and/or develop antibodies directed at RLYB116, or may require immunization with a meningococcal vaccine and prophylactic antibiotics. An immune response that causes adverse reactions or impairs the activity of RLYB116
could cause a delay in or termination of our development plans. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Some potential therapeutics that initially showed therapeutic promise in early-stage trials have
later been found to cause side effects that prevented their further development. In addition, side effects could affect patient recruitment or the ability of enrolled patients to complete a trial or result in potential clinical trial or product
liability claims. Inadequate training or failures by clinical trial personnel in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Furthermore, clinical trials by their nature
utilize a sample of the potential patient population. With a limited number of subjects and limited duration of exposure, rare and severe side effects of our product candidates or those of our competitors may only be uncovered when a significantly
larger number of patients have been exposed to the drug. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we or others later identify undesirable side effects caused by any product candidate that we develop
after the product is approved, several negative consequences could result, which could materially harm our business, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory authorities may suspend or withdraw approvals of such product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory authorities may require additional warnings on the label, limit the approved use of such product candidate, or
otherwise restrict distribution or marketing such as through requiring adoption of a REMS program; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may be required to conduct additional clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we could be sued and held liable for harm caused to patients; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot predict whether our product candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on
preclinical studies or early-stage clinical trials. Even if the side effects do not preclude the drug from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its
tolerability versus other therapies. Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly harm our business, results of operations, and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">25 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The regulatory approval processes of the FDA, EMA and comparable foreign regulatory authorities are lengthy, time-
consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for RLYB212, RLYB116 or any of our other product candidates, our business will be substantially harmed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, we are not permitted to market a product candidate until we receive approval of a BLA or a New Drug Application, or NDA, from the FDA. The process
of obtaining BLA and NDA approval is expensive, often takes many years and can vary substantially based upon the type, complexity and novelty of the products involved. Approval policies or regulations may change, and the FDA and other regulatory
authorities have substantial discretion in the approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. In addition, the FDA may require post-approval clinical trials or studies as a condition
of approval, which also may be costly. The FDA approval for a limited indication or approval with required warning language, such as a boxed warning, could significantly impact our ability to successfully market our product candidates. The FDA also
may require adoption of a REMS requiring prescriber training, post-market registries, or otherwise restricting the marketing and dissemination of these products. The FDA may inform us that an approved device, including a companion diagnostic, is
required to obtain marketing approval of RLYB212. Companion diagnostics are subject to regulation as medical devices and must be separately approved for marketing by the FDA. Certain of our product candidates will rely on delivery systems, such as
PFSs, <FONT STYLE="white-space:nowrap">pen-injectors</FONT> and/or autoinjectors, and may ultimately be regulated as a drug/device combination product. Although the FDA and similar foreign regulatory agencies have systems in place for the review and
approval of combination products, we may experience delays in the development and commercialization of our product candidates due to regulatory timing constraints and uncertainties in the product development and approval process. Despite the time
and expense invested in the clinical development of product candidates, regulatory approval is never guaranteed for our product candidates or a companion diagnostic, if required. Assuming successful clinical development, we intend to seek product
approvals in countries outside the United States, including in Europe. As a result, we would be subject to regulation by the EMA, as well as the other regulatory agencies in these countries. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Of the large number of drugs in development, only a small percentage successfully complete the regulatory approval processes and are commercialized. This lengthy
approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market our product candidates and we may be forced to abandon our development efforts for our product
candidate, which would significantly harm our business, results of operations, and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The time required to obtain approval by the FDA, EMA and other
comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors. In addition, approval policies, regulations, or the type and amount of
clinical data necessary to gain approval may change during a product candidate&#146;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that we will never
obtain regulatory approval for any product candidate. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we must
demonstrate to the satisfaction of the FDA, EMA or other comparable foreign regulatory authority, that such product candidates are safe and effective for their intended uses. Data obtained from preclinical studies and clinical trials are susceptible
to varying interpretations, and regulatory authorities may not interpret our data as favorably as we do, which may further delay, limit, or prevent development efforts, clinical trials, or marketing approval. Even if we believe the preclinical or
clinical data for our product candidates are sufficient to support approval, such data may not be considered sufficient to support approval by the FDA, EMA and other comparable regulatory authorities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For example, we have proposed to use real-world data from our FNAIT Natural History Alloimmunization Study to support our development program and related regulatory
submissions for RLYB212. Specifically, the natural history study data would assist us in assessing the frequency of women at higher risk of FNAIT among women of different racial and ethnic characteristics and the occurrence of <FONT
STYLE="white-space:nowrap">HPA-1a</FONT> alloimmunization in these women. The natural history studies and other real-world evidence we may submit to support applications for marketing approval may not be accepted by the FDA, EMA, or other comparable
foreign regulatory authorities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">26 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA, EMA or other comparable foreign regulatory authority can delay, limit, or deny approval of RLYB212, RLYB116 or
any of our other product candidates that we develop or require us to conduct additional preclinical or clinical testing or abandon a program for many reasons, including, but not limited to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA, EMA or other comparable foreign regulatory authorities may disagree with the design or implementation of our
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may be unable to demonstrate to the satisfaction of the FDA, EMA or other comparable foreign regulatory authorities
that our product candidate is safe and effective for its proposed indication; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals
using drugs similar to our product candidates, or other products containing an active ingredient in our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">negative or ambiguous results from our clinical trials or results that may not meet the level of statistical significance
required by the FDA, EMA or other comparable foreign regulatory authorities for approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety and efficacy
in the full population for which we seek approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA, EMA or other comparable foreign regulatory authorities may not accept clinical data from trials which are
conducted at clinical facilities or in countries where the standard of care is potentially different from that of the United States or the applicable foreign jurisdiction; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may be unable to demonstrate that our product candidate&#146;s clinical and other benefits outweigh its safety risks;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA, EMA or other comparable foreign regulatory authorities may disagree with our interpretation of data from
preclinical studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the data collected from clinical trials of our product candidates may not be acceptable or sufficient to support the
submission of a BLA or NDA or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA&#146;s or the applicable foreign regulatory authority&#146;s disagreement regarding the formulation, the labeling,
and/or the specifications of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA, EMA, or other comparable foreign regulatory authorities may require us to obtain clearance or approval of a
companion diagnostic test; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">additional time may be required to obtain regulatory approval for our product candidates because they are combination
products; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA, EMA or other comparable foreign regulatory authorities may fail to approve or find deficiencies with the
manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the approval policies or regulations of the FDA, EMA or other comparable foreign regulatory authorities may significantly
change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have never obtained marketing approval for a product candidate. It
is possible that the FDA may refuse to accept for substantive review any BLAs or NDAs that we submit for our product candidates or may conclude after review of our data that our applications are insufficient to obtain marketing approval of our
product candidates. If the FDA does not accept or approve our BLAs or NDAs for our product candidates, it may require that we conduct additional clinical, preclinical, or manufacturing validation studies and submit that data before it will
reconsider our applications. Depending on the extent of these or any other <FONT STYLE="white-space:nowrap">FDA-required</FONT> studies, approval of any BLA or NDA that we submit may be delayed or prevented, or may require us to expend more
resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve our BLA or NDA. Any delay in obtaining, or an inability to obtain, marketing approvals
would prevent us from commercializing our product candidates, generating revenues, and achieving and sustaining profitability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">27 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our product candidates target rare diseases and conditions, and the market opportunities for RLYB212 and RLYB116, if
approved, may be smaller than we anticipate. As a result, our commercial opportunity may be limited and because the target populations of our product candidates are for rare diseases, we must be able to successfully identify patients and capture a
significant market share to achieve profitability and growth. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our product candidates target rare diseases and conditions. We are developing RLYB212 for the
potential prevention of FNAIT, and we estimate that each year greater than 22,000 pregnancies are at high risk for FNAIT in the United States, Canada, United Kingdom, other major European countries and Australia, based on the presence of HLA
DRB3*01:01 positive and <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negative antibody in mothers and <FONT STYLE="white-space:nowrap">HPA-1a</FONT> positive in the fetus. With respect to RLYB116, we estimate that there are approximately 4,700
patients with PNH and up to 60,000 patients with gMG in the United States. Our projections of the number of eligible patients are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific
literature, population statistics and market research, and may prove to be incorrect. Further, new sources may reveal a change in the estimated number of eligible patients, and the number of patients may turn out to be lower than expected.
Additionally, the potentially addressable patient population for our current programs or future product candidates may be limited or may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to
identify or gain access to. For example, even if we obtain FDA approval for RLYB212 or RLYB116, the drug may be approved for a target population that is more limited than what we currently anticipate. Furthermore, even if we obtain significant
market share for any product candidate, if approved, the potential target populations for our product candidates are for rare diseases, and we may never achieve profitability. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, in many cases there are either no or limited screening or diagnostic tests for the indications our product candidates are being developed to potentially treat.
For example, the successful prevention of FNAIT in mothers at risk for developing this rare disorder will require identifying expectant mothers who are HPA-1 negative and HLA DRB3*01:01 positive and HPA-1a positive in the fetus. In collaboration
with partners, we may develop screening and diagnostics tests to help us to identify individuals at risk, and the FDA, EMA or other comparable foreign regulatory authorities may require us to do so. The lack of screening and diagnostic tests,
coupled with the fact that there is frequently limited awareness among certain health care providers concerning the rare diseases we may seek to treat, often means that a proper diagnosis can, and frequently does, take years to identify (or an
appropriate diagnosis may never be made for certain patients). As a result, even if one of our product candidates is approved for commercial sale, we may not be able to grow our revenues due to difficulty in identifying eligible patients. There can
be no guarantee that any of our programs will be effective at identifying patients that will benefit from our product candidates, and even if we can identify patients that our product candidates can help, the number of patients that our product
candidates may ultimately treat may turn out to be lower than we expect, they may not be otherwise amenable to treatment with our product candidates, or new patients may become increasingly difficult to identify, all of which may adversely affect
our ability to grow and generate revenue and adversely affect our results of operations and our business. In addition, even in instances where we are able to expand the number of patients being treated, the number may be offset by the number of
patients that discontinue use of the applicable product in a given period resulting in a net loss of patients and potentially decreased revenue. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The FDA, EMA
or other comparable foreign regulatory authorities could require the clearance or approval of an in vitro diagnostic or companion diagnostic device as a condition of approval for any product candidate that requires or would commercially benefit from
such tests. Failure to successfully validate, develop and obtain regulatory clearance or approval for companion diagnostics on a timely basis or at all could harm our drug development strategy and we may not realize the commercial potential of any
such product candidate. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If safe and effective use of RLYB212 or any of our other product candidates depends on an in vitro diagnostic, then the FDA
generally will require approval or clearance of that test, known as a companion diagnostic, at the same time that the FDA approves our product candidates. The process of development and approval of such diagnostic is time consuming and costly.
Companion diagnostics, which provide information that is essential for the safe and effective use of a corresponding therapeutic product, are subject to regulation by the FDA, EMA and other comparable foreign regulatory authorities as medical
devices and require separate regulatory approval from therapeutic approval prior to commercialization. The FDA previously has required in vitro diagnostic tests intended to select the patients who will respond to a product candidate to obtain <FONT
STYLE="white-space:nowrap">pre-market</FONT> approval, or PMA, simultaneously with approval of the therapeutic candidate. The PMA process, including the gathering of preclinical and clinical data and the submission and review by the FDA, can take
several years or longer. It involves a rigorous <FONT STYLE="white-space:nowrap">pre-market</FONT> review during which the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">28 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
applicant must prepare and provide FDA with reasonable assurance of the device&#146;s safety and effectiveness and information about the device and its components regarding, among other things,
device design, manufacturing, and labeling. After a device is placed on the market, it remains subject to significant regulatory requirements, including requirements governing development, testing, manufacturing, distribution, marketing, promotion,
labeling, import, export, record-keeping, and adverse event reporting. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Given our limited experience in developing and commercializing in vitro diagnostic devices,
including companion diagnostic tests, we do not plan to develop such tests internally and thus will be dependent on the sustained cooperation and effort of third-party collaborators in developing and obtaining approval for these in vitro diagnostic
tests. We may not be able to enter into arrangements with a provider to develop screening and/or diagnostic tests for use in connection with a registrational trial for RLYB212 or for commercialization of RLYB212, or do so on commercially reasonable
terms, which could adversely affect and/or delay the development or commercialization of RLYB212. We and our future collaborators may encounter difficulties in developing and obtaining approval for the such tests, including issues relating to
selectivity/specificity, analytical validation, reproducibility, or clinical validation. Any delay or failure by our collaborators to develop or obtain regulatory approval of in vitro diagnostic tests could delay or prevent approval of RLYB212 or
any of our other product candidates. In addition, we, our collaborators or third parties may encounter production difficulties that could constrain the supply of such tests, and both they and we may have difficulties gaining acceptance of the use of
such tests by physicians. We believe that adoption of screening and treatment into clinical practice guidelines is important for market access, third-party payer reimbursement, utilization in medical practice and commercial success. Both our
collaborators and we may have difficulty gaining acceptance of such screening and/or diagnostic tests into clinical practice guidelines. If such tests fail to gain market acceptance, it would have an adverse effect on our ability to derive revenues
from sales, if any, of RLYB212 if it is approved for commercial sale, or any other approved products that require an in vitro diagnostic test. In addition, any collaborator or third-party with whom we contract may decide not to commercialize or to
discontinue selling or manufacturing the test that we anticipate using in connection with development and commercialization of our product candidates, or our relationship with such collaborator or third-party may otherwise terminate. We may not be
able to enter into arrangements with another provider to obtain supplies of an alternative in vitro diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms,
which could adversely affect and/or delay the development or commercialization of our product candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We face significant competition from biotechnology
and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The biotechnology and pharmaceutical industries are
highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to acquire, develop, and obtain marketing approval for new products on a cost-effective basis and to market them
successfully. If a product candidate we develop is approved, we will face intense competition. There are many public and private biopharmaceutical companies, universities, government agencies and other research organizations actively engaged in the
research and development of products that may be like our product candidates or address similar markets. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated
among a smaller number of our competitors. These competitors also compete with us in establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our
programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. In addition, the number of companies seeking to develop and commercialize
products and therapies competing with our product candidates is likely to increase. However, we seek to build our portfolio with key differentiating attributes to provide a competitive advantage in the markets we target. We believe RLYB212 could be
a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antibody for the prevention of FNAIT, and no direct mechanistic based clinical competition currently exists. Our second product candidate, RLYB116 faces
competition from a number of companies for the treatment of patients with PNH and gMG, including Soliris and Ultomiris marketed by Alexion Pharmaceuticals, Inc., or Alexion. If we successfully develop and, if approved, commercialize RLYB116, this
therapy may compete, or potentially be used in conjunction, with currently marketed treatments, including Soliris and Ultomiris, and any new therapies that may become available in the future. See &#147;Business&#151;Competition.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">29 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Competition could render any product candidate we develop obsolete, less competitive, or uneconomical. In addition,
product candidates developed by our competitors may prove to be more safe or more effective than our product candidates. Our competitors may, among other things: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">have significantly greater name recognition and financial, manufacturing, marketing, product development, technical,
commercial infrastructure, and human resources than we do; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">more effectively recruit and retain qualified scientific and management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">more effectively establish clinical trial sites and patient registration; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">develop and commercialize products that are safer, more effective, less expensive, more convenient, or easier to
administer, or have fewer or less severe side effects; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtain quicker regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">better protect their patents and intellectual property or acquire technologies that are complementary to, or necessary
for, our programs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">implement more effective approaches to sales, marketing, pricing, coverage, market access, and reimbursement; or
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">form more advantageous strategic alliances or collaborations. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are not able to effectively compete for any of the foregoing reasons, our business will be materially harmed. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Disruptions in the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key
leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and
retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes and other events that may otherwise affect the FDA&#146;s ability to perform routine functions. Average review times at the agency have
fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed or approved by necessary government agencies, which would
adversely affect our business. For example, over the last several years, including for 35 days beginning on December&nbsp;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to
furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse
effect on our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, on March&nbsp;10, 2020, the FDA announced its intention to
postpone most inspections of foreign manufacturing facilities, and on March&nbsp;18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July&nbsp;10, 2020, the FDA announced
its intention to resume certain <FONT STYLE="white-space:nowrap">on-site</FONT> inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the
categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. In April 2021, the FDA released additional guidance on its handling of inspections
during the COVID-19 pandemic, addressing situations where FDA may request to conduct a remote interactive evaluation. While participation in a remote interactive evaluation is voluntary, declining FDA&#146;s guidance could impede the FDA&#146;s
ability to make a timely regulatory decision (e.g., regarding adequacy of a clinical trial used in support of a pending application or adequacy of a drug manufacturing operation described in the application). Regulatory authorities outside the
United States may also impose similar restrictions or other policy measures in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the
FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory
submissions, which could have a material adverse effect on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">30 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if we obtain FDA approval for a product candidate in the United States, we or our current or future
collaborators may never obtain approval for or commercialize the product candidate in any other jurisdiction, which would limit our ability to realize its full market potential. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In order to market any product in a particular jurisdiction, we or our current or future collaborators must establish and comply with numerous and varying regulatory
requirements regarding safety and efficacy on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. Approval by the FDA in the United States does not ensure approval by comparable regulatory
authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our or our collaborators&#146; ability to obtain approval elsewhere. In addition, clinical trials conducted in one
country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign
regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time- consuming. Regulatory requirements can vary widely from country to country and
could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory
approval in international markets. If we or our collaborators fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our
target market will be reduced and we will be unable to realize the full market potential of any product we develop. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if we obtain regulatory approval for
any of our product candidates, we will still face extensive and ongoing regulatory requirements and obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to
comply with regulatory requirements or experience unanticipated problems with any product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any product candidate for which we obtain marketing
approval, along with the manufacturing processes, post-approval preclinical and clinical testing, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, and advertising and promotional activities for such
product, among other things, will be subject to extensive and ongoing requirements of the FDA and other regulatory authorities. These requirements include submissions of safety and other post- marketing information and reports, establishment
registration and drug listing requirements, continued compliance with current Good Manufacturing Practice, or cGMP, requirements regarding the distribution of samples to physicians and recordkeeping and Good Laboratory Practice, or GLP, and GCP
requirements for <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and any clinical trials that we conduct post-approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may also require
costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. Additionally, the FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the
approved indications and in a manner that is consistent with the provisions of the approved labeling. If we market our products for uses beyond their approved indications or otherwise inconsistent with the
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> labeling, we may be subject to enforcement action for <FONT STYLE="white-space:nowrap">off-label</FONT> marketing by the FDA and other federal and state enforcement agencies, including the
Department of Justice. Violation of the Federal Food, Drug, and Cosmetic Act, or FDCA, and other statutes, including the False Claims Act, and equivalent legislation in other countries relating to the promotion and advertising of prescription
products may also lead to investigations or allegations of violations of federal and state and other countries&#146; health care fraud and abuse laws and state consumer protection laws. Even if it is later determined we were not in violation of
these laws, we may be faced with negative publicity, incur significant expenses defending our actions and have to divert significant management resources from other matters. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers, or manufacturing processes or failure to comply
with regulatory requirements, may yield various results, including, but not limited to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restrictions on manufacturing such products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restrictions in the labeling or on the marketing of products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restrictions on product distribution or use; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">31 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">requirements to conduct post-marketing studies or additional post-marketing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">issuance of warning letters or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">refusal to approve pending applications or supplements to approved applications that we submit, or delays in such
approvals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recalls or market withdrawals of products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">fines, restitution, or disgorgement of profits or revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">suspension or termination of ongoing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">suspension or withdrawal of marketing approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">refusal to permit the import or export of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">product seizure; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">injunctions, consent decrees, or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we obtain FDA approval for RLYB212 or RLYB116, safety risks not identified in our prior clinical trials may first appear after we obtain approval and commercialize
these product candidates. Any new post-marketing adverse events may significantly impact our ability to market the drugs and may require that we recall and discontinue commercialization of the products. Furthermore, if any confirmatory
post-marketing trial fails to confirm the clinical profile or clinical benefits of RLYB212 or RLYB116, the FDA may withdraw its approval, which would materially harm our business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative or executive action, either
in the United States or abroad. Further, the FDA&#146;s, EMA&#146;s and other comparable regulatory authorities&#146; policies may change, and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval
of a product candidate or increase the costs and regulatory burden of commercialization. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain
regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition, and results of operations. Furthermore, <FONT
STYLE="white-space:nowrap">non-compliance</FONT> by us or any collaborator with regulatory requirements, including safety monitoring or pharmacovigilance, may also result in significant financial penalties, which would adversely affect our business.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may seek Fast Track designation, Breakthrough Therapy designation, or PRIME designation for our product candidates, but we might not receive any such
designation, and even if we do, such designation may not actually lead to a faster development or regulatory review or approval process. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a drug is
intended for the treatment of a serious or life-threatening condition, and <FONT STYLE="white-space:nowrap">non-clinical</FONT> or clinical data demonstrate the potential to address an unmet medical need for this condition, the product candidate may
qualify for FDA Fast Track designation, for which sponsors must apply. Sponsors of fast track products may have more frequent interactions with the FDA, and, in some circumstances, the FDA may initiate review of sections of a fast track
product&#146;s application before the application is complete. We may submit an application for Fast Track designation for RLYB212 and RLYB116. The FDA has broad discretion whether to grant this designation, and we may not receive it. Moreover, even
if we receive Fast Track designation, Fast Track designation does not ensure that we will receive marketing approval or that approval will be granted within any particular time frame. We may not experience a faster development or regulatory review
or approval process with Fast Track designation compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development
program. Fast Track designation alone does not guarantee qualification for the FDA&#146;s priority review procedures. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also may seek a Breakthrough Therapy
designation for RLYB212 or other product candidates if future results support such designation. A Breakthrough Therapy is defined as a drug (including biologic) that is intended, alone or in combination with one or more other drugs, to treat a
serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in
clinical development. Sponsors of products that have been designated as breakthrough therapies are eligible to receive more intensive FDA guidance on establishing an efficient drug development program, an organization commitment involving senior
managers, and may be eligible </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">32 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
for rolling review. Drugs designated as breakthrough therapies by the FDA may also be eligible for other expedited review programs, including accelerated approval and priority review, if
supported by clinical data at the time the BLA or NDA is submitted to the FDA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Designation as a Breakthrough Therapy is within the discretion of the FDA.
Accordingly, even if we believe that RLYB212 meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. Even if we receive Breakthrough Therapy designation, the receipt of
such designation may not result in a faster development or regulatory review or approval process compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if
RLYB212 qualifies as a Breakthrough Therapy, the FDA may later decide that RLYB212 no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the European Union, or EU, we may seek PRIME designation for some of our product candidates in the future. PRIME is a voluntary program aimed at enhancing the
EMA&#146;s role to reinforce scientific and regulatory support in order to optimize development and enable accelerated assessment of new medicines that are of major public health interest with the potential to address unmet medical needs. The
program focuses on medicines that target conditions for which there exists no satisfactory method of treatment in the EU or even if such a method exists, it may offer a major therapeutic advantage over existing treatments. PRIME is limited to
medicines under development and not authorized in the EU and the applicant intends to apply for an initial marketing authorization application through the centralized procedure. To be accepted for PRIME, a product candidate must meet the eligibility
criteria in respect of its major public health interest and therapeutic innovation based on information that can substantiate the claims. The benefits of a PRIME designation include the appointment of a CHMP rapporteur to provide continued support
and help to build knowledge ahead of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review, meaning reduction in the review time for an
opinion on approvability to be issued earlier in the application process. PRIME enables an applicant to request parallel EMA scientific advice and health technology assessment advice to facilitate timely market access. Even if we receive PRIME
designation for any of our product candidates, the designation may not result in a materially faster development process, review or approval compared to conventional EMA procedures. Further, obtaining PRIME designation does not assure or increase
the likelihood of EMA&#146;s grant of a marketing authorization. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be unsuccessful in obtaining or may be unable to maintain the benefits associated
with orphan drug designation, including the potential for market exclusivity. If our competitors are able to obtain orphan drug exclusivity for products that constitute the same drug and treat the same indications as RLYB212 and RLYB116 or any of
our other product candidates, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Regulatory authorities in some jurisdictions, including the United States and the EU. may designate drugs for relatively small patient populations as orphan drugs.
Under the U.S. Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United
States, or a patient population of more than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the EU, the EMA&#146;s Committee for Orphan
Medicinal Products evaluates, and the European Commission grants, an orphan drug designation principally to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically
debilitating condition affecting not more than five in 10,000 persons in the EU. In addition, the product under consideration is indicated for a condition where there exists no satisfactory method of diagnosis, prevention or treatment authorized in
the EU or, if such method exists, that the medicinal product will be of significant benefit to those affected by that condition. Each of the FDA and the European Commission has granted orphan drug designation for RLYB211 and RLYB212 for the
treatment of FNAIT. We may seek orphan drug designation in the United States and the EU for our other product candidates but may be unsuccessful in doing so. There can be no assurance that the FDA or the EMA&#146;s Committee for Orphan Medicinal
Products will consider orphan designation for any indication for which we apply or <FONT STYLE="white-space:nowrap">re-apply,</FONT> or that we will be able to maintain such designation. In the United States, orphan drug designation entitles a party
to financial incentives such as opportunities for grant funding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">33 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
towards clinical trial costs, tax advantages and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. Orphan drug designation neither shortens the development time or regulatory review time
of a drug nor gives the drug any advantage in the regulatory review or approval process. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a product candidate with an orphan drug designation subsequently
receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same
drug or biologic for the same orphan designation for that time period, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient
product quantity. In the United States, the exclusivity period is seven years. The applicable exclusivity period is ten years in Europe, but such exclusivity period can be reduced to six years in Europe if a product no longer meets the criteria for
orphan designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for
designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. Similarly, in the EU, the market exclusivity can be broken if the
holder of the marketing authorization for the original orphan medicinal product is unable to supply sufficient quantities of the medicinal product. In addition, in both the United States and EU, if a different drug is subsequently approved for
marketing for the same or a similar indication as any of our product candidates that receive marketing approval, we may face increased competition and lose market share regardless of orphan drug exclusivity, which only protects against approval of
the &#147;same&#148; drug for the same indication. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may seek accelerated approval by the FDA for one or more of our product candidates. Accelerated
approval by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing
approval. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may in the future seek an accelerated approval for our one or more of our product candidates. Under the accelerated approval program, the FDA
may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a
surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. As a condition of approval, the FDA requires that a sponsor of a product receiving accelerated approval perform a post-marketing confirmatory
clinical trial or trials. In addition, the FDA currently requires as a condition for accelerated approval the <FONT STYLE="white-space:nowrap">pre-submission</FONT> of promotional materials to FDA for review. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to seeking accelerated approval for any of our product candidates, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and
receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit an NDA for accelerated approval or any other form of expedited development, review or approval.
Furthermore, if we decide to submit an application for accelerated approval there can be no assurance that such submission or application will be accepted or that the FDA will determine that the product candidate is eligible for or grant accelerated
approval. A failure to obtain any planned accelerated approval for our product candidates would result in a longer time period to commercialization of our product candidates, if approved, could increase the cost of development of our product
candidates and could harm our competitive position in the marketplace. If we receive accelerated approval for any of our product candidates, the FDA may withdraw accelerated approval if, among other things, a confirmatory trial required to verify
the predicted clinical benefit of the product fails to verify such benefit or if such trial is not conducted with due diligence. Withdrawal of any accelerated approval could substantially harm our business. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Although RLYB211 and RLYB212 have received FDA designation as rare pediatric disease drug products, any marketing application we submit for these products may not
qualify for issuance of a rare pediatric disease priority review voucher. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, RLYB211 and RLYB212 have received designation from the FDA
as rare pediatric disease drug products. Receipt of rare pediatric disease designation is a prerequisite to qualifying for receipt of a rare pediatric disease priority review voucher upon approval of a marketing application for the rare pediatric
disease drug product. The priority review voucher may be used to obtain priority review of a future marketing application that would not otherwise qualify to receive priority review. Priority review shortens the FDA&#146;s goal for taking action on
a marketing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">34 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
application from ten months to six months for an original BLA or NDA from the date of filing. As an alternative to using the priority review voucher to obtain priority review of one of its own
marketing applications, the sponsor of a rare pediatric disease drug product receiving a priority review voucher may also sell or otherwise transfer the voucher to another company. The voucher may be further transferred any number of times before
the voucher is used, as long as the sponsor making the transfer has not yet submitted an application relying on the priority review voucher. The FDA may also revoke any rare pediatric disease priority review voucher if the rare pediatric disease
product for which the voucher was awarded is not marketed in the United States within one year following the date of approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is no guarantee that, if we
ever submit and obtain approval for RLYB211 or RLYB212 or any other product candidate for which we may obtain rare pediatric disease designation in the future, we will receive a rare pediatric disease priority review voucher. In addition to
receiving rare pediatric disease designation, in order to receive a rare pediatric disease priority review voucher, the NDA or BLA must be granted priority review, rely on clinical data derived from studies examining a pediatric population and
dosages of the drug intended for that population, not seek approval for a different adult indication in the original rare pediatric disease product application and be for a drug that does not include a previously approved active ingredient. Under
current statutory sunset provisions, even if a marketing application meets all of these requirements, FDA may only award a voucher prior to September&nbsp;30, 2026 and only if the approved product received rare pediatric disease drug product
designation prior to September&nbsp;30, 2024. We cannot be certain that we will receive approval for any of our rare pediatric disease designated products prior to the statutory sunset date, if ever. Moreover, even if we believe that our marketing
application meets the other requirements to be eligible to receive a priority review voucher upon approval, FDA may disagree. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The successful
commercialization of any product candidate we develop will depend in part on the extent to which regulatory authorities and private health insurers establish coverage and reimbursement. Failure to obtain or maintain coverage and reimbursement for
our product candidates, if approved, could limit our or our collaborators&#146; ability to market those products and decrease our or our collaborators&#146; ability to generate revenue. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ability to obtain coverage and reimbursement for any product candidates by governmental healthcare programs, such as Medicare and Medicaid, private health insurers,
and other third-party payors is essential for most patients to be able to afford prescription medications. Our ability to achieve acceptable levels of coverage and reimbursement for products or procedures using our products by regulatory
authorities, private health insurers and other third-party payors will therefore have an effect on our ability to successfully commercialize any product candidates we develop. We cannot be sure that coverage and reimbursement will be available for
our product candidates, if and when such candidates obtain marketing approval, and any reimbursement that may become available may not be adequate or may be decreased or eliminated in the future. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, increasing efforts by governmental and third-party payors in the United States to cap or reduce healthcare costs may cause third-party payors to limit both
coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for any product we commercialize. We expect to experience pricing pressures in connection with the sale of our
product candidates due to the trend toward managed health care and additional legislative, administrative, or regulatory changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical
procedures and other treatments, has become intense and new products face increasing challenges in entering the market successfully. Third-party payors are increasingly challenging the price and examining the cost-effectiveness of new products in
addition to their safety and efficacy. To obtain or maintain coverage and reimbursement for any current or future product, we may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost-effectiveness of our
product. These studies will be in addition to the studies required to obtain regulatory approvals. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No uniform policy for coverage and reimbursement for products
exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor, and one third-party payor&#146;s decision to cover a particular product does not ensure that other
payors will also provide similar coverage. Additionally, the process for determining whether a third-party payor will provide coverage for a product is typically separate from the process for setting the price of such product or establishing the
reimbursement rate that the payor will pay for the product once coverage is approved. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for
the use of our product candidates to each payor separately, with no assurance that coverage and reimbursement will be obtained or will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">35 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
consistent across payors. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations
are likely. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates, and may not be able to obtain a satisfactory financial return on our product candidates.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We or our collaborators may also be subject to extensive governmental price controls and other market regulations outside of the United States, and we believe the
increasing emphasis on cost-containment initiatives in other countries have and will continue to put pressure on the pricing and usage of medical products. In many countries, the prices of medical products are subject to varying price control
mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could
restrict the amount that we or our collaborators are able to charge for products we or our collaborators commercialize. Accordingly, in markets outside the United States, the reimbursement for products we or our collaborators commercialize may be
reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if a product candidate we
develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors and the medical community.
Commercial success also will depend, in large part, on the coverage and reimbursement of our product candidates and associated screening and/or diagnostic tests by third-party payors, including private insurance providers and government payors.
Various factors will influence whether our product candidates are accepted in the market if approved for commercial sale, including, but not limited to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the efficacy, safety and tolerability of our products, and potential advantages compared to alternative treatments;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the clinical indications for which the product is approved, and product labeling or product insert requirements of the
FDA, EMA or other comparable foreign regulatory authorities, including any limitations or warnings contained in a product&#146;s approved labeling; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the effectiveness of sales and marketing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the prevalence and severity of any side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of treatment in relation to alternative treatments, including any similar treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to offer our products for sale at competitive prices; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the availability and access to screening and/or diagnostic tests; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the convenience and ease of administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the strength of marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the availability of third-party coverage and reimbursement for any of our products that are approved and any screening
and/or diagnostic testing, as appropriate; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any restrictions on the use of our product together with other medications. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Market acceptance of our product candidates is heavily dependent on patients&#146; and physicians&#146; perceptions that our product candidates are safe and effective
treatments for their targeted indications and willingness to use screening and/or diagnostic tests to identify at-risk target populations for our therapeutics. The perceptions of any product are also influenced by perceptions of competitors&#146;
products that are in the same class or that have a similar mechanism of action. Because we expect sales of our product candidates, if approved, to generate substantially all our revenues in the foreseeable future, the failure of our product
candidates to find market acceptance would harm our business and could require us to seek additional financing. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If approved, our product candidates that are
regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Biologics Price Competition and
Innovation Act of 2009, or BPCIA, was enacted as part of the Patient Protection and Affordable Care Act, or the ACA, to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway
establishes legal authority for the FDA to review and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">36 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
approve biosimilar biologics, including the possible designation of a biosimilar as &#147;interchangeable&#148; based on its similarity to an approved biologic. Under the BPCIA, reference
biological product is granted 12 years of data exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four
years after the date of first licensure of the reference product In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <FONT
STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still develop and receive approval of a competing biologic, so long as their BLA does not rely on the reference product, sponsor&#146;s data or submit the
application as a biosimilar application. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty, and any new policies or processes
adopted by the FDA could have a material adverse effect on the future commercial prospects for our biological products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that any of the product
candidates we develop that is approved in the United States as a biological product under a BLA should qualify for the <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity. However, there is a risk that this exclusivity could be
shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than
anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for <FONT STYLE="white-space:nowrap">non-biological</FONT>
products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. The approval of a biosimilar of our product candidates could have a material adverse impact on our business due to increased
competition and pricing pressure. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If the FDA, EMA or other comparable foreign regulatory authorities approve generic versions of any of our small molecule
investigational products that receive marketing approval, or such authorities do not grant our products appropriate periods of exclusivity before approving generic versions of those products, the sales of our products, if approved, could be
adversely affected. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once an NDA is approved, the product covered thereby becomes a &#147;reference listed drug&#148; in the FDA&#146;s publication,
&#147;Approved Drug Products with Therapeutic Equivalence Evaluations,&#148; commonly known as the Orange Book. Manufacturers may seek approval of generic versions of reference listed drugs through submission of abbreviated new drug applications, or
ANDAs, in the United States. In support of an ANDA, a generic manufacturer need not conduct clinical trials to assess safety and efficacy. Rather, the applicant generally must show that its product has the same active ingredient(s), dosage form,
strength, route of administration and conditions of use or labelling as the reference listed drug and that the generic version is bioequivalent to the reference listed drug, meaning it is absorbed in the body at the same rate and to the same extent.
Generic products may be significantly less costly to bring to market than the reference listed drug and companies that produce generic products are generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a
significant percentage of the sales of any branded product or reference listed drug is typically lost to the generic product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may not approve an ANDA for a
generic product until any applicable period of <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity for the reference listed drug has expired. The FDCA provides a period of five years of <FONT STYLE="white-space:nowrap">non-patent</FONT>
exclusivity for a new drug containing a new chemical entity. Specifically, in cases where such exclusivity has been granted, an ANDA may not be submitted to the FDA until the expiration of five years unless the submission is accompanied by a
Paragraph IV certification that a patent covering the reference listed drug is either invalid or will not be infringed by the generic product, in which case the applicant may submit its application four years following approval of the reference
listed drug. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Generic drug manufacturers may seek to launch generic products following the expiration of any applicable exclusivity period we obtain if our products
are approved, even if we still have patent protection for such products. Competition that our products could face from generic versions of our products could materially and adversely affect our future revenue, profitability, and cash flows and
substantially limit our ability to obtain a return on the investments we have made in those product candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to establish sales,
marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing any product candidates we develop, if approved. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In order to market and successfully commercialize any product candidates we develop, if approved, we must build our sales and marketing capabilities or enter into
collaborations with third parties for these services. We currently </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">37 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
have no sales, marketing or distribution capabilities and as a company have no experience in marketing products. If we commercialize any of our product candidates that may be approved ourselves,
we will need to develop an <FONT STYLE="white-space:nowrap">in-house</FONT> marketing organization and sales force across rare disease therapeutic areas, which will require significant expenditures, management resources, and time. There are
significant expenses and risks involved with establishing our own sales and marketing capabilities, including our ability to hire, train, retain, and appropriately incentivize a sufficient number of qualified individuals, generate sufficient sales
leads and provide our sales and marketing team with adequate access to physicians who may prescribe our products, effectively manage a geographically dispersed sales and marketing team, and other unforeseen costs and expenses. We will have to
compete with other pharmaceutical and biotechnology companies to recruit, hire, train, and retrain marketing and sales personnel. Any failure or delay in the development of a product candidate that affects the expected timing of commercialization of
the product candidate or results in the failure of the product candidate to be commercialized could result in us having prematurely or unnecessarily incurred costly commercialization expenses. Our investment would be lost if we are unable to retain
or reposition our sales and marketing personnel. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may also enter into collaborations for the sales and marketing of our product candidates, if approved. To the
extent that we depend on collaborators for sales and marketing activities, any revenues we receive will depend upon the success of those collaborators&#146; sales and marketing teams and the collaborators&#146; prioritization of our products and
compliance with applicable regulatory requirements, and there can be no assurance that the collaborators&#146; efforts will be successful. If we are unable to build our own sales and marketing team or enter into a collaboration for the
commercialization of product candidates we develop, if approved, we may be forced to delay the commercialization of our product candidates or reduce the scope of our sales or marketing activities, which would have an adverse effect on our business,
operating results and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Dependence on Third Parties </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We intend to continue to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> rights to additional product candidates or collaborate with third parties
for the development and commercialization of our product candidates. We may not succeed in identifying and acquiring businesses or assets, <FONT STYLE="white-space:nowrap">in-licensing</FONT> intellectual property rights or establishing and
maintaining collaborations, which may significantly limit our ability to successfully develop and commercialize our other product candidates, if at all, and these transactions could disrupt our business, cause dilution to our stockholders or reduce
our financial resources. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We acquired all rights to RLYB211 and RLYB212 from Prophylix in 2019 and rights to RLYB116 and RLYB114 from Sobi in 2019. We also
have entered into joint ventures with Exscientia for the development of small molecule therapeutics for rare diseases. An important component of our approach to product development is to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT>
rights to product candidates, products or technologies, acquire other businesses or enter into collaborations with third parties. We may not be able to enter into such transactions on favorable terms, or at all. Any such acquisitions, <FONT
STYLE="white-space:nowrap">in-licenses</FONT> or collaborations may not strengthen our competitive position, and these transactions may be viewed negatively by analysts, investors, customers, or other third parties with whom we have relationships.
We may decide to incur debt in connection with an acquisition, or <FONT STYLE="white-space:nowrap">in-license</FONT> or issue our common stock or other equity securities as consideration for the acquisition, which would reduce the percentage
ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the sellers of the acquired business. In addition, we may
not be able to successfully integrate the acquired personnel, technologies, and operations into our existing business in an effective, timely, and <FONT STYLE="white-space:nowrap">non-disruptive</FONT> manner. Such transactions may also divert
management attention from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> responsibilities, increase our expenses, and reduce our cash available for operations and other uses. We cannot predict the number,
timing or size of future acquisitions or <FONT STYLE="white-space:nowrap">in-licenses</FONT> or the effect that any such transactions might have on our operating results. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may not realize the anticipated benefits of any current or future collaboration, each of which involves or will involve numerous risks, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator may shift its priorities and resources away from our product candidates due to a change in business
strategies, or a merger, acquisition, sale, or downsizing; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator may seek to renegotiate or terminate its relationships with us due to unsatisfactory clinical results,
manufacturing issues, a change in business strategy, a change of control or other reasons; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">38 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator may cease development in therapeutic areas that are the subject of our collaboration;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator may not devote sufficient capital or resources towards our product candidates, or may fail to comply with
applicable regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator may change the success criteria for a product candidate, thereby delaying or ceasing development of such
candidate; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a significant delay in initiation of certain development activities by a collaborator will also delay payment of
milestones tied to such activities, thereby impacting our ability to fund our own activities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator could develop a product that competes, either directly or indirectly, with our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator with commercialization obligations may not commit sufficient financial resources or personnel to the
marketing, distribution, or sale of a product; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator with manufacturing responsibilities may encounter regulatory, resource, or quality issues and be unable to
meet demand requirements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator may terminate a strategic alliance; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a dispute may arise between us and a collaborator concerning the research, development, or commercialization of a product
candidate resulting in a delay in milestones or royalty payments or termination of the relationship and possibly resulting in costly litigation or arbitration, which may divert management&#146;s attention and resources; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator may use our products or technology in such a way as to invite litigation from a third-party.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any collaborator fails to fulfill its responsibilities in a timely manner, or at all, our research, clinical development, manufacturing, or
commercialization efforts related to that collaboration could be delayed or terminated, or it may be necessary for us to assume responsibility for expenses or activities that would otherwise have been the responsibility of our collaborator. If we
are unable to establish and maintain collaborations on acceptable terms or to successfully transition away from terminated collaborations, we may have to delay or discontinue further development of one or more of our product candidates, undertake
development and commercialization activities at our own expense, or find alternative sources of capital, which would have a material adverse impact on our clinical development plans and business. If we fail to establish and maintain collaborations
related to our product candidates, we could bear all of the risk and costs related to the development of any such product candidate, and we may need to seek additional financing, hire additional employees and otherwise develop expertise for which we
have not budgeted. This could negatively affect the development and commercialization of our product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may face significant competition in identifying
and acquiring businesses or assets, <FONT STYLE="white-space:nowrap">in-licensing</FONT> intellectual property rights and seeking appropriate collaboration partners for our product candidates, and the negotiation process may be time-consuming and
complex. In order for us to successfully partner our product candidates, potential collaborators must view these product candidates as economically valuable in markets they determine to be attractive in light of the terms that we are seeking and
other products or product candidates available for licensing from or in connection with collaborations with other companies. Our success in acquiring business or assets or in partnering with collaborators may depend on our history or perceived
capability of successful product development. Even if we are successful in our efforts to acquire businesses or assets, <FONT STYLE="white-space:nowrap">in-license</FONT> intellectual property rights or establish collaborations, we may not be
successful in developing such products candidates or technologies or able to maintain such collaborations if, for example, development or approval of a product candidate is delayed or sales of an approved product are disappointing. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our reliance on a central team consisting of a limited number of employees and third parties who provide various administrative, research and development, and
other services across our organization presents operational challenges that may adversely affect our business. </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of June 30, 2021, we had 28 full-time
employees, upon whom we rely for various administrative, research and development, business development and other support services shared among our subsidiaries and the Exscientia joint venture. The size of our centralized team may limit our ability
to devote adequate personnel, time, and resources to support the operations of all of our subsidiaries and the Exscientia joint venture, including their research and development activities, the management of financial, accounting, and reporting
matters, and the oversight of our third-party vendors and partners. If our centralized team or our third party vendors and partners </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">39 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
performing such functions fail to provide adequate administrative, research and development, or other services across our entire organization, our business, financial condition, and results of
operations could be harmed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties
we may engage in connection with development and commercialization may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Misconduct by our employees and independent contractors, including principal investigators, CROs, consultants, vendors and any third parties we may engage
in connection with research, development, regulatory, manufacturing, quality assurance and other pharmaceutical functions and commercialization, could include intentional, reckless or negligent conduct or unauthorized activities that violate:
(i)&nbsp;the laws and regulations of the FDA, and other similar regulatory authorities, including those laws that require the reporting of true, complete and accurate information to such authorities; (ii)&nbsp;manufacturing standards;
(iii)&nbsp;data privacy, security, fraud and abuse and other healthcare laws and regulations; or (iv)&nbsp;laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business
arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of
pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Activities subject to these or other laws could also involve the improper use or misrepresentation of information obtained
in the course of clinical trials, creation of fraudulent data in preclinical studies or clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not
always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from
governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government agency could allege such fraud or other misconduct, even
if none occurred. If any such actions are instituted against us or them and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the
imposition of significant civil, criminal, and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions,
individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We currently rely and will rely on third parties for the manufacture of drug substance for our preclinical studies and clinical trials and expect to continue to
do so for commercialization of any product candidates that we may develop that are approved for marketing. We also rely and will rely on third parties for the design and manufacture of companion diagnostics related to RLYB212 and any other product
candidates that may require a companion diagnostic. Our reliance on third parties may increase the risk that we will not have sufficient quantities of such drug substance, product candidates, or any products that we may develop and commercialize, or
that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
have limited personnel with experience in manufacturing, and we do not own facilities for manufacturing RLYB211, RLYB212 and RLYB116 or any other product candidate. Instead, we rely on and expect to continue to rely on contract manufacturers for the
supply of cGMP-drug substance and drug product of RLYB211, RLYB212 and RLYB116 and any other product candidates we develop and, in the future, for commercial supply. Reliance on third parties may expose us to more risk than if we were to manufacture
our product candidates ourselves. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may be unable to establish necessary supply agreements with third-party manufacturers or to do so on acceptable terms. Even if
we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the possible breach of the manufacturing agreement by the third-party; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the possible termination or nonrenewal of the agreement by the third-party at a time that is costly or inconvenient for
us; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reliance on the third-party for regulatory compliance, quality assurance, safety, and pharmacovigilance and related
reporting; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">40 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the possible inability of third-party suppliers to supply and/or transport materials, components and products to us in a
timely manner as a result of disruptions to the global supply chain, including in connection with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Third-party manufacturers may fail to comply with cGMP regulations or similar regulatory requirements outside the United States. Any failure to follow cGMP or other
regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our product candidates as a result of a failure of our facilities or the facilities or operations of third parties to
comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates, including leading to significant delays in the availability of our product
candidates for our clinical trials or the termination of or suspension of a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Moreover, our failure, or the failure of our
third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocations, seizures or recalls of
product candidates or medicines, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our business, financial condition, results of operations, and prospects.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While we provide oversight of manufacturing activities, we have limited ability to control the execution of manufacturing activities by, and are or will be
dependent on, our contract manufacturing organizations, or CMOs, for compliance with cGMP requirements for the manufacture of our product candidates by our CMOs. As a result, we are subject to the risk that our product candidates may have
manufacturing defects or fail to comply with regulatory requirements, which we have limited ability to prevent. CMOs may also have competing obligations that prevent them from manufacturing our product candidates in a timely manner. If a CMO cannot
successfully manufacture drug substance that conforms to our specifications and the regulatory requirements, we will not be able to secure or maintain regulatory approval for the use of our product candidates in clinical trials, or for commercial
distribution of our product candidates, if approved. In addition, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance, and qualified personnel, and we were not involved in developing our
CMOs&#146; policies and procedures. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The facilities and processes used to manufacture our product candidates are subject to inspection by the FDA, EMA and other
comparable foreign authorities. If the FDA, EMA or other comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval or finds
deficiencies in the future, we may need to find alternative manufacturing facilities or conduct additional studies, which would delay our development program and significantly impact our ability to develop, obtain regulatory approval for, or
commercialize our product candidates, if approved. Furthermore, CMOs may breach existing agreements they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement at a time that is costly or
otherwise inconvenient for us. Finding new CMOs or third-party suppliers involves additional cost and requires our management&#146;s time and focus. In addition, there is typically a transition period when a new CMO commences work. Any significant
delay in the supply of our product candidates or the raw materials needed to produce our product candidates, could considerably delay conducting our clinical trials and potential regulatory approval of our product candidates. If we were unable to
find an adequate CMO or another acceptable solution in time, our clinical trials could be delayed, or our commercial activities could be harmed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We rely on and
will continue to rely on CMOs to purchase from third-party suppliers the raw materials necessary to produce our product candidates. We have limited ability to control the process or timing of the acquisition of these raw materials by our CMOs. The <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic may also have an impact on the ability of our CMOs to acquire raw materials. Moreover, we currently do not have any agreements for the production of these raw materials. Supplies of raw materials
could be interrupted from time to time and we cannot be certain that alternative supplies could be obtained within a reasonable time frame, at an acceptable cost, or at all. In addition, a disruption in the supply of raw materials could delay the
commercial launch of our product candidates, if approved, or result in a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates. Growth in the costs and expenses of raw materials may also
impair our ability to cost effectively manufacture our product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">41 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
candidates. There are a limited number of suppliers for the raw materials that we may use to manufacture our product candidates and we may need to assess alternative suppliers to prevent a
possible disruption of the manufacture of our product candidates. Moreover, our product candidates utilize drug substances that are produced on a small scale, which could limit our ability to reach agreements with alternative suppliers. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As part of their manufacture of our product candidates, our CMOs and third-party suppliers are expected to comply with and respect the intellectual property and
proprietary rights of others. If a CMO or third-party supplier fails to acquire the proper licenses or otherwise infringes, misappropriates or otherwise violates the intellectual property or the proprietary rights of others in the course of
providing services to us, we may have to find alternative CMOs or third-party suppliers or defend against claims of infringement, either of which would significantly impact our ability to develop, obtain regulatory approval for, or commercialize our
product candidates, if approved. Further, the extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic impacts our ability to procure sufficient supplies for the development of our product candidates will depend on the severity
and duration of the spread of the virus, and the actions undertaken to contain <FONT STYLE="white-space:nowrap">COVID-19</FONT> or treat its effects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition,
given our limited experience in developing and commercializing companion diagnostics, we do not plan to develop companion diagnostics internally and thus will be dependent on the sustained cooperation and effort of third-party collaborators in
developing and obtaining approval for companion diagnostics if required. Reliance on these third-party collaborators exposes us to risks due to our limited control of their activities, including compliance by them with cGMP regulations or similar
foreign requirements and inspection of their manufacturing facilities by the FDA or comparable foreign regulatory authorities and their obtaining, maintaining and protecting their intellectual property rights necessary to develop and manufacture
companion diagnostics while not infringing on the intellectual property rights of others. We or our third-party collaborators also will need to source raw materials for any companion diagnostics, including obtaining amounts sufficient for widespread
adoption of testing and a potential commercial launch of RLYB212, if approved, and we may be dependent on our collaborators to identify and obtain reliable sources of raw materials. Our collaborators also may breach their agreements with us or
otherwise fail to perform to our satisfaction, which could impact the development timeline of our product candidates, and we may incur additional costs and delays if we need to transition to a new third-party companion diagnostic partner. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We rely, and will continue to rely, on third parties to conduct, supervise, and monitor our preclinical studies and clinical trials. If we fail to effectively
oversee and manage these third parties, if they do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We rely, and will continue to rely, on CROs, <FONT STYLE="white-space:nowrap">CRO-contracted</FONT> vendors, and clinical trial sites to ensure the proper and timely
conduct of our clinical trials. Our reliance on CROs for clinical development activities limits our control over these activities, but we remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol
and legal, regulatory, and scientific standards. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We and our CROs will be required to comply with the GLP requirements for our preclinical studies and GCP
requirements for our clinical trials. Regulatory authorities enforce GCP requirements through periodic inspections of trial sponsors, principal investigators, and clinical trial sites. If we, or our CROs, fail to comply with GCP requirements, the
clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or other comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot
assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements and may require a large number of patients. Our failure or any failure by our
CROs, investigators, CMOs or other third parties to comply with regulatory requirements or to recruit enough patients may delay ongoing or planned clinical trials or require us to repeat clinical trials, which would delay the regulatory approval
process. Failure by us or by third parties we engage to comply with regulatory requirements can also result in fines, adverse publicity, and civil and criminal sanctions. Moreover, our business may be implicated if any of these third parties
violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our CROs, vendors and clinical trial
investigators are not our employees, and we do not control whether they devote sufficient time and resources to our clinical trials. These third parties may also have relationships with other commercial entities, including our competitors, for whom
they may also be conducting clinical trials, or other drug development activities, which could harm our competitive position. We face the risk of potential unauthorized </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">42 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
disclosure or misappropriation of our intellectual property by CROs and other third parties involved in our preclinical studies and clinical trials, which may reduce our trade secret protection
and allow our potential competitors to access and exploit our proprietary technology. If our CROs and other third parties involved in our trials do not successfully carry out their contractual duties or obligations, or fail to meet expected
deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reason, our clinical trials may be extended, delayed or
terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, any product candidates that we develop. As a result, our financial results and the commercial prospects for any product candidates that we develop
would be harmed, our costs could increase, and our ability to generate revenue could be delayed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If our relationship with any CROs terminates, we may not be able
to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management&#146;s time and focus. In addition, there is a natural transition
period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no
assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition, and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Healthcare Laws and Other Legal Compliance Matters </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, if
approved, and may affect the prices we may set. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States and other jurisdictions, there have been, and we expect there will continue to be, a
number of legislative and regulatory changes, and additional proposed changes, to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal
and state levels that seek to reduce healthcare costs and improve the quality of health care. For example, in March 2010, the ACA was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. The
ACA expanded health care coverage through a Medicaid expansion and the implementation of the individual mandate for health insurance coverage. The ACA also imposed an annual fee payable on manufacturers of branded prescription drugs and biologic
agents (other than those designated as orphan drugs) and included changes to the coverage and reimbursement of drug products under government healthcare programs. Such changes included an expansion in the Medicaid drug rebate program and an increase
in the statutory minimum rebates a manufacturer must pay under the program as well as a new Medicare Part D coverage gap discount program requiring manufacturers to offer
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period in exchange for coverage of the drugs
under Medicare Part D. Under the Trump administration, there were ongoing efforts to modify or repeal all or certain provisions of the Healthcare Reform Act. For example, tax reform legislation was enacted at the end of 2017 that eliminated the tax
penalty established under the ACA for individuals who do not maintain the mandated health insurance coverage beginning in 2019. The ACA has also been subject to judicial challenge. For example, in June&nbsp;2021, the Supreme Court rejected a
challenge to the constitutionality of the ACA on the grounds that the states and individuals that brought the challenge did not have standing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Beyond the ACA,
there have been ongoing health care reform efforts, including a number of recent actions. Some recent healthcare reform efforts have sought to address certain issues related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including
an expansion of telehealth coverage under Medicare, accelerated or advanced Medicare payments to healthcare providers and payments to providers for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">COVID-19-related</FONT></FONT>
expenses and lost revenues. Other reform efforts affect pricing or payment for drug products, which was a focus of the Trump Administration. For example, subsequent to the ACA, the Medicaid Drug Rebate Program was subject to statutory and regulatory
changes and the discount that manufacturers of Medicare Part D brand name drugs must provide to Medicare Part D beneficiaries during the coverage gap increased from 50% to 70%. Several regulations were issued in late 2020 and early 2021, some of
which have been and may continue to be subject to scrutiny and legal challenge. For example, courts temporarily enjoined a new &#147;most favored nation&#148; payment model for select drugs covered under Medicare Part B that was to take effect on
January&nbsp;1, 2021 and would limit payment based on international drug price, and the Centers for Medicare &amp; Medicaid Services within the U.S. Department of Health and Human Services, or CMS, subsequently
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">43 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
indicated that the rule will not be implemented without further rulemaking. As another example, revisions to regulations under the federal anti-kickback statute would remove protection for
traditional Medicare Part D discounts offered by pharmaceutical manufacturers to PBMs and health plans. The revisions to the federal anti-kickback statute regulations referenced above were initially scheduled to take effect in 2022 but have now been
delayed to 2023. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The nature and scope of health care reform in the wake of the transition from the Trump administration to the Biden administration remains
uncertain but early actions suggest additional changes as well as challenges to actions taken under the Trump administration. President Biden temporarily halted implementation of new rules that were issued immediately prior to the transition from
the Trump administration to the Biden administration that had not yet taken effect (which include a number of health care reforms) to allow for review by the new administration. By Executive Order, President Biden directed federal agencies to
reconsider rules and other policies that limit Americans&#146; access to health care and consider actions that will protect and strengthen that access. President Biden supported reforms to lower prescription drug prices during his campaign for the
presidency. The American Rescue Plan Act of 2021, comprehensive <FONT STYLE="white-space:nowrap">COVID-19</FONT> relief legislation enacted early under the Biden administration, includes a number of healthcare-related provisions, such as support to
rural health care providers, increased tax subsidies for health insurance purchased through insurance exchange marketplaces, financial incentives to states to expand Medicaid programs and elimination of the Medicaid drug rebate cap effective in
2024. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General legislative cost control measures may also affect reimbursement for our product candidates. The Budget Control Act, as amended, resulted in the
imposition of 2% reductions in Medicare (but not Medicaid) payments to providers in 2013 and will remain in effect through 2030 (except May&nbsp;1, 2020 to December 31, 2021) unless additional Congressional action is taken. The Congressional Budget
Office has indicated that the American Rescue Plan Act of 2021 will likely trigger a statutory provision that requires that automatic payment cuts be put into place if a statutory action creates a net increase in the deficit and require reductions
in Medicare spending. Any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented and/or any significant taxes or fees that may be imposed on us could have an
adverse impact on our results of operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Adoption of new legislation at the federal or state level could affect demand for, or pricing of, any future products
if approved for sale. We cannot, however, predict the ultimate content, timing or effect of any changes to the ACA or other federal and state reform efforts. There is no assurance that federal or state health care reform will not adversely affect
our future business and financial results. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to
specialty drug pricing practices. Specifically, there have been administration efforts, Congressional inquiries and proposed federal and state legislation designed to bring more transparency to drug pricing, reduce the cost of prescription drugs
under Medicare, review the relationship between pricing and manufacturer patient assistance programs and reform government program reimbursement methodologies for drugs. Moreover, payment methodologies may be subject to changes in healthcare
legislation and regulatory initiatives. We expect that additional U.S. federal healthcare reform measures will be implemented in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and
services, which could result in reduced demand for our product candidates or additional pricing pressures. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Individual states in the United States have also become
increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access
and marketing cost disclosure and transparency measures, and, in some cases, measures designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other
restrictions could harm our business, results of operations, financial condition, and prospects. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of
discounts and list prices. These reforms could reduce the ultimate demand for our product candidates or put pressure on our product pricing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In markets outside of
the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. We cannot predict the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">44 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we, or any third parties
we may engage, are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any
regulatory approval that may have been obtained and we may not achieve or sustain profitability. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our business operations and current and future relationships
with contractors, investigators, healthcare professionals, consultants, third-party payors, patient organizations, customers, and others will be subject to applicable healthcare regulatory laws, which could expose us to penalties. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our business operations and current and future arrangements with contractors, investigators, healthcare professionals, consultants, third-party payors, patient
organizations, and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations,
including how we research, market, sell, and distribute our product candidates, if approved. Such laws, some of which may apply only after our products are approved for marketing, include: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. federal false claims, false statements and civil monetary penalties laws prohibiting, among other things, any person
from knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly making, or causing to be made, a false statement to get a false claim paid; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. federal healthcare program anti-kickback law, which prohibits, among other things, persons from offering, soliciting,
receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual for, or the purchasing or ordering of, a good or service for which payment may be made under federal healthcare programs such as Medicare and
Medicaid; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which, in addition to privacy
protections applicable to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. FDCA, which among other things, strictly regulates drug marketing, prohibits manufacturers from marketing such
products prior to approval or for <FONT STYLE="white-space:nowrap">off-label</FONT> use and regulates the distribution of samples; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government
or provide certain discounts or rebates to regulatory authorities or private entities, often as a condition of reimbursement under government healthcare programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. federal Open Payments (or federal &#147;sunshine&#148; law), which requires pharmaceutical and medical device
companies to monitor and report certain financial interactions with certain healthcare providers to the CMS for <FONT STYLE="white-space:nowrap">re-disclosure</FONT> to the public, as well as ownership and investment interests held by physicians and
their immediate family members; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities
that potentially harm consumers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws; state laws requiring
pharmaceutical companies to comply with specific compliance standards, restrict financial interactions between pharmaceutical companies and healthcare providers or require pharmaceutical companies to report information related to payments to health
care providers or marketing expenditures; and state laws governing privacy, security, and breaches of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus
complicating compliance efforts; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">similar healthcare laws and regulations in the EU and other jurisdictions, including reporting requirements detailing
interactions with and payments to healthcare providers and laws governing the privacy and security of personal information, such as, where applicable, the General Data Protection Regulation, or GDPR, which imposes obligations and restrictions on the
collection, use, and disclosure of personal data relating to individuals located in the EU and the European Economic Area, or EEA, (including health data). See &#147;&#151;Our business operations may subject us to data protection laws, including the
GDPR, the United Kingdom GDPR, the California Consumer Privacy Act and other similar laws&#148;; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">laws and regulations prohibiting bribery and corruption such as the FCPA, which, among other things, prohibits U.S.
companies and their employees and agents from authorizing, promising, offering, or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">45 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations or foreign
government-owned or affiliated entities, candidates for foreign public office, and foreign political parties or officials thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Efforts to
ensure that our business arrangements with third parties will comply with applicable healthcare and other laws and regulations will involve substantial costs. Given the breadth of the laws and regulations and narrowness of any exceptions, limited
guidance for certain laws and regulations and evolving government interpretations of the laws and regulations, regulatory authorities may possibly conclude that our business practices may not comply with healthcare laws and regulations, including
our consulting agreements and other relationships with healthcare providers. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If our operations are found to be in violation of any of the laws described above or
any other governmental laws and regulations that may apply to us, we may be subject to actions including the imposition of civil, criminal, and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in
Medicare, Medicaid, and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements, or oversight if we become subject to a corporate
integrity agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate
our business and our results of operations. Further, defending against any such actions can be costly, time consuming, and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that
may be brought against us, our business may be impaired. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our business operations may subject us to data protection laws, including the GDPR, the United
Kingdom GDPR, the California Consumer Privacy Act and other similar laws. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The GDPR applies to companies established in the EEA, as well as to companies
that are not established in the EEA and which collect and use personal data in relation to (i)&nbsp;offering goods or services to, or (ii)&nbsp;monitoring the behavior of, individuals located in the EEA. If we conduct clinical trial programs in the
EEA (whether the trials are conducted directly by us or through a clinical vendor or collaborator), or enter into research collaborations involving the monitoring of individuals in the EEA, or market our products to individuals in the EEA, we will
be subject to the GDPR. The GDPR puts in place stringent operational requirements for processors and controllers of personal data, including, for example, high standards for obtaining consent from individuals to process their personal data (or
reliance on another appropriate legal basis), the provision of robust and detailed disclosures to individuals about how personal data is collected and processed (in a concise, intelligible and easily accessible form), an individual data rights
regime (including access, erasure, objection, restriction, rectification and portability), maintaining a record of data processing, data export restrictions governing transfers of data from the EEA, short timelines for data breach notifications to
be given to data protection regulators or supervisory authorities (and in certain cases, affected individuals) of significant data breaches, and limitations on retention of information. The GDPR also puts in place increased requirements pertaining
to health data and other special categories of personal data, as well as a definition of pseudonymized (i.e., <FONT STYLE="white-space:nowrap">key-coded)</FONT> data. Further, the GDPR provides that EEA member states may establish their own laws and
regulations limiting the processing of genetic, biometric, or health data, which could limit our ability to collect, use, and share such data and/or could cause our costs to increase. In addition, there are certain obligations if we contract
third-party processors in connection with the processing of personal data. If our or our collaborators&#146; or service providers&#146; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation,
regulatory investigations, enforcement notices requiring us to change the way we use personal data, or fines of up to 20&nbsp;million Euros or up to 4% of our total worldwide annual revenue of the preceding financial year, whichever is higher, as
well as compensation claims by affected individuals, including class-action type litigation, negative publicity, reputational harm and a potential loss of business and goodwill. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, from January&nbsp;1, 2021, we may also have to comply with the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK
national law. The UK GDPR mirrors the fines under the GDPR with fines up to the greater of <FONT STYLE="font-family:Times New Roman">&#128;</FONT>20&nbsp;million (&pound;17.5 million) or 4% of global turnover. The relationship between the United
Kingdom and the EU in relation to certain aspects of data protection law remains unclear, and it is unclear how UK data protection laws and regulations will develop in the medium to longer term. On June&nbsp;28, 2021 the European Commission issued
an adequacy decision in respect of the UK&#146;s data protection framework, enabling data transfers from EU member states to the UK to continue without requiring organizations to put in place </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">46 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
contractual or other measures in order to lawfully transfer personal data between the territories. While it is intended to last for at least four years, the European Commission may unilaterally
revoke the adequacy decision at any point, and if this occurs it could lead to additional costs and increase our overall risk exposure. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Recent legal developments
in Europe have created complexity and uncertainty regarding transfers of personal data from the EEA and the United Kingdom to the United States. Most recently, on July&nbsp;16, 2020, the Court of Justice of the European Union, or CJEU, invalidated
the <FONT STYLE="white-space:nowrap">EU-US</FONT> Privacy Shield Framework, or Privacy Shield, under which personal data could be transferred from the EEA to US entities who had self-certified under the Privacy Shield scheme. While the CJEU upheld
the adequacy of the standard contractual clauses (a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism, and potential alternative to the Privacy Shield), it made clear that reliance on them
alone may not necessarily be sufficient in all circumstances. Use of the standard contractual clauses must now be assessed on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis taking into account
the legal regime applicable in the destination country, in particular applicable surveillance laws and rights of individuals and additional measures and/or contractual provisions may need to be put in place, however, the nature of these additional
measures is currently uncertain. The CJEU went on to state that if a competent supervisory authority believes that the standard contractual clauses cannot be complied with in the destination country and the required level of protection cannot be
secured by other means, such supervisory authority is under an obligation to suspend or prohibit that transfer. On June&nbsp;4, 2021, the European Commission released two revised sets of standard contractual clauses, which have been designed in part
to assist organisations in meeting the requirement of the CJEU&#146;s judgment.&nbsp;However, it is unclear how the use of these clauses will be scrutinised and enforced by supervisory authorities and privacy interest groups, and the process of
entering into agreements with new standard contractual clauses, and updating our existing agreements that contain the previous clauses, may lead to additional costs and increase our overall risk exposure. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These recent developments may require us to review and amend the legal mechanisms by which we make and/ or receive personal data transfers to/ in the United States. As
supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints
and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical
location or segregation of our relevant systems and operations, and could adversely affect our financial results. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are numerous U.S. federal and state laws
and regulations related to the privacy and security of personal information. In particular, regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure of individually identifiable health
information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability
of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing
interpretation. While we do not believe that we are directly subject to HIPAA as either a &#147;covered entity&#148; or &#147;business associate,&#148; U.S. sites at which we conduct clinical trials are likely to be covered entities and thus must
ensure that they obtain adequate patient authorization or establish another basis under HIPAA to disclose a clinical trial subject&#146;s individually identifiable health information to us and other entities participating in our clinical trials.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, The California Consumer Privacy Act, or the CCPA, came into effect in January 2020 and, among other things, requires new disclosures to
California individuals and affords such individuals new abilities to opt out of certain sales of personal information, and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil
penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Because we have not yet generated revenue and do not meet the CCPA&#146;s other jurisdictional tests, we do not yet
meet the applicable threshold for CCPA to apply to our business. If our business becomes subject to CCPA in the future, it could increase our compliance costs and potential liability. Further, the California Privacy Rights Act, or the CPRA, recently
passed in California, which will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain
uses of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">47 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement.
The majority of the provisions will go into effect on January&nbsp;1, 2023, though the obligations for covered businesses will apply to any personal information collected after January&nbsp;1, 2022. Similar laws have been proposed or passed at the
U.S. federal and state level, including the Virginia Consumer Data Protection Act, which will take effect on January&nbsp;1, 2023. We will need to review periodically our operations in comparison to developments in such laws. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with
environmental compliance or remediation activities. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our operations, including our development, testing and manufacturing activities, are subject to
numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release, and disposal of and the maintenance of a registry for, hazardous materials and biological
materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds, and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws
and regulations, we could be subject to fines or other sanctions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As with other companies engaged in activities similar to ours, we face a risk of environmental
liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be
required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, the production efforts of our third-party manufacturers or our development efforts may be interrupted or delayed.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Intellectual Property </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to
obtain, maintain and enforce patent protection for our technology and product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or
identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our success
depends in large part on our ability to obtain and maintain protection of the intellectual property we may own solely and jointly with others, or may license from others, particularly patents, in the United States and other countries with respect to
any proprietary technology and product candidates we develop. We seek to protect our proprietary position by filing patent applications in the United States and select other countries related to our technologies and product candidates that are
important to our business and by <FONT STYLE="white-space:nowrap">in-licensing</FONT> intellectual property related to such technologies and product candidates. If we are unable to obtain or maintain patent protection in jurisdictions important to
our business with respect to any proprietary technology or product candidate, our business, financial condition, results of operations and prospects could be materially harmed. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, defend or license all necessary or
desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. In some
circumstances involving technology that we license from third parties, we do not have the sole right to control the preparation, filing and prosecution of patent applications or to maintain, enforce and defend the
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patents. Therefore, these <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and applications may not be prepared, filed, prosecuted, maintained, defended and enforced in a manner
consistent with the best interests of our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The patent rights of pharmaceutical and biotechnology companies generally are highly uncertain, involve complex
legal and factual questions and have been the subject of much litigation in recent years. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged in the U.S. or in numerous foreign
jurisdictions. Various courts, including the United States Supreme Court, have rendered decisions that affect the scope of patent eligibility of certain inventions or discoveries relating to biotechnology. These decisions conclude, among other
things, that abstract ideas, natural phenomena and laws of nature are not themselves patent eligible subject matter. Precisely what constitutes a law of nature or abstract idea is uncertain, and certain aspects of our technology could be considered
ineligible for patenting under applicable law. In addition, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">48 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the scope of patent protection outside the United States is uncertain, and laws of foreign countries may not protect our rights to the same extent as the laws of the United States or vice versa.
For example, European patent law precludes the patentability of methods of treatment of the human body. With respect to both owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights, we cannot predict whether the patent
applications we and our licensors are currently pursuing will issue as patents that protect our technology and product candidates, in whole or in part, in any particular jurisdiction or whether the claims of any issued patents will provide
sufficient protection from competitors. Changes in either the patent laws or interpretation of the patent laws in the United States or other countries may diminish the value of our patents and our ability to obtain, protect, maintain, defend and
enforce our patent rights, narrow the scope of our patent protection and, more generally, affect the value or narrow the scope of our patent rights. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, third
parties may have intellectual property rights relating to our product candidates of which we are unaware. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States
and other jurisdictions are typically not published until 18 months after filing, or in some cases are not published at all. Therefore, neither we nor our licensors can know with certainty whether either we or our licensors were the first to make
the inventions claimed in the patents and patent applications we own or <FONT STYLE="white-space:nowrap">in-license</FONT> now or in the future, or that either we or our licensors were the first to file for patent protection of such inventions. As a
result, the issuance, scope, validity, enforceability and commercial value of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights are uncertain. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We, or our licensors, may be subject to a third-party <FONT STYLE="white-space:nowrap">pre-issuance</FONT> submission of prior art to the United States Patent and
Trademark Office, or USPTO, or become involved in opposition, derivation, revocation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others in the United States
and/or foreign countries. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete
directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. If the breadth or strength of protection provided by our patents and patent applications is
threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance.
Even if our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us, or
otherwise provide us with any competitive advantage. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents may be
challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which
could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Such challenges also may result in
substantial cost and require significant time from our management and employees, even if the eventual outcome is favorable to us. Furthermore, our competitors may be able to circumvent our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT>
patents by developing similar or alternative technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. For these reasons, our owned and <FONT STYLE="white-space:nowrap">in-</FONT> licensed patent portfolio may not
provide us with sufficient rights to exclude others from using or commercializing technology and products similar or identical to any of our technology and product candidates for any period of time. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Patent terms may not protect our competitive position for an adequate amount of time. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its
earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are
obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates,
patents protecting such candidates might expire before or shortly after such candidates are approved for use or commercialized. As a result, our owned and licensed patent portfolio may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">49 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours during periods when commercial exclusivity would be valuable to us. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, which if granted
could extend the term of our marketing exclusivity for any product candidates we may develop, our business may be materially harmed. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States,
the term of a patent that covers an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug may be eligible for limited patent term extension, or PTE, which permits patent term restoration as compensation for the patent term lost during the FDA
regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, permits a PTE of up to five years beyond the expiration date of the patent. The length of the PTE is related to the
length of time the drug is under regulatory review. A PTE cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. In addition, the patent term of only one patent applicable to an approved drug may
be extended, and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. Similar provisions are available in Europe and certain other <FONT STYLE="white-space:nowrap">non-United</FONT>
States jurisdictions to extend the term of a patent that covers an approved drug. While, in the future, if and when our product candidates receive FDA approval, we expect to apply for PTEs on patents covering those product candidates, there is no
guarantee that the applicable authorities will agree with our assessment of whether such extensions should be granted and, even if granted, the length of such extensions. We may not be granted PTE either in the United States or in any foreign
country, even where that patent is eligible for PTE, if, for example, we fail to exercise due diligence during the testing phase or regulatory review process, fail to apply within applicable deadlines, fail to apply prior to expiration of relevant
patents or otherwise fail to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the regulatory authority could be less than we request. If we obtain such
an extension, it may be for a shorter period than we had sought. If we are unable to obtain any PTE or the term of any such extension is less than we request, our competitors may obtain approval of competing products following the expiration of our
patent rights, and our business, financial condition, results of operations and prospects could be materially harmed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, for any future licensed patents,
we may not have the right to control prosecution, including filing with the USPTO or any foreign agency, of a petition for PTE under the Hatch-Waxman Act or analogous foreign provisions. Thus, for example, if one of our licensed patent applications,
if granted, is eligible for PTE under the Hatch-Waxman Act, we may not be able to control whether a petition to obtain a PTE is filed, or obtained from the USPTO. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our
products. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Changes in either the patent laws or interpretation of patent laws in the United States or other jurisdictions, including patent reform
legislation such as the U.S. Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase the uncertainties and costs surrounding the prosecution of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications and
the maintenance, enforcement or defense of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These changes include provisions that
switched the United States from a first- <FONT STYLE="white-space:nowrap">to-invent</FONT> system to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-inventor-to-file</FONT></FONT> system, affect the way patent applications
are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents and enable third-party submission of prior art to the USPTO during patent prosecution, and provide additional
procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Assuming that other requirements for patentability are met, under the
Leahy-Smith Act and pursuant to foreign laws outside of the United States, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third-party was the first to invent the claimed
invention. Such laws could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial
condition, results of operations and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are
particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has increased
uncertainty with respect to the validity and enforceability of patents once obtained. Similarly, foreign </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">50 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of
patent laws or changes to patent laws that might be enacted into law by U.S. and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which could be expensive, time-consuming and
unsuccessful. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Competitors and other third parties may infringe, misappropriate or otherwise violate patents or other intellectual property that we or our
licensors may own, obtain or acquire. As a result, we or our licensors may need to file infringement, misappropriation or other intellectual property claims, which can be expensive and time-consuming. Any claims we assert against others could
provoke them to assert counterclaims against us alleging that we infringe, misappropriate or otherwise violate their intellectual property rights. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The issuance of
a patent is not conclusive as to its inventorship, scope, validity or enforceability. In a patent infringement proceeding, the perceived infringers could counterclaim that the patents we or our licensors have asserted are invalid or unenforceable.
In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are common. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of
novelty, obviousness, or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or
made a misleading statement, during prosecution. Third parties may institute such claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include
<FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review, inter partes review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions, such as opposition proceedings in the European
Patent Office. The outcomes of allegations of invalidity or unenforceability are unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art of which the patent examiner and we or our licensing
partners were unaware during prosecution. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An adverse result in any such proceeding could put one or more of our current or future owned or <FONT
STYLE="white-space:nowrap">in-</FONT> licensed patents at risk of being invalidated or interpreted narrowly and could put any of our owned or <FONT STYLE="white-space:nowrap">in-</FONT> licensed patent applications at risk of not yielding an issued
patent. A court may also refuse to stop the third-party from using the technology at issue in a proceeding, for example, on the basis that our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents do not cover that technology.
Furthermore, if the breadth or strength of protection provided by our current or future patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or
commercialize current or future products, diagnostic tests, or services. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Interference or derivation proceedings provoked by third parties or brought by us or
declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it
from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license is offered and our
competitors gain access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the
uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into
development partnerships that would help us bring our product candidates to market. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, because of the substantial amount of discovery required in
connection with intellectual property litigation, there is a risk that some of our confidential information or trade secrets could be compromised by disclosure during litigation. Any of the foregoing could allow third parties to develop and
commercialize competing technologies and products and have a material adverse impact on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Third parties may allege that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be
uncertain and could have a material adverse effect on our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our commercial success depends upon our ability and the ability of our collaborators to
develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">51 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
otherwise violating the intellectual property and proprietary rights of third parties. There is considerable patent and other intellectual property litigation in the pharmaceutical and
biotechnology industries. We may become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our technology and product candidates, including interference proceedings, post
grant review, inter partes review and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions. Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties,
including our competitors, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our technologies or product candidates may
be subject to claims that they infringe the patent rights of third parties. Our competitors and others may have significantly larger and more mature patent portfolios than we have. In addition, future litigation may be initiated by patent holding
companies or other adverse patent owners who have no relevant product or service revenue and against whom our own patents may provide little or no deterrence or protection. Competitors may also assert that our product candidates infringe their
intellectual property rights as part of a business strategy to impede our successful entry into those markets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The legal threshold for initiating litigation or
contested proceedings is low, so that even lawsuits or proceedings with a low probability of success might be initiated and require significant resources and management attention to defend. The risks of being involved in such litigation and
proceedings may increase if and as our product candidates near commercialization and as we gain greater visibility as a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted
in the future, regardless of merit. Because patent applications can take many years to issue, pending patent applications may result in issued patents that our product candidates infringe. For example, there may be third-party patents or patent
applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the discovery, use or manufacture of our product candidates or technologies. We may not be aware of all such intellectual property rights
potentially relating to our technology and product candidates, or we may incorrectly conclude that third-party intellectual property is invalid or that our activities and product candidates do not infringe the intellectual property rights of third
parties. Thus, we do not know with certainty that our technology and product candidates, or our development and commercialization thereof, do not and will not infringe, misappropriate or otherwise violate any third-party&#146;s intellectual property
rights. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A court could hold that third-party patents are valid, enforceable and infringed. In order to successfully challenge the validity of any such United States
patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one that requires us to present clear and convincing evidence as to the invalidity of the claims of any such United States patent, there is no
assurance that a court would invalidate the claims of any such United States patent. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Parties making claims against us may obtain injunctive or other equitable
relief. For example, if any third-party patents were held to cover the manufacturing process of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to
block our ability to commercialize such product candidates. In the event of a successful claim of infringement against us, we may also have to pay substantial damages, including treble damages and attorneys&#146; fees for willful infringement,
indemnify customers, collaborators or other third parties, seek new regulatory approvals, and redesign our infringing products, which may not be possible or practical. If we are found to infringe, misappropriate or otherwise violate a
third-party&#146;s intellectual property rights, we may be required to obtain a license from such third-party to continue developing, manufacturing and marketing our technology and product candidates. However, we may not be able to obtain any
required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors and other third parties access to the same
technologies licensed to us and could require us to make substantial licensing and royalty payments. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on
our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Intellectual property litigation or other legal proceedings relating to intellectual
property could cause us to spend substantial resources and distract our personnel from their normal responsibilities. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if resolved in our favor,
litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">52 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
responsibilities, which would impair our ability to pursue our business. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or
developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating
losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of
our adversaries may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and may also have an advantage in such proceedings due to their more mature and developed
intellectual property portfolios. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings could compromise our ability to compete in the marketplace. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by
governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Periodic maintenance, renewal and annuity fees and various other government fees on any issued patent and pending patent application must be paid to the USPTO and
foreign patent agencies in several stages or annually over the lifetime of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications. The USPTO and various foreign governmental patent agencies require
compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application and prosecution process. In certain circumstances, we may rely on our licensing partners to pay these fees to, or comply with
the procedural and documentary rules of, the relevant patent agency. With respect to our patents, we rely on an annuity service, outside firms, and outside counsel to remind us of the due dates and to make payment after we instruct them to do so.
While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent
application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> events that could result in abandonment or lapse of a patent or patent application include
failure to respond to office actions within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to
enter the market with similar or identical products or technology. If we or our licensors fail to maintain the current and future patents and patent applications covering our product candidates, our competitors might be able to enter the market with
similar or identical products or technology, which would have a material adverse effect on our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to obtain licenses from third parties on commercially reasonable terms, our business could be harmed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to our existing licensing agreements, it may be necessary for us to use the patented or proprietary technology of third parties to commercialize our
products, if approved, in which case we would be required to obtain a license from these third parties. The <FONT STYLE="white-space:nowrap">in-licensing</FONT> and acquisition of third-party intellectual property rights is a competitive area, and a
number of more established companies are also pursuing strategies to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may
have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to
us. In addition, we expect that competition for the <FONT STYLE="white-space:nowrap">in-licensing</FONT> or acquisition of third-party intellectual property rights for product candidates that are attractive to us may increase in the future, which
may mean fewer suitable opportunities for us as well as higher acquisition or licensing costs. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, such as substantial licensing or royalty
payments, our business could be materially harmed. If we are unable to obtain a necessary license, the third parties owning such intellectual property rights could seek an injunction prohibiting our sales or we may be unable to otherwise develop or
commercialize the affected product candidates, which could materially harm our business. Even if we are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same
technologies licensed to us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property
rights we have, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a
technical or commercial basis. If we are unable to do so, we may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">53 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
be unable to develop or commercialize the affected technology and product candidates, which could harm our business, financial condition, results of operations, and prospects significantly. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we fail to comply with our obligations in our intellectual property licenses with third parties, or otherwise experience disruptions to our business
relationships with our licensors, we could lose intellectual property rights that are important to our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are party to license agreements that
impose, and we may enter into additional licensing and funding arrangements with third parties that may impose, among other things, diligence, development, and commercialization timelines, milestone payment, royalty, insurance and other obligations
on us. Under our existing licensing agreements, including our license agreement with Affibody, we are obligated to pay milestones and royalties on net product sales of product candidates or related technologies to the extent they are covered by the
agreements. If we fail to comply with such obligations under current or future license and funding agreements, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or
market, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other penalties under such agreements, or our counterparties may require us to grant them certain rights. Such an
occurrence could materially adversely affect the value of any product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements, or restrictions on our
ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in our having to negotiate new or reinstated agreements with less favorable terms, cause us to lose our rights
under these agreements, including our rights to important intellectual property or technology, which would have a material adverse effect on our business, financial condition, results of operations, and prospects, or impede, delay or prohibit the
further development or commercialization of, one or more product candidates that rely on such agreements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Disputes may arise regarding intellectual property that
is or becomes subject to a licensing agreement, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the scope of rights granted under the license agreement and other matters of contract interpretation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether and the extent to which our technology and processes infringe the intellectual property rights of the licensor
that are not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether our licensor or its licensor had the right to grant the license agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether third parties are entitled to compensation or equitable relief, such as an injunction, for our use of the
intellectual property rights without their authorization; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our involvement in the prosecution of licensed patents and our licensors&#146; overall patent enforcement strategy;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the amounts of royalties, milestones or other payments due under the license agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the sublicensing of patent and other rights under collaborative development relationships; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we do not prevail in such disputes, we may lose any or all of our rights under such license agreements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such
agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or
increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes
over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected technology and
product candidates, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">54 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Despite our efforts, our licensors or future licensors might conclude that we have materially breached our license
agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize product candidates and technology covered by these license agreements. If these
<FONT STYLE="white-space:nowrap">in-licenses</FONT> are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors could seek regulatory approval for and market products and technologies identical
to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may
not be able to protect our intellectual property and proprietary rights throughout the world. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Third parties may attempt to develop and commercialize
competitive products in foreign countries where we do not have any patent protection and/or where legal recourse may be limited. This may have a significant commercial impact on our foreign business operations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive. In addition, the laws of some
foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, and even where such protection is nominally available, adequate judicial and governmental enforcement of such
intellectual property rights may be lacking. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling our inventions in such countries or importing products
made using our inventions into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing
products to territories where we have patent protection or licenses, but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be
effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many companies have encountered significant problems in protecting and defending intellectual property
rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to
pharmaceutical and biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. In addition,
certain jurisdictions do not protect, to the same extent as the United States or at all, inventions that constitute new methods of treatment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Proceedings to
enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or
interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may
not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or
license. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many countries, including India, China and certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to
grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish
the value of such patents. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired and our business, financial condition, results of
operations, and prospects may be adversely affected. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be subject to claims challenging the inventorship or ownership of our patents and other
intellectual property. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our
owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, trade secrets or other intellectual property as an inventor, <FONT STYLE="white-space:nowrap">co-inventor,</FONT> owner or <FONT STYLE="white-space:nowrap">co-owner.</FONT> For
example, we or our licensors or collaborators may have inventorship or ownership disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to
defend against these and other claims challenging inventorship or our or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">55 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
our licensors&#146; or collaborators&#146; ownership of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, trade secrets or other intellectual property. If we or our
licensors or collaborators fail in defending any such claims, we may be required to pay monetary damages and we may also lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is
important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse
effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be subject to claims by third parties asserting that our employees,
consultants or contractors have wrongfully used or disclosed confidential information of such third parties, or that they have wrongfully used or disclosed alleged trade secrets of their current or former employers, or that we have misappropriated
their intellectual property, or that they own what we regard as our own intellectual property. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of our employees, consultants and contractors were
previously employed at or engaged by universities or other pharmaceutical or biotechnology companies, including our competitors or potential competitors. Many of them executed proprietary rights,
<FONT STYLE="white-space:nowrap">non-disclosure</FONT> and/or <FONT STYLE="white-space:nowrap">non-competition</FONT> agreements in connection with such previous employment or engagement. Although we try to ensure that the individuals who work for
us do not use the intellectual property rights, proprietary information, <FONT STYLE="white-space:nowrap">know-how</FONT> or trade secrets of others in their work for us, we may be subject to claims that we or they have, inadvertently or otherwise,
used, infringed, misappropriated or otherwise violated the intellectual property rights, or disclosed the alleged trade secrets or other proprietary information, of these former employers, competitors or other third parties. We may also be subject
to claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. Any litigation or the threat of litigation may adversely affect our ability to hire employees or engage consultants
and contractors. A loss of key personnel or their work product could hamper or prevent us from developing and commercializing products and product candidates, which could harm our business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, while it is our policy to require our employees, consultants and contractors who may be involved in the development of intellectual property to execute
agreements assigning such intellectual property to us, we may be unsuccessful in obtaining such an agreement from each party who in fact develops intellectual property that we regard as our own. Our intellectual property assignment agreements with
them may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could
have a material adverse effect on our business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we fail in prosecuting or defending any such claims,
we may be required to pay monetary damages, and we may also lose valuable intellectual property rights or personnel, which could have a material adverse effect on our competitive position and prospects. Such intellectual property rights could be
awarded to a third-party, and we could be required to obtain a license from such third-party to commercialize our technology or products, which license may not be available on commercially reasonable terms, or at all, or such license may be <FONT
STYLE="white-space:nowrap">non-exclusive.</FONT> Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and employees. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets and confidentiality agreements to protect our unpatented
<FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information to maintain our competitive position. We seek to protect our trade secrets and other proprietary technology, in part, by entering into <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract
manufacturers, consultants, advisors and other third parties. We also enter into confidentiality agreements with our employees and consultants. We cannot guarantee that we have entered into such agreements with each party that may have or has had
access to our trade secrets or proprietary technology. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies
for such breaches. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable.
In addition, some courts inside and outside the United States </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">56 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third-party, we would have no
right to prevent them, or those to whom they communicate such trade secrets, from using that technology or information to compete with us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, we expect
that, over time, our trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary information may be disseminated within the industry through independent development, the publication of journal articles and the movement of
personnel to and from academic and industry scientific positions. Consequently, without costly efforts to protect our proprietary technology, we may be unable to prevent others from exploiting that technology, which could affect our ability to
expand in domestic and international markets. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third-party, our competitive position would be materially and adversely harmed. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic
security of our information technology systems. These security measures may be breached, and we may not have adequate remedies for any breach. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If our
trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be
adversely affected. Our trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be
forced to stop using these trademarks or trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trademarks or trade names similar to ours, thereby
impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trademark or trade name infringement claims brought by owners of other registered trademarks or trade names that incorporate
variations of our trademarks or trade names. Over the long term, if we are unable to successfully register our trademarks and trade names and establish name recognition based on our trademarks and trade names, we may not be able to compete
effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks and trade names may be ineffective and could result in substantial costs and diversion of resources and could
adversely impact our financial condition or results of operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Intellectual property rights do not necessarily address all potential threats.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not
adequately protect our business or permit us to maintain a competitive advantage. For example: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we or our license partners or current or future collaborators might not have been the first to file patent applications
covering our or their inventions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">it is possible that our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> pending patent applications or those
we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future will not lead to issued patents; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by
our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our competitors or other third parties might conduct research and development activities in countries where we do not have
patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we cannot ensure that any of our pending patent applications, if issued, or those of our licensors, will include claims
having a scope sufficient to protect our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we cannot ensure that any patents issued to us or our licensors will provide a basis for an exclusive market for our
commercially viable product candidates or will provide us with any competitive advantages; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we cannot ensure that our commercial activities or product candidates will not infringe upon the patents of others;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">57 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we cannot ensure that we will be able to successfully commercialize our product candidates on a substantial scale, if
approved, before the relevant patents that we own or license expire; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the patents of others may harm our business; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may choose not to seek patent protection in order to maintain certain trade secrets or know- how, and a third-party may
subsequently file a patent covering such intellectual property. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Should any of these events occur, they could have a material adverse effect on
our business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Employees, Managing Our Growth and Our Operations </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are highly dependent on the expertise of the principal members of our management, scientific, and clinical teams. Our scientific and clinical development personnel
have extensive experience developing and implementing novel clinical trial designs and successfully conducting clinical trials in never-before treated patient populations. If we lose one or more of our executive officers or key employees, our
ability to execute our programs and implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited
number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize product candidates successfully. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms given
the competition among numerous biotechnology and pharmaceutical companies for similar personnel. We may also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of our employees were previously employed by Alexion, a potential competitor. To the extent we employ or engage personnel from competitors, we may be subject to
allegations that such individuals have been improperly solicited or have divulged proprietary or other confidential information, or that their former employers own their research output. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and
commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to
continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We expect to expand our development,
regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of clinical development, regulatory
affairs and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities or lease or acquire new facilities, and continue to recruit
and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our
operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution
of our business plans or disrupt our operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our business and operations would suffer in the event of system failures. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Despite the implementation of security measures, our computer systems, as well as those of our CROs and other contractors and consultants, are vulnerable to damage from
computer viruses, unauthorized access, natural and manmade disasters (including hurricanes), terrorism, war, and telecommunication and electrical failures. While we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">58 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
do not believe that we have experienced any such system failure or accident to date, if such an event were to occur and cause interruptions in our or their operations, it could result in delays
and/or material disruptions of our research and development programs. For example, the loss of preclinical or clinical trial data from completed, ongoing, or planned trials, or the loss of other proprietary data, could result in delays in our
regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we currently rely on third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating
to their computer systems could also have a material adverse effect on our business. To the extent that any disruption were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or
proprietary information, we could incur liability, and the development of our product candidates could be delayed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our proprietary or confidential
information may be lost, or we may suffer security breaches. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The U.S. federal and various state and foreign governments have enacted or proposed
requirements regarding the collection, distribution, use, security and storage of personally identifiable information and other data relating to individuals. In the ordinary course of our business, we and third parties with which we have
relationships will continue to collect and store sensitive data, including clinical trial data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, in data centers and
on networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our and our collaborators&#146; security measures, our information technology and infrastructure may be vulnerable to attacks
by hackers or internal bad actors, breaches due to employee error, technical vulnerabilities, malfeasance, or other disruptions. Several proposed and enacted federal, state and international laws and regulations obligate companies to notify
individuals of security breaches involving personally identifiable information, which could result from breaches experienced by us or by third parties, including collaborators, vendors, contractors, or other organizations with which we have formed
strategic relationships. Although, to our knowledge, neither we nor any such third parties have experienced any material security breach, and even though we may have contractual protections with such third parties, any such breach could compromise
our or their networks and the information stored therein could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure, notifications, <FONT STYLE="white-space:nowrap">follow-up</FONT> actions related to such a security breach
or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, and significant costs, including regulatory penalties, fines, and legal expenses, and such an event
could disrupt our operations, cause us to incur remediation costs, damage our reputation, and cause a loss of confidence in us and our or such third parties&#146; ability to conduct clinical trials, which could adversely affect our reputation and
delay the clinical development of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to this Offering and Our Common Stock </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We do not know whether a market will develop for our common stock or what the market price of our common stock will be, and, as a result, it may be difficult for
you to sell your shares of our common stock. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before this offering, there was no public trading market for our common stock. If a market for our common
stock does not develop or is not sustained, it may be difficult for you to sell your shares of common stock at an attractive price or at all. We cannot predict the prices at which our common stock will trade. It is possible that in one or more
future periods our results of operations may be below the expectations of public market analysts and investors, and, as a result of these and other factors, the price of our common stock may fall. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The market price of our common stock may be volatile, which could result in substantial losses for investors purchasing shares in this offering. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The initial public offering price for our common stock was determined through negotiations with the underwriters. This initial public offering price may vary from the
market price of our common stock after the offering. As a result, you may not be able to sell your common stock at or above the initial public offering price. Some of the factors that may cause the market price of our common stock to fluctuate
include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the success of existing or new competitive product candidates or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing and results of preclinical studies for any product candidates that we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure or discontinuation of any of our product development and research programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the success of the development of companion diagnostics, if required, for use with our product candidates;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">59 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">results of preclinical studies, clinical trials, or regulatory approvals of product candidates of our competitors, or
announcements about new research programs or product candidates of our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">commencement or termination of collaborations for our product development and research programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developments or disputes concerning patent applications, issued patents, or other proprietary rights;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the level of expenses related to any of our research programs or product candidates that we may develop;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the results of our efforts to develop additional product candidates or products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">actual or anticipated changes in estimates as to financial results, development timelines, or recommendations by
securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">announcement or expectation of additional financing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sales of our common stock by us, our insiders or other stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expiration of market <FONT STYLE="white-space:nowrap">stand-off</FONT> or <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">effects of public health crises, pandemics and epidemics, such as <FONT STYLE="white-space:nowrap">COVID-19;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">variations in our financial results or those of companies that are perceived to be similar to us; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in estimates or recommendations by securities analysts, if any, that cover our stock; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">general economic, industry, and market conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the other factors described in this &#147;Risk Factors&#148; section and elsewhere in this prospectus.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced
extreme price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may
seriously affect the market price of our common stock, regardless of our actual operating performance. These fluctuations may be even more pronounced in the trading market for our stock shortly following this offering. The market price of our common
stock may decline below the initial public offering price, and you may lose some or all of your investment. Following periods of such volatility in the market price of a company&#146;s securities, securities class action litigation has often been
brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>You
will incur immediate and substantial dilution as a result of this offering. </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you purchase common stock in this offering, you will incur immediate and
substantial dilution of $7.66 per share, representing the difference between the assumed initial public offering price of $14.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, and our pro forma net
tangible book value per share after giving effect to this offering. To the extent that shares are issued upon the exercise of options or the underwriters exercise their option to purchase additional shares, you will incur further dilution. For a
further description of the dilution you will experience immediately after this offering, see &#147;Dilution.&#148; </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If securities analysts do not publish
research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The trading market for
our common stock will rely in part on the research and reports that industry or financial analysts publish about us or our business. We do not currently have and may never obtain research coverage by industry or financial analysts. If no or few
analysts commence coverage of us, the trading price of our stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock
could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">60 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>A significant portion of our total outstanding shares is restricted from immediate resale but may be sold into the
market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing well. </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Sales
of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the
market price of our common stock. After this offering, we will have 30,749,972 shares of common stock outstanding, or 31,612,472 shares if the underwriters exercise their option to purchase additional shares in full, in each case based on the
24,999,972 shares of our common stock outstanding as of June 30, 2021. Of these shares, the 5,750,000 shares (or 6,612,500 shares if the underwriters exercise their option to purchase additional shares in full) we are selling in this offering may be
resold in the public market immediately, unless purchased by our affiliates. The remaining 24,999,972 shares are currently restricted under securities laws or as a result of <FONT STYLE="white-space:nowrap">lock-up</FONT> or other agreements, but
will be able to be sold after this offering as described in the &#147;Shares Eligible for Future Sale&#148; section of this prospectus. Moreover, after this offering, holders of an aggregate of 23,061,474 shares of our common stock will have rights,
subject to conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also plan to register all shares of common
stock that we may issue under our equity compensation plans or that are issuable upon exercise of outstanding options. Once we register these shares, they can be freely sold in the public market upon issuance and once vested, subject to volume
limitations applicable to affiliates and the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described in the &#147;Underwriting&#148; section of this prospectus. If any of these additional shares are sold, or if it is perceived that they
will be sold, in the public market, the market price of our common stock could decline. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Insiders will continue to have substantial influence over us
after this offering, which could limit your ability to affect the outcome of key transactions, including a change of control. </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After this offering, our
directors and executive officers and their affiliates will beneficially own shares representing approximately 57% of our outstanding common stock. As a result, these stockholders, if they act together, will be able to influence our management and
affairs and all matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. The interests of these holders may not always coincide with our corporate interests or the interests of
other stockholders, and they may act in a manner with which you may not agree or that may not be in the best interests of our other stockholders. This concentration of ownership may have the effect of delaying or preventing a change in control of
our company and might affect the market price of our common stock. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We could be subject to securities class action litigation. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the past, securities class action litigation has often been brought against companies following a decline in the market price of their securities. This risk is
especially relevant for us because biotechnology and pharmaceutical companies have experienced significant share price volatility in recent years. Because of the potential volatility of our stock price, we may become the target of securities
litigation in the future. Securities litigation could result in substantial costs and divert management&#146;s attention and resources from our business. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of
gain. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the
development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends in the foreseeable future. As a result, capital appreciation, if any, of our common stock will be your sole source of gain on an
investment in our common stock in the foreseeable future. See &#147;Dividend Policy&#148; for additional information. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are an &#147;emerging growth
company,&#148; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
are an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we may remain an emerging growth company until December&nbsp;31, 2026. For so long as we remain an emerging growth
company, we are permitted and plan to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include not being required to comply with the
auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or SOX Section&nbsp;404, not being required to comply with any requirement that may be adopted by the Public </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">61 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial
statements, reduced disclosure obligations regarding executive compensation, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not
previously approved. As a result, the information we provide stockholders will be different than the information that is available with respect to other public companies. In this prospectus, we have not included all of the executive compensation
related information that would be required if we were not an emerging growth company. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less
attractive as a result, there may be a less active trading market for our common stock, and our stock price may be more volatile. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the JOBS Act
provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until
those standards would otherwise apply to private companies. We have elected not to &#147;opt out&#148; of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or
private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i)&nbsp;irrevocably elect to &#147;opt out&#148; of such extended transition
period, or (ii)&nbsp;no longer qualify as an emerging growth company. Therefore, the reported results of operations contained in our financial statements may not be directly comparable to those of other public companies. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Provisions in our amended and restated certificate of incorporation, our amended and restated bylaws and Delaware law may have anti-takeover effects that could
discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective prior to the closing of this offering, and Delaware
law contain provisions that may have the effect of discouraging, delaying or preventing a change in control of us or changes in our management that stockholders may consider favorable, including transactions in which you might otherwise receive a
premium for your shares. Our amended and restated certificate of incorporation and bylaws, which will become effective prior to the closing of this offering, include provisions that: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">authorize &#147;blank check&#148; preferred stock, which could be issued by our board of directors without stockholder
approval and may contain voting, liquidation, dividend and other rights superior to our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">create a classified board of directors whose members serve staggered three-year terms; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">specify that special meetings of our stockholders can be called only by our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">prohibit stockholder action by written consent; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our
stockholders, including proposed nominations of persons for election to our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though
less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">provide that our directors may be removed only for cause; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">specify that no stockholder is permitted to cumulate votes at any election of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expressly authorize our board of directors to modify, alter or repeal our amended and restated bylaws; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">require supermajority votes of the holders of our common stock to amend specified provisions of our amended and restated
certificate of incorporation and amended and restated bylaws. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These provisions, alone or together, could delay or prevent hostile takeovers and
changes in control or changes in our management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, because we are incorporated in the State of Delaware, we are governed by the provisions of Section&nbsp;203 of the General Corporation Law of the State of
Delaware, or the DGCL, which prohibits a person who owns in excess </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">62 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our
outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any provision of our amended and restated certificate of
incorporation, amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also
affect the price that some investors are willing to pay for our common stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our amended and restated certificate of incorporation will designate the state
or federal courts within the State of Delaware as the exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for
disputes with us or our directors, officers or employees. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation, which will become effective prior to the
closing of this offering, will provide that, subject to limited exceptions, the state or federal courts (as appropriate) within the State of Delaware will be exclusive forums for (1)&nbsp;any derivative action or proceeding brought on our behalf,
(2)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3)&nbsp;any action asserting a claim against us arising pursuant to any provision of the DGCL,
our amended and restated certificate of incorporation or our amended and restated bylaws, (4)&nbsp;action against us or any of our directors or officers involving a claim or defense arising pursuant to the Exchange Act or the Securities Act, or
(5)&nbsp;any other action asserting a claim against us that is governed by the internal affairs doctrine. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to
have consented to the provisions of our amended and restated certificate of incorporation described above. This exclusive forum provision will not apply to claims which are vested in the exclusive jurisdiction of a court or forum other than the
Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction. For instance, the provision would not apply to actions arising under federal securities laws,
including suits brought to enforce any liability or duty created by the Exchange Act or the rules and regulations thereunder. This choice of forum provision may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds
favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of our amended and
restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which
could adversely affect our business and financial condition. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court
are &#147;facially valid&#148; under Delaware law, there is uncertainty as to whether other courts will enforce our federal forum provision. If the federal forum provision is found to be unenforceable, we may incur additional costs associated with
resolving such matters. The federal forum provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot specify with certainty the particular uses of the net proceeds we will receive from this offering. Our management will have broad discretion in the
application of the net proceeds, including for any of the purposes described in &#147;Use of Proceeds.&#148; Accordingly, you will have to rely upon the judgment of our management with respect to the use of the proceeds, with only limited
information concerning management&#146;s specific intentions. Our management may spend a portion or all of the net proceeds from this offering in ways that our stockholders may not desire or that may not yield a favorable return. The failure by our
management to apply these funds effectively could harm our business, financial condition, results of operations and prospects. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that
loses value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">63 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General Risks </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>A variety
of risks associated with operating internationally could materially adversely affect our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our business strategy includes potentially expanding
internationally. Doing business internationally involves several risks, including, but not limited to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">multiple, conflicting, and changing laws and regulations, such as privacy regulations, tax laws, export and import
restrictions, economic sanctions laws and regulations, employment laws, regulatory requirements, and other governmental approvals, permits, and licenses; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">failure by us to obtain and maintain regulatory approvals for the use of our products in various countries;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">additional potentially relevant third-party patent rights; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">complexities and difficulties in obtaining protection and enforcing our intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">difficulties in staffing and managing foreign operations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">complexities associated with managing multiple payor reimbursement regimes, government payors, or patient <FONT
STYLE="white-space:nowrap">self-pay</FONT> systems; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">limits in our ability to penetrate international markets; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and
regional financial crises on demand and payment for our products, and exposure to foreign currency exchange rate fluctuations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of
disease, boycotts, curtailment of trade, and other business restrictions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">certain expenses, including, among others, expenses for travel, translation, and insurance; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that
may fall within the purview of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, its books and records provisions, or its anti-bribery provisions, as well as other applicable laws and regulations prohibiting bribery and
corruption. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any of these factors could significantly harm any future international expansion and operations and, consequently, our results of
operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>U.S. federal income tax reform could adversely affect our business and financial condition. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The rules dealing with U.S. federal, state, and local income taxation are constantly under review through the legislative process and by the Internal Revenue Service
and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to
occur in the future. For example, the Tax Cuts and Jobs Act, or the TCJA, was enacted in 2017 and significantly reformed the Code. The TCJA, among other things, contains significant changes to corporate and individual taxation, some of which could
adversely impact an investment in our common stock. Additionally, on March&nbsp;27, 2020, President Trump signed into law the CARES Act, which included certain changes in tax law intended to stimulate the U.S. economy in light of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including temporary beneficial changes to the treatment of NOLs, interest deductibility limitations and payroll tax matters. There also may be technical corrections legislation or other
legislative changes proposed with respect to the TCJA and CARES Act, the effects of which cannot be predicted and may be adverse to us or our stockholders. Future changes in tax laws could have a material adverse effect on our business, cash flows,
financial condition or results of operations. In particular, the recent presidential and congressional elections in the United States could result in significant changes in, and uncertainty with respect to, tax legislation, regulation and government
policy directly affecting our business or indirectly affecting us because of impacts on our customers and suppliers. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an
investment in our common stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Potential clinical trial or product liability lawsuits against us could cause us to incur substantial liabilities and limit
commercialization of any products that we may develop. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The use of any product candidates we may develop in clinical trials and the sale of any products for
which we obtain marketing approval exposes us to the risk of clinical trial and product liability claims. Clinical trial or product liability claims might be brought against us by patients, healthcare providers, pharmaceutical companies or others
selling or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">64 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
otherwise coming into contact with our products. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. If we cannot
successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, clinical trial or product liability claims may result in: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">impairment of our business reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">withdrawal of participants from our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">significant costs to defend the litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">distraction of management&#146;s attention from our primary business; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">substantial monetary awards to patients or other claimants; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">inability to commercialize a product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">decreased market demand for any product; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">loss of revenue. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The clinical trial and product liability insurance we currently carry, and any additional clinical trial and product liability insurance coverage we acquire in the
future, may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in
sufficient amounts to protect us against losses due to liability. If we obtain marketing approval for any product candidate, we intend to acquire insurance coverage to include the sale of commercial products; however, we may be unable to obtain
product liability insurance on commercially reasonable terms or in adequate amounts. A successful clinical trial or product liability claim, or series of claims, brought against us could cause our share price to decline and, if judgments exceed our
insurance coverage, could adversely affect our results of operation and business, including preventing or limiting the commercialization of any product candidates we develop. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic
downturn, or additional global financial crises, could result in a variety of risks to our business, including weakened demand for our product candidates, if approved, or our ability to raise additional capital when needed on acceptable terms, if at
all. For example, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets. Similarly, the significant volatility associated with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has caused
significant instability and disruptions in the capital and credit markets. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate
all of the ways in which the current economic climate and financial market conditions could adversely impact our business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We will incur increased costs as a
result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a public company, and particularly after we are no longer an &#147;emerging growth company,&#148; we will incur significant legal, accounting, and other expenses
that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Market, and other applicable securities rules and regulations
impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We expect that we will need to hire additional accounting, finance, and other
personnel in connection with our becoming, and our efforts to comply with the requirements of being, a public company, and our management and other personnel will need to devote a substantial amount of time towards maintaining compliance with these
requirements. These requirements will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that the rules and regulations applicable to us as a public company may make
it more difficult and more expensive for us to obtain director and officer liability insurance, which could make it more difficult for us to attract and retain qualified members of our board of directors. We are currently evaluating these rules and
regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">65 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing
bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or SOX Section&nbsp;404, we will be required to furnish a report by our management on our internal
control over financial reporting beginning with our second filing of an Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> with the SEC after we become a public company. However, while we remain an emerging growth company, we will
not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with SOX Section&nbsp;404 within the prescribed period, we will be
engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants, adopt
a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a
continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over
financial reporting is effective as required by SOX Section&nbsp;404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial
statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">66 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_3"></A>SPECIAL NOTE REGARDING <FONT STYLE="white-space:nowrap">FORWARD-LOOKING</FONT>
STATEMENTS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus contains <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements that are based on management&#146;s beliefs and
assumptions and on information currently available to management. All statements other than statements of historical facts contained in this prospectus are <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements. In some cases, you can
identify <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148;
&#147;target,&#148; &#147;project,&#148; &#147;contemplate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions, although not
all <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements contain these words. <FONT STYLE="white-space:nowrap">Forward-looking</FONT> statements include, but are not limited to, statements concerning: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing of our planned CTA submission for RLYB116; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the initiation, timing, progress, results, and cost of our research and development programs, and our current and future
preclinical and clinical studies, including statements regarding the timing of initiation and completion of our clinical trials for RLYB211, RLYB212, and RLYB116, and the natural history study for our FNAIT prevention program, and related
preparatory work, and the period during which the results of the trials will become available; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the success, cost and timing of our clinical development of our product candidates, including RLYB212, RLYB116 and
RLYB114; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing of our planned nomination of a compound for our ENPP1 program under our joint venture with Exscientia;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to initiate, recruit and enroll patients in and conduct our clinical trials at the pace that we project;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions,
limitations or warnings in the label of any of our product candidates, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to compete with companies currently marketing or engaged in the development of treatments for diseases that
our product candidates are designed to target, including PNH and gMG; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our reliance on third parties to conduct our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our reliance on third parties to manufacture drug substance for use in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the size and growth potential of the markets for RLYB212, RLYB116, RLYB114 and any of our current product candidates or
other product candidates we may identify and pursue, and our ability to serve those markets; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to expand our pipeline through collaborations, partnerships and other transactions with third parties;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to identify and advance through clinical development any additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the commercialization of our current product candidates and any other product candidates we may identify and pursue, if
approved, including our ability to successfully build commercial infrastructure or enter into collaborations with third parties to market our current product candidates and any other product candidates we may identify and pursue;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to retain and recruit key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to obtain and maintain adequate intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our expectations regarding government and third-party payor coverage and reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our estimates of our expenses, ongoing losses, capital requirements and our needs for or ability to obtain additional
financing; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our expected uses of the net proceeds to us from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the potential benefits of strategic collaboration agreements, our ability to enter into strategic collaborations or
arrangements, including potential business development opportunities and potential licensing partnerships, and our ability to attract collaborators with development, regulatory and commercialization expertise; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">67 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our financial performance; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developments and projections relating to our competitors or our industry; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">other risks and uncertainties, including those listed under the section titled &#147;Risk Factors.&#148;
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements in this prospectus are only predictions and are based largely on our
current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements speak only
as of the date of this prospectus and are subject to a number of known and unknown risks, uncertainties and assumptions, including those described under the sections in this prospectus entitled &#147;Risk Factors&#148; and &#147;Management&#146;s
Discussion and Analysis of Financial Condition and Results of Operations&#148; and elsewhere in this prospectus. Because <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements are inherently subject to risks and uncertainties, some of
which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements as guarantees of future events. The events and circumstances reflected
in our <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the <FONT
STYLE="white-space:nowrap">forward-looking</FONT> statements. Moreover, we operate in an evolving environment. New risks and uncertainties may emerge from time to time, and it is not possible for management to predict all risks and uncertainties.
Except as required by applicable law, we are not obligated to publicly update or revise any <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements contained herein, whether as a result of any new information, future events, changed
circumstances or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">68 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate that the net proceeds to us from the sale of the shares of our common stock in this offering will be approximately $71.8 million, or approximately $83.0
million if the underwriters exercise their option to purchase additional shares in full, assuming an initial public offering price of $14.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and
after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A $1.00 increase (decrease) in the assumed initial
public offering price of $14.00 per share would increase (decrease) the net proceeds to us from this offering by approximately $5.3 million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains
the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase (decrease) of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this
prospectus, would increase (decrease) the net proceeds to us from this offering by approximately $13.0 million, assuming no change in the assumed initial public offering price per share, and after deducting the estimated underwriting discounts and
commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of June 30, 2021, we had cash and cash equivalents of $112.7 million. The principal purposes of this
offering are to increase our financial flexibility, create a public market for our common stock and to facilitate our access to the public equity markets. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
intend to use the net proceeds from this offering, together with our cash on hand, as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Approximately $75.0 million to $83.0 million to advance our FNAIT prevention program, including completion of our Phase
1/2 clinical trial for RLYB211 and completion of our Phase 1 and Phase&nbsp;1b clinical trials for RLYB212; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Approximately $35.0 million to $41.0 million to advance our complement program, including completion of our Phase&nbsp;1
clinical trial for RLYB116 and initiation of our Phase 1 clinical trial for RLYB114; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Approximately $10.0 million to $14.0 million to advance our joint ventures with Exscientia, including the initiation of
our Phase&nbsp;1 clinical trial for our ENPP1 inhibitor; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Any remaining proceeds for business development activities, working capital needs and other general corporate purposes.
</P></TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may also use a portion of the net proceeds from this offering to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or invest in
products, technologies or businesses. The amounts and timing of our actual expenditures will depend on numerous factors, including the progress of our preclinical development efforts, our operating costs and other factors described under &#147;Risk
Factors&#148; in this prospectus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our expected use of net proceeds from this offering represents our current intentions based upon our present plans and business
condition. As of the date of this prospectus, we cannot predict with complete certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the actual amounts that we will spend on the uses set
forth above. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based upon our current operating plan, we believe that the anticipated net proceeds from this offering, together with our existing cash and cash
equivalents as of June 30, 2021, will be sufficient to fund our operating expenses and capital expenditure requirements for the next 24 months. This estimate and our expectation regarding the sufficiency of the net proceeds from this offering to
advance the preclinical and clinical development of RLYB212, RLYB116 and any other product candidates are based on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. We do not
anticipate that the expected net proceeds from this offering, together with our existing cash, will be sufficient for us to fund any of our product candidates through regulatory approval, and we will need to raise substantial additional capital to
complete the development and commercialization of our product candidates, if approved. We may satisfy our future cash needs through the sale of equity securities, debt financings, working capital lines of credit, corporate collaborations or license
agreements, grant funding, interest income earned on invested cash balances or a combination of one or more of these sources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">69 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in the
application of the net proceeds. Pending the uses described above, we plan to invest the net proceeds from this offering in <FONT STYLE="white-space:nowrap">short-term,</FONT> <FONT STYLE="white-space:nowrap">interest-bearing</FONT> obligations, <FONT
STYLE="white-space:nowrap">investment-grade</FONT> instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">70 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_5"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have never made any cash distributions to our members. Subsequent to our Reorganization, we do not anticipate paying any dividends on our capital stock. We intend
to retain future earnings, if any, to finance the operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the
discretion of our board of directors after considering our financial condition, results of operations, capital requirements, business prospects and other factors our board of directors deems relevant, and subject to the restrictions contained in any
future financing instruments. Our ability to pay cash dividends on our capital stock in the future may also be limited by the terms of any preferred securities we may issue or agreements governing any indebtedness we may incur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">71 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_6"></A>THE REORGANIZATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>LLC Entity (Rallybio Holdings, LLC) </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Currently, the capital structure of
Rallybio Holdings, LLC, or the LLC Entity, consists of four classes of membership units: common units; Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred units; Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred units; and Series
B preferred units. The LLC Entity is the direct parent company of Rallybio Corporation and Rallybio Corporation is the direct parent of four subsidiaries: Rallybio, LLC, Rallybio IPA, LLC, Rallybio IPB, LLC and IPC Research, LLC. The subsidiaries of
Rallybio Corporation focus on developing, identifying, acquiring, and, if approved, commercializing our product candidates, as well as developing and holding intellectual property. Rallybio IPB, LLC jointly owns the joint venture entities with
Exscientia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Reorganization </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On June&nbsp;30, 2021, we completed a
series of transactions pursuant to which (i)&nbsp;Rallybio IPD, LLC was converted from a Delaware limited liability company to a Delaware corporation and changed its name to Rallybio Corporation, or the Corporation, and (ii)&nbsp;four
recently-formed direct subsidiaries of the Corporation, each a Delaware limited liability company, or collectively the Merger Subs, consummated a separate merger with one of the LLC Entity&#146;s direct subsidiaries, other than Rallybio IPD, LLC, or
collectively the Asset Subsidiaries, with the Asset Subsidiaries surviving the mergers and the LLC Entity receiving common stock of the Corporation in exchange for its interest in each Asset Subsidiary, which resulted in the Asset Subsidiaries
becoming subsidiaries of the Corporation and the Corporation becoming the only direct subsidiary of the LLC Entity. Prior to the completion of this offering, the LLC Entity will liquidate and distribute 100% of the capital stock of the Corporation,
consisting solely of common stock, to the unitholders of the LLC Entity. As a result of the Reorganization, the unitholders of the LLC Entity will become the holders of common stock of the Corporation. The Corporation will become the registrant for
purposes of this offering, and following the Reorganization our consolidated financial statements will be reported from the Corporation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result of the
Liquidation, the unitholders of the LLC Entity will receive 100% of the common stock of the Corporation outstanding immediately prior to the completion of the offering. The number of shares of common stock that the holders of each class of units
will receive in the Liquidation will be based on the value of the LLC Entity immediately prior to the Liquidation, determined by reference to the initial public offering price per share in this offering. In this prospectus, we have assumed a
valuation based on an initial public offering price of $14.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus. Assuming an initial public offering price of $14.00 per share, the common stock of the
Corporation will be allocated to the holders of existing units in the LLC Entity as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">holders of Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred units and Series
<FONT STYLE="white-space:nowrap">A-2</FONT> preferred units of the LLC Entity will receive an aggregate of 5,245,488 shares of common stock of the Corporation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">holders of Series B preferred units of the LLC Entity will receive an aggregate of 16,364,481 shares of common stock of
the Corporation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">holders of common and restricted common units of the LLC Entity will receive an aggregate of 893,094 shares of common
stock of the Corporation (including 188,020 shares of restricted common stock, which will continue to be subject to vesting in accordance with the vesting schedule applicable to such restricted common units); and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">holders of incentive units in the LLC Entity will receive an aggregate of 2,496,909 shares of common stock of the
Corporation. Shares of common stock issued in respect of unvested incentive units will be shares of restricted common stock and will continue to be subject to vesting in accordance with the vesting schedule applicable to such incentive units.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Assuming an initial public offering price of $15.00 per share, which is the high end of the price range set forth on the cover page of this
prospectus, the holders of Series A-1 and Series A-2 preferred units will receive an aggregate of 5,235,000 shares of our common stock, the holders of Series B preferred units will receive an aggregate of 16,331,760 shares of our common stock,
holders of common and restricted common units of the LLC Entity will receive an aggregate of 891,309 shares of our common stock, and holders of incentive units in the LLC Entity will receive an aggregate of 2,541,907 shares of our common stock. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">72 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Assuming an initial public offering price of $13.00 per share, which is the low end of the price range set forth on
the cover page of this prospectus, the holders of Series A-1 and Series A-2 preferred units will receive an aggregate of 5,257,590 shares of our common stock, the holders of Series B preferred units will receive an aggregate of
16,402,235&nbsp;shares of our common stock, holders of our common and restricted common units of the LLC Entity will receive an aggregate of 895,155 shares of our common stock, and holders of incentive units in the LLC Entity will receive an
aggregate of 2,444,990 shares of our common stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result of the Reorganization, assuming an initial public offering price of $14.00 per share, which is the
midpoint of the price range set forth on the cover page of this prospectus, the holders of existing units in the LLC Entity will collectively own an aggregate of 24,999,972 shares of our common stock of the Corporation immediately prior to the
consummation of this offering. Assuming an initial public offering price of $15.00 per share, which is the high end of the price range set forth on the cover page of this prospectus, the holders of existing units of the LLC Entity will collectively
own an aggregate of 24,999,976 shares of our common stock of the Corporation immediately prior to the consummation of this offering. Assuming an initial public offering price of $13.00 per share, which is the low end of the price range set forth on
the cover page of this prospectus, the holders of existing units of the LLC Entity will collectively own an aggregate of 24,999,970 shares of our common stock of the Corporation immediately prior to the consummation of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Holding Company Structure </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result of the Reorganization, the
Corporation is a holding company and the direct parent of: Rallybio, LLC, Rallybio IPA, LLC, Rallybio IPB, LLC and IPC Research, LLC. Except as disclosed in this prospectus, the audited consolidated financial statements for the years ended
December&nbsp;31, 2020 and 2019 and the notes thereto, the unaudited condensed consolidated financial statements for the three months ended March 31, 2021 and 2020 and the notes thereto, and selected historical consolidated financial data and other
financial information included in this prospectus are those of the LLC Entity and do not give effect to the Reorganization. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to the effectiveness of the
registration statement of which this prospectus forms a part, the members of the board of managers of the LLC Entity will become the members of the Corporation&#146;s board of directors and the officers of the LLC Entity will become the officers of
the Corporation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The purpose of the Reorganization is to reorganize our corporate structure so that the entity that is offering common stock to the public in this
offering is a corporation rather than a limited liability company, and so that our existing investors will own our common stock rather than units in a limited liability company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">73 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth our cash and capitalization as of March&nbsp;31, 2021: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">on a pro forma basis, to give effect to (i)&nbsp;the Reorganization, including the issuance by Rallybio Corporation of an
aggregate of 24,999,972 shares of its common stock and the subsequent distribution of those shares to members of Rallybio Holdings, LLC, prior to the completion of this offering, as if the Reorganization had occurred as of March&nbsp;31, 2021,
assuming an initial public offering price of $14.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus and (ii)&nbsp;the filing and effectiveness of our amended and restated certificate of
incorporation and amended and restated bylaws; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">on a pro forma as adjusted basis, to give further effect to our issuance and sale of 5,750,000 shares of our common stock
in this offering at an assumed initial public offering price of $14.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated
offering expenses. </P></TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The pro forma as adjusted information below is illustrative only and our capitalization following the closing of this
offering will change based on the initial public offering price and other terms of this offering determined at pricing. You should read the information in this table together with the financial statements and related notes as appearing at the end of
this prospectus and the information set forth under the sections titled &#147;Selected Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MARCH 31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>(in thousands, except share and per share amounts)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTUAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO<BR>FORMA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA&nbsp;AS<BR>ADJUSTED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">127,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">127,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable convertible preferred units:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable convertible preferred units , no par value; 137,921,220 shares authorized, issued or
outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">182,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Members&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Incentive Units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Common units, no par value; 5,700,000 units authorized, issued and outstanding, actual; no units
authorized, issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Preferred stock, $0.0001 par value: no shares authorized, issued or outstanding, actual; no shares
authorized and no shares issued or outstanding, pro forma; 50,000,000 shares authorized and no shares issued or outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Common stock, $0.0001 par value: no shares issued and outstanding, actual; 35,000,000 shares authorized,
24,999,972 shares issued and outstanding, pro forma; 200,000,000 shares authorized, 30,749,972 shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total members&#146;/stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(58,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">123,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">195,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">74 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A $1.00
increase (decrease) in the assumed initial public offering price of $14.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) each of cash and cash equivalents, additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; deficit and total capitalization on a pro forma as adjusted basis by approximately $5.3 million, assuming that the number of shares offered by us, as set forth on the cover
page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses. An increase (decrease) of 1,000,000 shares in the number of shares offered by us, as set forth on the
cover page of this prospectus, would increase (decrease) each of cash and cash equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; deficit and total capitalization on a pro forma as adjusted
basis by approximately $13.0 million, assuming that the assumed initial public offering price remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The outstanding share information in the table above as of March&nbsp;31, 2021 excludes: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">5,440,344 shares of our common stock reserved for issuance under the 2021 Plan, which will become effective in connection
with this offering, including 2,455,722 shares of our common stock that will be issued in respect of outstanding unvested restricted common units and outstanding unvested incentive units, 137,189 shares of our common stock were available for
issuance under the 2018 Plan and 734,080 shares of our common stock issuable upon the exercise of options to be granted in connection with this offering under the 2021 Plan with an exercise price per share equal to the initial public offering price
in this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">291,324 shares of common stock reserved for issuance under the ESPP, which will become effective in connection with this
offering. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">75 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_8"></A>DILUTION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the initial public
offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
historical net tangible book value (deficit) and historical net tangible book value (deficit) per share have not been presented as there were no common shares outstanding as of March&nbsp;31, 2021. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our pro forma net tangible book value as of March&nbsp;31, 2021 was $123.3 million or $4.93 per share of common stock. Pro forma net tangible book value represents the
amount of our total tangible assets less our liabilities, after giving effect to (i)&nbsp;the Reorganization, including the issuance by Rallybio Corporation of an aggregate of 24,999,972 shares of its common stock and the subsequent distribution of
those shares to members of Rallybio Holdings, LLC, prior to the completion of this offering, as if the Reorganization had occurred as of March&nbsp;31, 2021, assuming an initial public offering price of $14.00 per share, which is the midpoint of the
price range set forth on the cover page of this prospectus and (ii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation and amended and restated bylaws . Pro forma net tangible book value per share represents
pro forma net tangible book value divided by the total number of shares outstanding as of March&nbsp;31, 2021 after giving effect to the pro forma adjustments described above. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After giving further effect to our issuance and sale of shares of common stock in this offering at an assumed initial public offering price $14.00 per share, which is
the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses&nbsp;payable by us, our pro forma as adjusted net tangible book
value as of March&nbsp;31, 2021 would have been $195.1 million, or $6.34 per share. This represents an immediate increase in pro forma as adjusted net tangible book value of $1.41 per share to existing stockholders and an immediate dilution of $7.66
in pro forma as adjusted net tangible book value per share to new investors participating in this offering. Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering
from the assumed initial public offering price per share paid by new investors. The following table illustrates this dilution on a per share basis: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net tangible book value per share of common stock as of March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in net tangible book value per share of common stock attributable to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma as adjusted net tangible book value per share of common stock after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dilution per share of common stock to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The dilution information discussed above is illustrative only and will change based on the actual initial public offering price and other terms of this offering
determined at pricing. A $1.00 increase (decrease) in the assumed initial price to the public of $14.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as
adjusted net tangible book value by approximately $5.3&nbsp;million, or approximately $0.17 per share, and increase (decrease) the dilution per share to investors participating in this offering by approximately $0.83 per share, assuming that the
number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase of 1,000,000 in
the number of shares offered by us, as set forth on the cover page of this prospectus, would increase the pro forma as adjusted net tangible book value by approximately $13.0 million, or approximately $0.21 per share, and the dilution per share to
new investors participating in this offering would be approximately $7.45 per share, assuming that the assumed initial price to the public remains the same, and after deducting the estimated underwriting discounts and commissions and estimated
offering expenses payable by us. A decrease of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would decrease the pro forma as adjusted net tangible book value by approximately $13.0
million, or approximately $0.22 per share, and the dilution per share </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">76 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
to investors participating in this offering would be approximately $7.88 per share, assuming that the assumed initial price to the public remains the same, and after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the underwriters exercise in full their option to purchase additional
shares of common stock from us in this offering, our pro forma as adjusted net tangible book value per share after the offering would be approximately $6.53, representing an immediate increase in pro forma as adjusted net tangible book value per
share of approximately $1.60 to existing stockholders and immediate dilution in pro forma as adjusted net tangible book value per share of approximately $7.47 to new investors purchasing common stock in this offering, assuming an initial public
offering price of approximately $14.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable
by us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes, as of March&nbsp;31, 2021, on the pro forma as adjusted basis described above, the total number of shares of common stock
purchased from us, the total consideration and the average price per share (1)&nbsp;paid by existing stockholders and (2)&nbsp;to be paid by new investors participating in this offering at the assumed initial public offering price of $14.00 per
share, which is the midpoint of the price range set forth on the cover page of this prospectus, before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. As the table shows, new investors
purchasing common stock in this offering will pay an average price per share substantially higher than our existing stockholders paid. </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES&nbsp;PURCHASED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL&nbsp;CONSIDERATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AVERAGE<BR>PRICE&nbsp;PER</B><br><B>SHARE</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,999,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,749,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The table above assumes no exercise of the underwriters&#146; option to purchase additional shares in this offering. If the underwriters&#146; option to purchase
additional shares is exercised in full, the number of shares of common stock held by existing stockholders would be reduced to 79.1% of the total number of shares of common stock to be outstanding upon completion of this offering, and the number of
shares of common stock held by new investors participating in this offering will be increased to 20.9% of the total number of shares of our common stock to be outstanding upon completion of the offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A $1.00 increase (decrease) in the assumed initial public offering price of $14.00 per share, which is the midpoint of the price range set forth on the cover page of
this prospectus, would increase (decrease) the total consideration paid by new investors by approximately $5.8 million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same. We may
also increase or decrease the number of shares we are offering. An increase (decrease) of 1,000,000 in the number of shares offered by us would increase (decrease) total consideration paid by new investors by approximately $14.0 million, assuming no
change in the assumed initial public offering price. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The pro forma shares outstanding of 24,999,972 as of March&nbsp;31, 2021 and related share information
presented in the tables and discussions above excludes: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">5,440,344 shares of our common stock reserved for issuance under the 2021 Plan, which will become effective in connection
with this offering, including 2,455,722 shares of our common stock that will be issued in respect of outstanding unvested restricted common units and outstanding unvested incentive units, 137,189 shares of our common stock were available for
issuance under the 2018 Plan and 734,080 shares of our common stock issuable upon the exercise of options to be granted in connection with this offering under the 2021 Plan with an exercise price per share equal to the initial public offering price
in this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">291,324 shares of common stock reserved for issuance under the ESPP, which will become effective in connection with this
offering. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">77 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">New investors will experience further dilution when any new options are issued and exercised under our equity incentive
plans or we issue additional shares of common stock, other equity securities or convertible debt securities for lower consideration per share than in this offering in the future. In addition, we may choose to raise additional capital through the
sale of equity or convertible debt securities due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or
convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">78 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_9"></A>SELECTED FINANCIAL DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You should read the following selected financial data together with the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations&#148; of this prospectus and our financial statements and the related notes included elsewhere in this prospectus. The statements of operations and comprehensive loss data for the years ended December&nbsp;31, 2020 and 2019 and
the balance sheet data as of December&nbsp;31, 2020 and 2019 have been derived from our audited financial statements included elsewhere in this prospectus. The statements of operations and comprehensive loss data for the three months ended
March&nbsp;31, 2021 and 2020 and our balance sheet as of March&nbsp;31, 2021 have been derived from our unaudited financial statements included elsewhere in this prospectus. In the opinion of management, the unaudited financial data reflect all
adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of such financial information in those statements. Our historical results are not necessarily indicative of the results that may be expected in the future.
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED</B><br><B>DECEMBER 31, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE MONTHS ENDED<BR>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share amounts) </B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Statement of Operations and Comprehensive Loss Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,642</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,824</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,844</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value of Series A-2 financing right obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,749</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss on investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per common unit, basic and
diluted&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9.95</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average common units outstanding&#151;basic and diluted&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,659,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,715,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,228,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,968,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net loss per share, basic and
diluted&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma weighted average common stock outstanding, basic and diluted&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,348,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,195,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See Note 11 to our audited consolidated financial statements and Note 8 to our unaudited condensed consolidated financial statements included elsewhere in this prospectus for details on the calculation of basic and
diluted net loss per common unit attributable to common stockholders. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">The calculations for the unaudited pro forma net loss per share attributable to common stockholders, basic and diluted, and
the unaudited pro forma weighted-average common shares outstanding, basic and diluted, for the year ended December&nbsp;31, 2020 and the quarter ended March&nbsp;31, 2021 give effect to the Reorganization, including the issuance by the Corporation
of approximately 24,999,972 shares of its common stock and the subsequent distribution of those shares to members of the LLC entity, including all </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">79 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
preferred units, common units, and incentive units outstanding as of January&nbsp;1, 2020 or the issuance date of those units, if later, assuming an initial public offering price of $14.00 per
share, which is the midpoint of the price range set forth on the cover page of this prospectus, as if the Reorganization had occurred as of January&nbsp;1, 2020. </TD></TR></TABLE>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">140,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">127,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Working capital<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,014</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total members&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(58,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We define working capital as current assets, less current liabilities. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">80 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>You should read the following discussion and analysis of our financial condition and results of operations together with the &#147;Selected
Financial Data&#148; section of this prospectus and our financial statements and related notes included elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus,
including information with respect to our plans and strategy for our business and related financing, includes <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements that involve risks and uncertainties. As a result of many factors,
including those factors set forth in the &#147;Risk Factors&#148; section of this prospectus, our actual results could differ materially from the results described in or implied by the <FONT STYLE="white-space:nowrap">forward-looking</FONT>
statements contained in the following discussion and analysis. See &#147;Special Note Regarding Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical-stage biotechnology company built around a team of seasoned industry experts with a shared purpose and a track record of success in discovering,
developing, manufacturing and delivering therapies that meaningfully improve the lives of patients suffering from severe and rare diseases. Our mission at Rallybio is aligned with our expertise, and we believe we have assembled the best people,
partners and science to forge new paths to life-changing therapies. Since our launch in January 2018, we have acquired a portfolio of promising product candidates that consists of five programs, and we are focused on further expanding our portfolio
with the goal of making a profound impact on the lives of even more patients. We are drawing on our decades of knowledge and experience with a determination to tackle the undone, the too difficult, the inaccessible &#150; and change the odds for
rare disease patients. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our most advanced program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, or FNAIT, a potentially life-threatening
rare hematological disease that impacts fetuses and newborns. We are evaluating RLYB211, a polyclonal anti-HPA-1a antibody, in a Phase&nbsp;1/2 clinical trial, which we believe has established proof of concept for RLYB211 and provides support for
our proposed mechanism of action. We plan to move this program forward with our lead product candidate, RLYB212, a monoclonal anti-HPA-1a antibody, and submitted a CTA for RLYB212 in July&nbsp;2021. We are also focused on developing therapies that
address diseases of complement dysregulation, including paroxysmal nocturnal hemoglobinuria, or PNH, generalized myasthenia gravis, or gMG, and ophthalmic disorders. RLYB116 is a novel, potentially long-acting, subcutaneously administered inhibitor
of complement factor 5, or C5, in development for the treatment of patients with PNH and gMG. We expect to submit a CTA for RLYB116 in the fourth quarter of 2021. RLYB114 is a pegylated C5 inhibitor in preclinical development for the treatment of
complement-mediated ophthalmic diseases and we expect to submit a CTA for this product candidate in the first half of 2023. Additionally, in collaboration with Exscientia Limited, or Exscientia, we have two discovery-stage programs focused on the
identification of small molecule therapeutics for patients with rare metabolic diseases. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since inception, we have devoted substantially all of our resources to
raising capital, organizing and staffing our company, business planning, conducting discovery and research activities, acquiring or discovering product candidates, establishing and protecting our intellectual property portfolio, developing and
progressing our product candidates, preparing for clinical trials and establishing arrangements with third parties for the manufacture of our product candidates and component materials, including activities relating to our preclinical development
and manufacturing activities for each of our five programs and our Phase 1/2 clinical trial for RLYB211. We do not have any product candidates approved for sale and have not generated any revenue from product sales. Since our inception, we have
funded our operations primarily through equity financings and have received proceeds of approximately $182.0&nbsp;million, net of issuance costs of $0.5&nbsp;million, from the sale of our preferred units. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To date, we have devoted most of our financial resources to research and development, including our preclinical development and manufacturing activities for each of our
five programs and our Phase 1/2 clinical trial for RLYB211. We have not commercialized any products and have never generated revenue from the commercialization of any product. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have incurred significant operating losses since inception, including net losses of $26.4&nbsp;million and $17.6&nbsp;million for the years ended December&nbsp;31,
2020 and 2019, respectively, and net losses of $13.3&nbsp;million and $3.9&nbsp;million for the three months ended March&nbsp;31, 2021 and 2020, respectively. As of March&nbsp;31, 2021, we had </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">81 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
an accumulated deficit of $60.3&nbsp;million. These losses have resulted primarily from costs incurred in connection with research and development activities and general and administrative costs
associated with our operations. We expect to incur significant additional operating losses in the foreseeable future as we advance our programs through preclinical and clinical development, expand our research and development activities, acquire and
develop new product candidates, complete preclinical studies and clinical trials, finance our business development strategy, seek regulatory approval for the commercialization of our product candidates and commercialize our products, if approved.
Our expenses will increase substantially if and as we: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">file a CTA and initiate a Phase&nbsp;1 clinical trial for RLYB212, our lead product candidate for our FNAIT prevention
program; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">file a CTA and initiate our clinical trial for RLYB116, and file an IND or a CTA for other product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">initiate a natural history alloimmunization study of FNAIT and other studies to support our development program and
related regulatory submissions for RLYB212; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">continue to develop and conduct clinical trials with respect to RLYB211; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">seek regulatory approvals for RLYB212, RLYB116 and any other product candidates, as well as for any related companion
diagnostic, if required; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">continue and expand upon our discovery and development joint ventures with Exscientia; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">continue to discover and develop additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">hire additional clinical, scientific, and commercial personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">add operational, financial, and management personnel, including personnel to support our product development and planned
future commercialization efforts and to support our transition to a public company; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates or technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">maintain, expand, and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">secure a commercial manufacturing source and supply chain capacity sufficient to produce commercial quantities of any
product candidate for which we obtain regulatory approval; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establish a sales, marketing and distribution infrastructure to commercialize our programs, if approved, and for any other
product candidates for which we may obtain marketing approval. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result, we will need substantial additional funding to support our continuing
operations and pursue our growth strategy. Our inability to raise capital as and when needed could have a negative impact on our financial condition and ability to pursue our business strategies. There can be no assurances, however, that the current
operating plan will be achieved or that additional funding will be available on terms acceptable to us, or at all. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of March&nbsp;31, 2021, we had cash and cash
equivalents of $127.7&nbsp;million. We believe that the anticipated net proceeds from this offering, together with our existing cash and cash equivalents as of March&nbsp;31, 2021, will be sufficient to fund our operating expenses and capital
expenditure requirements for the next 24 months. This estimate and our expectation regarding the sufficiency of the net proceeds from this offering to advance the preclinical and clinical development of RLYB212, RLYB116, and any other product
candidates are based on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#147;&#151;Liquidity and Capital Resources.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic has impacted and may continue to impact our preclinical studies and clinical trials, including at our clinical sites and the startup activities for our clinical trials, as well as our manufacturing
and supply chain, and the pandemic may affect our ability to timely complete our clinical trials and delay the initiation and/or enrollment of any future clinical trials, disrupt regulatory activities or have other adverse effects on our business
and operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are monitoring the potential impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business and financial statements.
To date, we have not incurred impairment losses in the carrying values of our assets as a result of the COVID-19 pandemic and we are not aware of any specific related event or circumstance that would require us to revise our estimates reflected in
our financial statements. We plan to continue many of the protective measures we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">82 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
implemented in response to the pandemic and are assessing when and how to resume normal operations for office-based personnel. The effects of the public health directives and our work-from-home
policies may disrupt our business and delay clinical programs and timelines and future clinical trials, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct
business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, results of operations and financial condition, including our ability to obtain financing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot be certain what the overall impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic will be on our business and prospects. The extent to which
the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic will directly or indirectly impact our business, results of operations, financial condition and liquidity, including planned and future clinical trials and research and development costs,
will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning <FONT STYLE="white-space:nowrap">COVID-19,</FONT> the actions taken to contain or treat it, including the availability
and administration of vaccines, and the duration and intensity of the related effects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Components of Results of Operations </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Operating Expenses </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses consist primarily of costs incurred in connection with our research and development activities, including our drug discovery efforts
and the development of our product candidates. We expense research and development costs as incurred, which include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">external research and development expenses incurred under agreements with third parties, such as contract research
organizations, or CROs, as well as investigative sites and consultants that conduct our clinical trials and other scientific development services; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">costs related to manufacturing material for our clinical trials, including fees paid to contract manufacturer
organizations, or CMOs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">manufacturing <FONT STYLE="white-space:nowrap">scale-up</FONT> expenses and the cost of acquiring and manufacturing
clinical trial materials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">employee-related expenses, including salaries, bonuses, benefits, equity-based compensation and other related costs for
those employees involved in research and development efforts; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">costs of outside consultants, including their fees, and related travel expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs of acquiring and developing clinical trial materials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expenses to acquire technologies, such as intellectual property, to be used in research and development including <FONT
STYLE="white-space:nowrap">in-process</FONT> research and development, or IPR&amp;D, that has no alternative future use at the time of asset acquisitions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">costs related to compliance with regulatory requirements; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">facilities, depreciation and other indirect costs. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Costs for certain activities are recognized based on an evaluation of the progress to completion of each specific contract using information and data provided to us by
our vendors and analyzing the progress of our research studies or other services performed. Significant judgments and estimates are made in determining the expenses incurred balances at the end of any reporting period. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our direct, external research and development expenses consist primarily of fees paid to outside consultants, CROs, CMOs and research laboratories in connection with
our process development, manufacturing and clinical development activities. Our direct external research and development expenses also include fees incurred under license and intellectual property purchase agreements. We track these external
research and development costs on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not allocate
employee costs, costs associated with our development efforts and facilities, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified.
We use internal resources and third-party consultants primarily to conduct our research and development activities as well as for managing our process development, manufacturing and clinical development activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">83 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The successful development of our product candidates is highly uncertain. We plan to substantially increase our research
and development expenses in the foreseeable future as we continue the development of our product candidates and manufacturing processes and conduct discovery and research activities for our clinical programs. We cannot determine with certainty the
timing of initiation, the duration or the completion costs of current or future clinical trials of our product candidates due to the inherently unpredictable nature of preclinical and clinical development. Clinical development timelines, the
probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing
basis in response to the results of ongoing and future clinical trials, regulatory developments and our ongoing assessments as to each product candidate&#146;s commercial potential. We will need to raise substantial additional capital in the future.
Our clinical development costs are expected to increase significantly with our ongoing clinical trials. We anticipate that our expenses will increase substantially, particularly due to the numerous risks and uncertainties associated with developing
product candidates, including the uncertainty of: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the scope, rate of progress and expenses of our ongoing research activities and clinical trials and other research and
development activities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">successful enrollment in and completion of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether our product candidates show safety and efficacy in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">receipt of marketing approvals from applicable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">commercializing product candidates, if and when approved, whether alone or in collaboration with others; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">continued acceptable safety profile of the products following any regulatory approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any changes in the outcome of any of these variables with respect to the development of our product candidates in clinical development could mean a significant change
in the costs and timing associated with the development of these product candidates. We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our clinical trials. We may elect to
discontinue, delay or modify clinical trials of some product candidates or focus on others. For example, if the U.S. Food and Drug Administration, or the FDA, the European Medicines Agency, or EMA, or another regulatory authority were to delay our
planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to
expend significant additional financial resources and time on the completion of clinical development of that product candidate. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We anticipate that our research and
development expenses will continue to increase as we continue our current research programs, initiate new research programs, continue our preclinical development of product candidates and conduct future clinical trials for any of our product
candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General and Administrative Expenses </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and
administrative expenses consist primarily of salaries, benefits and equity-based compensation for our personnel in executive, legal, business development, finance and accounting, and other administrative functions. General and administrative
expenses also include legal fees relating to intellectual property and corporate matters, professional fees paid for accounting, auditing, tax and consulting services, insurance costs, travel expenses and direct and allocated facility costs not
otherwise included in research and development expenses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We anticipate that our general and administrative expenses will increase as we increase headcount that
provide administrative support to our research and development activities. We also anticipate that we will incur significantly increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs, as well as investor
and public relations expenses associated with operating as a public company. Additionally, if and when we believe a regulatory approval of a product candidate appears likely, we anticipate an increase in payroll and other employee-related expenses
as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of that product candidate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">84 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Total Other Income, Net </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Total
other income, net, includes interest income earned on cash and cash equivalents, interest expense and other income and expense items. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Loss on investment in
joint venture </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company recognizes its <FONT STYLE="white-space:nowrap">pro-rata</FONT> share of losses in the loss on investment in joint venture with
Exscientia on its consolidated statements of operations and comprehensive loss, with a corresponding change to the investment in joint venture on the consolidated balance sheets for equity method investments for which it does not have a controlling
interest in. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Results of Operations </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comparison of the Three
Months Ended March&nbsp;31, 2021 and 2020 </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our results of operations: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE&nbsp;MONTHS&nbsp;ENDED</B><br><B>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CHANGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,824</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,844</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other income, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss on investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,394</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Operating Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our research and development costs for each of the periods presented: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE&nbsp;MONTHS&nbsp;ENDED</B><br><B>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CHANGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Direct research and development by program</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">RLYB211</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">RLYB212</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">RLYB116</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other program candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Other unallocated research and development costs</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Personnel expenses (including equity-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">85 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses were $9.0&nbsp;million for the three months ended March&nbsp;31, 2021, compared to
$1.9&nbsp;million for the three months ended March&nbsp;31, 2020. The increase of $7.1&nbsp;million was primarily due to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a $3.7&nbsp;million increase in costs related to the development of RLYB212 and a $2.4&nbsp;million increase in costs
related to the development of RLYB116 mainly attributable to increased external clinical manufacturing activities for both programs as compared to the same period in 2020; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a $0.6&nbsp;million increase in personnel-related costs, including equity-based compensation expense, primarily due to an
increase in research and development related headcount as compared to the same period in 2020; </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses were $3.8&nbsp;million for the three months ended March&nbsp;31, 2021, compared to $1.9&nbsp;million for the three months ended
March&nbsp;31, 2020. The increase of $1.9&nbsp;million primarily related to an increase in payroll and personnel-related costs, including equity-based compensation, primarily due to an increase in general and administrative related headcount and
other professional fees associated with operating activities and the preparations for becoming a public company. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Total Other Income, Net </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Total other income, net, was $31,000 for the three months ended March&nbsp;31, 2021, compared to $95,000 for the three months ended March&nbsp;31, 2020. The decrease of
$64,000 is primarily attributable to a reduction in interest income as compared to the same period in 2020. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Loss on investment in joint venture </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the three months ended March&nbsp;31, 2021, the loss recognized was $0.5&nbsp;million as compared to $0.1&nbsp;million for the same period in 2020. The increase in
the loss recognized is due to increases in research cost recognized by the joint venture during 2021 as compared to 2020. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comparison of the Years Ended
December&nbsp;31, 2020 and 2019 </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our results of operations: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CHANGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,642</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,661</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other income, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss on investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,884</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">86 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and Development Expenses </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our
research and development costs for each of the periods presented: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CHANGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Direct research and development by program</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">RLYB211</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">RLYB212</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">RLYB116</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other program candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Asset acquisitions IPR&amp;D expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Other unallocated research and development costs</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Personnel expenses (including equity-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses were $17.6&nbsp;million for the year ended December&nbsp;31, 2020, compared to $11.4&nbsp;million for the year ended December&nbsp;31,
2019. The increase of $6.3&nbsp;million was primarily due to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a $3.5&nbsp;million increase in costs related to the development of RLYB212 and a $5.1&nbsp;million increase in costs
related to the development of RLYB116 mainly attributable to increased external manufacturing activities for both programs as compared to the same period in 2019 when the assets were acquired; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a $2.8&nbsp;million increase in personnel-related costs, including equity-based compensation expense, primarily due to an
increase in research and development related headcount as compared to the same period in 2019; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a $0.9&nbsp;million increase in RLYB211 related to an increase in clinical development costs as compared to the same
period in 2019; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a decrease of $6.1&nbsp;million in asset acquisition related IPR&amp;D expenses related to the asset acquisitions made in
2019. No asset acquisitions were executed in 2020. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses were $7.7&nbsp;million for the year ended December&nbsp;31, 2020, compared to $6.3&nbsp;million for the year ended December&nbsp;31,
2019. The increase of $1.4&nbsp;million primarily related to an increase in payroll and personnel-related costs, including equity-based compensation, primarily due to an increase in general and administrative related headcount and other professional
fees associated with operating activities and the preparations for becoming a public company. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Total Other Income, Net </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Total other income, net, was $0.4&nbsp;million for the year ended December&nbsp;31, 2020, compared to $0.2&nbsp;million for the year ended December&nbsp;31, 2019. The
increase of $0.2&nbsp;million is primarily attributable to the change in fair value of our Series <FONT STYLE="white-space:nowrap">A-2</FONT> financing right obligation expense for the year ended 2019, no such charges for financing obligation rights
were taken for the same period in 2020. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Loss on investment in joint venture </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the year ended December&nbsp;31, 2020, the loss recognized was $1.5&nbsp;million as compared to $0.1&nbsp;million for the same period in 2019. The joint venture
with Exscientia was established in July 2019 and the increase in the loss recognized is due to increases in research and development cost recognized by the joint venture during 2020 as compared to 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">87 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Sources of Liquidity </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since our inception, we have funded our
operations primarily through equity financings, and through March&nbsp;31, 2021, had received proceeds of approximately $182.0&nbsp;million, net of issuance costs of $0.5&nbsp;million, from the sale of our preferred units. As of March&nbsp;31, 2021,
we had $127.7&nbsp;million of cash and cash equivalents. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Uses of Liquidity </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently have no ongoing material financing commitments, such as lines of credit or guarantees, that are expected to affect our liquidity over the next five years,
other than our manufacturing, licensing and lease obligations described further below. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Funding Requirements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that the net proceeds from this offering, together with our existing cash and cash equivalents as of March&nbsp;31, 2021, will be sufficient to fund our
operating expenses and capital expenditure requirements for the next 24 months. We have based this estimate on assumptions that may prove to be wrong, and we could expend our capital resources sooner than we expect. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to incur significant expenses and operating losses in the foreseeable future as we advance our product candidates through clinical development, seek
regulatory approval and pursue commercialization of any approved product candidates. Furthermore, upon the closing of this offering, we expect to incur additional costs associated with operating as a public company. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because of the numerous risks and uncertainties, length of time and scope of activities associated with research, development and commercialization of pharmaceutical
product candidates, we are unable to estimate the actual amount of funds we will require for development, approval and any approved marketing and commercialization activities. Our future capital requirements, both near and long-term, will depend on
many factors, including, but not limited to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the initiation, progress, timing, costs and results of our clinical trials through all phases of development, including
our ongoing Phase 1/2 clinical trial for RLYB211, the planned clinical trials for RLYB212 and RLYB116 and the development of any other product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the identification, assessment, acquisition and/or development of additional research programs and additional product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the outcome, timing and cost of meeting regulatory requirements established by the FDA, EMA and other comparable foreign
regulatory authorities, including any additional clinical trials required by the FDA, EMA or other comparable foreign regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the willingness of the FDA, EMA and other comparable foreign regulatory authorities to accept our clinical trial designs,
as well as data from our completed and planned preclinical studies and clinical trials, as the basis for review and approval of RLYB212, RLYB116 and any other product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the progress, timing and costs of the development by us or third parties of companion diagnostics, if required, for
RLYB212 or any other product candidates, including design, manufacturing and regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of filing, prosecuting and enforcing our patent claims and other intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of defending potential intellectual property disputes, including patent infringement actions brought by third
parties against us; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs associated with potential clinical trial liability or product liability claims, including the costs associated
with obtaining insurance against such claims and with defending against such claims; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the effect of competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to develop and commercialize products that are considered medically and/or financially differentiated to
competitive products by physicians, patients and payers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost and timing of completion of commercial-scale manufacturing activities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of making royalty, milestone or other payments under any future
<FONT STYLE="white-space:nowrap">in-license</FONT> agreements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">88 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to maintain our collaboration with Exscientia on favorable terms and establish new collaborations;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the extent to which we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire additional product candidates or
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the severity, duration and impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which may adversely
impact our business; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of establishing sales, marketing and distribution capabilities for our product candidates, if approved;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the initiation, progress and timing of our commercialization of RLYB212 and RLYB116, if approved, or any other product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the availability of third-party coverage and reimbursement for and pricing of any approved products; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the costs of operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A change in the outcome of any of these, or other variables with respect to the development of any of our product candidates, could significantly change the costs and
timing associated with the development of that product candidate. We will need to continue to rely on additional financing to achieve our business objectives. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
addition to the variables described above, if and when any of our product candidates successfully complete development, we will incur substantial additional costs associated with regulatory filings, marketing approval, post-marketing requirements,
maintaining our intellectual property rights and regulatory protection, in addition to other commercial costs. We cannot reasonably estimate these costs at this time. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Until such time, if ever, as we generate significant revenue from product sales, we expect to finance our operations through the sale of equity, debt financings,
marketing and distribution arrangements and collaborations, strategic alliances and licensing arrangements or other sources. We currently have no credit facility or committed sources of capital. If we raise additional funds through debt financing,
we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, and we may need to dedicate a substantial additional portion of any
operating cash flows to the payment of principal and interest on such indebtedness. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required
to relinquish valuable rights to our technologies, intellectual property, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be
required to delay, limit, reduce or terminate product candidate development or future commercialization efforts. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Cash Flows </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our cash flows for each of the periods presented: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE&nbsp;MONTHS&nbsp;ENDED&nbsp;MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,026</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,929</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,072</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(562</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net (decrease) increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Operating Activities </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities was
$11.9&nbsp;million for the three months ended March&nbsp;31, 2021 as compared to $5.5&nbsp;million for the three months ended March&nbsp;31, 2020. The increase in cash used in operations was primarily due to the increase of $7.1&nbsp;million in
research and development for the increased efforts advancing the development of RLYB211, RLYB212 and RLYB116 product candidates and $1.9&nbsp;million in general and administrative expenses as compared to the same period the prior year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities was $22.0&nbsp;million for the year ended December&nbsp;31, 2020 as compared to $15.0&nbsp;million for the year ended
December&nbsp;31, 2019. The increase in cash used in operations was primarily due to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">89 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the increase of $6.3&nbsp;million in research and development for the increased efforts advancing the development of RLYB211, RLYB212 and RLYB116 product candidates and $1.4&nbsp;million in
general and administrative expenses as compared to the same period the prior year. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Investing Activities </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities was $0.6 million for the three months ended March 31, 2021 and 2020. Net cash used in investing activities was primarily related
to the investments in our joint venture during both periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities was $2.1&nbsp;million for the year ended December&nbsp;31, 2020
as compared to $0.2&nbsp;million for the year ended December 31, 2019. The increase in net cash used in investing activities was primarily related to the investments in our joint venture as compared to the same period the prior year. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Financing Activities </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There was no cash provided by financing activities for
the three months ended March 31, 2021 as compared to $85.1 million for the three months ended March 31, 2020. There were no financing events for the three months ended March 31, 2021 as compared to the same period in the prior year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities was $144.9&nbsp;million for the year ended December&nbsp;31, 2020 as compared to $31.6&nbsp;million for the year ended
December 31, 2019. The increase in financing activities was primarily attributable to the net proceeds from the issuance of Series B Preferred units of $144.9&nbsp;million as compared to the net proceeds from the issuance of Series A-2 Preferred
units of $31.6&nbsp;million from the prior year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Contractual Obligations </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our contractual obligations as of December&nbsp;31, 2020: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAYMENTS DUE BY PERIOD</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LESS&nbsp;THAN</B><br><B>1 YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">1-3&nbsp;YEARS</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">3-5&nbsp;YEARS</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MORE&nbsp;THAN</B><br><B>5 YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The contractual obligation amounts in the table above are associated with contracts that are enforceable and legally binding and that specify all significant terms,
including fixed or minimum services to be used, fixed, minimum or variable price provisions and the approximate timing of the actions under the contracts. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Purchase and Other Obligations </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We enter contracts in the normal course of
business with CROs and other third-party vendors for clinical trials and testing and manufacturing services. Aside from those included in the table above, most contracts do not contain minimum purchase commitments and are cancellable by us upon
written notice. Payments that may be due upon cancellation consist of payments for services provided or expenses incurred. These payments are not included in the table above as the amount and timing of such payments are not known. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may incur contingent payments upon our achievement of clinical, regulatory and commercial milestones, as applicable under agreements we have entered into with
various third-party entities pursuant to which we have acquired <FONT STYLE="white-space:nowrap">or&nbsp;in-licensed</FONT> intellectual property. Due to the uncertainty of the achievement and timing of the events that require payment under these
agreements, the amounts to be paid by us are not fixed or determinable at this time and have not been included in the table above. See &#147;Business&#151;License Agreement&#148; and &#147;Business&#151;Asset Purchase Agreements&#148; and Note 3
&#147;Asset Acquisitions&#148; to our audited consolidated financial statements included elsewhere in this prospectus for a description of these agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
consolidated financial statements are prepared in accordance with&nbsp;accounting principles generally accepted in the United States or U.S. GAAP. The preparation of our consolidated financial statements and related disclosures
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">90 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our
consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments
about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or
conditions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While our significant accounting policies are described in more detail in Note 2 &#147;Summary of Significant Accounting Policies and Basis of
Presentation and Principles of Consolidation&#148; to our audited consolidated financial statements included elsewhere in this prospectus, we believe that the following accounting policies are those most critical to the judgments and estimates used
in the preparation of our consolidated financial statements. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As part of the process of preparing our consolidated financial statements, we are required to estimate our research and development expenses that are incurred as of
each reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel and with vendors to identify services that have been performed on our behalf and estimating the level of service performed
and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones
are met. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if
necessary. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We base our expenses related to research and development activities on our estimates of the services received and efforts expended pursuant to quotes
and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in
which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the
level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid balance accordingly.
<FONT STYLE="white-space:nowrap">Non-refundable</FONT> advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received
rather than when the payment is made. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we do not expect our estimates to be materially different from amounts incurred, if our estimates of the status and
timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Incentive Units </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, we have periodically granted
incentive units to employees&nbsp;which vest over a four-year period. These incentive units have been issued in the form of profits interests providing the employee with compensation equal to the increase in the value of the unit over a
participation threshold per unit, as determined at the time of grant. The holder, therefore, has the right to participate in distributions of profits only in excess of such participation threshold. The participation threshold is based on the
valuation of a single common unit on or around the grant date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We measure equity-based compensation based on the grant date fair value of the unit-based awards and
recognize equity-based compensation expense on a straight-line basis over the requisite service period of the awards, which is generally the vesting period of the respective award. Unit-based compensation expense is classified in our consolidated
statements of operations and comprehensive loss based on the function to which the related services are provided or in the same manner in which the grantee&#146;s payroll costs are classified. Forfeitures are accounted for as they occur. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As there has been no public market for our common units, the estimated fair value of our common units has been determined by our board of managers after considering
valuation reports provided by an independent third-party valuation firm. In accordance with the guidance outlined in the American Institute of Certified Public Accountants&#146; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">91 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Accounting and Valuation Guide,&nbsp;Valuation of Privately-Held-Company Equity Securities Issued as Compensation,&nbsp;a third-party valuation firm prepared valuations of our common units using
an option pricing method, or OPM, which uses market approaches, and a Black-Scholes option pricing model to estimate our enterprise value. The OPM treats common units and preferred units as call options on the total equity value of a company, with
exercise prices based on the value thresholds at which the allocation among the various holders of a company&#146;s securities changes to value the common units of the company. A discount for lack of marketability of the common units is then applied
to arrive at an indication of value for the common units as of the valuation date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are significant judgments related to volatility and time to liquidity as
well as estimates inherent in these valuations. These judgments and estimates include assumptions regarding our future operating performance, the stage of development of our product candidates, the timing of a potential IPO or other liquidity events
and the determination of the appropriate valuation methodology at each valuation date. The assumptions underlying these valuations represent management&#146;s best estimates, which involve inherent uncertainties and the application of management
judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our equity-based compensation expense could be materially different. Following the completion of this offering, the fair value
of our common stock will be determined based on the quoted market price of our common stock. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the Reorganization, holders of common and
incentive units of Rallybio Holdings, LLC, or the LLC Entity, will receive shares of common stock and restricted stock of Rallybio Corporation, or the Corporation, based upon a conversion price to be determined by the board of managers of the LLC
Entity immediately prior to the Reorganization. Holders of incentive units of the LLC Entity that are vested as of the consummation of the Reorganization will, with respect to such units, received shares of common stock of the Corporation. Holders
of incentive units of the LLC Entity that are unvested as of the consummation of the Reorganization will, with respect to such units, receive shares of restricted stock of the Corporation. The shares of restricted common stock will be subject to the
same vesting conditions as the incentive units for which such shares are exchanged. The following table summarizes by grant date the number of incentive units granted from January&nbsp;5, 2018 through June&nbsp;30, 2021, the participation threshold
price per incentive unit and the pro forma number of shares of common stock that will be issued in the Reorganization for each grant of incentive units, assuming, in the case of the pro forma common stock issued in respect of incentive units, an
initial public offering price of $14.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>GRANT DATE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INCENTIVE&nbsp;UNITS<BR>GRANTED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OUTSTANDING&nbsp;INCENTIVE<BR>UNITS&nbsp;AS&nbsp;OF&nbsp;MARCH&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PARTICIPATION<BR>THRESHOLD&nbsp;PRICE<BR>PER UNIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA<BR>COMMON&nbsp;STOCK<BR>ISSUED&nbsp;IN&nbsp;RESPECT<BR>OF&nbsp;INCENTIVE&nbsp;UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">July 2018 &#150; January 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">July 2019 &#150; December 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,348,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,348,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">May 2020 &#150; December 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,232,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,232,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">655,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jan 2021 &#150; March 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,069,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,069,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,608,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">May 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">620,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">620,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">June 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Emerging Growth Company and Smaller Reporting Company </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As an emerging growth
company, or EGC, under the Jumpstart Our Business Startups Act of 2012, or JOBS Act, we may delay the adoption of certain accounting standards until such time as those standards apply to private companies. Other exemptions and reduced reporting
requirements under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, for EGCs include presentation of only two years of audited financial statements in a registration statement for an IPO, an exemption from the requirement to provide
an auditor&#146;s report on internal controls over financial reporting pursuant to Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board
regarding mandatory audit firm rotation, and less extensive disclosure about our executive compensation arrangements. Additionally, the JOBS Act provides that an EGC can take advantage of an extended transition period for complying with new or
revised </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">92 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
accounting standards. This allows an EGC to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to &#147;opt
out&#148; of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt
the new or revised standard and will do so until such time that we either (i)&nbsp;irrevocably elect to &#147;opt out&#148; of such extended transition period or (ii)&nbsp;no longer qualify as an EGC. We may choose to early adopt any new or revised
accounting standards whenever such early adoption is permitted for private companies. Therefore, the reported results of operations contained in our consolidated financial statements may not be directly comparable to those of other public companies.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may remain classified as an EGC until the end of the fiscal year in which the fifth anniversary of this offering occurs, although if the market value of our
common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700.0&nbsp;million as of any June&nbsp;30 before that time or if we have annual gross revenues of $1.07&nbsp;billion or more in any fiscal year, we will
cease to be an EGC as of December&nbsp;31 of the applicable year. We also will cease to be an EGC if we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over a three-year period. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to rely on&nbsp;certain of&nbsp;the other exemptions and reduced reporting requirements provided by the JOBS Act. As an EGC, we are not required to, among
other things, provide an auditor&#146;s attestation report on our system of internal controls over financial reporting pursuant to Section&nbsp;404(b), and comply with any requirement that may be adopted by the Public Company Accounting Oversight
Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements (auditor discussion and analysis). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are also a &#147;smaller reporting company&#148; meaning that the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the
proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700.0&nbsp;million and our annual revenue was less than $100.0&nbsp;million during the most recently completed fiscal year. We may continue to be a smaller
reporting company after this offering if either (i)&nbsp;the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million or (ii)&nbsp;our annual revenue was less than $100.0&nbsp;million
during the most recently completed fiscal year and the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million. If we are a smaller reporting company at the time we cease to be an
EGC, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited
financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As
of December&nbsp;31, 2020 and March 31, 2021, we did not have any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, as defined in Item&nbsp;303(a)(4)(ii) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Recently Issued Accounting Pronouncements </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A description of recently issued
accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 &#147;Summary of Significant Accounting Policies and Basis of Presentation and Principles of Consolidation&#148; to our
audited consolidated financial statements included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">93 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical-stage biotechnology company built around a team
of seasoned industry experts with a shared purpose and a track record of success in discovering, developing, manufacturing and delivering therapies that meaningfully improve the lives of patients suffering from severe and rare diseases. Our mission
at Rallybio is aligned with our expertise, and we believe we have assembled the best people, partners and science to forge new paths to life-changing therapies. Since our launch in January 2018, we have acquired a portfolio of promising product
candidates that consists of five programs, and we are focused on further expanding our portfolio with the goal of making a profound impact on the lives of even more patients. We are drawing on our decades of knowledge and experience with a
determination to tackle the undone, the too difficult, the inaccessible &#150; and change the odds for rare disease patients. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our most advanced program is for
the prevention of fetal and neonatal alloimmune thrombocytopenia, or FNAIT, a potentially life-threatening rare hematological disease that impacts fetuses and newborns. We are evaluating RLYB211, a polyclonal anti-HPA-1a antibody, in a Phase 1/2
clinical trial, which we believe has established proof of concept for RLYB211 and provides support for our proposed mechanism of action. We plan to move our FNAIT program forward with our lead product candidate, RLYB212, a monoclonal anti-HPA-1a
antibody. We submitted a clinical trial application, or CTA, for RLYB212 in July&nbsp;2021, and subject to the acceptance of our CTA submission, we expect to initiate a Phase&nbsp;1 first-in-human trial in Germany in the first quarter of 2022. We
are also focused on developing therapies that address diseases of complement dysregulation, including paroxysmal nocturnal hemoglobinuria, or PNH, generalized myasthenia gravis, or gMG, and ophthalmic disorders. RLYB116 is a novel, potentially
long-acting, subcutaneously administered inhibitor of complement factor&nbsp;5, or C5, in development for the treatment of patients with PNH and gMG. We expect to submit a CTA for RLYB116 in the fourth quarter of 2021 to support the initiation of a
Phase&nbsp;1 trial in healthy participants. RLYB114 is a pegylated C5 inhibitor in preclinical development for the treatment of complement-mediated ophthalmic diseases and we expect to submit a CTA for this product candidate in the first half of
2023. Additionally, in collaboration with Exscientia Limited, or Exscientia, we have two discovery-stage programs focused on the identification of small molecule therapeutics for patients with rare metabolic diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Approach </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At Rallybio, we do not accept that millions of patients
suffering from devastating rare diseases should have to live without transformative treatments. There are an estimated 25 to 30&nbsp;million people affected by as many as 7,000 rare diseases in the United States alone, with a significantly greater
number of affected people globally. We are building a diversified pipeline of product candidates that we believe have the potential to transform the lives of patients in need. Our goal is to deliver therapeutics that provide meaningful clinical
benefits to patients so they can become unbound and undefined by the diseases from which they suffer. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe the success of our company is built on three key
strengths: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Our extensive knowledge of rare diseases and our scientific expertise positions us to identify therapies with the
potential for transformative impact.</B> We seek to acquire and develop product candidates that possess a clear mechanism of action and that aim to address diseases with a well-understood pathophysiology for which there is a significant unmet
medical need. We believe that a product candidate&#146;s mechanism of action should target the causal biology of the disease to provide the highest probability of dramatically improving the lives of patients. We believe that our team&#146;s
extensive experience in rare diseases and our scientific expertise position us to identify opportunities where these links can be made, which may go unnoticed by others. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Our ability to source, to identify and to evaluate potential high-quality product candidates</B>. We apply decades of
experience across drug discovery, research, development, regulatory strategy and manufacturing to source, to identify and to evaluate therapeutic targets and product candidates that we believe have a high probability of success. Our ability to
source these product candidates is facilitated by our extensive network of relationships with leaders in industry and in academic clinical centers worldwide. We view ourselves as partners of choice given our team&#146;s track record of success in
developing and delivering new therapies to patients. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">94 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Our team&#146;s proven execution capability to drive product candidates through clinical development to regulatory
approvals. </B>We have assembled a team with a proven history of successfully advancing product candidates from discovery to clinical development and through regulatory approval. Members of our team have played critical roles in the approval of more
than 30 drugs, including seven approvals for rare disease therapeutics since 2013, and secured approvals from regulatory authorities in the Americas, Europe, Australia and Asia. In doing so, our employees previously developed and implemented novel
clinical trial designs and successfully conducted clinical trials in never-before treated patient populations. We believe this collective prior experience positions us to efficiently and expertly execute at each step in the research and development
process and enhances the value we can bring to product candidates and to patients. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Team </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our founders, Martin W. Mackay, Ph.D., Stephen Uden, M.D., and Jeffrey M. Fryer, CPA, were previously executives at Alexion Pharmaceuticals, Inc., or Alexion, and
worked together to successfully build, develop, and launch transformative therapies for patients with rare diseases. Several members of our team were integral in the successful development and/or approval of therapies such as Strensiq (asfotase
alfa) for patients with perinatal-, infantile-, and juvenile-onset hypophosphatasia, or HPP, Kanuma (sebelipase alfa) for patients with lysosomal acid lipase deficiency, or <FONT STYLE="white-space:nowrap">LAL-D,</FONT> Nulibry (fosdenopterin) for
patients with molybdenum cofactor deficiency, or MoCD Type A, Soliris (eculizumab) for patients with refractory gMG, Soliris for patients with relapsing neuromyelitis optica spectrum disorder, or NMOSD, Ultomiris
<FONT STYLE="white-space:nowrap">(ravulizumab-cwvz),</FONT> for patients with PNH and Ultomiris for patients with atypical hemolytic uremic syndrome, or aHUS. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
deep commitment to high ethical and professional standards is fundamental to our mission to bring new and transformative medicines to vulnerable patient populations suffering from rare diseases. We believe our team&#146;s prior contributions have
made a significant positive impact on the lives of thousands of patients around the world. As a strong and experienced team, we believe we can transform the lives of thousands more. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Pipeline </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our pipeline is illustrated in the chart below. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g02j59.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:8pt; font-family:ARIAL"><B>FNAIT: Fetal and neonatal alloimmune thrombocytopenia; <FONT STYLE="white-space:nowrap">HPA-1a:</FONT> Human
platelet antigen 1a; PNH: Paroxysmal nocturnal hemoglobinuria; gMG: Generalized myasthenia gravis; ABD: Albumin binding domain; HPP: Hypophosphatasia; ENPP1: Ectonucleotide pyrophosphatase/phosphodiesterase 1; PoC: Proof of concept; CTA: Clinical
trial application </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Prevention of FNAIT </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our most advanced
program is targeting the prevention of FNAIT, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns. FNAIT can arise during pregnancy due to an immune incompatibility between an expectant mother and
her fetus in a specific platelet antigen called human platelet antigen 1, or <FONT STYLE="white-space:nowrap">HPA-1.</FONT> This incompatibility can cause an expectant mother to develop antibodies that attack the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">95 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
platelets of her fetus. The destruction of platelets in the fetus can result in severely low platelet counts, or thrombocytopenia, potentially leading to devastating consequences including
miscarriage, stillbirth, death of the newborn, or severe lifelong neurological disability in those babies who survive. There is currently no approved therapy for the prevention or treatment of FNAIT. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate that there are over 22,000 pregnancies at high risk of developing FNAIT each year in the United States, Canada, United Kingdom, other major European
countries and Australia. Because there are no approved therapies to prevent FNAIT, expectant mothers are not currently screened for FNAIT risk. As a result, the vast majority of pregnancies at risk for FNAIT go unidentified and untreated. In those
pregnancies that are identified as <FONT STYLE="white-space:nowrap">at-risk,</FONT> typically due to the delivery of a prior FNAIT affected child, expectant mothers may be treated with weekly intravenously-administered high doses of immunoglobulin
G, or IVIG, along with the oral steroid immunosuppressant prednisone. However, IVIG administration does not prevent the immune response, called alloimmunization, and is costly, time-intensive, difficult to tolerate and associated with significant
treatment-related complications. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The lead product candidate in our FNAIT prevention program is RLYB212, a preclinical-stage monoclonal <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibody. We are evaluating RLYB211, a polyclonal <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibody, in a Phase
1/2 clinical trial, which we believe has established proof of concept for RLYB211 and provides support for our proposed mechanism of action. RLYB211 is derived from the plasma of women who have developed antibodies to
<FONT STYLE="white-space:nowrap">HPA-1a</FONT> as a result of a prior HPA-1 incompatible pregnancy. Data generated from the first cohort of healthy participants in our Phase 1/2 clinical trial for RLYB211, which was presented in July 2021 at the
International Society on Thrombosis and Haemostasis, or ISTH Congress, demonstrated the ability of an <FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT> antibody to rapidly eliminate transfused <FONT STYLE="white-space:nowrap">HPA-1a</FONT>
positive platelets from the circulation of healthy HPA-1a negative participants. Based on these results, we believe that targeting <FONT STYLE="white-space:nowrap">HPA-1a</FONT> with an anti-HPA-1a antibody has the potential to prevent maternal
alloimmunization and therefore the occurrence of FNAIT. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on the common mechanism of action, we believe that both product candidates will drive rapid
elimination of <FONT STYLE="white-space:nowrap">HPA-1a</FONT> positive platelets in the circulation of expectant mothers and potentially prevent them from alloimmunizing. Consequently, we are prioritizing the development of RLYB212 based on its
favorable attributes, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the potential for subcutaneous administration of RLYB212, which is the preferred route of administration based on primary
market research of OB/GYNs and maternal-fetal specialists in the United States and Europe, compared to RLYB211&#146;s intravenous injection administration; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a pharmacokinetic profile for RLYB212 that has the potential to maintain circulating concentrations of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibody at levels that are very close to peak exposure levels through the entire treatment period, thus maximizing the capacity of RLYB212 to neutralize fetal
antigen relative to RLYB211; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the ability to produce RLYB212 using standard monoclonal antibody manufacturing methods compared to the long-term need to
source plasma for RLYB211 from women who had developed antibodies to HPA-1a as a result of a prior HPA-1 incompatible pregnancy. </P></TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We submitted
a CTA for RLYB212 in July&nbsp;2021, and subject to the acceptance of our CTA submission, we expect to initiate a Phase&nbsp;1 first-in-human trial in Germany in the first quarter of 2022, with proof of concept data from a Phase&nbsp;1b trial
planned for mid-2022. We also anticipate reporting additional data from our Phase&nbsp;1/2 clinical trial for RLYB211 in the fourth quarter of 2021. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Treatment of Disorders Due to Complement Dysregulation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our next two
programs target diseases related to complement pathway dysregulation. The complement system plays a central role in innate immunity, as well as, shaping adaptive immune response. Dysregulation of the complement pathway has been implicated in the
pathogenesis of a growing number of diseases, making it an attractive target for therapeutic intervention. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Antibody inhibitors of C5 have been successfully
developed to treat diseases caused by complement pathway dysregulation, including PNH, aHUS, refractory gMG and relapsing NMOSD. Despite the approval of antibody-based C5 inhibitors for patients with these diseases, we believe there remains
significant need in the market for safe, effective, patient-friendly and accessible therapies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our team has a track record of success and significant expertise in
designing, developing and securing approval for complement inhibitors, including Soliris and Ultomiris, for patients with severe and rare complement-mediated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">96 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
diseases around the world. We believe this knowledge and expertise positions us to successfully advance our programs and deliver transformative benefits to patients in need. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our most advanced product candidate in this therapeutic area is RLYB116, an inhibitor of complement factor C5, which is a central component of the complement pathway.
RLYB116 is an Affibody<B><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></B> molecule attached to an albumin binding domain that has the potential to drive the rapid, complete and sustained inhibition of C5 with a subcutaneous injection.
We plan to pursue PNH and gMG as our lead indications for RLYB116, with additional complement-mediated indications to follow. We expect to submit a CTA for RLYB116 in the fourth quarter of 2021, and to initiate a Phase 1 clinical trial in healthy
participants in the first quarter of 2022. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our second C5 inhibitor, RLYB114, is a pegylated <FONT STYLE="white-space:nowrap">C5-targeted</FONT> Affibody<B><SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP></B> molecule with pharmacokinetic properties designed for the treatment of complement-mediated ophthalmic diseases. Preclinical data generated with RLYB114 demonstrate that it is well-tolerated
in animal models with no serious adverse effects. RLYB114 is in preclinical development, and we expect to submit a CTA for RLYB114 in the first half of 2023. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Artificial Intelligence Drug Discovery Collaboration </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We established
a partnership with Exscientia, an Oxford, <FONT STYLE="white-space:nowrap">UK-based</FONT> artificial intelligence-driven pharmatech company that is a leader in the use of computational tools and machine learning capabilities to rapidly and
efficiently discover novel small molecule drug candidates. Our partnership consists of two joint ventures that each focus on the discovery and development of small molecule therapeutics for the treatment of patients with rare metabolic diseases.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The first of these programs is targeting Ectonucleotide Pyrophosphatase/ Phosphodiesterase 1, or ENPP1, for the treatment of patients with HPP, a potentially
life-threatening disease due to defects of skeletal mineralization. Patients with HPP suffer from deficiencies in breaking down pyrophosphate due to loss of function mutations in the gene ALPL, which encodes Tissue
<FONT STYLE="white-space:nowrap">Non-specific</FONT> Alkaline Phosphatase, or TNSALP. ENPP1 is an enzyme involved in regulating extracellular levels of pyrophosphate, a natural inhibitor of calcium mineralization in bone formation. We believe that a
small molecule inhibitor of ENPP1 has the potential to bring meaningful benefit to HPP patients by reducing excess levels of pyrophosphate, thereby removing an inhibitor of calcium mineralization and bone formation. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The incidence of HPP has been reported to be 1 in 100,000 to 1 in 300,000 (United States and Canada) for severe disease and 1 in 6,370 (EU) for less severe forms. In
functional in vitro assays, we have observed that our lead ENPP1 inhibitors can promote mineralization. We intend to nominate a development candidate in this program in the first quarter of 2022. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we have a second joint venture with Exscientia, which is currently in the discovery stage, to identify a small molecule modulator for patients with an
undisclosed rare metabolic disorder.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Strategy </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our mission at
Rallybio is aligned with our expertise: to identify and accelerate the development of life-transforming therapies for patients with severe and rare disorders. To achieve this mission, our strategy includes the following key components: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Establish a leading rare disease company through a team that delivers transformative medicines to patients.</B> We
believe our team&#146;s expertise and knowledge are fundamental to our long-term success. Our research and development team is led by experienced drug development executives who were integral in the approvals of more than 30 drugs from leading
companies, including Alexion, Astellas Pharma Inc., Wyeth, LLC and Pfizer Inc. We plan to continue to leverage our team&#146;s expertise to enable focused clinical development of multiple product candidates in parallel, resulting in a diversified
portfolio that we believe will provide multiple opportunities to create value by significantly improving the lives of patients. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Advance RLYB212 into and through clinical development for the prevention of FNAIT. </B>Our polyclonal antibody,
RLYB211, is currently being evaluated in a Phase 1/2 clinical trial. Topline data from this trial was presented at the ISTH Congress in July 2021, which we believe establishes proof of concept for RLYB211 and an
<FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT> antibody approach. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">97 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
For RLYB212, in addition to the Phase&nbsp;1 and Phase&nbsp;1b trials, to further support our clinical development, we plan to initiate a global natural history study of FNAIT in the third
quarter of 2021. </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Advance RLYB116 and RLYB114 into and through clinical development for the treatment of diseases of complement
dysregulation. </B>We intend to submit a CTA for RLYB116 in the fourth quarter of 2021 with the goal of initiating a Phase 1 clinical trial in the first quarter of 2022. We plan to pursue PNH and gMG as our lead indications for RLYB116. We also plan
to evaluate the development of RLYB116 for the treatment of additional rare complement-mediated diseases. In addition, we are proceeding with preclinical development of RLYB114 for complement-mediated ophthalmic indications. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Identify and advance pipeline product candidates for rare metabolic diseases through our joint ventures with
Exscientia.</B> We have entered into a partnership with Exscientia to identify and develop candidates that are aligned with our overall drug discovery and development strategy. We plan to nominate a development candidate for our ENPP1 program in the
first quarter of 2022. We also continue to execute on a second target with Exscientia with the goal of identifying a small molecule modulator for the treatment of an undisclosed rare metabolic disorder and expect to pursue additional small molecule
targets in collaboration with Exscientia in additional joint ventures. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Expand our pipeline through partnering, acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> additional
product candidates that target validated biology. </B>We&nbsp;are focused on developing drugs that directly impact known disease pathways which we believe will allow us to increase the probability of clinical, regulatory and commercial success. We
continue to accelerate our business development activities and actively pursue the acquisition or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of additional product candidates as well as partnerships and collaborations. Our team has strong
relationships with key academic and industry leaders in the rare disease field built from our past success in developing and commercializing therapies for rare diseases. We plan to continue to leverage these relationships to further our business
development opportunities and thereby expand our pipeline. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Maximize the value of pipeline product candidates through commercial independence in key markets and select
partnerships. </B>We plan to build a fully integrated and focused commercial organization to launch our rare therapeutics, if approved, in key markets. We believe our commercial organization can be efficiently targeted at groups of specialists who
typically treat patients with the diseases to be addressed by our product candidates. For certain other markets, we plan to explore strategic partnerships to efficiently deliver our therapeutics to patients, with the goal of transforming patient
care in our focus areas around the globe. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Company </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We were founded in January 2018 by Drs. Mackay and Uden and Mr.&nbsp;Fryer to identify and accelerate the development of life-transforming therapies for patients with
severe and rare disorders. At Alexion, Dr.&nbsp;Mackay was Global Head of Research&nbsp;&amp; Development, Dr.&nbsp;Uden served as Head of Research, and Mr.&nbsp;Fryer was Chief Tax Officer. Many of our employees have worked together extensively
during their careers across different companies. During these years of collaboration, several members of our team were integral in the successful development and/or approval of transformative therapies for thousands of patients with rare diseases.
As a focused, cohesive and experienced Rallybio team, we hope to transform the lives of many thousands more. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To date, we have raised over $180&nbsp;million from
investors including 5AM Ventures, Canaan Partners, Connecticut Innovations, Fairview Capital, <FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital, Mitsui&nbsp;&amp; Co. Global Investment, New Leaf Venture Partners, Pivotal bioVenture Partners,
Solasta Ventures, Tekla Capital Management, TPG, and Viking Global Investors. In addition, employees of Rallybio have invested over $2.3&nbsp;million to date in our Series A-1, Series A-2, and Series B financing transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">98 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Product Candidates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>RLYB211 and RLYB212 for the prevention of FNAIT </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are developing two <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibody product candidates, RLYB211 and RLYB212, for the prevention of FNAIT, a maternal fetal blood disorder that can cause potentially devastating outcomes
including miscarriage, neonatal death and severe life-long neurological disability. RLYB211 is a polyclonal <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibody isolated from the plasma of women who
developed HPA-1a antibodies due to a prior HPA-1 incompatible pregnancy. We believe early data generated from the first cohort of our ongoing Phase 1/2 clinical trial for RLYB211 in healthy male participants supports the potential of our approach to
prevent material alloimmunization and therefore the occurrence of FNAIT. RLYB212 is a monoclonal antibody directed at the same <FONT STYLE="white-space:nowrap">HPA-1a</FONT> target and we intend to advance this product candidate into clinical trials
in the first quarter of 2022. We expect to report proof of concept data from this study in mid-2022. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Maternal fetal blood disorders </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">FNAIT is one of several devastating disorders that is caused by an immune incompatibility of a mother and fetus during pregnancy. One of the best-characterized prenatal
immune incompatibility disorders is Rh disease. This condition arises when the mother is RhD negative and her fetus is RhD positive. RhD incompatibility may lead to destruction of red blood cells in the fetus and can result in severe outcomes
including miscarriage or loss of a newborn. RhD disease is treated by giving <FONT STYLE="white-space:nowrap">at-risk</FONT> expectant mothers low doses of antibodies to RhD. These antibodies remove fetal red blood cells that have crossed into the
mother&#146;s circulation, thereby preventing her from developing an immune response that could destroy the red blood cells in the fetus. Since the approval of the first Rho (D)&nbsp;Immune Globulin in 1968, known as RhoGAM, expectant mothers in
many countries, including North America and Europe, are routinely screened for their RhD status, and Rh disease is largely prevented in <FONT STYLE="white-space:nowrap">at-risk</FONT> expectant mothers. We are pursuing a similar approach to
preventing FNAIT with our product candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>FNAIT disease background </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Like Rh disease, FNAIT is a disorder that occurs during pregnancy when an expectant mother&#146;s immune system attacks a specific antigen on the platelets of her
fetus, leading to their destruction. This results in an increased risk of bleeding in the fetus and newborn. In the majority of cases, the effects of FNAIT are mild; however, up to 20% of FNAIT cases experience intracranial hemorrhage, or ICH, which
can lead to devastating outcomes such as miscarriage, stillbirth, loss of the newborn and severe lifelong neurological disabilities in those babies that survive. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">FNAIT is caused by a mismatch in the type of human platelet antigen 1, or <FONT STYLE="white-space:nowrap">HPA-1,</FONT> that is expressed by the expectant mother and
the fetus. There are two predominant forms of <FONT STYLE="white-space:nowrap">HPA-1,</FONT> known as <FONT STYLE="white-space:nowrap">HPA-1a</FONT> and <FONT STYLE="white-space:nowrap">HPA-1b,</FONT> which are expressed on the surface of platelets.
These two alleles differ by a single amino acid. Individuals who are homozygous for <FONT STYLE="white-space:nowrap">HPA-1b,</FONT> meaning that they have two copies of the <FONT STYLE="white-space:nowrap">HPA-1b</FONT> allele and no copies of the <FONT
STYLE="white-space:nowrap">HPA-1a</FONT> allele, are also known as <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negative. Upon exposure to <FONT STYLE="white-space:nowrap">HPA-1a,</FONT> these individuals can develop antibodies to that antigen in
a process known as alloimmunization. In expectant mothers, alloimmunization can occur upon mixing of fetal blood with maternal blood. When alloimmunization occurs in an expectant mother, the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibodies that develop in the mother can cross the placenta and destroy platelets in the fetus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">99 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Pathophysiology of FNAIT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g96t09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are no approved therapies to treat or prevent FNAIT and, therefore, expectant mothers are not currently screened for FNAIT
risk. Today, expectant mothers at risk of FNAIT are typically only identified following the delivery of an FNAIT affected child. These mothers may be treated during subsequent pregnancies with weekly administration of IVIG, along with the oral
steroid immunosuppressant prednisone. While IVIG administration can potentially mitigate the detrimental effects of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibodies, it does not prevent
alloimmunization, is costly, time-intensive, difficult to tolerate and associated with significant treatment-related complications. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Babies with FNAIT are typically
diagnosed at the time of delivery by the presence of low platelet counts identified during routine analysis, the presence of petechiae on the skin or due to the manifestations of severe complications such as ICH or gastrointestinal bleeding. Upon
diagnosis, babies with FNAIT may receive platelet transfusions and may be admitted to the neonatal intensive care unit. In severe cases, babies may suffer life-long neurological disability or may not survive. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We project that there may be over 22,000 pregnancies annually that are at high risk of FNAIT in the United States, Canada, United Kingdom, other major European
countries and Australia. These pregnancies represent expectant mothers who are <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negative, who are at high risk of alloimmunization and who are carrying an <FONT STYLE="white-space:nowrap">HPA-1a</FONT>
positive fetus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While the frequency of <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negative status in <FONT STYLE="white-space:nowrap">non-Caucasian</FONT>
populations is not established, studies show that approximately 2% of the Caucasian population is <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negative. Based on this frequency and live birth rates of Caucasian women from 2018, we estimate that
there are approximately 110,000 <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negative expectant mothers in the aforementioned countries each year. From this population of expectant mothers, a subset is at higher risk of FNAIT due to the presence
of a specific HLA allele, known as DRB3*01:01. Genetic studies have found that expectant mothers who have this specific HLA allele are approximately 25 times more likely to develop antibodies to <FONT STYLE="white-space:nowrap">HPA-1a</FONT> than
those without this allele. This higher-risk group represents approximately 27% of <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negative expectant mothers, or approximately 30,000 individuals. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">100 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From this population, an estimated 89% of women would not already have antibodies to
<FONT STYLE="white-space:nowrap">HPA-1a</FONT> and, of these, an estimated 86% would be expected to be carrying an <FONT STYLE="white-space:nowrap">HPA-1a</FONT> positive fetus. As illustrated below, based on these estimates, we project there may be
over 22,000 pregnancies annually that are at high risk of FNAIT. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Pregnancies At Risk of FNAIT </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g07q54.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Given the well-established prevalence of <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negativity in the Caucasian population, our
current estimates of the FNAIT <FONT STYLE="white-space:nowrap">at-risk</FONT> population are derived from the estimated proportion of Caucasian births from approximately eight million live births per year in the above-mentioned countries. However,
we are committed to ensuring that all expectant mothers of any race or ethnicity who are at high risk of FNAIT are identified and eligible for treatment. We intend to initiate a natural history study of FNAIT in the third quarter of 2021, in part to
obtain better prevalence estimates of the FNAIT <FONT STYLE="white-space:nowrap">at-risk</FONT> population in racial and ethnic groups that may have been underrepresented in previously published studies. We believe that data from this study will
better inform the size of the total FNAIT <FONT STYLE="white-space:nowrap">at-risk</FONT> population. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that screening for FNAIT risk can be performed
routinely and cost effectively as part of standard prenatal testing provided to expectant mothers during pregnancy. Testing for maternal <FONT STYLE="white-space:nowrap">HPA-1</FONT> type and presence of the
<FONT STYLE="white-space:nowrap">HLA-DRB3*01:01</FONT> allele could occur during the first trimester, at the same time as other routine blood work and risk screening, and we don&#146;t expect that an additional blood draw would be required.
Importantly, U.S. and EU physicians have advised that our approach and timing for FNAIT screening would fit well within the established first trimester prenatal testing paradigm and could slot in at the same time as routine blood typing and Rh
testing. Based on our global market research with maternal-fetal medicine specialists, obstetricians-gynecologists and payers, we believe there is not only high awareness of the catastrophic impact of FNAIT, but also a strong desire to both screen
and provide preventive therapy to <FONT STYLE="white-space:nowrap">at-risk</FONT> expectant mothers, if there were an approved product to prevent FNAIT and affordable screening tests. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe screening and preventive treatment can have a significant impact on this potentially devastating disease. For example, screening and treatment in Rh disease
have been highly effective in reducing the number of affected births. In developed countries with access to prenatal testing and treatment, the prevalence of Rh disease is 2.5 per 100,000 compared to 276 per 100,000 worldwide. We believe that
applying a similar approach to the prevention of FNAIT could lead to a significant reduction in the number of babies at risk for FNAIT. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are working with Grifols
Laboratory Solutions Inc. to include screening tests for maternal <FONT STYLE="white-space:nowrap">HPA-1</FONT> type, maternal <FONT STYLE="white-space:nowrap">HLA-DRB3*D1:01</FONT> status, maternal <FONT STYLE="white-space:nowrap">HPA-1a</FONT>
antibodies and fetal <FONT STYLE="white-space:nowrap">HPA-1</FONT> genotype in our clinical development program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">101 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to initiate a natural history trial of FNAIT in the third quarter of 2021, which is described below, in which we
plan to implement this screening paradigm in a broad population of expectant mothers of different racial and ethnic characteristics to identify those at risk of developing FNAIT. We also plan to use this trial to operationalize the FNAIT-risk
laboratory test paradigm prior to implementing the laboratory tests in a future registration trial. We anticipate that data from this natural history trial, combined with data available from other literature-reported FNAIT screening studies, may be
sufficient to serve as a basis for future regulatory discussions regarding the use of historical control data to support a future single arm Phase 2/3 registrational trial. We also believe that the experience in recruiting expectant mothers into
this trial will accelerate recruitment into future FNAIT trials. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our solution: RLYB211 and RLYB212 </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are developing RLYB211, a polyclonal <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibody isolated from the plasma of
women who developed <FONT STYLE="white-space:nowrap">HPA-1a</FONT> antibodies due to a prior <FONT STYLE="white-space:nowrap">HPA-1</FONT> incompatible pregnancy, and RLYB212, a monoclonal <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibody developed from transformed memory <FONT STYLE="white-space:nowrap">B-cells</FONT> isolated from a mother with severe FNAIT affected pregnancies. Our dual approach is rooted in our goal to
provide a preventive therapy for FNAIT to mothers at risk as soon as practicable. We believe the early data generated from our ongoing RLYB211 Phase 1/2 clinical trial support the mechanism of action of RLYB211, and by extension that of RLYB212, to
remove fetal <FONT STYLE="white-space:nowrap">HPA-1a</FONT> platelets from HPA-1a negative expectant mothers and potentially prevent maternal alloimmunization, thereby eliminating the risk of FNAIT. We acquired all rights to both product candidates
from Prophylix AS, or Prophylix, in 2019. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In November&nbsp;2020, we announced that we dosed the first participant in our Phase&nbsp;1/2 trial of RLYB211.
Topline data from this trial was presented at the ISTH Congress in July&nbsp;2021, and we anticipate reporting additional data from this trial in the fourth quarter of 2021. For RLYB212, our lead product candidate, we submitted a CTA in
July&nbsp;2021, and subject to the acceptance of our CTA submission, we expect to initiate a Phase&nbsp;1 first-in-human trial in Germany in the first quarter of 2022, with proof of concept data from a Phase&nbsp;1b trial planned for mid-2022. </P>
 <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are prioritizing the development of RLYB212 based on the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Dose administration.</B> RLYB212 is dosed subcutaneously while RLYB211 is administered via intravenous bolus injection.
Subcutaneous administration simplifies the treatment regimen for <FONT STYLE="white-space:nowrap">at-risk</FONT> expectant mothers and is highly preferred by physicians in both the United States and EU, based on primary market research.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Pharmacokinetic profile.</B> Our pharmacokinetic modeling suggests that weekly subcutaneous administration of RLYB212
could maximize the capacity of RLYB212 to neutralize fetal antigen over the course of treatment compared to RLYB211, by maintaining higher trough levels and limiting fluctuations from peak to trough. </P></TD></TR></TABLE>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Standard manufacturing and stable supply</B>. Commercial quantities of RLYB212 are expected to be produced by standard
monoclonal antibody production methods. RLYB211, however, is purified from plasma collected from women who developed <FONT STYLE="white-space:nowrap">HPA-1a</FONT> antibodies due to a prior HPA-1 incompatible pregnancy. If RLYB211 is clinically
successful in preventing FNAIT, the number of women with <FONT STYLE="white-space:nowrap">HPA-1a</FONT> antibodies would decrease significantly, negatively impacting our ability to source a long-term supply of commercial product.
</P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical development of RLYB211: providing support for the RLYB212 approach </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are conducting a Phase 1/2 single-blind, placebo-controlled, dose escalation proof of concept trial designed to establish the dose of RLYB211 needed to rapidly clear
<FONT STYLE="white-space:nowrap">HPA-1a</FONT> positive platelets transfused to <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negative healthy male participants. In this trial, the elimination of transfused platelets is intended to serve as a
surrogate for assessing the ability of RLYB211 to drive rapid elimination of <FONT STYLE="white-space:nowrap">HPA-1a</FONT> positive fetal platelets from an expectant mother&#146;s circulation, thereby potentially preventing <FONT
STYLE="white-space:nowrap">HPA-1a</FONT> maternal alloimmunization and the occurrence of FNAIT in fetuses and newborns. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The trial is designed to enroll a total
of 24 participants across three cohorts, each investigating a different dose of RLYB211. In cohorts 1 and 2, platelet transfusion precedes single dose administration of either placebo or RLYB211 at 1,000 IU in cohort 1 and 4,000 IU in cohort 2. Data
from cohorts 1 and 2 will be used to evaluate the trial&#146;s primary endpoint of time to platelet clearance, based on t<SUB STYLE="font-size:85%; vertical-align:bottom">1/2</SUB> of 10x10<SUP STYLE="font-size:85%; vertical-align:top">9</SUP>
transfused HPA-1a positive platelets. Data from cohort 3, investigating a 10,000 IU dose, will be used to establish the RLYB211 pharmacokinetic profile. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">102 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Safety will be assessed across all cohorts. The trial is being conducted at the Clinical Research department of Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Branch for
Translational Medicine and Pharmacology (TMP) in Frankfurt/Main, Germany in collaboration with the German Red Cross (Deutsches Rotes Kreuz) Blood Service <FONT STYLE="white-space:nowrap">Baden-W&uuml;rttemberg-Hessen</FONT> in Frankfurt/Main,
Germany. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Design of Cohorts 1 &amp; 2 of the Phase 1/2 Trial of RLYB211 in HPA-1a Negative Healthy Participants </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g45t26.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the first cohort of this trial, a dose of 10x10<SUP STYLE="font-size:85%; vertical-align:top">9</SUP> <FONT
STYLE="white-space:nowrap">HPA-1a</FONT> positive (i.e., HPA-1ab) platelets was transfused into healthy participants to simulate a fetal bleed into the maternal circulation one hour before a 1,000&nbsp;IU dose of RLYB211. As illustrated below,
administration of RLYB211 markedly accelerated the clearance of the transfused <FONT STYLE="white-space:nowrap">HPA-1a</FONT> positive platelets compared with placebo, resulting in a half-life of mismatched platelets of 0.32 hours as compared to
65.29 hours with placebo (p value &lt;0.001). RLYB211 showed acceptable tolerability with no serious adverse events observed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">103 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RLYB211 Led to Rapid Clearance of Transfused <FONT STYLE="white-space:nowrap">HPA-1a</FONT> Positive
(i.e., HPA-1ab) Platelets from Healthy Participants </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g09r85.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Data from the first cohort provides proof of concept of the ability of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibodies to rapidly clear <FONT STYLE="white-space:nowrap">HPA-1a</FONT> positive transfused platelets in <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negative individuals. These data support
the potential for the administration of an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibody to drive the rapid elimination of HPA-1a positive fetal platelets from an expectant mother&#146;s
circulation, thereby preventing HPA-1a maternal alloimmunization and the occurrence of FNAIT in fetuses and newborns. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Given these positive results, we are now
seeking a protocol amendment in which four healthy <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negative male participants will receive RLYB211 seven days prior to an <FONT STYLE="white-space:nowrap">HPA-1a</FONT> positive platelet challenge. We
believe this amendment will allow the trial to more closely mimic the situation in expectant mothers who would be eligible to receive an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibody as a
preventive treatment in anticipation of potential exposure to <FONT STYLE="white-space:nowrap">HPA-1a</FONT> platelets from their fetuses. Data from this cohort are expected in the fourth quarter of 2021. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>RLYB212 preclinical data </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A mouse model of FNAIT has been created in
which the amino acids comprising the <FONT STYLE="white-space:nowrap">HPA-1a</FONT> antigen are reconstituted in the mouse gene. These transgenic mice (referred to as APLDQ mice based on the amino acid changes) recapitulate multiple aspects of
FNAIT. Administration of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibodies to APLDQ mice leads to destruction of APLDQ platelets and severe thrombocytopenia. Injection of platelets from APLDQ mice
into wild-type mice can induce an <FONT STYLE="white-space:nowrap">HPA-1a</FONT> specific immune response. Finally, wild-type female mice <FONT STYLE="white-space:nowrap">pre-immunized</FONT> with APLDQ platelets, when bred with APLDQ male mice,
give birth to severely thrombocytopenic pups, many of which exhibit an accompanying bleeding phenotype. Treatment of these pregnant female mice with IVIG resulted in lowering the level of anti-APLDQ antibodies in the fetus and a reduction in
thrombocytopenia. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">104 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In a prophylactic treatment model, a single large bolus intravenous injection of 1 x 10<SUP
STYLE="font-size:85%; vertical-align:top">8</SUP> APLDQ platelets (equivalent to about <FONT STYLE="white-space:nowrap">one-sixth</FONT> of the total blood volume in the host) was administered to wild-type mice. At a dose of 0.4 &micro;g (yielding a
peak concentration of approximately 0.2 &micro;g/ml), RLYB212 was able to drive rapid and complete elimination of APLDQ platelets, as shown in the first graph below, and prevent a host antibody response, as shown in the second graph below. As shown
in third graph below, this dose correlates to a concentration of RLYB212 projected to bind approximately 10% of the <FONT STYLE="white-space:nowrap">HPA-1a</FONT> antigen present on the transfused APLDQ platelets. Thus, the approximately 10%
receptor binding is sufficient to clear platelets and prevent alloimmunization. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RLYB212 Induced Rapid Elimination of APLDQ Platelets </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g11v45.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RLYB212 Prevented the Development of
Antibodies to APLDQ Platelets </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g11x65.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">105 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Ten Percent of APLDQ Platelets Bound by 0.4 &micro;g Dose of RLYB212 at C<SUB
STYLE="font-size:85%; vertical-align:bottom">max</SUB> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g14a01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical development of RLYB212 </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We anticipate initiating a Phase 1 single and multiple dose trial for RLYB212 in <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negative healthy participants in the
first quarter of 2022. The trial will evaluate the safety, tolerability and pharmacokinetics of RLYB212 following subcutaneous single dose administration and subcutaneous weekly doses for an estimated period of up to 12 weeks. The general design of
the planned trial is illustrated below. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Design of the Initial Phase 1 Trial of RLYB212 in <FONT STYLE="white-space:nowrap">HPA-1a</FONT> Negative
Healthy Participants </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g14b66.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A subsequent Phase&nbsp;1b proof of concept trial will assess the ability of RLYB212 to rapidly eliminate transfused <FONT
STYLE="white-space:nowrap">HPA-1a</FONT> positive platelets from the circulation of <FONT STYLE="white-space:nowrap">HPA-1a</FONT> negative healthy male participants in a design similar to that of the RLYB211 Phase&nbsp;1/2 trial. We expect to
report proof of concept data from the Phase 1b study in <FONT STYLE="white-space:nowrap">mid-2022.</FONT> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Design of the Phase 1b Trial of RLYB212
in Healthy Male Participants </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g14g85.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">106 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to successful completion of our planned Phase&nbsp;1 and 1b trials and future discussions with regulatory
authorities, we plan to conduct a registrational enabling Phase&nbsp;2/3 trial of RLYB212 in expectant mothers at higher FNAIT risk. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Prospective FNAIT
Natural History Alloimmunization Study </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to initiate a prospective, non-interventional, multinational natural history study in the third quarter of
2021. The primary objective of the study will be to determine the frequency of women who are HPA-1a antibody negative and have the HLA allele DRB3*01:01, and are therefore at higher FNAIT risk among pregnant women of different racial and ethnic
characteristics who present for prenatal care at gestation weeks 10 to 14. A secondary objective will be to identify the frequency of HPA-1a alloimmunization and pregnancy outcomes among women identified to be at higher FNAIT risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>RLYB116 for the treatment of disorders due to complement dysregulation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RLYB116 is an inhibitor of complement factor C5, a central component of the complement pathway, which plays a central role in innate immunity as well as shaping
adaptive immune response. Dysregulation of the complement pathway has been implicated in the pathogenesis of a growing number of diseases, making it an attractive target for therapeutic intervention. Antibody inhibitors of C5 have been successfully
developed to treat diseases caused by immune dysfunction, including PNH, aHUS, refractory gMG and relapsing NMOSD. Despite approved products for these indications, we believe there remains an unmet need in patients with these diseases for therapies
that are more patient-friendly and accessible. RLYB116 is an Affibody<B><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></B> molecule, which is an antibody mimetic protein that has a much smaller molecular weight than a traditional
antibody and may also be easier and less costly to produce. In contrast to <FONT STYLE="white-space:nowrap">C5-targeted</FONT> antibody therapeutics that are administered intravenously, RLYB116 has the potential to be administered as a small volume
subcutaneous injection. Additionally, RLYB116 includes an albumin binding domain, which may extend the half-life of the Affibody&reg; domain. In addition, amino acid changes have been made to RLYB116 that are intended to enhance stability. We view
RLYB116 as a potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pipeline-in-a-product.</FONT></FONT></FONT> Our lead indications for RLYB116 are PNH and gMG. However, we plan to evaluate the
development of RLYB116 for the treatment of additional rare complement-mediated diseases. We believe RLYB116 could potentially enable more patients suffering from PNH and gMG to be treated globally and could also provide a meaningful therapeutic
impact for patients suffering from a broad number of other diseases of complement dysregulation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on our team&#146;s experience studying and developing
therapies targeting the complement system, we believe there are four important attributes that could support clinical and commercial success in the treatment of patients suffering from complement-mediated diseases. These include a mechanism of
action targeting terminal complement, the ability to produce rapid, complete and sustained inhibition of C5, a safety profile consistent with C5 antibodies currently approved for therapeutic use and pricing flexibility to treat a broad range of
complement-mediated diseases. We believe RLYB116 has the potential to demonstrate these attributes, and if so, could have a life-transforming impact for patients. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The complement system </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The complement system includes over 30
proteins in plasma and on cell surfaces that support the body&#146;s adaptive or antibody-based immune system in the destruction of pathogenic bacteria. Complement proteins circulate in the blood in an inactive form prior to activation in response
to infection. Activation occurs through a pathway of proteolytic cleavage events initiated by pathogen recognition and resulting in pathogen destruction. Three complement pathways are known and are referred to as the classical, lectin and
alternative pathways. In the classical pathway, antibodies bind to antigens, which in turn trigger a protease cascade that activates complement protein C3 and then complement protein C5. Activation of C5 convertase generates C5b which can initiate
formation of membranes pores and subsequent lysis of cells. The binding of C5b to host cells is normally prevented by the presence of specific glycoproteins on the cell surface. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>PNH disease background </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">PNH is a rare, potentially life-threatening
hematologic disease characterized by complement-mediated destruction of red blood cells, or hemolysis. Early signs of PNH include hemoglobinuria, or dark colored urine, resulting from excretion of hemoglobin from lysed red blood cells, which is more
prominent in the morning and decreases during the day. More serious symptoms of PNH include anemia, excessive weakness, fatigue, severe abdominal pain, severe headaches and recurrent infections. PNH leads to over a
<FONT STYLE="white-space:nowrap">60-fold</FONT> increase in the risk of venous thromboembolism </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">107 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
compared to the general population and these thrombotic events lead to between 40% and 67% of deaths in PNH patients. Approximately two thirds of patients with PNH develop chronic kidney disease,
or CKD, and kidney failure is the cause of death in 8% to 18% of patients with PNH. In the absence of disease-modifying treatment, PNH results in the death of approximately 35% of affected individuals within five years of diagnosis. An analysis
conducted in 2006 estimated that there were approximately 4,700 patients living with PNH in the United States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In patients with PNH, blood precursor cells acquire
a mutation in a gene encoding a protein that anchors a specific set of proteins on the cell surface. When these proteins, known as glycoproteins, are in place on the blood precursor cells, then the cells are protected from immune attack. However, in
patients with PNH, these mutations cause the absence of these glycoproteins and renders red blood cells susceptible to destruction by the complement pathway. Once the cells are destroyed, by a mechanism known as lysis, the hemoglobin from these
cells is then removed from circulation by the kidneys and excreted in the urine. Excess hemoglobin and additional proteins from lysed red blood cells causes the kidney damage seen in most patients with PNH. The observed increase in the rate of
thrombosis in PNH patients is believed to be related to altered platelet function as well as to other activities associated with the C5a protein, such as vasoconstriction and increases in inflammation. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Current treatments for PNH and their limitations </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The only curative
treatment currently available for PNH is a stem cell transplant from a related donor. However, this procedure is associated with significant risk and is typically used only in those patients with severe disease, such as life-threatening thrombosis
or dangerously low blood counts. Various supportive therapies include anticoagulants, red blood cell transfusions and supplements of iron and folate. These therapies provide some relief from symptoms but do not address the underlying cause of the
disease. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are two approved disease-modifying drugs for PNH: eculizumab, marketed by Alexion as Soliris; and ravulizumab, marketed by Alexion as Ultomiris.
Both of these products are antibodies that bind to complement C5 and prevent its cleavage by C5 convertase to C5a and C5b, thus blocking a central step in the complement pathway. Both products are roughly equivalent in their ability to block C5
cleavage, prevent hemolysis, minimize the need for transfusions and to stabilize hemoglobin. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Eculizumab and ravulizumab are each administered intravenously by
healthcare professionals: eculizumab at biweekly intervals and ravulizumab at eight-week intervals. Despite the requirement for intravenous administration and limitations on access, wide adoption of these drugs has led to worldwide sales of
eculizumab and ravulizumab which in 2020 exceeded $5&nbsp;billion. We believe that a product that works through a similar mechanism but with a more convenient route of administration and improved patient access has the opportunity to further
transform PNH therapy for patients. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Potential benefits of our approach </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are pursuing PNH as part of our initial development strategy for three reasons. First, PNH has a well-understood disease pathophysiology driven by complement,
providing a sound biological rationale for a <FONT STYLE="white-space:nowrap">C5-targeted</FONT> intervention. Second, PNH offers the opportunity for early clinical validation using objective endpoints, including impact on lactate dehydrogenase, a
component of red blood cells that is increased in circulation as a result of hemolysis. And third &#150; and most importantly &#150; we believe that with a patient-friendly and accessible therapy, RLYB116 could potentially provide transformative
therapeutic impact for unserved and underserved patients with PNH globally. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Generalized myasthenia gravis disease background </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Generalized myasthenia gravis is a potentially life-threatening, rare autoimmune neuromuscular disorder. Patients with gMG develop antibodies that attack critical
signaling proteins at the junction between nerve and muscle cells, thereby inhibiting the ability of nerves to communicate properly with muscles. This inhibition leads to muscle weakness, which can occur in ocular muscles leading to droopy eyelids
as well as blurred or double vision due to partial paralysis of eye movements and in the muscles in the face, neck, throat and jaw, causing problems in chewing and swallowing. gMG can also cause respiratory problems, speech difficulties and weakness
in skeletal muscles leading to problems in limb function. The symptoms of the disease can be transient and can remit spontaneously in the early stages of the disease. However, as the disease progresses, symptom-free periods become less frequent and
disease exacerbations can last for months. Up to 20% of gMG patients experience respiratory crisis at least once in their lives. During crisis, a decline in respiratory function can become life-threatening and often requires intubation and
mechanical ventilation, and hospital stays for patients in crisis last a median of seventeen </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">108 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
days. According to a comprehensive epidemiological study of gMG in western Denmark form 1975-89, From the time of diagnosis, the overall survival rates at 3, 5, 10 and 20 years are estimated to
be 85%, 81%, 69% and 63%, respectively. In addition, patients with gMG suffer from poor quality of life due to the impact of their disease on physical function as well as the burden of treatment-related adverse events. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The most common proteins that have been targeted by these autoimmune antibodies are AchR, which are within the neuromuscular junction and bind to the acetylcholine
neurotransmitter released by the nerve; and muscle-specific kinase, or MuSK, a tyrosine kinase involved in propagating neuronal signals. The presence of these autoimmune antibodies blocks the signaling from neurons to muscles which results in
outward signs of muscle weakness. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The pathology in gMG arises not only from interrupting signal transduction, but from physical destruction of the post-synaptic
membrane through activation of the complement pathway. Over 80% of patients with gMG have antibodies to AchR and these antibodies can lead to complement-driven lysis of the post-synaptic membrane. Eculizumab is approved for the treatment of AchR
antibody-positive gMG based on its ability to lead to significant improvements in the Myasthenia Gravis-Specific Activities of Daily Living scale and the Quantitative Myasthenia Gravis score which measures muscle weakness. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, the prevalence of gMG is estimated to be 14 to 20 per 100,000, with as many as 60,000 patients estimated to be living with the disease. As with
many autoimmune diseases, there are no known genetic alterations that specifically cause gMG. In most patients, the disorder arises spontaneously. Approximately 3% of patients have a primary relative with gMG, suggesting that there are genetic
factors that may predispose development of the disease, but these genes have yet to be identified. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Current treatments for gMG and their limitations
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the first-line setting, patients presenting with symptomatic gMG are commonly treated with acetylcholinesterase inhibitors such as pyridostigmine in
order to improve neuromuscular transmission. As the disease progresses, patients may receive immunosuppressive therapies such as azathioprine, glucocorticoids, mycophenolate and cyclosporine. These therapies are used off-label for patients with gMG
and unfortunately, each of these can be associated with substantive treatment burden and in some cases, can lead to disease worsening. Soliris (eculizumab) has been approved in the United States, EU, Japan and other markets for the treatment of
patients with refractory gMG who are anti-AChR positive. Substantive symptom improvements have been noted with eculizimab treatment at the first assessment at one week after first dose administration. Rituximab may also be used off-label and is
believed to have more benefit in patients with gMG with anti-MuSK antibodies compared to those with anti-AChR antibodies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For patients with severe myasthenia or
recurrent exacerbation and crisis, there are a number of methods utilized to reduce circulating IgG antibodies, as published studies have shown that decreases in circulating IgG antibody levels are correlated with increased relief of symptoms and
decreases in the length of hospital stays. These procedures include: plasma exchange, a process whereby blood is taken from a patient and IgG antibodies are physically removed from the plasma before it is returned to the patient; and administration
of IVIG, which provides therapeutic benefit through multiple hypothesized mechanisms, including the saturation of the FcRn receptor, which may lead to increased degradation of the endogenous autoimmune antibodies. Both procedures are burdensome for
patients and repeat administration is usually required to obtain significant reduction in symptoms. In addition, the large volumes of intravenous fluid associated with the administration of IVIG can lead to pulmonary edema and kidney complications
in elderly patients. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Potential benefits of our approach </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are
pursuing gMG as part of our initial development strategy for two reasons. First, complement overactivity is known to contribute to the disease pathophysiology of gMG, again providing a sound biological rationale for a
<FONT STYLE="white-space:nowrap">C5-targeted</FONT> intervention. Second &#150; and most importantly &#150; we believe there is significant unmet need that we can address. We believe the convenience of subcutaneous self-administration may enable
treatment of a broad population of gMG patients at both earlier and late stages of disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">109 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our solution: RLYB116 </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RLYB116 is an engineered protein that includes an Affibody<B><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></B> molecule and an albumin binding domain. We
acquired rights to RLYB116 from Swedish Orphan Biovitrum AB, or Sobi. RLYB116 has been designed to be optimized for C5 binding, stability, and long half-life in serum. Potential benefits of RLYB116 include: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Subcutaneous administration</B>. The low molecular weight allows for a higher concentration of active molecules than
antibodies in an equivalent volume. This increases the probability of being able to deliver RLYB116 in a volume suitable for subcutaneous administration. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Efficiency of manufacturing</B>. RLYB116 is expressed in <I>E coli</I>, providing for a more streamlined manufacturing
process compared to antibodies or other biologics expressed in mammalian cell culture, which typically require larger scale and longer manufacturing times. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Less frequent dosing</B>. Linkage of the Affibody<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> domain to
an albumin binding domain may lengthen the dosing interval of RLYB116 by extending the biological half-life. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Broader indication opportunity</B>. Linkage to an albumin binding domain also may improve distribution to tissues
throughout the body creating the potential for additional tissue targets and indications. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Potentially lower risk of treatment conversion</B>. Due to 1:1 binding to C5, there is potentially lower risk of immune
complex formation when switching from treatment with an antibody. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Favorable stability.</B> The Affibody<B><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></B> platform
provides the possibility of delivering highly stable and soluble therapeutic agents that allow for high-concentration <FONT STYLE="white-space:nowrap">low-volume</FONT> products. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Affibody Scaffold and RLYB116 Structure </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g18h20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Pharmacodynamic properties of RLYB116 </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An ex vivo hemolytic inhibition assay suggests that RLYB116 may inhibit C5-mediated red blood cell destruction at a dose that could be clinically useful. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical development plans for RLYB116 </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to submit a CTA for
RLYB116 in the fourth quarter of 2021, with the goal of initiating a Phase&nbsp;1 clinical trial of RLYB116 in healthy adult participants in the first quarter of 2022. This trial will evaluate the safety, tolerability and pharmacokinetics of RLYB116
following subcutaneous administration of a single dose and multiple doses. We also plan to incorporate a measure of pharmacodynamic activity into the single and multiple ascending dose segments of the trial. The trial is planned to enroll up to 48
participants in the single ascending dose segment and evaluate up to 6 dose levels. The multiple ascending dose segment of the trial is planned to enroll up to 84 participants and up to 7 dosing strategies. A Phase&nbsp;1b trial is planned in
patients with PNH to assess the effect of RLYB116 on measures of pharmacodynamic activity as well as safety and pharmacokinetics. We anticipate conducting subsequent trials in patients with PNH and gMG, which are both indications in which C5
inhibition has been clinically validated. Beyond these initial indications, we plan to evaluate the development of RLYB116 for the treatment of additional rare complement-mediated diseases, given the growing numbers of diseases understood to be
mediated by complement dysregulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">110 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>RLYB114 for the treatment of ophthalmic disorders </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RLYB114 is a <FONT STYLE="white-space:nowrap">C5-targeted</FONT> Affibody<B><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></B> molecule conjugated to
polyethylene glycol, or PEG. The addition of PEG to protein therapeutics is a well-established method of extending the half-life and reducing the immunogenicity of these molecules in the body. Given the role of the complement system in retinal and
ocular pathology, we are exploring a range of ophthalmic diseases, including inflammatory and degenerative disorders, for the development of RLYB114. We expect to submit a CTA for RLYB114 in the first half of 2023. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Potential role of complement in ocular diseases </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Photoreceptors and
the retina encounter a number of innate immune activators. Dysregulation of the complement system may drive ocular inflammation and contribute to vision loss in multiple diseases such as <FONT STYLE="white-space:nowrap">age-related</FONT> macular
degeneration, or AMD. A number of genetic studies have shown links between alterations in genes encoding various complement factors and the risk of development of AMD. Several clinical trials of inhibitors of the complement pathway including C5
inhibitors have been conducted, with reports of modest efficacy. Reasons for this limited efficacy are unknown but could include the disease stage treated, level of intervention in the complement pathway, drug delivery mechanism and ability of the
therapeutic to cross Bruch&#146;s membrane to the retinal pigment epithelium. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Preclinical studies </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on an animal intravitreal pharmacokinetic study, RLYB114 may have a half-life comparable to Lucentis and Eylea. RLYB114 was also well tolerated in this study with
no major signs of ocular toxicities. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our solution: RLYB114 </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RLYB114 is in preclinical development. We plan to test multiple PEG moieties for C5 affinity and hemolysis inhibition in vitro, and characterize the pharmacokinetic and
safety profile after intravitreal administration in a rabbit model. Based on this series of nonclinical experiments, we expect to select a lead candidate for GLP toxicology studies and GMP manufacturing to support a regulatory submission in advance
of the conduct of a first-in-human study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Artificial Intelligence drug discovery collaboration with Exscientia </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We established a partnership with Exscientia, an artificial intelligence, or AI, and machine learning drug discovery company. Exscientia has built dedicated AI systems
that learn from a wide range of data and apply enhanced knowledge through iterations of design. Our partnership currently consists of two joint ventures that each focus on the discovery and development of small molecules for the treatment of
patients with rare metabolic diseases. The first of these joint ventures is targeting ENPP1, an enzyme involved in regulating extracellular levels of pyrophosphate, a natural inhibitor of calcium mineralization in bone formation, for the treatment
of patients with HPP. Our second joint venture with Exscientia is focused on identifying a small molecule modulator for the treatment of patients with an undisclosed rare metabolic disorder.</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Exscientia is a leader in the application of artificial intelligence to drug discovery. Their proprietary platform is built upon validated artificial intelligence
technology that has delivered multiple candidates to the clinic, including the first ever <FONT STYLE="white-space:nowrap">AI-designed</FONT> therapeutic candidate. Their approach is designed to streamline the drug discovery process by significantly
reducing the number of compounds synthesized, thereby reducing the time and cost of drug discovery. For Rallybio, this creates an attractive opportunity to continue building an early pipeline through a multi-target, shared-risk, joint venture with
Exscientia, combining their rapid and streamlined target execution process with our rare disease development expertise and track record of delivering therapies to patients. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>RE Ventures I: ENPP1 inhibitor program for the treatment of patients with hypophosphatasia </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are developing an ENPP1 inhibitor for the treatment of patients with HPP, a rare, potentially life-threatening genetic disease characterized by mutations in the ALPL
gene. These mutations lead to diminished activity of the TNSALP enzyme and the accumulation of inorganic pyrophosphate, or PPi, which inhibits bone mineralization causing multiple skeletal pathologies. ENPP1 is a Type&nbsp;II transmembrane
glycoprotein that cleaves ATP, producing PPi, and is a major source of PPi production in cells. We believe that controlling inhibition of ENPP1 may reduce PPi levels and restore balance within the bone mineralization process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">111 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>HPP disease overview </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">HPP is an inherited disorder that affects the development of bones and teeth. More than 300 mutations in the ALPL gene associated with HPP have been identified. These
mutations are associated with a wide range of disease severity. The most severe forms of the disorder tend to occur before birth and in early infancy. These infants have short limbs, an abnormally shaped chest, soft skull bones, poor feeding,
failure to gain weight, respiratory complications and high levels of calcium in the blood, or hypercalcemia, which can lead to life-threatening complications. In other cases, the disease is not recognized until later in childhood where it manifests
as rickets, pain, decreased mobility, deficits of growth and fractures. Children with less severe HPP can experience early loss of primary teeth and may have short stature with bowed legs or knock knees, enlarged wrist and ankle joints and an
abnormal skull shape. Findings in adults include a softening of the bones, known as osteomalacia, and recurrent fractures in the foot and thigh bones that can lead to chronic pain. The incidence of HPP has been reported to be 1 in 100,000 (United
States and Canada) to 1 in 300,000 (EU) for severe disease and 1 in 6,370 (EU) for less severe forms. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The various manifestations of HPP are caused by the
combination of a lack of phosphate and an excess of PPi due to a deficiency of TNSALP, the enzyme that converts PPi to phosphate. This deficiency negatively impacts bone formation by reducing the hydrolysis of PPi to phosphate required for normal
bone formation, resulting in a <FONT STYLE="white-space:nowrap">build-up</FONT> of PPi, a potent inhibitor of mineralization. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Strensiq, an enzyme replacement
therapy marketed by Alexion, is the only approved therapy to treat patients with perinatal-, infantile- and juvenile-onset HPP. The therapy has been shown to lead to significant improvements in morbidity and mortality in patients with perinatal- and
infantile-onset HPP, and improvements in morbidity for patients with juvenile-onset HPP. However, Strensiq has limitations, including its dosing regimen and patient access. Strensiq is administered by subcutaneous injection either three or six times
per week using a weight-based dosing scale, which can be both onerous and painful for patients. Furthermore, a population of adult patients may have difficulty accessing the therapy given reimbursement dynamics in countries around the world as a
result of weight-based dosing that drives high costs for heavier patients. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our solution: an ENPP1 small molecule inhibitor </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are developing an orally available, small molecule ENPP1 inhibitor designed to reduce PPi levels through the controlled inhibition of ENPP1, which we hypothesize may
restore the balance of PPi and phosphate needed to promote bone mineralization. This program is in its early stages and preclinical and clinical development is required. If an ENPP1 inhibitor is successfully advanced through clinical development and
obtains marketing approval, we believe that an oral small molecule ENPP1 inhibitor, administered as a stand-alone therapy or in combination with Strensiq, could have significant benefit in managing HPP and improving the lives of patients. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Lead molecules demonstrated encouraging activity in functional assays. We are currently optimizing these lead molecules and anticipate selecting a development candidate
in the first quarter of 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">112 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Scientific Rational: ENPP1 Inhibition for the Treatment of Hypophosphatasia </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g99471g20a01.jpg" ALT="LOGO">
</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Under normal conditions, the level of PPi and Pi is kept in balance by activity of TNSALP, ENPP1 and ANKH.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g99471g20b02.jpg" ALT="LOGO">
</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">In patients with hypophosphatasia, the reduction of PPi hydrolysis by TNSALP results in a relative increase in PPi, leading to an inhibition of mineralization, and inhibited hydroxyapatite formation.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">


<IMG SRC="g99471g20c03.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Through controlled inhibition of ENPP1, we aim to reduce PPi and improve mineralization, restoring hydroxyapatite formation.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Competition </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The biotechnology and
pharmaceutical industries are highly competitive and subject to significant and rapid technological change. There are many public and private biopharmaceutical companies, universities, government agencies and other research organizations actively
engaged in the research and development of products that may be like our product candidates or address similar markets. In addition, the number of companies seeking to develop and commercialize products and therapies competing with our product
candidates is likely to increase. However, we seek to build our portfolio with key differentiating attributes to provide a competitive advantage in the markets we target. The success of our product candidates, if approved, is likely to be a result
of their efficacy, safety, convenience, price, the level of biosimilar or generic competition and/or the availability of reimbursement from government and other third-party payors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>FNAIT</I></B>. There are currently no approved therapies for the prevention or treatment of FNAIT. In one frequently used approach to manage pregnancies where the
mother is known to have a history of FNAIT, physicians administer high levels of IVIG. Companies that currently market IVIG include ADMA Biologics, Bio Products Laboratory, CSL Behring, Grifols, Kedrion Biopharma, Leadiant Biosciences, Octapharma
and Takeda Pharmaceutical Company Limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">113 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>PNH</I></B>. The only curative treatment currently available for PNH is a stem cell transplant from a related donor.
However, this procedure is associated with significant risk and is used only in those patients with severe disease, such as life-threatening thrombosis or dangerously low blood counts. Various supportive therapies include anticoagulants, red blood
cell transfusions and iron and folate supplements. These therapies provide some relief from symptoms but do not address the underlying cause of the disease. There are two approved disease-modifying drugs for PNH: eculizumab, marketed by Alexion as
Soliris; and ravulizumab, marketed by Alexion as Ultomiris. Both of these products are antibodies that bind complement C5. There are several companies in <FONT STYLE="white-space:nowrap">mid-</FONT> to late-stage clinical trials developing
treatments for PNH. These include Akari Therapeutics, Alnylam Pharmaceuticals, Apellis Pharmaceuticals, Novartis, Regeneron Pharmaceuticals and Roche. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>MG</I></B>. Very early-stage MG is symptomatically treated by the use of acetylcholinesterase inhibitors such as pyridostigmine bromide, marketed as Mestinon by
Bausch Health. Eculizumab is also approved for the treatment of generalized MG in patients who are positive for anti-AChR antibodies. There are several other companies developing assets in <FONT STYLE="white-space:nowrap">mid-</FONT> to late-stage
clinical development for the treatment of MG using a variety of approaches and modalities. These companies include Argenx SE, Catalyst Pharmaceuticals, CureVac, Horizon Therapeutics, Immunovant, Inc. and UCB Biopharma. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>HPP</I></B>. There is one approved treatment for HPP, asfotase alfa, marketed by Alexion as Strensiq, is an alkaline phosphotase enzyme replacement therapy, and
the only approved therapy for the treatment of perinatal-, infantile- and juvenile-onset HPP. Alexion is developing a second generation enzyme replacement therapy, which is currently in preclinical development, and AM Pharma has an active discovery
program. There are several companies pursuing ENPP1 small molecule inhibitors for the treatment of cancer, including AbbVie, Inc., Angarus Therapeutics, Avammune Therapeutics, and Stingray Therapeutics. We are not aware of other small molecule
inhibitors in development for the treatment of patients with HPP. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of our competitors may have significantly greater name recognition and financial,
manufacturing, marketing, product development, technical, commercial infrastructure, and human resources than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being
concentrated among a smaller number of our competitors. These competitors also compete with us in establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary
for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Intellectual Property </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our success depends, in part, on our ability to
obtain, maintain, defend, and enforce patent rights and other intellectual property rights that protect our business, preserve the confidentiality of our trade secrets, and operate without infringing the valid and enforceable intellectual property
rights of others. In addition to our efforts to protect our product candidates and methods of using them, we also seek to secure or acquire patent rights regarding other products and methods that are important to the general development of
commercial products. We utilize a multi-layered approach that includes acquiring intellectual property rights through purchase or exclusive license, filing and prosecuting U.S. and foreign patent applications directed to our own innovations, and
developing and protecting proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> to maintain our competitive position. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ongoing efforts to secure patent
rights that protect our business constitute a key component of our business strategy. We also strive to protect as trade secrets or confidential <FONT STYLE="white-space:nowrap">know-how,</FONT> certain aspects of our programs and technological
innovations that are commercially valuable but are not amenable to or appropriate for patent protection. We achieve this, in part, through the use of confidentiality agreements with our employees, consultants, scientific advisors, collaborators,
licensors, and contractors, and by striving to maintain physical security of our premises and digital security of our electronic information and technology systems. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Notwithstanding our commitment to protecting our intellectual property rights, we, like other pharmaceutical and biopharmaceutical companies, are subject to several
sources of uncertainty that can affect those rights. For example, we cannot be certain that any patents that we currently own or <FONT STYLE="white-space:nowrap">in-license,</FONT> or that we may own or
<FONT STYLE="white-space:nowrap">in-license</FONT> in the future, will not be challenged, held to be invalid and/or unenforceable, have the scope of their claims narrowed, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">114 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
be circumvented by others. Nor can we be certain that such patents will successfully protect our products or our business from competition. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Similarly, with respect to patent applications that are currently pending, or that may be pending in the future, we cannot be certain that such patent applications will
result in the issuance of granted patents, or of patent claims with the desired claim scope. In order to secure an issued patent, an invention claimed in a patent application must meet certain legal requirements for patentability, which differ
between countries based on each country&#146;s particular patent laws. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, because of the significant amount of time required for clinical development and
regulatory review of products candidates, we cannot be certain that any of our product candidates will be commercialized while there is significant patent term remaining on patents relating to those products. The term of a patent depends upon the
legal requirements for determination of patent term in the country in which that patent is granted. In most countries, including the United States, the patent term is 20 years from the earliest claimed filing date of a
<FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. In the United States, a patent&#146;s term may, in certain cases, be lengthened by patent term adjustment, or PTA, which compensates a patentee for administrative delays by
the U.S. Patent and Trademark Office in examining and granting the patent. Likewise, a patent&#146;s term may be shortened if it is terminally disclaimed over an earlier-expiring patent with a common owner or inventor. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The term of a U.S. patent relating to an approved drug product may also be extended to compensate the patentee for delays due to the regulatory approval process. Such a
patent term extension, or PTE, cannot exceed five years, and cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Furthermore, the term can be extended for only one patent applicable to each
regulatory review period and only those claims covering the approved product, or a method for using it or manufacturing it, may be extended. In the future, if any of our product candidates receive approval by the U.S. Food and Drug Administration,
or the FDA, we expect to apply for PTE on any issued patents covering those products, depending upon the length of the clinical studies for each product and other factors. There can be no assurance that we will benefit from any PTE or favorable
adjustments to the terms of any patents we currently own or <FONT STYLE="white-space:nowrap">in-license</FONT> or that we may own or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to and separate from patent exclusivity, the FDA may also grant marketing exclusivity of varying lengths in connection with the approval of a New Chemical
Entity (5 years), Biologic (12 years), or Orphan Drug indication (7 years). Marketing exclusivity may also be granted for new clinical studies (3 years) and pediatric studies (6 months) on approved drugs. Depending on the length of the regulatory
approval process and the ability to make use of the procedures for obtaining PTE, any FDA exclusivity period may in part or in whole overlap with any patent exclusivity to which we are entitled. We intend to pursue relevant marketing exclusivities
in the US and in foreign countries in which any candidate product is approved. However, we cannot be certain that any such exclusivities will be granted or, if granted, will insulate our commercial product(s) from competition. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">With respect to trade secrets, while we have confidence in the protective measures that we employ, such measures can be breached, and we may not have adequate remedies
for any such breach. We also cannot be certain that any of our activities will not be subject to the intellectual property rights of others. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of July 15,
2021, we owned two patent families that were acquired from Prophylix and relate to the current product candidates in our FNAIT prevention program, RLYB211 and RLYB212. The acquired patent family covering RLYB212 and its use in treating and
preventing FNAIT includes patents issued in Australia, Europe, Mexico, Russia and the United States. Patent applications in this family are pending in Brazil, Canada, Israel, New Zealand and the United States. The granted patents in this family will
expire in 2035, excluding any PTA or PTE that may be awarded. The acquired patent family covering administration of RLYB211 for the prophylactic treatment of FNAIT includes patents issued in the United States, Europe and Canada. The foreign patents
and one of the U.S. patents will expire at the end of 2026, while the other U.S. patent expires in November 2030 due to a PTA granted by the U.S. Patent and Trademark Office. In addition, we filed and own three pending provisional patent
applications in the United States, covering dosing and administration of RLYB211 and RLYB212. We also exclusively <FONT STYLE="white-space:nowrap">in-license</FONT> certain rights to technology from Versiti Blood Research Institute Foundation, Inc.
pertaining to a mouse model of FNAIT. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of July 15, 2021, we owned two patent families relating to the current product candidates in our complement program,
RLYB114 and RLYB116, and certain aspects of their use. These two patent families, which were acquired </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">115 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
from Sobi, currently include three granted U.S. patents and one pending U.S. patent application, with granted patents and/or pending patent applications in more than 25 additional countries
worldwide, including granted patents in Australia, Canada, Europe (all European Patent Convention contracting states) and Japan. In the U.S., Australia, the European Patent Convention contracting states and Japan, both patent families have been
granted and are scheduled to expire between 2033 and 2034, excluding any PTA or PTE. In Canada, currently one patent family has been granted and is scheduled to expire in 2033. The second family patents are pending in Canada. We have also <FONT
STYLE="white-space:nowrap">in-licensed</FONT> certain patent rights relating to our current product candidates from Affibody, including patent rights relating to the Affibody<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> molecule
technology and Albumod albumin binding molecule technology. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>License Agreement </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Product License Agreement with Affibody AB </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2019, our
subsidiary IPC Research, LLC, or IPC Research, and Sobi entered into a Contract Assignment Agreement pursuant to which Sobi assigned to, and IPC Research assumed, all obligations in a certain Product License Agreement, referred to herein as amended
as the PLA, between Sobi and Affibody AB, or Affibody, dated March&nbsp;9, 2012, as amended on January&nbsp;1, 2018 and December&nbsp;22, 2020. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the
PLA, we obtained a license to the Affibody<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> platform technology and a particular albumin binding domain, or ABD, in order to further develop and commercialize certain Affibody ligands, which
we are now developing as RLYB116 and RLYB114. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the PLA, Affibody grants us (a)&nbsp;a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right under
certain patents to use the Affibody ligands alone or as a fusion protein and (b)&nbsp;an exclusive right to use the Affibody ligands alone or as a fusion protein, in each case, for human therapeutic use. Affibody also grants us (a)&nbsp;a <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> right under certain patents to use the ABD in combination with the Affibody ligands as a fusion protein and (b)&nbsp;an exclusive right to use the ABD solely in combination with the Affibody ligands as
a fusion protein, in each case, for human therapeutic use. Affibody grants us a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license under applicable <FONT STYLE="white-space:nowrap">know-how</FONT> needed to practice the rights and
licenses granted under the PLA. All licenses to us are sublicensable, provided that each sublicense is consistent with the terms and conditions of the PLA. Under the PLA, Affibody has an exclusive right under any product patents, which are a
category of certain patents that we own, to use the specific Affibody ligands outside of human therapeutics and a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right under <FONT STYLE="white-space:nowrap">know-how</FONT> needed to practice
the Affibody ligands outside of human therapeutics. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the PLA, Affibody is the exclusive owner of, and controls prosecution, maintenance, and defense of
intellectual property covering, platform technology. We are the exclusive owner of, and control prosecution, maintenance, and defense of intellectual property covering, product technology. Affibody agrees to disclose to us any improvement to the
Affibody technology that it deems commercially reasonable for us to practice and grants us an option to license any such improvement. We have the first right to enforce product patents against a third-party infringer and Affibody retains the first
right to enforce any other licensed patent. We agree to not provide or make available any Affibody Ligand to a third-party on a standalone basis except for research purposes or to commercialize a licensed product. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We agree to use commercially reasonable efforts to develop and commercialize a licensed product. We also will pay Affibody certain regulatory milestones up to an
aggregate amount of <FONT STYLE="font-family:Times New Roman">&#128;</FONT>7.5&nbsp;million and (a) a <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> royalty on annual net sales of products if such products are covered by a valid claim of a
product patent or a platform patent or <FONT STYLE="white-space:nowrap">(b)&nbsp;low-single-digit</FONT> royalties on annual net sales of products that are not covered by any such valid claim. Our obligation to pay royalties expires on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis on the later of (a)&nbsp;the expiration of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> valid claim of a patent covering a licensed product or (b)&nbsp;the 10th anniversary following first commercial sale of such product in such country. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The PLA will terminate when we are no longer obligated to pay royalties to Affibody. Either party may terminate the PLA upon material breach of the PLA by the other,
subject to a cure period, or immediately in the case of the other party&#146;s insolvency, bankruptcy or a similar event. Affibody may terminate the PLA immediately if we or any of our affiliates or third party transferees commences any proceeding
challenging the validity of the licensed patents or any of Affibody&#146;s other patents or challenging the confidentiality or substance of the licensed know-how or licensed technology. We may terminate the PLA for convenience upon 90 days prior
written notice and upon payment of any amounts due to Affibody through the effective date of such termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">116 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If Affibody terminates the PLA or if we terminate the PLA for convenience, (a) all rights and licenses granted under the
PLA will terminate, (b) at Affibody&#146;s request, we must transfer all rights to the product technology free of charge to Affibody and (c) we must return or destroy all of Affibody&#146;s confidential information. Furthermore, if we terminate for
convenience, we must grant Affibody an exclusive, royalty free perpetual right to use all regulatory filings, approvals and data provided to regulatory authorities in support of such filings or approvals that relate to the licensed product. However,
if we terminate the PLA as a result of Affibody&#146;s material breach of the PLA or its insolvency or bankruptcy, we will retain our license and rights under the PLA, provided that we will remain bound by certain obligations under the PLA with
respect milestone payments, royalties (subject to a reduction in rate, in the case of material breach), audits and indemnity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Asset Purchase Agreements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Asset Transfer Agreement with Swedish Orphan Biovitrum AB </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March
2019, through IPC Research, we entered into an agreement with Sobi, pursuant to which we acquired the right, title and interest in assets related to certain C5 inhibitor compounds. We are currently developing the assets acquired from Sobi as RLYB116
and RLYB114. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We paid Sobi an upfront purchase price of $5.0&nbsp;million and we are obligated to pay Sobi an aggregate amount of up to $51.0&nbsp;million upon
achievement of certain development milestones and an aggregate amount of up to $65.0&nbsp;million upon achievement of certain sales milestones. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also will pay
Sobi tiered, low single-digit royalties on annual net sales to third parties for products containing any compound transferred under the agreement as an active ingredient. Our obligation to pay royalties expires, on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and product-by-product basis, on the later of (a)&nbsp;the 10th anniversary following first commercial sale of such product in such country and
(b)&nbsp;the expiration date in such country of the last to expire of any issued patent included in the patent rights acquired from Sobi that includes at least one valid claim covering the sale of such product in such country. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are obligated to use commercially reasonable efforts to research, develop and exploit at least one product that contains a compound transferred under the agreement
as an active ingredient in each of the United States, EU and Japan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If, prior to the commercial launch in the United States of the first product containing the
compounds, we decide to divest our rights in the assets acquired from Sobi or to terminate all research, development and commercialization activities in respect of the acquired compounds, we must notify Sobi and negotiate in good faith with Sobi a
possible business transaction relating to the assets. This right of negotiation will not apply to a transaction to sell all or substantially all of the assets of IPC Research or an affiliate of IPC Research, a pledge of the assets as collateral or a
sale or transfer of the assets to an affiliate of IPC Research that agrees to be bound by the right of negotiation. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Asset Purchase Agreement with Prophylix
AS </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2019, though our subsidiary Rallybio IPA, LLC, or Rallybio IPA, we entered into an agreement with Prophylix to acquire all of Prophylix&#146;s
rights, title and interest in, to and under all assets, properties and rights related to Prophylix&#146;s plasma-derived <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> immunoglobulin, which we are
developing as RLYB211, and Prophylix&#146;s monoclonal antibody, which we are developing as RLYB212. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We paid Prophylix an upfront purchase price of approximately
$1.2&nbsp;million and reimbursed Prophylix approximately $1.8&nbsp;million for certain manufacturing costs incurred by Prophylix. We are obligated to pay Prophylix an aggregate of up to $19.0&nbsp;million upon achievement of certain development
milestones and an aggregate of up to $20.0&nbsp;million upon achievement of certain sales milestones. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also will pay Prophylix tiered, <FONT
STYLE="white-space:nowrap">mid-single-digit</FONT> royalties on annual net sales of products containing the monoclonal antibody and tiered <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mid-to-high-single</FONT></FONT> and <FONT
STYLE="white-space:nowrap">low-double-digit</FONT> royalties on annual net sales of products containing plasma-derived <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> immunoglobulin, subject to certain
offsets for royalties payable under certain third-party licenses. Furthermore, the then-applicable royalty rate will be reduced by a <FONT STYLE="white-space:nowrap">mid-double</FONT> digit percentage for the remaining royalty term on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis if it becomes reasonably likely that the Prophylix patents may no longer be enforceable in such country due to a challenge of the enforceability of
the patents or the enforceability of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">117 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
royalty payments following the expiration of all valid claims of the patents in such country. Our obligation to pay royalties terminates on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis on the later of (a)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">last-to-expire</FONT></FONT> valid claim of a Prophylix patent covering a product, (b)&nbsp;expiration of regulatory exclusivity for the product in such country or (c) the
10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> year anniversary following first commercial sale of such product in such country. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event the FDA
grants a priority review voucher for one of our product candidates developed using the technology acquired from Prophylix, we will pay Prophylix either: (a)&nbsp;if we sell such priority review voucher to a
<FONT STYLE="white-space:nowrap">third-party</FONT> within 12 months of its receipt, a <FONT STYLE="white-space:nowrap">mid-double</FONT> digit percentage of the proceeds we receive from the sale, net of taxes, or (b)&nbsp;if we do not sell the
priority review voucher to a third-party within 12 months of receipt, a <FONT STYLE="white-space:nowrap">mid-double</FONT> digit percentage of the fair market value of the priority review voucher as determined in accordance with the agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are obligated to use commercially reasonable efforts to develop and commercialize products containing plasma-derived <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> immunoglobulin in the United States and in at least one major European market. The agreement provides that if we provide notice to Prophylix that we determined that commercialization of products
containing plasma-derived <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> immunoglobulin is not feasible due to an insufficient plasma supply following our continued and diligent efforts to obtain a
sufficient plasma supply, then our obligation to develop products containing plasma-derived <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> immunoglobulin will cease, and we will be obligated to use
commercially reasonable efforts to develop and commercialize products containing the monoclonal antibody in the United States and in at least one major European market. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If, after using commercially reasonable efforts to develop and commercialize products containing plasma-derived <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> immunoglobulin and the monoclonal antibody in the United States and in at least one major European market, we decide not to pursue any further development or commercialization activities for such
products, then Prophylix will have the right to repurchase the remaining assets acquired under the agreement for approximately $1.2&nbsp;million. Prophylix also will have the right to repurchase the remaining assets acquired under the agreement for
approximately $1.2&nbsp;million if we elect to transfer all or substantially all of the assets acquired under the agreement to a third-party who does not agree to assume our obligations to develop and commercialize the products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Joint Venture Agreement </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2019, we entered into a partnership
with Exscientia and created RE Ventures I, LLC, or RE Ventures, which is jointly owned by Exscientia and one of our wholly-owned subsidiaries, each a Member and collectively the Members. The joint venture was formed to initiate early-stage drug
discovery of orally available small molecules targeting ENPP1 for the treatment of HPP, and thereafter for the future research, development, manufacture, sale and exploitation of any company-owned technology and compounds, including any resulting
compound identified by the steering committee of the joint venture. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the RE Ventures operating agreement, we received a 50% interest in the joint venture in
exchange for an initial contribution of &pound;0.5 million ($0.6 million, based on the exchange rate at the time).&nbsp;RE Ventures used this initial capital to fund stage 1 of the ENPP1 program, and we committed to fund additional amounts if costs
of stage 1 exceeded the initial funding. In June 2020, RE Ventures determined that the stage 1 objective of discovering compounds for ENPP1 with a certain potency had been achieved. In 2020, we contributed &pound;1.1&nbsp;million ($1.3 million,
based on the exchange rate at the time) in support of Stage 2 development of the ENPP1 program. During 2021, we have contributed approximately &pound;1.4 million ($2.0 million, based on the exchange rate at the time) to RE Ventures in support of
ongoing Stage 2 development of the ENPP1 program. The board of managers of RE Ventures may determine from time to time that additional capital is necessary or appropriate to enable RE Ventures to conduct its activities, and may seek (but not
require) additional capital contributions from the Members. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event that either Member does not fund a portion of committed additional amounts, the other
Member may contribute the unfunded amount and the respective membership interests in RE Ventures will be adjusted accordingly. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A steering committee is responsible
for oversight of RE Ventures&#146; research and deployment plans as well as intellectual property and regulatory matters. A <FONT STYLE="white-space:nowrap">two-person</FONT> board of managers manages the business and affairs of RE
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">118 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Ventures and is responsible for all management and other responsibilities not specifically reserved to the steering committee or to the Members. Each Member designates one member to the board.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each Member is subject to customary restrictions on its transfer of interests in RE Ventures, including a right of first refusal,
<FONT STYLE="white-space:nowrap">co-sale</FONT> right and drag-along provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Manufacturing and Supply </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not own or operate, and currently have no plans to establish, any internal manufacturing facilities. We currently rely and expect to continue to rely on
third-party contract manufacturer organizations, or CMOs, for the manufacture of our product candidates for preclinical and clinical testing, as well as for commercial production of any product candidates that are approved. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently rely on multiple CMOs for all of our preclinical and clinical supply requirements, including drug substances and drug products, and label and packaging for
our preclinical research and clinical trials. We believe that we will be able to contract with other CMOs to manufacture drug substances if our existing sources of drug substances were no longer available to us or with sufficient capacity, but there
is no assurance that the drug substance capacity would be available from other CMOs on acceptable terms, on the timeframe that our business would require, or at all. We do not currently have supply commitments or other arrangements in place with our
existing CMOs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not have any current contractual relationships for the manufacture of commercial supplies of any of our product candidates if they are
approved by the regulatory authorities, and we intend to enter into agreements with a CMO and one or more <FONT STYLE="white-space:nowrap">back-up</FONT> manufacturers for the commercial production of our product candidates as they near phase 3
clinical trials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any products to be used in clinical trials and any approved product that we may commercialize will need to be manufactured in facilities, and by
processes, that comply with the FDA&#146;s current Good Manufacturing Practice, or cGMP, requirements and comparable requirements of the regulatory agencies of other jurisdictions in which we are seeking approval. We currently employ internal
resources to manage our CMOs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that RLYB212, RLYB116 and RLYB114 can be manufactured in reliable and reproducible biologic and chemical processes from
readily available starting materials. We also believe that, despite being derived from human plasma, RLYB211 can also be manufactured in a reliable process, although our ability to source a sustained, dependable long-term supply will be challenging,
including due to the scarcity of potential donors who maintain an adequate level of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-HPA-1a</FONT></FONT> antibodies and because supply of plasma will decrease if RLYB211 becomes
clinically successful in preventing FNAIT. We believe that our manufacturing processes are amenable to <FONT STYLE="white-space:nowrap">scale-up</FONT> and will not require unusual or expensive equipment. We expect to continue to develop, on our own
or with our collaborators, product candidates that can be produced cost-effectively at contract manufacturing facilities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to rely on third parties for
the manufacture of any in vitro diagnostic device, companion diagnostics or companion drug delivery systems we develop. For example, we have engaged a third-party to assist in developing laboratory screening tests and in our evaluation of potential
companion diagnostics in conjunction with our development of RLYB212. Depending on the regulatory pathway and technology solutions we choose, we may engage third parties to continue the development and manufacturing of any device developed to
support our therapeutic products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Government Regulation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The research,
development, testing, manufacture, quality control, packaging, labeling, storage, record-keeping, distribution, import, export, promotion, advertising, marketing, sale, pricing and reimbursement of drug and biologic products are extensively
regulated by governmental authorities in the United States and other countries. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with compliance with applicable statutes and
regulations and other regulatory requirements, both <FONT STYLE="white-space:nowrap">pre-approval</FONT> and post-approval, require the expenditure of substantial time and financial resources. The regulatory requirements applicable to drug and
biological product development, approval and marketing are subject to change, and regulations and administrative guidance often are revised or reinterpreted by the agencies in ways that may have a significant impact on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">119 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>U.S. Government Regulation of Drug and Biological Products </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, the FDA regulates human drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA, and in the case of biologics, also under the Public
Health Service Act, or the PHSA, and their implementing regulations. Failure to comply with the applicable U.S. requirements may result in FDA refusal to approve pending NDAs or BLAs or delays in development and may subject an applicant to
administrative or judicial sanctions, such as issuance of warning letters, or the imposition of fines, civil penalties, product recalls, product seizures, total or partial suspension of production or distribution, injunctions and/or civil or
criminal prosecution brought by the FDA and the U.S. Department of Justice or other governmental entities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA must approve our product candidates for
therapeutic indications before they may be marketed in the United States. For drug products, the FDA must approve a NDA, and for biologic products, the FDA must approve a BLA. An applicant seeking approval to market and distribute a new drug or
biologic in the United States generally must satisfactorily complete each of the following steps: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">completion of preclinical laboratory tests and animal studies according to good laboratory practices, or GLP, regulations
or other applicable regulations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">manufacture and testing of the therapeutic or biologic moiety and its respective product formulation according to good
manufacturing practices, or cGMP, regulations or other applicable regulations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin and must be updated
annually and amended when certain changes are made; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approval by an independent institutional review board, or IRB, or ethics committee representing each clinical trial site
before each clinical trial may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, good
clinical practices, or GCPs, and other clinical-trial related regulations to evaluate the safety and efficacy of the investigational product for each proposed indication; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">preparation and submission to the FDA of an NDA or BLA requesting marketing approval for one or more proposed indications,
including payment of application user fees; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">review of the NDA or BLA by an FDA advisory committee, where applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the drug or
biologic and its respective finished product is produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the product&#146;s identity, strength, quality and purity;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">satisfactory completion of any FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the
clinical data submitted in support of the NDA or BLA; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">FDA review and approval of the NDA or BLA, which may be subject to additional post- approval requirements, including the
potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS and any other potential post- approval studies required by the FDA. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Preclinical Studies and IND </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before testing any drug or biological product
candidate in humans, the product candidate must undergo rigorous preclinical testing. The preclinical developmental stage generally involves laboratory evaluations of drug chemistry/biology, formulation, and stability, as well as in vitro and animal
studies to assess safety and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety and toxicology studies. The sponsor
must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin.
An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time, the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case,
the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Imposition of a clinical hold could cause </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">120 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
significant delays or difficulties in initiating and/or completing planned clinical trials in a timely manner. Certain long-term preclinical testing, such as animal tests of reproductive adverse
events and carcinogenicity, may initiate or continue after an IND for an investigational product candidate is submitted to the FDA and human clinical trials have been initiated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Human Clinical Trials in Support of an NDA or BLA </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical trials involve
the administration of an investigational product candidate to healthy volunteers or patients with the disease to be treated under the supervision of qualified investigators. Clinical trials are conducted under protocols detailing the objectives of
the study, inclusion and exclusion criteria, dosing procedures and the parameters to be used in monitoring the safety and effectiveness criteria to be evaluated. Each protocol, as well as any subsequent amendments, must be submitted to the FDA as
part of the IND. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An IRB representing each institution that is participating in the clinical trial must review and approve the plan for any clinical trial before it
commences at that institution, and the IRB must thereafter conduct a continuing review of the trial. The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors and the safety of human subjects. The
IRB must review and approve, among other things, the trial protocol and informed consent information to be provided to clinical trial subjects or their legal representatives and must operate in compliance with FDA regulations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical trials must also comply with extensive GCP standards intended to ensure protection of human subjects and the quality and integrity of the study data, including
requirements for obtaining subjects&#146; informed consent. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee.
This group may recommend continuation of the trial as planned, changes in trial conduct or cessation of the trial at designated checkpoints based on access to certain data from the study. The FDA may at any time while clinical trials are ongoing
impose a partial or complete clinical hold based on concerns for patient safety and/or noncompliance with regulatory requirements. This order issued by the FDA would cause suspension of an ongoing trial until all outstanding concerns have been
adequately addressed, and the FDA has notified the company that investigations may proceed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Human clinical trials to evaluate therapeutic indications to support
NDAs and BLAs for marketing approval are typically conducted in three sequential phases that may overlap or be combined: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 1: The product candidate is initially introduced into human subjects and tested for safety, dosage tolerance,
absorption, metabolism, distribution, and excretion, and if possible, to gain early evidence for effectiveness. Phase 1 trials may be conducted in healthy volunteers or, in the case of some products for severe or life-threatening diseases, including
many rare diseases, the initial human testing is often conducted in patients with the target disease or condition. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 2: Clinical trials are conducted in a limited patient population with a specified disease or condition to identify
possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted to obtain
information prior to beginning larger and more expensive Phase 3 clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 3: Clinical trials are undertaken with an expanded patient population to further evaluate dosage, and to provide
substantial evidence of clinical efficacy and safety in an expanded patient population, often at geographically dispersed clinical study sites. These studies are intended to establish the overall risk-benefit ratio of the product candidate and
provide, if appropriate, an adequate basis for product labeling. These trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used
to gain additional experience from the treatment of patients in the intended therapeutic indication, to document a clinical benefit in the case of drugs or biologics approved under FDA&#146;s accelerated approval regulations and to generate
additional safety data regarding use of the product in a clinical setting. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">121 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
approval of an NDA or BLA. Failure to exhibit due diligence with regard to conducting Phase 4 clinical trials could result in withdrawal of approval for the product. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being
exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the clinical protocol, GCP or other IRB requirements
or if the drug has been associated with unexpected serious harm to patients. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Information about certain clinical trials, including details of the protocol and
eventually study results, also must be submitted within specific time frames to the National Institutes of Health for public dissemination on the ClinicalTrials.gov data registry. Similar requirements for posting clinical trial information in
clinical trial registries exist in the EU and in other countries outside the United States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the development of a new drug or biological product, sponsors
have the opportunity to meet with the FDA at certain points, including prior to submission of an IND, at the end of phase 2 and before submission of an NDA or BLA. These meetings can provide an opportunity for the sponsor to share information about
the data gathered to date and for the FDA to provide advice on the next phase of development. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrent with clinical trials, companies usually complete
additional nonclinical studies and must also develop additional information about the physical characteristics of the drug or biological product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP
requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, potency and purity
of the final drug or biological product. For biological products in particular, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined in order to help ensure safety, purity and
potency. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does
not undergo unacceptable deterioration over its shelf life. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Marketing Application Submission and FDA Review </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, along with information relating to the
product&#146;s chemistry, manufacturing, controls (CMC) and proposed labeling, are submitted to the FDA as part of an NDA or BLA requesting approval to market the product for one or more indications. Data may come from company-sponsored clinical
trials intended to test the safety and efficacy of a product&#146;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality to
establish the safety and efficacy of the investigational product to the satisfaction of the FDA. The fee required for the submission of an NDA or BLA under the Prescription Drug User Fee Act, or PDUFA, is substantial (for example, for FY2021 this
application fee is approximately $2.9 million), and the sponsor of an approved NDA or BLA is also subject to an annual program fee, currently more than $300,000 per program. These fees are typically adjusted annually, but exemptions and waivers may
be available under certain circumstances. No user fee is required for orphan drug product applications, except when an application also includes an indication for a <FONT STYLE="white-space:nowrap">non-rare</FONT> disease or condition. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA conducts a preliminary review of all NDAs and BLAs within 60 days of receipt and informs the sponsor by the 74th day after the FDA&#146;s receipt of the
submission whether an application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA or BLA for filing. In this event, the application must be resubmitted with the additional
information. The resubmitted application is also subject to review before the FDA accepts it for filing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After the submission is accepted for filing, the FDA
begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> substantive review of the application. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has ten months from the filing date in which to complete its initial review of a
standard application and respond to the applicant and six months from the filing date for an application with &#147;priority review.&#148; The review process may be extended by the FDA for three additional months
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">122 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
to consider new information or in the case of a clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission. Despite these
review goals, it is not uncommon for FDA review of an NDA or BLA to extend beyond the PDUFA goal date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before approving a NDA or BLA, the FDA will typically
conduct a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing facilities for the therapeutic/biologic to determine whether the manufacturing processes and facilities comply with GMPs. The FDA will not approve the
product unless it determines that the manufacturing processes and facilities comply with cGMP requirements and are adequate to assure consistent production of the product within required specifications. The FDA also may inspect the sponsor and one
or more clinical trial sites to assure compliance with GCP requirements and the integrity of the clinical data submitted to the FDA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, the FDA may
refer any NDA or BLA, including applications for novel product candidates which present difficult questions of safety or efficacy, to an advisory committee for review, evaluation and recommendation as to whether the application should be approved
and under what conditions. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts. The FDA is not bound by the recommendation of an advisory committee, but it considers such
recommendations when making final decisions on approval. The FDA also may require submission of a REMS, if it determines that a REMS is necessary to ensure that the benefits of the drug outweigh its risks and to assure the safe use of the drug or
biological product. If the FDA concludes a REMS is needed, the sponsor of the NDA or BLA must submit a proposed REMS and the FDA will not approve the NDA or BLA without a REMS. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Pediatric Research Equity Act of 2003, or PREA, an NDA or BLA or certain supplements thereto must contain data that are adequate to assess the safety and
effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective, unless this requirement is
waived, deferred or inapplicable. Sponsors must submit a pediatric study plan to FDA outlining the proposed pediatric study or studies they plan to conduct, including study objectives and design, any deferral or waiver requests and other information
required by regulation. The FDA must then review the information submitted, consult with the sponsor and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time. In general, PREA requirements do not apply
to drugs or biologics for indications granted orphan drug designation by the FDA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA reviews an NDA or BLA to determine, among other things, whether a product
is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#146;s identity, strength, quality and purity. The approval process is lengthy and often difficult, and the FDA may refuse
to approve an NDA or BLA if the applicable regulatory criteria are not satisfied or may require additional clinical or other data and information. After evaluating the application and all related information, including the advisory committee
recommendations, if any, and inspection reports of manufacturing facilities and clinical trial sites, the FDA may issue either an approval letter or a Complete Response Letter, or CRL. An approval letter authorizes commercial marketing of the
product with specific prescribing information for specific indications. A CRL indicates that the review cycle of the application is complete and the application will not be approved in its present form. A CRL generally outlines the deficiencies in
the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. The CRL may require additional clinical or other data, additional pivotal Phase 3 clinical trial(s) and/or other
significant and time- consuming requirements related to clinical trials, preclinical studies or manufacturing. If a CRL is issued, the applicant may either resubmit the NDA or BLA addressing all of the deficiencies identified in the letter or
withdraw the application. If and when those deficiencies have been addressed to the FDA&#146;s satisfaction in a resubmission of the NDA or BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in response
to an issued CRL in either two or six months depending on the type of information included. Even with the submission of this additional information, however, the FDA ultimately may decide that the application does not satisfy the regulatory criteria
for approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a product receives regulatory approval from the FDA, the approval is limited to the conditions of use (e.g., patient population, indication)
described in the <FONT STYLE="white-space:nowrap">FDA-approved</FONT> labeling. Further, depending on the specific risk(s) to be addressed, the FDA may require that contraindications, warnings or precautions be included in the product labeling,
require that post-approval trials, including Phase 4 clinical trials, be conducted to further assess a product&#146;s safety after approval, require testing and surveillance programs to monitor the product after commercialization or impose
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">123 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS which can materially affect the potential market and profitability of the product.
The FDA may prevent or limit further marketing of a product based on the results of post-marketing trials or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes
and additional labeling claims, are subject to further testing requirements and FDA review and approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Regulation of Combination Products </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain products may be comprised of components, such as drug or biologic components and device components that would normally be regulated under different types of
regulations, and frequently by different centers at the FDA. These products are known as combination products. We expect to rely on a delivery system, such as <FONT STYLE="white-space:nowrap">pre-filled</FONT> syringes, <FONT
STYLE="white-space:nowrap">pen-injectors</FONT> and/or autoinjectors to deliver certain of our product candidates. Although we have not yet selected the delivery system to use for administration of such product candidates, including RLYB212 and
RLYB116, we expect that, if approved, any such product candidate would be regulated as a combination product, because it is composed of both a drug or biological product and a delivery system &#147;device.&#148; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the FDCA and its implementing regulations, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for review of a combination
product. The designation of a lead center generally eliminates the need to receive approvals from more than one FDA center for combination products, although the lead center may consult with other centers within the FDA. The determination of which
center will be the lead center is based on the &#147;primary mode of action&#148; of the combination product. Thus, if the primary mode of action of a drug-device combination product is attributable to the drug product, the FDA center responsible
for review of the drug product would have primary jurisdiction for the combination product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A combination product involving a novel drug or biological product and
delivery system generally would have a drug or biologic primary mode of action. A combination product with a drug or biologic primary mode of action would be reviewed and approved pursuant to the drug or biologic approval processes. In reviewing the
NDA or BLA for such a product, however, the FDA review division reviewing the application could consult with their counterparts in the device center to ensure that the device component of the combination product met applicable requirements regarding
safety, effectiveness, durability and performance. Approval may require the performance of certain clinical studies, such as clinical usability or human factors studies to demonstrate the safety and/or effectiveness of the device component of the
combination product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Similar considerations apply to regulation of drugs combined with delivery systems outside the United States, including in the EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Expedited Programs for Serious Conditions </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA is authorized to
designate certain products for expedited development or review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs include fast track designation, breakthrough
therapy designation, priority review designation and accelerated approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To be eligible for a fast track designation, the FDA must determine, based on the
request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need by providing a therapy where none exists or a therapy that may be
potentially superior to existing therapy based on efficacy or safety factors. Fast track designation provides opportunities for more frequent interactions with the FDA review team to expedite development and review of the product. The FDA also may
review sections of the NDA or BLA for a fast track product on a rolling basis before the complete application is submitted if the sponsor and the FDA agree on a schedule for the submission of the application sections and the sponsor pays any
required user fees upon submission of the first section of the NDA or BLA. Fast track designation may be rescinded by the FDA if the designation is no longer supported by data emerging from the clinical trial process. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, a new drug or biological product may be eligible for Breakthrough Therapy designation if it is intended, alone or in combination with one or more other
drugs or biologics, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically
significant endpoints, such as substantial treatment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">124 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
effects observed early in clinical development. Breakthrough Therapy designation provides all the features of Fast Track designation in addition to intensive guidance on an efficient development
program beginning as early as Phase 1 and FDA organizational commitment to expedited development, including involvement of senior managers and experienced review staff in a cross-disciplinary review, where appropriate. Breakthrough designation may
be rescinded by the FDA if the designation is no longer supported. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may designate a product for priority review if it is a drug or biologic that treats a
serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines at the time that the marketing application is submitted, on a case- <FONT STYLE="white-space:nowrap">by-case</FONT> basis,
whether the proposed drug or biologic qualifies for priority review. Significant improvement over available therapies may be illustrated, for example, by evidence of increased effectiveness in the treatment of a condition, elimination or substantial
reduction of a treatment-limiting drug reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended
to direct overall attention and resources to the evaluation of such applications and to shorten the FDA&#146;s goal for taking action on a marketing application from ten months to six months for an original BLA or NDA from the date of filing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Fast track designation, breakthrough therapy designation and priority review do not change the standards for approval and may not ultimately expedite the development or
approval process. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Finally, the FDA may grant accelerated approval to a product for a serious or life-threatening condition that provides meaningful therapeutic
advantage to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a condition
when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit,
taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. For drugs granted accelerated approval, FDA generally requires sponsors to conduct, in a diligent manner, additional
post-approval confirmatory studies to verify and describe the product&#146;s clinical benefit. Failure to conduct required post-approval studies with due diligence, failure to confirm a clinical benefit during the post-approval studies, or
dissemination of false or misleading promotional materials would allow the FDA to withdraw the product approval on an expedited basis. All promotional materials for product candidates approved under accelerated approval are subject to prior review
by the FDA unless FDA informs the applicant otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Post-approval Requirements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following approval of a new product, the manufacturer and the approved product are subject to pervasive and continuing regulation by the FDA, governing, among other
things, monitoring and recordkeeping activities, reporting of adverse experiences with the product and product problems to the FDA, product sampling and distribution, manufacturing and promotion and advertising. Although physicians may prescribe
legally available products for unapproved uses or patient populations (i.e., <FONT STYLE="white-space:nowrap">&#147;off-label</FONT> uses&#148;), manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws
and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant
liability. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If there are any modifications to the product, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be
required to submit and obtain FDA approval of a new NDA/BLA or an NDA/BLA supplement, which may require the applicant to develop additional data or conduct additional preclinical studies and clinical trials. The FDA may also place other conditions
on approvals including the requirement for a REMS to assure the safe use of the product, which may require substantial commitment of resources post-approval to ensure compliance. A REMS could include medication guides, physician communication plans
or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or
dispensing of products. Product approvals may be withdrawn for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards or if problems occur following initial marketing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">FDA regulations require that drug and biological products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP regulations include
requirements relating to organization of personnel, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">125 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution,
laboratory controls, records and reports and returned or salvaged products. The manufacturing facilities for our product candidates must meet cGMP requirements and satisfy the FDA or comparable foreign regulatory authorities&#146; satisfaction
before any product is approved and our commercial products can be manufactured. In addition, for any of our product candidates that include a device delivery system, the device component will be subject to aspects of the Quality System Regulations,
or QSRs, applicable to medical devices. Manufacturers of drug-device combination products may either opt to comply with all quality regulations governing each component of the product separately, or may take a &#147;streamlined approach&#148; to
cGMP that allows the manufacturer to demonstrate compliance with the drug cGMPs along with compliance with several specific provisions from the device QSR&#151;namely, management responsibility, design controls, purchasing controls, corrective and
preventive action, installation, and servicing, as applicable. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We rely, and expect to continue to rely, on third parties for the production of clinical and
commercial quantities of our products in accordance with cGMP regulations. These manufacturers must comply with cGMP regulations, including requirements for quality control and quality assurance, the maintenance of records and documentation and the
obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved drugs or biologics are required to register their establishments with the FDA and certain state
agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and
quality control to maintain cGMP compliance. Future inspections by the FDA and other regulatory agencies may identify compliance issues at the facilities of our CMOs that may disrupt production or distribution or require substantial resources to
correct. In addition, the discovery of conditions that violate these rules, including failure to conform to cGMPs, could result in enforcement actions, and the discovery of problems with a product after approval may result in restrictions on a
product, manufacturer, or holder of an approved NDA or BLA, including voluntary recall and regulatory sanctions as described below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once an approval of a
drug/biologic product is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems
with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety
information, imposition of post-market clinical trials requirement to assess new safety risks or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or
product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other
safety information about a product; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">mandated modification of promotional materials and labeling and issuance of corrective information; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">fines, warning letters, untitled letters or other enforcement-related letters or clinical holds on post-approval clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">refusal of the FDA to approve pending NDAs/BLAs or supplements to approved NDAs/BLAs, or suspension or revocation of
product approvals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">product seizure or detention, or refusal to permit the import or export of products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">injunctions or the imposition of civil or criminal penalties; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">consent decrees, corporate integrity agreements, debarment, or exclusion from federal health care programs; or mandated
modification of promotional materials and labeling and the issuance of corrective information. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the distribution of prescription
pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors
by the states. Additionally, the Drug Supply Chain Security Act, or DSCSA, imposes requirements related to identifying and tracing certain prescription drugs distributed in the United States, including most biological products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">126 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>United States Patent Term Restoration and Hatch-Waxman Marketing Exclusivity </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Depending upon the timing, duration and specifics of FDA approval for our product candidates, some of our United States patents may be eligible for limited patent term
extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch Waxman Amendments permit restoration of the patent term up to five years as compensation for patent
term lost during the FDA regulatory review process. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#146;s approval date, and only those claims covering such approved drug
product, a method for using it or a method for manufacturing it may be extended. The patent-term restoration period is generally <FONT STYLE="white-space:nowrap">one-half</FONT> the time between the effective date of an IND and the submission date
of an NDA or BLA plus the time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension, and the application for the extension must be submitted prior to the expiration
of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Regulatory exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of <FONT
STYLE="white-space:nowrap">non-patent</FONT> marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other
new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an ANDA, or a 505(b)(2) NDA submitted by another company for
another version of such drug. However, an application may be submitted after four years if it contains a certification of patent invalidity or <FONT STYLE="white-space:nowrap">non-infringement.</FONT> </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDCA also provides three years of exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability
studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and
does not prohibit the FDA from approving ANDAs for drugs containing the original active agent for other conditions of use. Three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA
would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, both drugs and biologics can obtain pediatric exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity
periods and patent terms. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance
with an <FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#147;Written Request&#148; for such a study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Biosimilars and Reference Product Exclusivity for
Biological Products </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2010, the Patient Protection and Affordable Care Act was enacted in the United States and included the Biologics Price Competition
and Innovation Act of 2009, or the BPCIA. The BPCIA amended the PHSA to create an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference
biological product. To date, the FDA has approved a number of biosimilars. No interchangeable biosimilars, however, have been approved. The FDA has also issued several guidance documents outlining its approach to reviewing and approving biosimilars
and interchangeable biosimilars. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the BPCIA, a manufacturer may submit an application that is &#147;biosimilar to&#148; or &#147;interchangeable with&#148; a
previously approved biological product or &#147;reference product.&#148; In order for the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product and proposed biosimilar
product in terms of safety, purity and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the
reference product and (for products administered multiple times) that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to
exclusive use of the reference biologic. Upon licensure by the FDA, an interchangeable biosimilar may be substituted for the reference product without the intervention of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">127 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
health care provider who prescribed the reference product, although to date no such products have been approved for marketing in the United States. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The biosimilar applicant must demonstrate that the product is biosimilar based on data from analytical studies showing that the biosimilar product is highly similar to
the reference product, data from animal studies (including toxicity) and data from one or more clinical studies to demonstrate safety, purity and potency in one or more appropriate conditions of use for which the reference product is approved. In
addition, the applicant must show that the biosimilar and reference products have the same mechanism of action for the conditions of use on the label, route of administration, dosage and strength, and the production facility must meet standards
designed to assure product safety, purity, and potency. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A reference biological product is granted 12 years of data exclusivity from the time of first licensure of
the product, and the first approved interchangeable biologic product will be granted an exclusivity period of up to one year after it is first commercially marketed. The FDA will not accept an application for a biosimilar or interchangeable product
based on the reference biological product until four years after the date of first licensure of the reference product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The BPCIA is complex and only beginning to
be interpreted and implemented by the FDA. In addition, recent government proposals have sought to reduce the <FONT STYLE="white-space:nowrap">12-year</FONT> reference product exclusivity period. Other aspects of the BPCIA, some of which may impact
the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation and meaning of the BPCIA is subject to significant uncertainty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Orphan Drug Designation and Exclusivity </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Orphan drug designation in the
United States is designed to encourage sponsors to develop products intended for the treatment of rare diseases or conditions. In the United States, a rare disease or condition is statutorily defined as a condition that affects fewer than 200,000
individuals in the United States or that affects more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available for the disease or condition will be
recovered from sales of the product in the United States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Orphan drug designation qualifies a company for certain tax credits. In addition, if a product candidate
that has orphan drug designation subsequently receives the first FDA approval for that drug for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other
applications to market the same drug for the same indication for seven years following product approval unless the subsequent product candidate is demonstrated to be clinically superior. Absent a showing of clinical superiority, the FDA cannot
approve the same product made by another manufacturer for the same indication during the market exclusivity period unless it has the consent of the sponsor or the sponsor is unable to provide sufficient quantities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A sponsor may request orphan drug designation of a previously unapproved product or new orphan indication for an already marketed product. More than one sponsor may
receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete orphan disease designation application. To qualify for orphan exclusivity, however,
the drug must be clinically superior to the previously approved product that is the same drug for the same condition. If a product designated as an orphan drug ultimately receives marketing approval for an indication broader than what was designated
in its orphan drug application, it may not be entitled to exclusivity. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RLYB211 and RLYB212 have each been granted orphan drug designation by the FDA for the
prevention of FNAIT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rare Pediatric Disease Designation and Priority Review Vouchers </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2012, Congress enacted the Food and Drug Administration Safety and Innovation Act requiring the FDA to award priority review vouchers to sponsors of
certain&nbsp;rare pediatric disease&nbsp;product applications. This program is designed to encourage development of new drug and biological products for prevention and treatment of &#147;rare pediatric diseases&#148; by, upon initial approval of an
application meeting certain specified criteria, providing companies with a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a&nbsp;rare pediatric
disease&nbsp;drug product receiving a priority review voucher may sell or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">128 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
otherwise transfer the voucher to another company. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet
submitted an application relying on the priority review voucher. The FDA may also revoke any rare pediatric disease priority review voucher if the&nbsp;rare pediatric disease&nbsp;product for which the voucher was awarded is not marketed in the
United States within one year following the date of approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In order to receive a rare pediatric disease priority review voucher upon BLA or NDA approval, the
product must receive designation from the FDA as a drug for a rare pediatric disease prior to submission of the marketing application. A &#147;rare pediatric disease&#148; is a disease that is serious or life-threatening, in which the serious or
life-threatening manifestations primarily affect individuals aged from birth to 18 years and affects fewer than 200,000 people in the United States, or affects more than 200,000 people in the United States but there is no reasonable expectation that
the cost of developing and making available in the United States a drug for such disease or condition will be recovered from sales in the United States of such drug.&nbsp;In addition to receiving rare pediatric disease designation, in order to
receive a rare pediatric disease priority review voucher, the NDA or BLA must be given priority review, rely on clinical data derived from studies examining a pediatric population and dosages of the drug intended for that population, not seek
approval for a different adult indication in the original rare pediatric disease product application and be for a drug that does not include a previously approved active ingredient. In addition, under current statutory sunset provisions, even if a
marketing application meets all of these requirements, FDA may only award a voucher prior to September&nbsp;30, 2026 and only if the approved product received rare pediatric disease drug product designation prior to September&nbsp;30, 2024. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RLYB211 and RLYB212 have each been granted rare pediatric disease designation by the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>FDA Approval or Clearance of Companion Diagnostics </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the FDCA, <I>in
vitro </I>diagnostics, including companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its<I> </I>implementing regulations, and other federal and state statutes and regulations govern, among other things,
medical device design and<I> </I>development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising<I> </I>and promotion, sales and distribution, export and import,
and post-market surveillance. Unless an exemption applies, diagnostic tests require<I> marketing clearance via 510(k) notification or approval via Premarket Approval (&#147;PMA&#148;) application from the FDA prior to commercial distribution.
</I></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and <I>in vitro </I>companion
diagnostics. According to the guidance, for novel drugs and biologics, a companion diagnostic device and its corresponding<I> </I>therapeutic should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic
product&#146;s labeling. Approval or<I> </I>clearance of the companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance<I> </I>characteristics in the intended population. In July 2016, the FDA
issued a draft guidance intended to assist sponsors of the therapeutic products<I> </I>and <I>in vitro </I>companion diagnostic devices on issues related to <FONT STYLE="white-space:nowrap">co-development</FONT> of the products. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA previously has required <I>in vitro </I>companion diagnostics intended to select the patients who will respond to a product candidate to obtain <FONT
STYLE="white-space:nowrap">pre-market</FONT> approval, or PMA, simultaneously with approval of the therapeutic product candidate. The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA,
can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#146;s safety and effectiveness and information about the device and its
components regarding, among other things, device design, manufacturing, and labeling. PMA applications are subject to an application fee, which for fiscal year 2021 is $365,657. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A clinical trial is typically required for a PMA application and, in some cases, the FDA may require a clinical study in support of a 510(k) submission. A manufacturer
that wishes to conduct a clinical study involving the device is subject to the FDA&#146;s investigational device exemption, or IDE, regulation. The IDE regulations distinguish between significant and
<FONT STYLE="white-space:nowrap">non-significant</FONT> risk device studies and the procedures for obtaining approval to begin the study differ accordingly. Also, some types of studies are exempt from the IDE regulations. A significant risk device
presents a potential for serious risk to the health, safety, or welfare of a subject. Significant risk devices are devices that are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">129 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
substantially important in diagnosing, curing, mitigating, or treating disease or in preventing impairment to human health. Studies of devices that pose a significant risk require both FDA and an
IRB approval prior to initiation of a clinical study. Many companion diagnostics are considered significant risk devices due to their role in diagnosing a disease or condition. <FONT STYLE="white-space:nowrap">Non-significant</FONT> risk devices are
devices that do not pose a significant risk to the human subjects. A <FONT STYLE="white-space:nowrap">non-significant</FONT> risk device study requires only IRB approval prior to initiation of a clinical study. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for
which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. In the United States, device manufacturers are also subject to FDA&#146;s medical device reporting regulations, which require
that a manufacturer report to the FDA if a device it markets may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or
serious injury, if the malfunction were to recur, and FDA&#146;s correction and removal reporting regulations, which require that manufacturers report to the FDA corrections or removals if undertaken to reduce a risk to health posed by the device or
to remedy a violation of the FDCA that may present a risk to health. A medical device manufacturer&#146;s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the Quality System Regulation, which
covers the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging, and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic
unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Regulation Outside of the United
States </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales
and distribution of our products outside of the United States. Whether or not we obtain FDA approval for a product candidate, we must obtain approval by the comparable regulatory authorities of foreign countries or economic areas, such as the <FONT
STYLE="white-space:nowrap">27-member</FONT> EU, before we may commence clinical trials or market products in those countries or areas. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The United Kingdom&#146;s,
or the U.K., withdrawal from the EU took place on January&nbsp;31, 2020. The EU and the U.K. reached an agreement on their new partnership in the Trade and Cooperation Agreement, or the Agreement, to be applied from January 1, 2021. The Agreement
focuses primarily on free trade by ensuring no tariffs or quotas on trade in goods, including healthcare products such as medicinal products. Thereafter, the EU and the U.K. will form two separate markets governed by two distinct regulatory and
legal regimes. As such, the Agreement seeks to minimize barriers to trade in goods while accepting that border checks will become inevitable as a consequence that the U.K. is no longer part of the single market. As of January&nbsp;1, 2021, the
Medicines and Healthcare products Regulatory Agency, or the MHRA, becomes responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland and Wales under domestic law whereas Northern Ireland will continue to
be subject to EU rules under the Northern Ireland Protocol. The MHRA will rely on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended), or the HMR, as the basis for regulating medicines. The HMR has incorporated into the domestic law the
body of EU law instruments governing medicinal products that <FONT STYLE="white-space:nowrap">pre-existed</FONT> prior to the U.K.&#146;s withdrawal from the EU. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">With the exception of the EU/EEA applying the harmonized regulatory rules for medicinal products, the approval process and requirements governing the conduct of
clinical trials, product licensing, pricing and reimbursement vary greatly between countries and jurisdictions and can involve additional testing and additional administrative review periods. The time required to obtain approval in other countries
and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval
in one country or jurisdiction may negatively impact the regulatory process in others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>European Union Drug Development, Review and Approval </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the EU, our product candidates also may be subject to extensive regulatory requirements. As in the United States, medicinal products can be marketed only if a
marketing authorization from the competent regulatory agencies has been obtained. Similar to the United States, the various phases of preclinical and clinical research in the EU are subject to significant regulatory controls. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">130 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Clinical Trials Directive 2001/20/EC, the Directive 2005/28/EC on GCP and the related national implementing provisions
of the individual EU Member States govern the system for the approval of clinical trials in the EU. Under this system, an applicant must obtain prior approval from the competent national authority of the EU Member States in which the clinical trial
is to be conducted. Furthermore, the applicant may only start a clinical trial at a specific study site after the competent ethics committee has issued a favorable opinion. The clinical trial application must be accompanied by, among other
documents, an IMPD (investigational medicinal product dossier principally based on the Common Technical Document developed by the International Council for Harmonization) with supporting information prescribed by Directive 2001/20/EC, Directive
2005/28/EC, and where relevant the implementing national provisions of the individual EU Member States and further detailed in applicable guidance documents issued by the European Commission and European Medicines Agency. All suspected unexpected
serious adverse reactions to the investigated drug that occur during the clinical trial have to be reported to the competent national authority and the Ethics Committee of the Member State where the clinical trial takes place. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2014, the new Clinical Trials Regulation, (EU) No 536/2014, or the Clinical Trials Regulation, was adopted and it is anticipated to come into application in
late 2021 but could be delayed, subject to the full functionality of the Clinical Trials Information System (CTIS) through an independent audit. The Clinical Trials Regulation will come into application in all the EU Member States, repealing the
current Clinical Trials Directive 2001/20/EC. Conduct of all clinical trials performed in the EU will continue to be bound by currently applicable provisions until the new Clinical Trials Regulation becomes applicable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The extent to which ongoing clinical trials will be governed by the Clinical Trials Regulation will depend on when the Clinical Trials Regulation will come into
application and on the duration of the individual clinical trial. According to the transitional provisions, if a clinical trial continues for more than three years from the day on which the Clinical Trials Regulation becomes applicable the Clinical
Trials Regulation will at that time begin to apply to the clinical trial. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Clinical Trials Regulation aims to simplify and streamline the approval of clinical
trials in the EU. The main characteristics of the regulation include: a streamlined application procedure via a single entry point, the &#147;EU portal&#148;; a single set of documents to be prepared and submitted for the application as well as
simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by the competent authorities of all EU Member States in
which an application for authorization of a clinical trial has been submitted (Member States concerned). Part II is assessed separately by each Member State concerned. Strict deadlines have been established for the assessment of clinical trial
applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned EU Member State. However, overall related timelines will be defined by the Clinical Trials
Regulation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For any of our product candidates that incorporate a medical device to administer the medicinal product and are intended to be commercialized as a
single integral product intended exclusively for use in the given combination and not usable separately, then the combination product is regulated by Directive 2001/83/EC or Regulation (EC) 726/2004 as a medicinal product. However, the medical
device used for administration must satisfy the requirements for its general safety and performance under EU law governing general medical devices. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The EU
regulatory regime currently provided under Directive 93/42/EEC, or the Medical Devices Directive, will be replaced by Regulation (EU) 2017/745 on medical devices, or the Medical Devices Regulation. The Medical Devices Regulation will come into
application on May&nbsp;26, 2021, subject to the transitional provisions for certain medical devices to remain on the EU market if they were certified under the Medical Devices Directive for a limited period. There are significant changes to the EU
regulatory system governing medical devices under the Medical Devices Regulation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Medical Devices Regulation, data relating to the general safety and
performance of the medical device must be contained in an application for marketing authorization for the combination product. Such information must be provided by the manufacturer of the medical device in its EU declaration of conformity or the
relevant certificate issued by a notified body allowing the medical device manufacturer to affix a European Conformity (&#147;CE&#148;) mark to the medical device. If the dossier submitted to support the marketing authorization does not include the
results of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">131 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the conformity assessment and where for the conformity assessment of the device, if used separately, the involvement of a notified body is required in accordance with the Medical Devices
Regulation, the medicinal products authority such as the EMA can require the applicant for a marketing authorization to provide an opinion on the conformity of the device part with the relevant general safety and performance requirements issued by a
designated notified body. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Marketing authorization applications, or MAA, can be filed either under the <FONT STYLE="white-space:nowrap">so-called</FONT> centralized
or national authorization procedures, albeit through the Mutual Recognition or Decentralized procedure for a product to be authorized in more than one EU member state. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Centralized Procedure </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The centralized procedure provides for the grant of a
single marketing authorization following a favorable opinion by the European Medicines Agency, or EMA, that is valid in all EU Member States, as well as Iceland, Liechtenstein and Norway, which are part of the EEA. The centralized procedure is
compulsory for medicines produced by specified biotechnological processes, products designated as orphan medicinal products, advanced-therapy medicines (such as gene-therapy, somatic cell-therapy or tissue-engineered medicines) and products with a
new active substance indicated for the treatment of specified diseases, such as HIV/ AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune diseases and other immune dysfunctions and viral diseases. The centralized procedure is optional
for products that represent a significant therapeutic, scientific or technical innovation, or whose authorization would be in the interest of public health. Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the
EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the Committee for Medicinal Products for Human Use, or the CHMP. Accelerated assessment might be
granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of an MAA under the accelerated
assessment procedure is of 150 days, excluding stop-clocks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>National Authorization Procedures </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are also two other possible routes to authorize medicinal products in several EU countries, which are available for medicinal products that fall outside the scope
of the centralized procedure: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I>Decentralized procedure</I></B>. Using the decentralized procedure, an applicant may apply for simultaneous
authorization in more than one EU country of medicinal products that have not yet been authorized in any EU country and that do not fall within the mandatory scope of the centralized procedure. The applicant may choose a member state as the
reference member State to lead the scientific evaluation of the application. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I>Mutual recognition procedure</I></B>. In the mutual recognition procedure, a medicine is first authorized in one EU
Member State (which acts as the reference member state), in accordance with the national procedures of that country. Following this, further marketing authorizations can be progressively sought from other EU countries in a procedure whereby the
countries concerned agree to recognize the validity of the original, national marketing authorization produced by the reference member state. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the above-described procedures, before granting the marketing authorization, the EMA or the competent authorities of the Member States of the EEA assess the
risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Conditional Marketing Authorization
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In specific circumstances, E.U. legislation (Article 14&#150;a Regulation (EC) No 726/2004 (as amended by Regulation (EU) 2019/5 and Regulation (EC) No
507/2006 on Conditional Marketing Authorizations for Medicinal Products for Human Use) enables applicants to obtain a conditional marketing authorization prior to obtaining the comprehensive clinical data required for an application for a full
marketing authorization. Such conditional approvals may be granted for product candidates (including medicines designated as orphan medicinal products) if (1)&nbsp;the product candidate is intended for the treatment, prevention or medical diagnosis
of seriously debilitating or life-threatening diseases; (2)&nbsp;the drug candidate is intended to meet unmet medical needs of patients; (3)&nbsp;a marketing authorization </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">132 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
may be granted prior to submission of comprehensive clinical data provided that the benefit of the immediate availability on the market of the medicinal product concerned outweighs the risk
inherent in the fact that additional data are still required; (4)&nbsp;the risk-benefit balance of the product candidate is positive, and (5)&nbsp;it is likely that the applicant will be in a position to provide the required comprehensive clinical
trial data. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies and with respect to the
collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions
or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Pediatric Studies </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to obtaining a marketing authorization in the EU,
applicants have to demonstrate compliance with all measures included in an <FONT STYLE="white-space:nowrap">EMA-approved</FONT> Pediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted a
product-specific waiver, a class waiver or a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization procedures are set forth in Regulation (EC) No 1901/2006, which is referred to as
the Pediatric Regulation. This requirement also applies when a company wants to add a new indication, pharmaceutical form, or route of administration for a medicine that is already authorized. The Pediatric Committee of the EMA, or PDCO, may grant
deferrals for some medicines, allowing a company to delay development of the medicine in children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when development of a medicine
in children is not needed or is not appropriate because (a)&nbsp;the product is likely to be ineffective or unsafe in part or all of the pediatric population; (b)&nbsp;the disease or condition occurs only in adult population; or (c)&nbsp;the product
does not represent a significant therapeutic benefit over existing treatments for pediatric population. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The EMA determines that companies actually comply with the
agreed studies and measures listed in each relevant PIP. This compliance check requirement applies to (a)&nbsp;a marketing authorization application based on a full stand-alone dossier provided under Article 8(3) of Directive 2001/83/EC and
(b)&nbsp;an application for variation or line-extension for a new pharmaceutical form or a new indication where the product is protected by a subsisting supplementary protection certificate (a form of patent extension under EU law) or a patent that
qualifies for grant of a supplementary protection certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>European Union Regulatory Data Exclusivity </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the EU, new products authorized for marketing (i.e., reference products) qualify for eight years of data exclusivity and an additional two years of market
exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or
biosimilar marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from
commercializing its product in the EU until ten years have elapsed from the initial authorization of the reference product in the EU. The <FONT STYLE="white-space:nowrap">ten-year</FONT> market exclusivity period can be extended to a maximum of
eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held
to bring a significant clinical benefit in comparison with existing therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>European Union Orphan Designation and Exclusivity </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The criteria for designating an orphan medicinal product in the EU are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000,
a medicinal product may be designated as orphan if (1)&nbsp;it is intended for the diagnosis, prevention or treatment of a life- threatening or chronically debilitating condition, (2)&nbsp;either (a) such condition affects no more than five in
10,000 persons in the EU when the application is made, or (b)&nbsp;the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment and (3)&nbsp;there exists no satisfactory method of
diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">133 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
affected by the condition. The term &#145;significant benefit&#146; is defined in Regulation (EC) 847/2000 to mean a clinically relevant advantage or a major contribution to patient care. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to
ten years of market exclusivity for the approved therapeutic indication. During this ten year market exclusivity period, the EMA or the competent authorities of the Member States of the EEA, cannot accept an application for a marketing authorization
for a similar medicinal product for the same indication. A similar medicinal product is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended
for the same therapeutic indication. The application for orphan designation must be submitted before the application for marketing authorization. The applicant will receive a fee reduction for the marketing authorization application if the orphan
designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval
process. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap">ten-year</FONT> market exclusivity in the EU may be reduced to six years if, at the end of the fifth year, it is
established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a
similar product for the same indication at any time if: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically
superior; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the applicant consents to a second orphan medicinal product application; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the applicant cannot supply enough orphan medicinal product. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RLYB211 and RLYB212 have each been granted orphan drug designation by the EMA for the prevention of FNAIT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PRIME Designation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The EMA grants access to the Priority Medicines, or
PRIME, program to investigational medicines for which it determines there to be preliminary data available showing the potential to address an unmet medical need and bring a major therapeutic advantage to patients. As part of the program, EMA
provides early and enhanced dialogue and support to optimize the development of eligible medicines and speed up their evaluation, aiming to bring promising treatments to patients sooner. Rallybio anticipates that it will request PRIME designation
for certain of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Periods of Authorization and Renewals </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A marketing authorization is valid for five years in principle and the marketing authorization may be renewed after five years on the basis of a <FONT
STYLE="white-space:nowrap">re-evaluation</FONT> of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To this end, the marketing authorization holder must provide the EMA or the competent authority
with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least nine months before the marketing authorization ceases to be valid. Once
renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any
authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid (the <FONT
STYLE="white-space:nowrap">so-called</FONT> sunset clause). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rest of the World Regulation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For other countries outside of the EU and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of
clinical trials, product licensing, pricing and reimbursement vary from jurisdiction to jurisdiction. Additionally, the clinical trials must be conducted in accordance with cGCP requirements and the applicable regulatory requirements and the ethical
principles that have their origin in the Declaration of Helsinki. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">134 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines,
suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Coverage, Pricing and
Reimbursement </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Sales of any biopharmaceutical products, if and when approved by the FDA or analogous authorities outside the United States, will depend in
significant part on the availability of third-party coverage and reimbursement for the products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, third-party payors include government
healthcare programs such as Medicare and Medicaid, private health insurers, managed care plans and other organizations. These third-party payors are increasingly challenging the price and examining the cost-effectiveness of medical products and
services, including biopharmaceutical products. Significant uncertainty exists regarding coverage and reimbursement for newly approved healthcare products. Coverage does not ensure reimbursement. It is time consuming and expensive to seek coverage
and reimbursement from third-party payors. We may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA regulatory approvals.
Third-party payors may take into account clinical practice guidelines in determining coverage and there may be significant delays before our products are addressed by such guidelines and we cannot predict what position such guidelines would take
with respect to our products if and when addressed. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication, or utilize other
mechanisms to manage utilization (such as requiring prior authorization for coverage for a product for use in a particular patient). Limits on coverage may impact demand for our products. Even if coverage is obtained, third-party reimbursement may
not be adequate to allow us to sell our products on a competitive and profitable basis. As result, we may not be sufficient to maintain price levels high enough to realize an appropriate return on investment in product development. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing
vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of
our product candidate to currently available therapies (so called health technology assessment, or HTA) in order to obtain reimbursement or pricing approval. For example, subject to the requirements set out in Directive 89/105/EEC relating to the
transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems, EU Member States have the legal competence to set national measures of an economic nature on
the marketing of medicinal products in order to control public health expenditure on such products. Accordingly, EU Member States can restrict the range of medicinal products for which their national health insurance systems provide reimbursement
and to control the prices of medicinal products for human use. An EU Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the
medicinal product on the market. Other EU Member States allow companies to fix their own prices for drug products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. There can be no assurance that
any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the EU do not follow price
structures of the United States and generally tend to be significantly lower. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The downward pressure on health care costs in general, particularly prescription
drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as
part of cost containment measures. Political, economic, and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member
States and parallel import or distribution (arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced member states) can further reduce prices. Any country that has price controls or reimbursement limitations for drug
products may not allow favorable reimbursement and pricing arrangements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">135 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other U.S. Health Care Laws and Regulations </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, biopharmaceutical manufacturers and their products are subject to extensive regulation at the federal and state level, such as laws intended to
prevent fraud and abuse in the healthcare industry. These laws, some of which will apply only if and when we have an approved product, include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">federal false claims, false statements and civil monetary penalties laws prohibiting, among other things, any person from
knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly making, or causing to be made, a false statement to get a false claim paid; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">federal healthcare program anti-kickback law, which prohibits, among other things, persons from offering, soliciting,
receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual for, or the purchasing or ordering of, a good or service for which payment may be made under federal healthcare programs such as Medicare and
Medicaid; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which, in addition to privacy
protections applicable to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">FDCA, which among other things, strictly regulates drug marketing, prohibits manufacturers from marketing such products
prior to approval or for <FONT STYLE="white-space:nowrap">off-label</FONT> use and regulates the distribution of samples; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or
provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">federal Open Payments (or federal &#147;sunshine&#148; law), which requires pharmaceutical and medical device companies to
monitor and report certain financial interactions with certain healthcare providers to the Center for Medicare&nbsp;&amp; Medicaid Services within the U.S. Department of Health and Human Services for
<FONT STYLE="white-space:nowrap">re-disclosure</FONT> to the public, as well as ownership and investment interests held by physicians and their immediate family members; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that
potentially harm consumers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">analogous state laws and regulations, including: state anti-kickback and false claims laws; state laws requiring
pharmaceutical companies to comply with specific compliance standards, restrict financial interactions between pharmaceutical companies and healthcare providers or require pharmaceutical companies to report information related to payments to health
care providers or marketing expenditures; and state laws governing privacy, security and breaches of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus
complicating compliance efforts; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">laws and regulations prohibiting bribery and corruption, such as the FCPA, which, among other things, prohibits U.S.
companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international
organizations or foreign government-owned or affiliated entities, candidates for foreign public office, and foreign political parties or officials thereof. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Violations of these laws are punishable by criminal and/or civil sanctions, including, in some instances, exclusion from participation in federal and state health care
programs, such as Medicare and Medicaid. Ensuring compliance is time consuming and costly. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Similar healthcare laws and regulations exist in the EU and other
jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers and laws governing the privacy and security of personal information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">136 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Health Care Reform in the United States and Potential Changes to Health Care Laws </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Health care reform has been a significant trend in the U.S. health care industry and elsewhere. In particular, government authorities and other third-party payors have
attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products and services. Under the Trump administration, there were efforts to repeal or modify prior health care reform legislation and regulation
and to implement new health care reform measures, including measures related to payment for drugs under government health care programs. The nature and scope of health care reform in the wake of the transition from the Trump administration to the
Biden administration remains uncertain but early actions include additional health care reform as well as challenges to actions taken under the Trump administration. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There has been heightened governmental scrutiny in recent years over the manner in which manufacturers set prices for their marketed products, which has resulted in
proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing and reform government program reimbursement methodologies for pharmaceutical and biologic products. At the state level,
individual states are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product
access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. These measures could reduce the ultimate demand for our products, once approved, or put
pressure on our product pricing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or
administrative or executive action, either in the United States or abroad. We expect that additional federal and state health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments
will pay for health care products and services. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For a more detailed discussion of health care reform in the U.S., see &#147;Risk Factors&#151;Risks Related to
Healthcare Laws and Other Legal Compliance Matters.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Data Privacy Regulation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>U.S. Privacy Law </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are numerous U.S. federal and state laws and
regulations related to the privacy and security of personal information, including laws requiring the safeguarding of personal information and laws requiring notification to governmental authorities and data subjects as well as remediation in the
event of a data breach. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There have been several developments in recent years with respect to U.S. state data privacy laws. In 2018, California passed into law the
CCPA, which took effect on January&nbsp;1,&nbsp;2020 and imposed many requirements on businesses that process the personal information of California residents. Many of the CCPA&#146;s requirements are similar to those found in the GDPR, including
requiring businesses to provide notice to data subjects regarding the information collected about them and how such information is used and shared, and providing data subjects the right to request access to such personal information and, in certain
cases, request the erasure of such personal information. The CCPA also affords California residents the right to <FONT STYLE="white-space:nowrap">opt-out</FONT> of &#147;sales&#148; of their personal information. The CCPA contains significant
penalties for companies that violate its requirements. It also provides California residents a private right of action, including the ability to seek statutory damages, in the event of a breach involving their personal information. Compliance with
the CCPA is a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance. On November&nbsp;3, 2020, California voters passed a ballot initiative
for the CPRA, which will significantly expand the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention and sharing of personal information of California residents be reasonably necessary and proportionate
to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. The CPRA will also expand personal
information rights of California residents, including creating a right to opt out of sharing of personal information with third parties for advertising, expanding the lookback period for the right to know about personal information held by
businesses, and expanding the right to erasure for information held by third parties. Most CPRA provisions will take effect on January&nbsp;1, 2023, though the obligations will apply to any personal information collected after January&nbsp;1,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">137 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
2022. Similar laws have been proposed or passed at the U.S. federal and state level, including the Virginia Consumer Data Protection Act, which will take effect on January&nbsp;1, 2023. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General data protection regulation (GDPR) </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many countries outside of the
United States maintain rigorous laws governing the privacy and security of personal information. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located
in the EEA, and the processing of personal data that takes place in the EEA, is subject to the GDPR, which became effective on May&nbsp;25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal
data, and it imposes heightened requirements on companies that process health and other sensitive data, such as requiring in many situations that a company obtain the consent of the individuals to whom the sensitive personal data relate before
processing such data. Examples of obligations imposed by the GDPR on companies processing personal data that fall within the scope of the GDPR include providing information to individuals regarding data processing activities, implementing safeguards
to protect the security and confidentiality of personal data, appointing a data protection officer, providing notification of data breaches and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the
transfer of personal data to countries outside the EEA, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to <FONT
STYLE="font-family:Times New Roman">&#128;</FONT>20&nbsp;million, or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory
authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR is a rigorous and time-intensive process that may increase the cost of doing business or require companies to
change their business practices to ensure full compliance. In July 2020, the Court of Justice of the European Union, or the CJEU, invalidated the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield framework, one of the mechanisms used to
legitimize the transfer of personal data from the EEA to the United States. The CJEU decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual clauses, for transfers of personal data
from the EEA to the United States. Following the withdrawal of the U.K. from the EU, the U.K. Data Protection Act 2018 applies to the processing of personal data that takes place in the U.K. and includes parallel obligations to those set forth by
GDPR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employees and Human Capital Resources </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our employees are driven
by our mission to identify and accelerate the development of transformative therapies for patients with rare disorders. We believe that our deep commitment to high ethical and professional standards is fundamental to our mission, and we are
determined to build a culture that values diversity, inclusiveness and equity, and empowers a skilled and experienced workforce to perform at the highest levels. We commit our resources and make investments, including through recruiting, training
and collaboration, to promote the culture that we desire, and we expect our employees to embrace the company&#146;s values and culture in all that we do. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of
June 30, 2021, we employed 28 full-time employees. Of our full-time employees, 17 employees are engaged in new product sourcing through business development, research, manufacturing, product development and clinical development, and 11 are engaged
in finance, human resources, legal and other administrative functions. None of our employees are represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees,
advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based incentive awards, in order to increase stockholder value and the
success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. We offer a benefits program that provides resources to help employees manage their health, finances and life outside of work.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Facilities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our corporate headquarters is located at 234 Church Street,
Suite 1020, New Haven, CT 06510, where we lease and occupy 4,500 square feet of office space. The current term of our New Haven lease expires May&nbsp;31, 2025. We also lease 117 square feet of office space at 400 Farmington Avenue, Suite R2846,
Farmington, CT 06032. The current term of our Farmington lease expires January&nbsp;31, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">138 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe our existing facilities are sufficient for our current needs. To meet the future needs of our business, we
expect to lease additional or alternate office space, and we believe suitable additional or alternative space will be available in the future on commercially reasonable terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Legal Proceedings </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, we may become involved in litigation
or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an
adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources, negative publicity and reputational harm and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">139 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_12"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our executive officers and directors,
their ages as of June 30, 2021, and their positions, are as set forth below: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>POSITION(S)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Martin W. Mackay, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">65</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer and Chairman</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stephen Uden, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">63</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Operating Officer and Chief Scientific Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jeffrey M. Fryer, CPA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">52</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer and Treasurer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Steven Ryder, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">70</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Non-Management</FONT> Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Helen M. Boudreau</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">55</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Rob Hopfner, R.Ph., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">48</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ronald M. Hunt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">56</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lucian Iancovici, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">39</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Kush M. Parmar, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">40</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Timothy M. Shannon, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">62</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Paula Soteropoulos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">53</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Executive Officers </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Martin W. Mackay, Ph.D., </I></B>is a <FONT
STYLE="white-space:nowrap">co-founder</FONT> of, and has been Chief Executive Officer and Chairman of the board of directors of Rallybio since January 2018. From March 2013 to December 2017, Dr.&nbsp;Mackay served as the Executive Vice President and
Global Head of Research&nbsp;&amp; Development at Alexion Pharmaceuticals, Inc., or Alexion, and, from July 2010 to January 2013, Dr.&nbsp;Mackay served as the President of Research&nbsp;&amp; Development at AstraZeneca PLC. Prior to AstraZeneca,
Dr.&nbsp;Mackay worked at Pfizer, Inc., or Pfizer, for 15 years where he held positions of increasing responsibility, including president, head of pharmatherapeutics research and development. Dr.&nbsp;Mackay currently serves on the board of
directors of 5:01 Acquisition Corp, Charles River Laboratories International, Inc., and Novo Nordisk A/S. Dr.&nbsp;Mackay earned a BSc First Class&nbsp;in microbiology from Heriot-Watt University and a Ph.D. in molecular genetics from the University
of Edinburgh. Dr.&nbsp;Mackay&#146;s extensive experience serving on other boards and leading research and development organizations at both global pharmaceutical and biotechnology companies provides our board of directors with a unique combination
of expertise. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Stephen Uden, M.D.,</I></B><B> </B>is a <FONT STYLE="white-space:nowrap">co-founder</FONT> of, and has been President, Chief Operating
Officer and Chief Scientific Officer of Rallybio since January 2018. Previously, Dr.&nbsp;Uden served as Senior Vice President, Research at Alexion from June 2014 to October 2017. Prior to Alexion, Dr.&nbsp;Uden served in various leadership roles in
the research organizations of Novartis (Japan), Wyeth (Japan), Neurogen and Pfizer. Dr.&nbsp;Uden earned a BSc in biochemistry and an M.B., B.S. in medicine from the University of London. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Jeffrey M. Fryer</I></B><B>, CPA, </B>is<B> </B>a <FONT STYLE="white-space:nowrap">co-founder</FONT> of, and has been Chief Financial Officer and Treasurer of
Rallybio since January 2018. Previously, Mr.&nbsp;Fryer served as Vice-President and Chief Tax Officer of Alexion from April 2008 to April 2017. Prior to Alexion, Mr.&nbsp;Fryer lead the corporate tax functions at Chemtura Corporation and Lydall,
Inc., and served for over ten years with PwC as a senior tax manager. He earned an M.S. in taxation from the University of Hartford and a B.S. in business administration with a concentration in accounting from Bryant University. Mr.&nbsp;Fryer is a
member of the Dean&#146;s Advisory Council for the Bryant University School of Business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Steven Ryder, M.D., </I></B>has been Chief Medical Officer of
Rallybio since January 2019. Previously, Dr. Ryder served as Chief Development Officer at Alexion from July 2013 to December 2018. From April 2008 to April 2013, Dr. Ryder served as President of Astellas Pharma Global Development at Astellas Inc, or
Astellas. Prior to joining Astellas, Dr. Ryder worked at Pfizer for 21 years where he held positions of increasing responsibility, including head of worldwide clinical development. Dr.&nbsp;Ryder earned an M.D. from the Icahn School of Medicine at
Mount Sinai. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">140 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Non-employee</FONT> Directors </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Helen M. Boudreau </I></B>has served as a member of our board of directors since September 2020. From June 2018 to June 2019, Ms.&nbsp;Boudreau served as Chief
Operating Officer of the Bill&nbsp;&amp; Melinda Gates Medical Research Institute, a <FONT STYLE="white-space:nowrap">non-profit</FONT> biotech. Previously, she served as Chief Financial Officer from July 2017 to June 2018 and as a board member from
February 2016 to July 2017 of Proteostasis Therapeutics, Inc. From October 2014 to June 2017, Ms.&nbsp;Boudreau served as Chief Financial Officer of FORMA Therapeutics, Inc., and from September 2008 to September 2014, Ms.&nbsp;Boudreau served in
senior finance roles at Novartis AG, including Chief Financial Officer Novartis Corporation US and Chief Financial Officer Global Oncology. Prior to Novartis, Ms.&nbsp;Boudreau served in roles of increasing responsibility in strategy and finance at
Pfizer Inc. from April 1999 to September 2008, including Vice President Finance Customer Business Unit and Commercial Operations and Vice President Finance, Pfizer Global Research and Development. Ms.&nbsp;Boudreau worked earlier in her career at
PepsiCo Inc. and YUM! Brands, Inc., McKinsey&nbsp;&amp; Company and Bank of America Corporation. Ms.&nbsp;Boudreau currently serves as a board member of Premier, Inc., Shattuck Labs Inc. and Field Trip Health Ltd. Ms.&nbsp;Boudreau previously served
on the board of directors of Evaxion Biotech A/S and Proteostasis Therapeutics, Inc. Ms.&nbsp;Boudreau earned a B.A. in Economics from the University of Maryland, where she graduated <I>summa cum laude</I>, and an M.B.A. from the Darden Graduate
School of Business at the University of Virginia. We believe Ms.&nbsp;Boudreau is qualified to serve on our board of directors because of her financial expertise and extensive experience as an executive and director with biotechnology companies.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rob Hopfner, R.Ph., Ph.D, </I></B>has served as a member of our board of directors since March 2020. Since October 2017, Dr.&nbsp;Hopfner has served as a
Managing Partner at Pivotal bioVenture Partners LLC, a venture capital firm. Prior to Pivotal, Dr.&nbsp;Hopfner served as a Principal at Bay City Capital LLC, a venture capital firm, from June 2007 to October 2009 and as a Managing Director and
Partner from October 2009 to September 2017. Dr.&nbsp;Hopfner currently serves as a board member of Vaxcyte, Inc. and Inozyme Pharma, Inc., and on the boards of a number of private life sciences companies. Dr.&nbsp;Hopfner earned a B.Sc. in Pharmacy
and a Ph.D. in Pharmacology from the University of Saskatchewan and an M.B.A. from the University of Chicago. We believe Dr.&nbsp;Hopfner is qualified to serve on our board of directors because of his experience in advising public and private life
sciences companies, as well as his research in the pharmaceutical field. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Ronald M. Hunt </I></B>has served as a member of our board of directors since March
2019. Since 2005, Mr.&nbsp;Hunt has served as a Managing Director and Member of New Leaf Venture Partners, L.L.C., a venture capital firm. Previously, Mr.&nbsp;Hunt served at the Sprout Group, a venture capital firm and was a consultant with
consulting firms Coopers&nbsp;&amp; Lybrand Consulting and The Health Care Group, Inc. Mr.&nbsp;Hunt worked earlier in his career in various sales and marketing positions at Johnson&nbsp;&amp; Johnson and SmithKline Beecham Pharmaceuticals PLC.
Mr.&nbsp;Hunt currently serves as a board member of Harpoon Therapeutics, Inc. and Iterum Therapeutics, Ltd., a clinical-stage therapeutics company, and on the boards of a number of private pharmaceutical and healthcare companies. Mr.&nbsp;Hunt
previously served on the board of directors of Neuronetics, Inc. Mr.&nbsp;Hunt earned a B.S. from Cornell University and an M.B.A. from the Wharton School of the University of Pennsylvania. We believe Mr.&nbsp;Hunt is qualified to serve on our board
of directors because of his investment experience, his experience in the pharmaceutical industry and service on the boards of other public and private biopharmaceutical and biotechnology companies. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Lucian Iancovici, M.D., </I></B>has served as a member of our board of directors since May 2020. Dr. Iancovici is currently a Managing Director of TPG Growth,
where he has worked since January 2018. From September 2012 to October 2017, Dr. Iancovici served as the head of the Qualcomm Life Fund, a venture fund focused on investing in digital health technologies. From January 2015 to October 2017, Dr.
Iancovici was a general partner at dRx Capital, a joint venture investment company launched by Novartis and Qualcomm. From 2011 to 2012, Dr. Iancovici was an associate at McKinsey &amp; Company. Lucian is a board certified internal medicine doctor,
who trained at Columbia University Medical Center in New York prior to joining McKinsey and Company. Dr. Iancovici earned his bachelor&#146;s degree in economics and an M.D., both from Tufts University. We believe that Dr. Iancovici is qualified to
serve on our board of directors because of his extensive experience in the venture capital industry, and his medical and scientific background and training. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Kush M. Parmar, M.D., Ph.D., </I></B>has served as a member of our board of directors since April 2018. Dr.&nbsp;Parmar is currently a Member of 5AM Venture
Management, LLC, where he has worked since 2010. Dr.&nbsp;Parmar also serves as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">141 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
<FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer and as member of the board of directors of 5:01 Acquisition Corp, positions he has held since its inception in September 2020.
Dr.&nbsp;Parmar currently serves as a board member of Akouos, Inc., Entrada Therapeutics, Inc., Ensoma Inc., Homology Medicines, Inc., Syngene International Ltd. and Vor Biopharma Inc., and previously served on the board of directors of Arvinas,
Inc., Audentes Therapeutics, Inc. and scPharmaceuticals, Inc. Dr.&nbsp;Parmar earned a B.A. in molecular biology and medieval studies from Princeton University, a Ph.D. in experimental pathology from Harvard University and an M.D. from Harvard
Medical School. We believe that Dr.&nbsp;Parmar is qualified to serve on our board of directors because of his extensive experience in the venture capital industry, medical and scientific background and training, and service on the boards of other
public and private biopharmaceutical and biotechnology companies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Timothy M. Shannon, M.D., </I></B>has served as a member of our board of directors since
April 2018. Dr.&nbsp;Shannon has been both a <FONT STYLE="white-space:nowrap">Non-Managing</FONT> Member of Canaan Partners IX LLC, a Managing Member of Canaan Partners X LLC, a Managing Member of Canaan Partners XI LLC, and a Managing Member of
Canaan Partners XII LLC, all entities affiliated with Canaan Partners, a venture capital firm, since November 2009. While at Canaan, Dr.&nbsp;Shannon served in a number of executive roles at biotechnology companies, including as President and Chief
Executive Officer of Aldea Pharmaceuticals, Inc. and of Arvinas, Inc. Prior to Canaan, Dr . Shannon served as Executive Vice President of R&amp;D and Chief Medical Officer of Curagen Corporation and Senior Vice President of Global Medical
Development, Bayer Healthcare LLC. Dr.&nbsp;Shannon currently serves as chairman of the board of directors of Arvinas, Inc. and of Ideaya Biosciences, Inc., as well as several privately held companies. Dr.&nbsp;Shannon previously served as a board
member of NextCure Inc., and CytomX Therapeutics, Inc. Dr.&nbsp;Shannon earned a B.A. in chemistry from Amherst College and an M.D. from the University of Connecticut. We believe Dr.&nbsp;Shannon is qualified to serve on our board of directors
because of his extensive experience in the venture capital industry, his executive leadership experience, his medical background and training, and his service on the boards of other public and private biopharmaceutical companies. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Paula Soteropoulos </I></B>has served as a member of our board of directors since October 2020. Ms.&nbsp;Soteropoulos currently serves as the Executive Chairman
of Ensoma, a private venture-backed company. She previously served as Chief Executive Officer and President of Akcea Therapeutics, Inc. from January 2015 to September 2019, where she was also a member of the board of directors. Prior to Akcea,
Ms.&nbsp;Soteropoulos served as Senior Vice President and General Manager, Cardiometabolic Business and Strategic Alliances at Moderna Therapeutics Inc., and prior to Moderna, she served in various roles of increasing responsibility at Genzyme
Corporation, including as Vice President and General Manager, Cardiovascular, Rare Diseases. Ms.&nbsp;Soteropoulos currently serves on the board of directors of uniQure N.V. Ms.&nbsp;Soteropoulos also serves as a Strategic Advisor to 5AM Venture
Management, LLC. Ms.&nbsp;Soteropoulos earned both a B.S. in chemical and biochemical engineering and an M.S. in chemical and biochemical engineering from Tufts University, and holds an executive management certificate from the Darden Graduate
School of Business at the University of Virginia. Ms.&nbsp;Soteropoulos serves on the Advisory Board for the Chemical and Biological Engineering Department of Tufts University. We believe Ms.&nbsp;Soteropoulos is qualified to serve on our board of
directors because of her extensive experience in the biotechnology industry, her executive leadership experience and her service on the boards of other public and private biopharmaceutical companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Composition and Election of Directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of managers currently
consists of eight members, all of whom were elected as managers pursuant to our Operating Agreement. The Operating Agreement will terminate prior to the consummation of this offering and there will be no further contractual obligations regarding the
election of our directors. Following the Reorganization, the board of directors of Rallybio Corporation, or the Corporation, will consist of the same eight members who will be duly elected in accordance with the bylaws of the Corporation. Our
directors hold office until their successors have been elected and qualified or until the earlier of their resignation or removal. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are no family
relationships among any of our directors and executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Classified Board of Directors </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In accordance with our amended and restated certificate of incorporation, which will be in effect prior to the consummation of this offering, our board of directors
will be divided into three classes of directors. At each annual meeting of stockholders, a class of directors will be elected for a <FONT STYLE="white-space:nowrap">three-year</FONT> term to succeed the class whose terms
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">142 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
are then expiring, to serve from the time of election and qualification until the third annual meeting following their election or until their earlier death, resignation or removal. Upon the
closing of this offering, our directors will be divided among the three classes as follows: </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Class&nbsp;I directors will be Drs. Mackay and Parmar and Ms.
Soteropoulos, and their terms will expire at our 2022 annual meeting of stockholders. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Class&nbsp;II directors will be Ms. Boudreau and Drs. Iancovici and
Shannon, and their terms will expire at our 2023 annual meeting of stockholders. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Class&nbsp;III directors will be Dr. Hopfner and Mr. Hunt, and their terms
will expire at our 2024 annual meeting of stockholders. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation for the Corporation will provide that the
authorized number of directors may be changed only by resolution of our board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as
possible, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. The division of our board of directors into three classes with staggered <FONT STYLE="white-space:nowrap">three-year</FONT> terms may delay or
prevent a change of our management or a change in control. See the section of this prospectus captioned &#147;Description of Capital <FONT STYLE="white-space:nowrap">Stock&#151;Anti-takeover</FONT> Effects of Our Amended and Restated Certificate of
Incorporation and Bylaws&#148; for a discussion of these and other <FONT STYLE="white-space:nowrap">anti-takeover</FONT> provisions found in our amended and restated certificate of incorporation and amended and restated bylaws, which will be in
effect prior to the consummation of this offering. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Director Independence </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the rules of the Nasdaq Stock Market, independent directors must comprise a majority of a listed company&#146;s board of directors within one year of the
completion of its initial public offering. In addition, the rules of the Nasdaq Stock Market require that, subject to specified exceptions, each member of a listed company&#146;s audit and compensation committees be independent and that director
nominees be selected or recommended for the board&#146;s selection by independent directors constituting a majority of the independent directors or by a nominating and corporate governance committee comprised solely of independent directors. Under
the rules of the Nasdaq Stock Market, a director will only qualify as &#147;independent&#148; if, in the opinion of that company&#146;s board of directors, that person does not have a relationship that would interfere with the exercise of
independent judgment in carrying out the responsibilities of a director and that such person is &#147;independent&#148; as defined under the rules of the Nasdaq Stock Market and the rules under the Securities Exchange Act of 1934, as amended, or the
Exchange Act. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Audit committee members must also satisfy the independence criteria set forth in <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3</FONT> under the
Exchange Act. In order to be considered independent for purposes of <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3,</FONT> a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit
committee, the board of directors or any other board committee: (1)&nbsp;accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries or (2)&nbsp;be an affiliated person of the
listed company or any of its subsidiaries. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based upon information requested from and provided by each director concerning his or her background, employment and
affiliations, including family relationships, our board of directors has determined that each of our directors, with the exception of Dr.&nbsp;Martin&nbsp;W. Mackay , is an &#147;independent director&#148; as defined under applicable rules of the
Nasdaq Stock Market, including, in the case of all the members of our audit committee, the independence criteria set forth in <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3</FONT> under the Exchange Act, and in the case of all the members of our
compensation committee, the independence criteria set forth in <FONT STYLE="white-space:nowrap">Rule&nbsp;10C-1</FONT> under the Exchange Act and are <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> directors&#148; as defined in <FONT
STYLE="white-space:nowrap">Section&nbsp;16b-3</FONT> of the Exchange Act. In making such determination, our board of directors considered the relationships that each such <FONT STYLE="white-space:nowrap">non-employee</FONT> director has with our
Company and all other facts and circumstances that our board of directors deemed relevant in determining his or her independence, including the beneficial ownership of our capital stock by each <FONT STYLE="white-space:nowrap">non-employee</FONT>
director. Dr.&nbsp;Martin&nbsp;W. Mackay is not an independent director under these rules because he is our Chief Executive Officer. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Board Committees
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee, each of which will
operate pursuant to a charter adopted by our board of directors that will become effective prior to the consummation of this offering. Our board of directors may also establish other committees from time to time to assist us and the board of
directors in their duties. Upon the effectiveness of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">143 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
registration statement of which this prospectus forms&nbsp;a part, the composition and functioning of all of our committees will comply with all applicable requirements of the <FONT
STYLE="white-space:nowrap">Sarbanes-Oxley</FONT> Act, the Nasdaq Stock Market and the Exchange Act. Upon our listing on the Nasdaq Global Market, each committee&#146;s charter will be available on the corporate governance section of our website at
www.rallybio.com. Information contained on our website is not incorporated by reference into this prospectus, and you should not consider information contained on our website to be part of this prospectus or in deciding whether to purchase shares of
our common stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The audit committee&#146;s
responsibilities upon completion of this offering will include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">appointing, approving the compensation of, and evaluating the qualifications, performance and independence of, our
independent registered public accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing the work of our independent registered public accounting firm, including through the receipt and consideration
of reports from such firm; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> all audit and permitted
<FONT STYLE="white-space:nowrap">non-audit</FONT> services to be performed by our independent registered public accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly
financial statements and related disclosures, including earnings releases; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and discussing with management and our independent registered public accounting firm any material issues
regarding accounting principles and financial statement presentations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing disclosures about any significant deficiencies or material weaknesses in our internal controls, including
disclosures in our annual and quarterly reports; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">coordinating our board of directors&#146; oversight of our internal control over financial reporting, disclosure controls
and procedures, code of business conduct and ethics, procedures for complaints and legal and regulatory matters; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">discussing our risk management policies with management; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing practices and guidance regarding hiring employees from our independent registered public accounting firm and
procedures for the receipt and retention of accounting related complaints and concerns; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">meeting independently with our independent registered public accounting firm and management; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and approving any related person transactions in accordance with Company policy; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing our guidelines and policies governing risk assessment and risk management; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing the integrity of our information technology systems, process and data; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">preparing the audit committee report required by SEC rules; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and assessing, at least annually, the adequacy of the audit committee&#146;s charter; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">performing, at least annually, an evaluation of the performance of the audit committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All audit services and all <FONT STYLE="white-space:nowrap">non-audit</FONT> services, other than de minimis <FONT STYLE="white-space:nowrap">non-audit</FONT> services,
to be provided to us by our independent registered public accounting firm must be approved in advance by our audit committee. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The members of our audit
committee are Ms. Boudreau, Dr. Hopfner and Mr. Hunt. Ms. Boudreau chairs the audit committee. Our board of directors has determined that each member of our audit committee has sufficient knowledge in financial and auditing matters to serve on the
audit committee. Our board of directors has also determined that Ms. Boudreau is an &#147;audit committee financial expert,&#148; as defined under Item&nbsp;407 of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K.</FONT> </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to satisfy the member independence requirements for the audit committee prior to the end of the transition period provided under the rules of the Nasdaq Stock
Market and SEC rules and regulations for companies completing their initial public offering. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our compensation committee&#146;s responsibilities upon completion of this offering will include: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing our overall management compensation strategy, including base salary, incentive compensation and <FONT
STYLE="white-space:nowrap">equity-based</FONT> grants; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">144 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and approving corporate goals and objectives relevant to compensation of our chief executive officer and other
executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recommending to our board of directors the compensation of our chief executive officer and other executive officers;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and making recommendations to the board of directors with respect to
<FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing and administering our cash and equity incentive plans; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing, considering and selecting, to the extent determined to be advisable, a peer group of appropriate companies for
purposing of benchmarking and analysis of compensation for our executive officers and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recommending to our board of directors any stock ownership guidelines for our executive officers and <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">retaining, appointing or obtaining advice of a compensation consultant, legal counsel or other advisor and determining the
compensation and independence of such consultant or advisor; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">preparing, if required, the compensation committee report on executive compensation for inclusion in our annual report on
Form <FONT STYLE="white-space:nowrap">10-K</FONT> and our annual proxy statement in accordance with SEC proxy and disclosure rules; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">monitoring our compliance with the requirements of <FONT STYLE="white-space:nowrap">Sarbanes-Oxley</FONT> relating to
loans to directors and officers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and approving all employment contract and other compensation, severance and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">change-in-control</FONT></FONT> arrangements for our executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing and periodically reviewing policies and procedures with respect to perquisites as they relate to our
executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing the risks associated with our compensation policies and practices; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing and presenting to our board of directors management&#146;s plans for succession to senior management positions
based on guidelines developed and recommended by the compensation committee to the full board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and overseeing the Company&#146;s strategies, initiatives and programs with respect to the Company&#146;s
management of human capital resources, including talent management, employee engagement and diversity and inclusion; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and assessing, at least annually, the adequacy of the compensation committee&#146;s charter; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">performing, on an annual basis, an evaluation of the performance of the compensation committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The members of our compensation committee are Drs. Iancovici and Shannon and Ms. Soteropolous. Dr. Shannon chairs the compensation committee. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Nominating and Corporate Governance Committee </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our nominating and
corporate governance committee&#146;s responsibilities upon completion of this offering will include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">identifying individuals qualified to become members of our board of directors consistent with criteria approved by the
board and receiving nominations for such qualified individuals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recommending to our board of directors the persons to be nominated for election as directors and to each committee of the
board; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing a policy under which our stockholders may recommend a candidate to the nominating and corporate governance
committee for consideration for nomination as a director; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and recommending committee slates on an annual basis; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recommending to our board of directors qualified candidates to fill vacancies on our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developing and recommending to our board of directors a set of corporate governance principles applicable to us and
reviewing the principles on at least an annual basis; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and making recommendations to our board with respect to our board leadership structure and board committee
structure; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">145 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing, in concert with our board of directors, our policies and program with respect to significant issues of
corporate public responsibility; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">making recommendations to our board of directors processes for annual evaluations of the performance of our board of
directors and committees of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing the process for annual evaluations of our board of directors and committees of our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">considering and reporting to our board of directors any questions of possible conflicts of interest of members of our
board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing with management the company&#146;s social corporate responsibility activities, policies, and program;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">providing new director orientation and continuing education for existing directors on a periodic basis;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing plans for director succession; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and assessing, at least annually, the adequacy of the nominating and corporate governance committee&#146;s
charter; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and overseeing the Company&#146;s initiatives regarding environmental, social and governance matters, including
related risks and opportunities, and the Company&#146;s public disclosure with respect to such matters; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">performing, on an annual basis, an evaluation of the performance of the nominating and corporate governance committee.
</P></TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The members of our nominating and corporate governance committee are Drs. Hopfner and Parmar and Mr.&nbsp;Hunt. Dr. Parmar chairs the
nominating and corporate governance committee. Our board of directors has determined that each member of the nominating and corporate governance committee satisfies the independence standards of the applicable rules of the Nasdaq Stock Market. </P>
 <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors may establish other committees from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Role of the Board in Risk Oversight </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors has, and, upon
the completion of this offering, its committees will also have, an active role in overseeing the management of our risks. Our board of directors is responsible for general oversight of risks and regular review of information regarding our risks,
including credit risks, liquidity risks and operational risks. The compensation committee will be responsible for overseeing the management of risks relating to our executive compensation plans and arrangements. The audit committee will be
responsible for overseeing the management of risks relating to accounting matters and financial reporting. The nominating and governance committee will be responsible for overseeing the management of risks associated with the independence of our
board of directors and potential conflicts of interest. Although each committee will be responsible for evaluating certain risks and overseeing the management of such risks, the entire board of directors will be regularly informed through
discussions from committee members about such risks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to the closing of this offering, we will adopt a written code of business conduct and ethics that applies to our directors, officers and employees, including our
principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions, which will become effective upon the effectiveness of the registration statement of which this prospectus
forms&nbsp;a part. Following this offering, a current copy of the code will be posted on the investor section of our website. In addition, we intend to post on our website all disclosures that are required by law or Nasdaq Stock Market rules
concerning any amendments to, or waivers from, any provision of the code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">146 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_13"></A>EXECUTIVE AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>The following discussion and analysis of compensation arrangements should be read with the compensation tables and related disclosures set forth below. This
discussion contains forward looking statements that are based on our current plans and expectations regarding future compensation programs. The compensation programs that we adopt in the future may differ materially from the programs summarized in
this discussion. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Introduction </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This section provides an overview of
the compensation awarded to, earned by, or paid to our principal executive officer and our next two most highly compensated executive officers listed below in respect of their service to us for the fiscal year ended December&nbsp;31, 2020. We refer
to these individuals as our named executive officers. Our named executive officers are: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Martin W. Mackay, Ph.D., Chief Executive Officer and Chairman; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Stephen Uden, M.D., President, Chief Operating Officer and Chief Scientific Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Jeffrey M. Fryer, Chief Financial Officer and Treasurer. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, the board of managers of Rallybio Holdings, LLC, or the LLC Entity (referred to as our board of managers for purposes of this executive and
director compensation discussion), was responsible for determining the compensation of our executive officers, based on recommendations from the compensation committee of our board of managers. Following this offering, the compensation committee of
the board of directors of Rallybio Corporation, or the Corporation (referred to as our board of directors for purposes of this executive and director compensation discussion), will be responsible for making such determinations. Drs. Mackay and Uden,
and Mr.&nbsp;Fryer are our founders and, since our inception, have received identical compensation. Following this offering, the compensation committee may make similar recommendations regarding the compensation payable to our founders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Summary compensation table </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the compensation
awarded to, earned by, or paid to our named executive officers in respect of their service to us for the fiscal year ended December&nbsp;31, 2020: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME AND PRINCIPAL POSITION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SALARY</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>STOCK<BR>AWARDS</B><br><B>($) <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NONEQUITY<BR>INCENTIVE&nbsp;PLAN<BR>COMPENSATION<BR>($) <SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ALL OTHER<BR>COMPENSATION</B><br><B>($) <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Martin W. Mackay, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">379,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">292,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; font-size:9.5pt; font-family:ARIAL"><I>Chief Executive Officer and Chairman</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stephen Uden, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">379,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">292,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; font-size:9.5pt; font-family:ARIAL"><I>President, Chief Operating Officer and Chief Scientific Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jeffrey M. Fryer, CPA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">379,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">292,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; font-size:9.5pt; font-family:ARIAL"><I>Chief Financial Officer and Treasurer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts shown in this column represent the grant date fair value of incentive units granted to Drs. Mackay and Uden and Mr.&nbsp;Fryer in fiscal year 2020 computed in accordance with FASB ASC Topic 718, excluding
the effect of estimated forfeitures. The assumptions used to value the incentive units for this purpose are set forth in Note 7 to our audited consolidated financial statements included elsewhere in this prospectus. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts shown in this column represent annual bonuses earned with respect to fiscal year 2020 that were paid in February 2021 under our annual bonus program as described below under &#147;Annual Bonuses.&#148;
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts shown in the &#147;All Other Compensation&#148; column reflect SIMPLE IRA matching contributions made by the LLC Entity, described below under &#147;Employee and Retirement Benefits.&#148; </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">147 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Narrative disclosure to summary compensation table </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Agreements with our named executive officers </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Drs. Mackay and
Uden and Mr.&nbsp;Fryer are each party to an amended and restated employment agreement with our operating company subsidiary, Rallybio, LLC, which sets forth the terms and conditions of the executive officer&#146;s employment with us. The material
terms of the agreements are described below. The terms &#147;cause&#148;, &#147;good reason&#148; and &#147;change in control&#148; referred to below are defined in the respective named executive officer&#146;s agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each amended and restated employment agreement provides for an initial annual base salary, subject to review for increase by our board of directors or the compensation
committee. Each amended and restated employment agreement also provides for a target annual bonus equal to 40% of annual base salary, with the actual amount of the bonus payable based upon the achievement of performance goals as determined by our
board of directors or the compensation committee. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Annual base salary </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Effective January&nbsp;1, 2020, the annual base salaries of Drs. Mackay and Uden and Mr.&nbsp;Fryer were increased from $370,000 to $379,500. Effective January&nbsp;1,
2021, the annual base salaries of our named executive officers were increased to $420,000. Effective in connection with this offering, the annual base salaries of our named executive officers will be increased to $470,000. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Annual bonuses </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">With respect to fiscal year 2020, each of Drs. Mackay
and Uden and Mr.&nbsp;Fryer was eligible to receive an annual bonus. For fiscal year 2020, the target bonus amount, expressed as a percentage of annual base salary, for each of Drs. Mackay and Uden and Mr.&nbsp;Fryer was 40%. Annual bonuses for
fiscal year 2020 for our named executive officers were based on the attainment of <FONT STYLE="white-space:nowrap">pre-established</FONT> corporate objectives as determined by our board of managers, including those related to building a world-class
team, business development, expanding the LLC Entity&#146;s pipeline, financing, and developmental and clinical goals. Following the end of fiscal year 2020, our board of managers determined that the performance goals were met at target and each of
Drs. Mackay and Uden and Mr.&nbsp;Fryer earned a bonus of $151,800. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Severance upon termination of employment; change in control; restrictive covenants.
</I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Employment Agreements</I>. Each of Drs. Mackay and Uden and Mr.&nbsp;Fryer is entitled to severance payments and benefits in connection with certain
qualifying terminations of employment under his respective amended and restated employment agreement. If the executive officer&#146;s employment is terminated by us without cause, as a result of our
<FONT STYLE="white-space:nowrap">non-extension</FONT> of the employment term or by him for good reason, he will be entitled to receive (i)&nbsp;any earned and payable, but unpaid, prior year annual bonus (or current year bonus if the termination
occurs on the last day of the calendar year), (ii) continued payment of his annual base salary for a period of 12 months following termination and (iii) subject to his timely election of COBRA coverage, payment of a monthly amount equal to the
monthly health premiums paid by us on behalf of the executive officer and his eligible dependents for 12 months following termination (or, if earlier until the executive officer ceases to be eligible for COBRA coverage or obtains health coverage
from another employer). If the executive officer&#146;s employment is terminated by reason of his death or disability, he will be entitled to receive (i)&nbsp;any earned and payable, but unpaid, prior year annual bonus (or current year bonus if the
terminaton occurs on the last day of the calendar year) and (ii)&nbsp;continued payment of his annual base salary for a period of six months following termination. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the executive officer&#146;s employment is terminated by us without cause, as a result of our non-extension of the employment term or by him for good reason, in any
event within the 12-month period following a change in control, he will be entitled to receive (i) any earned and payable, but unpaid, prior year annual bonus (or current year bonus if the termination occurs on the last day of the calendar year),
(ii) an amount equal to 1.5 times the sum of the executive officer&#146;s annual base salary and target annual bonus, payable over 18 months following termination and (iii) subject to his timely election of COBRA coverage, payment of a monthly
amount equal to the monthly health premiums paid by us on behalf of the executive officer and his eligible dependents for 18 months following termination (or, if earlier until the executive officer ceases to be eligible for COBRA coverage or obtains
health coverage from another employer). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">148 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Severance Subject to Release of Claims</I>. Our obligation to provide a named executive officer with severance
payments and other benefits under his respective amended and restated employment agreement is conditioned on the executive officer signing a release of claims in favor of us. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Restrictive Covenants</I>. Under their respective amended and restated employment agreements, each of Drs. Mackay and Uden and Mr.&nbsp;Fryer has agreed not to
compete with us during his employment and for one year following his termination of employment or solicit our customers, employees, representatives, agents, vendors, joint venturers or licensors during his employment and for one year following his
termination of employment. In addition, each named executive officer has agreed to a perpetual <FONT STYLE="white-space:nowrap">non-disparagement</FONT> covenant. Each of Drs. Mackay and Uden and Mr. Fryer is also party to a Confidential Information
and Invention Assignment Agreement under which each executive officer has agreed to a perpetual confidentiality covenant and an assignment of intellectual property covenant. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Equity compensation </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Drs. Mackay and Uden and Mr.&nbsp;Fryer received incentive equity grants in fiscal year 2020 under the 2018 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On July&nbsp;31, 2020, each of Drs. Mackay and Uden and Mr.&nbsp;Fryer was granted an award of 665,000 incentive units, which vested as to 25% of the underlying units
on April&nbsp;1, 2021 and vest in 36 equal monthly installments thereafter, generally subject to the executive officer&#146;s continued employment with us through the applicable vesting date. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In January 2021, each of our named executive officers received an award of 2,255,000 incentive units under the 2018 Plan, which vest as to 25% of the underlying units
on January&nbsp;1, 2022 and in 36 equal monthly installments thereafter, generally subject to the executive officer&#146;s continued employment with us through the applicable vesting date. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the liquidation of the LLC Entity and the distribution of the capital stock of the Corporation to the unitholders of the LLC Entity as described
above under the section of this prospectus captioned &#147;The Reorganization&#148;, all vested and unvested common units and incentive units, including those held by our named executive officers, will be canceled and shares of our common stock will
be distributed in respect of such units. Our named executive officers will receive unrestricted shares of our common stock in respect of any vested common units and incentive units that are so canceled and will receive restricted shares of our
common stock under the 2021 Plan (described below) in respect of any unvested restricted common units and incentive units that are so canceled. The restricted shares of our common stock will be subject to the same vesting conditions as the unvested
restricted common units and incentive units. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Employee and retirement benefits </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently provide broad-based health and welfare benefits that are available to all of our employees, including our named executive officers, including health, life
and AD&amp;D, disability, vision, and dental insurance. In addition, we maintain a SIMPLE IRA retirement plan for our full-time employees. The SIMPLE IRA plan provides that we will make matching employer contributions to the SIMPLE IRA plan equal to
up to 3% of eligible compensation contributed to the plan by an eligible employee for the applicable year (subject to tax code limits). Other than the SIMPLE IRA plan, we do not provide any qualified or
<FONT STYLE="white-space:nowrap">non-qualified</FONT> retirement or deferred compensation benefits to our employees, including our named executive officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">149 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Outstanding awards at fiscal <FONT STYLE="white-space:nowrap">year-end</FONT> 2020 </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth information concerning outstanding equity awards held by each of our named executive officers as of December&nbsp;31, 2020: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>STOCK AWARDS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF<BR>UNITS&nbsp;THAT&nbsp;HAVE<BR>NOT VESTED</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MARKET&nbsp;VALUE<BR>OF UNITS THAT<BR>HAVE NOT<BR>VESTED</B><br><B>($)&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Martin W. Mackay, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">562,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">665,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Steve Uden, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">562,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">665,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jeffrey M. Fryer, CPA<SUP STYLE="font-size:85%; vertical-align:top"> (5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">562,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">665,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Because the LLC Entity was not publicly traded during fiscal year 2020, there is no ascertainable public market value for these units. The market value reported in this table is based upon our board of manager&#146;s
determination of the fair market value of the LLC Entity&#146;s equity, $0.47 per common unit, which was determined taking into account an independent valuation as of January 1, 2021, the closest valuation date to fiscal <FONT
STYLE="white-space:nowrap">year-end.</FONT> Where applicable, the fair market value of an incentive unit included in this table reflects the value of a common unit less any unsatisfied distribution threshold. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents an award of 1,499,999 restricted common units of the LLC Entity issued on April&nbsp;19, 2018 pursuant to a contribution and restricted share agreement with each named executive officer, which vested as to
25% of the common units on the date of grant and vests as to the remaining common units in four equal installments on each of April&nbsp;20, 2019, April&nbsp;20, 2020, April&nbsp;20, 2021 and April&nbsp;20, 2022, generally subject to the executive
officer&#146;s continued employment with us through the applicable vesting date. </TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents an award of 400,000 restricted common units of the LLC Entity granted on April&nbsp;19, 2018 under the 2018 Plan, which became eligible to vest upon the initiation of a clinical program through one of our
affiliates, on September&nbsp;12, 2019. Twenty-five percent of the underlying common units vested on September&nbsp;12, 2020, and the remaining common units vest in 36 equal monthly installments thereafter, generally subject to the executive
officer&#146;s continued employment with us through the applicable vesting date. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents an award of 665,000 incentive units of the LLC Entity granted on July&nbsp;31, 2020 under the 2018 Plan, which vested as to 25% of the underlying units on April&nbsp;1, 2021 and vests in 36 equal monthly
installments thereafter, generally subject to the executive officer&#146;s continued employment with us through the applicable vesting date. </TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Fryer&#146;s grants are held by a revocable trust. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director compensation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the compensation awarded to, earned by or paid to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors during the fiscal
year ended December&nbsp;31, 2020. Dr.&nbsp;Mackay does not receive compensation for his service as a director. His compensation for 2020 is included with that of our other named executive officers above. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FEES&nbsp;EARNED&nbsp;OR<BR>PAID IN CASH</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>STOCK<BR>AWARDS</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top"> (2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Helen M. Boudreau</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Rob Hopfner, R.Ph., Ph.D.<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ronald Hunt<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lucian Iancovici, M.D. <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Kush M. Parmar, M.D., Ph.D. <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ketan Patel, M.D. <SUP STYLE="font-size:85%; vertical-align:top">(3)(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Timothy M. Shannon, M.D. <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Paula Soteropoulos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported in this column represent cash fees earned in fiscal year 2020. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">150 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported in this column represent the grant date fair value of incentive units granted to Mses. Boudreau and Soteropoulos computed in accordance with FASB ASC Topic 718, excluding the effect of estimated
forfeitures. The assumptions used to value the incentive units for this purpose are set forth in Note 7 to our audited consolidated financial statements included elsewhere in this prospectus. As of December&nbsp;31, 2020, Ms.&nbsp;Boudreau and
Ms.&nbsp;Soteropoulos held 12,115 and 8,077 vested incentive units of the LLC Entity, respectively. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Directors who are affiliated with our investors did not receive compensation in respect of their service as members of our board of managers in 2020. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Patel resigned from our board of managers effective January&nbsp;30, 2021. </TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Director compensation
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At the time each of Ms.&nbsp;Boudreau and Ms.&nbsp;Soterpoulos was appointed to our board of managers, we agreed to pay each of them a cash retainer of
$35,000 for board service and Ms.&nbsp;Boudreau a cash retainer of $5,000 for service as chair of the audit committee, and to provide each of them a grant of incentive units, as reported in the table above. The incentive units vest in 48 equal
monthly installments, generally subject to the director&#146;s continued service through the applicable vesting date. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Director compensation policy
</I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with this offering, we adopted a <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy for members of our
board of directors, which will become effective upon the completion of this offering. Under the&nbsp;non-employee director compensation policy, following this offering our&nbsp;non-employee&nbsp;directors will be compensated as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each&nbsp;non-employee&nbsp;director will receive an annual cash fee of $35,000 ($65,000 for the chair of our board of
directors and $50,000 for the lead independent director, if applicable); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each&nbsp;non-employee&nbsp;director who is a member of the audit committee will receive an additional annual cash fee of
$7,500 ($15,000 for the audit committee chair); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each&nbsp;non-employee&nbsp;director who is a member of our compensation committee will receive an additional annual cash
fee of $5,000 ($10,000 for our compensation committee chair); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each&nbsp;non-employee&nbsp;director who is a member of the nominating and governance committee will receive an additional
annual cash fee of $4,000 ($8,000 for the nominating and governance committee chair); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each&nbsp;non-employee&nbsp;director who is first elected or appointed to our board of directors after the completion of
this offering will be granted an option under our 2021 Plan to purchase&nbsp;26,880 shares of our common stock upon his or her initial election to our board of directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each&nbsp;non-employee&nbsp;director will annually be granted an option under our 2021 Plan to purchase 13,440 shares of
our common stock on the date of the first meeting of our board of directors held after the annual meeting of our shareholders, pro-rated for non-employee directors initially elected or appointed to our board of directors during the 12 months
preceding the grant date to reflect the number of months of service during such 12-month period. </P></TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to January&nbsp;1st of any year, a
non-employee director may elect to receive his or her annual cash retainer in the form of an option to purchase shares of our common stock, which is expected to vest in 12 equal monthly installments, on the last day of each month during such
calendar year, subject to the director&#146;s continued service on our board of directors through each applicable vesting date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The stock options granted to
our&nbsp;non-employee&nbsp;directors will have a per share exercise price equal to the closing price of a share of our common stock on the date of grant (or the immediately preceding date on which a closing price was reported if there is no closing
price on the date of grant) and will expire not later than ten years after the date of grant. The stock option granted to a non-employee director upon the&nbsp;non-employee&nbsp;director&#146;s initial election to our board of directors will vest in
three equal annual installments, subject to the director&#146;s continued service on our board of directors through each applicable vesting date. The annual stock options granted to our non-employee directors will vest in full on the earlier of the
first anniversary of the date of grant or the next annual meeting of our shareholders, subject to the director&#146;s continued service on our board of directors. Upon a change in control (as defined in our 2021 Plan (or as such term or similar term
is defined in any successor plan)), each initial stock option and each annual stock option that is then outstanding will vest in full, subject to the director&#146;s continued service on our board of directors through such change in control. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All cash fees will be paid quarterly, in arrears, or upon the earlier resignation or removal of the non-employee director. The amount of each payment will be prorated
for any portion of a calendar quarter that a&nbsp;non-employee </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">151 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
director is not serving on our board of directors, based on the number of calendar days served by such&nbsp;non-employee&nbsp;director. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each&nbsp;non-employee&nbsp;director is entitled to reimbursement for reasonable travel and other expenses incurred in connection with attending meetings of our board
of directors and any committee on which he or she serves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Equity and cash plans </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2018 Share Plan </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2018, our board of managers approved the 2018
Plan. The 2018 Plan has been amended from time to time to increase the aggregate number of common units of the LLC Entity reserved for issuance under the 2018 Plan, and was most recently amended on January&nbsp;20, 2021. The 2018 Plan permits the
grant of options to purchase common units, restricted common units and other awards that are convertible into or otherwise based on common units. Subject to adjustment, the maximum number of common units that may be granted under the 2018 Plan is
22,972,360. As of June 30, 2021, 20,869,704 incentive units and 1,200,000 common and restricted common units were outstanding under the 2018 Plan and 902,656 common units remained available for future issuance. It is anticipated that no further
awards will be made under the 2018 Plan following the completion of this offering. In connection with this offering, we adopted a new omnibus equity plan under which we will grant equity-based awards in connection with or following this offering.
This summary is not a complete description of all provisions of the 2018 Plan and is qualified in its entirety by reference to the 2018 Plan, which is filed as an exhibit to the registration statement of which this prospectus is part. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Plan administration </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of managers administers the 2018 Plan.
Our board of managers has the discretionary authority to grant awards, to construe award agreements and the 2018 Plan, to prescribe, amend and rescind rules and regulations relating to the 2018 Plan, to determine the terms and provisions of the
award agreements and to make all other determinations in the judgment of our board of managers necessary or desirable for the administration of the 2018 Plan. Our board of managers may delegate any or all of its powers to a committee. As used in
this summary, the term &#147;Administrator&#148; refers to our board of managers and its authorized delegates, as applicable. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Eligibility </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our and our affiliates&#146; employees, officers, managers, directors, advisors and consultants are eligible to participate in the 2018 Plan. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Vesting; terms of awards </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Administrator determines the terms and
conditions of all awards granted under the 2018 Plan, including the time or times an award vests or becomes exercisable, the terms on which an award remains exercisable. The Administrator may at any time accelerate the vesting or exercisability of
an award. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Transferability of awards </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except as the Administrator
may otherwise determine, options may not be transferred other than by will or by the laws of descent and distribution or pursuant to a qualified domestic relations order. Common units may not be transferred unless the transfer complies with all
provision of the 2018 Plan and the operating agreement of the LLC Entity. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Effect of certain transactions </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of change of control, as defined in the 2018 Plan, the Administrator may, with respect to outstanding awards, provide for the acceleration of
exercisability or issuance of common units in respect of any award, in full or in part or the <FONT STYLE="white-space:nowrap">cash-out</FONT> of awards. If not accelerated or cashed out, the awards will be assumed or substituted by the successor
company, and to the extent not assumed or substituted, any outstanding option will terminate and awards of common units will be repurchased. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Adjustment
provisions </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If, through or as a result of any recapitalization, reclassification, distribution, common unit split, reverse common unit split, liquidation,
exchange of common units, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination, consolidation or other similar transaction, (i)&nbsp;the outstanding common units are increased, decreased or exchanged for a different number or kind of common
units or other securities or (ii)&nbsp;additional common units or new or different common units or other <FONT STYLE="white-space:nowrap">non-cash</FONT> assets are distributed with respect to such common units or other securities, an appropriate
and proportionate adjustment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">152 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
will be made to (x)&nbsp;the maximum number and kind of common units reserved for issuance under the 2018 Plan, (y)&nbsp;the number and kind of securities underlying awards then outstanding and
(z)&nbsp;the exercise price for each option, without changing the aggregate purchase price as to which such options remain exercisable. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Amendments and
termination </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Administrator may at any time amend the 2018 Plan and may at any time terminate the 2018 Plan as to future grants. However, except as
expressly provided in the 2018 Plan, the Administrator may not alter the terms of the plan so as to adversely affect a participant&#146;s rights under an award without the participant&#146;s consent. Any amendments to the 2018 Plan will be
conditioned on member approval to the extent required. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2021 Compensation plans </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2021 Equity Incentive Plan </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with this offering, our
board of directors adopted the Rallybio Corporation 2021 Equity Incentive Plan, or the 2021 Plan, and, in connection with and following this offering, all equity-based awards will be granted under the 2021 Plan. The following summary describes the
material terms of the 2021 Plan. This summary is not a complete description of all provisions of the 2021 Plan and is qualified in its entirety by reference to the 2021 Plan, which is filed as an exhibit to the registration statement of which this
prospectus is a part. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with this offering, our board of directors granted an option to purchase 13,440 shares of our common stock to each of our
non-employee directors and an option to purchase 160,000 shares of our common stock to each named executive officer and to our Chief Medical Officer, Steven Ryder, M.D. The option granted to each non-employee director will vest as to 100% of the
shares underlying the stock option on the earlier of the one-year anniversary of the date of grant and the next annual meeting of our shareholders that follows the date of grant, subject to the director&#146;s continued service on our board of
directors through the vesting date. The option granted to each named executive officer and Dr. Ryder will vest as to 25% of the shares underlying the stock option on the one-year anniversary of the date of grant and as to the remaining 75% of the
shares underlying the stock option in 36 equal monthly installments thereafter, generally subject to the employee&#146;s continued service through the applicable vesting date. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Administration </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2021 Plan will be administered by our
compensation committee, which will have the discretionary authority to interpret the 2021 Plan and any awards granted under it, determine eligibility for and grant awards, determine the exercise price, base value from which appreciation is measured
or purchase price, if any, applicable to any award, determine, modify, accelerate and waive the terms and conditions of any award, determine the form of settlement of awards, prescribe forms, rules and procedures relating to the 2021 Plan and awards
and otherwise do all things necessary or desirable to carry out the purposes of the 2021 Plan or any award. Our board of directors may at any time act in the capacity of the administrator of the 2021 Plan (including with respect to such matters that
are not delegated to our compensation committee). Our compensation committee (or our board of directors) may delegate such of its duties, powers and responsibilities as it may determine to one or more of its members (or one or more other members of
our board of directors), may delegate the power to grant awards to our officers, to the extent permitted by law, and may delegate to employees and other persons such ministerial tasks as it deems appropriate. As used in this summary, the term
&#147;Administrator&#148; refers to our compensation committee, our board of directors or any authorized delegates, as applicable. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Eligibility </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our employees, directors and consultants are eligible to participate in the 2021 Plan. Eligibility for stock options intended to be incentive stock options, or ISOs, is
limited to our employees or employees of certain affiliates. Eligibility for stock options, other than ISOs, and stock appreciation rights, or SARs, is limited to individuals who are providing direct services to us or certain affiliates on the date
of grant of the award. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Authorized Shares </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to
adjustment as described below, the number of shares of our common stock that may be delivered in satisfaction of awards under the 2021 Plan is 5,440,344 shares, including 2,455,722 shares of our common stock that will be issued in respect of
outstanding unvested restricted common units and outstanding unvested incentive units and 137,189 shares of our common stock were available for issuance under the 2018 Plan. The share pool will automatically increase on January 1st of each year from
2022 to 2031 by the lesser of (i)&nbsp;five percent of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">153 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
number of shares of our common stock outstanding as of such date and (ii)&nbsp;the number of shares of our common stock determined by our board of directors on or prior to such date. Up to
22,989,975 shares may be delivered in satisfaction of ISOs. The number of shares of our common stock delivered in satisfaction of awards under the 2021 Plan will not be reduced by (i)&nbsp;any shares withheld by us in payment of the exercise price
or purchase price of an award or in satisfaction of tax withholding requirements or (ii)&nbsp;any shares underlying any portion of an award that is settled in cash or that expires, becomes unexercisable, terminates or is forfeited to or repurchased
by us without the delivery (or retention, in the case of restricted or unrestricted stock) of shares of our common stock. The number of shares available for delivery under the 2021 Plan will not be increased by any shares that have been delivered
under the 2021 Plan and are subsequently repurchased using proceeds directly attributable to stock option exercises. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Shares that may be delivered under the
2021 Plan may be authorized but unissued shares, treasury shares or previously issued shares acquired by us. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Director Limits </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2021 Plan provides that the aggregate value of all compensation granted or paid to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director with respect to
any calendar year for his or her services as a director during such calendar year may not exceed $750,000 ($1,000,000 for the director&#146;s first year of service on our board of directors) in the aggregate. This limitation does not apply to any
compensation granted or paid for services other than as a director, including as a consultant or advisor to us or one of our subsidiaries. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Types of Awards
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2021 Plan provides for the grant of stock options, SARs, restricted and unrestricted stock and stock units, performance awards and other awards that
are convertible into or otherwise based on our common stock. Dividend equivalents may also be provided in connection with awards under the 2021 Plan. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Stock options and SARs.</I> The Administrator may grant stock options, including ISOs, and SARs. A stock option is a
right entitling the holder to acquire shares of our common stock upon payment of the applicable exercise price. A SAR is a right entitling the holder upon exercise to receive an amount (payable in cash or shares of equivalent value) equal to the
excess of the fair market value of the shares subject to the right over the base value from which appreciation is measured. The exercise price per share of each stock option, and the base value of each SAR, granted under the 2021 Plan will be no
less than 100% of the closing price of a share on the date of grant (or, if no closing price is reported for that date, the closing price on the immediately preceding day on which a closing price is reported) (110% in the case of certain ISOs).
Other than in connection with certain corporate transactions or changes to our capital structure, stock options and SARs granted under the 2021 Plan may not be repriced, amended or substituted for with new stock options or SARs having a lower
exercise price or base value, nor may any consideration be paid upon the cancellation of any stock options or SARs that have a per share exercise or base price greater than the closing price of a share on the date of such cancellation, in each case,
without shareholder approval. Each stock option and SAR will have a maximum term of not more than ten years from the date of grant (or five years, in the case of certain ISOs). </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Restricted and unrestricted stock and stock units.</I> The Administrator may grant awards of stock, stock units,
restricted stock and restricted stock units. A stock unit is an unfunded and unsecured promise, denominated in shares, to deliver shares or cash measured by the value of shares in the future, and a restricted stock unit is a stock unit that is
subject to the satisfaction of specified performance or other vesting conditions. Restricted stock are shares subject to restrictions requiring that they be forfeited, redelivered or offered for sale to us if specified performance or other vesting
conditions are not satisfied. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Performance awards.</I> The Administrator may grant performance awards, which are awards subject to performance vesting
conditions. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Other share-based awards.</I> The Administrator may grant other awards that are convertible into or otherwise based on
shares of our common stock, subject to such terms and conditions as it determines. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>Substitute awards.</I> The Administrator may grant substitute awards in connection with certain corporate transactions,
which may have terms and conditions that are inconsistent with the terms and conditions of the 2021 Plan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">154 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Vesting; Terms of Awards </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Administrator determines the terms and conditions of all awards granted under the 2021 Plan, including the time or times an award vests or becomes exercisable, the
terms and conditions on which an award remains exercisable and the effect of termination of a participant&#146;s employment or service on an award. The Administrator may at any time accelerate the vesting or exercisability of an award. No term of an
award will provide for automatic &#147;reload&#148; grants of additional awards upon the exercise of a stock option or SAR. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Transferability of Awards
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except as the Administrator may otherwise determine, awards may not be transferred other than by will or by the laws of descent and distribution. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Effect of Certain Transactions </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of certain covered
transactions (including a consolidation, merger or similar transaction, a sale of all or substantially all of our assets or shares of our common stock, our dissolution or liquidation or such other corporate transaction as is determined by the
Administrator), the Administrator may, with respect to outstanding awards, provide for (in each case, on such terms and subject to such conditions as it deems appropriate): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The assumption, substitution or continuation of some or all awards (or any portion thereof) by the acquiror or surviving
entity; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The acceleration of exercisability or delivery of shares in respect of any award, in full or in part; and/or
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">A cash payment in respect of some or all awards (or any portion thereof) equal to the difference between the fair market
value of the shares subject to the award and its exercise or base price, if any. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except as the Administrator may otherwise determine, each award
will automatically terminate or be forfeited immediately upon the consummation of the covered transaction, other than awards that are substituted for, assumed or that continue following the covered transaction. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Adjustment Provisions </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of certain corporate
transactions, including a stock dividend, stock split or combination of shares (including a reverse stock split), recapitalization or other change in our capital structure, the Administrator will make appropriate adjustments to the maximum number of
shares that may be delivered under the 2021 Plan and the number and kind of securities subject to, and, if applicable, the exercise or purchase prices (or base values) of, outstanding awards and any other provisions affected by such event. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clawback </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Administrator may provide that any outstanding award,
the proceeds of any award or shares acquired under any award and any other amounts received in respect of any award or shares acquired under any award will be subject to forfeiture and disgorgement to us, with interest and other related earnings, if
the participant to whom the award was granted is not in compliance with any provision of the 2021 Plan or any award or any <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> <FONT
STYLE="white-space:nowrap">no-hire,</FONT> <FONT STYLE="white-space:nowrap">non-disparagement,</FONT> confidentiality, invention assignment or other restrictive covenant, or any company policy that relates to shares of our common stock or that
provides for clawback, or as otherwise required by law or applicable stock exchange listing standards. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Amendments and Termination </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Administrator may at any time amend the 2021 Plan or any outstanding award and may at any time terminate the 2021 Plan as to future grants. However, except as
expressly provided in the 2021 Plan or the applicable award, the Administrator may not alter the terms of an award so as to materially and adversely affect a participant&#146;s rights without the participant&#146;s consent (unless the Administrator
expressly reserved the right to do so in the 2021 Plan or at the time the award was granted). Any amendments to the 2021 Plan will be conditioned on shareholder approval to the extent required by applicable law or stock exchange requirements. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2021 Employee Stock Purchase Plan </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with this
offering, our board of directors adopted the Rallybio Corporation 2021 Employee Stock Purchase Plan, or the ESPP. During any time in which the Administrator (as such term is defined below) determines that the ESPP is not able to satisfy the
requirements of Section 423 of the Code, the ESPP will not be treated as an &#147;employee stock purchase plan&#148; under Section 423, but the Administrator will still be able to grant options to purchase shares of our common stock under the ESPP.
Otherwise, the ESPP is intended to qualify as an &#147;employee </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">155 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
stock purchase plan&#148; under Section&nbsp;423 of the Code. The following summary describes the material terms of the ESPP. This summary is not a complete description of all provisions of the
ESPP and is qualified in its entirety by reference to the ESPP, which is filed as an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Administration </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ESPP will be administered by our compensation
committee, which will have the discretionary authority to interpret the ESPP, determine eligibility under the ESPP, prescribe forms, rules and procedures relating to the ESPP and otherwise do all things necessary or desirable to carry out the
purposes of the ESPP. Our board of directors may at any time act in the capacity of the administrator of the ESPP (including with respect to such matters that are not delegated to our compensation committee). Our compensation committee (or our board
of directors) may delegate to one or more of its members (or one or more members of our board of directors) such of its duties, powers, and responsibilities as it may determine and to employees or other persons as it determines such ministerial
tasks as it deems appropriate. As used in this summary, the term &#147;Administrator&#148; refers to our compensation committee, our board of directors or any authorized delegates, as applicable. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Shares Subject to the ESPP </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to adjustment as described
below, the number of shares of our common stock available for purchase pursuant to the exercise of options under the ESPP is 291,324 shares. The share pool will automatically increase on January 1st of each year from 2022 to 2031 by the least of (i)
one percent of the number of shares of our common stock outstanding as of such date, (ii) 582,648 shares of our common stock and (iii) the number of shares of our common stock determined by our board of directors on or prior to such date (up to a
maximum of 6,117,804 shares in the aggregate). Shares will not be treated as delivered, and will not reduce the number of shares in the aggregate unless and until, and to the extent, they are actually delivered to a participant. If any option
granted under the ESPP expires or terminates for any reason without having been exercised in full or ceases for any reason to be exercisable in whole or in part, the unpurchased shares subject to such option will remain available for purchase under
the ESPP. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Eligibility </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Participation in the ESPP will
generally be limited to our employees and employees of our subsidiaries (i)&nbsp;who have been continuously employed by us or one of our subsidiaries, as applicable, for a period of at least 10 business days as of the first day of an applicable
offering period, (ii)&nbsp;whose customary employment with us or one of our subsidiaries, as applicable, is for more than five months per calendar year, (iii)&nbsp;who customarily work 20 hours or more per week and (iv)&nbsp;who satisfy the
requirements set forth in the ESPP. The Administrator may establish additional or other eligibility requirements, or change the requirements described in this paragraph, to the extent consistent with Section&nbsp;423 of the Code. Any employee who
owns (or is deemed under statutory attribution rules to own) shares possessing five percent or more of the total combined voting power or value of all classes of shares of us or our parent or subsidiaries, if any, will not be eligible to participate
in the ESPP. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>General Terms of Participation </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ESPP allows
eligible employees to purchase shares of our common stock during specified offering periods. Unless otherwise determined by the Administrator, offering periods under the ESPP will be six months in duration and commence on the first business day of
January and July of each year. During each offering period, eligible employees will be granted an option to purchase shares of our common stock on the last business day of the offering period. A participant may purchase a maximum of 5,000 shares
with respect to any offering period (or such other number as the Administrator may prescribe). No participant will be granted an option under the ESPP that permits the participant&#146;s right to purchase shares of our common stock under the ESPP
and under all other employee stock purchase plans of us or our parent or subsidiaries, if any, to accrue at a rate that exceeds $25,000 in fair market value (or such other maximum as may be prescribed by the Code) for each calendar year during which
any option granted to the participant is outstanding at any time, determined in accordance with Section&nbsp;423 of the Code. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The purchase price of each share
issued pursuant to the exercise of an option under the ESPP on an exercise date will be 85% (or such other percentage as specified by the Administrator) of the lesser of: (a)&nbsp;the closing price of a share of our common stock on the date the
option is granted (or, if no closing price is reported for that date, the closing price on the immediately preceding day on which a closing price is reported), which will be the first day of the offering period, and (b)&nbsp;the closing price of a
share of our common stock on the exercise date (or, if no closing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">156 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
price is reported for that date, the closing price on the immediately preceding day on which a closing price is reported), which will be the last business day of the offering period. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Administrator may change the commencement and exercise dates of offering periods, the purchase price, the maximum number of shares that may be purchased with
respect to any offering period, the duration of any offering periods and other terms of the ESPP, in each case, without shareholder approval, except as required by law. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Participants in the ESPP will pay for shares purchased under the ESPP through payroll deductions. Participants may elect to authorize payroll deductions between 1% and
15% of the participant&#146;s eligible compensation each payroll period. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Transfer Restrictions </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For participants who have purchased shares under the ESPP, the Administrator may impose restrictions prohibiting the transfer, sale, pledge or alienation of such
shares, other than by will or by the laws of descent and distribution, for such period as may be determined by the Administrator. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Adjustments </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of a stock dividend, stock split or combination of shares (including a reverse stock split), recapitalization or other change in our capital structure that
constitutes an equity restructuring, the Administrator will make appropriate adjustments to the aggregate number and type of shares available for purchase under the ESPP, the number and type of shares granted under any outstanding options, the
maximum number and type of shares purchasable under any outstanding option and/or the purchase price per share under any outstanding option. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Corporate
Transactions </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of certain covered transactions (including a consolidation, merger or similar transaction, a sale of all or substantially all of
our assets or shares of our common stock, our dissolution or liquidation or such other corporate transaction as is determined by the Administrator), the Administrator may provide that each outstanding option will be assumed, exchanged for a
substitute option or cancelled with the balances of participants&#146; accounts returned, or that the option period will end before the date of the proposed covered transaction. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Amendments and Termination </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Administrator has discretion to amend
the ESPP to any extent and in any manner it may deem advisable, provided that any amendment that would be treated as the adoption of a new plan for purposes of Section&nbsp;423 of the Code will require shareholder approval. The Administrator may
suspend or terminate the ESPP at any time. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2021 Cash Incentive Plan </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with this offering, our board of directors adopted the Rallybio Corporation 2021 Cash Incentive Plan, or the Cash Incentive Plan. Following its adoption,
the Cash Incentive Plan will provide for the grant of cash-based incentive awards to our executive officers and key employees. The following summary describes the material terms of the Cash Incentive Plan. This summary is not a complete description
of all provisions of the Cash Incentive Plan and is qualified in its entirety by reference to the Cash Incentive Plan, which is filed as an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Administration </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Cash Incentive Plan will be administered by our
compensation committee and its delegates, except that our board of directors may at any time administer the Cash Incentive Plan. As used in this summary, the term &#147;Administrator&#148; refers to our compensation committee, our board of directors
or any authorized delegates, as applicable. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Administrator will have the discretionary authority to interpret the Cash Incentive Plan and any awards, determine
eligibility for and grant awards, adjust the performance criterion or criteria applicable to awards, determine, modify or waive the terms and conditions of any award, prescribe forms, rules and procedures relating to the Cash Incentive Plan and
awards and otherwise do all things necessary or desirable to carry out the purposes of the Cash Incentive Plan or any award. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Eligibility and Participation
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Executive officers and key employees of us and our subsidiaries will be eligible to participate in the Cash Incentive Plan and will be selected from time
to time by the Administrator to participate in the Cash Incentive Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">157 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Awards; Performance Criteria </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Awards under the Cash Incentive Plan will be made based on, and subject to achieving, specified criteria established by the Administrator. For each award granted under
the Cash Incentive Plan, the Administrator will establish the performance criteria applicable to the award, the amount or amounts payable if the performance criteria are achieved and such other terms and conditions as the Administrator deems
appropriate. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Payments Under an Award </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A participant will be
entitled to payment under an award only if all conditions to payment have been satisfied in accordance with the Cash Incentive Plan and the terms of the award, except as otherwise determined by the Administrator in accordance with the Cash Incentive
Plan. Following the end of a performance period, the Administrator will determine whether and to what extent the applicable performance criteria have been satisfied and will determine the amount payable under each award. The Administrator has the
discretionary authority to increase or decrease the amount actually paid under any award. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Recovery of Compensation </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Payments in respect of an award will be subject to forfeiture and disgorgement to us if the participant violates a
<FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> confidentiality or other restrictive covenant or to the extent provided in any applicable company policy that provides for forfeiture
or disgorgement, or as otherwise required by law or applicable stock exchange listing standards. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Amendment and Termination </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Administrator may amend the Cash Incentive Plan or any outstanding award for any purpose, and may at any time terminate the Cash Incentive Plan as to any future
grant of awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">158 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_14"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following is a summary of transactions since January&nbsp;5, 2018, the date on which Rallybio, LLC was incorporated, to which we have been a party in which the
amount involved exceeded the lesser of (i) $120,000 or (ii)&nbsp;one percent of the average of our total assets at year end for the last two completed fiscal years, and in which any of our executive officers, directors, promoters or beneficial
holders of more than 5% of our capital stock had or will have a direct or indirect material interest, other than compensation arrangements which are described under the section of this prospectus captioned &#147;Executive and Director
Compensation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2018 Reorganization </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In January 2018, Drs. Mackay
and Uden and Mr.&nbsp;Fryer, collectively the Founders, formed Rallybio, LLC. Each Founder made an initial capital contribution of $300 and each received 3,000,000 common units of Rallybio, LLC. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2018, the Founders formed Rallybio Holdings, LLC, or the LLC Entity, each contributing $1 in exchange for 1 common unit in the LLC Entity. Subsequently, as
part of a reorganization in April 2018, the Founders contributed all of their common units in Rallybio, LLC to the LLC Entity in exchange for common units of the LLC Entity. As a result of their contribution, the Founders were each issued 1,899,999
common units in the LLC Entity, of which 374,999 common units were vested immediately, 1,125,000 common units vest in four equal yearly installments on the anniversary date of the reorganization, and 400,000 common units would begin vesting upon
achieving a clinical development milestone. In September 2019, this clinical development milestone was achieved and 25% of these common units vested on the one year anniversary of the date such milestone was achieved, and the remaining 75% vests in
equal monthly increments over the next <FONT STYLE="white-space:nowrap">thirty-36</FONT> months until fully vested. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Private Placements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> Preferred Units </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2018, we entered into a Series A Preferred Share Purchase Agreement to sell up to 5,999,999 units of Series <FONT STYLE="white-space:nowrap">A-1</FONT>
Redeemable Convertible Preferred Units, or Series <FONT STYLE="white-space:nowrap">A-1</FONT> Units, to investors at a purchase price of $1.00 per unit, and up to 26,956,516 units of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Redeemable
Convertible Preferred Units, or Series <FONT STYLE="white-space:nowrap">A-2</FONT> Units, upon the Company&#146;s achievement of certain milestone events, to investors at a purchase price of $1.15 per unit. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2018, we completed the sale of 5,549,999 shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Units to investors at a purchase price of $1.00 per
unit for an aggregate purchase price of $5,549,999. In addition, we issued an aggregate of 450,000 Series <FONT STYLE="white-space:nowrap">A-1</FONT> Units to the Founders in exchange for their capital contributions of convertible debt totaling
$450,000 owed to the Founders by Rallybio, LLC. The following table summarizes purchases of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> Units by our directors, executive officers and holders of more than 5% of our equity and their
respective affiliates. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME OF UNITHOLDER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACQUISITION<BR>DATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SERIES <FONT STYLE="white-space:nowrap">A-1</FONT><BR>CONVERTIBLE<BR>PREFERRED&nbsp;UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE<BR>PURCHASE&nbsp;PRICE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">5AM Ventures V, L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;20,&nbsp;2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,795,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,795,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Canaan XI L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;20, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,795,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,795,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">New Leaf Ventures III, L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;20, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,795,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,795,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jeffrey M. Fryer Revocable Trust dated April&nbsp;18, 2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;20, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Martin W. Mackay, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;20, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stephen Uden, MD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;20, 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Parmar, a member of our board of directors, is a managing member of 5AM Partners V, LLC, the general partner of 5AM Ventures V, L.P. and, as a result, may be deemed to share voting and investment power with
respect to the shares held by 5AM Ventures V, L.P. 5AM Ventures V, L.P. and its affiliates hold more than 5% of our voting stock prior to this offering. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Shannon, a member of our board of directors, is a manager of Canaan Partners XI LLC, the general partner of Canaan XI L.P. and, as a result, may be deemed to share voting and investment power with respect to
the shares held by Canaan XI L.P. Canaan XI L.P. and its affiliates hold more than 5% of our voting stock prior to this offering. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">159 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Hunt, a member of our board of directors, is a managing director at New Leaf Venture Partners, L.L.C., an entity affiliated with New Leaf Ventures III, L.P. and, as a result, may be deemed to share voting and
investment power with respect to the shares held by New Leaf Ventures III, L.P. New Leaf Ventures III, L.P. and its affiliates hold more than 5% of our voting stock prior to this offering. </TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Series&nbsp;A-2</FONT> Preferred Units </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2019, we completed the sale of 7,826,083 shares of our Series <FONT STYLE="white-space:nowrap">A-2</FONT> Units to investors and 521,740 Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Units to the Founders and employees at a purchase price of $1.15 per unit for an aggregate purchase price of $9,599,996. In July 2019, we completed the sale of 8,695,652 shares of our Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Units to investors at a purchase price of $1.15 per unit for an aggregate purchase price of $10,000,000. In October 2019, we completed the sale of 10,434,781 shares of our Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Units to investors at a purchase price of $1.15 per unit for an aggregate purchase price of $11,999,998. The following table summarizes purchases of our Series <FONT STYLE="white-space:nowrap">A-2</FONT>
Units by our directors, executive officers and holders of more than 5% of our equity and their respective affiliates. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME OF UNITHOLDER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACQUISITION<BR>DATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SERIES <FONT STYLE="white-space:nowrap">A-2</FONT><BR>CONVERTIBLE<BR>PREFERRED<BR>UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE<BR>PURCHASE&nbsp;PRICE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">5AM Ventures V, L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;5,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,538,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,918,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Canaan XI L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;5, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,538,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,918,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">New Leaf Ventures III, L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;5, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,538,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,918,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Mainstar Trst, Cust. FBO Jeffrey M. Fryer R2180643</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;5, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">115,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Martin W. Mackay, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;5, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">115,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stephen Uden, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;5, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">115,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Steven Ryder, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;5, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">115,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">5AM Ventures V, L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;23,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,820,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,243,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Canaan XI L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;23, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,820,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,243,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">New Leaf Ventures III, L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;23, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,820,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,243,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">5AM Ventures V, L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;8,&nbsp;2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,384,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,891,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Canaan XI L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;8, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,384,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,891,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">New Leaf Ventures III, L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;8, 2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,384,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,891,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Parmar, a member of our board of directors, is a managing member of 5AM Partners V, LLC, the general partner of 5AM Ventures V, L.P. and, as a result, may be deemed to share voting and investment power with
respect to the shares held by 5AM Ventures V, L.P. 5AM Ventures V, L.P. and its affiliates hold more than 5% of our voting stock prior to this offering. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Shannon, a member of our board of directors, is a manager of Canaan Partners XI, LLC, the general partner of Canaan XI L.P. and, as a result, may be deemed to share voting and investment power with respect to
the shares held by Canaan XI L.P. Canaan XI L.P. and its affiliates hold more than 5% of our voting stock prior to this offering. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Hunt, a member of our board of directors, is a managing director at New Leaf Venture Partners, L.L.C., an entity affiliated with New Leaf Ventures III, L.P. and, as a result, may be deemed to share voting and
investment power with respect to the shares held by New Leaf Ventures III, L.P. New Leaf Ventures III, L.P. and its affiliates hold more than 5% of our voting stock prior to this offering. </TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Series&nbsp;B Preferred Units </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2020, or the Initial Closing,
we entered into a Series B Preferred Share Purchase Agreement, or the Series B Agreement, to initially sell up to 92,269,898 Series B Preferred Units, or the Series B Units, at a purchase price of $1.4824 per unit. At the Initial Closing, we
completed the sale of 61,457,763 shares of Series B Units to investors at a purchase price of $1.4824 per unit for an aggregate purchase price of $91,104,988. In addition, the Series B Agreement gave us an option to sell up to an additional
27,606,455 Series B Units within 60 days of the Initial Closing. In April 2020, or the Second Closing, we completed the sale of 1,416,621 shares of Series B Units to investors at a purchase price of $1.4824 per unit for an aggregate purchase price
of $2,099,999. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May 2020, or the Final Closing, we completed the sale of 37,402,537 shares of Series B Units to investors at a purchase price of $1.3903 per
unit, or the Updated Purchase Price, for an aggregate purchase price of $51,999,999. To ensure the investors who participated in the Initial Closing and the Second Closing, or the Initial Purchasers, received the benefit of the Updated Purchase
Price, the LLC Entity issued additional Series B Units, for no additional consideration, to the Initial Purchasers such that the number of Series B Units that each Initial Purchaser held as of the Final Closing was increased to the number of Series
B Units that each Initial Purchaser </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">160 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
would have received with the Updated Purchase Price in respect of the aggregate purchase price paid by each investor. The LLC Entity issued an aggregate of 4,072,180 additional Series B Units to
the investors who participated in the Initial Closing, and an aggregate of 93,864 additional Series B Units to the investors who participated in the Second Closing. The following table summarizes purchases of units of our Series B Units by our
directors, executive officers and holders of more than 5% of our equity and their respective affiliates. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME OF UNITHOLDER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACQUISITION<BR>DATE(S)<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SERIES B<BR>CONVERTIBLE<BR>PREFERRED<BR>UNITS<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE<BR>PURCHASE<BR>PRICE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Viking Global Opportunities Illiquid Investments
<FONT STYLE="white-space:nowrap">Sub-Master&nbsp;LP</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">May&nbsp;14,&nbsp;2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,578,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">The Rise Fund Rascal L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">May&nbsp;14, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,385,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with 5AM Ventures<SUP STYLE="font-size:85%; vertical-align:top"> (4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">March&nbsp;27,&nbsp;2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,227,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,999,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pivotal bioVenture Partners Fund I L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">March&nbsp;27, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,789,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Life Sciences Fund VI LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">March&nbsp;27, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,789,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with Tekla Capital Management LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">March&nbsp;27, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,789,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Canaan XI L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">March&nbsp;27, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,315,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,999,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">New Leaf Ventures III, L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">March&nbsp;27, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,157,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Mainstar Trst, Cust. FBO Jeffrey M. Fryer R2180643</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">March&nbsp;27, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">149,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Martin W. Mackay, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">March&nbsp;27, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">149,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stephen Uden, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">March&nbsp;27, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">149,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Steven Ryder, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">March&nbsp;27, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents the date in which the unitholder first acquired Series B Units. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Reflects aggregate ownership of Series B Units, including all Series B Units acquired at the Final Closing, if applicable. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Iancovici, a member of our board of directors, is a Managing Director of TPG Growth, an affiliated entity of The Rise Fund Rascal L.P. Dr. Iancovici has no voting or investment power with respect to the shares
held by The Rise Fund Rascal L.P. The Rise Fund Rascal L.P. holds more than 5% of our voting stock prior to this offering. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Parmar, a member of our board of directors, is a managing member of 5AM Partners V, LLC, the general partner of 5AM Ventures V, L.P. and, as a result, may be deemed to share voting and investment power with
respect to the shares held by 5AM Ventures V, L.P. Dr.&nbsp;Parmar is also a managing partner of 5AM Opportunities I (GP), LLC, the general partner of 5AM Opportunities I, L.P. Entities affiliated with 5AM Ventures, including 5AM Ventures V, L.P.
and 5AM Opportunities I, L.P., collectively hold more than 5% of our voting stock prior to this offering. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Hopfner, a member of our board of directors, is a managing partner at Pivotal bioVenture Partners, an affiliated entity of Pivotal bioVenture Partners Fund I L.P. and, as a result, may be deemed to share voting
and investment power with respect to the shares held by Pivotal bioVenture Partners I L.P. Pivotal bioVenture Partners I L.P. and its affiliates hold more than 5% of our voting stock prior to this offering. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Shannon, a member of our board of directors, is a manager of Canaan Partners XI LLC, the general partner of Canaan XI L.P. and, as a result, may be deemed to share voting and investment power with respect to
the shares held by Canaan XI L.P. Canaan XI L.P. and its affiliates hold more than 5% of our voting stock prior to this offering. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Hunt, a member of our board of directors, is a managing director at New Leaf Venture Partners, L.L.C., an entity affiliated with New Leaf Ventures III, L.P. and, as a result, may be deemed to share voting and
investment power with respect to the shares held by New Leaf Ventures III, L.P. New Leaf Ventures III, L.P. and its affiliates hold more than 5% of our voting stock prior to this offering. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director Affiliations </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Some of our directors are affiliated with and, prior
to the closing of this offering have served on our board of directors as representatives of entities which beneficially own or owned 5% or more of our voting securities, as indicated in the table below: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>DIRECTOR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>AFFILIATED EQUITYHOLDER</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Kush Parmar, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">5AM Ventures V, L.P. and 5AM Opportunities I, L.P.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Timothy M. Shannon, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Canaan XI L.P.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lucian Iancovici, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The Rise Fund Rascal L.P.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ronald Hunt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">New Leaf Ventures III, L.P.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Rob Hopfner, R.Ph., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Pivotal bioVenture Partners Fund I L.P.</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">161 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Operating Agreement </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant
to the terms of our Operating Agreement, we have granted certain unitholders certain information rights and the right to participate in future stock issuances, which rights terminate prior to the consummation of this offering, as well as certain
registration rights. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information regarding these registration rights. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the terms of our Operating Agreement, the following directors were elected to serve as members on our board of directors and, as of the date of this
prospectus, continue to so serve: Mses. Helen M. Boudreau and Paula Soteropoulos, Drs. Rob Hopfner, Lucian Iancovici, Martin W. Mackay, Kush Parmar, Timothy M. Shannon and Mr.&nbsp;Ronald Hunt. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Operating Agreement will terminate prior to the consummation of this offering, and members previously elected to our board of managers pursuant to such agreement
will serve as directors of the Corporation until they resign, are removed or their successors are duly elected by the holders of our common stock. The composition of our board of directors after this offering is described in more detail under
&#147;Management&#151;Composition of the Board of Directors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director and Officer Indemnification and Insurance </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have agreed to indemnify each of our directors and executive officers against certain liabilities, costs and expenses, and have purchased directors&#146; and
officers&#146; liability insurance. We also maintain a general liability insurance policy which covers certain liabilities of directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Related Person Transaction Policy </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors intends to adopt a
written related person transaction policy, to be effective upon the effectiveness of the registration statement of which this prospectus forms&nbsp;a part, setting forth the policies and procedures for the review and approval or ratification of
related person transactions. This policy will cover, with certain exceptions set forth in Item&nbsp;404 of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K</FONT> under the Securities Act of 1933, as amended, or the Securities Act, any
transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we were or are to be a participant, where the amount involved exceeds the lesser of (i) $120,000 or (ii)&nbsp;one percent of the
average of our total assets at year end for the last two completed fiscal years, in any fiscal year and a related person had, has or will have a direct or indirect material interest, including without limitation, purchases of goods or services by or
from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit committee is
tasked with considering all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm&#146;s length transaction and the extent of the related
person&#146;s interest in the transaction. All of the transactions described in this section occurred prior to the adoption of this policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">162 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_15"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth certain information with respect to the beneficial ownership of our common stock at June&nbsp;30, 2021, as adjusted to reflect the sale
of common stock offered by us in this offering, for: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each person who we know beneficially owns more than 5% of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each of our directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each of our named executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">all of our directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The number of shares beneficially owned by each stockholder is determined under rules issued by the SEC. Under these rules, a person is deemed to be a
&#147;beneficial&#148; owner of a security if that person has or shares voting power or investment power, which includes the power to dispose of or to direct the disposition of such security. Except as indicated in the footnotes below, we believe,
based on the information furnished to us, that the individuals and entities named in the table below have sole voting and investment power with respect to all shares of common stock beneficially owned by them, subject to any applicable community
property laws. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ownership of our common stock before this offering is based on 24,999,972 shares of our common stock outstanding as of June 30, 2021, after
giving effect to the Reorganization, including the issuance by the Corporation of an aggregate of 24,999,972 shares of its common stock and the subsequent distribution of those shares to members of the LLC Entity in the Liquidation, prior to the
completion of this offering, as if such distribution had occurred as of June 30, 2021, assuming an initial public offering price of $14.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus. The actual
number of shares of common stock to be received by each holder of units of the LLC Entity is subject to change based on the initial public offering price. See &#147;The Reorganization.&#148; The ownership of our common stock after this offering is
based on 30,749,972 shares of our common stock outstanding as of June 30, 2021, after giving effect to the transactions as described above and our issuance of shares of our common stock in this offering. In computing the number of shares
beneficially owned by an individual or entity and the percentage ownership of that person, shares of common stock subject to options or other rights held by such person that are currently exercisable or that will become exercisable within
60&nbsp;days of June&nbsp;30, 2021 are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person. Unless noted otherwise, the address of all listed
stockholders is 234 Church Street, Suite 1020, New Haven CT, 06510. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">163 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENTAGE OF<BR>SHARES BENEFICIALLY<BR>OWNED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME OF BENEFICIAL OWNER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SHARES<BR>BENEFICIALLY<BR>OWNED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>BEFORE<BR>OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AFTER<BR>OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>5% or greater stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with 5AM Ventures <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,567,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Viking Global Opportunities Illiquid Investments Sub-Master LP <SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,380,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Canaan XI L.P. <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,327,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">The Rise Fund Rascal, L.P. <SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,253,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">New Leaf Ventures III, L.P. <SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,989,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Life Sciences Fund VI LP <SUP
STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,690,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pivotal bioVenture Partners Fund I L.P. <SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,690,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Tekla Capital Management LLC <SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,690,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Directors and Named Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Martin W. Mackay, Ph.D. <SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Helen M. Boudreau</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Rob Hopfner, R.Ph., Ph.D. <SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,690,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ronald M. Hunt <SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,989,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lucian Iancovici, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Kush M. Parmar, M.D., Ph.D. <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,567,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Timothy M. Shannon, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Paula Soteropoulos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jeffrey M. Fryer, CPA <SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stephen Uden, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">All executive officers and directors as a group (11 persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,610,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Less than 1% </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 281,395 shares of common stock to be received in the Reorganization in respect of shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred units held by 5AM Ventures V, L.P.; (ii) 1,369,829
shares of common stock to be received in the Reorganization in respect of shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred units held by 5AM Ventures V, L.P.; (iii) 1,126,992 shares of common stock to be received in the
Reorganization in respect of shares of Series B preferred units held by 5AM Ventures V, L.P and (iv) 788,894 shares of common stock to be received in the Reorganization in respect of shares of Series B preferred units held by 5AM Opportunities I,
L.P. 5AM Partners V, LLC is the general partner of 5AM Ventures V, L.P. and may be deemed to have sole investment and voting power over the shares held by 5AM Ventures V, L.P. Dr.&nbsp;Kush Parmar is a managing member of 5AM Partners V, LLC, and may
be deemed to share voting and dispositive power over the shares held by 5AM Ventures V, L.P. 5AM Opportunities I (GP), LLC is the general partner of 5AM Opportunities I, L.P. and may be deemed to have sole investment and voting power over the shares
held by 5AM Opportunities I, L.P. Dr.&nbsp;Parmar is a managing member of 5AM Opportunities I (GP), LLC, and may be deemed to share voting and dispositive power over the shares held by 5AM Opportunities I, L.P. Dr.&nbsp;Parmar is also a member of
our board of directors. The address of the above persons and entities is 501 2nd Street, Suite 350, San Francisco, California 94107. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 3,380,977 shares of common stock to be received in the Reorganization in respect of shares of Series B preferred units held by Viking Global Opportunities Illiquid Investments
<FONT STYLE="white-space:nowrap">Sub-Master</FONT> LP, or the Opportunities Fund. The Opportunities Fund has the authority to dispose of and vote the shares directly owned by it, which power may be exercised by its general partner, Viking Global
Opportunities Portfolio GP LLC, or the Opportunities GP, and by Viking Global Investors LP, which provides managerial services to the Opportunities Fund. O. Andreas Halvorsen, David C. Ott and Rose Shabet, as Executive Committee members of Viking
Global Partners LLC (the general partner of VGI) and Viking Global Opportunities GP LLC, the sole member of Opportunities GP, have shared authority to direct the voting and disposition of investments beneficially owned by VGI and Opportunities GP.
The address of the above entities is c/o Viking Global Opportunities Illiquid Investments <FONT STYLE="white-space:nowrap">Sub-Master</FONT> LP, 280 Park Avenue, New York, New York 10017. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 281,395 shares of common stock to be received in the Reorganization in respect of shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred units held by Canaan XI L.P.; (ii) 1,369,829
shares of common stock to be received in the Reorganization in respect of shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred units held by Canaan XI L.P.; and (iii) 676,195 shares of common stock to be received in the
Reorganization in respect of shares of Series B preferred units held by Canaan XI L.P. Canaan Partners XI LLC is the general partner of Canaan XI, L.P. and may be deemed to have sole investment and voting power over the shares held by Canaan XI,
L.P. Investment, voting and dispositive decisions with respect to the shares held by Canaan XI L.P. are made by the managers of Canaan XI LLC, collectively. Dr.&nbsp;Shannon, a member of our board of directors, is a manager of Canaan Partners XI
LLC. The address of the above person and entity is 2765 Sand Hill Road, Menlo Park, California 94025. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">164 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 2,253,984 shares of common stock to be received in the Reorganization in respect of shares of Series B preferred units held by The Rise Fund Rascal, L.P., a Delaware limited partnership. The general partner
of The Rise Fund Rascal, L.P. is The Rise Fund SPV GP, LLC, a Delaware limited liability company, whose managing member is The Rise Fund GenPar, L.P., a Delaware limited partnership, whose general partner is The Rise Fund GenPar Advisors, LLC, a
Delaware limited liability company, whose sole member is TPG Holdings&nbsp;I, L.P., a Delaware limited partnership, whose general partner is TPG Holdings&nbsp;IA, LLC, a Delaware limited liability company, whose sole member is TPG Group Holdings
(SBS), L.P., a Delaware limited partnership, whose general partner is TPG Group Holdings (SBS) Advisors, LLC, a Delaware limited liability company, whose sole member is TPG Group Holdings (SBS) Advisors, Inc., a Delaware corporation. David Bonderman
and James&nbsp;G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. and may therefore be deemed to beneficially own the securities held by The Rise Fund Rascal, L.P. Messrs.&nbsp;Bonderman and Coulter disclaim beneficial
ownership of the securities held by The Rise Fund Rascal, L.P. except to the extent of their pecuniary interest therein. Dr.&nbsp;Lucian Iancovici, a member of our board of directors, is a Managing Director of TPG Growth, an affiliated entity of The
Rise Fund Rascal, L.P. Dr.&nbsp;Iancovici has no voting or dispositive power over the shares held by The Rise Fund Rascal, L.P. The address of each of The Rise Fund Rascal, L.P., Messrs.&nbsp;Bonderman and Coulter and Dr. Iancovici is
301&nbsp;Commerce Street, Suite 3300, Fort Worth, Texas 76102. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 281,395 shares of common stock to be received in the Reorganization in respect of shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> preferred units held by New Leaf Ventures III, L.P.;
(ii) 1,369,829 shares of common stock to be received in the Reorganization in respect of shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-2</FONT> preferred units held by New Leaf Associates III, L.P.; and (iii) 338,098 shares of common
stock to be received in the Reorganization in respect of shares of Series&nbsp;B preferred units held by New Leaf Ventures&nbsp;III, L.P. New Leaf Venture Management&nbsp;III, L.L.C. is the general partner of New Leaf Associates&nbsp;III, L.P.,
which in turn is the General Partner of New Leaf Ventures&nbsp;III, L.P., and may be deemed to have sole investment and voting power over the shares held by New Leaf Ventures&nbsp;III, L.P. Ronald Hunt is a managing director at New Leaf Venture
Partners, L.L.C. and may be deemed to share voting and dispositive power over the shares held by New Leaf Ventures III, L.P. Mr.&nbsp;Hunt is also a member of our board of directors. The address of the above person and entity is 420&nbsp;Lexington
Avenue, Suite 408, New York, New York 10170. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 1,690,488 shares of common stock to be received in the Reorganization in respect of shares of Series&nbsp;B preferred units held by <FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Life
Sciences Fund&nbsp;VI LP. <FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Life Sciences Advisors Fund&nbsp;VI LP, or <FONT STYLE="white-space:nowrap">F-Prime</FONT> Advisors, is the general partner of
<FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Life Sciences Fund&nbsp;VI LP. <FONT STYLE="white-space:nowrap">F-Prime</FONT> Advisors is solely managed by Impresa Management LLC, the managing member of its general partner and its
investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC. Each of the entities listed above expressly disclaims beneficial ownership of the securities listed above except of any
pecuniary interest therein, if any. The address of the above entities is 245&nbsp;Summer Street, Boston, Massachusetts 02210. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 1,690,488 shares of common stock to be received in the Reorganization in respect of shares of Series B preferred units held by Pivotal bioVenture Partners Fund I, L.P. Pivotal bioVenture Partners Fund I
G.P., L.P. is the general partner of Pivotal bioVenture Partners Fund I, L.P. and may be deemed to have sole investment and voting power over the shares held by Pivotal bioVenture Partners Fund I, L.P. Dr.&nbsp;Rob Hopfner is a managing partner at
Pivotal bioVenture Partners and may be deemed to share voting and dispositive power over the shares held by Pivotal bioVenture Partners Fund I, L.P. Dr.&nbsp;Hopfner is also a member of our board of directors. The principal business address of
Pivotal bioVenture Partners Fund I, L.P. is 501 Second Street, Suite 200, San Francisco, CA 94107. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 777,624 shares of common stock to be received in the Reorganization in respect of shares of Series B preferred units held by Tekla Healthcare Investors, (ii) 563,495 shares of common stock to be received
in the Reorganization in respect of shares of Series B preferred units held by Tekla Healthcare Opportunities Fund and (iii) 349,367 shares of common stock to be received in the Reorganization in respect of shares of Series B preferred units held by
Tekla Life Sciences Investors. Tekla Capital Management LLC, or TCM, is an investment adviser to Tekla Healthcare Investors (NYSE: HQH), Tekla Healthcare Opportunities Fund (NYSE: THQ) and Tekla Life Sciences Investors (NYSE: HQL), collectively
referred to as the Tekla Funds. Daniel R. Omstead, Ph.D., serves as President and Chief Executive Officer of the Tekla Funds. Each of TCM and Daniel R. Omstead, through his control of TCM, has sole power to dispose of the shares beneficially owned
by the Tekla Funds. Neither TCM nor Daniel R. Omstead has the sole power to vote or direct the vote of the shares beneficially owned by the Tekla Funds, which power resides in the Board of Trustees for each Tekla Fund. TCM carries the voting of
shares under written guidelines established by the Board of Trustees. The address for the Tekla Funds is 100 Federal Street, 19th Floor, Boston, Massachusetts 02110. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;277,617 shares held directly by Dr.&nbsp;Mackay and (ii)&nbsp;437,068 shares held directly by a limited liability company, of which Dr.&nbsp;Mackay is the managing member. Dr.&nbsp;Mackay has voting
and dispositive power over such shares, and is deemed to be the beneficial owner of such shares. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;32,573 shares held by Mr.&nbsp;Fryer in a Roth IRA (the &#147;Fryer IRA&#148;), (ii)&nbsp;277,617 held in a revocable trust for which Mr.&nbsp;Fryer is the grantor (the &#147;Fryer Grantor
Trust&#148;) and (iii)&nbsp;an aggregate of 404,494 shares held in two irrevocable trusts for the benefit of Mr.&nbsp;Fryer&#146;s children (the &#147;Fryer Family Trusts&#148;). Mr.&nbsp;Fryer shares voting and dispositive power over the shares
held in the Fryer IRA and Fryer Grantor Trust. Mr.&nbsp;Fryer disclaims beneficial ownership of the shares held in the Fryer Family Trusts. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">165 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_16"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>The following description of our capital stock and provisions of our amended and restated certificate of incorporation and amended and restated bylaws as they will
be in effect prior to the consummation of this offering are summaries and are qualified in their entirety by reference to our amended and restated certificate of incorporation and amended and restated bylaws that will be in effect prior to the
consummation of this offering. Copies of these documents are filed as exhibits to the registration statement of which this prospectus is a part. The description of our common stock reflects the completion of the Reorganization, which will occur
immediately prior to the completion of this offering. See &#147;The Reorganization&#148; for more information concerning the Reorganization. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General
</B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the closing of this offering, our authorized capital stock will consist of 200,000,000 shares of common stock, with a par value of $0.0001 per
share, and 50,000,000 shares of preferred stock, with a par value of $0.0001 per share, all of which preferred stock will be undesignated. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of June 30, 2021,
giving effect to the Reorganization as if it had occurred on such date, assuming an initial public offering price of $14.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and prior to the closing
of this offering, there were 24,999,972 shares of common stock outstanding, held by 51 stockholders of record, and no shares of preferred stock outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Common Stock </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Holders of our common stock are entitled to one vote for each
share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the
election. Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the
future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of our liquidation or dissolution, the holders of common stock are entitled to receive an amount of our net assets available for distribution
to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights. Our outstanding
shares of common stock are, and the shares offered by us in this offering will be, when issued and paid for, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be
adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Preferred Stock
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the terms of our amended and restated certificate of incorporation that will be in effect prior to the consummation of this offering, our board of
directors is authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting
rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The purpose of authorizing our
board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with
possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a <FONT STYLE="white-space:nowrap">third-party</FONT> to acquire, or could discourage a
<FONT STYLE="white-space:nowrap">third-party</FONT> from seeking to acquire, a majority of our outstanding voting stock. Upon the closing of this offering, there will be no shares of preferred stock outstanding, and we have no present plans to issue
any shares of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investor Rights Agreement </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The LLC
Entity is party to an Amended and Restated Investor Rights Agreement with the investors party to our Operating Agreement, or the Investor Rights Agreement. Pursuant to the terms of this agreement, we granted these stockholders certain information
rights and the right to participate in future stock issuances, which rights terminate prior to the consummation of this offering, as well as certain registration rights. Immediately prior to the completion of this offering, we will enter into a
registration rights agreement, described below, with the shareholders of Rallybio Corporation, or the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">166 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following
the Reorganization and prior to the completion of this offering, we will enter into a Registration Rights Agreement with the shareholders of the Corporation, or the Registration Rights Agreement. The Registration Rights Agreement will grant the
parties thereto certain registration rights in respect of the &#147;registrable securities&#148; held by them, which securities include (i)&nbsp;the shares of our common stock held by our shareholders following the Reorganization and prior to the
consummation of this offering and (ii)&nbsp;any common stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or
in replacement of, the shares referenced in clause (i)&nbsp;above. The registration of shares of our common stock pursuant to the exercise of these registration rights would enable the holders thereof to sell such shares without restriction under
the Securities Act when the applicable registration statement is declared effective. Under the Registration Rights Agreement, we will pay all expenses relating to such registrations, including the fees of one counsel for the participating holders,
and the holders will pay all underwriting discounts and commissions relating to the sale of their shares. The Registration Rights Agreement will also include customary indemnification and procedural terms. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Holders of 23,061,474 shares of our common stock (after giving effect to the Reorganization, assuming an initial public offering price of $14.00 per share, which is the
midpoint of the price range set forth on the cover page of this prospectus) will be entitled to such registration rights pursuant to the Registration Rights Agreement. These registration rights will expire on the earlier of (i)&nbsp;such time after
this offering as Rule&nbsp;144 or another similar exemption under the Securities Act is available for the sale of all of such holder&#146;s shares without limitation during a <FONT STYLE="white-space:nowrap">three-month</FONT> period without
registration and (ii)&nbsp;the third anniversary of the consummation of this offering. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At any time beginning 180&nbsp;days after the effectiveness of the registration statement of which this prospectus forms&nbsp;a part, the holders of at least 30% of the
registrable securities then outstanding may request that we file&nbsp;a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> with respect to at least 20% of the registrable securities then outstanding, if the aggregate
offering price of the registrable securities requested to be registered would exceed $20&nbsp;million. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once we are eligible to use a registration statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-3,</FONT> the holders of not less than 25% of the registrable shares then outstanding may request that we file&nbsp;a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> with respect
to such holders&#146; registrable securities then outstanding, if the aggregate offering price of the registrable securities requested to be registered would exceed $3&nbsp;million. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Piggyback Registration Rights </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event that we propose to
register any of our securities under the Securities Act, either for our own account or for the account of other security holders, the stockholders party to the Investor Rights Agreement will be entitled to certain &#147;piggyback&#148; registration
rights allowing them to include their registrable securities in such registration, subject to certain marketing and other limitations. As a result, whenever we propose to file&nbsp;a registration statement under the Securities Act other than with
respect to a demand registration or a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-4</FONT> or <FONT STYLE="white-space:nowrap">S-8,</FONT> these holders will be entitled to notice of the registration and will have the
right to include their registrable securities in the registration subject to certain limitations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Anti-takeover</FONT> Effects
of Our Amended and Restated Certificate of Incorporation and Our Bylaws </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation and amended and restated bylaws,
which will be in effect prior to the consummation of this offering, will contain certain provisions that are intended to enhance the likelihood of continuity and stability in the composition of our board of directors, but which may have the effect
of delaying, deferring or preventing a future takeover or change in control of us unless such takeover or change in control is approved by our board of directors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These provisions include: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Classified board.</I> Our amended and restated
certificate of incorporation will provide that our board of directors will be divided into three classes of directors, with the classes as nearly equal in number as possible. As a result, approximately
<FONT STYLE="white-space:nowrap">one-third</FONT> of our board of directors will be elected each year. The classification of directors will have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">167 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the effect of making it more difficult for stockholders to change the composition of our board of directors. Our amended and restated certificate of incorporation will also provide that, subject
to any rights of holders of preferred stock to elect additional directors under specified circumstances, the number of directors will be fixed exclusively pursuant to a resolution adopted by our board of directors. Upon completion of this offering,
we expect that our board of directors will have eight members. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Action by written consent; special meetings of stockholders.</I> Our amended and restated
certificate of incorporation will provide that stockholder action can be taken only at an annual or special meeting of stockholders and cannot be taken by written consent in lieu of a meeting. Our amended and restated certificate of incorporation
and the bylaws will also provide that, except as otherwise required by law, special meetings of the stockholders can only be called pursuant to a resolution adopted by a majority of our board of directors. Except as described above, stockholders
will not be permitted to call a special meeting or to require our board of directors to call a special meeting. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Removal of directors.</I> Our amended and
restated certificate of incorporation will provide that our directors may be removed only for cause by the affirmative vote of at least 75% of the voting power of our outstanding shares of capital stock, voting together as a single class. This
requirement of a supermajority vote to remove directors could enable a minority of our stockholders to prevent a change in the composition of our board of directors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Advance notice procedures.</I> Our bylaws will establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our
stockholders, including proposed nominations of persons for election to our board of directors. Stockholders at an annual meeting will only be able to consider proposals or nominations specified in the notice of meeting or brought before the meeting
by or at the direction of our board of directors or by a stockholder who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given our Secretary timely written notice, in proper form, of
the stockholder&#146;s intention to bring that business before the meeting. Although the bylaws will not give our board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be
conducted at a special or annual meeting, the bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a
solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Supermajority approval requirements. </I>The DGCL
generally provides that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#146;s certificate of incorporation or bylaws, unless either a corporation&#146;s certificate of incorporation
or bylaws requires a greater percentage. Our amended and restated certificate of incorporation and bylaws will provide that the affirmative vote of holders of at least 75% of the total votes eligible to be cast in the election of directors will be
required to amend, alter, change or repeal specified provisions. This requirement of a supermajority vote to approve amendments to our amended and restated certificate of incorporation and bylaws could enable a minority of our stockholders to
exercise veto power over any such amendments. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Authorized but unissued shares.</I> Our authorized but unissued shares of common stock and preferred stock will be
available for future issuance without stockholder approval. These additional shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital, corporate acquisitions and employee benefit
plans. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult or discourage an attempt to obtain control of a majority of our common stock by means of a proxy contest, tender offer, merger or
otherwise. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Exclusive forum. </I>Our amended and restated certificate of incorporation will provide that, subject to limited exceptions, the state or federal
courts within the State of Delaware will be exclusive forums for (1)&nbsp;any derivative action or proceeding brought on our behalf, (2)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other
employees to us or our stockholders, (3)&nbsp;any action asserting a claim against us arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws, (4)&nbsp;any action to
interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws or (5)&nbsp;any other action asserting a claim against us that is governed by the internal affairs
doctrine; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or to any claim for which the federal courts have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">168 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
exclusive jurisdiction. Our amended and restated certificate of incorporation will also provide that, unless we consent in writing to the selection of an alternative forum, the U.S. federal
district courts shall be the exclusive forum for the resolution of any claims arising under the Securities Act. Although we believe these provisions benefit us by providing increased consistency in the application of Delaware and certain federal
securities law, these provisions may have the effect of discouraging lawsuits against our directors and officers. See &#147;Risk Factors&#151;Risks Related to This Offering and Our Common Stock&#151;Our amended and restated certificate of
incorporation will designate the state or federal courts within the State of Delaware as the exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#146; ability to
obtain a favorable judicial forum for disputes with us or our directors, officers or employees.&#148; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Section&nbsp;203 of the DGCL </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon completion of this offering, we will be subject to the provisions of Section&nbsp;203 of the DGCL. In general, Section&nbsp;203 prohibits a publicly held Delaware
corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a <FONT STYLE="white-space:nowrap">three-year</FONT> period following the time that this stockholder becomes an interested stockholder,
unless the business combination is approved in a prescribed manner. A &#147;business combination&#148; includes, among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder.
An &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or did own within three years prior to the determination of interested stockholder status, 15% or more of the corporation&#146;s voting stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:
before the stockholder became interested, the corporation&#146;s board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; upon consummation of the
transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of
determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances; or at or after the time the stockholder became interested, the business combination was approved by
the board of directors of the corporation and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by
the interested stockholder. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A Delaware corporation may &#147;opt out&#148; of these provisions with an express provision in its original certificate of
incorporation or an express provision in its certificate of incorporation or bylaws resulting from a stockholders&#146; amendment approved by at least a majority of the outstanding voting shares. We have not opted out of these provisions. As a
result, mergers or other takeover or change in control attempts of us may be discouraged or prevented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Listing </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have applied for listing of our common stock on the Nasdaq
Global Market under the symbol &#147;RLYB&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">169 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Immediately prior to this offering, there was no public market for our common stock, and no predictions can be made about the effect, if any, that market sales of our
common stock or the availability of such shares for sale will have on the market price prevailing from time to time. Nevertheless, future sales of our common stock in the public market, or the perception that such sales may occur, could adversely
affect the market price of our common stock and could impair our ability to raise capital through future sales of our securities. See &#147;Risk Factors&#151;Risks Related to This Offering and Our Common Stock&#151;A significant portion of our total
outstanding shares is restricted from immediate resale but may be sold into the market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing well.&#148; Furthermore,
although we have applied for listing of our common stock on the Nasdaq Global Market, we cannot assure you that there will be an active public trading market for our common stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the closing of this offering, based on 24,999,972 shares of our common stock outstanding as of June 30, 2021, giving effect to the Reorganization as if it had
occurred on such date, assuming an initial public offering price of $14.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, we will have an aggregate of 30,749,972 shares of our common stock
outstanding (or 31,612,472 shares of our common stock if the underwriters exercise in full their option to purchase additional shares). Of these shares of our common stock, all of the 5,750,000 shares sold in this offering (or 6,612,500 shares if
the underwriters exercise in full their option to purchase additional shares) will be freely tradable without restriction or further registration under the Securities Act, except for any shares purchased by our &#147;affiliates,&#148; as that term
is defined in Rule&nbsp;144 under the Securities Act, whose sales would be subject to the Rule&nbsp;144 resale restrictions described below, other than the holding period requirement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All remaining shares of common stock held by existing stockholders immediately prior to the completion of this offering will be &#147;restricted securities&#148; as
such term is defined in Rule&nbsp;144. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rules&nbsp;144 or 701 under the
Securities Act, which are summarized below. We expect that substantially all of these shares will be subject to the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period under the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements described below. Upon expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, all of the shares of common stock outstanding immediately prior to this offering and all of the
shares of our common stock offered hereby will be available for sale in the public market, subject in some cases to applicable volume limitations under Rule&nbsp;144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We and each
of our directors and executive officers and holders of all of our outstanding shares of common stock prior to this offering have agreed not to sell or transfer any common stock or securities convertible into, exchangeable for, exercisable for, or
repayable with common stock, for 180&nbsp;days after the date of this prospectus without first obtaining the written consent of Jefferies LLC and Cowen and Company, LLC. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, substantially all of the shares subject to such
<FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions will become eligible for sale, subject to the limitations discussed above. For a further description of these <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, please see
&#147;Underwriting.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After the date of the initial public filing of the prospectus, certain of our employees, including our executive officers, and/or
directors may enter into written trading plans that are intended to comply with <FONT STYLE="white-space:nowrap">Rule&nbsp;10b5-1</FONT> under the Securities Exchange Act. Sales under these trading plans would not be permitted until the expiration
of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements relating to the offering described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule&nbsp;144 </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Affiliate Resales of Restricted Securities </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, beginning
90&nbsp;days after the effective date of the registration statement of which this prospectus is a part, a person who is an affiliate of ours, or who was an affiliate at any time during the 90&nbsp;days before a sale, who has
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">170 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
beneficially owned shares of our common stock for at least six months would be entitled to sell (subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement referred to above, if
applicable) in &#147;broker&#146;s transactions&#148; or certain &#147;riskless principal transactions&#148; or to market makers, a number of shares within any <FONT STYLE="white-space:nowrap">three-month</FONT> period that does not exceed the
greater of: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">1% of the total number of shares then outstanding of our common stock, which will equal approximately 307,500 shares (or
316,125 shares if the underwriters exercise their option to purchase additional shares in full) of our common stock immediately after this offering; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the average weekly trading volume in shares of our common stock on the Nasdaq Global Market during the four calendar weeks
preceding the filing of a notice on Form&nbsp;144 with respect to such sale. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Affiliate resales under Rule&nbsp;144 are also subject to the
availability of current public information about us. In addition, if the number of shares being sold under Rule&nbsp;144 by an affiliate during any <FONT STYLE="white-space:nowrap">three-month</FONT> period exceeds 5,000 shares or has an aggregate
sale price in excess of $50,000, the seller must file&nbsp;a notice on Form&nbsp;144 with the SEC and the Nasdaq Global Market concurrently with either the placing of a sale order with the broker or the execution directly with a market maker. </P>
 <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Non-affiliate</FONT> Resales of Restricted Securities </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, beginning 90&nbsp;days after the effective date of the registration statement of which this prospectus is a part, a person who is not an affiliate of ours
at the time of sale, and has not been an affiliate at any time during the three months preceding a sale, and who has beneficially owned shares of our common stock for at least six months but less than a year, is entitled to sell such shares subject
only to the availability of current public information about us (as well as the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement referred to above, if applicable). If such person has held our shares for at least one year, such person can
resell under Rule&nbsp;144(b)(1) without regard to any Rule&nbsp;144 restrictions, including the <FONT STYLE="white-space:nowrap">90-day</FONT> public company requirement and the current public information requirement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-affiliate</FONT> resales are not subject to the manner of sale, volume limitation or notice filing provisions of Rule&nbsp;144.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule&nbsp;701 </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, under Rule&nbsp;701, any of an issuer&#146;s
employees, directors, officers, consultants or advisors who purchases shares from the issuer in connection with a compensatory stock or option plan or other written agreement before the effective date of a registration statement under the Securities
Act is entitled to sell such shares 90&nbsp;days after such effective date in reliance on Rule&nbsp;144. An affiliate of the issuer can resell shares in reliance on Rule&nbsp;144 without having to comply with the holding period requirement, and <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> of the issuer can resell shares in reliance on Rule&nbsp;144 without having to comply with the current public information and holding period requirements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The SEC has indicated that Rule&nbsp;701 will apply to typical options granted by an issuer before it becomes subject to the reporting requirements of the Exchange Act,
along with the shares acquired upon exercise of such options, including exercises after an issuer becomes subject to the reporting requirements of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Equity Plans </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to file one or more registration statements on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> under the Securities Act to register all shares of our common stock subject to outstanding options and shares of our common stock issued or issuable under our incentive plans. We expect to file the
registration statement covering shares offered pursuant to our incentive plans shortly after the date of this prospectus, permitting the resale of such shares by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> in the public market without
restriction under the Securities Act and the sale by affiliates in the public market, subject to compliance with the resale provisions of Rule&nbsp;144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration rights </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Immediately prior to the completion of this
offering, the holders of 23,061,474 shares of our common stock or their transferees (after giving effect to the Reorganization, assuming an initial public offering price of $14.00 per share, which is the midpoint of the price range set forth on the
cover page of this prospectus) will be entitled to various rights with respect to the registration of these shares under the Securities Act. Registration of these shares under the Securities Act would result in these shares becoming fully tradable
without restriction under the Securities Act </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">171 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
immediately upon the effectiveness of the registration, except for shares purchased by affiliates. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional
information. Shares covered by a registration statement will be eligible for sale in the public market upon the expiration or release from the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">172 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_18"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO
<FONT STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF OUR COMMON STOCK </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following discussion is a summary of the material U.S. federal income tax
consequences to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all
potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws are not discussed. This discussion is based on the U.S.
Internal Revenue Code of 1986, as amended, or the Code, Treasury Regulations promulgated thereunder, judicial decisions and published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or the IRS, in each case, in effect
as of the date hereof. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied
retroactively in a manner that could adversely affect a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no
assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This discussion is limited to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that hold our common stock as a &#147;capital asset&#148; within the meaning of
Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s particular circumstances,
including the impact of the alternative minimum tax or the Medicare contribution tax on net investment income. In addition, it does not address consequences relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders subject to special
rules, including, without limitation: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. expatriates and former citizens or <FONT STYLE="white-space:nowrap">long-term</FONT> residents of the United States;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion
transaction or other integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">banks, insurance companies and other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">brokers, dealers or traders in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations that
accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">partnerships or other entities or arrangements treated as partnerships or other pass-through entities for U.S. federal
income tax purposes (and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons deemed to sell our common stock under the constructive sale provisions of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons who hold common stock that constitutes &#147;qualified small business stock&#148; under Section&nbsp;1202 of the
Code, or &#147;Section&nbsp;1244 stock&#148; under Section&nbsp;1244 of the Code; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons who acquired our common stock in a transaction subject to the gain rollover provisions of the Code (including
Section&nbsp;1045 of the Code); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons that acquired our common stock pursuant to the exercise of warrants or conversion rights under convertible
instruments; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons who have elected to mark securities to market; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons that own, or have owned, actually or constructively, more than 5% of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all of the
interests of which are held by qualified foreign pension funds; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons subject to special tax accounting rules as a result of any item of gross income with respect to our common stock
being taken into account in an applicable financial statement. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This discussion does not address the tax treatment of entities or arrangements
treated as partnerships or other <FONT STYLE="white-space:nowrap">pass-through</FONT> entities or arrangements, or persons who hold our common stock through partnerships or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">173 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
<FONT STYLE="white-space:nowrap">pass-through</FONT> entities or arrangements, for U.S. federal income tax purposes. If an entity or arrangement treated as a partnership or other pass-through
entity for U.S. federal income tax purposes holds our common stock, the tax treatment of a partner, member, or other beneficial owner of such partnership or other pass-through entity will depend on the status of such partner, member, or other
beneficial owner, the activities of the partnership or other pass-through entity, and certain determinations made at the level of the partner, member, or other beneficial owner, as applicable. Accordingly, partnerships or other pass-through entities
holding our common stock and the partners, members and other beneficial owners thereof should consult their tax advisors regarding the U.S. federal income tax consequences of the purchase, ownership and disposition of our common stock to them. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S.
FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS, AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Definition of a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148;
is any beneficial owner of our common stock that is neither a &#147;U.S. person&#148; nor an entity or arrangement treated as a partnership for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes,
is or is treated as any of the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a corporation or any other entity taxable as a corporation for U.S. federal income tax purposes created or organized in or
under the laws of the United States, any state thereof, or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a trust that (1)&nbsp;is subject to the primary supervision of a U.S. court and all substantial decisions of which are
subject to the control of one or more &#147;United States persons&#148; (within the meaning of Section&nbsp;7701(a)(30) of the Code) or (2)&nbsp;has a valid election in effect to be treated as a United States person for U.S. federal income tax
purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Distributions </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As described in the section
entitled &#147;Dividend Policy,&#148; we do not anticipate declaring or paying any distributions to holders of our common stock in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such
distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S.
federal income tax purposes will constitute a return of capital and first be applied against and reduce a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in its common stock, but not below zero. Any remaining excess
will be treated as capital gain and will be treated as described below under &#147;&#151;Sale or Other Taxable Disposition.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the discussion below
on effectively connected income, FATCA, and backup withholding, dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock will be subject to U.S. federal tax withholding at a rate of 30% of the gross amount of
the dividends or such lower rate specified by an applicable income tax treaty, provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder furnishes a valid IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other applicable documentation) certifying qualification for the lower treaty rate. This certification must be provided to us or the applicable withholding agent
before the payment of dividends and must be updated periodically. If the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holds our common stock through a financial institution or other agent acting on the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s behalf, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be required to provide appropriate documentation to the agent, which then will be required to provide
certification to us or the applicable withholding agent, either directly or through other intermediaries. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that does not timely furnish the required documentation, but that qualifies for a
reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding their
entitlement to benefits under any applicable income tax treaty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">174 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder are effectively connected with the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent
establishment or fixed base in the United States to which such dividends are attributable), the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be exempt from the U.S. federal withholding tax described above. To claim the exemption, the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must furnish to the applicable withholding agent a valid IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8ECI,</FONT> certifying that the dividends are effectively connected with the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any such effectively connected dividends will be
subject to U.S. federal income tax on a net income basis at the same U.S. federal income tax rates applicable to United States persons (as defined in the Code). A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may
be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on its effectively connected earnings and profits attributable to such dividends, as adjusted for certain items. <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Sale or Other Taxable Disposition </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the discussion below on backup
withholding and FATCA, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable disposition of our common stock unless: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a
trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment or fixed base in the United States to which such gain is
attributable); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual present in the United States
for 183&nbsp;days or more during the taxable year of the disposition and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our common stock constitutes a U.S. real property interest, or USRPI, by reason of our status as a U.S. real property
holding corporation, or USRPHC, for U.S. federal income tax purposes, at any time during the five-year period preceding such disposition (or the Non-U.S. Holder&#146;s holding period, if shorter). </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the same U.S. federal income tax rates
applicable to United States persons (as defined in the Code). A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable
income tax treaty) on its effectively connected earnings and profits attributable to such gain, as adjusted for certain items. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder described in the second bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on gain realized upon
the sale or other taxable disposition of our common stock, which may be offset by certain <FONT STYLE="white-space:nowrap">U.S.-source</FONT> capital losses (even though the individual is not considered a resident of the United States), provided
that the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with respect to such losses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">With respect to the
third bullet point above, we believe we currently are not, and we do not anticipate becoming, a USRPHC. Generally, a corporation is a USRPHC if the fair market value of its USRPIs equals or exceeds 50% of the sum of the fair market value of its
worldwide real property interests plus its other assets used or held for use in a trade or business. Because the determination of whether we are a USRPHC depends on the fair market value of our USRPIs relative to the fair market value of our <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> real property interests and our other business assets, there can be no assurance we are not currently a USRPHC or will not become a USRPHC in the future. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our
common stock will not be subject to U.S. federal income tax if our common stock is &#147;regularly traded&#148; (as defined by applicable Treasury Regulations) on an established securities market, and such
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, actually and constructively, 5% or less of our common stock throughout the shorter of the <FONT STYLE="white-space:nowrap">five-year</FONT> period ending on the date of the sale or other
taxable disposition or the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period. No assurance can be provided that our common stock will be regularly traded on an established securities market for purposes of the rule
described above. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable income tax treaties that may
provide for different rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">175 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Payments of dividends on our common stock will not be subject to backup withholding, provided the applicable withholding agent does not have actual knowledge or reason
to know the holder is a United States person and the Non U.S. Holder either certifies its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status by furnishing a valid IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN,</FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or <FONT STYLE="white-space:nowrap">W-8ECI</FONT> or otherwise establishes an exemption. We must report annually to the IRS and to each Non-U.S. Holder the gross
amount of the distributions on our common stock paid to such holder and the tax withheld, if any, with respect to such distributions, regardless of whether any distributions constitute dividends or whether any tax was actually withheld. In addition,
proceeds of the sale or other taxable disposition of our common stock within the United States or conducted through certain <FONT STYLE="white-space:nowrap">U.S.-related</FONT> brokers generally will not be subject to backup withholding or
information reporting if the applicable withholding agent receives the certification described above and does not have actual knowledge or reason to know that such holder is a United States person, or the Non U.S. Holder otherwise establishes an
exemption. Proceeds of a disposition of our common stock conducted through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker that does not have certain enumerated relationships
with the United States generally will not be subject to backup withholding or information reporting. Non-U.S. Holders should consult their tax advisors regarding the application of the information reporting and backup withholding rules to them. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Copies of information returns that are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement to the tax authorities of
the country in which the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder resides or is established. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Backup withholding is not an additional tax. Any
amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s U.S. federal income tax liability, provided the required information is timely
furnished to the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Additional Withholding Tax on Payments Made to Foreign Accounts </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Withholding taxes may be imposed under Sections&nbsp;1471 to 1474 of the Code (such Sections together with any related Treasury Regulations, other Treasury Department
and IRS guidance issued thereunder, and intergovernmental agreements, legislation, rules and other official guidance adopted pursuant to such intergovernmental agreements, commonly referred to as the Foreign Account Tax Compliance Act, or FATCA) on
certain types of payments made to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial institutions and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a 30% withholding tax may be imposed on dividends on
our common stock paid to a &#147;foreign financial institution&#148; or a <FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (each as defined in the Code), unless such institution furnishes proper documentation
(typically on IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E)</FONT></FONT> indicating that (1)&nbsp;the foreign financial institution undertakes certain diligence and reporting obligations, (2)&nbsp;the <FONT
STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does not have any &#147;substantial United States owners&#148; (as defined in the Code) or furnishes identifying information regarding each substantial United States
owner, or (3)&nbsp;the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from these rules. Foreign financial institutions located in jurisdictions that have an
intergovernmental agreement with the United States governing FATCA may be subject to different rules. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the applicable Treasury Regulations and administrative
guidance, withholding under FATCA generally applies to payments of dividends on our common stock. While withholding under FATCA would have also applied to payments of gross proceeds from the sale or other disposition of our common stock on or after
January&nbsp;1, 2019, proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers and withholding agents generally may rely on these proposed Treasury Regulations until final Treasury Regulations are
issued. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If withholding under FATCA is required on any payment related to our common stock, investors not otherwise subject to withholding (or that otherwise would
be entitled to a reduced rate of withholding) on such payment may be entitled to seek a refund or credit from the IRS. Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their
investment in our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">176 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_19"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the terms and conditions set forth in the underwriting agreement, dated the date of this prospectus, among us and Jefferies LLC, Cowen and Company, LLC and
Evercore Group L.L.C., as the representatives of the underwriters named below and the joint book-running managers of this offering, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to
purchase from us, the respective number of shares of common stock shown opposite its name below:<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>UNDERWRITER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF&nbsp;SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriting agreement provides that the obligations of the several underwriters are subject to certain conditions precedent such as the receipt by the underwriters
of officers&#146; certificates and legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the shares of common stock if any of them are purchased. If an
underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be increased or the underwriting agreement may be terminated. We have agreed to indemnify the underwriters and certain of
their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that, following the completion of this offering, they currently intend to make a market in the common stock as permitted by applicable
laws and regulations. However, the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion. Accordingly, no assurance can be given as to the
liquidity of the trading market for the common stock, that you will be able to sell any of the common stock held by you at a particular time or that the prices that you receive when you sell will be favorable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters are offering the shares of common stock subject to their acceptance of the shares of common stock from us and subject to prior sale. The underwriters
reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. In addition, the underwriters have advised us that they do not intend to confirm sales to any account over which they exercise
discretionary authority. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Commission and Expenses </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have
advised us that they propose to offer the shares of common stock to the public at the initial public offering price set forth on the cover page of this prospectus and to certain dealers, which may include the underwriters, at that price less a
concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock. After the offering, the initial public offering price and concession to dealers may be reduced by the representatives. No
such reduction will change the amount of proceeds to be received by us as set forth on the cover page of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">177 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table shows the public offering price, the underwriting discounts and commissions that we are to pay the
underwriters and the proceeds, before expenses, to us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITHOUT<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITH<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITHOUT<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITH<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Underwriting discounts and commissions paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately $3.1
million. We have also agreed to pay the filing fees incident to, and the fees and disbursements of counsel for the underwriters in connection with, the clearance of this offering by the Financial Industry Regulatory Authority, Inc. in an amount up
to $30,000. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Determination of Offering Price </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this
offering, there has not been a public market for our common stock. Consequently, the initial public offering price for our common stock will be determined by negotiations between us and the representatives. Among the factors to be considered in
these negotiations will be prevailing market conditions, our financial information, market valuations of other companies that we and the underwriters believe to be comparable to us, estimates of our business potential, the present state of our
development and other factors deemed relevant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We offer no assurances that the initial public offering price will correspond to the price at which the common stock
will trade in the public market subsequent to the offering or that an active trading market for the common stock will develop and continue after the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Listing </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have applied for listing of our common stock on the Nasdaq
Global Market under the symbol &#147;RLYB&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stamp Taxes </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you
purchase shares of common stock offered in this prospectus, you may be required to pay stamp taxes and other charges under the laws and practices of the country of purchase, in addition to the offering price listed on the cover page of this
prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Option to Purchase Additional Shares </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have granted
to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase, from time to time, in whole or in part, up to an aggregate of 862,500 shares from us at the public offering price set forth on the cover page of
this prospectus, less underwriting discounts and commissions. If the underwriters exercise this option, each underwriter will be obligated, subject to specified conditions, to purchase a number of additional shares proportionate to that
underwriter&#146;s initial purchase commitment as indicated in the table above. This option may be exercised only if the underwriters sell more shares than the total number set forth on the cover page of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>No Sales of Similar Securities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We, our officers, directors and holders of
all, or substantially all, our outstanding capital stock, have agreed, subject to specified exceptions, not to directly or indirectly: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open
&#147;put equivalent position&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">16a-l(h)</FONT> under the Exchange Act, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">178 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">otherwise dispose of any shares of common stock, options or warrants to acquire shares of common stock, or securities
exchangeable or exercisable for or convertible into shares of common stock currently or hereafter owned either of record or beneficially, or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">publicly announce an intention to do any of the foregoing for a period of 180 days after the date of this prospectus
without the prior written consent of Jefferies LLC and Cowen and Company, LLC. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This restriction terminates after the close of trading of the
common stock on and including the 180th day after the date of this prospectus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Jefferies LLC and Cowen and Company, LLC may, in their sole discretion and at any
time or from time to time before the termination of the 180-day period release all or any portion of the securities subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. There are no existing agreements between the underwriters and
any of our stockholders who will execute a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, providing consent to the sale of shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stabilization </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that, pursuant to Regulation
M under the Exchange Act, as amended, certain persons participating in the offering may engage in short sale transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty bids in connection with this offering.
These activities may have the effect of stabilizing or maintaining the market price of the common stock at a level above that which might otherwise prevail in the open market. Establishing short sales positions may involve either &#147;covered&#148;
short sales or &#147;naked&#148; short sales. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to
purchase additional shares of our common stock in this offering. The underwriters may close out any covered short position by either exercising their option to purchase additional shares of our common stock or purchasing shares of our common stock
in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they
may purchase shares through the option to purchase additional shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#147;Naked&#148; short sales are sales in excess of the option to purchase additional shares
of our common stock. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the
price of the shares of our common stock in the open market after pricing that could adversely affect investors who purchase in this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A stabilizing bid is
a bid for the purchase of shares of common stock on behalf of the underwriters for the purpose of fixing or maintaining the price of the common stock. A syndicate covering transaction is the bid for or the purchase of shares of common stock on
behalf of the underwriters to reduce a short position incurred by the underwriters in connection with the offering. Similar to other purchase transactions, the underwriter&#146;s purchases to cover the syndicate short sales may have the effect of
raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open
market. A penalty bid is an arrangement permitting the underwriters to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the common stock originally sold by such syndicate member are purchased
in a syndicate covering transaction and therefore have not been effectively placed by such syndicate member. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither we nor any of the underwriters make any
representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common stock. The underwriters are not obligated to engage in these activities and, if commenced, any of
the activities may be discontinued at any time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters may also engage in passive market making transactions in our common stock on the Nasdaq Global
Market in accordance with Rule&nbsp;103 of Regulation&nbsp;M during a period before the commencement of offers or sales of shares of our common stock in this offering and extending through the completion of distribution. A passive market maker must
display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, that bid must then be lowered when specified purchase limits are
exceeded. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">179 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Electronic Distribution </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A
prospectus in electronic format may be made available by <FONT STYLE="white-space:nowrap">e-mail,</FONT> or on the web sites or through online services, maintained by one or more of the underwriters or their affiliates. In those cases, prospective
investors may view offering terms online and may be allowed to place orders online. The underwriters may agree with us to allocate a specific number of shares of common stock for sale to online brokerage account holders. Any such allocation for
online distributions will be made by the underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters&#146; web sites and any information contained in any other web site
maintained by any of the underwriters is not part of this prospectus, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Activities and Relationships </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters and certain of their
affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging,
financing and brokerage activities. The underwriters and certain of their affiliates have, from time to time, performed, and may in the future perform, various commercial and investment banking and financial advisory services for us and our
affiliates, for which they received or will receive customary fees and expenses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the ordinary course of their various business activities, the underwriters and
certain of their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of
their customers, and such investment and securities activities may involve securities and/or instruments issued by us and our affiliates. If the underwriters or their respective affiliates have a lending relationship with us, they routinely hedge
their credit exposure to us consistent with their customary risk management policies. The underwriters and their respective affiliates may hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps
or the creation of short positions in our securities or the securities of our affiliates, including potentially the common stock offered hereby. Any such short positions could adversely affect future trading prices of the common stock offered
hereby. The underwriters and certain of their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or
instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Selling
Restrictions </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in EEA </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
relation to each member state of the European Economic Area which has implemented the Prospectus Regulation, or each, a Relevant Member State, no offer of shares of our common stock which are the subject of the offering contemplated by this
prospectus has been or will be made to the public in that Relevant Member State, except that with effect from and including the Relevant Implementation Date, an offer of such shares of our common stock may be made to the public in that Relevant
Member State: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">to any legal entity which is a &#147;qualified investor&#148; as defined in the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Regulation), as
permitted under the Prospectus Regulation, subject to obtaining the prior consent of the representatives of the underwriters; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">in any other circumstances falling within Article 3(2) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">provided that no such offer of shares of our common stock shall require us or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus
Regulation or supplement a prospectus pursuant to Article 16 of the Prospectus Regulation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the purposes of this provision, the expression an &#147;offer to the
public&#148; in relation to any shares of our common stock in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the shares of our common stock to be offered so as
to enable an investor to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">180 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
decide to purchase or subscribe the shares of our common stock, as the same may be varied in that Relevant Member State by any measure implementing the Prospectus Regulation in that Relevant
Member State, and the expression &#147;Prospectus Regulation&#148; means Prospectus Regulation (EU) 2017/1129 (and amendments thereto, to the extent implemented in the Relevant Member States) and includes any relevant implementing measure in the
Relevant Member State. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in United Kingdom </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No shares have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in relation to our
shares of common stock which has been approved by the Financial Conduct Authority, except that the shares may be offered to the public in the United Kingdom at any time: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK Prospectus
Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">in any other circumstances falling within Section&nbsp;86 of the FSMA, provided that no such offer of the shares shall
require the Company or the underwriters to publish a prospectus pursuant to Section&nbsp;85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an
&#147;offer to the public&#148; in relation to the shares in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to
decide to purchase or subscribe for any shares and the expression &#147;UK Prospectus Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in Bermuda </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Securities may be offered
or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which regulates the sale of securities in Bermuda. Additionally, <FONT STYLE="white-space:nowrap">non-Bermudian</FONT> persons (including
companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so under applicable Bermuda legislation. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in Australia </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus is not
a disclosure document for the purposes of Australia&#146;s Corporations Act 2001 (Cth) of Australia, or Corporations Act, has not been lodged with the Australian Securities&nbsp;&amp; Investments Commission and is only directed to the categories of
exempt persons set out below. Accordingly, if you receive this prospectus in Australia, you confirm and warrant that you are either: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a &#147;sophisticated investor&#148; under section 708(8)(a) or (b)&nbsp;of the Corporations Act; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a &#147;sophisticated investor&#148; under section 708(8)(c) or (d)&nbsp;of the Corporations Act and that you have
provided an accountant&#146;s certificate to us which complies with the requirements of section 708(8)(c)(i) or (ii)&nbsp;of the Corporations Act and related regulations before the offer has been made; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a person associated with us under Section&nbsp;708(12) of the Corporations Act; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a &#147;professional investor&#148; within the meaning of section 708(11)(a) or (b)&nbsp;of the Corporations Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor
under the Corporations Act any offer made to you under this prospectus is void and incapable of acceptance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You warrant and agree that you will not offer any of
the shares of our common stock issued to you pursuant to this prospectus for resale in Australia within 12 months of those shares of our common stock being issued unless any such resale offer is exempt from the requirement to issue a disclosure
document under section 708 of the Corporations Act. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in Hong Kong </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No shares of our common stock have been offered or sold, and no shares of our common stock may be offered or sold, in Hong Kong, by means of any document, other than to
persons whose ordinary business is to buy or sell shares or debentures, whether as principal or agent; or to &#147;professional investors&#148; as defined in the Securities and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">181 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the
Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap. 32) or the Securities and Futures Ordinance (Cap. 571) of Hong Kong. No document, invitation or
advertisement relating to the shares of our common stock has been issued or may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of
which are likely to be accessed or read by, the public of Hong Kong (except if permitted under the securities laws of Hong Kong) other than with respect to shares of our common stock which are or are intended to be disposed of only to persons
outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus has not been registered with the Registrar of Companies in Hong Kong. Accordingly, this prospectus may not be issued, circulated or distributed in Hong
Kong, and the shares of our common stock may not be offered for subscription to members of the public in Hong Kong. Each person acquiring the shares of our common stock will be required, and is deemed by the acquisition of the shares of our common
stock, to confirm that he is aware of the restriction on offers of the shares of our common stock described in this prospectus and the relevant offering documents and that he is not acquiring, and has not been offered any shares of our common stock
in circumstances that contravene any such restrictions. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in Israel </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the Israel
Securities Authority. In Israel, this prospectus is being distributed only to, and is directed only at, and any offer of the shares of our common stock is directed only at, (i)&nbsp;a limited number of persons in accordance with the Israeli
Securities Law and (ii)&nbsp;investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment
advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50&nbsp;million and &#147;qualified individuals,&#148; each as defined in the Addendum (as it may be amended from time to
time), collectively referred to as qualified investors (in each case, purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors are
required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to
Prospective Investors in Japan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The offering has not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law
No.&nbsp;25 of 1948 of Japan, as amended), or FIEL, and the underwriters will not offer or sell any shares of our common stock, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means,
unless otherwise provided herein, any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in
Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from <FONT STYLE="white-space:nowrap">S-30</FONT> the registration requirements of, and otherwise in compliance with, the FIEL and any other applicable laws,
regulations and ministerial guidelines of Japan. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in Singapore </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in
connection with the offer or sale, or the invitation for subscription or purchase, of the shares of our common stock may not be issued, circulated or distributed, nor may the shares of our common stock be offered or sold, or be made the subject of
an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA,
(ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA and in accordance with the conditions specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to,
and in accordance with the conditions of, any other applicable provision of the SFA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">182 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Where the shares of our common stock are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person
which is: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which
is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary
of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the
beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares of our common stock pursuant to an offer made under Section&nbsp;275
of the SFA except: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising
from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations
2005 of Singapore. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in Switzerland </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The shares of our common stock may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or the SIX, or on any other stock exchange
or regulated trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for
listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this prospectus, nor any other offering or marketing material, relating to the
shares of our common stock, or the offering, may be publicly distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither this prospectus, nor any
other offering or marketing material relating to the offering, us or the shares of our common stock, have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with and the offer of
shares of our common stock will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of shares of our common stock has not been and will not be authorized under the Swiss Federal Act on Collective Investment
Schemes, or the CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares of our common stock. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in Canada </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(A) Resale Restrictions
</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The distribution of shares of our common stock in Canada is being made only in the provinces of Ontario, Quebec, Alberta and British Columbia on a private
placement basis exempt from the requirement that we prepare and file a prospectus with the securities regulatory authorities in each province where trades of these shares of our common stock are made. Any resale of the shares of our common stock in
Canada must be made under applicable securities laws which may vary depending on the relevant jurisdiction, and which may require resales to be made under available statutory exemptions or under a discretionary exemption granted by the applicable
Canadian securities regulatory authority. Purchasers are advised to seek legal advice prior to any resale of the shares of our common stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(B) Representations
of Canadian Purchasers </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">By purchasing shares of our common stock in Canada and accepting delivery of a purchase confirmation, a purchaser is representing to us
and the dealer from whom the purchase confirmation is received that: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the purchaser is entitled under applicable provincial securities laws to purchase the shares of our common stock without
the benefit of a prospectus qualified under those securities laws as it is an &#147;accredited investor&#148; as defined under National Instrument <FONT STYLE="white-space:nowrap">45-106&#151;Prospectus</FONT> Exemptions, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">183 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the purchaser is a &#147;permitted client&#148; as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103&#151;Registration</FONT> Requirements, Exemptions and Ongoing Registrant Obligations, </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">where required by law, the purchaser is purchasing as principal and not as agent, and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the purchaser has reviewed the text above under Resale Restrictions. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(C) Conflicts of Interest </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Canadian purchasers are hereby notified that each
of the underwriters are relying on the exemption set out in section 3A.3 or 3A.4, if applicable, of National Instrument <FONT STYLE="white-space:nowrap">33-105&#151;Underwriting</FONT> Conflicts from having to provide certain conflict of interest
disclosure in this document. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(D) Statutory Rights of Action </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if the prospectus (including any amendment thereto) such as this document contains a misrepresentation, provided that the
remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser of these securities in Canada should refer to any
applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(E) Enforcement of Legal Rights </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of our directors and officers as well,
as the experts named herein, may be located outside of Canada and, as a result, it may not be possible for Canadian purchasers to effect service of process within Canada upon us or those persons. All or a substantial portion of our assets and the
assets of those persons may be located outside of Canada and, as a result, it may not be possible to satisfy a judgment against us or those persons in Canada or to enforce a judgment obtained in Canadian courts against us or those persons outside of
Canada. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(F) Taxation and Eligibility for Investment </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Canadian
purchasers of shares of our common stock should consult their own legal and tax advisors with respect to the tax consequences of an investment in the shares of our common stock in their particular circumstances and about the eligibility of the
shares of our common stock for investment by the purchaser under relevant Canadian legislation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">184 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_20"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The validity of the shares of common stock offered by this prospectus will be passed upon for us by Ropes&nbsp;&amp; Gray,&nbsp;LLP, Boston, Massachusetts. Certain
legal matters will be passed upon for the underwriters by Wilmer Cutler Pickering Hale and Dorr LLP, New York, New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">185 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_21"></A>EXPERTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The financial statements of Rallybio Holdings, LLC as of December 31, 2020 and 2019 and each of the two years then ended included in this prospectus have been audited
by Deloitte &amp; Touche LLP, an independent registered public accounting firm, as stated in their report appearing herein. Such financial statements are so included in reliance upon the report of such firm given upon their authority as experts in
accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">186 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_22"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have filed with the SEC a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> under the Securities Act with respect to the shares of
common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith. For further
information about us and the shares of common stock offered hereby, we refer you to the registration statement and the exhibits and schedules filed thereto. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not
necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the registration statement. The SEC also maintains an Internet website that contains
reports, proxy statements and other information about registrants, like us, that file electronically with the SEC. The address of that site is www.sec.gov. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon
the effectiveness of the registration statement, we will be subject to the informational requirements of the Exchange Act and, in accordance with the Exchange Act, will file reports, proxy and information statements and other information with the
SEC. Such annual, quarterly and special reports, proxy and information statements and other information can be accessed at the SEC&#146;s website referenced above. We also intend to make this information available on the investor relations section
of our website, which is located at www.rallybio.com. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">187 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc99471_23"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Audited financial statements for the years ended December 31, 2020 and 2019:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin99471_1">Report of Independent Registered Public Accounting Firm </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin99471_2">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin99471_3">Consolidated Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin99471_4">Consolidated Statements of Changes in Redeemable Convertible Preferred Units and Members&#146;
 Deficit </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin99471_5">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin99471_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unaudited financial statements for the three months ended March 31, 2021 and 2020:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin99471_7">Unaudited Condensed Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin99471_8">Unaudited Condensed Consolidated Statements of Operations and Comprehensive
Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin99471_9">Unaudited Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred
 Units and Members&#146; Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin99471_10">Unaudited Condensed Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin99471_11">Notes to Unaudited Condensed Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-1 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin99471_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the members and the Board of Managers of Rallybio Holdings, LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Opinion on
the Financial Statements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have audited the accompanying consolidated balance sheets of Rallybio Holdings, LLC and subsidiaries (the Company) as of
December&nbsp;31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, changes in redeemable convertible preferred units and members&#146; deficit, and cash flows, for each of the years then ended and the related
notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2020 and 2019, and the results of its
operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Basis for Opinion </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These financial statements are the responsibility of the
Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States)
(PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America.
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we
engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the
effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our audits included performing procedures
to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and
disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our
audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">/s/ Deloitte &amp; Touche LLP </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Hartford, Connecticut </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">April&nbsp;27, 2021 </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have served as the Company&#146;s auditor since 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-2 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin99471_2"></A>RALLYBIO HOLDINGS, LLC AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Consolidated Balance Sheets </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">140,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">141,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Liabilities and members&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Commitments and contingencies (Note 10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable convertible preferred units:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A preferred units, no par value, 33,478,255 units authorized, issued and outstanding as of
December&nbsp;31, 2020 and 2019; liquidation preference of $37,600 as of December 31, 2020 and 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B preferred units, no par value, 104,442,965 units authorized, issued and outstanding as of
December&nbsp;31, 2020; liquidation preference of $145,204 as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Members&#146; deficit:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Common units, no par value, 5,700,000 authorized, issued and outstanding as of December&nbsp;31, 2020 and
2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Incentive units, 17,772,360 and 6,033,957 authorized, 6,865,704 and 1,633,000 issued and outstanding as of
December&nbsp;31, 2020 and 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,014</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total members&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities, redeemable convertible preferred units, and members&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">141,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes of the consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-3 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin99471_3"></A>RALLYBIO HOLDINGS, LLC AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Consolidated Statements of Operations and Comprehensive Loss </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating Expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,642</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income (expenses):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income and expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value of Series <FONT STYLE="white-space:nowrap">A-2</FONT> financing right
obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss on investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss attributable to common units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per common unit, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9.95</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average common units outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,659,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,715,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes of the consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-4 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin99471_4"></A>RALLYBIO HOLDINGS, LLC AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin99471_4"></A>Consolidated Statements of Changes in Redeemable Convertible Preferred Units and Members&#146; Deficit </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES A REDEEMABLE<BR>CONVERTIBLE&nbsp;PREFERRED<BR>UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES B REDEEMABLE<BR>CONVERTIBLE PREFERRED<BR>UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>COMMON UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INCENTIVE UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL<BR>MEMBERS&#146;<BR>DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Balance, December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,004</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,912</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Redeemable Convertible Preferred Units, net
of issuance costs of $33</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,478,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Incentive unit-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,423,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Common unit-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Balance, December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,478,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,633,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of Series B Redeemable Convertible Preferred Units, net of issuance costs of $319</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,442,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Incentive unit-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,232,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Common unit-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Balance, December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,478,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,442,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">144,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,865,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(47,014</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes of the consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-5 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin99471_5"></A>RALLYBIO HOLDINGS, LLC AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Consolidated Statements of Cash Flows </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash Flows from Operating Activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Equity based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value of Series <FONT STYLE="white-space:nowrap">A-2</FONT> financing right
obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss on investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,381</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,026</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash Flows used in Investing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,935</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,072</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash Flows from Financing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of Series A preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of Series B preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Preferred unit issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(319</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents&#151;beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents&#151;end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">140,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Supplemental Schedule of Noncash Investing and Financing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">(Decrease) in Series <FONT STYLE="white-space:nowrap">A-2</FONT> financing right obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,509</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unfunded investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses for purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes of the consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-6 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO HOLDINGS, LLC AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin99471_6"></A>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>1. BUSINESS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio Holdings, LLC holds 100% of the outstanding membership
units in five wholly-owned subsidiaries&#151;Rallybio, LLC, Rallybio IPA, LLC, Rallybio IPB, LLC, Rallybio, IPD, LLC, and IPC Research, LLC (collectively, the &#147;Company&#148;). Rallybio Holdings, LLC was incorporated in Delaware on
March&nbsp;22, 2018. The Company is a clinical-stage biotechnology company built around a team of seasoned industry experts with a shared purpose and a track record of success in discovering, developing, manufacturing, and delivering therapies to
meaningfully improve the lives of patients suffering from severe and rare diseases. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has raised $37.6&nbsp;million in
<FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT> financing and $145.2&nbsp;million in Series&nbsp;B financing. Refer to Note 6 &#147;Redeemable Convertible Preferred Units&#148;. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2020, the World Health Organization characterized the novel coronavirus as a global pandemic. Although there is significant uncertainty as to the likely
effects this disease may have in the future, to date there has not yet been a significant impact to the Company&#146;s operations or financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Basis of Presentation&#151;</B>The accompanying
consolidated financial statements have been prepared in accordance with accounting principles generally accepted (&#147;GAAP&#148;) in the United States. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the
Accounting Standards Codification (&#147;ASC&#148;) and Accounting Standards Updates (&#147;ASU&#148;) promulgated by the Financial Accounting Standards Board (&#147;FASB&#148;). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Principles of Consolidation&#151;</B>The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany
balances and transactions have been eliminated in consolidation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Use of Estimates</B>&#151;The preparation of the Company&#146;s consolidated financial
statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosures in the consolidated financial statements. While management believes that estimates and assumptions used
in the preparation of the consolidated financial statements are appropriate, actual results could differ from those estimates. The most significant estimates are those used in the determination of the fair value of its common units and incentive
units awarded to employees, for purposes of recording equity-based incentive compensation, as well as contracted research and development accruals. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Liquidity
and Ability to Continue as a Going Concern</B>&#151;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Management has evaluated whether there are conditions and events
that raise substantial doubt about the Company&#146;s ability to continue as a going concern within one year after the date the financial statements are issued. Since its inception, the Company has incurred net losses and negative cash flows from
operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the years ended December&nbsp;31, 2020 and December&nbsp;31, 2019, the Company incurred a net loss of $26.4&nbsp;million and $17.6&nbsp;million,
respectively, and used $22.0&nbsp;million and $15.0&nbsp;million in cash for operations, respectively. In addition, as of December&nbsp;31, 2020, the Company had an accumulated deficit of $47.0&nbsp;million. The Company expects to continue to
generate operating losses and negative cash flows in the foreseeable future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company currently expects that the cash and cash equivalents on hand of
$140.2&nbsp;million as of December&nbsp;31, 2020, will be sufficient to fund its operating expenses and capital requirements for more than 12 months from the date the consolidated financial statements are issued. Additional funding will be needed to
finance future clinical, <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> manufacturing, and commercial activities. To date, the Company has principally financed its operations through private placements of redeemable convertible preferred
units. In the event the Company does not complete an IPO, the Company will seek additional funding through private equity and debt financings and other arrangements. There is no assurance the Company will be successful in obtaining such additional
financing on terms </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-7 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
acceptable to it, if at all, and it may not be able to enter into other arrangements. If the Company is unable to obtain funding, it could be forced to delay, reduce or eliminate our research and
development programs, portfolio expansion or commercialization efforts, which could adversely affect its business prospects and ability to continue operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Company is subject to risks common to companies in the biopharmaceutical industry. There can be no assurance that the Company&#146;s research and development will be successfully completed, that adequate protection for its intellectual property will
be maintained, that any products developed will obtain required regulatory approval, or that any approved products will be commercially viable. Even if the development efforts are successful, it is uncertain when, if ever, the Company will generate
significant product sales and ultimately net income. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Variable Interest Entity</B>&#151;The Company evaluates its ownership, contractual, and other interests in
entities to determine if it has any variable interest in a variable interest entity (&#147;VIE&#148;). These evaluations are complex, involve judgment, and the use of estimates and assumptions based on available historical information, among other
factors. If the Company determines that an entity in which it holds a contractual, or ownership, interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its consolidated financial statements. The
primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to
receive benefits that in either case could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company&#146;s involvement with a VIE will cause the
consolidation conclusion to change. Changes in consolidation status are applied prospectively. The Company evaluated its investment in REV-I (defined in Note 9) and concluded that it represented a VIE and was not deemed the primary beneficiary. If
the Company is not deemed to be the primary beneficiary in a VIE, the Company accounts for the investment or other variable interests in a VIE in accordance with the applicable GAAP (See Note 9). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Equity Method Investments</B>&#151;The Company accounts for investments for which it does not have a controlling interest in accordance with ASC 323, <I>Investments
&#150; Equity Method and Joint Ventures</I>. The Company recognizes its <FONT STYLE="white-space:nowrap">pro-rata</FONT> share of income and losses in &#147;loss on investment in joint venture&#148; on the consolidated statements of operations and
comprehensive loss, with a corresponding change to the investment in joint venture on the consolidated balance sheets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Financial Instruments</B>&#151;The
Company&#146;s principal financial instruments are comprised of cash and cash equivalents, accounts payable, and accrued liabilities. The carrying value of all financial instruments approximates fair value. During 2019, the Company also recorded, at
fair value, a free-standing financial instrument related to the obligation to issue future Series <FONT STYLE="white-space:nowrap">A-2</FONT> units at <FONT STYLE="white-space:nowrap">pre-determined</FONT> prices upon the achievement of specific
milestone events. As of December&nbsp;31, 2019, all Series <FONT STYLE="white-space:nowrap">A-2</FONT> units were sold and therefore there is no longer a financing obligation outstanding. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Concentrations of credit risk&#151;</B>Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of
cash and cash equivalents. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#146;s
deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Cash and Cash Equivalents&#151;</B>The Company classifies amounts on deposit in banks and cash invested temporarily in various instruments, primarily money market
funds, with original maturities of three months or less at time of purchase as cash and cash equivalents. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Property and Equipment</B>&#151;Property and equipment
are recorded at cost and consists of computer and other equipment, furniture and fixtures, leasehold improvements, and capitalized software. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets,
which range from three to six years. Maintenance and repairs which do not extend the lives of the assets are charged directly to expense as incurred. Upon retirement or disposal, cost and related accumulated depreciation are removed from the related
accounts, and any resulting gain or loss is recognized as a component of income or loss in the consolidated statements of operations and comprehensive loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-8 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Impairment of Long-Lived Assets</B>&#151;When indications of potential impairments are present, the Company evaluates
the carrying value of long-lived assets. The Company adjusts the carrying value of the long-lived assets if the sum of undiscounted expected future cash flows is less than carrying value. No such impairments were recorded during the years ended
December&nbsp;31, 2020 or 2019. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Income Taxes</B>&#151;Rallybio Holdings, LLC is taxed under the provisions of <I>Subchapter K&#151; Partners and Partnerships
</I>of the Internal Revenue Code. Under those provisions, Rallybio Holdings, LLC does not pay federal or state corporate income taxes on its taxable income. Instead, the members include net income or loss for Rallybio Holdings, LLC on their
individual tax returns. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio, LLC, Rallybio IPA, LLC, Rallybio IPB, LLC, IPC Research, LLC, and Rallybio IPD, LLC have elected, for United States federal and
state income tax purposes, to be each treated as and taxed as corporations. These entities are not eligible to file a consolidated federal income tax return and will file separately as stand-alone taxpayers. Accordingly, each entity, on a standalone
basis, uses the asset and liability method of accounting for income taxes, as set forth in Accounting Standards Codification (ASC) 740, <I>Accounting for Income Taxes</I>. Under this method, deferred tax assets and liabilities are recognized for the
expected future tax consequence of temporary differences between the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently enacted tax rates. The Company evaluates whether
deferred tax assets are more likely than not of being realized in determining whether a valuation allowance is necessary. As of December 31, 2020 and 2019, the Company determined that it is not more likely than not that deferred taxes will be
realized and as a result recorded a valuation allowance against its deferred tax assets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Research and Development Expenses</B>&#151;Research and development
expenses are comprised of costs incurred in performing research and development activities including personnel salaries, benefits, and equity-based compensation; external research and development expenses incurred under arrangements with third
parties, such as contract research organization agreements, investigational sites, and consultants; the cost of developing and manufacturing clinical study materials, program regulatory costs, expenses associated with obligations under asset
acquisitions, license agreements and other direct and indirect costs. Costs incurred in connection with research and development activities are expensed as incurred. Costs are considered incurred based on an evaluation of the progress to completion
of each contract using information and data provided by the respective vendors, including the Company&#146;s clinical sites. Depending upon the timing of invoicing by the service providers, the Company recognizes prepaid expenses or accrued expenses
related to these costs. These prepaid expenses or accrued expenses are based on management&#146;s estimates of the work performed under service agreements, milestones achieved, and experience with similar contracts. The Company monitors each of
these factors and adjusts estimates accordingly. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Preferred Units</B>&#151;The Company records all preferred units at their respective fair values less issuance
costs on the dates of issuance. The preferred units are recorded outside of members&#146; deficit because, in the event of certain deemed liquidation events, which are events that are not considered solely within the Company&#146;s control, such as
a merger, acquisition or sale of all or substantially all of the Company&#146;s assets, the preferred units will become redeemable. The preferred units could also become redeemable due to certain change of control clauses that are outside of the
Company&#146;s control. In the event of a change of control of the Company, proceeds received from the event will be distributed to the preferred units in accordance with the liquidation preferences set forth in the Company&#146;s Operating
Agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Deferred Offering Costs</B>&#151;The Company capitalizes certain legal, professional accounting and other third-party fees that are specific
incremental costs directly attributable to an <FONT STYLE="white-space:nowrap">in-process</FONT> equity financings as deferred offering costs until such equity financings are consummated. After consummation of an equity financing, these costs are
recorded as a reduction of the common or preferred units generated as a result of the offering. Should the <FONT STYLE="white-space:nowrap">in-process</FONT> equity financing be abandoned, the deferred offering costs will be expensed immediately as
a charge to operating expenses in the consolidated statements of operations and comprehensive loss. Preferred unit issuance costs are presented as a direct reduction of the carrying amount of the Series B preferred units and totaled $319,265 for the
year ended December&nbsp;31, 2020. Preferred unit issuance costs are presented as a direct reduction of the carrying amount Series A preferred units and totaled $33,443 for the year ended December&nbsp;31, 2019. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Equity-Based Compensation&#151;</B>The Company accounts for equity-based compensation in accordance with ASC 718, Compensation&#151;Stock Compensation (&#147;ASC
718&#148;). Generally, equity-based compensation is measured at the grant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-9 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
date for all equity-based awards made to employees based on the fair value of the awards and is recognized over the requisite service period, which is generally the vesting period. Equity-based
compensation for awards with performance conditions are recognized over the service period when achievement of the performance condition is probable. The Company has elected to recognize the actual forfeitures by reducing the equity-based
compensation in the same period as the forfeitures occur.&nbsp;The Company classifies equity-based compensation in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipients&#146; payroll costs
are classified. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has issued incentive units and restricted common units to employees. Incentive units granted to employees generally vest over a
four-year period. The incentive units are common units issued in the form of profits interests, providing the employee with compensation equal to the increase in the value of the unit over a participation threshold of the unit, as determined at the
time of grant. The incentive units have defined rights within the Company&#146;s Operating Agreement. The holder, therefore, has the right to participate in distributions of profits only in excess of such participation threshold. The participation
threshold is based on the valuation of a single common unit on or around the grant date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of the Company&#146;s restricted common units and incentive
units is determined using an option pricing method (&#147;OPM&#148;) which uses market approaches and a Black-Scholes option pricing model to estimate its enterprise value. An OPM is then used which treats common units and preferred units as call
options on the total equity value of the Company, with exercise prices based on the value thresholds at which the allocation among the various holders of the Company&#146;s securities changes to value the common units of the Company. A discount for
lack of marketability of the common units is then applied to arrive at an indication of value for the common units as of the valuation date. Volatility is determined by comparing companies operating in the Company&#146;s comparable industry as well
as the Company&#146;s capital structure and risk profile relative to its peer group. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Fair Value Measurements</B>&#151;ASC Topic 820,&nbsp;Fair Value
Measurement&nbsp;(&#147;ASC 820&#148;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#146;s own assumptions (unobservable
inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#146;s
assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to
sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered
value hierarchy that distinguishes between the following: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Level&nbsp;1&#151;Quoted market prices in active markets for identical assets or
liabilities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Level&nbsp;2&#151;Inputs other than Level&nbsp;1 inputs that are either directly or indirectly observable, such as quoted market
prices, interest rates and yield curves. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Level&nbsp;3&#151;Unobservable inputs for the asset or liability (i.e. supported by little or no market
activity). Level&nbsp;3 inputs include management&#146;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values
requires more judgement. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized as Level&nbsp;3. A financial instrument&#146;s level within the fair value hierarchy is based on
the lowest level of any input that is significant to the fair value measurement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In determining fair value, the Company utilizes valuation techniques that maximize
the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-10 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of the Series <FONT STYLE="white-space:nowrap">A-2</FONT> financing obligation was measured on a recurring
basis and is considered a Level&nbsp;3 instrument in the fair value hierarchy. See Note 6 &#147;Redeemable Convertible Preferred Units&#148; for more information on the Series <FONT STYLE="white-space:nowrap">A-2</FONT> financing obligation. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes the Company&#146;s Series <FONT STYLE="white-space:nowrap">A-2</FONT> financing right obligation for the year ended December 31, 2019:
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding&#151;December 31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value of liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Milestones achieved</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,509</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding&#151;December 31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Segment information</B>&#151;Operating segments are defined as components of an enterprise for which discrete financial information is regularly reviewed by the
chief operating decision maker in deciding how to allocate resources and in assessing operating performance. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating
decisions. All tangible assets of the Company are held in the United States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Basic and Diluted Net Loss Per Unit</B>&#151;The Company calculates basic net loss
per unit by dividing the net loss by the weighted average number of common units outstanding during the period, without consideration of potential dilutive securities. Unvested restricted common units as of December&nbsp;31, 2020 and 2019 are not
considered participating securities and as such are excluded from the weighted average number of shares used for calculating basic and diluted net loss per share. Diluted net loss per unit is computed by dividing the net loss by the sum of the
weighted average number of common units outstanding during the period plus the dilutive effects of potentially dilutive securities outstanding during the period. Potentially dilutive securities include restricted common units, incentive units, and
redeemable convertible preferred units. The dilutive effect of redeemable convertible preferred units is calculated using the <FONT STYLE="white-space:nowrap">if-converted</FONT> method. The Company has generated a net loss for all periods
presented, therefore diluted net loss per unit is the same as basic net loss per unit since the inclusion of potentially dilutive securities would be anti-dilutive. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Recent Accounting Pronouncements</B>&#151;In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> <I>Leases</I>. This guidance
requires an entity to recognize lease liabilities and a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset for all leases on the balance sheet and to disclose key information about the entity&#146;s
leasing arrangements. ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> is effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December&nbsp;15, 2022, with earlier adoption
permitted. ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> must be adopted using a modified retrospective approach for all leases existing at, or entered into after the date of initial adoption, with an option to elect to use certain transition
relief. The Company is currently evaluating the impact of adopting ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> on its consolidated financial statements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Jumpstart Our Business Startups Act of 2012 permits an emerging growth company to take advantage of an extended transition period to comply with new or revised
accounting standards applicable to public companies until those standards would otherwise apply to private companies. As an emerging growth company, the Company has elected to take advantage of this extended transition period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>3. ASSET ACQUISITIONS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2019, the Company, through one of its
wholly-owned subsidiaries, entered into an asset purchase agreement and acquired intellectual property from Swedish Orphan Biovitrum AB. The purchase price includes an upfront payment of $3.0&nbsp;million with additional payments of
$1.0&nbsp;million due in September 2020 and March 2021. The assets were expensed upon purchase given the uncertainty of probable future revenue streams and are included in research and development expense on the consolidated statements of operations
and comprehensive loss. Discounted obligations in the amount of $1.0&nbsp;million and $1.9&nbsp;million which includes accretion of interest, are included in accrued expenses and accrued expenses long-term on the consolidated balance sheets as of
December&nbsp;31, 2020 and December&nbsp;31, 2019, respectively. Interest expense related to the discounted obligation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-11 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
was $49,422 and $39,281 for the years ended December 31, 2020 and 2019, respectively. In the event that the Company achieves certain milestones, milestone payments will become due, as well as
royalties due on future sales. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2019, the Company, through one of its wholly owned subsidiaries, entered into an asset purchase agreement and acquired
intellectual property from Prophylix AS for $1.2&nbsp;million. Pursuant to the agreement, the Company assumed liabilities for a sign on licensing fee in the amount of $0.1&nbsp;million, reimbursements for a manufacturing fee in the amount of
$0.5&nbsp;million and manufacturing liabilities in the form of future commitments of approximately $1.2&nbsp;million. The assets purchased and liabilities assumed, with the exception of the manufacturing commitment, were expensed upon purchase given
the uncertainty of probable future revenue streams and are included in research and development expense on the consolidated statements of operations and comprehensive loss. Costs associated with the manufacturing commitment are expensed to research
and development within the consolidated statements of operations and comprehensive loss, as the manufacturer fulfills its obligations. In the event that the Company achieves certain development and commercial milestones, milestone payments will
become due, as well as royalties on future sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>4. PROPERTY AND EQUIPMENT, NET </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Property and equipment consisted of the following as of December&nbsp;31, 2020 and 2019: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Computer and other equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Capitalized software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment&#151;net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Depreciation expense totaled $62,030 and $26,344 for the years ended December&nbsp;31, 2020 and 2019, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>5. ACCRUED EXPENSES </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accrued expenses consisted of the following at
December&nbsp;31, 2020 and 2019: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Employee expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Asset purchase obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unfunded obligation in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">$4,264</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">$2,949</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>6. REDEEMABLE CONVERTIBLE PREFERRED UNITS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Preferred Units</B>&#151;In
April 2018, Rallybio Holdings, LLC entered into a Series A Preferred Stock Purchase Agreement (the &#147;Series A Agreement&#148;) with a total potential aggregate purchase price $37.0&nbsp;million. Under the terms of the Series A Agreement,
Rallybio Holdings, LLC agreed to sell 5,999,999 units of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Redeemable Convertible Preferred Units (&#147;Series <FONT STYLE="white-space:nowrap">A-1</FONT> Units&#148;) to investors at a price of
$1.00 per share and up to 26,956,516 shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Redeemable Convertible Preferred Units (&#147;Series <FONT STYLE="white-space:nowrap">A-2</FONT> Units&#148;), upon the Company&#146;s achievement of
certain milestone events, to investors at a price of $1.15 per share (the &#147;Series A Financing Right Obligation&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-12 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2018, Rallybio Holdings, LLC sold 5,549,999 Series <FONT STYLE="white-space:nowrap">A-1</FONT> Units to investors
in exchange for $5.5&nbsp;million. Additionally, the Company issued 450,000 Series <FONT STYLE="white-space:nowrap">A-1</FONT> Units to the Company&#146;s founders in exchange for a capital contribution of convertible debt totaling $0.5&nbsp;million
owed to the founders by Rallybio, LLC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the Series A Agreement, the Company entered into a Connecticut Presence Agreement (the &#147;CPA&#148;)
with Connecticut Innovation, Incorporated (&#147;CII&#148;) relating to Series <FONT STYLE="white-space:nowrap">A-1</FONT> and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Units that would be issued to CII. The CPA provides that the proceeds
from CII&#146;s investment in the Company&#146;s preferred units be paid back to CII at a specified price. The CPA is only exercisable upon the Company&#146;s breach of the covenant which requires it to maintain a Connecticut presence, as defined
within the CPA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the Series A Agreement, the Company granted investors the right to purchase Series <FONT STYLE="white-space:nowrap">A-2</FONT>
Units at future milestone dates and at a predetermined price. Since the investors held rights that imposed an obligation on the Company to issue Preferred Units that were potentially redeemable, the future tranche rights were considered a
freestanding instrument and were recorded at the fair value of the tranche right and classified as a liability. Changes in the fair value of this liability are recorded in prior period earnings. The milestones were met during 2019, and preferred
units were redeemed by the investor and the liability attributable to the tranche rights was reclassified to Series A Preferred Units, as such, the freestanding instrument and the fair value of the tranche right a liability was $0.0 as of
December&nbsp;31, 2019. Refer to Note 2 fair value measurements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2019, upon achievement of certain milestones, the Company sold 27,478,256 Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Units to investors, founders and employees in exchange for $31.6&nbsp;million. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2020, with subsequent offerings
through May 2020, the Company entered into a Series B Preferred Stock Purchase Agreement (the &#147;Series B Agreement&#148;) with a total aggregate purchase price $145.2 million. Under the terms of the Series B Agreement, the Company agreed to sell
104,442,965 units of Series B Redeemable Convertible Preferred Units (&#147;Series B Units&#148;) to investors at a price of $1.39028 per share. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Series A and B
Preferred Units, (&#147;preferred units&#148;) have the following rights, preferences, and privileges: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Voting Rights</I></B>&#151;The holders of the
preferred units are entitled to vote together as a single class and on an as converted to common units basis in accordance with each such holder&#146;s percentage interests. In addition, the preferred units holders shall have the right to vote
separately as a series on any matter which would adversely alter or change the rights, powers or preferences of one series without a similar effect on the other series. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Conversion Rights&#151;</I></B>Each preferred unit is convertible, at the option of the holder thereof, at any time and from time to time, and without the payment
of additional consideration, into fully paid and nonassessable common units. The number of common units into which each preferred unit may be converted shall be determined by dividing the number of preferred units by their applicable original issue
price, potentially subject to adjustment for anti-dilution provisions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each preferred unit is automatically converted into fully paid and nonassessable common
units upon either the closing of the sale of common units to the public at a price of at least $2.08542 per unit in a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as
amended, resulting in at least $50.0&nbsp;million of gross proceeds to the Company, or at the occurrence of an event, specified in writing by the preferred units holders. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Dividends</I></B>&#151;The holders of preferred units may receive distributions declared and paid on the preferred units when determined by the Company&#146;s
Board of Managers. The Company may not declare, pay or set aside any distributions on any common units unless the preferred units holders first receive, or simultaneously receive, a distribution on each outstanding preferred unit in an amount at
least equal to the greater of 8% of the applicable original issue price of the preferred units, per year, from and after the date of the issuance on a <FONT STYLE="white-space:nowrap">non-cumulative</FONT> basis of any preferred units or the <FONT
STYLE="white-space:nowrap">pro-rata</FONT> distribution that the preferred units holder would receive had they converted their preferred units into common units. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No dividends were declared or paid during the years ended December&nbsp;31, 2020 and 2019. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Redemption Rights</I></B>&#151;The preferred units are only redeemable pursuant to a deemed liquidation event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-13 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Anti-Dilution Provisions</I></B>&#151;If the Company makes adjustments to any class of units for dividends, splits,
combinations or other similar events, or issues additional securities at a purchase price less than current conversion price for issued and outstanding preferred units, the preferred units conversion price shall be adjusted in accordance with a
formula, as defined in the Company&#146;s Operating Agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidation</I></B>&#151;The preferred units have preferential rights with respect to any
dissolution or liquidation of the Company and with respect to a sale of the Company. In the event of a dissolution, liquidation, or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, the holders of the preferred units are entitled to
receive, in preference to the holders of the common units and the incentive units, an amount equal to their original issue price. After payment of this preferential amount, remaining proceeds are distributed in accordance with a formula as defined
in the Operating Agreement for the Company. This formula provides additional preferences to the preferred unit holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>7. MEMBERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Common Units</B>&#151;In 2018, the Company issued 4,500,000 common units to its founders, including 3,375,000 restricted common units that vest over a four year
period. In 2018, the Company also issued 1,200,000 restricted common units to the founders, pursuant to restricted share purchase agreements, which begin vesting upon achievement of certain performance conditions. These restricted common units vest
into common units and therefore have been presented as common units within the consolidated statement of changes in redeemable convertible preferred units and members&#146; deficit. Restricted common units issued to the founders vest 25% upon the <FONT
STYLE="white-space:nowrap">1-year</FONT> anniversary of the Company initiating a clinical program through one of its controlled subsidiaries, monthly thereafter over the next 36 months. In 2019, it was determined that the performance condition of
these restricted common units became probable, vesting started, and the units began being expensed over the vesting period. No other restricted common units were granted in 2020 or 2019. Each common unit entitles the holder to one vote on all
matters submitted to a vote of the Company&#146;s members. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At December&nbsp;31, 2020 and 2019, of the 4,500,000 common units issued to the founders, 2,812,500 and
1,968,750 of these restricted common units were fully vested, respectively, and the remaining 1,687,500 and 2,531,250 units vest over the remaining weighted average period of 1.30 and 2.33 years, respectively. During the years ended
December&nbsp;31, 2020 and 2019, the Company recognized $0.1&nbsp;million of equity-based compensation expense relating to the issuance of these restricted common units for both years. As of December&nbsp;31, 2020 and 2019, there was
$0.2&nbsp;million and $0.3&nbsp;million of compensation expense relating to these restricted common units that remains to be amortized over the weighted average period of 1.30 and 2.33 years, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At December&nbsp;31, 2020 and 2019, of the 1,200,000 restricted common units issued to the founders that were issued subject to performance-based vesting conditions,
375,000 and 0 of these restricted common units were fully vested, respectively, and the remaining 825,000 and 1,200,000 units are expected to vest over the remaining weighted average period of 2.70 and 3.71 years, respectively.&nbsp;During the years
ended December&nbsp;31, 2020 and 2019, the Company recognized equity-based compensation expense of $95,584 and $13,125, respectively, on these restricted common units. At December&nbsp;31, 2020 and 2019, there was $0.1&nbsp;million and
$0.2&nbsp;million of compensation expense that remained to be amortized over a weighted average period of 2.70 and 3.71 years, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Incentive
Units</B>&#151;At December&nbsp;31, 2020 and 2019, the Company has reserved 18,972,360 and 7,233,957 common units, respectively, for issuance to officers and other employees of the Company pursuant to the Rallybio Holdings, LLC 2018 Share Plan
(&#147;2018 Share Plan&#148;). The reserve includes 1,200,000 restricted common units that were issued to the founders in 2018, discussed further below. At December&nbsp;31, 2020 and 2019, 10,906,656 and 4,400,957 incentive units, respectively,
remained available for future grants. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the years ended 2020 and 2019, 5,232,704 and 1,423,000 incentive units were issued to employees of the Company,
respectively. During the years ended December&nbsp;31, 2020 and 2019, the Company recognized equity-based compensation expense of $0.5&nbsp;million and $0.1&nbsp;million, respectively, relating to the issuance of incentive units. At
December&nbsp;31, 2020 and 2019, there was $2.2&nbsp;million and $0.5&nbsp;million of equity-based compensation expense that remains to be amortized over a weighted average period of 3.22 and 3.36 years, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-14 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The assumptions that went into the option pricing models for determining the fair value of our incentive units granted in
2020 and 2019 are as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected time to liquidity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.74</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table provides a summary of the activity under the 2018 Share Plan for incentive
units granted to employees. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INCENTIVE&nbsp;UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,423,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,633,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,232,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,865,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At December&nbsp;31, 2020 and 2019, 6,865,704 and 1,633,000 incentive units granted under the 2018 Share Plan are outstanding and expected to vest, respectively. At
December&nbsp;31, 2020 and 2019, 495,182 and 112,292 incentive units are fully vested, respectively, and the remaining 6,370,522 and 1,520,708 units are expected to vest over a weighted average period of 3.12 and 3.49 years, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Equity-based compensation, including common and incentive units are classified in the consolidated statements of operations and comprehensive loss for years ended
December&nbsp;31, 2020 and 2019 as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and Development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and Administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>8. INCOME TAXES </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The combined provision for income taxes of tax paying
subsidiaries of the Company is comprised of the following for the years ended December&nbsp;31, 2020 and 2019: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-15 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s effective income tax rates are different from the federal statutory tax rates in 2020 and 2019
predominantly due to the valuation allowance, tax credits, state taxes, and the federal net operating loss carryback tax benefit described below. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">U.S. federal statutory tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">State income taxes, net of federal income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33.6</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Effective Tax Rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March&nbsp;27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#147;CARES Act&#148;) was enacted in response to the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The CARES Act, among other things, allows net operating losses incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years to generate a refund of
previously paid income taxes. The CARES Act also eliminates the 80% of taxable income limitation allowing corporate entities to fully utilize net operating loss carryforwards to offset taxable income in 2018, 2019 and 2020. During 2019, two of the
Company&#146;s wholly owned, subsidiaries generated federal net operating losses in 2019, and in December 2020, each subsidiary filed Forms 1139 to carryback these losses and offset all remaining taxable income in the 2018 tax year. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">GAAP requires balance sheet presentation to reflect when the assets are expected to be monetized. Forms 1139 were filed in December 2020, and a refund is expected
within the next twelve months. The Company has reclassed the amount of <FONT STYLE="white-space:nowrap">tax-effected</FONT> net operating losses, which have been utilized on the Form 1139 carryback claims, from a deferred tax asset to a current
income tax receivable. Since the Company has provided a valuation allowance against the Company&#146;s deferred tax assets, this reclass has an impact on total income tax expense/(benefit). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On December&nbsp;27, 2020 the Consolidated Appropriations Act, 2021 (&#147;CAA&#148;) was signed into law. The CAA includes the COVID-related Tax Relief Act of 2020
(&#147;COVID TRA&#148;). The Company is continuing to assess the effect of the CAA and does not believe it will result in a material impact to the Company&#146;s income tax provision. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Deferred income taxes represent the tax effect of transactions that are reported in different periods for financial and tax reporting purposes. The combined temporary
differences and carryforwards of each tax paying component of the Company that give rise to a significant portion of the deferred income tax benefits and liabilities are as follows at December&nbsp;31, 2020 and 2019: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B><U>DEFERRED INCOME TAX ASSETS:</U></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>(in
thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total deferred income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net deferred income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At December&nbsp;31, 2020, the Company has approximately $38.7&nbsp;million of federal net operating loss carryforwards, which do not expire, and approximately
$38.8&nbsp;million of state net operating loss carryforwards, which begin expiring in 2038. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-16 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has provided a valuation allowance against the Company&#146;s deferred tax assets, since, in the opinion of
management, based upon the history of losses by the Company; it is not more likely than not that the benefits will be realized. All or a portion of the remaining valuation allowance may be reduced in future years based on an assessment of earnings
sufficient to fully utilize these potential tax benefits. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">ASC 740 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax
return should be recorded in the financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination by the taxing
authorities, based on the technical merits of the position. The Company has no material uncertain tax positions that qualify for either recognition or disclosure in consolidated financial statements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">It is the Company&#146;s policy to recognize interest and/or penalties related to income tax matters in income tax expense. As of December&nbsp;31, 2020 and 2019, the
Company has accrued no interest and penalties related to uncertain tax positions. The Company does not have any outstanding U.S. federal income tax or material state and local tax matters for periods through December&nbsp;31, 2020. There are no
federal or state and local income tax returns currently under examination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>9. INVESTMENT IN JOINT VENTURE </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2019, the Company through one its wholly-owned subsidiaries, entered into an agreement to establish a joint venture with Exscientia Limited
(&#147;Exscientia&#148;) to initiate early stage drug discovery on available small molecules and thereafter the future research, development, manufacture, sale and exploitation of any company-owned technology and compounds, including candidate
compounds that result therefrom. In July 2019, the Company and Exscientia completed the formation of the joint venture entity, RE Ventures I, LLC, a limited liability corporation <FONT STYLE="white-space:nowrap">(&#147;REV-I&#148;).</FONT> </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each member received a 50% interest when the joint venture was created. Pursuant to the operating agreement, at inception of the joint venture the Company was obligated
to initially contribute &pound;0.5&nbsp;million, or $0.6&nbsp;million, to fund stage I development. The Company&#146;s initial investment in REV-I in the amount of $0.6&nbsp;million at December 31, 2019 was unfunded and included in accrued expenses
on the consolidated balance sheets. The unfunded obligation was subsequently funded in January 2020. In 2020, REV-I determined that the stage 1 development objective had been achieved. During 2020, the Company funded an additional $1.3 million
associated with stage 2 development costs. The Company did not provide any additional financial support outside of capital contributions to REV-I during the years ended December 31, 2020 and 2019. The Company held a 50% interest in the joint venture
as of December 31, 2020. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on management&#146;s analysis, the Company is not the primary beneficiary of <FONT STYLE="white-space:nowrap">REV-I</FONT> since it
does not have both (1)&nbsp;the power to direct the activities that most significantly impact the entity&#146;s economic performance which consists primarily of research and development activities and (2)&nbsp;the obligation to absorb the losses of
the VIE or the right to receive the benefits from the VIE, which could be significant to the VIE. The research and development activities of REV-I are controlled by a management board under the joint control of the Company and Exscientia. All
decisions are made by consensus with each member having one vote. Accordingly, the VIE is not consolidated in the Company&#146;s financial statements as of December&nbsp;31, 2020. The Company accounts for its 50% interest under the equity method of
accounting. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the year ended December&nbsp;31, 2020 and 2019, the Company recorded its allocable share of <FONT STYLE="white-space:nowrap">REV-I&#146;s</FONT>
losses, which totaled $1.5&nbsp;million and $0.1&nbsp;million, respectively, as a loss on investment in joint venture within the consolidated statements of operations and comprehensive loss. After recognition of its share of losses for the year, the
carrying value and maximum exposure to risk of the <FONT STYLE="white-space:nowrap">REV-I</FONT> investment as of December&nbsp;31, 2020 and 2019, was $0.3&nbsp;million and $0.5&nbsp;million, respectively, which was recorded in investment in joint
venture in the accompanying consolidated balance sheets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-17 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>10. COMMITMENTS AND CONTINGENCIES </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Purchase Commitments&#151;</B>We enter contracts in the normal course of business with contract research organizations and other third-party vendors for clinical
trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancellable by us upon written notice. Payments that may be due upon cancellation consist of payments for services provided
or expenses incurred. As of December&nbsp;31, 2020, and 2019 there were no amounts accrued related to termination charges. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Lease Commitments</B>&#151; In June
2019, the Company entered into a <FONT STYLE="white-space:nowrap">six-year</FONT> lease to occupy office space located in New Haven, Connecticut, with the option to extend the initial term of the lease for one additional five year term. Pursuant to
the lease the Company was obligated to pay for its share of costs related to the <FONT STYLE="white-space:nowrap">build-out</FONT> of new space. All costs associated with the <FONT STYLE="white-space:nowrap">build-out</FONT> of the new space have
been capitalized as leasehold improvements and are being amortized over the life of the lease. In October 2020, the Company modified the existing New Haven lease agreement and leased additional space that coincides with the original lease term
expiration date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rent expense was $87,833 and $42,429 for the years ended December&nbsp;31, 2020 and 2019, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Future minimum annual lease payments are as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B><U>YEAR ENDING DECEMBER&nbsp;31</U></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>(in
thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">$507</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>11. NET LOSS PER COMMON UNIT </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Basic and diluted loss per common unit were
calculated as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B><U>NET LOSS PER COMMON UNIT</U></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>(in thousands except
share and per share amounts)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss attributable to common units-basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average number of common units outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,659,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,715,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per common unit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9.95</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following common stock equivalents have been excluded from the calculations of diluted loss per common unit because their inclusion would have been antidilutive:
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B><U>ANTIDILUTIVE UNITS</U></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unvested restricted common units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2,512,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3,731,250</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Incentive units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,865,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,633,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A Preferred Units, as converted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,478,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,478,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B Preferred Units, as converted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,442,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,299,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,842,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-18 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>12. SUBSEQUENT EVENTS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Company evaluated all material subsequent events through April&nbsp;27, 2021, the date the consolidated financial statements were available to be issued. The following events occurred subsequent to December&nbsp;31, 2020. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In January 2021, the Board of Managers of the Company approved an increase in the employee stock plan incentive pool shares available by an additional 4,000,000 common
units, for issuance to officers, managers, employees and consultants of the Company pursuant to the 2018 Share Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-19 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO HOLDINGS, LLC AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin99471_7"></A>Condensed Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MARCH&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">127,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">140,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">129,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">141,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Liabilities and members&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Commitments and contingencies (Note 7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable convertible preferred units:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A preferred units, no par value, 33,478,255 units authorized,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">issued and outstanding as of March&nbsp;31, 2021 and December&nbsp;31,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2020; liquidation preference of $37,600 as of March&nbsp;31, 2021 and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B preferred units, no par value, 104,442,965 units authorized,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">issued and outstanding as of March&nbsp;31, 2021 and December&nbsp;31,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2020; liquidation preference of $145,204 as of March&nbsp;31, 2021 and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Members&#146; deficit:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Common units, no par value, 5,700,000 issued and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">outstanding as of March&nbsp;31, 2021 and December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Incentive units, 19,934,704 and 6,865,704 issued and outstanding as of March&nbsp;31, 2021 and
December&nbsp;31, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,014</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total members&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities, redeemable convertible preferred units, and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">members&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">129,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">141,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes of the condensed consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-20 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO HOLDINGS, LLC AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin99471_8"></A>Condensed Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE MONTHS ENDED</B><br><B>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating Expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,824</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,844</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income (expenses):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,749</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss on investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss attributable to common units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per common unit, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average common units outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,228,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,968,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes of the condensed consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-21 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO HOLDINGS, LLC AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin99471_9"></A>Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Units and Members&#146; Deficit </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES A REDEEMABLE</B><br><B>CONVERTIBLE&nbsp;PREFERRED<BR>UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES B REDEEMABLE</B><br><B>CONVERTIBLE&nbsp;PREFERRED<BR>UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>COMMON UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INCENTIVE UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share<BR>amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL<BR>MEMBERS&#146;<BR>DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,478,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,633,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of Series B Redeemable Convertible Preferred Units, net of issuance costs of $248</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,457,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Incentive unit-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Common unit-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Balance, March&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,478,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,457,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,633,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,448</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,057</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,478,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,442,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">144,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,865,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(47,014</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Incentive unit-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,069,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Common unit-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Balance, March&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,478,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,442,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">144,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,934,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(60,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(58,777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes of the condensed consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-22 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO HOLDINGS, LLC AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin99471_10"></A>Condensed Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE MONTHS ENDED</B><br><B>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash Flows from Operating Activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Equity based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss on investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(981</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,172</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(630</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,929</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash Flows used in Investing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Investment in joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(590</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(562</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash Flows from Financing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of Series B preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.89em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents&#151;beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents&#151;end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">127,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">98,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Supplemental disclosures of noncash activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B preferred unit issuance costs in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B preferred unit receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">See accompanying notes of the condensed consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-23 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RALLYBIO HOLDINGS, LLC AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin99471_11"></A>Notes to Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>1. BUSINESS AND LIQUIDITY </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rallybio Holdings, LLC holds 100% of the
outstanding membership units in five wholly-owned subsidiaries&#151;Rallybio, LLC, Rallybio IPA, LLC, Rallybio IPB, LLC, Rallybio, IPD, LLC, and IPC Research, LLC (collectively, the &#147;Company&#148;). Rallybio Holdings, LLC was incorporated in
Delaware on March&nbsp;22, 2018. The Company is a clinical-stage biotechnology company built around a team of seasoned industry experts with a shared purpose and a track record of success in discovering, developing, manufacturing, and delivering
therapies to meaningfully improve the lives of patients suffering from severe and rare diseases. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has raised $37.6&nbsp;million in <FONT
STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT> financing and $145.2&nbsp;million in Series&nbsp;B financing. Refer to Note 4 &#147;Redeemable Convertible Preferred Units&#148;. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2020, the World Health Organization characterized the novel coronavirus as a global pandemic. Although there is significant uncertainty as to the likely
effects this disease may have in the future, to date there has not yet been a significant impact to the Company&#146;s operations or financial statements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Liquidity and Ability to Continue as a Going Concern</B>&#151;The accompanying consolidated financial statements have been prepared assuming that the Company will
continue as a going concern. Management has evaluated whether there are conditions and events that raise substantial doubt about the Company&#146;s ability to continue as a going concern within one year after the date the financial statements are
issued. Since its inception, the Company has incurred net losses and negative cash flows from operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the three months ended March&nbsp;31 2021 and
2020, the Company incurred a net loss of $13.3&nbsp;million and $3.9&nbsp;million, respectively, and used $11.9&nbsp;million and $5.5&nbsp;million in cash for operations, respectively. In addition, as of March&nbsp;31, 2021, the Company had an
accumulated deficit of $60.3&nbsp;million. The Company expects to continue to generate operating losses and negative cash flows in the foreseeable future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Company currently expects that the cash and cash equivalents on hand of $127.7&nbsp;million as of March&nbsp;31, 2021, will be sufficient to fund its operating expenses and capital requirements for more than 12 months from the date the consolidated
financial statements are issued. Additional funding will be needed to finance future clinical, <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> manufacturing, and commercial activities. To date, the Company has principally financed its
operations through private placements of redeemable convertible preferred units. In the event the Company does not complete an IPO, the Company will seek additional funding through private equity and debt financings and other arrangements. There is
no assurance the Company will be successful in obtaining such additional financing on terms acceptable to it, if at all, and it may not be able to enter into other arrangements. If the Company is unable to obtain funding, it could be forced to
delay, reduce or eliminate our research and development programs, portfolio expansion or commercialization efforts, which could adversely affect its business prospects and ability to continue operations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is subject to risks common to companies in the biopharmaceutical industry. There can be no assurance that the Company&#146;s research and development will
be successfully completed, that adequate protection for its intellectual property will be maintained, that any products developed will obtain required regulatory approval, or that any approved products will be commercially viable. Even if the
development efforts are successful, it is uncertain when, if ever, the Company will generate significant product sales and ultimately net income. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2. SUMMARY OF
SIGNIFICANT ACCOUNTING POLICIES BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Unaudited Financial Information</B>&#151;Our condensed consolidated
financial statements included herein have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP, and pursuant to the rules and regulations of the Securities and Exchange Commission, or
SEC. In our opinion, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the financial position and results of operations for the reported interim periods. We
consider events or transactions that occur after the balance sheet date but before the financial statements are issued to provide </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-24 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of
results to be expected for the full year or any other interim period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&nbsp;reviews&nbsp;new accounting standards as issued. As of March&nbsp;31, 2021
the Company has not identified any new standards that it believes will have a significant impact on the Company&#146;s financial statements. However, the Company is still evaluating the impact of adopting ASU
<FONT STYLE="white-space:nowrap">2016-02,</FONT> <I>Leases</I> on its condensed consolidated financial statements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There were no changes to the Company&#146;s
significant accounting policies during the three months ended March&nbsp;31, 2021 other than noted below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Deferred Offering Costs</B>&#151;The Company
capitalizes incremental legal, professional accounting and other third-party fees that are directly associated with the IPO as other current assets until the IPO is consummated. After consummation of the IPO, these costs will be recorded in
members&#146; deficit as a reduction of additional <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-capital</FONT></FONT> generated as a result of the offering. As of March&nbsp;31, 2021, there were deferred offering costs
of approximately $0.3&nbsp;million included in prepaid expenses and other assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>3. ACCRUED EXPENSES </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accrued expenses consisted of the following as of March&nbsp;31, 2021and December&nbsp;31, 2020: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MARCH&nbsp;31,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Employee expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Asset purchase obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>4. REDEEMABLE CONVERTIBLE PREFERRED UNITS </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Preferred Units</B>&#151;In April 2018, Rallybio Holdings, LLC entered into a Series A Preferred Stock Purchase Agreement (the &#147;Series A Agreement&#148;) with a
total potential aggregate purchase price $37.0&nbsp;million. Under the terms of the Series A Agreement, Rallybio Holdings, LLC agreed to sell 5,999,999 units of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Redeemable Convertible Preferred
Units (&#147;Series <FONT STYLE="white-space:nowrap">A-1</FONT> Units&#148;) to investors at a price of $1.00 per share and up to 26,956,516 shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Redeemable Convertible Preferred Units
(&#147;Series <FONT STYLE="white-space:nowrap">A-2</FONT> Units&#148;), upon the Company&#146;s achievement of certain milestone events, to investors at a price of $1.15 per share (the &#147;Series A Financing Right Obligation&#148;). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2018, Rallybio Holdings, LLC sold 5,549,999 Series <FONT STYLE="white-space:nowrap">A-1</FONT> Units to investors in exchange for $5.5&nbsp;million.
Additionally, the Company issued 450,000 Series <FONT STYLE="white-space:nowrap">A-1</FONT> Units to the Company&#146;s founders in exchange for a capital contribution of convertible debt totaling $0.5&nbsp;million owed to the founders by Rallybio,
LLC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the Series A Agreement, the Company entered into a Connecticut Presence Agreement (the &#147;CPA&#148;) with Connecticut Innovation,
Incorporated (&#147;CII&#148;) relating to Series <FONT STYLE="white-space:nowrap">A-1</FONT> and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Units that would be issued to CII. The CPA provides that the proceeds from CII&#146;s investment in
the Company&#146;s preferred units be paid back to CII at a specified price. The CPA is only exercisable upon the Company&#146;s breach of the covenant which requires it to maintain a Connecticut presence, as defined within the CPA. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with the Series A Agreement, the Company granted investors the right to purchase Series <FONT STYLE="white-space:nowrap">A-2</FONT> Units at future
milestone dates and at a predetermined price. Since the investors held rights that imposed an obligation on the Company to issue Preferred Units that were potentially redeemable, the future tranche rights were considered a freestanding instrument
and were recorded at the fair value of the tranche right and classified as a liability. Changes in the fair value of this liability are recorded in prior period earnings. The milestones were met during 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-25 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2019, upon the achievement of the certain milestones, the Company sold 27,478,256 Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Units to investors, founders and employees in exchange for $31.6&nbsp;million. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2020 the Company entered into a
Series B Preferred Stock Purchase Agreement (the &#147;Series B Agreement&#148;) with a total aggregate purchase price of $91.1&nbsp;million. Under the terms of the Series B Agreement, the Company agreed to sell 61,457,763 units of Series B
Redeemable Convertible Preferred Units (&#147;Series B Units&#148;) to investors at a price of $1.48 per share. The Company received proceeds of $85.1&nbsp;million as of March&nbsp;31, 2020. The remaining $6.0&nbsp;million was received on
April&nbsp;1, 2020. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April and May 2020, the Company entered into subsequent offerings of the Series B Agreement increasing the total aggregate purchase price
$145.2&nbsp;million. Under the terms of the updated Series B Agreement, the Company agreed to sell 104,442,965 total Series B Units to investors at a price of $1.39028 per share. An additional 4.2&nbsp;million units were granted to investors in May
2020 who participated in prior offerings. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Series A and B Preferred Units, (&#147;preferred units&#148;) have the following rights, preferences, and privileges:
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Voting Rights</I></B>&#151;The holders of the preferred units are entitled to vote together as a single class and on an as converted to common units basis in
accordance with each such holder&#146;s percentage interests. In addition, the preferred units holders shall have the right to vote separately as a series on any matter which would adversely alter or change the rights, powers or preferences of one
series without a similar effect on the other series. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Conversion Rights&#151;</I></B>Each preferred unit is convertible, at the option of the holder thereof,
at any time and from time to time, and without the payment of additional consideration, into fully paid and nonassessable common units. The number of common units into which each preferred unit may be converted shall be determined by dividing the
number of preferred units by their applicable original issue price, potentially subject to adjustment for anti-dilution provisions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each preferred unit is
automatically converted into fully paid and nonassessable common units upon either the closing of the sale of common units to the public at a price of at least $2.08542 per unit in a firm commitment underwritten public offering pursuant to an
effective registration statement under the Securities Act of 1933, as amended, resulting in at least $50.0&nbsp;million of gross proceeds to the Company, or at the occurrence of an event, specified in writing by the preferred units holders. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Dividends</I></B>&#151;The holders of preferred units may receive distributions declared and paid on the preferred units when determined by the Company&#146;s
Board of Managers. The Company may not declare, pay or set aside any distributions on any common units unless the preferred units holders first receive, or simultaneously receive, a distribution on each outstanding preferred unit in an amount at
least equal to the greater of 8% of the applicable original issue price of the preferred units, per year, from and after the date of the issuance on a <FONT STYLE="white-space:nowrap">non-cumulative</FONT> basis of any preferred units or the <FONT
STYLE="white-space:nowrap">pro-rata</FONT> distribution that the preferred units holder would receive had they converted their preferred units into common units. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No dividends were declared or paid during the three months ended March&nbsp;31, 2021 and 2020. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Redemption Rights</I></B>&#151;The preferred units are only redeemable pursuant to a deemed liquidation event. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Anti-Dilution Provisions</I></B>&#151;If the Company makes adjustments to any class of units for dividends, splits, combinations or other similar events, or
issues additional securities at a purchase price less than current conversion price for issued and outstanding preferred units, the preferred units conversion price shall be adjusted in accordance with a formula, as defined in the Company&#146;s
Operating Agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidation</I></B>&#151;The preferred units have preferential rights with respect to any dissolution or liquidation of the Company and
with respect to a sale of the Company. In the event of a dissolution, liquidation, or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, the holders of the preferred units are entitled to receive, in preference to the holders of the
common units and the incentive units, an amount equal to their original issue price. After payment of this preferential amount, remaining proceeds are distributed in accordance with a formula as defined in the Operating Agreement for the Company.
This formula provides additional preferences to the preferred unit holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-26 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>5. MEMBERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Common Units</B>&#151;As of March&nbsp;31, 2021 and December&nbsp;31, 2020, the Company has authorized 165,393,580 and 161,393,580 common units, respectively,
pursuant to the terms of the Company&#146;s Operating Agreement, which includes 137,921,220 common units reserved for issuance upon conversion of preferred units. Additionally, of the total common units authorized, 22,972,360 and 18,972,360 common
units are reserved for issuance to officers and employees of the Company pursuant to the Rallybio Holdings, LLC 2018 Share Plan (&#147;2018 Share Plan&#148;) at March&nbsp;31, 2021 and December&nbsp;31, 2020, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2018, the Company issued 4,500,000 common units to its founders, including 3,375,000 common units that vest over a four year period. In 2018, the Company also issued
1,200,000 restricted common units to the founders, pursuant to restricted share purchase agreements, which begin vesting upon achievement of certain performance conditions. These restricted common units vest into common units and therefore have been
presented as common units within the condensed consolidated statement of changes in redeemable convertible preferred units and members&#146; deficit. Restricted common units issued to the founders vest 25% upon the
<FONT STYLE="white-space:nowrap">1-year</FONT> anniversary of the Company initiating a clinical program through one of its controlled subsidiaries, and monthly thereafter over the next 36 months. In 2019, it was determined that the performance
condition of these restricted common units became probable, vesting started, and the units started expensing over the vesting period. No other common or restricted common units were granted or forfeited in the three months ended March&nbsp;31, 2021.
Each common unit entitles the holder to one vote on all matters submitted to a vote of the Company&#146;s members. The weighted average fair value of both the 4,500,000 common units and 1,200,000 restricted common units granted during 2018 was
$0.15. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of both March&nbsp;31, 2021 and December&nbsp;31, 2020, of the 4,500,000 common units issued to the founders, 2,812,500 of these restricted common units
were fully vested, and 1,687,500 units remain unvested. For each of the three months ended March&nbsp;31, 2021 and 2020, the Company recognized $31,641, of equity-based compensation expense relating to the issuance of these restricted common units.
As of&nbsp;March&nbsp;31, 2021 there was $0.1&nbsp;million of compensation expense relating to these restricted common units that remains to be amortized over the weighted average period of 1.1 years. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At March&nbsp;31, 2021 and December&nbsp;31, 2020, of the 1,200,000 restricted common units issued to the founders that were issued subject to performance-based vesting
conditions, 450,000 and 375,000 of these restricted common units were fully vested, respectively, and 750,000 and 825,000 units remain unvested, respectively.&nbsp;During the three months ended March&nbsp;31, 2021 and 2020, the Company recognized
equity-based compensation expense of $10,461 and $38,501, respectively, on these restricted common units. At March&nbsp;31, 2021 there was $0.1&nbsp;million of compensation expense that remained to be amortized over a weighted average period of 1.3
years. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Incentive Units</B>&#151;As of March&nbsp;31, 2021 and December&nbsp;31, 2020, the Company is authorized to issue up to an aggregate of 22,972,360 and
18,972,360 incentive units, respectively pursuant to the Plan. The reserve includes 1,200,000 restricted common units that were issued to founders in 2018. Incentive units are granted to employees and generally vest over a four year period. As of
March&nbsp;31, 2021, 1,837,656 incentive units, remained available for future grants. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the three months ended March&nbsp;31, 2021, the Company granted
13,069,000 incentive units to employees under the Plan. The weighted average fair value of incentive units granted to employees in the three months ended March&nbsp;31, 2021 was $0.33 per unit. The Company did not grant any incentive units for the
three months ended March&nbsp;31, 2020. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the three months ended March&nbsp;31, 2021 and 2020, the Company recognized equity-based compensation expense of
$479,791 and $34,588, respectively, relating to the issuance of incentive units. At&nbsp;March&nbsp;31, 2021, there was $6.1&nbsp;million of equity-based compensation expense remaining that is expected to be amortized over a weighted average period
of 3.5 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-27 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The assumptions that went into the option pricing models for determining the fair value of our incentive units granted for
the three months ended March&nbsp;31, 2021 are as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MARCH&nbsp;31, 2021</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">77.3%&nbsp;-&nbsp;99.5%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">0.58&nbsp;-&nbsp;1.00</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">.09%&nbsp;-&nbsp;0.1%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value of underlying common units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$0.47</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table provides a summary of the activity for the three months ended March&nbsp;31, 2021 under the 2018 Share Plan for incentive units granted to
employees: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>INCENTIVE<BR>UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED<BR>AVERAGE<BR>GRANT&nbsp;DATE<BR>FAIR&nbsp;VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,865,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,069,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding at March&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,934,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At March&nbsp;31, 2021 and December&nbsp;31, 2020, the Company had 19,934,704 and 6,865,704 incentive units granted under the 2018 Share Plan that are outstanding and
expected to vest, respectively. At March&nbsp;31, 2021 and December&nbsp;31, 2020, 715,913 and 495,182 incentive units are fully vested, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Equity-based
compensation, including common and incentive units are classified in the condensed consolidated statements of operations and comprehensive loss for the three months ended March&nbsp;31, 2021 and 2020 as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE&nbsp;MONTHS&nbsp;ENDED</B><br><B>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and Development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and Administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>6. INVESTMENT IN JOINT VENTURE </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has a 50% interest of the joint
venture entity, RE Ventures I, LLC, a limited liability corporation <FONT STYLE="white-space:nowrap">(&#147;REV-I&#148;).</FONT> For the three months ended March&nbsp;31, 2021, the Company funded an additional $0.5&nbsp;million associated with stage
2 development costs. For the three months ended March&nbsp;31, 2020 the Company funded the initial investment in <FONT STYLE="white-space:nowrap">REV-I</FONT> of $0.6&nbsp;million that was included in accrued expenses on the consolidated balance
sheets as of December&nbsp;31, 2019. The Company did not provide any additional financial support outside of capital contributions to <FONT STYLE="white-space:nowrap">REV-I</FONT> during the three months ended March&nbsp;31, 2021 and 2020. The
Company held a 50% interest in the joint venture as of March&nbsp;31, 2021. As of March&nbsp;31, 2021, based on management&#146;s analysis, the company is not the primary beneficiary of <FONT STYLE="white-space:nowrap">REV-1</FONT> and accordingly,
the entity is not consolidated in the Company&#146;s financial statements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the three months ended March&nbsp;31, 2021 and 2020, the Company recorded its
allocable share of <FONT STYLE="white-space:nowrap">REV-I&#146;s</FONT> losses, which totaled $0.5&nbsp;million and $0.1&nbsp;million, respectively, as a loss on investment in joint venture within the condensed consolidated statements of operations
and comprehensive loss. After recognition of its share of losses for the period, the carrying value and maximum exposure to risk of the <FONT STYLE="white-space:nowrap">REV-I</FONT> investment as of March&nbsp;31, 2021 and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-28 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
December&nbsp;31, 2020, was $0.3&nbsp;million and $0.3&nbsp;million, respectively, which was recorded in investment in joint venture in the accompanying condensed consolidated balance sheets.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>7. COMMITMENTS AND CONTINGENCIES </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Purchase Commitments</B>&#151;We
enter contracts in the normal course of business with contract research organizations and other third-party vendors for clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and
are cancellable by us upon written notice. Payments that may be due upon cancellation consisting of payments for services provided or expenses incurred. As of March&nbsp;31, 2021, and December&nbsp;31, 2020 there were no amounts accrued related to
termination charges. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Lease Commitments</B>&#151; In June 2019, the Company entered into a <FONT STYLE="white-space:nowrap">six-year</FONT> lease to occupy
office space located in New Haven, Connecticut, with the option to extend the initial term of the lease for one additional five year term. Pursuant to the lease the Company was obligated to pay for its share of costs related to the <FONT
STYLE="white-space:nowrap">build-out</FONT> of new space. All costs associated with the <FONT STYLE="white-space:nowrap">build-out</FONT> of the new space have been capitalized as leasehold improvements and are being amortized over the life of the
lease. In October 2020, the Company modified the existing New Haven lease agreement and leased additional space that coincides with the original lease term expiration date. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rent expense was $26,495 and $20,367 for the three months ended March&nbsp;31, 2021 and 2020, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There have been no significant changes to the disclosure of payments we have committed to make under our contractual obligations as summarized in our Audited Financial
Statements for the year ended December&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>8. NET LOSS PER COMMON UNIT </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Basic and diluted loss per common unit were calculated as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE MONTHS ENDED</B><br><B>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>NET LOSS PER COMMON UNIT</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>(in thousands except share and
per share amounts)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss attributable to common units-basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average number of common units outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,228,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,968,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per common unit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following common stock equivalents have been excluded from the calculations of diluted loss per common unit because their inclusion would have been antidilutive:
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>THREE MONTHS ENDED</B><br><B>MARCH&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>ANTIDILUTIVE UNITS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unvested restricted common units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,437,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,731,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Incentive units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,934,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,633,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A Preferred Units, as converted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,478,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,478,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B Preferred Units, as converted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,442,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,457,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160,293,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,300,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-29 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>9. SUBSEQUENT EVENTS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Company evaluated all material subsequent events through June&nbsp;7, 2021, the date the condensed consolidated financial statements were available to be issued. The Company noted the following material events occurred subsequent to March&nbsp;31,
2021. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May 2021, the Company contributed an additional $1.5&nbsp;million to <FONT STYLE="white-space:nowrap">REV-I</FONT> associated with stage 2 development
costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-30 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>  <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>5,750,000 Shares </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g99471g01k65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>PRELIMINARY PROSPECTUS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Evercore&nbsp;ISI</B></TD></TR>
</TABLE> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2021 </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PART&nbsp;II </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Information Not Required in Prospectus </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;13. Other Expenses of
Issuance and Distribution. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the costs and expenses, other than the underwriting discounts and commissions, payable by the
registrant in connection with the sale of common stock being registered. All amounts are estimates except for the SEC registration fee, the FINRA filing fee and the Nasdaq Global Market listing fee: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>ITEM</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT&nbsp;TO<BR>BE PAID</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Nasdaq listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">775,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Transfer agent fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,050,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>    <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;14. Indemnification of Directors and Officers. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As permitted by
Section&nbsp;102(b)(7) of the DGCL, we plan to include in our amended and restated certificate of incorporation a provision to eliminate the personal liability of our directors for monetary damages for breach of their fiduciary duties as directors,
subject to certain exceptions. In addition, our amended and restated certificate of incorporation and bylaws will provide that we are required to indemnify our officers and directors under certain circumstances, including those circumstances in
which indemnification would otherwise be discretionary, and we are required to advance expenses to our officers and directors as incurred in connection with proceedings against them for which they may be indemnified, in each case except to the
extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Section&nbsp;145(a) of the DGCL provides
that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative
(other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer,
employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection
with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interest of the corporation, and, with respect to any criminal action or proceeding, had no
reasonable cause to believe his conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent shall not, of itself, create a presumption that
the person did not act in good faith and in a manner which the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that
his conduct was unlawful. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Section&nbsp;145(b) of the DGCL provides that a corporation shall have the power to indemnify any person who was or is a party or is
threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of
the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys&#146; fees)
actually and reasonably incurred by him in connection with the defense or settlement of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-1 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and except that no
indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or
suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery
or such other court shall deem proper. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered into indemnification agreements with our directors and, prior to the completion of this offering, intend to
enter into indemnification agreements with certain of our officers. These indemnification agreements will provide broader indemnity rights than those provided under the DGCL and our amended and restated certificate of incorporation. These
indemnification agreements are not intended to deny or otherwise limit <FONT STYLE="white-space:nowrap">third-party</FONT> or derivative suits against us or our directors or officers, but to the extent a director or officer were entitled to
indemnity or contribution under the indemnification agreement, the financial burden of a <FONT STYLE="white-space:nowrap">third-party</FONT> suit would be borne by us, and we would not benefit from derivative recoveries against the director or
officer. Such recoveries would accrue to our benefit but would be offset by our obligations to the director or officer under the indemnification agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
underwriting agreement will provide that the underwriters are obligated, under certain circumstances, to indemnify our directors, officers and controlling persons against certain liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We maintain directors&#146; and officers&#146; liability insurance for the benefit of our directors and officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;15. Recent Sales of Unregistered Securities. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following list
sets forth information regarding all unregistered securities sold by us since January&nbsp;1, 2018. No underwriters were involved in the sales and the certificates representing the securities sold and issued contain legends restricting transfer of
the securities without registration under the Securities Act or an applicable exemption from registration. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>(a) &nbsp;&nbsp;&nbsp;&nbsp;Issuances of units
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2018, certain investors purchased an aggregate of 5,549,999 of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred units for an
aggregate of $5,549,999 at a price of $1.00 per unit. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2018, we issued an aggregate of 450,000 Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred
units to the Founders in exchange for their capital contributions of convertible debt for an aggregate of $450,000. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2019, certain investors purchased an
aggregate of 7,826,083 of our Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred units and our Founders and certain employees purchased an aggregate of 521,740 of our Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred units for
an aggregate of $9,599,996 at a price of $1.15 per unit. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2019, certain investors purchased an aggregate of 8,695,652 of our Series <FONT
STYLE="white-space:nowrap">A-2</FONT> preferred units for $10,000,000 at a price of $1.15 per unit. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2019, certain investors purchased an aggregate of
10,434,781 of our Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred units for $11,999,998 at a price of $1.15 per unit. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2020, certain investors
purchased an aggregate of 61,457,763 of our Series B preferred units for approximately $91,104,988 at a price of $1.4824 per unit. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2020, certain investors
purchased an aggregate of 1,416,621 of our Series B preferred units for approximately $2,099,999 at a price of $1.4824 per unit. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In May 2020, certain investors
purchased an aggregate of 37,402,537 of our Series B preferred units for approximately $51,999,999 at a price of $1.3903 per unit. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Also in May 2020, investors who
purchased Series B preferred units in March 2020 and April 2020 received an aggregate of 4,166,044 additional Series B preferred units, for no additional consideration, to provide such investors </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-2 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
with the benefit of the lower purchase price paid by investors at the May 2020 closing in accordance with the terms of the Series B Purchase Agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Through the date of this Registration Statement, we have issued an aggregate of 4,500,000 common units, for a purchase price of $0.79 per unit, which was paid through
the contribution of the holders&#146; equity interests in a subsidiary of the LLC Entity.</P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>(b) &nbsp;&nbsp;&nbsp;&nbsp;Grants </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Through the date of this Registration Statement, we have granted an aggregate of 20,869,704 incentive units, with a grant date fair value range of
$0.10&#150;$1.56&nbsp;per unit and a Participation Threshold of $0.10&#150;$1.91 per unit, to employees, directors and consultants pursuant to the 2018 Share Plan. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Through the date of this Registration Statement, we have granted the Founders an aggregate of 1,200,000 restricted shares (common), under the 2018 Plan, with a grant
date fair value of $0.15 per unit. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The issuances of the above securities were exempt either pursuant to Rule&nbsp;701, as transactions pursuant to a
compensatory benefit plan, or pursuant to Section&nbsp;4(a)(2), as transactions by an issuer not involving a public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;16. Exhibits and
Financial Statement Schedules. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(a)&nbsp;&nbsp;&nbsp;&nbsp;Exhibits </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">See
the Exhibit Index attached to this Registration Statement, which is incorporated by reference herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;Financial Statement Schedules
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements
or notes thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;17. Undertakings. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Insofar as
indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the
opinion of the SEC such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant
of expenses incurred or paid by a director, officer, or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities
being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public
policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The undersigned Registrant hereby undertakes that: </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">1.&nbsp;&nbsp;&nbsp;&nbsp;For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed
as part of this Registration Statement in reliance upon Rule&nbsp;430A and contained in a form of prospectus filed by the Registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this
Registration Statement as of the time it was declared effective. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">2.&nbsp;&nbsp;&nbsp;&nbsp;For the purpose of determining any liability under the
Securities Act, each <FONT STYLE="white-space:nowrap">post-effective</FONT> amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-3 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>EXHIBIT<BR>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>DESCRIPTION OF DOCUMENT</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">1.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d99471dex11.htm">Form of Underwriting Agreement. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">2.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d99471dex21.htm">Form of Plan of Liquidation and Dissolution. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">3.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d99471dex31.htm">Form of Amended and Restated Certificate of Incorporation of the Registrant (to be effective prior to the consummation of this offering). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">3.2</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d99471dex32.htm">Form of Amended and Restated Bylaws of the Registrant (to be effective prior to the consummation of this offering). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">4.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d99471dex41.htm">Specimen stock certificate evidencing shares of common stock. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">4.2</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d99471dex42.htm">Form of Registration Rights Agreement, among the Registrant and certain of its stockholders, to be in effect immediately prior to completion of this offering. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">5.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d99471dex51.htm">Opinion of Ropes&nbsp;&amp; Gray&nbsp;LLP. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.1+*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001739410/000119312521207662/d99471dex101.htm">Asset Purchase Agreement, by and between Rallybio IPA, LLC and Prophylix AS, dated June&nbsp;28, 2019. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.2+*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001739410/000119312521207662/d99471dex102.htm">Asset Transfer Agreement, by and between Swedish Orphan Biovitrum AB (PUBL) and IPC Research, LLC, dated March&nbsp;15, 2019.
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.3+*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001739410/000119312521207662/d99471dex103.htm">Product License Agreement, by and between Affibody AB and Swedish Orphan Biovitrum AB (PUBL), dated March 9, 2012, and assigned to IPC Research,
 LLC on March 15, 2019. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.4+*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001739410/000119312521207662/d99471dex104.htm">Amendment No. 1 to Product License Agreement, by and between Affibody AB and Swedish Orphan Biovitrum AB (PUBL), dated January 1, 2018, and
 assigned to IPC Research, LLC on March 15, 2019. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.5+*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001739410/000119312521207662/d99471dex105.htm">Amendment No. 2 to Product License Agreement, by and between Affibody AB and IPC Research, LLC, dated December 22, 2020. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.6+*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001739410/000119312521207662/d99471dex106.htm">Operating Agreement of RE Ventures I, LLC, by and between Rallybio IPB, LLC and Exscientia Limited, dated July 19, 2019. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.7#</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d99471dex107.htm">Form of Indemnification Agreement, between the Registrant and each of its directors and executive officers. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.8#*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001739410/000119312521207662/d99471dex108.htm">Rallybio Holdings, LLC 2018 Share Plan, as amended. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.9#</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d99471dex109.htm">Form of Restricted Share Agreement (Capital Interests) under the Rallybio Holdings, LLC 2018 Share Plan. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.10#</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d99471dex1010.htm">Form of Restricted Share Agreement (Profits Interests) under the Rallybio Holdings, LLC 2018 Share Plan. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.11#</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d99471dex1011.htm">Form of Contribution and Restricted Share Agreement. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.12#</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d99471dex1012.htm">Rallybio Corporation 2021 Equity Incentive Plan. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.13#</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d99471dex1013.htm">Form of Non-Qualified Stock Option Award Agreement under the Rallybio Corporation 2021 Equity Incentive Plan. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.14#</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d99471dex1014.htm">Form of Non-Qualified Stock Option Award Agreement for Non-Employee Directors under the Rallybio Corporation 2021 Equity Incentive Plan. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.15#</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d99471dex1015.htm">Form of Incentive Stock Option Award Agreement under the Rallybio Corporation 2021 Equity Incentive Plan. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.16#</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d99471dex1016.htm">Form of Restricted Stock Unit Award Agreement under the Rallybio Corporation 2021 Equity Incentive Plan. </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-4 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="91%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>EXHIBIT<BR>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>DESCRIPTION OF DOCUMENT</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.17#</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d99471dex1017.htm">Form of Restricted Stock Unit Award Agreement for Non-Employee Directors under the Rallybio Corporation 2021 Equity Incentive Plan. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.18#</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d99471dex1018.htm">Rallybio Corporation 2021 Cash Incentive Plan. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.19#</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d99471dex1019.htm">Rallybio Corporation 2021 Employee Stock Purchase Plan. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.20#</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d99471dex1020.htm">Amended and Restated Employment Agreement between Rallybio, LLC and Martin Mackay. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.21#</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d99471dex1021.htm">Amended and Restated Employment Agreement between Rallybio, LLC and Stephen Uden. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.22#</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d99471dex1022.htm">Amended and Restated Employment Agreement between Rallybio, LLC and Jeffrey M. Fryer. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.23#</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d99471dex1023.htm">Form of Equity Adjustment Notice. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">21*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001739410/000119312521207662/d99471dex21.htm">List of Subsidiaries of the Registrant. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">23.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d99471dex231.htm">Consent of Deloitte&nbsp;&amp; Touche&nbsp;LLP independent registered public accounting firm. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">23.2</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d99471dex51.htm">Consent of Ropes&nbsp;&amp; Gray&nbsp;LLP (included in Exhibit&nbsp;5.1). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">24.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1739410/000119312521207662/d99471ds1.htm#ii99471_sig">Power of Attorney (included on signature page). </A></TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Previously filed. </TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">#</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Indicates management contract or compensatory plan. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">+</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Portions of this exhibit (indicated by asterisks) have been redacted because they are both not material and the registrant customarily and actually treats such information as private or confidential. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-5 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="ii99471_sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of New Haven, Connecticut, on July&nbsp;22, 2021. </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>RALLYBIO CORPORATION</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">/s/ Martin W. Mackay</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Martin W. Mackay, Ph.D. <BR><I>Chief Executive Officer</I></TD></TR>
</TABLE></DIV>   <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by
the following persons in the capacities and on the dates indicated: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>SIGNATURE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>DATE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">/s/ Martin W. Mackay</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Martin W.
Mackay, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Chief Executive Officer and Director (Principal Executive Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>July&nbsp;22, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">/s/ Jeffrey M. Fryer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Jeffrey M.
Fryer, CPA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">Chief Financial Officer and Treasurer (Principal Accounting and Financial Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>July&nbsp;22, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Helen M. Boudreau</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>July&nbsp;22, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Rob Hopfner, R.Ph.,
Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>July&nbsp;22, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Ronald M. Hunt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>July&nbsp;22, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Lucian Iancovici, MD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>July&nbsp;22, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Kush M. Parmar, MD,
Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>July&nbsp;22, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Timothy M. Shannon,
MD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>July&nbsp;22, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Paula Soteropoulos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>July&nbsp;22, 2021</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">*By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Martin W. Mackay</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Martin W. Mackay, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attorney-in-fact</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-6 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d99471dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[&#149;] Shares of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Rallybio Corporation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>UNDERWRITING AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[&#149;], 2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">COWEN AND COMPANY, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EVERCORE GROUP L.L.C. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the several Underwriters </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o JEFFERIES
LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o COWEN AND COMPANY, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">599 Lexington Avenue, 25<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o EVERCORE GROUP L.L.C. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">55 East 52<SUP
STYLE="font-size:85%; vertical-align:top">nd</SUP> Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10055 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Introductory.</B>
Rallybio Corporation, a Delaware corporation (the &#147;<B>Company</B>&#148;), proposes to issue and sell to the several underwriters named in <U>Schedule A</U> (the &#147;<B>Underwriters</B>&#148;) an aggregate of [&#149;] shares of its common
stock, par value $[&#149;] per share (the &#147;<B>Shares</B>&#148;). The [&#149;] Shares to be sold by the Company are called the &#147;<B>Firm Shares</B>.&#148; In addition, the Company has granted to the Underwriters an option to purchase up to
an additional [&#149;] Shares as provided in Section&nbsp;2. The additional [&#149;] Shares to be sold by the Company pursuant to such option are collectively called the &#147;<B>Optional Shares</B>.&#148; The Firm Shares and, if and to the extent
such option is exercised, the Optional Shares are collectively called the &#147;<B>Offered Shares</B>.&#148; Jefferies LLC (&#147;<B>Jefferies</B>&#148;), Cowen and Company, LLC (&#147;<B>Cowen</B>&#148;) and Evercore Group L.L.C.
(&#147;<B>Evercore</B>&#148;)<B> </B>have agreed to act as representatives of the several Underwriters (in such capacity, the &#147;<B>Representatives</B>&#148;) in connection with the offering and sale of the Offered Shares. To the extent there are
no additional underwriters listed on <U>Schedule A</U>, the term &#147;Representatives&#148; as used herein shall mean you, as Underwriters, and the term &#147;Underwriters&#148; shall mean either the singular or the plural, as the context requires.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the execution of this Agreement, Rallybio Holdings, LLC, a Delaware limited liability company (&#147;<B>Rallybio LLC</B>&#148;),
completed a series of transactions described in the Prospectus (as defined below) under the captions &#147;Prospectus Summary&#151;Reorganization&#148; and &#147;The Reorganization,&#148; pursuant to which its wholly owned subsidiary, Rallybio IPD,
LLC filed a certificate of conversion with the Secretary of State of the State of Delaware (the &#147;<B>Certificate of Conversion</B>&#148;) and thereby was converted into the Company (the &#147;<B>Conversion</B>&#148;). Prior to the closing of the
offering of the Offered Shares, the holders of limited liability interests of Rallybio LLC will receive, by way of distribution, shares of Common Stock in the Company and Rallybio LLC will be dissolved in accordance with its plan of liquidation and
dissolution </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">dated as of July&nbsp;&nbsp;&nbsp;&nbsp;, 2021 (the &#147;<B>Plan of Dissolution</B>&#148;) and the Delaware
Limited Liability Company Act (&#147;<B>DLLCA</B>&#148;) (such transactions referred to as the Dissolution and the Conversion, collectively, the &#147;<B>Reorganization</B>&#148;). Unless the context requires otherwise, references to the Company are
to Rallybio LLC or Rallybio IPD, LLC prior to the Conversion and to the Company following the Conversion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement, the Certificate
of Conversion and the Plan of Dissolution are collectively referred to herein as the &#147;<B>Transaction Documents</B>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company has prepared and filed with the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1,</FONT> File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-257655,</FONT> which contains a form of prospectus to be used in connection with the public offering and sale of the Offered Shares.&nbsp;&nbsp;&nbsp;&nbsp;Such registration statement, as amended,
including the financial statements, exhibits and schedules thereto, in the form in which it became effective under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (collectively, the &#147;<B>Securities
Act</B>&#148;), including any information deemed to be a part thereof at the time of effectiveness pursuant to Rule&nbsp;430A under the Securities Act, is called the &#147;<B>Registration Statement</B>.&#148; Any registration statement filed by the
Company pursuant to Rule 462(b) under the Securities Act in connection with the offer and sale of the Offered Shares is called the &#147;<B>Rule 462(b) Registration Statement</B>,&#148; and from and after the date and time of filing of any such Rule
462(b) Registration Statement the term &#147;Registration Statement&#148; shall include the Rule 462(b) Registration Statement. The prospectus, in the form first used by the Underwriters to confirm sales of the Offered Shares or in the form first
made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 under the Securities Act, is called the &#147;<B>Prospectus</B>.&#148; The preliminary prospectus dated [&#149;], 2021 describing the Offered
Shares and the offering thereof is called the &#147;<B>Preliminary Prospectus</B>,&#148; and the Preliminary Prospectus and any other prospectus in preliminary form that describes the Offered Shares and the offering thereof and is used prior to the
filing of the Prospectus is called a &#147;<B>preliminary prospectus</B>.&#148; As used herein, &#147;<B>Applicable Time</B>&#148; is [&#149;][a.m.][p.m.] (New York City time) on [&#149;]. As used herein, &#147;<B>free writing prospectus</B>&#148;
has the meaning set forth in Rule 405 under the Securities Act, and &#147;<B>Time of Sale Prospectus</B>&#148; means the Preliminary Prospectus together with the free writing prospectuses, if any, identified in <U>Schedule B</U> hereto and the
pricing information identified in <U>Schedule C</U> hereto. As used herein, <B>&#147;</B><B>Road Show</B><B>&#148;</B> means a &#147;road show&#148; (as defined in Rule 433 under the Securities Act) relating to the offering of the Offered Shares
contemplated hereby that is a &#147;written communication&#148; (as defined in Rule 405 under the Securities Act). As used herein, &#147;<B>Section</B><B></B><B>&nbsp;5(d) Written Communication</B>&#148; means each written communication (within the
meaning of Rule 405 under the Securities Act) that is made in reliance on Section&nbsp;5(d) of the Securities Act by the Company or any person authorized to act on behalf of the Company to one or more potential investors that are qualified
institutional buyers (&#147;<B>QIBs</B>&#148;) and/or institutions that are accredited investors (&#147;<B>IAIs</B>&#148;), as such terms are respectively defined in Rule 144A and Rule 501(a) under the Securities Act, to determine whether such
investors might have an interest in the offering of the Offered Shares; &#147;<B>Section</B><B></B><B>&nbsp;5(d) Oral Communication</B>&#148; means each oral communication, if any, made in reliance on Section&nbsp;5(d) of the Securities Act by the
Company or any person authorized to act on behalf of the Company made to one or more QIBs and/or one or more IAIs to determine whether such investors might have an interest in the offering of the Offered Shares; &#147;<B>Marketing
Materials</B>&#148; means any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Offered Shares, including any roadshow or investor presentations made to
investors by the Company (whether in person or electronically); and &#147;<B>Permitted Section</B><B></B><B>&nbsp;5(d) Communication</B>&#148; means the Section&nbsp;5(d) Written Communication(s) and Marketing Materials listed on Schedule D attached
hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this Agreement to (i)&nbsp;the Registration Statement, any preliminary prospectus (including the Preliminary
Prospectus), or the Prospectus, or any amendments or supplements to any of the foregoing, or any free writing prospectus, shall include any copy thereof filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval
System (&#147;<B>EDGAR</B>&#148;) and (ii)&nbsp;the Prospectus shall be deemed to include any &#147;electronic<B> </B>Prospectus&#148; provided for use in connection with the offering of the Offered Shares as contemplated by Section&nbsp;3(n) of
this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms its agreements with the Underwriters as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1. Representations and Warranties of the Company. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby represents, warrants and covenants to each Underwriter, as of the date of this Agreement, as of the First Closing Date (as
hereinafter defined) and as of each Option Closing Date (as hereinafter defined), if any, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B><I>Compliance with
Registration Requirements</I></B><B>.</B> The Registration Statement has become effective under the Securities Act. The Company has complied, to the Commission&#146;s satisfaction with all requests of the Commission for additional or supplemental
information, if any. No stop order suspending the effectiveness of the Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending or, to the knowledge of the Company, are contemplated or threatened by
the Commission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>Disclosure</I></B><B>.</B> Each preliminary prospectus and the Prospectus when filed complied in all
material respects with the Securities Act and, if filed by electronic transmission pursuant to EDGAR, was identical (except as may be permitted by <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-T</FONT> under the Securities Act) to the copy
thereof delivered to the Underwriters for use in connection with the offer and sale of the Offered Shares. Each of the Registration Statement and any post-effective amendment thereto, at the time it became or becomes effective, complied and will
comply in all material respects with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not
misleading. As of the Applicable Time, the Time of Sale Prospectus did not, and at the First Closing Date (as defined in Section&nbsp;2) and at each applicable Option Closing Date (as defined in Section&nbsp;2), will not, contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Prospectus, as of its date, did not, and at the First Closing
Date and at each applicable Option Closing Date, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading. The representations and warranties set forth in the three immediately preceding sentences do not apply to statements in or omissions from the Registration Statement or any post-effective amendment thereto, or the Prospectus or
the Time of Sale Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with written information relating to any Underwriter furnished to the Company in writing by the Representatives expressly for use therein,
it being understood and agreed that the only such information consists of the information described in Section&nbsp;9(b) below. There are no contracts or other documents required to be described in the Time of Sale Prospectus or the Prospectus or to
be filed as an exhibit to the Registration Statement which have not been described or filed as required. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B><I>Free Writing
Prospectuses; Road Show</I></B><B>.</B> As of the determination date referenced in Rule 164(h) under the Securities Act, the Company was not, is not or will not be (as applicable) an &#147;ineligible issuer&#148; in connection with the offering of
the Offered Shares pursuant to Rules 164, 405 and 433 under the Securities Act. Each free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in
accordance with the requirements of the Securities Act. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or on behalf of or used or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
referred to by the Company complies or will comply in all material respects with the requirements of Rule 433 under the Securities Act, including timely filing with the Commission, retention and
legending, as applicable, and each such free writing prospectus, as of its issue date and at all subsequent times through the completion of the public offer and sale of the Offered Shares did not, does not and will not include any information that
conflicted, conflicts or will conflict with the information contained in the Registration Statement, the Prospectus or any preliminary prospectus unless such information has been superseded or modified as of such time. The representations and
warranties set forth in the immediately preceding sentence do not apply to statements made in reliance upon and in conformity with written information relating to any Underwriter furnished to the Company in writing by the Representatives expressly
for use therein, it being understood and agreed that the only such information consists of the information described in Section&nbsp;9(b) below. Except for the free writing prospectuses, if any, identified in <U>Schedule B</U>, and electronic road
shows, if any, furnished to you before first use, the Company has not prepared, used or referred to, and will not, without your prior written consent (such consent not to be unreasonably withheld, conditioned or delayed), prepare, use or refer to,
any free writing prospectus. Each Road Show, when considered together with the Time of Sale Prospectus, did not, as of the Applicable Time, contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements therein, in the light of the circumstances under which they were made, not misleading. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B><I>Distribution of
Offering Material By the Company</I></B><B>.</B> Prior to the later of (i)&nbsp;the expiration or termination of the option granted to the several Underwriters in Section&nbsp;2, (ii) the completion of the Underwriters&#146; distribution of the
Offered Shares and (iii)&nbsp;the expiration of 25 days after the date of the Prospectus<B>, </B>the Company has not distributed and will not distribute any offering material in connection with the offering and sale of the Offered Shares other than
the Registration Statement, the Time of Sale Prospectus, the Prospectus or any free writing prospectus reviewed and consented to by the Representatives, the free writing prospectuses, if any, identified on <U>Schedule B</U> hereto and any Permitted
Section&nbsp;5(d) Communications. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) </B><B><I>The </I></B><B><I>Underwriting Agreement.</I></B> This Agreement has been duly
authorized, executed and delivered by the Company and Rallybio LLC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) </B><B><I>The Reorganization</I></B><B>.</B> The Conversion was
duly authorized by all necessary action on behalf of Rallybio IPD, LLC and the requisite holders of its limited liability company interests and the conversion of Rallybio IPD, LLC to a Delaware corporation and change of its name to Rallybio
Corporation has been effected in accordance with the provisions of the Operating Agreement of Rallybio IPD, LLC (the &#147;<B>IPD Operating Agreement</B>&#148;) and has become effective under the Delaware Limited Liability Company Act<I>. </I>As of
the date of this Agreement, Rallybio LLC owns all of the outstanding capital stock of the Company and does not own or hold any other assets. Prior to the First Closing Date, the Plan of Dissolution will be duly authorized by all necessary action on
behalf of Rallybio LLC and the requisite holders of its limited liability company interests, and will be effected in accordance with the provisions of its operating agreement and the Delaware Limited Liability Company Act, and pursuant thereto<I>,
</I>all of the holders of limited liability interests of Rallybio LLC will receive, by way of distribution, shares of Common Stock in the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g) </B><B><I>Authorization of the Offered Shares</I></B><B>.</B> The Offered Shares have been duly authorized for issuance and sale
pursuant to this Agreement and, when issued and delivered by the Company against payment therefor pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and the issuance and sale of the Offered Shares is not subject to any
preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase the Offered Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h) </B><B><I>No Applicable Registration or Other Similar Rights</I></B><B>.</B> There
are no persons with registration or other similar rights to have any equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this Agreement, except for such rights as have been duly
waived. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) </B><B><I>No Material Adverse Change</I></B><B>.</B> Except as otherwise disclosed in the Registration Statement, the Time
of Sale Prospectus and the Prospectus, subsequent to the respective dates as of which information is given in the Registration Statement, the Time of Sale Prospectus and the Prospectus: (i)&nbsp;there has been no material adverse change, or any
development that would reasonably be expected to result in a material adverse change, in (A)&nbsp;the condition, financial or otherwise, or in the earnings, business, properties, operations, operating results, assets, liabilities or prospects,
whether or not arising from transactions in the ordinary course of business, of the Company and its subsidiaries, considered as one entity or (B)&nbsp;the ability of the Company to consummate the transactions contemplated by this Agreement or
perform its obligations hereunder (any such change being referred to herein as a &#147;<B>Material Adverse Change</B>&#148;); (ii)&nbsp;the Company and its subsidiaries, considered as one entity, have not incurred any material liability or
obligation, indirect, direct or contingent, including without limitation any losses or interference with their business from fire, explosion, flood, earthquakes, accident or other calamity, whether or not covered by insurance, or from any strike,
labor dispute or court or governmental action, order or decree, that are material, individually or in the aggregate, to the Company and its subsidiaries, considered as one entity, and have not entered into any transactions not in the ordinary course
of business; and (iii)&nbsp;except pursuant to the Plan of Dissolution as a result of the Reorganization, there has not been any material decrease in the capital stock or any material increase in any short-term or long-term indebtedness of the
Company or its subsidiaries and there has been no dividend or distribution of any kind declared, paid or made by the Company or, except for dividends paid to the Company or other subsidiaries, by any of the Company&#146;s subsidiaries on any class
of capital stock, or any repurchase or redemption by the Company or any of its subsidiaries of any class of capital stock (other than pursuant to the forfeiture or repurchase of securities underlying equity or equity-based awards under existing
equity incentive plans described in the Registration Statement, the Time of Sale Prospectus or the Prospectus). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)
</B><B><I>Independent Accountants</I></B><B>.</B> To the knowledge of the Company, Deloitte&nbsp;&amp; Touche LLP, which has expressed its opinion with respect to the financial statements (which term as used in this Agreement includes the related
notes thereto) filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus and the Prospectus, is (i)&nbsp;an independent registered public accounting firm as required by the Securities Act, the Securities Exchange
Act of 1934, as amended ,and the rules and regulations promulgated thereunder (collectively, the &#147;<B>Exchange Act</B>&#148;), and the rules of the Public Company Accounting Oversight Board (&#147;<B>PCAOB</B>&#148;), (ii) in compliance with the
applicable requirements relating to the qualification of accountants under Rule <FONT STYLE="white-space:nowrap">2-01</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Securities Act and (iii)&nbsp;a registered public
accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who has not requested such registration to be withdrawn. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k) </B><B><I>Financial Statements</I></B><B>.</B> The financial statements filed with the Commission as a part of the Registration
Statement, the Time of Sale Prospectus and the Prospectus present fairly in all material respects the consolidated financial position of the Company and its subsidiaries as of the dates indicated and the results of their operations, changes in
stockholders&#146; equity and cash flows for the periods specified. Such financial statements have been prepared in conformity with U.S. generally accepted accounting principles applied on a consistent basis throughout the periods involved, except
as may be expressly stated in the related notes thereto and except in the case of unaudited financial statements, which are subject to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments and do not contain certain
footnotes as permitted by the applicable rules of the Commission. No other financial statements or supporting schedules are required to be included in the Registration Statement, the Time of Sale Prospectus or the Prospectus. The financial
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
data set forth in each of the Registration Statement, the Time of Sale Prospectus and the Prospectus under the captions &#147;Prospectus Summary&#151;Summary Selected Financial Data,&#148;
&#147;Selected Financial Data&#148; and &#147;Capitalization&#148; fairly present in all material respects the information set forth therein on a basis consistent with that of the audited financial statements contained in the Registration Statement,
the Time of Sale Prospectus and the Prospectus. To the knowledge of the Company, no person who has been suspended or barred from being associated with a registered public accounting firm, or who has failed to comply with any sanction pursuant to
Rule 5300 promulgated by the PCAOB, has participated in or otherwise aided the preparation of, or audited, the financial statements, supporting schedules or other financial data filed with the Commission as a part of the Registration Statement, the
Time of Sale Prospectus and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l) </B><B><I>Company</I></B><B><I>&#146;</I></B><B><I>s Accounting System</I></B><B>.</B>
The Company and each of its subsidiaries make and keep books and records that are accurate in all material respects and maintain a system of internal accounting controls designed to provide reasonable assurance that: (i)&nbsp;transactions are
executed in accordance with management&#146;s general or specific authorization; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with U.S. generally accepted accounting principles and to
maintain accountability for assets; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; and (iv)&nbsp;the recorded accountability for assets is compared with existing assets at
reasonable intervals and appropriate action is taken with respect to any differences. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m) </B><B><I>Disclosure Controls and Procedures;
Deficiencies in or Changes to Internal Control Over Financial Reporting</I></B><B>.</B> The Company has established and maintains disclosure controls and procedures (as defined in <FONT STYLE="white-space:nowrap">Rules&nbsp;13a-15</FONT> and <FONT
STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act), which (i)&nbsp;are designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company&#146;s principal
executive officer and its principal financial officer by others within those entities, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared, it being understood that neither subsection
(k)&nbsp;nor this subsection (l)&nbsp;requires the Company to comply with Section&nbsp;404 of the Sarbanes Oxley Act of 2002 as of an earlier date than it would otherwise be required to so comply under applicable law; (ii)&nbsp;have been evaluated
by management of the Company for effectiveness as of the end of the Company&#146;s most recent fiscal quarter; and (iii)&nbsp;are effective in all material respects to perform the functions for which they were established. Since the end of the
Company&#146;s most recent audited fiscal year, there have been no significant deficiencies or material weaknesses in the Company&#146;s internal control over financial reporting (whether or not remediated) and no change in the Company&#146;s
internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. The Company is not aware of any change in its internal control over
financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n) </B><B><I>Incorporation and Good Standing of the Company</I></B><B>.</B> The Company has been duly incorporated and is validly existing
as a corporation in good standing under the laws of the jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the
Time of Sale Prospectus and the Prospectus and to enter into and perform its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is in good standing in the State of Connecticut and each
other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to so qualify or to be in good standing would not reasonably be expected,
individually or in the aggregate, to result in a Material Adverse Change. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o) </B><B><I>Subsidiaries</I></B><B>.</B> Each of the Company&#146;s
<B>&#147;</B>subsidiaries<B>&#148;</B> (for purposes of this Agreement, as defined in Rule 405 under the Securities Act) has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited
liability company, as applicable, in good standing under the laws of the jurisdiction of its incorporation or organization and has the power and authority (corporate or other) to own, lease and operate its properties and to conduct its business as
described in the Registration Statement, the Time of Sale Prospectus and the Prospectus. Each of the Company&#146;s subsidiaries is duly qualified as a foreign corporation, partnership or limited liability company, as applicable, to transact
business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to so qualify or to be in good standing
would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change.<B>&nbsp;</B>All of the issued and outstanding capital stock or other equity or ownership interests of each of the Company&#146;s subsidiaries
have been duly authorized and validly issued, are fully paid and nonassessable and are owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse claim. None of the
outstanding capital stock or equity interest in any subsidiary was issued in violation of preemptive or similar rights of any security holder of such subsidiary. The constitutive or organizational documents of each of the subsidiaries comply in all
material respects with the requirements of applicable laws of its jurisdiction of incorporation or organization and are in full force and effect. The Company does not own or control, directly or indirectly, any corporation, partnership, limited
liability company, association or other entity other than the subsidiaries listed in Exhibit&nbsp;21 to the Registration Statement. Rallybio, LLC, Rallybio IPA, LLC and IPC Research, LLC are the only &#147;significant subsidiaries&#148; of the
Company as defined in Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p) </B><B><I>Capitalization and Other Capital Stock Matters</I></B><B>.</B> The authorized, issued and outstanding capital stock of the
Company is as set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus under the caption &#147;Capitalization&#148; (as of March&nbsp;31, 2021, and on the actual basis, pro forma basis and pro forma as adjusted basis
presented therein). The Shares (including the Offered Shares) conform in all material respects to the description thereof contained in the Time of Sale Prospectus. All of the issued and outstanding Shares have been duly authorized and validly
issued, are fully paid and nonassessable and have been issued in compliance with all applicable federal and state securities laws. None of the outstanding Shares was issued in violation of any preemptive rights, rights of first refusal or other
similar rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or
exchangeable or exercisable for, any capital stock of the Company or any of its subsidiaries other than those described in the Registration Statement, the Time of Sale Prospectus and the Prospectus. All of the issued and outstanding limited
liability company interests in Rallybio LLC prior to the Dissolution and in Rallybio IPD, LLC prior to the Conversion were duly authorized and validly issued and issued in compliance with all applicable federal and state securities laws. None of the
outstanding limited liability interests of Rallybio LLC and none of the outstanding limited liability interests of Rallybio IPD, LLC outstanding prior the Conversion was issued in violation of any preemptive rights, rights of first refusal or other
similar rights to subscribe for or purchase securities of the any such entity. The descriptions of the Company&#146;s equity plans or arrangements, and the rights granted thereunder, set forth in the Registration Statement, the Time of Sale
Prospectus and the Prospectus accurately and fairly presents the information required to be shown with respect to such plans, arrangements, and rights. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q) </B><B><I>Stock Exchange Listing</I></B><B>.</B> The Offered Shares have been approved for listing on The Nasdaq Global [Select] Market
(the &#147;<B>Nasdaq</B>&#148;), subject only to official notice of issuance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r) </B><B><I><FONT STYLE="white-space:nowrap">Non-Contravention</FONT> of Existing
Instruments; No Further Authorizations or Approvals Required</I></B><B>.</B> Neither the Company nor any of its subsidiaries is in violation of its charter or <FONT STYLE="white-space:nowrap">by-laws,</FONT> partnership agreement or operating
agreement or similar organizational documents, as applicable, or is in default (or, with the giving of notice or lapse of time, would be in default) (&#147;<B>Default</B>&#148;) under any indenture, loan, credit agreement, note, lease, license
agreement, contract, franchise or other instrument (including, without limitation, any pledge agreement, security agreement, mortgage or other instrument or agreement evidencing, guaranteeing, securing or relating to indebtedness) to which the
Company or any of its subsidiaries is a party or by which it or any of them may be bound, or to which any of their respective properties or assets are subject (each, an &#147;<B>Existing Instrument</B>&#148;), except for such Defaults as would not
reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change. The execution, delivery and performance by the Company, Rallybio IPD, LLC and Rallybio LLC of the Transaction Documents to which such entity is a
party, consummation of the transactions contemplated hereby and by the Registration Statement, the Time of Sale Prospectus and the Prospectus and the issuance and sale of the Offered Shares (including the use of proceeds from the sale of the Offered
Shares as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus under the caption &#147;Use of Proceeds&#148;) (i)&nbsp;have been duly authorized by all necessary corporate action and will not result in any
violation of the provisions of the charter or <FONT STYLE="white-space:nowrap">by-laws,</FONT> partnership agreement or operating agreement or similar organizational documents, as applicable, of the Company or any subsidiary (ii)&nbsp;will not
conflict with or constitute a material breach of, or Default or a Debt Repayment Triggering Event (as defined below) under, or result in the creation or imposition of any material lien, charge or encumbrance upon any property or assets of the
Company or any of its subsidiaries pursuant to, or require the consent of any other party to, any Existing Instrument and (iii)&nbsp;will not result in any violation of any law, administrative regulation or administrative or court decree applicable
to the Company or any of its subsidiaries, except for such violations as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change. No consent, approval, authorization or other order of, or
registration or filing with, any court or other governmental or regulatory authority or agency, is required for the Conversion or the execution, delivery and performance of the Transaction Documents by the Company, Rallybio LLC and Rallybio IPD, LLC
to which such entity is a party and the consummation of the transactions contemplated hereby and by the Registration Statement, the Time of Sale Prospectus and the Prospectus, except such as have been obtained or made by the Company and are in full
force and effect under the Securities Act and such as may be required under applicable state securities or blue sky laws or the Financial Industry Regulatory Authority, Inc. (&#147;<B>FINRA</B>&#148;). As used herein, a &#147;<B>Debt Repayment
Triggering Event</B>&#148; means any event or condition which gives, or with the giving of notice or lapse of time would give, the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder&#146;s behalf)
the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or any of its subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s) </B><B><I>Compliance with Laws</I></B><B><I>.</I></B> The Company and its subsidiaries have been and are in compliance with all
applicable laws, rules and regulations, except where failure to be so in compliance would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t) </B><B><I>No Material Actions or Proceedings</I></B><B>.</B> There is no action, suit, proceeding, inquiry or investigation brought by
or before any legal or governmental entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries, which could be expected, individually or in the aggregate, to result in a Material
Adverse Change. No labor dispute with the employees of the Company or any of its subsidiaries exists or, to the knowledge of the Company, is threatened, except as would not, individually or in the aggregate, reasonably be expected to result in a
Material Adverse Change. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u) </B><B><I>Intellectual Property Rights</I></B><B>.</B> Except as disclosed in the
Registration Statement, the Time of Sale Prospectus or the Prospectus, the Company and its subsidiaries own, or have obtained valid and enforceable licenses for, the inventions, patent applications, patents, trademarks, trade names, service names,
copyrights, trade secrets and other intellectual property described in the Registration Statement, the Time of Sale Prospectus and the Prospectus as being owned or licensed by them or which are necessary for the conduct of their respective
businesses as currently conducted or as currently proposed to be conducted as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus (collectively, &#147;<B>Intellectual Property</B>&#148;), and, to the knowledge of
the Company, the conduct of their respective businesses does not and will not infringe, misappropriate or otherwise conflict in any material respect with any such rights of others. The Intellectual Property of the Company has not been adjudged by a
court of competent jurisdiction to be invalid or unenforceable, in whole or in part, and the Company is unaware of any facts which would form a reasonable basis for any such adjudication. To the knowledge of the Company: (i) except as disclosed in
the Registration Statement, the Time of Sale Prospectus or the Prospectus there are no third parties who have rights to any Intellectual Property, except for customary reversionary rights of third-party licensors with respect to Intellectual
Property that is disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus as licensed to the Company or one or more of its subsidiaries; and (ii)&nbsp;there is no infringement by third parties of any Intellectual
Property. There is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others: (A)&nbsp;challenging the Company&#146;s rights in or to any Intellectual Property, and the Company is unaware of any facts
which would form a reasonable basis for any such action, suit, proceeding or claim; (B)&nbsp;challenging the validity, enforceability or scope of any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis
for any such action, suit, proceeding or claim; or (C)&nbsp;asserting that the Company or any of its subsidiaries infringes or otherwise violates, or would, upon the commercialization of any product or service described in the Registration
Statement, the Time of Sale Prospectus or the Prospectus as under development, infringe or violate, any patent, trademark, trade name, service name, copyright, trade secret or other proprietary rights of others, and the Company is unaware of any
facts which would form a reasonable basis for any such action, suit, proceeding or claim. The Company and its subsidiaries have complied with the material terms of each agreement pursuant to which Intellectual Property has been licensed to the
Company or any subsidiary, and, to the knowledge of the Company, all such agreements are in full force and effect. To the knowledge of the Company, there are no material defects in any of the patents or patent applications included in the
Intellectual Property. The Company and its subsidiaries have taken commercially reasonable steps to protect, maintain and safeguard their Intellectual Property, including the execution of appropriate nondisclosure, confidentiality agreements and
invention assignment agreements and invention assignments with their employees, and, to the knowledge of the Company, no employee of the Company is in or has been in violation of any term of any employment contract, patent disclosure agreement,
invention assignment agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure agreement, or any restrictive covenant to or with a former employer
where the basis of such violation relates to such employee&#146;s employment with the Company. To the knowledge of the Company, the duty of candor and good faith as required by the United States Patent and Trademark Office during the prosecution of
the United States patents and patent applications included in the Intellectual Property have been complied with; and in all foreign offices having similar requirements, all such requirements have been complied with. To the knowledge of the Company,
none of the Company owned Intellectual Property employed by the Company or its subsidiaries has been obtained or is being used by the Company or its subsidiary in violation of any contractual obligation binding on the Company or its subsidiaries or
any of their respective officers, directors or employees. The product candidates described in the Registration Statement, the Time of Sale Prospectus and the Prospectus as under development by the Company or any subsidiary fall within the scope of
one or more claims of one or more patents or patent applications owned by, or licensed to, the Company or any subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v) </B><B><I>All Necessary Permits, etc</I></B><B>.</B> The Company and its subsidiaries
possess such valid and current certificates, authorizations or permits required by state, federal or foreign regulatory agencies or bodies to conduct their respective businesses as currently conducted and as described in the Registration Statement,
the Time of Sale Prospectus or the Prospectus (&#147;Permits&#148;), except where the failure to possess or obtain the same or so qualify would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Change. Neither
the Company nor any of its subsidiaries is in material violation of, or in material default under, any of the Permits or has received any written notice of proceedings relating to the revocation or modification of, or
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with, any such Permits that would not reasonably be expected, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, to have a Material Adverse Change.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w) </B><B><I>Title to Properties</I></B><B>.</B> The Company and its subsidiaries have good and marketable title to all of the
personal property and other assets reflected as owned in the financial statements referred to in Section&nbsp;1(j) above (or elsewhere in the Registration Statement, the Time of Sale Prospectus or the Prospectus), in each case free and clear of any
security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects, except such as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Change. The real property, improvements,
equipment and personal property held under lease by the Company or any of its subsidiaries are held under valid and enforceable leases, with such exceptions as are not material and do not materially interfere with the use made or proposed to be made
of such real property, improvements, equipment or personal property by the Company or such subsidiary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x) </B><B><I>Tax Law
Compliance</I></B><B>.</B> The Company and its subsidiaries have filed all necessary federal, state and foreign tax returns or have properly requested extensions thereof and have paid all income and franchise taxes required to be paid by any of them
and, if due and payable, any related or similar assessment, fine or penalty levied against any of them except as may be being contested in good faith and by appropriate proceedings, in each case, except such as would not reasonably be expected,
individually or in the aggregate, to have a Material Adverse Change. The Company has made adequate charges, accruals and reserves in the applicable financial statements referred to in Section&nbsp;1(j) above in respect of all federal, state and
foreign income and franchise taxes for all periods to and including the dates of such financial statements and as to which the tax liability of the Company or any of its subsidiaries has not been finally determined. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y) </B><B><I>Insurance</I></B><B>.</B> Each of the Company and its subsidiaries are insured by recognized, financially sound and reputable
institutions with policies in such amounts and with such deductibles and covering such risks as the Company reasonably believes are generally deemed adequate and customary for their businesses including, but not limited to, policies covering real
and personal property owned or leased by the Company and its subsidiaries against theft, damage, destruction, acts of vandalism and earthquakes and policies covering the Company and its subsidiaries for product liability claims and clinical trial
liability claims. The Company has no reason to believe that it or any of its subsidiaries will not be able (i)&nbsp;to renew its existing insurance coverage as and when such policies expire or (ii)&nbsp;to obtain comparable coverage from similar
institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change. Neither the Company nor any of
its subsidiaries has been denied any insurance coverage which it has sought or for which it has applied. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z) </B><B><I>Compliance with Environmental Laws</I></B><B>.</B> Except as would not
reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change: (i)&nbsp;neither the Company nor any of its subsidiaries is in violation of any federal, state, local or foreign statute, law, rule, regulation,
ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment
(including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or, to the knowledge of the Company, threatened
release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products (collectively, &#147;<B>Hazardous Materials</B>&#148;) or to the manufacture, processing, distribution, use, treatment,
storage, disposal, transport or handling of Hazardous Materials (collectively, &#147;<B>Environmental Laws</B>&#148;); (ii) the Company and its subsidiaries have all permits, authorizations and approvals required under any applicable Environmental
Laws and are each in compliance with their requirements; (iii)&nbsp;there are no pending or, to the knowledge of the Company, threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of
noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any of its subsidiaries; and (iv)&nbsp;to the knowledge of the Company, there are no events or circumstances that might reasonably be
expected to form the basis of an order for <FONT STYLE="white-space:nowrap">clean-up</FONT> or remediation, or an action, suit or proceeding by any private party or governmental body or agency, against or affecting the Company or any of its
subsidiaries relating to Hazardous Materials or any Environmental Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa) </B><B><I>ERISA Compliance</I></B><B>.</B> Except as would
not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change, (i)&nbsp;each &#147;employee benefit plan&#148; (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the
regulations and published interpretations thereunder (collectively, &#147;<B>ERISA</B>&#148;)) established or maintained by the Company, its subsidiaries or their &#147;ERISA Affiliates&#148; (as defined below) is in compliance with ERISA
(ii)&nbsp;no &#147;reportable event&#148; (as defined under ERISA) (other than those for which the thirty <FONT STYLE="white-space:nowrap">(30)-day</FONT> notice period is waived) has occurred or is reasonably expected to occur with respect to any
&#147;employee benefit plan&#148; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates, (iii)&nbsp;no &#147;employee benefit plan&#148; established or maintained by the Company, its subsidiaries or any of their
ERISA Affiliates, if such &#147;employee benefit plan&#148; were terminated, would have any &#147;amount of unfunded benefit liabilities&#148; (as defined in Section&nbsp;4001(18) of ERISA); (iv) neither the Company, its subsidiaries nor any of
their ERISA Affiliates has incurred or reasonably expects to incur any liability under (1)&nbsp;Title&nbsp;IV of ERISA with respect to termination of, or withdrawal from, any &#147;employee benefit plan&#148; or (2)&nbsp;Sections&nbsp;412, 4971,
4975 or 4980B of the Code; and (v)&nbsp;each employee benefit plan established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates that is intended to be qualified under Section&nbsp;401(a) of the Code is covered by a
favorable determination, opinion or advisory letter from the Internal Revenue Service and nothing has occurred, whether by action or failure to act, which would reasonably be expected to cause the loss of qualified status. &#147;<B>ERISA
Affiliate</B>&#148; means any entity that would be regarded as a single employer with the Company under Sections&nbsp;414(b), (c), (m) or (o)&nbsp;of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations
thereunder (&#147;<B>Code</B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb) </B><B><I>Company Not an </I></B><B><I>&#147;</I></B><B><I>Investment
Company.</I></B><B><I>&#148;</I></B> The Company is not, and will not be, either after receipt of payment for the Offered Shares or after the application of the proceeds therefrom as described under &#147;Use of Proceeds&#148; in the Registration
Statement, the Time of Sale Prospectus or the Prospectus, required to register as an &#147;investment company&#148; under the Investment Company Act of 1940, as amended (the <B>&#147;</B><B>Investment Company Act</B><B>&#148;</B><B>)</B>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc) </B><B><I>No Price Stabilization or Manipulation</I></B><B><I>; Compliance with
Regulation M</I></B><B>.</B> Neither the Company nor any of its subsidiaries has taken, directly or indirectly, without giving effect to activities by the Underwriters, any action designed to or that might reasonably be expected to cause or result
in stabilization or manipulation of the price of the Shares or of any &#147;reference security&#148; (as defined in Rule 100 of Regulation M under the Exchange Act (<B>&#147;</B><B>Regulation M</B><B>&#148;</B>)) with respect to the Shares, whether
to facilitate the sale or resale of the Offered Shares or otherwise, and has taken no action which would directly or indirectly violate Regulation M. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd) </B><B><I>Related-Party Transactions</I></B><B>.</B> There are no business relationships or related-party transactions involving the
Company or any of its subsidiaries or any other person required to be described in the Registration Statement, the Time of Sale Prospectus or the Prospectus that have not been described as required. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee) </B><B><I>FINRA Matters</I></B><B>.</B> All of the information provided to the Underwriters or to counsel for the Underwriters by the
Company, its counsel, its officers and directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with the offering of the Offered Shares is true, complete, correct and compliant
with FINRA&#146;s rules and any letters, filings or other supplemental information provided to FINRA pursuant to FINRA Rules or NASD Conduct Rules is true, complete and correct. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff) </B><B><I>Parties to <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</I></B><B>.</B> The Company has furnished to Jefferies
and Cowen (the &#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Representatives</B>&#148;)<B> </B>a letter agreement in the form attached hereto as <U>Exhibit</U><U></U><U>&nbsp;A</U> (the
&#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement</B>&#148;) from each director and officer of the Company and from all or substantially all of the securityholders of the Company. If any additional persons shall become directors or
officers of the Company prior to the end of the Company <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period (as defined below), the Company shall cause each such person, prior to or contemporaneously with their appointment or election as a
director or officer of the Company, to execute and deliver to the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Representatives a <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement.<B>&nbsp;</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(gg) </B><B><I>Statistical and Market-Related Data</I></B><B>.</B> All statistical, demographic and market-related data included in the
Registration Statement, the Time of Sale Prospectus or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate. To the extent required, the Company has obtained the written
consent to the use of such data from such sources. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hh) </B><B><I>Sarbanes-Oxley Act.</I></B> There is, and has been, no failure on the
part of the Company or any of the Company&#146;s directors or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002, as amended and the rules and regulations promulgated in connection
therewith, including Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B><B><I>No Unlawful
Contributions or Other Payments</I></B><B>.</B> Neither the Company nor any of its subsidiaries nor, to the best of the knowledge of the Company, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to
any official of, or candidate for, any federal, state or foreign office in violation of any applicable law or of the character required to be disclosed in the Registration Statement, the Time of Sale Prospectus or the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jj) </B><B><I>Anti-Corruption and Anti-Bribery Laws</I></B><B>.</B> Neither the Company nor any of its subsidiaries nor any director,
officer, or employee of the Company or any of its subsidiaries, nor to the knowledge of the Company, any agent, controlled affiliate or other person acting on behalf of the Company or any of its subsidiaries has, in the course of its actions for, or
on behalf of, the Company or any of its subsidiaries (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relating to political activity; (ii)&nbsp;made or taken any act in furtherance of an offer, promise, or authorization of any direct or indirect unlawful payment or benefit to any foreign or
domestic government official or employee, including of any government-owned or controlled entity or public international organization, or any political party, party official, or candidate for political office; (iii)&nbsp;violated or is in violation
of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &#147;<B>FCPA</B>&#148;), the UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption law; or (iv)&nbsp;made, offered, authorized, requested, or
taken an act in furtherance of any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment or benefit. The Company and its subsidiaries and, to the knowledge of the Company, the Company&#146;s controlled affiliates have
conducted their respective businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kk) </B><B><I>Money Laundering Laws</I></B><B>.</B> The operations of the Company and its subsidiaries are, and have been conducted at all
times, in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and
regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#147;<B>Money Laundering Laws</B>&#148;) and no action, suit or proceeding
by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ll) </B><B><I>Sanctions</I></B><B>.</B> Neither the Company nor any of its subsidiaries, directors, officers, or employees, nor, to the
knowledge of the Company, after due inquiry, any agent, controlled affiliate or other person acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any U.S. sanctions administered by the Office of
Foreign Assets Control of the U.S. Department of the Treasury (&#147;<B>OFAC</B>&#148;) or the U.S. Department of State, the United Nations Security Council, the European Union, Her Majesty&#146;s Treasury of the United Kingdom, or other relevant
sanctions authority (collectively, &#147;<B>Sanctions</B>&#148;); nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or the target of Sanctions, including, without limitation,
Crimea, Cuba, Iran, North Korea, and Syria; and the Company will not directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, or any joint venture partner or other
person or entity, for the purpose of financing the activities of or business with any person, or in any country or territory, that at the time of such financing, is the subject or the target of Sanctions or in any other manner that will result in a
violation by any person (including any person participating in the transaction whether as underwriter, advisor, investor or otherwise) of applicable Sanctions. For the past five years, the Company and its subsidiaries have not knowingly engaged in
and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mm) </B><B><I>Brokers</I></B><B>.</B> Except pursuant to this Agreement, there is no broker, finder or other party that is entitled to
receive from the Company any brokerage or finder&#146;s fee or other fee or commission as a result of any transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nn) </B><B><I>Forward-Looking Statements.</I></B> Each financial or operational projection or other &#147;forward-looking statement&#148;
(as defined by Section&nbsp;27A of the Securities Act or Section&nbsp;21E of the Exchange Act) contained in the Registration Statement, the Time of Sale Prospectus or the Prospectus (i)&nbsp;was so included by the Company in good faith and with
reasonable basis after due consideration by the Company of the underlying assumptions, estimates and other applicable facts and circumstances and (ii)&nbsp;is accompanied by meaningful cautionary statements identifying those factors that would
reasonably be expected to cause actual results to differ materially from those in such forward-looking statement. No such statement was made with the knowledge of an executive officer or director of the Company that it was false or misleading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(oo) </B><B><I>No Outstanding Loans or Other Extensions of Credit</I></B>. The Company
does not have any outstanding extension of credit, in the form of a personal loan, to or for any director or executive officer (or equivalent thereof) of the Company except for such extensions of credit as are expressly permitted by
Section&nbsp;13(k) of the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(pp) </B><B><I>Cybersecurity</I></B>. The Company and its subsidiaries&#146; information
technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#147;<B>IT Systems</B>&#148;) are adequate for, and operate and perform in all material respects as required in
connection with the operation of the business of the Company and its subsidiaries as currently conducted, and, to the knowledge of the Company, are free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other
corruptants. The Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect their material confidential
information and the integrity, continuous operation, redundancy and security of all IT Systems and data, including &#147;Personal Data,&#148; used in connection with their businesses. &#147;<B>Personal Data</B>&#148; means (i)&nbsp;a natural
person&#146;s name, street address, telephone number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or tax identification number, driver&#146;s license number, passport number, credit card number, bank
information, or customer or account number; (ii)&nbsp;any information which would qualify as &#147;personally identifying information&#148; under the Federal Trade Commission Act, as amended; and (iii) &#147;personal data&#148; as defined by the
European Union General Data Protection Regulation (&#147;<B>GDPR</B>&#148;)(EU 2016/679). There have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or
liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company and its subsidiaries are presently in material compliance with all applicable laws or statutes and all
judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of
such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qq) </B><B><I>Compliance with Data
Privacy Laws</I></B>. The Company and its subsidiaries are, and at all times since the Company&#146;s inception were, in material compliance with all applicable state and federal data privacy and security laws and regulations, including without
limitation the U.S. Health Insurance Portability and Accountability Act of 1996 (&#147;<B>HIPAA</B>&#148;), and the Company and its subsidiaries have taken commercially reasonable actions to prepare to comply with, and since May&nbsp;25, 2018, have
been and currently are in compliance with, the GDPR (collectively, the &#147;<B>Privacy Laws</B>&#148;). In furtherance of its efforts to comply with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and take appropriate
steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the
&#147;<B>Policies</B>&#148;). The Company and its subsidiaries have at all times since January&nbsp;5, 2018 made all disclosures to users or customers required by applicable Privacy Laws, and none of such disclosures made or contained in any Policy
have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material respect. The Company further certifies that neither it nor any subsidiary: (i)&nbsp;has received
notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice;
(ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree, or agreement that imposes any obligation or
liability under any Privacy Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(rr) </B><B><I>Emerging Growth Company Status</I></B>. From the time of initial
confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged in any Section&nbsp;5(d) Written Communication or any Section&nbsp;5(d) Oral Communication) through the date hereof,
the Company has been and is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act (an &#147;<B>Emerging Growth Company</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ss) </B><B><I>Communications</I></B>. The Company (i)&nbsp;has not alone engaged in communications with potential investors in reliance on
Section&nbsp;5(d) of the Securities Act other than Permitted Section&nbsp;5(d) Communications or Section&nbsp;5(d) Oral Communications, in each case, with the consent of the Representatives with entities that are<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP>QIBs or IAIs and (ii)&nbsp;has not authorized anyone other than the Representatives to engage in such communications; the Company reconfirms that the Representatives have been authorized to act on its
behalf in undertaking Marketing Materials, Section&nbsp;5(d) Oral Communications and Section&nbsp;5(d) Written Communications; as of the Applicable Time, each Permitted Section&nbsp;5(d) Communication, when considered together with the Time of Sale
Prospectus, did not, as of the Applicable Time, include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not
misleading; and each Permitted Section&nbsp;5(d) Communication, if any, does not, as of the date hereof, conflict with the information contained in the Registration Statement, the Preliminary Prospectus and the Prospectus (except where such
Permitted Section&nbsp;5(d) Communication has been superseded by the information contained in the Registration Statement, the Preliminary Prospectus and the Prospectus) and the Company has filed publicly on EDGAR at least 15 calendar days prior to
any &#147;road show&#148; (as defined in Rule 433 under the Act), any confidentially submitted registration statement and registration statement amendments relating to the offer and sale of the Offered Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(tt) </B><B><I>Preclinical and Clinical Data and Regulatory Compliance.</I></B> The preclinical tests and clinical trials, and other studies
(collectively, &#147;studies&#148;) that are described in, or the results of which are referred to in, the Registration Statement, the Time of Sale Prospectus or the Prospectus were and, if still pending, are being conducted in all material respects
in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material
respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are materially inconsistent with, or otherwise call into question, the results
described or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus; the Company and its subsidiaries have made all such material filings and obtained all such approvals as may be required by the Food and Drug
Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively,
the &#147;<B>Regulatory Agencies</B>&#148;) to conduct their businesses as currently conducted and as described in the Registration Statement, the Time of Sale Prospectus or the Prospectus; neither the Company nor any of its subsidiaries has
received any written notice of, or correspondence from, any Regulatory Agency requiring the termination or suspension of any clinical trials that are described or referred to in the Registration Statement, the Time of Sale Prospectus or the
Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(uu) </B><B><I>Compliance with Health Care Laws</I></B>. The Company and its subsidiaries are, and at all times have been,
in compliance in all material respects with all applicable Health Care Laws. For purposes of this Agreement, &#147;Health Care Laws&#148; means: (i)&nbsp;the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section&nbsp;301 et seq.), the Public
Health Service Act (42 U.S.C. Section&nbsp;201 et seq.), and the regulations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
promulgated thereunder; (ii)&nbsp;all applicable federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the Anti-Kickback Statute (42 U.S.C. <FONT
STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b)),</FONT> the Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the criminal false statements law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(a)),</FONT> 18 U.S.C.
Sections 286 and 287, the health care fraud criminal provisions under HIPAA (42 U.S.C. Section&nbsp;1320d et seq.), the Stark Law (42 U.S.C. Section&nbsp;1395nn), the civil monetary penalties law (42 U.S.C.
<FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7a),</FONT> the exclusion law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7),</FONT> the Physician Payments Sunshine Act (42 U.S.C.
<FONT STYLE="white-space:nowrap">Section&nbsp;1320-7h),</FONT> and applicable laws governing government funded or sponsored healthcare programs; (iii)&nbsp;the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and
Education Reconciliation Act of 2010; (iv) licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws; and (v)&nbsp;the directives and regulations promulgated pursuant to such statutes and any
state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> counterpart thereof. Neither the Company nor any of its subsidiaries has received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or
other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in material violation of any Health Care Laws nor, to the knowledge of the Company, is any such
claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened. The Company and its subsidiaries have filed, maintained or submitted all material reports, documents, forms, notices, applications,
records, claims, submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on
the date filed in all material respects (or were corrected or supplemented by a subsequent submission). Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent decrees,
settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, any of their respective employees, officers,
directors, or agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding,
or other similar action that would reasonably be expected to result in debarment, suspension, or exclusion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vv) </B><B><I>No Rights to
Purchase Preferred Stock.</I></B> The issuance and sale of the Shares as contemplated hereby will not cause any holder of any shares of capital stock, securities convertible into or exchangeable or exercisable for capital stock or options, warrants
or other rights to purchase capital stock or any other securities of the Company to have any right to acquire any shares of preferred stock of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ww) </B><B><I>No Contract Terminations.</I></B> Except as disclosed in any preliminary prospectus, the Prospectus, any free writing
prospectus or the Registration Statement, neither the Company nor any of its subsidiaries has sent or received any communication regarding termination of, or intent not to renew, any of the contracts or agreements referred to or described in any
preliminary prospectus, the Prospectus or any free writing prospectus, or referred to or described in, or filed as an exhibit to, the Registration Statement, and no such termination or <FONT STYLE="white-space:nowrap">non-renewal</FONT> has been
threatened by the Company or any of its subsidiaries or, to the knowledge of the Company, any other party to any such contract or agreement, which threat of termination or <FONT STYLE="white-space:nowrap">non-renewal</FONT> has not been rescinded as
of the date hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(xx) </B><B><I>Dividend Restrictions</I></B><B>.</B> No subsidiary of the Company is prohibited or restricted,
directly or indirectly, from paying dividends to the Company, or from making any other distribution with respect to such subsidiary&#146;s equity securities or from repaying to the Company or any other subsidiary of the Company any amounts that may
from time to time become due under any loans or advances to such subsidiary from the Company or from transferring any property or assets to the Company or to any other subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(yy) </B><B><I>Conformity with Descriptions. </I></B>Each of the Transaction Documents
conforms in all material respects to the description thereof contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus. The Reorganization conforms in all material respects to the description thereof contained in the
Registration Statement, the Time of Sale Prospectus and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any certificate signed by any officer of the Company or any of
its subsidiaries and delivered to any Underwriter or to counsel for the Underwriters in connection with the offering, or the purchase and sale, of the Offered Shares shall be deemed a representation and warranty by the Company (and not by any such
officer in his or her personal capacity) to each Underwriter as to the matters covered thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has a reasonable basis for
making each of the representations set forth in this Section&nbsp;1. The Company acknowledges that the Underwriters and, for purposes of the opinions to be delivered pursuant to Section&nbsp;6 hereof, counsel to the Company and counsel to the
Underwriters, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2. </B><B>Purchase, Sale and Delivery of the Offered Shares</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B><I>The Firm Shares</I></B><B>.</B> Upon the terms herein set forth, the Company agrees to issue and sell to the several
Underwriters an aggregate of [&#149;] Firm Shares. On the basis of the representations, warranties and agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Underwriters agree, severally and not jointly,
to purchase from the Company the respective number of Firm Shares set forth opposite their names on <U>Schedule A</U>. The purchase price per Firm Share to be paid by the several Underwriters to the Company shall be $[&#149;] per share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>The First Closing Date</I></B><B>.</B> Delivery of the Firm Shares to be purchased by the Underwriters and payment therefor
shall be made at the offices of Wilmer Cutler Pickering Hale and Dorr LLP (or such other place as may be agreed to by the Company and the Representatives) at 9:00 a.m. New York City time, on [&#149;], 2021<B>,</B> or such other time and date not
later than 1:30&nbsp;p.m. New York City time, on [&#149;], 2021 as the Representatives shall designate by notice to the Company (the time and date of such closing are called the &#147;<B>First Closing Date</B>&#148;). The Company hereby acknowledges
that circumstances under which the Representatives may provide notice to postpone the First Closing Date as originally scheduled include, but are not limited to, any determination by the Company or the Representatives to recirculate to the public
copies of an amended or supplemented Prospectus or a delay as contemplated by the provisions of Section&nbsp;11. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B><I>The
Optional Shares; Option Closing Date</I></B><B>.</B> In addition, on the basis of the representations, warranties and agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Company hereby grants an option
to the several Underwriters to purchase, severally and not jointly, up to an aggregate of [&#149;] Optional Shares from the Company at the purchase price per share to be paid by the Underwriters for the Firm Shares. The option granted hereunder may
be exercised at any time and from time to time in whole or in part upon notice by the Representatives to the Company, which notice may be given at any time within 30&nbsp;days from the date of this Agreement. Such notice shall set forth (i)&nbsp;the
aggregate number of Optional Shares as to which the Underwriters are exercising the option and (ii)&nbsp;the time, date and place at which the Optional Shares will be delivered (which time and date may be simultaneous with, but not earlier than, the
First Closing Date; and in the event that such time and date are simultaneous with the First Closing Date, the term &#147;<B>First Closing Date</B>&#148; shall refer to the time and date of delivery of the Firm Shares and such Optional Shares). Any
such time and date of delivery, if subsequent to the First Closing Date, is called an &#147;<B>Option Closing Date</B>,&#148; and shall be determined by the Representatives and shall not be earlier than two or later than five full business days
after delivery of such notice of exercise. If any Optional Shares are to be purchased, each Underwriter </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agrees, severally and not jointly, to purchase the number of Optional Shares (subject to such adjustments to eliminate fractional shares as the Representatives may determine) that bears the same
proportion to the total number of Optional Shares to be purchased as the number of Firm Shares set forth on <U>Schedule A</U> opposite the name of such Underwriter bears to the total number of Firm Shares. <B></B>The Representatives may cancel the
option at any time prior to its expiration by giving written notice of such cancellation to the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B><I>Public Offering
of the Offered Shares</I></B><B>.</B> The Representatives hereby advise the Company that the Underwriters intend to offer for sale to the public, initially on the terms set forth in the Registration Statement, the Time of Sale Prospectus and the
Prospectus, their respective portions of the Offered Shares as soon after this Agreement has been executed and the Registration Statement has been declared effective as the Representatives, in their sole judgment, have determined is advisable and
practicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) </B><B><I>Payment for the Offered Shares</I></B><B>.</B> (i)&nbsp;Payment for the Offered Shares shall be made at the
First Closing Date (and, if applicable, at each Option Closing Date) by wire transfer of immediately available funds to the order of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) It is understood that the Representatives have been authorized, for their own accounts and the accounts of the several Underwriters, to
accept delivery of and receipt for, and make payment of the purchase price for, the Firm Shares and any Optional Shares the Underwriters have agreed to purchase. Each of Jefferies, Cowen and Evercore, individually and not as the Representatives of
the Underwriters, may (but shall not be obligated to) make payment for any Offered Shares to be purchased by any Underwriter whose funds shall not have been received by the Representatives by the First Closing Date or the applicable Option Closing
Date, as the case may be, for the account of such Underwriter, but any such payment shall not relieve such Underwriter from any of its obligations under this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) </B><B><I>Delivery of the Offered Shares</I></B><B>.</B> The Company shall deliver, or cause to be delivered to the Representatives for
the accounts of the several Underwriters the Firm Shares at the First Closing Date, against release of a wire transfer of immediately available funds for the amount of the purchase price therefor. The Company shall also deliver, or cause to be
delivered to the Representatives for the accounts of the several Underwriters, the Optional Shares the Underwriters have agreed to purchase at the First Closing Date or the applicable Option Closing Date, as the case may be, against the release of a
wire transfer of immediately available funds for the amount of the purchase price therefor. Unless the Representatives otherwise elect, delivery of the Offered Shares shall be made by credit to the accounts designated by Jefferies through The
Depository Trust Company&#146;s full fast transfer or DWAC programs. If the Representatives so elect, any certificates for the Offered Shares shall be in definitive form and registered in such names and denominations as the Representatives shall
have requested at least two full business days prior to the First Closing Date (or the applicable Option Closing Date, as the case may be) and shall be made available for inspection on the business day preceding the First Closing Date (or the
applicable Option Closing Date, as the case may be) at a location in New York City as the Representatives may designate. Time shall be of the essence, and delivery at the time and place specified in this Agreement is a further condition to the
obligations of the Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3. Additional Covenants. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company further covenants and agrees with each Underwriter as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B><I>Delivery of Registration Statement, Time of Sale Prospectus and
Prospectus</I></B><B><I>.</I></B><I> </I>The Company shall furnish to you in New York City, without charge, prior to 10:00 a.m. New York City time on the second business day succeeding the date of this Agreement and during the period when a
prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Offered Shares, as many
copies of the Time of Sale Prospectus, the Prospectus and any supplements and amendments thereto or to the Registration Statement as you may reasonably request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>Representatives</I></B><B><I>&#146;</I></B><B><I> Review of Proposed Amendments and Supplements</I></B><B><I>.</I></B><I>
</I>During the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), the Company (i)&nbsp;will
furnish to the Representatives for review, a reasonable period of time prior to the proposed time of filing of any proposed amendment or supplement to the Registration Statement, a copy of each such amendment or supplement and (ii)&nbsp;will not
amend or supplement the Registration Statement without the Representatives&#146; prior written consent, which will not be unreasonably withheld, conditioned or delayed. Prior to amending or supplementing any preliminary prospectus, the Time of Sale
Prospectus or the Prospectus, the Company shall furnish to the Representatives for review, a reasonable amount of time prior to the time of filing or use of the proposed amendment or supplement, a copy of each such proposed amendment or supplement.
The Company shall not file or use any such proposed amendment or supplement without the Representatives&#146; prior written consent, which will not be unreasonably withheld, conditioned or delayed. The Company shall file with the Commission within
the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)
</B><B><I>Free Writing Prospectuses</I></B><B><I>.</I></B><I> </I>The Company shall furnish to the Representatives for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each proposed free writing
prospectus or any amendment or supplement thereto prepared by or on behalf of, used by, or referred to by the Company, and the Company shall not file, use or refer to any proposed free writing prospectus or any amendment or supplement thereto
without the Representatives&#146; prior written consent, which will not be unreasonably withheld, conditioned or delayed. The Company shall furnish to each Underwriter, without charge, as many copies of any free writing prospectus prepared by or on
behalf of, used by or referred to by the Company as such Underwriter may reasonably request. If at any time when a prospectus is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the
Securities Act or any similar rule) in connection with sales of the Offered Shares (but in any event if at any time through and including the First Closing Date) there occurred or occurs an event or development as a result of which any free writing
prospectus prepared by or on behalf of, used by, or referred to by the Company conflicted or would conflict with the information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted
or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such time, not misleading, the Company shall promptly amend or supplement such free writing prospectus to
eliminate or correct such conflict or so that the statements in such free writing prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances prevailing at such time, not misleading, as the case may be; <I>provided, however</I>, that prior to amending or supplementing any such free writing prospectus, the Company shall furnish to the
Representatives for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of such proposed amended or supplemented free writing prospectus, and the Company shall not file, use or refer to any such amended or
supplemented free writing prospectus without the Representatives&#146; prior written consent, which will not be unreasonably withheld, conditioned or delayed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B><I>Filing of Underwriter Free Writing Prospectuses.</I></B><I> </I>The Company shall not take any action that would result in an
Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of such Underwriter that such Underwriter otherwise would not have been
required to file thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) </B><B><I>Amendments and Supplements to Time of Sale
Prospectus</I></B><B><I>.</I></B><I> </I>If the Time of Sale Prospectus is being used to solicit offers to buy the Offered Shares at a time when the Prospectus is not yet available to prospective purchasers, and any event shall occur or condition
exist as a result of which it is necessary to amend or supplement the Time of Sale Prospectus so that the Time of Sale Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances when delivered to a prospective purchaser, not misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained
in the Registration Statement, or if, in the reasonable opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, the Company shall (subject to Section&nbsp;3(b) and
Section&nbsp;3(c) hereof) promptly prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the
Time of Sale Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to a
prospective purchaser, not misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the information contained in the Registration Statement, or so that the Time of Sale Prospectus, as amended or
supplemented, will comply with applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) </B><B><I>Certain Notifications and Required Actions</I></B><B>.</B> After the date
of this Agreement, the Company shall promptly advise the Representatives in writing (which may be by electronic mail) of: (i)&nbsp;the receipt of any comments of, or requests for additional or supplemental information from, the Commission;
(ii)&nbsp;the time and date of any filing of any post-effective amendment to the Registration Statement or any amendment or supplement to any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus;
(iii)&nbsp;the time and date that any post-effective amendment to the Registration Statement becomes effective; and (iv)&nbsp;the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any
post-effective amendment thereto or any amendment or supplement to any preliminary prospectus, the Time of Sale Prospectus or the Prospectus or of any order preventing or suspending the use of any preliminary prospectus, the Time of Sale Prospectus,
any free writing prospectus or the Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation the Shares from any securities exchange upon which they are listed for trading or included or designated for quotation, or
of the threatening or initiation of any proceedings for any of such purposes. If the Commission shall enter any such stop order at any time, the Company will use its reasonable best efforts to obtain the lifting of such order as soon as reasonably
practicable. Additionally, the Company agrees that it shall comply with all applicable provisions of Rule 424(b), Rule 433 and Rule 430A under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company
under Rule 424(b) or Rule 433 were received in a timely manner by the Commission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g) </B><B><I>Amendments and Supplements to the
Prospectus and Other Securities Act Matters</I></B><B><I>.</I></B> During the Prospectus Delivery Period, if any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus so that the Prospectus
does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance
with Rule 172 under the Securities Act or any similar rule) to a purchaser, not misleading, or if in the reasonable opinion of the Representatives or counsel for the Underwriters it is otherwise necessary to amend or supplement the Prospectus to
comply with applicable law, the Company agrees (subject to Section&nbsp;3(b) and Section&nbsp;3(c)) hereof to promptly prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, amendments
or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser,
not misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law. Neither the Representatives&#146; consent to, nor delivery of, any such amendment or supplement shall constitute a waiver of any of the
Company&#146;s obligations under Section&nbsp;3(b) or Section&nbsp;3(c). As used herein, the term &#147;Prospectus Delivery Period&#148; means such period of time after the first date of the public offering of the Shares as in the opinion of counsel
for the Underwriters a prospectus relating to the Shares is required by law to be delivered (or required to be delivered but for Rule 172 under the Securities Act) in connection with sales of the Shares by any Underwriter or dealer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h) </B><B><I>Blue Sky Compliance</I></B><B>.</B> The Company shall cooperate with the Representatives and counsel for the Underwriters to
qualify or register the Offered Shares for sale under (or obtain exemptions from the application of) the state securities or blue sky laws (or other foreign laws) of those jurisdictions reasonably designated by the Representatives, shall use
commercially reasonable efforts to comply with such laws and shall continue such qualifications, registrations and exemptions in effect so long as required for the distribution of the Offered Shares. The Company shall not be required to qualify as a
foreign corporation or to take any action that would subject it to general service of process in any such jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation. The Company will advise the
Representatives promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Offered Shares for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such
purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its best efforts to obtain the withdrawal thereof as soon as reasonably practicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) </B><B><I>Use of Proceeds</I></B><B>.</B> The Company shall apply the net proceeds from the sale of the Offered Shares sold by it in all
material respects in the manner described under the caption &#147;Use of Proceeds&#148; in the Registration Statement, the Time of Sale Prospectus and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j) </B><B><I>Transfer Agent</I></B><B>.</B> The Company shall engage and maintain, at its expense, a registrar and transfer agent for the
Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k) </B><B><I>Earnings Statement</I></B><B>.</B> The Company will make generally available to its security holders and to the
Representatives as soon as practicable an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter of the Company commencing after the date of this Agreement that will satisfy
the provisions of Section&nbsp;11(a) of the Securities Act and the rules and regulations of the Commission thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)
</B><B><I>Continued Compliance with Securities Laws</I></B><B>.</B> The Company will comply with the Securities Act and the Exchange Act so as to permit the completion of the distribution of the Offered Shares as contemplated by this Agreement<B>,
</B>the Registration Statement, the Time of Sale Prospectus and the Prospectus. Without limiting the generality of the foregoing, the Company will, during the period when a prospectus relating to the Offered Shares is required by the Securities Act
to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), file on a timely basis with the Commission and Nasdaq all reports and documents required to be filed under the Exchange Act.
Additionally, the Company shall report the use of proceeds from the issuance of the Offered Shares as may be required under Rule&nbsp;463 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m) </B><B><I>Listing</I></B><B>.</B> The Company will use its best efforts to list, subject to notice of issuance, the Offered Shares on
Nasdaq. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n) </B><B><I>Company to Provide Copy of the Prospectus in Form That May be Downloaded
from the Internet</I></B><B>.</B> If requested by the Representatives, the Company shall cause to be prepared and delivered, at its expense, within one business day from the effective date of this Agreement, to the Representatives an
&#147;<B>electronic Prospectus</B>&#148; to be used by the Underwriters in connection with the offering and sale of the Offered Shares. As used herein, the term &#147;<B>electronic Prospectus</B>&#148; means a form of Prospectus, and any amendment
or supplement thereto, that meets each of the following conditions: (i)&nbsp;it shall be encoded in an electronic format, satisfactory to the Representatives, that may be transmitted electronically by the Representatives to offerees and purchasers
of the Offered Shares; (ii)&nbsp;it shall disclose the same information as the paper Prospectus, except to the extent that graphic and image material cannot be disseminated electronically, in which case such graphic and image material shall be
replaced in the electronic Prospectus with a fair and accurate narrative description or tabular representation of such material, as appropriate; and (iii)&nbsp;it shall be in or convertible into a paper format or an electronic format, satisfactory
to the Representatives, that will allow investors to store and have continuously ready access to the Prospectus at any future time, without charge to investors (other than any fee charged for subscription to the Internet as a whole and for <FONT
STYLE="white-space:nowrap">on-line</FONT> time). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o) </B><B><I>Agreement Not to Offer or Sell Additional Shares</I></B><B>.</B> During
the period commencing on and including the date hereof and continuing through and including the 180th day following the date of the Prospectus (such period, as extended as described below, being referred to herein as the &#147;<B><FONT
STYLE="white-space:nowrap">Lock-up</FONT> Period</B>&#148;), the Company will not, without the prior written consent of the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Representatives (which consent may be withheld in their sole discretion),
directly or indirectly: (i)&nbsp;sell, offer to sell, contract to sell or lend any Shares or Related Securities (as defined below); (ii) effect any short sale, or establish or increase any &#147;put equivalent position&#148; (as defined in Rule <FONT
STYLE="white-space:nowrap">16a-1(h)</FONT> under the Exchange Act) or liquidate or decrease any &#147;call equivalent position&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">16a-1(b)</FONT> under the Exchange Act) of any Shares or
Related Securities; (iii)&nbsp;pledge, hypothecate or grant any security interest in any Shares or Related Securities; (iv)&nbsp;in any other way transfer or dispose of any Shares or Related Securities; (v)&nbsp;enter into any swap, hedge or similar
arrangement or agreement that transfers, in whole or in part, the economic risk of ownership of any Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise; (vi)&nbsp;announce the
offering of any Shares or Related Securities; (vii)&nbsp;submit or file any registration statement under the Securities Act in respect of any Shares or Related Securities (other than as contemplated by this Agreement with respect to the Offered
Shares); (viii) effect a reverse stock split, recapitalization, share consolidation, reclassification or similar transaction affecting the outstanding Shares; or (ix)&nbsp;publicly announce the intention to do any of the foregoing; <I>provided,
however</I>, that the Company may (A)&nbsp;effect the transactions contemplated hereby; (B)&nbsp;issue Shares or options to purchase Shares or otherwise issue equity or equity-based awards pursuant to any equity plan or arrangement described in the
Registration Statement, the Time of Sale Prospectus and the Prospectus, but only if the holders of such Shares or options agree in writing with the Underwriters not to sell, offer, dispose of or otherwise transfer any such Shares or options during
such <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period without the prior written consent of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Representatives (which consent may be withheld in its sole discretion); (C) file one or more
registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> with respect to any Shares or Related Securities issued or issuable pursuant to any stock option, stock bonus, or other stock plan or arrangement described in the
Registration Statement, the Time of Sale Prospectus or the Prospectus; (D)&nbsp;issue Shares in connection with the acquisition or license by the Company of the securities, business, property, technology or other assets of another person or business
entity or pursuant to any employee benefit plan assumed by the Company in connection with any such acquisition; (E)&nbsp;issue Shares or Related Securities, or enter into an agreement to issue Shares or Related Securities, in connection with any
merger, joint venture, strategic alliance, commercial or other collaborative transaction; provided that, in the case of immediately preceding clauses (D)&nbsp;and (E), the aggregate number of Shares issued or underlying such Related Securities
issued in connection with all such acquisitions and other transactions does not exceed 10%<B><SUP STYLE="font-size:85%; vertical-align:top"> </SUP></B>of the number of Shares outstanding after giving effect to the consummation of the offering of the
Offered Shares pursuant to this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement and provided further that the Company shall cause each recipient of such shares to execute and deliver to the Underwriters, on or prior to such issuance, a <FONT
STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreement, substantially in the form of <U>Exhibit A</U> hereto; and (G)&nbsp;assist any stockholder of the Company in the establishment of a trading plan by such stockholder pursuant to Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of shares of Common Stock, provided that such plan does not provide for the transfer of shares of Common Stock during the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, and the establishment of such plan does not require or otherwise result in any public filings or other public announcement of such plan during such
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period and such plan is otherwise permitted to be implemented during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period pursuant to the terms of the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement between such stockholder and the Underwriters in connection with the offering of the Offered Shares. For purposes of the foregoing, &#147;<B>Related Securities</B>&#148; shall mean any
options or warrants or other rights to acquire Shares or any securities exchangeable or exercisable for or convertible into Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for, or convertible into, Shares.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p) </B><B><I>Future Reports to the Representative</I></B><B><I>s</I></B><B><I>.</I></B><I> </I>During the period of five years
hereafter, the Company will furnish to the Representatives, c/o Jefferies, at 520 Madison Avenue, New York, New York 10022, Attention: Global Head of Syndicate, c/o Cowen, at 599 Lexington Avenue, New York, New York 10022, Attention: Head of Equity
Capital Markets, c/o Evercore, at 55 East 52<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> Street, New York, New York 10055: (i) as soon as practicable after the end of each fiscal year, copies of the Annual Report of the Company containing
the balance sheet of the Company as of the close of such fiscal year and statements of income, stockholders&#146;<I> </I>equity and cash flows for the year then ended and the opinion thereon of the Company&#146;s independent public or certified
public accountants; (ii)&nbsp;as soon as practicable after the filing thereof, copies of each proxy statement, Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT>
Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or other report filed by the Company with the Commission, FINRA or any securities exchange; and (iii)&nbsp;as soon as available, copies of any report or communication of the Company
furnished or made available generally to holders of its capital stock; <I>provided, however,</I> that the requirements of this Section&nbsp;3(p) shall be satisfied to the extent that such reports, statement, communications, financial statements or
other documents are available on EDGAR. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q) </B><B><I>Investment Limitation</I></B><B>.</B> The Company shall not invest or otherwise
use the proceeds received by the Company from its sale of the Offered Shares in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r) </B><B><I>No Stabilization or Manipulation</I></B><B><I>; Compliance with Regulation M</I></B><B>. </B>The Company will not take, and
will ensure that no affiliate of the Company will take, directly or indirectly, without giving effect to activities by the Underwriters, any action designed to or that would reasonably be expected to cause or result in stabilization or manipulation
of the price of the Shares or any reference security with respect to the Shares, whether to facilitate the sale or resale of the Offered Shares or otherwise, and the Company will, and shall cause each of its affiliates to, comply with all applicable
provisions of Regulation M. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s) </B><B><I>Enforce <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreement</I></B><B><I>s</I></B><B>.</B> During the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, the Company will enforce all agreements between the Company and any of its securityholders that restrict or prohibit, expressly or in
operation, the offer, sale or transfer of Shares or Related Securities or any of the other actions restricted or prohibited under the terms of the form of <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement. In addition, the Company will
direct the transfer agent to place stop transfer restrictions upon any such securities of the Company that are bound by such <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements for the duration of the periods contemplated in such
agreements, including, without limitation, <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements entered into by the Company&#146;s officers and directors and securityholders pursuant to Section&nbsp;6(i) hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t) </B><B><I>Company to Provide Interim Financial Statements</I></B><B>.</B> Prior to
the First Closing Date and each applicable Option Closing Date, the Company will furnish the Underwriters, as soon as they have been prepared by or are available to the Company, a copy of any unaudited interim financial statements of the Company for
any period subsequent to the period covered by the most recent financial statements appearing in the Registration Statement and the Prospectus; provided, however, that the requirements of this Section&nbsp;3(t) shall be deemed satisfied to the
extent such financial statements are available on EDGAR. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u) </B><B><I>Amendments and Supplements to Permitted
Section</I></B><B><I></I></B><B><I>&nbsp;5(d) Communications</I></B>. If at any time following the distribution of any Permitted Section&nbsp;5(d) Communication, during the Prospectus Delivery Period, there occurred or occurs an event or development
as a result of which such Permitted Section&nbsp;5(d) Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of
the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Permitted Section&nbsp;5(d) Communication to eliminate or
correct such untrue statement or omission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v) </B><B><I>Emerging Growth Company Status</I></B>. The Company will promptly notify the
Representatives if the Company ceases to be an Emerging Growth Company at any time prior to the later of (i)&nbsp;the time when a prospectus relating to the Offered Shares is not required by the Securities Act to be delivered (whether physically or
through compliance with Rule 172 under the Securities Act or any similar rule) and (ii)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period (as defined herein). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w) </B><B><I>Announcement Regarding <FONT STYLE="white-space:nowrap">Lock-ups</FONT></I></B><B>.</B> The Company agrees to announce the
Underwriters&#146; intention to release any director or &#147;officer&#148; (within the meaning of Rule <FONT STYLE="white-space:nowrap">16a-1(f)</FONT> under the Exchange Act) of the Company from any of the restrictions imposed by any <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Agreement, by issuing, through a major news service, a press release in form and substance satisfactory to the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Representatives or, if consented to by the <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Representatives, in a registration statement that is publicly filed in connection with a secondary offering of the Company&#146;s shares promptly following the Company&#146;s receipt of any notification from
the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Representatives in which such intention is indicated, but in any case not later than the close of the third business day prior to the date on which such release or waiver is to become effective;
<I>provided</I>, <I>however</I>, that nothing shall prevent the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Representatives, on behalf of the Underwriters, from announcing the same through a major news service, irrespective of whether the
Company has made the required announcement; and <I>provided, further,</I> that no such announcement shall be made of any release or waiver granted solely to permit a transfer of securities that is not for consideration and where the transferee has
agreed in writing to be bound by the terms of a <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement in the form set forth as <U>Exhibit A</U> hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>(x) Reorganization</I></B><B>.</B> The Plan of Dissolution shall be duly adopted by the holders of the limited liability interests of
Rallybio LLC and as of the Closing, Rallybio LLC shall have been dissolved as a limited liability company and such dissolution shall have been conducted in accordance with the Plan of Dissolution and the Second Amended and Restated Operating
Agreement of Rallybio LLC, dated as of March&nbsp;27, 2020, and shall have become effective under the Delaware Limited Liability Company Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">Lock-up</FONT> Representatives, on behalf of the several Underwriters, may, in their sole discretion,
waive in writing the performance by the Company of any one or more of the foregoing covenants or extend the time for their performance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4. </B><B>Payment of Expenses</B><B>.</B> The Company agrees
to pay all costs, fees and expenses incurred in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including without limitation (i)&nbsp;all expenses incident to the issuance and
delivery of the Offered Shares (including all printing and engraving costs), (ii)&nbsp;all fees and expenses of the registrar and transfer agent of the Shares, (iii)&nbsp;all necessary issue, transfer and other stamp taxes in connection with the
issuance and sale of the Offered Shares to the Underwriters, (iv)&nbsp;all fees and expenses of the Company&#146;s counsel, independent public or certified public accountants and other advisors, (v)&nbsp;all costs and expenses incurred in connection
with the preparation, printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Time of Sale Prospectus, the Prospectus, each free
writing prospectus prepared by or on behalf of, used by, or referred to by the Company, and each preliminary prospectus, each Permitted Section&nbsp;5(d) Communication, and all amendments and supplements thereto, and this Agreement, (vi)&nbsp;all
filing fees, reasonable and reasonably documented attorneys&#146; fees and expenses incurred by the Company or the Underwriters in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or
any part of the Offered Shares for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested by the Representatives, preparing and printing a &#147;Blue Sky Survey&#148; or memorandum
and a &#147;Canadian wrapper&#148;, and any supplements thereto, advising the Underwriters of such qualifications, registrations and exemptions, (vii)&nbsp;the costs, fees and expenses incurred by the Underwriters in connection with determining
their compliance with the rules and regulations of FINRA related to the Underwriters&#146; participation in the offering and distribution of the Offered Shares, including any related filing fees and the legal fees of, and disbursements by, counsel
to the Underwriters, (viii)&nbsp;the costs and expenses of the Company relating to investor presentations on any &#147;road show&#148;, any Permitted Section&nbsp;5(d) Communication or any Section&nbsp;5(d) Oral Communication undertaken in
connection with the offering of the Offered Shares, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees
and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company and any such consultants, and
50% of the cost of any aircraft chartered in connection with the road show, with the other 50% being paid by the Underwriters, (ix)&nbsp;the fees and expenses associated with listing the Offered Shares on Nasdaq, and (x)&nbsp;all other fees, costs
and expenses of the nature referred to in Item 13 of Part&nbsp;II of the Registration Statement; provided that the fees and expenses of counsel with respect to clauses (vi)&nbsp;and (vii) above shall not exceed $30,000 for fees and expenses related
to FINRA and $10,000 for fees and expenses related to blue sky laws. Except as provided in this Section&nbsp;4 or in Section&nbsp;7, Section&nbsp;9 or Section&nbsp;10 hereof, the Underwriters shall pay their own expenses, including the fees and
disbursements of their counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5. </B><B>Covenant of the Underwriters</B><B>.</B> Each Underwriter
severally and not jointly covenants with the Company not to take any action that would result in the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on
behalf of such Underwriter that otherwise would not, but for such actions, be required to be filed by the Company under Rule 433(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6. </B><B>Conditions of the Obligations of the Underwriters</B><B>.</B> The respective obligations of the
several Underwriters hereunder to purchase and pay for the Offered Shares as provided herein on the First Closing Date and, with respect to the Optional Shares, each Option Closing Date, shall be subject to the accuracy of the representations and
warranties on the part of the Company set forth in Section&nbsp;1 hereof as of the date hereof and as of the First Closing Date as though then made and, with respect to the Optional Shares, as of each Option Closing Date as though then made, to the
timely performance by the Company of its covenants and other obligations hereunder, and to each of the following additional conditions: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B><I>Comfort Letter</I></B><B>.</B> On the date hereof, the Representatives
shall have received from Deloitte&nbsp;&amp; Touche LLP, independent registered public accountants for the Company, a letter dated the date hereof addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives,
containing statements and information of the type ordinarily included in accountant&#146;s &#147;comfort letters&#148; to underwriters, delivered according to Statement of Auditing Standards No.&nbsp;72 (or any successor bulletin), with respect to
the audited and unaudited financial statements and certain financial information contained in the Registration Statement, the Time of Sale Prospectus, and each free writing prospectus, if any. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>Compliance with Registration Requirements; No Stop Order; No Objection from </I></B><B><I>FINRA</I></B><B><I>. </I></B>For the
period from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Shares purchased after the First Closing Date, each Option Closing Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Company shall have filed the Prospectus with the Commission (including the information required by Rule 430A under the Securities Act)
in the manner and within the time period required by Rule 424(b) under the Securities Act; or the Company shall have filed a post-effective amendment to the Registration Statement containing the information required by such Rule 430A, and such
post-effective amendment shall have become effective. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) No stop order suspending the effectiveness of the Registration Statement or any
post-effective amendment to the Registration Statement shall be in effect, and no proceedings for such purpose shall have been instituted or, to the knowledge of the Company, threatened by the Commission; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) FINRA shall have raised no objection to the fairness and reasonableness of the underwriting terms and arrangements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B><I>No Material Adverse Change or Ratings Agency Change</I></B><B>.</B> For the period from and after the date of this Agreement
and through and including the First Closing Date and, with respect to any Optional Shares purchased after the First Closing Date, each Option Closing Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) in the judgment of the Representatives there shall not have occurred any Material Adverse Change; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any
review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any &#147;nationally recognized statistical rating organization&#148; as
that term is defined in Section&nbsp;3(a)(62) under the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B><I>Opinion and Negative Assurance Letter of Counsel
for the Company</I></B><B>.</B> On each of the First Closing Date and each Option Closing Date the Representatives shall have received the opinion and negative assurance letter of Ropes&nbsp;&amp; Gray LLP, counsel for the Company and Rallybio LLC,
dated as of such date, with respect to the Company, Rallybio LLC and each of the Company&#146;s significant subsidiaries as defined under the Exchange Act, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) </B><B><I>Opinion of </I></B><B><I>Intellectual Property Counsel for the Company</I></B><B><I>.</I></B><I> </I>On each of the First
Closing Date and each Option Closing Date, the Representatives shall have received the opinion of Grimes&nbsp;&amp; Yvon, LLP, counsel for the Company with respect to intellectual property, dated as of such date, in form and substance reasonably
satisfactory to the Representatives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) </B><B><I>Opinion of Counsel for the Underwriters</I></B><B>.</B> On each of the
First Closing Date and each Option Closing Date the Representatives shall have received the opinion and negative assurance letter of Wilmer Cutler Pickering Hale and Dorr LLP, counsel for the Underwriters in connection with the offer and sale of the
Offered Shares, in form and substance satisfactory to the Underwriters, dated as of such date, with executed copies for each of the other Underwriters named on the Prospectus cover page. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g) </B><B><I>Officers</I></B><B><I>&#146;</I></B><B><I> Certificate</I></B><B>.</B> On each of the First Closing Date and each Option
Closing Date, the Representatives shall have received a certificate executed by the Chief Executive Officer or President of the Company and the Chief Financial Officer of the Company, on behalf of the Company and not in their individual capacities,
dated as of such date, to the effect set forth in Section&nbsp;6(b)(ii) and further to the effect that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) for the period from and
including the date of this Agreement through and including such date, there has not occurred any Material Adverse Change; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) the
representations, warranties and covenants of the Company set forth in Section&nbsp;1 of this Agreement are true and correct with the same force and effect as though expressly made on and as of such date; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) Each of the Company and Rallybio LLC has complied with all the agreements hereunder and satisfied all the conditions on its part to be
performed or satisfied hereunder at or prior to such date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h) </B><B><I>Bring-down Comfort Letter</I></B><B>.</B> On each of the First
Closing Date and each Option Closing Date the Representatives shall have received from Deloitte&nbsp;&amp; Touche LLP, independent registered public accountants for the Company, a letter dated such date, in form and substance satisfactory to the
Representatives, which letter shall: (i)&nbsp;reaffirm the statements made in the letter furnished by them pursuant to Section&nbsp;6(a), except that the specified date referred to therein for the carrying out of procedures shall be no more than
three business days prior to the First Closing Date or the applicable Option Closing Date, as the case may be; and (ii)&nbsp;cover certain financial information contained in the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) </B><B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</I></B><B><I>.</I></B> On or prior to the date hereof, the Company
shall have furnished to the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Representatives an agreement in the form of <U>Exhibit A</U> hereto from each director and officer and from all of the securityholders of the Company, and each such
agreement shall be in full force and effect on each of the First Closing Date and each Option Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j) </B><B><I>Rule 462(b)
Registration Statement</I></B><B>.</B> In the event that a Rule 462(b) Registration Statement is filed in connection with the offering contemplated by this Agreement, such Rule 462(b) Registration Statement shall have been filed with the Commission
on the date of this Agreement and shall have become effective automatically upon such filing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k) </B><B><I>Approval of
Listing</I></B>. At the First Closing Date, the Offered Shares shall have been approved for listing on Nasdaq, subject only to official notice of issuance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l) </B><B><I>The Reorganization. </I></B>The Certificate of Dissolution shall have been
filed with the Secretary of the State of Delaware and the Certificate of Conversion shall have been filed with the Secretary of the State of Delaware and shall not have been amended or modified since the date thereof.<I> </I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m) </B><B><I>Additional Documents</I></B>. On or before each of the First Closing Date and each Option Closing Date, the Representatives
and counsel for the Underwriters shall have received such information, documents and opinions as they may reasonably request for the purposes of enabling them to pass upon the issuance and sale of the Offered Shares as contemplated herein, or in
order to evidence the accuracy of any of the representations and warranties, or the satisfaction of any of the conditions or agreements, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the
Offered Shares as contemplated herein and in connection with the other transactions contemplated by this Agreement shall be satisfactory in form and substance to the Representatives and counsel for the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any condition specified in this Section&nbsp;6 is not satisfied when and as required to be satisfied, this Agreement may be terminated by
the Representatives by notice from the Representatives to the Company at any time on or prior to the First Closing Date and, with respect to the Optional Shares, at any time on or prior to the applicable Option Closing Date, which termination shall
be without liability on the part of any party to any other party, except that Section&nbsp;4, Section&nbsp;7, Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7. </B><B>Reimbursement of Underwriters</B><B>&#146;</B><B> Expenses</B>. If this Agreement is terminated by the
Representatives pursuant to Section&nbsp;6, Section 11 or Section&nbsp;12(i), or if the sale to the Underwriters of the Offered Shares on the First Closing Date is not consummated because of any refusal, inability or failure on the part of the
Company to perform any agreement herein or to comply with any provision hereof, the Company agrees to reimburse the Representatives and the other Underwriters (or such Underwriters as have terminated this Agreement with respect to themselves),
severally, upon demand for all reasonably documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses that shall have been reasonably incurred by the Representatives and the Underwriters in
connection with the proposed purchase and the offering and sale of the Offered Shares, including, but not limited to, fees and disbursements of counsel, printing expenses, travel expenses, postage, facsimile and telephone charges; <I>provided</I>,
<I>however</I>, that in the event any such termination is effected after the First Closing Date but prior to any Option Closing Date with respect to the purchase of any Optional Shares, the Company shall only reimburse the Underwriters for their <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, including the reasonable fees and disbursements of counsel for the Underwriters, incurred after the First Closing Date in connection with the proposed
purchase of any such Optional Shares. For the avoidance of doubt, it is understood that the Company will not pay or reimburse any costs, fees or expenses incurred by any Underwriter that defaults on its obligations to purchase the Offered Shares.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8. </B><B>Effectiveness of this Agreement</B>. This Agreement shall become effective upon&nbsp;the
execution and delivery hereof by the parties hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9. </B><B>Indemnification</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B><I>Indemnification of the Underwriters</I></B><B>.</B> The Company agrees to indemnify and hold harmless each Underwriter, its
affiliates, directors, officers, employees and agents, and each person, if any, who controls any Underwriter within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which
such Underwriter or such affiliate, director, officer, employee, agent or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the laws or regulations of foreign
jurisdictions where Offered Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of the Company), insofar as such loss, claim, damage,
liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (A) (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment
thereto, or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact
included in any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act, any Marketing Material, any
Section&nbsp;5(d) Written Communication or the Prospectus (or any amendment or supplement to the foregoing), or the omission or alleged omission to state therein a material fact necessary in order to make the statements, in the light of the
circumstances under which they were made, not misleading; or (B)&nbsp;the violation of any laws or regulations of foreign jurisdictions where Offered Shares have been offered or sold; and to reimburse each Underwriter and each such affiliate,
director, officer, employee, agent and controlling person for any and all expenses (including the reasonable and reasonably documented fees and disbursements of counsel) as such expenses are incurred by such Underwriter or such affiliate, director,
officer, employee, agent or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; <I>provided, however</I>, that the foregoing indemnity agreement
shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in
conformity with information relating to any Underwriter furnished to the Company by the Representatives in writing expressly for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any such free writing
prospectus, any Marketing Material, any Section&nbsp;5(d) Written Communication or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information consists of the information described in
Section&nbsp;9(b) below. The indemnity agreement set forth in this Section&nbsp;9(a) shall be in addition to any liabilities that the Company may otherwise have. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>Indemnification of the Company, its Directors and Officers</I></B>. Each Underwriter agrees, severally and not jointly, to
indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act, against any
loss, claim, damage, liability or expense, as incurred, to which the Company, or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, or other federal or state statutory law or regulation,
or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of such Underwriter), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as
contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, or any omission or alleged omission to state therein a
material fact required to be stated therein or necessary to make the statements therein not misleading or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact included in any preliminary prospectus, the Time of Sale
Prospectus, any free writing prospectus, that the Company has used, referred to or filed, or is required to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
file, pursuant to Rule 433 of the Securities Act, any Section&nbsp;5(d) Written Communication or the Prospectus (or any such amendment or supplement) or the omission or alleged omission to state
therein a material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue
statement or omission or alleged omission was made in the Registration Statement, such preliminary prospectus, the Time of Sale Prospectus, such free writing prospectus, such Section&nbsp;5(d) Written Communication or the Prospectus (or any such
amendment or supplement), in reliance upon and in conformity with information relating to such Underwriter furnished to the Company by the Representatives in writing expressly for use therein; and to reimburse the Company, or any such director,
officer or controlling person for any and all reasonable expenses (including the reasonable fees and disbursements of counsel) as such expenses are incurred by the Company, or any such director, officer or controlling person in connection with
investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. The Company hereby acknowledges that the only information that the Representatives have furnished to the Company expressly for use
in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus, any Marketing Material, any Section&nbsp;5(d) Written Communication or the Prospectus (or any amendment or supplement to the
foregoing) are the statements set forth in the first sentence of the third paragraph under the caption &#147;Underwriting&#148; regarding market making, the first sentence of the fifth paragraph under the caption &#147;Underwriting,&#148; the first
sentence of the sixteenth paragraph and the first sentence of the twenty-first paragraph under the caption &#147;Underwriting&#148; regarding stabilizing activities in the Preliminary Prospectus and the Prospectus. The indemnity agreement set forth
in this Section&nbsp;9(b) shall be in addition to any liabilities that each Underwriter may otherwise have. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B><I>Notifications
and Other Indemnification Procedures</I></B><B>.</B> Promptly after receipt by an indemnified party under this Section&nbsp;9 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made
against an indemnifying party under this Section&nbsp;9, notify the indemnifying party in writing of the commencement thereof, but the omission to so notify the indemnifying party will not relieve the indemnifying party from any liability which it
may have to any indemnified party to the extent the indemnifying party is not materially prejudiced as a proximate result of such failure and shall not in any event relieve the indemnifying party from any liability that it may have otherwise than on
account of this indemnity agreement. In case any such action is brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate
in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the
defense thereof with counsel reasonably satisfactory to such indemnified party; <I>provided, however</I>, that if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have
reasonably concluded based upon advice of counsel that a conflict may arise between the positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it
and/or other indemnified parties which are different from or additional to those available to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise
participate in the defense of such action on behalf of such indemnified party or parties. Upon receipt of notice from the indemnifying party to such indemnified party of such indemnifying party&#146;s election to so assume the defense of such action
and approval by the indemnified party of counsel, such approval not to be unreasonably withheld, delayed or conditioned, the indemnifying party will not be liable to such indemnified party under this Section&nbsp;9 for any reasonable and reasonably
documented legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i)&nbsp;the indemnified party shall have employed separate counsel in accordance with the proviso to the preceding
sentence (it being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
separate counsel (together with local counsel), representing the indemnified parties who are parties to such action), which counsel (together with any local counsel) for the indemnified parties
shall be selected by Jefferies (in the case of counsel for the indemnified parties referred to in <B></B>Section&nbsp;9(a) above) or by the Company (in the case of counsel for the indemnified parties referred to in Section&nbsp;9(b) above)) or
(ii)&nbsp;the indemnifying party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of commencement of the action or (iii)&nbsp;the indemnifying party has
authorized in writing the employment of counsel for the indemnified party at the expense of the indemnifying party, in each of which cases the fees and expenses of counsel shall be at the expense of the indemnifying party and shall be paid as they
are incurred. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B><I>Settlements</I></B><B>.</B> The indemnifying party under this Section&nbsp;9 shall not be liable for any
settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage,
liability or expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for the reasonable and
reasonably documented fees and expenses of counsel as contemplated by Section&nbsp;9(c) hereof, the indemnifying party shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered
into more than 30&nbsp;days after receipt by such indemnifying party of the aforesaid request and (ii)&nbsp;such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement.
No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any
indemnified party is or would reasonably be expected to have been a party and indemnity was or would reasonably be expected to have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an
unconditional release of such indemnified party from all liability on claims that are the subject matter of such action, suit or proceeding and does not include an admission of fault or culpability or a failure to act by or on behalf of such
indemnified party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;10. </B><B>Contribution</B>. If the indemnification provided for in Section&nbsp;9 is
for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall contribute to the
aggregate amount paid or payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received
by the Company, on the one hand, and the Underwriters, on the other hand, from the offering of the Offered Shares pursuant to this Agreement or (ii)&nbsp;if the allocation provided by clause&nbsp;(i) above is not permitted by applicable law, in such
proportion as is appropriate to reflect not only the relative benefits referred to in clause&nbsp;(i) above but also the relative fault of the Company, on the one hand, and the Underwriters, on the other hand, in connection with the statements or
omissions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, in
connection with the offering of the Offered Shares pursuant to this Agreement shall be deemed to be in the same respective proportions as the total proceeds from the offering of the Offered Shares pursuant to this Agreement (after deducting
underwriting discounts and commissions, but before deducting expenses) received by the Company, and the total underwriting discounts and commissions received by the Underwriters, in each case as set forth on the front cover page of the Prospectus,
bear to the aggregate initial public offering price of the Offered Shares as set forth on such cover. The relative fault of the Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference to, among other
things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand, or the Underwriters, on the other hand, and the
parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount paid or payable by a party as a result of the losses, claims, damages,
liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in Section&nbsp;9(c), any reasonable and reasonably documented legal or other fees or expenses reasonably incurred by such party in
connection with investigating or defending any action or claim. The provisions set forth in Section&nbsp;9(c) with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this Section&nbsp;10;
<I>provided, however,</I> that no additional notice shall be required with respect to any action for which notice has been given under Section&nbsp;9(c) for purposes of indemnification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section&nbsp;10 were
determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to in this Section&nbsp;10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the provisions of this Section&nbsp;10, no Underwriter shall be required to contribute any amount in excess of the
underwriting discounts and commissions received by such Underwriter in connection with the Offered Shares underwritten by it and distributed to the public. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of
the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#146; obligations to contribute pursuant to this Section&nbsp;10 are several, and not joint, in
proportion to their respective underwriting commitments as set forth opposite their respective names on <U>Schedule A</U>. For purposes of this Section&nbsp;10, each affiliate, director, officer, employee and agent of an Underwriter and each person,
if any, who controls an Underwriter within the meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as such Underwriter, and each director of the Company, each officer of the Company who signed the
Registration Statement, and each person, if any, who controls the Company within the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;11. </B><B>Default of One or More of the Several Underwriters</B><I>.</I> If, on the First Closing Date or any
Option Closing Date any one or more of the several Underwriters shall fail or refuse to purchase Offered Shares that it or they have agreed to purchase hereunder on such date, and the aggregate number of Offered Shares which such defaulting
Underwriter or Underwriters agreed but failed or refused to purchase does not exceed 10% of the aggregate number of the Offered Shares to be purchased on such date, the Representatives may make arrangements satisfactory to the Company for the
purchase of such Offered Shares by other persons, including any of the Underwriters, but if no such arrangements are made by such date, the other Underwriters shall be obligated, severally and not jointly, in the proportions that the number of Firm
Shares set forth opposite their respective names on <U>Schedule A</U> bears to the aggregate number of Firm Shares set forth opposite the names of all such <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or in such other
proportions as may be specified by the Representatives with the consent of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, to purchase the Offered Shares which such defaulting Underwriter or Underwriters agreed but failed or
refused to purchase on such date. If, on the First Closing Date or any Option Closing Date any one or more of the Underwriters shall fail or refuse to purchase Offered Shares and the aggregate number of Offered Shares with respect to which such
default occurs exceeds 10% of the aggregate number of Offered Shares to be purchased on such date, and arrangements satisfactory to the Representatives and the Company for the purchase of such Offered Shares are not made within 48 hours after such
default, this Agreement shall terminate without liability of any party to any other party except that the provisions of Section&nbsp;4, Section&nbsp;7, Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such
termination. In any such case either the Representatives or the Company shall have the right to postpone the First Closing Date or the applicable Option Closing Date, as the case may be, but in no event for longer than seven days in order that the
required changes, if any, to the Registration Statement and the Prospectus or any other documents or arrangements may be effected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement, the term &#147;<B>Underwriter</B>&#148; shall be deemed to
include any person substituted for a defaulting Underwriter under this Section&nbsp;11. Any action taken under this Section&nbsp;11 shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;12. </B><B>Termination of this Agreement</B><I>.</I> Prior to the purchase of the Firm Shares by
the Underwriters on the First Closing Date, this Agreement may be terminated by the Representatives by notice given to the Company if at any time: (i)&nbsp;trading or quotation in any of the Company&#146;s securities shall have been suspended or
limited by the Commission or by Nasdaq, or trading in securities generally on either Nasdaq or the New York Stock Exchange shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock
exchanges; (ii)&nbsp;a general banking moratorium shall have been declared by any of federal, New York or Connecticut authorities; (iii)&nbsp;there shall have occurred any outbreak or escalation of national or international hostilities or any crisis
or calamity, or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States&#146; or international political, financial or economic
conditions, as in the judgment of the Representatives is material and adverse and makes it impracticable to market the Offered Shares in the manner and on the terms described in the Time of Sale Prospectus or the Prospectus or to enforce contracts
for the sale of securities; (iv)&nbsp;in the judgment of the Representatives there shall have occurred any Material Adverse Change; or (v)&nbsp;the Company shall have sustained a loss by strike, fire, flood, earthquake, accident or other calamity of
such character as in the judgment of the Representatives may interfere materially with the conduct of the business and operations of the Company regardless of whether or not such loss shall have been insured. Any termination pursuant to this
Section&nbsp;12 shall be without liability on the part of (a)&nbsp;the Company to any Underwriter, except that the Company shall be obligated to reimburse the expenses of the Representatives and the Underwriters pursuant to Section&nbsp;4 or
Section&nbsp;7 hereof or (b)&nbsp;any Underwriter to the Company; <I>provided, however,</I> that the provisions of Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;13. </B><B>No Advisory or Fiduciary Relationship. </B>The Company acknowledges and agrees that (a)&nbsp;the
purchase and sale of the Offered Shares pursuant to this Agreement, including the determination of the public offering price of the Offered Shares and any related discounts and commissions, is an
<FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand, (b)&nbsp;in connection with the offering contemplated hereby and the process
leading to such transaction, each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of the Company, or its stockholders, creditors, employees or any other party, (c)&nbsp;no Underwriter has assumed or will
assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on
other matters) and no Underwriter has any obligation to the Company with respect to the offering contemplated hereby except the obligations expressly set forth in this Agreement, (d)&nbsp;the Underwriters and their respective affiliates may be
engaged in a broad range of transactions that involve interests that differ from those of the Company, and (e)&nbsp;the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby
and the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;14. Representations and Indemnities to Survive
Delivery</B><I>.</I> The respective indemnities, agreements, representations, warranties and other statements of the Company, of its officers and of the several Underwriters set forth in or made pursuant to this Agreement will remain in full force
and effect, regardless of any investigation made by or on behalf of any Underwriter or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary
notwithstanding, will survive delivery of and payment for the Offered Shares sold hereunder and any termination of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;15. </B><B>Notices</B>. All communications hereunder shall be in writing and shall be mailed, hand delivered,
electronically mailed or telecopied and confirmed to the parties hereto as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to the Representatives:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Jefferies LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">520 Madison Avenue</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, New York 10022</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile: (646) <FONT STYLE="white-space:nowrap">619-4437</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: General Counsel</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cowen and Company, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">520 Madison Avenue</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, New York 10022</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile: (646) <FONT STYLE="white-space:nowrap">562-1249</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Head of Equity Capital Markets</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Evercore Group L.L.C.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">55 East 52<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, New York 10055</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: General Counsel</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">with a copy to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Wilmer Cutler Pickering Hale and Dorr LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">7 World Trade Center</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">250 Greenwich Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, New York 10007</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile: (212) <FONT STYLE="white-space:nowrap">230-8888</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Lisa Firenze</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to the Company:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Rallybio</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">234 Church Street, Suite 1020</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New Haven, CT 06510</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Michael Greco</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">with a copy to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ropes&nbsp;&amp; Gray LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">800 Boylston Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Boston, MA 02199</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Marc Rubenstein; Zachary Blume</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any party hereto may change the address for receipt of communications by giving written notice to the others. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;16. </B><B>Successors</B><I>.</I> This Agreement will inure to
the benefit of and be binding upon the parties hereto, including any substitute Underwriters pursuant to Section&nbsp;11 hereof, and to the benefit of the affiliates, directors, officers, employees, agents and controlling persons referred to in
Section&nbsp;9 and Section&nbsp;10, and in each case their respective successors, and no other person will have any right or obligation hereunder. The term &#147;<B>successors</B>&#148; shall not include any purchaser of the Offered Shares as such
from any of the Underwriters merely by reason of such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;17. </B><B>Partial Unenforceability</B>.
The invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or provision of this Agreement
is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;18. Recognition of the U.S. Special Resolution Regimes</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the
transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any
such interest and obligation, were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In the event that any
Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted
to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, (A) &#147;<B>BHC Act Affiliate</B>&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and
shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k); (B) &#147;<B>Covered Entity</B>&#148; means any of the following: (i)&nbsp;a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R.
&#167; 252.82(b); (ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (iii)&nbsp;a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12
C.F.R. &#167; 382.2(b); (C) &#147;<B>Default Right</B>&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable; and (D) &#147;U<B>.S. Special Resolution
Regime</B>&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;19. </B><B>Governing Law Provisions</B><I>.</I> This Agreement shall be governed by and construed in
accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby may
be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in the Borough of Manhattan in the City of New York
(collectively, the &#147;<B>Specified Courts</B>&#148;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court, as to which such jurisdiction
is <FONT STYLE="white-space:nowrap">non-exclusive)</FONT> of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party&#146;s address set forth above shall be effective service of
process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and
unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;20. </B><B>General Provisions</B><B>.</B> This Agreement
constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may be
executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. Counterparts may be delivered fia facsimile, electronic mail (including any
electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, <I>e.g.</I>, www.docusign.com) or other transmission method and any
counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein
(express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. The section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the parties hereto acknowledges that it is a sophisticated business person who was adequately represented by counsel
during negotiations regarding the provisions hereof, including, without limitation, the indemnification provisions of Section&nbsp;9 and the contribution provisions of Section&nbsp;10, and is fully informed regarding said provisions. Each of the
parties hereto further acknowledges that the provisions of Section&nbsp;9 and&nbsp;Section 10 hereof fairly allocate the risks in light of the ability of the parties to investigate the Company, its affairs and its business in order to assure that
adequate disclosure has been made in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, each free writing prospectus and the Prospectus (and any amendments and supplements to the foregoing), as contemplated by the
Securities Act and the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, kindly sign and
return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours,</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>RALLYBIO CORPORATION</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>RALLYBIO HOLDINGS, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing Underwriting Agreement is hereby confirmed and accepted by the Representatives
in New York, New York as of the date first above written. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JEFFERIES LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>COWEN AND COMPANY, LLC </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EVERCORE GROUP L.L.C. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acting individually and as Representatives </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of the several
Underwriters named in </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the attached <U>Schedule A</U>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JEFFERIES LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COWEN AND COMPANY, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EVERCORE GROUP L.L.C.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule A </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Underwriters</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Firm&nbsp;Shares</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>to&nbsp;be&nbsp;Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#149;]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#149;]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#149;]&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#149;]&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Free Writing Prospectuses Included in the Time of Sale Prospectus </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[to be added] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Pricing Information </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Number of
Firm Shares: [&#149;] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Price per Share to the public: $[&#149;] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Number of Optional Shares: [&#149;] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">First Closing Date:
[&#149;] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Permitted Section&nbsp;5(d) Communications </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[to be added] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Form of <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement </U></B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April __, 2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">As Representatives of the
Several Underwriters </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">599 Lexington Avenue, 25<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">RE:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Proposed Public Offering by Rallybio </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies&nbsp;&amp; Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned is a director or
officer of Rallybio Holdings, LLC, a Delaware limited liability company (&#147;<B>Rallybio LLC</B>&#148;), and/or a holder of units or other interests in Rallybio LLC (each a &#147;<B>Unit</B>&#148; and collectively, &#147;<B>Units</B>&#148;), and
will become a holder of equity interests in a successor to Rallybio LLC (the &#147;<B>Company</B>&#148;). Rallybio LLC proposes to conduct a public offering of shares of common stock (&#147;<B>Shares</B>&#148;) of the Company (the
&#147;<B>Offering</B>&#148;) for which Jefferies LLC and Cowen and Company, LLC will act as representatives (together, the &#147;<B>Representatives</B>&#148;) of the underwriters. The undersigned recognizes that the Offering will benefit each of the
Company and the undersigned. The undersigned acknowledges that the underwriters are relying on the representations and agreements of the undersigned contained in this letter agreement in conducting the Offering and, at a subsequent date, in entering
into an underwriting agreement (the &#147;<B>Underwriting Agreement</B>&#148;) and other underwriting arrangements with the Company with respect to the Offering. Prior to the completion of the Offering, it is anticipated that Rallybio LLC will
complete a series of transactions pursuant to which the Company will succeed to the business of Rallybio LLC, and the holders of Units of Rallybio LLC will receive, by way of exchange, distribution or otherwise, Shares or other securities
exercisable for Shares in the Company (such transactions, the &#147;<B>Reorganization</B>&#148;). Unless the context requires otherwise, references to the Company include Rallybio LLC and any successor entity of Rallybio LLC or the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annex A sets forth definitions for capitalized terms used in this letter agreement that are not defined in the body of this letter agreement. Those
definitions are a part of this letter agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In consideration of the foregoing, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the undersigned hereby agrees that, during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, the undersigned will not (and will use reasonable best efforts to cause any Family Member not to),
subject to the exceptions set forth in this letter agreement, without the prior written consent of the Representatives, which may withhold their consent in their sole discretion: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sell or Offer to Sell any Shares or Related Securities currently or hereafter owned either of record or
beneficially (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) by the undersigned or such Family Member, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any Swap, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any demand for, or exercise any right with respect to, the registration under the Securities Act of the
offer and sale of any Shares or Related Securities, or cause to be filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicly announce any intention to do any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing restrictions will not apply to the registration of the offer and sale of the Shares, and the sale of the Shares to the underwriters, in each
case as contemplated by the Underwriting Agreement or any actions that the undersigned may be required to take in connection with the Reorganization pursuant to its terms; <I>provided </I>that any securities received in exchange for or upon
conversion of Units shall remain subject to the terms of this letter agreement and no public filing or announcements shall be made under the Exchange Act in connection therewith except any filings required on Form 4, or pursuant to Schedule 13G,
Schedule 13G/A or Form 13F, which such filings do not report a reduction in beneficial ownership. In addition, the foregoing restrictions shall not apply to (i)&nbsp;transfers or dispositions of Shares or Related Securities as a bona fide gift or
for estate planning purposes, by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or any Family Member of the undersigned, to a trust for the direct or indirect benefit of the undersigned
and/or a Family Member, or to a charitable organization or educational institution in each case under this clause (i)&nbsp;in a transfer not involving a disposition for value; (ii)&nbsp;transfers or dispositions of Shares or Related Securities to
any corporation, partnership, limited liability company or other entity, all of the beneficial ownership interests of which are held by the undersigned or any Family Member; (iii)&nbsp;if the undersigned is an entity, transfers, dispositions or
distributions of Shares or Related Securities to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate (within the meaning set forth in Rule 405 under the Securities Act of 1933, as amended,
and including the subsidiaries of the undersigned) of the undersigned, to any investment fund or other entity controlling, controlled by, managing or managed by or under common control with the undersigned or affiliates of the undersigned
(including, for the avoidance of doubt, where the undersigned is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership) or to its stockholders, limited partners, general partners,
limited liability company members or other equity holders or to the estate of any such stockholders, limited partners, general partners, limited liability company members or equity holders; (iv)&nbsp;the exercise by the undersigned of an option to
purchase Shares or Related Securities granted under any equity incentive plan or stock purchase plan of the Company described in the Prospectus (as defined in the Underwriting Agreement), provided that the underlying Shares or Related Securities
shall continue to be subject to the restrictions on transfer set forth in this letter agreement and, provided further that, no public filing under the Exchange Act shall be made unless required by Section&nbsp;16 of the Exchange Act, and, if
required under Section&nbsp;16 of the Exchange Act, shall indicate in the footnotes thereto that the filing relates to the exercise of a stock option, that no Shares were sold by the reporting person and that Shares received upon exercise of the
stock option are subject to this letter agreement; (v)&nbsp;the establishment of a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of Shares, provided that such plan does not
provide for any transfers of Shares or Related Securities during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period and no public disclosure or filing under the Exchange Act by any party to the transfer shall be required, or made
voluntarily, during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period; (vi)&nbsp;transfers or dispositions of Shares or Related Securities (other than those that are Company-directed) acquired in the Offering or on the open market following
the Offering, provided, no public disclosure or filing under the Exchange Act (other </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
than any required filing on Schedule 13G, Schedule 13G/A or Form 13F) shall be made; (vii)&nbsp;the transfer of Shares or Related Securities to a nominee or custodian of a person or entity to
whom a disposition or transfer would be permissible under clauses (i)-(iii) and (vi)&nbsp;above; (viii) transfers or dispositions of Shares or Related Securities as forfeitures to the Company to satisfy tax withholding obligations of the undersigned
in connection with the vesting or exercise of equity awards by the undersigned pursuant to the Company&#146;s equity incentive, stock option, stock bonus or other stock plan or arrangement described in the Prospectus (as defined in the Underwriting
Agreement); (ix) transfers to the Company of Shares or Related Securities pursuant to a net exercise or cashless exercise by the undersigned of outstanding equity awards pursuant to the Company&#146;s equity incentive, stock option, stock bonus or
other stock plan or arrangement described in the Prospectus (as defined in the Underwriting Agreement); (x) transfers or dispositions of the undersigned&#146;s Shares or Related Securities pursuant to a bona fide third-party tender offer for shares
of the Company, merger, consolidation or other similar transaction made to all holders of the Company&#146;s securities involving a Change of Control of the Company (including, without limitation, the entering into any
<FONT STYLE="white-space:nowrap">lock-up,</FONT> voting or similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose of common stock or other such securities in connection with such transaction, or
vote any common stock or other such securities in favor of any such transaction), provided that all other securities held by the undersigned not transferred in the transaction remain subject to the provisions of this letter agreement and, in the
event that such tender offer, merger, consolidation or other such transaction is not completed, such securities held by the undersigned shall remain subject to the provisions of this letter agreement; or (xi)&nbsp;transfers or dispositions of Shares
or Related Securities by operation of law, including pursuant to a domestic order or negotiated divorce settlement, or pursuant to a court order, provided that no public filing shall be made under the Exchange Act other than those required and which
include a description of the circumstances of the transfer; <I>provided that, </I>(A)&nbsp;in the case of a transfer pursuant to clause (viii)&nbsp;above, no public filing shall be voluntarily made and if the undersigned is required to make a filing
under the Exchange Act during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, the undersigned shall include a statement in such report to the effect that the purpose of such transfer was to cover tax obligations of the undersigned in
connection with such exercise, (B)&nbsp;in the case of a transfer pursuant to clause (ix)&nbsp;above, prior to the expiration of the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, no public disclosure or filing under the Exchange Act by any
party to the transfer (donor, donee, transferor or transferee) shall be made voluntarily and if the undersigned is required to file a report under the Exchange Act, such report shall include a statement to the effect that the filing relates to the
&#147;net&#148; or &#147;cashless&#148; exercise of options to purchase shares of common stock for the purpose of exercising such options, including, if applicable, the payment of taxes due as a result of such exercise and any Shares acquired upon
conversion or exercise described in clause (ix)&nbsp;shall be subject to the restrictions set forth in this letter agreement, and (C)&nbsp;in the case of clauses (i)-(iii) and (vii)&nbsp;it shall be a condition to such transfer or disposition that:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each transferee executes and delivers to the Representatives an agreement in form and substance satisfactory to
the Representatives stating that such transferee is receiving and holding such Shares and/or Related Securities subject to the provisions of this letter agreement and agrees not to Sell or Offer to Sell such Shares and/or Related Securities, engage
in any Swap or engage in any other activities restricted under this letter agreement except in accordance with this letter agreement (as if such transferee had been an original signatory hereto), and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to the expiration of the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, no public disclosure or
filing under the Exchange Act by any party to the transfer (donor, donee, transferor or transferee) shall be required, or made voluntarily, reporting a reduction in beneficial ownership of Shares in connection with such transfer.
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the undersigned is an officer or director of the Company, the undersigned further agrees that the
foregoing restrictions shall be equally applicable to any Company-directed Shares the undersigned may purchase or otherwise receive in the Offering (including pursuant to a directed share program). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, if the undersigned is an officer or director of the Company, (i)&nbsp;the Representatives agree that, at least three business days before the
effective date of any release or waiver of the foregoing restrictions in connection with a transfer of Shares or Related Securities, the Representatives will notify the Company of the impending release or waiver, and (ii)&nbsp;the Company (in
accordance with the provisions of the Underwriting Agreement) will announce the impending release or waiver by press release through a major news service at least two business days before the effective date of the release or waiver. Any release or
waiver granted by the Representatives hereunder to any such officer or director shall only be effective two business days after the publication date of such press release. The provisions of this paragraph will not apply if both (a)&nbsp;the release
or waiver is effected solely to permit a transfer not for consideration and (b)&nbsp;the transferee has agreed in writing to be bound by the same terms described in this letter agreement that are applicable to the transferor to the extent and for
the duration that such terms remain in effect at the time of the transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned also agrees and consents to the entry of stop transfer
instructions with the Company&#146;s transfer agent and registrar against the transfer of Shares or Related Securities held by the undersigned and the undersigned&#146;s Family Members, if any, except in compliance with the foregoing restrictions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the Offering only, the undersigned waives any registration rights relating to registration under the Securities Act of the offer and sale
of any Shares and/or any Related Securities owned either of record or beneficially by the undersigned, including any rights to receive notice of the Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned confirms that the undersigned has not, and has no knowledge that any Family Member has, directly or indirectly, taken any action designed to
or that might reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale of the Shares. The undersigned will not, and will cause any Family Member not to take,
directly or indirectly, any such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the underwriters have not provided any recommendation or investment
advice nor have the underwriters solicited any action from the undersigned with respect to the Offering and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether or not the Offering occurs as currently contemplated or at all depends on market conditions and
other factors. The Offering will only be made pursuant to the Underwriting Agreement, the terms of which are subject to negotiation between the Company and the underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is understood that, if (i)&nbsp;the Company, on the one hand, or the Representatives, on the other hand, notifies the other in writing that it does not
intend to proceed with the Offering, (ii)&nbsp;the registration statement relating to the Offering is withdrawn, (iii)&nbsp;the Underwriting Agreement relating to the Offering is not executed by September&nbsp;30, 2021, or (iv)&nbsp;the Underwriting
Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated for any reason prior to payment for and delivery of the Shares to be sold thereunder, this letter agreement shall immediately be terminated and
the undersigned shall automatically be released from all of the obligations under this letter agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants
that the undersigned has full power, capacity and authority to enter into this letter agreement. This letter agreement is irrevocable and will be binding on the undersigned and the successors, heirs, personal representatives and assigns of the
undersigned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>remainder of page left intentionally blank</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter agreement shall be governed by, and construed in accordance with, the laws of the State of New
York. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printed Name of Person Signing</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><I>(Indicate capacity of person signing if <BR>signing as custodian or trustee, or on behalf <BR>of an entity)</I></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain Defined Terms </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Used in <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the letter agreement to which this Annex A is attached and of which it is made a part: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Call Equivalent Position</B>&#148;<B> </B>shall have the meaning set forth in Rule <FONT
STYLE="white-space:nowrap">16a-1(b)</FONT> under the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Change of Control</B>&#148; shall mean the transfer (whether by tender offer, merger, consolidation or
other similar transaction), in one transactions or a series of related transactions, to a person or group of affiliated persons (other than an Underwriter pursuant to the Offering), of the Company&#146;s voting securities if, after such transfer,
such person or group of affiliated persons would hold at least 50% of the outstanding voting securities of the Company (or the surviving entity), <I>provided</I> that, for the avoidance of doubt, the Offering shall not constitute a Change of
Control. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Exchange Act</B>&#148;<B> </B>shall mean the Securities Exchange Act of 1934, as amended.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Family Member</B>&#148; shall mean the spouse of the undersigned, an immediate family member of the
undersigned or an immediate family member of the undersigned&#146;s spouse, in each case living in the undersigned&#146;s household or whose principal residence is the undersigned&#146;s household (regardless of whether such spouse or family member
may at the time be living elsewhere due to educational activities, health care treatment, military service, temporary internship or employment or otherwise). &#147;<B>Immediate family member</B>&#148; as used above shall have the meaning set forth
in Rule <FONT STYLE="white-space:nowrap">16a-1(e)</FONT> under the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Period</B>&#148; shall mean the period beginning on the
date hereof and continuing through the close of trading on the date that is 180 days after the date of the Prospectus (as defined in the Underwriting Agreement). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Put Equivalent Position</B>&#148; shall have the meaning set forth in Rule <FONT
STYLE="white-space:nowrap">16a-1(h)</FONT> under the Exchange Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Related Securities</B>&#148; shall mean Units or any options or warrants or other rights to acquire
Shares or Units or any securities exchangeable or exercisable for or convertible into Shares or Units, or to acquire other securities or rights ultimately exchangeable or exercisable for or convertible into Shares or Units. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Securities Act</B>&#148; shall mean the Securities Act of 1933, as amended. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Sell or Offer to Sell</B>&#148; shall mean to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sell, offer to sell, contract to sell or lend, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">effect any short sale or establish or increase a Put Equivalent Position or liquidate or decrease any Call
Equivalent Position </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pledge, hypothecate or grant any security interest in, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other way transfer or dispose of, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">in each case whether effected directly or indirectly. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B>Swap</B>&#148; shall mean any swap, hedge or similar arrangement or agreement that transfers, in whole
or in part, the economic risk of ownership of Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capitalized terms not defined in this Annex A shall have the meanings given to them in the body of this letter agreement. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>3
<FILENAME>d99471dex21.htm
<DESCRIPTION>EX-2.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-2.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 2.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RALLYBIO HOLDINGS, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PLAN OF LIQUIDATION AND DISSOLUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Plan of Liquidation and Dissolution (the &#147;<U>Plan</U>&#148;) is entered into as of the [ ] day of July, 2021, by Rallybio Holdings,
LLC, a Delaware limited liability company (the &#147;<U>LLC</U>&#148;). This Plan is intended accomplish the complete liquidation and dissolution of the LLC under and in accordance with the Limited Liability Company Act of the State of Delaware, 6
Del. C. &#167; <FONT STYLE="white-space:nowrap">18-101,</FONT> et seq. (&#147;<U>DLLCA</U>&#148;) and pursuant to the Second Amended and Restated Operating Agreement, dated March&nbsp;27, 2020 and as amended as of May&nbsp;14, 2020 (the
&#147;<U>Operating Agreement</U>&#148;) of the LLC. Capitalized terms that are not defined herein shall have the meanings ascribed to them in the Operating Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,
the LLC holds 100% of the outstanding shares of common stock in Rallybio Corporation (the &#147;<U>Corporation</U>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Corporation holds 100% of the membership units in each of: (i)&nbsp;RallyBIO, LLC (&#147;<U>RallyBIO</U>&#148;), a
Delaware limited liability company; (ii)&nbsp;Rallybio IPA, LLC (&#147;<U>IPA</U>&#148;), a Delaware limited liability company; (iii)&nbsp;Rallybio IPB, LLC (&#147;<U>IPB</U>&#148;), a Delaware limited liability company; and (iv)&nbsp;IPC Research,
LLC, a Delaware limited liability company; (&#147;<U>IPC</U>&#148;, and together with RallyBIO, IPA, and IPB, each a &#147;<U>Rallybio Subsidiary</U>&#148; and collectively the &#147;<U>Rallybio Subsidiaries</U>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Board of Managers has determined that it is in the best interest of the LLC to reorganize the organizational structure of
the LLC and the Rallybio Subsidiaries, and dissolve and liquidate the LLC, as described in this Plan; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, pursuant to
Section&nbsp;10.8 of the Operating Agreement, and subject to Section&nbsp;5.6 of the Operating Agreement, the requisite percentage of the LLC&#146;s members as set forth in the Operating Agreement, shall approve the reorganization of the LLC into
the Corporation, including by causing the Members to exchange their membership interests in the LLC, for capital stock in the Corporation; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, it is contemplated that the Corporation shall issue in an underwritten public offering (the &#147;<U>Public
Offering</U>&#148;) shares (the &#147;<U>Shares</U>&#148;) of its authorized but unissued common stock, par value $0.0001 per share (the &#147;<U>Common Stock</U>&#148;), said securities to be issued as hereinafter provided for, in such manner and
at such times, and in such amounts and at such prices as the Board of Directors or the pricing committee thereof (the &#147;<U>Pricing Committee</U>&#148;) may determine, which shall be in excess of the amounts required for a Qualified Public
Offering (as defined in the Operating Agreement); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the form of the reorganized structure of the LLC provides that,
when coupled with the sale of equity that would satisfy the requirements of a Qualified Public Offering, (a)&nbsp;each Member&#146;s relative percentage ownership interest of the outstanding common stock and preferred stock of the Corporation
immediately after such reorganization is such Member&#146;s relative percentage ownership interest in the LLC immediately prior to such reorganization (giving effect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to all preferred returns contemplated herein); and (b)&nbsp;the relative preferences, powers, rights, qualifications, limitations and restrictions in respect of the outstanding common stock and
preferred stock of the Corporation immediately after such reorganization is the same as the relative preferences, powers, rights, qualifications, limitations and restrictions in respect of the Member&#146;s interests immediately prior to such
reorganization, including with respect to liquidation preferences and any accruing distributions; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, all Members shall
provide all necessary cooperation, including, without limitation, the execution of any documents (including any voting agreement) or filings that may be required; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,<B> </B>the Company, which holds 100% of the outstanding shares of Common Stock, shall immediately after the determination by
the Pricing Committee of the price per share of Common Stock to be offered to the public in the Corporation&#146;s initial public offering (the &#147;<U>Pricing</U>&#148;, and the price per share of Common Stock, the &#147;<U>IPO
Price</U>&#148;<U>)</U>, be issued an additional number of shares based on the valuation of the Corporation, such that following such issuance, the total outstanding shares of the Corporation shall be equal to (i)&nbsp;the valuation of the
Corporation determined by the Pricing, divided by (ii)&nbsp;the IPO Price (the &#147;<U>Liquidating Stock Issuance</U>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in making the Liquidating Stock Issuance, while the Corporation shall have a single class of common stock and a number of
shares of Common Stock will be allocated to each interest holder of the LLC reflective of such Member&#146;s interests in the Rallybio Subsidiaries, as well as with respect to the Corporation and its predecessor, Rallybio IPD, LLC; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, immediately after the Liquidating Stock Issuance, the Company shall dissolve and liquidate its assets, pursuant to this Plan;
and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, it is contemplated that, after the Liquidating Stock Issuance, each of the shareholders of the Corporation that are
party to that certain Amended and Restated Investors&#146; Rights Agreement of the Company, dated as of, March&nbsp;27, 2020 (the &#147;<U>Investors Rights Agreement</U>&#148;), shall enter into a Registration Rights Agreement with the Corporation
(the &#147;<U>Registration Rights Agreement</U>&#148;), which shall provide registration rights to such parties substantially similar to those granted to such parties pursuant to the Investors Rights Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Requisite Preferred Holders and the Majority in Interest members, have reviewed and adopted this Plan; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, the parties agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <B><U>Approval of Plan</U></B>. The Board of Managers of the LLC has reviewed and adopted this Plan and presented the Plan to the
LLC&#146;s members necessary to take action on the Plan. The Plan has been adopted by the requisite action of the LLC&#146;s members as set forth in the Operating Agreement, including without limitation the Requisite Preferred Holders and the
Majority in Interest members, and this Plan shall constitute the adopted plan of dissolution and liquidation of the LLC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B><U>Certificate of Cancellation</U></B>. Subject to Section&nbsp;14 hereof, after the
Members approve the dissolution of the LLC (the &#147;<U>Approval Time</U>&#148;), the LLC shall file with the Secretary of State of the State of Delaware a certificate of cancellation (the &#147;<U>Certificate of Cancellation</U>&#148;) in
accordance with the DLLCA (the time of such filing, or such later time as stated therein, the &#147;<U>Effective Time</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.
<B><U>Cessation of Business Activities</U></B>. From and after the Approval Time, the LLC shall be voluntarily liquidated and dissolved. The Board of Managers shall cause the LLC to proceed with dissolution process as described in Section&nbsp;5
herein.&nbsp;After the Approval Time, the LLC shall not engage in any business activities except to the extent necessary to preserve the value of its assets, wind up its business affairs, and distribute its assets in accordance with this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <B><U>Continuing Employees and Consultants</U></B>. For the purpose of effecting the dissolution of the LLC, the LLC may hire or retain, at
the discretion of the Board of Managers, such employees, consultants and advisors as the Board of Managers deems necessary or desirable to supervise or facilitate the dissolution and winding up of the LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <B><U>Dissolution Process</U></B>. From and after the Approval Time, the LLC (or any successor entity of the LLC) shall complete the
following corporate actions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1 The LLC (a)&nbsp;shall pay or make reasonable provision to pay all claims and obligations, including all
contingent, conditional or unmatured contractual claims known to the LLC; (b)&nbsp;shall make such provision as will be reasonably likely to be sufficient to provide compensation for any claim against the LLC which is the subject of a pending
action, suit or proceeding to which the LLC is a party; and (c)&nbsp;shall make such provision as will be reasonably likely to be sufficient to provide compensation for claims that have not been made known to the LLC or that have not arisen but
that, based on facts known to the LLC, are likely to arise or to become known to the LLC within ten (10)&nbsp;years after the date of dissolution. Such claims shall be paid or provided for in full if there are sufficient assets. All such claims
shall be paid in full and any such provision for payment made shall be made in full if there are sufficient assets. If there are insufficient assets, such claims and obligations shall be paid or provided for according to their priority and, among
claims of equal priority, ratably to the extent of assets legally available therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2 The LLC shall distribute to the Members, in
accordance with the liquidation spreadsheet attached hereto as <U>Schedule A</U> (the &#147;<U>Liquidation Spreadsheet</U>&#148;), pending the determination of the IPO Price, all remaining assets, including all available cash, including the cash
proceeds of any sale, exchange or disposition, except such cash, property or assets as are required for paying or making reasonable provision for the claims and obligations of the LLC. Such distribution may occur all at once or in a series of
distributions and shall be in cash or assets, in such amounts, and at such time or times, as the Board of Managers in its absolute discretion, may determine. If and to the extent deemed necessary, appropriate or desirable by the Board of Managers,
in its absolute discretion, the LLC may establish and set aside a reasonable amount of cash and/or property to satisfy claims against the LLC, including, without limitation, tax obligations, all expenses related to the sale of the LLC&#146;s
property and assets, all expenses related to the collection and defense of the LLC&#146;s property and assets, and the liquidation and dissolution provided for in this Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.3 <B><U>Liquidating Stock Issuance</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Pursuant to Section&nbsp;5.2, immediately following the Liquidating Stock Issuance, and without any action on the part of the LLC or any
holders of any of the securities of the LLC, the outstanding membership interest holders of the LLC will receive Common Stock in the Corporation, pursuant to the Liquidation Spreadsheet, with economic value equivalent to that of their membership
interests in the LLC. If any membership interest holder holds membership interests in the LLC that were granted in connection with the performance of services to the LLC and that are unvested or subject to transfer restrictions at the time of the
Liquidating Stock Issuance, the Common Stock of the Corporation received in respect of such membership interests shall be subject to the same vesting schedule and transfer restrictions which applied to such membership interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) All of the outstanding membership interests of the LLC (the &#147;<U>Membership Interests</U>&#148;), for which Members receive capital
stock of the Corporation in respect of such Membership Interests, as provided in this Section&nbsp;5.3, shall no longer be outstanding and shall automatically be canceled and shall cease to exist, and each certificate (each a
&#147;<U>Certificate</U>&#148;), if any, previously representing any such Membership Interests, shall thereafter represent the right to receive the number of the Corporation&#146;s capital stock into which such Membership Interests represented by
such Certificate have been converted. Membership Interests shall be exchanged for certificates representing the respective class or series of shares of the Corporation&#146;s capital stock upon the surrender of such Certificates in accordance with
Section&nbsp;6 hereof, without any interest thereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <B><U>Cancellation of Membership Interests</U></B>. All of the outstanding
Membership Interests of the LLC (and all certificates representing such membership interests), without further action on the part of the LLC or its members shall be automatically canceled pursuant to Section&nbsp;5.3. From and after the Approval
Time, and subject to applicable law, each holder of membership interests of the LLC shall cease to have any rights in respect thereof, except the right to receive distributions pursuant to and in accordance with Section&nbsp;5.2 hereof. Prior to the
Effective Time, the Board of Managers, in its absolute discretion, may require the LLC&#146;s members to (i)&nbsp;surrender their certificates evidencing their membership interests, if any, to the LLC; or (ii)&nbsp;furnish the LLC with evidence
satisfactory to the Board of Managers of the loss, theft or destruction of such certificates, together with such surety bond or other security or indemnity as may be required by and satisfactory to the Board of Managers. Subject to applicable law,
the LLC shall be entitled to close its transfer books and discontinue recording transfers of membership of the LLC at any time after the Approval Time in order more efficiently to make any distributions to the members. From and after such closing
and discontinuance, certificates representing membership interests of the LLC, if any, will not be assignable or transferable on the books of the LLC except by will, intestate or other succession, operation of law or consent by the LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <B><U>Further Assurances</U></B>. If, at any time on and after the Effective Time, the Corporation, the Members or their respective
successors and assigns shall consider or be advised that any further assignments or assurances in law or any organizational or other acts are necessary or desirable (a)&nbsp;to vest, perfect or confirm, of record or otherwise, in the Members title
to and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
possession of any property or right of the LLC acquired or to be acquired by reason of, or as a result of, the Conversion, or (b)&nbsp;otherwise to carry out the purposes of this Conversion
Agreement, the LLC and its managers, officers and members shall be deemed to have granted to the Corporation an irrevocable power of attorney to execute and deliver all such proper deeds, assignments and assurances in law and to do all acts
necessary or proper to vest, perfect or confirm title to and possession of such property or rights in the Corporation and otherwise to carry out the purposes of this Conversion Agreement; and the director(s) and officer(s) of the Corporation are
fully authorized in the name of the LLC or otherwise to take any and all such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <B><U>Conduct of the LLC Following Approval of
the Plan</U></B>. After the Approval Time, the LLC shall continue for the purpose of winding up its affairs in an orderly matter as provided in this Plan with the LLC continuing in existence until the Certificate of Cancellation is filed with the
Delaware Secretary of State. The powers of the manager(s) continue during the aforesaid time periods in order to allow them to take the necessary steps to <FONT STYLE="white-space:nowrap">wind-up</FONT> the affairs of the LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <B><U>Absence of Appraisal Rights</U></B>. Under Delaware law, the LLC&#146;s members are not entitled to appraisal rights for their
membership interests in connection with the transactions contemplated by the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <B><U>Abandoned Property</U></B>. If any
distribution to a member cannot be made, whether because the member cannot be located, has not surrendered certificates evidencing the membership interests as required hereunder or for any other reason, the distribution to which such member is
entitled shall be transferred, at such time as the final liquidating distribution is made by the LLC, to the official of such state or other jurisdiction authorized by applicable law to receive the proceeds of such distribution. The proceeds of such
distribution shall thereafter be held solely for the benefit of and for ultimate distribution to such member as the sole equitable owner thereof and shall be treated as abandoned property and escheat to the applicable state or other jurisdiction in
accordance with applicable law. In no event shall the proceeds of any such distribution revert to or become the property of the LLC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.
<B><U>Member Consent to Sale of Assets</U></B>. Adoption of this Plan by the requisite vote of the outstanding membership interests shall constitute the approval of the members of the sale, exchange or other disposition in liquidation of all of the
property and assets of the LLC, whether such sale, exchange or other disposition occurs in one transaction or a series of transactions, and shall constitute ratification of all contracts for sale, exchange or other disposition that are conditioned
on adoption of this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <B><U>Expenses of Dissolution</U></B>. In connection with and for the purposes of implementing and assuring
completion of this Plan, the LLC may, in the absolute discretion of the Board of Managers, pay any brokerage, agency, professional and other fees and expenses of persons rendering services to the LLC in connection with the collection, sale, exchange
or other disposition of the LLC&#146;s property and assets and the implementation of this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <B><U>Authorization</U></B>. The
Board of Managers is hereby authorized, without further action by the members, to do and perform or cause the officers of the LLC, to do and perform, any and all acts, and to make, execute, deliver or adopt any and all agreements, resolutions,
conveyances, certificates and other documents of every kind that are deemed necessary, appropriate or desirable, in the absolute discretion of the Board of Managers, to implement this Plan and the transaction contemplated hereby, including, without
limiting the foregoing, all filings or acts required by any state or federal law or regulation to wind up its affairs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <B><U>Amendments and Modifications</U></B>. This Plan may be amended, waived, changed,
modified or discharged only by an agreement in writing signed by the LLC and the undersigned Members. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <B><U>Governing Law</U></B>.
This Plan shall be governed by and construed in accordance with the laws of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the
State of Delaware without regard its principles of the conflicts of laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <B><U>Headings</U></B>. The headings of the Articles and
sections herein are inserted for convenience of reference only and are not intended to be part of or to affect the meaning or interpretation of this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>RALLYBIO HOLDINGS, LLC</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Martin W. Mackay</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> P<SMALL>LAN</SMALL> <SMALL>OF</SMALL>
L<SMALL>IQUIDATION</SMALL> D<SMALL>ISSOLUTION</SMALL> <SMALL>AND</SMALL> C<SMALL>ONVERSION</SMALL> </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Liquidation Spreadsheet </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>4
<FILENAME>d99471dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RALLYBIO CORPORATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rallybio Corporation, a Delaware corporation (the &#147;<U>Corporation</U>&#148;), hereby certifies that this Amended and Restated
Certificate of Incorporation has been duly adopted in accordance with Sections 242 and 245 of the General Corporation Law of the State of Delaware (the &#147;<U>DGCL</U>&#148;), and that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. The name of the Corporation is: Rallybio Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. The Corporation filed its original Certificate of Incorporation with the Secretary of State of the State of Delaware on June&nbsp;30, 2021
under the name Rallybio Corporation, upon its conversion from a Delaware limited liability company originally formed on May&nbsp;11, 2020 under the name Rallybio IPD, LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. On July&nbsp;12, 2021, the Corporation filed a Certificate of Amendment of Certificate of Incorporation with the Secretary of State of the
State of Delaware to amend its Certificate of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">D. The Board of Directors of the Corporation, by written consent dated
July&nbsp;12, 2021 and filed with the minutes of the Corporation, pursuant to Section&nbsp;242 of the General Corporation Law of the State of Delaware duly adopted a resolution setting forth an amendment to the Certificate of Incorporation,
declaring such amendment to be advisable and calling for such amendment to be submitted to the stockholders of the Corporation for their approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">E. The proposed amendment was consented to and authorized by the sole stockholder of the Corporation by written consent dated July&nbsp;12,
2021, given in accordance with the provisions of Section&nbsp;228 of the General Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">F. This
Amended and Restated Certificate of Incorporation amends and restates the Certificate of Incorporation of the Corporation.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">G. The Certificate of Incorporation upon the filing of this Amended and Restated Certificate of Incorporation, shall read as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I &#151; NAME </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of the corporation is Rallybio Corporation (the &#147;<U>Corporation</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II &#151; REGISTERED OFFICE AND AGENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The address of the Corporation&#146;s registered office in the State of Delaware is located at the 251 Little Falls Drive, in the City of
Wilmington, County of New Castle, Delaware, 19808-1674. The name of the Corporation&#146;s registered agent at such address is Corporation Services Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III &#151; PURPOSE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the DGCL. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV &#151; CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Authorized Shares</U>. The total number of shares of stock which the Corporation shall have authority to issue is two hundred fifty
million (250,000,000) shares, consisting of two hundred million (200,000,000) shares of Common Stock, par value $0.0001 per share (&#147;<U>Common Stock</U>&#148;) and fifty million (50,000,000) shares of Preferred Stock, par value $0.0001 per share
(&#147;<U>Preferred Stock</U>&#148;). Such stock may be issued from time to time by the Corporation for such consideration as may be fixed by the board of directors of the Corporation (the &#147;<U>Board of Directors</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Common Stock.</U> Subject to the powers, preferences and rights of any Preferred Stock, including any series thereof, having any
preference or priority over, or rights superior to, the Common Stock and except as otherwise provided by law and this Article IV, the holders of the Common Stock shall have and possess all powers and voting and other rights pertaining to the stock
of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <I>Voting</I>. Each holder of Common Stock shall be entitled to one vote for each share of Common Stock held of
record by such holder on all matters on which stockholders generally are entitled to vote; <U>provided</U>, that, except as otherwise required by law, holders of Common Stock shall have no voting power with respect to and shall not be entitled to
vote on any amendment to this Amended and Restated Certificate of Incorporation (including any certificate of designations relating to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred
Stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to this Amended and Restated Certificate of Incorporation (including any certificate
of designations relating to any series of Preferred Stock) or pursuant to the DGCL. There shall be no cumulative voting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)
<I>Dividends</I>. Dividends of cash or property may be declared and paid on the Common Stock from funds lawfully available therefor as and when determined by the Board of Directors and subject to any preferential dividend rights of any then
outstanding Preferred Stock. Except as otherwise provided by the DGCL or this Amended and Restated Certificate of Incorporation, the holders of record of Common Stock shall share ratably in all dividends payable in cash, stock or otherwise and other
distributions, whether in respect of liquidation or dissolution (voluntary or involuntary) or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) <I>No Preemptive
Rights</I>. The holders of the Common Stock shall have no preemptive rights to subscribe for any shares of any class of stock of the Corporation whether now or hereafter authorized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) <I>No Conversion Rights</I>. The Common Stock shall not be convertible into, or exchangeable for, shares of any other class or classes or
of any other series of the same class of the Corporation&#146;s capital stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) <I>Liquidation Rights</I>. Upon the dissolution, liquidation or winding up of the
affairs of the Corporation, whether voluntary or involuntary, after payment or provision for payment of the debts and liabilities of the Corporation and of the preferential and other amounts, if any, to which the holders of Preferred Stock shall be
entitled, holders of Common Stock shall be entitled to receive all assets of the Corporation available for distribution to its stockholders, ratably in proportion to the number of shares held by each such stockholder. A merger or consolidation of
the Corporation with or into any other corporation or other entity or a sale or conveyance of all or any part of the assets of the Corporation, in any such case that does not in fact result in the liquidation of the Corporation and the distribution
of assets to its stockholders, shall not be deemed to be a voluntary or involuntary liquidation or dissolution or winding up of the Corporation within the meaning of this Article IV(b)(v). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Preferred Stock</U>. Shares of Preferred Stock may be issued in one or more series, from time to time, with each such series to consist
of such number of shares and to have such voting powers relative to other classes or series of Preferred Stock, if any, or Common Stock, full or limited or no voting powers, and such designations, preferences and relative, participating, optional or
other rights, and the qualifications, limitations or restrictions thereof, as shall be stated in the resolution or resolutions providing for the issuance of such series adopted by the Board of Directors, and the Board of Directors is hereby
expressly vested with the authority, to the full extent now or hereafter provided by applicable law, to adopt any such resolution or resolutions. Except as otherwise provided in this Amended and Restated Certificate of Incorporation, no vote of the
holders of the Preferred Stock or Common Stock shall be a prerequisite to the designation or issuance of any shares of any series of the Preferred Stock authorized by and complying with the conditions of this Amended and Restated Certificate of
Incorporation, the right to have such vote being expressly waived by all present and future holders of the capital stock of the Corporation. Any shares of Preferred Stock that are redeemed, purchased or acquired by the Corporation may be reissued
except as otherwise provided by law or this Amended and Restated Certificate of Incorporation. Different series of Preferred Stock shall not be construed to constitute different classes of shares for the purposes of voting by classes unless
expressly provided in the resolution or resolutions providing for the issue of such series adopted by the Board of Directors.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>No Class</U><U></U><U>&nbsp;Vote on Changes in Authorized Number of Shares of Preferred Stock</U>. Subject to the special rights of the
holders of any series of Preferred Stock pursuant to the terms of this Amended and Restated Certificate of Incorporation, any certificate of designations or any resolution or resolutions providing for the issuance of such series of stock adopted by
the Board of Directors, the number of authorized shares of Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the Common Stock
irrespective of the provisions of Section&nbsp;242(b)(2) of the DGCL.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V
&#151; BOARD OF DIRECTORS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Number of Directors; Vacancies and Newly-Created Directorships</U>. The number of directors
constituting the Board of Directors shall be not fewer than three (3)&nbsp;and not more than fifteen (15), each of whom shall be a natural person. Subject to the previous sentence and to the special rights of the holders of any class or series of
Preferred Stock to elect directors, the precise number of directors shall be fixed exclusively pursuant to a resolution adopted by the Board of Directors. Vacancies and newly-created directorships shall be filled exclusively pursuant to a vote of a
majority of the directors then in office, even if less than a quorum, or by a sole remaining </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
director, except that any vacancy created by the removal of a director by the stockholders for cause shall be filled, in addition to any other vote otherwise required by law, only by vote of a
majority of the outstanding shares of Common Stock. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director. A director elected to fill a vacancy shall be elected for the unexpired
term of his or her predecessor in office and a director chosen to fill a position resulting from an increase in the number of directors shall hold office until the next election of the class for which such director shall have been chosen, subject to
the election and qualification of his or her successor and to his or her earlier death, resignation or removal. Subject to the special rights of any holder of any class or series of Preferred Stock to elect directors, the directors of the
Corporation may be removed only for cause by the affirmative vote of the holders of at least seventy-five percent (75%) of the voting power of the outstanding shares of capital stock of the Corporation entitled to vote generally in the election of
directors, voting together as a single class, at a meeting of the stockholders called for that purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Classified Board of
Directors</U>. Subject to the special rights of the holders of any class or series of Preferred Stock to elect directors, the Board of Directors shall be classified with respect to the time for which directors severally hold office into three
classes, as nearly equal in number as possible. The initial Class&nbsp;I Directors shall serve for a term expiring at the first annual meeting of stockholders of the Corporation following the filing of this Amended and Restated Certificate of
Incorporation; the initial Class&nbsp;II Directors shall serve for a term expiring at the second annual meeting of stockholders following the filing of this Amended and Restated Certificate of Incorporation; and the initial Class&nbsp;III Directors
shall serve for a term expiring at the third annual meeting of stockholders following the filing of this Amended and Restated Certificate of Incorporation. Each director in each class shall hold office until his or her successor is duly elected and
qualified or until his or her earlier death, resignation or removal. At each annual meeting of stockholders beginning with the first annual meeting of stockholders following the filing of this Amended and Restated Certificate of Incorporation, the
successors of the class of directors whose term expires at that meeting shall be elected to hold office for a term expiring at the annual meeting of stockholders to be held in the third year following the year of their election, with each director
in each such class to hold office until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI &#151; LIMITATION OF DIRECTOR LIABILITY; INDEMNIFICATION AND ADVANCEMENT OF EXPENSES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Limitation of Director Liability</U>. To the fullest extent that the DGCL or any other law of the State of Delaware (as they exist on
the date hereof or as they may hereafter be amended) permits the limitation or elimination of the liability of directors, no director of the Corporation shall be liable to the Corporation or its stockholders for monetary damages for breach of
fiduciary duty as a director. No amendment to, or modification or repeal of, this Article VI(a) shall adversely affect any right or protection of a director of the Corporation existing hereunder with respect to any state of facts existing or act or
omission occurring, or any cause of action, suit or claim that, but for this Article VI, would accrue or arise, prior to such amendment, modification or repeal. If, after this Amended and Restated Certificate of Incorporation is filed with the
Secretary of State of the State of Delaware, the DGCL or such other law is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be
eliminated or limited to the fullest extent permitted by the DGCL or such other law, as so amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Indemnification and Advancement of Expenses to Directors and Officers</U>. The
Corporation shall indemnify and advance expenses to, and hold harmless, to the fullest extent permitted by applicable law as it presently exists or may hereafter be amended, any person (an &#147;<U>Indemnitee</U>&#148;) who was or is made, or is
threatened to be made, a party or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a &#147;<U>Proceeding</U>&#148;), by reason of the fact that he or she, or a person for whom he or
she is the legal representative, is or was a director or an officer of the Corporation or, while a director or an officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee, member, trustee or
agent of another corporation or of a partnership, joint venture, trust, nonprofit entity or other enterprise (including service with respect to employee benefit plans), against all liability and loss suffered (including expenses (including
attorneys&#146; fees and expenses), judgments, fines and amounts paid in settlement and reasonably incurred by such Indemnitee). Notwithstanding the preceding sentence, the Corporation shall be required to indemnify, or advance expenses to, an
Indemnitee in connection with a Proceeding (or part thereof) commenced by such Indemnitee only if the commencement of such Proceeding (or part thereof) by the Indemnitee was authorized by the Board of Directors of the Corporation or the Proceeding
(or part thereof) relates to the enforcement of the Corporation&#146;s obligations under this Article VI(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Indemnification and
Advancement of Expenses to Employees and Agents</U>.&nbsp;The Corporation may indemnify and advance expenses to any person who was or is made or is threatened to be made or is otherwise involved in any Proceeding by reason of the fact that such
person, or a person for whom such person is the legal representative, is or was an employee or agent of the Corporation or, while an employee or agent of the Corporation, is or was serving at the request of the Corporation as a director, officer,
employee or agent of another corporation or of a partnership, joint venture, limited liability company, trust, enterprise or nonprofit entity, including service with respect to employee benefit plans, against all liability and loss suffered and
expenses (including attorneys&#146; fees) reasonably incurred by such person in connection with such Proceeding.&nbsp;The ultimate determination of entitlement to indemnification of persons who are
<FONT STYLE="white-space:nowrap">non-director</FONT> or officer employees or agents shall be made in such manner as is determined by the Board of Directors in its sole discretion.&nbsp;Notwithstanding the foregoing sentence, the Corporation shall
not be required to indemnify a person in connection with a Proceeding initiated by such person if the Proceeding was not authorized in advance by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Insurance</U>. The Corporation shall purchase and maintain insurance on behalf of any person who is or was a director, officer,
trustee, employee or agent of the Corporation, or was serving at the request of the Corporation as a director, officer, trustee, employee or agent of another corporation, partnership, joint venture, trust,
<FONT STYLE="white-space:nowrap">non-profit</FONT> entity or other enterprise (including service with respect to employee benefit plans), against any liability asserted against the person and incurred by the person in any such capacity, or arising
out of his or her status as such, whether or not the Corporation would have the power or the obligation to indemnify such person against such liability under the provisions of this Article VI. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U><FONT STYLE="white-space:nowrap">Non-Exclusivity</FONT> of Rights</U>. The
indemnification provided by this Article VI is not exclusive of other indemnification rights arising under any bylaw, agreement, vote of directors or stockholders or otherwise, and shall inure to the benefit of the heirs and legal representatives of
such Indemnitee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Fulfillment of Standard of Conduct</U>. Any Indemnitee shall be deemed to have met the standard of conduct
required for such indemnification unless the contrary has been established by a final, <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment by a court of competent jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Indemnification Priority</U>. As between the Corporation and affiliates of the Corporation (other than its direct or indirect
subsidiaries) who provide indemnification to the Indemnitees for their service to, or on behalf of, the Corporation (collectively, the &#147;<U>Affiliate Indemnitors</U>&#148;) (i) the Corporation is the indemnitor of first resort with respect to
all claims indemnifiable pursuant to Article VI(b) against any such Indemnitee (i.e., the Corporation&#146;s obligations to such Indemnitees are primary and any obligation of any Affiliate Indemnitor to advance expenses or to provide indemnification
for the same loss or liability incurred by such Indemnitees is secondary), (ii) the Corporation shall be required to advance the full amount of expenses incurred by any such Indemnitee and shall be liable for the full amount of all liability and
loss suffered by such Indemnitee (including expenses (including attorneys&#146; fees and expenses), judgments, fines and amounts paid in settlement and reasonably incurred by such Indemnitee), without regard to any rights any such Indemnitee may
have against any Affiliate Indemnitor and (iii)&nbsp;the Corporation irrevocably waives, relinquishes and releases each Affiliate Indemnitor from any and all claims against such Affiliate Indemnitor for contribution, subrogation or any other
recovery of any kind in respect thereof. The Corporation shall indemnify each Affiliate Indemnitor directly for any amounts that such Affiliate Indemnitor pay as indemnification or advancement on behalf of any such Indemnitee and for which such
Indemnitee may be entitled to indemnification from the Corporation pursuant to Article VI(b). No advancement or payment by any Affiliate Indemnitor on behalf of any such Indemnitee with respect to any claim for which such Indemnitee has sought
indemnification from the Corporation shall affect the foregoing and the Affiliate Indemnitors shall be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Indemnitee against the Corporation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII &#151; MEETINGS OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>No Action by Written Consent</U>. Except as otherwise provided for or fixed by or pursuant to the provisions of this Amended and
Restated Certificate of Incorporation or any resolution or resolutions of the Board of Directors providing for the issuance of Preferred Stock, any action required or permitted to be taken by the stockholders of the Corporation may be effected only
at a duly called annual or special meeting of stockholders of the Corporation and may not be effected by any consent in writing by such stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Special Meetings of Stockholders</U>. Subject to the special rights of the holders of any series of Preferred Stock, and to the
requirements of applicable law, special meetings of stockholders of the Corporation may be called only by the Board of Directors pursuant to a resolution adopted by a majority of the total number of directors which the Corporation would have if
there were no vacancies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Election of Directors by Written Ballot</U>. Election of directors need not be by written ballot. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII &#151; AMENDMENTS TO THE BYLAWS AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Bylaws</U>. In furtherance and not in limitation of the powers conferred by law, the Board of Directors is expressly authorized to
make, alter, amend or repeal the bylaws of the Corporation (the &#147;<U>Bylaws</U>&#148;) subject to the power of the stockholders of the Corporation to alter, amend or repeal the Bylaws; <U>provided</U>, that with respect to the powers of
stockholders to make, alter, amend or repeal the Bylaws, the affirmative vote of the holders of at least seventy-five percent (75%) of the voting power of the outstanding shares of capital stock of the Corporation entitled to vote with respect
thereto, voting together as a single class, shall be required to alter, amend or repeal the bylaws of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Amendments
to the Certificate of Incorporation</U>. The Corporation reserves the right to amend, alter, change or repeal any provision contained in this Amended and Restated Certificate of Incorporation in the manner now or hereafter prescribed by the DGCL,
and all rights conferred upon stockholders herein are granted subject to this reservation. Notwithstanding anything to the contrary contained in this Amended and Restated Certificate of Incorporation, and notwithstanding that a lesser percentage may
be permitted from time to time by applicable law, no provision of Article IV, Article V, Article VI, paragraphs (a)&nbsp;and (b) of Article VII and Article VIII may be altered, amended or repealed in any respect, nor may any provision or bylaw
inconsistent therewith be adopted, unless, in addition to any other vote required by this Amended and Restated Certificate of Incorporation or otherwise required by law, such alteration, amendment, repeal or adoption is approved by the affirmative
vote of the holders of at least seventy-five percent (75%) of the voting power of the outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, at a meeting of
the stockholders called for that purpose. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX &#151; EXCLUSIVE JURISDICTION FOR CERTAIN ACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Exclusive Forum</U>. Unless the Board of Directors or one of its committees otherwise approves the selection of an alternate forum, the
Court of Chancery of the State of Delaware (or, if, and only if, the Court of Chancery of the State of Delaware dismisses a Covered Claim (as defined below) for lack of subject matter jurisdiction, any other state or federal court in the State of
Delaware that does have subject matter jurisdiction) shall, to the fullest extent permitted by applicable law, be the sole and exclusive forum for any (i)&nbsp;derivative claim brought in the right of the Corporation, (ii)&nbsp;claim asserting a
breach of a fiduciary duty to the Corporation or the Corporation&#146;s stockholders owed by any current or former director, officer or other employee or stockholder of the Corporation, (iii)&nbsp;claim against the Corporation arising pursuant to
any provision of the DGCL, this Restated Certificate of Incorporation or the Amended and Restated Bylaws, (iv)&nbsp;claim to interpret, apply, enforce or determine the validity of this Restated Certificate of Incorporation or the Amended and
Restated Bylaws, (v)&nbsp;claim against the Corporation governed by the internal affairs doctrine, or (vi)&nbsp;other claim, not subject to exclusive federal jurisdiction and not subject to paragraph (d)&nbsp;below, brought in any action asserting
one or more of the claims specified in clauses (a)(i) through (v)&nbsp;herein above (each a &#147;<U>Covered Claim</U>&#148;); provided, however, that the provisions of this Article IX(a) will not apply to claims brought to enforce any liability or
duty created by the Securities Exchange Act of 1934, as amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Personal Jurisdiction</U>. If any person or entity (a &#147;Claiming Party&#148;)
files an action asserting a Covered Claim in a court other than one determined in accordance with paragraph (a)&nbsp;above (each a &#147;Foreign Action&#148;) without the prior approval of the Board of Directors or one of its committees, such
Claiming Party shall be deemed to have consented to (i)&nbsp;the personal jurisdiction of the court determined in accordance with paragraph (a)&nbsp;in connection with any such action brought in any such court to enforce paragraph (a) (an
&#147;Enforcement Action&#148;) and (ii)&nbsp;having service of process made upon such Claiming Party in any such Enforcement Action by service upon such Claiming Party&#146;s counsel in the Foreign Action as agent for such Claiming Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Notice and Consent</U>. Any person or entity purchasing or otherwise acquiring any interest in the shares of capital stock of the
Corporation shall be deemed to have notice of and consented to the provisions of this Article IX and waived any argument relating to the inconvenience of the forums referenced above in connection with any Covered Claim. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Federal Forum</U>. Unless the Corporation consents in writing to the selection of an alternative forum, the federal district courts of
the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. Any person or entity purchasing or otherwise acquiring any interest in any security
of the Corporation shall be deemed to have notice of and consented to this provision. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X &#151; SEVERABILITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any provision or provisions of this Amended and Restated Certificate of Incorporation shall be held to be invalid, illegal or unenforceable
as applied to any circumstance for any reason whatsoever: (i)&nbsp;the validity, legality and enforceability of such provision or provisions in any other circumstance and of the remaining provisions of this Amended and Restated Certificate of
Incorporation (including each portion of any paragraph of this Amended and Restated Certificate of Incorporation containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or
unenforceable) shall not in any way be affected or impaired thereby and (ii)&nbsp;to the fullest extent possible, the provisions of this Amended and Restated Certificate of Incorporation (including each such portion of any paragraph of this Amended
and Restated Certificate of Incorporation containing any such provision held to be invalid, illegal or unenforceable) shall be construed so as to permit the Corporation to protect its directors, officers, employees and agents from personal liability
in respect of their good faith service to or for the benefit of the Corporation to the fullest extent permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[remainder of page
intentionally left blank &#150; signature page follows]<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned has caused this Amended and Restated Certificate of
Incorporation to be executed by the officer below this ____ day of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Rallybio Corporation</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Martin W. Mackay, Ph.D.</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>5
<FILENAME>d99471dex32.htm
<DESCRIPTION>EX-3.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED BYLAWS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 1 - STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.1. <U>Annual Meeting</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An annual meeting of the stockholders of Rallybio Corporation, a Delaware corporation (the &#147;<U>Corporation</U>&#148;), for the election
of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting shall be held at the place, if any, within or without the State of Delaware, on the date and at the time that the
board of directors of the Corporation (the &#147;<U>Board of Directors</U>&#148;) shall each year fix. Unless stated otherwise in the notice of the annual meeting of the stockholders of the Corporation, such annual meeting shall be at the principal
office of the Corporation. The Board of Directors may, in its sole discretion, determine that the meeting shall not be held at any place, but may instead be held solely or in part by any permissible means of remote communication, including
electronic transmission or telephonic means (a &#147;<U>virtual meeting</U>&#148;) in accordance with the General Corporation Law of the State of Delaware (the &#147;<U>DGCL</U>&#148;). The Corporation shall implement reasonable measures to ensure
stockholders may meaningfully participate in a virtual meeting through a secure and verifiable process, which focuses on access to the meeting, voting and access to the stockholder list. The Corporation&nbsp;shall also comply with all the
requirements of the Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;) for&nbsp;virtual meetings of stockholders, including for the electronic availability of proxy materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.2. <U>Advance Notice of Nominations and Proposals of Business</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Nominations of persons for election to the Board of Directors and proposals for other business to be transacted by the stockholders at an
annual meeting of stockholders may be made (i)&nbsp;pursuant to the Corporation&#146;s notice with respect to such meeting (or any supplement thereto), (ii) by or at the direction of the Board of Directors or (iii)&nbsp;by any stockholder of record
of the Corporation who (A)&nbsp;was a stockholder of record at the time of the giving of the notice contemplated in Section&nbsp;1.2(b), (B) is entitled to vote at such meeting and (C)&nbsp;has complied with the notice procedures set forth in this
Section&nbsp;1.2. Subject to Section&nbsp;1.2(h) and except as otherwise required by law, clause (iii)&nbsp;of this Section&nbsp;1.2(a) shall be the exclusive means for a stockholder to make nominations or propose other business (other than
nominations and proposals properly brought pursuant to applicable provisions of federal law, including the Securities Exchange Act of 1934 (as amended from time to time, the &#147;<U>Exchange Act</U>&#148;) and the rules and regulations of the SEC
thereunder), before an annual meeting of stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Except as otherwise required by law, for nominations or proposals to be
properly brought before an annual meeting by a stockholder pursuant to clause (iii)&nbsp;of Section&nbsp;1.2(a), (i) the stockholder must have given timely notice thereof in writing to the Secretary of the Corporation with the information
contemplated by Section&nbsp;1.2(c), including, where applicable, delivery to the Corporation of timely and completed questionnaires as contemplated by Section&nbsp;1.2(c), and (ii)&nbsp;the business must be a proper matter for stockholder action
under the DGCL. The notice requirements of this Section&nbsp;1.2 shall be deemed satisfied by a stockholder with respect to </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business other than a nomination if the stockholder has notified the Corporation of his, her or its intention to present a proposal at an annual meeting in compliance with applicable rules and
regulations promulgated under the Exchange Act and such stockholder&#146;s proposal has been included in a proxy statement prepared by the Corporation to solicit proxies for such annual meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To be timely for purposes of Section&nbsp;1.2(b), a stockholder&#146;s notice must be delivered to the Secretary of the Corporation at the
principal executive offices of the Corporation on a date (i)&nbsp;not later than the close of business on the ninetieth (90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day nor earlier than the close of business on the one hundred
twentieth (120<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day prior to the anniversary date of the prior year&#146;s annual meeting or (ii)&nbsp;with respect to the Corporation&#146;s 2022 annual meeting, during February 2022 or if
there was no annual meeting in the prior year or if the date of the current year&#146;s annual meeting is more than thirty (30)&nbsp;days before or after the anniversary date of the prior year&#146;s annual meeting, on or before ten (10)&nbsp;days
after the day on which the date of the current year&#146;s annual meeting is first disclosed in a public announcement. In no event shall any adjournment or postponement of an annual meeting or the announcement thereof commence a new time period for
the delivery of such notice. Such notice from a stockholder must state (a)&nbsp;as to each nominee that the stockholder proposes for election or reelection as a director, (A)&nbsp;all information relating to such nominee that would be required to be
disclosed in solicitations of proxies for the election of such nominee as a director pursuant to Regulation 14A under the Exchange Act and such nominee&#146;s written consent to serve as a director if elected, and (B)&nbsp;a description of all
direct and indirect compensation and other material monetary arrangements, agreements or understandings during the past three years, and any other material relationship, if any, between or concerning such stockholder, any Stockholder Associated
Person (as defined below) or any of their respective affiliates or associates, on the one hand, and the proposed nominee or any of his or her affiliates or associates, on the other hand; (b)&nbsp;as to each proposal that the stockholder seeks to
bring before the meeting, the text of the proposal (including the text of any resolutions proposed for consideration and, in the event that it includes a proposal to amend the bylaws of the Corporation, the language of the proposed amendment), a
brief description of such proposal, the reasons for making the proposal at the meeting, and any material interest that the stockholder has in the proposal; and (c)&nbsp;(A) the name and address of the stockholder giving the notice and the
Stockholder Associated Persons, if any, on whose behalf the nomination or proposal is made, (B)&nbsp;the class (and, if applicable, series) and number of shares of capital stock of the Corporation that are, directly or indirectly, owned beneficially
or of record by the stockholder or any Stockholder Associated Person, (C)&nbsp;any option, warrant, convertible security, stock appreciation right or similar instrument, right, agreement, arrangement or understanding with an exercise or conversion
privilege or a settlement payment or mechanism at a price related to any class (or, if applicable, series) of shares of capital stock of the Corporation or with a value derived in whole or in part from the value of any class (or, if applicable,
series) of shares of capital stock of the Corporation, whether or not such instrument, right, agreement, arrangement or understanding shall be subject to settlement in the underlying class or series of capital stock of the Corporation or otherwise,
and any other direct or indirect opportunity to profit or share in any profit derived from any increase or decrease in the value of shares of capital stock of the Corporation (each, a &#147;<U>Derivative Instrument</U>&#148;) directly or indirectly
owned beneficially or of record by such stockholder or any Stockholder Associated Person, (D)&nbsp;any proxy, contract, arrangement, understanding or relationship pursuant to which such stockholder or any Stockholder Associated Person has a right to
vote any securities of the Corporation, (E)&nbsp;any proportionate interest in shares of the Corporation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or Derivative Instruments held, directly or indirectly, by a general or limited partnership in which such stockholder or any Stockholder Associated Person is a general partner or beneficially
owns, directly or indirectly, an interest in a general partner, (F)&nbsp;any performance-related fees (other than an asset-based fee) that such stockholder or any Stockholder Associated Person is entitled to based on any increase or decrease in the
value of the shares of capital stock of the Corporation or Derivative Instruments, (G)&nbsp;any other information relating to such stockholder or any Stockholder Associated Person, if any, required to be disclosed in a proxy statement or other
filing required to be made in connection with solicitations of proxies for, as applicable, the proposal and/or for the election of directors in an election contest pursuant to and in accordance with Section&nbsp;14(a) of the Exchange Act and the
rules and regulations of the SEC thereunder, (H)&nbsp;a representation that the stockholder is a holder of record of the Corporation entitled to vote at such meeting and intends to appear in person or by proxy at the meeting to propose such business
or nomination, (I)&nbsp;a certification as to whether or not the stockholder and all Stockholder Associated Persons have complied with all applicable federal, state and other legal requirements in connection with the stockholder&#146;s and each
Stockholder Associated Person&#146;s acquisition of shares of capital stock or other securities of the Corporation and the stockholder&#146;s and each Stockholder Associated Person&#146;s acts or omissions as a stockholder (or beneficial owner of
securities) of the Corporation and (J)&nbsp;whether the stockholder intends to deliver a proxy statement and form of proxy to holders of, in the case of a proposal, at least the percentage of the Corporation&#146;s voting shares required under
applicable law to carry the proposal or, in the case of a nomination or nominations, a sufficient number of holders of the Corporation&#146;s voting shares reasonably believed by such stockholder to be sufficient to elect such nominee or nominees or
otherwise to solicit proxies or votes from stockholders in support of such proposal or nomination. For purposes of these bylaws, a &#147;<U>Stockholder Associated Person</U>&#148; with respect to any stockholder means (i)&nbsp;any
&#147;affiliate&#148; or &#147;associate&#148; (as those terms are defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act) of such stockholder, (ii)&nbsp;any beneficial owner of any capital stock or other securities of
the Corporation owned of record or beneficially by such stockholder, (iii)&nbsp;any person directly or indirectly controlling, controlled by or under common control with any such Stockholder Associated Person referred to in clause (i)&nbsp;or (ii)
above and (iv)&nbsp;any person acting in concert in respect of any matter involving the Corporation or its securities with either such stockholder or any beneficial owner of any capital stock or other securities of the Corporation owned of record or
beneficially by such stockholder. In addition, in order for a nomination to be properly brought before an annual or special meeting by a stockholder pursuant to clause (iii)&nbsp;of Section&nbsp;1.2(a), any nominee proposed by a stockholder shall
complete a questionnaire, in a form provided by the Corporation, and deliver a signed copy of such completed questionnaire to the Corporation within ten (10)&nbsp;days of the date that the Corporation makes available to the stockholder seeking to
make such nomination or such nominee the form of such questionnaire. The Corporation may require any proposed nominee to furnish such other information as may be reasonably requested by the Corporation to determine the eligibility of the proposed
nominee to serve as an independent director of the Corporation or that could be material to a reasonable stockholder&#146;s understanding of the independence, or lack thereof, of the nominee. The information required to be included in a notice
pursuant to this Section&nbsp;1.2(c) shall be provided as of the date of such notice and shall be supplemented by the stockholder not later than ten (10)&nbsp;days after the record date for the determination of stockholders entitled to notice of the
meeting to disclose any changes to such information as of the record date. The information required to be included in a notice pursuant to this Section&nbsp;1.2(c) shall not include any ordinary course business activities of any broker, dealer,
commercial bank, trust company or other nominee who is directed to prepare and submit the notice required by this Section&nbsp;1.2(c) on behalf of a beneficial owner of the shares held of record by such broker, dealer, commercial bank, trust company
or other nominee and who is not otherwise affiliated or associated with such beneficial owner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Subject to the certificate of incorporation of the Corporation (the &#147;<U>Certificate
of Incorporation</U>&#148;), Section&nbsp;1.2(h) and applicable law, only persons nominated in accordance with procedures stated in this Section&nbsp;1.2 shall be eligible for election as and to serve as members of the Board of Directors and the
only business that shall be conducted at an annual meeting of stockholders is the business that has been brought before the meeting in accordance with the procedures set forth in this Section&nbsp;1.2. The chairperson of the meeting shall have the
power and the duty to determine whether a nomination or any proposal has been made according to the procedures stated in this Section&nbsp;1.2 and, if any nomination or proposal does not comply with this Section&nbsp;1.2, unless otherwise required
by law, the nomination or proposal shall be disregarded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) For purposes of this Section&nbsp;1.2, &#147;<U>public
announcement</U>&#148; means disclosure in a press release reported by the Dow Jones News Service, Associated Press or a comparable news service or in a document publicly filed or furnished by the Corporation with or to the SEC pursuant to
Section&nbsp;13, 14 or 15(d) of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Notwithstanding the foregoing provisions of this Section&nbsp;1.2, a stockholder
shall also comply with applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to matters set forth in this Section&nbsp;1.2. Nothing in this Section&nbsp;1.2 shall affect any rights, if any, of stockholders
to request inclusion of nominations or proposals in the Corporation&#146;s proxy statement pursuant to applicable provisions of federal law, including the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Notwithstanding the foregoing provisions of this Section&nbsp;1.2, unless otherwise required by law, if the stockholder (or a qualified
representative of the stockholder) does not appear at the annual or special meeting of stockholders of the Corporation to present a nomination or proposed business or does not provide the information required by Section&nbsp;1.2(c), including any
required supplement thereto, such nomination shall be disregarded and such proposed business shall not be transacted, notwithstanding that proxies in respect of such vote may have been received by the Corporation. For purposes of this
Section&nbsp;1.2, to be considered a qualified representative of the stockholder, a person must be a duly authorized officer, manager or partner of such stockholder or must be authorized by a writing executed by such stockholder or an electronic
transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must produce such writing or electronic transmission, or a reliable reproduction of the writing or electronic
transmission, at the meeting of stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) All provisions of this Section&nbsp;1.2 are subject to, and nothing in this
Section&nbsp;1.2 shall in any way limit the exercise, or the method or timing of the exercise of, the rights of any person granted by the Corporation to nominate directors, which rights may be exercised without compliance with the provisions of this
Section&nbsp;1.2. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.3. <U>Special Meetings; Notice</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Special meetings of the stockholders of the Corporation may be called only to the extent and in the manner set forth in the Certificate of
Incorporation. Notice of every special meeting of the stockholders of the Corporation shall state the purpose or purposes of such meeting. Except as otherwise required by law, the business conducted at a special meeting of stockholders of the
Corporation shall be limited exclusively to the business set forth in the Corporation&#146;s notice of meeting, and the individual or group calling such meeting shall have exclusive authority to determine the business included in such notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.4. <U>Notice of Meetings</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notice of the place, if any, date and time of all meetings of stockholders of the Corporation, the record date for determining the
stockholders entitled to vote at the meeting (if such date is different from the record date for stockholders entitled to notice of the meeting) and the means of remote communications, if any, by which stockholders and proxy holders may be deemed
present and vote at such meeting, and, in the case of all special meetings of stockholders, the purpose or purposes of the meeting, shall be given, not less than ten (10)&nbsp;nor more than sixty (60)&nbsp;days before the date on which such meeting
is to be held (unless a different time is specified by law), to each stockholder entitled to notice of the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation may
postpone or cancel any previously called annual or special meeting of stockholders of the Corporation by making a public announcement (as defined in Section&nbsp;1.2(e)) of such postponement or cancellation prior to the meeting. When a previously
called annual or special meeting is postponed to another time, date or place, if any, notice of the place (if any), date and time of the postponed meeting, the record date for determining the stockholders entitled to vote at the meeting (if such
date is different from the record date for stockholders entitled to notice of the meeting) and the means of remote communications, if any, by which stockholders and proxy holders may be deemed present and vote at such postponed meeting, shall be
given in conformity with this Section&nbsp;1.4 unless such meeting is postponed to a date that is not more than sixty (60)&nbsp;days after the date that the initial notice of the meeting was provided in conformity with this Section&nbsp;1.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When a meeting is adjourned to another time or place, notice need not be given of the adjourned meeting if the time and place, if any, thereof
and the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present and vote at such adjourned meeting are announced at the meeting at which the adjournment is taken; <U>provided</U>, <U>however</U>,
that if the adjournment is for more than thirty (30)&nbsp;days, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting, or if after the adjournment a new record date for stockholders entitled
to vote is fixed for the adjourned meeting the Board of Directors shall fix a new record date for notice of such adjourned meeting in conformity herewith and such notice shall be given to each stockholder of record entitled to vote at such adjourned
meeting as of the record date for notice of such adjourned meeting. At any adjourned meeting, any business may be transacted that may have been transacted at the original meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.5. <U>Quorum</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any meeting of the stockholders, the holders of shares of capital stock of the Corporation entitled to cast a majority of the total votes
entitled to be cast by the holders of all outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, present in person or by proxy, shall constitute a quorum for all purposes, unless or except to
the extent that the presence of a larger number is required by applicable law or the Certificate of Incorporation. If a separate vote by one or more classes or series is required, the holders of shares entitled to cast a majority of the total votes
entitled to be cast by the holders of the shares of the class or classes or series, present in person or represented by proxy, shall constitute a quorum entitled to take action with respect to that vote on that matter. A quorum, once established,
shall not be deemed to cease to exist due to the subsequent withdrawal prior to the closing of the meeting of the Corporation&#146;s voting shares that would result in less than a quorum remaining present in person or by proxy at such meeting. For
the purposes of the immediately preceding sentence, an adjournment of a meeting shall not constitute the closing of such meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a
quorum shall fail to attend any meeting, the chairperson of the meeting may adjourn the meeting to another place, if any, date and time. At any such adjourned meeting at which there is a quorum, any business may be transacted that might have been
transacted at the meeting originally called. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.6. <U>Organization</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Chairperson of the Board of Directors or, in his or her absence, the person whom the Board of Directors designates or, in the absence of
that person or the failure of the Board of Directors to designate a person, the Chief Executive Officer of the Corporation or, in his or her absence, the person chosen by the holders of a majority of the shares of capital stock entitled to vote who
are present, in person or by proxy, shall call to order any meeting of the stockholders of the Corporation and act as chairperson of the meeting. In the absence of the Secretary or any Assistant Secretary of the Corporation, the secretary of the
meeting shall be the person the chairperson appoints. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.7. <U>Conduct of Business</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chairperson of any meeting of stockholders of the Corporation shall determine the order of business and the rules of procedure for the
conduct of such meeting, including the manner of voting and the conduct of discussion as he or she determines to be in order. The chairperson shall have the power to adjourn the meeting to another place, if any, date and time. The date and time of
the opening and closing of the polls for each matter upon which the stockholders will vote at the meeting shall be announced at the meeting. Except to the extent inconsistent with such rules and regulations as adopted by the Board of Directors, the
chairperson of the meeting shall have the right and authority to convene and (for any or no reason) to adjourn the meeting, to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such chairperson, are
appropriate for the proper conduct of the meeting. Such rules, regulations or procedures, whether adopted by the Board of Directors or prescribed by the chairperson of the meeting, may include the following: (i)&nbsp;the establishment of an agenda
or order of business for the meeting; (ii)&nbsp;rules and procedures for maintaining order at the meeting and the safety of those present; (iii)&nbsp;limitations on attendance at or participation in the meeting to stockholders entitled to vote at
the meeting, their duly authorized and constituted proxies or such other persons as the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
chairperson of the meeting shall determine; (iv)&nbsp;restrictions on entry to the meeting after the time fixed for the commencement thereof; and (v)&nbsp;limitations on the time allotted to
questions or comments by participants. The chairperson of the meeting of stockholders, in addition to making any other determinations that may be appropriate to the conduct of the meeting, shall, if the facts warrant, determine and declare to the
meeting that a nomination or matter of business was not properly brought before the meeting and if such chairperson should so determine, such chairperson shall so declare to the meeting and any such matter or business not properly brought before the
meeting shall not be transacted or considered. Unless and to the extent determined by the Board of Directors or the chairperson of the meeting, meetings of stockholders shall not be required to be held in accordance with the rules of parliamentary
procedure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.8. <U>Proxies; Inspectors</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) At any meeting of the stockholders, every stockholder entitled to vote may vote in person or by proxy authorized by an instrument in
writing or by a transmission permitted by applicable law, but no such proxy shall be voted or acted upon after three (3)&nbsp;years from its date, unless the proxy provides for a longer period. A proxy shall be irrevocable if it states that it is
irrevocable and if, and only as long as, it is coupled with an interest sufficient in law to support an irrevocable power. A stockholder may revoke any proxy that is not irrevocable by attending the meeting and voting in person or by delivering to
the Secretary of the Corporation a revocation of the proxy or a new proxy bearing a later date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Prior to a meeting of the
stockholders of the Corporation, the Corporation shall appoint one or more inspectors, who may be employees of the Corporation, to act at a meeting of stockholders of the Corporation and make a written report thereof. The Corporation may designate
one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the person presiding at the meeting may, and to the extent required by applicable law,
shall, appoint one or more inspectors to act at the meeting. Each inspector, before beginning the discharge of his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the
best of his or her ability. The inspectors may appoint or retain other persons or entities to assist the inspectors in the performance of the duties of inspectors. The inspectors shall have the duties prescribed by applicable law. Unless otherwise
provided by the Board of Directors, the date and time of the opening and the closing of the polls for each matter upon which the stockholders will vote at a meeting shall be announced at the meeting. No ballot, proxies, votes or any revocation
thereof or change thereto shall be accepted by the inspectors after the closing of the polls unless the Court of Chancery of the State of Delaware, upon application by a stockholder, shall determine otherwise. In determining the validity and
counting of proxies and ballots cast at any meeting of stockholders, the inspectors may consider such information as is permitted by applicable law. No person who is a candidate for office at an election may serve as an inspector at such election.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.9. <U>Voting</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise required by the rules or regulations of any stock exchange applicable to the Corporation, any law or regulation applicable
to the Corporation or by the Certificate of Incorporation, (i)&nbsp;all matters other than the election of directors shall be determined by a majority of the votes cast on the matter affirmatively or negatively and (ii)&nbsp;a nominee for director
shall be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
elected to the Board of Directors if the votes properly cast &#147;for&#148; such nominee&#146;s election exceed the votes properly cast &#147;against&#148; such nominee&#146;s election (with
&#147;abstentions&#148; and &#147;broker <FONT STYLE="white-space:nowrap">non-votes&#148;</FONT> not counted as votes cast either &#147;for&#148; or &#147;against&#148; any director&#146;s election); <U>provided</U> <U>that</U> if, as of a date that
is fourteen (14)&nbsp;days in advance of the date the Corporation files its definitive proxy statement with the SEC (regardless of whether or not thereafter revised or supplemented) with respect to any meeting, the number of persons properly
nominated for election to the Board of Directors at such meeting, including in accordance with the notice and other provisions of Section&nbsp;1.2 where applicable, (A)&nbsp;by or at the direction of the Board of Directors or a committee appointed
by the Board of Directors and (B)&nbsp;by any stockholders of the Corporation entitled to vote for the election of directors at the meeting exceeds the number of directors to be elected at such meeting, then the election of such directors shall be
determined by a plurality of the votes cast. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.10. <U>Stock List</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A complete list of stockholders of the Corporation entitled to vote at any meeting of stockholders of the Corporation, arranged in
alphabetical order for each class of stock and showing the address of each such stockholder and the number of shares registered in the name of such stockholder, shall be open to the examination of any such stockholder, for any purpose germane to a
meeting of the stockholders of the Corporation, for a period of at least ten (10)&nbsp;days before the meeting (i)&nbsp;on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided
with the notice of the meeting or (ii)&nbsp;during ordinary business hours at the principal place of business of the Corporation; <U>provided</U>, <U>however</U>, if the record date for determining the stockholders entitled to vote is less than ten
(10)&nbsp;days before the meeting date, the list shall reflect the stockholders entitled to vote as of the tenth (10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day before such meeting date. The stock list shall also be open to the
examination of any such stockholder during the entire meeting in the manner required by the DGCL. The Corporation may look to this list as the sole evidence of the identity of the stockholders entitled to vote at a meeting and the number of shares
held by each stockholder. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 2 - BOARD OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.1. <U>General Powers and Qualifications of Directors</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors. In addition to the powers
and authorities that these bylaws expressly confer upon them, the Board of Directors may exercise all such powers of the Corporation and do all such lawful acts and things as are not by the DGCL, the Certificate of Incorporation or these bylaws
required to be exercised or done by the stockholders. Directors need not be stockholders of the Corporation to be qualified for election or service as a director of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.2. <U>Removal; Resignation</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The directors of the Corporation may be removed in accordance with the Certificate of Incorporation and the DGCL. Any director may resign at
any time upon notice given in writing, including by electronic transmission, to the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.3. <U>Regular Meetings</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regular meetings of the Board of Directors shall be held at the place, if any, on the date and at the time as shall have been established by
the Board of Directors and publicized among all directors. A notice of a regular meeting, the date of which has been so publicized, shall not be required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.4. <U>Special Meetings</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Special meetings of the Board of Directors may be called by (i)&nbsp;the Chairperson of the Board of Directors, (ii)&nbsp;the Chief Executive
Officer of the Corporation, (iii)&nbsp;in the absence of the Chief Executive Officer of the Corporation, the President of the Corporation, or (iv)&nbsp;two or more directors then in office, and shall be held at the place, if any, on the date and at
the time as he, she or they shall fix. Notice of the place, if any, date and time of each special meeting shall be given to each director either (y)&nbsp;by mailing written notice thereof not less than five days before the meeting, or (z)&nbsp;by
telephone, facsimile or electronic transmission providing notice thereof not less than twenty-four hours before the meeting. Any and all business may be transacted at a special meeting of the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.5. <U>Quorum</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any meeting of the Board of Directors, a majority of the total number of directors then in office shall constitute a quorum for all
purposes.&nbsp;If a quorum shall fail to attend any meeting, a majority of those present may adjourn the meeting to another place, if any, date or time, without further notice or waiver thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.6. <U>Participation in Meetings by Conference Telephone, Video Conference or Other Communications Equipment</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Members of the Board of Directors, or of any committee thereof, may participate in a meeting of the Board of Directors or committee thereof by
means of conference telephone, video conference or other communications equipment by means of which all directors participating in the meeting can hear each other director, and such participation shall constitute presence in person at the meeting.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.7. <U>Conduct of Business</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any meeting of the Board of Directors, business shall be transacted in the order and manner that the Board of Directors may from time to
time determine, and all matters shall be determined by the vote of a majority of the directors present, provided a quorum is present at the time such matter is acted upon, except as otherwise provided in the Certificate of Incorporation or these
bylaws or required by applicable law. The Board of Directors or any committee thereof may take action without a meeting if all members thereof consent thereto in writing, including by electronic transmission, and the writing or writings, or
electronic transmission or electronic transmissions, are filed with the minutes of proceedings of the Board of Directors or any committee thereof. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in
electronic form if the minutes are maintained in electronic form. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.8. <U>Compensation of Directors</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors shall be authorized to fix the compensation of directors. The directors of the Corporation shall be paid their
expenses, if any, of attendance at each meeting of the Board of Directors and may be reimbursed a fixed sum for attendance at each meeting of the Board of Directors, paid an annual retainer or paid other compensation, including equity compensation,
as the Board of Directors determines. No such payment shall preclude any director from serving the Corporation in any other capacity and receiving compensation therefor. Members of committees shall have their expenses, if any, of attendance of each
meeting of such committee reimbursed and may be paid compensation for attending committee meetings or being a member of a committee. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 3 - COMMITTEES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors may designate committees of the Board of Directors, with such lawfully delegable powers and duties as it thereby
confers, to serve at the pleasure of the Board of Directors and shall, for those committees, appoint a director or directors to serve as the member or members, designating, if it desires, other directors as alternate members who may replace any
absent or disqualified member at any meeting of such committee. In the absence or disqualification of any member of any committee and any alternate member in his or her place, the member or members of the committee present at the meeting and not
disqualified from voting, whether or not he or she or they constitute a quorum, may by unanimous vote appoint another member of the Board of Directors to act at the meeting in the place of the absent or disqualified member, provided that such other
member satisfied all applicable criteria for membership on such committee. All provisions of this Section&nbsp;3 are subject to, and nothing in this Section&nbsp;3 shall in any way limit the exercise, or method or timing of the exercise of, the
rights of any person granted by the Corporation with respect to the existence, duties, composition or conduct of any committee of the Board of Directors. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 4 - OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.1. <U>Generally</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The officers of the Corporation shall consist of a Chief Executive Officer, President, one or more Vice Presidents, a Treasurer, a Secretary
and other officers as may from time to time be appointed by the Board of Directors. Each officer shall hold office until his or her successor is elected and qualified or until his or her earlier death, resignation or removal. Any number of offices
may be held by the same person. The salaries of officers appointed by the Board of Directors shall be fixed from time to time by the Board of Directors or a committee thereof or by the officers as may be designated by resolution of the Board of
Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.2. <U>Chief Executive Officer</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Chief Executive Officer shall, subject to the provisions of these bylaws and to the direction of the Board of Directors, have general
charge and supervision of the business of the Corporation and shall perform all duties and have all powers that are commonly incident to the office of chief executive officer or which are delegated to him or her by the Board of Directors. He or she
shall have the power to sign all stock certificates, contracts and other instruments of the Corporation that are authorized and shall have general supervision and direction of all of the other officers, employees and agents of the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.3. <U>President</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The President shall have the powers and duties delegated to him or her by the Board of Directors or the Chief Executive Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.4. <U>Vice Presidents</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Vice President shall have the powers and duties delegated to him or her by the Board of Directors, the Chief Executive Officer, or the
President. One Vice President may be designated by the Board of Directors to perform the duties and exercise the powers of the Chief Executive Officer or President in the event of such officer&#146;s absence or disability. The Board of Directors may
assign to any Vice President the title of Executive Vice President, Senior Vice President or any title selected by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.5. <U>Treasurer</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Treasurer shall have the responsibility for maintaining the financial records of the Corporation. He or she shall make such disbursements
of the funds of the Corporation as are authorized and shall render from time to time an account to the Board of Directors of all such transactions and of the financial condition of the Corporation. The Treasurer shall also perform other duties as
the Board of Directors may from time to time prescribe. The Treasurer shall have the power to appoint an Assistant Treasurer to assist the Treasurer in carrying out his or her responsibilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.6. <U>Secretary</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Secretary shall issue all authorized notices for, and shall keep minutes of, all meetings of the stockholders and the Board of Directors.
He or she shall have charge of the corporate books and shall perform other duties as the Board of Directors may from time to time prescribe. The Secretary shall have the power to appoint an Assistant Secretary to assist the Secretary in carrying out
his or her responsibilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.7. <U>Delegation of Authority</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors may from time to time delegate the powers or duties of any officer to any other officer or agent, notwithstanding any
provision hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.8. <U>Removal</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors may remove any officer of the Corporation at any time, with or without cause, without prejudice to the rights, if any,
of such officer under any contract to which it is a party. Any officer may resign at any time upon written notice to the Corporation, without prejudice to the rights, if any, of the Corporation under any contract to which such officer is a party. If
any vacancy occurs in any office of the Corporation, the Board of Directors may elect a successor to fill such vacancy for the remainder of the unexpired term and until a successor shall have been duly chosen and qualified. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.9. <U>Action with Respect to Securities of Other Companies</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise directed by the Board of Directors, the Chief Executive Officer, the President, or any officer of the Corporation authorized
by the Chief Executive Officer or President, shall have power to vote and otherwise act on behalf of the Corporation, in person or by proxy, at any meeting of stockholders or equityholders of, or with respect to any action of, stockholders or
equityholders of any other entity in which the Corporation may hold securities and otherwise to exercise any and all rights and powers which the Corporation may possess by reason of its ownership of securities in such other entity. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 5 - STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.1. <U>Certificates of Stock</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of the capital stock of the Corporation may be certificated or uncertificated, as provided in the DGCL. Stock certificates shall be
signed by, or in the name of the Corporation by any two authorized officers of the Corporation, certifying the number of shares owned by such stockholder. Any signatures on a certificate may be by facsimile. Although any officer, transfer agent or
registrar whose manual or facsimile signature is affixed to such a certificate ceases to be such officer, transfer agent or registrar before such certificate has been issued, it may nevertheless be issued by the Corporation with the same effect as
if such officer, transfer agent or registrar were still such at the date of its issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.2. <U>Transfers of Stock</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Transfers of stock shall be made only upon the transfer books of the Corporation kept at an office of the Corporation (within or without the
State of Delaware) or by transfer agents designated to transfer shares of the stock of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3. <U>Lost, Stolen
or Destroyed Certificates</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of the loss, theft or destruction of any certificate of stock, another may be issued in its
place pursuant to regulations as the Board of Directors may establish concerning proof of the loss, theft or destruction and concerning the giving of a satisfactory bond or indemnity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.4. <U>Regulations</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issue, transfer, conversion and registration of certificates of stock of the Corporation shall be governed by other regulations as the
Board of Directors may establish. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.5. <U>Record Date</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In order that the Corporation may determine the stockholders entitled to notice of any meeting of stockholders or any adjournment thereof,
the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall, unless otherwise required by law, not be
more than sixty (60)&nbsp;nor less than ten (10)&nbsp;days before the date of such meeting. If the Board of Directors so fixes a date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless
the Board of Directors determines, at the time it fixes such record date, that a later date on or before the date of the meeting shall be the date for making such determination. If no record date is fixed by the Board of Directors, the record date
for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day preceding the day on which notice is given, or, if notice is waived, at the close of business on the day
preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; <U>provided</U>, <U>however</U>, that the Board of
Directors may fix a new record date for determination of stockholders entitled to vote at the adjourned meeting, and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned meeting the same or an earlier
date as that fixed for determination of stockholders entitled to vote in accordance herewith at the adjourned meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In order that
the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the
purpose of any other lawful action, the Board of Directors may fix a record date, which shall not be more than sixty (60)&nbsp;days prior to such other action. If no such record date is fixed, the record date for determining stockholders for any
such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 6 - NOTICES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.1. <U>Notices</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided herein or permitted by applicable law, notices to directors and stockholders shall be in writing and delivered
personally or mailed to the directors or stockholders at their addresses appearing on the books of the Corporation. If mailed, notice to a stockholder of the Corporation shall be deemed given when deposited in the mail, postage prepaid, directed to
a stockholder at such stockholder&#146;s address as it appears on the records of the Corporation. Without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to stockholders of the Corporation may be
given by electronic transmission in the manner provided in Section&nbsp;232 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.2. <U>Waivers</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A written waiver of any notice, signed by a stockholder or director, or a waiver by electronic transmission by such person or entity, whether
given before or after the time of the event for which notice is to be given, shall be deemed equivalent to the notice required to be given to such person or entity. Neither the business nor the purpose of any meeting need be specified in the waiver.
Attendance at any meeting shall constitute waiver of notice except attendance for the sole purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 7 - MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.1. <U>Corporate Seal</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors may provide a suitable seal, containing the name of the Corporation, which seal shall be in the charge of the
Secretary. If and when so directed by the Board of Directors, duplicates of the seal may be kept and used by the Treasurer or by an Assistant Secretary or Assistant Treasurer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.2. <U>Reliance upon Books, Reports, and Records</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each director and each member of any committee designated by the Board of Directors shall, in the performance of his or her duties, be fully
protected in relying in good faith upon the books and records of the Corporation and upon such information, opinions, reports or statements presented to the Corporation by any of its officers, agents or employees, or committees of the Board of
Directors so designated, or by any other person or entity as to matters which such director or committee member reasonably believes are within such other person&#146;s or entity&#146;s professional or expert competence and that has been selected
with reasonable care by or on behalf of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.3. <U>Fiscal Year</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fiscal year of the Corporation shall be as fixed by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.4. <U>Time Periods. </U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In applying any provision of these bylaws that requires that an act be done or not be done a specified number of days before an event or that
an act be done during a specified number of days before an event, calendar days shall be used, the day of the doing of the act shall be excluded, and the day of the event shall be included. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 8 - AMENDMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These bylaws may be altered, amended or repealed in accordance with the Certificate of Incorporation and the DGCL. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 9 - SEVERABILITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any provision or provisions of these bylaws shall be held to be invalid, illegal or unenforceable as applied to any circumstance for any
reason whatsoever: (i)&nbsp;the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of these bylaws (including each portion of any paragraph of these bylaws containing any such provision
held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and (ii)&nbsp;to the fullest extent possible, the provisions of these bylaws
(including each such portion of any paragraph of these bylaws containing any such provision held to be invalid, illegal or unenforceable) shall be construed so as to permit the Corporation to protect its directors, officers, employees and agents
from personal liability in respect of their good faith service to or for the benefit of the Corporation to the fullest extent permitted by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>6
<FILENAME>d99471dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g156845dsp008.jpg" ALT="LOGO">

 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RALLYBIO CORPORATION </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE COMPANY WILL FURNISH WITHOUT CHARGE TO
EACH SHAREHOLDER WHO SO REQUESTS, A SUMMARY OF THE POWERS, DESIGNATIONS, PREFERENCES AND RELATIVE, PARTICIPATING, OPTIONAL OR OTHER SPECIAL RIGHTS OF EACH CLASS OF STOCK OF THE COMPANY AND THE QUALIFICATIONS, LIMITATIONS OR RESTRICTIONS OF SUCH
PREFERENCES AND RIGHTS, AND THE VARIATIONS IN RIGHTS, PREFERENCES AND LIMITATIONS DETERMINED FOR EACH SERIES, WHICH ARE FIXED BY THE CERTIFICATE OF INCORPORATION OF THE COMPANY, AS AMENDED, AND THE RESOLUTIONS OF THE BOARD OF DIRECTORS OF THE
COMPANY, AND THE AUTHORITY OF THE BOARD OF DIRECTORS TO DETERMINE VARIATIONS FOR FUTURE SERIES. SUCH REQUEST MAY BE MADE TO THE OFFICE OF THE SECRETARY OF THE COMPANY OR TO THE TRANSFER AGENT. THE BOARD OF DIRECTORS MAY REQUIRE THE OWNER OF A LOST
OR DESTROYED STOCK CERTIFICATE, OR HIS LEGAL REPRESENTATIVES, TO GIVE THE COMPANY A BOND TO INDEMNIFY IT AND ITS TRANSFER AGENTS AND REGISTRARS AGAINST ANY CLAIM THAT MAY BE MADE AGAINST THEM ON ACCOUNT OF THE ALLEGED LOSS OR DESTRUCTION OF ANY SUCH
CERTIFICATE. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="11" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0.50em; font-size:10pt; font-family:Times New Roman">The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written
out in full according to applicable laws or regulations:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="8" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.50em; font-size:10pt; font-family:Times New Roman">TEN&nbsp;COM&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.50em; text-indent:-0.50em; font-size:10pt; font-family:Times New Roman">-&#8202;as&nbsp;tenants&nbsp;in&nbsp;common</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT STYLE="white-space:nowrap">UNIF&nbsp;GIFT&nbsp;MIN&nbsp;ACT&nbsp;-</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;Custodian<U>&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Cust)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;(Minor)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.50em; font-size:10pt; font-family:Times New Roman">TEN&nbsp;ENT&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.50em; text-indent:-0.50em; font-size:10pt; font-family:Times New Roman">-&#8202;as&nbsp;tenants&nbsp;by&nbsp;the&nbsp;entireties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;under&nbsp;Uniform&nbsp;Gifts&nbsp;to&nbsp;Minors&nbsp;Act<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(State)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-4.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;JT&nbsp;TEN</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.50em; text-indent:-0.50em; font-size:10pt; font-family:Times New Roman">-&#8202;as joint tenants with right of survivorship and not as tenants in common</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="7" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">UNIF&nbsp;TRF&nbsp;MIN&nbsp;ACT&nbsp;-</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>Custodian&nbsp;
(until&nbsp;age<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Cust)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U>under&nbsp;Uniform&nbsp;Transfers&nbsp;to&nbsp;Minors&nbsp;Act<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Minor)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(State)&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="11" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:0.50em; font-size:10pt; font-family:Times New Roman">Additional abbreviations may also be used though not in the above list.</P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="50%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-right:0.50em; font-size:10pt; font-family:Times New Roman">For value
received,<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> hereby sell, assign and transfer unto</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>

<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:8pt">(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING POSTAL ZIP CODE, OF ASSIGNEE)</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Shares</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">of the common stock represented by the within Certificate, and do hereby irrevocably constitute and appoint</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Attorney</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">to transfer the said stock on the books of the within-named Company with full power of substitution in the premises.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Dated:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>20<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="9" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="9" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Signature(s) Guaranteed: Medallion Guarantee Stamp</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-right:1.00em; font-size:8pt; font-family:Times New Roman" align="left">THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (Banks, Stockbrokers, Savings and Loan Associations
and Credit Unions) WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE <FONT STYLE="white-space:nowrap">17Ad-15.</FONT></P> <P STYLE="font-size:20pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:50pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.50em; margin-right:1.00em; text-indent:-3.50em; font-size:10pt; font-family:Times New Roman">Notice:&#8194;The signature to this assignment must correspond
with the name as written upon the face of the certificate, in every particular, without alteration or enlargement, or any change whatever.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt"></TR>
</TABLE> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">


<IMG SRC="g156845sp17.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">The IRS requires that the named transfer agent (&#147;we&#148;) report the cost basis of certain shares or units acquired after
January&nbsp;1, 2011. If your shares or units are covered by the legislation, and you requested to sell or transfer the shares or units using a specific cost basis calculation method, then we have processed as you requested. If you did not specify a
cost basis calculation method, then we have defaulted to the first in, first out (FIFO) method. Please consult your tax advisor if you need additional information about cost basis. <B></B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>If you do not keep in contact with the issuer or do not have any</B> <B>activity in
your account for the time period specified by state law,</B> <B>your property may become subject to state unclaimed property</B> <B>laws and transferred to the appropriate state. </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g156845sp17a.jpg" ALT="LOGO">
</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>7
<FILENAME>d99471dex42.htm
<DESCRIPTION>EX-4.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">THIS REGISTRATION RIGHTS AGREEMENT (this &#147;<B>Agreement</B>&#148;), is made as of the [ ] day of
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021, by and among Rallybio Corporation, a Delaware corporation (including Rallybio Corporation&#146;s successors by merger,
acquisition, reorganization or otherwise, the &#147;<B>Company</B>&#148;), each of the investors listed on <U>Schedule A</U> hereto, any additional Investor who becomes a party to this Agreement (each an &#147;<B>Investor</B>&#148;, and
collectively, the &#147;<B>Investors</B>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>RECITALS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the undersigned Investors held membership units in Rallybio Holdings, LLC, a Delaware limited liability company (the
&#147;<B>LLC</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, prior to the date hereof, the LLC and such Investors were parties to that certain Amended and
Restated Investors&#146; Rights Agreement, dated as of, March&nbsp;27, 2020 (the &#147;<B>IRA</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, this Agreement
is made in connection with to the Plan of Liquidation and Dissolution, dated as of July [ ], 2021 (the &#147;<B>Plan</B>&#148;) whereby the outstanding membership interest holders of the LLC will receive stock in the Corporation, pursuant to the
Plan, such that the economic value of the membership interest holders investment in shares in Corporation will equal the economic value of such membership interest holders prior investment in membership interest in the LLC; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, to induce each Investor to execute and deliver the Plan, the Company has agreed to provide to each of the stockholders of the
Corporation that are party to that certain Amended and Restated Investors&#146; Rights Agreement of the Company, dated as of, March&nbsp;27, 2020 (the &#147;<B>Investors Rights Agreement</B>&#148;) registration rights under this Agreement to such
parties substantially similar to those granted to such parties pursuant to the Investors Rights Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in
consideration of the premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and each Investor hereby agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>.<B> </B>For purposes of this Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.1 &#147;<B>Affiliate</B>&#148; means, with respect to any specified Person, any other Person who or which, directly or
indirectly, controls, is controlled by or is under common control with such specified Person, including, without limitation, any general partner, limited partner, managing member, manager, member, officer, employee, trustee or director of such
Person, or any trust for the benefit of any of the foregoing or any Affiliate of the foregoing, or any venture capital fund or registered investment company now or hereafter existing that is controlled by or under common control with one or more
general partners, managing members or investment advisers of, or shares the same management company or investment adviser with, such Person. For purposes of this definition, the term &#147;control&#148; when used with respect to any Person shall
mean the power to direct the management or policies of such Person, directly or indirectly, whether through ownership of voting securities, by contract or otherwise, and the terms &#147;controlling&#148; and &#147;controlled&#148; shall have
meanings correlative to the foregoing. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.2 &#147;<B>Board</B>&#148; means the board of directors of the Company.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.3 &#147;<B>Certificate</B>&#148; means the Company&#146;s Certificate of Incorporation, as amended and/or restated from
time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.4 &#147;<B>Common Shares</B>&#148; means the voting common stock of the Company, par value $0.0001 per
share, and any securities into which such shares of voting common stock may hereinafter be reclassified. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.5
&#147;<B>Damages</B>&#148; means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or
liability (or any action in respect thereof) arises out of or is based upon: (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or
final prospectus contained therein or any amendments or supplements thereto; (ii)&nbsp;an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or
(iii)&nbsp;any violation or alleged violation by the indemnifying<B> </B>party (or any of its agents or Affiliates)<B> </B>of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities
Act, the Exchange Act, or any state securities law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.6 &#147;<B>Equity Securities</B>&#148; means any equity securities,
including the Common Shares, of the Company, whether now authorized or not, and rights, options or warrants to purchase Common Shares or other equity securities, and securities of any type whatsoever that are, or may become, convertible into Common
Shares or other equity securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.7 &#147;<B>Exchange Act</B>&#148; means the Securities Exchange Act of 1934, as
amended, and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.8 &#147;<B>Excluded Registration</B>&#148; means
(i)&nbsp;a registration relating to the sale or grant of securities to employees of the Company or a subsidiary pursuant to a Share option, Share purchase, equity incentive or similar plan; (ii)&nbsp;a registration relating to an SEC Rule 145
transaction; (iii)&nbsp;a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv)&nbsp;a registration
in which the only Common Shares being registered is Common Shares issuable upon conversion of debt securities that are also being registered. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.9 &#147;<B>Form S</B><B><FONT STYLE="white-space:nowrap">-1</FONT></B>&#148; means such form under the Securities Act as in
effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.10 &#147;<B>Form
S</B><B><FONT STYLE="white-space:nowrap">-3</FONT></B>&#148; means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC that permits forward
incorporation of substantial information by reference to other documents filed by the Company with the SEC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.11
&#147;<B>Founder Registrable Securities</B>&#148; means (i)&nbsp;the Common Shares held by the Founders, and (ii)&nbsp;any Common Shares issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued
as) a distribution with respect to, or in exchange for or in replacement of such shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.12 <B>&#147;Founders</B>&#148;
means collectively Martin Mackay, Stephen Uden and Jeffrey Fryer, with each individual a &#147;<B>Founder</B>&#148;. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.13
&#147;<B>Holder</B>&#148; means any holder of Registrable Securities who is a party to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.14
&#147;<B>Immediate Family Member</B>&#148; means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mother-in-law,</FONT></FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">father-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">son-in-law,</FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">daughter-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">brother-in-law,</FONT></FONT><B> </B>or<B> </B><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">sister-in-law,</FONT></FONT> including, adoptive relationships, of a natural person referred to herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.15 &#147;<B>Initiating Holders</B>&#148; means, collectively, Holders who properly initiate a registration request under this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.16 &#147;<B>IPO</B>&#148; means the Company&#146;s first underwritten public offering of its Common Shares
under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.17 &#147;<B>Person</B>&#148; means any individual, corporation, partnership, trust, limited
liability company, association or other entity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.18 &#147;<B>Registrable Securities</B>&#148; means (i)&nbsp;the Common
Shares held by the Investors as of the date hereof; (ii)&nbsp;the Founder Registrable Securities, provided, however, that such Founder Registrable Securities shall not be deemed Registrable Securities for the purposes of Subsections 2.1 (and any
other applicable Section or Subsection with respect to registrations under Subsection 2.1), 2.10, and 3.6; and (iii)&nbsp;any Common Shares issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is
issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the Common Shares held by the Investors as of the date hereof. As to any particular Registrable Securities, such securities shall cease to be
Registrable Securities when (x)&nbsp;a registration statement with respect to the sale of such securities shall have become effective under the Securities Act and such securities shall have been disposed of in accordance with such registration
statement, (y)&nbsp;such securities shall have been transferred pursuant to SEC Rule 144, or (z)&nbsp;such securities shall have ceased to be outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.19 &#147;<B>Registrable Securities then outstanding</B>&#148; means the
number of shares determined by adding the number of outstanding Common Shares that are Registrable Securities and the number Common Shares issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are
Registrable Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.20 &#147;<B>Restricted Securities</B>&#148; means the securities of the Company required to be
notated with the legend set forth in <U>Subsection </U><U>2.11(b)</U> hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.21 &#147;<B>SEC</B>&#148; means the
Securities and Exchange Commission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.22 &#147;<B>SEC Rule 144</B>&#148; means Rule 144 promulgated by the SEC under the
Securities Act including the relevant no action letters then interpreting such rule. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.23 &#147;<B>SEC Rule 145</B>&#148;
means Rule 145 promulgated by the SEC under the Securities Act including the relevant no action letters then interpreting such rule. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.24 &#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.25 &#147;<B>Selling Expenses</B>&#148; means all underwriting discounts, selling commissions, and Shares
transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in <U>Subsection
2.6</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Registration Rights</U>. The Company covenants and agrees as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.1 <U>Demand Registration</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Form <FONT STYLE="white-space:nowrap">S-1</FONT> Demand</U>. If at any time after the earlier of (i)&nbsp;four (4) years after the
date of this Agreement or (ii)&nbsp;one hundred eighty (180)&nbsp;days after the effective date of the registration statement for the IPO (as the case may be), the Company receives a request from Holders of at least thirty percent (30%) of the
Registrable Securities then outstanding that the Company file a Form <FONT STYLE="white-space:nowrap">S-1</FONT> registration statement<B> </B>with respect to at least twenty percent (20%) of the Registrable Securities then outstanding; provided
that the anticipated aggregate offering price, net of Selling Expenses, would exceed $20 million), then the Company shall (x)&nbsp;within ten (10)&nbsp;days after the date such request is given, give notice thereof (the &#147;<B>Demand
Notice</B>&#148;) to all Holders other than the Initiating Holders; and (y)&nbsp;as soon as practicable, and in any event within ninety (90)&nbsp;days after the date such request is given by the Initiating Holders, file a Form <FONT
STYLE="white-space:nowrap">S-1</FONT> registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested<B> </B>to be registered and any additional Registrable Securities requested to be
included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20)&nbsp;days of the date the Demand Notice is given, and in each case, subject to the limitations of <U>Subsections
</U><U>2.1(c)</U> and <U>2.3.</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Demand</U>. If at any time when it
is eligible to use a Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration statement, the Company receives a request from the Holders of at least twenty-five percent (25%) of the Registrable Securities then outstanding that the Company file
a Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $3&nbsp;million, then
the Company shall (i)&nbsp;within ten (10)&nbsp;days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii)&nbsp;as soon as practicable, and in any event within forty-five (45)&nbsp;days
after the date such request is given by the Initiating Holders, file a Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration
by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20)&nbsp;days of the date the Demand Notice is given, and in each case, subject to the limitations of <U>Subsections 2.1(c)</U> and <U>2.3.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this <U>Subsection
2.1</U> a certificate signed by the Company&#146;s chief executive officer stating that in the good faith judgment of the Board it would be materially detrimental to the Company and its Holders for such registration statement to either become
effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i)&nbsp;materially interfere with a significant acquisition, corporate reorganization, or other
similar transaction involving the Company; (ii)&nbsp;require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii)&nbsp;render the Company unable to comply with
requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly,
for a period of not more than one hundred (100)&nbsp;days after the request of the Initiating Holders is given; <U>provided</U>, <U>however</U>, that the Company may not invoke this right more than once in any consecutive twelve (12)&nbsp;month
period; and <U>provided</U> <U>further</U> that the Company shall not register any securities for its own account or that of any other Holder during such ninety (90)&nbsp;day period other than an Excluded Registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to <U>Subsection
</U><U>2.1(a)</U>: (i) during the period that is sixty (60)&nbsp;days before the Company&#146;s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180)&nbsp;days after the effective date of, a
Company-initiated registration, <U>provided</U> that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii)&nbsp;after the Company has effected two
(2)&nbsp;registrations pursuant to Subsection <U>2.1(a)</U>; or (iii)&nbsp;if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form <FONT STYLE="white-space:nowrap">S-3</FONT>
pursuant to a request made pursuant to <U>Subsection 2.1(b)</U>. The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to <U>Subsection 2.1(b)</U>&nbsp;(i) during the period that is thirty
(30)&nbsp;days before the Company&#146;s good faith estimate of the date of filing of, and ending on a date that is ninety (90)&nbsp;days after the effective date of, a Company-initiated registration, <U>provided</U> that the Company is actively
employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii)&nbsp;if the Company has effected two (2)&nbsp;registrations pursuant to <U>Subsection 2.1(b)</U> within the twelve
(12)&nbsp;month period immediately preceding the date of such request. A registration shall not be counted as &#147;effected&#148; for purposes of this <U>Subsection </U><U>2.1(d)</U> until such time as the applicable registration statement has been
declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to <U>Subsection
2.6</U>, in which case such withdrawn registration statement shall be counted as &#147;effected&#148; for purposes of this <U>Subsection 2.1(d)</U>; <U>provided</U>, that if such withdrawal is during a period the Company has deferred taking action
pursuant to <U>Subsection 2.1(c)</U>, then the Initiating Holders may withdraw their request for registration and such registration will not be counted as &#147;effected&#148; for purposes of this <U>Subsection 2.1(d)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.2 <U>Company Registration</U>. If the Company proposes to register (including, for this
purpose, a registration effected by the Company for stockholders other than the Holders) any of its Common Shares or other Equity Securities under the Securities Act in connection with the public offering of such securities solely for cash (other
than in an Excluded Registration), the Company shall, at such time, promptly give each Holder, notice of such registration. Upon the request of each Holder given within twenty (20)&nbsp;days after such notice is given by the Company, the Company
shall, subject to the provisions of <U>Subsection 2.3</U>, cause to be registered all of the Registrable Securities, as applicable, that each such Holder has requested to be included in such registration. The Company shall have the right to
terminate or withdraw any registration initiated by it under this <U>Subsection 2.2</U> before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other
than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with <U>Subsection 2.6</U>. For the avoidance of doubt, no person shall be granted demand or <FONT STYLE="white-space:nowrap">S-3</FONT> rights, or
piggyback registration rights on parity with or superior to those of the Investors, without the consent of the holders of at least sixty percent (60)% of the then outstanding Registrable Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.3 <U>Underwriting Requirements</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) If, pursuant to <U>Subsection 2.1</U>, the Initiating Holders<B> </B>intend to distribute the Registrable Securities covered by their
request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to <U>Subsection 2.1</U>, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the
Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder&#146;s Registrable Securities in such registration shall be conditioned upon such
Holder&#146;s participation in such underwriting and the inclusion of such Holder&#146;s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall
(together with the Company as provided in <U>Subsection 2.4(e)</U>) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this <U>Subsection 2.3</U>, if
the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that
otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as
nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders affected by such change; <U>provided</U>, <U>however</U>, that the number of
Registrable Securities held by the Investors to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above
provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(100)&nbsp;shares. If the managing underwriter(s) have not limited the number of Registrable Securities or other securities to be underwritten, the Company may include its securities for its own
account in such registration if the managing underwriter(s) so agree and if the number of Registrable Securities and other securities which would otherwise have been included in such registration and underwriting will not thereby be limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) In connection with any offering involving an underwriting of the Equity Securities pursuant to <U>Subsection 2.2</U>, the Company shall
not be required to include any of the Registrable Securities, in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in
their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by Holders to be included in such offering exceeds the number of
securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such
securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities
requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to) the number of Registrable
Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders affected by such change. To facilitate the allocation of shares in accordance with the above provisions, the Company or
the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100)&nbsp;shares. Notwithstanding the foregoing, in no event shall (i)&nbsp;the number of Registrable Securities included in the offering be reduced
unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii)&nbsp;the number of Registrable Securities included in the offering be reduced below twenty-five percent (25%) of the
total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder&#146;s securities
are included in such offering. For purposes of the provision in this <U>Subsection 2.3(b)</U> concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners,
retired members, members, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed
to be a single &#147;selling Holder,&#148; and any pro rata reduction with respect to such &#147;selling Holder&#148; shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such &#147;selling
Holder,&#148; as defined in this sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) For purposes of <U>Subsection 2.1</U>, a registration shall not be counted as
&#147;effected&#148; if, as a result of an exercise of the underwriter&#146;s cutback provisions in <U>Subsection 2.3(a)</U>, fewer than fifty percent (50%) of the Registrable Securities that Holders have requested to be included in such
registration statement are actually included. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.4 <U>Obligations of the Company</U>. Whenever required under this
<U>Section</U><U></U><U>&nbsp;2</U> to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred
twenty (120)&nbsp;days or, if earlier, until the distribution contemplated in the registration statement has been completed; <U>provided</U>, <U>however</U>, that (i)&nbsp;such one hundred twenty (120)&nbsp;day period shall be extended for a period
of time equal to the period the Holder refrains, at the request of an underwriter of Common Shares (or other securities) of the Company, from selling any securities included in such registration, and (ii)&nbsp;in the case of any registration of
Registrable Securities on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120)&nbsp;day period shall be
extended for up to sixty (60)&nbsp;days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus, as required by the
Securities Act, used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or <FONT STYLE="white-space:nowrap">blue-sky</FONT> laws of such jurisdictions as shall be reasonably requested by the selling Holders; <U>provided</U> that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) use its commercially reasonable efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number
for all such Registrable Securities, in each case not later than the effective date of such registration; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) promptly make available for inspection by the selling Holders, any underwriter(s)
participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent documents, and
properties of the Company, and cause the Company&#146;s officers, managers, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as
necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) after such
registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the
Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company&#146;s managers may implement a trading program under Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> of the Exchange Act.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.5 <U>Furnish Information</U>. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this
<U>Section</U><U></U><U>&nbsp;2</U> with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of
disposition of such securities as is reasonably required to effect the registration of such Holder&#146;s Registrable Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.6
<U>Expenses of Registration</U>. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to <U>Section</U><U></U><U>&nbsp;2</U>, including all registration, filing, and qualification
fees; printers&#146; and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements, not to exceed $50,000 per registration of one counsel for the selling Holders<B> </B>(&#147;<B>Selling Holder
Counsel</B>&#148;), shall be borne and paid by the Company; <U>provided</U>, <U>however</U>, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to <U>Subsection 2.1</U> if the registration
request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that
were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to <U>Subsections </U><U>2.1(a)</U> or <U>2.1(b)</U>, as the case may be;
<U>provided</U> <U>further</U> that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request
and have withdrawn the request with reasonable promptness (and in any event within ten (10)&nbsp;business days) after learning of such information then the Holders shall not be required to pay any of such expenses and shall not forfeit their right
to one registration pursuant to <U>Subsections 2.1(a)</U> or <U>2.1(b)</U>. All Selling Expenses relating to Registrable Securities registered pursuant to this <U>Section</U><U></U><U>&nbsp;2</U> shall be borne and paid by the selling Holders pro
rata on the basis of the number of Registrable Securities registered on their behalf. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.7 <U>Delay of Registration</U>. No Holder shall have any right to obtain or seek an
injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this <U>Section</U><U></U><U>&nbsp;2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.8 <U>Indemnification</U>. If any Registrable Securities are included in a registration statement under this
<U>Section</U><U></U><U>&nbsp;2</U>: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) To the extent permitted by law, the Company will indemnify and hold harmless each selling
Holder, and the partners, members, officers, directors, and members of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who
controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other
expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; <U>provided</U>, <U>however</U>, that the indemnity agreement contained in this
<U>Subsection </U><U>2.8(a)</U> shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company
be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or
other aforementioned Person expressly for use in connection with such registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) To the extent permitted by law, each selling
Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its managers, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the
Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other
Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder
expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending
any claim or proceeding from which Damages may result, as such expenses are incurred; <U>provided</U>, <U>however</U>, that the indemnity agreement contained in this <U>Subsection </U><U>2.8(b)</U> shall not apply to amounts paid in settlement of
any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and <U>provided</U> <U>further</U> that in no event shall the aggregate amounts payable by any Holder by
way of any indemnity or contribution under <U>Subsections 2.8(b)</U> and <U>2.8(d)</U> exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct
by such Holder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Promptly after receipt by an indemnified party under this <U>Subsection 2.8</U><B>
</B>of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying
party under this <U>Subsection 2.8</U>, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate
jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; <U>provided</U>, <U>however</U>, that an indemnified party (together with all other
indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the
counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i)&nbsp;any
party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this <U>Subsection 2.8</U> but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the
expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this <U>Subsection 2.8</U> provides for indemnification in such case, or
(ii)&nbsp;contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this <U>Subsection 2.8</U>, then, and in each such case, such parties will contribute to the aggregate
losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in
connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the
indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the
indemnifying party or by the indemnified party and the parties&#146; relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; <U>provided</U>, <U>however</U>, that, in any such case
(x)&nbsp;no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y)&nbsp;no Person guilty of
fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and <U>provided</U> <U>further</U> that in no
event shall a Holder&#146;s liability pursuant to this <U>Subsection 2.8(d)</U>, when combined with the amounts paid or payable by such Holder pursuant to <U>Subsection 2.8(b)</U>, exceed the proceeds from the offering received by such Holder (net
of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding the
foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions
in the underwriting agreement shall control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Unless otherwise superseded by an underwriting agreement entered into in connection
with the underwritten public offering, the obligations of the Company and Holders under this <U>Subsection 2.8</U> shall survive the completion of any offering of Registrable Securities in a registration under this
<U>Section</U><U></U><U>&nbsp;2</U>, and otherwise shall survive the termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.9 <U>Reports Under Exchange
Act</U>. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to
a registration on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> the Company shall: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) make and keep available adequate current
public information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)
furnish to any Holder, so long as such Holder owns any Registrable Securities, forthwith upon request (i)&nbsp;to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any
time after ninety (90)&nbsp;days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or
that it qualifies as a registrant whose securities may be resold pursuant to Form <FONT STYLE="white-space:nowrap">S-3</FONT> (at any time after the Company so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and
such other reports and documents so filed by the Company; and (iii)&nbsp;such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without
registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form <FONT STYLE="white-space:nowrap">S-3</FONT> (at any time after the Company so qualifies to use such form). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.10 <U>Limitations on Subsequent Registration Rights</U>. From and after the date of this Agreement, the Company shall not, without the
prior written consent of the holders of at least sixty percent (60%) of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that would (i)&nbsp;allow such
holder or prospective holder the right to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the
inclusion of such securities will not reduce the number of the Registrable Securities of the Holders that are included; or (ii)&nbsp;allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder
or prospective holder; <U>provided</U> that this limitation shall not apply to Registrable Securities acquired by any additional Investor that becomes a party to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.11 <U>Termination of Registration Rights</U>. The right of any Holder to request
registration or inclusion of Registrable Securities in any registration pursuant to <U>Subsections 2.1</U> or <U>2.2</U> shall terminate upon the earlier to occur of: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) when there shall no longer be any Registrable Securities outstanding; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) the third anniversary of an IPO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.1
<U>Successors and Assigns</U>. The rights under this Agreement may be<B> </B>assigned (but only with all related obligations) by a Holder to a transferee of Registrable Securities that (i)&nbsp;is an Affiliate of a Holder; (ii)&nbsp;is a
Holder&#146;s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder&#146;s Immediate Family Members; or (iii)&nbsp;after such transfer, holds at least twenty percent (20%) of such Holder&#146;s
Registrable Securities (subject to appropriate adjustment for share splits, distributions, combinations, and other recapitalizations); provided, however, that (x)&nbsp;the Company is, within a reasonable time after such transfer, furnished with
written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y)&nbsp;such transferee agrees in a written instrument delivered to the Company to be bound by and
subject to the terms and conditions of this Agreement. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1)&nbsp;that is an Affiliate or stockholder of a Holder;
(2)&nbsp;who is a Holder&#146;s Immediate Family Member; or (3)&nbsp;that is a trust for the benefit of an individual Holder or such Holder&#146;s Immediate Family Member shall be aggregated together and with those of the transferring Holder;
provided further that all transferees who would not qualify individually for assignment of rights shall, as a condition to the applicable transfer, establish a single
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure
to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Any assignment in violation of this <U>Subsection 3.1</U> shall be deemed null and void and of no force or effect. Nothing in this Agreement,
express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly
provided herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.2 <U>Governing Law</U>. This Agreement and any controversy arising out of or related to this Agreement shall be
governed by and construed in accordance with the internal laws of the State of Delaware, without regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.3 <U>Counterparts</U><U>; Electronic Signature</U>. This Agreement may be executed in two (2)&nbsp;or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf) or other transmission method and any counterpart so delivered shall be
deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.4 <U>Titles and Subtitles</U>. The titles and subtitles used in this Agreement are for
convenience only and are not to be considered in construing or interpreting this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.5 <U>Notices</U>. All notices and other
communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i)&nbsp;personal delivery to the party to be notified; (ii)&nbsp;when sent, if sent by
electronic mail or facsimile during the recipient&#146;s normal business hours, and if not sent during normal business hours, then on the recipient&#146;s next business day; (iii)&nbsp;five (5) days after having been sent by registered or certified
mail, return receipt requested, postage prepaid; or (iv)&nbsp;one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of
receipt. All communications shall be sent to the respective parties at their addresses as set forth on <U>Schedule A</U> hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the
Company, or to such email address, facsimile number, or address as subsequently modified by written notice given in accordance with this <U>Subsection 3.5</U>. If notice is given to the Company, a copy which shall not constitute notice, shall also
be sent to Evan Kipperman, Wiggin and Dana LLP, One Century Tower, 265 Church Street, New Haven, CT 06508. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.6 <U>Amendments and
Waivers</U>. Any term of this Agreement may be amended, modified or terminated and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the
written consent of the Company and the holders of at least sixty percent (60)% of the Registrable Securities then outstanding and held by Investors; <U>provided</U> that the Company may in its sole discretion waive compliance with <U>Subsection
</U>2.11(c) (and the Company&#146;s failure to object promptly in writing after notification in writing of a proposed assignment allegedly in violation of <U>Subsection </U>2.11(c) shall be deemed to be a waiver); and provided further that any
provision hereof may be waived by any waiving party on such party&#146;s own behalf, without the consent of any other party. Notwithstanding the foregoing, this Agreement may not be amended, modified or terminated and the observance of any term
hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, modification, termination, or waiver applies to all Investors in the same fashion. Notwithstanding the foregoing, <U>Schedule
A</U> hereto may be amended by the Company from time to time to add transferees of any Registrable Securities in compliance with the terms of this Agreement without the consent of the other parties. The Company shall give prompt notice of any
amendment, modification or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, modification, termination, or waiver. Any amendment, modification, termination, or waiver effected in accordance
with this <U>Subsection 3.6</U> shall be binding on each party hereto and all of such party&#146;s successors and permitted assigns, regardless of whether any such party, successor or permitted assign has consented thereto. No waivers of or
exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.7 <U>Severability</U>. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal
or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid,
legal, and enforceable to the maximum extent permitted by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.8 <U>Aggregation of </U><U>Shares</U>. All shares of Registrable Securities held or
acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.9 <U>Specific Performance</U>. In addition to any and all other remedies that may be available at law in the event of any breach of
this Agreement, each party hereto shall be entitled to specific performance of the agreements and obligations of the other parties hereunder and to such other injunction or other equitable relief as may be granted by a court of competent
jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.10 <U>Entire Agreement</U>. This Agreement (including any Schedules) constitutes the full and entire understanding and
agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. For avoidance of doubt, the Investors&#146;
Rights Agreement is hereby terminated in its entirety. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.11 <U>Dispute Resolution</U>. The parties (a)&nbsp;hereby irrevocably and
unconditionally submit to the jurisdiction of the federal and state courts located within the geographic boundaries of the City of New York, NY for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement,
(b)&nbsp;agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the federal and state courts located within the geographic boundaries of the City of New York, NY and (c)&nbsp;hereby waive,
and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from
attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such
court. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WAIVER OF JURY TRIAL:<B> </B>EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS
AGREEMENT, THE OTHER TRANSACTION AGREEMENTS, THE REGISTRABLE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE <FONT STYLE="white-space:nowrap">ALL-ENCOMPASSING</FONT> OF ANY AND ALL DISPUTES THAT MAY BE
FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS
BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH
PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.12 <U>Delays or Omissions</U>. No delay or omission to exercise any right, power, or
remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a
waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter
occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.13 <U>Acknowledgement</U>. The Company acknowledges that the Investors are in the business of venture capital investing and therefore
review the business plans and related proprietary information of many enterprises, including enterprises which may have products or services which compete directly or indirectly with those of the Company. Nothing in this Agreement shall preclude or
in any way restrict the Investors from investing or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the Company. The Company hereby agrees that, to the extent permitted
under applicable law, the Investors shall not be liable to the Company for any claim arising out of, or based upon, (i)&nbsp;the investment by an Investor in any entity competitive with the Company, or (ii)&nbsp;actions taken by any partner,
officer, employee or other representative of an Investor to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether or not such action has
a detrimental effect on the Company; <U>provided</U>, <U>however</U>, that the foregoing shall not relieve (x)&nbsp;any of the Investors from liability associated with the unauthorized disclosure of the Company&#146;s confidential information
obtained pursuant to this Agreement, or (y)&nbsp;any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of Page Intentionally Left Blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>RALLYBIO CORPORATION</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Martin W. Mackay</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Address:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">234 Church Street</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 1020</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">New Haven, CT 06510</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> R<SMALL>EGISTRATION</SMALL>
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>5AM VENTURES V, L.P</B><B><I>.</I></B><B></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: 5AM Partners V, LLC, its general partner</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Kush Parmar</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Member</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>5AM OPPORTUNITIES I, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: 5AM Opportunities I, LLC, its general partner</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Kush Parmar</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Member</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> R<SMALL>EGISTRATION</SMALL>
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AJU LIFE SCIENCE 3.0 VENTURE FUND</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">c/o Aju IB Investment, Co., Ltd.</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> R<SMALL>EGISTRATION</SMALL>
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CANAAN XI L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By: Canaan Partners XI LLC</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Its:
General Partner</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Tim Shannon</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">General Partner</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> R<SMALL>EGISTRATION</SMALL>
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>C<SMALL>ONNECTICUT</SMALL> I<SMALL>NNOVATIONS</SMALL>, I<SMALL>NCORPORATED</SMALL></B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David M. Wurzer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President and Chief Investment Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> R<SMALL>EGISTRATION</SMALL>
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CONSTITUTION FUND V, LLC - SERIES D</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Fairview Constitution Management V, LLC,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Its: Authorized Member of its Managing Member</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> R<SMALL>EGISTRATION</SMALL>
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><FONT STYLE="white-space:nowrap">F-PRIME</FONT> CAPITAL PARTNERS LIFE SCIENCES FUND VI LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: <FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Life Sciences Advisors Fund VI LP, its general partner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Impresa Holdings LLC, its general partner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Impresa Management LLC, its managing member</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Mary Bevelock Pendergast</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Vice President</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> R<SMALL>EGISTRATION</SMALL>
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MAR RLB Holdings LLC</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Colm O&#146;Connell</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Manager</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> R<SMALL>EGISTRATION</SMALL>
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>NEW LEAF VENTURES III, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">New Leaf Venture Associates III, L.P.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">New Leaf Venture Management III, L.L.C.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Partner</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Ron Hunt</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> R<SMALL>EGISTRATION</SMALL>
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PIVOTAL BIOVENTURE PARTNERS FUND I, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Pivotal bioVenture Partners Fund I G.P., L.P.,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pivotal bioVenture Partners Fund I U.G.P. Ltd,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">its general partner</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Robert Hopfner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Partner</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> R<SMALL>EGISTRATION</SMALL>
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TEKLA HEALTHCARE INVESTORS</B>*!</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Daniel R. Omstead, Ph.D.</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">* The name Tekla Healthcare Investors is the designation of the Trustees for the time being under an Amended&nbsp;&amp;
Restated Declaration of Trust dated April&nbsp;21, 1987, as amended, and all persons dealing with Tekla Healthcare Investors must look solely to the trust property for the enforcement of any claim against Tekla Healthcare Investors, as neither the
Trustees, officers nor shareholders assume any personal liability for the obligations entered into on behalf of Tekla Healthcare Investors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TEKLA LIFE SCIENCES INVESTORS</B>*!</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Daniel R. Omstead, Ph.D.</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">* The name Tekla Life Sciences Investors is the designation of the Trustees for the time being under a Declaration of
Trust dated February&nbsp;20, 1992, as amended, and all persons dealing with Tekla Life Sciences Investors must look solely to the trust property for the enforcement of any claim against Tekla Life Sciences Investors, as neither the Trustees,
officers nor shareholders assume any personal liability for the obligations entered into on behalf of Tekla Life Sciences Investors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TEKLA HEALTHCARE OPPORTUNITIES FUND</B>*!</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Daniel R. Omstead, Ph.D.</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*The name Tekla Healthcare Opportunities Fund is the designation of the Trustees for the time being under an
Amended&nbsp;&amp; Restated Declaration of Trust dated June&nbsp;11, 2014, and all persons dealing with Tekla Healthcare Opportunities Fund must look solely to the trust property for the enforcement of any claim against Tekla Healthcare
Opportunities Fund, as neither the Trustees, officers nor shareholders assume any personal liability for the obligations entered into on behalf of Tekla Healthcare Opportunities Fund. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">! A copy of the Declaration of Trust, as amended and restated, for each of Tekla Healthcare Investors, Tekla Life Sciences Investors and Tekla Healthcare
Opportunities Fund (collectively, the &#147;<B>Tekla Funds</B>&#148;) is on file with the Secretary of State of The Commonwealth of Massachusetts, and notice is hereby given that this Agreement is executed on behalf of the Tekla Funds by an officer
or trustee of the Tekla Funds in his or her capacity as an officer or trustee of the Tekla Funds, and not individually and that the obligations of or arising out of this Agreement are not binding upon any of the trustees, officers or shareholders
individually but are binding only upon the assets and property of each of the respective Tekla Funds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> R<SMALL>EGISTRATION</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MAINSTAR TRUST, CUST. FBO JEFFREY M. FRYER R2180643</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JEFFREY M. FRYER REVOCABLE TRUST DATED APRIL&nbsp;18, 2011</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jeffrey M. Fryer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Trustee</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> R<SMALL>EGISTRATION</SMALL>
R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>M. MACKAY FAMILY LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Martin Mackay</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL></B><SMALL></SMALL> <B>P</B><B><SMALL>AGE</SMALL> To </B><B>R</B><B><SMALL>EGISTRATION</SMALL>
</B><B>R</B><B><SMALL>IGHTS</SMALL> </B><B>A</B><B><SMALL>GREEMENT</SMALL></B><SMALL></SMALL> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Stephen Uden</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL></B><SMALL></SMALL> <B>P</B><B><SMALL>AGE</SMALL> To </B><B>R</B><B><SMALL>EGISTRATION</SMALL>
</B><B>R</B><B><SMALL>IGHTS</SMALL> </B><B>A</B><B><SMALL>GREEMENT</SMALL></B><SMALL></SMALL> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>MGI GLOBAL FUND L.P.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">by the General Partner of the Fund,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Kotaro Saijo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">President&nbsp;&amp; CEO</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Mitsui&nbsp;&amp; Co. Global Investment, Inc.</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL></B><SMALL></SMALL> <B>P</B><B><SMALL>AGE</SMALL> To </B><B>R</B><B><SMALL>EGISTRATION</SMALL>
</B><B>R</B><B><SMALL>IGHTS</SMALL> </B><B>A</B><B><SMALL>GREEMENT</SMALL></B><SMALL></SMALL> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>THE RISE FUND RASCAL, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David Mosse</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Vice President</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL></B><SMALL></SMALL> <B>P</B><B><SMALL>AGE</SMALL> To </B><B>R</B><B><SMALL>EGISTRATION</SMALL>
</B><B>R</B><B><SMALL>IGHTS</SMALL> </B><B>A</B><B><SMALL>GREEMENT</SMALL></B><SMALL></SMALL> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS <FONT STYLE="white-space:nowrap">SUB-</FONT> MASTER LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By: Viking Global Opportunities Portfolio GP LLC,</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Matthew Bloom</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signatory</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL></B><SMALL></SMALL> <B>P</B><B><SMALL>AGE</SMALL> To </B><B>R</B><B><SMALL>EGISTRATION</SMALL>
</B><B>R</B><B><SMALL>IGHTS</SMALL> </B><B>A</B><B><SMALL>GREEMENT</SMALL></B><SMALL></SMALL> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Investors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pivotal bioVenture Partners
Fund I L.P. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5AM Ventures V, L.P. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5AM
Opportunities I, L.P. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Canaan XI L.P. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New
Leaf Ventures III, L.P. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Connecticut Innovations, Incorporated </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">F-Prime</FONT> Capital Partners Life Sciences Fund VI LP </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Constitution Fund V, LLC &#150; Series D </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tekla
Healthcare Investors </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tekla Life Sciences Investors </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tekla Healthcare Opportunities Fund </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aju Life Science
3.0 Venture Fund </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MAR RLB Holdings LLC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MGI Global Fund L.P. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Viking Global Opportunities
Illiquid Investments <FONT STYLE="white-space:nowrap">Sub-Master</FONT> LP </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Rise Fund Rascal, L.P. </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>8
<FILENAME>d99471dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g156845sp69.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Exhibit 5.1</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">July&nbsp;22, 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rallybio Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">234 Church Street, Suite 1020 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Haven, CT 06510 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as counsel to Rallybio Corporation, a Delaware corporation (the &#147;<U>Company</U>&#148;), in connection with the Registration
Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-257655)</FONT> (as amended through the date hereof, the &#147;<U>Registration Statement</U>&#148;) filed by the Company with the
Securities and Exchange Commission (the &#147;<U>Commission</U>&#148;) under the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;), for the registration of up to<B> </B>6,612,500 shares of the common stock, $0.0001 par value
per share, of the Company<B> </B>(the &#147;<U>Securities</U>&#148;). The Securities are proposed to be sold pursuant to an underwriting agreement (the &#147;<U>Underwriting Agreement</U>&#148;) to be entered into among the Company and Jefferies
LLC, Cowen and Company, LLC and Evercore Group L.L.C. as representatives of the underwriters named therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this
opinion letter, we have examined such certificates, documents and records and have made such investigation of fact and such examination of law as we have deemed appropriate in order to enable us to render the opinions set forth herein. In conducting
such investigation, we have relied, without independent verification, upon certificates of officers of the Company, public officials and other appropriate persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The opinions expressed below are limited to the Delaware General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing, we are of the opinion that the Securities have been duly authorized and, when issued and delivered
pursuant to the Underwriting Agreement and against payment of the consideration set forth therein, will be, validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to your filing this opinion as an exhibit to the Registration Statement and to the use of our name therein and in the
related prospectus under the caption &#147;Legal Matters.&#148; In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations
of the Commission thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Ropes &amp; Gray LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ropes&nbsp;&amp; Gray LLP</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>9
<FILENAME>d99471dex107.htm
<DESCRIPTION>EX-10.7
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS INDEMNIFICATION AGREEMENT (this &#147;<B>Agreement</B>&#148;) is made and entered into as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 between Rallybio Corporation, a Delaware corporation (the &#147;<B>Company</B>&#148;), and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&#147;<B>Indemnitee</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WITNESSETH THAT: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
highly competent persons have become more reluctant to serve corporations as directors or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and
actions against them arising out of their service to and activities on behalf of the corporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the board of directors of the
Company (the &#147;<B>Board</B>&#148;) has determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the
Company and its subsidiaries from certain liabilities. Although the furnishing of such insurance has been a customary and widespread practice among United States-based corporations and other business enterprises, the Company believes that, given
current market conditions and trends, such insurance may be available to it in the future only at higher premiums and with more exclusions. At the same time, directors, officers, and other persons in service to corporations or business enterprises
are being increasingly subjected to expensive and time-consuming litigation relating to, among other things, matters that traditionally would have been brought only against the Company or the business enterprise itself. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indemnitee may be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (&#147;<B>DGCL</B>&#148;)
and/or the certificate of incorporation of the Company (as amended and restated, from time to time, the &#147;<B>Certificate of Incorporation</B>&#148;). The DGCL expressly provides that the indemnification provisions set forth therein are not
exclusive, and the Certificate of Incorporation thereby contemplates that contracts may be entered into between the Company and members of the Board, officers and other persons with respect to indemnification; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the uncertainties relating to such insurance and to indemnification have increased the difficulty of attracting and retaining such
persons; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the
best interests of the Company&#146;s stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on
behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, this Agreement is a supplement to and in furtherance of the Certificate of Incorporation and any resolutions adopted pursuant
thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Indemnitee does not regard the protection available under the Certificate of
Incorporation and the Company&#146;s insurance as adequate in the present circumstances, and may not be willing to serve as an officer or director without adequate protection, and the Company desires Indemnitee to serve in such capacity. Indemnitee
is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that he or she be so indemnified; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Indemnitee may have certain rights to indemnification and/or insurance provided by other entities and/or organizations, which
Indemnitee and the other entities and/or organizations intend to be secondary to the primary obligation of the Company to indemnify Indemnitee as provided herein, with the Company&#146;s acknowledgement and agreement to the foregoing being a
material condition to Indemnitee&#146;s willingness to serve on the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of Indemnitee&#146;s
agreement to serve as [a director][an officer] of the Company from and after the date hereof, the parties hereto agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
<U>Indemnity of Indemnitee</U>. The Company hereby agrees to hold harmless and indemnify Indemnitee to the fullest extent permitted by law, as such may be amended from time to time. In furtherance of the foregoing indemnification, and without
limiting the generality thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Proceedings Other Than Proceedings by or in the Right of the Company</U>. Indemnitee shall be
entitled to the rights of indemnification provided in this <U>Section</U><U></U><U>&nbsp;1(a)</U> if, by reason of his or her Corporate Status (as defined in <U>Section</U><U></U><U>&nbsp;13</U> of this Agreement), Indemnitee is, or is threatened to
be made, a party to or participant in any Proceeding (as defined in <U>Section</U><U></U><U>&nbsp;13</U> of this Agreement) other than a Proceeding by or in the right of the Company. Pursuant to this <U>Section</U><U></U><U>&nbsp;1(a)</U>,
Indemnitee shall be indemnified against all Expenses (as defined in <U>Section</U><U></U><U>&nbsp;13</U> of this Agreement), judgments, penalties, fines and amounts paid in settlement actually and reasonably incurred by him or her, or on his or her
behalf, in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and with respect to any
criminal Proceeding, had no reasonable cause to believe that Indemnitee&#146;s conduct was unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Proceedings by or in the
Right of the Company</U>. Indemnitee shall be entitled to the rights of indemnification provided in this <U>Section</U><U></U><U>&nbsp;1(b)</U> if, by reason of his or her Corporate Status, Indemnitee is, or is threatened to be made, a party to or
participant in any Proceeding brought by or in the right of the Company. Pursuant to this <U>Section</U><U></U><U>&nbsp;1(b)</U>, Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by Indemnitee, or on
Indemnitee&#146;s behalf, in connection with such Proceeding if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company; provided, however, that, if applicable law so
provides, no indemnification against such Expenses shall be made in respect of any claim, issue or matter in such Proceeding as to which Indemnitee shall have been adjudged to be liable to the Company unless and to the extent that the Court of
Chancery of the State of Delaware (the &#147;<B>Delaware Court</B>&#148;) shall determine that such indemnification may be made. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Indemnification for Expenses of a Party Who is Wholly or Partly Successful</U>.
Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his or her Corporate Status, a party to and is successful, on the merits or otherwise, in any Proceeding, he or she shall be indemnified to the
maximum extent permitted by law, as such may be amended from time to time, against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection therewith. If Indemnitee is not wholly successful in such Proceeding
but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or her or on his or
her behalf in connection with each successfully resolved claim, issue or matter. For purposes of this Section&nbsp;1(c) and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without
prejudice, shall be deemed to be a successful result as to such claim, issue or matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Additional Indemnity</U>. In addition to,
and without regard to any limitations on, the indemnification provided for in <U>Section</U><U></U><U>&nbsp;1</U> of this Agreement, the Company shall and hereby does indemnify and hold harmless Indemnitee against all Expenses, judgments, penalties,
fines and amounts paid in settlement actually and reasonably incurred by him or her or on his or her behalf if, by reason of his or her Corporate Status, he is, or is threatened to be made, a party to or participant in any Proceeding (including a
Proceeding by or in the right of the Company), including all liability arising out of the negligence or active or passive wrongdoing of Indemnitee. The only limitation that shall exist upon the Company&#146;s obligations pursuant to this Agreement
shall be that the Company shall not be obligated to make any payment to Indemnitee that is finally determined (under the procedures, and subject to the presumptions, set forth in <U>Sections 6</U> and <U>7</U> hereof) to be unlawful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Contribution</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
Whether or not the indemnification provided in <U>Sections 1</U> and <U>2</U> hereof is available, in respect of any Proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such Proceeding), the Company shall pay,
in the first instance, the entire amount of any judgment or settlement of such Proceeding without requiring Indemnitee to contribute to such payment and the Company hereby waives and relinquishes any right of contribution it may have against
Indemnitee. The Company shall not enter into any settlement of any Proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such Proceeding) unless such settlement provides for a full and final release of all
claims asserted against Indemnitee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Without diminishing or impairing the obligations of the Company set forth in Section&nbsp;3(a),
if, for any reason, Indemnitee shall elect or be required to pay all or any portion of any judgment or settlement in any Proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such Proceeding), the Company shall
contribute to the amount of Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred and paid or payable by Indemnitee in proportion to the relative benefits received by the Company and all officers, directors or
employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such Proceeding), on the one hand, and Indemnitee, on the other hand, from the transaction or events from which such Proceeding arose;
provided, however, that the proportion determined on the basis of relative benefit may, to the extent necessary to conform to law, be further adjusted by reference to the relative fault of the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company and all officers, directors or employees of the Company other than Indemnitee who are jointly liable with Indemnitee (or would be if joined in such Proceeding), on the one hand, and
Indemnitee, on the other hand, in connection with the transaction or events that resulted in such expenses, judgments, fines or settlement amounts, as well as any other equitable considerations which applicable law may require to be considered. The
relative fault of the Company and all officers, directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such Proceeding), on the one hand, and Indemnitee, on the other hand,
shall be determined by reference to, among other things, the degree to which their actions were motivated by intent to gain personal profit or advantage, the degree to which their liability is primary or secondary and the degree to which their
conduct is active or passive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Company hereby agrees to fully indemnify and hold Indemnitee harmless from any claims of
contribution which may be brought by officers, directors or employees of the Company, other than Indemnitee, who may be jointly liable with Indemnitee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee
for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses,
in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i)&nbsp;the relative benefits
received by the Company and Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such Proceeding; and/or (ii)&nbsp;the relative fault of the Company (and its directors, officers, employees and agents) and Indemnitee in
connection with such event(s) and/or transaction(s). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Indemnification for Expenses of a Witness</U>. Notwithstanding any other
provision of this Agreement, to the extent that Indemnitee is, by reason of his or her Corporate Status, a witness, or is made (or asked) to respond to discovery requests, in any Proceeding to which Indemnitee is not a party, he or she shall be
indemnified against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.
<U>Advancement of Expenses</U>. Notwithstanding any other provision of this Agreement, the Company shall advance all Expenses incurred by or on behalf of Indemnitee in connection with any Proceeding by reason of Indemnitee&#146;s Corporate Status
within thirty (30)&nbsp;days after the receipt by the Company of a statement or statements from Indemnitee requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or
statements shall reasonably evidence the Expenses incurred by Indemnitee and shall include or be preceded or accompanied by a written undertaking by or on behalf of Indemnitee to repay any Expenses advanced if it shall ultimately be determined that
Indemnitee is not entitled to be indemnified against such Expenses. Any advances and undertakings to repay pursuant to this <U>Section</U><U></U><U>&nbsp;5</U> shall be unsecured and interest free. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Procedures and Presumptions for Determination of Entitlement to Indemnification</U>. It is the intent of this Agreement to secure for
Indemnitee rights of indemnity that are as favorable as may be permitted under the DGCL and public policy of the State of Delaware. Accordingly, the parties hereto agree that the following procedures and presumptions shall apply in the event of any
question as to whether Indemnitee is entitled to indemnification under this Agreement: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a
written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification. The Secretary
of the Company shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification. Notwithstanding the foregoing, any failure of Indemnitee to provide such a request to the
Company, or to provide such a request in a timely fashion, shall not relieve the Company of any liability that it may have to Indemnitee unless, and to the extent that, such failure actually and materially prejudices the interests of the Company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Upon written request by Indemnitee for indemnification pursuant to the first sentence of <U>Section&nbsp;6(a)</U> hereof, a
determination with respect to Indemnitee&#146;s entitlement thereto shall be made in the specific case by one of the following four methods, which shall be at the election of the Board: (1)&nbsp;by a majority vote of the Disinterested Directors (as
defined in <U>Section</U><U></U><U>&nbsp;13</U> of this Agreement), even though less than a quorum, (2)&nbsp;by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum,
(3)&nbsp;if there are no Disinterested Directors or if the Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee, or (4)&nbsp;if so directed by the Board, by the
stockholders of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to
<U>Section</U><U></U><U>&nbsp;6(b)</U> hereof, the Independent Counsel shall be selected as provided in this <U>Section</U><U></U><U>&nbsp;6(c)</U>. The Independent Counsel shall be selected by the Board. Indemnitee may, within ten (10)&nbsp;days
after such written notice of selection shall have been given, deliver to the Company a written objection to such selection; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not
meet the requirements of Independent Counsel (as defined in <U>Section</U><U></U><U>&nbsp;13</U> of this Agreement), and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the
person so selected shall act as Independent Counsel. If a written objection is made and substantiated, the Independent Counsel selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that
such objection is without merit. If, within twenty (20)&nbsp;days after submission by Indemnitee of a written request for indemnification pursuant to <U>Section</U><U></U><U>&nbsp;6(a)</U> hereof, no Independent Counsel shall have been selected and
not objected to, either the Company or Indemnitee may petition the Delaware Court or other court of competent jurisdiction for resolution of any objection which shall have been made by Indemnitee to the Company&#146;s selection of Independent
Counsel and/or for the appointment as Independent Counsel of a person selected by the court or by such other person as the court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act
as Independent Counsel under <U>Section</U><U></U><U>&nbsp;6(b)</U> hereof. The Company shall pay any and all reasonable fees and expenses of Independent Counsel incurred by such Independent Counsel in connection with acting pursuant to
<U>Section</U><U></U><U>&nbsp;6(b)</U> hereof, and the Company shall pay all reasonable fees and expenses incident to the procedures of this <U>Section</U><U></U><U>&nbsp;6(c)</U>, regardless of the manner in which such Independent Counsel was
selected or appointed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) In making a determination with respect to entitlement to indemnification hereunder, the person or persons or
entity making such determination shall presume that Indemnitee is entitled to indemnification under this Agreement. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
convincing evidence. Neither the failure of the Company (including by its directors or Independent Counsel) to have made a determination prior to the commencement of any action pursuant to this
Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or Independent Counsel) that Indemnitee has not met
such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Indemnitee shall be deemed to have acted in good faith if Indemnitee&#146;s action is based on the records or books of account of the
Enterprise (as defined in <U>Section</U><U></U><U>&nbsp;13</U> of this Agreement), including financial statements, or on information supplied to Indemnitee by the officers of the Enterprise in the course of their duties, or on the advice of legal
counsel for the Enterprise or on information or records given or reports made to the Enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by the Enterprise. In addition, the
knowledge and/or actions, or failure to act, of any director, officer, agent or employee of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement. Whether or not the foregoing
provisions of this <U>Section</U><U></U><U>&nbsp;6(e)</U> are satisfied, it shall in any event be presumed that Indemnitee has at all times acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best
interests of the Company. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) If the person, persons or entity empowered or selected under <U>Section</U><U></U><U>&nbsp;6</U> to determine whether Indemnitee is
entitled to indemnification shall not have made a determination within sixty (60)&nbsp;days after receipt by the Company of the request therefor, the requisite determination of entitlement to indemnification shall be deemed to have been made and
Indemnitee shall be entitled to such indemnification absent (i)&nbsp;a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#146;s statement not materially misleading, in connection with the
request for indemnification, or (ii)&nbsp;a prohibition of such indemnification under applicable law; provided, however, that such <FONT STYLE="white-space:nowrap">60-day</FONT> period may be extended for a reasonable time, not to exceed an
additional thirty (30)&nbsp;days, if the person, persons or entity making such determination with respect to entitlement to indemnification in good faith requires such additional time to obtain or evaluate documentation and/or information relating
thereto; and provided, further, that the foregoing provisions of this <U>Section</U><U></U><U>&nbsp;6(f)</U> shall not apply if the determination of entitlement to indemnification is to be made by the stockholders pursuant to
<U>Section</U><U></U><U>&nbsp;6(b)</U> of this Agreement and if (A)&nbsp;within fifteen (15)&nbsp;days after receipt by the Company of the request for such determination, the Board or the Disinterested Directors, if appropriate, resolve to submit
such determination to the stockholders for their consideration at an annual meeting thereof to be held within seventy-five (75)&nbsp;days after such receipt and such determination is made thereat, or (B)&nbsp;a special meeting of stockholders is
called within fifteen (15)&nbsp;days after such receipt for the purpose of making such determination, such meeting is held for such purpose within sixty (60)&nbsp;days after having been so called and such determination is made thereat. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Indemnitee shall cooperate with the person, persons or entity making such determination with respect to Indemnitee&#146;s entitlement to
indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee
and reasonably necessary to such determination. Any Independent Counsel, member of the Board or stockholder of the Company shall act reasonably and in good faith in </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
making a determination regarding Indemnitee&#146;s entitlement to indemnification under this Agreement. Any costs or expenses (including attorneys&#146; fees and disbursements) incurred by
Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee&#146;s entitlement to indemnification) and the Company hereby indemnifies and
agrees to hold Indemnitee harmless therefrom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) The Company acknowledges that a settlement or other disposition short of final judgment
may be successful if it permits a party to avoid expense, delay, distraction, disruption and uncertainty. In the event that any Proceeding to which Indemnitee is a party is resolved in any manner other than by adverse judgment against Indemnitee
(including settlement of such Proceeding with or without payment of money or other consideration), it shall be presumed that Indemnitee has been successful on the merits or otherwise in such Proceeding. Anyone seeking to overcome this presumption
shall have the burden of proof and the burden of persuasion by clear and convincing evidence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The termination of any Proceeding or of
any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of
Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal
Proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Remedies of Indemnitee</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In the event that (i)&nbsp;a determination is made pursuant to <U>Section</U><U></U><U>&nbsp;6</U> of this Agreement that Indemnitee is
not entitled to indemnification under this Agreement, (ii)&nbsp;advancement of Expenses is not timely made pursuant to <U>Section</U><U></U><U>&nbsp;5</U> of this Agreement, (iii)&nbsp;no determination of entitlement to indemnification is made
pursuant to <U>Section</U><U></U><U>&nbsp;6(b)</U> of this Agreement within ninety (90)&nbsp;days after receipt by the Company of the request for indemnification, (iv)&nbsp;payment of indemnification is not made pursuant to this Agreement within ten
(10)&nbsp;days after receipt by the Company of a written request therefor or (v)&nbsp;payment of indemnification is not made within ten (10)&nbsp;days after a determination has been made that Indemnitee is entitled to indemnification or such
determination is deemed to have been made pursuant to <U>Section</U><U></U><U>&nbsp;6</U> of this Agreement, Indemnitee shall be entitled to an adjudication in an appropriate court of the State of Delaware, or in any other court of competent
jurisdiction, of Indemnitee&#146;s entitlement to such indemnification. Indemnitee shall commence such proceeding seeking an adjudication within one hundred eighty (180)&nbsp;days following the date on which Indemnitee first has the right to
commence such proceeding pursuant to this <U>Section</U><U></U><U>&nbsp;7(a)</U>. The Company shall not oppose Indemnitee&#146;s right to seek any such adjudication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event that a determination shall have been made pursuant to <U>Section</U><U></U><U>&nbsp;6(b)</U> of this Agreement that
Indemnitee is not entitled to indemnification, any judicial proceeding commenced pursuant to this <U>Section</U><U></U><U>&nbsp;7</U> shall be conducted in all respects as a de novo trial on the merits, and Indemnitee shall not be prejudiced by
reason of the adverse determination under <U>Section</U><U></U><U>&nbsp;6(b)</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If a determination shall have been made pursuant to
<U>Section</U><U></U><U>&nbsp;6(b)</U> of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding commenced pursuant to this <U>Section</U><U></U><U>&nbsp;7</U>,
absent (i)&nbsp;a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#146;s misstatement not materially misleading in connection with the application for indemnification, or (ii)&nbsp;a
prohibition of such indemnification under applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) In the event that Indemnitee, pursuant to this
<U>Section</U><U></U><U>&nbsp;7</U>, seeks a judicial adjudication of his or her rights under, or to recover damages for breach of, this Agreement, or to recover under any directors&#146; and officers&#146; liability insurance policies maintained by
the Company, the Company shall pay on his or her behalf, in advance, any and all expenses (of the types described in the definition of Expenses in <U>Section</U><U></U><U>&nbsp;13</U> of this Agreement) actually and reasonably incurred by him or her
in such judicial adjudication, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement of expenses or insurance recovery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Company shall be precluded from asserting in any judicial proceeding commenced pursuant to this <U>Section</U><U></U><U>&nbsp;7</U>
that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court that the Company is bound by all the provisions of this Agreement. The Company shall indemnify Indemnitee against any
and all Expenses and, if requested by Indemnitee, shall (within ten (10)&nbsp;days after receipt by the Company of a written request therefore) advance, to the extent not prohibited by law, such expenses to Indemnitee, which are incurred by
Indemnitee in connection with any action brought by Indemnitee for indemnification or advance of Expenses from the Company under this Agreement or under any directors&#146; and officers&#146; liability insurance policies maintained by the Company,
regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement of Expenses or insurance recovery, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification under this Agreement
shall be required to be made prior to the final disposition of the Proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.
<U><FONT STYLE="white-space:nowrap">Non-Exclusivity;</FONT> Survival of Rights; Insurance; Primacy of Indemnification; Subrogation</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The rights of indemnification as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at
any time be entitled under applicable law, the Certificate of Incorporation, the bylaws of the Company (as amended and restated, from time to time, the &#147;<B>Bylaws</B>&#148;), any agreement, a vote of the Company&#146;s stockholders, a
resolution of directors of the Company, or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by
such Indemnitee in his or her Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in the DGCL, whether by statute or judicial decision, permits greater indemnification than would be afforded currently under
the Certificate of Incorporation, the Bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to
be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or
employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To the extent that the Company maintains an insurance policy or policies providing
liability insurance for directors, officers, employees, agents or fiduciaries of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that such person serves at the request of the
Company, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any director, officer, employee, agent or fiduciary under such policy or policies. If, at the
time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has directors&#146; and officers&#146; liability insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers in
accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such proceeding in
accordance with the terms of such policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Company hereby acknowledges that Indemnitee may have certain rights to
indemnification, advancement of expenses and/or insurance provided by the other entities and/or organizations (collectively, the &#147;<B>Fund Indemnitors</B>&#148;). The Company hereby agrees (i)&nbsp;that it is the indemnitor of first resort
(<I>i.e.</I>, its obligations to Indemnitee are primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary), (ii) that it shall be
required to advance the full amount of expenses incurred by Indemnitee and shall be liable for the full amount of all Expenses, judgments, penalties, fines and amounts paid in settlement to the extent legally permitted and as required by the terms
of this Agreement and the Certificate of Incorporation or the Bylaws (or any other agreement between the Company and Indemnitee), without regard to any rights Indemnitee may have against the Fund Indemnitors, and (iii)&nbsp;that it irrevocably
waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment
by the Fund Indemnitors on behalf of Indemnitee with respect to any claim for which Indemnitee has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to
the extent of such advancement or payment to all of the rights of recovery of Indemnitee against the Company. The Company and Indemnitee agree that the Fund Indemnitors are express third-party beneficiaries of the terms of this Section&nbsp;8(c).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except as provided in paragraph (c)&nbsp;above, in the event of any payment under this Agreement, the Company shall be subrogated to
the extent of such payment to all of the rights of recovery of Indemnitee (other than against the Fund Indemnitors), who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as
are necessary to enable the Company to bring suit to enforce such rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Except as provided in paragraph (c)&nbsp;above, the Company
shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Except as provided in paragraph (c)&nbsp;above, the Company&#146;s obligation to indemnify or advance Expenses hereunder to
Indemnitee who is or was serving at the request of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company as a director, officer, employee or agent of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount
Indemnitee has actually received as indemnification or advancement of expenses from such other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Exception to Right of Indemnification</U>. Notwithstanding any provision in this Agreement, the Company shall not be obligated under
this Agreement to make any indemnity in connection with any claim made against Indemnitee: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) for which payment has actually been made
to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision, provided, that the foregoing shall not affect
the rights of Indemnitee or the Fund Indemnitors set forth in <U>Section</U><U></U><U>&nbsp;8(c)</U> above; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) for an accounting of
profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of <U>Section</U><U></U><U>&nbsp;16(b)</U> of the Securities Exchange Act of 1934, as amended, or similar provisions of
state statutory law or common law; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee,
including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (i)&nbsp;the Board authorized the Proceeding (or any part of any Proceeding)
prior to its initiation or (ii)&nbsp;the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Duration of Agreement</U>. All agreements and obligations of the Company contained herein shall continue during the period Indemnitee
is a director or officer of the Company (or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise) and shall continue thereafter so
long as Indemnitee shall be subject to any Proceeding (or any proceeding commenced under <U>Section</U><U></U><U>&nbsp;7</U> hereof) by reason of his or her Corporate Status, whether or not he or she is acting or serving in any such capacity at the
time any liability or expense is incurred for which indemnification can be provided under this Agreement. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and their respective successors
(including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), assigns, spouses, heirs, executors and personal and legal representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Security</U>. To the extent requested by Indemnitee and approved by the Board, the Company may at any time and from time to time
provide security to Indemnitee for the Company&#146;s obligations hereunder through an irrevocable bank line of credit, funded trust or other collateral. Any such security, once provided to Indemnitee, may not be revoked or released without the
prior written consent of Indemnitee. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Enforcement</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company expressly confirms and agrees that it has entered into this Agreement and assumes the obligations imposed on it hereby in
order to induce Indemnitee to serve as an officer or director of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as [a director][an officer] of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all
prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
The Company shall not seek from a court, or agree to, a &#147;bar order&#148; which would have the effect of prohibiting or limiting Indemnitee&#146;s rights to receive advancement of expenses under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Definitions</U>. For purposes of this Agreement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>Corporate Status</B>&#148; describes the status of a person who is or was a director, officer, employee, agent or fiduciary of
the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that such person is or was serving at the express written request of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>Disinterested Director</B>&#148; means a director of the Company who is not and was not a party to the Proceeding in respect of
which indemnification is sought by Indemnitee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Enterprise</B>&#148; shall mean the Company and any other corporation,
partnership, joint venture, trust, employee benefit plan or other enterprise that Indemnitee is or was serving at the express written request of the Company as a director, officer, employee, agent or fiduciary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Expenses</B>&#148; shall include all reasonable attorneys&#146; fees, retainers, court costs, transcript costs, fees of experts,
witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending,
preparing to prosecute or defend, investigating, participating, or being or preparing to be a witness in a Proceeding, or responding to, or objecting to, a request to provide discovery in any Proceeding. Expenses also shall include Expenses incurred
in connection with any appeal resulting from any Proceeding and any federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, including the premium, security for,
and other costs relating to any cost bond, supersede as bond, or other appeal bond or its equivalent. Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Independent Counsel</B>&#148; means a law firm, or a member of a law firm, that is experienced in matters of corporation law and
neither presently is, nor in the past five (5)&nbsp;years has been, retained to represent: (i)&nbsp;the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning Indemnitee under this Agreement,
or of other indemnitees under similar indemnification agreements), or (ii)&nbsp;any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the term &#147;Independent Counsel&#148; shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in
representing either the Company or Indemnitee in an action to determine Indemnitee&#146;s rights under this Agreement. The Company agrees to pay the reasonable fees of the Independent Counsel referred to above and to fully indemnify such counsel
against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>Proceeding</B>&#148; includes any threatened, pending or completed action, suit, arbitration, alternate dispute resolution
mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought by or in the right of the Company or otherwise and whether civil, criminal, administrative or investigative, in which
Indemnitee was, is or will be involved as a party or otherwise, by reason of his or her Corporate Status, by reason of any action taken by him or her or of any inaction on his or her part while acting in his Corporate Status; in each case whether or
not he or she is acting or serving in any such capacity at the time any liability or expense is incurred for which indemnification can be provided under this Agreement; including one pending on or before the date of this Agreement, but excluding one
initiated by an Indemnitee pursuant to <U>Section</U><U></U><U>&nbsp;7</U> of this Agreement to enforce his or her rights under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Severability</U>. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of
any other provision. Further, the invalidity or unenforceability of any provision hereof as to either Indemnitee shall in no way affect the validity or enforceability of any provision hereof as to the other. Without limiting the generality of the
foregoing, this Agreement is intended to confer upon Indemnitee indemnification rights to the fullest extent permitted by applicable laws. In the event any provision hereof conflicts with any applicable law, such provision shall be deemed modified,
consistent with the aforementioned intent, to the extent necessary to resolve such conflict. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Modification and Waiver</U>. No
supplement, modification, termination or amendment of this Agreement shall be binding unless executed in writing by both of the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any
other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Notice By Indemnitee</U>.
Indemnitee agrees promptly to notify the Company in writing upon being served with or otherwise receiving any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject
to indemnification covered hereunder. The failure to so notify the Company shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise unless and only to the extent that such failure or delay
materially prejudices the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Notices</U>. All notices and other communications given or made pursuant to this Agreement
shall be in writing and shall be deemed effectively given: (a)&nbsp;upon personal delivery to the party to be notified, (b)&nbsp;when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient, and if not so
confirmed, then on the next business day, (c)&nbsp;five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d)&nbsp;one (1) day after deposit with a nationally recognized overnight courier,
specifying next day delivery, with written verification of receipt. All communications shall be sent: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) To Indemnitee at the address set forth below Indemnitee&#146;s signature hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To the Company at: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Rallybio Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">234
Church Street, Suite 1020 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New Haven, CT 06510 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">or
to such other address as may have been furnished to Indemnitee by the Company or to the Company by Indemnitee, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.
<U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile,
electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly
delivered and be valid and effective for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>Headings</U>. The headings of the paragraphs of this Agreement are inserted
for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>Governing
Law and Consent to Jurisdiction</U>. This Agreement and the legal relations between the parties hereto shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws
rules. The Company and Indemnitee hereby irrevocably and unconditionally (a)&nbsp;agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court and not in any other state or
federal court in the United States of America or any court in any other country, (b)&nbsp;consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this
Agreement, (c)&nbsp;waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (d)&nbsp;waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court
has been brought in an improper or inconvenient forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <U>Interpretation</U>. Except where the context expressly requires otherwise:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) the words &#147;include,&#148; &#147;includes&#148; and &#147;including&#148; shall be deemed to be followed by the phrase
&#147;without limitation;&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) the word &#147;will&#148; shall be construed to have the same meaning and effect as the word
&#147;shall;&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) all dollar ($) amounts herein are in United States dollars (USD); </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) the words &#147;herein&#148; &#147;hereof&#148; and &#147;hereunder,&#148; and words of
similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) the term
&#147;or&#148; shall be interpreted in the inclusive sense commonly associated with the term &#147;and/or;&#148; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) whenever this
Agreement refers to a number of days, such number shall refer to calendar days unless business days are specified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(<I>Signature page
follows</I>.) </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Agreement on and as of the day and
year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="70%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>COMPANY</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Martin W. Mackay, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INDEMNITEE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> T<SMALL>O</SMALL> I<SMALL>NDEMNIFICATION</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>10
<FILENAME>d99471dex109.htm
<DESCRIPTION>EX-10.9
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.9 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RALLYBIO HOLDINGS, LLC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2018 SHARE PLAN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NOTICE OF GRANT FOR CAPITAL INTERESTS </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Address:</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You have been granted common shares (the &#147;<B><I><U>Common Shares</U></I></B>&#148;) of Rallybio Holdings, LLC, a Delaware
limited liability company (the &#147;<B><I><U>Company</U></I></B>&#148;), subject to the terms and conditions of the Company&#146;s 2018 Share Plan and the attached Restricted Share Agreement (the &#147;<B><I><U>Share Agreement</U></I></B>&#148;),
as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Date of Grant:&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Total Number of Shares:&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Purchase Price: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Common Shares shall be
&#147;capital interests&#148; as such term is defined in the Code and Treasury Regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Vesting Schedule: </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Common Shares shall vest, in whole or in part, in accordance with the following schedule: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(a) The Common Shares subject to this grant shall begin to vest in accordance with paragraph 1(b) of this
Notice of Grant below upon written confirmation from the Company&#146;s Board of Managers that the Company has initiated a clinical program through one of its controlled affiliates (the date upon which this occurs being the &#147;Trigger
Date&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b) Subject to the continuation of your Business Relationship with the Company on such dates, 1/4 of the
Common Shares subject to this grant shall vest on the one year anniversary of the Trigger Date and an additional 1/48 of the Common Shares subject to this grant shall vest after each calendar month after the one year anniversary of the Trigger Date,
so that all of the Common Shares subject to this grant shall be fully vested on the four year anniversary of the Trigger Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of calculating
the number of Common Shares that become vested as set forth above, the number of vested Common Shares shall be rounded down to the nearest full share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
order to accept this grant, you must execute the attached Restricted Share Agreement and return a copy of your signature page to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. If you have any
questions, please contact &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; at &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capitalized but otherwise undefined terms in this Notice of Grant and the attached Restricted Share Agreement shall have the same defined meanings as in the
Company&#146;s 2018 Share Plan. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RALLYBIO HOLDINGS, LLC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>RESTRICTED SHARE AGREEMENT </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
<B>RESTRICTED SHARE AGREEMENT </B>(this &#147;<B><I><U>Agreement</U></I></B>&#148;) dated as of the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; day of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; between Rallybio Holdings, LLC, a Delaware limited liability company (the
&#147;<B><I><U>Company</U></I></B>&#148;), and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (the &#147;<B><I><U>Recipient</U></I></B>&#148;) relating to common shares of the
Company (&#147;<B><I><U>Common Shares</U></I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, pursuant to the Company&#146;s 2018 Share Plan (the
&#147;<B><I><U>Plan</U></I></B>&#148;), the Company approved the issuance to the Recipient, effective as of the date set forth above,
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common Shares (the &#147;<B><I><U>Shares</U></I></B>&#148;), upon the terms and conditions hereinafter set forth. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW</B>, <B>THEREFORE</B>, in consideration of the premises and the mutual covenants herein contained and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Recipient hereby agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Issuance
of Shares </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 <U>Defined Terms</U>. Capitalized but otherwise undefined terms in this Agreement shall have the same defined
meanings as in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 <U>Agreement to Issue Shares</U>. The Company hereby agrees to issue the Shares to the Recipient. The
Company and the Recipient agree that, unless otherwise specified in Section&nbsp;2.1, the Shares shall initially be deemed &#147;Unvested Common Shares&#148; within the meaning of Section&nbsp;3.2 of the Plan and shall initially be subject to all of
the restrictions set forth herein and therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 <U>Operating Agreement</U>. By execution of this Agreement, the Recipient agrees to
become bound by the terms and conditions of the Operating Agreement of the Company, dated as of April&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2018, as amended, modified or supplemented from time to time (the &#147;<B><I><U>Operating
Agreement</U></I></B>&#148;), as a member thereunder, and agrees that the Shares shall be bound by all of the terms and conditions of the Operating Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Lapse of
Restrictions </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Lapse</U>. All of the Shares shall be subject to the restrictions set forth in Article III and shall be
&#147;Restricted Shares&#148; on the date hereof. Shares shall vest and become &#147;Unrestricted Shares&#148; in accordance with the schedule set forth in the Notice of Grant. No further action on behalf of the Company or the Recipient shall be
required to convert the Restricted Shares into Unrestricted Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Delivery of Unrestricted Shares</U>. Promptly following receipt
of a written request from the Recipient, the Company shall deliver to the Recipient a certificate for the whole number of Unrestricted Shares with respect to which the restrictions have lapsed. Such Unrestricted Shares shall be free of all such
restrictions, except any that may be imposed by law, including without limitation securities laws, on the Recipient or the Recipient&#146;s beneficiary or estate, as the case may be. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Acceleration of Vesting</U>. Upon the occurrence of a Change of Control, all
Restricted Shares not yet vested shall vest and become Unrestricted Shares; provided, however, all proceeds to be received in connection with such Change of Control related to the Recipient&#146;s Restricted Shares (as determined immediately prior
to such Change of Control) will be held in a third party escrow account (the &#147;<B><I><U>Escrow Funds</U></I></B>&#148;) to be released to the Recipient on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the Change of Control
(the &#147;<B><I><U>Anniversary Date</U></I></B>&#148;) so long as the Recipient&#146;s Business Relationship with the Company or its successor has not been terminated prior to the Anniversary Date for Cause (as defined in that certain Employment
Agreement by and between the Recipient and the Company dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, as the same may be amended from time to time (the &#147;<B><I><U>Employment Agreement</U></I></B>&#148;)) by the Company or its successor
or by the Recipient without Good Reason (as defined in the Employment Agreement); and provided, further, the Escrow Funds will be released immediately to the Recipient in the event the Recipient&#146;s Business Relationship is terminated prior to
the Anniversary Date by the Company or its successor without Cause or by the Recipient for Good Reason. Otherwise, unless accelerated in the sole discretion of the Board of Managers of the Company, the Shares shall vest and become Unrestricted
Shares only as set out in <U>Section</U><U></U><U>&nbsp;2.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <U>End of Vesting</U>. No further Restricted Shares shall become
Unrestricted Shares, and all rights of the Recipient to such Restricted Shares shall terminate without further obligation on the part of the Company, after the date the Recipient&#146;s Business Relationship with the Company is terminated or the
date the Recipient fails to satisfy any other conditions prescribed by the Board of Managers of the Company applicable to such Restricted Shares. Upon any such termination of the Recipient&#146;s rights with respect to Restricted Shares, such
Restricted Shares shall be transferred to the Company in accordance with the Plan without further action by the Recipient. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5 <U>Change
of Position</U>. Anything in this Agreement to the contrary notwithstanding, the Shares shall not be affected by any change of duties or position of the Recipient (including a transfer to or from the Company, its parent or any of its affiliates), so
long as the Recipient continues in a Business Relationship with the Company, its parent or any of its affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6 <U>No Evidence of
Employment or Service</U>. Nothing contained in the Plan or this Agreement shall confer upon the Recipient any right to continue in a Business Relationship with the Company, its parent or any of its affiliates or interfere in any way with the right
of the Company, its parent or its affiliates (subject to the terms of any separate agreement to the contrary) to terminate the Recipient&#146;s Business Relationship with the Company or to increase or decrease the Recipient&#146;s compensation at
any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7 <U>Section 83(b) Election</U>. Upon execution of this Agreement, the Recipient may file an election under Section&nbsp;83
of the Code, in substantially the form attached hereto as <U>Exhibit A</U>. The Recipient acknowledges that if he or she does not file such an election within 30 days of the date of this Agreement, as the Restricted Shares become Unrestricted Shares
in accordance with this Agreement, the Recipient will have income for tax purposes equal to the fair market value of such Shares at such date, less the price paid for such Shares by the Recipient. The Recipient acknowledges that he or she is not
relying on the Company for any tax advice and has obtained such guidance or counsel as the Recipient has deemed necessary in order to determine whether to make such an election. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Restriction on Transfer </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Restricted Shares</U>. Neither the Restricted Shares nor any interest therein may be Transferred until such Restricted Shares vest and
become Unrestricted Shares in accordance with Section&nbsp;2.1 and the satisfaction of any other conditions prescribed by the Board of Managers of the Company relating to such Restricted Shares. The Company shall not be required to Transfer any
Restricted Shares on its books which shall have been Transferred in violation of this Section&nbsp;3.1, or to treat as the owner of such Restricted Shares, or to accord the right to vote as such owner or to pay distributions to, any person or
organization to which any such Restricted Shares shall have been so Transferred in violation of this Section&nbsp;3.1. Notwithstanding the foregoing, unless otherwise restricted by the Operating Agreement or the Plan, the Recipient may Transfer any
or all of the Recipient&#146;s Restricted Shares (i)&nbsp;for bona fide estate planning purposes, either during the Recipient&#146;s lifetime or on death of the Recipient by will or intestacy to the Recipient&#146;s family members, or any other
person approved by the Board of Managers of the Company, or any custodian or trustee of any trust, partnership or limited liability company for the benefit of, or the ownership interests of which are owned wholly by, the Recipient or any such family
members, or (ii)&nbsp;to a trust, so long as the trust is for the benefit of a nonprofit organization and the Recipient is a trustee, in the case of both clauses (i)&nbsp;and (ii); provided that (a)&nbsp;the Recipient (or the Recipient&#146;s
representative in the case of death) shall deliver prior written notice to the Company of such Transfer, (b)&nbsp;such Restricted Shares shall at all times remain subject to the terms and restrictions set forth in this Agreement, (c) such transferee
shall, as a condition to such Transfer, agree to be bound by all the terms and conditions of the Plan and the Operating Agreement (but only with respect to such Restricted Shares) and (d)&nbsp;such Transfer is made pursuant to a transaction in which
there is no consideration actually paid for such Transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Unrestricted Shares</U>. Subject to Article IV, all Unrestricted Shares
shall be Transferable free of all restrictions except any that may be imposed by the Plan, the Operating Agreement or by law including without limitation securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3 <U>Transferees</U>. Notwithstanding the foregoing, Restricted Shares shall continue to be Restricted Shares in the hands of any holder
other than the Recipient (except for the Company), and except as otherwise provided herein, each such other holder of Restricted Shares shall succeed to all rights and obligations attributable to the Recipient as a holder of Restricted Shares
hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4 <U>&#147;Market <FONT STYLE="white-space:nowrap">Standoff-Off&#148;</FONT> Agreement.</U> The Recipient shall be subject
to the &#147;market <FONT STYLE="white-space:nowrap">stand-off&#148;</FONT> agreement as set forth in the Plan. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Right of First Refusal and Forfeiture </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Scope</U>. The Shares shall be subject to a right (but not an obligation) of first refusal by the Company or its assignee, and also
shall be subject to forfeiture, as set forth in, and subject to the terms and conditions of, the Plan and the Operating Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2
<U>Termination of Rights as Member</U>. The Recipient shall cease to have any rights with respect to Shares (a)&nbsp;repurchased by the Company or its assignee in accordance with the Plan immediately upon receipt of the applicable purchase price for
such Shares as specified in the Plan or (b)&nbsp;forfeited by the Recipient in accordance with the Plan. If the Recipient becomes obligated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to sell any Shares to the Company or its assignee pursuant to the Plan and fails to deliver such Shares in accordance with the Plan, the Company or its assignee, as the case may be, may, at its
option, in addition to all other remedies it may have, send to the holder the applicable purchase price for such Shares as set forth in the Plan. Upon any such repurchase or forfeiture, the Company shall cancel on its books any certificate(s)
representing such Shares. Notwithstanding anything to the contrary herein or in the Share Plan, Shares that have vested and become Unrestricted Shares pursuant to the terms of this Agreement shall not be subject to repurchase by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 <U>Custody of Share Certificates</U>. As security for the Recipient&#146;s faithful performance of the terms of this Agreement and to
ensure that the Restricted Shares will be available for delivery in accordance with Section&nbsp;2.4, upon issuance, the certificates, if any, for the Restricted Shares shall be held in custody by the Company (or its agent) until the Restricted
Shares become Unrestricted Shares in accordance with Article II. If applicable, any substitute securities issued to the Recipient due to an adjustment described in Article V shall also be delivered and held in custody by the Company (or its agent)
in accordance with this Section&nbsp;4.3. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Adjustments </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1
<U>General</U>. The Plan contains provisions covering the treatment of the Shares in a number of contingencies such as share splits and mergers. Provisions in the Plan for adjustment with respect to the Shares and the related provisions with respect
to successors to the business of the Company are hereby made applicable hereunder and are incorporated herein by reference. In general, the Recipient should not assume that Restricted Shares would vest and become Unrestricted Shares upon a Change of
Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Recapitalization and Related Transactions</U>. If, through or as a result of any recapitalization, reclassification,
share dividend, share split, reverse share split, liquidation, exchange of shares, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination, consolidation, conversion of the Company into a corporation or other similar transaction, (a)&nbsp;the
outstanding Common Shares are increased, decreased or exchanged for a different number or kind of shares or other securities of the Company or (b)&nbsp;additional shares or new or different shares or other
<FONT STYLE="white-space:nowrap">non-cash</FONT> assets are distributed with respect to such Common Shares or other securities, such different or distributed shares, securities or assets shall be subject to the provisions of this Agreement that are
applicable to the Shares with respect to which such shares, securities or assets were distributed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <U>Reorganization, Merger and
Related Transactions</U>. If the Company shall be the surviving company in any reorganization, merger or consolidation of the Company with one or more other entities, the provisions of this Agreement shall pertain to and apply to the securities,
cash and any other assets to which the Recipient is entitled in respect of the Shares immediately following such reorganization, merger or consolidation in the same manner as such provisions apply to the Shares with respect to which such securities,
cash or other assets relate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Miscellaneous </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1
<U>Notices</U>. All notices or other communications which are required or permitted hereunder shall be in writing and sufficient if (a)&nbsp;personally delivered or sent by telefax or other electronic mail, (b)&nbsp;sent by nationally-recognized
overnight courier or (c)&nbsp;sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">if to
the Recipient, to the address set forth in the Notice of Grant to which this Agreement is attached. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">if to the Company, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Rallybio Holdings, LLC </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Email: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as the party to whom notice is to be given may have furnished to the other party in writing in accordance herewith. Any such
communication shall be deemed to have been given (x)&nbsp;when delivered, if personally delivered or delivered by telefax or other electronic mail, (y) on the first Business Day (as hereinafter defined) after dispatch, if sent by nationally-
recognized overnight courier and (z)&nbsp;on the third Business Day following the date on which the piece of mail containing such communication is posted, if sent by mail. As used herein, &#147;Business Day&#148; means a day that is not a Saturday,
Sunday or a day on which banking institutions in the city to which the notice or communication is to be sent are not required to be open. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 <U>Third Party Beneficiaries</U>. Nothing herein expressed or implied is intended or shall be construed to confer upon or give to any
person or entity, other than the parties to this Agreement and their respective permitted successors and assigns, any rights or remedies under or by reason of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3 <U>Successors and Assigns</U>. This Agreement may not be assigned by either party without the prior written consent of the other party.
This Agreement is intended to bind and inure to the benefit of and be enforceable by the Recipient and the Company and their respective successors and assigns (including subsequent holders of the Shares). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4 <U>Consent of Spouse</U>. If the Recipient is married as of the date of this Agreement, the Recipient shall cause the Recipient&#146;s
spouse to acknowledge and consent to the existence and binding effect of all restrictions contained in this Agreement by such spouse&#146;s executing and delivering a Consent of Spouse in the form of <U>Exhibit B</U> hereto, effective as of the date
hereof. Such consent shall not be deemed to confer or convey to the spouse any rights in the Shares that do not otherwise exist by operation of law or the agreement of the parties. If the Recipient marries or remarries subsequent to the date hereof
and the restrictions set forth in this Agreement remain applicable to all or a portion of the Shares, the Recipient shall, not later than 60 days thereafter, obtain the Recipient&#146;s new spouse&#146;s acknowledgment of and consent to the
existence and binding effect of all restrictions contained in this Agreement by such spouse&#146;s executing and delivering a Consent of Spouse in the form of <U>Exhibit B</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.5 <U>Severability</U>. In the event one or more of the provisions of this Agreement should, for any reason, be held to be invalid, illegal
or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been
contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.6 <U>Entire Agreement</U>. This Agreement (including the Exhibits hereto), the Plan and the Operating Agreement
constitute the entire agreement between the parties with respect to the subject matter hereof and supersede all previously written or oral negotiations, commitments, representations and agreements with respect thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.7 <U>Counterparts; Electronic Execution</U>. This Agreement may be executed in
counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument. Facsimile or other electronic execution and delivery of this Agreement shall be legal, valid and binding execution
and delivery for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.8 <U>Remedies</U>. The Recipient and the Company agree and acknowledge that money damages shall not be
an adequate remedy for any breach of the provisions of this Agreement and that the Company shall be entitled to specific performance and injunctive relief in order to enforce or prevent any violations of the provisions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.9 <U>Amendments and Waivers</U>. Any provision of this Agreement may be amended or waived only with the prior written consent of the Company
and the Recipient. No waiver of any breach or condition of this Agreement shall be deemed to be a waiver of any other or subsequent breach or condition, whether of like or different nature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.10 <U>Modification of Rights</U>. The rights of the Recipient are subject to modification and termination in certain events as provided in
this Agreement and the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.11 <U>Recipient Undertaking</U>. The Recipient hereby agrees to take whatever additional actions and
execute whatever additional documents the Company may in its reasonable judgment deem necessary or advisable in order to carry out or effect one or more of the obligations or restrictions imposed on the Recipient pursuant to the express provisions
of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.12 <U>Governing Law</U>. This Agreement shall be governed by and construed in accordance with the laws of the State
of Delaware without regard to its conflicts of law principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.13 <U>Headings</U>. The captions set forth in this Agreement are for
convenience only and shall not be considered as part of this Agreement or as in any way limiting the terms and provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.14
<U>WAIVER OF JURY TRIAL</U>. THE RECIPIENT HEREBY EXPRESSLY, IRREVOCABLY AND UNCONDITIONALLY WAIVES TRIAL BY JURY IN ANY LEGAL ACTION OR PROCEEDING RELATING TO THIS AGREEMENT AND FOR ANY COUNTERCLAIM THEREIN. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.15 <U>Legends</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
Securities Laws. All certificates representing the Shares and, until such time as the Shares are sold in an offering which is registered under the Securities Act of 1933, as amended, and any applicable state securities law or unless an exemption
from such registration is available and the Company shall have received, at the expense of the Recipient, evidence of such exemption reasonably satisfactory to the Company (which may include, among other things, an opinion of counsel satisfactory in
form and content to the Company that such registration is not required in connection with a resale (or subsequent resale) of the Shares), all certificates issued in Transfer thereof or substitution therefor, shall, where applicable, have endorsed
thereon a legend substantially in the form set forth in Section&nbsp;6.15(a) of the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Restrictions</U>. Until the rights of first refusal referred to in Section&nbsp;4.1
have terminated, all certificates representing the Shares shall have endorsed thereon a legend substantially in the form set forth in Section&nbsp;6.15(b) of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[signature page follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have executed this Agreement as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Rallybio Holdings, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Recipient:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>11
<FILENAME>d99471dex1010.htm
<DESCRIPTION>EX-10.10
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.10</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.10 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RALLYBIO HOLDINGS, LLC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2018 SHARE PLAN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NOTICE OF GRANT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp; Address: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You have been granted common shares (the &#147;<B><I><U>Common Shares</U></I></B>&#148;) of Rallybio Holdings, LLC,
a Delaware limited liability company (the &#147;<B><I><U>Company</U></I></B>&#148;), subject to the terms and conditions of the Company&#146;s 2018 Share Plan and the attached Restricted Share Agreement (the &#147;<B><I><U>Share
Agreement</U></I></B>&#148;), as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Date of Grant: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Vesting Commencement Date: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Vesting Completion Date: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total
Number of Shares Granted: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Common Shares issued pursuant to this Notice of Grant shall constitute an interest in the future income and
losses and appreciation of the Company and shall not entitle the holder thereof to any portion of the value or capital accounts of the Company immediately prior to the issuance of the Common Shares. The Common Shares shall be &#147;profits
interests&#148; and not &#147;capital interests&#148; as such terms are defined in the Code and Treasury Regulations promulgated thereunder, and the issuance of the Common Shares shall be interpreted consistently with such intent. Accordingly, upon
a sale of the Company and the distribution of any proceeds thereafter, the Common Shares issued pursuant to this Notice of Grant shall not participate in any such distribution until the proceeds of such sale exceed the fair market value of the
Company as of the date of this Notice of Grant, such that the holder only participates in appreciation in the value of the Company from the date of receipt forward. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Vesting Schedule: </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Common Shares
shall vest, in whole or in part, in accordance with the following schedule: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the continuation of your Business Relationship with
the Company on such dates, twenty five percent of the Common Shares subject to this grant shall vest on the <FONT STYLE="white-space:nowrap">one-</FONT> year anniversary of the Vesting Commencement Date and an additional 1/48 of the Common Shares
subject to this grant shall vest after each calendar month after the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the Vesting Commencement Date, so that all of the Common Shares subject to this grant shall be fully vested on the
Vesting Completion Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of calculating the number of Common Shares that become vested as set forth above, the number of
vested Common Shares shall be rounded down to the nearest full share. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to accept this grant, you must execute the attached Restricted Share Agreement and
return a copy of your signature page to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. If you have any questions, please
contact&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;at&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized but otherwise undefined terms in this Notice of Grant and the attached Restricted Share Agreement shall have the same defined
meanings as in the Company&#146;s 2018 Share Plan. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RALLYBIO HOLDINGS, LLC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>RESTRICTED SHARE AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>RESTRICTED SHARE AGREEMENT </B>(this &#147;<B><I>Agreement</I></B>&#148;) dated as of
the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;day of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;between Rallybio Holdings, LLC, a Delaware
limited liability company (the &#147;<B><I><U>Company</U></I></B>&#148;), and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (the &#147;<B><I><U>Recipient</U></I></B>&#148;) relating to common shares
of the Company (&#147;<B><I><U>Common Shares</U></I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, pursuant to the Company&#146;s 2018 Share Plan, as
amended, modified or supplemented from time to time (the &#147;<B><I><U>Plan</U></I></B>&#148;), the Company approved the issuance to the Recipient, effective as of the date set forth above,
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common Shares (the &#147;<B><I><U>Shares</U></I></B>&#148;), upon the terms and conditions hereinafter set forth. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW</B>, <B>THEREFORE</B>, in consideration of the premises and the mutual covenants herein contained and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Recipient hereby agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Issuance
of Shares </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 <U>Defined Terms</U>. Capitalized but otherwise undefined terms in this Agreement shall have the same defined
meanings as in the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 <U>Agreement to Issue Shares</U>. The Company hereby agrees to issue the Shares to the Recipient. The Company
and the Recipient agree that, unless otherwise specified in Section&nbsp;2.1, the Shares shall initially be deemed &#147;Unvested Common Shares&#148; within the meaning of Section&nbsp;3.2 of the Plan and shall initially be subject to all of the
restrictions set forth herein and therein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 <U>Operating Agreement</U>. By execution of this Agreement, the Recipient agrees to become
bound by the terms and conditions of the Second Amended and Restated Operating Agreement of the Company, dated as of March&nbsp;27, 2020, as amended, modified or supplemented from time to time (the &#147;<B><I><U>Operating
Agreement</U></I></B>&#148;), as a member thereunder, and agrees that the Shares shall be bound by all of the terms and conditions of the Operating Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Lapse of
Restrictions </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Lapse</U>. All of the Shares shall be subject to the restrictions set forth in Article III and shall be
&#147;Restricted Shares&#148; on the date hereof. Twenty-five percent of the Shares shall not be subject to the restrictions set forth in Article III and shall become &#147;Unrestricted Shares&#148; on the
<FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the Vesting Commencement Date and an additional 1/48 of the Shares shall vest and become &#147;Unrestricted Shares&#148; after each calendar month after the <FONT
STYLE="white-space:nowrap">one-year</FONT> anniversary of the Vesting Commencement Date so that all of the Shares shall be fully vested and become Unrestricted Shares on the four-year anniversary of the Vesting Commencement Date. For purposes of
calculating the number of Restricted Shares that become Unrestricted Shares as set forth above, the number of Unrestricted Shares shall be rounded down to the nearest full share. No further action on behalf of the Company or the Recipient shall be
required to convert the Restricted Shares into Unrestricted Shares. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Delivery of Unrestricted Shares</U>. Promptly following receipt of a written request
from the Recipient, the Company shall deliver to the Recipient a certificate for the whole number of Unrestricted Shares with respect to which the restrictions have lapsed. Such Unrestricted Shares shall be free of all such restrictions, except any
that may be imposed by law, including without limitation securities laws, on the Recipient or the Recipient&#146;s beneficiary or estate, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Acceleration of Vesting</U>. Unless accelerated in the discretion of the Board of Managers of the Company or as otherwise provided in
the Notice of Grant or in the Plan, the Shares shall vest and become Unrestricted Shares only as set out in Section&nbsp;2.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <U>End
of Vesting</U>. No further Restricted Shares shall become Unrestricted Shares, and all rights of the Recipient to such Restricted Shares shall terminate without further obligation on the part of the Company, after the date the Recipient&#146;s
Business Relationship with the Company is terminated or the date the Recipient fails to satisfy any other conditions prescribed by the Board of Managers of the Company applicable to such Restricted Shares. Upon any such termination of the
Recipient&#146;s rights with respect to Restricted Shares, such Restricted Shares shall be transferred to the Company in accordance with the Plan without further action by the Recipient. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5 <U>Change of Position</U>. Anything in this Agreement to the contrary notwithstanding, the Shares shall not be affected by any change of
duties or position of the Recipient (including a transfer to or from the Company, its parent or any of its affiliates), so long as the Recipient continues in a Business Relationship with the Company, its parent or any of its affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6 <U>No Evidence of Employment or Service</U>. Nothing contained in the Plan or this Agreement shall confer upon the Recipient any right to
continue in a Business Relationship with the Company, its parent or any of its affiliates or interfere in any way with the right of the Company, its parent or its affiliates (subject to the terms of any separate agreement to the contrary) to
terminate the Recipient&#146;s Business Relationship with the Company or to increase or decrease the Recipient&#146;s compensation at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7 <U>Section 83(b) Election</U>. Upon execution of this Agreement, the Recipient may file an election under Section&nbsp;83 of the Code, in
substantially the form attached hereto as <U>Exhibit A</U>. The Recipient acknowledges that if he or she does not file such an election within 30 days of the date of this Agreement, as the Restricted Shares become Unrestricted Shares in accordance
with this Agreement, the Recipient will have income for tax purposes equal to the fair market value of such Shares at such date, less the price paid for such Shares by the Recipient. The Recipient acknowledges that he or she is not relying on the
Company for any tax advice and has obtained such guidance or counsel as the Recipient has deemed necessary in order to determine whether to make such an election. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Restriction on Transfer </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Restricted Shares</U>. Neither the Restricted Shares nor any interest therein may be Transferred until such Restricted Shares vest and
become Unrestricted Shares in accordance with Section&nbsp;2.1 and the satisfaction of any other conditions prescribed by the Board of Managers of the Company relating to such Restricted Shares. The Company shall not be required to Transfer any
Restricted Shares on its books which shall have been Transferred in violation of this Section&nbsp;3.1, or to treat as the owner of such Restricted Shares, or to accord the right to vote as such owner or to pay distributions to, any person or
organization to which any such Restricted Shares shall have been so Transferred in violation of this Section&nbsp;3.1. Notwithstanding the foregoing, unless otherwise restricted by the Operating Agreement or the Plan, the Recipient may Transfer any
or all of the Recipient&#146;s Restricted Shares for bona fide estate planning purposes, either during the Recipient&#146;s lifetime or on death of the Recipient by will or intestacy to the Recipient&#146;s family members, or any other person
approved by the Board of Managers of the Company, or any custodian or trustee of any trust, partnership or limited liability company for the benefit of, or the ownership interests of which are owned wholly by, the Recipient or any such family
members; provided that (a)&nbsp;the Recipient (or the Recipient&#146;s representative in the case of death) shall deliver prior written notice to the Company of such Transfer, (b)&nbsp;such Restricted Shares shall at all times remain subject to the
terms and restrictions set forth in this Agreement, (c)&nbsp;such transferee shall, as a condition to such Transfer, agree to be bound by all the terms and conditions of the Plan and the Operating Agreement (but only with respect to such Restricted
Shares) and (d)&nbsp;such Transfer is made pursuant to a transaction in which there is no consideration actually paid for such Transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Unrestricted Shares</U>. Subject to Article IV, all Unrestricted Shares shall be Transferable free of all restrictions except any that
may be imposed by the Plan, the Operating Agreement or by law including without limitation securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3 <U>Transferees</U>.
Notwithstanding the foregoing, Restricted Shares shall continue to be Restricted Shares in the hands of any holder other than the Recipient (except for the Company), and except as otherwise provided herein, each such other holder of Restricted
Shares shall succeed to all rights and obligations attributable to the Recipient as a holder of Restricted Shares hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4
<U>&#147;Market <FONT STYLE="white-space:nowrap">Standoff-Off&#148;</FONT> Agreement.</U> The Recipient shall be subject to the &#147;market <FONT STYLE="white-space:nowrap">stand-off&#148;</FONT> agreement as set forth in the Plan. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Right of
First Refusal and Forfeiture </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Scope</U>. The Shares shall be subject to a right (but not an obligation) of first refusal by
the Company or its assignee, and also shall be subject to forfeiture, as set forth in, and subject to the terms and conditions of, the Plan and the Operating Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Termination of Rights as Member</U>. The Recipient shall cease to have any rights with respect to Shares (a)&nbsp;repurchased by the
Company or its assignee in accordance with the Plan immediately upon receipt of the applicable purchase price for such Shares as specified in the Plan or (b)&nbsp;forfeited by the Recipient in accordance with the Plan. If the Recipient becomes
obligated to sell any Shares to the Company or its assignee pursuant to the Plan and fails to deliver such Shares in accordance with the Plan, the Company or its assignee, as the case may be, may, at its option, in addition to all other remedies it
may have, send to the holder the applicable purchase price for such Shares as set forth in the Plan. Upon any such repurchase or forfeiture, the Company shall cancel on its books any certificate(s) representing such Shares. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 <U>Custody of Share Certificates</U>. As security for the Recipient&#146;s faithful
performance of the terms of this Agreement and to ensure that the Restricted Shares will be available for delivery in accordance with Section&nbsp;2.4, upon issuance, the certificates, if any, for the Restricted Shares shall be held in custody by
the Company (or its agent) until the Restricted Shares become Unrestricted Shares in accordance with Article II. If applicable, any substitute securities issued to the Recipient due to an adjustment described in Article V shall also be delivered and
held in custody by the Company (or its agent) in accordance with this Section&nbsp;4.3. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Adjustments </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1
<U>General</U>. The Plan contains provisions covering the treatment of the Shares in a number of contingencies such as share splits and mergers. Provisions in the Plan for adjustment with respect to the Shares and the related provisions with respect
to successors to the business of the Company are hereby made applicable hereunder and are incorporated herein by reference. In general, the Recipient should not assume that Restricted Shares would vest and become Unrestricted Shares upon a Change of
Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Recapitalization and Related Transactions</U>. If, through or as a result of any recapitalization, reclassification,
share dividend, share split, reverse share split, liquidation, exchange of shares, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination, consolidation, conversion of the Company into a corporation or other similar transaction, (a)&nbsp;the
outstanding Common Shares are increased, decreased or exchanged for a different number or kind of shares or other securities of the Company or (b)&nbsp;additional shares or new or different shares or other
<FONT STYLE="white-space:nowrap">non-cash</FONT> assets are distributed with respect to such Common Shares or other securities, such different or distributed shares, securities or assets shall be subject to the provisions of this Agreement that are
applicable to the Shares with respect to which such shares, securities or assets were distributed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <U>Reorganization, Merger and
Related Transactions</U>. If the Company shall be the surviving company in any reorganization, merger or consolidation of the Company with one or more other entities, the provisions of this Agreement shall pertain to and apply to the securities,
cash and any other assets to which the Recipient is entitled in respect of the Shares immediately following such reorganization, merger or consolidation in the same manner as such provisions apply to the Shares with respect to which such securities,
cash or other assets relate. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Miscellaneous </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1
<U>Notices</U>. All notices or other communications which are required or permitted hereunder shall be in writing and sufficient if (a)&nbsp;personally delivered or sent by telefax or other electronic mail, (b)&nbsp;sent by nationally-recognized
overnight courier or (c)&nbsp;sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">if to
the Recipient, to the address set forth in the Notice of Grant to which this Agreement is attached. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">if to the Company, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Rallybio Holdings, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">234
Church Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Suite 1020 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New Haven, CT 06510 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention:
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as the
party to whom notice is to be given may have furnished to the other party in writing in accordance herewith. Any such communication shall be deemed to have been given (x)&nbsp;when delivered, if personally delivered or delivered by telefax or other
electronic mail, (y) on the first Business Day (as hereinafter defined) after dispatch, if sent by nationally- recognized overnight courier and (z)&nbsp;on the third Business Day following the date on which the piece of mail containing such
communication is posted, if sent by mail. As used herein, &#147;Business Day&#148; means a day that is not a Saturday, Sunday or a day on which banking institutions in the city to which the notice or communication is to be sent are not required to
be open. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 <U>Third Party Beneficiaries</U>. Nothing herein expressed or implied is intended or shall be construed to confer upon or
give to any person or entity, other than the parties to this Agreement and their respective permitted successors and assigns, any rights or remedies under or by reason of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3 <U>Successors and Assigns</U>. This Agreement may not be assigned by either party without the prior written consent of the other party.
This Agreement is intended to bind and inure to the benefit of and be enforceable by the Recipient and the Company and their respective successors and assigns (including subsequent holders of the Shares). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4 <U>Consent of Spouse</U>. If the Recipient is married as of the date of this Agreement, the Recipient shall cause the Recipient&#146;s
spouse to acknowledge and consent to the existence and binding effect of all restrictions contained in this Agreement by such spouse&#146;s executing and delivering a Consent of Spouse in the form of <U>Exhibit B</U> hereto, effective as of the date
hereof. Such consent shall not be deemed to confer or convey to the spouse any rights in the Shares that do not otherwise exist by operation of law or the agreement of the parties. If the Recipient marries or remarries subsequent to the date hereof
and the restrictions set forth in this Agreement remain applicable to all or a portion of the Shares, the Recipient shall, not later than 60 days thereafter, obtain the Recipient&#146;s new spouse&#146;s acknowledgment of and consent to the
existence and binding effect of all restrictions contained in this Agreement by such spouse&#146;s executing and delivering a Consent of Spouse in the form of <U>Exhibit B</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.5 <U>Severability</U>. In the event one or more of the provisions of this Agreement should, for any reason, be held to be invalid, illegal
or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been
contained herein. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.6 <U>Entire Agreement</U>. This Agreement (including the Exhibits hereto), the Plan and
the Operating Agreement constitute the entire agreement between the parties with respect to the subject matter hereof and supersede all previously written or oral negotiations, commitments, representations and agreements with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.7 <U>Counterparts; Electronic Execution</U>. This Agreement may be executed in counterparts, each of which shall be deemed to be an
original, but all of which together shall constitute one and the same instrument. Facsimile or other electronic execution and delivery of this Agreement shall be legal, valid and binding execution and delivery for all purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.8 <U>Remedies</U>. The Recipient and the Company agree and acknowledge that money damages shall not be an adequate remedy for any breach of
the provisions of this Agreement and that the Company shall be entitled to specific performance and injunctive relief in order to enforce or prevent any violations of the provisions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.9 <U>Amendments and Waivers</U>. Any provision of this Agreement may be amended or waived only with the prior written consent of the Company
and the Recipient. No waiver of any breach or condition of this Agreement shall be deemed to be a waiver of any other or subsequent breach or condition, whether of like or different nature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.10 <U>Modification of Rights</U>. The rights of the Recipient are subject to modification and termination in certain events as provided in
this Agreement and the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.11 <U>Recipient Undertaking</U>. The Recipient hereby agrees to take whatever additional actions and
execute whatever additional documents the Company may in its reasonable judgment deem necessary or advisable in order to carry out or effect one or more of the obligations or restrictions imposed on the Recipient pursuant to the express provisions
of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.12 <U>Governing Law</U>. This Agreement shall be governed by and construed in accordance with the laws of the State
of Delaware without regard to its conflicts of law principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.13 <U>Headings</U>. The captions set forth in this Agreement are for
convenience only and shall not be considered as part of this Agreement or as in any way limiting the terms and provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.14
<U>WAIVER OF JURY TRIAL</U>. THE RECIPIENT HEREBY EXPRESSLY, IRREVOCABLY AND UNCONDITIONALLY WAIVES TRIAL BY JURY IN ANY LEGAL ACTION OR PROCEEDING RELATING TO THIS AGREEMENT AND FOR ANY COUNTERCLAIM THEREIN. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.15 <U>Legends</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>Securities Laws</U>. All certificates representing the Shares and, until such time as the Shares are sold in an offering which is registered under the Securities Act of 1933, as amended, and any applicable state securities law or unless an
exemption from such registration is available and the Company shall have received, at the expense of the Recipient, evidence of such exemption reasonably satisfactory to the Company (which may include, among other things, an opinion of counsel
satisfactory in form and content to the Company that such registration is not required in connection with a resale (or subsequent resale) of the Shares), all certificates issued in Transfer thereof or substitution therefor, shall, where applicable,
have endorsed thereon a legend substantially in the form set forth in Section&nbsp;6.15(a) of the Plan. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Restrictions</U>. Until the rights of first refusal referred to in Section&nbsp;4.1
have terminated, all certificates representing the Shares shall have endorsed thereon a legend substantially in the form set forth in Section&nbsp;6.15(b) of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[signature page follows] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have executed this Agreement as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Rallybio Holdings, LLC</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recipient:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address:</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>12
<FILENAME>d99471dex1011.htm
<DESCRIPTION>EX-10.11
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.11</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.11 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RALLYBIO HOLDINGS, LLC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONTRIBUTION AND RESTRICTED SHARE AGREEMENT</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This<B> CONTRIBUTION AND RESTRICTED SHARE AGREEMENT</B> (this &#147;<U>Agreement</U>&#148;), effective (the &#147;<U>Effective
Date</U>&#148;), is entered into by and between Rallybio Holdings, LLC, a Delaware limited liability company (the &#147;<U>Company</U>&#148;), and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(the
&#147;<U>Recipient</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Recipient
owns&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common Shares (the &#147;<U>Sub</U> <U>Shares</U>&#148;) of RallyBIO, LLC, a Delaware limited liability company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Recipient desires to assign to the Company, and the Company desires to acquire from the Recipient the Sub Shares, in
consideration for the issuance of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common Shares (the &#147;<U>Shares</U>&#148;) of the Company,
plus&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common Shares (the &#147;<U>2018</U> <U>Plan Shares</U>&#148;) of the Company pursuant to the Company&#146;s 2018 Share Plan; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Recipient and the Company desire to consummate (i)&nbsp;the sale, assignment, transfer, conveyance and delivery of the Sub
Shares to the Company, and (ii)&nbsp;the issuance of the Shares to the Recipient. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW</B>, <B>THEREFORE</B>, in consideration of the
premises and the mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Recipient hereby agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Issuance
of Shares</U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 <U>Defined Terms</U>. The following terms shall have the respective meanings. Capitalized but undefined terms in
this Agreement shall have the same defined meanings as in the Operating Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#147;<U>Business Relationship</U>&#148; shall mean
serving the Company or any of its affiliates in the capacity of an employee, officer, manager, board advisor or member of the Company&#146;s advisory board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<U>Change of Control</U>&#148; shall mean a (i) &#147;Change of Control&#148; as defined in the Operating Agreement, or (ii)
&#147;Deemed Liquidation Event&#148; as defined in the Operating Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<U>Transfer</U>&#148; shall mean any sale, pledge,
assignment, encumbrance, gift or other disposition or transfer by any person or entity of outstanding Shares or any legal or beneficial interest therein, including any tender or transfer in connection with any merger, recapitalization,
reclassification or tender or exchange offer (for all or part of the outstanding equity of the Company), whether or not the person or entity making such transfer votes for or against any transaction involving any such Transfer. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &#147;<U>Vesting Completion Date</U>&#148; shall
mean&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 <U>Ass</U><U>ignment</U>. In
exchange for the Shares, the Recipient hereby unconditionally and irrevocably transfers, assigns and sets over to the Company all of Recipient&#146;s right, title and interest in, to and under the Sub Shares, effective as of the Effective Date (the
&#147;<U>Assignment</U>&#148;) and the Company does hereby accept the Assignment. If and to the extent that the Recipient receives any proceeds from any of the Sub Shares, it shall immediately transfer the same to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 <U>Agreement to Issue and Subscribe to Shares</U>. The Recipient hereby irrevocably subscribes
for&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares of the Company, plus&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018 Plan Shares (pursuant
to the terms of that certain Restricted Share Agreement dated as of the date hereof), in exchange for the contribution from Recipient of the Sub Shares. The Company acknowledges that the Recipient has paid to the Company in full the consideration
for the Shares and the 2018 Plan Shares. The Company hereby agrees to issue the Shares and the 2018 Plan Shares to the Recipient. Recipient shall be registered on the share ledger of the Company as the record owner of the Shares and the 2018 Plan
Shares. The Company and the Recipient agree that, unless otherwise specified in <U>Section</U><U></U><U>&nbsp;2.1</U>, the Shares shall initially be deemed &#147;<U>Restricted Shares</U>&#148; and shall initially be subject to all of the
restrictions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4 <U>Tax Treatment</U>. It is the intent of the parties to this Agreement that the Assignment and
receipt of the Shares and the 2018 Plan Shares not result in the recognition of taxable income under the principles of Section&nbsp;721 of the Internal Revenue Code of 1986, as amended, and the corresponding provisions of applicable state income tax
laws, unless otherwise required by law. Further, each party hereto acknowledges and agrees that it will not take a position inconsistent with such treatment on any tax return filed by such party, unless otherwise required by law. For purposes of
Article III of the Operating Agreement, the Recipient&#146;s total initial Capital Account for the aggregate of the Shares and the 2018 Plan Shares shall
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Notwithstanding anything to the contrary herein or in the Operating Agreement, in the event it is determined that any deductions or items of Loss are
realized by the Company during any Fiscal Year attributable to the issuance of the 2018 Plan Shares to the Recipient, the Recipient shall be specially allocated deductions or items of Loss in an amount equal to such deductions or items of Loss that
are realized by the Company attributable to the issuance of the 2018 Plan Shares but only to the extent permissible under Section&nbsp;704(b) of the Code and the Treasury Regulations promulgated thereunder, and only if such special allocation would
not be materially adverse to other Members of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5 <U>Operating Agreement</U>. The Recipient will execute and hereby agrees
to be bound by the terms and conditions of the Operating Agreement of the Company, dated as of April&nbsp;19, 2018, as amended, modified or supplemented from time to time (the &#147;<U>Operating Agreement</U>&#148;), as a member of the Company, and
agrees that the Shares shall be bound by all of the terms and conditions of the Operating Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Lapse of Restrictions</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Lapse.</U> Of the Shares, (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares are
not subject to the risk of forfeiture and the restrictions set forth in Article III and are Unrestricted Shares on the date hereof, and (b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares are
subject to the risk of forfeiture and the restrictions set forth in Article III and are Restricted Shares on the date hereof. The Restricted Shares shall vest and shall become Unrestricted Shares in four (4)&nbsp;equal yearly installments commencing
on the one year anniversary of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;so that all of the Shares shall be fully vested and become Unrestricted Shares on the Vesting Completion Date. For purposes
of calculating the number of Restricted Shares that become Unrestricted Shares as set forth above, the number of Unrestricted Shares shall be rounded down to the nearest full share. No further action on behalf of the Company or the Recipient shall
be required to convert the Restricted Shares into Unrestricted Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Delivery of Unrestricted Shares</U>. Promptly following
receipt of a written request from the Recipient, the Company shall deliver to the Recipient a certificate for the whole number of Unrestricted Shares with respect to which the restrictions have lapsed. Such Unrestricted Shares shall be free of all
such restrictions, except any that may be imposed by law, including without limitation securities laws, or the Operating Agreement, to the Recipient or the Recipient&#146;s beneficiary or estate, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Acceleration of Vesting</U>. Upon the occurrence of a Change of Control, all Restricted Shares not yet vested shall vest and become
Unrestricted Shares; provided, however, all proceeds to be received in connection with such Change of Control related to the Recipient&#146;s Restricted Shares (as determined immediately prior to such Change of Control) will be held in a third party
escrow account (the &#147;<U>Escrow Funds</U>&#148;) to be released to the Recipient on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the Change of Control (the &#147;<U>Anniversary Date</U>&#148;) so long as the
Recipient&#146;s Business Relationship with the Company or its successor has not been terminated prior to the Anniversary Date for Cause (as defined in that certain Employment Agreement by and between the Recipient and the Company
dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, as the same may be amended from time to time (the &#147;<U>Employment Agreement</U>&#148;)) by the Company or its successor or by the Recipient
without Good Reason (as defined in the Employment Agreement); and provided, further, the Escrow Funds will be released immediately to the Recipient in the event the Recipient&#146;s Business Relationship is terminated prior to the Anniversary Date
by the Company or its successor without Cause or by the Recipient for Good Reason. Otherwise, unless accelerated in the sole discretion of the Board of Managers of the Company, the Shares shall vest and become Unrestricted Shares only as set out in
<U>Section</U><U></U><U>&nbsp;2.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <U>End of Vesting</U>. No further Restricted Shares shall become Unrestricted Shares, and all
rights of the Recipient to such Restricted Shares shall terminate without further obligation on the part of the Company, after the date the Recipient&#146;s Business Relationship with the Company is terminated or the date the Recipient fails to
satisfy any other conditions prescribed by the Board of Managers of the Company applicable to such Restricted Shares. Upon any such termination or failure, such Restricted Shares shall be automatically transferred hereby to the Company without
further action by the Recipient. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5 <U>Change of Position</U>. Anything in this Agreement to the contrary notwithstanding,
the Shares shall not be affected by any change of duties or position of the Recipient (including a transfer to or from the Company, its parent or any of its affiliates), so long as the Recipient continues in a Business Relationship with the Company,
its parent, or any of its affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6 <U>No Evidence of Employment or Service</U>. Nothing contained in this Agreement shall confer
upon the Recipient any right to continue in a Business Relationship with the Company, its parent or any of its affiliates, or interfere in any way with the right of the Company, its parent or its affiliates (subject to the terms of any separate
agreement to the contrary) to terminate the Recipient&#146;s Business Relationship with the Company or to increase or decrease the Recipient&#146;s compensation at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7 <U>Shareholder Rights as to Restricted Shares</U>. Except as provided in this Agreement, the Recipient has the rights and privileges of a
member as to the Restricted Shares, including the right to vote such Restricted Shares. At the discretion of the Board of Managers, cash and equity distributions with respect to the Restricted Shares may be either currently paid or withheld by the
Company for the Recipient&#146;s account and interest may be paid on the amount of cash dividends withheld at a rate and subject to such terms as determined by the Board of Managers of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary herein, the 2018 Plan Shares shall be subject to vesting only as set forth in Notice of Grant
attached hereto as <U>Exhibit A</U>. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Restriction on Transfer</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Restricted Shares</U>. Neither the Restricted Shares, nor any interest therein, may be Transferred until such Restricted Shares vest
and become Unrestricted Shares in accordance with<U> Section</U><U></U><U>&nbsp;2.1</U> and the satisfaction of any other conditions prescribed by the Board of Managers of the Company relating to such Restricted Shares. The Company shall not be
required to Transfer any Restricted Shares on its books which shall have been Transferred in violation of this <U>Section</U><U></U><U>&nbsp;3.1</U>, or to treat as the owner of such Restricted Shares, or to accord the right to vote as such owner or
to pay distributions to, any person or organization to which any such Shares shall have been so Transferred in violation of this <U>Section</U><U></U><U>&nbsp;3.1</U>. Notwithstanding the foregoing, to the extent permitted by the Operating
Agreement, the Recipient may Transfer any or all of the Recipient&#146;s Restricted Shares (i)&nbsp;for bona fide estate planning purposes, either during the Recipient&#146;s lifetime or on death of the Recipient by will or intestacy to the
Recipient&#146;s family members, or any other person approved by the Board of Managers of the Company, or any custodian or trustee of any trust, partnership or limited liability company for the benefit of, or the ownership interests of which are
owned wholly by, the Recipient or any such family members or (ii)&nbsp;to a trust, so long as the trust is for the benefit of a nonprofit organization and the Recipient is the trustee, in the case of both clauses (i)&nbsp;and (ii), on the condition
that (A)&nbsp;the Recipient (or the Recipient&#146;s representative in the case of death) shall deliver prior written notice to the Company of such Transfer, (B)&nbsp;such Restricted Shares shall at all times remain subject to the terms and
restrictions set forth in this Agreement, (C)&nbsp;such transferee, as a condition to such Transfer, agrees to be bound by all the terms and conditions of this Agreement and the Operating Agreement (but only with respect to such Restricted Shares),
and (D)&nbsp;such Transfer is made pursuant to a transaction in which there is no consideration actually paid for such Transfer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Unrestricted Shares</U>. Subject to Article IV and any restrictions in the Operating
Agreement, all Unrestricted Shares shall be Transferable free of all restrictions except any that may be imposed by the Operating Agreement or by law, including without limitation, securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3 <U>Transferees</U>. Notwithstanding the foregoing, Restricted Shares shall continue to be Restricted Shares in the hands of any holder
other than the Recipient (except for the Company), and except as otherwise provided herein, each such other holder of Restricted Shares shall succeed to all rights and obligations attributable to the Recipient as a holder of Restricted Shares
hereunder. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Right of First Refusal and Forfeiture</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Scope</U>. The Shares shall be subject to a right (but not an obligation) of first refusal by the Company or its assignee, as set forth
in, and subject to the terms and conditions of, the Operating Agreement. The Restricted Shares shall be subject to forfeiture as set forth in, and subject to the terms and conditions of, this Agreement and the Operating Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Termination of Rights as Member</U>. The Recipient shall cease to have any rights with respect to Shares (a)&nbsp;transferred to the
Company or its assignee in accordance with this Agreement or the Operating Agreement immediately upon receipt of any applicable purchase price for such Shares as set forth in this Agreement or the Operating Agreement, or (b)&nbsp;forfeited by the
Recipient in accordance with this Agreement. If the Recipient becomes obligated to sell any Shares to the Company or its assignee pursuant to this Agreement or the Operating Agreement and fails to deliver such Shares in accordance with this
Agreement or the Operating Agreement, the Company or its assignee, as the case may be, may, at its option, in addition to all other remedies it may have, send to the holder the applicable purchase price for such Shares as set forth in this Agreement
or the Operating Agreement. Upon any such transfer or forfeiture, the Company shall cancel on its books any certificate(s) representing such Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 <U>Custody of Share Certificates</U>. As security for the Recipient&#146;s faithful performance of the terms of this Agreement and to
ensure that the Restricted Shares will be available for delivery in accordance with <U>Section</U><U></U><U>&nbsp;2.2</U>, upon issuance, the certificates, if any, for Restricted Shares shall be held in custody by the Company until the Restricted
Shares become Unrestricted Shares in accordance with Article II. If applicable, any substitute securities issued to the Recipient due to an adjustment described in Article V shall also be delivered and held in custody by the Company in accordance
with this <U>Section</U><U></U><U>&nbsp;4.3</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Adjustments</U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1
<U>Recapitalization and Related Transactions</U>. If, through or as a result of any recapitalization, reclassification, share dividend, share split, reverse share split, liquidation, exchange of shares,
<FONT STYLE="white-space:nowrap">spin-off,</FONT> combination, consolidation, conversion of the Company into a corporation or other similar transaction, (a)&nbsp;the outstanding Common Shares are increased, decreased or exchanged for a different
number or kind of shares or other securities of the Company or (b)&nbsp;additional shares or new or different shares or other <FONT STYLE="white-space:nowrap">non-cash</FONT> assets are distributed with respect to such Common Shares or other
securities, such different or distributed shares, securities or assets shall be subject to the provisions of this Agreement that are applicable to the Shares with respect to which such shares, securities, or assets were distributed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Reorganization, Merger and Related Transactions</U>. If the Company shall be the surviving company in any reorganization, merger, or
consolidation of the Company with one or more other entities, the provisions of this Agreement shall pertain to and apply to the securities, cash and any other assets to which the Recipient is entitled in respect of the Shares immediately following
such reorganization, merger, or consolidation in the same manner as such provisions apply to the Shares with respect to which such securities, cash, or other assets relate. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Miscellaneous </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1
<U>Notices</U>. All notices or other communications which are required or permitted hereunder shall be in writing and sufficient if (a)&nbsp;personally delivered or sent by telecopy or other electronic mail, (b)&nbsp;sent by nationally-recognized
overnight courier or (c)&nbsp;sent by registered or certified mail, postage prepaid, return receipt requested, addressed to the addresses set forth on the signature page to this Agreement, or to such other address as the party to whom notice is to
be given may have furnished to the other party in writing in accordance herewith. Any such communication shall be deemed to have been given (x)&nbsp;when delivered, if personally delivered or delivered by telefax or other electronic mail,
(y)&nbsp;on the first Business Day (as hereinafter defined) after dispatch, if sent by nationally-recognized overnight courier and (z)&nbsp;on the third Business Day following the date on which the piece of mail containing such communication is
posted, if sent by mail. As used herein, &#147;<U>Business Day</U>&#148; means a day that is not a Saturday, Sunday or a day on which banking institutions in the city to which the notice or communication is to be sent are not required to be open.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 <U>Third Party Beneficiaries</U>. Nothing herein expressed or implied is intended or shall be construed to confer upon or give to any
person or entity, other than the parties to this Agreement and their respective permitted successors and assigns, any rights or remedies under or by reason of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3 <U>Authorization and Enforceability</U>. The Company and the Recipient represent and warrant to the other that (a)&nbsp;such party has the
fully capacity, power and authority to enter into this Agreement and to carry out the transactions contemplated by this Agreement, and (b)&nbsp;this Agreement is binding upon such party and is enforceable against such party in accordance with
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the terms of this Agreement, except as enforceability may be limited or otherwise affected by applicable bankruptcy, insolvency, reorganization, fraudulent conveyance or transfer, moratorium, or
other law affecting creditors&#146; rights or contractual obligations generally or equitable principles affecting the enforceability of remedies (regardless of whether enforceability is considered in a proceeding at law or in equity). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4 <U>Further Assurances</U>. Currently with and from time to time after the execution of this Agreement, the parties hereto shall execute
and deliver such documents as may be necessary from time to time to effectuate the consummation of the transaction contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.5 <U>Successors and Assigns</U>. This Agreement may not be assigned by either party without the prior written consent of the other party.
This Agreement is intended to bind and inure to the benefit of and be enforceable by the Recipient and the Company and their respective successors and assigns (including subsequent holders of the Shares). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.6 <U>Severability</U>. In the event one or more of the provisions of this Agreement should, for any reason, be held to be invalid, illegal
or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been
contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.7 <U>Entire Agreement</U>. This Agreement (including the Exhibits hereto) and the Operating Agreement constitute the
entire agreement between the parties with respect to the subject matter hereof and supersede all previously written or oral negotiations, commitments, representations and agreements with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.8 <U>Counterparts; Electronic Execution</U>. This Agreement may be executed in counterparts, each of which shall be deemed to be an
original, but all of which together shall constitute one and the same instrument. Facsimile or other electronic execution and delivery of this Agreement shall be legal, valid and binding execution and delivery for all purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.9 <U>Remedies</U>. The Recipient and the Company agree and acknowledge that money damages shall not be an adequate remedy for any breach of
the provisions of this Agreement and that the Company shall be entitled to specific performance and injunctive relief in order to enforce or prevent any violations of the provisions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.10 <U>Amendments and Waivers</U>. Any provision of this Agreement may be amended or waived only with the prior written consent of the
Company and the Recipient. No waiver of any breach or condition of this Agreement shall be deemed to be a waiver of any other or subsequent breach or condition, whether of like or different nature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.11 <U>Modification of Rights</U>. The rights of the Recipient are subject to modification and termination in certain events as provided in
this Agreement and the Operating Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.12 <U>Recipient Undertaking</U>. The Recipient hereby agrees to take whatever additional
actions and execute whatever additional documents the Company may in its reasonable judgment deem necessary or advisable in order to carry out or effect one or more of the obligations or restrictions imposed on the Recipient pursuant to the express
provisions of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.13 <U>Governing Law</U>. This Agreement shall be governed by and construed in accordance
with the laws of Delaware without regard to its conflicts of law principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.14 <U>Headings</U>. The captions set forth in this
Agreement are for convenience only and shall not be considered as part of this Agreement or as in any way limiting the terms and provisions hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.14 <U>WAIVER OF JURY TRIAL</U>. THE RECIPIENT HEREBY EXPRESSLY, IRREVOCABLY AND UNCONDITIONALLY WAIVES TRIAL BY JURY IN ANY LEGAL ACTION OR
PROCEEDING RELATING TO THIS AGREEMENT AND FOR ANY COUNTERCLAIM THEREIN. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.15 <U>Tax Withholding</U>. The Company shall be entitled to
deduct and withhold any tax that it reasonably believes may be required in connection with the transactions set forth in this Agreement (which may be satisfied through payments to be made to the Recipient by the Company or any of its Affiliates, or
in such other manner as the Company may determine), and the Recipient agrees to indemnify and hold the Company and each other Member harmless from and against any such withholding taxes, on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[</B><B><I>Signature page follows.</I></B><B>] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>the parties hereto have executed this Agreement as of the
Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>RALLYBIO HOLDINGS, LLC</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Contact Information:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>RECIPIENT</B></P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Contact Information:</B></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature page to Restricted Share Agreement]</I> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>13
<FILENAME>d99471dex1012.htm
<DESCRIPTION>EX-10.12
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.12</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.12 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2021 EQUITY INCENTIVE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINED TERMS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Exhibit A</U>, which is incorporated by reference, defines certain terms used in the Plan and includes certain operational rules related to
those terms. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PURPOSE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan has been established to advance the interests of the Company by providing for the grant to Participants of Stock and Stock-based
Awards. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ADMINISTRATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan will be administered by the Administrator. The Administrator has discretionary authority, subject only to the express provisions of
the Plan, to administer and interpret the Plan and any Awards; to determine eligibility for and grant Awards; to determine the exercise price, base value from which appreciation is measured, or purchase price, if any, applicable to any Award, to
determine, modify, accelerate or waive the terms and conditions of any Award; to determine the form of settlement of Awards (whether in cash, shares of Stock, other Awards or other property); to prescribe forms, rules and procedures relating to the
Plan and Awards; and to otherwise do all things necessary or desirable to carry out the purposes of the Plan or any Award. Determinations of the Administrator made with respect to the Plan or any Award are conclusive and bind all persons. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SHARE POOL; LIMITS ON AWARDS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Number of Shares</U></B><B>.</B> Subject to adjustment as provided in Section&nbsp;7(b) below, the maximum number of shares of
Stock that may be delivered in satisfaction of Awards under the Plan is 5,440,344 shares (the &#147;<B>Initial Share Pool</B>&#148;). The Initial Share Pool will automatically increase on January
1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of each year beginning in 2022 and continuing through and including 2031 by the lesser of (i)&nbsp;five (5) percent of the number of shares of Stock outstanding as of such date and
(ii)&nbsp;the number of shares of Stock determined by the Board on or prior to such date for such year (the Initial Share Pool, as it may be so increased, the &#147;<B>Share Pool</B>&#148;). Up to 22,989,975 shares of Stock from the Share Pool may
be delivered in satisfaction of ISOs, but nothing in this Section&nbsp;4(a) will be construed as requiring that any, or any fixed number of, ISOs be granted under the Plan. For purposes of this Section&nbsp;4(a), shares of Stock shall not be treated
as delivered under the Plan, and will not reduce the Share Pool, unless and until, and to the extent, they are actually delivered to a Participant. Without limiting the generality of the foregoing, the Share Pool shall not be reduced by (i)&nbsp;any
shares of Stock withheld by the Company in payment of the exercise price or purchase price of an Award or in satisfaction of tax withholding requirements with respect to an Award or (ii)&nbsp;any shares of Stock underlying any portion of an Award
that is settled in cash or that expires, becomes unexercisable, terminates or is forfeited to or repurchased by the Company, in any case, without the delivery (or retention, in the case of Restricted Stock or Unrestricted Stock) of Stock. For the
avoidance of doubt, the Share Pool will not be increased by any shares of Stock delivered under the Plan that are subsequently repurchased using proceeds directly attributable to Stock Option exercises. The limits set forth in this Section&nbsp;4(a)
will be construed to comply with the applicable requirements of Section&nbsp;422. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U>Substitute Awards</U></B><B>. </B>The<B> </B>Administrator may grant
Substitute Awards under the Plan. To the extent consistent with the requirements of Section&nbsp;422 and the regulations thereunder and other applicable legal requirements (including applicable stock exchange requirements), shares of Stock delivered
in respect of Substitute Awards will be in addition to and will not reduce the Share Pool. Notwithstanding the foregoing or anything in Section&nbsp;4(a) above to the contrary, if any Substitute Award is settled in cash or expires, becomes
unexercisable, terminates or is forfeited to or repurchased by the Company without the delivery (or retention, in the case of Restricted Stock or Unrestricted Stock) of Stock, the shares of Stock previously subject to such Award will not increase
the Share Pool or otherwise be available for future delivery under the Plan. The Administrator will determine the extent to which the terms and conditions of the Plan apply to Substitute Awards, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><U>Type of Shares</U></B><B>.</B> Stock delivered by the Company under the Plan may be authorized but unissued Stock, treasury
Stock or previously issued Stock acquired by the Company. No fractional shares of Stock will be delivered under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>
<B><U>Director Limits</U></B>. In addition to the foregoing limits, the aggregate value of all compensation granted or paid to any Director with respect to any calendar year, including Awards granted under the Plan and cash fees or other
compensation paid by the Company to such Director outside of the Plan for his or her services as a Director during such calendar year, may not exceed $750,000 in the aggregate ($1,000,000 in the aggregate with respect to a Director&#146;s first year
of service on the Board), calculating the value of any Awards based on the grant date fair value in accordance with the Accounting Rules, assuming a maximum payout. For the avoidance of doubt, the limitation in this Section&nbsp;4(d) will not apply
to any compensation granted or paid to a Director for his or her services to the Company or a subsidiary other than as a Director, including, without limitation, as a consultant or advisor to the Company or a subsidiary. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ELIGIBILITY AND PARTICIPATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator will select Participants from among Employees and Directors of, and consultants to, the Company and its subsidiaries.
Eligibility for ISOs is limited to individuals described in the first sentence of this Section&nbsp;5 who are employees of the Company or of a &#147;parent corporation&#148; or &#147;subsidiary corporation&#148; of the Company as those terms are
defined in Section&nbsp;424 of the Code. Eligibility for Stock Options, other than ISOs, and SARs is limited to individuals described in the first sentence of this Section&nbsp;5 who are providing direct services on the date of grant of the Award to
the Company or to a subsidiary of the Company that would be described in the first sentence of <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(5)(iii)(E)</FONT> of the Treasury Regulations (after applying the third sentence thereof). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RULES APPLICABLE TO AWARDS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) <U>All Awards</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> <B><U>Award Provisions</U></B><B>.</B> The Administrator will determine the terms and conditions of all Awards, subject to the
limitations provided herein. No term of an Award shall provide for automatic &#147;reload&#148; grants of additional Awards upon the exercise of an Option or SAR. By accepting (or, under such rules as the Administrator may prescribe, being deemed to
have accepted) an Award, the Participant will be deemed to have agreed to the terms and conditions of the Award and the Plan. Notwithstanding any provision of the Plan to the contrary, Substitute Awards may contain terms and conditions that are
inconsistent with the terms and conditions specified herein, as determined by the Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> <B><U>Term of
Plan</U></B><B>.</B> No Awards may be made after ten years from the Date of Adoption, but previously granted Awards may continue beyond that date in accordance with their terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(3)</B> <B><U>Transferability</U></B><B>.</B> Neither ISOs nor, except as the Administrator otherwise expressly provides in accordance with
the third sentence of this Section&nbsp;6(a)(3), other Awards may be transferred other than by will or by the laws of descent and distribution. During a Participant&#146;s lifetime, ISOs and, except as the Administrator otherwise expressly provides
in accordance with the third sentence of this Section&nbsp;6(a)(3), SARs and NSOs may be exercised only by the Participant. The Administrator may permit the gratuitous transfer (<I>i.e.</I>, transfer not for value) of Awards other than ISOs, subject
to applicable securities and other laws and such terms and conditions as the Administrator may determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(4)</B> <B><U>Vesting;
Exercisability</U></B><B>. </B>The Administrator will determine the time or times at which an Award vests or becomes exercisable and the terms and conditions on which a Stock Option or SAR remains exercisable. Without limiting the foregoing, the
Administrator may at any time accelerate the vesting and/or exercisability of an Award (or any portion thereof), regardless of any adverse or potentially adverse tax or other consequences resulting from such acceleration. Unless the Administrator
expressly provides otherwise, however, the following rules will apply if a Participant&#146;s Employment ceases: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(A)</B> Except as provided in (B)&nbsp;and (C) below, immediately upon the cessation of the Participant&#146;s Employment,
each Stock Option and SAR (or portion thereof) that is then held by the Participant or by the Participant&#146;s permitted transferees, if any, will cease to be exercisable and will terminate and each other Award that is then held by the Participant
or by the Participant&#146;s permitted transferees, if any, to the extent not then vested, will be forfeited. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(B)</B>
Subject to (C)&nbsp;and (D) below, each vested and unexercised Stock Option and SAR (or portion thereof) held by the Participant or the Participant&#146;s permitted transferees, if any, immediately prior to the cessation of the Participant&#146;s
Employment, to the extent then exercisable, will remain exercisable for the lesser of (i)&nbsp;a period of three months following such cessation of Employment or (ii)&nbsp;the period ending on the latest date on which such Stock Option or SAR could
have been exercised without regard to this Section&nbsp;6(a)(4), and will thereupon immediately terminate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(C)</B> Subject to (D)&nbsp;below, each vested and unexercised Stock
Option and SAR (or portion thereof) held by a Participant or the Participant&#146;s permitted transferees, if any, immediately prior to the cessation of the Participant&#146;s Employment due to his or her death or by the Company due to his or her
Disability, to the extent then exercisable, will remain exercisable for the lesser of (i)&nbsp;the <FONT STYLE="white-space:nowrap">one-year</FONT> period ending on the first anniversary of such cessation of Employment or (ii)&nbsp;the period ending
on the latest date on which such Stock Option or SAR could have been exercised without regard to this Section&nbsp;6(a)(4), and will thereupon immediately terminate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(D)</B> All Awards (whether or not vested or exercisable) held by a Participant or the Participant&#146;s permitted
transferees, if any, immediately prior to the cessation of the Participant&#146;s Employment will immediately terminate upon such cessation of Employment if the termination is for Cause or occurs in circumstances that in the determination of the
Administrator would have constituted grounds for the Participant&#146;s Employment to be terminated for Cause (in each case, without regard to the lapsing of any required notice or cure periods in connection therewith). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(5)</B> <B><U>Recovery of Compensation</U></B>. The Administrator may provide in any case that any outstanding Award (whether or not vested
or exercisable), the proceeds from the exercise or disposition of any Award or Stock acquired under any Award, and any other amounts received in respect of any Award or Stock acquired under any Award will be subject to forfeiture and disgorgement to
the Company, with interest and other related earnings, if the Participant to whom the Award was granted is not in compliance with any provision of the Plan or any applicable Award or any <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT
STYLE="white-space:nowrap">non-solicitation,</FONT> <FONT STYLE="white-space:nowrap">no-hire,</FONT> <FONT STYLE="white-space:nowrap">non-disparagement,</FONT> confidentiality, invention assignment or other restrictive covenant by which he or she is
bound. Each Award will be subject to any policy of the Company or any of its subsidiaries that relates to trading <FONT STYLE="white-space:nowrap">on&nbsp;non-public&nbsp;information</FONT> and permitted transactions with respect to shares of Stock,
including limitations on hedging and pledging. In addition, each Award will be subject to any policy of the Company or any of its affiliates that provides for forfeiture, disgorgement, or clawback with respect to incentive compensation that includes
Awards under the Plan and will be further subject to forfeiture and disgorgement to the extent required by law or applicable stock exchange listing standards, including, without limitation, Section&nbsp;10D of the Exchange Act. Each Participant, by
accepting or being deemed to have accepted an Award under the Plan, agrees (or will be deemed to have agreed) to the terms of this Section&nbsp;6(a)(5) and to any clawback, recoupment or similar policy of the Company or any of its subsidiaries and
further agrees (or will be deemed to have further agreed) to cooperate fully with the Administrator, and to cause any and all permitted transferees of the Participant to cooperate fully with the Administrator, to effectuate any forfeiture or
disgorgement described in this Section&nbsp;6(a)(5). Neither the Administrator nor the Company nor any other person, other than the Participant and his or her permitted transferees, if any, will be responsible for any adverse tax or other
consequences to a Participant or his or her permitted transferees, if any, that may arise in connection with this Section&nbsp;6(a)(5). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(6)</B> <B><U>Taxes</U></B><B>.</B> The grant of an Award and the issuance, delivery, vesting and retention of Stock, cash or other
property under an Award are conditioned upon the full satisfaction by the Participant of all tax and other withholding requirements with respect to the Award. The Administrator will prescribe such rules for the withholding of taxes and other amounts
with respect to any Award as it deems necessary. Without limitation to the foregoing, the Company or any affiliate of the Company will have the authority and the right to deduct or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
withhold (by any means set forth herein or in an Award agreement), or require a Participant to remit to the Company or an affiliate of the Company, an amount sufficient to satisfy all U.S. and <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> federal, state and local income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other <FONT STYLE="white-space:nowrap">tax-related</FONT> items related to participation in the
Plan and any Award hereunder and legally applicable to the Participant and required by law to be withheld (including, any amount deemed by the Company, in its discretion, to be an appropriate charge to the Participant even if legally applicable to
the Company or any affiliate of the Company). The Administrator, in its sole discretion, may hold back shares of Stock from an Award or permit a Participant to tender previously-owned shares of Stock in satisfaction of tax or other withholding
requirements (but not in excess of the maximum withholding amount consistent with the Award being subject to equity accounting treatment under the Accounting Rules). Any amounts withheld pursuant to this Section&nbsp;6(a)(6) will be treated as
though such amounts had been paid directly to the applicable Participant. In addition, the Company may, to the extent permitted by law, deduct any such tax and other withholding amounts from any payment of any kind otherwise due to a Participant
from the Company or any of its affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(7)</B> <B><U>Dividend Equivalents</U></B><B>. </B>The Administrator may provide for the
payment of amounts (on terms and subject to such conditions established by the Administrator) in lieu of cash dividends or other cash distributions with respect to Stock subject to an Award whether or not the holder of such Award is otherwise
entitled to share in the actual dividend or distribution in respect of such Award; <I>provided, however</I>, that (a)&nbsp;dividends or dividend equivalents relating to an Award that, at the dividend payment date, remains subject to a risk of
forfeiture (whether service-based or performance-based) shall be subject to the same risk of forfeiture as applies to the underlying Award and (b)&nbsp;no dividends or dividend equivalents shall be payable with respect to Stock Options or SARs. Any
entitlement to dividend equivalents or similar entitlements will be established and administered either consistent with an exemption from, or in compliance with, the applicable requirements of Section&nbsp;409A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(8)</B> <B><U>Rights Limited</U></B><B>.</B> Nothing in the Plan or any Award will be construed as giving any person the right to be
granted an Award or to continued employment or service with the Company or any of its subsidiaries, or any rights as a stockholder except as to shares of Stock actually delivered under the Plan. The loss of existing or potential profit in any Award
will not constitute an element of damages in the event of a termination of a Participant&#146;s Employment for any reason, even if the termination is in violation of an obligation of the Company or any of its subsidiaries to the Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(9)</B> <B><U>Coordination with Other Plans</U></B><B>. </B>Shares of Stock and/or Awards under the Plan may be issued or granted in tandem
with, or in satisfaction of or substitution for, other Awards under the Plan or awards made under other compensatory plans or programs of the Company or any of its subsidiaries. For example, but without limiting the generality of the foregoing,
awards under other compensatory plans or programs of the Company or any of its subsidiaries may be settled in Stock (including, without limitation, Unrestricted Stock) under the Plan if the Administrator so determines, in which case the shares
delivered will be treated as awarded under the Plan (and will reduce the Share Pool). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(10) <U>Section 409A</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(A)</B> Without limiting the generality of Section&nbsp;11(b) hereof, each Award will contain such terms as the
Administrator determines and will be construed and administered, such that the Award either qualifies for an exemption from the requirements of Section&nbsp;409A or satisfies such requirements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(B)</B> Notwithstanding anything to the contrary in the Plan or any Award agreement, the Administrator may unilaterally
amend, modify or terminate the Plan or any outstanding Award, including, without limitation, changing the form of the Award, if the Administrator determines that such amendment, modification or termination is necessary or desirable to avoid the
imposition of an additional tax, interest or penalty under Section&nbsp;409A. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(C)</B> If a Participant is determined on
the date of the Participant&#146;s termination of Employment to be a &#147;specified employee&#148; within the meaning of that term under Section&nbsp;409A(a)(2)(B) of the Code, then, with regard to any payment that is considered nonqualified
deferred compensation under Section&nbsp;409A, to the extent applicable, payable on account of a &#147;separation from service&#148;, such payment will be made or provided on the date that is the earlier of (i)&nbsp;the first business day following
the expiration of the <FONT STYLE="white-space:nowrap">six-month</FONT> period measured from the date of such &#147;separation from service&#148; and (ii)&nbsp;the date of the Participant&#146;s death (the &#147;<B>Delay Period</B>&#148;). Upon the
expiration of the Delay Period, all payments delayed pursuant to this Section&nbsp;6(a)(10)(C) (whether they would have otherwise been payable in a single lump sum or in installments in the absence of such delay) will be paid, without interest, on
the first business day following the expiration of the Delay Period in a lump sum and any remaining payments due under the Award will be paid in accordance with the normal payment dates specified for them in the applicable Award agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(D)</B> For purposes of Section&nbsp;409A, each payment made under the Plan or any Award will be treated as a separate
payment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(E)</B> With regard to any payment considered to be nonqualified deferred compensation under
Section&nbsp;409A, to the extent applicable, that is payable upon a change in control of the Company or other similar event, to the extent required to avoid the imposition of an additional tax, interest or penalty under Section&nbsp;409A, no amount
will be payable unless such change in control constitutes a &#147;change in control event&#148; within the meaning of <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5)</FONT> of the Treasury Regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) <U>Stock Options and SARs</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> <B><U>Time and Manner of Exercise</U></B><B>. </B>Unless the Administrator expressly provides otherwise, no Stock Option or SAR
will be deemed to have been exercised until the Administrator receives a notice of exercise in a form acceptable to the Administrator that is signed by the appropriate person and accompanied by any payment required under the Award. The Administrator
may limit or restrict the exercisability of any Stock Option or SAR in its discretion, including in connection with any Covered Transaction. Any attempt to exercise a Stock Option or SAR by any person other than the Participant will not be given
effect unless the Administrator has received such evidence as it may require that the person exercising the Award has the right to do so. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> <B><U>Exercise Price</U></B><B>.</B> The exercise price (or the base value from
which appreciation is to be measured) per share of each Award requiring exercise must be no less than 100% (in the case of an ISO granted to a <FONT STYLE="white-space:nowrap">10-percent</FONT> stockholder within the meaning of
Section&nbsp;422(b)(6) of the Code, 110%) of the Fair Market Value of a share of Stock, determined as of the date of grant of the Award, or such higher amount as the Administrator may determine in connection with the grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(3)</B> <B><U>Payment of Exercise Price</U></B><B>.</B> Where the exercise of an Award (or portion thereof) is to be accompanied by a
payment, payment of the exercise price must be made by cash or check acceptable to the Administrator or, if so permitted by the Administrator and if legally permissible, (i)&nbsp;through the delivery of previously acquired unrestricted shares of
Stock, or the withholding of unrestricted shares of Stock otherwise deliverable upon exercise, in either case, that have a Fair Market Value equal to the exercise price; (ii)&nbsp;through a broker-assisted cashless exercise program acceptable to the
Administrator; (iii)&nbsp;by other means acceptable to the Administrator; or (iv)&nbsp;by any combination of the foregoing permissible forms of payment. The delivery of previously acquired shares in payment of the exercise price under clause
(i)&nbsp;above may be accomplished either by actual delivery or by constructive delivery through attestation of ownership, subject to such rules as the Administrator may prescribe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(4)</B> <B><U>Maximum Term</U></B><B>.</B> The maximum term of Stock Options and SARs must not exceed 10 years from the date of grant (or
five years from the date of grant in the case of an ISO granted to a <FONT STYLE="white-space:nowrap">10-percent</FONT> stockholder described in Section&nbsp;6(b)(2) above). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(5)</B> <B><U>No Repricing</U></B><B>. </B>Except in connection with a corporate transaction involving the Company (which term includes,
without limitation, any stock dividend, stock split, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, <FONT STYLE="white-space:nowrap">split-up,</FONT> <FONT STYLE="white-space:nowrap">spin-off,</FONT>
combination or exchange of shares) or as otherwise contemplated by Section&nbsp;7 below, the Company may not, without obtaining stockholder approval, (i)&nbsp;amend the terms of outstanding Stock Options or SARs to reduce the exercise price or base
value of such Stock Options or SARs; (ii)&nbsp;cancel outstanding Stock Options or SARs in exchange for Stock Options or SARs that have an exercise price or base value that is less than the exercise price or base value of the original Stock Options
or SARs; or (iii)&nbsp;cancel outstanding Stock Options or SARs that have an exercise price or base value greater than the Fair Market Value of a share of Stock on the date of such cancellation in exchange for cash or other consideration. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EFFECT OF CERTAIN TRANSACTIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Mergers,</U></B><B><I><U> etc</U></I></B><B><I>.</I></B> Except as otherwise expressly provided in an Award or other agreement
or by the Administrator, the following provisions will apply in the event of a Covered Transaction: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> <B><U>Assumption or
Substitution</U></B><B>.</B> If the Covered Transaction is one in which there is an acquiring or surviving entity, the Administrator may provide for (i)&nbsp;the assumption or continuation of some or all outstanding Awards or any portion thereof or
(ii)&nbsp;the grant of new awards in substitution therefor by the acquiror or survivor or an affiliate of the acquiror or survivor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> <B><U><FONT STYLE="white-space:nowrap">Cash-Out</FONT> of Awards</U></B><B>.
</B>Subject to Section&nbsp;7(a)(5) below, the Administrator may provide for payment (a &#147;<B><FONT STYLE="white-space:nowrap">cash-out</FONT></B>&#148;), with respect to some or all Awards or any portion thereof (including only the vested
portion thereof, with the unvested portion terminating without payment due as provided in Section&nbsp;7(a)(4) below), equal in the case of each applicable Award or portion thereof to the excess, if any, of (i)&nbsp;the fair market value of one
share of Stock multiplied by the number of shares of Stock subject to the Award or such portion, minus (ii)&nbsp;the aggregate exercise or purchase price, if any, of such Award or such portion thereof (or, in the case of a SAR, the aggregate base
value above which appreciation is measured), in each case, on such payment and other terms and subject to such conditions (which need not be the same as the terms and conditions applicable to holders of Stock generally), as the Administrator
determines, including that any amounts paid in respect of such Award in connection with the Covered Transaction be placed in escrow or otherwise made subject to such restrictions as the Administrator deems appropriate. For the avoidance of doubt, if
the per share exercise or purchase price (or base value) of an Award or portion thereof is equal to or greater than the fair market value of one share of Stock, such Award or portion may be cancelled with no payment due hereunder or otherwise in
respect thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(3)</B> <B><U>Acceleration of Certain Awards</U></B><B>. </B>Subject to Section&nbsp;7(a)(5) below, the Administrator
may provide that any Award requiring exercise will become exercisable, in full or in part, and/or that the delivery of any shares of Stock remaining deliverable under any outstanding Award of Stock Units (including Restricted Stock Units and
Performance Awards to the extent consisting of Stock Units) will be accelerated, in full or in part, in each case on a basis that gives the holder of the Award a reasonable opportunity, as determined by the Administrator, following the exercise of
the Award or the delivery of the shares, as the case may be, to participate as a stockholder in the Covered Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(4)</B>
<B><U>Termination of Awards upon Consummation of Covered Transaction</U></B><B>. </B>Except as the Administrator may otherwise determine, each Award will automatically terminate (and in the case of outstanding shares of Restricted Stock, will
automatically be forfeited) immediately upon the consummation of the Covered Transaction, other than (i)&nbsp;any Award that is assumed, continued or substituted for pursuant to Section&nbsp;7(a)(1) above and (ii)&nbsp;any Award that by its terms,
or as a result of action taken by the Administrator, continues following the Covered Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(5)</B> <B><U>Additional
Limitations</U></B><B>.</B> Any share of Stock and any cash or other property or other award delivered pursuant to Section&nbsp;7(a)(1), Section&nbsp;7(a)(2) or Section&nbsp;7(a)(3) above with respect to an Award may, in the discretion of the
Administrator, contain such restrictions, if any, as the Administrator deems appropriate, including to reflect any performance or other vesting conditions to which the Award was subject and that did not lapse (and were not satisfied) in connection
with the Covered Transaction. For purposes of the immediately preceding sentence, a <FONT STYLE="white-space:nowrap">cash-out</FONT> under Section&nbsp;7(a)(2) above or an acceleration under Section&nbsp;7(a)(3) above will not, in and of itself, be
treated as the lapsing (or satisfaction) of a performance or other vesting condition. In the case of Restricted Stock that does not vest and is not forfeited in connection with the Covered Transaction, the Administrator may require that any amounts
delivered, exchanged or otherwise paid in respect of such Stock in connection with the Covered Transaction be placed in escrow or otherwise made subject to such restrictions as the Administrator deems appropriate to carry out the intent of the Plan.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(6)</B> <B><U>Uniform Treatment</U></B><B>.</B> For the avoidance of doubt, the
Administrator need not treat Participants or Awards (or portions thereof) in a uniform manner, and may treat different Participants and/or Awards differently, in connection with a Covered Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) <U>Changes in and Distributions with Respect to Stock</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> <B><U>Basic Adjustment Provisions</U></B><B>.</B> In the event of a stock dividend, stock split or combination of shares (including
a reverse stock split), recapitalization or other change in the Company&#146;s capital structure that constitutes an equity restructuring within the meaning of the Accounting Rules, the Administrator shall make appropriate adjustments to the Share
Pool and shall make appropriate adjustments to the number and kind of shares of stock or securities underlying Awards then outstanding or subsequently granted, any exercise or purchase prices (or base values) relating to Awards and any other
provision of Awards affected by such change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> <B><U>Certain Other Adjustments</U></B><B>.</B> The Administrator may also make
adjustments of the type described in Section&nbsp;7(b)(1) above to take into account distributions to stockholders other than those provided for in Sections 7(a) and 7(b)(1) above, or any other event, if the Administrator determines that adjustments
are appropriate to avoid distortion in the operation of the Plan or any Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(3)</B> <B><U>Continuing Application of Plan
Terms</U></B><B>.</B> References in the Plan to shares of Stock will be construed to include any stock or securities resulting from an adjustment pursuant to this Section&nbsp;7. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LEGAL CONDITIONS ON DELIVERY OF STOCK </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will not be obligated to deliver any shares of Stock pursuant to the Plan or to remove any restriction from shares of Stock
previously delivered under the Plan until: (i)&nbsp;the Company is satisfied that all legal matters in connection with the issuance and delivery of such shares have been addressed and resolved; (ii)&nbsp;if the outstanding Stock is at the time of
delivery listed on any stock exchange or national market system, the shares to be delivered have been listed or authorized to be listed on such exchange or system upon official notice of issuance; and (iii)&nbsp;all conditions of the Award have been
satisfied or waived. The Company may require, as a condition to the exercise of an Award or the delivery of shares of Stock under an Award, such representations or agreements as counsel for the Company may consider appropriate to avoid violation of
the Securities Act of 1933, as amended, or any applicable state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> securities law. Any Stock delivered under the Plan will be evidenced in such manner as the Administrator determines appropriate,
including book-entry registration or delivery of stock certificates. In the event that the Administrator determines that stock certificates will be issued in connection with Stock issued under the Plan, the Administrator may require that such
certificates bear an appropriate legend reflecting any restriction on transfer applicable to such Stock, and the Company may hold the certificates pending the lapse of the applicable restrictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>AMENDMENT AND TERMINATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator may at any time or times amend the Plan or any outstanding Award for any purpose which may at the time be permitted by
applicable law, and may at any time terminate the Plan as to any future grants of Awards; <I>provided, however</I>, that except as otherwise expressly provided in the Plan or the applicable Award, the Administrator may not, without the
Participant&#146;s consent, alter the terms of an Award so as to affect materially and adversely the Participant&#146;s rights under the Award, unless the Administrator expressly reserved the right to do so in the Plan or at the time the applicable
Award was granted. Any amendments to the Plan will be conditioned upon stockholder approval only to the extent, if any, such approval is required by applicable law (including the Code) or stock exchange requirements, as determined by the
Administrator. For the avoidance of doubt, without limiting the Administrator&#146;s rights hereunder, no adjustment to any Award pursuant to the terms of Section&nbsp;7 or Section&nbsp;12 hereof will be treated as an amendment requiring a
Participant&#146;s consent. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>OTHER COMPENSATION ARRANGEMENTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The existence of the Plan or the grant of any Award will not affect the right of the Company or any of its subsidiaries to grant any person
bonuses or other compensation in addition to Awards under the Plan. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MISCELLANEOUS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Waiver of Jury Trial</U></B><B>.</B> By accepting or being deemed to have accepted an Award under the Plan, each Participant
waives (or will be deemed to have waived), to the maximum extent permitted under applicable law, any right to a trial by jury in any action, proceeding or counterclaim concerning any rights under the Plan or any Award, or under any amendment,
waiver, consent, instrument, document or other agreement delivered or which in the future may be delivered in connection therewith, and agrees (or will be deemed to have agreed) that any such action, proceedings or counterclaim will be tried before
a court and not before a jury. By accepting (or being deemed to have accepted) an Award under the Plan, each Participant certifies that no officer, representative, or attorney of the Company has represented, expressly or otherwise, that the Company
would not, in the event of any action, proceeding or counterclaim, seek to enforce the foregoing waivers. Notwithstanding anything to the contrary in the Plan, nothing herein is to be construed as limiting the ability of the Company and a
Participant to agree to submit any dispute arising under the terms of the Plan or any Award to binding arbitration or as limiting the ability of the Company to require any individual to agree to submit such disputes to binding arbitration as a
condition of receiving an Award hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U>Limitation of Liability</U></B><B>.</B> Notwithstanding anything to the
contrary in the Plan or any Award, none of the Company, nor any of its subsidiaries, nor the Administrator, nor any person acting on behalf of the Company, any of its subsidiaries, or the Administrator, will be liable to any Participant, to any
permitted transferee, to the estate or beneficiary of any Participant or any permitted transferee, or to any other person by reason of any acceleration of income, any additional tax, or any penalty, interest or other liability asserted by reason of
the failure of an Award to satisfy the requirements of Section&nbsp;422 or Section&nbsp;409A or by reason of Section&nbsp;4999 of the Code, or otherwise asserted with respect to any Award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><U>Unfunded Plan</U></B><B>. </B>The Company&#146;s obligations under the Plan
are unfunded, and no Participant will have any right to specific assets of the Company in respect of any Award. Participants will be general unsecured creditors of the Company with respect to any amounts due or payable under the Plan. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ESTABLISHMENT OF <FONT STYLE="white-space:nowrap">SUB-PLANS</FONT> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator may at any time and from time to time (including before or after an Award is granted) establish, adopt, or revise any rules
and regulations as it may deem necessary or advisable to administer the Plan for Participants based outside of the U.S. and/or subject to the laws of countries other than the U.S., including by establishing one or more
<FONT STYLE="white-space:nowrap">sub-plans,</FONT> supplements or appendices under the Plan or any Award agreement for the purpose of complying or facilitating compliance with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws or taking advantage
of tax favorable treatment or for any other legal or administrative reason determined by the Administrator. Any such <FONT STYLE="white-space:nowrap">sub-plan,</FONT> supplement or appendix may contain, in each case, (i)&nbsp;such limitations on the
Administrator&#146;s discretion under the Plan and (ii)&nbsp;such additional or different terms and conditions, as the Administrator deems necessary or desirable and will be deemed to be part of the Plan but will apply only to Participants within
the group to which the <FONT STYLE="white-space:nowrap">sub-plan,</FONT> supplement or appendix applies (as determined by the Administrator); <I>provided, however</I>, that no <FONT STYLE="white-space:nowrap">sub-plan,</FONT> supplement or appendix,
rule or regulation established pursuant to this provision shall increase the Share Pool. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GOVERNING LAW </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Certain Requirements of Corporate Law</U></B><B>.</B> Awards and shares of Stock will be granted, issued and administered
consistent with the requirements of applicable Delaware law relating to the issuance of stock and the consideration to be received therefor, and with the applicable requirements of the stock exchanges or other trading systems on which the Stock is
listed or entered for trading, in each case, as determined by the Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U>Other Matters</U></B><B>.</B> Except as
otherwise provided by the express terms of an Award agreement, under a <FONT STYLE="white-space:nowrap">sub-plan</FONT> described in Section&nbsp;12 above or as provided in Section&nbsp;13(a) above, the domestic substantive laws of the State of
Delaware govern the provisions of the Plan and of Awards under the Plan and all claims or disputes arising out of or based upon the Plan or any Award under the Plan or relating to the subject matter hereof or thereof without giving effect to any
choice or conflict of laws provision or rule that would cause the application of the domestic substantive laws of any other jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><U>Jurisdiction</U></B><B>. </B>Subject to Section&nbsp;11(a) above,<B> </B>by accepting (or being deemed to have accepted) an
Award, each Participant agrees or will be deemed to have agreed to (i)&nbsp;submit irrevocably and unconditionally to the jurisdiction of the federal and state courts located within the geographic boundaries of the United States District Court for
the District of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon the Plan or any Award; (ii)&nbsp;not commence any suit, action or other proceeding arising out of or based upon the Plan or any Award,
except in the federal and state courts located within the geographic boundaries of the United States District Court for the District of Delaware; and (iii)&nbsp;waive, and not assert, by way of motion as a defense or otherwise, in any such suit,
action or proceeding, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any claim that he or she is not subject personally to the jurisdiction of the above-named courts that his or her property is exempt or immune from attachment or execution, that the suit, action
or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that the Plan or any Award or the subject matter thereof may not be enforced in or by such court. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[The remainder of this page is intentionally left blank.] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Definition of Terms </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following terms, when used in the Plan, have the meanings and are subject to the provisions set forth below: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Accounting Rules&#148;: </B>Financial Accounting Standards Board Accounting Standards Codification Topic 718, or any successor
provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Administrator&#148;: </B>The Compensation Committee, except that the Board may at any time act in the capacity of the
Administrator (including with respect to such matters that are not delegated to the Compensation Committee by the Board (whether pursuant to committee charter or otherwise), if applicable). The Compensation Committee (or the Board) may delegate
(i)&nbsp;to one or more of its members (or one or more other members of the Board) such of its duties, powers and responsibilities as it may determine; (ii)&nbsp;to one or more officers of the Company the power to grant Awards to the extent
permitted by applicable law; and (iii)&nbsp;to such Employees or other persons as it determines such ministerial tasks as it deems appropriate. For purposes of the Plan, the term &#147;Administrator&#148; will include the Board, the Compensation
Committee, and the person or persons delegated authority under the Plan to the extent of such delegation, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Award&#148;: </B>Any or a combination of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Stock Options. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) SARs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Restricted Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Unrestricted Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Stock Units, including Restricted Stock Units. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) Performance Awards. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) Awards (other than Awards described in (i)&nbsp;through (vi) above) that are convertible into or otherwise based on
Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Board&#148;: </B>The Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;</B><B>Cause</B><B>&#148;</B><B>: </B>In the case of any Participant who is party to an employment, change of control or
severance-benefit agreement that contains a definition of &#147;Cause,&#148; the definition set forth in such agreement applies with respect to such Participant for purposes of the Plan for so long as such agreement is in effect. In every other
case, &#147;Cause&#148; means, as determined by the Administrator, (i)&nbsp;a substantial failure of the Participant to perform the Participant&#146;s duties and responsibilities to the Company or any of its subsidiaries or substantial negligence in
the performance of such duties and responsibilities; (ii)&nbsp;the commission by the Participant of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
felony or a crime involving moral turpitude; (iii)&nbsp;the commission by the Participant of theft, fraud, embezzlement, material breach of trust or any material act of dishonesty involving the
Company or any of its subsidiaries; (iv)&nbsp;a significant violation by the Participant of the code of conduct of the Company or any of its subsidiaries of any material policy of the Company or any of its subsidiaries, or of any statutory or common
law duty of loyalty to the Company or any of its subsidiaries; (v)&nbsp;material breach of any of the terms of the Plan or any Award made under the Plan, or of the terms of any other agreement between the Company or any of its subsidiaries and the
Participant; or (vi)&nbsp;other conduct by the Participant that could be expected to be harmful to the business, interests or reputation of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Change in Control&#148;: </B>The consummation of (i)&nbsp;the sale of all or substantially all of the assets of the Company on a
consolidated basis to an unrelated Person; (ii)&nbsp;a merger, reorganization or consolidation pursuant to which the holders of the Company&#146;s outstanding voting securities immediately prior to such transaction do not own more than fifty percent
(50%) of the outstanding voting securities of the surviving or resulting entity (or its ultimate parent, if applicable); (iii) the acquisition of more than fifty percent (50%) the outstanding voting securities of the Company in a single transaction
or a series of related transactions by any Person; or (iv)&nbsp;the complete dissolution or liquidation of the Company; <U>provided</U>, <U>however</U>, that the Company&#146;s initial public offering, any subsequent public offering or anther
capital raising event, a merger effected solely to change the Company&#146;s domicile or any acquisition by the Company or any employee benefit plan (or related trust) sponsored or maintained by the Company or any of its subsidiaries or affiliates
shall not constitute a &#147;Change in Control&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Code&#148;: </B>The U.S. Internal Revenue Code of 1986, as from time to
time amended and in effect, or any successor statute as from time to time in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Company&#148;:</B> Rallybio Corporation
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Compensation Committee&#148;: </B>The Compensation Committee of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Covered Transaction&#148;: </B>Any of (i)&nbsp;a consolidation, merger or similar transaction or series of related transactions,
including a sale or other disposition of stock, in which the Company is not the surviving corporation or which results in the acquisition of all or substantially all of the Company&#146;s then outstanding common stock by a single person or entity or
by a group of persons and/or entities acting in concert; (ii)&nbsp;a sale or transfer of all or substantially all the Company&#146;s assets; (iii)&nbsp;a dissolution or liquidation of the Company or (iv)&nbsp;any other transaction the Administrator
determines to be a Covered Transaction. Where a Covered Transaction involves a tender offer that is reasonably expected to be followed by a merger described in clause (i) (as determined by the Administrator), the Covered Transaction will be deemed
to have occurred upon consummation of the tender offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Date of Adoption&#148;:</B> The earlier of the date the Plan was
approved by the Company&#146;s stockholders or adopted by the Board, as determined by the Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Director&#148;:</B> A
member of the Board who is not an Employee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Disability&#148;:</B> In the case of any Participant who is party to an employment,
change of control or severance-benefit agreement that contains a definition of &#147;Disability&#148; (or a corollary term), the definition set forth in such agreement applies with respect to such Participant for purposes of the Plan for so long as
such agreement is in effect. In every other case, &#147;Disability&#148; means, as determined by the Administrator, absence from work due to a disability for a period in excess of ninety (90)&nbsp;days in any twelve (12)-month period that would
entitle the Participant to receive benefits under the Company&#146;s long-term disability program as in effect from time to time (if the Participant were a participant in such program). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Employee&#148;: </B>Any person who is employed by the Company or any of its subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Employment&#148;: </B>A Participant&#146;s employment or other service relationship with the Company or any of its subsidiaries.
Employment will be deemed to continue, unless the Administrator otherwise determines, so long as the Participant is employed by, or otherwise is providing services in a capacity described in Section&nbsp;5 of the Plan to, the Company or any of its
subsidiaries. If a Participant&#146;s employment or other service relationship is with any subsidiary of the Company and that entity ceases to be a subsidiary of the Company, the Participant&#146;s Employment will be deemed to have terminated when
the entity ceases to be a subsidiary of the Company unless the Participant transfers Employment to the Company or one of its remaining subsidiaries. Notwithstanding the foregoing, in construing the provisions of any Award relating to the payment of
&#147;nonqualified deferred compensation&#148; (subject to Section&nbsp;409A) upon a termination or cessation of Employment, references to termination or cessation of employment, separation from service, retirement or similar or correlative terms
will be construed to require a &#147;separation from service&#148; (as that term is defined in <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h)</FONT> of the Treasury Regulations, after giving effect to the presumptions contained therein)
from the Company and from all other corporations and trades or businesses, if any, that would be treated as a single &#147;service recipient&#148; with the Company under <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h)(3)</FONT> of the
Treasury Regulations. The Company may, but need not, elect in writing, subject to the applicable limitations under Section&nbsp;409A, any of the special elective rules prescribed in <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h)</FONT> of
the Treasury Regulations for purposes of determining whether a &#147;separation from service&#148; has occurred. Any such written election will be deemed a part of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Exchange Act&#148;: </B>The Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Fair Market Value&#148;: </B>As of a particular date, (i)&nbsp;the closing price for a share of Stock reported on the Nasdaq Global
Market (or any other national securities exchange on which the Stock is then listed) for that date or, if no closing price is reported for that date, the closing price on the immediately preceding date on which a closing price was reported or
(ii)&nbsp;in the event that the Stock is not traded on a national securities exchange, the fair market value of a share of Stock determined by the Administrator consistent with the rules of Section&nbsp;422 and Section&nbsp;409A to the extent
applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;ISO&#148;: </B>A Stock Option intended to be an &#147;incentive stock option&#148; within the meaning of
Section&nbsp;422. Each Stock Option granted pursuant to the Plan will be treated as providing by its terms that it is to be an NSO unless, as of the date of grant, it is expressly designated as an ISO in the applicable Award agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;NSO&#148;: </B>A Stock Option that is not intended to be an &#147;incentive stock
option&#148; within the meaning of Section&nbsp;422. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Participant&#148;: </B>A person who is granted an Award under the Plan.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Performance Award&#148;:</B> An Award subject to performance vesting conditions, which may include Performance Criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Performance Criteria&#148;: </B>Specified criteria, other than the mere continuation of Employment or the mere passage of time, the
satisfaction of which is a condition for the grant, exercisability, vesting or full enjoyment of an Award. A Performance Criterion and any targets with respect thereto need not be based upon an increase, a positive or improved result or avoidance of
loss and may be applied to a Participant individually, or to a business unit or division of the Company or to the Company as a whole. A Performance Criterion may also be based on individual performance and/or subjective performance criteria. The
Administrator may provide that one or more of the Performance Criteria applicable to such Award will be adjusted in a manner to reflect events (for example, but without limitation, acquisitions or dispositions) occurring during the performance
period that affect the applicable Performance Criterion or Criteria. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Person&#148;:</B> An individual, entity or group (within
the meaning of Section&nbsp;13(d)(3) or 14(d)(2) of the Exchange Act). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Plan&#148;: </B>This Rallybio Corporation 2021 Equity
Incentive Plan, as from time to time amended and in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Restricted Stock&#148;: </B>Stock subject to restrictions requiring
that it be forfeited, redelivered or offered for sale to the Company if specified performance or other vesting conditions are not satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Restricted Stock Unit&#148;: </B>A Stock Unit that is, or as to which the delivery of Stock or of cash in lieu of Stock is, subject
to the satisfaction of specified performance or other vesting conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;SAR&#148;: </B>A right entitling the holder upon
exercise to receive an amount (payable in cash or in shares of Stock of equivalent value) equal to the excess of the Fair Market Value of the shares of Stock subject to the right over the base value from which appreciation under the SAR is to be
measured. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Section</B><B></B><B>&nbsp;409A&#148;: </B>Section&nbsp;409A of the Code and the regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Section</B><B></B><B>&nbsp;422&#148;: </B>Section&nbsp;422 of the Code and the regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Stock&#148;: </B>Common stock of the Company, par value $0.0001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Stock Option&#148;: </B>An option entitling the holder to acquire shares of Stock upon payment of the exercise price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Stock Unit&#148;: </B>An unfunded and unsecured promise, denominated in shares of
Stock, to deliver Stock or cash measured by the value of Stock in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Substitute Award&#148;: </B>An<B> </B>Award
granted under the Plan in substitution for one or more equity awards of an acquired company that are converted, replaced or adjusted in connection with the acquisition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Unrestricted Stock&#148;: </B>Stock not subject to any restrictions under the terms of the Award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>14
<FILENAME>d99471dex1013.htm
<DESCRIPTION>EX-10.13
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.13</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.13 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Name:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>[_________]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Number of Shares of Stock subject to the Stock Option:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>[_________]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exercise Price Per Share:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>$[_________]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Date of Grant:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>[_________]</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>[Vesting Commencement Date:]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>[_________]</B></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2021 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>N<SMALL>ON</SMALL><FONT STYLE="white-space:nowrap">-S</FONT><SMALL>TATUTORY</SMALL> S<SMALL>TOCK</SMALL> O<SMALL>PTION</SMALL>
A<SMALL>GREEMENT</SMALL> </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This agreement (this &#147;<B>Agreement</B>&#148;) evidences a stock option granted by Rallybio
Corporation, a Delaware corporation (the &#147;<B>Company</B>&#148;), to the individual named above (the &#147;<B>Participant</B>&#148;), pursuant to and subject to the terms of the Rallybio Corporation 2021 Equity Incentive Plan (as from time to
time amended and in effect, the &#147;<B>Plan</B>&#148;). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Grant of Stock Option</U>. On the date of grant set forth above (the &#147;<B>Date of Grant</B>&#148;), the Company granted to the
Participant an option (the &#147;<B>Stock Option</B>&#148;) to purchase, pursuant to and subject to the terms and conditions set forth in this Agreement and in the Plan, up to the number of shares of Stock set forth above (the
&#147;<B>Shares</B>&#148;), with an exercise price per Share as set forth above, in each case subject to adjustment pursuant to Section&nbsp;7 of the Plan in respect of transactions occurring after the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stock Option evidenced by this Agreement is a <FONT STYLE="white-space:nowrap">non-statutory</FONT> option (that is, an option that is not
intended to qualify as an incentive stock option) and is granted to the Participant in connection with the Participant&#146;s Employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Vesting</U>. The term &#147;<B>vest</B>&#148; as used herein with respect to the Stock Option or any portion thereof means to become
exercisable and the term &#147;<B>vested</B>&#148; as used herein with respect to the Stock Option (or any portion thereof) means that the Stock Option (or portion thereof) is then exercisable. Unless earlier terminated, forfeited, relinquished or
expired, the Stock Option will vest as to [_________], in each case, subject to the Participant&#146;s continued Employment through the applicable vesting date.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Exercise of the Stock Option</U>. No portion of the Stock Option may be exercised until such portion vests. Each election to exercise
any vested portion of the Stock Option will be subject to the terms and conditions of the Plan and must be in written or electronic form acceptable to the Administrator, signed (including by electronic signature) by the Participant or, if at the
relevant time the Stock Option has passed to the estate or beneficiary of the Participant or a permitted transferee, by such estate or beneficiary or permitted transferee. Each such written or electronic exercise election must be received by the
Company at its principal office or at such other place or by such other party as the Administrator may prescribe and must be accompanied by payment in full of the exercise price by cash or check, through a broker-assisted exercise program acceptable
to the Administrator, or as otherwise provided in the Plan. Subject to earlier termination as set forth herein or in the Plan (including Section&nbsp;6(a)(4) of the Plan), the latest date on which the Stock Option or any portion thereof may be
exercised is the tenth (10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) anniversary of the Date of Grant (the &#147;<B>Final Exercise Date</B>&#148;) and, if not exercised on or prior to such date, the Stock Option or any remaining
portion thereof will thereupon immediately terminate. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Cessation of Service</U>.<B> </B>If the Participant&#146;s Employment ceases for any
reason, except as expressly provided for in a written agreement between the Participant and the Company or one of its affiliates that is in effect at the time of such cessation of Employment, the Stock Option, to the extent not then vested, will be
immediately forfeited for no consideration, and any vested portion of the Stock Option that is then outstanding will remain exercisable for the period, if any, described in Section&nbsp;6(a)(4) of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Nontransferability</U>.<B> </B>The Stock Option may not be transferred except as expressly permitted under Section&nbsp;6(a)(3) of the
Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Forfeiture; Recovery of Compensation</U>. By accepting, or being deemed to have accepted, the Stock Option, the Participant
expressly acknowledges and agrees that his or her rights, and those of any permitted transferee, with respect to the Stock Option, including the right to any Shares acquired under the Stock Option and any amounts received in respect thereof, are
subject to Section&nbsp;6(a)(5) of the Plan (including any successor provision). The Participant further agrees to be bound by the terms of any applicable clawback or recoupment policy of the Company. Nothing in the preceding sentence will be
construed as limiting the general application of Section&nbsp;8 of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Taxes</U>. The Participant expressly
acknowledges and agrees that the Participant&#146;s rights hereunder, including the right to be issued Shares upon exercise of the Stock Option, are subject to the Participant promptly paying to the Company in cash or by check (or by such other
means as may be acceptable to the Administrator) all taxes and other amounts required to be withheld. No Shares will be issued pursuant to the exercise of the Stock Option unless and until the person exercising the Stock Option has remitted to the
Company an amount in cash sufficient to satisfy any withholding requirements, or has made other arrangements satisfactory to the Company with respect to such amounts. The Participant authorizes the Company and its subsidiaries to withhold any
amounts due in respect of any required withholdings from any amounts otherwise owed to the Participant, but nothing in this sentence will be construed as relieving the Participant of any liability for satisfying his or her tax obligations relating
to the Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Provisions of the Plan</U>. This Agreement is subject in its entirety to the provisions of the Plan, which are
incorporated herein by reference. A copy of the Plan as in effect on the Date of Grant has been made available to the Participant. By accepting, or being deemed to have accepted, the Stock Option, the Participant agrees to be bound by the terms of
the Plan and this Agreement. In the event of any conflict between the terms of this Agreement and the Plan, the terms of the Plan will control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Acknowledgements</U>. The Participant acknowledges and agrees that (i)&nbsp;this Agreement may be executed in two or more counterparts,
each of which will be an original and all of which together will constitute one and the same instrument, (ii)&nbsp;this Agreement may be executed and exchanged using facsimile, portable document format (PDF) or electronic
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
signature, which, in each case, will constitute an original signature for all purposes hereunder, and (iii)&nbsp;such signature by the Company will be binding against the Company and will create
a legally binding agreement when this Agreement is countersigned by the Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature page follows.] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company, by its duly authorized officer, and the Participant have executed this
Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RALLYBIO
CORPORATION</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Name:</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Title:</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Agreed and Accepted:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[Participant&#146;s Name]</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page to Stock Option Agreement</I> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>15
<FILENAME>d99471dex1014.htm
<DESCRIPTION>EX-10.14
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.14</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.14 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Name:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>[_________</B></TD>
<TD NOWRAP VALIGN="bottom"><B>]&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Number of Shares of Stock subject to the Stock Option:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>[_________</B></TD>
<TD NOWRAP VALIGN="bottom"><B>]&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Exercise Price Per Share:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>[_________</B></TD>
<TD NOWRAP VALIGN="bottom"><B>]&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Date of Grant:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>[_________</B></TD>
<TD NOWRAP VALIGN="bottom"><B>]&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[Vesting Commencement Date:]</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>[_________</B></TD>
<TD NOWRAP VALIGN="bottom"><B>]&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2021 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>N<SMALL>ON</SMALL><FONT STYLE="white-space:nowrap">-S</FONT><SMALL>TATUTORY</SMALL> S<SMALL>TOCK</SMALL> O<SMALL>PTION</SMALL>
A<SMALL>GREEMENT</SMALL> </U></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">(Non-Employee</FONT> Directors and Consultants) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This agreement (this &#147;<B>Agreement</B>&#148;) evidences a stock option granted by Rallybio Corporation, a Delaware corporation (the
&#147;<B>Company</B>&#148;), to the individual named above (the &#147;<B>Participant</B>&#148;), pursuant to and subject to the terms of the Rallybio Corporation 2021 Equity Incentive Plan (as from time to time amended and in effect, the
&#147;<B>Plan</B>&#148;). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
<U>Grant of Stock Option</U>. On the date of grant set forth above (the &#147;<B>Date of Grant</B>&#148;), the Company granted to the Participant an option (the &#147;<B>Stock Option</B>&#148;) to purchase, pursuant to and subject to the terms and
conditions set forth in this Agreement and in the Plan, up to the number of shares of Stock set forth above (the &#147;<B>Shares</B>&#148;), with an exercise price per Share as set forth above, in each case subject to adjustment pursuant to
Section&nbsp;7 of the Plan in respect of transactions occurring after the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stock Option evidenced by this Agreement is a <FONT
STYLE="white-space:nowrap">non-statutory</FONT> option (that is, an option that is not intended to qualify as an incentive stock option) and is granted to the Participant in connection with the Participant&#146;s Employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Vesting</U>. The term &#147;<B>vest</B>&#148; as used herein with respect to the Stock Option or any portion thereof means to become
exercisable and the term &#147;<B>vested</B>&#148; as used herein with respect to the Stock Option (or any portion thereof) means that the Stock Option (or portion thereof) is then exercisable. Unless earlier terminated, forfeited, relinquished or
expired, the Stock Option will vest as to [_________], in each case, subject to the Participant&#146;s continued Employment through the applicable vesting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Exercise of the Stock Option</U>. No portion of the Stock Option may be exercised until such portion vests. Each election to exercise
any vested portion of the Stock Option will be subject to the terms and conditions of the Plan and must be in written or electronic form acceptable to the Administrator, signed (including by electronic signature) by the Participant or, if at the
relevant time the Stock Option has passed to the estate or beneficiary of the Participant or a permitted transferee, by such estate or beneficiary or permitted transferee. Each such written or electronic exercise election must be received by the
Company at its principal office or at such other place or by such other party as the Administrator may prescribe and must be accompanied by payment in full of the exercise price by cash or check, through a broker-assisted exercise program acceptable
to the Administrator, or as otherwise provided in the Plan. Subject to earlier termination as set forth herein or in the Plan (including Section&nbsp;6(a)(4) of the Plan), the latest date on which the Stock Option or any portion thereof may be
exercised is the tenth (10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) anniversary of the Date of Grant (the &#147;<B>Final Exercise Date</B>&#148;) and, if not exercised on or prior to such date, the Stock Option or any remaining
portion thereof will thereupon immediately terminate. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Cessation of Service</U>.<B> </B>If the Participant&#146;s Employment ceases for any
reason except as expressly provided for in a written agreement between the Participant and the Company or one of its affiliates that is in effect at the time of such cessation of Employment, the Stock Option, to the extent not then vested, will be
immediately forfeited for no consideration, and any vested portion of the Stock Option that is then outstanding will remain exercisable for the period, if any, described in Section&nbsp;6(a)(4) of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Nontransferability</U>.<B> </B>The Stock Option may not be transferred except as expressly permitted under Section&nbsp;6(a)(3) of the
Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Forfeiture; Recovery of Compensation</U>. By accepting, or being deemed to have accepted, the Stock Option, the Participant
expressly acknowledges and agrees that his or her rights, and those of any permitted transferee, with respect to the Stock Option, including the right to any Shares acquired under the Stock Option and any amounts received in respect thereof, are
subject to Section&nbsp;6(a)(5) of the Plan (including any successor provision). The Participant further agrees to be bound by the terms of any applicable clawback or recoupment policy of the Company. Nothing in the preceding sentence will be
construed as limiting the general application of Section&nbsp;8 of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Taxes</U>. The Participant is responsible for
satisfying and paying all taxes arising from or due in connection with the Stock Option, its exercise and any disposition of any Shares acquired upon exercise of the Stock Option. The Company will have no liability or obligation related to the
foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Provisions of the Plan</U>. This Agreement is subject in its entirety to the provisions of the Plan, which are
incorporated herein by reference. A copy of the Plan as in effect on the Date of Grant has been made available to the Participant. By accepting, or being deemed to have accepted, the Stock Option, the Participant agrees to be bound by the terms of
the Plan and this Agreement. In the event of any conflict between the terms of this Agreement and the Plan, the terms of the Plan will control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Acknowledgements</U>. The Participant acknowledges and agrees that (i)&nbsp;this Agreement may be executed in two or more counterparts,
each of which will be an original and all of which together will constitute one and the same instrument, (ii)&nbsp;this Agreement may be executed and exchanged using facsimile, portable document format (PDF) or electronic signature, which, in each
case, will constitute an original signature for all purposes hereunder, and (iii)&nbsp;such signature by the Company will be binding against the Company and will create a legally binding agreement when this Agreement is countersigned by the
Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature page follows.] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company, by its duly authorized officer, and the Participant have executed this
Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">RALLYBIO CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Agreed and Accepted:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[Participant&#146;s Name]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page to
Stock Option Agreement</I> </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>16
<FILENAME>d99471dex1015.htm
<DESCRIPTION>EX-10.15
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.15</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.15 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Name:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>[_________</B></TD>
<TD NOWRAP VALIGN="bottom"><B>]&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Number of Shares of Stock subject to the Stock Option:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>[_________</B></TD>
<TD NOWRAP VALIGN="bottom"><B>]&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Exercise Price Per Share:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>[_________</B></TD>
<TD NOWRAP VALIGN="bottom"><B>]&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Date of Grant:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>[_________</B></TD>
<TD NOWRAP VALIGN="bottom"><B>]&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>[Vesting Commencement Date:]</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>[_________</B></TD>
<TD NOWRAP VALIGN="bottom"><B>]&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2021 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>I<SMALL>NCENTIVE</SMALL> S<SMALL>TOCK</SMALL> O<SMALL>PTION</SMALL> A<SMALL>GREEMENT</SMALL> </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This agreement (this &#147;<B>Agreement</B>&#148;) evidences a stock option granted by Rallybio Corporation, a Delaware corporation (the
&#147;<B>Company</B>&#148;), to the individual named above (the &#147;<B>Participant</B>&#148;), pursuant to and subject to the terms of the Rallybio Corporation 2021 Equity Incentive Plan (as from time to time amended and in effect, the
&#147;<B>Plan</B>&#148;). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
<U>Grant of Stock Option</U>. On the date of grant set forth above (the &#147;<B>Date of Grant</B>&#148;), the Company granted to the Participant an option (the &#147;<B>Stock Option</B>&#148;) to purchase, pursuant to and subject to the terms and
conditions set forth in this Agreement and in the Plan, up to the number of shares of Stock set forth above (the &#147;<B>Shares</B>&#148;), with an exercise price per Share as set forth above, in each case subject to adjustment pursuant to
Section&nbsp;7 of the Plan in respect of transactions occurring after the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stock Option evidenced by this Agreement is
intended to be treated as an ISO to the maximum extent provided under the Code. To the extent the Stock Option does not qualify as an ISO, the Stock Option will be treated as an NSO. The Participant acknowledges and agrees that the Administrator may
take any action permitted under the Plan without regard to the effect such action may have on the status of the Stock Option as an ISO and that such action may cause the Stock Option to fail to be treated as an ISO. Without limiting the Plan, the
Administrator shall have no liability with respect to any action taken by it that causes the Stock Option to fail to be treated as an ISO. To the extent that the aggregate Fair Market Value (determined at the time of grant) of the Shares subject to
the Stock Option and all other ISOs the Participant holds that are exercisable for the first time during any calendar year (under all plans of the Company and its subsidiaries) exceeds $100,000, the stock options held by the Participant or portions
thereof that exceed such limit (according to the order in which they were granted in accordance with Section&nbsp;422) will be treated as NSOs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Vesting</U>. The term &#147;<B>vest</B>&#148; as used herein with respect to the Stock Option or any portion thereof means to become
exercisable and the term &#147;<B>vested</B>&#148; as used herein with respect to the Stock Option (or any portion thereof) means that the Stock Option (or portion thereof) is then exercisable. Unless earlier terminated, forfeited, relinquished or
expired, the Stock Option will vest as to [_________], in each case, subject to the Participant&#146;s continued Employment through the applicable vesting date.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Exercise of the Stock Option</U>. No portion of the Stock Option may be exercised
until such portion vests. Each election to exercise any vested portion of the Stock Option will be subject to the terms and conditions of the Plan and must be in written or electronic form acceptable to the Administrator, signed (including by
electronic signature) by the Participant or, if at the relevant time the Stock Option has passed to the estate or beneficiary of the Participant or a permitted transferee, by such estate or beneficiary or permitted transferee. Each such written or
electronic exercise election must be received by the Company at its principal office or at such other place or by such other party as the Administrator may prescribe and must be accompanied by payment in full of the exercise price by cash or check,
through a broker-assisted exercise program acceptable to the Administrator, or as otherwise provided in the Plan consistent with the regulations promulgated under Section&nbsp;424 of the Code. Subject to earlier termination as set forth herein or in
the Plan (including Section&nbsp;6(a)(4) of the Plan), the latest date on which the Stock Option or any portion thereof may be exercised is the tenth (10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) anniversary (or the fifth (5<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>) anniversary, in the case of a <FONT STYLE="white-space:nowrap">10-percent</FONT> stockholder within the meaning of Section&nbsp;422(b)(6) of the Code) of the Date of Grant (the &#147;<B>Final
Exercise Date</B>&#148;) and, if not exercised on or prior to such date, the Stock Option or any remaining portion thereof will thereupon immediately terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Cessation of Service</U>.<B> </B>If the Participant&#146;s Employment ceases for any reason, except as expressly provided for in a
written agreement between the Participant and the Company or one of its affiliates that is in effect at the time of such cessation of Employment, the Stock Option, to the extent not then vested, will be immediately forfeited for no consideration,
and any vested portion of the Stock Option that is then outstanding will remain exercisable for the period, if any, described in Section&nbsp;6(a)(4) of the Plan. The Participant acknowledges and agrees that in the event any portion of the Stock
Option is exercised after the date that is three (3)&nbsp;months after the date of the cessation of the Participant&#146;s employment with the Company and its subsidiaries (subject to certain exceptions in the case of the Participant&#146;s death),
the Participant will lose the tax treatment afforded to ISOs under the Code with respect to any portion of the Stock Option so exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Nontransferability; Disposition of Shares</U>.<B> </B>The Stock Option may not be transferred except as expressly permitted under
Section&nbsp;6(a)(3) of the Plan. If the Participant transfers or otherwise disposes of any Shares acquired upon exercise of the Stock Option within two years from the Date of Grant or within one year after such Shares were acquired pursuant to the
exercise of the Stock Option, within fifteen (15)&nbsp;days following such transfer or disposition, the Participant will notify the Company in writing of such transfer or disposition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Forfeiture; Recovery of Compensation</U>. By accepting, or being deemed to have accepted, the Stock Option, the Participant expressly
acknowledges and agrees that his or her rights, and those of any permitted transferee, with respect to the Stock Option, including the right to any Shares acquired under the Stock Option and any amounts received in respect thereof, are subject to
Section&nbsp;6(a)(5) of the Plan (including any successor provision). The Participant further agrees to be bound by the terms of any applicable clawback or recoupment policy of the Company. Nothing in the preceding sentence will be construed as
limiting the general application of Section&nbsp;8 of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Taxes</U>. The Participant expressly acknowledges and agrees that the
Participant&#146;s rights hereunder, including the right to be issued Shares upon exercise of the Stock Option, are subject to the Participant promptly paying to the Company in cash or by check (or by such other means as may be acceptable to the
Administrator) all taxes and other amounts required to be withheld. No Shares will be issued pursuant to the exercise of the Stock Option unless and until the person exercising the Stock Option has remitted to the Company an amount in cash
sufficient to satisfy any withholding requirements, or has made other arrangements satisfactory to the Company with respect to such amounts. The Participant authorizes the Company and its subsidiaries to withhold any amounts due in respect of any
required withholdings from any amounts otherwise owed to the Participant, but nothing in this sentence will be construed as relieving the Participant of any liability for satisfying his or her tax obligations relating to the Stock Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Provisions of the Plan</U>. This Agreement is subject in its entirety to the provisions of the Plan, which are incorporated herein by
reference. A copy of the Plan as in effect on the Date of Grant has been made available to the Participant. By accepting, or being deemed to have accepted, the Stock Option, the Participant agrees to be bound by the terms of the Plan and this
Agreement. In the event of any conflict between the terms of this Agreement and the Plan, the terms of the Plan will control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.
<U>Acknowledgements</U>. The Participant acknowledges and agrees that (i)&nbsp;this Agreement may be executed in two or more counterparts, each of which will be an original and all of which together will constitute one and the same instrument,
(ii)&nbsp;this Agreement may be executed and exchanged using facsimile, portable document format (PDF) or electronic signature, which, in each case, will constitute an original signature for all purposes hereunder, and (iii)&nbsp;such signature by
the Company will be binding against the Company and will create a legally binding agreement when this Agreement is countersigned by the Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature page follows.] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company, by its duly authorized officer, and the Participant have executed this
Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">RALLYBIO CORPORATION</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Agreed and Accepted:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[Participant&#146;s Name]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page to Stock Option Agreement </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>17
<FILENAME>d99471dex1016.htm
<DESCRIPTION>EX-10.16
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.16</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.16 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Name:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[_________]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Number of Restricted Stock Units:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[_________]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Date of Grant:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[_________]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>[Vesting Commencement Date:]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[_________]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2021 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>R<SMALL>ESTRICTED</SMALL> S<SMALL>TOCK</SMALL> U<SMALL>NIT</SMALL> A<SMALL>GREEMENT</SMALL> </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This agreement (this &#147;<B>Agreement</B>&#148;) evidences a grant (the &#147;<B>Award</B>&#148;) of Restricted Stock Units
(&#147;<B>RSUs</B>&#148;) by Rallybio Corporation, a Delaware corporation (the &#147;<B>Company</B>&#148;), to the individual named above (the &#147;<B>Participant</B>&#148;), pursuant to and subject to the terms of the Rallybio Corporation 2021
Equity Incentive Plan (as from time to time amended and in effect, the &#147;<B>Plan</B>&#148;). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Grant of RSUs</U>. On the date of grant set forth above (the &#147;<B>Date of Grant</B>&#148;), the Company granted to the Participant
the number of Restricted Stock Units (&#147;<B>RSUs</B>&#148;) set forth above, giving the Participant the conditional right to receive, without payment and pursuant to and subject to the terms and conditions set forth in this Agreement and in the
Plan, one share of Stock (a &#147;<B>Share</B>&#148;) with respect to each RSU subject to this Award, subject to adjustment pursuant to Section&nbsp;7 of the Plan in respect of transactions occurring after the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The RSUs are granted to the Participant in connection with the Participant&#146;s Employment with the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Vesting</U>. Unless earlier terminated, forfeited, relinquished or expired, the RSUs will vest [_________], subject to the Participant
remaining in continuous Employment from the Date of Grant through the applicable vesting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Cessation of Service</U>.<B> </B>If
the Participant&#146;s Employment ceases for any reason, except as expressly provided for in a written agreement between the Participant and the Company or one of its affiliates that is in effect at the time of such cessation of Employment, the
RSUs, to the extent not then vested, will be immediately forfeited for no consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Delivery of Shares</U>. The Company shall,
as soon as practicable upon the vesting of any RSUs (but in no event later than thirty (30)&nbsp;days following the date on which such RSUs vest), effect delivery of the Shares with respect to such vested RSUs to the Participant (or, in the event of
the RSUs have passed to the estate or beneficiary of the Participant or a permitted transferee, to such estate or beneficiary or permitted transferee). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Nontransferability</U>. The RSUs may not be transferred except as expressly permitted under Section&nbsp;6(a)(3) of the Plan. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Forfeiture; Recovery of Compensation</U>. By accepting, or being deemed to have
accepted, the RSUs, the Participant expressly acknowledges and agrees that his or her rights, and those of any permitted transferee, with respect to the RSUs, including the right to any Shares acquired in respect of the RSUs and any amounts received
in respect thereof, are subject to Section&nbsp;6(a)(5) of the Plan (including any successor provision). The Participant further agrees to be bound by the terms of any applicable clawback or recoupment policy of the Company. Nothing in the preceding
sentence will be construed as limiting the general application of Section&nbsp;8 of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Taxes</U>. The Participant
expressly acknowledges and agrees that the Participant&#146;s rights hereunder, including the right to be issued Shares upon settlement of the Award, are subject to the Participant promptly paying to the Company in cash or by check (or by such other
means as may be acceptable to the Administrator) all taxes and other amounts required to be withheld. No Shares will be issued in respect of the Award unless and until the Participant has remitted to the Company an amount in cash sufficient to
satisfy any withholding requirements, or has made other arrangements satisfactory to the Company with respect to such amounts. Unless otherwise determined by the Company, the Company shall automatically satisfy any tax withholding obligations by
withholding from the Shares that would otherwise be delivered in connection with a vesting date a number of Shares having a fair market value equal to the minimum statutory amount required to be withheld to satisfy such tax withholding obligations
and/or by causing such number of Shares to be sold in accordance with a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sell-to-cover</FONT></FONT> arrangement. The Participant authorizes the Company and its subsidiaries to
withhold any amounts due in respect of any required withholdings by withholding from the Shares otherwise deliverable in connection with the RSUs, by causing such Shares to be sold in accordance with a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">sell-to-cover</FONT></FONT> arrangement and/or by withholding from any amounts otherwise owed to the Participant. If a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sell-to-cover</FONT></FONT>
arrangement is selected as contemplated hereunder, the Participant shall bear all costs associated with the sale of Shares under such arrangement. Nothing in this Section&nbsp;7, however, shall be construed as relieving the Participant of any
liability for satisfying his or her tax obligations relating to the Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Provisions of the Plan</U>. This Agreement is subject in
its entirety to the provisions of the Plan, which are incorporated herein by reference. A copy of the Plan as in effect on the Date of Grant has been made available to the Participant. By accepting, or being deemed to have accepted, the Award, the
Participant agrees to be bound by the terms of the Plan and this Agreement. In the event of any conflict between the terms of this Agreement and the Plan, the terms of the Plan will control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Acknowledgements</U>. The Participant acknowledges and agrees that (i)&nbsp;this Agreement may be executed in two or more counterparts,
each of which will be an original and all of which together will constitute one and the same instrument, (ii)&nbsp;this Agreement may be executed and exchanged using facsimile, portable document format (PDF) or electronic signature, which, in each
case, will constitute an original signature for all purposes hereunder, and (iii)&nbsp;such signature by the Company will be binding against the Company and will create a legally binding agreement when this Agreement is countersigned by the
Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature page follows.] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company, by its duly authorized officer, and the Participant have executed this
Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">RALLYBIO CORPORATION</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Agreed and Accepted:</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[Participant&#146;s Name]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page to Restricted Stock Unit Agreement </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>18
<FILENAME>d99471dex1017.htm
<DESCRIPTION>EX-10.17
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.17</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.17 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Name:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[_________]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Number of Restricted Stock Units:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[_________]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Date of Grant:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[_________]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>[Vesting Commencement Date:]</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[_________]</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2021 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>R<SMALL>ESTRICTED</SMALL> S<SMALL>TOCK</SMALL> U<SMALL>NIT</SMALL> A<SMALL>GREEMENT</SMALL> </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">(Non-Employee</FONT> Directors and Consultants) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This agreement (this &#147;<B>Agreement</B>&#148;) evidences a grant (the &#147;<B>Award</B>&#148;) of Restricted Stock Units
(&#147;<B>RSUs</B>&#148;) by Rallybio Corporation, a Delaware corporation (the &#147;<B>Company</B>&#148;), to the individual named above (the &#147;<B>Participant</B>&#148;), pursuant to and subject to the terms of the Rallybio Corporation 2021
Equity Incentive Plan (as from time to time amended and in effect, the &#147;<B>Plan</B>&#148;). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Grant of RSUs</U>. On the date of grant set forth above (the &#147;<B>Date of Grant</B>&#148;), the Company granted to the Participant
the number of Restricted Stock Units (&#147;<B>RSUs</B>&#148;) set forth above, giving the Participant the conditional right to receive, without payment and pursuant to and subject to the terms and conditions set forth in this Agreement and in the
Plan, one share of Stock (a &#147;<B>Share</B>&#148;) with respect to each RSU subject to this Award, subject to adjustment pursuant to Section&nbsp;7 of the Plan in respect of transactions occurring after the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The RSUs are granted to the Participant in connection with the Participant&#146;s Employment with the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Vesting</U>. Unless earlier terminated, forfeited, relinquished or expired, the RSUs will vest [_________], subject to the Participant
remaining in continuous Employment from the Date of Grant through the applicable vesting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Cessation of Service</U>.<B> </B>If
the Participant&#146;s Employment ceases for any reason, except as expressly provided for in a written agreement between the Participant and the Company or one of its affiliates that is in effect at the time of such cessation of Employment, the
RSUs, to the extent not then vested, will be immediately forfeited for no consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Delivery of Shares</U>. The Company shall,
as soon as practicable upon the vesting of any RSUs (but in no event later than thirty (30)&nbsp;days following the date on which such RSUs vest), effect delivery of the Shares with respect to such vested RSUs to the Participant (or, in the event of
the RSUs have passed to the estate or beneficiary of the Participant or a permitted transferee, to such estate or beneficiary or permitted transferee). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Nontransferability</U>. The RSUs may not be transferred except as expressly permitted under Section&nbsp;6(a)(3) of the Plan. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Forfeiture; Recovery of Compensation</U>. By accepting, or being deemed to have
accepted, the RSUs, the Participant expressly acknowledges and agrees that his or her rights, and those of any permitted transferee, with respect to the RSUs, including the right to any Shares acquired in respect of the RSUs and any amounts received
in respect thereof, are subject to Section&nbsp;6(a)(5) of the Plan (including any successor provision). The Participant further agrees to be bound by the terms of any applicable clawback or recoupment policy of the Company. Nothing in the preceding
sentence will be construed as limiting the general application of Section&nbsp;8 of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Taxes</U>. The Participant is
responsible for satisfying and paying all taxes arising from or due in connection with the Award, its vesting and/or settlement and any disposition of any Shares acquired upon the vesting of the Award. The Company will have no liability or
obligation related to the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Provisions of the Plan</U>. This Agreement is subject in its entirety to the provisions of the
Plan, which are incorporated herein by reference. A copy of the Plan as in effect on the Date of Grant has been made available to the Participant. By accepting, or being deemed to have accepted, the Award, the Participant agrees to be bound by the
terms of the Plan and this Agreement. In the event of any conflict between the terms of this Agreement and the Plan, the terms of the Plan will control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Acknowledgements</U>. The Participant acknowledges and agrees that (i)&nbsp;this Agreement may be executed in two or more counterparts,
each of which will be an original and all of which together will constitute one and the same instrument, (ii)&nbsp;this Agreement may be executed and exchanged using facsimile, portable document format (PDF) or electronic signature, which, in each
case, will constitute an original signature for all purposes hereunder, and (iii)&nbsp;such signature by the Company will be binding against the Company and will create a legally binding agreement when this Agreement is countersigned by the
Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature page follows.] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company, by its duly authorized officer, and the Participant have executed this
Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">RALLYBIO CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Agreed and Accepted:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[Participant&#146;s Name]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page to
Restricted Stock Unit Agreement</I> </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>19
<FILENAME>d99471dex1018.htm
<DESCRIPTION>EX-10.18
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.18</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.18 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2021 CASH INCENTIVE PLAN </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINED TERMS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Exhibit A</U>, which is incorporated by reference, defines certain terms used in the Plan and sets forth operational rules related to those
terms. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PURPOSE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan has been established to advance the interests of the Company by providing for the grant of cash-based incentive Awards. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ADMINISTRATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan will be administered by the Administrator. The Administrator has discretionary authority, subject only to the express provisions of
the Plan, to interpret the Plan and any Award; to determine eligibility for and grant Awards; to adjust the Performance Criterion or Criteria applicable to Awards; to determine, modify or waive the terms and conditions of any Award; to prescribe
forms, rules and procedures relating to the Plan and Awards; and to otherwise do all things necessary or desirable to carry out the purposes of the Plan or any Award. Determinations of the Administrator made with respect to the Plan or any Award are
conclusive and bind all persons. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ELIGIBILITY AND PARTICIPATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator may select Participants from among executive officers and key employees of the Company and its subsidiaries. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GRANT OF AWARDS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Participant who is granted an Award will be entitled to a payment, if any, in respect of the Award only if all conditions to payment have
been satisfied in accordance with the Plan and the terms of the Award, except as otherwise determined by the Administrator in accordance with Section&nbsp;6 below. By accepting (or being deemed to have accepted) an Award, the Participant agrees (or
will be deemed to have agreed) to the terms and condition of the Award and the Plan. The Administrator will select the Participants, if any, who receive Awards for each Performance Period and, for each Award, will establish the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> the Performance Criterion or Criteria applicable to the Award; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> the amount or amounts that will be payable (subject to adjustment in accordance with Section&nbsp;6 below) if the Performance
Criterion or Criteria are achieved in whole or in part; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> such other terms and conditions as the Administrator determines
with respect to the Award. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DETERMINATION OF PERFORMANCE AND AMOUNTS PAYABLE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As soon as practicable after the end of the applicable Performance Period, the Administrator will determine whether and to what extent, if at
all, the Performance Criterion or Criteria applicable to each Award granted for such Performance Period have been satisfied. The Administrator will then determine the amount payable, if any, under each Award. The Administrator may, in its sole
discretion and with or without specifying its reasons for doing so, after determining the amount that would otherwise be payable in respect of any Award, adjust the actual payment, if any, to be made with respect to such Award. The Administrator may
exercise the discretion described in the immediately preceding sentence either in individual cases or in ways that affect more than one Participant. In each case, the Administrator&#146;s discretionary determination, which may affect different
Awards differently, is conclusive and will bind all persons. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PAYMENTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator will determine the payment dates for Awards under the Plan. Except as otherwise determined by the Administrator: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> all payments under the Plan will be made, if at all, not later than the later of (i)&nbsp;two and
<FONT STYLE="white-space:nowrap">one-half</FONT> months following the end of the Company&#146;s fiscal year in which the Performance Period ends and (ii)&nbsp;March 15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the calendar year
immediately following the calendar year in which the Performance Period ends; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> payment will not be made with respect to an
Award unless the Participant has remained employed with the Company and its subsidiaries through the date of payment; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
awards under the Plan are intended to qualify for exemption from Section&nbsp;409A of the Code and shall be construed and administered accordingly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything herein to the contrary, the Administrator may authorize elective deferrals of any Award payments in accordance with the deferral
rules of Section&nbsp;409A. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TAX WITHHOLDING </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All payments under the Plan will be reduced by all tax and other amounts required to be withheld with respect to the payment. Any amounts
withheld pursuant to this Section&nbsp;8 will be treated as though such amounts had been paid directly to the applicable Participant. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>AMENDMENT AND TERMINATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator may at any time or times amend the Plan or any outstanding Award for any purpose which may at the time be permitted by
applicable law, and may at any time terminate the Plan as to any future grants of Awards.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>For the avoidance of doubt, no adjustment to any Award or determination made with respect to any Award, in
each case, in accordance with the terms of the Plan will be treated as an amendment that requires the consent of any Participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RECOVERY OF COMPENSATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator may provide in any case that any outstanding Award and any amounts received in respect of any Award will be subject to
forfeiture and disgorgement to the Company, with interest and other related earnings, if the Participant to whom the Award was granted is not in compliance with any provision of the Plan or any applicable Award or any
<FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> <FONT STYLE="white-space:nowrap">no-hire,</FONT> <FONT STYLE="white-space:nowrap">non-disparagement,</FONT> confidentiality, invention
assignment or other restrictive covenant by which he or she is bound. In addition, each Award will be subject to any policy of the Company or any of its affiliates that provides for forfeiture, disgorgement or clawback with respect to incentive
compensation that includes Awards under the Plan and will be further subject to forfeiture and disgorgement to the extent required by law or applicable stock exchange listing standards, including, without limitation, Section&nbsp;10D of the
Securities Exchange Act of 1934, as amended. Each Participant, by accepting (or being deemed to have accepted) an Award under the Plan, agrees (or will be deemed to have agreed) to the provisions of this Section&nbsp;10 and any clawback, recoupment
or similar policy of the Company or any of its subsidiaries and further agrees (or will be deemed to have further agreed) to cooperate fully with the Administrator to effectuate any forfeiture or disgorgement described in this Section&nbsp;10.
Neither the Administrator nor the Company nor any other person, other than the Participant, will be responsible for any adverse tax or other consequences to a Participant that may arise in connection with this Section&nbsp;10. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MISCELLANEOUS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Waiver of Jury Trial</U></B><B>.</B> By accepting (or being deemed to have accepted) an Award under the Plan, each Participant
waives (or will be deemed to have waived), to the maximum extent permitted under applicable law, any right to a trial by jury in any action, proceeding or counterclaim concerning any rights under the Plan or any Award, or under any amendment,
waiver, consent, instrument, document or other agreement delivered or which in the future may be delivered in connection therewith, and agrees (or will be deemed to have agreed) that any such action, proceedings or counterclaim will be tried before
a court and not before a jury. By accepting (or being deemed to have accepted) an Award under the Plan, each Participant certifies that no officer, representative, or attorney of the Company has represented, expressly or otherwise, that the Company
would not, in the event of any action, proceeding, or counterclaim, seek to enforce the foregoing waivers. Notwithstanding anything to the contrary in the Plan, nothing herein is to be construed as limiting the ability of the Company and a
Participant to agree to submit any dispute arising under the terms of the Plan or any Award to binding arbitration or as limiting the ability of the Company to require any individual to agree to submit such disputes to binding arbitration as a
condition of receiving an Award hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U>Section 409A</U></B><B>.</B> Without limiting the generality of
Section&nbsp;11(c) hereof, each Award will contain such terms as the Administrator determines and will be construed and administered, such that the Award either qualifies for an exemption from the requirements of Section&nbsp;409A or satisfies such
requirements. Notwithstanding anything to the contrary in the Plan or any Award agreement, the Administrator may unilaterally amend, modify or terminate the Plan or any outstanding Award, including but not limited to changing the form of the Award,
if the Administrator determines that such amendment, modification or termination is necessary or desirable to avoid the imposition of an additional tax, interest or penalty under Section&nbsp;409A. If a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Participant is determined on the date of the Participant&#146;s termination of Employment to be a &#147;specified employee&#148; within the meaning of that term under Section&nbsp;409A(a)(2)(B)
of the Code, then, with regard to any payment that is considered nonqualified deferred compensation under Section&nbsp;409A, to the extent applicable, payable on account of a &#147;separation from service&#148;, such payment will be made or provided
on the date that is the earlier of (i)&nbsp;the first business day following the expiration of the <FONT STYLE="white-space:nowrap">six-month</FONT> period measured from the date of such &#147;separation from service&#148; and (ii)&nbsp;the date of
the Participant&#146;s death. For purposes of Section&nbsp;409A, each payment made under the Plan or any Award will be treated as a separate payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><U>Limitation of Liability</U></B><B>.</B> Notwithstanding anything to the contrary in the Plan or any Award, neither the
Company, nor any of its subsidiaries, nor the Administrator, nor any person acting on behalf of the Company, any of its subsidiaries, or the Administrator, will be liable to any Participant or to any other person by reason of any acceleration of
income, any additional tax, or any penalty, interest or other liability asserted by reason of the failure of an Award to satisfy the requirements of Section&nbsp;409A or by reason of Section&nbsp;4999 of the Code, or otherwise asserted with respect
to any Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><U>Unfunded Plan</U></B><B>.</B> The Company&#146;s obligations under the Plan are unfunded, and no
Participant will have any right to specific assets of the Company in respect of any Award. Participants will be general unsecured creditors of the Company with respect to any amounts due or payable under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><U>Governing Law</U></B><B>. </B>Except as otherwise provided by the express terms of an Award, the domestic substantive laws of
the State of Connecticut govern the provisions of the Plan and of Awards under the Plan and all claims or disputes arising out of or based upon the Plan or any Award under the Plan or relating to the subject matter hereof or thereof, without giving
effect to any choice or conflict of laws provision or rule that would cause the application of the domestic substantive laws of any other jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B><U>Jurisdiction</U></B><B>. </B>By accepting (or being deemed to have accepted) an Award, each Participant agrees (or will be
deemed to have agreed) to (i)&nbsp;submit irrevocably and unconditionally to the jurisdiction of the federal and state courts located within the geographic boundaries of the United States District Court for the District of Connecticut for the
purpose of any suit, action or other proceeding arising out of or based upon the Plan or any Award; (ii)&nbsp;not commence any suit, action or other proceeding arising out of or based upon the Plan or any Award, except in the federal and state
courts located within the geographic boundaries of the United States District Court for the District of Connecticut; and (iii)&nbsp;waive, and not assert, by way of motion as a defense or otherwise, in any such suit, action or proceeding, any claim
that he or she is not subject personally to the jurisdiction of the above-named courts, that his or her property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the
venue of the suit, action or proceeding is improper or that the Plan or any Award or the subject matter thereof may not be enforced in or by such court.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B><U>Other Compensation Arrangements</U></B><B>.</B> The existence of the Plan or the grant of any Award will not affect the right
of the Company or any of its subsidiaries to grant any person bonuses or other compensation in addition to Awards under the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B><U>Rights Limited</U></B><B>.</B> Nothing in the Plan or any Award will be
construed as giving any person the right to be granted an Award or to continued employment or service with the Company or any of its subsidiaries. The loss of any Award will not constitute an element of damages in the event of a termination of a
Participant&#146;s employment for any reason, even if the termination is in violation of an obligation of the Company or any of its subsidiaries to the Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><U>Effective Date</U></B><B>.</B> The Plan will be effective upon adoption of the Plan by the Administrator and will supersede
and replace the Company&#146;s annual cash bonus program with respect to awards granted to eligible executive officers and employees for fiscal years beginning after the date of adoption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[The remainder of this page is intentionally left blank.] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>XHIBIT</SMALL> A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Definition of Terms </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following terms, when used in the Plan, have the meanings and are subject to the provisions set forth below: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Administrator&#148;: </B>The Compensation Committee, except that the Board may at any time act in the capacity of the Administrator.
The Compensation Committee (or the Board) may delegate (i)&nbsp;to one or more of its members (or one or more other members of the Board) such of its duties, powers and responsibilities as it may determine; (ii)&nbsp;to one or more officers of the
Company the power to grant Awards to the extent permitted by applicable law; and (iii)&nbsp;to such Employees or other persons as it determines such ministerial tasks as it deems appropriate. For purposes of the Plan, the term
&#147;Administrator&#148; will include the Board, the Compensation Committee, and the person or persons delegated authority under the Plan to the extent of such delegation, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Award&#148;: </B>A cash bonus award that is granted to a Participant with respect to a Performance Period. An Award opportunity may
be expressed as a percentage of the Participant&#146;s base salary, as a fixed dollar amount, or in such other form determined by the Administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Board&#148;: </B>The Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Code&#148;: </B>The U.S. Internal Revenue Code of 1986, as from time to time amended and in effect, or any successor statute as from
time to time in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Company&#148;:</B> Rallybio Corporation, a Delaware corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Compensation Committee&#148;: </B>The Compensation Committee of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Participant&#148;: </B>A person who is granted an Award under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Performance Criteria&#148;: </B>Specified criteria, other than the mere continuation of employment or the mere passage of time, the
satisfaction of which is a condition for the grant, exercisability, vesting, or full enjoyment of an Award. A Performance Criterion and any targets with respect thereto need not be based upon an increase, a positive or improved result, or avoidance
of loss and may be applied to a Participant individually, or to a business unit or division of the Company or to the Company as a whole. A Performance Criterion may also be based on individual performance and/or subjective performance criteria. The
Administrator may provide that one or more of the Performance Criteria applicable to such Award will be adjusted in a manner to reflect events (for example, but without limitation, acquisitions or dispositions) occurring during the Performance
Period that affect the applicable Performance Criterion or Criteria. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Performance Period&#148;: </B>A specified performance
period, consisting of the Company&#146;s fiscal year or such other period as the Administrator determines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Plan&#148;: </B>This
Rallybio Corporation 2021 Cash Incentive Plan, as from time to time amended and in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;</B><B>Section</B><B></B><B>&nbsp;409A</B><B>&#148;</B><B>: </B>Section&nbsp;409A of the Code and the regulations thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>20
<FILENAME>d99471dex1019.htm
<DESCRIPTION>EX-10.19
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.19</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.19 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RALLYBIO CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2021 EMPLOYEE STOCK PURCHASE PLAN </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINED TERMS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Exhibit A</U>, which is incorporated by reference, defines the terms used in the Plan and sets forth certain operational rules related to
those terms. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PURPOSE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Plan is intended to enable Eligible Employees to use payroll deductions to purchase shares of Stock, and thereby acquire an interest in the Company. During
any time in which the Administrator, in its discretion, determines that the Plan is not able to satisfy the requirements of Section&nbsp;423, the Plan shall not be treated as an &#147;employee stock purchase plan&#148; under Section&nbsp;423, but
the Administrator shall still be able to grant Options hereunder. If, or as of such time as, the Administrator, in its discretion, determines that the Plan is able to satisfy the requirements of Section&nbsp;423 and that it will operate the Plan in
accordance with such requirements, the Plan is intended to qualify as an &#147;employee stock purchase plan&#148; under Section&nbsp;423 and will be operated and construed with that intent. In any event, the Plan is intended to be exempt from the
requirements of Section&nbsp;409A of the Code, and is to be construed consistently with that intent. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ADMINISTRATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan will be administered by the Administrator. The Administrator has discretionary authority, subject only to the express provisions of
the Plan, to interpret the Plan; to determine eligibility under the Plan; to prescribe forms, rules and procedures relating to the Plan; and to otherwise do all things necessary or desirable to carry out the purposes of the Plan. Determinations of
the Administrator made with respect to the Plan are conclusive and bind all persons. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SHARE POOL </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Number of Shares</U></B><B>. </B>Subject to adjustment pursuant to Section&nbsp;17 below, the maximum aggregate number of
shares of Stock available for purchase pursuant to the exercise of Options granted under the Plan will be 291,324 shares (the &#147;<B>Initial Share Pool</B>&#148;). The Initial Share Pool will automatically increase on January 1<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP> of each year beginning in 2022 and continuing through and including 2031 by the lesser of (i)&nbsp;one (1) percent of the number of shares of Stock outstanding as of such date, (ii) 582,648 shares
of Stock and (iii)&nbsp;the number of shares of Stock determined by the Board on or prior to such date for such year, up to a maximum of 6,117,804 shares in the aggregate (the Initial Share Pool, as it may be so increased, the &#147;<B>Share
Pool</B>&#148;). For purposes of this Section&nbsp;4(a), shares of Stock shall not be treated as delivered under the Plan, and will not reduce the Share Pool, unless and until, and to the extent, they are actually delivered to a Participant. Without
limiting the generality of the foregoing, if any Option granted under the Plan expires or terminates for any reason without having been exercised in full or ceases for any reason to be exercisable in whole or in part, the unpurchased shares of Stock
subject to such Option will not reduce the Share Pool and will remain available for purchase under the Plan. If, on an Exercise Date, the total number of shares of Stock that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
would otherwise be purchased upon the exercise of Options granted under the Plan exceeds the number of shares then available in the Share Pool, the Administrator shall make a pro rata allocation
of the shares then available in as uniform a manner as is practicable and as it determines to be equitable. In such event, the Administrator shall notify each Participant affected by such reduction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U>Type of Shares</U></B><B>.</B> Stock delivered by the Company under the Plan may be authorized but unissued Stock, treasury
Stock or previously issued Stock acquired by the Company. No fractional shares of Stock will be delivered under the Plan. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ELIGIBILITY </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Eligibility Requirements</U></B><B><I>.</I></B><I> </I>Subject to the limitations contained in the Plan, each Employee
(i)&nbsp;who has been continuously employed by the Company or a Designated Subsidiary, as applicable, for a period of at least ten (10)&nbsp;Business Days as of the first day of an Option Period, (ii)&nbsp;whose customary Employment with the Company
or a Designated Subsidiary, as applicable, is for more than five (5)&nbsp;months per calendar year, (iii)&nbsp;who customarily works twenty (20)&nbsp;hours or more per week, and (iv)&nbsp;who satisfies the requirements set forth in the Plan, will be
an Eligible Employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U>Five Percent Stockholders</U></B><B><I>.</I></B><I> </I>No Employee may be granted an Option under
the Plan if, immediately after the Option is granted, the Employee would own (or pursuant to Section&nbsp;424(d) of the Code would be deemed to own) shares possessing five percent (5%) or more of the total combined voting power or value of all
classes of stock of the Company or of its Parent or Subsidiaries, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><U>Additional Requirements</U></B><B>.</B><I>
</I>The Administrator may, for Option Periods that have not yet commenced, establish additional or other eligibility requirements, or amend the eligibility requirements set forth in subsection (a)&nbsp;above, in each case, consistent with the
requirements of Section&nbsp;423 to the extent that the Option Period is intended to satisfy the requirements of Section&nbsp;423. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>OPTION PERIODS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan will generally be implemented by a series of separate offerings referred to as &#147;<B>Option Periods</B>&#148;. Unless otherwise
determined by the Administrator, the Option Periods will be successive periods of approximately six (6)&nbsp;months commencing on the first Business Day in January and July of each year, anticipated to be on or around January&nbsp;1 and July&nbsp;1,
and ending approximately six (6)&nbsp;months later on the last Business Day in June or December, as applicable, of each year, anticipated to be on or around June&nbsp;30 and December 31. The last Business Day of each Option Period will be an
&#147;<B>Exercise Date</B>&#148;. The Administrator may change the Exercise Date, the commencement date, the ending date and the duration of each Option Period, in each case, to the extent permitted by Section&nbsp;423 (to the extent that the Option
Period is intended to satisfy the requirements of Section&nbsp;423); <I>provided, however, </I>that no Option may be exercised after 27 months from its grant date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>OPTION GRANTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the limitations set forth herein and the Maximum Share Limit (as defined below), on the first day of an Option Period, each
Participant will automatically be granted an Option to purchase shares of Stock on the Exercise Date; <I>provided</I>, <I>however</I>, that no Participant will be granted an Option under the Plan that permits the Participant&#146;s right to purchase
shares of Stock under the Plan and under all other employee stock purchase plans of the Company and its Parent and Subsidiaries, if any, to accrue at a rate that exceeds $25,000 in Fair Market Value (or such other maximum as may be prescribed from
time to time by the Code) for each calendar year during which any Option granted to such Participant is outstanding at any time, as determined in accordance with Section&nbsp;423(b)(8) of the Code. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PARTICIPATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Election</U></B><B>.</B> To participate in an Option Period, an Eligible Employee must execute and deliver to the
Administrator an election form, in accordance with the procedures prescribed by, and in a form acceptable to, the Administrator. Such election form must be delivered not later than five (5)&nbsp;Business Days prior to the first day of an Option
Period, or such other time as specified by the Administrator. An Eligible Employee will become a Participant as of the first day of the Option Period for which he or she timely delivered such election form and will remain a Participant with respect
to subsequent Option Periods until his or her participation in the Plan is terminated as provided herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U>Election
Amount</U></B><B>.</B><I> </I>Each election form will authorize payroll deductions as a whole percentage from one percent (1%) to fifteen percent (15%) of the employee&#146;s Eligible Compensation per payroll period, to be deducted from the Eligible
Employee&#146;s pay during each payroll period occurring during the applicable Option Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><U>Payroll Deduction
Account</U></B><B><I>.</I></B><I> </I>All payroll deductions made pursuant to this Section&nbsp;8 will be credited to the Participant&#146;s Account. Amounts credited to a Participant&#146;s Account will not be required to be set aside in trust or
otherwise segregated from the Company&#146;s general assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><U>Changes to Election for Current Option
Period</U></B><B><I>.</I></B><I> </I>During an Option Period, elections and rates of contributions may be reduced, but may not be increased. Any reduction to a Participant&#146;s payroll deduction authorization must be delivered to the Administrator
in accordance with the procedures prescribed by, and in a form acceptable to, the Administrator and will be effective as soon as administratively practicable. A Participant may also terminate his or her payroll deduction authorization during an
Option Period by canceling his or her Option in accordance with Section&nbsp;14 below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><U>Changes to Election for
Subsequent Option Periods</U></B><B>.</B> A Participant&#146;s election form will remain in effect for subsequent Option Periods unless the Participant files a new election form not later than five (5)&nbsp;Business Days prior to the first day of
the subsequent Option Period (or such other time as specified by the Administrator) or the Participant&#146;s Option is cancelled in accordance with the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>METHOD OF PAYMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Participant must pay for shares of Stock purchased upon the exercise of an Option with the accumulated payroll deductions credited to the
Participant&#146;s Account. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PURCHASE PRICE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Purchase Price of shares of Stock issued pursuant to the exercise of an Option on each Exercise Date will be eighty-five percent (85%) (or
such other percentage specified by the Administrator, to the extent permitted under Section&nbsp;423 for any Option Period intended to satisfy the requirements of Section&nbsp;423) of the lesser of (i)&nbsp;the Fair Market Value of a share of Stock
on the date on which the Option was granted (<I>i.e.</I>, the first day of the Option Period) and (ii)&nbsp;the Fair Market Value of a share of Stock on the date on which the Option is deemed exercised (<I>i.e.</I>, the Exercise Date). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EXERCISE OF OPTIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Purchase of Shares</U></B><B><I>.</I></B><I> </I>Subject to the limitations set forth herein, with respect to each Option
Period, on each Exercise Date, each Participant will be deemed to have exercised his or her Option and the accumulated payroll deductions credited to the Participant&#146;s Account will be applied to purchase the greatest number of shares of Stock
(rounded down to the nearest whole share) that can be purchased with such Account balance at the applicable Purchase Price; <I>provided, however, </I>that no more than 5,000 shares of Stock may be purchased by a Participant on any Exercise Date, or
such other number as the Administrator may prescribe in accordance with Section&nbsp;423 (the &#147;<B>Maximum Share Limit</B>&#148;). As soon as practicable thereafter, the shares of Stock so purchased will be placed, in book-entry form, into a
recordkeeping account in the name of the Participant. Any accumulated payroll deductions in a Participant&#146;s Account that are not sufficient to purchase a whole share of Stock will be retained in the Participant&#146;s Account for the subsequent
Option Period, subject to earlier withdrawal by the Participant as provided in Section&nbsp;14 below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U>Return of Account
Balance</U></B><B><I>.</I></B><I> </I>Except as provided in Section&nbsp;11(a) above, any accumulated payroll deductions in a Participant&#146;s Account for an Option Period that are not used to purchase shares of Stock, whether because of the
Participant&#146;s withdrawal from participation in an Option Period or for any other reason, will be returned to the Participant (or his or her designated beneficiary or legal representative, as applicable), without interest, as soon as
administratively practicable after such withdrawal or other event, as applicable. If the Participant&#146;s accumulated payroll deductions for an Option Period would otherwise enable the Participant to purchase shares of Stock in excess of the
Maximum Share Limit or the maximum Fair Market Value set forth in Section&nbsp;7 above, the excess of the amount of the accumulated payroll deductions over the aggregate Purchase Price of the shares of Stock actually purchased will be returned to
the Participant, without interest, as soon as administratively practicable after such Exercise Date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INTEREST </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No interest will accrue or be payable on any amount held in the Account of any Participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TAXES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payroll deductions will be made on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis. The Administrator will have the right, as a
condition to exercising an Option, to make such provision as it deems necessary to satisfy its obligations to withhold federal, state, local or other taxes incurred by reason of the purchase or disposition of shares of Stock under the Plan. In the
Administrator&#146;s discretion and subject to applicable law, such tax obligations may be satisfied in whole or in part by delivery of shares of Stock to the Company, including shares of Stock purchased under the Plan, valued at Fair Market Value,
but not in excess of the maximum withholding amount consistent with the award being subject to equity accounting treatment under the Accounting Rules. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CANCELLATION AND WITHDRAWAL </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Participant who holds an Option under the Plan may cancel all (but not less than all) of such Option and terminate his or her participation
in the Plan by delivering a notice to the Administrator in accordance with the procedures prescribed by, and in a form acceptable to, the Administrator. To be effective with respect to an upcoming Exercise Date, such notice must be delivered not
later than five (5)&nbsp;Business Days prior to such Exercise Date (or such other time as specified by the Administrator). Upon such termination and cancellation, the balance in the Participant&#146;s Account will be returned to the Participant,
without interest, as soon as administratively practicable thereafter. For the avoidance of doubt, a Participant who reduces his or her rate of payroll deductions for future payroll periods to zero percent (0%) in accordance with Section&nbsp;8 above
will be deemed to have terminated his or her participation in the Plan as to all current and future Option Periods, unless and until the Participant has delivered a new election for a subsequent Option Period in accordance with the rules of
Section&nbsp;8 above. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERMINATION OF EMPLOYMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the termination of a Participant&#146;s employment with the Company or a Designated Subsidiary, as applicable, for any reason (including
the death of a Participant during an Option Period prior to an Exercise Date) or in the event the Participant ceases to qualify as an Eligible Employee, the Participant&#146;s participation in the Plan will terminate, any Option held by the
Participant under the Plan will be canceled, the balance in the Participant&#146;s Account will be returned to the Participant (or his or her estate or designated beneficiary in the event of the Participant&#146;s death), without interest, as soon
as administratively practicable thereafter, and the Participant will have no further rights under the Plan. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EQUAL RIGHTS; RIGHTS NOT TRANSFERABLE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All Participants granted Options in during an Option Period under the Plan will have the same rights and privileges, consistent with the
requirements set forth in Section&nbsp;423, to the extent that the Option Period is intended to satisfy the requirements of Section&nbsp;423. Any Option granted under the Plan will be exercisable during the Participant&#146;s lifetime only by him or
her and may not be sold, pledged, assigned, or transferred in any manner. In the event any Participant violates or attempts to violate the terms of this Section&nbsp;16, as determined by the Administrator in its sole discretion, any Options granted
to the Participant under the Plan may be terminated by the Company and, upon the return to the Participant of the balance of his or her Account, without interest, all of the Participant&#146;s rights under the Plan will terminate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CHANGE IN CAPITALIZATION; COVERED TRANSACTION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Change in Capitalization</U></B><B>.</B> In the event of a stock dividend, stock split or combination of shares (including a
reverse stock split), recapitalization or other change in the Company&#146;s capital structure that constitutes an equity restructuring within the meaning of the Accounting Rules, the Administrator shall make appropriate adjustments to the aggregate
number and type of shares of stock available under the Plan, the number and type of shares of stock granted under any outstanding Options, the maximum number and type of shares of stock purchasable under any outstanding Option, and/or the Purchase
Price under any outstanding Option, in any case, in a manner that complies with Section&nbsp;423. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U>Covered
Transaction</U></B><B>.</B><I> </I>In the event of a Covered Transaction, the Administrator may, in its discretion, (i)&nbsp;provide that each outstanding Option will be assumed or exchanged for a substitute option granted by the acquiror or
successor corporation or by a parent or subsidiary of the acquiror or successor corporation; (ii)&nbsp;cancel each outstanding Option and return the balances in Participants&#146; Accounts to the Participants; and/or (iii)&nbsp;terminate the Option
Period on or before the date of the Covered Transaction. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>AMENDMENT AND TERMINATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Amendment</U></B><B><I>.</I></B><I> </I>The Administrator reserves the right at any time or times to amend the Plan to any
extent and in any manner it may deem advisable; <I>provided</I>, that any amendment that would be treated as the adoption of a new plan for purposes of Section&nbsp;423 will have no force or effect unless approved by the stockholders of the Company
within twelve (12)&nbsp;months before or after its adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U>Termination</U></B><B><I>.</I></B> The Administrator
reserves the right at any time or times to suspend or terminate the Plan. In connection therewith, the Administrator may provide, in its sole discretion, either that outstanding Options will be exercisable on the Exercise Date for the applicable
Option Period or on such earlier date as the Administrator may specify (in which case such earlier date will be treated as the Exercise Date for the applicable Option Period), or that the balance of each Participant&#146;s Account will be returned
to the Participant, without interest. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>APPROVALS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholder approval of the Plan will be obtained prior to the date that is twelve (12)&nbsp;months after the date the Plan is approved by the
Board. In the event that the Plan has not been approved by the stockholders of the Company prior to the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the date the Plan is approved by the Board, all Options granted under the Plan
will be cancelled and become null and void. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything herein to the contrary, the obligation of the Company to issue and
deliver shares of Stock under the Plan will be subject to the approval required of any governmental authority in connection with the authorization, issuance, sale or transfer of such shares of Stock and to any requirements of any national securities
exchange applicable thereto, and to compliance by the Company with other applicable legal requirements in effect from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PARTICIPANTS&#146; RIGHTS AS STOCKHOLDERS AND EMPLOYEES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Participant will have no rights or privileges as a stockholder of the Company and will not receive any dividends in respect of any shares of
Stock covered by an Option granted hereunder until such Option has been exercised, full payment has been made for such shares, and the shares have been issued to the Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nothing contained in the Plan will be construed as giving to any Employee the right to be retained in the employ of the Company or any
Designated Subsidiary or as interfering with the right of the Company or any Designated Subsidiary to discharge, promote, demote or otherwise <FONT STYLE="white-space:nowrap">re-assign</FONT> any Employee from one position to another within the
Company or any Designated Subsidiary or any other Subsidiary at any time. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>21.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RESTRICTIONS ON TRANSFER; INFORMATION REGARDING DISQUALIFYING DISPOSITIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Restrictions on Transfer</U></B><B>.</B> Shares of Stock purchased under the Plan may, in the discretion of the Administrator,
be subject to a restriction prohibiting the transfer, sale, pledge or alienation of such shares of Stock by a Participant, other than by will or by the laws of descent and distribution, for such period following such purchase as may be determined by
the Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U>Disqualifying Dispositions</U></B><B>.</B> By electing to participate in the Plan, each Participant
agrees (or will be deemed to have agreed) to provide such information about any transfer of Stock acquired under the Plan that occurs within two years after the first day of the Option Period in which such Stock was acquired and within one year
after the day such Stock was purchased as may be requested by the Company or any Designated Subsidiary in order to assist it in complying with applicable tax laws. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>22.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MISCELLANEOUS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Waiver of Jury Trial</U></B><B>.</B> By electing to participate in the Plan, each Participant waives (or will be deemed to
have waived), to the maximum extent permitted under applicable law, any right to a trial by jury in any action, proceeding or counterclaim concerning any rights under the Plan or with respect to any Option, or under any amendment, waiver, consent,
instrument, document or other agreement delivered or which in the future may be delivered in connection therewith, and agrees (or will be deemed to have agreed) that any such action, proceedings or counterclaim will be tried before a court and not
before a jury. By electing to participate in the Plan, each Participant certifies that no officer, representative, or attorney of the Company has represented, expressly or otherwise, that the Company would not, in the event of any action, proceeding
or counterclaim, seek to enforce the foregoing waivers. Notwithstanding anything to the contrary in the Plan, nothing herein is to be construed as limiting the ability of the Company and a Participant to agree to submit any dispute arising under the
terms of the Plan or in respect of any Option to binding arbitration or as limiting the ability of the Company to require any individual to agree to submit any dispute to binding arbitration as a condition of receiving an Option hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U>Limitation of Liability</U></B><B>.</B> Notwithstanding anything to the
contrary in the Plan, neither the Company, nor any of its subsidiaries, nor the Administrator, nor any person acting on behalf of the Company, any of its subsidiaries, or the Administrator, will be liable to any Participant or to any other person by
reason of any acceleration of income, any additional tax, or any penalty, interest or other liability asserted by reason of the failure of the Plan or any Option to satisfy the requirements of Section&nbsp;423, or otherwise asserted with respect to
the Plan or any Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><U>Unfunded Plan</U></B><B>. </B>The Company&#146;s obligations under the Plan are unfunded, and no
Participant will have any right to specific assets of the Company in respect of any Option. Participants will be general unsecured creditors of the Company with respect to any amounts due or payable under the Plan. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>23.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ESTABLISHMENT OF <FONT STYLE="white-space:nowrap">SUB-PLANS</FONT> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing or any provision of the Plan to the contrary, consistent with the requirements of Section&nbsp;423, the
Administrator may, in its sole discretion, amend the terms of the Plan, or an offering and/or provide for separate offerings under the Plan in order to, among other things, reflect the impact of local law outside of the United States as applied to
one or more Eligible Employees of a Designated Subsidiary and may, where appropriate, establish one or more <FONT STYLE="white-space:nowrap">sub-plans</FONT> to reflect such amended provisions. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>24.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GOVERNING LAW </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><U>Certain Requirements of Corporate Law</U></B><B>.</B> Options and shares of Stock will be granted, issued and administered
consistent with the requirements of applicable Delaware law relating to the issuance of stock and the consideration to be received therefor, and with the applicable requirements of the stock exchanges or other trading systems on which the Stock is
listed or entered for trading, in each case as determined by the Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><U>Other Matters</U></B><B>.</B> Except as
otherwise provided by the express terms of a <FONT STYLE="white-space:nowrap">sub-plan</FONT> described in Section&nbsp;23 above or as provided in Section&nbsp;24(a) above, the domestic substantive laws of the State of Delaware govern the provisions
of the Plan and of Options under the Plan and all claims or disputes arising out of or based upon the Plan or any Option or relating to the subject matter hereof or thereof without giving effect to any choice or conflict of laws provision or rule
that would cause the application of the domestic substantive laws of any other jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><U>Jurisdiction</U></B><B>.
</B>By electing to participate in the Plan, each Participant agrees or will be deemed to have agreed to (i)&nbsp;submit irrevocably and unconditionally to the jurisdiction of the federal and state courts located within the geographic boundaries of
the United States District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon the Plan or any Option; (ii)&nbsp;not commence any suit, action or other proceeding arising out of or
based upon the Plan or any Option, except in the federal and state courts located within the geographic boundaries of the United States District Court for the District of Delaware; and (iii)&nbsp;waive, and not assert, by way of motion as a defense
or otherwise, in any such suit, action or proceeding, any claim that he or she is not subject personally to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
jurisdiction of the above-named courts that his or her property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the
venue of the suit, action or proceeding is improper or that the Plan or any Option or the subject matter thereof may not be enforced in or by such court. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>25.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EFFECTIVE DATE AND TERM </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan will become effective upon adoption of the Plan by the Board and no rights will be granted hereunder after the earliest to occur of
(i)&nbsp;the Plan&#146;s termination by the Administrator; (ii)&nbsp;the issuance of all shares of Stock available for issuance under the Plan and (iii)&nbsp;the day before the ten (10)-year anniversary of the date the Board approves the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[The remainder of this page is intentionally left blank.] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Definition of Terms </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following terms, when used in the Plan, have the meanings and are subject to the provisions set forth below: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;401(k) Plan&#148;:</B> A savings plan qualifying under Section&nbsp;401(k) of the Code that is sponsored by the Company or one of its
Subsidiaries for the benefit of its employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Account&#148;: </B>A notional payroll deduction account maintained in the
Participant&#146;s name in the records of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Accounting Rules&#148;:</B> Financial Accounting Standards Board
Accounting Standards Codification Topic 718, or any successor provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Administrator&#148;:</B> The Compensation Committee,
except that the Board may at any time act in the capacity of the Administrator (including with respect to such matters that are not delegated to the Compensation Committee by the Board (whether pursuant to committee charter or otherwise), if
applicable). The Compensation Committee (or the Board) may delegate (i)&nbsp;to one or more of its members (or one or more other members of the Board) such of its duties, powers and responsibilities as it may determine and (ii)&nbsp;to such
Employees or other persons as it determines such ministerial tasks as it deems appropriate. For purposes of the Plan, the term &#147;Administrator&#148; will include the Board, the Compensation Committee, and the person or persons delegated
authority under the Plan to the extent of such delegation, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Board&#148;:</B> The Board of Directors of the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Business Day&#148;:</B> Any day on which the established national exchange or trading system (including the Nasdaq
Global Market) on which the Stock is traded is available and open for trading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Code&#148;:</B> The U.S. Internal Revenue Code of
1986, as from time to time amended and in effect, or any successor statute as from time to time in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Company&#148;:</B>
Rallybio Corporation, a Delaware corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Compensation Committee&#148;: </B>The Compensation Committee of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Covered Transaction&#148;: </B>Any of (i)&nbsp;a consolidation, merger or similar transaction or series of related transactions,
including a sale or other disposition of stock, in which the Company is not the surviving corporation or which results in the acquisition of all or substantially all of the Company&#146;s then outstanding common stock by a single person or entity or
by a group of persons and/or entities acting in concert; (ii)&nbsp;a sale or transfer of all or substantially all the Company&#146;s assets; (iii)&nbsp;a dissolution or liquidation of the Company or (iv)&nbsp;any other transaction the Administrator
determines to be a Covered Transaction. Where a Covered Transaction involves a tender offer that is reasonably expected to be followed by a merger described in clause (i) (as determined by the Administrator), the Covered Transaction will be deemed
to have occurred upon consummation of the tender offer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Designated Subsidiary&#148;:</B> A<B> </B>Subsidiary of the Company that has been
designated by the Board or the Compensation Committee from time to time as eligible to participate in the Plan as set forth on <U>Exhibit B</U>, as amended from time to time (with the initial list of Designated Subsidiaries as of the date of
adoption of the Plan by the Board set forth on <U>Exhibit B</U>). For the avoidance of doubt, any Subsidiary of the Company, whether or not a Subsidiary on the date the Plan was adopted by the Board, shall be eligible to be designated as a
Designated Subsidiary hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Eligible Compensation&#148;:</B> Regular base salary, regular base wages, annual bonuses and
commissions (excluding, for the avoidance of doubt, any long-term or equity-based incentive payments or awards). Eligible Compensation will not be reduced by any income or employment tax withholdings or any contributions by the Employee to a 401(k)
Plan or a plan under Section&nbsp;125 of the Code, but will be reduced by any contributions made on the Employee&#146;s behalf by the Company or any Subsidiary to any deferred compensation plan or welfare benefit program now or hereafter
established. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Eligible Employee&#148;:</B> Any Employee who meets the eligibility requirements set forth in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Employee&#148;:</B> Any person who is employed by the Company or a Designated Subsidiary. For the avoidance of doubt, independent
contractors and consultants are not &#147;Employees&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Exercise Date&#148;: </B>The date set forth in the Plan or otherwise
designated by the Administrator with respect to a particular Option Period on which a Participant will be deemed to have exercised the Option granted to him or her for such Option Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Fair Market Value&#148;: </B>As of a particular date, (i)&nbsp;the closing price for a share of Stock reported on the Nasdaq Global
Market (or any other national securities exchange on which the Stock is then listed) for that date or, if no closing price is reported for that date, the closing price on the immediately preceding date on which a closing price was reported or
(ii)&nbsp;in the event that the Stock is not traded on a national securities exchange, the fair market value of a share of Stock determined by the Administrator consistent with the rules of Section&nbsp;422 and Section&nbsp;409A to the extent
applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Maximum Share Limit&#148;:</B> The meaning set forth in Section&nbsp;11 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Option&#148;:</B> An option granted pursuant to the Plan entitling the holder to acquire shares of Stock upon payment of the Purchase
Price per share of Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Option Period&#148;: </B>An offering period established in accordance with Section&nbsp;6 of the Plan.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Parent&#148;: </B>A &#147;parent corporation&#148; as defined in
Section&nbsp;424(e) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Participant&#148;:</B> An Eligible Employee who elects to participate in an Option Period under
the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Plan&#148;:</B> This Rallybio Corporation 2021 Employee Stock Purchase Plan, as from time to time amended and in
effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Purchase Price&#148;: </B>The price per share of Stock with respect to an Option Period determined in accordance with
Section&nbsp;10 of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Section</B><B></B><B>&nbsp;423&#148;: </B>Section&nbsp;423 of the Code and the regulations
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Stock&#148;:</B> Common stock of the Company, par value $0.0001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Subsidiary&#148;:</B> On and after the date the Plan is operated as a plan intended to qualify as an &#147;employee stock purchase
plan&#148; under Section&nbsp;423, a &#147;Subsidiary&#148; shall be limited to a &#147;subsidiary corporation&#148; as defined in Section&nbsp;424(f) of the Code. Prior to such date, a &#147;Subsidiary&#148; may also include a subsidiary of the
Company that would be described in the first sentence of <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(5)(iii)(E)</FONT> of the Treasury Regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Designated Subsidiaries </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(as of July&nbsp;15, 2021) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Rallybio, LLC </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>21
<FILENAME>d99471dex1020.htm
<DESCRIPTION>EX-10.20
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.20</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.20 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>AMENDED AND RESTATED EMPLOYMENT AGREEMENT</B> (this &#147;<U>Agreement</U>&#148;) dated as of July&nbsp;15, 2021 by and between Rallybio,
LLC, a Delaware limited liability company (the &#147;<U>Company</U>&#148;), and Martin W. Mackay (the &#147;<U>Executive</U>&#148;) and effective as of the day prior to the date on which Rallybio Corporation (&#147;<U>Parent</U>&#148;) becomes
subject to the reporting obligations of Section&nbsp;12 of the Securities Exchange Act of 1934, as amended (the &#147;<U>Securities Exchange Act</U>&#148;) (such date, the &#147;<U>Effective Date</U>&#148;). This Agreement amends and restates in its
entirety the employment agreement by and among the Company and the Executive, effective as of April&nbsp;20, 2018 (the &#147;<U>Prior Agreement</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>W I T N E S S E T H</U>: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company desires to continue to employ the Executive as the Chief Executive Officer of the Company; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company and the Executive desire to enter into this amended and restated Agreement as to the terms of the Executive&#146;s
continued employment with the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the foregoing, of the mutual promises contained herein
and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>POSITION AND DUTIES</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>GENERAL</B>. During the Employment Term (as defined below), the Executive shall serve as the Chief Executive Officer of the Company. In
this capacity, the Executive shall have the duties, authorities and responsibilities commensurate with the duties, authorities and responsibilities of persons in similar capacities in similarly sized companies and such other duties, authorities and
responsibilities as may reasonably be assigned by the board of directors of Parent (the &#147;<U>Board</U>&#148;) to the Executive from time to time that are not inconsistent with the Executive&#146;s position with the Company and do not
unreasonably interfere with his duties to the Company. For so long as the Executive is employed by the Company as its Chief Executive Officer, Parent will nominate the Executive to serve as a member of the Board at each annual meeting of
Parent&#146;s stockholders at which the Executive&#146;s then-current term expires and, if so elected at such meeting, the Executive will continue to serve as a member of the Board. Upon the termination of the Executive&#146;s employment as Chief
Executive Officer, the Executive shall immediately resign from the Board as well as from any other position(s) to which the Executive was elected or appointed or that the Executive otherwise holds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>OTHER ACTIVITIES</B>. During the Employment Term, the Executive shall devote all of the Executive&#146;s business time and energy,
business judgment, knowledge and skill and the Executive&#146;s best efforts to the performance of the Executive&#146;s duties with the Company, <U>provided</U> that the foregoing shall not prevent the Executive from (i)&nbsp;serving on the boards
of directors (and board committees) of <FONT STYLE="white-space:nowrap">non-profit</FONT> organizations (provided, that the Executive provides the Board with advanced written notice prior to accepting or serving in any such position), (ii) serving
on the boards of directors (and board committees) of <FONT STYLE="white-space:nowrap">for-profit</FONT> organizations (provided, that the Executive receives prior written approval from the Board, which shall not be unreasonably
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
withheld, delayed or conditioned), (iii) participating in charitable, civic, educational, professional, community or industry affairs, (iv)&nbsp;spending a de minimis amount of time on activities
that provide de minimis compensation to the Executive, and (v)&nbsp;spending a de minimis amount of time managing the Executive&#146;s passive personal investments; <U>provided</U>, such activities do not interfere or conflict with the
Executive&#146;s duties hereunder or create a potential business or fiduciary conflict or otherwise violate Section&nbsp;11 of this Agreement; <U>provided</U> <U>further</U>, each of the Executive&#146;s activities listed on <U>Schedule A</U>
attached hereto is permitted under this Agreement so long as such activities listed on <U>Schedule A</U> do not materially interfere or conflict with the Executive&#146;s duties hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B>EMPLOYMENT TERM</B>. The Company agrees to employ the Executive pursuant to the terms of this Agreement, and the Executive agrees
to be so employed, for a term of one (1)&nbsp;year (the &#147;<U>Initial Term</U>&#148;) commencing as of the Effective Date. On each anniversary of the Effective Date following the Initial Term, the term of this Agreement shall be automatically
extended for successive one (l)-year periods; <U>provided</U>, <U>however</U>, that either party hereto may elect not to extend this Agreement by giving written notice to the other party at least sixty (60)&nbsp;days prior to any such anniversary
date. Notwithstanding the foregoing, the Executive&#146;s employment hereunder may be earlier terminated in accordance with <U>Section</U><U></U><U>&nbsp;6</U> hereof, subject to the provisions of <U>Section</U><U></U><U>&nbsp;7</U> hereof. The
period of time between the Effective Date and the termination of the Executive&#146;s employment hereunder shall be referred to herein as the &#147;<U>Employment Term</U>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B>BASE SALARY</B>. During the Employment Term, the Company agrees to pay the Executive a base salary at an annual rate of,
initially, $470,000. The base salary shall be paid in cash in accordance with the regular payroll practices of the Company with respect to salaried employees, but in no event less frequently than semi-monthly. The Executive&#146;s base salary shall
be subject to review by the Board or the Compensation Committee of the Board (the &#147;<U>Compensation Committee</U>&#148;), and may be increased from time to time by the Board or the Compensation Committee in its respective sole discretion. The
base salary as determined herein and adjusted from time to time shall constitute the &#147;<U>Base Salary</U>&#148; for purposes of this Agreement, and any section herein providing for payment of the Base Salary to the Executive shall mean payment
of the Base Salary rate in effect at the time of payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>ANNUAL BONUS</B>. With respect to each fiscal year during the
Employment Term, the Executive shall be eligible to receive an annual cash incentive payment (the &#147;<U>Annual Bonus</U>&#148;). The target amount of the Annual Bonus shall be (forty percent) 40&nbsp;% of the Base Salary; <U>provided</U>, in any
event, the actual Annual Bonus to be paid in respect of any fiscal year, if any, which may be more or less than the target bonus amount, will be based on the attainment of individual and/or Company performance goals for such year established by the
Board or the Compensation Committee as determined by the Board or the Compensation Committee in its respective sole discretion. Any Annual Bonus awarded hereunder shall be paid in the calendar year following the calendar year to which such bonus
relates at the same time annual bonuses are paid to other senior executives of the Company, except as otherwise provided in <U>Section</U><U></U><U>&nbsp;7</U> hereof, but not later than March
15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of such following calendar year. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B>EMPLOYEE BENEFITS</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>BENEFIT PLANS</B>. During the Employment Term, the Executive shall be entitled to participate in any employee benefit plan that the
Company has adopted or may adopt or maintains or contributes to for the benefit of its employees generally, subject to satisfying the applicable eligibility requirements, and except to the extent such plans are duplicative of the benefits otherwise
provided hereunder. The Executive&#146;s participation will be subject to the terms of the applicable plan documents and generally applicable Company policies. Notwithstanding the foregoing, the Company may modify or terminate any employee benefit
plan at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>BUSINESS EXPENSES</B>. Upon presentation of reasonable substantiation and documentation as required by the
Company&#146;s expense reimbursement policies, that the Company may modify from time to time, the Executive shall be reimbursed for all reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> business
expenses incurred and paid by the Executive during the Employment Term and in connection with the performance of the Executive&#146;s duties hereunder or otherwise incurred at the direction of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>VACATION</B>. The Executive shall be entitled to take vacation in accordance with the Company&#146;s policy then in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>TERMINATION</B>. The Executive&#146;s employment and the Employment Term shall terminate on the first of the following to occur:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>DISABILITY</B>. Upon ten (10)&nbsp;days&#146; prior written notice by the Company to the Executive of a termination due to
Disability. For purposes of this Agreement, &#147;<U>Disability</U>&#148; shall be defined as the inability of the Executive to have performed the Executive&#146;s material duties hereunder, with or without reasonable accommodation due to a physical
or mental injury, infirmity, limitation or incapacity which has lasted or can reasonably be expected to last for one hundred eighty (180)&nbsp;days (including weekends and holidays) in any three hundred sixty-five
<FONT STYLE="white-space:nowrap">(365)-day</FONT> period as determined by the Board in its reasonable discretion. The Executive (or the Executive&#146;s representative) shall cooperate in all respects with the Company if a good faith question arises
as to whether the Executive has become disabled (including, without limitation, submitting to reasonable examinations by one or more medical doctors and other health care specialists reasonably selected by the Company and authorizing such medical
doctors and other health care specialists to discuss the Executive&#146;s condition with the Company). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>DEATH</B>. Automatically
upon the date of death of the Executive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>BY THE COMPANY FOR CAUSE</B>. Immediately upon written notice by the Company to the
Executive of a termination for Cause. &#147;<U>Cause</U>&#148; shall mean (i)&nbsp;the Executive having been indicted for, or having pleaded guilty or <I>nolo contendere</I> to, (A)&nbsp;a felony or (B)&nbsp;a crime involving dishonesty or moral
turpitude; (ii)&nbsp;the Executive&#146;s commission of any act of fraud, or embezzlement, theft, or material dishonesty or intentional misappropriation of the property of the Company, Parent or any of their respective direct or indirect
subsidiaries (collectively, the &#147;<U>Company Group</U>&#148;) or any of their respective affiliates or of any customer or supplier of the Company Group; (iii)&nbsp;the Executive&#146;s repeated use of illegal drugs or repeated abuse of alcohol
that materially impairs the Executive&#146;s ability to perform the Executive&#146;s duties contemplated hereunder; (iv)&nbsp;the Executive&#146;s material breach of this Agreement or any other agreement with the Company Group, or a material
violation of any of the Company Group&#146;s written policies or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
procedures; or (v)&nbsp;any other willful misconduct or gross negligence in the performance of the Executive&#146;s duties to the Company Group that has caused material injury (including by way
of reputational harm or other damages) to any member of the Company Group. Notwithstanding the foregoing, the Company shall not terminate Executive&#146;s employment for Cause pursuant to <U>Section</U><U></U><U>&nbsp;6(c)(iii)</U> or
<U>(iv)</U>&nbsp;unless the Company has first given Executive written notice of the acts or omissions constituting Cause thereunder, and, if such acts or omissions are susceptible to cure, the Executive has failed to cure such acts or omissions to
the Company&#146;s reasonable satisfaction within thirty (30)&nbsp;days after receipt of such notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>BY THE COMPANY WITHOUT
CAUSE</B>. Upon thirty (30)&nbsp;days&#146; prior written notice by the Company to the Executive of an involuntary termination without Cause (other than for death or Disability); <U>provided</U>, that the Board may, in its sole discretion, elect to
provide Base Salary to the Executive in lieu of such notice (in whole or in part).<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>BY THE EXECUTIVE FOR ANY REASON</B>. Upon sixty (60)&nbsp;days&#146; prior written notice by the Executive to the Company of the
Executive&#146;s voluntary termination of employment for any reason (including for Good Reason); <U>provided</U>, that the Board may, in its sole discretion, elect to accelerate the date of termination without the payment of additional compensation.
&#147;<U>Good Reason</U>&#148; means: (i)&nbsp;a failure by the Company to pay the Executive his Base Salary when due, (ii)&nbsp;any involuntary material diminution in the Executive&#146;s duties, authorities or responsibilities (other than
temporarily while physically or mentally incapacitated or as required by applicable law), (iii) any change to the Executive&#146;s title to which the Executive did not consent in writing, or (iv)&nbsp;the Executive being required to relocate to a
principal place of employment more than fifty (50)&nbsp;miles from the Executive&#146;s principal place of employment with the Company Group at such time; which, in each case, is not cured by the Company Group within thirty (30)&nbsp;days of the
Company&#146;s receipt of written notice thereof from the Executive specifying the particulars of the conduct constituting Good Reason; <U>provided</U>, that the Executive gives such notice to the Company within ninety (90)&nbsp;days of the
Executive having knowledge of the occurrence of such event and, if such event is not cured by the Company, the Executive terminates his employment within thirty (30)&nbsp;days after the end of the Company&#146;s cure period; otherwise, Good Reason
shall be deemed waived with respect to such event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <B>EXPIRATION OF EMPLOYMENT TERM;
<FONT STYLE="white-space:nowrap">NON-EXTENSION</FONT> OF AGREEMENT</B>. Upon the expiration of the Employment Term due to a <FONT STYLE="white-space:nowrap">non-extension</FONT> of the Agreement by the Company or the Executive pursuant to the
provisions of <U>Section</U><U></U><U>&nbsp;2</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B>CONSEQUENCES OF TERMINATION</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>DEATH OR DISABILITY</B>. In the event that the Executive&#146;s employment and the Employment Term end on account of the
Executive&#146;s death or a termination by the Company due to the Executive&#146;s Disability, the Executive&#146;s estate or the Executive, as applicable, shall be entitled to the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) any earned and unpaid Base Salary through the date of termination; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) reimbursement for any unreimbursed business expenses incurred through the date of termination; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) all other accrued and vested payments, benefits or fringe benefits to which the
Executive is entitled in accordance with the terms and conditions of the applicable compensation or benefit plan, program or arrangement of the Company (collectively, <U>Sections 7(a)(i)</U> through <U>7(a)(iii)</U> hereof shall be hereafter
referred to as the &#147;<U>Accrued Benefits</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) any earned but unpaid Annual Bonus with respect to a calendar year ending
on or preceding the date of termination, payable as provided in <U>Section</U><U></U><U>&nbsp;4</U> hereof (without regard to any continued employment requirement); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) subject to the Executive&#146;s continued compliance with the obligations in this Agreement (in the event of a termination by the Company
due to the Executive&#146;s Disability), a monthly amount equal to the Base Salary rate (as in effect immediately prior to the date of Executive&#146;s termination), which amount shall be paid in cash to the Executive or his estate, as applicable,
in equal installments commensurate with the Company&#146;s regularly scheduled payroll in accordance with the payment procedures set forth in <U>Section</U><U></U><U>&nbsp;3</U> for six (6)&nbsp;months, commencing on the first regularly scheduled
payroll date following the date the general release of claims in <U>Section</U><U></U><U>&nbsp;8</U> is effective and irrevocable (only with respect to a termination by the Company due to the Executive&#146;s Disability); <U>provided</U>,
<U>however</U>, that if the sixty <FONT STYLE="white-space:nowrap">(60)-day</FONT> period in which the release of claims must be effective and irrevocable begins in one tax year and ends in a later tax year, the payments will commence on the first
payroll date following the effective date of the release of claims that begins in the later tax year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>TERMINATION FOR CAUSE, BY
THE EXECUTIVE WITHOUT GOOD REASON OR AS A RESULT OF THE EXECUTIVE&#146;S <FONT STYLE="white-space:nowrap">NON-EXTENSION</FONT> OF THIS AGREEMENT.</B> If the Executive&#146;s employment is terminated (i)&nbsp;by the Company for Cause, (ii)&nbsp;by
the Executive for any reason (other than for Good Reason), or (iii)&nbsp;as a result of the Executive&#146;s <FONT STYLE="white-space:nowrap">non-extension</FONT> of the Employment Term as provided in <U>Section</U><U></U><U>&nbsp;2</U> hereof, then
the Company shall pay to the Executive only the Accrued Benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>TERMINATION BY THE COMPANY WITHOUT CAUSE, BY THE EXECUTIVE FOR
GOOD REASON OR AS A RESULT OF THE COMPANY&#146;S <FONT STYLE="white-space:nowrap">NON-EXTENSION</FONT> OF THIS AGREEMENT</B>. If the Executive&#146;s employment by the Company is terminated (x)&nbsp;by the Company other than for Cause (and not on
account of the Executive&#146;s Disability or death), (y) as a result of the Company&#146;s <FONT STYLE="white-space:nowrap">non-extension</FONT> of the Employment Term as provided in <U>Section</U><U></U><U>&nbsp;2</U> hereof or (z)&nbsp;by the
Executive for Good Reason, in any event other than within the twelve (12)-month period immediately following a Change in Control, then the Company shall pay or provide the Executive with the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the Accrued Benefits; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)
any earned but unpaid Annual Bonus with respect to a calendar year ending on or preceding the date of termination, payable as provided in <U>Section</U><U></U><U>&nbsp;4</U> hereof (without regard to any continued employment requirement); and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) subject to the Executive&#146;s continued compliance with the obligations in this
Agreement, (1)&nbsp;an amount equal to the Executive&#146;s Base Salary (as in effect immediately prior to the date of Executive&#146;s termination), which amount shall be paid in cash to the Executive in equal installments commensurate with the
Company&#146;s regularly scheduled payroll in accordance with the payment procedures set forth in <U>Section</U><U></U><U>&nbsp;3</U> for twelve (12)&nbsp;months following the date the Executive&#146;s employment terminates, and (2)&nbsp;provided
that the Executive timely elects to continue his coverage and that of any eligible dependents in the Company&#146;s group health plans under the federal law known as &#147;COBRA&#148; or similar state law, a monthly amount equal to the monthly
health premiums for such coverage paid by the Company on behalf of the Executive and any eligible dependents immediately prior to the date of termination until the earlier of (x)&nbsp;the date that is twelve (12)&nbsp;months following the date that
the Executive&#146;s employment terminates, (y)&nbsp;the date that the Executive and the Executive&#146;s eligible dependents cease to be eligible for such COBRA coverage under applicable law or plan terms and (z)&nbsp;the date on which the
Executive obtains health coverage from another employer, in each case commencing on the first regularly scheduled payroll date following the date the general release of claims in <U>Section</U><U></U><U>&nbsp;8</U> is effective and irrevocable;
<U>provided</U>, <U>however</U>, that if the sixty <FONT STYLE="white-space:nowrap">(60)-day</FONT> period in which the release of claims must be effective and irrevocable begins in one tax year and ends in a later tax year, the payments will
commence on the first payroll date following the effective date of the release of claims that begins in the later tax year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments and benefits
provided in this <U>Section</U><U></U><U>&nbsp;7(c)</U> shall be in lieu of any termination or severance payments or benefits for which the Executive may be eligible under any of the plans, policies or programs of the Company or applicable law
(including the Worker Adjustment Retraining Notification Act of 1988 or any similar state statute or regulation). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>CHANGE IN
CONTROL</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) If the Executive&#146;s employment by the Company is terminated (x)&nbsp;by the Company other than for Cause (and not on
account of the Executive&#146;s Disability or death), (y) as a result of the Company&#146;s <FONT STYLE="white-space:nowrap">non-extension</FONT> of the Employment Term as provided in <U>Section</U><U></U><U>&nbsp;2</U> hereof or (z)&nbsp;by the
Executive for Good Reason, in any event within the twelve (12)-month period immediately following a Change in Control, then in lieu of the payments and benefits described in <U>Section</U><U></U><U>&nbsp;7(c)</U>, the Company shall pay or provide
the Executive with the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Accrued Benefits; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any earned but unpaid Annual Bonus with respect to a calendar year ending on or preceding the date of
termination, payable as provided in <U>Section</U><U></U><U>&nbsp;4</U> hereof (without regard to any continued employment requirement); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subject to the Executive&#146;s continued compliance with the obligations in this Agreement, (1)&nbsp;an amount
equal to one and one half (1.5) times the sum of the Executive&#146;s Base Salary and the Executive&#146;s target Annual Bonus (in each case, as in effect immediately prior to the date of Executive&#146;s termination), which amount shall be paid in
cash to the Executive in equal installments commensurate with the Company&#146;s regularly scheduled payroll in accordance with the payment procedures set forth in <U>Section</U><U></U><U>&nbsp;3</U> for a period equal to eighteen (18)&nbsp;months
following the date the </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Executive&#146;s employment terminates, (2)&nbsp;provided that the Executive timely elects to continue his coverage and that of any eligible dependents in the Company&#146;s group health plans
under the federal law known as &#147;COBRA&#148; or similar state law, a monthly amount equal to the monthly health premiums for such coverage paid by the Company on behalf of the Executive and any eligible dependents immediately prior to the date
of termination until the earlier of (x)&nbsp;the date that is eighteen (18)&nbsp;months following the date that the Executive&#146;s employment terminates, (y)&nbsp;the date that the Executive and the Executive&#146;s eligible dependents cease to be
eligible for such COBRA coverage under applicable law or plan terms and (z)&nbsp;the date on which the Executive obtains health coverage from another employer, in each case commencing on the first regularly scheduled payroll date following the date
the general release of claims in <U>Section</U><U></U><U>&nbsp;8</U> is effective and irrevocable; <U>provided</U>, <U>however</U>, that if the sixty <FONT STYLE="white-space:nowrap">(60)-day</FONT> period in which the release of claims must be
effective and irrevocable begins in one tax year and ends in a later tax year, the payments will commence on the first payroll date following the effective date of the release of claims that begins in the later tax year. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Any outstanding and unvested equity awards, the vesting of which is based only on the passage of time, held by the Executive as of the
Change in Control shall vest in full upon the consummation of the Change in Control, subject to the Executive remaining employed by the Company through the date of such Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) As used herein, &#147;<U>Change in Control</U>&#148; shall mean the consummation of (i)&nbsp;the sale of all or substantially all of the
assets of Parent on a consolidated basis to an unrelated individual, entity or group (within the meaning of Section&nbsp;13(d)(3) or 14(d)(2) of the Securities Exchange Act) (a &#147;<U>Person</U>&#148;); (ii) a merger, reorganization or
consolidation pursuant to which the holders of Parent&#146;s outstanding voting securities immediately prior to such transaction do not own more than fifty percent (50%) of the outstanding voting securities of the surviving or resulting entity (or
its ultimate parent, if applicable); (iii) the acquisition of more than fifty percent (50%) of the outstanding voting securities of Parent in a single transaction or a series of related transactions by any Person; or (iv)&nbsp;the complete
dissolution or liquidation of Parent; <U>provided</U>, <U>however</U>, that Parent&#146;s initial public offering, any subsequent public offering or anther capital raising event, a merger effected solely to change Parent&#146;s domicile or any
acquisition by Parent or any employee benefit plan (or related trust) sponsored or maintained by Parent or any of its subsidiaries or affiliates shall not constitute a &#147;Change in Control&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments and benefits provided in this <U>Section</U><U></U><U>&nbsp;7(d)</U> shall be in lieu of any termination or severance payments or benefits for which
the Executive may be eligible under any of the plans, policies or programs of the Company or applicable law (including the Worker Adjustment Retraining Notification Act of 1988 or any similar state statute or regulation). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>OTHER OBLIGATIONS</B>. Upon any termination of the Executive&#146;s employment with
the Company, and as a condition to receipt of any funds pursuant to <U>Section</U><U></U><U>&nbsp;7</U>, the Executive shall promptly resign from any position as an officer or director of any Company Group-related entity and will promptly cooperate
in the execution of the appropriate documents to effect the resignation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <B>EXCLUSIVE REMEDY</B>. The amounts payable to the
Executive following termination of employment and the Employment Term hereunder pursuant to <U>Sections 6</U> and <U>7</U> hereof shall be in full and complete satisfaction of the Executive&#146;s rights under this Agreement and any other claims
that the Executive may have in respect of the Executive&#146;s employment with the Company or any of its affiliates, and the Executive acknowledges that such amounts are fair and reasonable, and are the Executive&#146;s sole and exclusive remedy, in
lieu of all other remedies at law or in equity, with respect to the termination of the Executive&#146;s employment hereunder or any breach of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B> <B>RELEASE; MITIGATION; <FONT STYLE="white-space:nowrap">SET-OFFS</FONT></B>. Any and all amounts payable and benefits or additional
rights provided pursuant to this Agreement in connection with the Executive&#146;s termination of employment beyond the Accrued Benefits shall only be payable if the Executive (or his legal representative in the case of a termination due to the
Executive&#146;s Disability) delivers to the Company and does not revoke a general release of claims in favor of the Company Group, including with respect to any claims the Executive may have related to the Executive&#146;s employment with the
Company Group or the termination of such employment, in a form reasonably satisfactory to the Board. Such release shall be executed and delivered (and no longer subject to revocation, if applicable) within sixty (60)&nbsp;days following termination.
In no event shall the Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to the Executive under any of the provisions of this Agreement, and such amounts shall not be offset by any
amount received by the Executive from any other source. Subject to the provisions of this Agreement and the limitations of applicable wage laws, the Company&#146;s obligations to pay the Executive amounts hereunder is subject to <FONT
STYLE="white-space:nowrap">set-off,</FONT> counterclaim or recoupment of amounts owed by the Executive to the Company or any of its affiliates (including any member of the Company Group). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B>SECTION 280G</B>. If any payment or benefit that the Executive may receive, whether or not payable or provided under this
Agreement (&#147;<U>Payment</U>&#148;), would (i)&nbsp;constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Internal Revenue Code of 1986, as amended (the &#147;<U>Code</U>&#148;), and (ii)&nbsp;but for this
sentence, be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;<U>Excise Tax</U>&#148;), then such Payment shall be reduced to the Reduced Amount. The &#147;<U>Reduced Amount</U>&#148; shall be either (A)&nbsp;the largest
portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (B)&nbsp;the largest portion, up to and including the total amount, of the Payment, whichever of the amounts determined under (A)&nbsp;and (B),
after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Executive&#146;s receipt, on an <FONT
STYLE="white-space:nowrap">after-tax</FONT> basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting &#147;parachute
payments&#148; is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the following order: reduction of cash payments; reduction of employee benefits; and cancellation of accelerated vesting of outstanding equity
awards. In the event that acceleration of vesting of outstanding equity awards is to be reduced, such acceleration of vesting shall be undertaken in the reverse order of the date of grant of the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Executive&#146;s outstanding equity awards. All calculations and determinations made pursuant this <U>Section</U><U></U><U>&nbsp;9</U> will be made by an independent accounting or consulting firm
or independent tax counsel appointed by the Company (the &#147;<U>Tax Counsel</U>&#148;) whose determinations shall be conclusive and binding on the Company and the Executive for all purposes. For purposes of making the calculations and
determinations required by this <U>Section</U><U></U><U>&nbsp;9</U>, the Tax Counsel may rely on reasonable, good faith assumptions and approximations concerning the application of Section&nbsp;280G of the Code and Section&nbsp;4999 of the Code. The
Company shall bear all costs the Tax Counsel may reasonably incur in connection with its services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B>SECTION 409A.
</B>Notwithstanding anything to the contrary in this Agreement, if at the time the Executive&#146;s employment terminates, the Executive is a &#147;specified employee,&#148; as defined below, any and all amounts payable under this Agreement on
account of such separation from service that would (but for this provision) be payable within six (6)&nbsp;months following the date of termination, shall instead be paid on the next business day following the expiration of such six (6)-month period
or, if earlier, upon the Executive&#146;s death; except (A)&nbsp;to the extent of amounts that do not constitute a deferral of compensation within the meaning of Treasury regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)</FONT>
(including without limitation by reason of the safe harbor set forth in <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(9)(iii),</FONT> as determined by the Company in its reasonable good faith discretion); (B) benefits that qualify as
excepted welfare benefits pursuant to Treasury regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(a)(5);</FONT> or (C)&nbsp;other amounts or benefits that are not subject to the requirements of Section&nbsp;409A of the Code. For
purposes of this Agreement, to the extent required to avoid adverse tax consequences under Section&nbsp;409A of the Code, all references to &#147;termination of employment&#148; and correlative phrases shall be construed to require a
&#147;separation from service&#148; (as defined in <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h)</FONT> of the Treasury regulations after giving effect to the presumptions contained therein), and, for purposes of this Agreement, the term
&#147;specified employee&#148; means an individual determined by the Company to be a specified employee under Treasury regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(i).</FONT> Each payment made under this Agreement shall be
treated as a separate payment and the right to a series of installment payments under this Agreement is to be treated as a right to a series of separate payments. In no event shall the Company or any of its affiliates have any liability to the
Executive or any other person relating to the failure or alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B>RESTRICTIVE COVENANTS</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>NONCOMPETITION</B>. The Executive acknowledges that (i)&nbsp;the Executive will continue to perform valuable services for the Company,
and that the Executive&#146;s performance of such services to a competing business will result in irreparable harm to the Company Group, (ii)&nbsp;the Executive has had and will have access to certain confidential information which, if improperly
disclosed in violation of the Agreement, would unfairly and inappropriately assist in competition against the Company Group or any of its affiliates, and (iii)&nbsp;the Executive has generated and will generate goodwill for the Company Group and its
affiliates in the course of the Executive&#146;s employment. Accordingly, during the Executive&#146;s employment or service with the Company Group and for a period thereafter equal to twelve (12)&nbsp;months, the Executive agrees that the Executive
will not, directly or indirectly, own, manage, operate, control, be employed by (whether as an employee, consultant, independent contractor or otherwise, and whether or not for compensation) or render services to any person, firm, corporation or
other entity, in whatever form, engaged in the Business (as defined below), in any locale of any country in which the Company </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Group conducts the Business. For purposes hereof, the term &#147;<U>Business</U>&#148; shall mean the business of developing biological medicines for treating patients with devastating diseases,
or any business in which the Company Group is engaged in upon the termination of Executive&#146;s employment or in which the Company Group has actively and in writing planned, on or prior to such date, to be engaged in on or after such date.
Notwithstanding the foregoing, nothing herein shall prohibit the Executive from being a passive owner of not more than two percent (2%) of the equity securities of a publicly traded corporation engaged in a business that is in competition with the
Company Group, so long as the Executive has no active participation in the business of such corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>NONSOLICITATION;
NONINTERFERENCE</B>. During the Executive&#146;s employment or service with the Company Group and for a period thereafter equal to twelve (12)&nbsp;months, the Executive agrees that the Executive shall not, except in the furtherance of the
Executive&#146;s duties hereunder, directly or indirectly, individually or on behalf of any other person, firm, corporation or other entity, (i)&nbsp;solicit, aid or induce any customer of the Company Group or any of its affiliates with whom the
Executive had direct dealings while employed by the Company Group to purchase goods or services then sold by the Company Group or any of its affiliates from another person, firm, corporation or other entity or assist or aid any other person or
entity in identifying or soliciting any such customer, (ii)&nbsp;solicit, aid or induce any employee, representative or agent of the Company Group or any of its affiliates to leave such employment or retention or to accept employment with or render
services to or with any other person, firm, corporation or other entity unaffiliated with the Company Group, or hire or retain any such employee, representative or agent, or take any action to materially assist or aid any other person, firm,
corporation or other entity in identifying, hiring or soliciting any such employee, representative or agent, or (iii)&nbsp;knowingly interfere, or knowingly aid or induce any other person or entity in interfering, with the relationship between the
Company Group or any of its affiliates and any of their respective vendors, joint venturers or licensors. An employee, representative or agent shall be deemed covered by this <U>Section</U><U></U><U>&nbsp;11(b)</U> while so employed or retained and
for a period of nine (9)&nbsp;months thereafter. Notwithstanding the foregoing, the provisions of this <U>Section</U><U></U><U>&nbsp;11(b)</U> shall not be violated by general advertising or solicitation not specifically targeted at Company
Group-related persons or entities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>NONDISPARAGEMENT</B>. Both during the Employment Term and at all times thereafter, regardless
of the reason for termination, the Executive agrees not to make comments materially injurious to the reputation of the Company Group or otherwise disparage the Company Group or any of their officers, directors, employees, shareholders, members,
agents or products. Any disclosure by the Executive in good faith in connection with any legal proceedings between the Executive and the Company Group, in response to legal process, required governmental testimony or filings, or administrative or
arbitral proceedings (including, without limitation, depositions in connection with such proceedings) shall not be deemed to violate this <U>Section</U><U></U><U>&nbsp;11(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>RETURN OF COMPANY PROPERTY</B>. On the date of the Executive&#146;s termination of employment with the Company for any reason (or at
any time prior thereto at the Company Group&#146;s request), the Executive shall return to the Company all property belonging to the Company Group or its affiliates including, but not limited to, any Company-provided laptops, computers, cell phones,
wireless electronic mail devices or other equipment, or any property belonging to the Company Group and any Documents. The Executive also agrees to disclose to the Company, at the time his employment terminates or at such earlier time or times as
the Board or its designee may specify, all passwords necessary or desirable to obtain access to, or that would assist in obtaining access to, any information which the Executive has password-protected on any computer equipment, network or system of
the Company Group or any of its affiliates. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>REASONABLENESS OF COVENANTS</B>. In signing this Agreement, the Executive gives the
Company Group assurance that the Executive has carefully read and considered all of the terms and conditions of this Agreement, including the restraints imposed under this <U>Section</U><U></U><U>&nbsp;11</U>. The Executive agrees that these
restraints are necessary for the reasonable and proper protection of the Company Group and its affiliates and their confidential information and that each and every one of the restraints is reasonable in respect of subject matter, length of time and
geographic area, and that these restraints, individually or in the aggregate, will not prevent the Executive from obtaining other suitable employment during the period in which the Executive is bound by the restraints. The <FONT
STYLE="white-space:nowrap">non-prevailing</FONT> party will reimburse the prevailing party for all costs (including reasonable attorneys&#146; fees) incurred in connection with any action to enforce any of the provisions of this
<U>Section</U><U></U><U>&nbsp;11</U>. It is also agreed that each of the Company Group&#146;s affiliates will have the right to enforce all of the Executive&#146;s obligations to that affiliate under this Agreement, including without limitation
pursuant to this <U>Section</U><U></U><U>&nbsp;11</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <B>REFORMATION</B>. If it is determined by a court of competent jurisdiction
in any state that any restriction in this <U>Section</U><U></U><U>&nbsp;11</U> is excessive in duration or scope or is unreasonable or unenforceable under applicable law, it is the intention of the parties that such restriction may be modified or
amended by the court to render it enforceable to the maximum extent permitted by the laws of that state. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <B>TOLLING</B>. In the event
of any violation of the provisions of this <U>Section</U><U></U><U>&nbsp;11</U>, the Executive acknowledges and agrees that the post-termination restrictions contained in this <U>Section</U><U></U><U>&nbsp;11</U> shall be extended by a period of
time equal to the period of such violation, it being the intention of the parties hereto that the running of the applicable post-termination restriction period shall be tolled during any period of such violation; <U>provided</U>, that tolling period
shall not exceed sixty (60)&nbsp;days after the Company Group has knowledge of such violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <B>SURVIVAL OF PROVISIONS</B>. The
obligations contained in <U>Sections 11</U> through <U>13</U> hereof shall survive the termination or expiration of the Employment Term and the Executive&#146;s employment with the Company and shall be fully enforceable thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B>COOPERATION</B>. In connection with any termination of the Executive&#146;s employment with the Company, the Executive agrees to
assist the Company Group, as reasonably requested by the Company Group, in its succession planning efforts to facilitate a smooth transition of the Executive&#146;s job responsibilities to the Executive&#146;s successor. In addition, upon the
receipt of reasonable notice from the Company Group (including outside counsel), the Executive agrees that while employed by, or providing services to, the Company Group and thereafter, the Executive will respond and provide truthful information
with regard to matters in which the Executive has knowledge as a result of the Executive&#146;s employment with the Company Group, and will reasonably cooperate with the Company Group, its affiliates and their respective representatives in defense
of all claims that may be made against the Company Group or its affiliates, and will cooperate with the Company Group and its affiliates in the prosecution of all claims that may be made by the Company Group or its affiliates, to the extent that
such claims may relate to the period </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the Executive&#146;s employment or service with the Company Group and the Company reasonably believes that the Executive has pertinent knowledge or information related to such claims. The
Executive agrees to promptly inform the Company (to the extent that the Executive is legally permitted to do so) if the Executive becomes aware of any lawsuit involving such third party claims that may be filed or threatened against the Company
Group or its affiliates. The Executive also agrees to promptly inform the Company (to the extent that the Executive is legally permitted to do so) if the Executive is asked to assist in any investigation of the Company Group or its affiliates (or
their actions), regardless of whether a lawsuit or other proceeding has then been filed against the Company Group or its affiliates with respect to such investigation, and shall not do so unless legally required. Upon presentation of appropriate
documentation, the Company shall pay or reimburse the Executive for all reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> travel, duplicating or telephonic expenses incurred by the Executive in
complying with this <U>Section</U><U></U><U>&nbsp;12</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B>EQUITABLE RELIEF AND OTHER REMEDIES</B>. The Executive
acknowledges and agrees that the Company&#146;s remedies at law for a breach or threatened breach of any of the provisions of <U>Section</U><U></U><U>&nbsp;11</U> or <U>Section</U><U></U><U>&nbsp;12</U> hereof would be inadequate and, in recognition
of this fact, the Executive agrees that, in the event of such a breach or threatened breach, in addition to any remedies at law, the Company Group shall be entitled to seek equitable relief in the form of specific performance, a temporary
restraining order, a temporary or permanent injunction or any other equitable remedy which may then be available, without the necessity of showing actual monetary damages and without posting any bond or other security. In the event of a violation by
the Executive of <U>Section</U><U></U><U>&nbsp;11</U> or <U>Section</U><U></U><U>&nbsp;12</U> hereof, any severance being paid to the Executive pursuant to this Agreement or otherwise shall immediately cease, and any severance previously paid to the
Executive shall be immediately repaid to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B>NO ASSIGNMENTS</B>. This Agreement is personal to each of the parties
hereto. Except as provided in this <U>Section</U><U></U><U>&nbsp;14</U>, no party may assign or delegate any rights or obligations hereunder without first obtaining the written consent of the other party hereto. The Company may assign this Agreement
to any successor to all or substantially all of the business and/or assets of the Company or to any of its subsidiaries or affiliates; <U>provided</U> that the Company shall require such assignee to expressly assume and agree to perform this
Agreement in the same manner and to the same extent that the Company would be required to perform it if no such assignment had taken place. As used in this Agreement, &#147;Company&#148; shall mean the Company and any successor to its business
and/or assets or assignee of this Agreement, which assumes and agrees to perform the duties and obligations of the Company under this Agreement by operation of law or otherwise. Each member of the Company Group is an intended third party beneficiary
of this Agreement and shall be entitled to enforce the provisions of this Agreement as if a direct party to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B>
<B>NOTICE</B>. For purposes of this Agreement, notices and all other communications provided for in this Agreement shall be in writing and shall be deemed to have been duly given (a)&nbsp;on the date of delivery, if delivered by hand, (b)&nbsp;on
the date of transmission, if delivered by confirmed facsimile or by electronic mail, (c)&nbsp;on the first business day following the date of deposit, if delivered by guaranteed overnight delivery service, or (d)&nbsp;on the fourth business day
following the date delivered or mailed by United States registered or certified mail, return receipt requested, postage prepaid, addressed as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">If to the Executive: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">At the
address (or to the facsimile number or email address) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">shown in the books and records of the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">If to the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Rallybio, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">234 Church
Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Suite 1020 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New
Haven, CT 06510 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as either
party may have furnished to the other in writing in accordance herewith, except that notices of change of address shall be effective only upon receipt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B>SECTION HEADINGS; INCONSISTENCY</B>. The section headings used in this Agreement are included solely for convenience and shall
not affect, or be used in connection with, the interpretation of this Agreement. In the event of any inconsistency between the terms of this Agreement and any form, award, plan or policy of the Company Group, the terms of this Agreement shall govern
and control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B> <B>SEVERABILITY</B>. The provisions of this Agreement shall be deemed severable. The invalidity or
unenforceability of any provision of this Agreement in any jurisdiction shall not affect the validity, legality or enforceability of the remainder of this Agreement in such jurisdiction or the validity, legality or enforceability of any provision of
this Agreement in any other jurisdiction, it being intended that all rights and obligations of the parties hereunder shall be enforceable to the fullest extent permitted by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18.</B> <B>COUNTERPARTS</B>. This Agreement may be executed in several counterparts, each of which shall be deemed to be an original but
all of which together will constitute one and the same instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>19.</B> <B>GOVERNING LAW; JURISDICTION</B>. This Agreement, the
rights and obligations of the parties hereto, and all claims or disputes relating thereto, shall be governed by and construed in accordance with the laws of the State of Connecticut, without regard to the choice of law provisions thereof. Each of
the parties hereby irrevocably and unconditionally consents to the exclusive jurisdiction of the courts of the State of Connecticut and the United States District Court for the District of Connecticut, as well as to the jurisdiction of all courts to
which an appeal may be taken from such courts, for the purpose of any suit, action or other proceeding arising out of or in connection with this Agreement or any of the transactions contemplated hereby, and irrevocably and unconditionally waives, to
the fullest extent permitted by law, any and all objections such party may now or hereafter have to the laying of the venue of any such suit, action or proceeding in any such court or that any such suit, action or proceeding brought in any such
court has been brought in an inconvenient forum. In that context, and without limiting the generality of the foregoing, each of the parties hereto irrevocably and unconditionally (a)&nbsp;submits in any proceeding relating to this Agreement or the
Executive&#146;s employment by the Company or any affiliate, or for the recognition and enforcement of any judgment in respect thereof (a </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;<U>Proceeding</U>&#148;), to the exclusive jurisdiction of the courts of the State of Connecticut and the United States District Court for the District of Connecticut, as well as to the
jurisdiction of all courts to which an appeal may be taken from such courts, and agrees that all claims in respect of any such Proceeding shall be heard and determined in such Connecticut State court or, to the extent permitted by law, in such
federal court, (b)&nbsp;consents that any such Proceeding may and shall be brought in such courts and waives any objection that the Executive or the Company may now or thereafter have to the venue or jurisdiction of any such Proceeding in any such
court or that such Proceeding was brought in an inconvenient court and agrees not to plead or claim the same, (c)&nbsp;WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY PROCEEDING (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO
THIS AGREEMENT OR THE EXECUTIVE&#146;S EMPLOYMENT BY OR SERVICE WITH THE COMPANY OR ANY AFFILIATE OF THE COMPANY, OR THE EXECUTIVE&#146;S OR THE COMPANY&#146;S PERFORMANCE UNDER, OR THE ENFORCEMENT OF, THIS AGREEMENT, (d)&nbsp;agrees that service of
process in any such Proceeding may be effected by mailing a copy of such process by registered or certified mail (or any substantially similar form of mail), postage prepaid, to such party at the Executive&#146;s or the Company&#146;s address as
provided in <U>Section</U><U></U><U>&nbsp;15</U> hereof, (e)&nbsp;agrees that nothing in this Agreement shall affect the right to effect service of process in any other manner permitted by the laws of the State of Connecticut and (f)&nbsp;expressly
waives any and all rights to bring any suit, action or other proceeding arising out of or in connection with this Agreement in or before any court or tribunal other than the courts of the State of Connecticut or the United States District Court for
the District of Connecticut and any courts to which an appeal may be taken from such courts, and covenants that such party shall not seek in any manner to resolve any dispute other than as set forth herein or to challenge or set aside any decision,
award or judgment obtained in accordance with the provisions hereof. Except as may be explicitly set forth in this Agreement, the parties acknowledge and agree that in connection with any dispute hereunder, each party shall pay all of its own costs
and expenses, including, without limitation, its own legal fees and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>20.</B> <B>MISCELLANEOUS</B>. No provision of this
Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing and signed by the Executive and such officer or director of the Company as may be designated by the Board or the Compensation
Committee, and in any case must be approved by the Board or the Compensation Committee. In addition, notwithstanding anything to the contrary in this Agreement, the Company may not terminate this Agreement (including by notice of <FONT
STYLE="white-space:nowrap">non-renewal)</FONT> or the Executive&#146;s employment without Board or Compensation Committee approval. No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any
condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time. This Agreement together with all exhibits hereto
(if any) set forth the entire agreement of the parties hereto in respect of the subject matter contained herein and supersede any and all prior agreements or understandings between the Executive and the Company with respect to the subject matter
hereof, including the Prior Agreement. No agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by either party which are not expressly set forth in this Agreement. Any
references in this Agreement to &#147;$&#148; shall mean U.S. dollars. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21. REPRESENTATIONS. </B>The Executive represents and warrants to the Company that
(a)&nbsp;the Executive has the legal right to enter into this Agreement and to perform all of the obligations on the Executive&#146;s part to be performed hereunder in accordance with its terms, and (b)&nbsp;the Executive is not a party to any
agreement or understanding, written or oral, and is not subject to any restriction, which, in either case, could prevent the Executive from entering into this Agreement or performing all of the Executive&#146;s duties and obligations hereunder.<B>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>22.</B> <B>TAX MATTERS</B>. The Company Group may withhold from any and all amounts payable under this Agreement or otherwise such
federal, state and local taxes as may be required to be withheld pursuant to any applicable law or regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>23.</B> <B>OTHER</B>.
Nothing contained in this Agreement limits, restricts or in any other way affects the Executive&#146;s communicating with any governmental agency or entity, or communicating with any official or staff person of a governmental agency or entity,
concerning matters relevant to such governmental agency or entity and the Executive will not be held criminally or civilly liable under any federal or state trade secret law for disclosing a trade secret (i)&nbsp;in confidence to a federal, state,
or local government official, either directly or indirectly, or to an attorney, solely for the purpose of reporting or investigating a suspected violation of law, or (ii)&nbsp;in a complaint or other document filed under seal in a lawsuit or other
proceeding; <U>provided</U>, <U>however</U>, that notwithstanding this immunity from liability, the Executive may be held liable if he unlawfully accesses trade secrets by unauthorized means. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;* </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the parties hereto have executed this Agreement as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="98%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>RALLYBIO,
LLC</B></P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Jeffrey M.
Fryer</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="86%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey M. Fryer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title: &nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer and Treasurer</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ Martin W. Mackay</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Martin W. Mackay</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>22
<FILENAME>d99471dex1021.htm
<DESCRIPTION>EX-10.21
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.21</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.21 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>AMENDED AND RESTATED EMPLOYMENT AGREEMENT</B> (this &#147;<U>Agreement</U>&#148;) dated as of July&nbsp;15, 2021 by and between Rallybio,
LLC, a Delaware limited liability company (the &#147;<U>Company</U>&#148;), and Stephen Uden (the &#147;<U>Executive</U>&#148;) and effective as of the day prior to the date on which Rallybio Corporation (&#147;<U>Parent</U>&#148;) becomes subject
to the reporting obligations of Section&nbsp;12 of the Securities Exchange Act of 1934, as amended (the &#147;<U>Securities Exchange Act</U>&#148;) (such date, the &#147;<U>Effective Date</U>&#148;). This Agreement amends and restates in its
entirety the employment agreement by and among the Company and the Executive, effective as of April&nbsp;20, 2018 (the &#147;<U>Prior Agreement</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>W</U> <U>I</U> <U>T</U> <U>N</U> <U>E</U> <U>S</U> <U>S</U> <U>E</U> <U>T</U> <U>H</U>: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company desires to continue to employ the Executive as the President and Chief Operating Officer and Chief Scientific
Officer of the Company; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company and the Executive desire to enter into this amended and restated Agreement as to
the terms of the Executive&#146;s continued employment with the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the foregoing, of the
mutual promises contained herein and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>POSITION AND DUTIES</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>GENERAL</B>. During the Employment Term (as defined below), the Executive shall serve as the President and Chief Operating Officer and
Chief Scientific Officer of the Company. In this capacity, the Executive shall have the duties, authorities and responsibilities commensurate with the duties, authorities and responsibilities of persons in similar capacities in similarly sized
companies and such other duties, authorities and responsibilities as may reasonably be assigned by the board of directors of Parent (the &#147;<U>Board</U>&#148;) to the Executive from time to time that are not inconsistent with the Executive&#146;s
position with the Company and do not unreasonably interfere with his duties to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>OTHER ACTIVITIES</B>. During the
Employment Term, the Executive shall devote all of the Executive&#146;s business time and energy, business judgment, knowledge and skill and the Executive&#146;s best efforts to the performance of the Executive&#146;s duties with the Company,
<U>provided</U> that the foregoing shall not prevent the Executive from (i)&nbsp;serving on the boards of directors (and board committees) of <FONT STYLE="white-space:nowrap">non-profit</FONT> organizations (provided, that the Executive provides the
Board with advanced written notice prior to accepting or serving in any such position), (ii) serving on the boards of directors (and board committees) of <FONT STYLE="white-space:nowrap">for-profit</FONT> organizations (provided, that the Executive
receives prior written approval from the Board, which shall not be unreasonably withheld, delayed or conditioned), (iii) participating in charitable, civic, educational, professional, community or industry affairs, (iv)&nbsp;spending a de minimis
amount of time on activities that provide de minimis compensation to the Executive, and (v)&nbsp;spending a de minimis amount of time managing the Executive&#146;s passive personal investments; <U>provided</U>, such activities do not interfere or
conflict with the Executive&#146;s duties hereunder or create a potential business or fiduciary conflict or otherwise violate Section&nbsp;11 of this Agreement; <U>provided</U> <U>further</U>, each of the Executive&#146;s activities listed on
<U>Schedule A</U> attached hereto is permitted under this Agreement so long as such activities listed on <U>Schedule A</U> do not materially interfere or conflict with the Executive&#146;s duties hereunder. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B>EMPLOYMENT TERM</B>. The Company agrees to employ the Executive pursuant to the
terms of this Agreement, and the Executive agrees to be so employed, for a term of one (1)&nbsp;year (the &#147;<U>Initial Term</U>&#148;) commencing as of the Effective Date. On each anniversary of the Effective Date following the Initial Term, the
term of this Agreement shall be automatically extended for successive one (l)-year periods; <U>provided</U>, <U>however</U>, that either party hereto may elect not to extend this Agreement by giving written notice to the other party at least sixty
(60)&nbsp;days prior to any such anniversary date. Notwithstanding the foregoing, the Executive&#146;s employment hereunder may be earlier terminated in accordance with <U>Section</U><U></U><U>&nbsp;6</U> hereof, subject to the provisions of
<U>Section</U><U></U><U>&nbsp;7</U> hereof. The period of time between the Effective Date and the termination of the Executive&#146;s employment hereunder shall be referred to herein as the &#147;<U>Employment Term</U>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B>BASE SALARY</B>. During the Employment Term, the Company agrees to pay the Executive a base salary at an annual rate of,
initially, $470,000. The base salary shall be paid in cash in accordance with the regular payroll practices of the Company with respect to salaried employees, but in no event less frequently than semi-monthly. The Executive&#146;s base salary shall
be subject to review by the Board or the Compensation Committee of the Board (the &#147;<U>Compensation Committee</U>&#148;), and may be increased from time to time by the Board or the Compensation Committee in its respective sole discretion. The
base salary as determined herein and adjusted from time to time shall constitute the &#147;<U>Base Salary</U>&#148; for purposes of this Agreement, and any section herein providing for payment of the Base Salary to the Executive shall mean payment
of the Base Salary rate in effect at the time of payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>ANNUAL BONUS</B>. With respect to each fiscal year during the
Employment Term, the Executive shall be eligible to receive an annual cash incentive payment (the &#147;<U>Annual Bonus</U>&#148;). The target amount of the Annual Bonus shall be (forty percent) 40&nbsp;% of the Base Salary; <U>provided</U>, in any
event, the actual Annual Bonus to be paid in respect of any fiscal year, if any, which may be more or less than the target bonus amount, will be based on the attainment of individual and/or Company performance goals for such year established by the
Board or the Compensation Committee as determined by the Board or the Compensation Committee in its respective sole discretion. Any Annual Bonus awarded hereunder shall be paid in the calendar year following the calendar year to which such bonus
relates at the same time annual bonuses are paid to other senior executives of the Company, except as otherwise provided in <U>Section</U><U></U><U>&nbsp;7</U> hereof, but not later than March
15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of such following calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B>EMPLOYEE BENEFITS</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>BENEFIT PLANS</B>. During the Employment Term, the Executive shall be entitled to participate in any employee benefit plan that the
Company has adopted or may adopt or maintains or contributes to for the benefit of its employees generally, subject to satisfying the applicable eligibility requirements, and except to the extent such plans are duplicative of the benefits otherwise
provided hereunder. The Executive&#146;s participation will be subject to the terms of the applicable plan documents and generally applicable Company policies. Notwithstanding the foregoing, the Company may modify or terminate any employee benefit
plan at any time. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>BUSINESS EXPENSES</B>. Upon presentation of reasonable substantiation and
documentation as required by the Company&#146;s expense reimbursement policies, that the Company may modify from time to time, the Executive shall be reimbursed for all reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> business expenses incurred and paid by the Executive during the Employment Term and in connection with the performance of the Executive&#146;s duties
hereunder or otherwise incurred at the direction of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>VACATION</B>. The Executive shall be entitled to take vacation in
accordance with the Company&#146;s policy then in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>TERMINATION</B>. The Executive&#146;s employment and the
Employment Term shall terminate on the first of the following to occur: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>DISABILITY</B>. Upon ten (10)&nbsp;days&#146; prior
written notice by the Company to the Executive of a termination due to Disability. For purposes of this Agreement, &#147;<U>Disability</U>&#148; shall be defined as the inability of the Executive to have performed the Executive&#146;s material
duties hereunder, with or without reasonable accommodation due to a physical or mental injury, infirmity, limitation or incapacity which has lasted or can reasonably be expected to last for one hundred eighty (180)&nbsp;days (including weekends and
holidays) in any three hundred sixty-five <FONT STYLE="white-space:nowrap">(365)-day</FONT> period as determined by the Board in its reasonable discretion. The Executive (or the Executive&#146;s representative) shall cooperate in all respects with
the Company if a good faith question arises as to whether the Executive has become disabled (including, without limitation, submitting to reasonable examinations by one or more medical doctors and other health care specialists reasonably selected by
the Company and authorizing such medical doctors and other health care specialists to discuss the Executive&#146;s condition with the Company). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>DEATH</B>. Automatically upon the date of death of the Executive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>BY THE COMPANY FOR CAUSE</B>. Immediately upon written notice by the Company to the Executive of a termination for Cause.
&#147;<U>Cause</U>&#148; shall mean (i)&nbsp;the Executive having been indicted for, or having pleaded guilty or <I>nolo contendere</I> to, (A)&nbsp;a felony or (B)&nbsp;a crime involving dishonesty or moral turpitude; (ii)&nbsp;the Executive&#146;s
commission of any act of fraud, or embezzlement, theft, or material dishonesty or intentional misappropriation of the property of the Company, Parent or any of their respective direct or indirect subsidiaries (collectively, the &#147;<U>Company
Group</U>&#148;) or any of their respective affiliates or of any customer or supplier of the Company Group; (iii)&nbsp;the Executive&#146;s repeated use of illegal drugs or repeated abuse of alcohol that materially impairs the Executive&#146;s
ability to perform the Executive&#146;s duties contemplated hereunder; (iv)&nbsp;the Executive&#146;s material breach of this Agreement or any other agreement with the Company Group, or a material violation of any of the Company Group&#146;s written
policies or procedures; or (v)&nbsp;any other willful misconduct or gross negligence in the performance of the Executive&#146;s duties to the Company Group that has caused material injury (including by way of reputational harm or other damages) to
any member of the Company Group. Notwithstanding the foregoing, the Company shall not terminate Executive&#146;s employment for Cause pursuant to <U>Section</U><U></U><U>&nbsp;6(c)(iii)</U> or <U>(iv)</U>&nbsp;unless the Company has first given
Executive written notice of the acts or omissions constituting Cause thereunder, and, if such acts or omissions are susceptible to cure, the Executive has failed to cure such acts or omissions to the Company&#146;s reasonable satisfaction within
thirty (30)&nbsp;days after receipt of such notice. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>BY THE COMPANY WITHOUT CAUSE</B>. Upon thirty (30)&nbsp;days&#146; prior written
notice by the Company to the Executive of an involuntary termination without Cause (other than for death or Disability); <U>provided</U>, that the Board may, in its sole discretion, elect to provide Base Salary to the Executive in lieu of such
notice (in whole or in part).<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>BY THE EXECUTIVE FOR ANY REASON</B>. Upon
sixty (60)&nbsp;days&#146; prior written notice by the Executive to the Company of the Executive&#146;s voluntary termination of employment for any reason (including for Good Reason); <U>provided</U>, that the Board may, in its sole discretion,
elect to accelerate the date of termination without the payment of additional compensation. &#147;<U>Good Reason</U>&#148; means: (i)&nbsp;a failure by the Company to pay the Executive his Base Salary when due, (ii)&nbsp;any involuntary material
diminution in the Executive&#146;s duties, authorities or responsibilities (other than temporarily while physically or mentally incapacitated or as required by applicable law), (iii) any change to the Executive&#146;s title to which the Executive
did not consent in writing, or (iv)&nbsp;the Executive being required to relocate to a principal place of employment more than fifty (50)&nbsp;miles from the Executive&#146;s principal place of employment with the Company Group at such time; which,
in each case, is not cured by the Company Group within thirty (30)&nbsp;days of the Company&#146;s receipt of written notice thereof from the Executive specifying the particulars of the conduct constituting Good Reason; <U>provided</U>, that the
Executive gives such notice to the Company within ninety (90)&nbsp;days of the Executive having knowledge of the occurrence of such event and, if such event is not cured by the Company, the Executive terminates his employment within thirty
(30)&nbsp;days after the end of the Company&#146;s cure period; otherwise, Good Reason shall be deemed waived with respect to such event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <B>EXPIRATION OF EMPLOYMENT TERM; <FONT STYLE="white-space:nowrap">NON-EXTENSION</FONT> OF AGREEMENT</B>. Upon the expiration of the
Employment Term due to a <FONT STYLE="white-space:nowrap">non-extension</FONT> of the Agreement by the Company or the Executive pursuant to the provisions of <U>Section</U><U></U><U>&nbsp;2</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B>CONSEQUENCES OF TERMINATION</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>DEATH OR DISABILITY</B>. In the event that the Executive&#146;s employment and the Employment Term end on account of the
Executive&#146;s death or a termination by the Company due to the Executive&#146;s Disability, the Executive&#146;s estate or the Executive, as applicable, shall be entitled to the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) any earned and unpaid Base Salary through the date of termination; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) reimbursement for any unreimbursed business expenses incurred through the date of termination; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) all other accrued and vested payments, benefits or fringe benefits to which the Executive is entitled in accordance with the terms and
conditions of the applicable compensation or benefit plan, program or arrangement of the Company (collectively, <U>Sections 7(a)(i)</U> through <U>7(a)(iii)</U> hereof shall be hereafter referred to as the &#147;<U>Accrued Benefits</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) any earned but unpaid Annual Bonus with respect to a calendar year ending on or preceding the date of termination, payable as provided in
<U>Section</U><U></U><U>&nbsp;4</U> hereof (without regard to any continued employment requirement); and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) subject to the Executive&#146;s continued compliance with the obligations in this
Agreement (in the event of a termination by the Company due to the Executive&#146;s Disability), a monthly amount equal to the Base Salary rate (as in effect immediately prior to the date of Executive&#146;s termination), which amount shall be paid
in cash to the Executive or his estate, as applicable, in equal installments commensurate with the Company&#146;s regularly scheduled payroll in accordance with the payment procedures set forth in <U>Section</U><U></U><U>&nbsp;3</U> for six
(6)&nbsp;months, commencing on the first regularly scheduled payroll date following the date the general release of claims in <U>Section</U><U></U><U>&nbsp;8</U> is effective and irrevocable (only with respect to a termination by the Company due to
the Executive&#146;s Disability); <U>provided</U>, <U>however</U>, that if the sixty <FONT STYLE="white-space:nowrap">(60)-day</FONT> period in which the release of claims must be effective and irrevocable begins in one tax year and ends in a later
tax year, the payments will commence on the first payroll date following the effective date of the release of claims that begins in the later tax year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>TERMINATION FOR CAUSE, BY THE EXECUTIVE WITHOUT GOOD REASON OR AS A RESULT OF THE EXECUTIVE&#146;S
<FONT STYLE="white-space:nowrap">NON-EXTENSION</FONT> OF THIS AGREEMENT.</B> If the Executive&#146;s employment is terminated (i)&nbsp;by the Company for Cause, (ii)&nbsp;by the Executive for any reason (other than for Good Reason), or (iii)&nbsp;as
a result of the Executive&#146;s <FONT STYLE="white-space:nowrap">non-extension</FONT> of the Employment Term as provided in <U>Section</U><U></U><U>&nbsp;2</U> hereof, then the Company shall pay to the Executive only the Accrued Benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>TERMINATION BY THE COMPANY WITHOUT CAUSE, BY THE EXECUTIVE FOR GOOD REASON OR AS A RESULT OF THE COMPANY&#146;S <FONT
STYLE="white-space:nowrap">NON-EXTENSION</FONT> OF THIS AGREEMENT</B>. If the Executive&#146;s employment by the Company is terminated (x)&nbsp;by the Company other than for Cause (and not on account of the Executive&#146;s Disability or death), (y)
as a result of the Company&#146;s <FONT STYLE="white-space:nowrap">non-extension</FONT> of the Employment Term as provided in <U>Section</U><U></U><U>&nbsp;2</U> hereof or (z)&nbsp;by the Executive for Good Reason, in any event other than within the
twelve (12)-month period immediately following a Change in Control, then the Company shall pay or provide the Executive with the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the Accrued Benefits; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)
any earned but unpaid Annual Bonus with respect to a calendar year ending on or preceding the date of termination, payable as provided in <U>Section</U><U></U><U>&nbsp;4</U> hereof (without regard to any continued employment requirement); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) subject to the Executive&#146;s continued compliance with the obligations in this Agreement, (1)&nbsp;an amount equal to the
Executive&#146;s Base Salary (as in effect immediately prior to the date of Executive&#146;s termination), which amount shall be paid in cash to the Executive in equal installments commensurate with the Company&#146;s regularly scheduled payroll in
accordance with the payment procedures set forth in <U>Section</U><U></U><U>&nbsp;3</U> for twelve (12)&nbsp;months following the date the Executive&#146;s employment terminates, and (2)&nbsp;provided that the Executive timely elects to continue his
coverage and that of any eligible dependents in the Company&#146;s group health plans under the federal law known as &#147;COBRA&#148; or similar state law, a monthly amount equal to the monthly health premiums for such coverage paid by the Company
on behalf of the Executive and any eligible dependents immediately prior to the date of termination until the earlier of (x)&nbsp;the date that is twelve (12)&nbsp;months following the date that the Executive&#146;s employment terminates,
(y)&nbsp;the date that the Executive and the Executive&#146;s eligible dependents cease to be eligible for such COBRA </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
coverage under applicable law or plan terms and (z)&nbsp;the date on which the Executive obtains health coverage from another employer, in each case commencing on the first regularly scheduled
payroll date following the date the general release of claims in <U>Section</U><U></U><U>&nbsp;8</U> is effective and irrevocable; <U>provided</U>, <U>however</U>, that if the sixty <FONT STYLE="white-space:nowrap">(60)-day</FONT> period in which
the release of claims must be effective and irrevocable begins in one tax year and ends in a later tax year, the payments will commence on the first payroll date following the effective date of the release of claims that begins in the later tax
year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments and benefits provided in this <U>Section</U><U></U><U>&nbsp;7(c)</U> shall be in lieu of any termination or severance payments or benefits
for which the Executive may be eligible under any of the plans, policies or programs of the Company or applicable law (including the Worker Adjustment Retraining Notification Act of 1988 or any similar state statute or regulation). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>CHANGE IN CONTROL</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) If the Executive&#146;s employment by the Company is terminated (x)&nbsp;by the Company other than for Cause (and not on account of the
Executive&#146;s Disability or death), (y) as a result of the Company&#146;s <FONT STYLE="white-space:nowrap">non-extension</FONT> of the Employment Term as provided in <U>Section</U><U></U><U>&nbsp;2</U> hereof or (z)&nbsp;by the Executive for Good
Reason, in any event within the twelve (12)-month period immediately following a Change in Control, then in lieu of the payments and benefits described in <U>Section</U><U></U><U>&nbsp;7(c)</U>, the Company shall pay or provide the Executive with
the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Accrued Benefits; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any earned but unpaid Annual Bonus with respect to a calendar year ending on or preceding the date of
termination, payable as provided in <U>Section</U><U></U><U>&nbsp;4</U> hereof (without regard to any continued employment requirement); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subject to the Executive&#146;s continued compliance with the obligations in this Agreement, (1)&nbsp;an amount
equal to one and one half (1.5) times the sum of the Executive&#146;s Base Salary and the Executive&#146;s target Annual Bonus (in each case, as in effect immediately prior to the date of Executive&#146;s termination), which amount shall be paid in
cash to the Executive in equal installments commensurate with the Company&#146;s regularly scheduled payroll in accordance with the payment procedures set forth in <U>Section</U><U></U><U>&nbsp;3</U> for a period equal to eighteen (18)&nbsp;months
following the date the Executive&#146;s employment terminates, (2)&nbsp;provided that the Executive timely elects to continue his coverage and that of any eligible dependents in the Company&#146;s group health plans under the federal law known as
&#147;COBRA&#148; or similar state law, a monthly amount equal to the monthly health premiums for such coverage paid by the Company on behalf of the Executive and any eligible dependents immediately prior to the date of termination until the earlier
of (x)&nbsp;the date that is eighteen (18)&nbsp;months following the date that the Executive&#146;s employment terminates, (y)&nbsp;the date that </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
the Executive and the Executive&#146;s eligible dependents cease to be eligible for such COBRA coverage under applicable law or plan terms and (z)&nbsp;the date on which the Executive obtains
health coverage from another employer, in each case commencing on the first regularly scheduled payroll date following the date the general release of claims in <U>Section</U><U></U><U>&nbsp;8</U> is effective and irrevocable; <U>provided</U>,
<U>however</U>, that if the sixty <FONT STYLE="white-space:nowrap">(60)-day</FONT> period in which the release of claims must be effective and irrevocable begins in one tax year and ends in a later tax year, the payments will commence on the first
payroll date following the effective date of the release of claims that begins in the later tax year. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Any outstanding
and unvested equity awards, the vesting of which is based only on the passage of time, held by the Executive as of the Change in Control shall vest in full upon the consummation of the Change in Control, subject to the Executive remaining employed
by the Company through the date of such Change in Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) As used herein, &#147;<U>Change in Control</U>&#148; shall mean the
consummation of (i)&nbsp;the sale of all or substantially all of the assets of Parent on a consolidated basis to an unrelated individual, entity or group (within the meaning of Section&nbsp;13(d)(3) or 14(d)(2) of the Securities Exchange Act) (a
&#147;<U>Person</U>&#148;); (ii) a merger, reorganization or consolidation pursuant to which the holders of Parent&#146;s outstanding voting securities immediately prior to such transaction do not own more than fifty percent (50%) of the outstanding
voting securities of the surviving or resulting entity (or its ultimate parent, if applicable); (iii) the acquisition of more than fifty percent (50%) of the outstanding voting securities of Parent in a single transaction or a series of related
transactions by any Person; or (iv)&nbsp;the complete dissolution or liquidation of Parent; <U>provided</U>, <U>however</U>, that Parent&#146;s initial public offering, any subsequent public offering or anther capital raising event, a merger
effected solely to change Parent&#146;s domicile or any acquisition by Parent or any employee benefit plan (or related trust) sponsored or maintained by Parent or any of its subsidiaries or affiliates shall not constitute a &#147;Change in
Control&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments and benefits provided in this <U>Section</U><U></U><U>&nbsp;7(d)</U> shall be in lieu of any termination or severance payments or
benefits for which the Executive may be eligible under any of the plans, policies or programs of the Company or applicable law (including the Worker Adjustment Retraining Notification Act of 1988 or any similar state statute or regulation). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>OTHER OBLIGATIONS</B>. Upon any termination of the Executive&#146;s employment with the Company, and as a condition to receipt of any
funds pursuant to <U>Section</U><U></U><U>&nbsp;7</U>, the Executive shall promptly resign from any position as an officer or director of any Company Group-related entity and will promptly cooperate in the execution of the appropriate documents to
effect the resignation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <B>EXCLUSIVE REMEDY</B>. The amounts payable to the Executive following termination of employment and the
Employment Term hereunder pursuant to <U>Sections 6</U> and <U>7</U> hereof shall be in full and complete satisfaction of the Executive&#146;s rights under this Agreement and any other claims that the Executive may have in respect of the
Executive&#146;s employment with the Company or any of its affiliates, and the Executive acknowledges that such amounts are fair and reasonable, and are the Executive&#146;s sole and exclusive remedy, in lieu of all other remedies at law or in
equity, with respect to the termination of the Executive&#146;s employment hereunder or any breach of this Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B> <B>RELEASE; MITIGATION; <FONT STYLE="white-space:nowrap">SET-OFFS</FONT></B>. Any
and all amounts payable and benefits or additional rights provided pursuant to this Agreement in connection with the Executive&#146;s termination of employment beyond the Accrued Benefits shall only be payable if the Executive (or his legal
representative in the case of a termination due to the Executive&#146;s Disability) delivers to the Company and does not revoke a general release of claims in favor of the Company Group, including with respect to any claims the Executive may have
related to the Executive&#146;s employment with the Company Group or the termination of such employment, in a form reasonably satisfactory to the Board. Such release shall be executed and delivered (and no longer subject to revocation, if
applicable) within sixty (60)&nbsp;days following termination. In no event shall the Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to the Executive under any of the provisions of
this Agreement, and such amounts shall not be offset by any amount received by the Executive from any other source. Subject to the provisions of this Agreement and the limitations of applicable wage laws, the Company&#146;s obligations to pay the
Executive amounts hereunder is subject to <FONT STYLE="white-space:nowrap">set-off,</FONT> counterclaim or recoupment of amounts owed by the Executive to the Company or any of its affiliates (including any member of the Company Group). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B>SECTION 280G</B>. If any payment or benefit that the Executive may receive, whether or not payable or provided under this
Agreement (&#147;<U>Payment</U>&#148;), would (i)&nbsp;constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Internal Revenue Code of 1986, as amended (the &#147;<U>Code</U>&#148;), and (ii)&nbsp;but for this
sentence, be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;<U>Excise Tax</U>&#148;), then such Payment shall be reduced to the Reduced Amount. The &#147;<U>Reduced Amount</U>&#148; shall be either (A)&nbsp;the largest
portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (B)&nbsp;the largest portion, up to and including the total amount, of the Payment, whichever of the amounts determined under (A)&nbsp;and (B),
after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Executive&#146;s receipt, on an <FONT
STYLE="white-space:nowrap">after-tax</FONT> basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting &#147;parachute
payments&#148; is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the following order: reduction of cash payments; reduction of employee benefits; and cancellation of accelerated vesting of outstanding equity
awards. In the event that acceleration of vesting of outstanding equity awards is to be reduced, such acceleration of vesting shall be undertaken in the reverse order of the date of grant of the Executive&#146;s outstanding equity awards. All
calculations and determinations made pursuant this <U>Section</U><U></U><U>&nbsp;9</U> will be made by an independent accounting or consulting firm or independent tax counsel appointed by the Company (the &#147;<U>Tax Counsel</U>&#148;) whose
determinations shall be conclusive and binding on the Company and the Executive for all purposes. For purposes of making the calculations and determinations required by this <U>Section</U><U></U><U>&nbsp;9</U>, the Tax Counsel may rely on
reasonable, good faith assumptions and approximations concerning the application of Section&nbsp;280G of the Code and Section&nbsp;4999 of the Code. The Company shall bear all costs the Tax Counsel may reasonably incur in connection with its
services. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B>SECTION 409A. </B>Notwithstanding anything to the contrary in this Agreement,
if at the time the Executive&#146;s employment terminates, the Executive is a &#147;specified employee,&#148; as defined below, any and all amounts payable under this Agreement on account of such separation from service that would (but for this
provision) be payable within six (6)&nbsp;months following the date of termination, shall instead be paid on the next business day following the expiration of such six (6)-month period or, if earlier, upon the Executive&#146;s death; except
(A)&nbsp;to the extent of amounts that do not constitute a deferral of compensation within the meaning of Treasury regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)</FONT> (including without limitation by reason of the safe harbor
set forth in <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(9)(iii),</FONT> as determined by the Company in its reasonable good faith discretion); (B) benefits that qualify as excepted welfare benefits pursuant to Treasury regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-1(a)(5);</FONT> or (C)&nbsp;other amounts or benefits that are not subject to the requirements of Section&nbsp;409A of the Code. For purposes of this Agreement, to the extent required to avoid adverse
tax consequences under Section&nbsp;409A of the Code, all references to &#147;termination of employment&#148; and correlative phrases shall be construed to require a &#147;separation from service&#148; (as defined in
<FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h)</FONT> of the Treasury regulations after giving effect to the presumptions contained therein), and, for purposes of this Agreement, the term &#147;specified employee&#148; means an individual
determined by the Company to be a specified employee under Treasury regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(i).</FONT> Each payment made under this Agreement shall be treated as a separate payment and the right to a series
of installment payments under this Agreement is to be treated as a right to a series of separate payments. In no event shall the Company or any of its affiliates have any liability to the Executive or any other person relating to the failure or
alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B>RESTRICTIVE COVENANTS</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>NONCOMPETITION</B>. The Executive acknowledges that (i)&nbsp;the Executive will continue to perform valuable services for the Company,
and that the Executive&#146;s performance of such services to a competing business will result in irreparable harm to the Company Group, (ii)&nbsp;the Executive has had and will have access to certain confidential information which, if improperly
disclosed in violation of the Agreement, would unfairly and inappropriately assist in competition against the Company Group or any of its affiliates, and (iii)&nbsp;the Executive has generated and will generate goodwill for the Company Group and its
affiliates in the course of the Executive&#146;s employment. Accordingly, during the Executive&#146;s employment or service with the Company Group and for a period thereafter equal to twelve (12)&nbsp;months, the Executive agrees that the Executive
will not, directly or indirectly, own, manage, operate, control, be employed by (whether as an employee, consultant, independent contractor or otherwise, and whether or not for compensation) or render services to any person, firm, corporation or
other entity, in whatever form, engaged in the Business (as defined below), in any locale of any country in which the Company Group conducts the Business. For purposes hereof, the term &#147;<U>Business</U>&#148; shall mean the business of
developing biological medicines for treating patients with devastating diseases, or any business in which the Company Group is engaged in upon the termination of Executive&#146;s employment or in which the Company Group has actively and in writing
planned, on or prior to such date, to be engaged in on or after such date. Notwithstanding the foregoing, nothing herein shall prohibit the Executive from being a passive owner of not more than two percent (2%) of the equity securities of a publicly
traded corporation engaged in a business that is in competition with the Company Group, so long as the Executive has no active participation in the business of such corporation. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>NONSOLICITATION; NONINTERFERENCE</B>. During the Executive&#146;s employment or
service with the Company Group and for a period thereafter equal to twelve (12)&nbsp;months, the Executive agrees that the Executive shall not, except in the furtherance of the Executive&#146;s duties hereunder, directly or indirectly, individually
or on behalf of any other person, firm, corporation or other entity, (i)&nbsp;solicit, aid or induce any customer of the Company Group or any of its affiliates with whom the Executive had direct dealings while employed by the Company Group to
purchase goods or services then sold by the Company Group or any of its affiliates from another person, firm, corporation or other entity or assist or aid any other person or entity in identifying or soliciting any such customer, (ii)&nbsp;solicit,
aid or induce any employee, representative or agent of the Company Group or any of its affiliates to leave such employment or retention or to accept employment with or render services to or with any other person, firm, corporation or other entity
unaffiliated with the Company Group, or hire or retain any such employee, representative or agent, or take any action to materially assist or aid any other person, firm, corporation or other entity in identifying, hiring or soliciting any such
employee, representative or agent, or (iii)&nbsp;knowingly interfere, or knowingly aid or induce any other person or entity in interfering, with the relationship between the Company Group or any of its affiliates and any of their respective vendors,
joint venturers or licensors. An employee, representative or agent shall be deemed covered by this <U>Section</U><U></U><U>&nbsp;11(b)</U> while so employed or retained and for a period of nine (9)&nbsp;months thereafter. Notwithstanding the
foregoing, the provisions of this <U>Section</U><U></U><U>&nbsp;11(b)</U> shall not be violated by general advertising or solicitation not specifically targeted at Company Group-related persons or entities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>NONDISPARAGEMENT</B>. Both during the Employment Term and at all times thereafter, regardless of the reason for termination, the
Executive agrees not to make comments materially injurious to the reputation of the Company Group or otherwise disparage the Company Group or any of their officers, directors, employees, shareholders, members, agents or products. Any disclosure by
the Executive in good faith in connection with any legal proceedings between the Executive and the Company Group, in response to legal process, required governmental testimony or filings, or administrative or arbitral proceedings (including, without
limitation, depositions in connection with such proceedings) shall not be deemed to violate this <U>Section</U><U></U><U>&nbsp;11(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>RETURN OF COMPANY PROPERTY</B>. On the date of the Executive&#146;s termination of employment with the Company for any reason (or at
any time prior thereto at the Company Group&#146;s request), the Executive shall return to the Company all property belonging to the Company Group or its affiliates including, but not limited to, any Company-provided laptops, computers, cell phones,
wireless electronic mail devices or other equipment, or any property belonging to the Company Group and any Documents. The Executive also agrees to disclose to the Company, at the time his employment terminates or at such earlier time or times as
the Board or its designee may specify, all passwords necessary or desirable to obtain access to, or that would assist in obtaining access to, any information which the Executive has password-protected on any computer equipment, network or system of
the Company Group or any of its affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>REASONABLENESS OF COVENANTS</B>. In signing this Agreement, the Executive gives the
Company Group assurance that the Executive has carefully read and considered all of the terms and conditions of this Agreement, including the restraints imposed under this <U>Section</U><U></U><U>&nbsp;11</U>. The Executive agrees that these
restraints are necessary for the reasonable and proper protection of the Company Group and its affiliates and their confidential information </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and that each and every one of the restraints is reasonable in respect of subject matter, length of time and geographic area, and that these restraints, individually or in the aggregate, will not
prevent the Executive from obtaining other suitable employment during the period in which the Executive is bound by the restraints. The <FONT STYLE="white-space:nowrap">non-prevailing</FONT> party will reimburse the prevailing party for all costs
(including reasonable attorneys&#146; fees) incurred in connection with any action to enforce any of the provisions of this <U>Section</U><U></U><U>&nbsp;11</U>. It is also agreed that each of the Company Group&#146;s affiliates will have the right
to enforce all of the Executive&#146;s obligations to that affiliate under this Agreement, including without limitation pursuant to this <U>Section</U><U></U><U>&nbsp;11</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <B>REFORMATION</B>. If it is determined by a court of competent jurisdiction in any state that any restriction in this
<U>Section</U><U></U><U>&nbsp;11</U> is excessive in duration or scope or is unreasonable or unenforceable under applicable law, it is the intention of the parties that such restriction may be modified or amended by the court to render it
enforceable to the maximum extent permitted by the laws of that state. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <B>TOLLING</B>. In the event of any violation of the
provisions of this <U>Section</U><U></U><U>&nbsp;11</U>, the Executive acknowledges and agrees that the post-termination restrictions contained in this <U>Section</U><U></U><U>&nbsp;11</U> shall be extended by a period of time equal to the period of
such violation, it being the intention of the parties hereto that the running of the applicable post-termination restriction period shall be tolled during any period of such violation; <U>provided</U>, that tolling period shall not exceed sixty
(60)&nbsp;days after the Company Group has knowledge of such violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <B>SURVIVAL OF PROVISIONS</B>. The obligations contained in
<U>Sections 11</U> through <U>13</U> hereof shall survive the termination or expiration of the Employment Term and the Executive&#146;s employment with the Company and shall be fully enforceable thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B>COOPERATION</B>. In connection with any termination of the Executive&#146;s employment with the Company, the Executive agrees to
assist the Company Group, as reasonably requested by the Company Group, in its succession planning efforts to facilitate a smooth transition of the Executive&#146;s job responsibilities to the Executive&#146;s successor. In addition, upon the
receipt of reasonable notice from the Company Group (including outside counsel), the Executive agrees that while employed by, or providing services to, the Company Group and thereafter, the Executive will respond and provide truthful information
with regard to matters in which the Executive has knowledge as a result of the Executive&#146;s employment with the Company Group, and will reasonably cooperate with the Company Group, its affiliates and their respective representatives in defense
of all claims that may be made against the Company Group or its affiliates, and will cooperate with the Company Group and its affiliates in the prosecution of all claims that may be made by the Company Group or its affiliates, to the extent that
such claims may relate to the period of the Executive&#146;s employment or service with the Company Group and the Company reasonably believes that the Executive has pertinent knowledge or information related to such claims. The Executive agrees to
promptly inform the Company (to the extent that the Executive is legally permitted to do so) if the Executive becomes aware of any lawsuit involving such third party claims that may be filed or threatened against the Company Group or its affiliates.
The Executive also agrees to promptly inform the Company (to the extent that the Executive is legally permitted to do so) if the Executive is asked to assist in any investigation of the Company Group or its affiliates (or their actions), regardless
of whether a lawsuit or other proceeding has then been filed against the Company Group or its affiliates with respect to such investigation, and shall not do so unless legally required. Upon presentation of appropriate documentation, the Company
shall pay or reimburse the Executive for all reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> travel, duplicating or telephonic expenses incurred by the Executive in complying with this
<U>Section</U><U></U><U>&nbsp;12</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B>EQUITABLE RELIEF AND OTHER REMEDIES</B>. The Executive acknowledges and agrees
that the Company&#146;s remedies at law for a breach or threatened breach of any of the provisions of <U>Section</U><U></U><U>&nbsp;11</U> or <U>Section</U><U></U><U>&nbsp;12</U> hereof would be inadequate and, in recognition of this fact, the
Executive agrees that, in the event of such a breach or threatened breach, in addition to any remedies at law, the Company Group shall be entitled to seek equitable relief in the form of specific performance, a temporary restraining order, a
temporary or permanent injunction or any other equitable remedy which may then be available, without the necessity of showing actual monetary damages and without posting any bond or other security. In the event of a violation by the Executive of
<U>Section</U><U></U><U>&nbsp;11</U> or <U>Section</U><U></U><U>&nbsp;12</U> hereof, any severance being paid to the Executive pursuant to this Agreement or otherwise shall immediately cease, and any severance previously paid to the Executive shall
be immediately repaid to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B>NO ASSIGNMENTS</B>. This Agreement is personal to each of the parties hereto. Except
as provided in this <U>Section</U><U></U><U>&nbsp;14</U>, no party may assign or delegate any rights or obligations hereunder without first obtaining the written consent of the other party hereto. The Company may assign this Agreement to any
successor to all or substantially all of the business and/or assets of the Company or to any of its subsidiaries or affiliates; <U>provided</U> that the Company shall require such assignee to expressly assume and agree to perform this Agreement in
the same manner and to the same extent that the Company would be required to perform it if no such assignment had taken place. As used in this Agreement, &#147;Company&#148; shall mean the Company and any successor to its business and/or assets or
assignee of this Agreement, which assumes and agrees to perform the duties and obligations of the Company under this Agreement by operation of law or otherwise. Each member of the Company Group is an intended third party beneficiary of this
Agreement and shall be entitled to enforce the provisions of this Agreement as if a direct party to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B>
<B>NOTICE</B>. For purposes of this Agreement, notices and all other communications provided for in this Agreement shall be in writing and shall be deemed to have been duly given (a)&nbsp;on the date of delivery, if delivered by hand, (b)&nbsp;on
the date of transmission, if delivered by confirmed facsimile or by electronic mail, (c)&nbsp;on the first business day following the date of deposit, if delivered by guaranteed overnight delivery service, or (d)&nbsp;on the fourth business day
following the date delivered or mailed by United States registered or certified mail, return receipt requested, postage prepaid, addressed as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If to the Executive: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">At the
address (or to the facsimile number or email address) shown in the books and records of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If to the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Rallybio, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">234 Church Street
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Suite 1020 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New Haven, CT
06510 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email:
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as either party may have furnished to the other in writing in accordance herewith,
except that notices of change of address shall be effective only upon receipt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B>SECTION HEADINGS; INCONSISTENCY</B>. The
section headings used in this Agreement are included solely for convenience and shall not affect, or be used in connection with, the interpretation of this Agreement. In the event of any inconsistency between the terms of this Agreement and any
form, award, plan or policy of the Company Group, the terms of this Agreement shall govern and control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B> <B>SEVERABILITY</B>.
The provisions of this Agreement shall be deemed severable. The invalidity or unenforceability of any provision of this Agreement in any jurisdiction shall not affect the validity, legality or enforceability of the remainder of this Agreement in
such jurisdiction or the validity, legality or enforceability of any provision of this Agreement in any other jurisdiction, it being intended that all rights and obligations of the parties hereunder shall be enforceable to the fullest extent
permitted by applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18.</B> <B>COUNTERPARTS</B>. This Agreement may be executed in several counterparts, each of which shall
be deemed to be an original but all of which together will constitute one and the same instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>19.</B> <B>GOVERNING LAW;
JURISDICTION</B>. This Agreement, the rights and obligations of the parties hereto, and all claims or disputes relating thereto, shall be governed by and construed in accordance with the laws of the State of Connecticut, without regard to the choice
of law provisions thereof. Each of the parties hereby irrevocably and unconditionally consents to the exclusive jurisdiction of the courts of the State of Connecticut and the United States District Court for the District of Connecticut, as well as
to the jurisdiction of all courts to which an appeal may be taken from such courts, for the purpose of any suit, action or other proceeding arising out of or in connection with this Agreement or any of the transactions contemplated hereby, and
irrevocably and unconditionally waives, to the fullest extent permitted by law, any and all objections such party may now or hereafter have to the laying of the venue of any such suit, action or proceeding in any such court or that any such suit,
action or proceeding brought in any such court has been brought in an inconvenient forum. In that context, and without limiting the generality of the foregoing, each of the parties hereto irrevocably and unconditionally (a)&nbsp;submits in any
proceeding relating to this Agreement or the Executive&#146;s employment by the Company or any affiliate, or for the recognition and enforcement of any judgment in respect thereof (a &#147;<U>Proceeding</U>&#148;), to the exclusive jurisdiction of
the courts of the State of Connecticut and the United States District Court for the District of Connecticut, as well as to the jurisdiction of all courts to which an appeal may be taken from such courts, and agrees that all claims in respect of any
such Proceeding shall be heard and determined in such Connecticut State court or, to the extent permitted by law, in such federal court, (b)&nbsp;consents that any such Proceeding may and shall be brought in such courts and waives any objection that
the Executive or the Company may now or thereafter have to the venue or jurisdiction of any such Proceeding in any such court or that such Proceeding was brought in an inconvenient court and agrees not to plead or claim the same, (c)
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY PROCEEDING (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE EXECUTIVE&#146;S EMPLOYMENT BY OR SERVICE
WITH THE COMPANY OR ANY AFFILIATE OF THE COMPANY, OR THE EXECUTIVE&#146;S OR THE COMPANY&#146;S PERFORMANCE UNDER, OR THE ENFORCEMENT OF, THIS AGREEMENT, (d)&nbsp;agrees that service of process in any such Proceeding may be effected by mailing a
copy of such process by registered or certified mail (or any substantially similar form of mail), postage prepaid, to such party at the Executive&#146;s or the Company&#146;s address as provided in <U>Section</U><U></U><U>&nbsp;15</U> hereof,
(e)&nbsp;agrees that nothing in this Agreement shall affect the right to effect service of process in any other manner permitted by the laws of the State of Connecticut and (f)&nbsp;expressly waives any and all rights to bring any suit, action or
other proceeding arising out of or in connection with this Agreement in or before any court or tribunal other than the courts of the State of Connecticut or the United States District Court for the District of Connecticut and any courts to which an
appeal may be taken from such courts, and covenants that such party shall not seek in any manner to resolve any dispute other than as set forth herein or to challenge or set aside any decision, award or judgment obtained in accordance with the
provisions hereof. Except as may be explicitly set forth in this Agreement, the parties acknowledge and agree that in connection with any dispute hereunder, each party shall pay all of its own costs and expenses, including, without limitation, its
own legal fees and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>20.</B> <B>MISCELLANEOUS</B>. No provision of this Agreement may be modified, waived or discharged unless
such waiver, modification or discharge is agreed to in writing and signed by the Executive and such officer or director of the Company as may be designated by the Board or the Compensation Committee, and in any case must be approved by the Board or
the Compensation Committee. In addition, notwithstanding anything to the contrary in this Agreement, the Company may not terminate this Agreement (including by notice of <FONT STYLE="white-space:nowrap">non-renewal)</FONT> or the Executive&#146;s
employment without Board or Compensation Committee approval. No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this Agreement to be performed by such other
party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time. This Agreement together with all exhibits hereto (if any) set forth the entire agreement of the parties hereto in
respect of the subject matter contained herein and supersede any and all prior agreements or understandings between the Executive and the Company with respect to the subject matter hereof, including the Prior Agreement. No agreements or
representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by either party which are not expressly set forth in this Agreement. Any references in this Agreement to &#147;$&#148; shall mean U.S.
dollars. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21. REPRESENTATIONS</B>. The Executive represents and warrants to the Company that (a)&nbsp;the Executive has the legal right
to enter into this Agreement and to perform all of the obligations on the Executive&#146;s part to be performed hereunder in accordance with its terms, and (b)&nbsp;the Executive is not a party to any agreement or understanding, written or oral, and
is not subject to any restriction, which, in either case, could prevent the Executive from entering into this Agreement or performing all of the Executive&#146;s duties and obligations hereunder. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>22.</B> <B>TAX MATTERS</B>. The Company Group may withhold from any and all amounts
payable under this Agreement or otherwise such federal, state and local taxes as may be required to be withheld pursuant to any applicable law or regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>23.</B> <B>OTHER</B>. Nothing contained in this Agreement limits, restricts or in any other way affects the Executive&#146;s communicating
with any governmental agency or entity, or communicating with any official or staff person of a governmental agency or entity, concerning matters relevant to such governmental agency or entity and the Executive will not be held criminally or civilly
liable under any federal or state trade secret law for disclosing a trade secret (i)&nbsp;in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, solely for the purpose of reporting or
investigating a suspected violation of law, or (ii)&nbsp;in a complaint or other document filed under seal in a lawsuit or other proceeding; <U>provided</U>, <U>however</U>, that notwithstanding this immunity from liability, the Executive may be
held liable if he unlawfully accesses trade secrets by unauthorized means. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;* </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the parties hereto have executed this Agreement as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>RALLYBIO,
LLC</B></P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Martin W. Mackay</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Martin W. Mackay</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Stephen Uden</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Uden</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>23
<FILENAME>d99471dex1022.htm
<DESCRIPTION>EX-10.22
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.22</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.22 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>AMENDED AND RESTATED EMPLOYMENT AGREEMENT</B> (this &#147;<U>Agreement</U>&#148;) dated as of July&nbsp;15, 2021 by and between Rallybio,
LLC, a Delaware limited liability company (the &#147;<U>Company</U>&#148;), and Jeffrey M. Fryer (the &#147;<U>Executive</U>&#148;) and effective as of the day prior to the date on which Rallybio Corporation (&#147;<U>Parent</U>&#148;) becomes
subject to the reporting obligations of Section&nbsp;12 of the Securities Exchange Act of 1934, as amended (the &#147;<U>Securities Exchange Act</U>&#148;) (such date, the &#147;<U>Effective Date</U>&#148;). This Agreement amends and restates in its
entirety the employment agreement by and among the Company and the Executive, effective as of April&nbsp;20, 2018 (the &#147;<U>Prior Agreement</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>W</U> <U>I</U> <U>T</U> <U>N</U> <U>E</U> <U>S</U> <U>S</U> <U>E</U> <U>T</U> <U>H</U>: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company desires to continue to employ the Executive as the Chief Financial Officer and Treasurer of the Company; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company and the Executive desire to enter into this amended and restated Agreement as to the terms of the Executive&#146;s
continued employment with the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the foregoing, of the mutual promises contained herein
and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>POSITION AND DUTIES</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>GENERAL</B>. During the Employment Term (as defined below), the Executive shall serve as the Chief Financial Officer and Treasurer of
the Company. In this capacity, the Executive shall have the duties, authorities and responsibilities commensurate with the duties, authorities and responsibilities of persons in similar capacities in similarly sized companies and such other duties,
authorities and responsibilities as may reasonably be assigned by the board of directors of Parent (the &#147;<U>Board</U>&#148;) to the Executive from time to time that are not inconsistent with the Executive&#146;s position with the Company and do
not unreasonably interfere with his duties to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>OTHER ACTIVITIES</B>. During the Employment Term, the Executive shall
devote all of the Executive&#146;s business time and energy, business judgment, knowledge and skill and the Executive&#146;s best efforts to the performance of the Executive&#146;s duties with the Company, <U>provided</U> that the foregoing shall
not prevent the Executive from (i)&nbsp;serving on the boards of directors (and board committees) of <FONT STYLE="white-space:nowrap">non-profit</FONT> organizations (provided, that the Executive provides the Board with advanced written notice prior
to accepting or serving in any such position), (ii) serving on the boards of directors (and board committees) of <FONT STYLE="white-space:nowrap">for-profit</FONT> organizations (provided, that the Executive receives prior written approval from the
Board, which shall not be unreasonably withheld, delayed or conditioned), (iii) participating in charitable, civic, educational, professional, community or industry affairs, (iv)&nbsp;spending a de minimis amount of time on activities that provide
de minimis compensation to the Executive, and (v)&nbsp;spending a de minimis amount of time managing the Executive&#146;s passive personal investments; <U>provided</U>, such activities do not interfere or conflict with the Executive&#146;s duties
hereunder or create a potential business or fiduciary conflict or otherwise violate Section&nbsp;11 of this Agreement; <U>provided</U> <U>further</U>, each of the Executive&#146;s activities listed on <U>Schedule A</U> attached hereto is permitted
under this Agreement so long as such activities listed on <U>Schedule A</U> do not materially interfere or conflict with the Executive&#146;s duties hereunder. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B>EMPLOYMENT TERM</B>. The Company agrees to employ the Executive pursuant to the
terms of this Agreement, and the Executive agrees to be so employed, for a term of one (1)&nbsp;year (the &#147;<U>Initial Term</U>&#148;) commencing as of the Effective Date. On each anniversary of the Effective Date following the Initial Term, the
term of this Agreement shall be automatically extended for successive one (l)-year periods; <U>provided</U>, <U>however</U>, that either party hereto may elect not to extend this Agreement by giving written notice to the other party at least sixty
(60)&nbsp;days prior to any such anniversary date. Notwithstanding the foregoing, the Executive&#146;s employment hereunder may be earlier terminated in accordance with <U>Section</U><U></U><U>&nbsp;6</U> hereof, subject to the provisions of
<U>Section</U><U></U><U>&nbsp;7</U> hereof. The period of time between the Effective Date and the termination of the Executive&#146;s employment hereunder shall be referred to herein as the &#147;<U>Employment Term</U>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B>BASE SALARY</B>. During the Employment Term, the Company agrees to pay the Executive a base salary at an annual rate of,
initially, $470,000. The base salary shall be paid in cash in accordance with the regular payroll practices of the Company with respect to salaried employees, but in no event less frequently than semi-monthly. The Executive&#146;s base salary shall
be subject to review by the Board or the Compensation Committee of the Board (the &#147;<U>Compensation Committee</U>&#148;), and may be increased from time to time by the Board or the Compensation Committee in its respective sole discretion. The
base salary as determined herein and adjusted from time to time shall constitute the &#147;<U>Base Salary</U>&#148; for purposes of this Agreement, and any section herein providing for payment of the Base Salary to the Executive shall mean payment
of the Base Salary rate in effect at the time of payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>ANNUAL BONUS</B>. With respect to each fiscal year during the
Employment Term, the Executive shall be eligible to receive an annual cash incentive payment (the &#147;<U>Annual Bonus</U>&#148;). The target amount of the Annual Bonus shall be (forty percent) 40&nbsp;% of the Base Salary; <U>provided</U>, in any
event, the actual Annual Bonus to be paid in respect of any fiscal year, if any, which may be more or less than the target bonus amount, will be based on the attainment of individual and/or Company performance goals for such year established by the
Board or the Compensation Committee as determined by the Board or the Compensation Committee in its respective sole discretion. Any Annual Bonus awarded hereunder shall be paid in the calendar year following the calendar year to which such bonus
relates at the same time annual bonuses are paid to other senior executives of the Company, except as otherwise provided in <U>Section</U><U></U><U>&nbsp;7</U> hereof, but not later than March
15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of such following calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B>EMPLOYEE BENEFITS</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>BENEFIT PLANS</B>. During the Employment Term, the Executive shall be entitled to participate in any employee benefit plan that the
Company has adopted or may adopt or maintains or contributes to for the benefit of its employees generally, subject to satisfying the applicable eligibility requirements, and except to the extent such plans are duplicative of the benefits otherwise
provided hereunder. The Executive&#146;s participation will be subject to the terms of the applicable plan documents and generally applicable Company policies. Notwithstanding the foregoing, the Company may modify or terminate any employee benefit
plan at any time. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>BUSINESS EXPENSES</B>. Upon presentation of reasonable substantiation and
documentation as required by the Company&#146;s expense reimbursement policies, that the Company may modify from time to time, the Executive shall be reimbursed for all reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> business expenses incurred and paid by the Executive during the Employment Term and in connection with the performance of the Executive&#146;s duties
hereunder or otherwise incurred at the direction of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>VACATION</B>. The Executive shall be entitled to take vacation in
accordance with the Company&#146;s policy then in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>TERMINATION</B>. The Executive&#146;s employment and the
Employment Term shall terminate on the first of the following to occur: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>DISABILITY</B>. Upon ten (10)&nbsp;days&#146; prior
written notice by the Company to the Executive of a termination due to Disability. For purposes of this Agreement, &#147;<U>Disability</U>&#148; shall be defined as the inability of the Executive to have performed the Executive&#146;s material
duties hereunder, with or without reasonable accommodation due to a physical or mental injury, infirmity, limitation or incapacity which has lasted or can reasonably be expected to last for one hundred eighty (180)&nbsp;days (including weekends and
holidays) in any three hundred sixty-five <FONT STYLE="white-space:nowrap">(365)-day</FONT> period as determined by the Board in its reasonable discretion. The Executive (or the Executive&#146;s representative) shall cooperate in all respects with
the Company if a good faith question arises as to whether the Executive has become disabled (including, without limitation, submitting to reasonable examinations by one or more medical doctors and other health care specialists reasonably selected by
the Company and authorizing such medical doctors and other health care specialists to discuss the Executive&#146;s condition with the Company). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>DEATH</B>. Automatically upon the date of death of the Executive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>BY THE COMPANY FOR CAUSE</B>. Immediately upon written notice by the Company to the Executive of a termination for Cause.
&#147;<U>Cause</U>&#148; shall mean (i)&nbsp;the Executive having been indicted for, or having pleaded guilty or <I>nolo contendere</I> to, (A)&nbsp;a felony or (B)&nbsp;a crime involving dishonesty or moral turpitude; (ii)&nbsp;the Executive&#146;s
commission of any act of fraud, or embezzlement, theft, or material dishonesty or intentional misappropriation of the property of the Company, Parent or any of their respective direct or indirect subsidiaries (collectively, the &#147;<U>Company
Group</U>&#148;) or any of their respective affiliates or of any customer or supplier of the Company Group; (iii)&nbsp;the Executive&#146;s repeated use of illegal drugs or repeated abuse of alcohol that materially impairs the Executive&#146;s
ability to perform the Executive&#146;s duties contemplated hereunder; (iv)&nbsp;the Executive&#146;s material breach of this Agreement or any other agreement with the Company Group, or a material violation of any of the Company Group&#146;s written
policies or procedures; or (v)&nbsp;any other willful misconduct or gross negligence in the performance of the Executive&#146;s duties to the Company Group that has caused material injury (including by way of reputational harm or other damages) to
any member of the Company Group. Notwithstanding the foregoing, the Company shall not terminate Executive&#146;s employment for Cause pursuant to <U>Section</U><U></U><U>&nbsp;6(c)(iii)</U> or <U>(iv)</U>&nbsp;unless the Company has first given
Executive written notice of the acts or omissions constituting Cause thereunder, and, if such acts or omissions are susceptible to cure, the Executive has failed to cure such acts or omissions to the Company&#146;s reasonable satisfaction within
thirty (30)&nbsp;days after receipt of such notice. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>BY THE COMPANY WITHOUT CAUSE</B>. Upon thirty (30)&nbsp;days&#146; prior written
notice by the Company to the Executive of an involuntary termination without Cause (other than for death or Disability); <U>provided</U>, that the Board may, in its sole discretion, elect to provide Base Salary to the Executive in lieu of such
notice (in whole or in part).<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>BY THE EXECUTIVE FOR ANY REASON</B>. Upon
sixty (60)&nbsp;days&#146; prior written notice by the Executive to the Company of the Executive&#146;s voluntary termination of employment for any reason (including for Good Reason); <U>provided</U>, that the Board may, in its sole discretion,
elect to accelerate the date of termination without the payment of additional compensation. &#147;<U>Good Reason</U>&#148; means: (i)&nbsp;a failure by the Company to pay the Executive his Base Salary when due, (ii)&nbsp;any involuntary material
diminution in the Executive&#146;s duties, authorities or responsibilities (other than temporarily while physically or mentally incapacitated or as required by applicable law), (iii) any change to the Executive&#146;s title to which the Executive
did not consent in writing, or (iv)&nbsp;the Executive being required to relocate to a principal place of employment more than fifty (50)&nbsp;miles from the Executive&#146;s principal place of employment with the Company Group at such time; which,
in each case, is not cured by the Company Group within thirty (30)&nbsp;days of the Company&#146;s receipt of written notice thereof from the Executive specifying the particulars of the conduct constituting Good Reason; <U>provided</U>, that the
Executive gives such notice to the Company within ninety (90)&nbsp;days of the Executive having knowledge of the occurrence of such event and, if such event is not cured by the Company, the Executive terminates his employment within thirty
(30)&nbsp;days after the end of the Company&#146;s cure period; otherwise, Good Reason shall be deemed waived with respect to such event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <B>EXPIRATION OF EMPLOYMENT TERM; <FONT STYLE="white-space:nowrap">NON-EXTENSION</FONT> OF AGREEMENT</B>. Upon the expiration of the
Employment Term due to a <FONT STYLE="white-space:nowrap">non-extension</FONT> of the Agreement by the Company or the Executive pursuant to the provisions of <U>Section</U><U></U><U>&nbsp;2</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B>CONSEQUENCES OF TERMINATION</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>DEATH OR DISABILITY</B>. In the event that the Executive&#146;s employment and the Employment Term end on account of the
Executive&#146;s death or a termination by the Company due to the Executive&#146;s Disability, the Executive&#146;s estate or the Executive, as applicable, shall be entitled to the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) any earned and unpaid Base Salary through the date of termination; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) reimbursement for any unreimbursed business expenses incurred through the date of termination; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) all other accrued and vested payments, benefits or fringe benefits to which the Executive is entitled in accordance with the terms and
conditions of the applicable compensation or benefit plan, program or arrangement of the Company (collectively, <U>Sections 7(a)(i)</U> through <U>7(a)(iii)</U> hereof shall be hereafter referred to as the &#147;<U>Accrued Benefits</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) any earned but unpaid Annual Bonus with respect to a calendar year ending on or preceding the date of termination, payable as provided in
<U>Section</U><U></U><U>&nbsp;4</U> hereof (without regard to any continued employment requirement); and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) subject to the Executive&#146;s continued compliance with the obligations in this
Agreement (in the event of a termination by the Company due to the Executive&#146;s Disability), a monthly amount equal to the Base Salary rate (as in effect immediately prior to the date of Executive&#146;s termination), which amount shall be paid
in cash to the Executive or his estate, as applicable, in equal installments commensurate with the Company&#146;s regularly scheduled payroll in accordance with the payment procedures set forth in <U>Section</U><U></U><U>&nbsp;3</U> for six
(6)&nbsp;months, commencing on the first regularly scheduled payroll date following the date the general release of claims in <U>Section</U><U></U><U>&nbsp;8</U> is effective and irrevocable (only with respect to a termination by the Company due to
the Executive&#146;s Disability); <U>provided</U>, <U>however</U>, that if the sixty <FONT STYLE="white-space:nowrap">(60)-day</FONT> period in which the release of claims must be effective and irrevocable begins in one tax year and ends in a later
tax year, the payments will commence on the first payroll date following the effective date of the release of claims that begins in the later tax year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>TERMINATION FOR CAUSE, BY THE EXECUTIVE WITHOUT GOOD REASON OR AS A RESULT OF THE EXECUTIVE&#146;S
<FONT STYLE="white-space:nowrap">NON-EXTENSION</FONT> OF THIS AGREEMENT.</B> If the Executive&#146;s employment is terminated (i)&nbsp;by the Company for Cause, (ii)&nbsp;by the Executive for any reason (other than for Good Reason), or (iii)&nbsp;as
a result of the Executive&#146;s <FONT STYLE="white-space:nowrap">non-extension</FONT> of the Employment Term as provided in <U>Section</U><U></U><U>&nbsp;2</U> hereof, then the Company shall pay to the Executive only the Accrued Benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>TERMINATION BY THE COMPANY WITHOUT CAUSE, BY THE EXECUTIVE FOR GOOD REASON OR AS A RESULT OF THE COMPANY&#146;S <FONT
STYLE="white-space:nowrap">NON-EXTENSION</FONT> OF THIS AGREEMENT</B>. If the Executive&#146;s employment by the Company is terminated (x)&nbsp;by the Company other than for Cause (and not on account of the Executive&#146;s Disability or death), (y)
as a result of the Company&#146;s <FONT STYLE="white-space:nowrap">non-extension</FONT> of the Employment Term as provided in <U>Section</U><U></U><U>&nbsp;2</U> hereof or (z)&nbsp;by the Executive for Good Reason, in any event other than within the
twelve (12)-month period immediately following a Change in Control, then the Company shall pay or provide the Executive with the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the Accrued Benefits; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)
any earned but unpaid Annual Bonus with respect to a calendar year ending on or preceding the date of termination, payable as provided in <U>Section</U><U></U><U>&nbsp;4</U> hereof (without regard to any continued employment requirement); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) subject to the Executive&#146;s continued compliance with the obligations in this Agreement, (1)&nbsp;an amount equal to the
Executive&#146;s Base Salary (as in effect immediately prior to the date of Executive&#146;s termination), which amount shall be paid in cash to the Executive in equal installments commensurate with the Company&#146;s regularly scheduled payroll in
accordance with the payment procedures set forth in <U>Section</U><U></U><U>&nbsp;3</U> for twelve (12)&nbsp;months following the date the Executive&#146;s employment terminates, and (2)&nbsp;provided that the Executive timely elects to continue his
coverage and that of any eligible dependents in the Company&#146;s group health plans under the federal law known as &#147;COBRA&#148; or similar state law, a monthly amount equal to the monthly health premiums for such coverage paid by the Company
on behalf of the Executive and any eligible dependents immediately prior to the date of termination until the earlier of (x)&nbsp;the date that is twelve (12)&nbsp;months following the date that the Executive&#146;s employment terminates,
(y)&nbsp;the date that the Executive and the Executive&#146;s eligible dependents cease to be eligible for such COBRA </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
coverage under applicable law or plan terms and (z)&nbsp;the date on which the Executive obtains health coverage from another employer, in each case commencing on the first regularly scheduled
payroll date following the date the general release of claims in <U>Section</U><U></U><U>&nbsp;8</U> is effective and irrevocable; <U>provided</U>, <U>however</U>, that if the sixty <FONT STYLE="white-space:nowrap">(60)-day</FONT> period in which
the release of claims must be effective and irrevocable begins in one tax year and ends in a later tax year, the payments will commence on the first payroll date following the effective date of the release of claims that begins in the later tax
year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments and benefits provided in this <U>Section</U><U></U><U>&nbsp;7(c)</U> shall be in lieu of any termination or severance payments or benefits
for which the Executive may be eligible under any of the plans, policies or programs of the Company or applicable law (including the Worker Adjustment Retraining Notification Act of 1988 or any similar state statute or regulation). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>CHANGE IN CONTROL</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) If the Executive&#146;s employment by the Company is terminated (x)&nbsp;by the Company other than for Cause (and not on account of the
Executive&#146;s Disability or death), (y) as a result of the Company&#146;s <FONT STYLE="white-space:nowrap">non-extension</FONT> of the Employment Term as provided in <U>Section</U><U></U><U>&nbsp;2</U> hereof or (z)&nbsp;by the Executive for Good
Reason, in any event within the twelve (12)-month period immediately following a Change in Control, then in lieu of the payments and benefits described in <U>Section</U><U></U><U>&nbsp;7(c)</U>, the Company shall pay or provide the Executive with
the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Accrued Benefits; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any earned but unpaid Annual Bonus with respect to a calendar year ending on or preceding the date of
termination, payable as provided in <U>Section</U><U></U><U>&nbsp;4</U> hereof (without regard to any continued employment requirement); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subject to the Executive&#146;s continued compliance with the obligations in this Agreement, (1)&nbsp;an amount
equal to one and one half (1.5) times the sum of the Executive&#146;s Base Salary and the Executive&#146;s target Annual Bonus (in each case, as in effect immediately prior to the date of Executive&#146;s termination), which amount shall be paid in
cash to the Executive in equal installments commensurate with the Company&#146;s regularly scheduled payroll in accordance with the payment procedures set forth in <U>Section</U><U></U><U>&nbsp;3</U> for a period equal to eighteen (18)&nbsp;months
following the date the Executive&#146;s employment terminates, (2)&nbsp;provided that the Executive timely elects to continue his coverage and that of any eligible dependents in the Company&#146;s group health plans under the federal law known as
&#147;COBRA&#148; or similar state law, a monthly amount equal to the monthly health premiums for such coverage paid by the Company on behalf of the Executive and any eligible dependents immediately prior to the date of termination until the earlier
of (x)&nbsp;the date that is eighteen (18)&nbsp;months following the date that the Executive&#146;s employment terminates, (y)&nbsp;the date that </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
the Executive and the Executive&#146;s eligible dependents cease to be eligible for such COBRA coverage under applicable law or plan terms and (z)&nbsp;the date on which the Executive obtains
health coverage from another employer, in each case commencing on the first regularly scheduled payroll date following the date the general release of claims in <U>Section</U><U></U><U>&nbsp;8</U> is effective and irrevocable; <U>provided</U>,
<U>however</U>, that if the sixty <FONT STYLE="white-space:nowrap">(60)-day</FONT> period in which the release of claims must be effective and irrevocable begins in one tax year and ends in a later tax year, the payments will commence on the first
payroll date following the effective date of the release of claims that begins in the later tax year. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Any outstanding
and unvested equity awards, the vesting of which is based only on the passage of time, held by the Executive as of the Change in Control shall vest in full upon the consummation of the Change in Control, subject to the Executive remaining employed
by the Company through the date of such Change in Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) As used herein, &#147;<U>Change in Control</U>&#148; shall mean the
consummation of (i)&nbsp;the sale of all or substantially all of the assets of Parent on a consolidated basis to an unrelated individual, entity or group (within the meaning of Section&nbsp;13(d)(3) or 14(d)(2) of the Securities Exchange Act) (a
&#147;<U>Person</U>&#148;); (ii) a merger, reorganization or consolidation pursuant to which the holders of Parent&#146;s outstanding voting securities immediately prior to such transaction do not own more than fifty percent (50%) of the outstanding
voting securities of the surviving or resulting entity (or its ultimate parent, if applicable); (iii) the acquisition of more than fifty percent (50%) of the outstanding voting securities of Parent in a single transaction or a series of related
transactions by any Person; or (iv)&nbsp;the complete dissolution or liquidation of Parent; <U>provided</U>, <U>however</U>, that Parent&#146;s initial public offering, any subsequent public offering or anther capital raising event, a merger
effected solely to change Parent&#146;s domicile or any acquisition by Parent or any employee benefit plan (or related trust) sponsored or maintained by Parent or any of its subsidiaries or affiliates shall not constitute a &#147;Change in
Control&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments and benefits provided in this <U>Section</U><U></U><U>&nbsp;7(d)</U> shall be in lieu of any termination or severance payments or
benefits for which the Executive may be eligible under any of the plans, policies or programs of the Company or applicable law (including the Worker Adjustment Retraining Notification Act of 1988 or any similar state statute or regulation). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>OTHER OBLIGATIONS</B>. Upon any termination of the Executive&#146;s employment with the Company, and as a condition to receipt of any
funds pursuant to <U>Section</U><U></U><U>&nbsp;7</U>, the Executive shall promptly resign from any position as an officer or director of any Company Group-related entity and will promptly cooperate in the execution of the appropriate documents to
effect the resignation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <B>EXCLUSIVE REMEDY</B>. The amounts payable to the Executive following termination of employment and the
Employment Term hereunder pursuant to <U>Sections 6</U> and <U>7</U> hereof shall be in full and complete satisfaction of the Executive&#146;s rights under this Agreement and any other claims that the Executive may have in respect of the
Executive&#146;s employment with the Company or any of its affiliates, and the Executive acknowledges that such amounts are fair and reasonable, and are the Executive&#146;s sole and exclusive remedy, in lieu of all other remedies at law or in
equity, with respect to the termination of the Executive&#146;s employment hereunder or any breach of this Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B> <B>RELEASE; MITIGATION; <FONT STYLE="white-space:nowrap">SET-OFFS</FONT></B>. Any
and all amounts payable and benefits or additional rights provided pursuant to this Agreement in connection with the Executive&#146;s termination of employment beyond the Accrued Benefits shall only be payable if the Executive (or his legal
representative in the case of a termination due to the Executive&#146;s Disability) delivers to the Company and does not revoke a general release of claims in favor of the Company Group, including with respect to any claims the Executive may have
related to the Executive&#146;s employment with the Company Group or the termination of such employment, in a form reasonably satisfactory to the Board. Such release shall be executed and delivered (and no longer subject to revocation, if
applicable) within sixty (60)&nbsp;days following termination. In no event shall the Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to the Executive under any of the provisions of
this Agreement, and such amounts shall not be offset by any amount received by the Executive from any other source. Subject to the provisions of this Agreement and the limitations of applicable wage laws, the Company&#146;s obligations to pay the
Executive amounts hereunder is subject to <FONT STYLE="white-space:nowrap">set-off,</FONT> counterclaim or recoupment of amounts owed by the Executive to the Company or any of its affiliates (including any member of the Company Group). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B>SECTION 280G</B>. If any payment or benefit that the Executive may receive, whether or not payable or provided under this
Agreement (&#147;<U>Payment</U>&#148;), would (i)&nbsp;constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Internal Revenue Code of 1986, as amended (the &#147;<U>Code</U>&#148;), and (ii)&nbsp;but for this
sentence, be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;<U>Excise Tax</U>&#148;), then such Payment shall be reduced to the Reduced Amount. The &#147;<U>Reduced Amount</U>&#148; shall be either (A)&nbsp;the largest
portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (B)&nbsp;the largest portion, up to and including the total amount, of the Payment, whichever of the amounts determined under (A)&nbsp;and (B),
after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Executive&#146;s receipt, on an <FONT
STYLE="white-space:nowrap">after-tax</FONT> basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting &#147;parachute
payments&#148; is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the following order: reduction of cash payments; reduction of employee benefits; and cancellation of accelerated vesting of outstanding equity
awards. In the event that acceleration of vesting of outstanding equity awards is to be reduced, such acceleration of vesting shall be undertaken in the reverse order of the date of grant of the Executive&#146;s outstanding equity awards. All
calculations and determinations made pursuant this <U>Section</U><U></U><U>&nbsp;9</U> will be made by an independent accounting or consulting firm or independent tax counsel appointed by the Company (the &#147;<U>Tax Counsel</U>&#148;) whose
determinations shall be conclusive and binding on the Company and the Executive for all purposes. For purposes of making the calculations and determinations required by this <U>Section</U><U></U><U>&nbsp;9</U>, the Tax Counsel may rely on
reasonable, good faith assumptions and approximations concerning the application of Section&nbsp;280G of the Code and Section&nbsp;4999 of the Code. The Company shall bear all costs the Tax Counsel may reasonably incur in connection with its
services. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B>SECTION 409A. </B>Notwithstanding anything to the contrary in this Agreement,
if at the time the Executive&#146;s employment terminates, the Executive is a &#147;specified employee,&#148; as defined below, any and all amounts payable under this Agreement on account of such separation from service that would (but for this
provision) be payable within six (6)&nbsp;months following the date of termination, shall instead be paid on the next business day following the expiration of such six (6)-month period or, if earlier, upon the Executive&#146;s death; except
(A)&nbsp;to the extent of amounts that do not constitute a deferral of compensation within the meaning of Treasury regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)</FONT> (including without limitation by reason of the safe harbor
set forth in <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(9)(iii),</FONT> as determined by the Company in its reasonable good faith discretion); (B) benefits that qualify as excepted welfare benefits pursuant to Treasury regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-1(a)(5);</FONT> or (C)&nbsp;other amounts or benefits that are not subject to the requirements of Section&nbsp;409A of the Code. For purposes of this Agreement, to the extent required to avoid adverse
tax consequences under Section&nbsp;409A of the Code, all references to &#147;termination of employment&#148; and correlative phrases shall be construed to require a &#147;separation from service&#148; (as defined in
<FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h)</FONT> of the Treasury regulations after giving effect to the presumptions contained therein), and, for purposes of this Agreement, the term &#147;specified employee&#148; means an individual
determined by the Company to be a specified employee under Treasury regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(i).</FONT> Each payment made under this Agreement shall be treated as a separate payment and the right to a series
of installment payments under this Agreement is to be treated as a right to a series of separate payments. In no event shall the Company or any of its affiliates have any liability to the Executive or any other person relating to the failure or
alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B>RESTRICTIVE COVENANTS</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <B>NONCOMPETITION</B>. The Executive acknowledges that (i)&nbsp;the Executive will continue to perform valuable services for the Company,
and that the Executive&#146;s performance of such services to a competing business will result in irreparable harm to the Company Group, (ii)&nbsp;the Executive has had and will have access to certain confidential information which, if improperly
disclosed in violation of the Agreement, would unfairly and inappropriately assist in competition against the Company Group or any of its affiliates, and (iii)&nbsp;the Executive has generated and will generate goodwill for the Company Group and its
affiliates in the course of the Executive&#146;s employment. Accordingly, during the Executive&#146;s employment or service with the Company Group and for a period thereafter equal to twelve (12)&nbsp;months, the Executive agrees that the Executive
will not, directly or indirectly, own, manage, operate, control, be employed by (whether as an employee, consultant, independent contractor or otherwise, and whether or not for compensation) or render services to any person, firm, corporation or
other entity, in whatever form, engaged in the Business (as defined below), in any locale of any country in which the Company Group conducts the Business. For purposes hereof, the term &#147;<U>Business</U>&#148; shall mean the business of
developing biological medicines for treating patients with devastating diseases, or any business in which the Company Group is engaged in upon the termination of Executive&#146;s employment or in which the Company Group has actively and in writing
planned, on or prior to such date, to be engaged in on or after such date. Notwithstanding the foregoing, nothing herein shall prohibit the Executive from being a passive owner of not more than two percent (2%) of the equity securities of a publicly
traded corporation engaged in a business that is in competition with the Company Group, so long as the Executive has no active participation in the business of such corporation. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <B>NONSOLICITATION; NONINTERFERENCE</B>. During the Executive&#146;s employment or
service with the Company Group and for a period thereafter equal to twelve (12)&nbsp;months, the Executive agrees that the Executive shall not, except in the furtherance of the Executive&#146;s duties hereunder, directly or indirectly, individually
or on behalf of any other person, firm, corporation or other entity, (i)&nbsp;solicit, aid or induce any customer of the Company Group or any of its affiliates with whom the Executive had direct dealings while employed by the Company Group to
purchase goods or services then sold by the Company Group or any of its affiliates from another person, firm, corporation or other entity or assist or aid any other person or entity in identifying or soliciting any such customer, (ii)&nbsp;solicit,
aid or induce any employee, representative or agent of the Company Group or any of its affiliates to leave such employment or retention or to accept employment with or render services to or with any other person, firm, corporation or other entity
unaffiliated with the Company Group, or hire or retain any such employee, representative or agent, or take any action to materially assist or aid any other person, firm, corporation or other entity in identifying, hiring or soliciting any such
employee, representative or agent, or (iii)&nbsp;knowingly interfere, or knowingly aid or induce any other person or entity in interfering, with the relationship between the Company Group or any of its affiliates and any of their respective vendors,
joint venturers or licensors. An employee, representative or agent shall be deemed covered by this <U>Section</U><U></U><U>&nbsp;11(b)</U> while so employed or retained and for a period of nine (9)&nbsp;months thereafter. Notwithstanding the
foregoing, the provisions of this <U>Section</U><U></U><U>&nbsp;11(b)</U> shall not be violated by general advertising or solicitation not specifically targeted at Company Group-related persons or entities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <B>NONDISPARAGEMENT</B>. Both during the Employment Term and at all times thereafter, regardless of the reason for termination, the
Executive agrees not to make comments materially injurious to the reputation of the Company Group or otherwise disparage the Company Group or any of their officers, directors, employees, shareholders, members, agents or products. Any disclosure by
the Executive in good faith in connection with any legal proceedings between the Executive and the Company Group, in response to legal process, required governmental testimony or filings, or administrative or arbitral proceedings (including, without
limitation, depositions in connection with such proceedings) shall not be deemed to violate this <U>Section</U><U></U><U>&nbsp;11(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <B>RETURN OF COMPANY PROPERTY</B>. On the date of the Executive&#146;s termination of employment with the Company for any reason (or at
any time prior thereto at the Company Group&#146;s request), the Executive shall return to the Company all property belonging to the Company Group or its affiliates including, but not limited to, any Company-provided laptops, computers, cell phones,
wireless electronic mail devices or other equipment, or any property belonging to the Company Group and any Documents. The Executive also agrees to disclose to the Company, at the time his employment terminates or at such earlier time or times as
the Board or its designee may specify, all passwords necessary or desirable to obtain access to, or that would assist in obtaining access to, any information which the Executive has password-protected on any computer equipment, network or system of
the Company Group or any of its affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <B>REASONABLENESS OF COVENANTS</B>. In signing this Agreement, the Executive gives the
Company Group assurance that the Executive has carefully read and considered all of the terms and conditions of this Agreement, including the restraints imposed under this <U>Section</U><U></U><U>&nbsp;11</U>. The Executive agrees that these
restraints are necessary for the reasonable and proper protection of the Company Group and its affiliates and their confidential information </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and that each and every one of the restraints is reasonable in respect of subject matter, length of time and geographic area, and that these restraints, individually or in the aggregate, will not
prevent the Executive from obtaining other suitable employment during the period in which the Executive is bound by the restraints. The <FONT STYLE="white-space:nowrap">non-prevailing</FONT> party will reimburse the prevailing party for all costs
(including reasonable attorneys&#146; fees) incurred in connection with any action to enforce any of the provisions of this <U>Section</U><U></U><U>&nbsp;11</U>. It is also agreed that each of the Company Group&#146;s affiliates will have the right
to enforce all of the Executive&#146;s obligations to that affiliate under this Agreement, including without limitation pursuant to this <U>Section</U><U></U><U>&nbsp;11</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <B>REFORMATION</B>. If it is determined by a court of competent jurisdiction in any state that any restriction in this
<U>Section</U><U></U><U>&nbsp;11</U> is excessive in duration or scope or is unreasonable or unenforceable under applicable law, it is the intention of the parties that such restriction may be modified or amended by the court to render it
enforceable to the maximum extent permitted by the laws of that state. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <B>TOLLING</B>. In the event of any violation of the
provisions of this <U>Section</U><U></U><U>&nbsp;11</U>, the Executive acknowledges and agrees that the post-termination restrictions contained in this <U>Section</U><U></U><U>&nbsp;11</U> shall be extended by a period of time equal to the period of
such violation, it being the intention of the parties hereto that the running of the applicable post-termination restriction period shall be tolled during any period of such violation; <U>provided</U>, that tolling period shall not exceed sixty
(60)&nbsp;days after the Company Group has knowledge of such violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <B>SURVIVAL OF PROVISIONS</B>. The obligations contained in
<U>Sections 11</U> through <U>13</U> hereof shall survive the termination or expiration of the Employment Term and the Executive&#146;s employment with the Company and shall be fully enforceable thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B>COOPERATION</B>. In connection with any termination of the Executive&#146;s employment with the Company, the Executive agrees to
assist the Company Group, as reasonably requested by the Company Group, in its succession planning efforts to facilitate a smooth transition of the Executive&#146;s job responsibilities to the Executive&#146;s successor. In addition, upon the
receipt of reasonable notice from the Company Group (including outside counsel), the Executive agrees that while employed by, or providing services to, the Company Group and thereafter, the Executive will respond and provide truthful information
with regard to matters in which the Executive has knowledge as a result of the Executive&#146;s employment with the Company Group, and will reasonably cooperate with the Company Group, its affiliates and their respective representatives in defense
of all claims that may be made against the Company Group or its affiliates, and will cooperate with the Company Group and its affiliates in the prosecution of all claims that may be made by the Company Group or its affiliates, to the extent that
such claims may relate to the period of the Executive&#146;s employment or service with the Company Group and the Company reasonably believes that the Executive has pertinent knowledge or information related to such claims. The Executive agrees to
promptly inform the Company (to the extent that the Executive is legally permitted to do so) if the Executive becomes aware of any lawsuit involving such third party claims that may be filed or threatened against the Company Group or its affiliates.
The Executive also agrees to promptly inform the Company (to the extent that the Executive is legally permitted to do so) if the Executive is asked to assist in any investigation of the Company Group or its affiliates (or their actions), regardless
of whether a lawsuit or other proceeding has then been filed against the Company Group or its affiliates with respect to such investigation, and shall not do so unless legally required. Upon presentation of appropriate documentation, the Company
shall pay or reimburse the Executive for all reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> travel, duplicating or telephonic expenses incurred by the Executive in complying with this
<U>Section</U><U></U><U>&nbsp;12</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B>EQUITABLE RELIEF AND OTHER REMEDIES</B>. The Executive acknowledges and agrees
that the Company&#146;s remedies at law for a breach or threatened breach of any of the provisions of <U>Section</U><U></U><U>&nbsp;11</U> or <U>Section</U><U></U><U>&nbsp;12</U> hereof would be inadequate and, in recognition of this fact, the
Executive agrees that, in the event of such a breach or threatened breach, in addition to any remedies at law, the Company Group shall be entitled to seek equitable relief in the form of specific performance, a temporary restraining order, a
temporary or permanent injunction or any other equitable remedy which may then be available, without the necessity of showing actual monetary damages and without posting any bond or other security. In the event of a violation by the Executive of
<U>Section</U><U></U><U>&nbsp;11</U> or <U>Section</U><U></U><U>&nbsp;12</U> hereof, any severance being paid to the Executive pursuant to this Agreement or otherwise shall immediately cease, and any severance previously paid to the Executive shall
be immediately repaid to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B>NO ASSIGNMENTS</B>. This Agreement is personal to each of the parties hereto. Except
as provided in this <U>Section</U><U></U><U>&nbsp;14</U>, no party may assign or delegate any rights or obligations hereunder without first obtaining the written consent of the other party hereto. The Company may assign this Agreement to any
successor to all or substantially all of the business and/or assets of the Company or to any of its subsidiaries or affiliates; <U>provided</U> that the Company shall require such assignee to expressly assume and agree to perform this Agreement in
the same manner and to the same extent that the Company would be required to perform it if no such assignment had taken place. As used in this Agreement, &#147;Company&#148; shall mean the Company and any successor to its business and/or assets or
assignee of this Agreement, which assumes and agrees to perform the duties and obligations of the Company under this Agreement by operation of law or otherwise. Each member of the Company Group is an intended third party beneficiary of this
Agreement and shall be entitled to enforce the provisions of this Agreement as if a direct party to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B>
<B>NOTICE</B>. For purposes of this Agreement, notices and all other communications provided for in this Agreement shall be in writing and shall be deemed to have been duly given (a)&nbsp;on the date of delivery, if delivered by hand, (b)&nbsp;on
the date of transmission, if delivered by confirmed facsimile or by electronic mail, (c)&nbsp;on the first business day following the date of deposit, if delivered by guaranteed overnight delivery service, or (d)&nbsp;on the fourth business day
following the date delivered or mailed by United States registered or certified mail, return receipt requested, postage prepaid, addressed as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">If to the Executive: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">At the
address (or to the facsimile number or email address) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">shown in the books and records of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">If to the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Rallybio,
LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">234 Church Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Suite 1020 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New Haven, CT 06510
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as either party may have furnished to the other in writing in accordance herewith,
except that notices of change of address shall be effective only upon receipt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B>SECTION HEADINGS; INCONSISTENCY</B>. The
section headings used in this Agreement are included solely for convenience and shall not affect, or be used in connection with, the interpretation of this Agreement. In the event of any inconsistency between the terms of this Agreement and any
form, award, plan or policy of the Company Group, the terms of this Agreement shall govern and control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B> <B>SEVERABILITY</B>.
The provisions of this Agreement shall be deemed severable. The invalidity or unenforceability of any provision of this Agreement in any jurisdiction shall not affect the validity, legality or enforceability of the remainder of this Agreement in
such jurisdiction or the validity, legality or enforceability of any provision of this Agreement in any other jurisdiction, it being intended that all rights and obligations of the parties hereunder shall be enforceable to the fullest extent
permitted by applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18.</B> <B>COUNTERPARTS</B>. This Agreement may be executed in several counterparts, each of which shall
be deemed to be an original but all of which together will constitute one and the same instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>19.</B> <B>GOVERNING LAW;
JURISDICTION</B>. This Agreement, the rights and obligations of the parties hereto, and all claims or disputes relating thereto, shall be governed by and construed in accordance with the laws of the State of Connecticut, without regard to the choice
of law provisions thereof. Each of the parties hereby irrevocably and unconditionally consents to the exclusive jurisdiction of the courts of the State of Connecticut and the United States District Court for the District of Connecticut, as well as
to the jurisdiction of all courts to which an appeal may be taken from such courts, for the purpose of any suit, action or other proceeding arising out of or in connection with this Agreement or any of the transactions contemplated hereby, and
irrevocably and unconditionally waives, to the fullest extent permitted by law, any and all objections such party may now or hereafter have to the laying of the venue of any such suit, action or proceeding in any such court or that any such suit,
action or proceeding brought in any such court has been brought in an inconvenient forum. In that context, and without limiting the generality of the foregoing, each of the parties hereto irrevocably and unconditionally (a)&nbsp;submits in any
proceeding relating to this Agreement or the Executive&#146;s employment by the Company or any affiliate, or for the recognition and enforcement of any judgment in respect thereof (a &#147;<U>Proceeding</U>&#148;), to the exclusive jurisdiction of
the courts of the State of Connecticut and the United States District Court for the District of Connecticut, as well as to the jurisdiction of all courts to which an appeal may be taken from such courts, and agrees that all claims in respect of any
such Proceeding shall be heard and determined in such Connecticut State court or, to the extent permitted by law, in such federal court, (b)&nbsp;consents that any such Proceeding may and shall be brought in such courts and waives any objection that
the Executive or the Company may now or thereafter have to the venue or jurisdiction of any such Proceeding in any such court or that such Proceeding was brought in an inconvenient court and agrees not to plead or claim the same, (c)
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY PROCEEDING (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE EXECUTIVE&#146;S EMPLOYMENT BY OR SERVICE
WITH THE COMPANY OR ANY AFFILIATE OF THE COMPANY, OR THE EXECUTIVE&#146;S OR THE COMPANY&#146;S PERFORMANCE UNDER, OR THE ENFORCEMENT OF, THIS AGREEMENT, (d)&nbsp;agrees that service of process in any such Proceeding may be effected by mailing a
copy of such process by registered or certified mail (or any substantially similar form of mail), postage prepaid, to such party at the Executive&#146;s or the Company&#146;s address as provided in <U>Section</U><U></U><U>&nbsp;15</U> hereof,
(e)&nbsp;agrees that nothing in this Agreement shall affect the right to effect service of process in any other manner permitted by the laws of the State of Connecticut and (f)&nbsp;expressly waives any and all rights to bring any suit, action or
other proceeding arising out of or in connection with this Agreement in or before any court or tribunal other than the courts of the State of Connecticut or the United States District Court for the District of Connecticut and any courts to which an
appeal may be taken from such courts, and covenants that such party shall not seek in any manner to resolve any dispute other than as set forth herein or to challenge or set aside any decision, award or judgment obtained in accordance with the
provisions hereof. Except as may be explicitly set forth in this Agreement, the parties acknowledge and agree that in connection with any dispute hereunder, each party shall pay all of its own costs and expenses, including, without limitation, its
own legal fees and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>20.</B> <B>MISCELLANEOUS</B>. No provision of this Agreement may be modified, waived or discharged unless
such waiver, modification or discharge is agreed to in writing and signed by the Executive and such officer or director of the Company as may be designated by the Board or the Compensation Committee, and in any case must be approved by the Board or
the Compensation Committee. In addition, notwithstanding anything to the contrary in this Agreement, the Company may not terminate this Agreement (including by notice of <FONT STYLE="white-space:nowrap">non-renewal)</FONT> or the Executive&#146;s
employment without Board or Compensation Committee approval. No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this Agreement to be performed by such other
party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time. This Agreement together with all exhibits hereto (if any) set forth the entire agreement of the parties hereto in
respect of the subject matter contained herein and supersede any and all prior agreements or understandings between the Executive and the Company with respect to the subject matter hereof, including the Prior Agreement. No agreements or
representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by either party which are not expressly set forth in this Agreement. Any references in this Agreement to &#147;$&#148; shall mean U.S.
dollars. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21. REPRESENTATIONS. </B>The Executive represents and warrants to the Company that (a)&nbsp;the Executive has the legal right
to enter into this Agreement and to perform all of the obligations on the Executive&#146;s part to be performed hereunder in accordance with its terms, and (b)&nbsp;the Executive is not a party to any agreement or understanding, written or oral, and
is not subject to any restriction, which, in either case, could prevent the Executive from entering into this Agreement or performing all of the Executive&#146;s duties and obligations hereunder.<B> </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>22.</B> <B>TAX MATTERS</B>. The Company Group may withhold from any and all amounts
payable under this Agreement or otherwise such federal, state and local taxes as may be required to be withheld pursuant to any applicable law or regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>23.</B> <B>OTHER</B>. Nothing contained in this Agreement limits, restricts or in any other way affects the Executive&#146;s communicating
with any governmental agency or entity, or communicating with any official or staff person of a governmental agency or entity, concerning matters relevant to such governmental agency or entity and the Executive will not be held criminally or civilly
liable under any federal or state trade secret law for disclosing a trade secret (i)&nbsp;in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, solely for the purpose of reporting or
investigating a suspected violation of law, or (ii)&nbsp;in a complaint or other document filed under seal in a lawsuit or other proceeding; <U>provided</U>, <U>however</U>, that notwithstanding this immunity from liability, the Executive may be
held liable if he unlawfully accesses trade secrets by unauthorized means. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp; *&nbsp;&nbsp;&nbsp;&nbsp;
*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;* </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the parties hereto have executed this Agreement as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>RALLYBIO, LLC</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Martin W. Mackay</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Martin W. Mackay</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Jeffrey M. Fryer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey M. Fryer</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>24
<FILENAME>d99471dex1023.htm
<DESCRIPTION>EX-10.23
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.23</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.23 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RALLYBIO HOLDINGS, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EQUITY ADJUSTMENT NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This notice (this &#147;<B>Notice</B>&#148;) describes certain amendments that are being made to the Restricted Share Agreement(s) and/or
Contribution and Restricted Share Agreement(s) (each, as amended from time to time, your &#147;<B>Award Agreement(s)</B>&#148;) between you and Rallybio Holdings, LLC (the &#147;<B>LLC</B>&#148;) and to the restricted common units and/or incentive
units you hold under such Award Agreement(s) (collectively, your &#147;<B>Award(s)</B>&#148;) in connection with the initial public offering (the &#147;<B>IPO</B>&#148;) of shares of common stock of Rallybio Corporation (&#147;<B>Rallybio</B>&#148;)
and the dissolution of the LLC (the &#147;<B>Dissolution</B>&#148;) undertaken pursuant to that certain Plan of Liquidation and Dissolution of Rallybio Holdings, LLC entered into by the LLC on or about July&nbsp;22, 2021 (the &#147;<B>Plan of
Dissolution</B>&#148;) in connection with the IPO. The LLC, its subsidiaries, and Rallybio are collectively referred to in this Notice as the &#147;<B>Company</B>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Dissolution and the IPO, the LLC will dissolve and distribute all of the common stock of Rallybio (&#147;<B>Rallybio
Shares</B>&#148;) to the unitholders of the LLC, all vested and unvested restricted common units and incentive units will be cancelled and Rallybio Shares will be distributed in respect of such cancelled units, and Rallybio Shares are expected to
become publicly traded on the Nasdaq Global Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You are receiving this Notice because you and/or persons related to you (which we
together refer to as &#147;<B>you</B>&#148; or the &#147;<B>Participant</B>&#148;) currently hold restricted common units and/or incentive units issued pursuant to your Award Agreement(s) and the Rallybio Holdings, LLC 2018 Share Plan (as amended
from time to time, the &#147;<B>2018 Plan</B>&#148;) that will be cancelled in connection with the Dissolution. The purpose of this Notice is to inform you of certain amendments that are being made to the terms of your Award(s) and that,
notwithstanding anything to the contrary in your Award Agreement(s), the 2018 Plan and/or the operating agreement of the LLC (as amended from time to time, the &#147;<B>LLC Agreement</B>&#148;) or any other plan or agreement applicable to you or to
which you are a party, will apply to your Award(s) as of and following the effective time of this Notice, as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.
<U>Effective Time; Defined Terms</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">a. The adjustments described in this Notice, in their entirety, are effective as of the
consummation of the Dissolution (the &#147;<B>Effective Time</B>&#148;) and are to be effected by the Plan of Dissolution. For the avoidance of any doubt, in the event that the Effective Time does not occur or your Award(s) are not outstanding as of
immediately prior to the Effective Time, the treatment described herein shall not apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">b. Capitalized terms used and not defined herein
have the respective meanings ascribed to such terms in the 2018 Plan, the LLC Agreement or your Award Agreement(s), in each case, as applicable. To the extent that the restricted common units and/or incentive units under your Award(s) (or any
portion thereof) are cancelled and Rallybio Shares are distributed to you in </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connection with the Dissolution, references in the governing documents to the &#147;Company&#148; shall be construed to refer to (or to also include) Rallybio, and references in the governing
documents to the &#147;Board&#148; shall be construed to refer to (or to also include) the board of directors or the compensation committee of the board of directors of Rallybio, in each case, to the extent necessary or appropriate to give effect to
such distribution and the transactions described herein, in each case, as determined by Company in its sole discretion. In no event shall the transactions contemplated herein or any restructuring prior to, or in connection with, the IPO, including
the cancellation of restricted common units and incentive units of the LLC and distribution of Rallybio Shares in connection with the Dissolution, constitute a &#147;Change of Control&#148; or a &#147;Sale of the Company&#148; for purposes of such
restricted common units and/or incentive units or the Rallybio Shares distributed to you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B></B><B><U>Organizational
Transactions</U></B><B>. </B>In connection with the Dissolution, restricted common units and/or incentive units in the LLC will be cancelled and Rallybio Shares will be distributed in respect of such cancelled units. If the restricted common units
and/or incentive units with respect to which Rallybio Shares are received were unvested at the time of such cancellation and distribution, such Rallybio Shares will be issued in the form of unvested restricted stock under, and subject to the terms
of, the Rallybio Corporation 2021 Equity Incentive Plan. Such unvested Rallybio Shares will be subject to the same vesting schedule and transfer restrictions which applied to the unvested restricted common units and/or incentive units to which they
relate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">a. <U>Restricted Common Units</U>. If you hold restricted common units, the restricted common units will be cancelled and you
will receive restricted Rallybio Shares in accordance with the Plan of Dissolution. <U>Exhibit A</U> sets forth information regarding the number of restricted Rallybio Shares to be distributed to you in respect of restricted common units, if any.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">b. <U>Incentive Units</U>. If you hold incentive units, the incentive units will be cancelled and you will receive restricted Rallybio
Shares in accordance with the Plan of Dissolution. <U>Exhibit A</U> sets forth information regarding the number of restricted Rallybio Shares to be distributed to you in respect of incentive units, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B><U>Participant Group</U></B><B>.</B> In the event that &#147;you&#148; is construed to refer to a current or former individual
employee of, or other service provider to, the Company, and related persons (<I>e.g.</I>, permitted transferees of such individual), the individual employee or other service provider shall be responsible for ensuring the compliance of all persons
related to such individual with the requirements hereunder and for obtaining from such persons any agreements, consents or other documents that the Company may require to give effect to the provisions set forth herein from time to time. All
determinations regarding any allocations of rights and obligations among any such individual and any related persons will be made by the Company in good faith and will be binding on all persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B><U>Required Actions</U></B><B>. </B>You must sign (including by Docusign or other electronic means, if required by the Company)
and return this Notice to <B>[***]</B><B> at </B><B>[***]</B><B> not later than </B><B><U>July</U></B><B><U></U></B><B><U>&nbsp;30, 2021</U></B>. By delivering your executed signature page (or causing it to be delivered, including, if applicable, by
electronic means), you will be confirming that: (a)&nbsp;you have reviewed and understand the terms set forth of this Notice and agree to be bound thereby (notwithstanding any applicable local laws regarding the use or enforceability of electronic
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
signatures); and (b)&nbsp;you authorize the Company to take all action it deems necessary or appropriate to effectuate the foregoing on behalf of you without further notice to date to effect such
terms. If you receive unvested Rallybio Shares in connection with the transactions described in this Notice, you must make a Section&nbsp;83(b) election not later than <B>thirty (30)</B><B></B><B>&nbsp;days following the Effective Time</B>,
substantially in the form attached hereto as <U>Exhibit B,</U> and must promptly provide a copy of such election to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B><U>Binding Effect</U></B><B>. </B>This Notice constitutes (and serves as your consent to) an amendment to the terms applicable to
your Award(s), which (a)&nbsp;will be binding upon the executors, administrators, estates, heirs and legal successors of the Participant; (b)&nbsp;will be governed by and construed in accordance with the laws of the State of Delaware, without regard
to the principles of conflicts of laws; and (c)&nbsp;if applicable, will be subject to any existing arbitration agreement that you have with the Company. Except as described in this Notice, your Award(s) and any restricted common units and/or
incentive units received thereunder will remain subject to their existing terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Remainder of Page Intentionally Left Blank] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>RALLYBIO HOLDINGS, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>RALLYBIO CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Rallybio Holdings, LLC and Rallybio Corporation</I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Notice of Amended Award Terms Signature Page]</I> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>ACKNOWLEDGED AND AGREED BY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The&nbsp;Participant</I><I>:</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>On
behalf on himself or herself</I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>and all related persons</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Sign Name:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Print Name:</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Rallybio Holdings, LLC </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Notice of Amended Award Terms </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Participant Signature Page] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ALLYBIO</SMALL> S<SMALL>HARES</SMALL> </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELECTION PURSUANT TO SECTION 83(b) OF THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTERNAL REVENUE CODE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
undersigned hereby elects pursuant to Section&nbsp;83(b) of the Internal Revenue Code of 1986, as amended, to include in the undersigned&#146;s gross income for the taxable year indicated below the excess (if any) of the fair market value of the
property described below, over the amount the undersigned paid for such property, if any, and supplies herewith the following information in accordance with the Treasury regulations promulgated under Section&nbsp;83(b): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. The undersigned&#146;s name, address and taxpayer identification (social security) number are: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right"></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Social&nbsp;Security&nbsp;#:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The undersigned&#146;s spouse&#146;s name, address and taxpayer identification (social security) number are
(complete if applicable): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Social&nbsp;Security&nbsp;#:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. The property with respect to which the election is made consists of ___________ unvested restricted shares of common stock
(the &#147;<U>Award</U>&#148;) of Rallybio Corporation, a Delaware corporation (the &#147;<U>Company</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. The date on which the Award was
transferred to the undersigned was __________, 2021 and the taxable year to which this election relates is 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. The Award is subject to the following
restrictions: the unvested portion of the Award will be forfeited if the undersigned ceases to provide services to the Company prior to the vesting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. The fair market value of the Award at the time of transfer (determined without regard to any restrictions other than those which by their terms will never
lapse) is $_______. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. The amount paid for the Award by the undersigned was $_______. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. The amount to include in gross income is $0. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
undersigned will file this election with the Internal Revenue Service office with which the taxpayer files his or her annual income tax return not later than 30 days after the date of the transfer of the property. A copy of the election will also be
furnished to the Company. The undersigned is the person performing the services in connection with which the property was transferred. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">Participant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">Participant&#146;s Spouse</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>25
<FILENAME>d99471dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use in this Amendment No.&nbsp;1 to Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (No. <FONT
STYLE="white-space:nowrap">333-257655)</FONT> of our report dated April&nbsp;27, 2021 relating to the financial statements of Rallybio Holdings, LLC. We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration
Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte &amp; Touche LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hartford,
Connecticut </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;22, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g156845dsp008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g156845dsp008.jpg
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M1CX@/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0](G(B/S[_[@ .061O8F4
M9,     !_]L A  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0(! 0(" @$"
M @,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P/_P  1" '^ T@# 1$  A$! Q$!_\0 ^0   0,% 0$!
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MWECV@7,:1NUVNP",74Q[2="KF]MI;L>+^A7C>;R^%B+S4F5B<M@YG)8"X\<
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M**1K%$E+@C36+Q=AEK.N,DF*TXX;(*I8>IF8K4UF%'1(I=1,TZMBU-!5($S
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ME2_XE6_N+#3T4'UK5/JY]&LGZ48/%SYN7\QE\AW-RB#)B6,Q08C/9LB"'?\
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M6BP5APJR>RS=HE)N4%U@47-YE1.7E^16-8EDLJ;;>U;V5MZC=;<55K$*25!
ML-!2#ZM?4'%X['XO&Y QXV(T':98,83!<;(&5CPG($/??'@R%6:+&>1L>-TC
M*Q#MIMO3/'7"-AFIRQ3..*\]F[+#05?L$D=)RDXF8JLP%OJU?;R)D'*172L3
M7;Y+,T5C *Y$'?;W_E(^.$Y;D8XUB29Q&C,RCX%F1FM\+LB$CI<?:;X^/^J_
MU%XOC\;BL#E\N/CL/(FG@C!4K%+D3XN3.T=U.T2SX6-*Z#V%XK[??)N4V&':
M>W>S[N0:%ETY?)\/EB-9N$RM6U;LT!4JM4H@\41B+<#(LF]6(L0%>\/(N<!
M2@4 H_(9!1%4[=L)B)]65G9S>_Q+6T] *X>5Y]STN/BP8LG8:#AI>-D=3N;(
MQY\K)RI1(7W:NV24.VWM12""23BV+ >(+9#MH&P4:,D8IG8[C:V[<SB3;G)-
MY"7G7-Z5,Z:/F[Q5C;E+,^"09'4,R=D<"11$Q"D*68>4SX)#+%*P<HB^G2/;
MLT(M=-J[3U%M#6;B?J=YYP>>_)\5R4T6;)B8N,S;8V!AP1"N&-K(RA\48\/8
ME"B:,H&5PQ8E<<8EQPZN89!7J,4>W^D09'E^U<HK-VT9/PJ)7+ BY8QTH6(L
M[YJ*BB)U#(+]AC"4B8$QC.RQC_*"1OE[WM]Y4]>HU53UZB_J:ZZ+SGRV'Q__
M  M'G3C@MY<1::,TD,QVN1W%'=QX9-JN%#IN !9BT?PW%7 -=)66\!CMI"1U
M285N,AX.)F[1'UI1A395Q.5!K.UAI.)5ZU)U66<F7C?FC9X+$P%\(D A +RI
M.;Y28NTLI9Y"Q+$*6NXLY#$;EW#1MI%_6];1R'UK^J'*MF2\IRLF3EYTN1)+
M-+#COD!\N-8<IH<AH3/C')B4)D?+21=X7[FXLQ,GTG'-'QRS=1](K4;7&CTT
M<=VDP(INX-$P<56XX5E5U%EC^EA81J@&YNOC[QW.8YC<+(R\C+8-D.787M?[
M6+']I)/ZZTWR+RSR/RS(3*\CS)LN>,2!2Y'M[LTF1)8  #=--(YT_M;1954!
MZZX]:]1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2
MC2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4
M:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C
M2E&E*-*4:4HTI1I2HQ4>IAF9G'?.K,"IL8R+T*\5 ?T:HF2U12 S2SKS]H69
M$QP033\6XM3G'NZ;#LZPM_@Q\CLXVS^IHO>O_P 0#V'/;"V_N3;<3N_&%%O6
MM&?)0?4N/#^9SNX>"D?Y?;_P9 RHE[Q;=_YD$[%7;_=,QW:6J3M:Q6\UH9D+
MZE7$3&-GR?3+5D&52LV&;/6*CDJ)CJ5;I):KR]R8R4C6P<+-H@S5VTE&D2N8
MBK8ZP?" #L)B@.Z\?].?,>3@Q,G&QE,&=$\D![B#>L9 ?JVFTGUM]E:=G>>^
M+\=-E8^3D$38<B)* C$JT@)3H-;@'I>FA'?5AX3RKYO'1^0+6Z>NEFK=%LEB
M[(AW)UGICD:I%:%K8NSJK+$\8)E(*G>(!V]=<^?Z3^<XL33S8T8C4$_W\7IU
M_M] -;UP\?ZE^(9,@ABR7+GXQ2#^*BJ?_IM'!929?5YMEQR[FV+E%D6,0I]K
M!W(OEW\Q')L(A%Q$H&E)$Z\$X$C9'N<+$ HI$/WE :CZ4>=_+KER887'8$[N
M['8+8'<?=H-1KT%2WU+\-68XXR[S VL$:Y.HL--3H=*MN_JT\(6!WJ4AD:R,
M'4:<4I%F]QS>&CI@H!0'L>H+PB9VAA-N7\SM^(!W]@CJ8OI-YQDH)8<96C;H
M5FB(/W'=K4O]2O$(B5ER2KCJ#&X(^_32KRWU8N$C98J+C(UB0.9,RY0<8YO3
M8?3E542%R)'$$DJ"'<D.YNW8O0#;&$ ')'])//) 9%Q4V=/[Z+K_ .O5)/J;
MX?'8-D2:_P#S4G_W- _5DX0DC4YISDJ;80SD7*;"5DJ%<8]E+NVC99TM'01W
MD0B>>DB)(_$@S*NH05$P.!?(3NPK]*_-WF^7AQ0^0.JB6-B!>US9M!\";7J[
M?4KQ!(N_)DLL)T!,;BYZV%UU/W5<3^J]PD<P$=:&62IY_ R;ARS;R3''5[<L
MP=M6;>15:K.TX$6I'01[Q!<J7>*AT7"9RE$IM]5'TL\WERGPOE0F3&+D&6-3
M8DJ#JW2X(^\59OJ1XBN,N7\PS8[="(Y#\#Z+\"#]QI5H?U0N'N2KQ3<=TZ\6
M23M%ZE20U?;+4&W1S55Z=)5;9U(2,6U:-DB%2$#G$P@0P@4=C" :IR?TQ\TX
M;CY>2S\9$PX![F[B'^#$G7X"K<?]1/%>4SX^-PIG;+E-E';<?O(%JW<4NU=2
M.8AGBFY1#V-EQ P" & 2CX_8)1 =:,()GMM%;O<51^NZW_?%?\*O_4UD^6G_
M )347H_75;_O:O\ A5_ZFGRT_P#*:7H_7=;_ +XK_A5_ZFGRT_\ *:7H_7=;
M_OBO^%7_ *FGRT_\II>C]=5O^]J_X5?^II\M/_*:7H_75;_O:O\ A5_ZFGRT
M_P#*:7H_7=;_ +XK_A5_ZFGRT_\ *:7H_7=;_OBO^%7_ *FGRT_\II>C]=UO
M^^*_X5?^II\M/_*:7H_7=;_OBO\ A5_ZFGRT_P#*:7H_7=;_ +XK_A5_ZFGR
MT_\ *:7H_7=;_OBO^%7_ *FGRT_\II>C]=UO^^*_X5?^II\M/_*:7H_7=;_O
MBO\ A5_ZFGRT_P#*:7H_7=;_ +XK_A5_ZFGRT_\ *:7H_7=;_OBO^%7_ *FG
MRT_\II>C]=UO^^*_X5?^II\M/_*:7H_7=;_OBO\ A5_ZFGRT_P#*:7H_7=;_
M +XK_A5_ZFGRT_\ *:7H_7=;_OBO^%7_ *FGRT_\II>C]=UO^^*_X5?^II\M
M/_*:7H_7=;_OBO\ A5_ZFGRT_P#*:7H_7=;_ +XK_A5_ZFGRT_\ *:7H_7=;
M_OBO^%7_ *FGRT_\II>C]=UO^^*_X5?^II\M/_*:7H_7=;_OBO\ A5_ZFGRT
M_P#*:7H_7=;_ +XK_A5_ZFGRT_\ *:7H_7=;_OBO^%7_ *FGRT_\II>C]=UO
M^^*_X5?^II\M/_*:7H_7=;_OBO\ A5_ZFGRT_P#*:7H_7=;_ +XK_A5_ZFGR
MT_\ *:7H_7=;_OBO^%7_ *FGRT_\II>C]=UO^^*_X5?^II\M/_*:7H_7=;_O
MBO\ A5_ZFGRT_P#*:7H_7=;_ +XK_A5_ZFGRT_\ *:7H_7=;_OBO^%7_ *FG
MRT_\II>C]=UO^^*_X5?^II\M/_*:7H_7=;_OBO\ A5_ZFGRT_P#*:7H_7=;_
M +XK_A5_ZFGRT_\ *:7H_7=;_OBO^%7_ *FGRT_\II>C]=UO^^*_X5?^II\M
M/_*:7H_7=;_OBO\ A5_ZFGRT_P#*:7H_7=;_ +XK_A5_ZFGRT_\ *:7H_7=;
M_OBO^%7_ *FGRT_\II>C]=UO^^*_X5?^II\M/_*:7H_7=;_OBO\ A5_ZFGRT
M_P#*:7H_7=;_ +XK_A5_ZFGRT_\ *:7H_7=;_OBO^%7_ *FGRT_\II>C]=UO
M^^*_X5?^II\M/_*:7H_7=;_OBO\ A5_ZFGRT_P#*:7H_7=;_ +XK_A5_ZFGR
MT_\ *:7H_7=;_OBO^%7_ *FGRT_\II>C]=UO^^*_X5?^II\M/_*:7H_7=;_O
MBO\ A5_ZFGRT_P#*:7H_7=;_ +XK_A5_ZFGRT_\ *:7H_7=;_OBO^%7_ *FG
MRT_\II>C]=UO^^*_X5?^II\M/_*:7H_7=;_OBO\ A5_ZFGRT_P#*:7H_7=;_
M +XK_A5_ZFGRT_\ *:7H_7=;_OBO^%7_ *FGRL_\II>C]=UO^^*_X5?^II\M
M/_*:7H_7=;_OBO\ A5_ZFGRT_P#*:7I M67J/3:Q8K?./WJ4+5H.6L,LHUC'
MSQR2-A8QW+OSMFC=%1=TN5DQ5,1,@"8XE[0ZB&K1<=EY$\<$*DRRR!%&X#5B
M /WD5AR<J##QY,K(8+#$A=C\%4$G]PK1MI]77@V]1060R+:!*Y*<42CC2]E,
M<2)&5,4H_(A3/T(8.\IA3[RB7N[@$-?06^C_ )Z@).*E@/\ V\7_ -UU^RM$
M3ZI>&.1MR7))_P#92?\ W/[Z5)GZL?!BO.HEE.Y;?0[F99(2+5.6HMXC#),7
M+"9DV[QYZ^ ;>C9K,()98JRFR7B.D?N[%2&'AXWTK\[RU<XN&71&(8]V+1@0
M"-&^)M]]<F?ZD>'XQ43985F (&Q^A!(/X?@*J=?5;X7,#-"2%\L[(T@U%]&"
MOCNZ C*L@ #%>1+E.(4:RC)8FYDUVYU$52%$Q#F#KJ\?TM\VD+!<5&*FQVRQ
MG:?@WNT/V&QJ'^I'B48!DR&4,+B\;ZCXC34?:*Q ^K3PA%H1^&1[%Z-1<6R3
MG]W5Y!!5P"CE+PIK#!^(ZO<U,': ]PFV)MY-R!D/TE\]#6&(GW&:,']FZL7_
M #-\.(N,ER/LBDM_V:OH?5@X3NR2*K3(EA=-H9(5YM^3'MS2C() "$-YIN5<
MQ"$;%(B90I"G75(0ZIBIE$3F*4:R?2KS:-EB;&02L0%'=C+,3Z* UR?N&@UJ
MT?U+\1D1I%R'V*+DF-P !ZDE;#]=5QGU8>#TV2Q*0F49:9"KI+.)8(F@7F1,
MDR05:H*22?I(%4#Q95'[;^TB(( 5TB83=BI##7(^EGG&*T8RL/MB5@JEI(P"
MQ!(%]W4V.GV&LB?4?Q&0.8LDML7<0(W)VBPO^'IJ/VBD=Y]7K@RR1=K*9%M!
MP9'%-9-+&=[44[@W  */R,J7YAP[2")@!0W0N^N2/H_Y^7$:XB&^M^[&=+?]
M:N*/JEX61N^9?_[U(/\ _&MJL7<KL%YDR7<\/X_N@361\>5BI7"[58T+.,'5
M<@KS&,)BKN'SQ_'-XQ564C9-%4J:"ZIR 80-L)1VU'DO&.>XCC8.8Y" IQ>3
M+)'%)<$.T1*N!8W]K @W ^RMJP/(.'Y/-EXW"F#YT"(\B6(*JX#*=1;4$=#6
MQFNCKN:-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*
M4:4HTI1I2HR4DB!F5I$?J>6*J?&4C)?HT(\PP:Q$[5%M1LYY3S=I99L97TI6
M_CW,BJ8_=TVULRXS?X-?+^5BVCDT3YC?^:"8';L[+?W9MO+WT90+:WK1GS4'
MU+CX[Y[(#G@I)/D^W^00,J)?F3+NL)5OVA'MU1RV[2U2;K6:WFO%1S,:M)?D
MG]3>/A(Z8<SI^27&5!VJZF8YS%NWJU0NZ+1!G$@P8RS(K=NH0.X[M=,JVQR
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M.OW?;7KBE7"8/5R />H )"9-L7R 0113Z;EV333W'IW" ;:\9HIVWZ#<:]@
M[5%^NT4F;N3_ (2I)![O(<RI]OO(D)" /W=YM9?;\2:7-6SJ]I@*K(;&#_FT
MP1*;_-_+ BZNIU]%J#]IK[N4>H'DC>P>GE*4?X#%3+M]W\FFOV5.GVU=%NN4
MJ1A;38$7,'A.(F %!';8J9S*@!M]_87?2Y_W:C]M5'0=)&.4Z,PD**?E4 Z
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M$Q53J(F1(F8@;G ^X'4()=^H"7< TM]M+FL90'27C%8R#<%1#Q=Q%EC*[[;
MF&Z/?ON'L =3;[&_A4;C]E5'2=IF,"@R)1*!14*2.51["J"!2"856YQ**AN@
M==A'3]0_6:>OK5LY3IB<BA94IR")3$,((G*/V"3N1V,'OZ:7_P"K2]AZU1[]
MQ+*!W%VV%0=@#IM\(+" &^_2_P!JU(^V]!CD* B9P^2#WF5*H)0Z>\5$%"@'
MW[AH ?0 _I]]-/MJM,RJI?R7B:X![C$34Z]=]S-SI"&P?:'34'3\0(_3[::^
MAK[Y%B]%$1,'O.W/Y/X?$8"*[!_F]XCI8>A_;^G^JES47YZ,FYX]YV(4PF*;
M#V2TU0(JDW<)@I1[$0!3,Z,F5%<AS /Q!^$!W#;?78\*I'/X-_\ Z<@_\1:Z
M3R(__4+-_P#A9O\ PS7D!Q/*!5"N&KJ*CY:_JQ<.E0*ZZ(@M$L!F6<U.25LD
M5;/9*K56#6MU""?O6+4\J0PR HK.$3-TQ*?VESZM."_<$?$JQ.1( P;V$+M4
MHKL0S':S!39;@:FO(7#LN,1&R,W)L@[*W!T<7+,&*K[0-P!8:V)^U]6*\R>(
M:VZ?7&0H%XSYD>$D7UPG+L@ZR(%,JMD;U]6'9/;>2TNJ)&65XP/+J(-XII)2
M;)J9(YY=@J9-#72X>!#Y%E <><G%\4Q)%$?9(A[K*&W-M*B1EN4NSLJL?^[8
M>ZN=E9LG!XI;-^7G\CR4/<WJ9>VK;=JE@=BL0&T4,P']L=*PV%1E$2(NK%;\
MK\8(FT^)K!Q-UI"%_P "R;=M*1U;KM7AG,BM#P..)%M!6][.D@Y.(4*@N*;@
MD@J*@B3+/EJK&'#@PN6FANSO%*8<Q5-W9V N9M4"F1&Z>TJ!:]H,9RH:>;,X
MZ&467N1"7')&BJIN.V"&)"NO6QW$]'HEA)BW72L[K*N.4+ NL[2DX<L-7'E/
M9T5M!-GWR-C1'=R(TCSUR,<MI-"56,2,5V9)(N57Q7@K\0^1RR6QCA9?R:J&
M1MS"0REM29.WJ&(,90>\>XV"[;<V/@D([XS,;YXWWK92HC T';WZ$:.'_#;;
MJ6W7CV7KM@48N+!%VK*_):*@FZ\=)R$92CT+CK"K"R(\L<<QC&CZ6;Y+<8\L
MT$E(^GC&$,TB4WXNBR &12('909$)E&+D18'%9+6(4RF7-D ]JDL0.SW$8KN
M=F9K6V]37 R()4B^8B;(Y''4V+[.WC(3J1MU[FU@&LJJHO>_I3A9W*3R[7%[
M_CR=H^/,V4>(8.IQS2B)8Z:W'&S&H3\-)34=*2-J8XQLPPE<LC!S*L56];DS
MLH9ZY,K*>-PJ7CY&!C<)DG Y49&7XODMM0RMW>S.65@& 4S*&96V,&D4,ZK9
M+J#R(,V;E\9<[CC#!Y! MVV#M]R(*5)6["([58;E(5B%)]UB:CK+[]I:GT@K
M&5QK5[HSCILN3J:U2])'0-G@9A[#/EXA&)L-GK4E6%W0HBFT2DWBS1=-T)"@
MW!(X]YPJ9.+$@RI!+@L1\O*=6D1TN-Q*JRL!<:J+BQ.MZZ?DWAFD;LKV\E5/
M=C'X4=6L; $@AM"=38WMI7?GZ:!XHWU)N9I6J+]&3#C5Q/,^WDHYW!J-%,;T
MH[ (E!FP;.2':AWIJJ.%5A/L7L$"AMKSS]2!-_RPX+<P,/\ 4L^PUN/SI+W-
MR/V5]R\#*'ZA<M8'?_3\.Y]/[M.@]*]"&O/U?;:-*4:4HTI1I2C2E&E*-*4:
M4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2HV4DQ#,#2&_5@E*?&TA
M)_H;Y2<07%.T1C3]6?/?'XR"U!7T?I.[<WF\FWP[ZV5<:_A[YGRER.21/F>Y
MTO [=CM7N=UNYW+:;=M]:TE\XCZC1\;_ %"P/"22_(]H^ZV5$GS??M8;;]GM
M7N=^^VEZDG6M5NU>*WG$M8VO(GZBDD=!E'-8OD]QEDZG(#%0C11TZC:O?5'8
M*V!J4DHY$[DITS>I\IVB)E/ 9%84E"^T_!EQW\=\8C4N[MQG(*Z[F:VZ2(:*
M?;TUL"+D"]_7R=YD\HYOR!B%4+GX14V O9)#JW77IZ]3:U:PP<GXZV.,\/V"
M2IL9FQQ/VRI2D,6-ITD>W5>#2K*F)K)E)>+=C8)=V_C9AQ%IG<*MU&LLW4>;
MO#@FZV/)Q[Y[\MSZ)+_3PD,JL6=!%(^X9"Q7!4 =L/Z[D.WVBXUR"57QAQO$
ML8QF$RI:RN9%7:83)8[C<.5'2S+?W&QD"HHL:%A;&QJ2XD69\R0BE\DLIP;
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M'[]]-P_E_?2CPCMMZA_UZ (1X;AO[]_1B&VFX>@'[?\ ;4_MJHS<2AOYWO\
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M<CCXL+<JI RXXUAETW$+)M42H;>TA5*OH+7&R]]9<QC5U:6&<,DV"2?Y,O\
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MQ2CJR(\CB.,7=B !\2= /UFN5@8.7R>=#QO'QM+GY$J11HNK/)(P5$4>I9B
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M9.$73<QT5#)*D*L@=1,3)*D$I@ =RF 0'J&C*R':X(;[=*9&-DX<I@RXWBF
M!*NI5K$7!L0#8@@CXC6AD_8R3<KN.>M'[4YE"%<LG"+IN8Z*ADE2%60.HF)D
ME2"4P .Y3 (#U#1E9#M<$-]NE,C&R<.4P9<;Q3  E74JUB+@V(!L001\1K5A
MM,Q#URHS9RL:[=H@<5FK9\U7<I F8"*"H@DJ=4@$.( .X!L([#J6CD4;F4A3
MZD&LDW'Y^/$,C(@F2!K69D95-]18D &XU&M?6TQ$O5C-F<I'.W!/)WH-GK9=
M8GB,!%>Y))4YR^,P@!MPZ"/71HY%&YE(7[0:38&=CQB;(AE2(VLS(R@WU&I
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MK$@MRE+XEHQ-01,1*-6*]65WV'<$MSE$1]_8B?;^EJ/Q?;]^GZ?MJ=VW[J^
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MNLK1D=NXBV+99M%9K*#?K]&/+<%D<N_T^7&=<M+GN"5-ENVK"0'?K)=M8K7
MNUM=.8U-QM8:WRXI6)6L0G;H3D)B/+#60<+2-2J=IR+=<&+SUPQ]-RZ[6818
MPR[1I1PC8^RN2D'T\LY.#M95$02^L\CRD6?X3/S2E\7.XO,QU2RNR0Q9&V.5
M4)'OW!]QC'0JHV@&Q^:8/'OA>4P\80N1B\ABS%O<BM))!>2,L!HA4IM#D"X+
M:FHC83=RR%BOF!D^S.WDOE2XH+4&30"PC)U^!JQFC&ZM*;3SC+L8MC#(0%6>
MG<O'2)(UVC$,T&SAXZ?D!WW4\7%\=S/ \7B(B<-%^=?80TC@E.Y,;$[][)8
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MJ]*K1I2HU4<*_OA:-?FU9!$<:R+@8(S(HW(ZI;1%IA+(R/I!.6LI$,**B/G
M!='(;QCMW!LJQK_@]Y>UE;_ZD@[N[_AP.PY[93=;O'\0;;^ ,-VMCI#S2?\
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M;TI7U%(J*9$@Z]NXG./05%#=3JF_SCG$3#^W0FYO2L=N +&,[,&_E 2H;_\
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M).72Z8+1C!XT;JF$!>'4[8\Y0 H@<2G.N_<$-[A,5$!$! 2AH0!HQ!/P]?\
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MHWXT\3RFFT5Y0%'Y%<;4<Y6H,W#A2)11;FW4#TB:9"&4$FVP!KX%]2PY^EG
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MQ=G>4:N/9J052["LBR,A)_V$B@H''M,.L.7/E28C/*8!W'7=M<,[$ V)4.P
MZWVJNMKUTOE_/>5\AXI-E<H_!*,[)QOF?ELV*;-R6CC<Q2R8Z9DZ1(#<RF"'
M'_.*]U=0*@GC8%?/EADZ:,(!6,<(71E1WL?)OI2RQ#>)8UTR->M,4-VF35!O
M$5651.U:.&RYT5))4'2C>0<F34['EN]\D58MO!4O< *;EO<IV#==AJ0==HV@
MJMQ]*^KO]57PB2&>7*7,5L1\Q'C2/'E:5Y[SXTGRD7S32Y,;B26.1 ZP)V%E
MQ80ZS[A^=OKN]S[.Q9:Q[/UE_P#/I.I4%M-0MMR"SB&<NG#%D'%AA&-31)%Q
MTRP?MUDCLI<Q5#$1%\!VZ@*=9G1XRXZM%#*LPL&>Q5"2+VVDMJ05(-UTUVZB
MWS'SWC/&8/&L7(XG@^5Q>8B[,>3FM%+C8+RM$9=BP3/DDR21/"ZL)L4%0TGR
MQ65=FT>NGKXQ7&S*U%QZ[YWH6F0J;]U9VV6\.+MH;YC6FV0;,_<1^(U#Y'HD
M0MA&;G9O$5-_1,/\X7"Y1XQWR>>!(J)'3A![]!P<O,'C/RZR 8_R\H)LW;47
MF_+<B95$K[WV#M-NWQ7O8%??_A/DOE4'^6AN%Q<Z).&?@N5#2[,AL''17Y,#
M S91R\,,/*9?S>5\JG]*G[_S7&%S(T,4F/V3U\^KP!7.'DV2S<>,]5+F! P,
MC9*"K5#8WSG%PR(N9..KOK2NHJUI(]Y0,DQ5!(#F'9,IFI"*'(5;O+NG!]CF
M.)D\<E=4R^YW("= 6M8I^O7]I(O:U>MOHXW#_5;Z8Y_T%Y/*BQ/*%S?G^'DE
M.V.2?85DQB;=7&ZPU8B1F56,>UDWG!]43#'!ZNXPE[73+_?I#,M9F+/0&-41
M@F4>LSB$8!80L<I-2S5U"$<ELC<2F19O3@ 'W)N4"F>,^#\EY-+/'!)#$N,X
M60N3>YW?A %C;:>K+Z:UR_\ +C_DR^H/^8[E>9P>$Y#B^+Q?'\R+'S7R3,[A
MY3./R(X8F68K\O)<-+"+[?=8W'EZOF*.?7UA;UE7EC#8N62JU/JWI*/$JN74
M57U(*OO%56&,<5OY1N@-UM9?7/'[M8OB15>G5 YVZB[5J/W'$Y'Q/Z=XD/ 2
M3WGD?WD6+;F&LD@!]BZ #X"UMP5F'[,>,^<?Y8?\A/C7"?0_D.:4\UGYN[,E
M"K).)IU ?D>12-C\IC'9%#$IW.L03:LJQS3#>O!G^\"7W"E 88EY1\=[3:LI
MX\CT*RZL;>?_ $1/S2D0@5FU_7=7LM?6=Q%C!)$@/7*1C X5[E/3)B(E'5.5
M^E&'R.6<_A,R-,&9MP6P8*#UV,'%UO?:/0:;C7FGZD__ "77C'U$\HE\Y^C/
ME>%A>%\K*<A8&A^<@B$K;F^3R()U66"Y/:C8#8MD[S  B,\:U?DS];KF/0,V
M90H"N/>*V)WC%,Y42/C55G68B53G7M'K\U((,E+K>KU($31E'S=)--FT[3G(
MD5!L@KSLV?A/IGX[-QF#-WN=G!UTW%B+!R!?:B#50;W-P"268;CY?S7T>_\
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M_'Z!,2=QMS !O2"'<;<=S"0 WUY*6^T[NI<_Z?W7KU5:Z+MU&T?PK'7$/[.
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M8.E2%*<QFYP#N0470$>XH!N I]2#U'4,+CW:V_:*D?960U#L7=H-Q%JJ10'
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M]33>N$RWI]/M]Q7C'<LA3ZG9K:O$Q2(*RLLC6(-_.*Q<8F)3 I)2*; 44"B
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M987RV:TMF[:-IEJJ$>VG*^<)!">(HX;HZD"ZGK8TOJ#_ &A_"H_A/K+U6O\
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MW,ED2G!RV[1 Q0*8_NGQ](>5A5<^*$/$;.DB*2DNP;B=&4_[K_ _?7C+F6;
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MG;Z)3%W$WP__ "LAU\91Z[C]OLZ:?\H^(_\ QBW_ *JU/_YJSZ27L?J#E?\
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ML$1"A13H38_?Z5%K5?2"5C_*Z%H4J;E0SE\!8Q$2-%!+V"HF(M1 &R*9 !0
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MZ83&3>%E3I7=O37LX-;5^5>E2B5TE5@5$QS*(K')BN-URIJ]Y-MC^&MO>7W
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MA*)2%]HJ!]QA"FU ;D]/MJ-+6H16F&:)6H-5#O2&,0"&9HE4=JG R@.U#BW
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M/Q)@(_:(FZ:=?6G\*0K 420EA6__ *>G#3::(#[$G!H]RFHN >P&IC&$A!Z
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MT '*P'0:&,40^ 02[TSA[2B8GV:@7"V_M5.A-8<<@)Y.,56/X"J)2*2RR_\
MJS& I5FQ@VW.HLHQ NQ2@/L$-PU+-["!]GZ?MJ@.OVT\Q<M&X;,T.]4!ZNG1
M0,;I[T6XB9)+]IN\W[-80&/4Z5>Q]:QMG3Y41_-<JCN.XB90P![]S#T(0 ^T
M0#5M%%3:KX(LT-O4KBN?;<468E$ _P T[HX"F4=_;VE/^W5?>>G2H(-?0D#$
MZ-4$6H_S3D**BX??ZA83G*(^_M[0^[4=L#4G2K:5BO$7RK)ZZ5 YDR-7)O.Z
M.)$SF!(W:7RKF#N$QA#H41-]FI#(I%OW5+D!=*;+1NS(S0(LL902K-)!RDU2
M,;LBSM6I?"*C@2%[G!!-L&P[@4VLN]F-UT]-?C6'4TL$<,BR)W*;4#LU"J>F
M,\<'4(9XB3M=.NU#TZ8$.V+L3<1#8AQZ[[Z6;98GW>OW>@JPZU]9.'"JBB16
MR)$$T5 8)$9D-LP7'90Z@F(H;N#?L#<=RHB4/>;5"$&H/N]?OJ!H?LK(:)3+
MPQD5Q=>F;I@HS*Z6! CMJ<#))O#E5.F @F3=(H;;B'QC^(-2S1J+C4GX>E3H
M=#TJD$WSI92.7?I&;M@#O47D2J [2#8H-0."BH* @)@*N(;[AV@/XC;1N0>[
M:;_I^@J+C]54 19NX)')R#03K$$[945U3E:HEW X+;(B/<D/^I*/XR_<0PZ7
M0^ZQJ-.E5BW)#@0A9%J9HL<Q4"I+.3J$?*")_" &;E[A?*B(E]P*".X@ ](W
M*_H;C^%3H*K(W>LCJ/RR: G7["OB)/E"E23+\*:B("5/N(VWV4V_&7<P]0#4
MDQGVV/V5&@UJI0DN\62>MW .2L^[TQ2O6RP/P(<1.&RBY@,BF.XH&V$!5^+V
M;;@4 (M:_P"G_35M#J*B#.>!\<\DJ@C2<I4U*RQY1._BYANA\NL=756**"TC
M!SK%'U<>Z< GXCI&$Z"XE_-3/XPVJ52]V-+V.AK25Q],F'<-"5A_RPY9CC@A
MS(FQ^CD K1BI&&-L,29X=)9'T@I? (>C[1#KV@.JV] VM7W_   O6[^#N/\
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M_7CRS^DX6-B2S-AX61OD!5"RK/G3D8T7N #"*/(5KV64'6O2(%6K)1 0KD$
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M[!$(Q.OI, *9V/I4ZK.O+-7R)]SH=PBYZ06<I[[[G4$#;EV !RIVO=VUO?\
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M-JL44:CI;]]>MERA(,TU739HR0*@CL=#PL")N") !2 /<!S)N1  *53M$3=
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M-;8T'_#@!_=4A5.OW%&)@U[/>;)\X1^7.)2+36KL@R[6+.:8C%N)(L DY?\
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M,.^P';U_":QG7[Q61$RZB:J+5ZJ1)_N?T+U(Y0;RR*>W<HB(; 1R4! JR(@
M@;?X0 0#5672Z]/7XB@)/6G89NB^(<Z!4TWA2"<[9,-B. VW,=L7J!50]HI^
MP0_#[-M80S B_2L]QT]:9LA)J-EA8,'/I7YD3*+.RE$X1;8P !EC%((&,Y63
M,((I_B,([[=H".N2 I]QU'\?T]:H]P*H18(BQ K) $G:_C2)'F 3)Q[7P@1-
M^[,4_:JZ!H510Z11$41,.WP_%JI.NO3^/V50 D:5G)J"FX:@Q4$H^0[ES(G
MABJ)MT3D%)(ANY(4BF5*'L%(GL#N'46TN?V5)N#:K[E!)8S,\:0S=AW.%EU#
M& 52JD;^,_B,<>\R*WG 2N#^WV!N(=VH73\77]/TM67<+=:MHJF*HS08D C4
M[@?*;^\)$17.J5 # ?R'$?\ GC[@!A 0[AU+J&!W?B_3]+5 8 U<E&Z2:14H
MKXVKE5(I7I]S%*<SA(%$S#N(NWZ7L4V'8-MQ'^;I&QN=_I^G[*D^X:4C63PH
M5RR(I$%588*8.Y.<W4N\:YW4>+@ E*(%W[" &^W0I0+JRW+@_P!F^E8G]1ZU
MG1:EM]!!#'.*T2("(HW8D^:2RDH"!#&&WE.LV=IM!67AQ0+%B! !)T"AG '3
M$I0X!:#7>'[EVZ6M_N_OON^RUK&MAQCP/R0&8F:>0VY%RC1"/<8U^4L&4O99
M=YR=;M&4$6UP2;J)\C=J?J7M&$^T5YO3QUB*41+979YSQ>21,( K31039[[]
MDJ"BBG<W$I DMA^@DMKZK_*+>G\U[_[MK:ZUS9&\0N>S'RFW\VVY\?\ ^EU$
M-[1^F7O:6W7&**EI0S&/+=<\O5]RNSCJY%SG97'LF$C#UNQR3$CQ2U+-&*9$
MDY,B[QY&UH6XN(\@@X=N%5%T3%02$FN5!%Q\JAG8K[P+%E!MMO\ #H6O9N@
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M:>P2B)EO*3Z<JQ7B9>08KPD[8,>,Z]7T&TP<'$FR[5RH.&0)('73VG&AS_\
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M3P?\M>S7[RZV$+&/$XZ3F1=+!$1D@LW5=HL9&3%'T+%VJU0.H5-4Y#F3*)@
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M"W^J/(]7$^3<-XJ?2=$0C9>HU2\W:LY K<9).ZI&P[0L;1"LGD*T",;,RH1
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MFN%SOBOB7CS1-)S\6<DAD1QB0,SHR=&!F>**2%C==\<K$,#H=;9SFS9/C+)
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M.NUBA[K&U>H7R$2BZY VV'K[:7:S;ZSKO[8WFHI\O)(J1#%ZX59LQ.BR7 1
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MW07M8C]5_N]BCTZ1UR>J2]/L@W,BX34V0*(MT@*+=TF(>(H@'L-V@8/M#7B
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MHEBW*9$%D1:/=@2/W=VY##N ZM"H#JH)4%AJ/37K^JNQX0=SFL2-\A\5#DQ
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M;&)C$9=-@JCV=J@#XD55$JP<7FYW&DX\L<L ?\-@&8A6E(4L1N<+O8I?[.I
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MAK/8:?I]@I9;7]/N_P!M):%^YVH*)BQXO\=VID3 9'NYD7)8B:A3=#$=/^)
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MA8:\J5&$.R4.B'>H41<GW* @ ZV'@.9P>'>1LW!AS0X6PDM[+;KVNCCW7%]
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M-'U;H>U,'!RJ1IM^]R8W_1MDQ'\LA/;OMK%%^+]59)/P_KK&8F547(D=Z?\
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M@6*1@;V_,(O6W>1?5;Z5<AP7DL_ >78V#RODO#/EY@CQ<B%QS3YO"HT$*0*
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M2X=K9%=<%4TE7)3B4P@ #3%"2.;^\JC';KJ0+V-K'3J0/A6L^+8,&9R$[Y$
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M,*+CEN QP3>0^[*G4%%EE52=B*&98H;V4$EB6T',3A9/'8)GER O-SD "/\
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MS?\ U)-;GY2W9?0CI\Q_*;7[6ZM*<O\ \Q8UW<;V_P"BR:$#^H7^:BU4VO\
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MX0V^T1#;V@&LD@]M4C(W5G2Y>YX=,FW:V(DW#?W^)),H[>WIN&_[1U$0TO\
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MP0^5(&2VX99DC-QZ@P)N O8BX]1>O4OU.^N@.'R7A:YODO(KD8AC[\?E;Y^
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M!141%51&/:I-$CJ"(B(J'(D B.X]=?-)9#+(TIZLQ/[3>OSFY'-DY+D)^1E
M$L\SR$#H"[%B!]@)TI3U2N'1I2C2E1LHFI^]]HKZ*H"B&-I!,9$S@GZ]*H-G
MC# R0:>H\HU Y0%153Q"4'I4P[P$=AV167_"#IOS-_\ 4D.RQ^5MV']Q:UOF
M/11NOVRQMZUI+H__ #&CD[7'=O\ HD@[A8?/W^:B]BINO\H1[G;9;O!!N!T,
MDZUNMVKQB<I6L7-\K/J8Q;5]%5J8'D;QO!Y*7&W)Q%:57+1[X2-<MHMO .%T
M'(,SF$#&65%P*9U/A[  ?97BT\^%XGXMDL))8C@9X58DO)_>Q7N2UB/U:?;7
ME7R;'AR/(?((MT:$YN&2TCV0$));HO[=;]:@B$R&SA*M-5N=KM9M$"[<+%=Q
M$A,/T#$DH!DX;#8X>1C6["3A+ Y0DS)QYTE#I+J(* LFH0@)#WN5QQR,F/,Q
MI9(,Q+6;VDA)/Q(X-PRW34$7'H1>]=!!R79QWQ)DCEQGN2HO8M'T9+6(.IL0
M=1J;]*?C2?O\C $QX%P/;,;LG4[)0=8J,/\ KG)%(JU09/:U+PLI*-9&D%@H
M.<@(]FS=/56SMO"*1JA48]PHT36#K9\+C$R_ZM% T7*@JK2NW:@EDE.X.%VN
M)'5BS!+KN#"[C=:N7%F\B^...ER!)QIN5B11)+&B>TJ22I1=H52WNVE=%-KU
M6DAC:EP,H?'^%HJ+&*8QRQ)*T-U\DV)['/36 K6(2E+@9TT4<0K6><-7KI!!
MNY.S5(1RJX/UUA4\MR&4K\GG.[O?:J'Y=%-E:Y2,^VX4$7)&[46Z5S&7 Q,8
MK@8L:6ZLP[S,!?3=(->MC8#30_&LF+D:&A)J1$+B)",@W[:9O$_%W:)6LZDK
M*2[E:4490\].KO9RO,V"2AD8@C-= Z#TSE4#^H %CWS(\_Y9IYLUFG&V-6B;
MM[0OJRI8->P[A(-_:#H;5@Q9,49"0)BA87!<K(-^XG4 ,UR-NI0 Z:GK6/&!
M"T:33O.):-*XZ>,EJG8YY"0;S-UQ(B9V\BZY46UF-+6://C.-I2$0DH8QV\^
MC(HIE%T@<R2:A<;297*D\=S\PS 0Z+M*QY#  O)M94;O&2Y UC(-]K6O?*(\
M3C9OG>(A?'92KMNW20 DV7<';\O81>_N!N+CI9!;9!DZU8Y";M4C Y,RP[.\
MBGF6?G[EVW9@PE;E"-UJ;#^A;Q4;)-&UZD#NA>?,Q8L5D%6ITE#=>8>)Q,C"
M&'A&?#X=3?Y9E 8[C&29#^(@E%L/;<@[@=:X;<K/!F'*R!'D<E8 3@EE !D%
MD'0$!VN?<0+;2-*D7AVDZE.6_'JQDL5(A5$<J+,0C5K&H:?D'",&\0E)2*C3
MPX!+MI%DZ40V*HF.XJ=H] -KA>:S+!XAGX@BR'C;%&H6R*-]@#KI:PTKG>)1
M/-Y5A9/<A5TR"+$G>WM-S:WK>U>M\VWC;;& _P#9&FQ@ 2@8/3);' H[" &]
MNPZ\>#21P.FX_P :]7#^[7_JC^%6]7JM&E*SG0_^'QX>[=V/\(JAN/\ $4-8
M?^\KD)^&L9$ ,LD4?8*A '^$P:R/^$UA3\0K(D%!,]=E$ Z.5QW_ /LIO\NL
M<2@'=660^RWW5<8#VIOC![0:;?P&70*(?P@.DHO^RJH;#]=8)QW,/\'_ !!J
M\7X!5'-V)I1<$#T#$O78/5*AU#VBL)?XMBZPAOS!]]9B/:?NK 0#== -M]UD
MPV^T!, ?^W6:3\-8X_Q?JJ\_-W/GAM@#=RM[/9^,=MOV!I'^&DGI]U7V@]K2
M2.!0$Q6Z10W^PSE'_P!NL<B^_P"^LB'VBL O4X#]I@'^765Q["/LK$GXQ]]*
M;T \# @>YL<QMMM^X[E8>O\  4-<9&VZCK69Q<'[_P#1544V,JZ2$O1--9(5
M5!$ *F 'Z!N.P"<PAL!?:(ZEB6()'2H4;01\:MN'@$,LDV*)4E#"*BIM@6<#
MN)MS[=4T]Q_ '0?:.XZNL89;W-5,A5OC2!;V9WF/+L@2--+^K@I!K\H35,@K
M+]\:^ 8MNJ1-4Q578G FX$-MOOL/L&<6RY"7;: XU^&O7]5=_P".3+!Y%@3O
M.,54RXF,Q&X16=3W"+BX6U^HZ=1UK25''1ET@CV^"<UM47,U&-'DFME8[J-6
MC2ECVBRC3O>KR+: ,B!C'0(U243%+<#)'[CD[\Y0+;OF,?1"0.WK?4ZZ6+7Z
M&YZ^M>AY_-!$YRF\H\;8IC2,D0XS;()/S&&\A%C?(O;:YE93NM:1;*TC>C-5
MD7%<E.,=@M-?J7S\L=9I^9@K"9S!M)1^^;%3E;@5W.*+._7K+HH&*5%,JAB)
MF$.TRG%8+,PF^:59'V^U01K8 Z+9;"PN>OV?#6)Y$YF>/F,?S3%P.3SUQ]^-
M!%/CVF:*-&/:Q=L*JI14>2Y=BH9EO<(ITRHNIR0R)<V6'YVB6.T,';-PG;[\
M]90=A@;;\P4DUH(()I-N(=^V4<E4$ :MU0</#B!TS"8#8Y\CMB/'$Z21(;C:
MERI6P%]UKC]9%@*XO.>11\;B<5X_/Y!B\GPV"P=/E,%7FQY\;8L0F[S0K,C
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M+40&39$(!U&ZX)**=%'S<>3QL6+RDJN\,JE&;\8B!(>'<5<D.-K@G\+7T()
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MKP<,(V6"&5-B/"SF[2;6/M:,)[G L"2$OK5,Z3B.-5,&.,3<KW TTJ-O*3!
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MF\X#R-30K4VH=)_+N$(IJ9#9D"G3X3F.)5%.-+(L\2#YF%=5L FUE-K&[ :
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MHVU,,NRL<R/Z:&8+&-)GFGZ2D9Z!\U32*=NFJJ=<OD5/WG5VM%FDPB0S8Z2
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M75M-;7'!&1+'CR87$%(LG/\ SX@!OE]H)>&YL%=7+[%O9A\":FS!<'"8OQG
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M#)H&6<*=Q]MG"9AZAU.H8 'M+[]M5MN.E3TM5KS%5,DW;%,5MY";$Z"HL;N
M/(L8 W.H/N /A+OL'VC!%NM6'Q]:RG:B;5RZ.7L.X.NL8#;@9)J45#[=!#91
M<0_:4G[?8]=.M1J1KTKXOXR-V*SDPB4R"AR)=P@HY44<*&,8QA$QB);"&YA#
M<WL#[=3M)J+BY%5#^:R(NY.!4!<J&$I.FY44B$2;MR>PA=SFZ_S0W$=Q]KKI
MZTZ'2KHG*=@DNXV(U.JH=-!(=O(" =B2"8AVCL)U#B<X]1 /MV#34&QZU'KI
MUI6;D [MLF<2"HT;@L*8% 46HJE[@ 2?A\ISF I ]H 03#U'3[:J>GV4W9QZ
M5=0&[83>D1,<=^X1]0N<PBJX4]HF,8?9O[OVZRQ?#UJ'_#>D#6:L-&E*-*5]
M YB" EZCO_P'4%0PL:NC6-S3ZCWI))FJ@J8GJBH@@('^(KE/VH^0/8!TU  .
M[V@!M<8J5:]JRW7T-8#KP^@;E5.;Q$,HU!0Q>YRQ5(/>B14H;"( 41*8N^P@
M4#!UT ):_45;U(]:H? 45B).C%)YD4E4%P,)P2.J4/(!C;"8[518IC>\2[]/
M>&HZ]*+\15+U0"+F2=ALDJ1%;N#M.= ZJ1 452, CWIG.41$N^QM]^@Z=3:I
M'2XJE<QVY&)P,FJDJV.F8-^Y!PDFNJ)>XOM 0*<!#^<0?O#4'32@LUS5/:EZ
M)XHW,(I JU,8AA#RMS 8X=IQ#\1/B#M/L&X#UV'?4V-M/6E]=>M?6:J;IRW\
MQ@(Z!='L6]A7  <OY:VW0%1+T*?WCL!O;OJ+?&H.@TZ4GBL=L\<$,7X3&.5=
M%4H@4Q2GW #E'82F+_-,&P@.LMCLII>LYPF Q[95 #G;F5<F'N#<R)CE0()#
MC[!+WE'8WL']O36.UOU5!U:J8U7R/&Z;D!,"9@,@L.QE$@2*"GC.;_G$![/8
M/4/=]@V)&T6.M+$#[*2E47+9;?8Q#@/E24(;H8HB(D524 0W*/N$/X=9MR6Z
MBL05KW%[7I:$HNX]("E(1RH[<*>(NQ"N1323*<R?L335W-^$/Q#OMUZ:PG4Z
M=*RZBDUN9=-TD">_YARHJ$,&Y5 ,H!!353-L!@#[!#<!^P= 1M(]:6-9D@D"
MKATX0,)R^93RD'\:(]X@!A]QTC^XP?A]@_:,4%Z^1Z@)-'X+%$Z)_ 04.[MW
M,=0QO(0_M(H4B8[#[/MU+D&UJG6_VUB.VPD*11(WF;J'#QK ';OL&YDU2[CX
MUB[]0WZ^T-PT0[3KTM4WN+>M*2ZJ78S:N V3(R0V5*7=1 ZG<J)@]@G3$#AN
M7^+5?6HZ7-8[)L=&31[]A( BN14@]R:B::?D!1,^P;E^#]H>P=AU<GV@'\51
MUN1TI#'<PC]IA'^,=9_[/ZJP#\7ZZ53#V12@>]1XB7^!)%8Y@_@,J&L2ZR7K
M+)T%)A.IB^_J&_[ ]O\ )J\GX:HER:59 0(X!(3!^2W:I>T.@E;IB8/_ 'C#
MK"%8C2K@@=>M?(_M%P!^@E2276$=^GY:"HA_$8-+$&Q]:D]+TG', E  'W_R
M!OK(BE3KTM5&((L*STP$D8H AU6> !1^TJ*([[>X0[E=0Y!8$5*"U[]:3.PP
M>[_BU<.H&IJK@EB1TI2E@V7(G_T2#5,0Z=!*W3W_ )1U2/UJ[$;:2]9JP4:4
MJ$^3)%3\<LY%15606_=)DH4EVBY63Y!3]"V,J:C!^8BWHWY3F#Q+ 0XI&'N
M!VUVWCW_ .4&%I_]%P_;_P!XOI^EZZOG_P#ZQ9?_ ,++_P!AJ\IE,OZ%8C*W
MF.RM*I'6*MP:>$;9,2[&6LY8U:W-"1V-\G5R@%DUH^1D86"4GX>85>@Z79M&
MZ#Y=PNH[=D'UMR?&/E3R<#B&63$FE.3'J%)$)O/CN^FC,$DC T9CM  45Y<P
M>03'6+FYA%'D11C'?0D#NBT4R)K9E4LCDW*BS>IJ0<%XV7:6/(UPR\PK5NM-
M4LKS'T)09A@QD&:EW?MFSNOVB[UZOO30;"NI8N%F>KLS)++2K18CI9),I50-
MU_.\EC/C8W%\&TN+A2Q=UY%)4M&"5>.,FS,QE#+*1^#;M!-Q7,X3CY5R<CD>
M55)LZ.7MHC -9SK')(+D#\NQ0?VP;^AK=]@WQSD#%63)_E5D./8X1(#A56?>
M6-"OFKV388@H4 :VXB49=1:U0R9%4T8AE&O$WZ2 (G:+I-P#6@S'D>/Y?&A\
M-@?^NH;; @<O$Y]XE#6LA-B7<BQ/X@6K=HUP\[B\B7RZ>/\ I#+??O*!)%_
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M]AKI^KT^VL)-PW:HOCD>L3@;TGB.#EN9-=-110"AV&4W.0XE$!*/4!Z>W60
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M7$A..V;!$A#F_=5D<$O)W>,B_P"A;(*1S@5!T82@(;#LF<=AZ%,.P#VOCO\
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M&%61(^2](P9)-4VT>S**9RE^$I2"J)AV30$$MGBR5CB$7S2V&FL9)].I]?\
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M^._2GZP^2<YSO+\7R,L>;P^=_3YFR1Q\?'G,:(2%85_J'9EDV[7,D(91&V\
MC;$)8QTTH.4*W"WFB8ZR*^IUC<#-1%VD,XK/*8B#5)\22C9HD.[EG[%C!.:X
M9HO&^B47155[%$2G,H4.MSVR\.9L7*DA7(0;2G:LWI8BX )(:X:]B-0;6K1_
M+6\I\(YC)\8\HY?B(_(,-.S+AIPJIEG<4,<D)E2)'>9<@2ID=Y4=5W)(RJC&
M-K'S#XLV6>@*#!5FH6:TNY-J[B6V-XG)M=DRKSSDL/&M)DSO#\$JW9S$F@1)
M(7(>B,J0ICJ"DBY)KL8/&^>@QVRY@\<(!N7,;"RZFUI3>PZVUL?B16_>/_Y?
M_KAPW$9?D?)YG(87#11,'?D)>.R(R(5[LIB"<K.&:*-BS",]T*Q 0/)"U.:)
M<XG<TV8R:EC88S#\.C95I/)LEE27-6:\QH\HM7+>O)II0;Z8,A79*%6:N!(U
M6.)V@#L<SDJBO'DBSQD#![E^0<KMC$8W$N R :V]P8$:]#]EAU&?B^=1>11>
M$/S'>\[R&Q^SQ\?&Q?,329D8GQ5C)F2*\\<R2)>1 !+_ &5A*IC9HRQ@Z@6=
MS!Y'QC/1=I2A$?DS#!L_8I%=.G+OEFJER?0]'K"TE5ZNHDHZ'YU((MD'!062
M3 Q@7-J_%\;R>7CB3#D0P[M3,% W6OL!=@&;I[%)(T)]*?3SP+ZF>6^/QY_B
M?-8LW$?-,)7YF#'C4Y:HKC#67-R!'DY(/;MB0/(Z'MNY [8J6\8RV,+%*4M*
M J\:+K)T)*S&,VF4LN.[Q6\@UJK(5U:6M5$+&QUTKZ@PK1PU.H[54:N 4>]I
M>[R*^/K<Z#.2.3ND_D,!(4CV%&;=9'OL(W$$ 6(]OV"M$\SP/-.,XW/_ *MF
MS"/A<J.'D'X[BUPY\'(R3.(L3-[DF).O>=9%6-5DCM#=K;$W17D>XXGB7F77
M=ZQ7#5]/$(5%OD,\+D9>!K]6C[<R4-69!"/8PC07GZI0,!VB;-([M\H4")IE
M<O&Q3\_!Q<]X\=<>1F.06[=X[EBI]PN3_9]2=%&I-E-;MX;XYYUG87!XOCG-
MY.6WD+Y)P!-@":?(DQ6_XE"[S-M^686F:9EBA4EG<PX\S*H\<[GBW*[JZ3V.
M,:PLK8:!$(I3=(R#9+/'V(2SL7)G@CHT:X4B/D3FE'A7"#=T9N@U7,HH1NH<
M"I)HTY;#S^/[<>;(1#*20Z!"OM(O[T<C0$$BY(TN!<D\/ZK^-^=>!+QO&>8<
MQD0<1R<S-#F8./COC_D/&)KYN+F21VC7MO)$'>1 J&5%)D>1MP5JPK:<;7/)
M->QCDN0QUC)Q=E<E62H9A\-;KTS3B"QN#.0!HO'NW3FI0A@=G(FW,BBBCW)&
M6*5$ZN>3&Y.'+CPW>(94^P1J\7N8/^"UP19VT%S<DZVUMVG+>._4;AO,>.\3
MY/FN'A\LYI,,<?C9?$[LB:++(?$>,NLBJF7,.TK,X9G?;(L;&14GAI9<:,\6
MTF[M:CC2R5;+X5AOCA_8KL]N-PM<GDUFL]K-70EE:B^ 5GS4Z@HI^N*W:G*L
M0JI3;=W5-C9KYTN&YD7(Q]W<LNT(([!F(W#H>NGPTKYEF<+YAE^;\CXM/G\Q
MA\YX\,@YZX^&F)B8L?',J9.0T0RD]J/M#-V2[@QL4*DVTI@.1W%V=G24UG55
M L#N?=52*2DL@6N%BI2YGE7T0[K#.W3%4C:8[E7$VB\8)D3>B19T)O#W$12!
M'8I>%YV&$Y3D]D(&-D5B$L#N*!BX&VS:KH.O4W]'<C](/K=P_%/Y#D9H_I<>
M(F1*8\'%FEBP^VDJY+XL65)EK$L!BF8M#=8MO<LTCF3=MWC,Z=/A(1A@%K*(
M3KXSF581%Z,KD&L)-WC<X)/)M_ MW$9&+*-RJ$2(NKV*=Q#"58>\-;7*!R&F
M^8L5%@2GL8D? '7X7_T:5YKB\L6;GLGEY?*9('Q8@L;2X5L&<LK"Z0I.RRN-
MQ4NR+<6.L?M."7'39X^59'P/FVN,W,HW:1LK.YE<1\'$@U*[A&:RR4;*23F)
MKZ" E7,@D@N84NP2D'L NKOEE!_YC&<A=0(M3T)ZJ+GTZ_KKFS^72P0B;_%'
MCF9+' 3)%#Q*R32$[)7VF2.-99RUT#,Z#=N!8;BU;;T:"&O)6%0:Q0:T9=&/
M*D%%>@[2DRJIJH@O)_\ @$"*1VR9%"(=%=TQ-U)L)1Z65R]@6=E^+#^&I_77
MP+R3/^?:!AG<IF[!(+YJ[=A+ VB_/GN&T:3\%CMT:]Z>9.QTENL?L<D+N14Y
MP*15,F^Y5U#B!2J%*&X',/7V#K"W7:.M:TJDD6N;GH/] I!:72J2:2*T#;JM
M+MV!"%=NXFPPTDW:.EG"9#IN%F;U=%(QEW"26QQ#N.<I?:8 '*V+D1?WD<BN
M!H"I%_7U%=OF^/\ /\=*N/R.!G8\T@NJRX\T;,+%KJKH"?:&;0&P5CT!LKQ<
MO7)1^Z&-G8-VZAVZ,C,QK&6C7;B+;N&XO(]VZ;MG*BK1A()@!TCJ%*4Q.H")
M1 =8VCE50[*P4DVN"+D=0/C8]?A7%GXKE,2&.;+Q<F*"9F6-WBD19&1MKJC,
MH#LC>UE4DJVA .E-QID2DF,W$+K2UR2J#ERT3+;( X2C1H9P#UTP$LB/JT6)
MVJOD52[BHF2/W"'8;;(V+DI_W<GV^UM+] =-";Z7ZWKL&\8\F'<#\9R*F%U6
M2^+..VSVV*]X_8SAEVJUBP9; [A?)/>L>^F9I,;]2G2LWWN8Q%.VUY5P]:LA
M6(J9HF21,9Z5!<AP4.D!RE%,=]MAVCY3)U/:DV V/M;3[#II^NI?Q;RJ)))I
M>+Y)8H6"R$XLX",;6#DQ^PD$6#6)N+7O7QI=*6JUDA-<*HO&QQW 2SU.S0:B
M,"LV502=G>KE?BE'BV6<ID7(L8G:90@&V,8NXQY&Y08W!/0;6N>O336]CT^%
M8F\<\A22*!N/SQD9 4Q*<>8-+O!*]M=EWW!6*E0;A6(N%-KUDM%2B#)+2UMK
M$4P*TC!;/I.Q0T>T6;R";@8M=-P\>HH"E+>C<&;#OLN"*G8)NP^UHHLDW$<;
MLU^@4GIUZ#TN+_"XO5,7Q[GN0F.-@X&=/D R K%CRR,#$5$H*HC&\9=!(+>S
M>NZVY;U05DJS\\JM%VBN20029C2HQT_$/OE2YQ5;MTY/TCQ4(]0[@!*4%NP1
M,4P!U =JR)D J9(W6XTNI%_NN-?U57)X+FL 1#,PLR'YC6+N02IW0 "3'N0=
MP $$E+V!!Z$4G+VBH),7TPXMM7;Q4:^-&2DHM8X5*+C)1,Q4U(R0D%'I6;&1
M(H8"B@J<BH"(!V]=2BY((A6-RY%P-K7(^(%KD?:-*NGCG/39<>#%@9S9\\0D
MCB7'E,DD9%Q)'&$+O&0"0Z@K;UK,:6^G2$>Z^76ZJR!&JB2LDHPLD*\)'H'
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M2 ;$BLZ)L=66<2*C2T5MV>!,"<JFWGXAP>+>KK R8M9(B+PYH]RXD5"))IK
M0YU?@* FZ:HRY!MNC<!A<>TZ@#J--1;72N-+P7-XRQ&;"S$6=2T1:"51*JKO
M9HR4'<54]S,EP%]Q(&M6FLM 2#ITR83T*_?,WZD6]9,9>->/&<HD1=56,=M6
MSE5PVD4DFJIC('*54I4CB)=B&V%YD4%T8*5N"00"/B#\.FO34?&L.1P_)XL*
M9.7C946-)$)4=XI$1XR5 D5F4*T9+* X)4EE -V%\5G8JI(M7;Z.M5;D&+!P
M#1^^86"'>LF+LWX6KUVV>*MVCDWN34,4X_9JS')1@KQN&(N 58$CX@$:UFR/
M'N:PYX\;+PLV+)E3<B/!*CNO\R*R!F7_ 'E!'VTKH&:.0.+9V@Y!/Q H+9=%
MP"8KMT7: '%$YP(*[1PFJ3?;O24*<-RF*(T,SK^);?M^[^.GWUU\N)+"0)TD
M0F]MRE;V8J;7 O9E93\&5E.H($&<IU#,^-F=%2IK+%'$>32J%00]0KX_T%9C
M&$B8"'QAV!V^T!-L&W77=^,-W/(L$G_Z<@_\5:UWR<]OQ_-(U(Q9?_#:O$'6
M+(C$U[*,L]*[7A6] >1\I#/#%*A+3TX1**JJJ;,B\:_<RM<>+.9U-Q'BK(M?
M0JJ))K(^9(/?W(XV^?#@BUR#E J1:ZQIK+K8C:P]A#^TW T-J\28&2?E\F1]
M(A +];%WT1;:'VGW@CW"Q.HN*V^<T]I>QQ#3IB5;U3'O'W'6.RY>N<B]=52Q
M1MSN>-8>V-\ U%5S'QDTVL$@P*4'HL(=V$:M*+/'R96J")P^;)GGCQG9T$;9
M')\ODS_+1J ZB**4Q-ER"]K$D[267<% 74FM\GP1GKB02.D>!@PQG(D8D$NT
M8=,=/6YMJ IVW);0"E66M3RB<A9//=6]0P#DN]QS.0[^<CE92C0&7L:1[F,M
M%'LKUU:TQA+)9&2"LC"2,@J^;/$%5$#*><BAM3C88S_%QXME ._%)*A",J3R
M02L&CD4;;LJ'V2*FT@@&UB*ID938GD/^(L4"-<]HV&Y2T2RH-KHWNL&/XD9]
MVA(O<&NE+S/? Z+K+3E)5X3%C7D+8+Y;DF.3T\P0#N6D<CRF.64 _C5VGSHL
MM+5TJ)6KQO4W#H6;!9=%;N,*A@/\M7QGZ@S3_P"#\I\L^/10(S0=E]@B$I<'
M\-A)J091[CJ+V M](?R'PJ''_P 40)C#GGF=1+W1N,O;"_&_;T![9]HT/J:Y
MCT:80L.8)7D1:/7OF&*J=D3"(.8XTA4J9=LGY/F'T'<T*!)(620D$H^DUNTS
M"4K86IT&HR:S06R2H(J /U7D\<P\&GB>%M67+R(LHBRO+%#  Z"9=HUD=4VH
MVXA=VZUQ7SC RNYRS>0Y-VQ\6)\>XW*DDDP*DQ&]P$#/N*V%[6O3<E*;^[[&
MW(G$S:P-+75,C46ZY*PGD*".]F)3*$5C@*E)VVJ60L9'3TJTNV.*FW0=G;R3
M"/D$$"OE"MTFCM/NRIR<?+\MQ7-F(P9^%/'CY4#V586G#A)5!(4I*Y(W LM]
M@O<&W'?#?C>/Y#B=RR867#)-CS)=C*(BI=&ZD2(MM"%.K&UB*UFR+8DI1S7Y
MEL5RA$2^/X>2@(.+!JNUKJ";=RRL5>9L <S@1[IG=V[]<P.E32+@KCN>['<*
MI&W[A<39#+CL?SX\EDD8WW,3[D8FR@_ELH]HV BR= :TKE,CWPRJ+0O"I11:
MR #:Z@:V.\$FYN;W/6U>DCZ=*TD?ZEO* AIL'D&7B'Q;-'09K":06AG)L:XD
M%RY^0>58]?1E4O&)?(8YG!D#&*<X 8P^7OJ)V1],N)"J1..7Y'<VT@'\^:PW
M=&M]G2]>CO!^Y_S Y$EAV_Z5A6%^GY46MO2]>@C7P$=*^U4:FE&E*-*4:4HT
MI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4J,5&Z/[YF;O
MY;;!7#&,BW"7*K_\HI$36J*4&-71\&PVQ0Y052-Y V9E4#M'VALZR/\ X,>+
MN8G;_J:'MV_XF_8<;P;_ -P![6%O[PKKZ5HSPQ_\RX\CL<AW?Z%(O>!_X$#Y
MJ(]MEV_^;)&Y3N_N0XV^M2=K6*WFO%ASIAPG.8/U"H2$3D@>2V>N)$?-R+E:
M*<1K8CZF3Z1_0I)^DFTUFD>KN4ICNTDW)TS^F62\A2^T?",B3%\-\:GG[9A&
M%R10"^XD.FC#4$$_<?MO7E'S+'3(\FYV&'>'.7@[CIM%U:Y'0@Z_;UZ6K7NE
MQ+_.,1<WV.&#-ADVL KC>J4UU7+,K^E<>6^/>M7,76;?C/YU-N9>:O-4G#2"
M[HC)<9.2[T#H%.U;#W?(9#>/9\,?+%I.$R",AYMR$O-&5(9TD** D;Q@;01M
M07!LQK7L&%><Q9?Z> G)0@PK'9AMB<,"%= 22SI)>Y&K:$:"KM'M\)D"JU&A
M2KN K.7*@]?U&M2-P%.*)<:O$, +!5[YZHW4AHK(U)5B%X;T#T8Q5Z@*!"'.
ML4Q-<C/PY<',ESD$TW Y/YI$1N8Y&_&[+HQBDW!V92^PWO84P\A,G"BPI3%#
MS..#&.X#9T7\"AO1U VA2%N+=36VUEREC1YB4O'W*G'ZM<F<JO#.YW'-+7$E
MGC\+0GHW"3^:M#^M;7:GW:TR3MF_^5LI5F0D<Z:JO52E3.V5T#$X7E(>:'D/
M"Y\O$<.KA9IM8SDN3<"-6NDB( 5[C)^(,%!N"-QRN3X[^E#A>8PX^2Y!Q>&,
M$.,<="SLMI$9B=VU6_"03468;M'$K!UO:Y.LGT[#Q](AXF'%]:D29%O5QJ-E
M7C'\RQO]0;9?D;)3FS"P1Z +1+)=JDNV5(D"3Q,Y%1-WG.X7F_-\>W%P>3]W
M,=F;M7AC61=P0Q,8 LA()LQO8@].E=3PV;XOPV7\[F< L>)&/[P=UW5NHD42
MDI8C4 BX^/6E#*[]G,VXV3,KW*C.Z;)V)GY++ 3Z%T>Y/^=2*BR,KC5E'HNY
M:QSDPS1\:A3-F 1BZG:^.W.F<I*<+!)C\=_2^'Q\I.25+!&3M#'*@ ]XDV5-
M20;MO_L@WJ.8GCFSSR7*3P-Q[-<E'WF;=>W: 'XM "+  ];6J":S$S_(2QY+
MR-8X>#A<#2:1ZY8V;R"N5FKM?K-.A9[(-:KL*SJ[9S7Y)[4:E5$!<F<OVST2
M@4!<H_-VIA[SDLS&\;QL7CL:0S>1(V]2&C4M)(5C<L6LRAW86 0J?@2C5TG'
M8^5S\\^?D+VN#==K J[ +'=T46N"553>[ _ @,*?W$6POKMR^XM79)L95PQS
M<K3;38'J<(PDK0JS^<2D5:Y6/AI%S#1UA9P<F@QE"-P5]<6.:+(MFIWCE<G'
M\R@^0\+Y3CW:V[![J(K,PCNRAH@S*&*%P7%_P[F&XA0#SO%9?G/*^/SD75,S
MM,Y 4N0K$.5!*AE0A3;KM!M<DU[.2@446PB('$&C,04 -@,'HT-CE !$  WM
M_AUX@E)$C?:3_&O8<7]VOW#^%?-8:ST:4JI,PI*%5+T.4Q3 (?TBB E_E*&K
MACT/2H(!K+>D*"YSD#8BH NGMT#L5*"@!L CU*81#^#1JJ">E?&0]QU$.FSA
M(R8;AO\ F (*);?YPJ$  _;J%/I4MTO6*8-O=M[=0: UG;>5BF;<.YLJ*8E]
M@^)<>XAMQ_$ *%$/NWU:WMJIT:L(FY3E$!V,!@$!^P0'I_+JHZU<]*4UFZ1E
MSNS?"V4 BPB7H8PKAWB@G[A4[RB'^: ;CK)J=/2L?\:J27%RH= VP)N$3-TD
M@'M*CVB51N4FX]0!0NW7J/</OU&AITUJPDD1LF5=8@=XA^0@8!^,Y1'N64V_
MYE,_L#IWC]P#ITU/6IN>@JI81=-DE#;J*H*F2.(]3"18PJ(CN'M$#]Q0#[-.
MM0+@_9513!'F "E 78"453?B*B3<!,@7W"J<.AQW^$/A^W2P%+D]>E6U&O<Z
M,1/;QFW7*81V3(@8OE[S>P"E*0>O[-O;I:YJ02!62"B1T5V;<!!,A073,8!
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MOY+&YOK>XZZWKM?&?J3XSQ/T"QN0\HR?%_)!/YMF&(Y:9V*F/LXW 4*(\/\
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MQM 0%4@)1J?U"*:B*CDS5,BJJXIC$F+F\7RV=RG(;(N((RP;QA6D$@E$:J2
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MVBAQYHB,.1=<F95RDDEG[<[",B*3='+HG1%9PY,245:!S&YL[S((TQDU:15
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M:WCQM)R-\BZE862*4?!E5HU.R'$2A63CUU@LL_+ED9M[%MKP,>1$&#1JXCR
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MYV]PO$;E=NZY)];=;F]]+;B =OX_PGZE8.;%X['RF8V;_3UG02\3([O N/\
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M< [B;G<'W;PNFT2!/^[VIM8R,8K4Q5#@B<XF;LUS;[I'.'<L'=_,1'<H"/\
M-,;?[==2!IK7Q)P#H>GK4+(X5J+1[WB%H.@VD)Q[%PB]GE%(&O+V-E:(^<3@
M(@%2-&*4BE<GYA$WE.F*A 2.1))-,O,/(91%CLO8 G:-S!2I&X]3;8O[[W))
MK?)?J)Y%-!V_^#$[10I+,N/$)YQCOC20F>6Q9S&<2 "VU6"L75GD=SCRV!<8
MM9MC=]Y:'E:C%((.9!*:*#5.'AH6K1JJBXOVCX[8C2-I#(JRS4S9UVHG4*J
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MZZ>FJM'^09*>>9'EH;%<!"STDC9T$&;ENL^CDUR ?Y@<4E&P\7CIDBEDAXO
MF&)!%VGR%8%A*#L&V%&F9T&PLP(5ATVBX-9LJ"1H5FY++C&3-)W5@*D#MZL=
MTCK&%8[K"VX?[VA%1T^!! KAG/X]RYB<'+5T]=,9JI.<@UA*#>M)*0481-TK
MT5&FF3NH&0BTDWH,G$8[>S*)DG!6IO,/:XTA<J</)P<YC_*XBDN+*2\3D[+-
MNNI8, A)!.E<&=$6ZY$&5AQ:WW(TD9O=@%D4>XE=MB 5);0@:U]WD4%5']QK
M=R@IE:&KS^,@(2FVZURUJJ-@>J&J\JS<N8>NL8\Y95TW4<'=* 0J3QNL*93
M= F8SX\G_P!;Y8GAW,&D>2-$C=!=@=7)TN!8'4$?;6+M3H__ !:NLMAM54=F
M9"?:0" +=#J1H0?LI5KS:!;3%9E+>SGN/D0230>?K?(<6TM.392G62($6$S#
MXS:.*M+T]*#D32#5X],U<,'SI,O@?%!LIOP<B2>3'GAX_M<M)L(,4#%(%=3[
M@9B&5V8;2%#!E'5=17-CA5)HFRVEX^,L+22J&DV-T(B!#* ;@L003T;0U(RZ
MSE"3882R-=7[ZT',_EZ7DF!_4*]4<M9Z3N@^*U5=>@TF\02<]:*H9ZUD?DSA
MLDO,=ZBYF7B4#K,<'Y=_(.'QU3&.U)L9RO=4J$N8RLCHQ"-M8,ZG:AL-VE<K
M("-DIP_)S$Y UBG6_;:Y:P<%%8#<NX$*PNPUMK3KXDNIECS8P'29]T)5X/.9
M7,M&2CTIFI;A',IIDY<.6B12)-I1NG'KH* 542JJ);@ ;]:>9Q84_@W(<CBJ
M-LF "K#\00[2 -2"!<6_C63Q>3*B\RX_"G;<5S#<$>W=[M=+$$^M_6O9:7_4
MI="!_96O1,0,F']D1Z)F 1 R8?S1#H(:\1/_ 'C?]8U[$C_NU_ZH_A5K45:C
M2E&E*S6RI/+XCCLDX+X5!$.A>\0[#[!_T9]A^[44-6#$,B<Q5 V,41(8/>!@
M'K_Q:FE9(?VEL8@=#-C"JF C[4CCLL0 _P P1 P?=OIZ6IZUBE2.8Q2E#<QC
M 4H%W$1,([% /VCI2E-\.Q"@F)3E5'9P<G0IG:1 *<HCMU(4?B*'LW'?45 K
M'8E$%C=^WA\9RN!'\)4C!L8=NNY^OPAMOW;:&I-4/A$%?%MVD1 4TR![ 3 =
MRGW_ )YE2CW";W[Z"@Z5E-"=S4QE2 <$3*+-B&Z>4Q"E%8G;L/>D38#C_HB'
MOTJ#UI-,HHJJ*ASB=0QNX3C[1'W" >[;W 'L#H&E32N[,"*8+=NR[OX5Q 0_
M),4H>5, _F*+@;N-[P =OMTJ!6(S-WK"D ? X(9)3?;8A=P,54?< (G #;_=
MI0_&J7*O8;TP 8J:!S!L(?C5]AE3E$=NX0#8/L#V:FI^VD&Z-0?T*T$4BEIP
M20,JT)#MG7H5Y<%6RG@9$?=I_3B"AA*)^TWM*7M'?8<N.=LZ&^T!AK:]M>M=
MSXW,,?R'"F,RXP3*C/=9=XCLP]Y33<!U(N/O'6M-GV.RL8:#K"7'LEGB%B%L
M,LYJ%Y*]N$.<6R9?T_(S\C#QKH5/0]J16A%S L/:(*@'>J/<QY):5ISDA90=
MHW)[6UZ@ GUUO;3X=!7WW#\P;)Y3)YR3RLX?(*W8B7*PMF+,-Q_/C@CED6V^
M[&4H-@N#&?:E4,\;)/9@S93"^6:FZE6P/$9JXYK>M:RU2(Q8F^1.20KR9<-$
M44F()$239JD\_:!Q AQ,%Y<DQQ^V>!P#:RQ#<=3KJ!?K\:SYOF#8/'[D\BX+
M.B@?8T6)Q"-DM=WM*IE2%7)+[F=I5.R^T%D +;Y0VVJ8;QC8,DW[!-:5I6/6
M@VF6L.+K$C&/0.M(-8F'@P70K46\5?OI0[;= Q#-B;)BHH"7=MFX/$GY/-3"
MQ9R,F4[0)!<6L23U(  OKUZV%Z[GZ(\!S?U&\PQ/$?%_)LP>1<I+\M'!R6.9
M%(V-+++9LB1 B1B3W@B0@OL3?:_(QS9\09"Q+RGLDG)42\<CLAX-RS*$8UO-
M@3D7BFA5"E2T[ 8NIL8Q0D',U%THD>JK(OSB*EBF6BSA<P(.&Q0^@KC\CB<G
MQ\$<<T/"PY<(N\)4RR-(JM*Y-K%[@*O_ ':$*-0U>\X>)^H'BGG_ (/Q&'!R
MG&?1_B?)N+B+Y'#]B3D\W+S(H)N2RY':-89,LNJX\ ]N!B2QQ1@RQ3$S#5LD
M05U:ST,MGR,SE*.L3V^K57&N(8_%-!1DCL:/8I!Q8D'E6-&SZZ=;C45U5C^-
M0': KD\6P "W73X$N*R2+@OB1B=&>60RO:[J +,-ON-O7K;7X?/^=\/Y/QF?
M&SH_%IO&<%.=Q<G*Y'E).3SC'OS((UQRN2)(!\Q(45!N7M/VFWW/Y:)3\5Y1
MJ^,^&M]SO/2\]Q964XXM;-49UI&U,E1M+"&H<GAZW6ARB.0EEL))VJ.8QTLY
M10AI5-VN4SSM8KNR$RY&9@S\AR4'%QHO/7R=K;BV]"T@F519+3;"S(#O6P]O
MN"D]MY%YMX3S/F/U"\<^F&+CXOUPV^0-C94+R9)R\9ILV+EL;&4C! Y@XSS3
MXL;OEXS1HPQ[Y,4#-(%/R'B7!+/,5&Y'8\3JV3VV<,P7BRP#^].89QDZN7RY
MS<O2I;'< PAU?WD1+VGF80K5M$)O%DSQ8LCH('.")^'E86=RIQLKAY.Y@_*P
MHI" B)HT5761B?RR'W.2Q (;>">M:GS_ (EYS]3Y?'?)_I'RQSO"SXWQ6'CS
M1X:RCC\C"Q(8LR'/G>4?T^5,L3YDLN4T2%<D9*RR*O<61,+84L-(^G[<AN&"
MTH"Q0&%<V/(ZIW2Z.Y2;C:_:HF]S5,@6-:"(E$7$O2ZK)M6Z@*.$7*!DC)[>
M9$$T.)R/(PY7ET9Q\@/ V5!=E0 %E,:NU[C1G!(]#<'H;G4OJ']1^(\I_P T
M^"> \F.5P^1Y)PXDRL/$6.&2?&EPH,N9LCNQE8LO*BD=2J/&X8/_ '<A>36A
M' .6J_A[B%<+=+9YLM;2R7Q E'-!<1^)ZW4IA:SN:RR:1D/-5-E"V\']<CU2
ME:N7!D/2J  K&,<!./>'E<"7D.2AACQ8Y^QF 2;IF:RAB20Y9/>>H .ATTTK
M[,_U5\%Y;SSS_A>!@\7P^8_I'E42YPDY/(RHACKD.TDL.4\V+LR'4F2.,/W%
MTC"J0H?IK[CS'W#/DAQEFZU25>0\U,\E,>UG$MLF'LIR(EI/,>0;JXQD-0K[
MFK.W5IBGC.[1SYL_CI%5B8IUW)UDE$UB%XJX67E^287.1EOZ.JXLCS* (5$,
M<8DWMN 4@HP*L =  #<5K<7C'E?E7^8;Q#ZQ\=F<E_RGAQ?'L_)Y3%B2/@HH
M^)P,-<\94ZY*KC2J^)D120SP+,"(H5C=&C8L:,PA<&.<,^Y<H6"+"\R1A/(.
M*&MBK#6]%6'(>,7?';&ZN1,:*F)V ,E/N&R4Q7UT2D4C9<4$RE\(K@'*EY/&
MDXK"XW-R4&#E0RE6*?W<HR9NW+]R@E)!_:2YZ@5WG)?4WQ[,^G'BW@?E'E&)
M'X=Y+Q7*-CY+85OD.13G^07 Y$7O^7 K-B9R,67(Q.ZY;N"(TW,*W#&..&7#
MFXY(C86/JU^X\<DQ++K7!.GSZI'7(:B34.#N0D(=@6"ETHJ-4*VCDSJ&5,=4
MP+)B)SER<IBYN>>1@P@S31YF,;!"XTQY5.@)N+G5O333TKL_J/X]YIYAD?4+
MQ_PZ7)FYSBO+?'OREQ#EP KP.=#*5CCE?O1&613)D,JA0$!C<!5;/EJ58,K7
MR+ON'ZCD+#U'S7S1PZGA?(5Q=29(!L^KW'.\U7(MJ:UYTNT=RC2R3,.5%E*^
MF['!8\JA%.PQ.^JY$.#@G#SWBR,O&XN;O(MKV;)C=$+ &Q56N5O[=UB+].-@
M^1\3X-XM/XM]0,_B?(?)O&_ISRQY? Q%C,[)/Y!A9.!C-D*&6-\>&4O-B]R\
M9G*,FX-M5>3%6O-5;<O:WGJ(@[MF,W%.=7Q1D3'<9!T7&Z^"(Z74EY]]#4V'
M@C/9+(%:OKY!*SMG[YZL5%XP<LRI-#K'#'P4V+*W&R\43%QO]07NQN2\@G(V
MKN<FW;:,'MLJJ+APUV K@_1GF_&><F^G_,?2V?)XWZ>#SJ <G@9\DV;R"\W)
M$(H$FRY9@D>#D8*.W'200PH7BRH<@R3K&M)L#:JY=JM?:BGR-KF<)*2P7EXL
M/CYE)T&ONF<G%4*4FTYCUU-3?SDE\B0@U%1;@0R;@&IBGW!;\R)<6;%R(<@X
M$F(BY45Y&[C"QD M9P%%RPUOZZ=-.5RG!\OXWSG%<^_A^9XSAP^3\5WLYX\Z
M=7CESHH3#LRRD,?>:95[FX,G<!76/V/1]D7'?(?&G&W%N&*4>\9@K\MQ><1K
M_"-C%=*N1..I"JS63K7:'C&+CF-.6)4FDE'&D'CA,RCMX1JF18_=W8H\'+XC
M/SL_D6[/'2)E ]U;;S('$2J#<O=RKV L I8D"M=Q?$?+OI)YEYCYO]1>1'&?
M3_+Q_)%D3F<?:<B7/CRH>.Q<9'DD?+!RFQ\@011L%BB:=VC6UMA<L428ON:L
M'83IF$WY5JZF;/F5:;GG-$P%)L=&Q\LVK]'KTXNS@LBL5U)[)LFUD#)KL5%'
MH02FX F=0Y>GXW(AQ..RN4RIP W_  \3PQ*75Y+M(P&Z(^V(%;AA;N"VH /R
M;P/R?C_%OIQY-]2?(O)(C'EL.#XS+X3B(OG,?-SPT^;/"KS\>ZB#CHY( R3*
ML/SJ6.]44Z32&+@NUCPGQ)RWA4YK%AS-.6,;O"U:^*=KG'TO@#*MXP%<:U83
MQ$*>4D*;6$VJ;"7%L5RNYJ8 J@DJ<4S;2F:,2#,\BX[(_*RL6&3W)_W@R(8\
MA&6[6#M<LMR LNA(UKTEB>;'QOA_)?KWX%Y&!Q'D/C?%\@GS.$/;GQ<[QF%S
MF)D0"681QY>296GQ>X8TCY2Z2.BAPUK7!W)E$<MFV6<;)0&1<*\=N,U8O3^P
MS[T\9=W33.DR^1R96&;:)D(R59W*I@V5=L4W":$<_0<D YQ[@"^,^*9./;CI
M=V%D9>2Z #W1@P(O:;4&Z/< G5E*GX5W?!<EX]D9_@4W@?,-E>(>2>7>19.$
MD$""3#5^%A0\=DNTL<D3XF5W%BF9&?(@>%BJC:3N>I;,><A^0G'U]@;$EYR!
M,XZO]WR9EJTT&^E?52$QU9:5;:PI3OUB1>(AXU]/7"9AG1(<BPN#),7)S%,5
M,5S:_'C9?#\1FQ\K+'"DT,<<2.EG:19$;?LL6(5 X+D6NRCUM7G_ ([@?+OI
M-]*O*\/ZH\[QO%\=RW%X7'\7C9N%V\J;/Q\S%R!E_*%999$AQ8LJ(Y;)L#30
MJ"&<1!W\K,W4W%+&O<:D7])Q!/98J"EZON0\GY'--7_&&)7$DP@I>NU&9M5?
M69FRW= CG2$4@R>NTX-5%]*&+^4W%7B<!Q.1R!?FS&^3#!)L2...Z236W N%
M/]TEP7) WW6,=3;I/HC]..?\XFROK')#R//\9PG(?)8>!QW']K"Y'E%C>:+(
MRHL:=7'%XA>.3)>:*)LQ7QL)3^9,$THR98,*0V7N/,KAJY5KC_BEGAK+U.K]
M[8W6JWRL2[V&N6-&KJN(25J!M&%D_(N)')P.9T9=0SPQNAUM;+A0<E/Q^;'R
M4,N9GG*A=HRKQN+I+[R%!-O0"U@/:/05Z(\0XKZB\CX)Y;QWU#X_,\K\XD\@
MXG*GPWQ,K"R(EEP^09<EH\;=)VO;>,;1$$48X&JQU,3VNS>49;B*AAW+-:RO
M;9NU\D&,OERG1E2L\TT:MZ/699_ R]=(2OUFLK1[5R@JW31>*F SC<.PX%*3
MKD:/"BY'^H8KX^.J8Y6%V=;_ )C ,&(+,+@W.WT^^OGL'*\9X3B>?O\ 4+@L
MS@O'\;!\?>+B\N3*QH69LS(BCGBR#W\C(61E=7+Q*+);W+N9HPFL6W)2,S/7
M,M8AS/=<]5')?':\YO(WE4X&GW'B;0KLY7KQ<<46LJRDF\@25AE(K2#(/U!)
MM9ALJB!U/[,D//CSL=&QI,";'BXIX,E("=63*DC ;NNU@&+% K?EJ4(-A[C6
MZX'FWC\'(>.\IX-SWCO&_2[.X;GL+A]T9FR\3R?-PU$_]0S<@11I.<E\=()C
M\CC28LD<A5/SG&XV<;SC+D/9.-=$P'5\6YFGJUE-CE2U6##-H/,/ZKC"(I]@
MK]O@L@W!2K09Z5+9*-9$HDC5XL#UVY6%<Z)3-S*)ZYQ>'E\+CYV1RIEQX9,<
MQH)5MOD+JR&-;G>(]I?<!90+7]UCY\^F_C'F/TAX3S'R7ZHYO->/<5G<(_'8
MT/+8XB3)Y&7*@GQ)L'$&3-\W'QWR[Y321)V8HT$:R,)@KNIIPBPC,5XM-7XB
M/6U<E+<%KE5'F99U!L2V*M21K:YOY!N#B72,<BX/U2D Q".EP7%(5DC=G&/D
MW*1S?-C.!R%CV#\I?PWOL Z?[OW"U[&NDE_S)_4C!Y-O)XO/8WY?&X[Y6,)Q
M,)8XV\R'%1&VQ$ KV5N03'&8@XC<;I1<\<J''9'D,F,>*<](6MC%-:BTN.*<
MC.&7Z@8-8RO1\0_4!X:#:R+B-"-.J#T4TU&STZRNZBKE=0G"3ELQ\(8#YBC'
M+;BCI?:;L3T!(O?4>HL.B@5HN)]7O)\[Q"'PO)\XQ8N"FG;*;$Y/ 5SCR/).
M\J#9WF19#(%,.YEDA$:>Q(8D:6ZGC-)&=W1Q+8H-Q4TB1R;?+V7)&9K]E!1Y
M*HD>MHMLVM+.673\IW)5'** D_LADPW*/9UV5E$I;O(P;7\N, KH-+^TCX:7
MOK6B^1>92'C]DG.XN1'F'>6XKBTAGQR$B8J96;&>)6(";8W<$=\.=?<B7.HJ
MR\A)N#\<&A21I&L2W>4>[M(.OR22#H5$Y=JU:Q+ 7!/3'*8#'1*(IB0FWPZR
MX\HCC%LFQ;4AD)(-NE[G_IO7:>.\]'@8,13R^3?-ND9,S#::>-F6QC9FE?;J
M""%<@-N>^M25QTK 5R1M(FQ7+8^2>L(EL*K^X#:0D%$%#)@W0+V$!!>/\14C
M&W-Y?3BI_P ^!U>+R4W=5!WEEU/1=MOM_7U_7;TTTKZL\Y_5L7"7^MP<L4EE
M-H\3Y8Q[A?<=3N#WW 6&WN!/^[VIM(\***A&P]2H)[%';X5/(/<=4/<(',&W
MW &VNHM7Q4?&LEKNN7RF 3+LR@*0B(;+  ""*)N[;<Z8AW!MN(E+MI4'3[J0
MGS-I)LWD?)-6\@PD6KAE(,GB1'#1\R>)'0=M':"@&3<-G;=0R:I# )3D,(#T
M'5E9D8.A(<&X(Z@CH1]M<G%RLG!R8\W"D>+,AD5XW0E71U(975AJ&5@"I&H(
M!%(4MC#'$D^;SKVBU1S*F=HR2S]>%9'=)/"-XYNU.X,5$HNB)HQ#8Z15@.5,
M6Z1B@!TRF#.N9EI'VDD<1VM:YMZG]74_M/QKO,;S/R["PFXW#Y/.CP#&4[:S
M.%VDR,547]MVEDW%;$B1P258@Z?J9?PQ3E+16$^.=H/$TZ>BXR91:56.D&"3
MZN3XKUI[ I.UU_4HP]HJ2RS([?M*T7C"K$ H'1,;O5P>0R"DS9:;Y$-KL0;,
MON#6'JK"]^H:Q]:^]X_@'U%\A&%R\GEV$,SDL622,MDR)(8YX+9"S%57:TF-
ME*LP>YE3):)B=LBAV1F<<<O)2TMQP_:X5Q48/]=>&4BF"<:Y=Q"C^?C20'<X
M/'FM+E2Y ^$Z1"JE/**'4,)FZOCP2<=EJJ,,A&5VV:$W -EU]=OMV_\ HZ=1
M71<C]-/+X,3"E7R#!R,?/R?D@8Y',BQRB.!S/91)\LHQ##9B5MCJJ "5-R&3
M,>+HM9\C#\?HZ8DTXZ18]]>-3GK5>.C*<X=R:9Y C8B"U9>5UPJS@G!@\$R!
M7"2)4DDU-9EP,V07DRBJW!&[<#<O8:?S!K,XZIH3<D5VJ?3_ ,US84DY'RJ7
M'Q.ZCKW_ )M&667*"1^PL2,A)U6;-C!WX9,3R%W=*0(C-6"Z],/9(<')UJ3K
M#N6C7CM@2NKKPT_4:L>029/&J!D213N6*L6,KSE8A5I94Y@1 A";&O)QW)RQ
MB/YG>C@$ [M0[VT)ZV_$X&BCK<USL_Z;_4[E,"/"/DIS,/-CBD5'.0HE@RLG
MMET9KF18BIR,Z-&*XJA2Y9FN,*&R'A]\X<P"?%EJE/LW[IY(A$(U]C'(.:^G
M+/%G[&1=C&.(]-&);G#RII().I(CAL<2BCY#99<3/5!+\[^7M'7<2=U@ 0+W
MU/VV6S>MJ[#D_%//\?%CY-O-G/'20HJF4SO(Z3&)%1XT[BN3(P)4L[1X[13J
M")-@QH_/>-HBJ6Y\I@)5K3K2J\[8R/%%PE:%(R+K<_9HZ1C7;$&B4BTE+6Y.
MQ61(1M(+(F\9B* "AJOQF8\\:C*OD);4Z;;EE4@@]+(+WU4'732L>5]*O,N0
MY[C\5/*E?R+"5+R/=3C"27(@QY(Y%?<8VBQ8Q,CDR0*PWJRDH'\PR#ARSR,E
M1)/  Q<#!0,S98PTK!UR0:R3.%4L5?CE&$>80>J35G;V"0;H'*914[N47:JG
M\BZ@FX\F+GP 9,>5>1F"FS,"+A6-STLI53\+*&&@%:UR/BWU X?&A\GX_P J
M[W)9.5#C/VILB-HVE$$\@D?\ AQV@@D=2%01X\<Z+LC4! ;YAQ,U9N63#C^S
ML!1;MUU(R+=U2PM7RD C 7!FY<OUTU2K0\:I&LQ82"FZ9YR+.S3 JS,#ZNN!
MG,^]LHI;2YW+^(E+6'J;G<O\C!CHU=J/I_YW)DKFY7E<F*59@))$R8&3OM/B
M,JHI%I9.Y-WX%LRX62N0Y:/(VUL3C&)HTG4XV2AL=L*>@VGYHR==<H-W80T[
M774U2'#QB8 .T*11@DX3;*H$3*+)QV@4 ,(:ZG-DR4G*2RF0E1[AI=6"O8^O
M6U[^HKX[YMG^387/S8?(\O+R$KXL-\A69>]#D+#F*C]')#E&D5RQ[T=R20#4
MB0L!!5MG\NKT/&PC#N1/Z*+:(LFW>W8,HMN;PH%(3N0C(UNW)T^%%!,@?"4
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M/R3BP8B<=Y%BW<B1A)'+&670NCEO>K*Q)A #)8,0":[>::'"QN_/D29O"3D
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M1F@]RK.P(8*; A&1=R/<DVO>P05P^.8+,WCO/1=Q<<L!+HQA747!)]P9@KJ
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M-0 #0(I.H'Z?ZZI9M6HF<ND4D6ZRSD'TN9!(J2DBJFW0:D?.3I% 7#WTS-%
M5%!$_8FF&^Q0 )8DV#&X L/L'P'^K[:R32RS*B3,SI&FQ Q)"*69MJWOM7<S
M-86&YF-KDU:.[7\YE@4$#B8#;E,8   '<I Z]2%WV /9MJ !:J!%(Z"LXQ@0
M1.[1,( Y#Q-R;C^0)=A7 ?=LCV[)[=0[MP]FHTO5=JDV(^/[_P#7ZTE]YS[
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MS63.D$T6$+\RN2%>0OL,<,K,XD33<5,<>T6&K,017C_B<>%Y(ILIBO&-!N1
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MT#X!]0U__M7PQ#$H>6Y"P( M^?+Z_BU]02;>E?</!S;ZB<FI WCB\*YN3?\
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M WQ+)B=5/8  3)B'YB0%#V@3;<@![ #;44M:OB7]F1%;V+K )6^_04R?\XL
M>XP[=I1_:.IIUTKXX)Z@J3DA=Q5-XE2E#V.   WV#V>8!W#[]]*D:5<\@-#
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MX>T0'QMS^W<!(.Y@^T?M#2YJ#KJ:H.U*HN040'PN/C3$PB )@ _F$.;V!X0
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M\1Z:&O27].=>;-]2WE U?3B;F*:\1>+B;*!+8V\@I'27[M,1&EWBM>*LHO
MZ$Z)2].Q8"".XCU'R_\ 4)(O^6/#NJ6D/+<A=MMKCOS6%_6VM_A>O17A!?\
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MO#?XC>GW\?[-A]FHJ@^-8C0HBL!^[L*D'E.?K\)2" ]/O,.P!]N^E2>E77H
MJ<CA,/RE@V*7</R3$V [?;V!XQZAM[0'45 ^%769P;IBNH(@FJ)4"%  $1.
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M5-E2*&]IRJ?$!C?YWN'[PU-2*S2AL@9D(B5=0!5)U#8N_:<K<=NH>4.HA_2
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M* B54!'\($_G;>TN^IH?C7QZ82JBCL)4T/RDBCU^$.O?O[/S1$3=.@[Z#6I
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MJKCV4NF-%:<YA)Z.D+]$-+Q:R1<0QLKVJ83QC-PZDP><J4W'R:OK;I:7*A6
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M-BSKED>UJCXSPO3JG)*1LXO6*)2W,(YBWR:MKJ\VB=:QNUW+N0$JRS-)PY(
M!QB</W./7)P^*QI6)EC#R3Y,C"X#RR!K@&-T8B,!56PW$+5I,Z7DWCS6QLK/
MR8U&Q]J10(IU98UM8G<K#<Y+,VM@326TDZ1<FIXUCQ'G7]-3=.8RYFI,I%0%
MGC)>,9-H:S1[ K^/G;#/NZ1!+*?-7Q"J0\TB5!=6-;G< W&_8Y##5LG(YR-<
MT@-'W0SJ1>Z[MI5%$G15/N4W =@-U5,F'ED18_$2/BZK)VR$:Y&MB06)3J6&
MC#4@7 I5=Y'S1GMS$XSJN7+G84Y"<J3"YU'(M9B,;925?3AHMY'1>2IZHM&T
M#D8T)"N$VIU3E4=++^=1S&F=HCX\*<=P/C"'F,["A0+%(T<D$AF@N#8M"LAW
M1[B+VZ#HLEB+YI,[FN<=>+Q,F20,ZJ\<P6*901<"8H+2;1I?K_,FAJXQ+8JD
M\_<K@@C"8D%HN43RMFDL]!S2CLD] Y(HLY+NY^A9#:8^JT'6J3'60S-HM/V&
M0&4F4%#BFX39LT,$C8O)1_XC\D+!%D'RN(H9-I5HI NR2,R.SNT5SMC4(K6)
M!8G,#E\=DC@.#5>ZT9^8R39MP=9$)W(^Q0@#@"['<03J  \N(I3PO,#!5!@$
MU#5,N;W5FBW,P*+=5R\/$S +3)&[5!HUKK>SL8PQ?3IBH<Z[GP.%G([G'-YF
MJR>&9O(Y 'SYP1&]K^P$K==22Q4GJ=-+@ :5A\0W0>78>#"Q;%^;9UO;W$ Z
MZ6 #6Z?O->O0O^J3W @#Z9MN"8]R8#Z5+H0P;@8@>X?>&O&;BSL!TN:];Q_@
M4GK85:U%6HTI1I2JTP,8Y * F,8P$* =!$QA[2@'WB(Z5-9CTQ0$B!#=R;?\
MON_IJ;;K'^_N4W#?W@ :BH%4,R <XF.&Z2)155]VY0V I-_<*ANFGK0U?(L*
MIE"+G'M7.)@/UV16,/10H![";?"8 _F_LT^^HZ:BJA*9H@J90!(LJ8S<@"/4
MI V%=0IMNOD^$H"'N$=*G^%6BB+Q($A#== NZ8[[F61+_P UU]JJ742^\2]/
MLT_C0Z:U]74,V%)NF;;P")U#E]HN3=3CN ]03Z$#]@_;I0:ZFK@()N#$=;@F
MD.YW9"B&Z0D#O-V%]OC7V^'[!';[-34=-*QP=F.N<Z@"*:P]JJ8&V_*]A2%]
MP"F4 [?L$-14V_;5XR?H4C* 8#F<AXT# /M0V 55>GX3B(@0=^OMTH3>N2]R
MXL9CMA^?U]C6,0%XNS_-41Q]36BK3$Y3=IRF&*#!5-:GY25RVWJ$)4Y2<;23
M1FT&MM#(.C',9XGN949&E3TJ_/V[+S_E!5>1S'#_ "A:83976EUUW4 Q_:2W
M04X+C=R:A[!9E\/MGYYC]*_O"R/76 /3M02=R;0%T_(@V1=#%!:VO6LIPWR[
M8\7\H(2O4CD15<\4C-6<^47&:S3%+M*-1EY>/<)6+$M(^</)-E!S];OL?(J5
M^4JJ[A#N9OWB!0:N445T@^WI3X#[*S,I\=\Z3E;X_P"(&$;4;C2(K.K"[W2\
MY L.2KS+7!U/87SA*Y(M^>Z3 N\:)1L4IF"R,0AF$/8GS!JX58I^G0;-4T F
MH/[ZA,F#.:.*K2C+0@6O)&/\:U>=XMM40N=QCKM<\?Y#JMGGIO)M0Q3)FLL0
MI5Z-FVZUYG"2C^U.+&PIE'52 7!ECK+Q<5.AZ4J8OQ7E1M>X5VOB3.D5R!9Y
MUXOV$N:I)6R,<>QF JO@7CE"YMK]DMCNREJ]BCI7]/W&&5KY&SUZO8W978(D
M.7UR2H-NGI3TS36N8\KGC+.8JE29QYC"2KEZXJP5,C+E/%NTA0)3%\NO%YDB
M,9IQC>JE W)%X@LE8"S*<T2JE/V-@3V#2IL+?;4"2N%N4%;EL:8]S#0\Y9GP
MGB6N<18T]EB'\U=+-D?'K:T9'F[56+S7J],I6&P9*Q$H[8Q5A=F354GHM&,D
M5#K+K.TD51UU]:VK>X7R]:^%%HQC'MLTXV0O'*"H/\61;.T/&F<<-<="\F<>
M3;,%)M29DWT.YJ518RDRWC';QT:/A/%&.4Q*BJT*H.OZJB."I6?9R]VFQ\T<
M)Y-R7BYADK)\!-U'%:$[;J_<[W'X@XLT[&'("O8\J]B0G7&+;FTI5V/',O&L
M%1L,RH+I AR%D4E-.@J,'>%^>L#1L@6R.89BM4Y-8EXZX@G\:/L@C+2AZ6[O
M5X?Q]RK,V,\=B^S=QVAYB*:W!X@[ ;/%*R)3+O7;:..:;:@4NM;6\H(;G1D"
MT4VRT"A4R/5XT#(9P9-*GEN^,JYEVUFN)&M2QO$=^.(@][L+G#=;L\7*PDJG
M'0321ND6NB_55:@HC%!8:'UJ!"XOS \MG((L1BKDRBUR;2LZ/;G:$H9]2LV5
MMM:,A5BR5F#@KVZRLKA#E"P7@UW:=;A4HR#GZY76IX95^V7=+)J0=1>E16\P
M]EMVXQ6VEL*V]EB6L3')M".19\:<^W:M2WZFC^-#FH6(>+)^0L;><$B^E(>U
MM8]NM.NHOR,GSQJS:$F"E"]ZMI4U3N,\K)\B+C9*;BK/,FI:V]U9#*&C9S&5
MBIU D>-TG6:\YP]R"#)2N+T*\-F:QS:+QM;ZZXEJ_;G*DB=T0K(KQ2/OJ*BV
MOX0Y0VK',WQWQ1CZV8\J5SM%-M$KF6[(Y:XK$)^[JB3#P[*5HRUGSC*5S(2V
M6QJ+N0F:XDU@+ZC'R1%$2$05<.'VTTZU0VIW+:]\B6^7+%B#)E4OT_=>/LI-
M1:-%N$;#1]?C^/-;H.<H^+SRVRDWQW7<=Q]_3F7Y:VK67SRR'11!)1%21(X:
MJG3I3JNT/E7)N(>!$',8?SXV/AV@N*GG=ED7CCE?)9%+M^X.I0#*1?T>MY(Q
MM.7M,MNBWQ$IU.4<M6STPF.4XN"JZ7II<_"MI^5U!D[EACCU&Q-0R.]@:X^9
M/IBNP>&[+D*MM")8W>PL+%Y@XX1&1JAEB3KQ7CPWH BIY62JDVDU7<G6(4[A
M->HK7NIXYYK(TN4L$RPM-4A4N0G!6XRV#/063)N39"FX_IW%8F625+-,GEHC
MI:$C754FDI1J\BY%P^<LWY'+ARJY47&?6E,P,)\XYV(<U#(M217:<CLS8#Y(
M6%=*S73*5.Q184<N(*9BQODVMB\Q7(0%39XJE:XW3KT),+1*AJK*JE=F47$%
M5Z:4SD<!9N@+=08C*&-[K,0-18\D8V:;PN!LL\@,-L;'/9IQ_8Z=^XZJU;.=
M9LE.QS,X]15=0BTW(RSJ.55DHY4J9T>P5[4TMI6Y6$J)D6$YRR]P;XVRDK#V
M2XY@>VZW7VOVF "J4N4@P/12P67(3(SG&&:\92<DSCFL!2GM9;V.E^<QU7*8
ML%Q=U;32J]12+<,<927R9<';;&^8G?)=]RJ8VJB\@8]],%Q1%\5$KC"OEJH>
MRDFR59A6B86;/ZP\IBC3YA(6U49 C0YE22I('6K'X?94H<7N/.6<.\4G\(P6
MIU=Y#W;C] HQ\HQJEHK,] 99-BA="+')\C:LG93;6RSP=^E?(]DVR<:@HJ18
MYFI@, %MU%ZKI?[*U^1QL[_1M;CZ#QIY35.I13_!J_+ROV*P6=A8,VQL&M:4
M[[7JW6GUS=2&6;FPLSMA,VJQPZID;?7D#12+J5%0K0L5-,:7Q_REHV5J)F7
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MJIO\OD\!")YD&1Y'D_:&$09"Q(52'WLH-BY6Q;3=H:9V5BW.HS]MLEF<?/\
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M_E"/<[;+=X(-P.ADG6MUNU>,;E.]J).4OU.BRT;<7[)+D'QS"Q-Z_<ZY#N)
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MVW(;'CWGTU)IF/./5OM4[-FQ]4UHJ\\I[ >G8:Q&O7K!:VUC3LTO<6CMK)2
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M1D)0[6<M[F3O,NA(Y,2=(I-$FBSYJW<%\2"J2)746UTJX.ES71])(Q#/6)Q
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M654,EBSV++N,ED0 ,0H.TD"W+&3EX,(X#@3+D9TH/?=+A6+!+A4.AV[/<]R
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ME;%*5LL[#5YLI(MVA7UBEXV#:+R3Q82H1Y'4HZ:-U7STX&*FB4PJ*#N!2CJ
M"#0V(L*I>3]<1F9&#"PP'S:,:+2KZ("<BOFL?#I& JDK(1HO/6L8Q QNT[A4
MA42&Z&, Z%;]**;#6D3'.3:-E%I;C4.PLK,RJMFD*9,2$=W+1J=I@XR%GGC)
MA( 'I)9L6'LC90KIJ=9LIY>TIQ,0P%MM(4&H.IO3H\A?L'^3_+JFTU;<*^>0
MOV#_ "?Y=-IIN%'D+]@_R?Y=-IIN%0/RC.4W'7-( 82C^Z[(PAN5$0,(4*T"
M #YC F  /Q;COMV_9N(;!XNO_P!D&"#_ /3D/_BK71>3&_!9=O3%E_[#5Y&(
M&VNJUB*0D6CE]9I+% ,6985_/2K:/L.)LAS\0UN]:??(6S^SV+Y=:$6S^),!
M3'*\FY%5T5RU56)KV3F\:G(<ZL+D0X^:Q)(124R(@3$WN*JN]?:_IM10MF K
MR;C<@<7AVD3<\V( H&X@-#+;N*=MV.P^Y/7<Q)N":V6X_5FNT)_DRJU(TB6Y
M6BJPUOJLQ83L*S<+AQOO5?<9F%_B^MDFG$U)S,0*#AM<2G(YEUQ9&<"S2:*'
M(35?(N5GY1<7.SU'].CF>)PFYHX\V%^R.^=HT;K!8A0&L3N OLG!X4?'29&+
MA:9QA21=UM\F+(O</:%SJO2;JQ(N!MO4WU'D)1>-M7:S"M2?9$RCEVJY 8T+
M'#>0@FT=/XZ>-?!9\B7BP2+&Q0%)Q23T?ISKNF"JKQXKZ9N@82KG)K^9XWR/
MF&2^/W5QN*P94,N1M)9)2?;%&JE6DGL;@!@H6[,1I?N<3G..\9B7("//GYL3
MB.$FPDC_ +3NS JD-Q:Y&XFP ZVU2-D?D=#1T9D^3^G9Q()1F=^G[22IHY$E
M"V)DFG!!+&=/)1?(TM$OJNB5)9=I''CG7BDF:ACL>PXIK;B>(\4R'?A(O)^8
M^?\ E0H8Q+VVNQ]JJ(PP>Y]QW [&_'\-=3D/($5>7;Q_B_D_F&.W>VX$*+W/
M<*[=-!MM<?A^.V&0<]4'D,SF\G,(25I-YQU,52K9HH<ZO&#)8X])"-H*I69A
M*QJ,='7/&]M@XLAX*88,B(NRH_&BBOL4-)XO@>2\8EAXF9A+A9,;R03+>TX!
MO(A5KE)D.CJ22+Z$C6MFY+F<7R!).46-H\B"1(YHR0>SI:-E(L&B<:JPZVU
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M3%7C;7>JJ=ZDX" ^:R3I_7TF#]!1JV2>-S*X>5W1X?:F,(R3*&95-V/M8;F
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M+*(>/)+$Y8U"?I#:X1DK+R5XJ:,/69RN2JK1LT8SLFX2:.%G"[<C0BAA453
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MQS3QO>GJ+2S6!M!UR?2=VBL)@G+,HERW8@=!1P"C@EM]Q8BC?9UJ%Z!]-?+
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MJJN9I(K-4#@@8H>I7W;E3#7NO.A[D^+%-NBB^95Q)_:,R.I2,6!VF074$_\
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MSFR<K/E&?"MH\POEY!6=6!8$&-=?N//*'+F0<GX3EL@4Z AZGR"KKY&A79#
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MI+QE'DI9[C(;!)VFKIP9;\XBK7:X1E<ZO!LY./L)V 0<DX(=9JQ+)'1.#A-
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MXE_JW'.(N1 53>-C$ZW-A(" 6/\ *2-\8)MH2*U/#[3H>-Y"-GPG)868+(K
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MLKC2%D+TS@6-JON9\,3>$[!$54 @PMLE)S.,E'?H8X\@\80RJ*CQBW:!YQ/
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MV5&>.T% 2^7,G4F2-6(")W!B=ZNWTWQXSR<=C19!Y \>&-PL,30@;VN0Y)D
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M*T(P8A'K%<'QC60_&LA("Z_"K=OX9<B'YF%84K[K(%2AK_57&&3O.0DY%1N
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MHX66#'+$RS[K=M([7&YBJ[V-D'N&V^X]*\:<+)'$QDFC[V05 CB*[BY<FQL
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MGC8IC.1]YK<GD@/UA%-6R[E9^^[VY5'ZB9Q(+E#B<6KCE<@815YQO$>Z-=K
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M62+AL-U<KB9&=,V<6XP2XI;D6BQ<7*3)$Q&0<OORIOE=N<RWCAMS'Q-%(NJ
MWC+8M@F-LU0F\R*T]UE-O&9'M<K71M%='*]0!JPQY.MRKP_@@9M::DI#TQB.
M$R&;IY_'P#P$\A$VZ/OE76'>(B8T#;6[3W,@T>\B!%7==2;GMO\ +_CQ3?0'
MG,V1.4?+P5YF3'RH>*&4O'-)@8T4_P M/_3<K<^="Q3*WYN(N)!#W@T3,)7[
M(@        &P '0  /8 ![@#7S^O 1))N>M?=*5S;Y[8/RWF)_1&^+L3U.]
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MII7UCK@T:4KA-R]D)J$RWENM5+$4=E&N6>3O4A89,M.Y+JN6N2\CX,Q]C?\
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MZ52X?Y=3:'6*37W*[M1_"TB AX&"6D9 @!(NW<)7VD:T74F$0#S*';F,L!1
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M$ I>T!'<0 =#>UCH?C4>M5F5$ABK.7J<<CV@(QKT6Z9.P1V!-,%#)M"IF,8
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M/>,J1[R6+[?:!*I/=W"V_P! ;&TEK"NB^F[8P^JGD9Y>;DL/C?FF:>;..,3
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MMH.B@;3UM6DL$E,\A+G>K7>$:Q%\>)9J]C;0SF&UJF<?U2$QS'SN1J\W8EC
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M\#R*K]"YUVVK-,WM<C72EXW<X7D.44/6H6Z6C)-2X\J13R/,R;(1,0O 0N4
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M,RSV1D2QWE37&,;/I5T^=,HPRZ)#F;(G30,=,AA*(D*(6GS<K)4).Y9 ;VT
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MRI7^L/EI2/FI256KS*YQ[]^E+C5;#,QQW;6/L,7(Q[I!@]?1S@KE&8=E<.2
M5-379Y63E8V6P^7EGXS()5X]@9HFL5#JK6W)(-6"/H8U*C4UUN/CXV9BW$\<
M7(0C<LC&PD'XBA9?PLAT7<IN';<:S;4?&N7&C4\H6XRF<H>:8UK)L1$P35LR
MOSTU,CJTXLCRX8X4LD&Z(SM-1?/)>2<I1BK,'AUCG27(LZ-APTYSQZ4J@@3@
M9 S0,[DF!=[/VQ%)9F)C=0L8+AK6U! J^4>*YE%D8S'FX[+*$06F.T)W"Z7
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MWB'<;V!VATU/4$+^GWU'34T.S=R97#P"D;IN&Q@;"8IB!^>0I#NA .U54IA
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MN/Q)]VV_4A]@$!+G206V^G\*QMTN.M8T?*).A;'51*JD\;&;K-TQ 2]S43J
MHQ*L!-P(!U.Y!02B3H'P=#"*D7^(/Z7_ -=4&II00;JD([4: ,G%$=J$4\93
M**M?*FDL9-1)0H+AV"H/<FJ4#@._:)@V#3<!^/1K59=-*O1DDJ@Q;@!"R# O
MD[$#*"5TW("Z@@5@[-\0%*7_ )E7N*'L#M'IK&\8D)/QK(I 'VU]CT6Z[-!>
M+=I$,H J*L7?<V(914WD,43"7Q(N %0 $?RS;^TINFK-=39AH/6L5C;2OK0Z
MZ:)#F379.C^5QL8I1,5)RL=0AMC%.V=-C@8-A$#D'[ 'V48!M.HJR==:^M)!
MJIY@E&2?]K<J>-RU/X6RQ" 5LF4R"WG214.#<#=H_";?X1'W#$P_NSTK)N%4
M$!NFX<JH+K':E,BT*W71.=9 J1#*+&06(<XN"$46V$A@$_P[%'<.W5]K6 /X
MNM8FN2;=*O@'J'9'#"8:I&0;B;S$663*H=8WC*DX2423\GC13'<H['(!^@@/
M35=NT69#UK("*OF?R"ZS=BH];%6,H#I4IGB2J2J3005!5%8X#Y""X[ VZ&*/
MX@]XQM6U]IM4W'2LIXZ>@W4*649%.N(-R=BZ1C=RX^,3@":9A_*((G'V= U"
MJ+W*FHO^VKQWGID![YLI$D$]Q(W]:?9-(FX%+VHI$'H&P=0W]G34;;G\)J;^
MM8[)VW;H))K*.GOD$5G#=8B0(^=<PJ*@ J*KG*8#&V[B]H[ &I93UJ=*5$4V
M[DHBRCA06ZFW>G57;B'=T C@/&@GL'3\PO;]^J7(.ITI58*R+("^=VBR14W.
M#=,"J)KE$-C=J#1(Z2@"'3J.H/N-QU^--*QQ7A%%!_L[@AS!MW=QB-14W]ID
M"'4=%*/V 81W]V@60#KK3T^RLP"SB!151*1FS  4%RB=-)N)!'8AEE%-US@
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MOVT+8*W(&_3J;4DH6&Q_<HJ7HVY%D)^NK.*W*14E\P(QV(Z 3/#=AD_(;L4
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MO'C#;)&#:_N)8S,1[I"S!B1<'T/'Y'QSCLV88T>1D?U19+)).=Z.5Z J HB
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MD*=I(%9_&0(/(N.RIW$G(Y.7=;=&B!*[S<+U-STN1<C=7K!<',HX7[RE(HF
M$4(4W>4H@BF)0(8  #%$A@$!]X#KR+T4C_?/\:]6I^$ ];#^%)7F%)TJV(4%
M5G2:;E!/W%[ !LLHJ/7L2()2#]IA-L'75K7%_05?UJVL ,EV[A0%%UW)CLCC
ML *+J' %4$TDQ$ 31(=,0  '8G=N([[B,CW CH.M.E?7)111%ZY'=5J<JH 0
M#'(BGOVJH-P .XZJB1S )MNXYN@;!TT&IVKT-/M-5KHBL@HNY_+)VB9N03?E
MHJ ("FJ82[@JX\@!L(;]N^Q=QW$0.MA3[:I#9ZW]2[**+=1(3D04#HGY"]HG
M< &_>X*(_"3KV#TZFT_";#K2LEDY%9AM*(G49J$,4C(.JZ#H2BV.Z(4 V]<)
M@$ 3ZD*'0?B^(M63WC;^(?L_Z*K:XK&=MER,6KX>QRJ\(U%H">YTFX)JHBX(
M<0W%-5$?]?OL(]"E^$0W(_OV'2U+Z?;6$\>=I7#005=>4B;5$X=OE4E'CD4C
MNBF'H*#'L PI[>,QR@7;8NH[;#5;!>I^[_;5V86-.(D/\O:-R-3 Y:%+L#A,
M#"8RIS=RPN2B'<FX45.(CW=#"/01T#AOQ:&JJ1TK*;._$F+9RD+AMW"(I&W*
M=$P].Y%7;N0.(]1 .AO>&J/&U]RU<&U5'C_,!E&)Q<D*'<=$P=KQ$-NOD1]I
MR!M^(FX 'MV]FFXK^(?ZJC4ZU:;NW#<#)@7RH''\Q!4@G2./N-V[AVJ /L,4
M0,'VZR,BMKT-01>FR]:H(OS*(*BR:.E6KXI%5  C1ZDX(@_70<=HB0H-G!3J
M <-C)@;<1[>L@D+<ZVTJEMIOZ4J)DD(]V^6)NT?MQ3%<Z8B5L^0*V2$JA54^
MY,Q#%$  P"84S?";<-M\>Y7 T.W]]23K]M607*>.*L1H!7HHD2<)I;-E%G3C
M8@E<$V,@5RFJKN4_:'<'XNX-A"]FW6!]E0-1<5?<,T%4!/%O01=CXV94GJ*B
M)P$1\'B>"GYD^Y!,1-W[@8I0 0^$=A!M;./;^G2I)!Z=:R12D 0$C4JY':)D
MVS<K14JZK==;9-(Z0H>0BK<Q [A'M$BA"CN&^X!0[&T.@^--/UU].]<-6XM'
M\<U6431\"(+LA2];^%(I2^($S^4Z@AWD'<0$=PW#J$!4!N&/^JGI6.DHTBT
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MFAM>E$?F9/A$&C'<1#<Q6C4Q-PZ[CL*X!^W5/;:^IH+7%6%4BC\3V6!P/]%
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M@ ^W?5AMO>Y JA%8R:H'3[G<,F0R8F3=% 'C<I52!^:F(^44P3, ]P#L&Y#
M/LU8Z?A;[J7I!_4,''&91\I(-X1*5=EC85H]GVT4ZM#E0HJ-6<<W?&25E%BH
ME$H-D0.NH!>X0 H[&E@WH02?W?[:J+M]U4(V>M.)*3AXN5CGL@R<I1[]LUL$
M8\7@I-=$QQAI9HW,==G)KHI"L@Q4 BRB?<(%["B.H"R6W7%7&FE7E+-6H)-Q
M+*33=!BH8J,K(N+,P12"0215<-_6NP,DB@JHT*H(%,<H$(4#=" (@O(1:XTJ
MK&QO2,&1J.Z=12P7.BO3N%3M(R-+>(61(J8# F86"*4SO)/&KK8I_$4WB[C
M !U$9 TVWT^/QIM/4U6M>J\^8(3;*V5!*")*I0Q96/L$ 1H^DW@%3+"MI1)Z
M9$)!<ARG3;%4]4ML D)L(")50:7N3^G[:=>E94I*QC5Y&Q:UAKL?)N%W1(YF
M_G8M%\\)&]Z<RVA8Q1UZV5=1B/>+E-!,_IA+^<!1#M$&6^H)O4D_"K4W9*36
MVK5U(VRO,RJ*LW 2$C.1,7%JH2:2Q6[L\E*/FQ7A7B '4;@0!\Y4C"3X"F$
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MO_,]I/:7<.@/Q&W]JG3[J^-T3MTDSH[*"H!5G*!3 9-914?(JJ@/X2KB<_\
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MG<ND?'1_U^8,?'\[?("23)#.JC=CR,5!;>VX17UTVM;0'9N-OR3CAHB$YO$
M0J  DD6[29!<@;009 -"#<7U(;]AS)FSD?/-,*\=,JV'%&+9278TZG6W";:&
M-DK,TJQ7DJ]8K_;;6=\R6I%7DY&/^60E?;231VHF(NGFYE4TM9\#A?'_ !F
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M&_:8!'?MU6Z[KD']/]%"15IKZHOD;R$ND=V.RZJQ5'"Y'8& " HF":0EV1
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M-R%$3&+["FV$-@$0U LW7J/W_94G2KJA09D,X0#=--,/,B78172(0.TZ0;@
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M+@A"NB*O$VX#V+@8Y'+</;^6Z*!AV .NQP,'[-83M0]0":R*C,"R@D#J?A5
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M10./8*1&I4Q(D<OC))G*HY#M<'V I@$-RHB CU 0TW/;;87_ $TIZW-**Y6
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M8^+\Q!M/)H_8V_G$B!QW0]_[H7V%;?C(-_2M&?$0_4N//^3RS(."DC^:W_\
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MIO3"EVB&R0$ZO+YSP!<;-@XS!6*63#DCA=HW<B1S.6)+2G:-,986"@Q#??\
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M+MT.0=]_MU.TJ+@_I^G[:7N=:^>4R3HA7!S';-B )')O:FJOW%(1U]H)I (
MH ;#W!W;>T6VZZ=3^FE+ZT' 471/"05&B"8N#MR!OXU51,DF=L'\XH)@<12]
MVX"7^B*Q*Z_B/Z:T]?LKX _VL'#/M51*B*RR)#  *JN3BEY$A'L*1SV)& 0'
M8#[[#L/74$:;6ZWIZZ5]1.7U#MTV#R("*"3AMM\?D[154,1(^W8X 5OS$QV
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MH:^/.K94 ]XIE />(F63  _:(Z+^*AZ5D:J>M35UNJ*"Z*X!N**J:H!]HIG
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M)!U*G(V7'0B(.)BATT\HD0<5]BU0;5H[7]W"LL[P6P6%&RF6=516>D'SH;@
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M[-BE#P["J<VQG!O((?BV((_S??J!^&R]:D]=:^KJ++E0! !03!TW %U" !A
M3"7=N@?8-NT1#N. !L/0IM  +[M3;]-:'[*NK(D3:N@* F,=!43J*#W**"5(
MVPG4'J.VW0/8'NVU4&[#X4MI6641'M$?:/:(_M'81_EU6K5"?(%=HVXXYU4>
M^E].AB+*1%5'AB$:()(TFT$,X=G5,1)-)% HB8QA[2>T>@:[C@U=N>PK>N7!
M_P"(M=!Y&R#@LS=Z8LW_ (;5Y$,.K6:-GG^/*.5:2R/:ZI$/2W2+0?F1J%.<
M5F7N%Q,!ZX5:RGFIJKMT(E=R+ Q&S>7,1$BBJR9P]J>1/A-@)RN7=>*@E=>R
M3[II0P2,68A;![R!=P#%!?05Y!X4Y0D; Q/?G3Q*>XM[11[2\AN+M?;9";&P
M8VU(IP35@L6+J^SX[8;G[Q*W:<:/ELAR='BW30DP^GF58EGE(K58295.;L+*
M"C(9TK)/7@LHKND#I]PH%746ZW'PL?G,AO*/(8((N-0+\O'*1=%7<-SN"RJ2
M6&U0&DT%M; =B^3-Q>.O \+-++F/N[[)?W,VUMJ@@,P7;[F)":D'0WK)D,50
M<*>2O6<Z0S=/&MB1;6?(W'?)[.+LU(L-DFH^'C_WD42)B7$=,L24)G,QQK)7
M'[9)1PDJDL?N0;^8.:R)W3 X3*;:R$Q8^9!=)$523V)F(8'N%&[4JD[;6ZFU
M6XQ(E;*YB%+J_OFQYK,CL=#+$ 5(V!UW(0-W7H+N$Y^/B"YIASDS(J]Z;/)>
MSSMO+.7]*:>QBD69*39O;3^C@=259D4'KV,:1@0K19*45>>1V5L@V(CPMOE\
MB!(\+$^2VJJQCM[ U_Q*@DMN! 9FWFZ;;+N+$YV/C*OOER9VR]S,7]X)76ZD
M[+V()4#:/?>[6  :3;##=VE'6K"U!:PSR>+.J5>VYWR5$6',F1EHXDG2,A2E
M'I<I&QM7I328>UM)-F_FI!5]*NFCIJ@X,FHJN'.'/$2OQW.9/<2-1W(L6 IC
M0[[.BS3+>24@$W5%  -R+BU<9N(1X(\CB,?8[,=DF1*&GEVW5S'$UE2Y LSD
MW(L#8WJ\WF9C/%:?8@RO/7AEENBIHS=-=7",F)!Y)-("O37S/'<]#C#6NY5&
MVM(>UORQ)S@NT<NX^/:IKE4=-5-5?"A\9SQS?"PX\GCN4I298RMDWD;95+.L
M;(652]@" S%AH:R1SS<_AGBN6EG3FL<AXF8&[; ;QD*I92%+;;DWVJ =132S
M9(V.2MUDK-[$(')6/Z_8TKW99 %2M+PVC7JS5M<$7,^<]B2E7\*Z(L9VJR2:
MN&*+9=06ZJYP/VW 18<&!'FX0[O%9,R]E 07B8CW1^WV[58$6N2"6 N%!KK>
M;DR)LIL7/M'R./$>XUK"0#H]CKN92-=H!L#U-=[/ITI1BGU1.6<DWDR.I-[Q
M#XI&D6:4(9B@DW_=KBI2-?)2WS5ZVE2O4U%"@#=,B*1$B@(F$=S>??J(TO\
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MQ8V-R,;;)2T>1(Q&2,J%,6YC6-&GC./)*\://CG;O8,F]=LN*U&DXY:RQ<S
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MSRS,K9?'JC%]H4R8K%F<-(VC21G<  -4C4M[CKKJS0\J(.,LRP9K,+$[@N0
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ME]B*BK3LE5:6JU;S'0G+F).VK9VZ*-:QT]K$]&1<1$6C"-B@&;<8F648M@.
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MC]8I]U?3 (&$YVBR2IOQ+LEBF[QZ?$<OY1E-P_I)FT_6+?;2K9U>XHE55(<
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MKQZ)=@$I#$11W#IN.[)*/('WF5';[=1;7VV'Z???]U#\#6>BLL&_ITF+4IP
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MDE),$^[N-W8_LQ"I)D( G4-UW H%.([="F]FNTX(VY[")U_XR'_Q%KI_(O\
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M.I4SR9FGLC*/7$BI#,BK*K+'5428MDC&%-L@1.D^=E9*[)G)CTTL !:]K
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M @AW"/\ 3,V%4BG_ "P'4B_2X(_3XU%Q5/F O:!7BXB.X@"D<J??;V@)R()
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M OPB8#;D3F3E 2B4=^@[;#I<?']U+5B&R4BF;REQ5F)BJ8>T%28W744$PCU
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M%:=-C*1;^5LDPU6GH9-G(B227!VNU?\ F,F5!8"&WGC)GQLO)XC'*/!C37B
M]P[4IWK9@%!V,2I*W%UM<L":U#DH%;&@Y&7<LL\/O)]OO0;&NI)(W* P#6-C
M\#7='Z=*S ?JA\KTB-Y<91'B!Q6!ZY=R#-[&I,@QSBOY8T9-D6J;F+<&$5U%
M4U%5 5W*H $WV'X)]13(OTIX9VV=D<MR%K [K]^:]R38_985]M\&"_\ ,/DK
M;M_]+PKW(M_=16TZBO0GKS^IN 1\*^UT:FE&E*-*4:4HTI1I2C2E&E*-*4:4
MHTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4J-5'"O[X6C7YM601'&LBX&",R*
M-R.J6T1:82R,CZ03EK*1#"BHCYP 71R&\8[=P;*L:_X/>7M96_\ J2#N[O\
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M5'\H_?2F1<*8YM*D8JA(-H-:+87)FBX;LS.G8*VJJ2%:2=)N@5:*(JQBKX'
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MT]!_HK -&/3]%(URH&VP HS5. ?L[DQVVU;NH.C 4V,>HJT$.[+OV,'Z>_\
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M[Z=E_A2\PK4D5%L#ZH645DA=E4[*Q-*^0%6SOTZS@XLNO@<F2[2D$X"4/B(
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M_P!ST[@_F_?3LO\ "C])VW_TM9__ ""8_P"YZ=P?S?OIV7^%'Z3MO_I:S_\
MD$Q_W/3N#^;]].R_PH_2=M_]+6?_ ,@F/^YZ=P?S?OIV7^%'Z3MO_I:S_P#D
M$Q_W/3N#^;]].R_PH_2=M_\ 2UG_ /()C_N>G<'\W[Z=E_A1^D[;_P"EK/\
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GKSRQ"-GA 72<5CQJD*DH *I%6L:*W8< W #E(;;V@ ]-14CK7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g156845sp17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g156845sp17.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M20':<XH ?0 4 9P:]%Y),+7$87;MW\M@\&@"S!=>9*8GB:)L;E#$9(H L8H
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MSU[GH/QH >;K]S&XV@LVT[FP 0#D?F* (QJ PNY ,[L8/4A@./KF@"XN=HW
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M  H =0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * *DUENE:>&1HYC[_ "DCU% $"?:KJY>*8O L
M8!!C/#'Z_P!* +$%A!!(9!N9R,9=LT 0WFGF5)/(VJ9!\RG@$]C]: +T898U
M#D%@!DCN: '4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
9!0 4 % !0 4 % "4@%H *8!0 4 % '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g156845sp17a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g156845sp17a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M^(=RL2"3P5XG,@4;B+$<GO\ Q4 =!X?U]]>BG=]&U+3/*8#;?PB,OGNO)R*
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>T/% &E##%;PI#!$D42#"HB@*H] !TH ?0 4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g156845sp69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g156845sp69.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M *_KSL_(I*\^1?U_6CZ[HQ+CXC>1I+WS6NG)GR&CCEU15:..4@*TPV$Q<'/
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M'7A:YL;:*VEN)9H)C$@7S$\O(#8ZX(IK6+N2XJ,XV)M5_P"2I^'_ /KSN?\
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M36S<M.UHWM]_WHQE)P@_2+OZRM^7XH+SQEJ-@E@IN9Y3#=7#W;K:&3= DYC
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..@ H * "@ H * "@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g99471g01k65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g01k65.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1= 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %R2^620X0DE-! 0      !D< 5H  QLE1QP"   ".HT< @4 !5!R:6YT
M #A"24T$)0      $&WL@;C9!'*,$ AL'"C%O<DX0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q <@            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ ._
M_C4  @ " [_^-0 "  (X0DE-!"8       X             /X   #A"24T$
M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              ".   !Y0
M   !                          $              >4   ".
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   ".     %)G
M:'1L;VYG   !Y0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG    C@    !29VAT;&]N9P   >4    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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M8GZ#&?X2QW\VQ"<0>$Q'S=%.PDO*C]=_KGU&]YP"6AO-&)C^L&C_ (1]
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M%S)"(U)Q@1@9&BABD:$D)2<I-T-4L7?1X?_$ !P!  $% 0$!
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MV+6)FH@XR"DTPHN(.$H(*9LQR@EH4022T_/XJ^%:YFIY"2S*H]YD9FNMV1M
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M5L??JIOO^^;;<.>^W=_*(>0[<^H>L7"<38^W53IO^<V^W/<!';?O#U >@<P
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MP\4@HLHY=,(V29)-G,[@.(*6 <]35./=C74\JW(!D(!.I"JH+L;  \CC+D]
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M1Z?_ +]^W.#/U#7_ ,14_P#;18Y3_!_J-]KVL+]!?0=SU'6V'9!Y@(#L(#N
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MAKR^( =00'92 %C&O+O]WK>]_L[8^1T.CMQ\>)0&X\\:H!ON CR?X7VYB/\
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#C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g99471g02j59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g02j59.jpg
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ML4=\)&WP88\YM P:ZEO>5&^;2ZKT[2M:4[F<E*UI;;2M?LUI2E*_8IJ>V+C
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M4AHY%DX8++=OMLD@O+>[N)>YUQ-J>55#03Z=+R_C#WJC/*0ZXN?!60D@C<>
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MD/@,GDYMK'+(B(;CK;9 GAA.I!L0+O),?=FZ+8G=O*%I&5/3%LA)DP]\](H
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M.T;U>>SNAG(&;>49)!  RF\D[@.<G<*=U-F-D+M&P8COCIO+<X53EF.)-P4
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MDF*"=X\;!JD!;P%4=63H$ _<*5KQ4;DK7JH5[FWDF8TC*2PRM&@6,12)$O)
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M]C-C_P#>?LE_]*[%*CNKJO,4TI32E-*4TI32E-*4TI32E-*5R_N1_P#L9_\
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M4ED[N>DTM.6W]\X;MGMQ=:]A?;53O6YE4*(-TZVV=BI?12MUU5*TK2VG/_\
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M*IJN7=US]:-Q(4L57L6HBZ*7O'+=!HW62:HUMQ&L4@1<X,-M(<G/?2V\4K^
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MS(P+,-+ *T:-([CM6YNLQHK!BVBW*!202SC?@&E>_C'>;@;(F>8 V+1>V*9
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M930&.?2"PD2;VO-<4>TKR.,1!XWC"",)-;6UPNA9'E52)X9,A)'=DSG1J(7
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M$(H02A%MV"( H)@EE?)$?LI,RNY5]+.K!65ET(55LK)6.ML$U0E(_(*T.;V
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ME332E-*4TI4;DW\'$_A)'_I)#2E232E-*4TI32E-*56'MO\ A2.)W\D/#O\
MS=W-:M[OVGV1^?VI_6LZ5VQF/$XK*%N-2;P2.-E\29-&94B0\N5)AQBLB8Q>
M70N[MUV,;$+JI5C\W/6)H/1)=@JXO1HNQYU$G;6NBN)K=9Q"0.V(3;R9'/&9
M(Y2 <$J=<2'4 2 "/#7-=M?)%JV>EK).'3,5V\L,4L6?QB+/#',\$F,,DAM[
MA<KH:(!^4CYAIP\,)&;B9IT.E>)Y"=DV0BY1' 65Y[CYFK&LG*@7,TQV\?QU
M>-7$87)2\>0EA 0V$!6XV5E3I:/4&/RY8B4[HMM;050)C;SZ5B51/!'<A6M]
M8@E!F0DSQHYC$A U1A8V5E1:RLY;\PZMH):1SL[$16KRSQ11 XB4SS1PO/+I
MRTDHM[=<MR:QD1B6220K8=A'#2D=E&'8\X9SS&\:'CL:7R^42(I&FY*+X'2V
M^Q%.3-D5;W;X2G!&0\:8N1I<]<*6N"R7.)WVWUF;:]W=<I'<N#%/(S3\G&BN
M5DO#>R:"1@,9BS+G<-R^QKJ+EL@^$G.!OWMJ./!SUZ&W/8G <(;;X)A!V^7N
MD$6F1K*JT[Q\X+P1\(RA)535A E!U4"3TD'CX6-'G.-(^%*/BZ"V-&C6,'DR
M;)5V@KE?;6FN[Z:["C1)$EN(9PDP>",)I$PTJK2/(@G=U52)R9$*M@T9R6+>
M#&,'>,#C\N_/'?6U+-I&&T&J?:C.6LY @JQ(MIVWG<KID!O)&)N72"LOMF"I
M14NK)"#Z=RUH8=N5UV9>.&WD-(,7$/OH!IS=T;G.\QE,%3$8H^1,92-.3,04
M)H BC*@ %9%$H(E[^HUM\&.&!C&X8QPW?'G?S[ZV_CS'4:QD"7!1JTHM0@6(
M2$X9/F",BDDED1:^R\B=D)XNX=$29%Q:BV:(U56HU&BV0X((;#PHL:/:<\T[
MSN'?2,*J(B(L<:(OL41% 50-Y.[+,6=BSLS&"2>?XMPQ@5EV_P!UQ?\ !R._
M2<HUJ\ ^,^9:Q\)^(>=JB4APAA:7!PT>EF(<7R<!'1"\?CX.0P"*&@X( ZJ.
MN= PPPD)<LA@AS<($U7&LD$&2U18ZJB%U63;L6U;B="S)/,C.P9F61U+,,X9
MB&!9AJ;!.2,G?O-37HW[?<"**G5U,(XAO6E+A-W)EK\:PRY61.D6LD9).3JE
MP6MY=PDSF4O:)K$*N%+&LJDC>VZB1PG8ZGMFY[W_ %B?O!A/QLG>C*G"]]WH
MRB'=C>BG^*,*R0W"V' QA&0B,38S%'V[0(/0.#8'%F)A!A&4@Z,;9(DVHI)Z
MFTCZ,> )!&UB]J(I(&'386-[!C*B&)N)V72TTK+ECI,CE<OJUG!;&6U-J..^
MU-G.3E7KQ[!>$HB;8R:*8=Q7&)(,MNL&R"/8]B04V/LO&WAK[6)4:(;/VEMP
MA105=:W<)TN&J7L:TJUON2K+7%PZE'GF=#SJTKLIWZMZEB#WW?<W/OYZ5Z/[
MW?;_ ,^4*> O#O9)N4H<FE_@RA7/EYNA]>54,2B[N)RGRE)0Y<R2A K5V[H?
M<+F.S=T55'%T]M7/>?ZQ/^+&F/\ '2=XNG1I3ON]&@!,+@:>]YMU*^3';U@(
M61$F!N#L/CBP!P&=@BC'&D+:$0KN.L  J/NA+UN%3<CG (7%(N-#+,U45!C"
M-@&;*Y!N'')MANKDA@;B<A@P8&60A@Y9F# M@AB[E@<Y+L3DL<JE,LQEC>>M
M2S*=8^A$T9GF@-@=:2R* 9&U-,(R0)%HVR+-S#!XD1:1XJ9,$P;9Y8LB)(%2
M3UA8W<OG2BN"2RQE3'+)&5+%2CLI4N KE2I&"RJJL1@L  <@"E16'[><!X](
MM#$#PCB2%F& FD?8%HMCF( 2C&/VM[V:0!D1%AVKQJ#08J7,&P=!9,:U'\U@
MW;),[+$;<Y+JYE!62XGD4MK*O*[ OG.H@L06)WEB,D[R<[Z5M4<.'B![$2)8
MLQ8H6S:CA@P<U09#QP]DA8V9,6+)M8DV:,VC9)-NU:MTTT&Z"=B25EB=EMM-
M))8EF)+$DDDDDDG)))WDD[R3O)I7N:BE59\2W^97^\?_  'JXV3_ "C^:_O*
M5L'*N#)MG#;YM OQ^Z!-)1AXQC[-X-20D7HT=?+(5MYR,QQJDZ58#2:ZXM3*
M\@@=)0UHA2JL.I([DNV7%B#!YIAN([>YO>4U:)UDMVT@$Z)+F(RXR0 >1630
M=^'T^#>%<OCME.\V.7$(U'9_$QT;F$T?SV=F@V3\J1MV>DF4"2B^X$@_CP)4
M=&7=LNJ2>D(TB3CT@(!7*SIU&CN/" 45=(^PW]@^'>)RT<8CC5HH7"I$/]64
M,V7&C #D.H8##K*K'2J;XXVK[SV+@9'YCE<F+Q^D+Q4&(#8KG?*+,@C%(W+,
M%NB$5$.VUB1$27"0*'Y5A;Z;1,M"#<UNDJ!V2/9(9E5[W&V$MY8G+QPJ92T[
M O;0D:W2X =LG#!I)(9!&ZR+&4TJ%5,2J\4VVT[^&T&%Q['>8*.CCS&4/=G#
M\ISIF2\H*W"CXA)!TBDX1\T>-N2 /#RD;>TB1- ] EE1_.6Q$X6+%## EWLX
MR,TD&%$T@14M[?2;4NA5'!!_&A=8#KIE&K^'&E056,8%@9O&F+P\.D*C!4LP
M-SLBO>,75<LZH22?R>3CZ)K+MVJERE@XPTL<VU0MM3=6K)67*IV6JWU=Q(LL
MI=<X*1+O&#E(D0\?"IQ\%*W#K12FE*JLVJ$+1&^_C'%;TJKVC,F[32%R-MU+
M+EK66R3%KFJ5M]:74LJI1*ME+JVW4MK7EK2O)R:N+T9V=L,<8;T=.T)A4#G;
MX_W"I3BWB48]DL/;3;)L<2A<9)Q:$S 7+L<%I=FF I#I/ \B9*E0F22YGC*%
MV1V48?A&,S,HRPPN&/PD:"FH>HUDA0I)&PE+";94J2&.%C(X>2,I*L=O(2DD
M42,B&:34D\DRI"=09V60: $+&<UM,;Q#-IY*.2"54R3<T$15FN^/J.H[(+E6
M+8<(E,FD*B*;,<[H6[T8=#R\VE] EY.L;B5XPR5[70+CK7.D[,O0RKR.2YPO
M?)@DLB*,EAC7)(L::L:WRHR0<*]1IQ#=M186]*1TY*Y*F,09]UZ 8/)";4&4
M,FB<8C (Z::,5@(HK+90.1 1M-P4[ 3=EA3M)QW*<*D&\]S+L,%94343IU2(
MI9557=E4D,51&UOWN0 1C. 5>&.\03!9".KR&2*22+H#0T-D$F3[TYB90@8[
M(C.RD!;3THUC* P":F$@1+1("/;.BS5](1=6*9.JSUHG?+;,N ^A-#DM(B?C
M(UY0Q'\88P7)944J[$@$*<XW&E;:8;J,4E(HI*6-)NLK2=CL9MX==CZ7-L@/
MYN8APO(P@&RACL4@:45(8Y,C9]VRH@DR'119P3,N1O<TJDQT&SF#Z#R>.3,I
MDY6,Q"-9#$S&0,5W2@Q8SDO@*#E<J^6W_<2&W$.<G$H@#=MH%"I%"PD2F#Z\
MHU7R"QF&(L>Y>1D3>/%(^)< !=@?) -HP1<OR!-Y<FY<D6(.[L#-5<VK6HA$
MC#E)%D9XQ@\D8YY8"I968,=43$X  Y@6YZ5T9KEI58?#!^U&^_\ M/-Z?Y[B
MM6^U_9;-_1%A_9M4#F^5O.:L\U45--*4TI32E-*55]BSX8#>+^(ULL_2SNTU
M;S>T=C^D;_\ L+*E;$B7#YQU$9="9FWF<U-DQSMA),I-I:6+3 /ES((J63&?
M#9NX!RHT9#8]7:SG*F8Y52/X_8!8]>6R0^7[0M4#B[T]4FTY9$DC,<:J04A*
M*L;0Q%(XS'J15:4&.&!"TI9],0&<,:5!(KPVA$&[P7$9RG19_C!6/.(CWV8W
M"R<.LN$Q?#<;K*RH-4X-3/7N[XHK(6RK-T#<"W9%!%NNHL*0(+['VHTG*AX=
MTP82:)61L--)+WC:3IQRFD@A@P!)&&*TKVHWPW8W"JX]LBN3'M6^&4'5^*[9
M9"0TG<W$CA+%Y.2+9=>(D@BF5!ERN*@B4/%HVPM6%INZWMB)-S'H4O&(?:KR
M<KKB'X\CEM$C)N43*@AR&Y$XF;E">4Y3&\#5)K5LC:[L_MV[S8J5M+H$XS'L
M08@P_C9M:X1N=UNAN.H%!\EY$("V4< C8F3R@PQ-A<,^AH=U(08VS$;.2C23
M%U,S 0=KO+[MJ-5TZ6:>>>7<0/QDLLD40)=BXA,]PPD(1CRY0J>3#,KN;5=2
MFE*:4KZMNW3A [/-[LBWI9HSCC4;(ISXQ_?A%;#B[\ZBX< 06X26U'-;T1Q=
MHUML:.7A"EE>UK5KNR777WWV53KKU5[MC:%B+""UN7BC[E;-<HH3 9K6/)[Y
M&.\!?#CX,UB0<Y!QN^.NE/<X'#=]#PGI.5>W]<7X2;9\>EZ(OLJ8;W7]$4]S
M@<-WT/">DY5[?T_"3;/CTO1%]E3#>Z_HBGN<#AN^AX3TG*O;^GX2;9\>EZ(O
MLJ8;W7]$4]S@<-WT/">DY5[?T_"3;/CTO1%]E3#>Z_HBL+(/W.9PXV M1RWP
M^)HK1V+1MY"<I_\ 2Z*,VJE/](_R>^FM?3W_ /C_ ,=!V2;9/\NE\/@B\ S^
M3H0P_C</ /"<5FO<X'#=]#PGI.5>W]/PDVSX]+T1?94PWNOZ(I[G X;OH>$]
M)RKV_I^$FV?'I>B+[*F&]U_1%/<X'#=]#PGI.5>W]/PDVSX]+T1?94PWNOZ(
MI[G X;OH>$])RKV_I^$FV?'I>B+[*F&]U_1%/<X'#=]#PGI.5>W]/PDVSX]+
MT1?94PWNOZ(K"T_<YG#CK(E!_@?$]K6A47E*=TY3R=GO?+HUK]O^=R]CLI3[
M/)_]=/PDVSC/;TOA\$7@Q_\ +^&H[[.-7@S[$5FO<X'#=]#PGI.5>W]/PDVS
MX]+T1?95.&]U_1%/<X'#=]#PGI.5>W]/PDVSX]+T1?94PWNOZ(I[G X;OH>$
M])RKV_I^$FV?'I>B+[*F&]U_1%=-;5^#1LFVBY#4R=BG%8 5*[QR@NPI?8^(
MNT62JJ:RK=JN9>D;V2;A5)*YU1E5O<ZHBC8XJI8E9;;RW>V-HWT8BN;F26,-
MJ",5"Z@" Q"JH)&=V<@;\#)--)/.Q(X8Q_G_ #PJV%-.Q*RQ-*RU-.RVEMEE
ME*6VVVTIR4MMMIR4I2E/L4IJLK*H[#Z5MCH^E?LTJ\I7_P"-'[JE=*A=XSQ)
M\YJ2Z5--*4TI32E1N3?P<3^$D?\ I)#2E232E-*4TI32E-*56'MO^%(XG?R0
M\._\W=S6K>[]I]D?G]J?UK.E6>:J*4TI32E-*4TI32E1QO\ =<7_  <COTG*
M-3X!\9\RU'A/Q#SM4CU%332E-*4TI32E-*4TI32E-*4TI56?$M_F5_O'_P !
MZN-D_P H_FO[RE;0R!C/)&5L';-8UCPI:%:-S4%+Y!)O+I4L!:PEKMOR<U1K
M) T)R5B64R$6M.WL(;M1@F:L;FT@5"''K4@-#/&M^B*6*&XO7E4L=,BQJ- 8
MR&ZB)TM)#.BD1B0DM&<KJ4$%@:5IB7,-^[::22(!F\P9XNA4LPHM$7&.5L>-
MT3L$A>8MM2Y1(&7FA%_/^W))C5OG2D^CTSD\X4,I#70=5\&:*QVF4.A#LTQH
MY,?+2).'$HE[R22"Z U+&!%A)3;\DT:1Z<AL$AA$J9[4%]ZLERN)DNY&.2V.
MQ<; LO#V38T<Q^Y2L*2AGM * 1Y%KCP3#1IAR&E(#/@R.%R$+1)C!J!A"PX7
M"&P9R0Z[T6"0LEJR,QDA)*K+G"&]#$&4N5#(UL759"K-@Z5(955QEA#%_$0@
M<+Q@X3#933*@6>W>DY3*R-I4C8_&X5W%Q7<$4$1C(NX7-0>;SU!_),>E1,G,
M/HCCB?Y':X^6OQFT8122&%^^XEV7))-WT.&[:Y/2ATX,]J]JK/%:V[1QD)*K
M(JO+'$TN)B710KI]W)>)!1L\J( RAT4L3R$C$FY4-@9 47QTV'YNK!97/G-C
MU@Y&;C7+IEA*ED4"7@L3N'ARY$M'A@Z^;O(!R!-EY&IDQF/7I:Y++*3;\HD0
MT[[4 W UN6G[W<Y/)\JKLO:F+R,)Q812RBYGSR1OLK9J,CG>3[HO2;.86:RM
M+BD"7,-(7?WL"J*PYT%O8AA+00D(85;#U@ !TW7#LN&\:)IAR(B"B&W4B'7R
M8D6%%D"F3OVPX;+,6U')U,#J*ND]<E*JMVIT9UWX<8VA%*JX^N3MIE'Z-.6M
M5F?[R3%O;25*6W67<JB'9+*<E]E>6OO76U]^EQ>Y[G;#QS\C>X^/NA-BH'.W
MQ_N%2.&[C]I.58QMQ@9[%IV/03(X$Q#\'L9DYQS+8E6/N<6"8FK'9*ZQOE+)
M+&+VR>$9+%8]&A,F*"B1D]*1D6[2K(S09!]C):WL+74JS*\D3"2Y,8E234)B
M^M>5AB+Z9(C*6AU!50OG0K$3GK_STUAJ9%V)% #HJ7@TGF3>#[2LC[E^Z4\K
M)LB'W.(\I8[C;[+T36DTUE\A)&L@*XP)8W;2B*'32RPR&32$#Q)*P"362:SR
M6T5;2LB1E[V*TQ'HB59H97$#A(T4+%RPE*.BX:2.0L-8&5;>Q+%\,Y$E.7\=
MJ;><J!E,?2>&QJ?R_+DV SBV22J&NXUG;'X^^1)9QR7/Y&NQ;Y*!S80^/,TQ
MS<:[MBQ1\V7$619IIF>>)()>V83RJ2-$D$;1Z$D#6\IT]KQ1J"8FC8*<EAK4
M$'65;%2V5[9DF:(^F-.RL+10<*_8NIC/WC.2CXVV4;Q:R;-G<J71GCF(*+."
M<-(32P\0B$@=O9+&G0N0O'1-;5V_=ZM7*]]J9@1'$"C.<OR>$_%B3 $@CTAU
M 1PR@"E;'+X'Q4:&F1;J,K,TSLL!SMZ0 R.4Q>1-YC&XA'<?A9(%E4:-B9-&
MRS.$14)%;G<=+BU'8)N['/:N&Y8O8^TK<3*5(8'2C1@,B.AC9VD9&1U9'4R.
MSX93AL$8*KA4BQ_C& XK%NP>/(N-B0=ZJ$67&";5DV7.CD+BV/ 5J#=595-J
MB,A<)BL?:MVMJ+>QD&;752N<7N%UL99I9F#2N78:@"W/W\CRMTR2.QSX6/@P
M*5/-:Z55]PXJ+N6&^&Z**)!6J?$FWB(DT9"C?)W#LZG-!M"9%@Y&KQ%,<)=J
M5LN8A7#0H\'66WV.#Q2M]%$[;:NH'9^LAO\ \JL2NE2F$Y,Z5;+/J8>%AI!\
M"+6(SX".<^#X3\(JQWM67^7(WZJE.N6JK=P/2.JIW\1T'KIVK+_+D;]52G7+
M3=P/2.JF_B.@]=.U9?Y<C?JJ4ZY:;N!Z1U4W\1T'KIVK+_+D;]52G7+3=P/2
M.JF_B.@]=.U9?Y<C?JJ4ZY:;N!Z1U4W\1T'KJMC&=CV[BP[M&S9PU2E*6RW9
MZJ5,KM%7$?>AE<H[IK1# ?&DWK8B,)L729-8B6<RPLU*(/&#9L%#J#G#HK:R
MZNXUD21H[?O@%P0X;D;/)+ZB"I& %$8(()+-D -_$='_ +U9/VK+_+D;]52G
M7+55NX'I'53?Q'0>NG:LO\N1OU5*=<M-W ](ZJ;^(Z#UT[5E_ER-^JI3KEIN
MX'I'53?Q'0>NG:LO\N1OU5*=<M-W ](ZJ;^(Z#UT[5E_ER-^JI3KEINX'I'5
M3?Q'0>NG:LO\N1OU5*=<M-W ](ZJ;^(Z#UT[5E_ER-^JI3KEINX'I'53?Q'0
M>NJW>&?8]<0G=U6..&HI%+B1;]$"J9MFM(%7LB1W RFPZ4'K,'T9L&!2+^BK
MD2!<H%WP5G>FQ>20\LE<05M=K9$EEK(8]RMF$:05 0VD>E2"7RP7 9@5#')"
M(#I#?Q'0>NK(NU9?Y<C?JJ4ZY:JMW ](ZJ;^(Z#UT[5E_ER-^JI3KEINX'I'
M53?Q'0>NG:LO\N1OU5*=<M-W ](ZJ;^(Z#UT[5E_ER-^JI3KEINX'I'53?Q'
M0>NH_*&TKH'OJJ:CU]G= )_HIQ@DG=SJFQU+*\^Z7*TY+;^;==;S.6^VEUE+
MK*W4OMD8SS'F/A' _!4'/$<X\!XCX:D':LO\N1OU5*=<M1NX'I'54[^(Z#UT
M[5E_ER-^JI3KEINX'I'53?Q'0>NG:LO\N1OU5*=<M-W ](ZJ;^(Z#UT[5E_E
MR-^JI3KEINX'I'53?Q'0>NG:LO\ +D;]52G7+3=P/2.JF_B.@]=1^UM*^^I6
MG=J/=E[WV]:W][!+L?8^Z+FE+>Q=]W.I?2[EK53LU;:VUI;V.E:<ZL[L#<><
M^$?!\%8[]7./8\/A^.I!VK+_ "Y&_54IURU&[@>D=59;^(Z#UT[5E_ER-^JI
M3KEINX'I'53?Q'0>NG:LO\N1OU5*=<M-W ](ZJ;^(Z#UT[5E_ER-^JI3KEIN
MX'I'53?Q'0>NG:LO\N1OU5*=<M-W ](ZJ;^(Z#UU'XLVE=03.J1J/6)\][S;
M5(P25OI_K[KG<M]LN2MKRW<M:<B=O)2M+:\ZM*W5;N!Z1U5BN=(WCP^#X3\-
M2#M67^7(WZJE.N6F[@>D=59;^(Z#UT[5E_ER-^JI3KEINX'I'53?Q'0>NG:L
MO\N1OU5*=<M-W ](ZJ;^(Z#UT[5E_ER-^JI3KEINX'I'53?Q'0>NH](VTKH@
M+[(:CU]*R$%2RED8))UM4J11['?=6Z7*\ZRV[DK>G2EEU]O+;:HG6O.HW<#T
MCJIOXCH/74A[5E_ER-^JI3KEINX'I'53?Q'0>NG:LO\ +D;]52G7+3=P/2.J
MF_B.@]=.U9?Y<C?JJ4ZY:;N!Z1U4W\1T'KIVK+_+D;]52G7+3=P/2.JF_B.@
M]=.U9?Y<C?JJ4ZY:;N!Z1U4W\1T'KJMW;W8]OXEO$A08.&K:1H8IV"W2(J\9
MK/@A1JL W&U!(A8^B^'OP+@<FF1M+.7TEDB9J]TRO9M %K!=,E:W6KN3LHD@
MH9MI:% (92&M-19RQ#@[M(")IP<E\C#?Q'0>NK(NU9?Y<C?JJ4ZY:JMW ](Z
MJ;^(Z#UT[5E_ER-^JI3KEINX'I'53?Q'0>NG:LO\N1OU5*=<M-W ](ZJ;^(Z
M#UT[5E_ER-^JI3KEINX'I'53?Q'0>NG:LO\ +D;]52G7+3=P/2.JF_B.@]=.
MU9?Y<C?JJ4ZY:;N!Z1U4W\1T'KJ/H-I7WU%:4-1ZBM(^ K??6,$JIW)U)27L
M=MJ??=2ZV^VZBE;[ZJWVWVWV6VIIU3NN5G=@;CSGPCX/@J-^3O',/ >)^&I!
MVK+_ "Y&_54IURU&[@>D=53OXCH/73M67^7(WZJE.N6F[@>D=5-_$=!ZZ=JR
M_P N1OU5*=<M-W ](ZJ;^(Z#UT[5E_ER-^JI3KEINX'I'53?Q'0>NG:LO\N1
MOU5*=<M-W ](ZJ;^(Z#UT[5E_ER-^JI3KEINX'I'53?Q'0>NG:LO\N1OU5*=
M<M-W ](ZJ;^(Z#UT[5E_ER-^JI3KEINX'I'53?Q'0>NG:LO\N1OU5*=<M-W
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MV^67>F"DWBJC8I2VV*V($W%BTA3> S[47FVR[D%])C9$9@TFO2@"(\CL68
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MS<T!=RI=658]3%PB!6V,)[B=I# 3/Y)B".F(S.".%G>Z2:8^?!)0!//P16.
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MU>)V77MEZV+6VW764I6]VA/);7.Q[B(@2P;-V9-&2-0#Q#6N0=Q&H#(\(W5
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M$C$ <I)WJY>34Y"@$D "E8E':I@-%^'*U@";HN%D+:5V&2,DEY0T:D; Q")
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M33=Q/0.NF_@.D]5._&4_$0'SQ'ZFF[B>@==-_ =)ZJ=^,I^(@/GB/U--W$]
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M,I^(@/GB/U-56[B>@==-_ =)ZJ=^,I^(@/GB/U--W$] ZZ;^ Z3U4[\93\1
M?/$?J:;N)Z!UTW\!TGJIWXRGXB ^>(_4TW<3T#KIOX#I/56#D<MDJHJ^Q1D"
MI;VZ(NY;%B%;N<F78J64_P!*SDY*WVVTN_EI;6M:>_R:D8SSGF/@' _#4'/
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M33=Q/0.NF_@.D]5._&4_$0'SQ'ZFF[B>@==-_ =)ZJ=^,I^(@/GB/U--W$]
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M"G4(P\:$J6C:,R8[[2S%WE,>IHQ*Y;#8S2L$UX<6&V&0 \Z8RF=I6QXI#B0
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M%1/)$2BJ6*QB0&3OCA"-ZE0=8(;*BE<@N.(><91]BL[RQMGLEA['D?ESV,)
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ME8X894JURZV=[G;W\I499S5;CBF1!\TM;O,GY'=/9"';1C.8DI"%"0N/Q]W
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M4I2O/K6O-IENT\Y]EP^#XZC?D;AS'PGB/@K,=GD7DL+T^^ZMZQW<3T#KJ=_
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M.4U,I61=P!1G5VWJMI32E54;$YY$L6XPXBF3)^;;QJ"X\W_[Y9O,Y$[2=+M
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M(BKE1ELLRJ"1DJZB<G  ))QG</@\.\BM.1[?MA!A$TR6=SH7;[-F<^G.,9%
MY9(V1Y4;+,<+,*2QV,.@6][8Q"![ P",*SAPR#B!P\V/MD5H(A>HQ2ZGV->-
M)ILT>^A:"*XCFBC9-44^H1AD<Y68LCKR(+LS(=&M<,9,;9[T:@1D$<#QX'X,
MYJ%5XCN);<G4B]S<?3%MRK=_9F^DGI?%ZPMSMO1W'(SBHRT#5Q8%J"6L%7W7
MD*6HH<XZLNFWLO8V[NX-SVOR@+&YP1VGR?XSE1?]H&'5KP7U]]C3O/> $X)G
MDSC._.<:<;\Z@N.?X1YOAK?>1]UV)<:SF*P4K(&+XH:D+*/'$!2A L6CKL_!
M)=.H<@A'@@HN5DQ67,X@]1$@@:2Q6]JK:6HWO9VIT7X8-FW,\,DRHRJJ,Z%M
M*JXCFBAE)=V58UB,JEG?"Y[W.>: C$%L8 XX&=X!YSNP3X=U9VFY#%78%CG?
M?'E(?W#"D&1=F^(OC[\V8E4CAUL4;PAH&5/J2!(]&WP2T$VL<RF^1M2T=7C;
M0@)7M5Q[0N<Z.2?E=;*R%0$5%CCEY4REM CT2*Y<D1A"KB0JPQ&EB<8.?_8'
MG^+?D[L>&MI0V:Q;((!M)X<9;' CI=ZTHZ;VKH*MB QVL/*BB;!XBV(B#(@B
MV<CBX8JT9E1)!NX8D6;9V@JC9S2PR0.8Y4*. IP<'*L RLK E61E(974E64A
ME)!!J""#@[C_ )_SGPU[Z/W1$?O*%_+C^L/ /C/F6L?"?B'G:M.&]T."8[9*
MEBL]12;PM$\ZD+MI'Y649-F$2(WAYH58O18)ZT-AH(:L[B3\T#6)"H(;O1#2
MYX%)KHM5.E;.Y?1IBSRA4("Z DN-4:D,P*M(O?1*P#2+ED#*":FI^ RA I/(
M+(D'D;5267PX5D"L5?-WX>3H0TV2(!QAYW'S+1@89,W!06^87VO&:#AJY1M2
M=HH7.&_9=3PRHNMD.CE#%K!#(9%4,5#J2I(5@=Q.0=W,:5ZL+R]C?(3\^,AT
MJ9&7L9JA<52M;D&5E6;IV98,S(IP29LV\@CCY_')"P8R8 J3CSU\!-,VA-9R
M*?)(3);S1!&DC*A_8G(.\!25;23H<!E)1]+@,I*@,,JE :5QJ0L;B04X,(L;
M"I(%>Y;NDKD[# @HN$)#+JW76UM>M"S99BHA6E+ZKV4MLI=2].Z[!HW0X96!
MP&P0?8LH8'XBI!SPI7MM3@EZNLV:OT%5D5DF]:<MUEBZBPUN73[254ML2(65
M&ND'55F-[A&RRZZV^^U1)6RR"C  D'!WYX8)7?PW@C!P:5_$#HARZN:(/VZB
MU$1Z]M:75H@NF4H]JP[4=UMHU>WN+1SR^B31996RQ'GJV66*)77BC 9*GP^#
M>-.,Y'.,9'.!STK'R6:1&&Q@]-99)@4<B,7'O"LCDIDHS'A 8T>C5=\]*$G*
MR;1F@U1ISUKUU;*6TK;3[-UM*RD<DCK'&C/(Y"HBJ2S$\P  R<TJ(F,X8EC[
M)V1-3V/CF; \I%G2[ES?;:G(TL=79;J#I;1*Z]4G?CBVLM09I6J+.!EUG:]B
MKE1-O=L6VG8@+$Q)3E!@<Z<KR&KGQIY;\63S!N?=OI7QC.<,43$X.C<;F@PD
M=*LGSQH,M1(-G-%1;LDP+!7E'K-M8-E8AT%-)EX81N:2T50,75(!6R(M^HW/
M;3QJ7>,A%(!;*D=\%*L,$Y1@RZ7&4;4N&.1E6UM:*567Q%_YG?[PO\#ZN-D_
MRC^:_O*5W7AK^)_%/R;0;\UQ>JVX_P!HG_/2_P!=J5LG6FE-*4TI32E-*4TI
M57FV=\L,WK\7PDWI95P/R'M>?(45MK<G59ILNQFNE12VVZRZZRMZ=M+[:76U
MK;RTI=2M>6ES=@-L_82GF,5X#\1VA,*@<[?'^X5KJ/[Z):U 0(Q+G^(<](%,
M<XZRHN]AB 2$,H3.)#@O<1D]W )%(3LUE\?!$TW6)!RH U;1E(!0QZ52)A2%
M[T.L[W/LV,M(J"XMB)IH )-4IDC2YM(1*BI'&[+B<ZUWJS!2K##8D=/Q5/+.
M*!#KG5B2D$;MV:0(Q<_)/)-*QEB<O$Q_(1J\>+$&<4C),<B';^/"<3<'&(+O
M_LD]7[5AB0H/CYPFSU'8S@9Y4DEET@)&Q,;-$N2RW#(LF)0X4L8M&"9U+J"K
MT+.*3&4A;8N0QHW2:NHWDAVWM&3HB;<O)5C>;YLAA,6FT98YH[ Q.J6$3DI<
M2[(*$&+61MT]7#0F0/HK)6(^3L5]143'(>$=]$% 2:.WD5L\J0S_ .L*FB+E
M%UC#2J'0E7?F",L)YMQD'R(F'2 W$"\Q!N1C8Q:?9HOH7,S\+(*L2W<\.Y<L
MG;Z/N';9,H$!'&22UK ^""FFK\8UK+J#M:9HM6K"QL&*Z21)&L@!7+ $!L'2
MS*<95F4@E6W]<]*:4II2J<MKN'VFX3;7Q4<"OSCB,,<U[SN(7B=Y)&C)(D[
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M[3B:,VYMY!:F,PZ1..6$/^KNOXTQ%3()K=9&)C*%&,2HBA2(UC!&DX(QN._
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M(#[4TP.(\O53)X'R==.Y,H\V7G20'VII@<1Y>JF3P/DZZ=R91YLO.D@/M33
MXCR]5,G@?)UU71PYH^4:B]Z=!:*<@M<<1?=RZ?W#UDVE Y1>8#+GL?>4,W#+
MG) 4I2B+MV,H^#.+[J7#B;U*EU]+7:I+'9^04QLJQ4:B#J C.'&DMA6YP&PP
M_C*#3/P'P\/ 2.-6+]R91YLO.D@/M355@<1Y>JF3P/DZZ=R91YLO.D@/M33
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MM55ID_'I$78!ET\F'#DX4D@X5N*>;E(7 <OP_";L%+3LQEPX":MMCR<742$
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MB:9F,3HLRQ1%G/*,@7D06_&8#EI"P3DT5G"R8*TJ-6<3QRR8P]Z:C4 &I*9
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M@]E(P;H,GCQB71K0RI FYERMDM4.3D)"*WSU\_*MX$WD-6DR:XW&T(Y[;D1
M4?2BZM>5)5@QE*^QY4J.2U!0_) +RNG,958UJJI32E-*5^0OQ6OA&-['XVFZ
M;]9#*^OMFQ?:NP_Y.S_9(*57OJTI32E-*5]R[]SF<(?*@_*D#WYY@3D<$0C*
M3HCB2'IO"8 D0:G!3P6O)I?8S<,G:@LB+?.$1<2=UN:DVCFKV0-5F=[8>O\
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MV)LZD;/*-G4G)Z"#G=IY*+&-WXJ/W"X5L"/XMQS%)1(IM&H3&@<MEERU\BD
MP2T:%"MSMWW1?5<.4D[;[:DR7(4+=A['W6*TH3)=M/Z4<4U--*Z+&\CLB8T*
MS$A<# P#P&Y?<C<,#=2I[K72FE*J]V>?"#<7KY7MG_ZEN*-6]][6;$_,7W[?
M/4#G;X_W"K0M5%332E-*4TI32E-*4TI58?#!I2HC?A2M.6E>)YO3I6E?L5IW
M[B_>KJWVO[+9OZ(L/[-J@<WRMYS75S/9_M6'(8Z:CMNV&Q[3$;8JRQBT8X]C
M+1I!69LJX/%&D9:MQR: ML[/NW)^Y!NG:DD>6O-H6)%*]MZXC?7C&4FZG)G(
M,Q,KDR%0%!<D]\0H"Y._2-)W;JFOZ4V@;6#;-N.+[>\0DF#4.K'463V!QYPT
MMCZ^,T,,+@;VZC&Y)4*OBAJTQZN*5LO8+1-DQ#*-[FC)HFB6^O%)*W4ZDL'R
M)7!UB4SAL@YU"8F75SZR6SDFE?,;M$VN!XX>B(O;_B1C&I0'7 R,*W@P!-@;
M%.I'=,7#8HE1E_KERLONNEESE>M[OOGKWP47H7I1Y0U[>,RNUS.61M2L9'RI
MT<GD;]WXOO,<VCO?8[J5D(?M:VWX]E8"<P7!F+8C,(J ;Q>.2..PH$)*A0C4
M6J"0:CW3)DBHW53!+N ?;]E:$;@KAP)O=W#G"S:^'O+J5&CDN)G1V+NC2,59
MBP;+ G>-0#8.X,-0&=]*VM$H=%($#2C4*CH>*Q]$@=+)!0+!N,&IDY.=)2>1
M/[&;5--&UV;D1@J;)KTL[(\*$7CQ>Z]=PI?=I>1Y&UR,SL0JZF))PBA%&3X%
M554<  /!2JXL6?# ;Q?Q&ME?Z6=VFK2;VCL?TC?_ -A94K7Q'$G$ 5QF9B(Z
M2S)@@4/RR*H1I [A!>HR%FX!E:2,\@,9:11=S*LL'Y=IC4,+9NIDX%-PA%X@
M]B+H,B[("=O+[,Y=9-$9PL;Z]-P,R++"IB,8Q'H,'*L2(PQ8 APV%97PGT$X
MAB4QMD<?=9#,E(T!R4"ADI!/]L#1>1&&^0]U;'$;[*0(Y0)'741(P%]MX)3.
MZ+Q9A(QUI-ZI'V(21)S%!@BDV7R95Q$H=X6D1A=G2G)6AG$+*68.)!=!-;E6
M( 8LG)DJ_O>IQ&8K(,SNX[?D-1I)"T^-XW9B2VVHG&ADBHX/ML0"G#";N5'H
M3$I&]%T=SE:*LLR.JY-P)U!GB;Y3)" YKV6Z0!Q%E%C64LMV&*][RY#1C#3C
M<+<MF(!91*,<CE5DF#AN41T(7OS#(2I^:DY=-B=Z1-O!FZ4>CJ\I*(P^.B.\
M(,)'KB646;B'2+@PL;DRKI\\[M&EEK4V3"JN#$9!R"JJ".,;N4[Y]"F1FY1F
M.HN6!TZ4P!I4#>5;@UHI32E-*5^=MG'@C;D=_6YW>IN!Q/+X6+C-^^S>9!%!
M9MF>6)(DHQN'G[ETXO4'M%FM6[BPRA1"VBE5:534Y]M*5MY?I4/9';;*M;"U
ME@FD;N=82ZD:,+A[6( 88@Y!4Y\%8EL'&"=V=U:Z]RY[W_/O&_1\J_[#67X:
MV7BEQ^O%Z5-7_"W13W+GO?\ /O&_1\J_[#3\-;+Q2X_7B]*FK_A;HJQ7AL_N
M9N0X[SDPR7NY,1N< (<LS)Q.'"AS^T"Z.(*W*V%I):631N)VC;TT;Q@FU"YC
M>[KVV_N7M;)-;ZO:W9:;JV,%E');<IE9I&93(4(]A&4)T:MX=^?&Y<$YJ"2V
MX @>$GS?YY_BK[K4:C(>)!V8,&R18L&*-B*22-E+:<EE*4Y;N3WZUK]FM:UK
M77B"2=YK(  8%>.5_:53[X@OIT;H.?Y&\QH>;Y5\XJ1ZBIII2FE*:4II2HY;
M]URWX.-_I-UJ? /C/F6L?X__ $_OJ1ZBLJ:4II2FE*:4J.1+[0,?Z[[Z0=Z5
MBGL1\OG-2/2LJ:4II2FE*C<F_@XG\)(_])(:4J2:4II2FE*:4II2JP]M_P *
M1Q._DAX=_P";NYK5O=^T^R/S^U/ZUG2M!2OA?9%)Y?>O1$TAW@P-3(U*79,L
MBZ=2L:.-/TG*P=(0H,79O2;5%.J+<C869-G:E;73FQM<E8WK^(-J?Z-NW[GL
MKFEM=K[)_!N\VM>;2ENKE99-IV]O>3K(]F+1K9X9KF- 52X6YABF8B601%5C
MK]Z;'_TLNQFT["X(;S86V_PLL=B6.R(;2S>&+8]U=6-LT4=\UZMU%-;VDLC:
MY+5K.>6!088C*KF6NF=S^TC*V3]RVWS.V-C@:T/B;&D[QS(HL6S3FO#C@ZA+
M9]B.8MW)!YB)@^1R#'4FN-G@XWCV>)J1207E&RI%!>UK6W7[%C18T2-<Z8T5
M%U$LVE0%&6.\G WD[R=YK\'22-+))*V-4CO(VD!5U.Q8Z5&Y1DG &X#<-U<"
M)\)_>0.%0<4!W4 14OCM<J-:YVOE&5#\JC@/+N/(C$G T#CB=H39!^;P^B K
M",$SD1EC',DC<)!1@K,KYR9?SD5*,ZPKYY'X4&YB=(16^-SW&&%HX 919E(L
M'8MRKE9UC_(SH&/RR/?R,[*\H8RR,H++D"L^C<[[ XQG*D:R*&M.S.KI50?D
ML>I6<DG!JF<K$ QLGS+6<N;I?0ED OD":9+DI7(49 YNVG9%@;62WT49"7TB
MCL4PIEP3W4:A1*"4CRR_*#4629@]?:I4TPCPT=Q^,,Q8IFTGRW"9R-@^?:Y<
M?3E].,T^$,=C2W&LG@UNVR/11=56#$\>JRHNCEM0N;>MN;*RIMI=%%WC,3*J
MO+Y*5=*W^ZXO^#D=^DY1J? /C/F6H\)^(>=JRCP4+(MUVI :P?-72R+ARV>,
MV[INX<-JH5;KKHKIWIK+(5:MJHJJ6W7I5;H5LNMJDGS0)!!!((! ()! .<@?
M <G/')XU-81."0=%*J*,-BB2-4DT*HIQX0FE5!&J=44:IVLZ6522JDE5-.M.
M995-.MMM.9;R9<I)^4?GS[)N<\YY^<TJ3)))-TDD$$DT4$4[$D44K+4TDDD[
M:6)I))V4ML333LMI99992EMMM*6VTI2E*:PY^>E>32E-*4TI32E-*4TI32E5
M9\2W^97^\?\ P'JXV3_*/YK^\I6>Q#OZPZ/Q-B]@M&\EW+,L=PIHK<D'B]R=
MRC:-#$5+DZWS*RZME;K*ULK=99=6VM*UMMKRTIKGV?,9ICJBWRR?QG]V?^"E
M;$\8+AGS9R=T-%>NFM7<Z?W47ZS^A2GC!<,^;.3NAHKUTT[G3^ZB_6?T*4\8
M+AGS9R=T-%>NFG<Z?W47ZS^A2GC!<,^;.3NAHKUTT[G3^ZB_6?T*4\8+AGS9
MR=T-%>NFG<Z?W47ZS^A2GC!<,^;.3NAHKUTT[G3^ZB_6?T*57/M6WK8K!;X^
M*1)G8#("C"<92VLOA*+85'+WC=('M)QH =VD4U96BBDHH\9*JMZ-G#NV]M<G
M>K>BK6Y&RUO;&9MG;'4-'E(;P');'?7TS#'><#OSC?4#G;X_W"K&/&"X9\V<
MG=#17KIJJ[G3^ZB_6?T*FGC!<,^;.3NAHKUTT[G3^ZB_6?T*4\8+AGS9R=T-
M%>NFG<Z?W47ZS^A2GC!<,^;.3NAHKUTT[G3^ZB_6?T*4\8+AGS9R=T-%>NFG
M<Z?W47ZS^A2GC!<,^;.3NAHKUTT[G3^ZB_6?T*4\8+AGS9R=T-%>NFG<Z?W4
M7ZS^A2J[>'7O7Q7$!>]!,D R O61\1+=O+V-6(J.*T2&GY@-<,T'?;$K;5L?
M)665HY21HNWLOY*).5J<MU+3:MC*YV?AHQIV78H<EN=4(.,(=W#P_!4#P_ 3
MY=_[ZL2\8+AGS9R=T-%>NFJON=/[J+]9_0J:>,%PSYLY.Z&BO733N=/[J+]9
M_0I3Q@N&?-G)W0T5ZZ:=SI_=1?K/Z%*>,%PSYLY.Z&BO733N=/[J+]9_0I3Q
M@N&?-G)W0T5ZZ:=SI_=1?K/Z%*KHQOO7Q6SXIVZN<*@,@7"3FSC:/'6C=,5'
M*D4WH#)NYQ\\5<I72NUM8U52-M+6UZ3M9:]1-Q15!&VQ.]:UEL9CL:S35'D7
M]ZY.6QAH;0#^)G.5.=W#?P>#/Q>7/55B_C!<,^;.3NAHKUTU5=SI_=1?K/Z%
M*>,%PSYLY.Z&BO733N=/[J+]9_0I3Q@N&?-G)W0T5ZZ:=SI_=1?K/Z%*>,%P
MSYLY.Z&BO733N=/[J+]9_0I3Q@N&?-G)W0T5ZZ:=SI_=1?K/Z%*>,%PSYLY.
MZ&BO733N=/[J+]9_0I3Q@N&?-G)W0T5ZZ:=SI_=1?K/Z%*KKX;V]7%,-AN[-
M C'I^LK(>(IOFF#:X>)C:EMH^39XDI(>D[N7E36ZC]%HHDB[L3M7034L[&@Z
M<)6VJ5M=K6,SR61#1[ME;-3>S<Z6J*<=X=Q()'P<X!I5BGC!<,^;.3NAHKUT
MU5=SI_=1?K/Z%*>,%PSYLY.Z&BO733N=/[J+]9_0I3Q@N&?-G)W0T5ZZ:=SI
M_=1?K/Z%*>,%PSYLY.Z&BO733N=/[J+]9_0I6!DW$ PVL(O3MC63:5J_#7\M
MP:+4IR)F1ZEWV)G6O+6VRM*>]]GDY:TI[])79TY.-<6\'^,_ _\ !4'?TCR$
M&L]XP7#/FSD[H:*]=-1W.G]U%^L_H5-/&"X9\V<G=#17KIIW.G]U%^L_H4IX
MP7#/FSD[H:*]=-.YT_NHOUG]"E/&"X9\V<G=#17KIIW.G]U%^L_H4IXP7#/F
MSD[H:*]=-.YT_NHOUG]"E8&WB 8;[Z%5^]K)O,J 02Y.XT6YW.H1<W\O)WY\
MG-Y*T]_EY>7^3D]_4]SI](.N+G/\9_"!_P 'P5&.^S\&/+6>\8+AGS9R=T-%
M>NFH[G3^ZB_6?T*FGC!<,^;.3NAHKUTT[G3^ZB_6?T*4\8+AGS9R=T-%>NFG
M<Z?W47ZS^A2GC!<,^;.3NAHKUTT[G3^ZB_6?T*4\8+AGS9R=T-%>NFG<Z?W4
M7ZS^A2L!&.(#AM$&S3NC63:W6WO.6MH:*UI_I/G-U.3EF=*_8K3E][[.I.S9
MP<:XOUG^SJ%& !_GGK/^,%PSYLY.Z&BO734=SI_=1?K/Z%33Q@N&?-G)W0T5
MZZ:=SI_=1?K/Z%*>,%PSYLY.Z&BO733N=/[J+]9_0I3Q@N&?-G)W0T5ZZ:=S
MI_=1?K/Z%*P$AX@&&UD!E+8UDRE4SX1:O.#1:G+:D01ONI3DF=?]*M*>]2O)
M2M?LUI3W]2-FSG/?Q;AGV3_9TK/^,%PSYLY.Z&BO734=SI_=1?K/Z%*>,%PS
MYLY.Z&BO733N=/[J+]9_0I3Q@N&?-G)W0T5ZZ:=SI_=1?K/Z%*>,%PSYLY.Z
M&BO733N=/[J+]9_0I3Q@N&?-G)W0T5ZZ:=SI_=1?K/Z%*KLP%O7Q6*XCO$2F
M#@!D"\9+L7;$V(U!$5'+GR"T7 [A4R%SY*^5IMTDUKB[:K.J#IS<I2Q?L]C>
MMJ=%;2YL96V5LM T>4GVEG);!U-:$8[S/@WY ^6E6)^,%PSYLY.Z&BO7357W
M.G]U%^L_H4IXP7#/FSD[H:*]=-.YT_NHOUG]"E/&"X9\V<G=#17KIIW.G]U%
M^L_H4IXP7#/FSD[H:*]=-.YT_NHOUG]"E/&"X9\V<G=#17KIIW.G]U%^L_H4
MIXP7#/FSD[H:*]=-.YT_NHOUG]"E8%#B 8;I*"B]8UDWF7@ *5*=QHMSJ7)$
M9'?=6M._/DYM:+6\VM*UK6M+N6E*4I6L]SI\#OHN<_QGX+_P5'A)^ >3/76>
M\8+AGS9R=T-%>NFH[G3^ZB_6?T*FGC!<,^;.3NAHKUTT[G3^ZB_6?T*4\8+A
MGS9R=T-%>NFG<Z?W47ZS^A2GC!<,^;.3NAHKUTT[G3^ZB_6?T*4\8+AGS9R=
MT-%>NFG<Z?W47ZS^A2GC!<,^;.3NAHKUTT[G3^ZB_6?T*4\8+AGS9R=T-%>N
MFG<Z?W47ZS^A2GC!<,^;.3NAHKUTT[G3^ZB_6?T*4\8+AGS9R=T-%>NFG<Z?
MW47ZS^A2GC!<,^;.3NAHKUTT[G3^ZB_6?T*57!Q!-Z>+9=X).YH"?H=S^_WL
MW;PJ.I\[MOO+['V+L$J<\[F]K*<_G\SDY;.;SN6[FV^R["9>7RT6_DN9F_\
'F?\ !2O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g99471g07q54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g07q54.jpg
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M 0$! ?_  !$( 0L"4 ,!$0 "$0$#$0'_Q  ?  $   8# 0$
M! 4&!P@) 0,* @O_Q !H$   !@$"!@$" @8$" 8*"!<! @,$!08'  @)$1(3
M%!46%R$Q01@B(R1180HE,G$S0E)R@8*1H28H-#E&MQDV0U1B<W9WHK(:)SI$
M4V.QLT5'55AE=7AY@X22DY25H[2UML'"QM76_\0 '0$!  (# 0$! 0
M      (# 00%!@<("?_$ %P1  (! P(#!00## 0)"08%!0$" P $$1(A!1,Q
M%")!46$&<8&A,D*1!Q4C)#-28G*QP='P0V.BX313<X*2D[*STA87-415@Y3"
MPPATA-/5\25%1L34&'6CI.+_V@ , P$  A$#$0 _ />#?\F8WQ1!!:<I9 I&
M-:R+UO&A8K_:X&G00R+L%!:, E[$_CH\7KH$E1;M0<=]8$U!33-T&Y25'<Z4
M5G/7"J6.// !-0>2.)=4CI&N<:G947)Z#+$#/QJD<I9@CJ7A>[Y6I:+#)K^(
MQE>K]C^K5F79OG.4W]2I\O:V%<J#B/,^]NZG@BRM&JD4C(& K@'!$E2$$!DB
M:I%1LH"ZJY(QH!8*2V<8QGQQ49)0D+RIB0B-W15(/,*J6"J1USC&V>M>=S9G
MQ4MYV1<Y;%F^1LE[3L[TO?2MD0MCP9@>%DV>6=J3:IL%I%K)VM<MCFGR4=&\
MNBR$NK4ZH)1DXTC7:RS0DL/4N+.W2.YTI/$UL5Q)*1RY]1QA1I&Y&ZZ2=L$]
M:X5IQ*[DEL^9):SI>&35# ");8*,@L=3' Z-K&VX!/6O0=N1W-X2VC8O>YFW
M!7/X#C>/FH&O/;&,#9;&1O*V:03BX9!2.JD/.2Q4G+U0B:CSP?#9D$5WKAN@
M4R@<R*&2=Q'$NIR"0,@9"@DXR1DX'0;GP%=NXN8;6,S3OHC#*I;2S8+'"[*"
M<$^.,#J<#>L'$>-QPU%Y&XPR6X-P,Q46+*2:Q XMRX66R"PD7R<;'O,21AJ.
M#[*+=\[5*HT5I;>7(XB"KV9(QJLU=3:&P>'W8"GE;-MG6F$.,D2'5B/ ZZ\8
M.W7:M/[\</RX$^Z $#ERYD!. 8AHS*#URF1I[V=(+"D=Q/$KQK<MGF,=T&TC
M=)C"C4^W[C*3B5Y?LF8JRI;&2KQV$T%BQ@\HU>I,M<ZO=W_CL7$=*3L"PA&K
M$$I%24".EXMV\E%:.L[PSPNS+$TFA713@8PX8L%91OL&)/3J#B,_$(WM([FU
MN(T1[A(M<D4K#)+!H]"H75S@$%E"@88G203:/+O$'W&4W='Q?,3PDE4B5#9G
ML70S[A)%S5FSA^QR&?"T5>#.;&^,X ]@BO?/%E BW!$4@:]#;N=)>H9QVL30
MV+D-JN+KE2=[8IS NP\#CQJJ:^N$N.*1*5TVEF)X<J"0_*#]X_6&?#R\:J'"
M&^O,.02\']S<LXXGITWO&Q??;9E'&3_%UW?67,DQ!4V*FD@QG8JU7)FF8Y1K
M#IT>0F$KC8:^G+,W*+2'._<I*HDQ);1IV_3&["WD54?6H$8+E>^I(9]0&!I!
MP=SM68;V5_O5KFB0W<;O)&8I"TI50WX-E5DC"YWULN0<#)K(?*'&4X<F'<O3
M>$KYN)8,;A4[ C4[O(Q5)R'9:+1;0X<J,B5^X9"KM5E*;"22+Y%=C)IKS)DH
M%ZV>-9]6+68O2-Z4L+J1!(L1*L-2@LBLZXSE$9@S#&XP#D;C-;$G%K"*5H7G
M =&".0DC(C$D:7D52BD$$,"W=P=6,'%WL^<2#9CMDMM4HV9LSLZY:;YCSZI4
M2,BJI>KH%VIRDB>*8.JD_I-9L,;8)28?IBC!UV+>.9^:()7<;&N60^2$([6>
M569(\JKB-B65=+$9[P8@@#Q)P!XFK)^(6ELZI-*%9X^:@"N^M,X&DHK!B3]%
M0=3=0" 2+@[4MY.W;>Q097(^W*_!=J]7K(\I]G;/(&Q52Q5>SL6[=VXAK!6;
M7%PTY'.!:NV[ANNHR,Q>IG/X;MP9NY*C&>"6W<)*NDD:AN&#*20""I((R#XU
M9;7<%XADMWUJK%&!5D96'4,K $'Q&V".AK";(.\K,]>XKDWM"9SE6B<*LN'O
M8MQI5G]9,_EXW(\;>INOHS#N59@O)NH!E&,45G,$T9+*.#)*"@5190J8["P1
MFQ$^"9#=B'K@:"FK&#@9SXDBM-[N9>)FUU*L(L6N,E<L) [+DD;E0!G2!DU-
M=EG$8QA;\,[-HK.VXZCY+S;NZD<RQ>*;UCW$.7Z!C+*TGC'(%HAY.'@BW*A0
M!*C+UR+:1%?<Q]S^.O+%.$(XKZ,HA,Q:SQ<6CK)<&.)DC@$9=&DC=T#HI!.&
M)8$DG*YP#@XP<9L^(1O%:":=9)KLS")XX9HXY#$[ J-<:Z"H &'TEC]'(85E
M5-;[]J%;OVX7&M@R]%PEFVITN"O^X)63@[6SK.-*W9V#&3KQI>ZK01:@]FII
MG(M3QE6A9N3L[U<ZC-O$*/4%VZ= MIBD3B,E9V*18(+.RG!PN=6 >K8TCQ-;
M37MLKSQM*%:V17G)5M,:N 5R^G26;.R ECY51&UCB7;--Y=OEL?X&RJYF[U%
M5U.YDJ%KHU]QQ/SE(7<(M4+I5V%_K5<4L]:57<($._A!>F9@X;'D$6:;EL96
M4UI<6ZAI$ 4G3J5E=0PZJQ0D*WH<9\,X-0MN(6EVYC@E+.%#Z61XV*$X#J'5
M=2Y\5SC(SC-8^\6+?%?=CB&RNS5BR52I4;*>\''.,LY3UMADI5E&8:D2.I"\
M2#9=0Y3PSAA#LG3T99 BRS1) YR)'$.0VV-LMR;A65F9+=WC"G!,@P%'KDG&
M/&J.)WCV?8V5D1);I(YF<9 B.[D'ZI R<[XJ[F+N)CM/W05K/L7MWS.V3R3A
MG&UGNTW#W_'>2*;,UJ%9PCAU%9"6I5NJD-9K-3&CI6-=/U*_&23LB+R.:.FC
M=W-Q"#VN2TGA,9EC[DC!5*NC!CG!4,K%5;K]+'CY'%L7$+:Y6<02_A(8V=E>
M.1&4!<ARCJK,F2"< G<# )%63Q'Q4=O&*MG>UW,N\7=+09R:S^PRVK6\JT/$
MN8*]0\A.,76J=0G2P=7D*"VLM66AHDD1!),K5#0CNSV!(Z=:0EE'[,JUCV<K
MSSQP0L!$4U(SHS(& QDAL-DY)*YTCZ6*IBXE!%:6TUW<(3.)=,J12JCF-FSA
M2@9,* ,.%+-LN21FP:''TVX7#>YMQV]8X?*/,*9<IR3VR90L.-\S1EN2R7<G
MKB&Q?CR$ISVEQ;AE&R;Q:"E96_KH3M5,QFTT#OH-&,>RBUOWLE6WEE;',C;
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M>62AQ*5TA^V0%1/];515E^DI&>F01TZ]:V%96SI96QC.D@XSN,X/B-QYU/\
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M1DC0P"*0^*K:"\2/EQ"085EC*OT*1Q01EM,\) Q&9AJ,BDR,&C+8%;Z@ 0
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M/YQ_L_\ #3Z'YF3_ ,#O-SBKR_*0H&UI<!_O\';]%CR_CR$H_P !#3M=J?\
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MI&+_ "US9/N<>PTOT_9CA9]1"R'[4=2/A5@XI?@8%R_Q5#\RI-5W'\0W?=&
M4&N[_<,;I_#V&4+-,C]OM^L,R]D.O_7ZN8_<>>M-_N5>P+__ *=M4]$EN5_]
M;/SJ8XO?C^GS[T3]RC^>E5BRXI/$/C^7C;N,JFY<N7FFJLK^'X<QE:T]$W\^
MKF(_GSUIO]Q_V!?_ /)V3]2[N5_]0U,<9OO\8A]\:_NZ_&JG:\7GB5,^78W9
MVX>G\/*H6%'_ /M&0QBZ$W^L(_SYZUF^XK[!-G_\/O%S^;Q"X&/=N?GFI#C=
M\/&(^^/_ /ZJ?-^,YQ.4/M^E3(+E#ER*XPWMR4_OYG##I51Y_GS4'^7+[ZH;
M[B'L&>EMQ)>OT>)2_P#F5AMX;5+[^7OE!_JV_P".IJCQKN)BERZ]QJ#CE^(+
M8<P27G_?V,9H#_L$-5'[AGL*1LG%E/F.(9_; :#CMYXK ?\ ,?\ ^94P+QN^
M)24.0YXAE/Q^ZF'\/\_Q^W^#I*8?;\/P_P!^H?\ ,5[$>'WV_P#' _\ H"I?
M?Z[_ ,7!_HO_ ,==P<<'B3   .;J\(@ !S'$&*>8_P QY5( YC^(\@ /X  :
MQ_S$^Q/YW%__ !R__(K'W]O/S(?]%O\ BKD>.#Q)A 0^MU=#F'XAB#%/,/YA
MSJ0AS#^8"'\0'3_F)]B?SN+G_P"-7_Y'\*??V\_,A_T6_P"*N@W&[XE)@Y!G
M>%)_,F'\/\_Q_P#C*2H'/\OPY?RYZS_S%>Q'C]]O_' ?^@:S]_KO_%P?Z+_\
M=0"W&OXF"HCT;C&[?G^2.',%& /Q_#R,:+C_ +1'\/[^<Q]PSV% W3BS'S/$
M,?L@%8/';SP6 ?YC_P#S/'W5*5^,YQ.5_L&ZB00*/XE0PWMR)_Z9L.G5#E_(
MX?SYZM7[A_L&.MMQ)OUN)2_/2JBL??R]\H!_W;?O>I$ZXO7$K> (+[L[: &_
M'Q:#A./'_0,?C!J)?]40_ER'5R_<5]@EQ^(7C8_.XA<'/OP143QN^/C$/='_
M !8U3#WBE<1"0Y^3NXRH7G^/A?$XO_8,56&0E_T<N7Y??6TGW'_8%/\ \G9_
MU[NY/_J"HGC-\?KH/=&O_P!JHY_Q#]]\F!@=;OMPI>KGS\#)UDAQ^X<OU1AG
MD>)/[R=(@/W 0'[ZVX_N4^P,?_Z>MG_RDMRW_K"H'B]__C@/^[C_ 'J:H22W
MC;P9@#%E=V^Z5^F;\4'.XG,2C;[_ (@#4;IXY0'\P*D #^ ARUNQ_<X]AHOH
M>S'"Q^M"SG[7=B?C4#Q2_.QN7^"H/V(*MQ+YBS#8.KY!E[*\_P!8"!_>9)NL
MP!P'\0.$E..>L!_/JYZZ,/L;[*08Y7L]PE<=/Q*!L8_61JK-_>MUN9?/9L?L
MQ]G2K:O$49%<74BD1^Z'\7+XH.W _F/-=P"BH\Q#F/,X\Q^_XZZ47!>#PC$/
M">&Q>/X.QM4WZYRL0.?6JVN;EOI3S'/G*Y_\U$VZ"/\ @D4DO_%ID)_ZI0UO
M1PPQ?DH8H_\ )QHG^R!51=V^DS-[V)_::[=6U&J@J55L%ZM5;I-3BW,W:;?/
M1%8KD,S*!W<K.SK]O%Q,<V*(E**[Q\Z0;I]1BE Z@"8Q2@(AKW=U;V-K<7MU
M*L-M:02W-Q,YPD4$"-)+(Q\D168^@VJ2*SLJ*,L[!5 \2QP!\2:_1TV<;;*_
MM*VWXOP5 ^,X7J,"DI:IELF) LEYES&E+A/B8Y07,B_G'+L(Q-R915C"HQD8
M!Q18I 7^?7M;[0W'M3[0\2XW/J47<Y%M"QSV>RB'+M(-CI!C@5.85P'F,DF,
MN:]]:VZVMO%"OU%[Q_.<[NWQ8G'D,#PJ]U_OM-Q71KADO(EBC:C0J!69NXW*
MTS"PMXJO5FN1SB6FYA^J4ISE:Q\>T<.502346.5/H1245,0AN!#%)/+'!"C2
M2S.L<<:C+.[L%55'FS$ 5>2 "2<  DGR W)K4-@#CX; ]Q&9\=86KCO-M&>Y
MIFW5;P9D++&'YRB8KS5/MWQ8Q&(Q];7CMTHY>R$B=&,CDY^+KX.)ATQ@3&3G
M9!A&N?0W?LGQ:SMIKEQ:RBU4/=0V]RDT]LA&2TT8 P%&2Q1GPH9]T5F%"743
MLJ@L-60I92 Q!Q@'^(&^!U(!NXOQ>MJ[?=07:R>#S29P.X!KM.-GHE 9FVYI
M[H7D#\@;X#/>ODH6+ZAG1_J\6Y*2>#)*<VYYPJ)3.0UQ[/7QL.W![;_ SQ#L
MG-;MG8 ^@W?*Y>CDYWSS=97<(>E2YZ:]&&^EHU8&C7^;G.<_#J:RNJV[#'5V
MW793VA5.'ND[>\)8RH^2,KW1C'09\8T9UDE\\)1L:S4V>Q$L9,F6.O1[N\,H
M5M4G$*2G)DD'5B;OEV\8KH26$T5A!Q&1HEBNIY8;>,LW/E$ '-F5=&CD(Y$1
M<R!N9W0A )$PX+M& 254%CMI&KHI.<ZB-^F,>/A63NM&ITTI5+W2\4K&]8EK
MMD2WU>A4R!207G+==+!$U:L0J#EVW8-EI:?G';&*CDG#YVU9(*/':)%7;ENV
M3$RRR9#256=@J*S,>BJ"S'QV R3MY5%W2-2\CJB+NSNP50,XR68@#<@;GK4C
MM.7\34>AM\IW7*&.Z?C%XUAGK3(UINU:K]#=,K%XXU]VWM\M)M*^NUG0=M!A
MG"4@9*3\IOX1U^\GU96-V;0J.S[C0JDMD=1I SMX[;>-1:6)$YKR1I'@'F,Z
MJF&QI.LD+ALC!SOD8ZU1.0MU.V#$DRSKF5MR&!<96&0AV=A80.0LP8]I<R^@
M)%5RC'SC.+LEBC7SF'?K,GB3.310.R=*M'*:"YS(*@220S2#5'#*X!P2D;L
M1U&0",C(VZ[U"2YMHF"RW$$;$!@LDL:,5.<, S D'!P>AP:N)0,EXYRO7D[;
MBV_TG)545<K,TK-0+5!7*O*O&P)BX:IS5=?R,:=R@"J0K(%<BJD"B8G(4#EY
MP9'0Z75D;KAE*G!Z'! -6))'*NJ-TD7.-2,KKD=1E21GXU 1&7\2V#(5CQ)
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M19L4UUTD5'KL&SAX+5H10Q3.7(-&CMT*"('5\9JX7Z>TBH8K]W6L$@8R0,G
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MF TJ6"_5J4D(35*7[BR<\IIW+CH V?%B, KMTSXU97 W$%=\,^L9@;YTV[9
MS!FU\XQ=O5XK6:Z]9ZI7BX"M&\VWQ,#BS'5>I%@4<67(">*J>_J%4-4:Z^80
MM<:1T@]BWID7DB1GLW?"!QJ2V[+>0V]J.?PS@%JZ2/VJ/AL;/<3/*G<A-Q*)
M).:X+R%E##928++R0VM&9MI)V&.Z9#A0!U.!@8&P^W'J_071=((N6ZA%F[A)
M-=!9,P&3515("B2A#!]C$4(8IBF#["40$->!(P2#U&QK>KMTI6I/CK_\T[O%
M_P#)&A_]<..];W#?\.M_UF_W;US.,_\ 1EW^HG^]2O/EQ#=RN^2Z\'"C8PRE
MPZGN',#-,>[6F4=N35W0XOO2$K%UXE(^&S 8I@H%I:V07T&D<)&*T@9>N>T
M)(ZXM%NKJ6D-LE^72[$DNJ;\#R77!.K4-98J=._AOC:N%Q"XO7X6D<M@880E
MOBX[3&^0NG2>4%#C7MMG*YWSBKR;Y'^.8[C+85<91V<7G?/6/^QLT%/Z'8]Q
MI%97L R1[C=?#N'Q6842:>#7R@LBZD^KNLADTBD 07-JJ#6>'R:+A;9NVO\
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M4AK P;-Y]@W7@9DCF(>D=P4G),BE2.X(X2VK&[DL+N"\B2*26W<21K,I>/6
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M*7.A 5BY+)N4="68AL[@$MX'; Z[UJQ\&@2S>S,LC!I^TQR[+)%(%1%*D;9
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M6+?5EU>RW31,P"&(;!<X+D@M)O\ 68@?95-CPR&Q6=4)D$Y[VL#(C (6/U4
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MPH*MU5@5;K/V\HV(_/&C$2='MU[)\2X]%[/\1X)/:0<>]E^(Q\1L!?<SL=P
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M$>56[A'W/N)7L/MK?>UEQ9+QCVSMQ9NG#.;+:\,MH82EMRFG"O+(DBP.4)9
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M=RWA(P&<4@Y4335<),R+*D*H<P:^N<!X1#P#@O#.#6[F2+AMG!:B5@%:9HT
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M(CL.G<W6O1X"'3S.0?TLZ.TZ1^=R,G\IA:;^GSZ9^6WOW\JEB*NZ/Q6XN&.
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MZ>;%C(U8U<CG$X..:(@.X7(=[T^?E_''P]:B'"NYSDKXK+! FYRW8!Q*9!*
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M"?%-W;$Y=4]2E>7X]RDQ@<_[^THG^/\ +E_+EJL_<M]DCTM[T>Z]E_>#6?\
ME!Q+\^+_ %2U$!Q5-V0!R]G0A_F-+;\Q_P!CT _V &H_\U?LG_BK_P#\:W_!
M6?\ E#Q'\Z'_ %0_C0>*INR$.7LZ$'\PI;?F'^UZ(?[0'3_FL]D_\5?_ /C6
M_P""G_*'B/YT/^J'\:AU.*=NV/SZ9ZE)<_\ (I,:/+^[NJ*?[^>I#[EOLD.M
MO>GWWLO[@*Q_R@XE^?%_JE_C4 KQ0MWRG/HN59;_ /BJ+63<O[N^Q6_#^?/\
M/O\ GJQ?N8>R ZV=RWZU]<C_ &76L'C_ !(_TD8]T*?O!J3N.)?O+7Y]O*C%
MIS_[WQ]CHW+^[RZJZ_#^?/5R_<U]C5Z\*=_UN(<1'^Q=K43Q[B9Z3J/=##^]
M#5.N^(;O(>@(+9LE"<_Q\2K4)@/^@6-4;"7_ %>6MA/N>^QR?1X)$?U[J_D_
MWEVU5GC7$SUNF^$<(_9&*I5]O;W8R &!?/%_3ZN?/P9)&,'[_P !C6S02_ZO
M+E^6MN/V)]E(_H\!X><?XR(R_P"]9\_&JSQ7B)ZWDWP(7_9 JAY+<ON+F.H)
M+/.8G9#<^:*F2;@#?[_CR;)S!&Y>?Y]*8<_PUNQ>S7L[#CE<!X.A'UAPVSU?
MZ9A+'XFJFO[Y_I7ER?3GR ?8& ^56YEKO=)\#A.V^T30'Y]82T_+20'Y_CU@
M\=K ;G^?/GSUT8;&RM\<BSM8,=.3;Q1X]VA%Q5#33/\ 3ED;]9V;]I-4OK:J
MNFE*]!_",PQ\=QO<,V2K3HDL@R0UJL*JDY')4ZPX.62=-C\@'M2]F%=JX(/4
M GK#8Y1 ##S_ #]]UOC/:.)6?!(GS%P^+M-TH.QN[E1RU8?G0VVEU/E=,*]G
M[-VO+@DNF&&F;0GGRT.Y'HSY'^8#6X'7R"O2TTI32E:9MS/'=V);7<R7["-F
M-G#)-CPZK'H9RL6%<1RM_H>$G$B9,$T,D6LLA%-&"S45"I2"<(E/&82!',(Y
M[<\Q?1;;TEE[*\5OK:&Z06L*7.HVJ7-PL,MT%\8(R&)SU77HU+AQW"K'7>YB
M1BAU,5^D5&0OO.1\LX.0=QBLC]R'$^VF[9-KF*=X]KLEJO.!<USM2@<=6C%%
M2?7-Y-*W6I6>ZP3Y6&%6,D(UB,-49=.1]BDV?1,J1&(D6+9^99%'2LN!\0OK
MZ?AT:1Q7=LDCS1W$@B"\J1(G75W@6U2+C!(9<LI(P3-YHT19"258@ J,]02/
M=L#\=JQMVE<>#8IO2W"TK;'A@N<0RC?&-GDH5O<<3O:S!HL*C5YNVRKR5EEI
M9UZ]L:.@'K5DNJV,BZE564<4Y5G1-;O$/97BO#+.6^N>R\B(HK&.X61M4CK&
MH50HU'+@D Y"Y;H*@ES%(P1=1)SU7 V!.Y^'VU="6XO>UB&W3DVM.H+-2BP9
M_KNT]WGMM0&*NW..W/6N!5GX' [R\FLY+&%_?(I'8]IM27,"VD@,@ZG4$DEG
M"="^SU^UAVX/; =D?B M#,>V-8QOH>[$6@IR5.Y)E#Z=PG05(SH'T8;Z037@
M:-9Z)G.<GH-L9\:ROKV[#'5NW99$V>5>&ND_D#$.**?E7*=QCHZ#4QE0 R#*
MO&=%QW8YM2QI6)#)=KAH]_=(F!:U-W%C3FIY1W/-'"K9@OH/831\/AXC(T20
MW%Q);P1L7Y\W)4&69%"%#!&S")G,@;F'2$(!(F)%,C1C)95#,=L#)V!WSDC?
MIC'C63NM&IU2UUO-*QM5Y:[Y%N%6H-+@$D%YVWW6P1-5J\*@Z=MV#9:6GYUV
MPBHY)P^=M62"CQVB15VY;MDQ,LLF0TE5G8*BLS'HJ@LQ\=@,D[>51=TC4O(Z
MHB[L[L%4#.,EF( W(&YZU([3F#$M&H;?*EURCCJGXP>-89\TR/:;M6J_0W3*
MQ^/\>>-[?+2;2O+M9WS&GIG"4B9*4\IOX)U^^EU96-V;0J.SY(T*I+9&<C2!
MG(P<[;8.:BTL2)S7DC2,@$2,ZJA#?1.LD+ALC&^^=J[TLK8N6O;3%J.2:"KD
MU_5R7=CCE*XUU2]O:6HN=JG;VE0+(C8'%74<IG;DGT8\\49<AT2NQ4*)0QH?
M3KT-HU:=>DZ=773JQC5C?&<TYL6L1<R/F%=8CUKK*?G!,ZBOZ6,>M5]J-65;
MFCYAQ)DV5N,%C;*6.<A3F.Y8('($-1[O6;9*T6=%S(LPA;C'0,F_=UB6%W#R
M[4(Z;18O!<Q4B@"/=8N2I3:-T"ET= XRA92H8;'*D@!A@C<9&X\ZK26*0N(Y
M(Y#&=+A'5BC;C2X4DJ<@C!P=CY&JNL5BK]0@)NUVR=AJO5ZU%2$]8[)8I-E"
MP$!!Q+55]*S,W,22[:.BHJ,9(+O)"1?.4&;-JBJX<K)HIG.$0"Q"J"S$@  $
MDD]  -R3X 5-F5%9G8*J@LS,0JJH&26)P  -R2< =:L/3]Y&T+(=ACJC0-U6
MVZ\VN87(UB*Q3\Y8QLUAE'2@\B-HZ%A;0]DGRYQ^Q$6S950P_8"CJQH)T!9X
M954=2T;J![R5 JA+NUD8)'<V[L=@J31LQ/D%#$GX"JJRAN.V\X0?147FG/&&
M<0R4ZT7?PD=E#*%(H#Z88M5BMW+V*:6N<B7$@T;N#%07<M$UD4EC%24.4X@4
M<)%+("8XI) -B41F /D=(./C4I+B"$@33PQ%AD"21$) V) 9@2,^(J/QCGG!
MN;4Y)7#.9\49<2ANS[A3&.1:A?DXKR1.#?V1ZK,2Q6/D"FH"/E"EW13."?5T
MFY8>.2/:1'0GH'5E_P!H"LQSPS9Y,T4N.O+D1\>_23CXU:<N_/8T=R#(F\[:
M@=X9;QBM"[BL0&<BXZ^WV 0"X"J*W<_4[0$Z^O\ 5Z>K[:L[-<XSV>?'GRI,
M?;IJOMMGG':[;.<8Y\6<^6-><U?BVY,QO0*<MD2]Y!I%*Q^W;,WJ]ZMMK@:W
M3D&<CVO7NUK/,OV4(DV?=Y'PUSOBI.NZEV#G[A.=2H[-I569CL%526)'48 )
M^57/)&B&1Y$2, $N[*J 'H2Q(7!\#FOFJ9.QM>Z6GDBC9!I%TQXLS>R"-[J5
MK@K)35F$8"II%XC9H9^]A56K $%A>+IO3)-NRKWC$Z#<C(ZMI965AL592&!/
M08(!^5%DC=.8DB/'@D.C*R$#J0RD@@>AKA+*&-5L=M,O)Y!I0XH?5EC=&>3#
M6B$3H+FGR3)&1CK2C;U'I8 ]=?1[EN]:3(2'KG#1=)PDX,DH0XM#AS'H;6&*
ME-)U:@<%=.,YSMC&:<R/EB7F)RBH<2:ET:",AM>=.DC?.<8WS7&.LI8QS!6T
M[EB3(U$RE4%73ABE:L=6^OW>MJOFH)BZ9ISE9D).,.Z; JD+AN5T*R(*IBH0
MO67F='C.ET9&ZZ74J<>>" :1RQRKKBD25"2 \;JZDCJ-2DC(\=Z[HW)6.9F\
M63&4/?Z5*Y)IL=%2]OQ]&VJ"?7BJQ,ZD1>$E+)4VK]6>@XZ81436BGLFP:MI
M!)0BC158ABB(HX4.58(Q(5BI"L1U ;&"1X@':@DC+M&'0R( S1AE+JK?1+*#
MJ /@2 #X56"ZZ+9%9RY62;MVZ2B[APNH1)%!%(@J*K+*J"5-))(A3'44.8I"
M$*)C"  (ZCUZ5/IUJV6-,Y83S06;/AW,.+<L$K+M-A8S8TR#4KV6OOEN[VF4
MV:K2\J$4[5["_;;/Q;K'[*O20>V?IF\<D>-:.F1D:U9<CS&0,CW55'-#-JY4
ML4NDX;ER*^D^3:2<'8[''2IZ_P E8ZBKS XOE+_2HW)=JB9&>J^/']J@F=YL
MD'#]P9:9@:DX?IS\Q$Q8)*^QD8^/<,V/;4\E9+H-RP%8J7"L44@%@#I!/0%L
M8!/@"=ZD9(PZQ&1!(P++&64.RCJRH3J('B0"!XU,[9;ZG0:W,7*]6BNTNH5Y
MF>1G[5;)J-KE;@X],Q2J/IB<F'+.,C&:9CD*=T]=((%,<H&. F !PJLQ"JI9
MB<!5!))\@!DD^ZLNZ(I=V5$499G8*JCS+$@ >I-66I.\':3DJQ1]/QSNDVZ7
M^VRR@HQ57I.;<:6JQ2:Q2&4,E'PD%9G\F]4 A#'$C9JH8"%,80Y%$0L:"= 2
M\,J =2T;J![R0!5*7=K(P6.YMW8[!4FC9B?(!6)/P%9%ZJK8II2J;M]QJ&/J
MU+W.^VJMTBGU]KYT_:[?.1E:K4&R[B:/F2\[,NF47&M>\JDEY#UT@CW%$R=?
M4<H#E59R%52S'8*H))/D ,D_"HNZ(I=V5$499G8*JCS+$@ >I-=\7:*S.1=;
MG(2Q04Q"7%HRD*C,1<O'R$7:F$C$J3T>]K<@T<+-)QH_@D5IIDYC%G2+J)24
MD4#J,R&6 002"""I(8$$$$'!!!W!!V.?':@92%(92' *$$$,"-0*D;,"NXQG
M(WZ5):EDW&]^DK?"T7(-(NDQCZ>6JU^B:E:X&QR5'L[<ZR;BN6]A#OWCJM3R
M"C9P1:(FDF4@D=!8IVY12.!<LCJ%+(RAQJ4LI 9?-20,CU&16%DC<N$=',;:
M7"LK%&_-< DJWH<'TJM]1J=-*52]TO%*QO6):[Y$M]7H5,@$47$[;KI8(FK5
MB%0<ND&+=>6GYQVQBHY%=\Z:LT5'CM$BKIR@W(8RRR9#256=@J*S,>BJ"S'Q
MV R3MY5%W2-2\CJB+NSNP50,XR68@#<@;GK5),<[80E,9+YKC,R8JD<--4'K
MEUEMCD.HN\9-FT;)*0TBX7OK>84JJ*#"725BGJJDJ5-K))*,5S)NB&2#)BD#
M\LQN)-OP91M>XR.[C5N-QMTWJ FA,9F$T1B&291(AC !P27!T['8[['8U/\
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M9[OHGBKVG;2GC"+"[6;=E2:ZM U6MP6;%;B3LU;(=YDXMDSJ+C'[E9S*2L?
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M%&QAE/AU.\-X%:8]VM,H[<FINDQ=>T96+KQ*0%,F Q1!0#2UL@OH-(X2L5I
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MJ&,C=YCB/2VRE1W2!L-P<+DUYKL[7=K9Q6O#)89P(&-Z46)#A1JE#@Y<,<2
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MMX>)7>N48Z/:,6B1C$:I"'K8?;+B<-M;VBVO"W@MHHXHEDM'?"QH$#',^"Y
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M"W\@,&^R]6GY?9&_>#[KX18.]X_6'D>K^I'Q7M]W][^$?(.K^OO6ZE^(Y/\
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MY^O]WSJ 4_27]<KV?H9[;TP]CN#?O7?(?@,7R[O2'D^F^J/NN?1^_? ?5_\
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MU>4^^YF_<XIVF7S'^B*EZV[7/BO]F[)(!_!&L5/_ .5:#5'_ '\_]VK![)<
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M+E9D#:Z5>'EGDW5G O&Z[3LSC%BIY**J'3W4SD+EHY%57:-U1_H,RL%;]5B
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MTZ53;H%45.4@R1'D8+&C.QSA44LQQN<!02<#<[5"26.)2\LB1(" 7D=44$[
M%F(&2=AOO5<IJ$5(15(Y%$U"%4343,!R*$. &(<ARB)3$,40,4Q1$# (" B
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M5G"J:#=)1=94X)I(HD,JJH<P\BD33(!CG.8?L!2@(B/V -8)"@LQ"J 222
M!U))V 'B32NYXQ>QRYFL@S=,7)0*8S=XW5;+E*;[E,9)<A%  P?<HB4 '\M8
M21)%#QNDBGHR,&4XZX*DC;WT((V(P?(U]GC9%-FG(J,'J<>L<4T7YVJY6:J@
M<^::;HR8('.'2;F4IQ-^J/V^PZP)8RYC$B&11DQAU+@>93.H#U(I@XS@X\_#
M[:@M3I44DQ>KMG+Q!FZ6:,^WYCI)NJHV:]XW0CY*Y""DAW3@)4^Z8O<-^J7F
M/VU$NBLJ,ZAWSH4L SZ1EM*DY; W. <#K2OMM'2#Q)RX9L'KI!F3N.UFS5==
M)JGR$>XY423.1 G(IAZE3%+R 1Y_8=8:2-"JO(B,YPBLZJ7/DH)!8[C89.],
M$YP"<=?3WUT-VSAVNFV:(+.G*Q@(BW;I'675./,0(FDF4RAS" "(%*41^P_;
M4F944L[*J@9+,0J@>9)P /?2N7+9RS74:NVZ[5RB;H6;N4E$%TC\@'I425*5
M0AN0@/28H#R$!Y<AT5E=0R,K*PRK*0RD9QD$9!&01L>HI71K-*:4JH*I7G=L
MLU?K#'GY<_,1T0@8"B8$C/W2385S@'X)(%4,LJ8>12)IG,80* B&O=W"6EK<
M74GT+>&29ATSRT+:1ZL0% \20!O65!9@HZD@?;6_J,CFD/&QT2P2!!C%L6D<
MR1#\$6C%NFV;)!RY?9-%(A ^P?8-? I9'FDDFD.J25WD=CU9W8LQ/O8DUU@
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M1X5_AT/NE_W3UQN/_P#1DWZ\/^]6M1_%GW!;_<E[1=NU2W)</J.VT8H9;CL
M/X?+37=+BO,"TS.L("TM(.!&CTYHC.QY9V+=2<J:3<*"UC1BP8N0%=ZB(;UG
M%:I/*T-V9I.5-F,P21X!&YU-ML<;=37-XE/?26UNEQ8"WB%Q;D2BYBERPU +
MH3O#4"3DY Q@]:K;=)*46*X[NZE:_;"K+Q"(Q7:EBI!EB>KXTJF3WM1DC,,6
M&3R$XB+<U=L8QHT;D<5L\RT2!\@K9$FJ9NR[6*:,.O[VP:+I;4\^3+L[)J'>
M[H*[D^.#MMUJ5R4'&KC79-? VL8$:QK(4/X/OD." .JZNHU8&Q-9,\.>NY+X
M:.UOB<[T<Y85=;8,.7"[2V9L![49ZQ)2$A16,0UL[*O5]=)NL*<*]R!.V2A8
MYC6KQ**DSFK3%5:,81 PIU:;LK=S6=O'()I%01R3 8#$D$G?KI 9B>AR3YU?
M8"3A]MQ&[FA-O"SF:"U+9*8# +Z&0F.,9P>Z-@,5IJX>VXS$VTC=?L2W4AN1
MKF1\D[V'F7:%Q!:DTG%5WE"G<R9.+8L<VR>3<HIMV8-I*6J4U<5D#+DBG50L
M+0 2/+&66Z%W%)/!<P\DJEMRVM6('>6--+J.G4 X\PPQT%<JQGBM;FRNA<+)
M)>&6.^3.Z--)J1SL,8)0N>@*''TB:]>S_BG[,(S=^GL5>9!GT]R*EJC:82HE
MQ_=%(D;!+5UK:F+7Y:2&-6P25A7K=P9T,EXZ:AQ;J*%7*8@<(6=P8.TA!R<%
MM>M.BL5/=U:NH(Z?*O4'B5H+KL6MNT:@FG0^-14,.]C3]$YSGTZUII?[:[I@
M;C\</.SY1W!9!W&9.S)1]V=HL-JN32-@8"K0L9B'+C6I4#'-,B!685*I5J/?
M."F:H.U_;3#J2G5$F2T@HT2WQ*LG#+H)$D2(\"@+DECK0EG8[LQ/P P!TS7)
M-N\'&[!I)Y)Y)ENG9GP%4"&4+'&@V1%!.PZDD[9P+G\2G?YNDPGFC<7$8GWK
M[?\ '37!V,6EXH6W#&FW#(.Z3+UR=QE1<6BS(;D+2VJGQ#;I'KG;E=1DXK-G
MBH^G/V4O.>&+9Q)O86EM#(D.NWE<RN5>5IDAC4:@HY2DZI2,[KLQ884'.!;Q
M"^N89KA8KN!!#$'2WCMY+F5B$+-VA@H6W&V0VH@(0S8ZUNQV/YUL.YS:%MRW
M 6Z+BX6UY:Q)3[G9HV#(Y2A&T_*1:)I@8=!XX>/&T4O($<.(]HZ>/7#1HJBV
M6>O%$C.5>?<Q"&>:)22L<C*">N =LXVR!L>F3X#I77LYFN+6WG< /+$CL%SI
MU$;X!R0"=P"3@;9/6O')Q8,TX4WF;S-\LS:]Q=?Q2^V$X<A<;[.89W8'42_R
M#N.I]]:7;)[V!3:).$5Y(CNM7;&2#A1RS0/*N,<3(.T_6'3+WK&.2WM[8+"7
M%U(7N#IR%A*E$!SX'4)/';4,;UY3B<T5W=WI:X6+L,0CM!J(,DZN'D*XQOE7
MCZ]3&P.1BMQ>X?BQ9I7X6^QK>7MG=TOZJYVSYAC#61(6SQ+>2KPVA]"9%B<G
MU)5#D=U M760*24(Z6:I$E&U;<-7[-+I>I=6A%91B]N+>;5HCCE=&&S:1I*,
M/ ]T[CH3D9KK3\3F^]UG=V^CFSSPPR*XR-1$@D7;=<NFQ SI((&XJHH3<'Q'
MJ'ONRGP_LM[@,,9%GLI[';7N/PQE:N8-)1X_#UW+89JJQL.I5D;1+.K;4XF0
M@+"51*PS<A.RS<E>D0E8I092,7&*T:V2ZCBD0)<+#(ADU%Q@-D-I 5B".B@#
M?8UD3WZ7LMC+/#(9+-YXY5AT")\E0-.HZU!4_2;)&#D'(K2QA:_9MQ#_ $>Z
M7RS:GV&LQX^L.XRL-<6XSRIA^$OC>I2)\RY ;9.FKBO:%9%E=I.SSCF+F*V]
M<LF[JKBS=D35<*/!4)O2I%)Q7EJ)(V6)N8Z2%=6(4*!=."@"C# 'O>ZN1%)-
M%P)I6Y,L9G7E1RQ"32>;()"^HD.6)!4X!7!ZYK9Q=:INCN_'SW95C:KER@8*
MMK[9)C)Q9\GWK'(975A:TRD<;J(1]4I+B=@8EY/3-A/"M7,G.KNXV)KQ)M=)
M@ZESQ:8Z@,*\,MVF1Y +B0!%?EY)U9+-I8@  [ 9)QN!FNDZW+\:N5MI8X6-
MG&7E>/FZ5!3 5-2@LS8!)R N3UQF00O&8W=R6UZK8P0K&*7&_FS\0E_PY6=Z
M=QT@AAE.QLG,$V/F!S!-E@.+@'%DCH4L$B<D2=\FYM@1@QB9*:OD\/@$S.2_
M9EM!=Z<@R:2#^#)P,="<X)QL3G>HCBUT;9(],?;6OCP_60>4&!4<TJ/'O!=/
M3/?QC"')^K[X-XVRG=U*[4-]%ZQUN<@+;M5RCN?Q;EO&6/$<46AHZP]7KA:K
MAC^T51@Z>P7@NH:B6'TLPW14<^4:%.J[=GDG\9!4M;V\]N)[=7A*SI"\;OS
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M,5<>0SWB"/EKIE"I0MT)DZ\UA> 7AY0T8-7A7;Q!DB\DR.45!>.BBI'MER%
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MJ@68((HA(0SXYQC@P2+C)P3CE.,D1QL!G/C(SQYZ?@]9[KBF_E\_?_=]OI4
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M(M9E=NZF8H*HQ@77'6W9A&HRNX[*$U:VK%*8-&4_%R*\%"LW$P@L:?LD*K#
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MP%V R-CU-<JSLVNKGBN+NYMU%].K+ X0.#))NVQW\/4'%7>XEVS;$&R/#W#
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MZ$['X]?V]*W^'D2\1XG/&0T1,**ZD%&95P=+#9L:<Y&>H.=QGT'1#$TE)L&
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MA*\\107G:.;LEZP#7+N[V"55B4N4,BF5E7!,:G)":\=XG!&H8!&];4<;*=1
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MY_QY7Z=-_3K\L_MQ\Z@4QS/V$NZ&,/*\=#O]LUK['E^AGO)[747N>/\ )_C
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M.]TEZ.Y\>^7"YZ/U?<A7 2_<1DQ"/XOC^FS@?F8SIDS\-?*Q^CS,[Z:S_/\
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M;9-$?]J()ZM6ZN%Z32?%R?VDUC0GYJ_8*@#T>K'_ !BBE$?\AT])_N*Y /\
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M:,1NAU!B3I TOJV.25(VI+PQIM8>Y+"6VAAD8Q .TMO(98Y04=$4:CWHPF"
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M2CZB3DCQN-Q476693>#MII^/:'F/-L.VVO[ILDSF"\1;K<G;496XO:-8</\
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MR\Q#HQ<>1@]0!HAV^,7<_6;HPZGHQ)8>@8DDCH<G(WKTW*CQCEIC*M]$'O(
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6*4TI32E-*4TI32E-*4TI32E-*5__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g99471g09r85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g09r85.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2(:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (?Z^AP(X0DE-! 0      %4< 5H  QLE1QP"   "@  < E  "')R,CDS
M-S0Y' (% #1-:6-R;W-O9G0@4&]W97)0;VEN=" M(%,Q($EM86=E<R!F;W(@
M-RXR(&9I;&EN9RYP<'1X #A"24T$)0      $&A-HNZ.KT,!A"93%GKS;PPX
M0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0    !0
M<W138F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R:6YT
M4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $       ]P
M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q 8T            IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M        /X   #A"24T$#0      !    !XX0DE-!!D       0    >.$))
M30/S       )           ! #A"24TG$       "@ !          (X0DE-
M _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $
M,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M '   /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      S4    &
M      +<   #RP         !                          $
M     \L   +<                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   +<     %)G:'1L;VYG   #RP    9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "W     !2
M9VAT;&]N9P   \L    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     @X0DE-! P     %XH    !    H    'D   '@  #BX
M%VX &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( 'D
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MWNO=N-K;=KW5OJMVMV-L_/\ ])^B6DHV,%C',)+=PC<.0?WF
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! ?_  !$( <@"70,!$0 "$0$#$0'_Q  ?  $  @(" P$!
M" D'"@$& @,%! O_Q !:$   !@(! 00#!A((! 0% @<! @,$!08 !P@1"1(3
M(105,1DB05%WM@H6&",W.%=866%Q=I*4EM76UQ<R.8&1L;+P)'BAT4*WP?$E
M,U)RX3:7)C169&>$Q__$ !T! 0$  @,! 0$            !!@<$!0@# @G_
MQ !'$0 ! P," @<&!0,# P,"!@,!  (#! 41!B$2,0<305%A<? 4(H&1L=$(
M(S*AP17A\19"4B0SDB5#8C2"%R8U15-D97*B_]H # ,!  (1 Q$ /P#8^[/[
ML_\ ASM/AUHC86PM#5"V72V5%>6L5BEEIY61EY)6>F"*/'BA)@A3K'(0A1,4
MA0$"A[T/8#UZ]?=%,;W,#@-][)K_ /2L'[ZPB>Y@<!OO9-?_ *5@_?6$3W,#
M@-][)K_]*P?OK")[F!P&^]DU_P#I6#]]81/<P. WWLFO_P!*P?OK")[F!P&^
M]DU_^E8/WUA$]S X#?>R:_\ TK!^^L(GN8' ;[V37_Z5@_?6$3W,#@-][)K_
M /2L'[ZPB>Y@<!OO9-?_ *5@_?6$3W,#@-][)K_]*P?OK")[F!P&^]DU_P#I
M6#]]81/<P. WWLFO_P!*P?OK")[F!P&^]DU_^E8/WUA$]S X#?>R:_\ TK!^
M^L(GN8' ;[V37_Z5@_?6$3W,#@-][)K_ /2L'[ZPB>Y@<!OO9-?_ *5@_?6$
M3W,#@-][)K_]*P?OK")[F!P&^]DU_P#I6#]]81/<P. WWLFO_P!*P?OK")[F
M!P&^]DU_^E8/WUA$]S X#?>R:_\ TK!^^L(GN8' ;[V37_Z5@_?6$3W,#@-]
M[)K_ /2L'[ZPB>Y@<!OO9-?_ *5@_?6$3W,#@-][)K_]*P?OK")[F!P&^]DU
M_P#I6#]]81/<P. WWLFO_P!*P?OK")[F!P&^]DU_^E8/WUA$]S X#?>R:_\
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MW#F$"G$0*0WO3F$.A3>]$0'RPB\TG39=,54'""R11, J)+)J)@)?ZP"<AA*
ME_\ $ CY?#A$0=-7*9E6SE!PD41*91!9-5,IB_U@,=,QB@)?A 1 0^'"+Q*]
M9G1.X([:G03Z^(N5PD9$G=_K=]0#B0O=^'O&#I\.$7Q9ZV5NL0TU9)^>B8F
MKD8ZF)V5?/FR#&)BV3<[IT^?N#J 1LV103.J910Q2]PHB C[,?%%\ND;&I&Q
M*=7[_3+1#6"FVJ.:2U=L3!ZB>.EH]\D"S1TU7$Q2G(NF('('0#"40'NAA%W;
MO%$ ,!@$H@ @;J'00$.H" ^P0$/,!^+"+T(.VKGO^C.6[CPS=T_@+)J]PW_T
MG\,QNZ;\0]!_%A%Y"Y;%.JF9P@4Z*8*K$%5,#I)" B"BI1-U33$ $0.< *(
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M)Q4Y]-K,)A!/YM\_2 JDRFJK*.&H@"IO#4.87[=^?7]O%7[^/KR[>>5M2![
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M:_$,3&8<\.>"OOT#M0-G2/'C=-NEJY2K;LZB;:I>HJ(_K[*?KM.MDOL51NC
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MG5I;DK(ZWH\=O1#DIJS=,1I5+8)7$$]A=9:JE=3A'+W@& -&\A+M)IU-) *
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M (]/@WI)I;H3J;))?8M12T5'!0BX5)%Q8^:GB,+9GL,$L1>]\0=PEK&N+G#
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M$3"(=1$1$<V*UH:UK6_I:T-:.X 8'[+R/+(Z:66:0@OFD?(\@!H+Y'%SB ,
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MRTM14]4 Z3V>"2;JVD@ OZMKN$$D %V 3LO8TE8M^(E8R3!X8 $1*U=MW @
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M.5Y3H-/WNZ7B+3]NM5?67R>H=216JGII9*Y]2TD.A%.&F02,+7<8<T< :2[
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M&2UPPHI\=^,.T>-VPW<16MS2EPXW.8QX,9KR^$4F;53ICO@#%K7+,;HN>"3
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M'K9G!K<.SKU9K,[YJ;KK=:FY==[$TFLH1,8PKL<J!0)%-'B(E<K)(F XE64
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MW')45<\M1-([_D^29SWN/B2OK=TOD'0/+V>0?B_[!_AG[P-]N?-<1<Y47
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MIRN]>+E0%T^>JG7<*G'NE+R;38H+5)/.)IJJKJ0ULE1-P AC""UC6L:QH!<
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MMBU679LTQDMF+VJ9>23TRNQ)N8KB3UP)?&;L$(R6*T;H)" "#4B@@EWNZ)0
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M/?)IF$J1$^A1#K(]"4-#<8:^R5M?:&ME;)44=/,Z2CJ&MW+#%*YW!Q9():2
M-@T=F95?XG=2ZGTE<=+=)&FM-=(,LU!)26G4=WHHZ?45GG+."&I9<:2-DE7U
M'ZFQ3D!SAE[G9*D-R,Y!M..=6A[C+4#8-Z@G4V2-G5=?PJD^]JL<9!58T]*,
M$#@Y4CDSD(W,#<IU?%5+T* >>=[?KXVP4T59-0UM9 Z7@G=11=<::/A)ZV1H
M(/!G SYDD;!:QZ+^C67I0O-=8*/4VFM.7*&WNJ[<S4MQ;;8+Q5"5D8MU)4R#
MJFU+PYT@ZUS6!K#EV3@_MT9RAT;R(C57VJ=@0]D<M4RJR4$*IF=EAP,!!%.6
M@G@)23(Z1C@FH*R $*?WO?$<MFU'9[]&7VRNBG<!E\&>"HB[^LB=AXP=L@<.
M=LE?+I Z).D+HOJFT^M--5]JBF>64EQX/:+57;D!]%<8"^EG8\ N;P29+?>Q
MS6?_ !"=>G>#J/E\/^P_OSO%KA>0& P=0'J'LPBYPB81,(F$3")A$PB81,(F
M$3"+4Z^B%/L\:%^2:8^=[W"O8/,_1JO/[+[[0;C+^8)_G!-844M-HNK$6@W5
MC29:#B+\^I]H3HSJ?60)&HV<L(]-$/'R2Q@!:/8R'HSF1]Z)$VA%#J=" (@^
MG?Z]?R5+_%Q'>9=ZZS]62N\&DVG(J_5!/]T;DH-VU-9XTD0Y+*I:3JL'.2,I
M'O75C]&>0BA&;0C*"(N@X$.O=R'.-N>WKU\ KZY#Q[?,CT KX2^P/A\@\_9\
M&51<X1,(F$3"*O'<?]I)PH^1'EC_ *=39.T^0^KE>P>9^C58=E43")A$PB81
M,(F$3")A%X'3*<.Z8 $/8(" & 0Z" @(#[0$!$! ?C'X<A'B1Y$A%6GRM[+?
MC9R97=6AM$*:EVJ8O>;;$U\T91RKMR4O>3^F6 (1&)L2 J=TRP.DTW2G3WSD
M1Z==B:6Z3M2::#:5THNUJ!(?;[@]\@C81N::?+IJ=V,XX7%H/)H&0NKK;125
MAZP@T]0!AM3!ADNW+C&.&0#_ (O!& !V!4-W[B3RU[/ZSN+HUDKI5JVDX R.
M_./"3R9J*S8G</W=K:4%0 2:"1 1DGS(")&#Q%NZ[,<$QWK;]5Z3U]3"B?'1
MU50YF'6'4'!#5M<<C_TN\$9+MQU<;SD' ]W&5CDE!6VQYD:Z6-@.164+2Z,C
MM-9;_>;@]KX.PN)+>8R4KOK2^]Z@B^YT<9Z)M6D+E]"+RYXO,B>N8EPH*8>E
M[ K<0V;6FKR "4IG(33,"E.FH1%@L0.H]:+%>K#5N9H;4M?:JUIX_P#2>IWG
MJ96;G@H*F9SJ:IC&3PF&3)!W>,X'VDJ*6KAXKI14]7 ?=%QH096M(V+I8QBH
MIW8QG8M:<@N&Y$1N56M:YQ?U=7KUP=YK7J^Z@W<I8*?,:^9S;TKJ"8-XOUE)
M-K DQ>$*Q1!HX19^$_A8U_XIU>^<2=\V99I:Y3ZGN=30ZXT504%WLOL]9#<)
M(8RVH>Z4QQOIS(SWSQM+\QS2,P!VD!=1<*9U!3,GLEUJ74U2Y\1AXW3,B:(R
M]V'#+HRUHQNT$9 />K1>'CF&[5/LQ+-QXV&X(KM/3J;2IP5C>"DN^;2L!'HO
MM>64JJISNNCMD4:[-+?6_&0!T4#F$_4NL=7LFZ+.DVEU#;F\-KNY?53T[,L8
M8:B0LN%-P@-:>%Y]IA!!P[!V&2>ZMDD>H]/OIJ@?G1M%.]YR29HPUT<P))W(
MX2=\'WAMR60.Q Y%6,E6V%PAV^+J-VOQYG9<D+&RJA@?'IA'R+)[$I@KU,M]
M+DX=<$A3,8GJR0:>$'@(@8>#TUZ=IQ5V_6MH$<EJU## 9Y8=V"L+'/CE..1J
M(  =@.LC?D\3E]-+UDI@FM562*NV/,?">;X<X8_).2T?I![1PG&X*O\ <T2L
MJ3")A$PB81,(N!*!NG7X!ZX1  "AT#_W'"+G")A$PB81,(F$7B<H'#H(B'GU
M\OC#_,/Q810]V-Q5+8]G6':-#OSK6]FO%::5*\O&56@)U[+1#5$S-)6(DI(I
M7T!(^@'.S55:*J(+D\)55 54"&S&*_3@J+C-<J2L]AJ*NG;35;FTM//))$UO
M!^5)*TOA<8_<=P$M<,$M)"W3IGI@_I6D[9H[46FX=56G3]UFO6GH*B\7*W4]
M'6SR-F>RMI*1QI[E2^T-$[&3,9)&[B8R4,D<%(ZB4.OZ^J-9I5?;>'#U.%8P
M43XX@NY(S8I%2**C@X>(<Z@E\14W4"F5,8W3SZ9WE'1P4--3TE.WABIH6PQ<
M7O$,;RR>TD[GENM8:@U!<]37J[7ZZ3<==>J^HN-;U8ZN%T]0\N=PQM/"UC00
MU@YM8 ,[87<BI@4>H"/3XOQ]?\OQ!T#XLY0'ESSL,???Q72^O7W7LRHF$3")
MA$PB81,(F$3"+TF1*?J!NABF'J)#%*8H_E P" ]<A&01ZYY^OS[502#D$@]X
M.#\^:P;M71L-L%"#=PDN]UU;JM8 L]<N-581P/V4L=HJP=&?L5D09S+-^R54
M:NVC\#$5+W#=\#)E$.IN5HBKF0NAE=0U5/.*F"KIV,+V2<)8[B:X<$C'L<6N
M:\$$86?:0Z0*[3,MPAN%#!JBR7BV?TBZ6.\5%5[//1-G94Q"FJ(I.OH9Z>H8
MV6">G(<QW$,%KG X,:]GKQQL#B;L>XJ?';KV):I129LVPKFP10F9%T+=NT;M
MVJ$6=NUBXUDU;)(M&+0/#2 IS"8QCF$>F;HBQ3NEJ+K2LNM?/)UE16U+>"5[
MN%C0 V%S6,8 P$,;L"3C .%L-_XF.E.VQ6^UZ&OM7H'2]HHVT-ITS8*J22@I
MH1)+-++-+5MEFK*NHFF?)/4S'C>>$ !K0!)C4>EM;:+J84;5E;;U2K!)O9<L
M2T6<+(D?R I"Z5(=TJLJ4#^"F $[_<*!0[H!Y]>_MMJH;/3>R6Z!M-3"1\HB
M:7.:'OQQN'$XG<-';WK56M==:IZ0[T=0ZPNTMYO!I8*)U;,R*.1U/3!_4L<(
M&1L)9QN][AXCG<G"B#<^S*X\W*QS]K4GMUP<U8Y1Y,22E>V];8MH#U\J=9<S
M5BDY,W;I"H81(@F4$TPZ%* %  S%JOH\L-74S59END,T\KY7F"XS-:'R'+BU
MCN,#?< ;>&P6[+%^*_I-L5JMUFCMV@;A06NC@H:5ETT19*N8P4[!&SKJAT(E
MED+0 Z1SN)QR2<[J8%!UBPUMK"(UE"3=@D&$%".81A-V64<3=A4*OZ2*;I_*
M.!\=XZ2,X]ZL<P'Z)IAU\LRJCM\=!;XK?%+.^."%\,<LTG'-AW&0^1^Q>YI=
MSV&    %H_4FJJG5.K*[5MPH+9355RN$5PJ;?:J.*@MC71]2'P4M'$.JIX9&
MQ;QM'"'.<<8.%0_2N,G+'C;R#T]$S86'8NGYC;S%V\N# C"?F:S(^N'TJ,JU
M7:)(S,-!6)@Y".M"4JNX0,0AP.HH8J&:;I=/:EL%\M3)S45MLFND;GU4>)Y8
M']:YYFXFAKX8IVN+:@2<0P#QN.&!?T3OW2WT,=*O1GKBMM_],TOK>WZ*G@@L
ME2:FVT%XIC0T]'[%/%.]]!<+C:ZF'VJS24<<3P7#A:SBE6QCF]%_,->D[=)0
MIR*E!0I^O>*< ,42CY"40$! Q1#V@(" Y" 1@XP>8(R"/([;]NW]JTN:X.:X
MM(W!:2"#W@C<$=F,?;&T%I?5-6NDIL.M4"JU^ZS<:G$2]CAX5C'2<C'IK"X*
MW=K-$4@6 5A!0YSE%10Q2B<YNZ7IP(+5;::KEKJ>AIH*N:,1RSPPLC?(P.XL
M.X  23N7$<1P,DX"RFXZXUC>+#1Z7NNI;S<K!;ZIU;16NNKZBKI*6I='U76P
MQSR2%A$?N@ AK03PAN55-VCVQ^3FL=CUN9K<V['CXC5 F9JOUF6D*/:)";C'
MRJ$LSC[LP;.S&FC1SA.1B8)T"+60*T53 JJA.AM<:[K=0T%;#-3SO-C]E;--
M!3R.HZ@S1.?UHCJF,?Q3.:1)'"7!C@P[$YXO8?X6M+=$NK=+W2@NMO@'2;)>
M'6^W72[45-J&TTE!5P-DHIZK3]3+ !0-J874M;<H>LEIC.PY:QV1.[@]M*=W
M#QOH=]GGTA**3(S!(R4F4$VL[(PS*8>LHUS.MT?K2,N"" )/NX'=542](Z%\
M;IF9Z3N$ESL5'6RO?*9C,(Y) .MDB9*]C'38 '6\+</(V)&1L0O/'3_I&@T-
MTJ:DTU;X*6D90>PNJZ2@D?-;J6OJ**"HJXK;*\E\E#UDA?3\7O1L?U9SP;2Z
MS)%IE,(F$3")A$PB81,(F$3")A%J=?1"GV>-"_)-,?.][A7L'F?HU7G]E]]H
M-QE_,$_S@FL*+(_,2&ORFG+5:]1T;3MTVC5:[9U( -V23J&IT;$25>D6EG.Y
ME&31TJ@1W&]&SI%<6K!TS,LD^>MT ,<L..?+LV];^'/?DJ/7COZY;JC'@[M'
M5%FY(Z2@8"G]FM0M@I/#GL*FFFVRYK9;UX%;=JR414#RU-@Z[%/'"QQ=#)%G
M'K88U-4&7IB2Z2XWU]T\?L.[^3W=FWAL^![ _(&%%SA$PB81,(J\=Q_VDG"C
MY$>6/^G4V3M/D/JY7L'F?HU6'95$PB81,(F$3")A$PB81,(F,#N]#DB_.Y;(
MNT56SA%)=NNF=)=!=,JJ*R2A>Z=-5(Y3$4(<HB4Y#E$IBB(& 0$0P"YK@YI+
M2TY!:2UP<""TAPP00=P000458.^>R[U9<[ ^VGQ[L4KQ@W2J"BRECUVD1*F6
M941 YF=VH &1@YE@\, E>%311!7Q#J.$7@@!!V58NDRZT-.RUW^"'4UE:0&T
M]Q)-;2M P'T=><S0R,YLR3C  <SF.IJ;1#)(:BEDDH:HC>6# 9)MRFA&&2M.
M^>(<6#L1VZ[O/+2NTN/\0]>[BT(36-WE9#U&IR3XZR0Q6H]EP,@U=E<QMNUL
M@4K&'LTVHB@5?P%X8JQ3NW"\<X*FF3/0.@[S:[]*QEGOKKI111B<:;U%%UMV
MML[7-+9*2Y./62TL <XMRV<@M8T2C<C$[Q#)1LDDJ:9U)*_+#<;:<03M.?=G
MI<G#GX +B2-\\>V%&#LR^7LUPTY%P%VD!=#JB[E1J^SX],RIT!K[EX1NE8D$
M$NI1>5>3.B]*/<%0S0SEN =U81S*.DS24&L=/3T+"TW6A)J;;(<<1J&,+S3N
M<=^"IB#F$9QQ<+AR*Z?3EPDMU7USABBJ6AL[>;6X<(Q,W P.KDQQ_P#Q=G)
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MQ7:/4%GN=556K4\,$!BETG>XI/\ IZ"M#GF22*K@/60U75LB<[+&D@94M2F
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MLG ,QD_",FW5($@XK!UE5CE,5..DX=R=,@+)D*/LZP:@BUEIJBOE&YM/4U<
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M/&A?DFF/G>]PKV#S/T:KS^R^^T&XR_F"?YP36%%,;8"23BB79NX90DB@K5+
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M(4!%5#Q$P#J8!#KKM1/N-NJZ*.IEHY*B%S(JF!W#)#)CB8\.P< . X\;EA<
M02"LLT+J2#2&KK#J.KL]OO\ 1VJX0U%99KI RHHKC2!P;44\L3\-<Y\1=U3B
M<,DX7'(!!BOPDW;L*QHV_CYOMHLSW[HHS..L<@5!88N]U)YXB57OD6^Z"@X"
M6;(]V03$R:R;XBAQ0(500+CFDKQ75 J[)>F<%[L[FLJ'AKNKJZ5^U/61O(+7
M=8&^\,@\G$ D@;?Z>^C_ $S:I;'TF=&\[)^C;I$;/56NE,D?MFG;U!PON^G*
MRG!$D?L4LG%3.P^-T#@!(2-Y^9FB\Z)A$PB81,(F$3")A$PBU.OHA3[/&A?D
MFF/G>]PKV#S/T:KS^R^^T&XR_F"?YP36%%)[>S&'DM+;=C[!$/I^"?:SO+2:
M@XM=1K)R\2XK,DC(1D<Y3(L=!^_;'4:M%4T%3D74(<B9S% HD5,/%&W:?VSL
M7CW5+)R"V-=6VK'#*;T;IR9XZ3>MU]?SD5674*UC[)L5O7F[>R$B()=ZP6.]
M<MFLJX*F^,(J"1,9X[\O6W>GAGQ^7GW9];*_0O\ 5+\'D'LZ^SIY>WS_ ,<J
M+RPBQ!OO<<!Q_P!17;;]G92<E#4J,3?.(Z'1!:1?+NWK6+8-&Y3&*F3QY!\U
M35<*F*DU1,HY5'N)&PBA*GVA<P6K2<6XT9*&Y -]KU+3L5J!A>*U(0\U:;Q5
M7EYKYVFQTCEK_H'TI1[Z0DEA(*D>Z;>@J)F5.!L)CU_;G\5+GCGON*W]J:/V
M>6&=TM7UK9:Y9*[-/&;A:M6:G3LA7+'%KR354[%TFSE(UP1-XDH5)=+N* !>
M]W"D48]KR<;)=I'PL&.D&+\$M(\L 4%D[;N@3$Q=3]T#^ HIW1'H/3O=.OP9
M.T^0_E7L'F?X5CF51,(F$3")A$PB81,(F$3")A$PB81,(OBV.!B[3 S%;G&2
M,C"ST8^AY9BY3*J@[CI)JJS>-U4S@)3$5;K*)F 0$/?>8=,^D,TM-/#4P/,<
M]/+'-#(TD%DD;P]C@1V@@$%0@.!:X AP((/(@C!!\"-EI:Z/GY7LS>U 6UM<
ME%$]>EL<CJV3.^$56LGIS8CT7E1DUQ5223<MXA\X8/%0*CW3K$?)&$Z9>F>Q
M[W31=)/1D+E1 &X>S1W2,,]UT5XMS VKC!!):Z6-DC,DY#2P@9W6NZ64V._"
MEE.(G$PM.<#V2H>7T_<,0SDQC.2 YQ)PKC=:047P=Y<W/B'<VR2O#WF>A.3V
MFO6(^/#5C8LX@1A;-9K+K=U!JRGVP/%H]O\ 7"J"K'' W?65[NH+G._6^DJ/
M5U&2W5^C'007CJ_=FJ;?3NZREN+&C)<^G=P"1^ 6@2-QD#.1P-_IM?)028-!
M<C))2@CW8ZAP/74W+&)1Q2,;C'ZQV ''W9Y7J4X.<OML]FSLV043I4[,O-A<
M;9N15$47;*?(E(_2ZW<*>"F(R34ZYB()I 4L[&22!!,HX)W^PU_11:VTE:>D
M>VQYK:>%EOU)#&T<3)*?B9[0]HR[$;@W+B=X98W<@5Q[0\VRX5-DE.(2755M
M<3^J%YR^'/>QQ) QC8XQ@!;"Q1 P=0^/_KY>0>SKT]GY>N:#SE94O+")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A%^%^P9/VXHOF;5ZB"B2P(ND$G"?C(G*=!4$UBG)XB2@%.F?IWB& #%$! ,
M_+F,D'"]C7C(.'-#AD;@X((R.8/9S7UAGFIG];3S2T\G"]G60R/B?P2#AD9Q
M,<T\,C26O;G#FD@@Y*P(VY(:^-R!D.-3H)>'V$WIK6[Q9I-D5I"6:(774;N2
M5M\*QAD7<89,1?HE23% /,HG A^[TK+[1?UN2P.ZZ.MCIF54?6,X8ZB-WZA
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MLAK>B;!G30]&GY6)D)AF:J2(2#5!G'+H%D)GT5)3Z7U%1%6.E3-WC0R;@H&
MBJ5T*CJ^CWWB#>(JU[OML[NMX^8S51<<N+CM=#6TS+5U[.5\MTH;U\H@[B#1
MR"[>;=2:+7U%-BV:@BN<0/CUZ];J]_\ ?;URW_N+UR_U2^S^J'L]GL^#\6%%
MSA%@#E+JFP[PT!L_5-5L"=7G[I731<=,+$%1LFH5XU=JLG@%(HH1E+-VRL2]
M62(=5!J]672*8Z90$?6,?RBJ\J' G?E%U^WM%&J>FJ7L2G<CZ9OO7.@8VVV5
MWJ2&-6*'*Z^F8]2\N88UA*ZMJ$T\L3@XQ2R+%^FBV3[R0G,$QS\1CL\?/O\
M+YJYVQZ[/#EW[\P%.WC9Q>)4.,K_ $MN^.KMI=W^?V);MF0,4O(+U4\ELRW2
M]LF(*,>*@QD748Q6D_0T71RM5U01\0"I@8 RJ<U%)/C/HGCQVD7$0-+ZWA*
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M*UN/6Z:HU6:.LD(N4&\]%+,2O#&#JL5ZLX BAT$S9C-X<[HNZ3JN1L+G6*Z
MNGI2W,53:+B0*J$-.&O=3RB0M&,-X&M) <5VM(]M_L<#PX,J6AKA(-W0U=.<
M,>#V;@'L):X@\U"'E-)6_F%P[I?+N#9N*MS3X&7$*YNF)8H&;3K-*KR@N%IP
M[),A77HJ2S:/L[8YTRH)HK3K8@^&D8<S72\='I#5];I*:1M5HW7=(:FS3//%
M3O=4Q<+8!(7<'&0Z2G(!))$#CN5UMRZ^X6V.XQ-,5VLTI,L8_4U\/_>9C<EK
MQB1O,.:<#)*OEX)<S*!S)T;4;Q7IR(&^-H&/2V72T7S<\W5+&B*D>^.]C2*
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M5<_]8_3VSH>^0:GLUNJ*YL<M/J*@EL5YB."/ZO01/A8YP<<9K+>">(AV7-B
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MYYMS'+5G8E-DE:?M>D.R*HO*G=(XAB/6IDU1,8S%Z*1WD8MWS@HV. "('3,
M?#2^H&:@MYF=&:>NI)#2W*D<"UU/5QY#VX)/N.()9N=@022%V?39T3U71-JQ
MMNBJV7?2]]I&7S1FH8'MD@O5@JB'4\W&P- J:?B$%7'PM+)6Y +7-)EIF2+3
MJZ_9W5>C(*2F+01EZB@VCB;D5WS4CINS;Q2*CY9\*1DU1[S5-$ZQ#)D,J4Q
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MTVV2O'THT6I46_2]Y;*5&$MC>2A4:K(G,Z<-I@IBG3@@35E!C"%,VF_#]6R
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MGW&SEJ84QDVC8';8#N"KD'S=TN]&<]AK*C4EFA,EDK)>MK(8QEULJ9G9>2P
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M!.U5XBIF_I$.F) ;H*K**"JW4)$R0@X3CGYM[4M?0],-KCL]UDAM^OK; _\
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M4))@H5%8KOW9.W;W>8[\8.V%AC>'"+F]$[HV3L+53?>]VLNP%N+UB=V)AO\
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M=7Q"&"OE9/#.&BAN;&_DU(((ZJH;EW45(/NEK_=>=FD'+5Z>8_!?9_'6>?\
M-#LT'SFAW5HD>9VGI6LBFO1=DU_JJ]>3$353*^J'KDA%#.'4 W1!-V@'IL +
M.33*5S^M'ZXM>HH&:-Z28VU]"\B"UWFIXA76ZH]UC8)JK E8P_H9.XY8065
M?&3C\W*UU-&]]SL1$-2"'5%& /9ZQ@W)ZO(:V4 ;%N"[.,AV'+(G!;MG-/\
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M>?V7WV@W&7\P3_.":PHI4[G7L[+46TWM(D(N)NC?7MQ7J<I..&K6$CK(C79
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M@V?@5,RH=],ABD4YJE4J[1*W"5"I1+2"K==C6T3#1#!(B#1BQ:D B2*29
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M0O<\-)X8VO<3AE9%/::L&V2GV6$MJ9[;(9 QW%Q MHBV)_ZFASC"7!K7AN,
MD&\/BAVFG&CE$HSK+.;D=5[95:M%7.IMK-DJG:%U'*93=^N'>+@QLS%503>A
MJ1R_IRR0>*I'HE >[I75/1MJ32X?4O@CNMI#WM;=;4XU=,T-<1BI$;0^E>T
M<8D9U;2<"0GGW]#>:*OPUKWP5! <::J;U,^#VAC_ -;2<X<PD'!Y8.+$>\53
MOE*'O@Z^8AT\P'X.O^(?&'GFOB<[ '?(W&!L<'/([=XV/82NU5-7:&]F8YW'
M,)<F>*<P?4/+>H&+*-)J D5J^RV&1DFJ86<FX9I&*SLZA.XW93!R>BR*92QT
MX51JH1RWV_T?])+;+"=,ZJA%WTC6?DOAJ(VU+[?UA XXVO(+Z4$\3H0>*/\
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MF&%CWAH)>X AC2< Y1:K)N$$UT1 R2I"J)F#V'(H4IRG#\1BF 0^+V9V+3D
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M22<QJQ04)#6LI3I/W2:(#4;TUCI1'P?3H97-O.;2UT4%N]H#J:K$=QTU=HI
MX&6G_/BB;(/=ZZE."QI/_5T3Y(G?HE"QHR30O?7=5B:G+J6\T)& 8YORY)@T
M[]54 -<XM&(IPUX.'9.TKV+O+MCL;74AQ@LME--6G4,<WE=734@<A'USTA)&
M$M=[W50YEYJCJB-9GVY3K*,P29%554.18X>8.F/2,ENN4>IZ6GZBENTCHKI!
M'GJZ*]Q__4[8]V&NVJ:=Q#0_,G"&@@'.]/U[)H31.EZU].UCZ:0D<4]#)M _
M_P"4D('4U&[BV1N7'+PKS<TJLC3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PBAIS[U-.[DXI;7IM4CGDO; BFUBJ\7'D!1_(V"LO6\U&,6A3G
M* KNG#,J)/?%$3'Z=0 1S%-:VN:[Z;N-)31OEJ@QL]-'&,O?/ \21M:,C))&
M,=OBMX_APUC;="=,>C;[>:J&ALIK)K7>*RI<64U);+M3RT%94SN <1%!#.Z1
MVQ  .RD)IYQ8W6JM=N+?'.HBTJ4RN#8(M\4I'D?,!%-2OVCHI!,4JZ+D%"*@
M!AZ' 0$>N=Y:G5#[;0.JXGPU)I*?VB*3'''*(FB1K\;<0<#GQ6M=:QVN'5^J
M(K)5PUUH9?KJ+964Y+H*FA-9,ZFFA) )C?"6.8<#W2-AR61\YZQA,(F$6IU]
M$*?9XT+\DTQ\[WN%>P>9^C5>?V7WV@W&7\P3_.":PHI?[(:SCZ@W=G5PC/IF
M=5*QM:^,T5J>(&:7B'B<664*_;/6 QPO3H^F@]9NFOHWB>.V71[Z9GKUE%2?
MP8&+;[NBC,^-'$*'N*CF8@-@;(UCR\+L>QL;!$,$G4ZX@=5.* R81;Y19=LJ
M[C85[%!%,GPE;'!D!4CSGY^/9]_AXC/-._?Y9W'9MMV_3X"^8O\ 5+_]H?Y9
M47.$3")A$PBKQW'_ &DG"CY$>6/^G4V3M/D/JY7L'F?HU?9YA_9=X-?\Q;K_
M ,O;/CM'D?JU.P^8^CE/7*HF$3")A$PB81,(F$5>]W_M*M*_\M-_^=R.0\V^
M?\%4<G>7\A6"I_U"_DRJ+SPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A%B3<NDM<[^I#G76U:Z-FJ#R2C95S$^LI*+!1_$.!=1SGTN)
M>,7A3-7 $<)%*X*4%R)J" F3*(=G:+S<;#6-N%JG]FJV1R1-EZN*7#)APR-X
M)6/9AS<M=[N>$D#F5\IH(JB,Q3,#XW$%S22 2TAS<X(.S@"-^8"@IL/LB.'5
MT;.9*OU6VZUV0FJW?P6VZ=?;8%\@9AD4?0'[>1EIB1*\]'4!,QT'A3>,5(B0
M+)%*0Q<VM_2SK&B<R.>II;C;L/9/:*RAI!05$+S^9&Z.&&/JRX' +2.$DD@K
MK:BQVZI)D,;H:G +*N%[VU+'-_21*27$-.#PGB:< .:1LJ">>O#WFYQQV,WW
MY9X>-Y#UR,B35JT[AKD!W']^HIV!8UU!;WI3(SA4KP\)UC'5T:IK"Y!!M)NI
M4DHR8KM]\Z$U?HK45N-@IYI-/5$LOM-+:*F;B905P?UK9[%6O ' )OS&43BW
M@RZ-D75/>#B5WH+K0SMN'5,KC&WJYJF-O"^JIB.%T%=3-)#B6>Z)HVN (!<&
MX:%7Y0=F37$_;NH>2VCI!R[HJ<^XGZBV=O05D8MN8Z:.QM*6\4A\072#%VHR
M0>+MT49I@O&69@BBH]72;9_7VR#55IO&F[W&UE<ZG;3U;HV<,<CAO;KW1YV#
M3(P.<UKBZ&1LM-(2&,ST\50;;/25U$YSZ,R/DI^(Y=$'8%9;IA_RQO&2W!+6
MO',E;]FE=NTW>VK*-MVAR))*JWZNQMBBUBF[ZC<KUN0[B->%#_Y,C%N_'CY!
MN8 ,B\;+$$/>AG@^\6JKL5TK[1<&&.JH*B6GE!!P[JW8;(SL,<C>&2,CFQS7
M=I6UJ>>.J@BJ(7!\4S&O8X$'(< ?F,X/B".Q93SKE]DPB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81>AR8"(J'$IC 0HG$I>G>-W0$>Z4!$ $P].
M@=1Z=?;Y9'<B>[?UD@''/=4#B(;D#B(&3D 9[21D@=Y6!>/_ "#J'(>N6:QT
MZ/G(IM4[W9=?2S&P-TFC]&;J[L&;XP)-UW*?HZIA*JW-XHF.F("8I1'NYTUC
MOE)?8*B>C;,QM+63T4K)VACVS0%H?LTN'">(.:<Y(/9@@;"Z2.C6]]&%TM-J
MOE305DMZT]:M3451;)9)J:2@O$!GIQQRQQ.ZU@!9*TM :\8!(P5('.Z6O$PB
M81:G7T0I]GC0OR33'SO>X5[!YGZ-5Y_9??:#<9?S!/\ .":PHLH<LMJZNHNM
MI:E[)->9#^EZ%LE!B:KJN!E+/LV>0EH-XUG5JE#0Z2KT[F'BG*S]5\0"DCP(
MFN?O^](8BK;X4<(8*=O;/D(UW;&737L->*]8ZA2HK4BFKKW3+GK.CJ:H9P%_
M?NIR1>N'J->,8+K$.(MBO+6$B,HJJF0"IGG/T1W=GK;P*OKE\/7CXJ\DOL#\
M@?Y95%SA$PB81,(J\=Q_VDG"CY$>6/\ IU-D[3Y#ZN5[!YGZ-7V>8?V7>#7_
M #%NO_+VSX[1Y'ZM3L/F/HY3URJ)A$PB81,(F$3")A%7O=_[2K2O_+3?_G<C
MD/-OG_!5')WE_(5@J?\ 4+^3*HO/")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3"(/F A\?Q>W"+T+M4'22B#A)-=!5,Z2R*I"*)+)*
M%$JB:J9RB10ARB)3D, D,41 2B C@9#FN:2TM.06D@@@@@@C!!!&000<]J>M
M]Q\CLM27MGNS.0UB\E.5.AX@(O5\U*-%-QT. 9 C'4N9<J @G?H>(8ID;D@I
M!58$YMLW1 T7(+>F(@5F]6!KZLZ&^DIUR;'I:^3=;<X(Y&V>OJ'YDK86CB=;
MYII"7&>)HS YQQ*QO"X%[ 3K_5%CX.*X4G$R![FNKH(1LQPV;5LC&!EO_NEH
MR1DC?B"ZGV.O:-5'BU(6+C+R#N#:*U5/RWTQ:UO@E>2$#79^6\ C]B]7016<
M1M<L2*:#Y!RLW(C$2P.BR)&I73E5'E=+_1W5ZI93ZFT_2/ENE/"::Y4 ZN.>
MIIX>(L>QKR&RU5.2YA8UV987-ZLO#6@_+3-YCMI?:J^9@B<\2T=07%T9$V_!
MQ?[&/)XV\1'"\N:[&!G;AB+O4Y[U1ZEL]=EPL$:O,07JR88/1FHEJ9N1S)Q?
MHRZOIS!LH[:IN'34%44#KHD5.0RA2CY/?25D/7=?33Q"GD;#4&6&2(PS/#G,
MBE#A^7(YK'N:QX:XAI(! 6PP]AX<.:>,%S<.!XF@X)&.8R1N/Y7:PZ]//_?Q
M?"/P?C_[9\1O_9?I<X1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81>M
M7H)! >O0>@>0=?;Y>8?%Y^>0^O7]CY)G&_+&_P MU!CBGHF_:/VCRI/*H,F^
MM-C[.C[YK<B$FB\<"I*QB@VLSIDF('CC*2@D$B:P%,J! ,43% !S#]-V6LL]
MPU&9!&+=<+@RMH&LD#G-XF'V@N8T-X,OX=NYHY]N_P#IBZ1=.=(.D>AT4<M1
M)JO2ND:G3FJS+1RP1 4E8W^CMAG<.&I#:/B#G,)$9(&V3F=>9BM )A$PBU.O
MHA3[/&A?DFF/G>]PKV#S/T:KS^R^^T&XR_F"?YP36%%]+EEH7?&QM@:!VWQZ
MM&HX.\Z1F+H[".W+#7&7JLTPN=;-7W)2A2).)ET'K,!*NB8SD4% [Q5"CY!A
M%B'B'Q_YVZ'LUD8;$N7$JPZTV#M6];7NI*56-Q,+RUEKNMZ:XC:RZGK*Z@4V
M#%VF@1 THS<KF:BL!U#*F*<'?Z]>O(4G/T]>OWRK00#H !\0 '^&%%SA$PB8
M1,(J\=Q_VDG"CY$>6/\ IU-D[3Y#ZN5[!YGZ-7V>8?V7>#7_ #%NO_+VSX[1
MY'ZM3L/F/HY3URJ)A$PB81,(F$3")A%7O=_[2K2O_+3?_G<CD/-OG_!5')WE
M_(5@J?\ 4+^3*HO/")A$PB81,(F$3")A$PB81,(F$3")A$PB81<"/3S'(3CY
MX\O/P1>/B%\_(?+\7X^GEY^?Q_B#V],9^OGV;';O[._;O1>0& ?C#I[0'VA@
M'/KUZ*+Q$X![0'V]/9_^?[_R>>,^!_;X=O;R'CLB=\O7IY]?/XO^_P /GT_(
M/7ICB';MYD??'KQ">O7KM0#@/7V^7MZA_OK_ '=<9&_A].:)WP_]^@?YC_OH
M.,[XWS_'?Y?XYHG?#XC>SK[/8'G[?/\ %[/;^+IC.X'?Y??/[(N0. CT#K_O
M^_&<X\<_Y[T7EE1,(OBV. A;5 3-:L<8RFH"?C7D/-1$B@FY8R<9(H':/6+M
MNJ4R:R#ENJ=%0ABB!BF$/;TSZ0U$U)+%4T\KX9Z>1DT,L1+9(I8W![)&%I!#
MFN <"#S'P4<UKVECP'-<"US7#(+2,$$=H(YA:%7:=\$IO@WO(A(!JK)Z1O;Y
M[8=52STI7A8U,KH[A_0I@QBD\9U @9(B0JE[LE$+M7'>,N+LB?NGHRUU#K>Q
MO]H=U5\HHV4]TB8XLZP\(;%<( TG#*C<[',4H+,!N"M2:CM,EGJHY(0'44DC
MGP<3>(1.+N)U*\$ =6 ,L&^6Y!.05D7BPXW':+?%;FX*L-H5O:U/<O(:OZ>:
MA7+QJZ)@9"!K*>S3-#W#84;.L81].RA9PD+]+C^/;HFATBRRLHU%5OU^J&V>
MEHY[/KE]LJ+56-9-47=WM%#<Y:B*HJ76SC%+;I89)V01=29C4,D+NM/5-B>
M[L[<)ZDQUUF-1!)&3$VB>(YJ.(.$7M(8)*F.6.(R<+L-&/T; G V$R;-[9?5
M215;;H/C?R*A6JQ 6=:WM3^F7%VW$A3&4286"791*9P[IRF2*Q4,58W03&1
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MCIY"#Q134^7MX3AN7!N"7!H.V0 X@G*[J?DWR#$Q?1^UFC3D$H]161W"@8!
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M9'Q#W8&OJ(0*>(#B<6@-#W'9Q)(X-TM%?)/"TQVVF_+?@P,E;"0'#/$70O\
MS'$CA&V0';\\YYX?\+^2]ZX_0K^N\1>)VV*Z_F[&=M:]LR%G@[^"R4DLS<L7
M?H8PCDL>@NB=:*$Z1@,T724(H)1(4G1:NUGINAO\T=1JW55IJ&04_%2VJ.EG
MH.%T;7->WC$S3(YI E&<\0(([^7;K76&BB'].M50T\>):HS"9WYC\\6(@< D
MAAV]S&-L%97G.RMY+S22I"\%.'<0JJ _\3#;:VDS53$0$.J936-5 HAUZ_\
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MK:F_F3C(\?D?LF#X?,?=/JW=P?@]N7/ZKJ;^9.,CQ^1^R8/A\Q]UQ]6WM_\
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MQ3;)',X622,19*(;O%Z_E_OZ#TZX1>6$3"+@1  $1$   $1$1Z  !YB(B/D
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MY*R6-CGD-$KF%FK)"^'K?U\4]>O0\UL!('%1%,XE.F)R%/X:@=%$^\4#"0X
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MUG95*CJ;8U\M-HCK6[,M4'6FI1VO88&Q2=FBD#HN#-(A28K:Z;]15LS6;MW
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M?(G*H4X'3(]>O[?%%);KU_RPB]*Z"*Y (LDFL4JB:A2J)D4 JB9@,10H' 0
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M1>RX9J^+?*&V<.3JQ:D7/2==^F&(4>-FQY*I6!S%'DX&10%P'JY\Q([.1PH
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M !_%[<(N1* ^T.O^/X_^X_XX10]Y9Z*+MJ"A;2[K\YM8NJ"2MSK7'8TY%P-
MVUL1LDG])A[^K()$1D6-;>@=^Q82+L89-T8'SIFZ<M&@%G+^V3RY#M[!OX\M
MRG\_+UZ*JWUCOG;?#UKM]Z2ET;8O?Y(UYMR>LI9H]+82.]]CM:/"*:AXN:^9
MLW#F4::^IBU:<.G,^+9*870F7R;E0Y7!4:IW^O7]E?K$S<3-H+N8F382:+9V
MXCW2C!XW>$:R#-047C!P=NHH5%XT5 4G38X@J@H E4(0W4 *KZH@ A\8#A%^
M-^V4=-'39!RJR5<-ET4GC<J8K-%54CD3<HE5*=,56YQ*JF"A#IF.0H'*)>\
MD5!W(;CTYT%.T4RE0EK+1(#<.O=CJ;$?2L++<@^7?*ZQ3;@*+37UH<)D2HNN
MH"1(W=6)5X$>S"*:$B85%%L4XGGK]_6>]/7KQY]WU5CW$WE!<-QS6UM>;;@M
M?U39.JKJA4W1=>VU:SU"QJKUN/LCUG R$H@PD'DQ52/@C[8V1;*HQSP"!XO=
M/T*]>N?9\SW(IP9400Z_[Z?Y815X\NN.]OM=C:[FHD"CMW9</&,J7JRD;*DH
M[^A?33J>.LWM.Z'5961(K89V-CNX<4Q.]DSD02911&Z:[@V3MSG&W;R^O9V]
M^>\*^O7QY]JAEP^Y(V#1D-QTTW5*3'V'CY?]BVO6=4V%8+*#?;]TLZ$C.R]\
MVDSU^S:!'0.IF%I3E&:";YRVDHV-,Q%1$ .4QF_G^WR[_F!G]IMZWW_97E14
MM%SD>UE8:18RT:]3\5I(1KI!ZR=)=1#Q&[INHJBLGU 2]],YB]0$.O4!RHOH
MX11PY5\:JERRTS8=(W65EH.MVE=AZSE:\2.+8FK5HX!=8(&2D6;TT%)+E***
M,U'D1DF13G,U73,8W4BC9MJ\O^*VNM?\1N'M&C;#N]_15VVN(VQ(*L*!0:M$
M$,PD=M[9L+5)FT]5,9 WI+IFU6&=L<NJ<J#<$Q<KE@^)\_'U\$]>L>BN[=G5
MMVS;AXT0DW=YJ0M-RKMLO-%M%U=/49"+O$]4;/(Q$G:JB\19QQ7%.D'2)R5X
MPL4!38()IF%02"J:JGL\O6?7+"G9A1<"4#>T/@Z81:VG/'BE5=&;<V?R2V;M
M!!?2-Y?/-@CI.NEM9MR\@=UO9"!1I^G)UM"N'+*U:=AIV#K]B8-DX?UY!+IO
M2C*-XX#'R<_'Z>7KXHK4.#=PY$3.M&CG=],G:]!LJXUD6]PV+)-4MEW:S/W#
MB7L,J]I<3Z0QIM09H.4HZNQ+IR2:23CS^E,$$CI&&GUZ_;;=%+?5^V=<;HJJ
M%WU;<8>[U5PZ=L$YB&6.= CZ/7.W>LW""Z:#MF[;JEZ*-WB""W<,FJ!!2434
M.19%$.OMPBA1SQXQ/.5&CW%*AIN%A;+6)Z-OU6^FYN[?424L%;2=JQL9>8]B
MLV?NJVNHL)GAV#EN]:&23=MEB*I!U(J;>(DELK5N[I/5W'A2]\J;;4(>,6WG
MM(\U(1>H[7N&28H0K.&E-A64RCISKG2=:3"/K<%!K3LW(+NC"[5=+,Q,2>O[
M<_';F/+94_X^/\_X[%L+3^VZ51)?754V)98:L6W9;L\)5XY91R#":LC.,-(O
MX>-D56Y6P+>&DN9BF^5:KO@(5)L11P<J.5192 0'V#UPBU._HA3[/&A?DFF/
MG>]PKV#S/T:KS^R^^T&XR_F"?YP36%%/;")A$PB81,(F$3")A$PBP)NW3,;L
M9M#6V-AZK(;;ULVLDCIJ:O#1_*UBIW2>B#1*=@?PC-PD1^HT2[HH*^&=VT'Q
M!8J('5.(ST/V14E)P<9Q.Y#0VT4?Z49N?H]HGV^Z]F2KR7'8?.GD-L"F/8B+
MU!K'7A7"$(]IU9</H68//C&,HVKQM8C&*4D+.*>.E6_H=O?S_;Z(KA^+W)BE
M\AX&V*0EWHUCN5'M3JK["JE.ETI@==V-NQC73ZGOY%(")3B\&X>*1ZUCC"'A
M9)RBL5DN<R"I"WUW(I4X1>IPB1P@LW5 3)KI*(J% QBB)%2&(< ,40,41*80
M Q1 P#Y@(#A%33RLXF56F5F)CBT>1N?&^H.VDAK?BSJYK,,IG:'(>V3+I="[
M;AN0/$GCBO5Q^NA,,Y \HT&+7*YDY!9R=FR0!Z]>:+K7%KF'6M$U36NB-I;4
MKHQ-;N"VO9O>%FGUGE)G]JV*Q2DDGQ^U5(/CJ3%L0UG%/6L#+7EVH,)&!&H,
MWK]5RN)R#Y93&/G\C@?+P[]U=VBH19,BJ1R'25*51(Z9@,0Z9R@8IR'*(E,4
MP" @8HB4W7J B AA%[#%[P=!]GP^77J'Q810#Y+\5&4\/T]ZC5KNH;:M$O*O
ML;:4/!O7E\K^F%32-@NS#4;!@DM&0U]LSP$FZL\6-4?JHK*F*=9T1L4I.2PY
MV8FCI#6S':UTJ%/LFFN.>PWT$KI32=NDI5]:F:<21ZC:=JVUG+KNU82?VE+*
M&FE(HCGQ2LRMW+]!!ROX1"*U\ Z!T_\ Q_EA%SA%T38M!C-D4NS4F3D)R%:6
MJ$?UYU.5:2/"6>-82B?@O#PLTD11S&N54A%/QT>ARD,(!U'H(/7KU^^Z*C7?
M.C]O:IV'3'%8;TWCWH[0]<M3+4FQ&WHIJ+H;73B&"NWS;UK?KD"2N7(6[LY1
M] T.M @ZBV7I2D[)"^E%/-CXJ_?EOMS/P'QYJ=_!WE72=I&E=/HZ]VQK"W0,
M"-^K+7<S5)*W;9U4ZDD*_&[I56;*K @>TS9%RO(V2382;=ST5%F"*H=R>';C
M)V^&?14/9GR'UPK%@'J #\8=<J+TKHIN$SI+$(JBH0R:B2A"J)J$. @<BA#
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MZFVKT=2:P\C:#5X..*S:/EX>O1C9I 1*\B<JKA) P-&Y&[0KQV;_ (AR"0F
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M'>S(/:F\Z;6M=>DLZX82T*[2U>K-=FI115U'HOTT&B"4G,%,9NY[IG2:9?$
MH0[;[GP^W^>T^ 3;..7HX^RB^QYL\F;%V<=+WDQK[0>2.P=J3.JV[2@49U?8
MN D6.W[73E7T?5#.VY9E.-KU;, &?R#%FZ?F(LNX0(MTRIMGMQM\.6?/MQ]=
ME):B\JW5&X177DCL.V/MVRFK(R[2%S"+I,?JZQC+U61.TD*,]J(/I)A!66#6
M$D6]*9\X24<%\85!*<HB5[3CEOCR6(I'M17E:0M3BZ<8-BUHFMSZOG]I -RI
MTH>E:RW(Y:L=?7H4V(]Z;=R3QR",E4([I*PY$'"[AP<A!*)3[?OOMX<N9[_+
M/Y%.THFH*7M54AM0W'<]I9[2Y3PC1I&250HS>%J/&YU!'G57#M^L[0?)>@3
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MS9TYBII<LFS4(NV0$I%C&N=DGJ*N46 HC;8^P7#" UI0]9MWJX0/I:\;0>1
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M''8VRI9>WQCEQ?+1QU9UYA7W+NEI5Q.4;R+J&KK"$64;V)*'6\%"078&7;I
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g99471g11v45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g11v45.jpg
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M 0$! ?_  !$( 3 !I0,!$0 "$0$#$0'_Q  ?  $  @,  P$! 0
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M<@A@1HJP4A3^>=*/)JC?2W44:?"P&9FDC#D,H**9H@PX,K<@Z,X9@-1*#(Q
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M,['W9B/).M#S7,N/B5VVZTBTB$<;OC%=3SJ.V>.X1(&]\Q1M)CMQ5].;4@P
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MW:U>%^"CG,Q[J2E$ *;T')V&!%D-2]J9G4]ZNC%BTY*J)CW+T,KFQG9N=R
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MB*^&-E\:OO=Q'_)YO_ZBM4 R3_A%_P )X%]S Z^I9,-D_G_,C=)V^C]>V/\
MLIJ2F'1E';YY_AC;[F$\_P!.-_I_CZ9<3?'WB5?\J2/_ -EFJ!L]C![3.W^3
M#*/_ %D6HPV_X2AQ 5VV2KRENTK75SG.J'["I&.O4E]OZ-?EL4LH4XUUSG^G
M.&N^^,?/Y)[9_A[;\DW _.DMD^OSRD?ZE/[*C_A!9G_@X;N7?MVX5(_TR#W^
MGBOY_P NU9,G_C4OPC_B+3_13_\ =UG54& S??&?^CLJY QZ;H()Y_[2F5-]
M-,?/.=LXQY^347\^^M%_'4F]?Z0?]7GQ3\M.VNUB[]]^WW3#_P!57_G/L/QI
MCXJOQ39;_HZ]^!Y<HW[G\$'ED7/I&?G\_P"&N7 TY5,5_'^7\,[8W*_P_CC.
MVOR^KSX*R7\_(Q_L2(MX_:'/G^;^FAR62;PF'E'X&2;7](,:Z_9R_GIGJW_A
M#LK_ )\6^&7S17[=7Y_9<6/>D8D'VL9_HRNSCMX "?\ ,^>,[8V8(YV^6?IU
MQG^&'9Q:^]Y,_P#D1%=?SLA']&Z?$YU_S<?;Q_KDF5O/[%F4_P"@?MJ/;<$?
M\)/N"J+.C1 -PA6 ^35],P;X7 "4RUGKED7CA)@Z'0HL\,3UF.ESM!?=K'"+
MDJR09F%6;E4BRT2V=([H<0CH?\*?BRG;!./@[^8 *2H^H V0/KYWI*.H)8I%
M(LH@\;J0A?GIE((0DR /YTI)T&T=Z\UQC1UT_%EJ+D>(7777:7PV)-2E,05A
M&SO)DT&QFJG<&'Q43@25JJ?)GH#5\GB]E1E=BL"+1HS/ "Q,KJY<MR1[5XQ5
M)S2)8R3M&]O=K)(Q*SJQDY%CL.NF=61@0P8!O&O;R:J0S9.*U2:.[Q[0PQA6
MM7"Q=L*-&-RR1NLBZXLK.H)WY;8)F3X=?QCJXY!J*&4#W?0M[\ABY%*K L"E
MI>?K&7/J8959:TX.67#H=&W.S#][8C<(&RY&-Q]8?'9(P: 1S1%Z^#)L]6*.
MEU8//(TMK)%<:55D4.HDYHH1F8$\26*EB>0))\ ^]2V&5CM8D@O8)[4,SO$[
M1L81'*[2(BD_/Q0-Q72L HT2H&J^FRG[UICH*)MYU1UIP*V8BX^WK@] 90'D
M[%LNII]S#(CL*=N5!1)/&-M7 LDFT(M5--TG+5)5/?37D21R1-QD1D;\&4@_
MS;]Q^L>*]#%/#.H>&6.53_*1@P'X@Z)T1[$'1!\$5*WM*EIY2GE*>4IY2GE*
M>4IY2GE*_F<8SC.,XQG&<9QG&<?/&<9_AG&<9_AG&<?PSC/]/E*];\%E_P"#
M:_\ RZ7_ -GL[/XG^DUC0_ ?T"GX++_P;7_Y=+_[/-G\3_2::'X#^@56L\^'
MW8$2?S2.\Y=DVMSM1EC2>2RZ0U!'Z_JJ:KP@Q.BKLS//Y I_,X^_/4^.DI4B
M3.(ALM)>(BDB*D2\,8Q_"Z;1"V+I2%,L"2R*  Y=U#!1I>ZBD*Y &B?E+* &
MW[GGFP=2ZP74L$,C%S$L<3\"Y+2=F1U+1AR2='F$8DH%&A7;U-TI6]"5=!Z=
MK./(A8+7H!K'H\Q<**$GVS=OG=5R0*E'N57Q<V7?K.RYPP^55>EB[YZ1>*J.
M7*N^U>25Y':1V)9B22/ _F T ![  : \5<BACAC2*-0$10J@^3^LDGR6)V6)
M\DDD^34E_@LO_!M?_ETO_L]IL_B?Z34FA^ _H%>=-))'7Z$DTTM?GG/TIZ:Z
M:_//RQG/RUQC'SSC&/GGY?/^&/8V3[G=9T![#544]$_#N,"C7.\?BM?6S>=-
M5JAV;("N:[5Y(*6FQLCJ+H2+7R@D3B'8:36BB%>AWNDA8L30<6YLP8[%QW1-
MUJ*<R#!?HQ70(E+,D<C_  RCEW@A2&)HB=P;DY'Y3HD(=G>]#7$GL&4VZI'-
M/#&+MCVS:F7N7-PL_E+O4!C4\@& ,HTNB06WU3#>0[@L:M.>++MZV952G;-1
MQB;Q+2W*A:U<Y<.:WELJ5?#ZLL^(+0=]34]'ZQ8- EY6S!1 2 &68!(22KW<
M;'KI?DPM/&CRI&BR6[LK<).?YX71=&Y=Q3LMQ)8DJ0'#&K26DTD5O)-*\-Y$
MKIW8NT3VW?8BD0QF&3Y%CY\451(I:+@"*Z:YLYP2Y[:VJ0(V9-+>GUWV;O;5
MFSR;#X2$<E95K!H37#)N%CM?Q>)QP !&1&OHRP9L$V#Q\JX0=OR)9\Y>;[Z1
M32]W@."HL:<$52QTO)G.RQ))+,Q^@&]   59M[?L=TF1Y7GE[LCN$!+\$C 5
M8T154)&@ T3X))))-0]2O/=OUY&NHJG"S8M4@22]/V%<U)6I%&4 EA/6'W<6
M%6_. 6\5FHF4"1SL/:LBLZ,;I&H_LFK'' ,P#=:NE5-1^\DL;-"Y42%84CD1
MN2CE&#&IY*5)';"'P?<$'?N88;>6-;F)7,*M<R30RKP<\)B)7'%PP4B5I%T5
MUQXD'SXE3D'FIQR52\9HQM;4SM>(P4>/ P1>;A((()QB,#&:;9J!3<0B,QK4
MPGA755WN1.Z$2NZJVR>7GV-$T]=)Y1-(TG;5&8DMQ+$%B=[^9FU^&AH?JJ6T
MMOA(4@$KRI&H6/F$!55&@NT5=_CL[/ZZTT+Q! @D,J^%-Y=+UF%6=<SSL$0[
M6_1OS",TGUC6W9#^+DOH&ZH_M=B3MXP/9Y:I(%MF(L9E9_NXRZ56V-PY9FXK
MMH%@/O\ FHB("//YQ" GZ;)\5&MDBI&@=R([N2[!.MEY))9"I\?F@RD#ZZ \
M^]<6]C\"F9#(8^<AL-L2Y(+-.K+(Z5NB+PEUSFXL82<E/.48HR-BX/%^HM6G
M/TFA:>T4;E)-I.D2$S&KN$U8<ZTU6()XG@N0 0S+&RPI#&S=W@0LID)8P_>A
MOFT./RD?G54N[%BRLB2S(]U)<S(AM^X&:W2!0BW.H&0<>3<SS'\@^2*DKFGG
M7J(I/.>))TKJ(8USS6TOH]4$4>;UFA8K$[.B*-<4PA98>DX\#I)*35;0"]@!
MWKZL&J,95(66BT';.UP#TJ1TEEA"S+%OE+VP[#GP(7YY.!D)DT\H0@/YTNS[
MZ$EM;W1>W:YXB.W$[1(>UW SD)#W!"JPAXH.XI,0X[DT">/)NA[-X?@-H!>T
M A:72\<AVR)B(F=K#OT7[L21AU<AZW8JQ+\D:MIE1T,#(/W?ZSJ1UR_55PCA
M)O\ 0EK$D[(T#!5/8)*[W\VV+_-Y_$_37BK$MDDJWBL[@7@4/K6TXQK&..P?
M<*#YWY_57CZ%X<@711.^BLDF4SCKF_>;H/S6=S'L <XC\<@5@6)8HJ2 \%1)
M'3>0."]C$&KQ,EH\%[L!S'1)DFONX64S%<-$(@%5A%*THWOR65%(.B/&D'MH
M^3YK$]E'.T[L[J9[:.V;CQ^58Y)) R[!^8M(0=[&@/'O4;V[R]?TUA5;U#*K
MOF/0L6DO3=%V#:<JGT=I: [P6JJ+DZ5UK!18RKH9 E)(K/K#KZ!0Q5'8<9?L
M6D@>D]G(X6.=[*;)-&K,ZQK&1%(B*ID;D\JF/9+LV@J.S>X\@>YK26VG=(X6
MG>=6N8))7=88RD4#=[B!$B<N<D<::T2 Q.P!5D7JM="GE*>4IY2GE*>4IY2G
ME*I5[S@4(EW1XB(P+G'J'IN_CU8H65-(]5O=%K\JUY!*L"E]H5'RSO5K;L1@
MBLJEAYH4'   2/)OSB@(Z7/EAZ#/9ZOT+9V6$LTL$48?@I>VCF=G(Y'WC9N*
MC6R3XV  3XKC7T4;W 5+>ZN9VB[CK%>R6T:1*0BD_>JG)SL*JKMBK%B/>INX
MBYKY2/Q^I^M*73Z<%$'X^0J,(U;W4?3$XS%SZ>LBKN=0^<5[.;CF,&)2"('$
M9+&WZ+Q@:8CI$)_5@CO9RR&D]([B:8%X).R1L;:.&%>0\,K*ZQJP##1&B-J=
M'P2*FLK6U*Q7</Q2DAB$FN;A^+?-&Z21O*Z%D;DI!# ,-@^ :T '5G0MHW_W
M6C/^;9O5=7=C4+ Z4$V$4L2C)'I#-X%7]YQDB;/QR'V<;DJ[61N+&#I1U$,,
M(.45=5MSR8=LENXUR7B2.V*RJ[P2-(5"R#?)XR "R!? 0[V1^K=:K%/+/>]R
MW>**[@2$.9(6X<$F4DJDC-INX..E)'\H"H:EO(G5'7-6490MSU./H-ASWS#?
MM5&['=6'"YN"L^V;0Y9E'*,<-UH'A10K)F%=-0\ZEM@%W=C"(7)FJR<>CK6+
M$E-B))K(L\,#R2QN93)-$X7@RE$2=9R'+>.9**H"%AHL2P]J@>TN;N*&":(6
MXM[:>,R=R-UDEEMFM5,:IMA&%D=R9 C A5"'R1TQ4==],VU>?)]AWG2.M#B>
M1ZBLH$57=V' IWM:UNV3&(5 5'=?MH&:-+BZR!Q\#*R_ZM/-(I+B3\['A^L*
M9IL";W$+M#'',D4G<[SH1\C+PC0LWS<@-N25&EY+H,=[(JS"ES+-:R3P"!;6
M&16W(DG<ED5$W'P)U&JJYW($<EE' >:GWON@F72G+TWK-VS,$%,&8%,F3 "E
MEP3(.8'.X]*U1B+;&<;N-"H\6^%KZ(ZJ.M$7FZ[)%9ZBW2WX^2LHLE8W-A<;
M,%W&(IU'N\7<1I(P?<=Q5*<AY4-L>U>BQG6O47IS>Q];](0&XZIZ<AO+WI]0
MG=,.5>RN;2SO1!Q;XEL=+<B_6UXGXIK86_\ XRJ42[?6)R%K!CR.(S*]PVYI
ME#RZ> TAWCS1=LQ4+-8^]U;$M@S9RZ9L]WZ33+%%=PV;Y5U462TVF$91%U&4
MC74:Z7B@T/E1= *-*#I1[ >!H5^#,C8YN.2:\RUGE(Y;B5YI[K(V]VDD\\[L
M\DLL]R@:26:1F9W=F>1RS$EB36V1#X2]>O8K7=JQWCOGV[IU;G3H>0W8_P"E
MW$L8JPOFPD.9C#J]7!0Q-H+<EV6!"1F*HF1CQ)7)MUC827'[LUFEC$)'B[(V
M-M)-;6Z/?7$,4070GO;VXOI%/@%(^[<.$"_F1A5&@*_8D74W4OJ+8X;JGK"V
M6[ZA?$=,X&ZO;_NBXOL1TGT]B^EL3D)0[%Y+RZQ&&L9;FXEV]Y<M/>'D+@&N
MPHI6'PP*^D/5#:8?#RI[GV"\C[Q!247Q;_+%6@*TG@N4@W!G8S5LY?A"I*7,
M8^JW2%F\))HN4R10&W:H.G)1%'2\S7CB'5T\K3AN,:3NSJ0=:==@*3OQ[^ ?
M;56DCQT;W/*PBMUM0G*>6VB6-PP)W%(02X!\'Z[( V3JK'JTK;G;>-1J95'7
M-/-XK* 8>3120P2$P]@*,QXXP;%0AD0\#"FZ+@>2&NFKUBY0VRFLV6253VSK
MMKGU1GEV5=Y-@D,&9M@@D$$$^X.P?YZZ$<<!57BCBXLH961$ 96&P00-$$'8
M(\$&ILUUUTUUTTUUUTUQC7777&-===<8^6-==<?+&,8Q_#&,8QC&/X8]'4U?
MWRE/*4\I3RE<^R/DSEF8V,VN&6\V4+)[89N&SMK9DAJ* &9ZB\983PR>:2TB
M <'L/&.$D\,7>7^7#/77&&RB6/GC,HGF5#&LLJH?=!(P4_B.(.M'ZC7FH&MK
M9Y!*UO TH]I&B0R#7L>94ML?0[\?2I5G, @EG1DE"K)A<3L&'&4OLEXI-HZ(
ME4;*(_+./MD AQF^&O-,8VS\M7#93&OSSG'RS[169"&1F5A[,I*D?L(T14CQ
MI*I21%D1O!1U#*?VJP(/]%4C7#\ 7G#>6.+;XDM:X_A_79K]Q5G(Z/E9US!5
MEU-_O*)%(,[.CB2(Q;?71/<'%YE&([^/E5)8&Z34RG[H1Y.;B$N$CNH_;4JC
MD/IL/KW_ %D$_KKD2X2WY]VSEEL9OHT+$I^/E"0=; ^575?^344_R]?'1X$_
MT/0%"P?XEM'"?YJMH\^YWC-Z,1:?\Q)P9A@H"B[+NFC+3+EXW85<725614P2
ML3.R^'V=^WC;G?:E>SE)\)+\T1)/T;?RCZ>7&OHIT:B[V9L?$T"9"$?^,A^6
M8#Z\E V3KZ",^1YD\UV9RW\;KX?G4#]"(ZVJI0UK8<Y&OZFZ,9(U;)FIC13\
M=42U-DGKB"ER6SS51JV$C96N?5WTUU7"M55-4?038ZZA'+AW8_<21'FI'T.A
M\P'ZR-?KJW;9BQN3P[O9EWHQ3CM,&]N()/ G?C08MOZ5;:FHFLFFLBIHJDKI
MHHDJGOKNFHGOKC;11/?7.==]-]<XVTWUSG7;7.,XSG&<9]1KJ>_M7[\I3RE/
M*4\I3RE/*4\I3RE/*4\I3RE/*4\I3RE/*4\I3RE/*4\I3RE/*4\I3RE/*4\I
M3RE/*4\I7@W=-4W*#-1RAH[<IKK-FNZR>KEPBURCJZ500VVPJJFVV<M\+J)Z
M[:HY<(X4SKE5/ZFC[Z\#W/X;]J;'MOR?8?CKWKS^4IY2GE*XDOCA\#>%OM+P
M&]!]/4-.TJV$521<4!8$5AK"0Q(%*)++Q*)YM(*_F*[MVR,RPRHDNW=-$L(K
M)I[-\[IY4WL1W!C3MF*&1>9<=Q68AB%4ZTR^"%%4Y[-9I1,)[F%^V(R8)%0,
MJLS#EM&)(+'ZC]E:3SOP'&^3S4>D$>ZY[!D4*BQ>:FU*RM2V($5J<P8LE_)2
M4@?2(./JZ-/73I[,)D3ES7=$\RS^[5&CS?#A/&[)?,MR9@088%8A1S1&#@(%
M  /,C\U0I\'QOZ^:T@L5M2K+=7912[=N25#$3(6+%E$:^[.6]Q\VC5B/JU7Z
M>4IY2GE*I5[>K0O:O<#2.Q91)M.V/PP.HI)7;Y5)LOJSG('H/FEX!QLF\T49
M_9)*X5".]W**R23$HY5PGE31/;6OEEOGP&3&,D[60 Y63F..0?$I;W#Q(4E5
MHR)'41GDIT')'D"K?36(]/\ ,]?]'6GJEBAF.@AD[-^IK7X_(8QX\2]_:V]_
M>Q7V+N;2^ADL;2>>Z40W$?=[79D/;D<5E_A'W5+]ZY3YNMD!:2MK1AK++&<S
M0^X2E4$>Q4M)!J P*QE34L_T &F2Y=1JA"56K9NFS&/BHY?9%?9LCXGHF?+6
MEN,)G[;(#+<;K*->3R1W=I-!/<IJ-;J*61(9TDE93:$* $>6,E6T/T9Z^R>C
M_75Q)ZH^@/4G15WZ8XZZZ?\ 32#IG$8_)=,]0X?*83 2\)Y<!E\7CKK*8:YQ
MV/MYH.IHY+@SO<P6-UJXMI'-N<KB45GD;-0V<1F/S.(24>X$R**2L*-D4;/B
MG>GVW0PT#+MG@LJ/<Z?S'#)\U7;+:?S5$ML?P][]692&5BK [#*2"#^((T0?
MV5^9G1)%9'571AIE=0RL#[AE(((/X$:J#'W*-2.^@:IZ0;H28)-J7JZ04_!(
M['9,0!5FPA4AV2^\S<5Z.RA'EUQR"6&HG?5NBW;-TV&%6KA4%'51$G>?M/%X
M*NXD8D N6&_Y1\C>]G\?Q\G<)MHC/%<?,KPQM$BJQ6,(WT,8^4Z^GCQX]]+J
M"1:'?_/U,UD#=N(OWM<![HMJ+LN9.L0SF]E!N?)4>,NWTJ9A6^RPL^2KL2F*
M8)B!VJIHE@EMLW:&_P!'VV(2'X:21R.5L@BVB^9>4J@:4GP0'._)WKZ^_B ?
M'00QJ>-[*UQJ1R4@"0.Q);6M,8QH:'S$>?FUYF8)V!312SNEZO*NY%!%^3A4
M+.VY/;' JP>JF@6;QIU*V18-8)Y=J"?C0XEFOO('SI4>U8;:Y505>,]%7:>A
M@D"0N &[Y81JA#.2A"D%%V023X'N:F%W"9+B,ED^%"-*\BE(@'4ML2-I2% /
M(G6OIL>:Z- 'P4K!!I1%S0F1QJ1BAYV/2$"1:%P9T(6:(OQ1@.5'K.&!,638
MN$'H\@R77:/&BR3ANJHBIIOF(@@D$$$$@@C1!'@@@^00?!!]JL*RLH92&5@&
M5E(*LI&P01X((\@CP1Y%9;V*S3RE/*4\I3RE/*5QGU)\/;C3LU@NWZ*H&"3L
MRHVPU;3E)@I&K)&IZ)_0WT'V)&%A$P2;-LX343&*EUQ"NR2>KL>Y1QE+-B&Z
MN+<_=2L@_1WM#YWY0[7^?6_)\U4N;&TNP1/ CG6@X'&0?LD73>/PV1^((\54
MDI\);O'BE10S\+7OJ5HPEAONY;<L]7YTF]:JMM=LKKBH_(6XD@+!9>8QAFV_
M38-%2V==&V"$\T^E1WI=^.MKCQ>VJ\CX,\'R/_E$$_,?J=L1[Z7Z5R_R7>V9
MY8V];@#_ !:Y^>/7OI6T0OX#2*WMN3ZU[@KXV-\\KDF$-^*[PE:/.^^[I$9K
MT#3#%6RJ',/5-\:8<XV0)%=!;?Z/DMLPC\\L*18PNAHJ":[[9TP./BG!:QN4
ME^O9D/"4?J\@;^ODJH\>Y]ZRN7GMB$R=E+ ?;OPCN0GZ;]R!Y^BN[>1L"KF^
M=.PN7^M8_P#N7G&\:]MEBFW3=/V$:.(XE -%7.N$_P!S0LCJPF$75WSOIC1"
M1 QBVWU:YU3SC;&<\^6": \98WC/TY#P?V-^:?YB:ZT%W;72\K>:.4>Y"M\P
M_P I#IU_8R@UTEZ*K%/*4\I3RE1K<5HAZ5K":6J?!RR2!H.&5.$0<&"9D4L(
MMD544=T0P?\ )9)NU]<K855V</&;1JU37>/'39HW66THY*_CQ=A=9":*XGBM
M8C*\5I%WKAU! (BCY*&(WL[955069@H)'J^A^D;WKWJW ]'8W(8;%7W4%\F/
MM<AU#?C%X:UE='=7OK[M3M#&>!1!'!/--,T<$$,LTL<;:$ATC%E[ HVNM85:
MJ92_($7L*.%W$(<-XY$Q@8"TD#D18Q-9YHI%)(HW>HL4Q.[1[E(OLD.?+LUW
M@_#NH,W;M>8JR%KD!)E[.6]@D-J5AMXXHEF:.]D+ V\Y#A!'Q?4FD<J63EZ*
M3TLS$?37J#U0<]T<]GZ<]1V/3.4LH^H(I<IF;N_R,^-BO>E[1(&7,XI)8'N'
MO5F@#V0>ZMXYXX+KL1R1[=@ VH;8N56K[_5!5#:K^I#<<0J]QM-CYL<;# 53
M\1 JEDDRT04=FD%$S+I^-5T3;/4'+!N1238K4GZIM$QV0R9L,P8L=D'QTL"V
M#&ZFE26.$S6\)D'<MBTH(D9T("L&17 4^HMO0'J2ZZVZ-Z%3J[TV3(=;='6W
M6N/RDG5T0P&.L+K'WV13&YK(I9NUGFUAL)$:QAM[J-GEMY(KF6U=KA/E*OGX
MN':4TNZ23&#VQ):KB8>3$483789@*:B0P(>_62&,Y4*(C76DG,JH):*G]Y*F
M_24(JNV[1F/&IM1K7\_9?U%ZGN<K/<VF0GQ]O%.XM;*)(UCCB1R$6XC>-N_*
M0-S&<,"Y8*J(%1?['>G/V*_0; ] 8O!]0=&8KK#-7V)M9,_U/?W-Y->7V1N;
M9'NY\/>6MW"<18)([)C5Q+6[K:I#+-/=7;37<WTO4)WXVEW'%!]'6/7EAD#E
MGS +4YD36<(>R'.DU<'3$67ER W+Q!1K 7C\$L]4?HN7ZC!P_;Q]JD3+8207
M^X8GJ];CIK$9N]LKUY;^YBQ\L=C:--_A32R6YN5CY K9L\1;F"Y1G6%1))H'
M^4?J-]F^7">N7J1Z6]+]3],6V/Z1PE_UE8WO5G4%OC V BQUCF(\++=""19N
MI(+;(QP+;216RW,=M+DI7M+(O)'U'GHN+XM.VZEQ#+3V-TY7HJQSAU.$.UHA
M)!1=BJ_;AX,:2=;[R63::(J-MA"3)M]]^D[8L'+QT-*),>_^6H/C\CCOAK\R
MXVSCO991:,;::.1"ZQ6LH8]^?0*]H*O)PR(69) GR+_<PR_\$.B^L_R[T>+#
MKGJ:\Z6Q^.;J"%,WBKRRN$MI;[J&P>)5Q6)9I%E%Z\\O;MGAN+B*"&ZLWN-R
MI>U@UX5=#+8CP*71D+-Q6Q8<#G@3$=EH]OJ[<L\)F0^KM^FU54W:[+M]T'KM
MJ[9*MGK1RNV<)*;6<9D(LK86N0ABN8(KJ/N)%=Q=FX0<F74L89PI)4D<7964
MJRL58&N%UWT=?>G_ %=G>C<GD<+EK_ 7@LKK(=.Y#\J86YD,,4Y>QOC#;M,B
MB81RB2"&:&=)8)HHY8G0?/ARY;-IR.[.968>:]="K.L7M'M%C84[N:WYQ).3
M+9HBH;BZ+$D:FK*$S"P99%6UE1V*!80PA@2"U_!2XM."2^0*DW , 55(^EG1
M!'+M;<HEO;\%1%6=)9(X3S=E16*LQ;9=V!+J-;(U\OM99&EMM/=B66\O!(\T
MTC6LL,,TX,4:/(R"14"<%C2,_=R-LJK!K+N8A\VZ(YFZ]@L@MJSP9XYUU\0F
MK(G982:R1M/:T$ ^EK6BU?J0F1(E4"H9K7+!D(;Q,*R?-A \6(9@4FN@7&S+
M-28K%- P1"!!:NR%1Q<F&-FY#6CS)/(D;)).]^:Z-L'N+:\C:656-W?Q)(KL
M)(PMQ*L?!M[41@ ( =  *!Q\5PNK=_6%R\O]ZW_/Y).*;D7%W$_2_-:82#RX
MI&A4M[*@E:'SMW]##$HX_'Z.!,:>QZ -*%)/$EW,94-3\F(59OG*+G%D1P)/
M;1H%D6XN(93R4$K S@1Q'8.B06,H'@Z0'8!W2[UU-:WT\C20M9V5S;\49D#7
M<<;--<+Q8;52L?8)&UVY&M[J3>0I/,=^E7M+%#G9=+0.XN+?UZ*Q[IVUI#:T
MTG%LB9 +93BV.>K!E4_OIG%]:^BTP [2&+$9L.<.2<IBAYK6.!8$B47CG"]G
MN:MY&2XTQA18U5"I*I(BI$6YE6TP4^%8<]D5+:._Q/9+7<22V?)1<2M*TDH9
M0\MO([S\1&KKR4N-EU81D FIPYABI]IT[U3%*&N>[9)SM%*JBM<$I=;5JSKH
M5B&[)3-S!S,W=8'[BD$S?+J0*'O(DG:4;&ETX$C.'S&-8#-#8"3,6,<I':A,
ML<8D9RX5(UB)@TH7F(U7\Y@W%B"^@2205J:V1A<W*02SM;K$L9>65YPMWR?G
MVFE9R>"<.XH/;#Z4 ,' V7A5E9K^(]W5N5OFUIA)(;V);5<0BVK()B9W-(LT
MVIJEB0Y^,%DA#>#-&@612$K(1<,%Q05 &+QVX:,XNV%KJLM\7!0-;L(T56@1
MF1-JI/<D'OLMY  Y%BQ \DFM[(2<+R,SRNR74L:2R$.Z_=0D$ @)X8E@@4("
M=!0/%;/\.!Y+\P#HV.3*R;%M9U7_ &ITK7H66VE)W$LEJL:BDL:, [)R041:
M,FK5JE]S9L(!C0\?&?>4;!0XQCJDT3Q=A>415%0-;PN50:7;+L_B3^TDL?J2
M?-;V'+A<*\DDO"[N$#2N7?BK#0V?  ^BJ J^RJ!H5QUT3;<^$G_B@VS#Y*1B
M\SK^<\0\+5O*67V=B%;1BU7=,')W-XX@]2<,6)_4KUH3+Z%EFBWY+F P]5WJ
MNU!LTDIXD75FC %62XN64_RRG<"J?(V"(  -_P HCZ^:5Q+(&R4J,R/')964
M;CWC60PL\B@[ 8&Z+;(/+MIO8  ZBI((6H+O24<Y1BP[<F=0S3D@)=Z8*XK;
ML6[3$0LB,6VZK\P5 3&U))+9>-&3\(=8.RT;_6]H\D:BZI(&-&;/"*2L,A$M
ML)62-9%G,>XT6,%#'R *HJJ2I'AOSM-IB= U:A4P7K6Z22O$]JLP6:628I(L
MIC)5Y6=P)%(++RXAEVH&SOEF_'5@VB!^*_?J-W777$QX=?2*/<V!H%;,Y@\$
MASJG.4JSZ'<R.:5Q'#HN"6QBRIM.2HR3(VM'9BRS!F;$$%0&826<K31\4-E$
M8XV6Y ,Q:-6=@\[Q:5R"Z<%4$&,K\Q.]ZT*DY>5<I/WIHGL2RVX25XXU[5K%
M/R>-7$<O<=R&[JL.&@ /._-V9+Y7'EJ.O\,\Z\K212R:<GS.57NWMB:XXMHV
MNS$BA3:SH;.Z4C$[>C2XN4@&Y@*2(2VDRK=I+IN'/G[5BD:$[K@\0!3W(SV&
M55G"QF-?B)&"MP*R%0002".,@V%(",?!VO'93#<*;N-F>U=IA+)\'!&73NI)
M"CD,'7:DO"VG=6:1$4E=R[K>2"J[SJ.QHX7Z_@*SWHWGG>:] D+8F3GBZ"5,
M1E0"/32LY/347G12.Y0L%GI^T&QV44BT;C[!F8F2';@CHL<BY;XM]/%(A$#:
MBEXQ\%%PT@5BKK(R\ODWRT)/*J5",2 =K[E%/%(INT/Q$!>X,TGP<<1=5>-H
M5D*_>#Y.30#3NKM*%!([CZ[Z L6B&O/XVJX'%; F=]]# J&&#YG*B,.CP/:0
M5G:LXTE1$P*!21]LS"N:];;D&#4.[>/Q:S]N.U_4MF?SKP1))W2[,JQ1&3:J
M&)TZ+QT2/?G[[\'6_&ZNW4\D'8$2*[SW @ =BBKRBEDY$@,= QC8 V03KSJN
M-!/?/4HUN8DM@T92;""4]V+ N-+P*1FT)B0D)^3V79=?UX$L6I@3Z#-FC**
MM+=K<V5!3(RH>+*.98)9JC-(\,,26?X:$Z"R2<G@>XC#(H 5$=F1R&)+$QN
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M[8)HDR+M@/!YHM[DA_571?#-2FNJ>H+RYVO'H0EM.:!ONSFUN.R<RHVHK&Z
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MPS?,7B:S5VU73VV36;N$E$E=,YUWTVUSG'L@D'8)!'L1X(_GK! 8$, 0?!!
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M$2"K9=.5QAL$JP"MI-![A%PZ;&33@R@\>DRK\V/+O7JCC&)9S*Q9HXN18.S
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M[G?[#L[@-HH-V\4LL4MV%#2<B_;**55HT8Z70)WK1]M$ +K*BX-U[#YSRE'
MUL5O/:-@E;&XOU))K& F&UZVM-1D,'BH5-H;D DI$!*Q:6M%CLQ9OW+--LT>
M/T&?ZTLNSV'X+0,LY,;K(S@PA&';12Q+*W+YCI?"D>Y'G7UR$ND>U42QR0I&
MRW+R*>]*X0!'7C\@VP+/^TC1\:C0KV/<E147;]U='\=6V <06^B%:P*M*&>!
M.@K!LRKWLC QZ%6^S$@'01N%9&52[UP4 $7B9(6U$9<YTW4)L66V_8C>1(XI
MT(:+FSR@Q(CA2S1DG>R-:!UHD_SU&;N:*&::XM)5*3F...$B>22,LJI* NM
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MW$MQ'5EI\2SKW;?37/PH.D=<;;:ZYV_737\,9SC&<_SZATT_AC^/\[?37_\
MJVUQ\\X\".N.HR?_ /'V<_SLO_7C@/Z2*_7[?93]$PI/_AD^E9T"=?D^P\Z&
M]?+UJQ\_J4G\ 3XJX<0\<$10P@['.@[M\/9/'0A]NW4>BG#ILDNN.>*-%5VN
M[IBIOLV<;MEUF^RJ6^455$\Z[Y^DQLSQQNR-$SHK-&Q4M&S*"48J2I9"2I*D
MKL'1(\U^'[V"*UO+NV@NHKZ&WN9X(;VW658+R**5XX[J%9DCF6*X11+&LL<<
MH1U$B*X*C_.<+WQ>.Q4GMM<MK;;;$'NVVV;$E^<[;9<JYSG.<F/GG.<_QSG/
M\<Y]^+I<QE^Y)_OID?SW_P#]VY_2/_.U_J$LO3KT^%E: ="]&@"UMP .F,(
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M7 )(5G4L'(T7X G96H2^*?7+6,::7^.I(^/Q$)32-@V%VX!M!R[FO-D%@-A
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MW4]24-/FP:II\#D-^1RUW5$&G9P0HXM\H+I<Q#X/?P%,<EA*TVDGEH DJ^3
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M]+/L^].R167I=<7.03.+8E(<I?)8P6V-6QMK6^L+;*SKG6RL^7?\@PX5,?\
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M2-)9S8TGD)5R*R6V!.!1DA$5A>\0<J LR]^7FS\OF:/M,>*Z,?;$04C6O"
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M:UL"+IHM%7:%=GXLKEZ/%$=%=" H:Y:[M<S,1ME'%Q( D42*7'LS*B*KD?\
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M3!O'[9!N6W"EM6"CC8:\PCG1 #$$*20#HZ)&M@'V)&QO7ML;]ZU#*6*!E+*
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MKC_XG3_CS_$J_P#TN3O_ *NL?]W?/X5]<?\ F%+_ .D4_P#<T_\ ![^RG_\
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M05]4Z3!J(D1,N<E(>/X9PF4FQ]2)W$$ADUV.V\<:E5 >9A\I70!+1D]QGV2
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MJKQN&4<5 \")#LGW8DDDDD^3H:  &D<?;R4NGD;N6@=N;E@"9W "K^:BJ-*
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MV,;:YTT=($!^SP6^]#EK&XR%F;>VR5UBI>]#+\7:!#,$BD#O%\_CC*H*M_\
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M#9X1.O&ZR;)3;7:7FD4@6Q>W5PJR2.)F^4.K !I %7;A=G6R0 "-U% 89KB
MOEH;QXF=X88VM5VYB="Q6(EW*QM)H;T 2Q!UXN@]0KL4\I3RE/*575(/ZVJH
M_P"[JZ*_S+<N^LK_ !.3]YA_LIZH-_C2']PN/]HM:L5]6J_3RE/*5P3\2>#3
M>6<H6"?J]+"MD5LV2G<:1_ 3);O&0I7365L$V:NJFJZRD65*OF27VE<JDQP]
M+.FR>^^,\#J=\O#A+Z?!D')P(LL$9A6?NJKJ)HUC<$,_9+O%H'<J(I!4L#[G
MTQZ4]'^L?4/I3#^N4+'T\FOIQEKY<S=X%<5(;.X-G?7.1M)87BQ_Q:P6V2+R
M(L=A<7%Q')%/##*G/EVU1*?B%\GT58U3?I57=+4O,8A,HKM*'6K-G#IU']12
M<TC*Q2/:2C"(9SNB,DP)PT1>;O\  :+8?I#LKOD&G!ZAPF2ZGPF*N8HTQ?46
M-N+6_@%RZ<;>Z0H+J(S6INE[3E5FB*%BQA@601DR*GV?T#]:?3/TF]0^O;"T
MR[^H_H7UCBL_T7E9>G[.\2;)X5TF.$N3BNH8>GKN/(VMO</C;Z"\2V6*WR>2
MGLGO839SW-KT<,-#P0>49%@AQ-=#[:Y..O4B 5P_:[[-">H]TBLXUW10((.6
M_P!&RVZR&Z6R"_R734QCW$,JS1)(LD4H(T7A8/$74\7","=A7#+HDD$:/D&O
MS=D[&;'7]S:3V=_8-')RCM<G ]M?QV\RB:U-S"Z1E9);:2*7DJ+'(KB2/<;*
M3S]))-):FN1286==580_G"6!8S7=?0 R+81V0[WB<-K.=7*<M=*I:D\&Q;<B
MDW"Z*;_=V^IWAFPP)?$"W&GGGQV3-S?Y2PML)<Q6]E96<L:0S'*RREN0N6([
MG=C#@1 G?YW%.V[R?2<5B<5UET,N$Z3Z#ZMS?JAA;_+=3]2]1V%W<Y/&+Z?8
M_'QPF)L+"CFT./O);5Y+]E7@"(#/<F]M[:RZ<]WJ^3T\I3RE/*4\I3RE/*4\
MI3RE/*4\I3RE/*4\I3RE/*5JA><P\ =!Q@U)! R027;;0$(>/$D7I/;7?[>,
M-T=L_//W5O\ 0-_K^C#EQC+=O]U?&4\8V 0"1L^P_&N=<Y?&6=Y:8^ZOK:WO
M;\E;.VED599R#Q 13^DWR1\M=R3[N/D_RUM?LUT:>4IY2M)!V77$G.$HQ&K
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M?B-CS1)$D!,;HX!T2C!@#^!T3H_J/FLLQDL<)I&5QI\(00CA!Z(D*S$JQ=I
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M)@,6BXJ;GY<!&PXZ2A@@/*52*"D?(O[$/!HO!DVI=#95BJC*9!(08H,\PO\
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MF&(UQ:R@8GQNVX0O(-_HZGGWYUY.]>:Z\B@&K::^)G(D*V%P2L*[V^'R(.W
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M[4DQ569N56;M)-VS56;[J-7:"[5RGJIG9!RBJ@KC55/?7%F.6.9!)%(DJ$L
M\;JZ$JQ5@&4D$JP*L-[# @^0:XE[8WN-N&M,C9W5A=(D4CVU[;S6MPB3Q)/
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M.1K.,P2VT4,RW3WNN#0/6\9$\W@-9Q5=CKB7RS3IZ<2H 3C)R3"-!V<M"-<
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MN-W*ZR++"WX[@)IG[&L[1Y^*7-S)/8W4;P1G V4D;P]FX2W<2+>SK\SQS7'
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M'GG_ !M._P#_ )?[Y?\ [D'5'_&L+_\ >KS_ .'U_1'_ .<8]"?_ *#]3/\
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M87,;\3%%(Q0," W !@.0VI!+#_8Q]?.H^E<%U?T[TYALWBNHL18YO'1V?56
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M=?+E/5793.^/GZI<V%E>0/:W=I;7-O*XED@GACDBDD5Q()'C=2K.'4/R()Y
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M>'8MB,QE<4S;VV-R%W8L=C1V;6:(G8\'?N*BBX.6N=K^<#WMR4Y!+!(B1^1
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M7N>VJ"GE*>4IY2GE*>4IY2GE*>4IY2GE*>4IY2GE*>4IY2GE*KJD'];54?\
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M27W/N+_;V;)XTUV5\7G_ %0Q^'R'P-I9KF(S!%*MY99&!H6:7E]VICBN%9D
M&R'WLZXC6S^G?23["'5_J/T<W5/4/4UQZ;7B9/(6$O3O4W1N3BR4$-B(=7MP
M+[(XB6&*X[CF,-:\ D?/NMR*I/? /Q(PO>!NRP@RIBE:K5R+C9159_+FDH3+
M)R%V7:82TU;@ >S+=GL+QOG.WY.J^KC./]#E+_2]?H_K>+JZ6^BCQTEB;&."
M0E[E9Q()FD70"PQ%"ICWYY;W]->?G?VD/LMWWV>+#I2_NNLK/JI.J+O*VB);
M86;$-9MC(;*;FQDR60%PLXO-:':,9CW]X'^2S/WNJ_*-/*4\I3RE/*5"72UN
MYY_YTON]L#$S6],4U9MJ)!E=U$DBZ\ A9J5("E54LX422(K"M&:BNF<;):+9
M4QG&=?GB2&/NRQ1>W<D1-_AR8+O^;>ZAN9OA[>>?7+LPRR\?TNVC,!_/K5<-
MU7/^GZFZ!Y'@MU7LK>P'KNHK1,R(21KRN(0UJ6VZXBL*L%/2L'D!C0 N^K4P
M$-2L"H%L@C.94S="H^3TFJ^7)%FK8=89(IFCC[9@= "'=NXCLR[<.2 X(4[0
M*""05%4HGNHI[5)I^^MU%(S@QQIVI8T1QVC&JGM$%P5D,C@A3S/D5:CZG73J
MIGH*[J=YZ^)Y2<_O>T('3D&+<&]!P\7,++E(:%QHC*W/0?-AIO&F1N0.V YR
M=6#BB91,4BXW>[CV#QWJCE!NKOK<BCDEM94B1I&%Q"Q5%+,%$<P)T 3K9 W[
M;(KF3S109&%YI8XD-E<*'D=44L9[8A0S$#D0"=;WH$_2I^_Y3SX<G_GJY-_]
M?*S_ -X_:?!W?_%I_P#-/_=4_P"4+#_CMK_GXO\ M4_Y3SX<G_GJY-_]?*S_
M -X_/@[O_BT_^:?^ZGY0L/\ CMK_ )^+_M4_Y3SX<G_GJY-_]?*S_P!X_/@[
MO_BT_P#FG_NI^4+#_CMK_GXO^U3_ )3SX<G_ )ZN3?\ U\K/_>/SX.[_ .+3
M_P":?^ZGY0L/^.VO^?B_[5/^4\^')_YZN3?_ %\K/_>/SX.[_P"+3_YI_P"Z
MGY0L/^.VO^?B_P"U4*]#=Z<66[4DGKJI>M^=;"GLE6CZ 2&0JX8)(I0=PRD@
MDH0;B0HDXZ(OU&PUB[?N4FJ"F^C)HY6WQA))3.(Y;6Y2-G>"9571+-&X &P-
MDD:%>%]2KRWFZ*S,=O=022$6!X1S(SLBY*S9P%5B3I02P_1!K(43W/Q32M2P
MRN[7ZGY^JV>!FI58Y#)[;$)B<H';%)"8)LW#\*;,LB#=,DQ=-R#)55#71RR<
M(+([;);Z9\AMKB2-7C@E=3L!E1F!()!\@:\'Z?2L^FU]81]%X6,W-O&Z+>B5
M'EC1UD.1NV;DI;8+<@PW[JRD:! K#=.]U\17=SI>-059V#S1-['LJJYS"X5$
M8W=5?F#LAD<@CS\>,%BQ8\ZX>O73EROIKH@V056WQ\_ITV^7R]R>H\3?WN!S
M%G%;R"6ZQ]U;1F1&1 \T31J78C2J&8%F^@V:^[>EO7_3/I_ZC]#]<Y_(1)A.
MD.I\/U)E6MW2:Y-CAKV*_N4MH5?E-<R1P-';PC1EF9$!!;=59Q&%B8C" D$;
MIX>B! -$&IJ[U^Y@@EAOE%ZJZ2WSOIG!!3==9=#'S1U^_LDGKJEC77%?&XRW
MQN+M,3&.[;VUHEH>X W>4)QD:13L'O$LSK^;\Y4 +H5^(?4GU2ZC]2/5?JOU
M=O9CB^I.I>K;OJR%\<Y@.&N6O1<XN"PFC$<BG#Q16EO:W)U<-\+'/*[3L\C5
M\6G*_A[T9)2E96K4\G#SY5V-/"9CM<J3&+ZQDHJT537U@;G9L6>,$5&IH3ME
M(WHMEPBJHELKAKJUW^37G2>&M,W+ .A.I[ZP%S$Z7^+&0O;'M/#$[H(K>)W*
MQREUDB%P)57V\<%/]M_3/[2?KIZF?9FQ_4>)^UOZ%=/>JDF#S6,GP'7MOT=T
MSU.F9QV=R%M;23WF5N(L9%>WO3XQ\]AD9, ^+FNI89;D*3=SQV+QGX]U-2.!
M1WG>.LORI09;B:M#6!F60\EH1:/GJ$?&YUB"RS@DZ>D ZC<-G*KIR^4=KY*[
MH*.MOQ/>YMNI\DMW#8+T3U;!CU=+9,C-B;]8XH54(D\T<EOS2)=#N/++R2,&
M5_(9*_-'5_V>G'HUU#U9D_M0_9TROJA_!_(Y[,],6'7/2LIO;QII;[+8NPNK
M'(+87.5EQ9N([:&QQ*V5QEBEG9A;>2*Z')W2=P<LU]-(L&N\[/0<S=B$"@-U
M'[('16(H1O8D0;K;2J-(:-):94</FCM-@_ FQ^&VR6VJZ+S1)5#:AU5CK*\S
M6*DOL+U1DH$MY%EN,)!>S6,*\W*1WJV$#7+/S/,""XCD565BCJ=-YC[&/4GJ
MAAOL]>LUIZ6>IGH3T5U-=]6XJ3"XSU3ONEK'J6]NDL,8N3N^EKCK#(#IVV1L
M;QM^YFL-?6,MS&\:7%K<*L\$WTI\;7FBCJ78456L@EPMVU.F""=ISR>Q>P$&
M"90JX).TA08@\?E&@;.F$F(=@Y:DUV*2ZKI]JY)+.GVT>%SK8G_>J'I/K:''
M+<W+QWU[B\E>&-9)'D4",V[W*P;TD4>I)44AI>4AD<_:?6/T<Z\]0ND(.O&]
M?OLLW_K!)T[TQ:Y7IOIGK+H;INVO;RR@M+3)21WDV1M^F)<T8^[/?7;K98JY
MFCFBQB6MJN/MHX5N;XGO,-_V2(GYFZ^AX-(40(B.&VH&Z!\>ITA^A,'C?<\/
MBD'*M9B#<G'6Z1%1LP(90P_546<MTTUED]>3<W,>7Z@%[?X;U%L[,1M"$BML
MM!CG$*NL4OP]A$M_%W=ARL4F^Z09!Q,E?1(^F?4GTY^SK;=->GGJ']BWJ3U,
M:7&92]N[[*^GN3ZJBGR#VLF;L+/,=:WTW160-BRM;Q39.S2 X];A,>PG6QK8
M>>?BPTA1.)8WC/1?0!XU,,!VZQ:\I]&+(@D6:!5"3MUO$P/ZB;-MR)I=PU8(
MD'K-;=,4FHB_2R[V1?,]^FLFV(R%^)K'U!DL[HL(9,OC\A?6ULD4DC1]N**&
M:Y#RHRISX$@ "4'?-:OVC_3[KKU#]*>BI>D>H?L<VOJ/@UQ;]0V?IYU3T=TM
MD\Q<W^/MH,W_ +XYK)8WIR6WL<A$;E+66XBC:)YWQY[BQ6\\VWG\;*@N@PT"
M B;2N:ABD64?/Y'((38K2'@9@\7#I,]D7:E>2)U-=FS<@FJ] CU54AFF72F3
M:3A5%INATI^I8LS<Q0W>*ZYPUM;BX?OVMED[6.Y<A5B$YQJ/?: #/$GB+F=3
MA@%UXF_]"O4KTTZ%;)^GG6?V3O4[KW,S=,VN2Q.?ZBZ#SDF"M$2>XSDF 7U"
MNK3I+Y[TVUM?7,Q?)'&1R?D@I.[<N:*:^)Y'(%/!LI6[HZ8E2 IL]<8CER&!
M1R".U]T<(_BO$!EB3EZ=VRDJXT9:O8\'3U5PF1R]8/D&R.W Z;R-U:Y>2?)7
MGJ!-:113FWARF+OY+5W+ (LPMGO))7[18QAK>*/F [.C*B'ZY]I/H?J#/>DV
M%QGI)T=]CBUZ[OLI@HNJ+[HGK?H^PR]K8_"RR9*?#2=2P=*XVQLAEDMENY(\
MQ?Y$8]FM[6TN4EN+B+O:ROCXT)9L-7B<#D<LI<X\'K_K,U(YBCASIIAKKILU
MAJX,Y+' XHX<[J*M7A,3KJD@CKKH[1=;ZXV]9'UM;7ZW-M/B>J<.IADX7;XF
MY+DC0XP&VBNVCG()9&EB$8T0SABH/Y]ZX^RWZL=%VW2N=Z!ZP^S[ZG91,]CE
MS/38Z_P:V,=HT;/)/D8^I;_IFVN\(MRJP7RV61;)]F1)+>V>,3RP\'5]\48V
MW=EMSWQ ;T)(IB%U!VDEAE<1M)%_IMILGAHJ%EMJ;&G_ -/_ %#8JR"C=OIV
MRXW<_>U;I>.P&9R'>O?RSF>M!$MLS6G=P)M]R GR#;C)F68+HQQRK% 3RYE_
ME4?I#[17IK=6^'Z&/H5Z1_9=OLK<=36T/6:P^K$.62/%&&/B"N=EZ 6PP\MP
M9TR5[B[G(YR"(6S6,5O]_.;'ROQ_*!-,(^C"'YJ.O 3;5[+WMF XMC>8Y:(M
M-,CXVWA,RD;=D[)+:OUG6KW]*30RHRT8.<)Z.OM^SL>OL?.D@N<;U!9/;P+)
MRO,1,#=NHTR0+9FY596(!"R&)/FTK$*VOS/ZK?9)]9<#>=-/Z=]0>C76-KF^
MH9+/*087U$QA7IK'RR1-:W&2EZG;I^:3%QQO<+<W>.&2OX_A4+6X>=%EX=BW
MQA+1?N['>ENVI2R:81?O(0R)4=S\#W1T6</E6K=LS9#;%U(O&^GZ>V38$3C!
M+3397&Q)[]2KYCY+"]5969<R^6S/4%NR0L^+C/3-G"2Q[S:5([2_$LB$0HL4
MLT*D,VY'\O%^B/7+T%ML+D?1>S]&?2#T:ZEL;[.Q6GJI?3>MW4V0^%L(CB(U
MDDGO>I^C),=C;F&3.75SE<9B\K>)<6MFD=C:EX['*=/4U\=..,JYA;*R;$3E
MDZC#DJ0LX\?@,6BKN<"W!E=40&@HN$2UZ!T*,0?TLUWI!M&$G!+=@ILURS;D
MWR_;Z=Z\B.*<9TY-LE:)))*\F&:V-Z"[F.*TCM3)"TJ)PC;N"U#,RMKBLDB_
M+OM$_93Z_M/5#IA/0;$>GDWIUU/D[2PO8HO4N+,CHZ..+'17E_G[WJ%L9D[7
M&W#/D;^&2P7J6=!:O;@">6QQ]UBK(^-ZC*Y!:D@IVW4X#$&<=#_R90V=5W#M
MI!N>1#;_ *KN7<LRDW2-X(23375+5J9#IL@JZ.FS+5P@X)[P_P .UO(L[<PW
M.1QO9M8SAK*ZPX[LDZP,6[I5+P7!ENPJ<5G@$<# D!@TR]'/?9:ZVZ4ZH]">
MG++H[H7U!Q&<ZEO(?63K#$>H\WPF+PDF:M(XA8)/?=+28-<?TS)=7L5S)B,[
M)D<U;F!2\;0XRZQ7-'QR)>BV*E.DIO7AED-.#-E T8B/Z;)'T:W2^@AF.9;E
M& Y\8W544V0;O\-FR"K5OEV[09.EED8.E_4"9L?D;GJ>5A<V\B&VM;;&SQRS
M0E/:$!0DLKRDH59D6,*KNZHY9>I]I'[)N?L?4[TNZ;^SGTM97W1'4-O<)UGU
M5G>M<?>6F$OQ?\)#D7:\-SBK#'XE5OH)X;7(2Y6XFEL;6WDN;9(9YTNGXZE>
M%8N;+\Y$A@4@%#95;"[@B_W#!Z1*KJ9;-& V.3%9HH#V0U126>:ED7K9PLNN
MY21:MD/SNI=^HN,FP^1NL:\]KD+9#\+:Y*QDYW,V@8U6*&1@\3MN-V69&A(,
MCA4"\_"VOV/_ %GPGK9Z8]*=0=.X+JGTOZEN%_AKU=T;U5:]OIK'B>:/(2RY
M#(PVQQ]_C[58,A96]QAKVWS;2_DZSE:Z[QM-%YT^.>5?BUI!TFZK!DT8'_PW
MT=KR,2!G*UP2S1KAL1"HE9J69DW?YZSC*R6VS1!%LSWT<;-\KHNO4>GO4>&7
M$W=[U)+#;WL%P4CL;.SN$GF@*1]MXDEFE$S/(T@8AXUB$>W !#-ZGUU^QWUY
MBO6OHCH?T'Z5O\]Z<YWI[XS/=>]4=18NYL,1FTN\H+RSO;VPL\<N'BM+&VQD
MMK#/C\A<9>;(/'92.\,L5O*UN_'1KQ./'I+0;6.E,#!B34;&K2&E1<F*R5RX
M3QA=-B D6R60+5LKKMOLBYW44W1=87>,L[(:XNWOJ5ACA;W(8V0?'P%8[?'Y
M"&2*:>5FCT1%$Y9H>+,3(D@"E"'*^.7E,-]C;URM_7OH;T^ZMZ7$WIAG+.:^
MZG]1.D<C;7MCA8(;?)-)"<I?1):V>32YMK**+&W>+GGO4O$DM.XID:WAT%\=
MF?+5*1FIN*4GF=,2NC-"OF6)DQ<D6VQ <G]U!=Q)22^B>PU0@ZR1PW69-UM$
MVZNFZJ647/+M_4Y&Z9N,G<-C5S<5P(XL0HN$,L9EB4$*TKRD&%I93.I[2%0C
M*6!#>^S_ -BSJZV^U!TYZ7X+I_K*Z]#,GTS/D\KZMSMB[H8S))B\K/P>X@M+
M3%PM%F+?&8I<!/;G+7L5S)DH+J.T<-;=;)?&WYR5.H'-G6R%6X;ZL7C?<6_W
MM#0]LPRX_(;1[5YJ@N!T?9T8?D_CZZ;-_K(9?)N-?TG/H5]2>E3CSD#?%=2"
M)K(I_A_,D>5M0>;0@;;O>(]#182?(?CEQ]CW[447K!%Z<1>G*3].2X>3*CU
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MFB+ Z(J:?V#!/[%1+_#@?_8_;<W_ $F_K'^^O7\$_17^J/[J?L&"?V*B7^'
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M8]$YS%GKL03'EAZ1^.C_ -1&/6Q!AERT5T6SB2)XB ZZY#:D%65AL@E64LK
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M*4\I6HSR=Q&L8>?GT[-MH[$8NPW)'#+I-RNFT:ZJ)HZ83:L4'3]\[<N5D&;
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M70%@R?E+H4/..H[3Z>IC$\X++0*BI^/E"RRU44W82[<+M4S;H"K(\&J:-.+
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MT>5)+AV"L/#<$D0,02 3Q]P15GGJE=*GE*>4IY2GE*>4J*[ON:!<\U+/KLM
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MY2F,8Q_#&/EC_NQY2GE*>4IY2GE*>4IY2GE*>4IC&,8^6,?+&/X8QC^C&/\
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)4\I3RE/*5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g99471g11x65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g11x65.jpg
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M"[EF:;;(2P**I*QD8(4D$;GW*<@@ #UJS>>Y"RR,X1K9+8O"JH4D>15>8,S
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M*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5!]T==*JO\
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MDU,38NYK3YNG8 RT Y^-2*93^35\U87:Z5?7!I$*RD$J)UW7KBSGKAV[G+Z
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M]8%9J0D]Q3"!FI0:./PP".!L,(Y'JQC\?B*;1AEUE&32S4C[,),%G'AE!C9
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M=W.4&#LQN8$%0><6&"69:EI-^_,+BQP3%)13ECKU;2<J8!6CY<.Y-=0>OUP
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MF-:OI;=9,1+J]AM.I%REEO"$EBE+04[J>#5%&"KH>III!R"V-QDR0/M#YNQ
M&^H*?')*-:L&[2I[5(&5P(P5=I,! %:1A@NP]-P]5Q@(>4"FJ?L$/;:/?,0R
M)$&,I++%&VY8E)!\A/#[@S2#AV8 8YW:O6@I+.GU_=98]8<E/%;9IFVJRCTN
MM,DV**@G5@P$M#Q*;Q>,@1&4HV#6?(+Z-6 I1VW;8<:M_6W]%/6"2A9XIBH
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M-:1W$DKE3M<;2UJ$&0/.N6DPQVF,K^,".2]>^R-XW:ROF%NK4A4),5G'Z9G
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MNVR37:N"WPK7+[+9+BGB%U-;]7]7:OKUI ]O:73V\5JDH43-!9VL-I'-.%)
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MAYY$(L+?RR=7NX<#B ET0(LHW7P;XW#5U*"(@%;R,G;CB1BP1I'+%=H)DV#
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M652 RJ%8MVS&A8_$+PV,<E0/CFJ)LE"-&DD@1Y%9D9BR!>\)I%1?@7(*Y).
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MLIQSR"1D$$? YJ[T^_N]+OK+4["9K:^T^ZM[VSN$QO@N;659H)5# J3'*BL
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M#>WUH_KB9X,_-=4UZ!;'-_G6L1:NUZ<3Q&6SG;2Z3(<[\&$M#[+O/W/=CRA
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M-FK9NCKNJNX<+;Z)(HI:;**J;ZZ::[;;8QG2V945G=@J(I9F8X554$LQ)X
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MD9^"NB?O G\NOZOAUW_E_HS[G:R_LH)R_M?O:W_80_[-:ZYT/^!?2'[K]/\
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MI\@78=4TN #/!6+&.5II9SUPO%W318"L-S)7B^^ CADL,W8[:-%FJC?.R.>
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MG5V$,(ZY_?E4650:/<:8SCUM4=D-\Y35WQG:IXEGBDB;T=2 ?DWJK?V6 /\
M"ODKJGI^UZIT#5-"N\"/4+9HXY2NXV]RA$MI<J/4M;W*12X!&\*4/E8@UIZ&
M=;7_ %]JT@M+6"36QIN76?2737;1;8<+$+NF$=#)N-/]U5'1#+HUOMK[,^N:
M40W][#5/.+73[4VT1WC$LC9?XX"DA5R.#\6_M8^%:'X/]#3=&=/SOJ4*Q:YJ
MURTM\ 5<P6ULTD-E:AUX90IENB1SONBC9[:XO-R_KK=.*4XI3BE9'=LO\V_Q
M!_=UY*_RQZ_\5,>X_P"E/^:O+7_/A.?TCXK_ *QYEQ7GXG]K_A615S]W.UMC
M=D7F3_<CIG0D<H3R=]BJ-IB/V-5I!]((6+K:HK*C0RX+.=IVF'R>@K\!8:]8
MK*X'QMFG/I %/*FM6@UV(6Z/T/H.MZMHW73:9I=]?++TY#9QM;6TLJRW:]3=
M.7QM8V52LER+*UN+CL(3*8XV8(1C.(U2ZM+:XTGOS1Q'VLRL'D52(S97L0<@
M\JO==%WG*Y../A.'8OLE9O;G]FRLKL#<;B+O+)G IRRDKR%"5047>*07NZA7
M8MX($KD2RK-!T%B8UPKIL1=84<J+K:J8T4UTUYTZ/&[QR(T<D;,DD;J4='0E
M61U8!E96!#*0"""" 1687;N!4Y4C*D$$$%<@@C@@@\$<&K-^2S^)NO'];+QI
M_P#9Z_YBK'[]UG_7;?\ EEA6]]3?@QX:_NKKG^_/5E7J[[=9B/8.NP+R&LD'
M%C0PZU^2X4WT0P0!2!VS&GAR[C;&-4T6F?@C^%5<[802$O$D=/?>[^]/4+4W
M,2E!F6-AM_.K$!A_#AO[) ]:^8O&'H.?K/1+.72X4DUS2[N/V4,P3OV=[)%!
M>0.YX58CV;W>V=B6TRHNZ8@VJJ2M0=/UM#ZVCVN/EL4#-QWQ'IZI*$7^?><%
MB[C37.==71<HN\).<:YSKJLZWUT]FFNN,7<,2PQ)$OHB@9^9]2?XG)KH?3>A
M6G3.A:9H5D!V-.M4A[FT*T\QS)<W3@<"2ZN'EN) . \A P !4C<JUG*<4IQ2
MG%*<4IQ2G%*<4IQ2G%*R0\1'\+>0;^K7Y!/S<UXJ;^J_J)]@K6_BH4XI3BE.
M*4XI3BE>N[=M&#=5X^<MV;1#7WUW3M9-NW1T]N,>^JNMMHDGK[<XQ[V^VN/;
MG&/;[<XYXS*@+,P51R68@ #YDG '\:JPPS7$J0V\4L\TAVQPPQM++(V"=J1H
M&=C@$X4$X!-?MKMKOKKOIMKOIOKC;3?7.-M=M=L8SKMKMC.<;:[8SC.,XSG&
M<9QG&?9ST$$9!R#R"/0CYU3(*DJP*LI(92"""#@@@\@@\$'D&N@I>_G-[U8[
M>3.P*[L]S&JNB%CFA4.I9P""J0MY! )UPP:")@Q6'[%"AB0#&GJR WL21-,2
M+]W]&WH-NU&MV7';SJW5QJ<LT,YCMXIV6*T*)VC"CE0DH*[F9U&7?=N5F/;*
M *!^FW37T</#<]"Z?I>JZ.EYK-_I-O/?]0I<W U"/4[JV262>PD640P6]K,^
MVTMNRUO)%$GMD=R[S/+WT8P85D,:CQ]<<Y#KG 8DPL(>^WXP6J38-WJ@YW[=
M$\_$L=U]FR_MTTSZJ6_^YK_Y8Z_&V^-'*E=Z*VT^J[E!VGTY&<'@>E?FC>0+
M:W=U:K,EPMM<SP+/'_5SK#*T8FCY/DD"[TY/E8<GUKVC)D/' Y60R$J-!  0
MU\9-FS+YL,$!Q QJJ])%2I)ZJ@S'CA[-!9V^?.UD6S1LBJNNJFDGOOB=6U4Y
MZR^1SH_W(E\N@'6;LA7UM32#-U7\AC()4NP+Z"F[M%@X.AFL@%!]Y3'&SURT
M:N9)%OG()NN^'IK$=-B#+"ZI%67U!'Z:PW_:0>K-\69FD+^@04M-:QKF/F8/
M+P8;VO'T./RJ3B]A$CT":;Y>/6TP77&QQPZ&-G*C5\%#-GNNFK]EMGZ;^CSU
M/H>F_P!-:%?S166I:C/#>VD\WD2[@M;:7O6QF(V(]HJR7"K(RAXYIF3/;>M&
MZOL;J<6UU"K20PJT<B+R8WD==K[?4B0X0D D%5!]X5?CP3=7KTZN=.C82^ Y
M2''K#M4U8D?KPUOC!B(QQY&HJ ;[&F7O[[!2YYV!=%' -3.KA@TV'[D$6I5R
M09MM&\;NIM$ZFZNAFT.6*[@T_2X=/N-0A'W&[N$N;J=NR^ )H8$G2-9QE9'[
M@C+1+&[97IBRNK'3V2Z5HWEG:5(F]Z-"B* PSY68J6*G!&1D D@?Q-NBDG,]
MB2D4$2H$A&9%J0L/Y@\4=Y,"HR]D/PSQCD?JUV3?&&;IUENRSJZ39O4=$W;E
MPQVW5;I?*-UTK/)K+V\=Q$()@]YO;=W(X&FVLFP+AY59B$PP5P S%.5'Z)Z!
M](;2;#PRM-7O='U&35M+-MTS[-"L L;S5;?3!+!<>TF8/;V4T,(EG!A:>!R\
M,,5PH25]GQ[% 8P8C6N-\-A[-LQ;X4VSNIA!HCHW1QOOG&,[[^FGK[VV<8SM
MM[<^S]_.E(@C1$7W4547/)PH &3\>!7PI<W$EW<7%U,09;F:6XE*@*IDFD:1
MRJCA1N8X X XKW.2JC7JO'S(>C\0_>-6+?U$TO7>.$FR/JK;X313]5;?33U%
M5-M=$]/>][??;&NN,[9QCD694&YV51D#+$*,DX R2!DD@ ?$\"JL-O/<OVK>
M&6XDVL_;AC>5]B*6=MB*S;44%F;&%4$D@"O:Y*J5.*4XI76%_:BKLLSKEURZ
M=W73DDWA]FP+MODE#Y0DP&%%P)1]1EO!LDFK(RS(#%GC9H2<[L]GC)RD@ZPD
MX]+;=+7BJL(!9@?0J<_6*Q@_9^.[O:KN%Y3*<8=F[HE=SYJVB^RFT')S3(Y\
M=#)3EK UI&SV.HL6Y8BQ<K1@0JT9E';U 7E)?09HT2=+I[JJ2*JH=HQDKGU^
M&<?;6D78NC.I%H]\_(2=[(MH:B6:^0/QRP006DD_>0-VI6LVH.BV-NB47#22
M /B@^T8]]Z8?Y]5Q&4$\F&;X0IA1WMU[PIU_J[3I.H+/IZ:_>U&@:WJ+6MO9
MB_ACU2VTR=M.N!$\%PL=Q)<111JJA?;-B0RI,$1%UCJ"TT^:.QDNTB#^U00[
MWD[3&![@"9=P="4"$DDD]O)8%<DF?*1CL9B'AV\YT1A+!B*A<4NCS!QB'"A>
M^5!8N*1^/2T1'!@S?*BWO#1X9FR9L/8JIC#1%'&N^VN,9SRR_O+W4+VZO=1G
MFN;ZYGDENY[AF::2=F.\R%N0P/&W " !%554 9Z&.*%8(H45(D6-8T0 *J@\
M 8^'QS\?4DDYKT^\4RB#_P 3DX"L95''AC>AO$D.T%-3@QP2V(1SL;5&)"QU
M8HNMW67@++UE@PVPEE89EVUP]T0^(2]_6[:YMWUG48TN(6D]FL4[:RQL^^%[
M[O)L#%MT6]>ZN,Q[EW 9&>I:SH>M6_AIT3?7&CZI!8C6NKKDWDVGW<5J+?4[
M7I4Z;<&X>%81#J @G-C*7[=WV9>PTG;?':'YF:Y;3BE<!FMKU;6JP9O8UDP&
M .)$YV91]":S&.Q58Z\UV3UV:ADSI%AN3<Z[*I:Y09:KJXV53USK[=]<9L[K
M4+"Q,2WM]9V;3MMA6ZN8;<S,, K$)70R-D@83)Y''(K9- Z-ZOZJ2^EZ7Z5Z
MDZDBTN(3ZG)H&AZGK":= 0Q$U\^G6MPMI$0CD27!C0A&.["G'/==M=M==M=L
M;:[8QMKMKG&==M<X]N-M<X]N,XSC.,XSC/LSC]^.7E:X002""""001@@C@@@
M\@@^HKSQ7E.*5D=VR_S;_$']W7DK_+'K_P 5,>X_Z4_YJ\M?\^$Y_2/BO^L>
M9<5Y^)_:_P"%=,WN?2]LV/WH[<$:YJ6PI8/EG>CL?6D>?1>''3C2260+FYJ1
ME8F*=BV#E$C)6\>?M#[@2DIN_;A%/CU$=6+959+[C\'.I^EX_#ZQMQJ.GV$^
MB0W3ZW#<W$-M);L][(QOI^ZZEK>X[\/;N>8][I:[A(G;7EW4MA?G5Y',,TR7
M7:%JR(SJP$2KVEV@@.A1\IP2 9,8;<=QT]L$?V54HFP8KIJ[C9(/U8ZH[9<J
M$&WD')#W.NJ">-M]EW3]%;?">N,J;J*XQ[OOYSCGR7X@ZOIFM]8]1:OI0":;
M=W[RP2;3&LRQQ1QS795@K*+N:.6[.]5<=[,@#[@.B:)9W45I863J\MV$2$11
MAI9&DD)$<"*NYG==RQ*J [F "9!%6@[U7G +0F_6D9$'9%\X)^8;QUS9FHH.
M52;;QT$=@T ?/MG&-U---?I&AANW][.-%T'#1;7?VN4],\JT?5[&\U'4XH9"
M7N)TGA#+M$D<-G:6[["3YF#Q.P49)C&_TSCZ&\1_#7JSIGHOH;4-5L42VTG1
M[W2=2:"7OM9W>I=2=0ZS:BX54':B:UOK:)I9"JK>2"U/W4J#V.^;-7!*<4IQ
M2G%*<4IQ2G%*<4IQ2G%*<4IQ2NLE$^T\IZ5>-7S1=EX*Q;OYQ7/DQ[[H0O#Q
M--PS'RZ==AXW7$://6BVNR+]G&C<N8R)V-5QA,DW%J,=]M-7&=]552-SH#Z%
M4^P5U./#_P!_^W<=\I76@J2ORU)JGV&ON#UC<@J:SB32D1/P=I29G%23J0C"
MK]\U=E BAK4['264-' 4D/;9:KMV.72"JJTB+L/ &!QQZ?5\_P#]UVE_VBON
MU=50F*>ZRU%.S]<BYK"B5E6.6B!1V"DL@'+2!W&XQ'M3PU9L4'@DW &0NC#%
MDY1T.;K,6[_91FTW;./I3Z/O2W3^L2:WJ^J6MMJ-]IDMG;V=K=(D\-JEQ',[
M7C6T@:.265H^U!)(A[)AE,>';<N@=77]Y;+:V\#O#%.)&DDC)5G*%1V@XP0H
M#!F (W97/ P9/_9QNU5NWG6'8NI;6GAZP4Z.,U86AI66EWI^2BP-HMK$;K1]
M4P26<D'(1@_KA9R$;NW"^1^7Y!FVW28),VK?&?2"T+0='UW1;C2;:UL;O4K&
MZDU*SM(XX(L031):WAMX@J))<[[F)W5%$IM=QW2"1C7Z1NKNYM+A;AY)4AE1
M899"S,=RDO'O;)81^1@"25$F/3 KXUD=@)_/[$*V-I.R^F4S#QW%G08XZ;#0
M0AN[5V&( ]FBZ:#9JW;:)9V72QA1VIA1T\46<K+*[_"NI:CJ$NHSRRSSQS13
MR(B+(Z>S]MRJQQA2-NS&#CECEF)8DG]>NA^B.B]/Z'TC3K'2=*OM,U'1[.YO
M;FXM+:Y.L-=VD<LUY>2R(YF,^\LH9MD$96*%8XHT1=*NQ'<F1P_QX0KLE6Y<
M4[EMI0^LM8K*L(,G@W5[.A;=^\E(I@MJHP(>\,0)D@:"B2[+515F[=-'3)NN
MT5WCJ76-1TGI3^D(EV:BT-E&[L@(MIKCMK+*8R"FY&+*BL-@E9-RL 4;Y%\%
M/#;HWQ!\?ST;?S&YZ-M]4ZGN[>VANI(GUG3=&:[FT^PCNXY%G$5S%'#+<S02
M+<26,5P89H976>/*3QQ=UK^>=LH+ K#MB83^)V\1. 2@:;R$C(M&YC6.FCHH
MA&-2B[K<*Z;/!.NCAH(PV'JAMGNCAI[K5HX9<UZ$ZCUVXZBM[.XOKN_MKT7'
MM$=S-).L7;@EF6:(R%NQM=%4A-J,C;"I;M[?M?Z5W@OX5Z1X-:MU'HW2_3W2
M>M=+R:/_ $/=Z)I]II4E_P"V:K8Z;/IM^MI'$=5[UM<S7"270GNH;B 7(F6+
MVL31]Y];XFIF_(9U\;%WK*NX5 @LR? 6SM1-F<FDH?F/_%BS9'?5)YD0#8#6
M81-XFIN-4=FG#7;34JI[;3Q?U2\?5K/2-\D=C!91WG;!(2>XGEF0RL!@.(DB
M6./=GML9BN-YK<__  V^@>FK;P[ZE\1_9[2\ZLU7JB]Z<-\R1RW.D:-I5AIE
MRFG6[L&DM'O[G4)+V^[3(+R!=,656%K&:N?X1[@DT^Z2]A((3E1$LI34JD8"
M,J.7;I5S$A,AK45)& !D[U7T<MFK!\Y=&F#9%1+9AJ8]C59-+*"3?=O"J349
M>E9/:7=HDO;F/3'E);$"QQ!E3.?N"77>"CT#"51PH ^5_P#Q![/HNQ^D!9'1
M+>VBU"XZ6T6\ZZ@T](X>[J\]]J#Q3W00*/Z5N] _HV2>0\R6[6,[EI9)&;HW
MMHS8TN#R*: HM.9-@; 9%<1@VT$G7CI*%A@;Z6F)X1*;(Y61%I#6;HHO('3C
M5)3?7*F'2CG?3&^JV^F:A-JB6303"Z]H43;D)V?=/NDSD@J8QRYD.48<@L",
M_2.K]==&Z;T'<]3Q:OIK=/#1I#I[6]U&@NLVA2UTVTC1A*MZ[&.U6T55N+>4
M[)4C:-]O^IEUN(/RW7:A"I1Z[)$R=+5:0(D7[A5V^?OWL&!.7CUXZ7W47<NW
M3A11=PX64W5664W44WVWVVSGO5?CS64O[1?;R]1^)/LIACH1^96@I *A9.1S
MK5IAFA,IP%WD&[]7WL*[CGD3%'Q3AJCHIL]V(I,UM=&B[A9)52(9<?FY^JNC
MY^SK&]@GF'ZA;?,2K!$J[N (X2%^YG4GJ2H:SDT!Q311PAIL*V>ZM7;CVZ.=
MTU6;=9!O\0DBN@JXF_JV_A]HK<7]HWO&TCO;@'09&4N_\)8% (K,X[#FF/@Q
MVTFEZ#Q,N<,:-U]L'"">@W1H(<DDL*!6BQ!L-31T(OUGWV1]';1=/AZ:U'75
M6&74K[4YK*2;:IEM;6SBMVCM0YRT?=DF:YE"E1*K6V]6[2&N6=8W4S7L-IEE
M@C@64+DA9'D9@7(X!VA BYSM(?!&XBM1/V?N_;&L+H?>H2:3H@5&4!-#L-@;
M][KE^7AP#:N1,XU':/G67*Q!B'<G?B03%TFLD*9>D*:Z?+4&C-OQOQZM],M>
MO;H:7%%'.^EV4^J1Q*L:'59?:'+LJX42361L996 !>1VE<F1W8[3T<7FT^U%
M](ZV[79C64Y9DL]Z*[+G);MMWMHYX4*.,"JX&KR*B6K^_2]HE?6# 5YX[M7Y
MSJN\3##1&Y522I%&^N6BC/02EL[2T;(9&*,_8@BSRRVU;Y^*UGU";4EF5YFU
M%K@;2-PE[V_&S;^* ?(8\!0N4("Y%?L%-H_16F]#S:7-;:9#T5!HS&5"(FL6
MTSV?N&Z,HSW9I5(N%NPS7$UPRSK(T[!CK;W@[9691?2BH)S!27I6%;C"  5)
MD^:L57H?YW ',H-GFC+*6P[Y\\W'Y;MO:SW9LLO7;Q!+19HTQS>NN]<OM"T5
M)K$B.YN[I+3VC:&%NK0S2NZ!@5[C=K9'N!"@LX&Y17QW]%'PLZ7\5?$ZZT[J
MH/=:)H&AW74)TCNM"=8D@U#3K"VM;IX628649OQ<78@D1Y6CAMV;LSRU1GQ2
M=R+LEO856F[3LV36''IY&I(2"Z3DX^D1@7*(ZUP=]\*5++NB*3%<*U,Z/ ^B
M_P OQZ;=TW1;[MM\+Z7X<]0ZS>ZO/I][>7-_;26DMP6NI'G>WDC>(*Z2R%G6
M-]YC,6[9N9"H!!S]-_3.\'O#3IGP\TOJ[IKIW1.DM;L]?T_1XXM#LK;2K76+
M.]MKUY;>XL;..&VGO+?V5;R.],7M(BAN8Y9)%D4QT1\Y=\R>?]P"5.9*%$8/
M2,;B@QE'LN5= [F62F/LIF9E'P6-L)J$5ALD#@<.E==MTVH7&K;*:;A?*^H>
M*VKW%YU(^F=R06FEP6Z+#N(B:XN(4NI9]G +F.>*'<<X6+RD!CGZ:_\ #W\.
MM(Z;\$;7KD6=H_4'7^JZS=3ZF(D:^BT71]3GT&QTCVC!=;6.[TJ^U(PJ5#37
MQ,H9HHQ'K/XR.U)P#XJK+N6:$24\4ZN,+P])!ZLZ6)N0-80IM8HN+[$W?O[N
M=&K$FF''KX55;C!VK,7KNEH+V11ZIT!>WL?0\-[?EYQ;1ZA):EV+R/9VK2=M
M"Q);RO'+%'N/EB6,#RA:_/\ ^E_TITO>_2OU#I7I.*UTIM>O.C;/7EM8$@LK
M7J7J&&R-[=1PQJD6Z:VO;#4+TQC,VH3WDDF;B24GIO4[W&['#NXT*[++6[+5
M[7,6A'R4EDQ$Z3W;G!A21M/F\8-,TE=T5H0['KKB5(NDVR)9A<ZL!S!!)NU3
M2TNSU'4&U:WO%N)6NY;J,,Q=CW.Y*H,3#.#$P.SMXVA<*H  Q]6=3=$=&Q^'
M>K]-3:+80=.Z?H-\T4$=M$#9>QV,LB:A!(5WKJ$+1BX]M+>T23@RRR.SN6_T
M[.=YK\?JQ1\OU5UW=]B>+FI+:B(>>5O/^]JL<F$1/H;.!1P.\ZW7MZS5QJGN
MDNBIHIHDY:/&B[=\P>H-WS%RV>-T%TU33C>02#L/(.#ZK\J@&"]"^I/0SRU=
M"HAU.IH/4@:;]=.\QN7[-3LPEAF1/QF]#("LEI+.Y%*)([:"$7[],0-4*_+1
M>'[_ &8M$%'SO=94MS,C[CG!3']]=>7S%PB52/RA=U#47A,I,#F]ET?$RAH1
M'2I(;O+3?6>E5P '8@R9KML&2K'*28H3LKA\_P MU_@VZON;YQ]F^ &K]/IT
MA<:>ES:6VK6U_>7>J132Q0SRPL$:"]\[*TEK%;(L+2 E('B??L#J7YGU=;7I
MOXIBDDEL\,<=NRAF16#,'BP,[7:0[L8!<,N,D'&R_C:A:CGP-^1&M3S5[!BN
MN_?"O9DW/CUQ9"*R5O3S6,2W4T+?:MG+!\#,)D-"S1YH@LF\9NL.,)[YW]GS
M?XM:GI%]UMU+J6@]JXL2Z.);8@P7EY!90I>S0%!M=)[N.4]Y-RW#EKA&=903
MT'H[3Y[@:#IE_-[*UW>6EJ\TO/LD%U>+&CR D8$$,@9E8KM"[#C:34:]@I%.
M)]U0D= G["?(UX)A]8-6R3UF!T319T-)X1/86BJLD+;Y;97*UR!:%WK/"#Q\
MT6>XWV46<?O^;=,ZAU1]6MS)+W4NKB.&2 1H$"32!#V@%W(R;MRD-EBH$A8%
ML_HOUSX*] V7AYK*6&GMI]WH.B7NHV>K->73W+W&FV<MP/;6DF:&XBNNT8I8
MS"$B$I:TCA9(@NO'E^[-V#1U9UU7];F7L5,7&^EWS:5"'JK ZPC<(3C.2 P,
M\;*)/!ZYAY+!FCLDS4T<(,&CAEIOI@EG?6]\2=<OM*T^SM;&1[=M2DG66ZB9
MDECBMA"3%&ZD&-IC,,NI#=N-U'O$C1/H4>%G2W7_ %?U+KW55I:ZO;]%6FDR
MZ?H=]%%<65YJ&M2:BD=]>6LRO%=P:;%IDNVWE1X3=7EM,X)@16K5X9>R%DRV
MP[(HZ;S<Y+@R<!6L>,-I.6?&B(18))8['3:8EX05<.D13_,N%JO&&5\M$7J"
M+EH@BN](J.<-X7ZIJ=W-J5G<SSW5G##%.CSR/*;>=Y"@C1W+,JSH'<IG:&A+
M* 6<MTCZ=G0?0V@:=T5U)HFE:7H74>I:G?Z7=0:5:6]@FKZ9;V:W#7ES;VR1
M0R3Z9<-:VZW/;$S1:BL,TDD<-LL6*?E=MHA;G?"^7:[DCL)@4C2JF/#GZ^5D
MQ+.O&2$>,HC],9]QNQ*2]K))$FEIC&<J&55%/:IOMGG+?$/4)-0ZMU8L9.W9
MS+801N21&EHBQ2;!Z*DMP)IP!Z]TD\FOT(^AIT=:=&_1T\.HH8[3VSJ/39NK
M]4NK5 K7ESU'=3:A9M=,.9+FQT>33-*D9B=HT]4 "J .PO0G;HG17A1CO:5S
MNK89ZKJCE8L,B1V<93?2&-6=(*EB @LKZF76P>/EVP<05725U<;AQ3E5OMHI
MLGG'>.F]0N+'H'3;^XW3SP:;N02;LLO>>.S#$^8HL1@!8>L:[@<$&OR2\;>C
M=&ZL^F!UMT?H_8TK2M5ZX[5VUGV]D,RZ9;7_ %+) JKVENY[^/5)%C9=J7LO
M;D'E85UM/']Y7.[CGOM1^;+[!3ZQH?>EUP2LIW YD=<$('HPM*7#8<DYBL3W
M]@*#.P) ZT*A\0UB"TV58(C7>K@6Z>LW&LZ'K^L2:S:++=SW*7=RD4T$CEH@
MDK8=XX_<A[0)D':5!A-I\I(KO?BQX.>&EEX7=12V'3FD:'=].:'=ZCIFK6=N
MD&HM=Z? TT%O>W_WSJ7](.BV3C4);DLUR)(]LZQR+W]N=AK\RZR.[9?YM_B#
M^[KR5_ECU_XJ8]Q_TI_S5Y:_Y\)S^D?%?]8\RXKS\3^U_P *Z;7<>ZK=I_R
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M+W=HZ<ZTZGZ2-S_]/:O/IRW8'M$2QV]Q!*R@JLAM[R&X@695)59EC655X#@
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M%O9+/&SPR!H9)(V[EW-DKA59(^2K^8KQ$?U"$?\ 3?>_%33T?]0_:M>.P?\
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MWT9HJJ[Z[9WPGC;;$EC9FC7!42,%5B" <D#(..0,\XJ#S(BRL&5C"C.Z*P+
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DXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g99471g14a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g14a01.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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MK(JNC7[^A.0[H.A=<.SZJB43461MZ?0/QS*UI1ITDADC<Q[:&V2/J-Q'(M(
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MI0 XP(MA+&1L(M'!'L.RMZWH>@[UO&C]O?VF-C[CQ[_PU[_Y3RE&EGEEG$F
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M\_:>YB9C$1B(Q$8B,1&(C$36)Y24--OM'JHU8<GX^B\U?(A:2.NEW7:1N4H
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M #KD X^C2?#E77/5N_AC\'V>7[+9>G979U^S[W<UL_FY>=:KV#=7]'U\>/\
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MB,1&(C$3%9K!819,<7P^Q8;%9]$G7X.G.+36/-$ICCCI.: \C2]D?$:]L6?
M/++.)^82F?#-  P'M&$(M;*S(0R,RL/9E)4C^XC1FKHEBE7174^ZNH93KVV"
M"#_E/9BD1BD$CS7$8/&(]#8HQI_DV2,11E;8['F=)\09ORK6RM"9&VMZ?XIA
MAGP$B8DKXA@Q^WW"%O>"2Q)8EB?<DDD_WD^3"JJ*%1511[*H"J/[@  /\)D.
M8FT8B,1&(C$2EG;]<R&X*P.K%OIVP[:89:TRQO=2JYZ(5T(H:'56SA:6(F9
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M1H'3*='0V-'0EK'M>U;!8%%E-STOPWQ8J%964-LJ&1U)4EN)V.3#1.!>0/\
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MFK7D;J4,&-=2HQ4@KR#,Q 8>&"A@NP2#KY25U+N(K 7NRL@NR++45@58(51
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M"1&!D3H1M)8CSY!O3#Z?U3I>9571F-F](LYBRO-?EDX6JV935=H&RMG54"$
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MZFJ 4NDZ,+:SQEAD#FYJP[+5@9FDM<^():JQ:Q4N$TK,-@DL54MH >/8'RQ
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MIOZ)@5W8?1W.LOJ-R=NW+JW\U&'6WDI8!IK#XT2M@4 U6_#NK^H?5OZ0X_\
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M9I&]H9$3HYN!SZP#)5/".U6M;TE56IKOUK$.;@_!5# U\66DE0';3[)(UH^
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MD<+R#LS@ [ ("@ MX\[)V#]->\X_2.CW8-SY&1967*&M$J+,-,5)9F95_LZ
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M-]G;:HC7BRD?/:/W4\G4LO4-F>7"U(>HE:ZL^)ZT/(F=C1'49L0KIEAD1R>
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M!"6_5:KY,5(?YO!4#DV]:!FG?ZIV\A^SC T-8%3CD<KQ6@<-4-?,')X(1O;
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M\C?^/Y*TQ$9I,E5W3R%MG5E,I\BTVK$_8-#J@O"AC3*$9KHB9@$#=7!'I:B
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M9O,0:9LZR!R+^I.SL1&U+JM9D)J)L3H6Q'LG%U5@$%EN)D*50*@9A8RI\JZ
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+1B(Q$8B,1&(G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g99471g14b66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g14b66.jpg
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MCIZXH\C(XFEBQ]J&7M:*$-Q+O(URM&06B2MQS<\._?*%9WSM,^!3M<=D+@N
MQ&N1K:D87L]P F+:EXD^U'C.%RM"L=[ [7#E(E5B6+AXX\F7+./-Y8E4R! [
M21A"VNN>C+HYCD"W+RX9=1I:1K+.[( BHR2RZR-K:LP6."9W$)D,:PRLX41N
M5NIYX2\EVYUD*!HJZ3RYNCTN-A(Y(P,;\E:'1Z+E3#!@[:TDJ:8S)MHCIE)V
M&+EJG&/-V@/[FG:% "'#1B<&"/2#"62)GO(8'E@X1LI9(F=(]C)<'7:!YH=8
M00R3%5E<[)2XS7(G9ET3QY)9TBP^XND@NC:&>"&=8I)1<PV8V:W,5O/J&ZN(
M;<,\$>4T@C8!\P,)V15%CT^](([9L.>X4].C,GD+<WOB;2<Y:RJ5K@V%N";8
M1F%G$ =6EV:56@#V8B=FIS:E@"'!O5IB>A:7MI?1M+9SQW$:2&)FC.86155R
MIS ()1T==V3(Z.I*,I/)OL.OL,E2'$+66TEDB6>-)EU2\3.\8==Y! DCDB;?
MFDL<D;A9$=1/BZ*G[,;B]_W?:?\ 7A9F?.&GOX6XO_+M/V"TK[([E/X :/\
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M32Y,9DU<12+0-AM)!4LT56,;!X?:P;J9XHM7.ZURC86L5@E$.;D:V1AM<W1
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ML_\ GD,^[>;'&YC_ )HPWT+WZQ5G>##NG/ZR#W:ZI11I:XC%HU%$3AI2CC#
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MLNGDXG!/T@<G_;VM/P=QQHZ1='PGJUU]=IQ&:(=-T@ZY8?9=/)Q."?I Y/\
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M9=/)Q."?I Y/^WM:?@[CC1TBZ/A/5KKZ[3B,T0Z;I!URP^RZ>3B<$_2!R?\
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M>SIPF+_B^C_O3RK/I5?]OR.^AY%]],> N._%9]8/9TX3%_Q?1_WIY5GTJO\
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MYN%$.&U_(IK'6:9RL#DO4M3>..1EP<4[R]!7.:-6WI!-R-1I0M3*$I6QG$F
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MK ZBLV9 7=EGF0#G5$L3.*-(X(C='HUR8A8D/#H00G)E10#R#0A&$(PZ,*&
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M_P"&M77F&MBF*5&1_**_\(NGU_$JT?\ WU*Y+/<P^\:3_FEG^IB%0%W</O\
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M'HX9+Y9(#&%D:F8Q^D+ZO<GY[,;4)",QW>G X[9BUU<ADB6."H?8V>K.-,[
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M]4E>=*U>E^R$^VE4B6)G+1I@-H5"122IT480:$.CWY;65.!OKOJ:J;0ZS;0
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M5E_-^+,[JY/<]FSM,YLZ-Y+8.?3U0L9"Y:K86 PJ,,I+640*G?Q<R>#',_\
M-'99_2?HJG@H_3EZN>V_U]%912<)Z@2P2V*RVQ(%L#O&161*;2C;J)Z=4,K>
MK;/4J9^>>)P>U"EO(?3E:@8432>@1M>QA\#D(.YE=H[^+O\ W*=^\_#?'_\
MMT\%'Z<O5SVU8E;.EYQH;D($JAFD,B7>')%(5<GF5BVK-)L[.4FJ&14*M\.3
M643QUE#RA0U%*7J%1]J<G52V1M$I"O8DB!Z*+<M._B[_ -RG?R_#?_751HJX
MW\-3,#+/@[?/_P [^K?\0JIL_32XXL$^C%C-+ Y)'R(G0UQ:&K4RL4V#&2:O
M(2FK>#3IXKHZ9F0606%%8*D2QIGG3Y'W"4)T*5$:)S,7-S>K2U[^+T8^N_\
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MD=1%;W!8$N+LG(DFN;/E,=0>JW9/M]%_L?/5<4]]YWM.KS>_7A>/O"_D]?\
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MH-+)(()G<:-...-'HLHDHHME$,PTP8@@++ $0QC%H(=;WO6LH>Y1>@$G&+,
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M[JG.,,VHT O/HYH/>X[A#WL=U#9I<7#1H98W=I8+?+,IJ$?!O<9AP2<WMD(
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MJ+[Z8XQ-$_.$O4;WL*<4.GOFB'])X9];KHMTH>D+?5/<RVNS.54&9HTU4S%
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MM'#=V<:6-C$L\%SLY+F-)[F;7@>1%D6V>")/&SU+F8$ Y5B;JJ\)NH)U!.2
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M++++"$!998 Z"   !UH(  #K00A#K00AUK6M:UK+22223F3O)/*3\9JX
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M2BPA++++"$  !"$(=!UK6"222222222<R2=Y))WDD[R3RT "@*H"JH 50
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M@ #D1F-QW5KO:6\DFV>(-)XF9);([,DQZRYZC:A)*ZRG([QOJL,/%#CK%QP
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M5BMJ=C"5A:92@4')=IM$C$'=XN)@<Q(WWM8M^1&S4ZRID01D#O'S[ZPM8VK
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MD;Y,_25\)DK\^N##)G=X8/#3F^)RG!2[$-9+ALP.RP*0$#,*%5IYG559R0@
M7D&0 R S !R \F>56):6T;.Z1*&D+,^99@S,VLS%6)7,MO) !K,U;5M!*>@4
M4J^L8PUPN 0=F2Q^*19F*&2V,K0B#L*=&E":8:<+6MB&8:<><<H4'&&*%!QI
CYIA@K'=I&9W)9F)9F/*2>4UFCC2)%CC4(B *JCD4#R"O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g99471g14g85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g14g85.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( ',"/P,!$0 "$0$#$0'_Q  ?  $
M @(# 0$! 0          !@<$" 4)"@,+ @'_Q !6$   !@(! 0(*!@0)!@L)
M   " P0%!@<  0@)6-01$A,7&!F2EI?5%!4A4E31%B(W=B,Q.#E!=[6VMR0V
M0E5AAB4G-%97<W1UL[C6,S5&45.%D[+"_\0 ' $!  (" P$
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MQ@3HZ.*LP1RM>XN$5:5:Y:I-%X1&J%2DXT\XP6_&&88(6_MWEY !(\ 6 >X
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MQ+!B@]>#PJ=Z^W8=:WX=?Q;WEFX/!$0\2S$MOH2RVHM_8^M4DVDJYV&)T%.
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MYDK_ &)ZT\(.Q7I+A72!U)ZT?IZ=KFFO>3?=L=Z.TW,E?[$]:>$'8KTEPKI
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M,;LL;C*;W;8ZBUK'56X**TC>"CRRDF49&VE) :3(+6>2T!I+KW  .@6<WU]
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9,4<+2<Q;$QL;2ZP&8A@ )L +VO8 >1?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g99471g18h20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g18h20.jpg
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M:3$79A;22H4B/"MQ,RN+9^3'EEBY/$^<X\2:OSS1*F+QEW=$6)K69YL7/?\
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M)D(,&.*7#OE3P;P7WMG8/QXR<^>>SCZU"66L#"\,3O-7)-F5I)X9D^%A0>)
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MYZ]$<+2R.X+N2MIW9<+6AEI1L 8ULVGEB%A@>>7@CC;L@^%DD$HX>.,CM?Y
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MC33C33C33C33C33C33C37/YV;]%R^3O::;[?=,>RCO7?9=IG9.V3<6;%2F1
MK=86GT6R9@;)!&++:CK>X6<7/5F7@90)\R2E/!JHPUF)!DK$[\K1X>/"9[%#
M*5(8TAC=73EH(B#!')%(O3U0!56*5)$8*B?*'4NT+Y_TKNS;BFW-M;/'"7[$
MSV98VCDZ4LS BS+#/"W4([19GF@EAD5GDD^?ML(DN?J%Z.EKUQV?;[D]O.PQ
M/8S=L<=F9@VAHHX:(9LK40F!C+'.S<R4N0FUU^(2R-6(0.&@8V!=!C7VG"6
M!0F/'-[YAM8@X+"8Q<7CW7MR$NK.8C)W7BCC10L8DD^:60R2/(&=2!U,QN-L
M^E]BAN#^E&Y<VV<RT;]V$+&ZQBP(A"D\TLK%Y>Q%PM>%(H8X2D; LJ*B[C^H
MKZ<FLO4*UW 0-DG2Z!L>ADR)FN]E1L6S,NQ"9AL9$S!3L(Z7&XGJU+Y! (?#
M:DXP\*0 #-CY%EO,B%)8/:^Z;>V;4LL4:V:ME46U4=S&'Z"3')'(%;MS)U,H
M8HZLKLK(3TLFT;XV-0WM1AAGF:E>IL[4;\<8F,0E"B6&:$O'WH)>A&*B2-T=
M%=' [B20XM^@1VKV!FF4'?'?22M6D**2QBNU9I[8MN7 1@S7TB1*?5;C/MU.
MHE.1ONCABPUFL1;#F$I D!FOHW=Y/J3AZW?LX[;:0Y"P&[LQ%6#NNQZNJ>:"
M(SSCK^=E;I+D?O*3U"+QZ-;BNFK3S&\9+.)ILH@K@WK)AC4=/15K6IA6JL4_
M9JR%UC4_N.HZ#,]V&Z2E6[HF1T@ZWVR*TS6W*Q6=?L3TU'GV!UBCQ4B+(V,9
MY(!,>^=-W/(CHU@DGW$I.1-SI#K?U!2<IT/&9]8-Q#<&5A>_*)IK)BC=8@;#
MJRQ$%@X6.OU!HD ^4QQ@'I4\RGG-IM9V>VTL%8BQ<!KUZ2S3(\Q6I%(LDZGH
M*%YK705GD;]\33,1U,"-/>KGH0]0=8ZG"K/8ND0/8#:.9J:D938#<ML:G!*C
MBR$(AH6/A(6Z@CM#1H##:G7WVW"B#R37%.Y8^G;;SN7]1<Y;NM+B[$F-I]N-
M4K%*L[=:C]I(TDE=B2[$\ '@*%''/.M8V]Z/[9Q^-2OG*D.9R/=E>2Z);U5.
MVS<11)%%:10L: <E@69V<\]/2!^70GTD;]T2[87;<]0W?7)G3MRCKQ57]89K
M,XQ-,TZ5F4SM&8<FB9DL(F<JQD;"L$23HN5%!JFFF%-9D5>6X]ZUMQ8:O0GQ
M\L=Z!Z\PM]Z,QF=$[=@]L1JPCF5Y"%!\,(R>>G5-F^FMW9^Y+>5K9:"7%VH[
M=8T.Q,)A5DE$U13*TK(TU=HXE:0@EE[H!'7K]-J>DA<]A^IO%]^AMS5B,KD?
MLO3E]5KE^J2I$VX/K"H4>LEQR9UN5;!2]+.U)XL9_(.6QFS6FW6W5-+4NE+>
ML%7:;[;-"5Y6J7ZWQ0G01@W)[,JOVRA;B,3A2.KEBI((Y\,CZ:V[V_X]Y+E*
MT<"9#%731:O*TQ7'5J<#)WA($ZI36+*>GA0X!!X/,Y'(^U+NH-^^GI(7/N)V
M^U]V9A-S5BD15+K^N85^J2M4E9>0/<H]MFK*0^S)"2H@S*)!J50*RA8RU,.,
MJ<7E:5X3B0=N;U@P>$LXF2A+8>>2U()DG1%46(8X@"C(Q/24Y/GR#P.-1'O'
MTUM[HW/2S\.4KU(JL%&)J\E>661S4LRSLP=9%4!Q(% (\$$GP=3D<C[4N:C=
M]1CTU]7^H72:X!8+ ;KO9U!7(KH6RHN+8FE!"2V!\RE>LD$Z9&?J"N'/""F-
MCM2L9(1<BPDN.D&F"I8"4VK:^Z[FV;$K11+:J6>CXFH[F/J9.>B6*4*_:E4,
MRDE'1U/#H2J,FB;YV'C][5($FF>CD*1D-*_'&)>A9>GN03PEH^] Y56 $D;Q
MR#JC<!I4DA__ /L#.V>P&*EKS>/?N3LVD:42-FNU5+NR+DU! AM*$:8JM.MU
MD&J=6*^W*<CQ20WBVHQAW*&Q#!T9%=W?_P"Y&&K&>UC]MI#D+"GNS<58#(Q/
M5S-/!"9YEZN&*L%+$?O*3U",O_LWN2Z*U++[SDL8FHR]BMS?M"%%!4"O5LSK
M6KMT<HK*6$8)X5@.ENB33_7'7F@.OD)USU*"N"I=9J,K6HETYS!LB4;,MG/2
MUCG"6FQL'S,U,R)LU+O,LBLNF%/(#&#$2.,S&%[*6LGDY,I=;N3S3I*X4=*J
MJ%0D48)/3''&JQQ@DD*HZF9N29NQ>"I87"PX/&H8:M>M)7C+GKD9Y0YEGF8!
M0\LLLCRRD!068A55>E1S8U+^'8['T$@LRB]WXNEER#*!CRJE6KW7"#1VG/E;
M'+?A[@&Z2RV[G+B&GE+;0Y^]*<*_/)4G]3\79"K9V\UA5)*B>:M*%)'!*B2!
M@"1X)'!(U!%;T1SU)F>GNR*HS@*[5H;L#.H/(5C%80L ?(!) /G4PGIJ]%=V
M=*D[F3N/LA)=@\[)5KW-=S(N6US])8J&+MB5PS^J;!.YQ]]S9XW+GT/TOG[.
MCZGY_#'Q:1NO<6/S_P !\#BDQGPGQ7=Z! ._W_ANCGLQ1_U79?CJZOZP\<>>
M9/V'M#+[5^]?O7.R9KX_X+L=;63\-\-\7W./B9I?Z[XB/GHZ?ZH=7/CB+^S>
M@AV*QO/9F[=7=T@M53=\O%]LX9U0@KS7;)%Q5WL4C-/0CD_7;;&%O-88,;%.
M2TXV,9EGW+9]GM3C;H?4?%_=U3'W,"UV.M7K0LL\E>6)WKQ+&)!%+ Z@DJ2O
M/)7GCG4?6/1S._?&0RV.W4F.EN7+MA'K17()XX[<\DQA,T%B-B.'"N 0K<>1
MQK<CH/Z+5.ZF[B5V.VWM^6[![J%S*E5R1.@7H."KDW/L$B3=G*5)S]FF[;:R
M1##6!)J3.CV L2)I68DB5P#*!8+<F_9\U1^ZJ5%,90;H65%D$DDL<1#1PKT1
MPQP0AE4M&BL6Z%7K"=2-M.S?2JKMO*??F2R<F:RJ]UH'>$PPP33AEEL-W)K$
MMFRRLX6:1T"=QV[;2]$B3@<C_4M:<::<::<::<::M6S?WJI?ZJ'_ -GFN5'L
MWZ?S&J'W7]?Y'5U<IJNG&FG&FN,3U6>IUET=ZC=E[>R.C8K9&C-@M5&W,#V"
M(EIC5I%WCZX!7;7%W]JNG11,<:7*1K5F''ECA(R>=D\+]\LEF6CVX<]0UR>-
MNP92GBXK],\/.9(9)XNXJ=)2RD+Q.L9\.K%@K-R&9ARFOT8^R'+LK>FVLOL;
M/[]O[2W*5:KA_@\E5Q61^&EG[R6,/:R$-BM):7J-5H4B,\<7+1!&*RKLQ4O7
M5ME)IP,!7NL&IX*.A(Y@6.BJO-RM>K@K;+:&\-@0H<<ZV +^W/QCMOKRTCVI
MRZYE.5JURMZPW8HDA&"Q\00!0L,LT40^AZ8@IZ1^74>/8GZZE?+?_3OVY<N6
M<A)ZJ;JM&P\L[RW\90OW9>HEP9;K6H^^_!^>4Q+UMR_0G/2(6NZF_P ;U K&
MNP[&T%H*A%AO.)'M>K*>_7=F2CZ?#.%SUX7*&&S@X6$J2./*@$@_4+6YD)2&
M6T\QF9]2K\K0DT*",QZYECBD4-$P_JS(SLY<@\]7(Z1Q\OGQO.P/L2[0Q]7(
M"?=>Z)4$78Q5FS<JR&&W'(I:Y'3CKQ5TBA9#%V.HF;EOVB="NU)T1UK7O0E&
MO1-N:_KML)C24PT/=8;80AMG-C0B2L"PJJ73[S&_7.!BN*3B3.AVWW,NI0TV
MVE&>:[A<?1S^3CCH9(8^W+(3%4O06)#)U<N\,5BK'*C<<<AI5@\@'GWYZ!]2
M/4C=OI;LFQ>W;L3^F&"Q-.*&[N7;&;Q-+LP+VZ\-S)8;.24K%9V=HNY'BY\N
M.X2$X5@NHOJYOZ,CA\!I';&1AUYQQO*?;GY77%..Y7E7M7E>%YRC'NQC.$)2
MCQC*<)QG+NW)'=I)5DZO"J6#<<   #P0 1\WO]>?<ZB_:/VBL51J1TJ4E6*#
MKEF:)67DRS2&21G8,"[<GI#$$]M44<*H Z(/1[NO7: CKYOCM?OFJ432[H\C
M2([2-DEB96-VZ>;&J8EYFW:\$&EOO=4KC!Z&H=9D0^@JR*<?;?'3 NH*SVRZ
M>'Q-ZS8RF6BA01& 8LRO(+1E4AI;55 _<BB0_LNM#S*P8 =OAHA^U?N+>GK!
MM##;:V5Z7/N&6U,F3N;[;$553"TZE@&+'8?/W.Q'7MY">!S?6&T&6E$(.A_B
MSVIO]-^J)Z,%AV)#ZRUIL'7,;95>P2))F=1W2MP,?])C S+2;5:Z:%#00[:?
MA;;(?/ !PE;"/G\X3A.]X^KZ;8B3XVAA\!C)+$_3\<F&KU"UB7D_M+'PJ,C.
M069W91]68<C7YX3>D7K)?ENXZ/%Y+,7\7CY<C:P]#*09*_%CZQC6::&E6M2M
M9$/=4&*J)IB>>F(@'6DO9_I)Z@NK[%:]D]>S8#L-JF;F):TP+50F4";!!@Y<
MQ^58:+@25C!6%QEE_#;1=2D)5R4QA!;4<-E[([<'[M^SS4R.0R&:I.]X9*U8
MONT<D;3-);D>=F*$*D@ZGX4PERR\>!SXPN/WO:HI'CK<3U9J:+4D@FB:'MO"
M.T4=" T;+P0Z.BE6!! X/%4Z"[=W==*OM<2W7*SZGW5#2B:?$5FTC?0R\&.V
M,-)'J-C;,(X=#*GB,B"A230C"<*BR!UO?&ZZE7/>5GS'HYN1JN#L6L/<RF,6
M/[REJ1 -"UDO-CXYK$+?!RN]>!FDCZ&/2BETC=FUML8K;EH1V[52"Y5K3O\
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M;F]\9N2C#CY\QZK[]W1BX8+52W')@LYD89\7/S3EEC@:6%"35D*3P<!98D/
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MSR-6!!!((((/!!'!!_ @^0=?UYQ_GC_OY]:II[D_G\X_']?SC\?_ !_[\?\
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M5E+ [2WG,I0G]RU82C/M0G&5*S^U.,YSC@>2J_5F"C\R?8:'_P".?QU&]/\
M=RK6:GS8V[.OFZM=:*V'!R$/$;:.AXJU4RPUBQ"%QN)&3;IDI,SM3%DX]Y9(
M>)N-')4PO#F&TX3A><A4::E=KV:TR"W2LQ6(2#TA9J\BRQMRWRLO4H/!\'V/
MOJRNUHK]*W2LIUUKM:>K,I!Y:&S$\,B\#R"4=AU>.!R?&N<G7>O0M4W>9@(>
M5!GZE#6Z1)@;0$ZU]JE:Q]1A^,E_ERYE B78[+#A@I.6B(]_YA2VVGV'$I[.
MJ;LVU=VE7MQY*I5XK.URK-*D4U.TQ:2:NT+,)"8W)5&52)5 9 00-<1XS8.[
M,'O"_C;.+N7 ;LIHW(8GDANT PBK64GX[:-) J/+U$]F0E9#RK<9\V1MT:2
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M)<K1O T OPRP1WH%FDBR\%WI3J$'?=@E8+;.X5C>H:3U=@ZN3.5'$E#&3\2
M_'1] 1]NA0_TP$\RMF&A+#)8D7CSUX.LC ^<.LY!-U?=RY:62+(9'IW@<%%
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M]I*\TD+>//!,;+RO/NIY!^HUZLJN"K*&!^A (_SU%E->@ST*/FR#X&*V;2(
MIQQQ=&K-YRNJC9<S[L-QB+#%3TS&#-KRK+ @LPD<9*OB$;'92EO$G4O6?>U*
MG'4,V/MF%52*S;I=5E47@!&:&6".0   &2-FX'DGZ8N3"4))6E,;HS<=2I(5
M4D?7CSP3[D@CG_'5E[H_A_.F=_@6 =5S>SM"38L?D5,I6;$JWQLH9A2U(E+#
M#W7$H0:9E*TLO*B9F"P\RPPE6,*;RM=_B?73>=&25L@N-S4<C]02U5%9X!X'
M17>F855/'/3+'-PQ)^I&OB7!4)2I"/&5''RN3U#_ ,75SR?/O[^WX:CZZ&>F
M+OGTW?55U+([(M<7N#3VSZ!N*MZ[VE!AG1.8RU"57[OF&MU;,)/57)DR'%/8
MC5L24I%2B'G6Q)'!C;P+6;W9ZF0[YV-EZDA3'WJ\^*LG'-VU[Z+<C1S5D4*;
M"QM(LCJR"6-$ZBI0%QY04H,?;K<= [S211OSPS/V7DZ2.#\W0C'W(X!_'C76
MUSGWWUGM.--.--.--.--:J=Q.Q#G6W4!-OBP1I.VSLL)4Z8"=E> ,STDP41@
MZ0RA3><A1@(99SC.76<%/-,!Y?820I]O?O3C9G]-]QQXV>62OCJM>3(92:(
MS"I"R)VH 0P[T\TL42MTOVU9Y.AR@1HI]8_45O339TN9JUXK68OVX<3A*]@D
M5CD+*2R":T0RGL5H(9IV7K3N.B1%XU=I$@^:[:]W8.05<#=N!F1H+@,BL8^;
MUL_59EA\B9RB- 9$?:8DT/NU^9 ?&@2,R3"PG&/D9(R/E75#^G?I;;@^[8MO
M2Q3RK-"LD-7-ID*SI'6YGF>16> JMRM,CVT$#"57Z60.!PM'ZO\ KK1M_?5C
M=U::I$\-DQ3W=LR8>[$TMS_9ZR0LJ6E9Z%RO(E"3XI#"8^M9&B9I^>N&Z0-_
MZ>J.SPP_MCTT*\-,1>5J<3&ST62['3 C3J_"GA4G#NN O+QA;H3HZW,8<4M.
M.0MZ;9FV?N3)8&:43K5D1ZUCP#/3L1K/6D=1X64Q.JS(/"RJX4E0#K]!?3?>
MU;U"V;AMU5X?AGOPO'<J<L15R%65Z]R%&8!GA$T;/7<@,\#Q,P5BRC.7G'^>
M/S_3\_UYJVMZU_#K+3Z%M/-MNMN(4VXVXA*T+0K'A2%H5C*5(5C\*2K&<9QG
M.,XSC.>-/?6OMVH^H-9QDK?6XHJA+QAI@PS7DA(U-V0(-)';82]#PA84)*GO
MD)8;01(QQ+R6_>G+J&%.XSKF[MV8G9.W<GN;.RR1XO$5S8L&*/O3,.I8TB@B
M+*'EED=$1.I02>20!R/>M6EN3QUX &DD8!>HA5_4D@\ >_C6#F-S[(26_BBV
MN'L\<A27,Q.R0A_O([9*W"&6_OM*;BOH6\L.):'Q)UZ:(^)E"G2"'/E>5SE3
M^U)B<S*HQFWKM:E8CD-7(WYD9F(/".*4/"2J /G1;JE6('6>/.??;4L/(EG1
MG4CJC0<\<\#]_J/ \\>5'GD\?C!%W ]1OMM?>QF]NH=CT%8]<ZOI&N +3 ;G
MAY:87&3D\1'11H+XLOB,B8DV'/E"R@(489>)T20B'G9)A"T%#QN0W!DCNW';
M7SL>^S,)LLT4^TJWPU..<2"6#_::L$DE\340ADZ+,DU8M.".ENT[6IC%7XB
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MVI+%J'@3I ^<FXY2\84]#MS1KX$:>WY'D4L/$#J4W[<YP$O[.O' >.X9&FD
M(/1\H1%;@GYN.6(_L\@$ \ZQ%$&YF+F44'X5:<6.J2$<"R$F>>S.G@<PB1HX
MHW\]?;=ARI4G8_EIK8-.--.--.--.--.--:S]G.T%$ZOU$*Q6M@N8F)PEX*L
M5:+4TW)39 N&5&O8??QE@*.CFWV%G'/8<^/+X[++!!#[3*MVV-L/+;[R4M+'
M-%6KU8UFR&1L!C!5C?K$*]"?/+/.R.L,2\<A'9W1$9Q&?JAZI8#TLPT.3S"3
M7+=Z5H,5B:K(EF_+%VVG;N2<QP5JR2(T\[ANDR1QHDDDB(=$]:>K94K':X^"
MV!K(RD0DK)C M6@*RMSPL.V4[AE!4X&["Q#R!&%*0HPD)TA;#.7'4B.X;]JI
M8SOV>,G1QTUO#9V++6Z\#RM0FHM3>RT:]1CJR+9LJTK\$11RA S=*F0%N1 N
MU_M>8;*9BOC]P[7GP-&W;CKKE8,FN0AII(P437H9*=)UAC)YFE@:4QQAG[1"
MG4P#3K;[3;S*T.M.H2XTXA6%H<;7C"D+0I.<I4E2<XRE2<YQG&<9QG.,\YR(
M*DJP(8$@@@@@@\$$'R"#X(/D'78JLKJKHP96 964AE96'(92.0000002"#R-
M?IRFJZL/:&MZQM[7MOUG<F"2*S=H&0K\ND(E81[0L@PIKZJ/-;QEP.1"<RV7
M'EHQE8IC#+Z4JRCVYM;M.OD*L].U&LL%A#'(C $%?<>"".0?(Y'N//.J@D$$
M>XU!C&^FOL_K#(&DT4S.T->,'.KBWP\9Q>HZ+PKY6LSL1EH=B1(;PI;3I, Z
M8HC*</Y %PM2$<L^KOH_N#)XRRV BCRL 5C\(KB*ZJ%>&*1L%CE( '"Q-UL.
M3TD\*<WBLA%!91YB5X//))*_3CJ_+Z^XX^O@C6R*=F@1-;<:EU/Q9T0,E@\8
MYIT5\=;*$I\/#NI0^TZK./W-.(2[YQG.48SC&><,7+VXL=$FU+^(RE/-0D4Q
M5M5IH!(0W0LB%PH"]'07=CT^[#D>^^Q"LW%M)HVAXZV<.A8<CD@D>/<<+Y\C
MP20=6;U5O\5W+;[E=9;*9*)H4CKRO03)#92?N03=X'OD'/R42P^X^V*\.IB&
M*!\H4VV2(RX0E2G,(Y^@OV5L9G=G[:GBR.4GLY'XZ+*K$+=B6MCGG[ZM6I=Q
M@8H^CH$RPA(V?YAU=1=XUW;'2SRVJCP 5+,$M9_E'4Z, 0[ \KU*Q#*./H.>
M=14W/TN]Y=-')@@=K&S-4!*>)C[U7!W,F1\4VZ[\6+C7_P FQ!C J&EFG").
M@LY5E:)!O/N8:_5'TU]0=OY'#08&:RM#,B0A*MH]M+;,.!\)8),<KL3P(6Z)
MR3\JN.2.$M\^E6Y-O;CL9^*'[SV^R)_ME0-)/31'+GX^L%#0JB#DSQ]R#@<L
MR>VO3<-G1\%7H-3,F2*= 1H[R<AY?:*%*9:1[7$/-*0IAYO"<Y2M+B'49SCQ
M[?ZXW"CA9K=BP&AC:*Q*X;N!6B>,MPP*GGJ3SP?!4\'3+;HI8FI')++(LE:&
M-E$9994=4ZD7J\=+,""H!Z@".0-3D>E=V7G.S'6Z1L-GDB)68H6Q;%KAZ2D,
MN+DRPHF,@)F+?E"5)P@PW(,ZAM927'EN--,Y)=65\ZL\D^I%#'8[=V3@Q4"U
M:/[%DA7A8UF:,?$&- >(XWE#-&@^50>%"CY1TOZ4YZ_N+9N/R&2=I+1ELQEI
M.#)V%EYJB1@3UN(&0,Y))X!))\G;/;O:#06APHV2W%M>C:YB9FPA5*,E;?/Q
M\)&'V:220L.!'./>8%=E"&A27,!H<4ZAIAYYU*&FW%)B"?=^!ANR8];ILVX#
M_M<=&M;OBFJ\=;W)*<$\=58^1W&G9%C!!D*\ZD\59C'W"H1>.5[C*A?R1\@8
M@MY'TUIMNG9FG7=Y:L@M,6*O1.V#[5!6>\V&OS80,4UKD&2019$3@(3ZTV*:
MG6FOM45'@QYTI)/EI20I0 Y3HFP8//XO.T;%G%Y*GEZ*2O4$M.Q%;ACM!%D(
M62-W566,AF*MSY56 YX%O- \+A)(WCD'2>&# ](/'Y>_'U^76Z,WL*:NT,N&
MU7#6IB6FWGHMJYV.G3E=KU5'2UATNQ.MV<6$.F<MC_*U CQ 4BT?-+!27D>(
MP;(#^Y''U!_0\_KY_+]?\?.J<_\ /\1_K\^/'Y^-97AZS!P4-'0,;&BL1<8U
MA @OQ(4A*\J6XZ0OWISETLE]QTHLIWW$$E//$ON+?=6M50S+R59E)'!*L5)'
MX<@@\:^61'XZT5^#R.H!@#^(!Y /YC^9U7<8PG&,8\8QC\8Q_3'/G7WK%L[L
MQA,J55*3#EWFVC8:0:)'.?2UZ 4\M&/_ "JM;C+T7#O-LJR3F(9^X61UC"'1
MH1UIYMW+]?\ 7^OII_K_ %_KSJ S=/0;L+1[=8Y"MT,?8]8NROJGFZ&<K_D*
MB[#&V$R"P%*X;F?IQ70'(Z/D\B$LN@+8,)4R7AP%/9VS?5_:^5PN+@SF6CP>
M;Q42I,;L4AK7)(J4]-;<,R<Q%9!*)Y()'BE$RM&B-&5E/YP^HOV>]ZX#<V<M
M;6V_-NC;.>E>2LN/LQK=Q\,^2JY)Z-J"8K-UQ-7-:*S$DT+0-'-(XF$D.MV^
MA_479U%V38M_[@ "JTM,Q<K$5NBL.CDF1 \H4"O)!>15O"18@$8$W#0T2.0X
M^.#E224"I:987&OJSZC8++X6EL_;4TM^K5L5[%[+NKI':DKI*!''W DEB2:>
M5K5JRZ!'FX,9<LSB9O0/T?W3@-R9+U#WG#!BK]^G:IXS (T<LU&&W+ Q>;LL
M\-6&O6@CITJ<;F2.'J658@B*TM?.>]=<:M6S?WJI?ZJ'_P!GFN5'LWZ?S&J'
MW7]?Y'5U<IJNG&FG&FG&FG&FM4^Z_762[3=<KQIZ L055M$H36;#4YR4'>*A
MA;-3;+%6F(8FQQD.D+AY$B*^VR#K#!3X;!BCV CGA4!OX#<^&?/86UC89E@G
MD,$U>60%HEGK3QSQB4*"W;<Q]#E0Q4-UA6*A3,?H)ZGU/1_U1V_OC)8N?,XB
MI%EL9FL=3DCAOS8G.XFYA[LF/EE9(EO58KGQ=9))(8YY(!6DGKI,T\>E$[T:
M[*=@MI;FV/V1LVDZFWMWI;+=81XS39=WFG:E/KV#%7:&L#F+9!0B;%$?6B2$
MG(X5(Q1B$%B59D8E@-RS$ZS+M;-9>]DKN:GQE<9';,F#$>-:U*:\QN1VHYC\
M1%%WH^M7=^71N&6 *RIWVGO'_:#]*O33:&Q-K>EF)W]F7V3Z\TO5N2WOJ';]
M!,UC5VU;P%[&+]S9'('%W?AY:U2J15N0,T,V8DEADF7$Q5.L=..U%^N>D['V
M)L>B(T'JWIO:>MM2C:C>NQ)=[LFS-<LZP)M5_>L<#%M5F(%KP0):8&N,2W_.
M?JUX5D#+ O/N#;>>MV<9-F9\4BX+&WZ6/&/-EFMSWJ0HM8MF:*,01K"JMVH1
M)S)U'PG"ZM,OZY>CVW,#O[%>F&+]1;5CU?WUL_=6])=ZQ[?BAV[BMI[IDW=#
MA]MQXK(W'RUV;)SV(3D<I)2_V#LKQ\3W9M5S4'1;:>OY'TSBYBQ:\+9Z7UKL
M+#[,1&R-B=78#-M4;]-5UZB)*JPB9!D&2\$S2[ JM.CC8^4%N0?_ )//7';5
MOU)-D-)-38;:@S$5X(\Q,SY"J((35#0*'"/\TIF,!5?*!SXU8;W^T-L_<M7[
M6$-'%[FA?UXRWIG>VFUNKBT7&0;+W#][9./<1AS$YK/8J_LJ"XT95))?DL/6
MC_::Q0UT$[2UG7>L:57[OKBP5Z WOV$V-M#5#NS]OZUI&SZWM>1P=K_$W<=?
MUH6VO%Z])41)GU1Z-779DHI3+QIK(S>'[ ;2ST%.C5AM4IH8<KF+E_'F]D:5
M6_!D'ZZG=LTX%LEJ;%G>N4,,I8AF<  [B_VD/2#+;GW;GLEM_=.-RF2].O3/
M:VT-YIM'9&ZL_M'*[-J&ON4T,'N7+2X6.#<T(BJ5LS';7*4(H5DC@@>5S'6]
M&^GAN/6 /4B.F;)J=UGKQV2W=MNP?IR0N#8TM4-DQ9@L"#6@9.LJ='F@"3,M
M'1,G)Y!#!8:4/9)<A2\<]<5L[)4$V\DDV/(P^:R>0E[+V0)*UV-EB6%9("1*
MC/PT<DA544<3R$G6/]0OM.;&W=8]:;5'%[R23U.]*_3_ &7C?O2M@VEI9S:E
MRO-DK&5L5,L$EH68JX>M=J5!8GL2.)<52B"G55@O3\V[%]=-&:A>L^ME636/
M>F'[/S\@S)V?,*=1H_8-HM;L1%$*J*#W[<J,F@QF@S8X*'R8R^TJ<0.AHAW[
MBVAD4PV*QQGI&:CNJ/.S.'G[354MSV#%&?APYL%)54*R)'U CN\ $V>0^TIL
MJYZH>H>]DQ.ZABMV_9YO>D>-K25,3\?6W!:VSB,*EVY$,TU:/"BW0GF>:"U8
MNB&2-QCVE9XTE[Y(FN)M.--.--.--.--.--.--.--6=L&D1.R*98:-.OR T1
M90%1Q[\4\.Q(M,*=:=RH1XL4T=MWW-)QA3HCZ/;E6/9YSC.,-N#!U-R87(X*
M^]B*GDZYK6)*KQQV%C+*Y,3RQ3QJW*#R\3CCGY>?(MK=6.[6FJREUCG0HYC(
M#@<@\J65E!Y'U4C\M8F@^N8,,&?%$;;W=8H.0J\Q4G("R7*+D85F+F(A^%4X
M."BLC(07'B/Y7&.+4XP,^VTMP=]M.6E:G1].8*<-BK)NW>^1HV,7<Q#4,EF:
MMFDE6Y3>D6C@&-C59J\3]55B62*14+1NH*''Q89(U>-LAE)HG@DKF&>S&\0C
MEC,1*J(%X9%/*'R%('((\:N:J:.J5/L-3LL8?87CZ=JH34$6T<9'.B/5D(\>
M0:,.;8BAG79Q3PS:7"F'Q@<M96E,:E><+3D\3L;$8?(XG)U9\@]C#;4AV?56
M>:N\3XN">.PDTZQU8W>\7B4-*CQP%20*P)##WKXNO6FKSHTS/6H+CD#LA4P*
MX<,X6-29>1P64JG!/R<\$6U7.L6MZX+K@%#U@EP=8PE]KT,%-E1)8TK&[&66
MJPM6!MB%$^L5ALT@<+(68Y#;"\H)07G.59QF.],-MXV+;==7R%ROMBCG\?2@
MO2U)HK5;<C2G(ID%2E%WCTS21PF U@L9Z9!+R2?&'!TH5I)S-(E&*W#&LK1L
MLB7>KO"8")>KP[!>GH !X8-KRXZQU<2)I(4'=MD5^8UZ%,0U7MT9-Q&+(+6I
MM[+I%6+?(K[\?(0@>,I;B6RXYPZ-0RQA@[^7^[S'ICBH:F#@HYO<F/M[=AN4
M\7EZMZI]YQ8RZ_7)BII)<?)7L48?E6JLU9YZRH@CG^7S\_<D"Q54BM789*:2
M106(Y8^\L$IY,#%H61XE\"/J0NG2O#^/-XQ>DJO%3FL["B7MI\GJR&LD+!D3
M,Y]X>E&K4PVS*EV(R0$?D#S/Y?R"9%, %$RKX&A,!M#BLYFKLG%U;NV<@+F7
ML6=JT\G2HR7;WQCVDRR(EN7(S6(GL6)ODZH3%-7BAY[:1"%8XDN8\9!'+2F$
MMAWH1S11&67NF03@"1IG=2[MXY7I=%7V"]("C,7-PUD=.--.--.--.--.--.
M--.--6V=3ZM(.2!!5>AG#)40@$^0Q'"-R)0I3"AGVG3T,X+5AQA66\YR[G.$
M^,8SCQCQ4,P]B?'D>3Q_AKS,,3$DQJ6((+=(ZN#[CJXZO\]<S_8'T7^T=+,F
M)_K#NL/8->R667&4*YENU>V1\>I3C@D4).$/'5ZP/C(RD;!4@16</I0EU;>'
M,Y1G)QY!@ '+@_WE/(_P/M^?' _#6E7-G5F+-!'$ZDDA&4(XY^@/E6^G')4G
MCDGG7Z]+>B3>Q4MN=N=6;;DMJTF9EJZ7KV<^N@*NH)E_[G$3;TB*R S*PLF@
MQ;&98&V9B"5A9'8P^^RMIW=L=O7(XC!3T,;:K53/8DFELF,2W7ZXXXE2,.61
M%1(_E/:Y!=B2">K6,Q5:YC,C-CHL/*\<K"83D-V5YC5>)).4B"!U?P)2_P Q
MZ4;P#,9<-"P5+U8FJ.#0,%790V*JM7U%K2(:IE%=FITI 3"YUT'VS5R?"'R_
M)+Q+E#1IBP?^+BGOQYTMKLURV9I9)9I"QEDLV9#-.RJ>MO+ *@)'M&H()/!]
MM;%E*MG[NE-VP)I90E>O2K*:]-;%EUABZAUO-9$;.'_;.4/06$2\>-WX.*'@
MH:)A1$-MBQ,:#&CH9;0RTED$5H9M+3+>$MLMX0UC"&D8PA"<82G&,8\<Q;,7
M9F/NS%C_ !/.MDKQ"""&!?W88HXA^D:! ?X@:JG/G7MIQIIQIIQIIQIIQIJ'
M/U3M:6N8FM*;-CB2XRHU=^1@[1:@@I&071G#Y2+/ LA0D4R0>H1"!RO8^,S[
MFS1!A\NMO&"YSTEZ!YW'5:VZ,%.D<^1R$<-O'X^66&$980U[,4U&.2PR0B7E
MX^4D;YHI9'"LL4FN-OM5;9R]RYLC=%666IB,3-8I97+006++X$SVJD]?)S0U
M8Y;!@ CE"R1(I2Q%$C2*TT6HNB9VRW\^7UW09B5O$QL$JFTZ&A8DNTE"' Q;
M$3@VRS6)F-@6G[-,'P\$W)2S\?AL41F<^=Y(6 BG)YCJT</#6S68K5\56PT.
M2R-FW9CQZ20RSM9,5&M\-/<9*->&S;,-9)NJ21ZG2#+W8ARW/DLMN.:]MS;F
M0N9ZYN&;#8>GCZ<^6DBFKUHZ@LY2Z+E:@DF4NV*E!;-Z2OQ%$MXN4A,,S]&M
M)NTQIJDTVF;@K9\,%5:E6Z^O9,&01;J,:[% LQ&'IDT>."L%6?=2(R8:58*^
M+7!<E_"W92\LN+YP/F;D63S&5R,$9ABR&2O78H&X#11VK4LZ1GIY7Y%<+X/T
M\:_53;N-FPVW\%B+$PLSXO#XS'33CJXFFI4H*TLP+$L1(\;..KSY\GGSK/3-
MOJC\<-+LV:ON11B?>))-S,<L$E'N]GN'+23D=Y/O_;Y:<5CW?CSYYC-9G5BS
MN]]35\<HDBZ1THD)MUTMBJL2-U.&;8;?==6]'4\*</:2V@8A2U.#I2G#+GNS
MCV9\><TL=>"6S.Z1001O--+(RQQQQ1J7>1W<JJHB LS,0JJ"20-%!8@ $DD
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MI04:RGMPH 7;S)+(?,DTK>[22L2[,3[G@>.!K4&<NQ8^Y^GCQ^7C6:^7^O@
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M'5VZ\U8(\-ABO$)9)$:4JA:($R+SMM3[7$N0R]?'[RVK2HX2]*E.;(T)K#_
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M%='YZ&5NEBK=+!NEE]U/!/##Z@^1]1J\N>.OK3C35,FYN&K4-+V.Q2T9 5^
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MQ-626&O4=)^I7M=AJY5" KROU<'CK#_VP>>.&4<<?O;)B]I>T,+4Y^O::VG
MZ;LVU/XDO;74"2MU7T_J).&]362.D1G/O%?9IH43<+.$8Q'SC]NLB"[G99&)
M!'LUHD@,OL.8PXS&/+')<K26XZOIW4RRQ2V[?FVA4CHD[Q>&)@600Q\0Q*[&
M*)6X(]C/, 1&XC+Y>2 LL<?[A\>1T@,P\$L?F8CYF.JML[O+W4ZZZT]0'2KW
M9(ZYV'2O=WJYUYHO:C9%$UU^J=1ZN[(0P<W9KE:XNOURNT"9<IF$*CXN3F(!
MH9@R=6\M+0S$/'QU*V$P^0L8&X,<L,=S"Y*_/C*TUCM6[..<I'%$TDDMA!-S
MU,J2$E8P!RQ=F/9L1):C,Q8QV885F94ZHTE'+,P "GI]@2!P3S^FNG8*7OVE
M=W>LBXYV%#[/6_6GIW=?QXO96PZ+IRT2'L?V-"28]=V#4X^H*U5:).*;FW7F
M5R%)1]1"G03LJ(7+CNRQ>0HI!<I;1 Q[8R&SN"\6KUY[D:GBNZ&2O*TOQ42N
M4X/3-X=9 A5"$7RF+QR7_P!KWF2K#P[K&Q\N#PRA>@\<GW7VXYY/G6Y6T-W=
MT[UM?NY2=:]MK3HFA=6/3JT9V7IE?H^L]/R+QVQG-.3MM=BB#[-2)5R/H\](
MPKSEEA(UM@MW#<0) R,#$BR<9,8>M2P\-7#3V<5'>GR>X+N-FDGLW% KBVD0
M8".9>J9%?]F[<CRS2+(Y5DN'DL/)91)VB6&I',H5(_WS&6XY*'A"1Y X^G!
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M5WJ#*7A6>%*[0?$R]LP1IVUB"]7"QB/]F57@,@"-RH 'S\+7ZQ)V8^L,7#=
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MEC165.VI"@%8^>>@'Z+SYX]N=7-J_56MM)T6#UCJ*C5C6^O*S]R_3U+IL.'
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M5C.6Q_R,K#D#)T^L'@?*.GD]1X0<<L0.3J _IGNK75^DHN2V_K&3NE-FBD,
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MY;!AB@S7Q\K>;^:%U^0_'6+Y%Y:QEEZX?I?#2'6#F8V9%5\3F='Y^=>/N/\
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M;!,@<E65V1E'21R.5X'/'OU<^RFH]4O5)[A;0V+Z<4SNRC=:X#27J(47L*7
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MC +/09XTMH6$4C1JB.RE3\RHHX('!(+'(5)GGC<RA1)'-)"W1STDQGCJ ))
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M.DK1SI7;HDC"AW=HU":7NP8_+5GHB)3&T4U>>0(%9UE!0%3]>@CJ1F *NO(
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MRM:]-/26;866P6;WEA8+6/R2/>I002#(G'QS1]RM7G$J1F.Q62>)G16=69)
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ML%:)C;$T2)*P-B2V^K TI%GAF$-K?0V4ES+J'NQ_2KU9QF[7&V[=U'SU: O
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MX5#*WGCD'71B5\=O'9T%>,3TL9FL555(XB@L5:[I$PA0NLD?7"$[08JZ<KU
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(IIQIIQIK_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g99471g20a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g20a01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1WD4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '<B^=B0X0DE-! 0      $T< @   @  ' )0  AR<C,V,# S,AP"!0 T
M36EC<F]S;V9T(%!O=V5R4&]I;G0@+2!3,2!);6%G97,@9F]R(#<N,B!F:6QI
M;F<N<'!T>  X0DE-!"4      ! )+8H1BD1D^-XSNWF3K3J(.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      -!    !@             ".
M _4    & &< ,@ P &$ ,  Q     0                         !
M          /U   ".                      !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   ".     !29VAT;&]N9P   _4    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   C@
M    4F=H=&QO;F<   /U     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,     !-.     0   *    !:   !X
MJ,   !,R !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
MA  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,
M# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1
M" !: * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P !
M @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"
M! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+1
M0P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25
MQ-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%
M!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C
M<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2E
MM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#K>H]6
MQ>G=1LP[NGYUM+&L(RJ&&QA<\L:*M(][?4_])>I9[%7N^LO3ZJWN/2^IAX@,
M:ZH .<X>UN]EEFWW?^HO56L<G)_TKOO3?:<G_2N^].L=OQ6V.SEOZ_BTYF1B
MW]+SB:7L96^EIL%CG5#)</<*6LV;MGT_^&L]*KU/3:_ZPXPQCD8G2>H9 ;9;
M4^MS/3>TUUUW^LYCMWZL[UMGJ_\ ;=5JU?M.3_I7?>E]IR?]*[[TK';\56.S
MFL^L/3RYE1Z9U/U7@D-;27-.TL8XL>7,_.L_.V6_\$S?5Z@&_6KIL.LLZ=U!
MM!&ZEX9+G-#0^Q[VG976UKCM9LNNW_SBV?M.3_I7?>E]IR?]*[[TKCV_%-CL
MY8^LN -XLZ7U-KF[BUC:MSMK"UKR_P!S6,>USOH-?9_[$6UT+4R*A5<^L&0T
MB">=1N3_ &G(_P!*[[T"V]K'-W[W/M= (!=J>[W?F(&N@I0'$: 9)))X26KP
M8GQ3*'H5^OZ\'U W:#)B/ZGT41!<:TJ]M;[K)2G(30BAQ?K9U[)Z%@8V3CMI
M<Z_)9CO=D!YK8US7O-GZ%]3O;L_?7-_^.-U'W .Z82V==EX!AVS\[,:YV_Z;
M=C-__!_SGI]\TN:=#$\J7J6>)3XRB!K#B\;0;Z&G@'_XQ.HLWD.Z8\,#R"UE
MWOV3M:QOVW=OL_E?OU^GZOZ7TG/^,/J/^DZ4=7!OLR-2'LJ9/ZU[&6M<^W?_
M *.O](N^]1_[Q379-./0;;KPTC\SO"/' [8Q]J""!9GMX1?/;O\ &+U$M?6+
M, &'#U*F6S(-FPUEV9^>VEC_ '-_P]?Z-:/U9^L5;?VGU+J=HO&-8W$I>PGT
MG!X=9ZT%UGTG5LV>];=G6\_J6:WIM5-F/29%F3M<VMM<?S]=^W99^:_'_P!-
M^C0*C5T)U]POLZSEN:&2:Y+&$R[TZ*S;O:ZWT_5L_,_1IQ,>&A&KK8K"=;O:
MQ<N_]6/Z3__0[90>VQSV%MKF,:9=6 (=X;C])3216@D:CR^U90-CA:*Q6XM(
M)-LC:/Y&WZ>Y3):!+B&@>)A.DH6!9C8D"!?_ '*RC-_JQ[!2&Z<[R[S_ #=J
MEQK^"C58;&;S6ZJ288^-T><))C8B3I^[KOKV9I)(&;;=3@9=] W7TT6V4M@N
MFQE;WU-V#Z>ZQK?9^>DM3IUY[5]<?K.64FZ[:ZP VAO3R?3._:X']'^D_5_T
MWZ/_  GZ-=-]4>J]4ZITV_(ZFW;:S)=5435Z!=4&UN:XT_UGN3Y8Y1%FOH5
MW]/!VG,L=8QPL+:VSNK 'N/;W?24Y3*#&VA[W/LWM=&QNT#:!_U:C7W8U/RB
MHBMV.UF.+;B;+-QW.&KR(_-J9^ZB-+GUAPFMSFR-PU:2/SF_R0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
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M/^)*RD'[O"J38_G$\W. *4 \!@V]'MN-[L;[?$;'^1OB0V-ZM^U%T\U"NJ[
M=.LJ=TGQ?7C*<@ML1S7274_.[K5?'M4O:;:S:56$.@U3RO+K"SP>CQ7LU2<1
MUHK7:FONZ"GQ=NKNJVGJ<#EA&6$^-X?FB#39$8R'PXT62+)QX4QWQ] Q,A2^
M/'$JS/)J EQ6YF1V?G5F:8$\&.:_<-_>?:((N_3VMA0KTV"([/W:V]N-JW9T
M6-9SHMCFDUA==HC',0R:[R/LYZE,P-/\6'3+7/+,]HP*UDT6.7V%,9#ANF.,
M89J[6Y??53>09>#5K99#'LJZ$KN9IOA3&622++DR0F$\L:)G0W-)]XQ(X'I>
M=XY3'-D22XKQJW)%LJ%202ESU%;[V.FQNNEBZ ;<;_#A@\MUQ]K1VA:K&J34
M?2_7-K^">8Z69Y=0</[,FKO9\7%<_MM*NUQ4:IZ2P,II\OM[+533C!;V+IA7
M5.I-+=5D6^FW>/6<-UJR>K;%Z7'B>&\-I7AR<4^9'DPH9=0QLT20ID:<^-DF
M-XE7&GF0Y!;'=6Y51U(*\R@K<@[?Z>W+U!YA^(W1H7U]#WX>&!VMO:K8D]:8
M-0X-K#4Z<X/A_99QLLEN>PGK!J5F.&TEQA&-EK?GN,3K'.3L>T+=8%EKU)@C
M>.R+:5GN0A?9WJ#9U7T;I^[8W,9M.\/2<LK38S3RRZBX1-8Q88I'6608<,BK
M%R8:31\TWF4(8^2&%6YIN5!S-9H;"JM6NN^Y(L_L\)JAU2]KAJ5=X3D^L6,:
MRRH&:X)V/\R@:38[H7JAI!C6-9IBOM"Z_%M4UR#*<3S ;G$KZ'HQ!KL[R?%<
MI>E0,DT[RT9L^LG8KIM>2LG=?'\-01RQXTF*&BFU2(Y,F9CY4DD4FBM)C%(I
M(N21#EL88Y(U#19$5*R23HL9KS$@FP"%L $5[6YN]MNH)JNNP-NGI[VI_;0:
MD5E5CTO I6G=UD&HV%U&6Y]D?8ZRBIB:/V\O1WM*9?JGIG0XG:ZDS6=5M/<-
MS/ =$L;P_M#M7%;CF26VHJ5C7T_)>CPFX\^G^%H'9Q/YZ)!,T4,>IQL<E1E8
M$6-D/(L ./-+#-ER2X10O&L',2@LD N=JJS1)'38]+(L76_0W].M%;FFH^HW
M8LT U UIQ1S!M7\ST^TGRC4S#9%184#V+:AWF%Q[#,:):&X-RUI#K+R391/H
MFQ==GUH-+#E/.O,N.%E,V*"#4,N'%D$V-%E9$>/*&5_,A21UB?G7V6YD"GF4
M -U %UPUDWY0O8\RV/?OPP;B>"_9PUQ75O\ $5]+_6_RX#X:939/7?Y[\-%"
M+H6.*X+D;T_,?UX*CZ'Z<5P80WOM^^W!A2>U?'C(4W)/AU^[_'AWAWW=/A[O
MY>O&ZP*F:"B^*HF_HN^WZ_N^_A+-RB_H/4^GQXD8V-)E3QPQ*6D=@J*HLEF(
M   W))V %V=NI'&W)%(LA8KIB,D! S84A[T!<$3 C;_2%"$A(55/K"0JFZ*B
MJU1.]&B0+/0D]K]>+S5/#&J:3C0967C21X^06$4QIHV=+YTYT+*'6B&0D,"#
M[( (&'7T3[_\."XS_(WNXOZ_O_.W X(H1OU^'%EVV7?P\_'T_#\^?#BMV/R_
MI^_TZ)XU74V7Y*O[-N'.$ 4[>\7?Z_G^G 7 X7Q7 X'%<#@<>?[_ (1_"FR^
MPQIN_%B29+%;VH\%G63T>.Z\U A'I;K17!+FN-@0Q8I6%A!@B^^K;13)L2,A
MJ](9 ]Y]GA4:UDV0"=,F"@D L?O6&Q"@G<TI) L@ GH#P[#^/Y'CS'R];]#:
MC1"GK,4H836M%%IWHNPWD<JN<E5]ADN(ZHWV1WM*Y2RL9"$W(C4KT-ZVOW[R
M5%R:OEMT2LFD)QLO09SL%<%%CC'WV/&Q )2+#2QY;RNG(8JL1D%Y#(RR*WED
M6O'(HO"7BS)\5Y,^HY4S>%\S6O%#MA).(YH<'4?#V+@XF6,J//,IC?*61,;#
M7%BDP)XCEAAYH8+RNUZT3E9[J[_!BZT_T?Q4\0TZH])IL[2>?G-/%;AY5%R_
M42,_0S<5OI4JPNI5IE%>,FZB10?@G7U06#%=$C.MOKJ&&<C+,3X^'%Y,$>*6
MQ#/'0E$V2IC:)V+2%I%!<"UY4YE4 BGG\&^*H]&\-_?\36O$VH_XGK>7XCBA
M\10Z3DR-+ITFF:)(N9%J&)''#BQX^!.8\620I-Y^0T#SR2*P-CKUV5W])<WQ
M2NQ!EMRTS7-<DQ[$IN.06(L7&)^LN)7=141[F+C,V]J<O:T^C743'94+,6,9
MK*YZXI;9I^1)KD?4VH:4<2:)81;SSR1PM&H58FS(I$02"(R)*(%=8^681JI=
M'4DK9P^#OM#3Q)I>HSZC(5@TK2<+,U*+-E>23/A\,:CB9.0^+)G1XF3IK:R^
M)+G)+IKY\\R8N3C,J)D%#N?KAV>1S+#K6_RK"LZI(&I&7Y.,>DT.3%6<?T.E
MX7=5PZ$V58WC]0W;V^33I595U$H'[:FPF;%>R-C*5>EO.(IL[3_.A9Y8)XUR
M99:3"6(1X+0,OW)E\M.>21BJJ;9(2#(LW,21%B\)>-6TS4\?#T[5=(RIM#TW
M ,F7XK;47S/%D>JXLQ\703G,R#C8V!#'D9&5&5Q\K58Y$PFT_EC52U-MKAID
MXYVE*]E[#[)S)LO"ST*RTL E5CF*4N>OQL8SN-#J&*PAK6:33?W6%!KYB.-U
M5U3'9XL[(L)*2Y,5\[&)U)087\V8'!E\@IY4<]13A5">R$Q@%"G9'7FB):B=
M#C>$M?4>!9WCU3'&#IK0>+M-&L1Y":CE:.LF?I$DN0^1_';+USS)I9XZ?(Q<
MH8^HJD*>7&\-]KIV1*_/L3S7#7)KE?@NE^J.DS=2UIU5XQ:W42HJ(PZ2Y1 =
ML:K/<<F7]I)L;>"]E64TH6@OP(4S(,<ALBVKDM\_2%FBGAYN6#%R<,(,>.-W
M5%48DJ\Z9$;2/S.K22IS K;QJ".,UA^$/M*FTC4=*U58A-J^O^'_ !&^0VM9
M&?C8LN1D2_\ ,>!*(,C1\Z+$QDAQIDT[3\HXY6:2+#SI7YJ0V0:V]F^YT:R^
M/00J[!=6<AS*\UWQVLK=.8=C1X?FT?-JV%C&GK>5R&&2?K6=/*NQE.T\7$&<
M$DW64')?EPS@!3M,29^G/ARB-5@RY)7SHPN.K)#.)U$6/YI YD&,K'RQ"(#)
M)=KR\G%MA>$O'6+XHTY\R6?5O#F%IF)X0S9YM;EQ\S4])?2<B7/UDZ=&[A)F
MUK(AC3*?4VUF/%P!&L<RS?>20:A]HO"[?+-4,GQ^PH$FKFV@[^F;S.G=1"CL
M8IC-1G'\/6QK3QAF  ?2V2 4IJWB%+M>]85A);-=&]T1/J4+S9$J-'S>;@G&
M(QT"B.,3>?[/E!1O)N'6V-4"% $O1? ^K8VF^'\#-@S?+_PKQ>FOJ^M9,KMJ
M.?D:1_@[&<9[3,?N^"PC?%D\K'Y'YS&T\AD6^8=H#1O+,+[64(,@QV#>Y?J9
MDLK2<6L)6C.PTT9K9L#&:JO6MTPN&8"$S[HT,*RL<*L.]49D^[%YHQ<>EU##
MEQ]57S(Q)/E2MBW#R7BA"(D'+BR 7L K- UCF:2[XJM-\&>*-.U;[.I6P<^7
M#TW0-/C\1$ZJ<L0Z\T\<VH9$OGZ_C/*0_F,9L>#582MQPXI5@1V)]AQJQD&E
MO8<U[^A6Y3%HFM&09[!BBV\V[D-!CNGF!P,B*N3D%9SE*RDFR3W<GA"/6W@*
M(OLH)<-\:8+3:G@9++>,8$PI'%5%.\LTD(<]A*"5'-0#<G^L<=:UG5XL;)?!
MC=?ORX1U!(;]J3&CE,4Q4=>:*@_+=NG.5'\-J=+)/:<7,RVD/#9R5']!%[QQ
M$V$B\-TWVZ].J\.8NC1)"H- [FJO]1QR+4/%$QRG*O8]2?>?=^S?'KF/M)9P
M._\ X-QA?)/Z%9^/]\?G;CD?(/4_E_3COGWN3F(Y4VZFF_\ +][\ KVELZ3_
M )KQ;_4[3?\ _5^!R#U/Y?TX!RY!T5#_ -W]3_;C#^4SG7]E8O\ ZG9_[WX+
MRQV/\_Z<']ZD_P!*?1O_ "XLO:8SORJ\6^V%:+__ '"<)(4'<DGO0'T^6_U^
M/#9S9!T5#\F_+V^*_E,9W_9>+?ZE:?[XX'L?]7Y<%]]E_P!,?T;_ ,^*_E,9
MW_9>+?ZE:?[XX'L?]7Y<#[[+_IC^C?\ GQ7\IC._[+Q;_4K3_?' ]C_J_+@?
M?9?],?T;_P ^*_E,9W_9>+?ZE:?[XX'L?]7Y<#[[+_IC^C?^?%?RF,[_ ++Q
M;_4K3_?' ]C_ *ORX'WV7_3']&_\^*_E,9W_ &7BW^I6G^^. .0D#VM_AP/O
MLO\ IC^C?^?&2=IC.U5$^B\6W_ZE:>G_ &OZ\+\L>IX=^]2?Z4^C?KS?G7RX
MR_E*YW_9>+?ZG:?[WX'(/4_E_3@OO4O^F/\ _M_7@0>TGG*IUK,7\?\ [%9_
M[WX'(/4_E_3A+9D@-<J?_P!O_+BB[2><CMM68OU]85G_ +WX'(/4_E_3@US)
M&OV4'R;_ ,N&WSC4W*,_2*U=.Q6(4,U>8KJ]ER/#200JVLAQ'GI+SKR 1 !.
M/$+0FX+(M]XYS&%"]/V.$22O)^(B@;  H?S/N^'OWX0*M&H<RCL/FN^R_#;_
M !V\/!> 647OTX/R)2O,$;EZ\W;]^X\:JILJIZ<*X:_EMQ9$WZ)P. =N!$;]
M5^[]_P#AP.!O_7_?^W @CY)^?BO X(FA?&O8QY#T&4Q'?<BO2([S3,EM$5QD
MS;(!=!%5$4FU+G%%5$)41%79>B&&X.Q KJ:Z&^O:^Q]?3;BVT+57T?5,'4UC
MCE;#R8,E8I=XY?)D60(X[JU<K>XGUX9#333S4*DRNZR7-\U7)%EQU@UT*.S(
M8CQV%?9=*1(*2^\X<I18::;;12;8;[Q$==0@[M32VAC  6PQ("]0" .]FB>I
MV[;CCK/VB_:EA^,M*TW2M.T.+28,27[S-RLC<\QBDC*H$B15C_BR,6/M.2NR
MT0TBP!.5-^O3XI^W[>$JH(LCKOW%?GT]..*LQ!H'I\#_ "XL0[=4\/U?G\_%
M++6XZ?I^_P!^\U:]CU_7]_OW8?G_ "^?3I^WQ1P3J!N/G_7W<!&'3S7IUWZK
M\_L_#;A\&P#PPP/XAU'Z;_UXUB3E7X+X<'P:MS?$<8)\?S\NG7UX'!CO\?W]
M>OY<46^R[<#@'Z?O][]O=P ;+4EHV9#3;[)[(;3P"ZV:(J%L0&A"2(0B2(2*
MB$**G5-T,$@V"01T(-$?,< ==NVW\B![NE]OF#P$U0TJ[;T]7UW_ .;XOAM_
M[E//[^G"O,D_^X__ '-_7@@S<Y',: Z FNW]?RX'^@*+^Q:G^[H?_<\--++S
M'^))_P![>GQX79]3]3Q;Z HT_P"9JOKNO_F^(FWW,HG[?V&LTG0R/[O;;^O7
M]_$6?4_4\7^@:/\ L:K_ -0B_P#=<.>9)_\ <?\ [F_KP+;U/U/%?0%'_8U4
MOQ6NAJO_ ,GADS2DWYD@]W.W]>!9]3]3Q7T!1?V+4_W=#_[G@O.E_P#NR?\
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MA?UZ#A]8V4$\I/O /T'[Z\#\/\,<5P.!Q@C1'OR[JB=>B;KMMNJ_)/M_>PU
MD#?T'<_#Y_[\6&+A96:>2"%YG()Y45F8@=P%!/QKIWK@#F^LJ+ZHB;(O[>%H
M>WO]?RKZ_N^(L\$F.YCE5E931# @@]*(._\ 3OQB0;^">/BG[OS\N'.(Q7NI
MKUZ_OY=. E9\?%/FJ;)]Z_MX' !<=1?S X"423Q1?\/7Y>? L>O#A! L@@>I
M!KBPINJ?C\N!PAC0L=>@_?RXW '9$7;JJ?8B>73TZ)\>") %_EZ\!5H>_O\
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MT:QLI"EO:?\ Y5)-EW7HF^WE\EVWZ\,43T!/' *4$'IU[_O\N-'Z*B=^LI6
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MG9T:O?U;RRN>D2&(ZN6.DFI49B-[P8 +\HUQLS9C@AHXZYW9\C2*:"2)U)O
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MSR)&&DD9GED5#(Q(I8T51NY;JBIKNNR]/+P_=QE.-LS&R =A[OZ\%FV_AO\
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MXS'VB:!JGBS08] TR7 B@SM1Q&U>3/.28CIN&SYGDI'B-%/*V1G8^%%(B9$
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M8-&VI9"HH =;)H;WU'Y?[]NI^#/M+SO".G9^EII^!JF#FMYWDYJ,1%D!47S
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M:1U(4>:J,2 MD\O+N "38&G=UVZ[>O?IZ?G7'=) 3IONJ^B?M^7S^'7SQ/*
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MD2*N221)* )'5<;)4D$U_#4_Y:#9]EB#M?3:NGO[]_7MOQW.W3U3PW^SCGW
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M1S"5U^*S%U'2I\-V\X 1*?+B=B%)$:W(RH!21):@%J))+'J&,J*=64%!1V-
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M*23A<B&K#SAE]941455'<554V)>799(,^1&TD4GFQ%"**<I':P *()%6-^Y
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MJWE$-9%VRXX+;J53+RG%[@G"0!<.=%[]MQ.9QLH";#]=-M+X?C>&1M11N22
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MQ<<,]Q.@-!2IA-VT9(%.;IMVT=.L/I,ON=8]3:VJI*<(<R$]:R7K&\E.R#D
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ML7 M28>*XL=W%;4$6RA,N )@_%= N5)VM>(LS%QL>/3UCQ4N0!^57>B%HH"
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MD=N8EA[-D !V%%B&RLDT.1ILN/J")CY& Q;!AQ\"'&,SY+('5U@@CC$8"FI
M0S,8U(=8PT<)L0SMO'<@COO25+O7'!0E%'P SW3NCVWV0^;EV1.9.J[(G5(;
MZC$TCF9_X=F[L5R[@_0;=!9LGU6NGR8L&.L"'SV"\@1 _,&_RDCUO<&B3\ >
M#:;J&F3WLYMJ8HL1)H!')=TY05051:15YP:!Q33E05523;;IOQ986? \Q6%@
M0X&W3F8*+-$;][/0V?6C59VE97W(S3(2\# <U+_#0R<Q1=^8 *0*%U578'"@
MU2.XH[5ZIM+6/WD9@#CN1)02([@]VBHZ$@#Y'0+HF[>_1%1-MNJ9,UN1'6TC
M:]G!7H>A4C:K[]#UOBP&F*)9H9^226)$9&1@ZA"EAE8#E//?M$DE1M0[XZ/Y
M+D=T;K#<A8;41DW%DOR76(SKZ*B-,$YW9--*\I(BO2U:C@@GWCB*B*M/-X@$
M%F1/,5B0 *)H7\/D0?0]^)F!X974W,>/)]V9%YV<EU4'F&Q%&[W-$52L;VL]
M5= -0L5TXL#:!J%(S.='CM69C-<2:ZZH19+L0FP>" ,6&PR,Y6 =<6>X(2#?
M#NR!O#:MF2ZE([L2(@Q:..P>4&_7>^MFJ - 42>.Q^&=%Q-"QXXU"OD,BK+D
M<O*9" +"@"E6P&(!;F(LD$ "5.7]H:7!P7,PK^X$JIF(4%MA9$F61RWFG+"Y
M=FJ:>Z2F(2R4CQ3'G;E1D[AHF48+B@^Z@R*#\02*!._**%&BU#N+O?BH^U7Q
M%J6A^!]<U+2XY9LC#QHY&$',9(L=LB),S(0K9#XV$T\P-'E,8?M?'-Z/K\[=
M9F,4K7W2N1\>\>?=<-0(T7OC=(UW)7%10)215VYB4555X@R3,SLK2-SH2Q6]
MKW%#UV&XWNMNG'SW7QOJ>1JT$\LAQ=+FE"F23S'D0$ O+(1S-3DA')LKS!F!
M)KA":Y:W5V[U=0E[ZVVV"R)#"&X:N-CL9B0#N(JH\XD*JNQ*B]4YN(.1.(_:
M4<[?Z0+"WU9B2:-WUKE-7N*(U[4V\1S_ ''3V6/3U*^;ER$H<B5312%B%/)=
M,K+;-9 H#F#2Z8:H79749V/)<-^4HM0S,W2!AQ>@$X*J1(@[IR[$/]5=M]Q/
M#F$H/,K#?M5B@3VKJ!M[Q],Y/'J.@9L&1@SGSP.1>8OY;<W*BD@L=XR0>Q*B
MCL!P2=I^?D-[4#0V\CWD'7@M%[H2,D6.ZT/.H@JES$KAH(JB*/,HBJ"J\1]5
M3G@"+^$GG)()8<C#XT/;%4;Y2?AQH/#>IZFNOG*U+(\V7&#QQ(K*D1^]Q."6
ML  _PY#3'V+]D"]]W23*8^"5$"/B#JM1GZ]6I1))!\Y$ET460LT6EW:=-4-$
M;<Y"[M-@ 6T%!&&T20I'$I"J/:(8<Q<@\U^A8[D77J*6^*;4=3\08VL9NJ#(
M,.5D%X&1HF6!L;F(58P&',L>Y5@Q+ M;!FVB?KS=W-IG8[QG%6P49)":*G.)
M(+:&"$H]")"ZJJ[HB;;\4^HL[92H%H$+0/4K0ZG;H;/:R=NP/1_ <&.^D9>?
ME3!YU>3GD JIF9I)+ +&BH0+5D;[]^'JTFT7@ZB1G8#[H5]G$C,O\J@@$;9(
MHJJ.+RCRH0JI)RG^GRBNZ(IV6-AQ2QVX96! M>HV%=1N#5B^O45Q0Y.=J&1J
M9Q=/DQW)C>8+D.2K<K@."RGV67F45N#9O?V>)*5/9_.C$:@+-)+Q-HJJ""Z/
M=@B$FVQ!LJ<RKX<VR;INFW%DD$42\OMFB;-@FS='H1TV/0"MJXH=0T;6,O.(
MDDPQ.R!@D2M(H15!(YO,1K%GJ"U;[K7'9KL)8;@F 8I(@0;GW[-+P0L+EB0T
ML=6HL1QUJ-'KT-5%UAA'>\D&+BO*ZZ*.MM #:<5FL1Y#+$0O_IHP5C96#66
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MA]D7?I&"$-N7$;BHU"KSY41H3='NQ]10/*;8!=Z ]03>_J +)X(8]U7*X_S
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M5 LPX[JZ,Z':DW6*:>L.1;1)*:=X<W#AE%DMS:Y+"DB-LUBL]%:?>?!X#9=
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MS CS%4ULU'=BQ)M :((NSS66_-G_ )D2,J5.2%YCS1K.5 0IMRN  &#[UR
M T;((?G1GM<87 B.T6I&$P)5/]#0JV).QZ)"AW3$B)8E)2>Y-D-NHX\4:1*
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MQ,33/6R1:U\&ED@^#L0&ZG)Z\1KR:I[WN5;_ )YP":9&*#D9XF)@3'H[SS[
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M!>!Z*VX0-/@FS;H"2B#@[]4$PV,479514WWWXUV')]X@BF(KG0.%.Y *@UU
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M0Q(0(;" ,/KN-R;L U0VX\Y^*OM!\0:GJ,GB3'R(XETF95P\:6,-%"F9%/\
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M4_/@YJZD7312=+KM_IG\_@GEXHGPX6(P2 :-_38U\>^Q[;['A$N0Z5N=R.Y
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M P/H-CV]^_Y<(5F%;]374]J'RV/7A W?,C)*+CB+U5/KEMNB^?7S].J?/@
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;N-$C$24=M]E\?\E3ALJ";WXDW7I] ?U''__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g99471g20b02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g20b02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1V*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '6Z^=30X0DE-! 0      $T< @   @  ' )0  AR<C,V,# S,AP"!0 T
M36EC<F]S;V9T(%!O=V5R4&]I;G0@+2!3,2!);6%G97,@9F]R(#<N,B!F:6QI
M;F<N<'!T>  X0DE-!"4      ! )+8H1BD1D^-XSNWF3K3J(.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      -!    !@             ".0
M _4    & &< ,@ P &( ,  R     0                         !
M          /U   ".0                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   ".0    !29VAT;&]N9P   _4    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   CD
M    4F=H=&QO;F<   /U     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,     !+S     0   *    !:   !X
MJ,   !+7 !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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M-<'$V.],M=[=JSO^<UWN NP26SK^D#3#O3Y?<USM_P#.,]-CW_0WUL_2>ET
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M#)NRA6VV[T6;VM83M;_.6U;?<?=L:B 2: MDE0CQ2-D?I_HW\@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
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M_P#JC\ORQ7\WO4W^QJ_]<-_[' *S-A;QW^N![N__ &HC_P!7Y_MBOYO>IO\
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M /7D'\-AV^?W=.P !YA/AR]+_?+P64.#^@J^OK;YXR_GI>%KUU\T]_U\@?\
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MO?N%_7=>G=/N5R*6.G^25 ]">,6C\0]?H<(J/])7FG_W#[\O#'/- .X/H/\
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MAC?]UPP3))ZX/4K^Y7Q/ZXM]24O^BJS_ +%&_P"[X+ UK_N5_P Q_7%*I*8
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M3A"S CK],.XL5! *C_D]1L-SVW]?D?ATV[\-08M^O^8W/A<VQ(IPDN)U1!4
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M,W%E>?WZ;8,I<"@>H^8[[[[=1_N[$< @'?!A4&%6Z'D?TQF0%=#V(Z=>_O\
MGZ>A'[FE)*;C;Z>>%@D&Q(V^_3!5,&.'?-\M)7OOOL-SO^)'N'RX28Y"/69^
M6) ><4DI*U1TDQ\.7^<'-NFP]/V?KIP6$D$@@7)&+ []/7W>O PR008(@XQ4
MA"NJ@#\_]_ P 3RG[M\<$;1Z9$KY;U:RAZ:B.\J*TM00AU\-J+394H\J0MP)
M3S*(0-]R1U(%C8[3Y_?CC2\,+H&LXRYW-D*7ER*I@UJ4)U*-.'$]K";:B&R3
MIW5&D;W9;3K*]4,NRN\DY9BSF+T$6.F/":DK;0J7.0XRGS(S D25IC(CH=+K
MY<Y'G7D>6I>R@AU:F@V$I!UZAWC$D01 CD20;FT;#GW#VG_[CYCE>2Y=P=4)
MS?-.W4MUVGIU!Y-,XVN&5J##(4HNJ;[-E*"IM*%ZDIU=Y]]VU[I2M*R#LK9:
M5;* V(W22-QZCTZ$CKPU!&XC' ,PRBMRIY+5;3NTKI2E82ZA3:BE4PH)6 2D
MP0%)L;Q<&"?U7##YD^0V'R.7S"A(7R@D\O-MN4[DD D@$]!OP9GI'Q_/$4/N
MJ2&^U64:@=.HD28$QM) $]8OA)9/J3AV)(+=I;16)29+3"X:EJ2^$NM^9YP2
MI ;4A/,E/+YH=4M6P04A2PXTRMU4)M&VWA!-Y'7I$&QW[/PW['\QX@X?_C3;
MA:0Y2/U-.LH2NG/8N+;#3BPX'$N.*0HC2TM*$B5$F$X5K3<>6E+_ "I4%!*D
MDIW[]0>H!WX00!N+W]-KCX'F>NT8XJ_K96IL*(TJ*3?>/ 2+S@ZE*4]$_H?K
MITX*=O#;[\<1P%+,"YV^_OKBRR$C=9&WNVVWZ;]=SU'K^'!8DBE<2I.I*@#$
M$I(W^^>V^$%=ZHX;12XM=,MHJ9\B>*\Q0X?.;?*V6D%2%(2E27'72V@-N*<*
MVG>=M(\LK>:86[)3T)O8  3OZ3?J(YX[91^QS,:KA5SB$N%M(RY.9-!3:2PZ
MTIM;J6@\'"M+Q;2%DEKLTZT)U$ZBEP67 M 4.RAS _#]=?X\)0>1Z3Y=?3X8
MX<\C2LCF#&V_,>/AXX;?5+6+2O12B@Y5J]J#B6FF,65[ QF'D6:WD'':-R]M
M&I;U?6N6MF]'@QWY3,&8Z@R7V6@W&=6MQ*4$\/4])55SJVZ.G=J7$H4Z6V4*
M<7V:("EZ$@J(!*9@$W P:1  ^^ORPTVKM'CGBCT7O(>CNH^'7=D5M3,3S#&<
MEK\AQUB[C(2X(D^SQUZT:,*P@/KCR SYKK*9,><AEU3#2%M/,/TZ^S?9=87$
MZ'FUMKCKI6$F/3 0OLG-6X([P&\?K(GETYXXU5/@!\366:@.8I>:AZ3HD5+M
M7,RV%7YI,M;^CI;)U?ES7*=-0E_GD,LO>R-NEI"W"TIQ;;;J%EL D_7#YJ4:
M;)6)$"P D1S"MA,^5O#'H*P;#*+3S$,=PG&HWLE)C-5$J:]HD*<4U&;"52)"
MPE/FRY;I<E2WBD*?E///*^TLDO[8@W,D[DDF\W)]/A PFM9M/'-4M-\HPR)8
M?4]M90'%T-SLLBJO(X+M;,<2W_2*C>>!&GH;_I7*^1+:;(6M)X(@$?0],+;6
M6UA0$Q8CJ#O^OZ['AE9_1V^-V9.D/_7VFSH4XH(=.96P\Q 4>58"Z(+ 4#N
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MR_(*R6EYZ/>XWG6 Y$VXVK=MY<:)DWU!'L6DC9N:]AKKB7?Z92%N)0I'6W.
M<E?054=96,A0@%#S-0UM%@IO5'6'02+3CDJ./>+$9$>'$9W4IR=22CW,*2 &
ME3J8#T%X,F3+06$?TE.DE)Z=:;_^4QZ.S/98^JGAEU&Q-)\MN5-P+,<;SM"
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M4)62%  9FE]GU8]697FV<4N056=4G >8</5F9I:2Y4U.?+]RI:+-$U#M&EX
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M5N23WF4(9TM)96L]VR,2*1&;3U"-C]R??WV'-M[MNOH>FQX:U $P)'28&\[
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M"7FG@S)4VAYQ$>8VVN(^M#3BD-O*7Y;FWEJU'".;463YY0U]>P:FD9=*G6T
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M(0^T0"'(;2#8GFG4"8[T BJX9]H**',7*/-:UYY50D.-LOZNVI7P2E;"BZH
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M7J) SJ1F%_CJDB$W=UU:AEUNS;@)#4=R(^ZXCZNE*CI1'==6S/:4A"%-QVW
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M;>3.GQ $LLAU=U Q;&--XUG?5EHC,,65=,UD1*UOUT*4L.1WY"^1"GN>.^T
MLCE1*8EL<A;CAU>3R9O)JVMSEUFD=8<I:M#*GUP$OJ;3I4E(U#LP%I4=,&4*
M2J=2H&[SZNXKRO+N%F*K,*>L9S7+'*L4;0)51MNJ#B5K6$CM=33J %?A[5+B
M(*&]2DU39,ZV_$LI:IEVZV^W*2)".2%LI27%M)',^E;04I*0I2O,7UYF4C8<
M7U14%Q*F6REA!04]PDN&!IDV2H$BY $#;48G%709>AI;56\EVM>"TN@N@)9N
M0L@ %8*9( 58F_=M=U7?%*WA+L.3,MJZJ2PKF16HEB5)6VGHK:&V5O)2ZXI:
M?*0D(*3SE+>_%+4\.TF84SS3C2G X(+BD:1)%BD[%20!"]YO)C&PH>+<SRVL
MIE4SC;9:4 ED.!1T;Z5I) 0%**AH-BD[ F,+]OQ,ZS^(VCE8KH!C\F@E.+77
M6V8/.(;?@H<0DF1&GO[P<?2II2E(6IR=;GE)KDLR0CFY!F_#F7<.UNJO>]X9
M@.,LF 5"2 E:$R72"!,:$$'O")CU1PAQ KB#+4U2D!IY*BVZA"B4:@ K4@F%
M000(.QD2H 87/AO^CPTKT<RI&KN=HCZIZW.R7;)O+;Z.9T#&;.4KS9$W&HUC
MY[Z[Q3JW/,RNP4JX<YUJA(J4OR6GJ+->)ZRN9-%331Y> $EEHZ5/(3 2ETH@
M!L "&4]P0-17"2-@E W,'I:8'KUY_7$H\<T&P7%]<=2_$)6&Z.H&JV)8)A64
M>U6*'J-%)IVJY7CZ:JM$5MR%)4N]G*L'E2Y"92O)*6V?+//2.5S[M#39>H([
M"E=?>:A)#A74:.TUJF%"&TA(TB!-S.%0 9)Z_K^7V( $UWU)B:4Z99?F\M:4
MHQZDF3VTK.R7926RW!CG90/^,3'&&!L0273MUZ\1$B5 >/RYX@UE1V##SW-*
M"4@[:HA(\;Q^<#'GQTR^E)S'#LJOG\LFRLLK[=E:8\"?8K J[1+A4W)BA#7*
MW#6DN-N08Z6$%);*%A3/,J46DF(@1O CKXDGES'TQC*?.:]A;BW=50E0)2E:
MH"57(*1<A-KIM:+]V,='/"Q](%!UKR08;DT6+6VULMQ-#+K_ #D17EH;<=,*
M6V])D.L2%(;4J,_S^4^M/D<J'"V7$.LA D3U(/+G8[&+'KSY6O<BXC+E6A#Z
M$I<URV0.X=,G0H*F3 -YA0Y8F!C>F&:-9ZQD]UG3UKC]:)0IJ5N,\RO_ !AM
MYIH3I#DMYM2(K<EY26HS3:'WU!\AE(4RM';*T*1I2 J),=Z+$B9,7 VD'P@8
M]*\6>V)KB'A0</L9#39?45)85F%8VL%+I9+:]3;26D*"G%M-RIQ:RA T JLL
M/??XM0Y3!^KLAJ*ZZ@%:'#$M(4:?%+K9^PYY,IIUL+02KD<Y.9/,>4CJ.&H,
M3%OT^_CXXXS0YQF.5OE_+JVIH:B% /4E0[3/!*OQ)ULK0J%0-208( D;'!Z!
M!KZ2&Q#A,1H4.,VAF/&8;;CQV&6TA+;3++24-M--@ (0A"4I2   !P!^OT_+
M$2IJ'JIU;]0ZXZZXLK<==6IQQ:U*U*4M:R5*4HDRI1))))N3)P3XRM]GFCMW
M^T.GOW'?];>_@0>F&-0ZCXXT>04M3EM3,I;%(E09K1:?:2ZXTOEY@M*D.M*;
M=:=;<2EQMUI:'$+2%I4"!P<D&02#>\WOXXM<ESJOR&OI\RRNI52UM*O6R\W$
MI.DI4-)!2I*D**%(4"A224J!!(PF=/\ 2_%=-X<J'C<-R.F=(]JFR),J1-F2
MW@"ELORY3CKZT-)*DLM<P::"EEM 4XXI2BXM4:E$Q,29B3-OWFUC;%GQ1Q?G
MW&%6BLSRM75NM-!EH:4---(F2&VFPE"2HP5J@J40-1(2D!QMA[AT'N^?3A,D
M;$CUQD5"#'P\L7X+!8#=;#J"D]B"/GN-C^O]X%B""-_O[]#RPI"RA04#!!!^
M!GPOAE6_#II8F^>S7^2T)5Y_*QC*6UK<E+AL9&Y7RXKU['K5OJKF;1YH-EV6
MU&2XM]EJ6K>8VA]-.WP_D[56JN10TZ*EQTOJ=2@!7;$:5/*  !<4-U022 K\
M5\;Q_P!I7&-5DS>1/Y]7N98S1)RUNG6\5 9>A9<;HM<%SW9"IT,E90E"E-@!
MM127>\]F*E*"M(.P&Q5LGH/3KU^'I[M^_&C9IW5@E"%* &X2;#T'UY1MMCGZ
MW1J))DDF9,<_OP\<"AY#@Y@>A]W7MT[CA)!22"((W&$*&HRFXB)_SYX3^-:.
M1\1\QEZ]NK=3*&TI]N>;0@K,<KV0MB,$N%UW?R@%)&R%()6X$H<T8RIDW$D&
MXDC8]=MM^9ZVG&1_C+P)!@$1.X![H-MQT'A!YVPYD>B ;=4&0%QU^SK2MQ:6
MENH"2ZMA_P"V76TI4"3Y""W]M#G*L= <L9! T3/B9 BQ(F!/GY;X5_%WR%=X
M@ID?T@=;&).\FP&X(&(Q^*/-UX1I1F5I42TPK:FC5[MFW7O-2;.!765E%K$O
MMC9#L8K3*_I9B&WFXI"G@X4!#G&MX0R6DJ<XI6GF$.(67"VA8'9K<::6M*3)
M.H2B=)C62 9-BJFS%3U6RVZHP521JL"$R-41(@"=Q/@<>=O4GQ<8WA]Y LT7
MU@Y-<4APVD23=.2$MJF%]#[8L)OLCCR4I<:6(J&VWTJ4VI8<)=X]%4'"U16,
MNM%AM+8D=DI+(280D%)"$%03<$:M6D\BD!.-0[4,MA(5<&)WB)Z&!MTWB)QR
M!\4.,838:>8B_7WN1ZK^(#5?/56.197D01-M8>/1VYZ:W&:6)'2(%(Q)L;*O
MD/U].SY2BB.ER6KF5!B1,PRI^D6H/ !M)2VVXL@%00)<TH,!+*-20G\,DJ)$
M03(;>0I/<@;*(B09VZ#4=S<VD3OCI%H'9ZR^%S',ETWQB_;3HFPTQG6-P4.Q
M[)^@U*)K,>RO%(]5+GMVRH5RS%?R9#"V1%K;%$]"V?;)_._%;R/+7<Q[44FI
M=0TAE3Q[BDL!)<2HN0I)0I02 I)N"!J"4V8=1)[59E28$7*3!,#1([R18D\@
M)/+$[/"=](3<3[I:[U4!.)*N(5++E2[%QP1ER7 TIUJ*\\ZE4E@%R4?9FF?,
M0V4+\QMM*45_%GL]I'F=*6IK0RMYHH93J.A.H)4K2"4$@(TK)"293I))Q"J%
M]JPM3:BA200"%1)N()) .VY@#G81CO-09=5Y!41;JJ;7;5DI/G1YL!+;Z9,=
M/F?XPP$J\M4=382MM'G/3G%MO)+#8Y5*\[5>4^ZOK8=:#;C:RE:%"%)4.2A\
M]M)&QN<4'\1="BE6N4V(YR"=743:P!),$@1C>1["'-?<;:;4WY:F4<W.76G1
M)_XAYE;+:^=I:@MLO*6EKS6W$C<(*N(*\O;@0D B2;$6WO-YZ#ZBV'V\T<),
MJ)!,<C<S<1N+<K=,77)K@@J4]RA+ZXR]DG_E(2A;;#14E/FK>0KG9#?.7$*0
MKE"22&59<FT2/B;1SVO]QN<24YJH<QTL"),].=B-C^XC,94@ \KC2%;;*?0&
MMP><))0M:'$;E"OLK0A8V)Y>AX8.7JF N1RFWG-HF>73$@9H"DD@#X>F\$>%
MIW(VQ94,[%22% %(W!VZ*2%!0!W)!!/4 C8*/8;\-*HG1L)^^EOD388=3F*#
MN;?/YG]1Z[!&([UY1S ;'<$$%)) .X)'7N.VXZ]MMV54;FY29\((Z=>NUIYQ
M&SGOK2C,@;#G?GTO:_EMC#V9_;?RU;'J"$J/3W]!V^/"?=W 8[,CE.DW\)B3
MAT5; V(^(GYWQ8,.'LD]MQT/4;$[CIUZ GY#?MP79.?^6N__  G"O>VC-Q;?
MO#%E,.['="^QZA)Z ?,#I[^![NX5 Z53R&DF=_IZCQ&&EU35SJ$QL3SBW+;K
M]>D1M;;NW<N(];4SY-<_ ,<OI1SH$F+-YD.EI0* HK0I;:?M<O\ 1*"U =4]
M@X&H6J:B<J'4-N*J"H * U-EK\.H&X@PK:^H6V!X#[2JYZMS!FD8>=9%-V:G
M%!1"7$/SJ"2" 5%/= -B4G48VY_:C:GYC59',8QV-,R2 'VX[K<UYM3H<*^1
MI+32W$'F?6E&X:\WG3LRXIQ*=STAFBI7&$FI*6'-)6"VA1! N22D0 D'F1!,
M@"<<4KL\KZ2L<30)56L!26UHJ'6TK2O4D(#:5K05%PQ.C5([CA)%X[8[H7"U
M4M+"Z?I;RGNO->7[/#2Y#;GS'5\Q,N20VVTE*5.//2 A:U%*6U#F?#Z'7JQV
MF6AMA]HTYC6I6E0;2F?PIO<P E (%Y (24X3E]$WFS+SM715*:A)4&FB5MEY
MU9F"[:6T)U**U)44P$R-6O&AS[0M.*NM19+Z8UD.5Y&TAR0MS=(7Y#KJNJE<
MA"B=E _9*5$HV,D%YYM;C;I=:TD?ATE.X_"-Q*=Q,7D0;T>:LLY>M#"V$TU0
M5)4 %EQ+D@$M]H3(41R(T['6=@]N183*R7+--&,INVZN!CF#8/C[L&J*/;V(
MHHH,R:%-M*<69/M%A+V'E<BEMA/0I)5DLA0^PQFCE*R7%5%?6OAQT?RUK6ZH
M(,J $!*$;W!)YXV_$@:J\RX:;S*J;89HLERFD53T\FH0@4K:G1I;*G O6XX
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M1)3"H/,$\K  3J&^^R>T1H<6O),5O)9D^+6/PK6;9O1%M"4Z[$C.I:9:6_\
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M&)4=BP=?<AU]@A,J?'$"PC5[%B]+6])EM241F&D1VW'%I<0MY"Q?F""#>/\
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MWRRJ<#R7"VZ\C0V0M2%(4 M) 58 W W$ZH (DM25.J6-( 04RL$R1O  />V
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M5)6RXII14-B2A12=QL%!6Z=R"-Q\.,@X@H4I)&Q(FWES\A/IN,;=E]#C86"
M0+C?E(D]-XO&_HM,?O<FQ^L9BU[<A$21-$Q?D)*2YL^P>99^R3N(<< \WVD
MC8)0HJLZ5*T,I(!YDW\1'D8 /J+=8CQ;6X=2@#$"1YW!.X!D&#&X)P[*M<,F
M:K3&^W[0IR(A#CR-G4+8EO27UE:#_2%[F#15LI(0G<$J(XEJ=7I("E 3S_*\
M#;D2.47Q"%"PM844-DQ.I(%]Q<1!-YDWGJ1B/,^?8Y1D4RZ4$)E2G ^\A)/E
M<VXWZ*)*4J4%*.Y)!4=R>*-Y6MU:B-U*'I/CUB3Z^MHA*&&=%P .74S] 2!]
M#AQ:EU64SVJ=PQZ]+,=3DB9)(1%8;92$J4"TE3CBG#LEI*4@N*[E*>923::+
MJPD3RD])Y^/EB'V!:!<2L&\B;$CQF!(Z7O:<3,\/&*,4$B?.HYWMTV69":P>
MT(C">]4OCS8CD<.M'R)"@I$=Y+[;K3H:>#H0=AJ<M0W3$A!.I8O(%[$@1^$6
MZ\R3MBCS1#CX[R0$INI4R 08,1)(',!,V$;&)Z8OEI8KY4;&VYEIDLN._-=/
MUI2>7(F.P(YAHN4S(T9YUIE)69:"5A+<:(X\\XXMHNWR'6QL0HG82D01>\<I
ML#80.5\9EVG=_JU)3:3"B"">4@@VW%Y)',0F8VF>L[UM7PZ66TZAV$EJHRFO
M0:LLU-YY!:YW5I*8QB-N1G%,S&YKK#LB1'2@%3L?SI"5)6#;]X )N-R+;3-L
M15MJ00-Q$[@#> 18&#:1,@V4(@XF)@.<6\QN/45MS)DS(+Z(KTJ3!<;?-8X$
M!H-O$1HH?*&F>5!6IQ]3*BW&4OS VA:$&\#:;SXS^M^1)F,(2MP;*-C>1!CH
M)O;_ !M!>T:T,X_E3$-VU@A^!(B-R:^<K:T:M)09F1(,=N/[2LMST2 WYYC/
M+8=2EOE6ES9N(Y2MN(4#$J!@I@B_,@P#M,6D'J<2F:U;+B%@GNJ22DS-KB"D
M\]K"1R!@X\L'TC&KMY>_2X,8UGFI>25ND%:YH[62J>SS>[QK%:;&+# *&\MV
M)2(=Q21*IF7;V=C96JF),0&PF20F8I/ENGH7!67Y>&:%%534H:<K'#4EQ#82
MH=JI)*W.Z=.A*4@ZDG2$@Z3(&GS^IS5'L_SBLR(U3F<IRRM7ERJ-E3U8JK2Z
MXEKL6"T^7'A&D)+3P!%@M(!/./)=<\D_PZ8+G6A^>:GXOB4?*\$KH\^)EV84
MD1_-ZKZE?R2PQ^BLLXRR[HZ29*D(DP:^ROK5:67EI5(0ETP(MQF]'ECJ*A5-
M14XI5,*:(+" A;J6?YI0VM3JTH)(*0I:CSD$P)W"0SFFRT4/$E6FJSE"WZM*
M2XBI?9RQ^J=30-5=;3T.74E75-MH+;SS%)3I*DCN*LZY](=N8T[N$*3MN2"#
MZ;]-NNY &PW&XV(]XX\S+IGFR=3:K7L.77UZ;XM$5C3@[KB=R)\=XO81X\L9
M>:CW_L_CPR4J&X/P.'04$?C3Z7QX"X[B% @@!7J.FWIN#T/??T']W7TQ/>'A
M/ARCF/'UMC@S@4.<QZR/7YC;?#HZ58Y295FN.T606;=/565K"B3[)U(6B#%?
MD(0_)+94GG+2%K6E!4D*4D)4M*25!C,'5,4CKC:=2DI*@G:;&+GX&QMRM!WW
MLLX9I.+^-LBR"MK&Z)C,\PIJ1=2\4A+?;.I3,J(3J,Z&P2 IQ24DB2<2S\7N
MD?A_T^;QMO1Z_M[:1(BM_6J+5V&\KG1'0IY])B,-(9 E%;21SJ#[1;<#;"BI
MOC/Y+7U50\MI\H)(*@E$G2 0+]XV,V'*_P"*)QZQ_P!H;V&\*>SW@6ASZ@6Y
M19F<U.7FB=K6JQ%93*:?=:JF5)IZ=;=0D,)-2@)4R.U 3I*0IWC->R#?^(2H
MJ&R51L7KF9,@;<P;<9B/6B%C;H"9,Z"T21NE0 [@#CI"$AC)75BRJAPI%X)!
M4EL[\M*5FT"/(X\BTJ11\'552HCM*^H6VV=B0IU+!&T_@9>5SD'QG'0'PW5.
MF=SJI00M5I;\3#E/.KLA'=$9Z66H[CD>"F5RD1/:I"4-*>VY@@J0VI#BT*3A
M,Y>?8I5+9@* 2%*,D)DP57Y 1>\3?GCK'^SKPIPUQ?QK193Q)4T[-.\U5*9:
MJ'%,MUE6TRI=+1J=2I+B$O.#4K0I+C@06FE)=<0H.5XOH>AT#/66M$(DJ!0F
M-S28<F<NP#+WGN!@(D.CS%.&/R>?MRME:0MMM <*.(N0U+[Z' \OM0DP7 .[
M,"P4.AF8L)'B3TG_ &J?9_P9P4KA]&0^XTV;5=$ZO-LNH'7G*=I3:T)8JVD5
M+U0_3IJ];R0TXZH'L-20#J48W8I23<BN(-36L+DS)\AF+&8:0IQYY]]Q+;;;
M;8YE+<6XH)0A"22H[ ;G;C3N/(IT%U2@$@$DFP@#GR  'RQXWRC(Z[B+,:;*
M<O9745=8^W3L,M)U..NN+#;;2$)DJ6M2DH2D7)( G$J=4_#7J9HA IIF=T3M
M,U=1VI$3S'X;Y(>8;DM)=3%D2"PM;#B'VFW@V7&5%;7. H!C+LYI*]:D,K"E
M(WLI)W(E(5!(FWGO%IW?'WL.XQX"RBGSG-J-L9=4/+HTU--54U8RU6-!2G*-
M]=*Z\EJH3H<[BR 2TZE*B6G EJX3R5(Y2LIW&_3<'?H>IV^??;IMUXOT@* ,
MS^FPY^%CM-CL<<&<*PJ+CE %XL"8V]!'3?&,E&Y'VB2>@)Z^@]2?7?KUZ]>O
M!A((G;PF8@W^/CA/:+@;1/S'K;E /B<4N,2TE8W)] .W3;J1TZ$'<]_7KUX.
M$S$0?,W\KWCPPDND[J,@^:>7/E\;G;&CE1G%!73<$@]NH'O]-R1UV_=PA39D
M%/D /+GR G>W2(Y.H<&RCR(.^W0;Q/Y>4IIZ!LM1.XZ^X@;[>[T';U'7UX:B
M\$&?^(0;;28O/A(B\3?#J5$BP"A.\GTD"_/?Y[DEUQP$J W!'7]_;Y[ ;;>_
MX\"!M C:V_*#,<N?U-Q@PX9$6Y6,Q<0!]3X<SMC4N)*2>@Z @[#8A738#UZ[
M[[?'W \-D08Y3(!O,&TXF-+)($F)N.4$&3U@\N9$VP32=UGH>O3;W=O0G]$]
M>_"!<WY$D$'>]^7(0#O\L3"0!,SSL=]/W>.4X%?84I((ZD#<;=OT3\]]^GP"
MD@S  Z?OZ6VMOOAMIX2$JL">OJ+[S)Z@84FG3BV<SH25%L?6,=KGW(Y2\YY/
M,2G8CE#G,2-SLGIZ<2LL5HK&B1,N)20.BI2?#GY8K>(Y5E-4I%UMM%]$;J+!
M[:!YZ+09!\;8D9K="6WD#<-UCRE(;9D*"0I*2B5&CK04\^RBE7*M:2KJH+Y]
MOM <7>:#4U3:;W<,DS?5I,^(C8=(G;&<R]*D9G7.KA.JGI$ <I ><4J-[]HD
M\M4SN<-I75B%A(*=O0 #<JZ=?X[[#?OUXITMGF;FYM?PCKX=,7:W](M?H3M?
MH!)D^)\=L/YIK1QVH=Y,57*E)9BAH2"E*FV9TX*9KFE+4.1"W>682=^K33J0
M-MRBWHV2E,@A!4L6F"I"$E2Y,W"=23YE,&^,]6U78O5%<^"JGH\M<,@2$NU#
MA"=N]J4EB!S("@!)PR>2,LMV$D,) :\UQ*5#8)6$'E#@Z[;.;!8^!^&_%?6.
M=J\M1D@DQ/38;CH)/G\;#)$N)H6NVD/*':.I(@AQTEQ:=OZ"HH&]D@6PA);'
M,20/P[D'TWV/S[]N() !,\]A!$1-R!R VZ^&^+L&USL#:PL8$3!GR\)Y8*JA
MA2-]BD[;D<O?[^W7T&VW7N>G!0 ;BTQ,Q\NOA\A?"M5Q!(/A>#?KN=A:/,XU
M$DO-;AMQ:2.J=B=A\=@3W)[?EPAQI,  6Z^/H!RP\R^H+$F0#UCZDWO.-6JU
ML6ULE4EX^03Y:5+4I* 5<Q+8/1/,1N>78DC[^("V!J,)'>W,P=K3U^?ZWK52
MHH$*) $@3(%P;"1!GD(G?GAX\J\1VK.9M(CWF63Y# ""66PRPRM:*WZI+BFV
M6TI6ZN!_0N;@A0.Y *6^2(JB;()A2AXE6PO;IY[D0.1)L$9J\"!#:1,2&TF>
MZ$R9DG:1-@3( BT.LOK/Y09'*D&$TP5):+OE<Q2Z[[.CS9"N8DAR0YS/.)3L
M$J60@!( '/LSI^QKG4)$ +D3S"H5Z1/Q]<=!RS,"JB:<*S*A<VC4#!B!X&!$
M[8>JFP+$W8-+'?FQR@5C2G 67.3V@0(DB.EU24=S-6^P[_DH0 2K[*BK24M&
MM5.VKLU$!M)&E) ,I$6!DR18CD9YSBI>SEI#RT%]I*U+(*5+ -B1O9*2I,0"
M1)D38@:34'2"II8;EG%FQ7V$-3'X;T>0TM+HAJ::7L$G<;N..<H6/ZK9*>A/
M#-73(;;4J(@201L -0\K#^H"9MM)GT.9N+<2),:KD*%[PH@S!@VM8'?$8:['
M%1&"^A)4Y-=6EI(3_DA6R2" .ZB   1[MNW&0*"I1B+F=P(F\1/H,:!VK"H!
ML$ &>IM)(/2)Z;6YX7T/2:^2M*F6WTS7U,L*;0A969<I+*F64<G5:2'B$%&_
M-L20"4\VAI*'0VDB0HW62.=CN0+ &WQD8BKS)*B 8*2 4G>1/03)GE&Y(&]G
M"I:/(<3DNQ?Y4834RZU;L1R)/U(PBKM8<I*G ^W,K9^21IT&8T_S,S8<EJ._
M&6A3;S2'D;)MD9;60"BDJE((!2I-,^H*&X*5!LI((V()!Y3AU354H BE>((F
M.S58'D1 ,]9O,B+84='D>3X](=Y<SP=]#S;$9MQC5+3X&,RM[GD*2I&6-EPE
M)>*P\%@AQ+93NI/(X*"N"@H45:#O'NC_ #',]F1._.#8;80JDJ5I*/=G=/70
MH>,B;QTD S!@;"4F'^(IB Y->N$:2S)#TI4B4^]J-IY'D38=?2IB0X[CR,D"
MI4E4YEMYIQ941RH>:Y7PA:7TLYD+&AK"!:]'42J\$DI;$R/A),0,05Y(ZM4B
MG?1$D")$W,#5.D&;_P!VQ&)<:4^-+%6LDJ8>19-IOCE5&G4S"+1G5# I4:)%
MB5K\F65UDK+O87VY%B4-!UYL.,2 U+2M+K9#KZ6ZX1JH:T@S)%'4R+P/_#Z>
M(.YL2(KW>'ZO_P .G>GH4 =;DI@3-]CN.@Q.&I\2'A1R2S9R2PUCT#IW,O$;
M'\@@'6C"Z>Z%8V1$38VDMW,FJYA<=Z+#G,J6$.(8+CQ?6ZQ':+@9JR/^YUG,
MWI*BW@ 6A^MS Q#5D>9;>XO[ 2$*,]?ZIZ]28$F-HUZ^^#KZ*OQ-Y]?ZJZB>
M*O2Z%G$NNH:Y+>,>*G22LKI-115Z*>O9G&\N;I<VXAQ8L> F1$FML&JBP''$
MONI>D.65+79M1MAEJEJ"T%*5"Z&H40I5U:2$#NDR8(_$57B,75#4<14%*BE9
MR\J;:U%L.4SJE)"UJ6I.I*T:N\I1$@F\:B  &@P?P _1'U-K2,V'B8HVV<2R
M:GR=G'K7Q;:'66.6U^XB 7'%6%$^@NUJ?8HD6Q]CGHE+C-+:"XKJ2LRG,WSM
M;2FO=W0A168% ^"G4-)4)2844@;B! D'!FKX@+[E4<G2BI6PFG+Z:6H4X6D+
M6M"!_-*=+;CBUB4F2HF"+8]#$;/X$9J-*B35S8\Y2GZ@1VY;B94!E3;$VPCJ
M0Q*9GU2%O)D1Y]4W(95"+,A(6D^:K+JIT+_I3,7D@CG @D7_ #D7MC,FI>96
MI"@MM:5*2M"TE"TJ22% I(M!$$1*8,BV#4+/WKAM<R-*JA%+@1'<4;L"0WY3
M3BGFS]7,I6V77'&T+;"VR&]DN* V2RJ@:G\/+D!;STF)BYF][X=&9N1_J0.4
ME6WJ/2UO6<>'P#RR%@C;L>F^W;KT[[ 'J=^A/IQH1)^-O+QGY],8\J*@)%QY
M?YZ].7,'&\K7W@X@LDA?38IYM]P2 1MM^.W;Y\.:4N(A8!'.;VF#O,_IY8%/
M4U-'4-NT:UH>2L%LMDA05N((O(,1L9@CEA7VR,CD1D2;!,QQGD"4.O\ F+V0
M-]DA2^P .VV^V_;;H>(]+3T+"U"G;9:43J4&T)05*ZG2 3!YW(FT<MCQ/G_'
MO$=+3/<2YCG.:4],V&Z968UE55I9;.Z&C4.N]FFUTI@&+@P<-TY7P!.58"%$
M%@651U3O9F1.+"B@J85*Y/.+1+;9+97Y9*$;IW2-IQ4O3HU*""0K1)TS$2!,
M3$WWN<8<//! I^U<+,E?8ZUEH+ ("@WJ" 0%*A6F0";WP56IUE16VI2%#W$A
M6WN'4=_OWZ^_B(ZVE4A0!!O'+R/ER^AVQ:9?7U%"M+C#JVE@@A23I((.]MB#
M,<P=H-L/AHAH9J'X@<G3C&"U3US;>0Y+<;+C;34>,T0EQZ0^^XEMML+6E(!)
M6M:@&TJ/05E55TV6(2I8"$F$A*1N3>$I !V$Q$"#..K\'\$<5>U2LJ&Z5T.I
MI6O>:VMK:D-4U,SK2T':BI>5"96M#:$ K<<*M*$&#&YL\7S'P^ZCMQ;-E%?D
MV+V4:6V$NLRFD28KB)$9]IYA:V'FE%*' 4K((Z$)6DA,ELM9M1+2@DH<2I-[
M0%"+A0\[7Z7P5?E?$_\ L_\ M"RJJS2C:1F.455#FU,E:DOTM4TAU#].XAQM
M6EVG?"-)*5I< UH/9N-J"5YJKXA<WUA%>QD,Q]YF$D!IE3KCC27"@-J6 KW(
MW0D=2E*BD$CAG*,C70/*=<>"P 0E*&^S $@W[RBHF!%PD"3!)QO/;E_M.GVJ
M\-4/#>7\/4^1T354C,*SLW_>5U%8AIYI!0I-/3)9:2E]U2DE"W%J*27 $D+;
MJJ84L JW&W7X[GEV!'J-_0$=-CTZ<:U)(3L9Y"T[F-^L3)Z\X./%CZ^\3M$]
M3SF\?*XO'3&S7'65 @;@$;;]1^1_:/?V]%@[3(WM!Z^5O6,1^TVGO0/B?,<O
ML>.P;:66]R-P =]NO;OT_;V[^[?<X@;;DQYS>?6>F&5* /*\<]A;SV!Y]-\
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M@;GU'%\$29B?$[>O([^)QD5O!-R8Y$3\_/ISPJ* -0K"*]*0%,(=0IQ'_P
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M5-52,HS.MH/>63+3_NE2Y3]J@7.E>C6$FXU!)$IN05%\L]!S [D'H1MV'O\
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M=AV&W#:D"=@1\8\#\<2J=V003XCQ!Z"1!_7;? .R%#L.ON(]_P"?O[=NW""
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MP)@0;^'CX?/Y;1AJLFF+Y5 = .FW8>[T[?W^_A$_B/-,Q?F2>OWSB<2$I'=
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M&77MQG'74LU.(7D0QU"2CREF:EPD+YFD )*JRIS%BE=#+B75**4JE"4%,*)
MNIQ)FQFQ\SB\I<CJ:^G-2PNG0@+4@AQ;@7*0)@(96([PB538SA@=9-)<CT1U
M N=-\MFTMC>4;<!<N7CTF?+J5IL(C4UGV9ZSKJF6I2&GT)=\V"T$N!005I 6
MJ8T\E]M+B00%3&H *L8O!(Y6N<5533.4;RF5E!6F"2V24F?%24D^,C#/*4GF
>(V/0[=0/4 _OX44@F8!]2/H,+2%18@ _XZ>&/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g99471g20c03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g20c03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1X84&AO=&]S:&]P(#,N,  X0DE-! 0
M    '?R^=G8X0DE-! 0      $T< @   @  ' )0  AR<C,V,# S,AP"!0 T
M36EC<F]S;V9T(%!O=V5R4&]I;G0@+2!3,2!);6%G97,@9F]R(#<N,B!F:6QI
M;F<N<'!T>  X0DE-!"4      ! )+8H1BD1D^-XSNWF3K3J(.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      -!    !@             ".0
M _4    & &< ,@ P &, ,  S     0                         !
M          /U   ".0                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   ".0    !29VAT;&]N9P   _4    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   CD
M    4F=H=&QO;F<   /U     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,     !.!     0   *    !:   !X
MJ,   !-E !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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M]Z?+&8BR1]"H&^_V.RYCW6,<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M';@=HGQ^7ZX5[L[_ ,OQ_;&'YM&??TCBO]86G\EX;)U&?AY?$X;-&\23*/\
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M7BD8H=.8DG&<.U%9S:MCXQAL7)7Q9L'(<33RIF(42+BK6&O7&4RI;\B.[$2
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MYGP+=3\!^N![Z]T1_I/_ %8K\Y+4+_-L;_JV9_,^!;J?@/UP/?7NB/\ 2?\
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M]C]\;!'_ (J?7_%?V?V> P1( D_WP'L8SS\*5&9?<C')CN,MR&MD<:)P"!'
M4D44,%+G!"W151$7=%X0H=X& 1SG:U[_ *\L6N1YJYD^9T69MMH<<HZABI2V
MZ-3;A9<2X$+2-TJTPH2" 3<&#AD=,],<SQO*;K),MS9_)SF,E"KH;<1R'$B1
M"?9?)YT')4HW99JPTV*H2-L@CB(KG.*MJ4Z5(+=@F0HF+R 0!N9,'F>1L(QU
M;VA^U1'&V69;E=-DM/E-/1N"H=[-8<4[4=FMONZ6FPAJ'%D@ZE*4H73$JD4
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M<U3!Z[[#VI^T:@XV7EK659.G**++&7$-MRCM%K>T:K-C0VT@-I2E()F2HZ1
M#RBJ\ON5.B;^'P_A[_KX;QQDCO=9N8'QC?S_ &QN+=50?-/%?GMNO"$P 5<B
M;#G:?GB6@6)Z\O*<$U_CU;DM7,IKB*U.K9S7=28KW,@.#S(2*A 0N-F!(A@X
MV8. 8B;9B8HJ'K'*1\C>WESYGTC%OE&<9CD=:SF.5U;M'64Z@IE]E6A:"9!@
MQ!24E04E<I4E12H%)(P487@6,X%7E5XQ5L5<(WBD.MM&\\;T@T$2>?D277I+
M[G*  A/.FH@ @.PHB"%+VDS%AMYV L+G>)ML=Q,S[B;.>):P5V=U[^85*4!M
M+CQ2-#8DA"$(2AMM(*B2$(2)),$DG"TX+6.AQ2:QT.*X&L1L9^4_'!=IX?/]
ML5PV5$[_  P@DG<XKA6M7@?OPC!A2AS^/W.*X6E4S._Y??Y86E4V/GC8!>2_
M5_#A6%;??R_3^V-PDH^*;IY[>_SVWV^']GCP,$4S'(VN/OX8$"XBIU7Z_-/G
M^.NWGP")L< $@PKX\C](Z8V*B%T7S3IU\4\_G]Z>'#2DZ;C;Z>?G^WFH$@R+
M$;' =(C*.=XH)SHN^^R)OX?9MUZ)U\U7KPF=K;?$^?Y8D)=61!6J!RFWF!RW
M\IB,"MNGP\/Q^-^"P1!((&_K^6+(N_P7W;I^[@89(*3!$'%E 2ZJB+\^#D_>
MWPVP6"^U<FL5TMRK%LYXQWBB"ZO*V<A )61,T0E$2/85+E+E1>945$5.!8D:
MI(F_/Z^0\<:/AFIH*/.,NJ,T:4]0-53#E6TD J6PEP%P)![LZ+@& 2 )$G#(
M:;7NK^1Y7>S<ZQYO&Z)E@8M?%)^"X_,F"ZRBR66:^3*89C-1VC$C,@-]Z0)"
MA[&HO+4V4)2E/>"@=1YI -N9@D[$\M@(QV'VL<0\"9CE.4T'"RUU=4RZIY^K
M<:<0IIEQ"@:8N/H;<5_,*%! 24-I; D2)D#R=-ME7HGO\O-/=]7#,'H?@<<!
MA(,R ;\^?QP$^CX_>=ZK*<WCOR]4^O;Z_+@X.^F+=#\;X7VJB-.LD<AJ\<"D
M1$Z(FR=?/Y>7XVV^/"<-+&QZS^6+HBEOM[O)?EX+OY?CXC"V6''E=Q)5%[ \
MH/P\<6W3?;?K^.GX^._Q'W]_#"7FUMJ(6"#M!!!$<MA'AB_ PUBOQ^/J_">'
M PZB(\>?W]\\;QVY4]VW]_#Z8TCI']\-JG4>L_VQI5=U5>&29).'@( &&)[1
MFD,O6O2K(L*I[EO',G>;:G8KD#PO.,5=Y$)59.8W'7O7:^8P;]?.!L7#"/**
M0RV4F.QQ,R^L]RJ4/E':($I<;L-:#O!-@H&%),;B#8G%9FM#[]2N,)7V3BAJ
M;=@G0X#8D @E)$A0F;R+@8X$8IV"]1]0-<[_ $:L^U9H9<9EI^WC]]JC@>-W
MV2V6<8WB]Z^BLRUJI%!#CK(=8[OF:*2BURSZERS&(%M5E+Z,GBQRBRY-4QE%
M2RFI#C5'5NEL4Y>0D@G8E>@RI(,!90I()"%QS!_V:U-=5L.5^9L*HPZA;[;;
M+H==;2K4IM"U* 25@:2LR4!14 2 #Z$I?:FTN[/V!UFD6*LQZ.BP*L;QFKKC
MY D@%</</2)BHJ*[/FO"<F8^6Y//.$2D2*BKBZ/+7JQX/N*4XIU7:*6HE16I
M9U*429)*B9)))),=0>AUV<4N64GN[24-(9;#:&TA*4M(0 E* D0$I2D)"4@0
M  !$#'/6=VLJO6#5"OTX<27:56HYOX/.;JU1RPB,WQ"U%N(0[D(R:"P;B78/
MF)(PU#>(O9-S?;YEDK--D:LP4M+3]"MMU@J  <*UH;4P4W)#H-HOJ2#9()QR
M[*.)JBMXI1E+;:WZ;,VWV:@(NIA+;3CJ*L&0$AA28)(NE93=92#%B^]%UVPY
MUO/D0M;M+WH92'4B.R967Q)+L9'"[AQ^*UCDMN.\;:B3C(2I(-FJ@+[J(AE6
M,<5T+380<O>)%S"VR)@3!(!CS&+VHX)S-YU2QF=/!VEER8DQ,J-XW ) -ACO
MGQSS'1,5PZ$#G\OI]QAP(M<W^GG]C%E1%Z+PDA2=OB/SPE22GRZXPY%3]5=D
M]W5/X[\'K!W3]#]<(@'< ^F+[$G5%W^"^:?6OX]_ E!M$>-M_3\YP"E)Y>L0
M?SQ7,J>(K\?=^S@: =E?G^>$=GX_+]\5SBOC]Z;I^/JX+0H7'IR/WZX+01M!
MY6-_7T^N,5!/$43SWV\_X^?!A1F%?,1'RPVL%6^XZ_3PZXP1.9?/9%157PVV
M5%\_QT7A9,#QY#J<(2A0()$>?.W*,;FA4B5!3JJ[)]_G]F_!*%A)L 2KS'V3
M;$]M"G%!($DD#S,<MOVWP+>BN,B).(J<R;CNBINB^"IOMT\>J;[KTX2E:28
M@; ]3X_D2;^,C%M49/7TC"*A^D=;9<_ XMI00J;]U:@ ;7CI<6P&X2H &UIO
M\SBG58GEBN$X+&!$N_*GCT^_;AQ*1&H^/E;Z[?M@;3C%5-/%?V<*&@[ ?#]L
M$% [?G^F,^9$!2)=D1%4E]R)ONOV)OPV4PJ!SVO^9P>.+$CT^/8'_**7C50[
MK?E$YBPEU\1S&]*GIS-N<-QT2D5,>1>PK5^.Z#)OL]_6Q9/<)SNQFE0A'<,^
MS[B!P(*!2!:T@ALO*4X)&HI(0TL%0YZ5*%C!(OA;J44S2JBH?IZ9EL K=?=#
M3;8)"05N.0A(*B "5 $D#<XV1_3Q]B:75K>1,:[2<JE1WN5N(^C+KU6CWK Q
M.Y6P:R,XB.^MF$7N^^Y_6#%G;O%05D#V=<2%':!NE4B8UAQXHF=,:NP(F2!$
M[VWPTNMH&G_='<QR]%44ZO=E5C"*C3H+NKL5K2[I[(%S4$D: 5SI$XI_T^/8
M.K+B+1Y&QKSBDR0[%!U<DTDD5Z06)3@@,Z9%"\D6:0P%2=,XM?*>-H"]78>/
M8%0[[/\ B%G4%HI M*9[,OK2LVD !QE !.PU%*9Y@7P_3.L5C7;4=335;,E/
M;4[[;[14G\2>T:*T:AS$V.\8[31Y+4AIJ0P:&R^VV\TZ._*XTX*&!IN@KL8*
M*IS(B[*FZ)MMQB2""01!!((Z$6(PK?E(M^M_LS@>V>_153?[-O/IOOLB^"\)
M(D$=<)_"8Y&X/3G!GZ^/PW^.R_C\?CW<,D$;CUY8<!(,C""U U*I]-*9;V[B
M29$!2<CJY'111F0XPZL577.Y>$ )\1YN<-C%":$P-P"0TMZU7(  !(,W&Y,3
M>W0&";[8[#[*.%\HXHS.II,QJZ6G=;90]3M5:B$5 #J$OA(2MM2UH9U%"4K$
M*4'"%):4"&TUS5W/\:B9(==(KFI[CY1&Y31,N/Q0=5MF5W1JI@V^B$K?-MS@
M*.AN!@2O.(0@G0K4(!OR5\.D6,&\$#&=]I.4Y/D?%%?EN2OHJ*-@M]YMP.I;
M=4VE3K07'>"'"1,DIU%"E%:58<;P39/E\OQ^/?Q'WQ@4IGRYG&:!S(N_@O\
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M<\9?C\?;]_"D1'U^_*,!$0>L_+%MD]R?8G"B)%C'CA2A,7B#.+\  #;[\\&
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MAU_G.GF3XOC-PM#=VE>K5;:*A$U'D@\W(;&0@"9^K2.Z6-)Y ,Q8><(6W51
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MQ!%55\.OU?C[5\.(24DF((^4'U^>UN>&R8$GEB(&JFJ6*85J3$NW9@2[&JK
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M=.W4.H9=CM&DN+2A<&1J0"$*(,$2#%NF#+NA1M0'9$VV3RZ)MLGUKXKTWWX
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M2UK+IC^9'9 I!O,F28BL_P &\.4N9JSZARV@&;4N44V5Y,E5-2BGRE% BO\
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M2JZX9D8O#PDM6V@?W$W,$3TZ'J,.>\N:K+5,C92@.H$3:1XVO.QQ#?MO=L+
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MVOM ((E$FUU CJ=N8YP(VP/Q.6]3P&'*$'&8:,^K/FT9$OK+P&9A*5.@NO\
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MT^'Z9Z_'CS20A@.0@D-Y#I%!ERD>-EYF;ZKW1R"$5=>)E>4T*R3-I)%$HF"
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ML*424.).@242GNE, I!F!!F,,C5>D6K<PNH4'*:M(V-%DMM8%$I73C/3VZB
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MG-"^S9GN8YM%H9=;8T<>/,6/<VMC#>8BTXM&0N@Z<A8[+DHE$ABP4?!V4ZB
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M5F$I222K8#<S?8"_.PQXXR+AZNXGS6CR7+67*BLKZAJFIV&QJ<=>>6&FFD7
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MMMDH_P#24=_90MM175*V*8K3^(]U).R2J8,FW1(VO'(@XYKDN7MUV8H:680
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MML.+)FNR1,A9Y77.Z%ELE,V" E_2]XU0YSFU;25J&:="-$!:UNZH(*BG2(4
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MX&R<);0%500D7RY?=X^/1.GUJO3?A);0=^6Q@;?J?(WYQA0?<092HSOS)^9
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METZ 6W%:AWDC25?B%XM))$ VM B1O\LXEIS1(34+*7FDZ?PJ5VFFP@IF5:0
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M)M>-/LEXHFZI]W@O7P7;;SX28-CSP_J4DV,C[^O/;S."N3#(R513I]OGOO\
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304@F;^G]L20; VN)N ?J/#'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>g99471g45t26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g45t26.jpg
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M2B+QC?I3G_C;3'_T_;3_ ,V5KVSX+?\ PK6_[Q'_ )9Z^??A5_+K@!_>J?\
MK%9>7/BM-M* ./H^-316'.)I(YURM>(@9';5F *2X@./>JR&LXQM$C,(T<E,
M?B\IF6,A!Z[.1XE%E&TW<%?HZ21XABO+(QRVH16GW'/BXP1,AT\%[/""^/;N
M3B>2NV)[(WO9%L/G:\/S$&Y8\8CD]N:0&^3)+NG&#XHQG._&<X_/G>.E4QK%
MH$PY \=I*>4TVYX_;8UIQ8TMLE=AL+4.;V/)S[CQKV [>ES^/-SA$_ IKK^2
M>-DQM.)5&&C./;'CS(Q(5'=W&;4GD9)G4[L;/"1<K3ZA:@#H;.'\5=GFK1AY
M8UDT4T?%Q\5'(2^!Y:P#&6L#:;^+LD-!WC=EH!.,[B#DY(W'>?SY ZPV%I2=
M:2FA8M'=00H:<V3S+&VCKZ:<>Q;6!0-CQCT7%^.3.2PF; <-Q[2'!#(PLA#Y
M%K$R&F[Z?C)-+F>4CGQ!TBYT[$%F&U$UK[,KF0::=ML5QSII3>MR72R:)QK5
MR]KF\:R=CHA$YD;MB)H(D%I!W 9+]V6[@&C9SD9=OST;\Y.\K&O9?TW&M?:(
MBZ+O0<MF3^2:?D061Q<MQUSBVK$&<$<-!^MN\-S3XB47D-R["2<@)9M-B.C%
M]HQ=!+P@N[^F);)=V#8?-;D(N1Q-998]DC;O&3DS F?.R T,V',IQP%T@@D)
MPT;,;,3T ;B=W1LX&[HZ=^?ZQ/E'[3^RD*&\?>E""@R&F,H\Y'GRL#62EVF<
MFQ+!GRQU=,0:6G3RQFZA7//5S*7N\PVKB+I5^%;YB7[%RM@/84C<[B=!>]MG
M;#F-E'%V<MSIUB)WA+ WQ?PYC&U.T ..TT@9*DXS)C&/)O']L$8_9G<%KAKF
MU6MH?0J?TK?!']O\6_P7]<%PF_\  -5_NC_XM5D7RK/T@OZXM?/BY1*(E$2B
M)1$HB41*(E$2B)1%"_)#^;OOK]B^TOW'.U9#\K%^L9]8*J?Y";]5)]1RFBJU
M:E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(H<X[?S?M%?L<UC^Y(2K)OE9?UC_K%50?(0_JH_J-4QU6K4HB41*(E$
M2B**M[?R(;D_95L/]T3%9Q_*1_IM^L%5/\A-^JD^HY20-_BYA_N37_ 3K%W2
M?G/\58WH'S#^"[M0I2B)1$HB41*(E$2B)1%IKZ3[^C]Z2/\ OQ!?\JXT5V_@
M1^5.A_IV/\O<7G7PF?D)PI^:I_G=-4F="Q_1D<7?[+V;_P Z]DTX>_E;J_Z=
M3_(5%G\%7Y <'OU>H?ZM?6TBNH+T)*(E$2B)1%Y(/TA]F)(<K.%S \%&24$^
MC#QF:CAI-RJ&/B7.QQ:)$*629NF3Q0859YK,7Z;5XT<YM5U<4'3=6^*N'MOP
M5Q"?3-:A+WQB:S%$9(R&R,$E=S"^,N:YH>W.TPN:X!P!+2-R^>?A:>8^&O 1
M[<$LFK/ .\$MU:N1D;LC(W[QN6-$9XC<496'0+C>"O#!')^4,! @I^+VJU*'
MRH$4-,$V(O"^S\V7?TF1<?='%^^8V>.'.#5G=PXZT[=TLZ#0JS.ADU?A,>+B
MAGFECGJ/B@BGEDAB?*12V]DOADVMAC]AK2]^RW>O3X]5O2L#VQTAESF-:YLH
M<]S&A[@W\+L[FN&,N&2<#)5()\6., K%\LOT=?%]PQ&9"TWY5C#MN/!#1<RR
M'OQS5P31VEDS1=.$2C''!NJK@KDLX32QQRRSP[JV+@[IDNP&\(=;:^3C3'%)
M?HLF>V%\D<CFQ.I;;F-=%(2X C9:22 #C%^K7V9S7KD-V07-BF+07!I:-KC<
M9(<-W3DX77<\7>,S-0NB[Z-OCDU5 -D'AU)SK[<R"@1HZ3R6:NB^"NSL<AK9
MREADJ@N\LBDLGCEFGEEC:][9-X.:6\0EG"75GBPYS("W4]/<)GL.'LA(ID2.
M:2 YK-HM.X@%0=7U ;6:D(V "_,$XV 1D%V9?%!&\$X!"JQ?B'QT"R1U$W71
ML\;ECC94E@FT8P+<CRY!N)=JLGA(5WG9V61(5@LCGW!)KBHTSPOCG92ULK53
M#H6D3UF6V<)=7$#A$2]^HT&<6Z9C7LCEVJ8XN4M<,QO(>#NPLG:KJ+'F,U(=
MH;6X0S':#207-Q+XS01^,-WYU8?D2X:6_AX$<3/=S:/S9K?^)]?MK7_\74^P
M*GEVWZ&KW<GOD\B?#/U".)GNYM'YLT^)]?MK7_\ %U/L"<NV_0U>[D]\LK.#
MFIN+ ;EQH$K#^&G&R"2=CL,2X"3"* MAMI''GV";CO1$.N3V25'I/4;7RLGD
M['/$;6RR[I'+]75U_A5P7AJ<'=7LMU76IG0TI)!%/9K/A>06^+(UE.-SFGR@
M/:?SK;H:Q9GN5X7Q5PV20-):R0. .=X)E(!^<%>P^OFY=S2B)1$HB41*(E$2
MB)1$HB410OR0_F[[Z_8OM+]QSM60_*Q?K&?6"JG^0F_52?4<IHJM6I1$HB41
M*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B*'
M..W\W[17['-8_N2$JR;Y67]8_P"L55!\A#^JC^HU3'5:M2B)1$HB41*(HJWM
M_(AN3]E6P_W1,5G'\I'^FWZP54_R$WZJ3ZCE) W^+F'^Y-?\!.L7=)^<_P 5
M8WH'S#^"[M0I2B)1$HB41*(E$2B)1%IKZ3[^C]Z2/^_$%_RKC17;^!'Y4Z'^
MG8_R]Q>=?"9^0G"GYJG^=TU29T+']&1Q=_LO9O\ SKV33A[^5NK_ *=3_(5%
MG\%7Y <'OU>H?ZM?6TBNH+T)*(E$2B)1%Y.>G]"E))S,X(QT&S4(FCS%N%$#
MT;IXK/BA3:@1B/9I9*YII8J.7:Z*&%U%,$[99VOGGCCUY6]M^"N:*OIFM6)W
MB.&"S%--([.RR**NY\CS@$X:QI<< G W KYY^%MKG\-. K& N<^:NUK1TESM
M6K@ ?G)("O1CQ6YQ"((C!06H-@@V>9^2F2S@3)A;!,XVD86-A<Q)%DT-H8+M
M6J %QUW7673<I%G+;-NFGCG=QW1_"K@/-?-^?5]/G>*]:&%LM660P/K3V9Q-
M'(^!Q:YSIV_BM:6F%K@XG&SZ.VAJS(.)96G8#(][BV1K0\/8QFR6APR &=))
MR'$8QTRV!TORTCZ3ARUXH'5#JKX&[P)K'X:JCDF!7UZZ:-W-EF*IVR5W$"P[
MZ@(D@9@X1*Y>&L';L>V>Y\38UK@G8+6OX5P"NUD[3$*]P.!L-U!KW,+7B#.S
M?.'35II&F(;$C&2.8-IE?48\N;IK]LEAR9(B#L<20""W;Z8AD-D:TAV]I+05
M;8OCARK QTY%PO&B?I#7[=_@(=%97KD\:&+EP1T"53<E"<75OF*=-C:ML6,:
M;Q!XFED03S*KK%7#G#9EX1\%9[$%J;A+0,L;XS*V*IJ->"5L4]>>(MBBM#$K
M'0#,EEUMA(C(B:(FL.#:>HL8^-M";9<#LETD$CVES'L=E[XR=DA^X1B(@;0V
MB7$JL/\ 07*,@X.)J\6-A)BI-())+#:"&Q(PD6L?DDC@<D6L&,8B;8# C1U
M!J" Q<:2=YIN55E"UW+,8LRJCU_@O&V CA3IYEJUZU2 NTZT8O!ZU:_6''0F
M7,L[VZA*YTK98F M:T0ACY6ODU-0.V#I\VS(]\K_ ,/'M[;WPO\ $=LX:P&!
MH#2UQP3X^0TB 3G"'F&>-&#CK1$A0<FBA LX1:.(ZBU17(NUGBR39+Z;R[TW
M346RP13[K+N$[8X]U?JZZYZ#AOP/@AA@;KM=S88HXFN>VPYY;&P,!<>(&7$
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MHB41*(HJWM_(AN3]E6P_W1,5G'\I'^FWZP54_P A-^JD^HY20-_BYA_N37_
M3K%W2?G/\58WH'S#^"[M0I2B)1$HB41*(E$2B)1%IKZ3[^C]Z2/^_$%_RKC1
M7;^!'Y4Z'^G8_P O<7G7PF?D)PI^:I_G=-4F="Q_1D<7?[+V;_SKV33A[^5N
MK_IU/\A46?P5?D!P>_5ZA_JU];2*Z@O0DHB41*(E$7F%Z9/^DOZ+?^_VN_\
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MW-PA@TSP5RQ<Y+HXHWSNKA;*-AW1C?YMR<8S&=H8.,'R'/1O_/Y%0)9R@T3
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M?/\ N/\ )48CR!U*'( !)>7,!965/W0J+C".7@)"2%&0I^>>C0+)S=)R8?M
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M-))+9I'$@EV[\&YH R!N#?ZHQGOEKJ;88Y991U];'&U\LKWNWZK6M;KO>_\
MVW^RUNNM?;;Y_P!Q_DMW8=YOWC^:BK9,.*2+2&\7Z.2C,:*U%LIRX(6M>U[J
MH0HTM@U:WZ[=VXS[G'N[VOW*">7?%.N^22:N;'8EC'E,C/V>,%5*TF&;R 12
M;_\ T'H_/_!;+\;=SC:W7>_5:UNO*_7E?JMU==[_ *NN]_X;WZOX:UEMK]HB
M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1%#G';^;]HK]CFL?W)"59-\K+^L?]8JJ#Y"']5']1JF.JU:E$2B)1$HB411
M5O;^1#<G[*MA_NB8K./Y2/\ 3;]8*J?Y";]5)]1RC-M)9!BW0QQ,$,<<44L<
M<;.5+6MC;#&UK6MW7ZK6M^JUJ[NRA2+&$UH22UI)V!O) )*Z&_4;P>\"U. '
M.  D.  3@+F\9Y#YY(_>E?Q5ER?2ZK#] +'E&_UN?O'*%M[;VGFIX@.D85H\
M.XO9,-!F"Q!U)?%R"AGK,DY<S67>*D?E4APCC!PQ:"G3E@%5:L'AI@1D!$!%
MV9N0BL74*0&ZK"=^/Q!N_.<;\)RE?ZW/WCO]_P"]^[)5'B'*QO(K0D:N4)DI
M'*8Q&),15UDY,;5U\#'S B<#1<O?8T<#I"7,7E):,GTHZ?<M!O=LQZCX^PCR
M=\L<(%*C@?T6$[@3LL! S_\ @J>4;Q.!;GW]'X1QW'HWC<<X(R/,K;CO._54
MHP@2XV:S)!EL<5##T;(&8I+@#7Z#V4;?1K6IDI]-#&+@6+V$?&OAD1?.T,&Y
M3-%)[WQ$6_&OWCP*AD?T:'> <[  WY Z?SA1RE>ZW/OQ_7=Y>CU^3_\ "^A?
M.K6QYD+=1^2[!/NI 7""8V$#PR7OC\BPE$/FT]BQH8*2'7<8QV0Q?7,T(,3;
M_P !9-E0#]@64&D$KM:>!4.K0^3_ )8\H)]6 =_1N*<I7LX%N<^;$CM_E&/G
M_P![U4?],B+WQ&/&,DE$G8RU["V,#:PV.3(^<D2TWU<=V\&[L:B'3\#1>0F-
M&#.#QPJDR8H-L6YEP.?*X-KSX#1&?Z+#Y,88/*"?X GYOSIRE?W?TN??N VW
M952 <P(9*Y%$H]&))-3N,V=AAH"0LHY),(JN7/ZN2W4+#.3KQFU:LR;C5;AK
M,_!W-D[8#W*;/)2QC%8:D%&@<8JPG/\ ]L>4;7[-WGWIRE>W8MSG/_W'?/O_
M &?Q"R \9Y#YY(_>E?Q5ER?2ZK#] )RC?ZW/WCD\9Y#YY(_>E?Q4Y/I=5A^@
M$Y1O];G[QR\['3!RGE=&-?SY_$]B/'7%_;.WT=8[H@*\2A1+%K+Q>L]33*'&
M\I4\C3J:,&<E3$9LETVDA9#V;V)L&^./=R%9!?N' BIH3]9=%)28S5:<(N4)
MVS3L#H7\;!.SB&S-KO=$7APVHG.<V9Q.Z($>7?"I<X3PZ )Z^HROT'4;')^J
M5'5ZLFQ9C\'M59?"75W6XV6!&6G9G8QCZ[ -\Y!OCH.YKR=-ZV.-#.Q"3'C3
MJY-]"-90-N B[%L[EYTRO-)00PD#<$E*'34#D8SSNBN:6:N'LI[U;_4$6;)[
MW#FAH@M,>*$+]4MEL]JR72N<(8XQ!$TQF0Q R!@WA@(;%G^OE<?\$^I\)I*,
MK)-4G9H.GA]2A2;'7:UUF:4VK#Q.V$67-AXTDATQ:Y]G'1%LC??XSR'SR1^]
M*_BKH/)]+JL/T O8>4;_ %N?O')XSR'SR1^]*_BIR?2ZK#] )RC?ZW/WCD\9
MY#YY(_>E?Q4Y/I=5A^@$Y1O];G[QR>,\A\\D?O2OXJ<GTNJP_0"<HW^MS]XY
M/&>0^>B-O_NE/_[>G)]+JL/T G*-_K<_>.7A_P"DEV]S"B?-1LUW9M!_,YIQ
M[D[&0Z$FSN(P@0JG%%3[2;P0Y@Q 1@4$,N4W+9A]*)D&!)JF=&E!2EE4&ZR&
M7L7!W3]%=HT@HTXZ\&H1NBU"!DDKFNDXMT$["7R.>T%KG;.'-/%O:[I.5\S\
M,]6X2Q<)6'5-1EM6M&G9-I%I\%9CFP&9MJK*UL4$<<C@YK.,#VO:)HWQ[P"#
MZW^*SSD.2XZ:T<<HYV3FNX3HQM+Y4LY$1^-91Q\74^E!$:1&140$'MWD7&K,
MQI-Q=LJX<ETRE\G*K)1!!+RS4Z&C>'6!I]&"*HQYCBQMR;88-ETNU*Y[B)'9
M<T9 #"T8SDGZ T#4.$7)--VLZE8L:C+&)K!+8H>*,IVV0<7!'$P.A86L>2TD
MRAYVBW9 RA\9Y#YY(_>E?Q5H<GTNJP_0"YCE&_UN?O')XSR'SR1^]*_BIR?2
MZK#] )RC?ZW/WCD\9Y#YY(_>E?Q4Y/I=5A^@$Y1O];G[QR>,\A\\D?O2OXJ<
MGTNJP_0"<HW^MS]XY/&>0^>2/WI7\5.3Z758?H!.4;_6Y^\<GC/(?/)'[TK^
M*G)]+JL/T G*-_K<_>.3QGD/GDC]Z5_%3D^EU6'Z 3E&_P!;G[QR>,\A\\D?
MO2OXJ<GTNJP_0"<HW^MS]XY/&>0^>2/WI7\5.3Z758?H!.4;_6Y^\<GC/(?/
M)'[TK^*G)]+JL/T G*-_K<_>.3QGD/GDC]Z5_%3D^EU6'Z 3E&_UN?O')XSR
M'SR1^]*_BIR?2ZK#] )RC?ZW/WCD\9Y#YY(_>E?Q4Y/I=5A^@$Y1O];G[QR>
M,\A\\D?O2OXJ<GTNJP_0"<HW^MS]XY/&>0^>2/WI7\5.3Z758?H!.4;_ %N?
MO')XSR'SR1^]*_BIR?2ZK#] )RC?ZW/WCE\YR609X989&2-\<\<L<K>%*_P9
M6O:__P 7_E>G)]+JL/T G*5_K<_>._FH:W83(CN/VXA;-^[08):CV,ABVP74
M[W=/.'F;*6SM>_\ VF2O=975SSOEDIEEEEG>][WO4.HTP"X5H@X D.V!D$#(
M(\Q!Z%!U"Z06FU-LD$$;;L$'<1T]!RIG\9Y#YY(_>E?Q5/)]+JL/T IY1O\
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M0 ,[@,+DJCHWUXI8XA"V=OA!C  (?.>-D+L  O<][G/=TN<23O*F,<.'AQ[
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MG"QG:JW*<)A:_;8^,.9.V4.RM>-=G724HB41*(E$2B+UG_HQW\0<S/[9T/\
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?1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>g99471g96t09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g99471g96t09.jpg
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M5F)R<X*(LM+5)D-%4R@I6&6HM55H='9XF**WN,+&_\0 '@$  00# 0$!
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MR7%[,%#;DZ3YG<$@^7%N;3'5+PHGR =0_E@V<8Z^8AV'MV' ]A[CK#Q*ZD@
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M-9!7F6LE2L<&@D)QYS.Y2#?,D2$ ,!SG662 @FZ"8P"(@ <PSO5U&,SZ=G8
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MD/O-4*;,?#54:5:F**69$546H0E HL,<2Z9RVCK?T?O;5#60Y?6)D/6BYEE
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M;>?IY>6'D3DAK&X]=_SQW!?891 */I(<=A_:??B_;2?IU'U*A=%K"^K\-/\
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M%XBBF*)HS$DT[RU+;E7C<V!"WP=5^UZS[;OI"X&GVT<G$S3]C7+HRBW<ZH^
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M(I#"1Y&9F(V;4P(()&)"?(LGJ<F/3M1EM)49&U F5ME<\*RT;9?'"L$=*89
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MX]<4!N3\S^>,1)$!'(9 N,9]^,=/?^/WZ>I\(!&VP_+RXPW=N;VL";?C]_\
M9\\*1$"B!0*4<@ =A'.,?$<?ZM.0@.["^KD]B21<^0%SSM;MY%LS<W)L=[7/
M\_R,;/?127AE5>)Q:CR9C)L=ZMN[/MRD?FP0DZ(L;76RB7^.9W+UA&+* Y,"
MDFF8H"9+E/8.G:E:#-:2:^DLWAWORC6!&Y(Y%[V!%^;8HOM(RR3,>DY_ %ZR
MCJHZVD>Q8IH!5B%X8%&;9@5\@38B[6]=:6C)^6;G(8# X6$"B7!B"14Y13'H
M7 DP(&R & 0P8 -D->E%TM CV!# D6/(;?MYWY'H3CSQDTZQR-&VP(LX)_Y=
MEUS-<\:I3(=-[*25   &*/VAN)%S!Y<HEQ\0$0'W8SUQ^759S2(LK%18:;][
M&U[^?&W\C%^R9@DP(Y+ @W^S<V!_C>_?C$7/$P*8PXP("(A]>?RC^(-4:HCT
MZKC>Y/)\C;O^>^.DTDA(3?8@7V^=_/R^?Y!&$1 PX\A']>OSZ8[7^7\_N_F^
M)1!KN6%[;+V^'^VW??Z8RFZH\PB8W4,<H]A#OGMC.?CD?QY6CD )8WNMK7N.
M>>V_ \[8TG5=.PWWM\[CS^6);HLPHPDV+HIQ 2*D$1R >8%SCH';\7F..EVR
M6I)".3=D.Q'8/=3<;#<;CRY%CQS3J.C<L70 LP91L#PIOL>3V%[7-Q\KB\<%
M=+N?PT;-[QL&X*R^UTV[VZM;E,H**+UVWH?*M86=" "9-"&F8:6:)J&$"'7L
MR:.!,DGS5?KK+A#FD55%M%5Q@N3?_"[$6[&ZZCMN;7-Q8*I[*,U.O,^GB3"R
M,U=\6X=EE6)FNQ)&\X-N#>]B1<ZCB-\FY>3J&<^6>_GT]WXNO75.CC)8!KD6
MV!N.!V.]N>+<=\=H_P $X24AM5SJ&VP%Q:PX^?)^0QDE;\HER4 #(>>>_P!8
M=]+F$<Z;@$&UR3L0>XL=]^.//&',0#,OVK&QO?\ ,GMMQMVMC=EZ$W<!K3M[
M-^JR_@8:SL+WP^V#PXF;3%1F>9KDW#*1[@"D()O$;1\S-J<I0*)PP0BB*AA.
M+.KRNHK\PRYJ6J>DD:IAUO&UF95924WOLUOB'< WON#6^K\XH<OR-JNMH8ZV
M-$8,C;E3(IC$BCLR,PL=B-R+7OB0E.%3>?B#O,Q7=IJ1)3QB/@1D9]<@Q]4@
M06$W(K,SS@H,&Q4TP,86Z2JSY0J?WAJN;*>NRYSU)E73V61MF==&]4L16&F5
ME,DCJ /#"*-6F^E=3$$A@18XXKT?TSG&>LWN\#^#4SB0.T95::G=R0Y-OB9%
M8L18@!=R=SC8UL#Z&';W;1:&W'WVW%6N5VK\VPD&--I+UQ!5N/DV*I9)B\4D
M'#9.Q3A&:[0I@60- HBN8$#-%,$5-PW._:'59VTM%E] :.)XV268DR:HW!1U
M!)94U*S7L"P-R& VQZ'Z;Z&H\L"O6U(FDA(DCM=;O&1(MP& -F \@1:]^^V^
MWV)R^F%;8]BV+6=G4$#/+(A#LXZ6L:<65.-8KR4JV;-W4RI&MF#>+;.7!U3-
M6[%%HF8I4"E"F9?EM/"CPPZ@BL=49E=]#,H8BS,2I8'45[ZC_6Q?6J2UF.DB
MVQ*+ON;'BQL?0V\^#B/I*5;NT6:J!':3P$W(RB[AP19%TY,Z5.DHU2!!,[8J
M;<2$7356='6< =4%2E,!"R%-3LC/J(*$@1@!@4  U!B6-SJN195 6P[7PS=H
MW&XWL1?5Z[^7;[^UN3KYXCO20\)7#'Z\RONY[">N#,1*;;V@BE;;CX_*80;.
MV3!<&,*H<Q?# T](19"'$>81 I^5ZK#=3&"P[*H+; 6N!:UQ8[VML=MSA)5"
MFX<V]6-N^][\_+RVMC3?NEZ>S<R?7=LM@-@(:OL#E6;MK'NE+O)Z46(<N$GA
M*[7%8B.8J$#!BMW,W-(<P<QP.0YD2KQTDKM_@RJFQL2U[<D +L!O8#<;?3&D
ME3#'?45-BQX N1MN6O<VW.P^=]\49M_I&?2&;B*J*O-^IBHMW ',9C08:&JJ
M"(*9$R23EHP-)\@ (@459!8Q<=.41$^I%,HD< D-8CS=;GML.#OS;Z;X9RYG
M#&NL,-S<#X3Z6 %Q]#OZG88A"2WPXN)WF-,\3^_CWG."ADC;L7A)N)P$1*8&
MK>82;%,7F' @D'* B!<!@-*KD=^0W>W[20'<\'?T_+#%\VB8EC<ZN25&W;F]
M]OIZ;X6*AQ!<6E,E$'\9Q*;]>K\R@.8\V\&XR3-<5&ZK<CA5-I9&HG79"L5V
MS.H)B%<HI^*DN@55!7#Y C @Z22"+,=1_P#FN>?6Y[#&\>91D7#:=]B .UM[
M6._X>9%[XN9M7Z47TA>VTC#Q]>XJ]R+%&/[8V(U:6]I$[B6. K,>9RB+-=I:
MXUO79=U,(O4%S*I2J"S56(7 %V+9T8R\+7=*4(#/+ A_9V))T@LQ)O<&]QQL
M#R+7(.)*FSBHDD2D@<^([*PTK>ZV -K[$&QW8WN+'2"N-SFS?IZ>*6K%CZAQ
M/[([:7R+2C^2:L,&WL^WUH<E&/4<D,ZC@1N<4H:1$4$VJ#>"8M3>.BLY<HM!
M.Z3YS4].&.I:2D9E0$FP;4NS;[W7@7!!M\[XZ+'EAGI(8V!$TB L]V#!K7!N
M&%N1L+ _3"/:]Y/1(\>IY%@E*3'!YN])+B4[B7;1%(C9N3.<2F2!\U6D]OIM
MHLY.4JI79X"8?"F98#$,<!-*TTM73*T$K%E< +<@@ ;&YL&'.PN #MN1?"4T
M7473\:5L:M7TD5VDCT+JC"VM9E&IM6_+&UK#N!K0XJN##>OA68.+0[:M]T=J
MD2&6:[A4)J[DVK=B(@*#B?B&I7B\3XR)DU!= N[AB")@3EE.XO4HM'[:-OBD
MV8,0VPWX)(&Y[ $_ABVY;[4LGS.GIZ:LEDH9T;2(F15(>P5KFP8\ [W\[7QK
M<'?^ 0."A$W_ "%$!(H5 J6.4P"4P8<J&+@2@8!Y2X$ , ]LJHK\$A3;<E1W
M[ D6[W'?8>HQ*S]5B-TCIZ#WF+[8K!+*0X TZ"JMHN;EB0+[<VN,+L7Q&T\S
MI%9R+KF!0#+<I@166*<RGB@=4%DE$_&!97G6%-8Q>?G*"@E*4=3 6)(E&KYC
MU.X&UC;N#YVYL]BZNIY0OO65JA!!UL\A(;D C58ZK\D'SW(Q.,+N-5+,4@5N
M>:@=5JU*O#F.=-TX%KZV0JRC51#PE3) ;QU#>*L!%G F;'%(#@CHL3Q-XBN"
MRAK  $7*E>"+;>O'VA?G$W^NZ7,!':.(M\.E  EP"-5F0 _9U;WN#WL=GLDD
MU*W04,].150KD2H-4EE';<S=%$S158Z_J[46KU94J8G:N7"[5)%PJHWYS-4U
MM*.5WJ-=6?$D1[PD@!00?ZJ@*_/# C;G:XD,QIR].D674:TPGC*RSJTDFFZC
MXAK+!;6MZ7XY!?4!=_ 508R*CA1H9-!(7[@B15FSD0(!P4\)10JC4Q^8J2HF
M!8A *94OX0:N%'F:Q2P)"^AFDC$A/Q*02 1I;4!<7(L 03<''',UZ?.8Y97"
MI@TO3M+()?B3Q&0$\@J"25'??N=\3W7IQU$/4'C)4"J(G3'(GRFJB(#][,4,
M>(BL0?;$!QR@4Y0,8"ZO5-7:'UJY5KWOMS;G3QZ;;<[6QQW,<CBJ:=J2JA$B
M,C(H:]UU*0#?[6UQ8W[ ^1Q8"'72*1&U5WF2;B<%92,)CF9J$-A5PB0@F$"%
M./.Y3SRIE.#DF"'%,G0*#-!44UJI]8TWOLIV N"1;Z]C;L;7\U]8=$-EE612
MQ@:6-K:R"-K'XC< 7^=^VYM=A*MT#BTV&N_#QND0'$%>8)2-0? ":DA 31">
M) V>)%81*G*U^4!O)LU!#D6,B9LN)VKAP4]1ZSZ=][IVEIP5<*UCO<6!TG3N
M+@WV(M<>8 Q5>D>I*CIO/6JB]XJAO^,+90CZV"N-(V 87W2Q!L01<XX;N(78
M>[<-N\%ZV7W#CE&-HI,XXC5%?"41:2\8;[_#6&-%8H&5BIV,4;2<<L41YVRY
M0/RJ%$I>"20/')X#C1*K!2>VQW/<;V(VOZ8]A4%=%F%#35U+*)(I0K&QO]H*
M=) L1:]B+#?YVQ!QR=P$!  $0_+]?X](O$$=U(!96921W*D@G8VW(^6))7&H
MVN/B)%]]NP\[6^O??'AC @!NP9#]?K_7&-('N.USM_;_ &X=HX)M?^RW'R'\
MGOCP. @838]@1Z#VP !\?+X^0_B9S0@DD#D>9\@+\[87M8 @[^7<;['^?3'Q
MJ.>G:Q:QVV[^OKO;RVQN'N=]O6^WW?R?7O@TR*6/Q;GM\OO\[\[^>-P+<\W\
M[_S]-L?!R@8.ON^OW?CTC(HU 6VL3WYO;"B.5X-@3OCM_P#L,\O+]T>Z8S^T
M_P#\J+].HVN 'A6[Z_\ [,/H22&)XVL?/G^?Y..GC:C@ZAI&>WO=[\;>P4TR
MM&ZDK:Z,Z&5$[\D0_D)AP<P/8&0;23!)TFX8G<QKAP1)8Y$Q7;G.@ D@8J12
MTQGC!U2ED-][$D\J;@&XN"?F,>F^L/;;74N7=!0^SWJ3,*"?*>D:3)^H(?=
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M9@=.J(<@[FQ.WS%[S$724.9T#19G")*6.SB(FWB!2&M(VD7!90;"U[<VN<=
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MV7D(BL[OJ,I>,GX]PWB[)'.2'.Q=%$[?U>5</6?,4&<BDF9TX @KE(V<$4=
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M0>?Q^C34J&()O<"WTQA23>_D/Q%SCN!^PT_]\=_[H'^5%J,S%0O@VOOXG/\
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M:._T=T?WGZO_ #Y3_P#49/\ S&#^Z.+_ "63_:+_ -W!]U_JO\A]@_QVCO\
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M*<12BK9I7F<"[G1,^Y(6<&->%81CATY*/JBKZ2=J 6 ?KG$7O)(\[(3#(,4
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M\8QF.VEYD+''U9.N22$I)W)I0&QGC=1I&A;GL@G%HPRTLL4L:BZ!VJ0% .Y
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M_0?_ '8?48& *'Z]]1\IO]3_ #Z[8<-MI[[#\3^Z^)OJBP.HE1J(@*C%4PE
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M$6VTW-P2222!OMVQL0*^;(IE HD332(4J:92E*FFF0,$(0N * %    Q@"@
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M4G, %42,(ASX#S_71F*LJH[6"3-;BQ!N0 ;7/EVXN><>O^D:]<RZ>H:L$G1
MD4@8C470 $FQ([@B]OON<:HG!!P)NWPQ@>@AU^GR^&H^6!F%[@7VL;^6U_Q^
M5\6Y7 0+8[;@CR(O8??A-5()@Z8#&1^?X:BI(SI)N.6'?N3_  PO$X!W!.]O
MK<B_\^6,0Z8@ !T$<!@?H ?=IDWVB/4_@?[</EE!M\/ M<^EK_GCQ-[!1Y@
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MP!^8QVZ_8:A1+]T=SY_M0?I_W4.JKU$I7W.]M_>./3P/XXF<O(/BV_\ R?\
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MVD0X;S/K<JLR:+PSAO+-EUHY=)R>&DZ@R:9)9HJ^%XXT@9F"R L)Y#%%X:E
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M0 !)+V %^,=K4 OL*&R;]*5*@?<7U1T<OWAP,S\J&56^3RL51*"/J8%!+Q0
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MB0B!<-IM"09M?D^!8R#5RR>(2#:5**P.CM?W&,%-TO1HL(CJ:M)*6&!*:93
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M!G!)"AXT@E;7B1#<Y6TU>7TAT$<%)X$&I')MD\AC[XX=B;F <].48X2UCO\
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M09B[I8J1J)-[L M]][,;F]]C?',<QBJ9LVS,YP/'I4H@JZK0@((@$4/(5#D
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M]\OI'_+Y_P#J-9_X.#]1YC_BD_VL?_>P?<U.+C_D+!_X\U'_ -6T?WR^D?\
M+Y_^HUG_ (.#]1YC_BD_VL?_ 'L'W-3BX_Y"P?\ CS4?_5M']\OI'_+Y_P#J
M-9_X.#]1YC_BD_VL?_>P?<U.+C_D+!_X\U'_ -6T?WR^D?\ +Y_^HUG_ (.#
M]1YC_BD_VL?_ 'L9[#T;?%H@IS*4:$ ,AVO%2'R^$MI*3VD=),-J^?@#_P!!
MK/._^)PJF2Y@H(,2;G_&Q_U2/ZWKAZMO1_\ $]&MEG+NFPZ:+9 ZZQBW&L*"
M5)!,RBA@*23,8P@4HB!2@)A'H ".F$OM Z7D;X:V8WL!>CJAO?UB[_[[863*
M:Y2+QK])(_ZH'];&FQ'TDG"C'.EV;JWV(B[1RHW7 M)LIRE5;JG24*!BL! P
M <H@ @.! ,ATQJPZ7D&I48AMP38;,#8[GU_/RQ%&JA'PES< K]A]CL-SI\P=
MQMY'G#S8^D^X0DP #W.RA[7-_M$M ]/H8?'35Z"K>]H3Q:Y9!S??[5[?3SMA
M45]*H :0CYI(!S_JX>3'TIG!TD!1/=;. 8 ?]H5J[?T?IJ^45[7M"."/\)&/
M/OJM;ZXV&94:D$RFW_LI=^>/@^ORP[6OI6>#),4S'N]H#)1Y0^T"U9, ].@!
M']<B'XM,WR#,R0O@H&DN44S1787[6<^1[_/&_P"N<N1U#5!&K8?L9MSY7\/G
MC;G#_KGI4^#F5>-HUA;K>\?.#@1NV0V[MACG,(Y$3",>!2%(&#'.<Q2$#J80
MR&H'/:-\ARVLS;.)J.@H*,:IYZFK@C4 #[**7U2-N 0H.YQ:>D,IS/K[.J;I
M[I&@K<]SBKD$4%#14L\DK,+78_LP$C7^D[D*"+:MB,2W;/2-[ UFJ2;^E&F[
M]>B-BD@ZJ:"E(5B,@X Q&ZTW+2S=FQCXUN<!5=*J+BLJ5,R34HG-XB?FS/?;
M1D5113R9+)4U3*7B@3W>6%9)%N/$D=M+&F!.H>'=I5&E -ROL[I?]"WVF09Q
MER=:4E#DN5.T<^83TV9Y?FN8T], )##!EM)43R"ME'[*/WE8X8G):9]*&-])
M5HFMVMW]^:HYXAG,S&);IS+%(9.,40E$RP+MR9%%.%/#GDD6K&,37;(EC&"2
MCEBV,11%BX<N42._/%964 DS/J7J1:C-IDI6JBQD_I@?LX@A;PZ>-%!"1+I5
M%LQ(W)]O9SG6<>SSV;UG3OLLRW*\BERBFBAH<KE94CJ!$^K,,SS">2TD]?5P
MDF:69RTDL8"-ILBQUQ,\*NXG"_86T=<6B*D-+O)1*!FBRD6Z4FFL:ND!G2C%
MI(N9*.,LV=L7!4I!JV /&.0ACE044/5^DNM<GZQI7J\L58Q#,8982&#Q.5#@
M,K(HV5AI(L"=QW 9]!=?95U=EM/44DU0U;'#!'G,<OB>",Q\+_C HW=55X2X
M<_ QTC3JXNU5Y&84510:) 5N0HB)DRAR IU#D\3(@*AL9]Y0YA$.X:MD=.$G
M+R$G59A<]MS;C8>8^EQ;%ZK\UD<1TT82!!>X92/$O;2+<$C<-?S]<?+=O*/F
MRJ[]1-*+:D4,*882*<HE$@)$Y0*9TN;F 1SX@D[#C& 58Q"=-! +,/B[+H.K
M>VPWV%[[GL 3A%*>MJ8VDJI$]QIHY6>G) $PE0QA%4VUL+AB!>P!^6'5OGN=
MOIQ1QE J5JEG_P!H6V4)78&NUN/%=.#45C(QO$GL4\D4XDE;+)D8H'!W( =)
MF4JS6.*FF=P!KGF_6^:9A24]-4U3BGHX? CC#D A5"+O<[%018&][8\Y]*?H
M^=.9%U%G>=9-ERIF.=YE-F,U7-&"D<;N[R4ZDBRMJD1P+6LC7U6)$R4;8P]7
MVAF; 5D(%(FVBG)U41;JEEG$TR6Y"IK F<YO42I*<Y0.7D]L#"00.;F=?433
M3"J8-'!& I#;:G8Z4^EF/D;$X]9]*9/E67P+E,9AJ,QJE:9S%I?0(%#2!B!8
M:2;$W!V(%^ X(I_"5:!B6]@22*LJH[D&OB%6*NBV/X;7!2 FJ@JB\%L8A2J)
M& QDS<N!$3 Q4-,VN.'Q[ZCL00"05N=1L?/@D6MZ8N@J/< (WJVIHXBNKPV&
MO0""T87OJ T,MQK5BN_.,!W=:E(E,B151%LJ4Z2B"S<P("!PQR@WY0$H8
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M\C;".KMQ,6?Q$8M@!DP]E5ZN HM$0$H!DR@E$RH@&?8;D5,7'M@7(9PLSD@
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MF_;&Z(ZD-(P9 ?C ((T@&]]^#:_\,48D-_W.ZD\YA(-63,#=4B;I9-BNF@V
M2BI]\5>@P P 4O9N5<>O8.@C)K"WA/9BC:&TMW4D?: ]#N3?:PL<1/ZSBGFF
MA*Z52_R.WG\@">P'T&,3=/;FV06WR%V>PLHE5W$VA7"SKM+P6[J=D(D9QBU1
M36,1R8'D4 O&R_@ U63R":QA(8=+T>=]//F\735-7+/7K 9JLQ.LABE0/\,X
M0MX9UHT=I"#J#*+$$"LU-?')/-'I8HMQKM918-R;6 \]]K$@\#%1^&>+&P;^
M2<R5,3M(!.8?J")1, F(@$&@</, ]:<IKEZ\W*3.1P(ZZ10BU*HW&Q-CMR/7
MU/Y]ACE9!GZB<L"!NP)!L18?$#_5W._')!V%]C"YS'6,4>HF/R@'_../+CMY
M%$PAGKT#IC.K9EX;418VV-KGR\CN1W^G:V(;/)B%.H6LVDZMK-P%-SLVWV>?
MW/VD%29KN)=<@"E&-'<BL(]N1HB=? ].O.) )R@("8QBE'H(XN5$AJA14I&Q
MGMP3INW)ML-_.W/W\?ZEJ%RNDKY9P36R1,8&( (#;J-QV7>UMK?0J>U3HZTL
M*ZQQ%1PN"RIS>:AUC'.(].N3&$1'/?N/7&NN$10PQPBQ,,:P@WO_ (-0E_\
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M;'OV^6-EV87V^?R_M&$9<,@/?(%Z?3G3.4<]OF/(#]^V',/V1\O_ +FQVO\
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MF(63C6+AT;H9)HH)1#(>TH %)UP;&2\X_P#:QT[C5JAM2(Q[J;[$;DV \O\
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ML+;=[7/?TQ+T\!GL1N([&]R-SP2+_P"B2#;[][WODG"D"Q:IQ@ N]4P=R %
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M6=F(##6Q8,%T6).H"POP,> F4, $YC' HB)A)R@3E*)O:%0W*&/+)A#(CCS
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MOJ -FV)!(O6_API9W"CW=2>:F37?%.RJK=<,*IL,&26DL#V4<DPDD/M ("Z
MIC<Y3%[K0P%4)068!BHX%[&UQ8#3?8\@<'C:G,9YV:MG4A)+A0P.D$C:P.UK
M[;  [W&]L;NO1R.R#?=Z%UE2I(FV8E2"HHLFB'/]LE:4(F!CG*;)R)G.( &
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M*-3$ADT%'YU?#\(YQ!!-,Y/$7='YBII**)IEU!PPS&[H66QN3MH4=]6U["X
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M^AXUJX9)O'*35%)%522('K*QW"7@K&*D7E(IJ6:*$*'>UM0#V5C(247X0S
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M Y$>X]0Z"&J18V)]0?P__N'XX]:$D %B25M<DW-M-E'T!4;;#Y#"&^*; A\
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MZ^CJ9:BGKC4QVG@6"6.6E=$>ZI-,I1]8*6<E0/B))L%U8EG4@ K;@W!#7(Y
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M:*IBJ-0%7$^IDBHX&7Q$010Z71F;4T]'*M.9"D5XJ)=:S1#6[(!+&4 /AL+
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M@\6FC9=*JNEM+1E+C^MIU&Q)8VV\XN)>)KF154 Q55#',02^&H59,I3"(X
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MJ!;:!R5,?%R"%&^YVV8=^*?I42QQ^RO)Z=IQ$T_5N7U;&X&J"*@S"23=B0%
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MFSD!\1LR%+J/7G$HCUZUK,@P#BYVOMZ>7R /U]>ULRNXIYVX=(P$('V1VL+
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M@EI!XJ8[A19F*\4N9;R #@V;&2(!4T44C@DB1-N1(@?/3VMY%%TW[6>M,O\
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M$P$6>2)@*4QWCU0@&]7*'(V;E02*"?*=)-]-I:(ZS<DW"FXM;:[$:268@;<
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M\,#\K\_X8[2_L.WFY_2+@(8 !X1L9#W_ +9W/YM<YZV&^6GS]\_#W3%GZ>
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M^9Y[ :/IJK]F71V3=15N85Z5O5N7TLR4TU/D+W]_S"G$1D,\X5'$4-K:@3N
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M$?&$(-]PMC8DVY-SVL3]-S;'&:^HURD*C<@LKDN1Z?M-8W\K>0.]L6\VZ@P
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MH6UHI>0LR:38#PRGPKI<E25Q4>=4\65>*=\*F ,>>.GG[@#]?/V_3K:&$<?
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MI9EE==((5R%-S\8!V:^VQML ;;7&]L71<QIYXP\1:-@ LL=KQ^(-V"D_:%B
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M!!=GE&E%!!+,PN=*BY;864&P/=*3=QGA.9YVD#&$8D54%Z],)%E%$L"<ZQ#
M4A$R  D*!0'F-RE(!^;(R$66YA6YA2Y/0K+6YG6M&(*>B0U#!92 C,(RQ!4'
M4_9 "6  PSDSO*,CR?,NL>HGBRGI_+8*BIFK,P=*<Q>ZQM)(TP<J@0,I52K-
MXSLJPZ[XI!N9?'%]G@D!!1",;<[.(:'$W,W9 IS&<*AD %=X?[XKDI1(F!$
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MVMO??L=AC9'12U#9/;>U;S[CNTHNHT>#=3,@Z6$I%%P;$'U2-9$/@7$E*OO
M81S4H'%P[711 H\^N:]49JRQB",J6D!  /Q7OL=AP+[^MS<;8F>F<F?.<XBI
MUA,T&I2\^X5-QJ!!!4VN;[W(%B-QCDKXD=\[-Q%[RWK=ZU\R;VURZZT;%^*9
M5"O5UJ(MJ]7&9C  F;0L2FU8E5$ .X425=*??G"PFI<*".,A=F<%F8FY#-\3
M'RM<W V [ #;'J_+Z9,NI(:.&P$%/# & M_@D$9.DDV)T;W)-^2;#%=%@[Y'
ML8P_/T#IW\]-2"NH%BQ#"[$6)^UVQ(K>VY+'>Y[FQ._\]N_?#>=#E8P^\"_D
M#35S=CZ.!\^!^_#@>7E8?@/XX17@>P8V?>&/G$1SGZ--F6ZF_8%OJ"1;& -R
M?](G[KC]^&PY-D##CO@--B-]7D#M]_?ZX<(;CY;80G8\R@#_ ,W&F53]I1Y+
M;&&Y3Y_O&.TS[#O#!O2+![AX1_\ *=USKK;_ /%G_P ;_P#FF+/T_P 58_\
M8?CXW\,=L6J'BR8-&#!HP8-&#!HP8-&#!HP8-&#!HP8-&#!HP8-&#!HP8-&#
M!HP8-&#!HP8-&#!HP8-&#!HP8-&#!HP8-&#!HP8-&#!HP8-&#!HP8-&#!HP8
M-&#"7.?P+,?S7(?U1;6R?;7_ %E_,8,?DC3O^V"?#W3$D/UO7 _BU[&IO\&I
M\TC(_P"@,<4E-V)_TG_^K'\1ZAGW!C]?JU*T^]CZ$?</]V(UOA8CFS7^Z_\
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MY45$ZE3('BC8?!-%)&R2=])".6&D?%<BW:]\(9?#=*&*N[33* "<%#BH4PB
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M.^WUPH$, =>O4/T:E$-U!&_/X$C#"53OQR!]1_NQDD/R%* !@P9 39ST$ P
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MOJ *[Z]1-69\A9U4@%=<1/-M!!U,)S<ML6YS$,M)E H (E(B\. "/<H^(8H
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M:89HLN7/,UB.I<TSJ,5,:,RL)/\ ]'L3 ^I68(?A\)RLJ@E%&/%7M9_3G_2
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M'443$4S  "'3 @)NG3L'QQGJ " ]?/47+FD<T:LJR1L\22E)5"R(LEPH90S
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M-B5W52=KLX8V'!L!?MN#BV9'T=F6= /X:04YMK\=FC=D/VB%$;@[#90PVY(
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M%C.)&9G9)Y*R;Y8XCS*N7SY5=RL;R 3J#@,%  *  $BL4%. L:J1VLMB+>7
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M)+#[N=K\?F//#<5'E ^<]AQ_VLXTP8$'5MQ<?2P_/"14AE!M<*#] <([D1[
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M@:G_ /J]3\L>")@QT'K@/R=>_P ^GL+>1WL!]PWY^>-!O<CL;'Y_R,*Z!P'
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M6.<E(JV=-72?@NF[A%3G*H@JB<Z:R8ARJIF,4P&*8=0?4.6BKB.F-@1\:NI
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M[C7>Z!3P-9 &H; D$[#?GH](].FFN,7>0HGY_D)_7*N0!-S"F6OU.$CEDO\
MFBW=)+HF*  !3D, XP.H.C<&B=[C5).Q(%KZ2Q.KD;$;W/;SQZ+R"'W?):..
MS)>.+2&&ECL-@#SN-@+_ #)-\40<'R/* E$.HC@0'SR'4!^.M93Q:QM8^?KV
M^0Q8X4.Y((^U;:VQ/R\CA+6.!A'J7OTP(>\V?/YOQ::2D-N"#OV]!_NPX:Q3
MX=]R2!ON2/\ ?A(6/_%$0# B.,]>G0//Y]:ZE2UR!QJO\B;_ ,?+TP]A4"X-
MP#W.W8\?=A%<'*/,(F+D1$._OR';/P#4?(RDM8CGS\B>//D<=C?C&T0TL18V
MN=['U]/480UU,F$ $,=0^;H =>O33)CNWEJ&_:UQO?CSPZ NQYW8_=J._P"-
M[X05C>T<PB ?'R[  :;N=B?/]_/X7PXXVXW/W\G"&Z4$HB("&!'&1]V/[=-7
M) [6[D]K;COZ8UMN?+8_6YW_  'IAON3E'/M%\P[AY /YN^F[$:P;BW%[CUM
M^["ZL@V##L>?.P_'R\\(JYPSGF+@"B/<,9ZY_-I"=EN-QL-]^/\ ?^[YXU?<
M[;[=M^Y\L(*YQ ##D.H_1C(]OK_'IC.VQW%[7^M_[,+(MG4B]@"+_ECM;^PX
MQ#/I&>OGPB?Y3^N<]7$%J&Q!_P#2?RIL6?(O_6O_ ''_ &V.V_5-Q8,&C!@T
M8,&C!@T8,&C!@T8,&C!@T8,&C!@T8,&C!@T8,&C!@T8,&C!@T8,&C!@T8,&C
M!@T8,&C!@T8,&C!@T8,&C!@T8,&C!@T8,&C!@T8,&C!A*G?X#F?YJD?ZHMK9
M/MK_ *R_F,&/R'; 8?M@FQ#RF)0 \\_NYQKUQ P,,6X_P:\$=E'[M\<BEMXC
M[WN[$<>>X'R[_NQZ$, E+@0$<!V$.^-/KCS_ )_DC",FP%]M^_R_M&%!$PB!
M?+& #Y@Z"/XM;H?BY_'OMAC*#8[7!/E<;[[85$A >P@/3KUSUZ#^H:>QL"R&
MXOJ%_2S6Q&E2KM\) N+;&WVEOA01-RB'4,]>GT^[YL_7J00C7V^=^=O]P^>$
M9XKAR;[V]"+#G]X];>=L*R1PP =!#(] ZB _7\P]=2$=@P&I?OMVMW)Q'O"
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M-9,X9R10!#&!TXZ:KA/ O9D 1A<7!0LMMNUU(MYBQ[8\_5%,])--$P*E:B1
M#>Y (*D7W(*L#N//R.-05_BC-7KE,Q!P!U! <8Z"/7RZ=<CY=LC@>UX8B6,
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M^#<PXP(X#IC/P_MT_@D9@/B.Q&US]G>X'Y;?@,)$787WNUF':V_[[<85$E3
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M,ST[9G5,Y?Q<PTRQ(2;VBI@!"%!L0)A,P87#CC#2*4I2@4I0*4H !2E  *4
MZ   &   #H !T#38DDDDDD[DDW)/F2><7Y555"J JJ JJH 55 L  -@ -@!L
M!L,?W6,9P:,&#1@P:,&#1@P:,&#1@P:,&#1@P:,&#1@P:,&#1@P:,&#1@P:,
M&#1@P:,&#1@P:,&#1@PUKE2*EN%!JUNZU^,LL(JJ5QZA*-P731=%351(]9J
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M-6BRPQU,@?+2\BYLT7]RM7F8FG)8(*3WJ1(D*0@B>E4^(S:XXU8,M@17)#5
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M$5*T>QDB=P)4:S37->_8OG7<!(;-P#Q/8&;V?*6NUX3%D7,79IM^UL=D1%W
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M#,U1$II82$F?P_$D4%/MR&&(R'_E&C1GU,H(S[]678^\S LH1B'8$J-5E._
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M4T1#FDA:FIRUUW,-.S0(>1"S1;H2N,BMJU*E:B8%=>DAR+>(XD>W^LX#G_2
M/.,&(WKW>@'9'T)N9>(MZG##7DW;*S2R#@D+\LR-C+'E6(Z!0$$K!+RDXA@W
M.WEY!W(H'3>+J+&4FR7**A#'/EE#*AF]X*24T3*9_!CIO$*E;%C3Q10-M9H8
MTB8%%"C5:NJ0W2HE4Z EP[ Z YD"\]G9G'?4Q:]R<9$3OMO/!)1Z,-NC>HQ*
M*B$8*-396640*RB&SU219L6P$<!X23!^LH\CA+A2.<',JQ.W-UUK+D633F1I
MLKH93+,T\I>FB8O,R")Y&NNYDC 22^TBBT@;&5K*M  M1,H50@L[;*#<*-^
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-T8,&C!@T8,&C!C__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
